PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fujiki, T; Miura, T; Maura, M; Shiraishi, H; Nishimura, S; Imada, Y; Uehara, N; Tashiro, K; Shirahata, S; Katakura, Y				Fujiki, T.; Miura, T.; Maura, M.; Shiraishi, H.; Nishimura, S.; Imada, Y.; Uehara, N.; Tashiro, K.; Shirahata, S.; Katakura, Y.			TAK1 represses transcription of the human telomerase reverse transcriptase gene	ONCOGENE			English	Article						telomerase; hTERT; TAK1; Sp1; HDAC	HISTONE DEACETYLASE INHIBITOR; BETA SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT HTERT; CANCER-CELLS; PROMOTER; IDENTIFICATION; ACTIVATION; DIFFERENTIATION; BINDING; PATHWAY	In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, namely, the human telomerase reverse transcriptase ( hTERT). However, the molecular mechanisms involved in the regulation of hTERT expression have not been completely clarified. We have previously reported that transforming growth factor beta (TGF-beta) represses the expression of the hTERT gene. In the present study, we demonstrated that TGF-beta-activated kinase 1 (TAK1), originally identified as a mitogen-activated kinase kinase kinase, represses the hTERT core promoter activity in an E-box-independent manner, and it also represses the transcription of the hTERT gene in human lung adenocarcinoma cell line, A549 cells. This TAK1-induced repression was found to be caused by the recruitment of histone deacetylase to Sp1 at the hTERT promoter and a consequent reduction in the amount of acetylated histone H4 at the hTERT promoter. Finally, we demonstrated that TAK1 induces cellular senescence programs in normal human diploid cells. Thus, we assume that TAK1 triggers the repression mechanisms of the hTERT gene as a result of evoking cellular senescence programs. Considered together, TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan	Kyushu University	Katakura, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan.	katakura@grt.kyushu-u.ac.jp	Uehara, Norihisa/ABB-8106-2020; Uehara, Norihisa/F-5933-2012					Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Katakura Y, 2005, BIOCHEM BIOPH RES CO, V334, P450, DOI 10.1016/j.bbrc.2005.06.109; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	21	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5258	5266		10.1038/sj.onc.1210331	http://dx.doi.org/10.1038/sj.onc.1210331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325661				2022-12-25	WOS:000248674200009
J	Pakuts, B; Debonneville, C; Liontos, LM; Loreto, MP; McGlade, CJ				Pakuts, Benjamin; Debonneville, Christophe; Liontos, Larissa M.; Loreto, Michael P.; McGlade, C. Jane			The Src-like adaptor protein 2 regulates colony-stimulating factor-1 receptor signaling and down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; C-CBL; M-CSF; FDC-P1 CELLS; KINASE-C; INDUCED-DIFFERENTIATION; NEGATIVE REGULATOR; TYROSINE KINASE; FMS; MACROPHAGES	Src-like adaptor protein 2 (SLAP-2) is a hematopoietic adaptor protein previously implicated as a negative regulator of T-cell antigen receptor (TCR)-mediated signaling. SLAP-2 contains an SH3 and an SH2 domain, followed by a unique carboxyl-terminal tail, which is important for c-Cb1 binding. Here we describe a novel role for SLAP-2 in regulation of the colony-stimulating factor 1 receptor (CSF-1R), a receptor tyrosine kinase important for growth and differentiation of myeloid cells. SLAP-2 co-immunoprecipitates with c-Cb1 and CSF-1R in primary bone marrowderived macrophages. Using murine myeloid cells expressing CSF-1R (FD-Fms cells), we show that SLAP-2 is tyrosine-phosphorylated upon stimulation with CSF-1 and associates constitutively with both c-Cbl and CSF-1R. In addition, we show that expression of a dominant negative form of SLAP-2 impairs c-Cb1 association with the CSF-1R and receptor ubiquitination. Impaired c-Cb1 recruitment also correlated with changes in the kinetics of CSF-1R down-regulation and trafficking. CSF-1-mediated differentiation of FD-Fms cells and activation of downstream signaling events was also enhanced in cells stably expressing dominant negative SLAP-2. Together, these results demonstrate that SLAP-2 plays a role in c-Cb1-dependent downregulation of CSF-1R signaling.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1L7, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McGlade, CJ (corresponding author), Hosp Sick Children, 101 Coll St TMDT 11-601, Toronto, ON M5G 1L7, Canada.	jmcglade@sickkids.ca		Debonneville, Christophe/0000-0003-4759-2165; Liontos, Larissa/0000-0003-0977-2536				Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dragone LL, 2006, J IMMUNOL, V176, P335, DOI 10.4049/jimmunol.176.1.335; Fixe P, 1997, EUR CYTOKINE NETW, V8, P125; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Junttila I, 2003, J LEUKOCYTE BIOL, V73, P281, DOI 10.1189/jlb.0702359; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Loreto MP, 2003, ONCOGENE, V22, P266, DOI 10.1038/sj.onc.1206114; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Manes GA, 2006, FEBS J, V273, P1791, DOI 10.1111/j.1742-4658.2006.05199.x; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; Motoyoshi K, 1998, INT J HEMATOL, V67, P109; Myers MD, 2005, J CELL BIOL, V170, P285, DOI 10.1083/jcb.200501164; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Novak U, 1998, GROWTH FACTORS, V15, P159, DOI 10.3109/08977199809002114; Pandey A, 2002, J BIOL CHEM, V277, P19131, DOI 10.1074/jbc.M110318200; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	38	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17953	17963		10.1074/jbc.M701182200	http://dx.doi.org/10.1074/jbc.M701182200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17353186	hybrid			2022-12-25	WOS:000247302000002
J	Conrad, S; Genth, H; Hofmann, F; Just, I; Skutella, T				Conrad, Sabine; Genth, Harald; Hofmann, Fred; Just, Ingo; Skutella, Thomas			Neogenin-RGMa signaling at the growth cone is bone morphogenetic protein-independent and involves RhoA, ROCK, and PKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; SPINAL-CORD-INJURY; AXON GUIDANCE; NEURONAL DIFFERENTIATION; ACTIN CYTOSKELETON; EXPRESSION PATTERN; COLORECTAL-CANCER; MULTIPLE ROLES; LIM-KINASE; RECEPTOR	The repulsive guidance molecule RGMa has been shown to induce outgrowth inhibition of neurites by interacting with the transmembrane receptor neogenin. Here we show that RGMa-induced growth cone collapse is mediated by activation of the small GTPase RhoA, its downstream effector Rho kinase and PKC. In contrast to DRG cultures from neogenin(-/-) mice, in which no RGMa-mediated growth cone collapse and activation of RhoA occurred, treatment of wild type DRG neurites with soluble RGMa led to a marked activation of RhoA within 3 min followed by collapse, but left Rac1 and Cdc42 unaffected. Furthermore, preincubation of DRG axons with the bone morphogenetic protein ( BMP) antagonist noggin had no effect on RGMa-mediated growth cone collapse, implying that the role of RGM in axonal guidance is neogenin- and not BMP receptor dependent. Pretreatment with 1) C3-transferase, a specific inhibitor of the Rho GTPase; 2) Y-27632, a specific inhibitor of Rho kinase; and 3) Go6976, the general PKC inhibitor, strongly inhibited the collapse rate of PC12 neurites. Growth cone collapse induced by RGMa was abolished by the expression of dominant negative RhoA, but not by dominant negative Rac1. In contrast to RGMa, netrin-1 induced no growth cone retraction but instead reduced RGMa-mediated growth cone collapse. These results suggest that activation of RhoA, Rho kinase, and PKC are physiologically relevant and important elements of the RGMa-mediated neogenin signal transduction pathway involved in axonal guidance.	Univ Tubingen, Ctr Regenerat Med & Biol, Dept Expt Embryol, Sect Tissue Engn, D-72074 Tubingen, Germany; Inst Anat, Dept Expt Embryol, Sect Tissue Engn, D-72074 Tubingen, Germany; Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Hannover Medical School	Skutella, T (corresponding author), Univ Tubingen, Ctr Regenerat Med & Biol, Dept Expt Embryol, Sect Tissue Engn, Osterberg Str 3, D-72074 Tubingen, Germany.	Thomas.Skutella@uni-tuebingen.de	Genth, Harald/HHS-0118-2022					Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Charron F, 2005, DEVELOPMENT, V132, P2251, DOI 10.1242/dev.01830; Fitzgerald DP, 2006, DEV DYNAM, V235, P1720, DOI 10.1002/dvdy.20744; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Leonardo ED, 1997, COLD SPRING HARB SYM, V62, P467; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Matsunaga E, 2006, J NEUROSCI, V26, P6082, DOI 10.1523/JNEUROSCI.4556-05.2006; Mehlen P, 2005, CELL DEATH DIFFER, V12, P1003, DOI 10.1038/sj.cdd.4401708; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Redowicz MJ, 1999, ARCH BIOCHEM BIOPHYS, V364, P122, DOI 10.1006/abbi.1999.1112; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Schwab JM, 2005, ARCH NEUROL-CHICAGO, V62, P1561, DOI 10.1001/archneur.62.10.1561; Schwab JM, 2005, EUR J NEUROSCI, V21, P1569, DOI 10.1111/j.1460-9568.2005.03962.x; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Vielmetter J, 1997, GENOMICS, V41, P414, DOI 10.1006/geno.1997.4688; Watanabe K, 2006, DEVELOPMENT, V133, P1379, DOI 10.1242/dev.02312; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Xie Y, 2005, NAT CELL BIOL, V7, P1124, DOI 10.1038/ncb1321	39	77	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16423	16433		10.1074/jbc.M610901200	http://dx.doi.org/10.1074/jbc.M610901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389603	hybrid			2022-12-25	WOS:000246794300050
J	Holst, B; Mokrosinski, J; Lang, M; Brandt, E; Nygaard, R; Frimurer, TM; Beck-Sickinger, AG; Schwartz, TW				Holst, Birgitte; Mokrosinski, Jacek; Lang, Manja; Brandt, Erik; Nygaard, Rie; Frimurer, Thomas M.; Beck-Sickinger, Annette G.; Schwartz, Thue W.			Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGAND-BINDING POCKET; CONSTITUTIVE ACTIVITY; STRUCTURAL BASIS; PITUITARY-GLAND; C5A RECEPTOR; ACTIVATION; SITE; BETA(2)-ADRENOCEPTOR; SECRETAGOGUES	The carboxyamidated wFwLL peptide was used as a core ligand to probe the structural basis for agonism versus inverse agonism in the constitutively active ghrelin receptor. In the ligand, an efficacy switch could be built at the N terminus, as exemplified by AwFwLL, which functioned as a high potency agonist, whereas KwFwLL was an equally high potency inverse agonist. The wFw-containing peptides, agonists as well as inverse agonists, were affected by receptor mutations covering the whole main ligand-binding pocket with key interaction sites being an aromatic cluster in transmembrane (TM)-VI and -VII and residues on the opposing face of TM-III. Gain-of-function in respect of either increased agonist or inverse agonist potency or swap between high potency versions of these properties was obtained by substitutions at a number of positions covering a broad area of the binding pocket on TM-III, -IV, and -V. However, in particular, space-generating substitutions at position III:04 shifted the efficacy of the ligands from inverse agonism toward agonism, whereas similar substitutions at position III:08, one helical turn below, shifted the efficacy from agonism toward inverse agonism. It is suggested that the relative position of the ligand in the binding pocket between this "efficacy shift region" on TM-III and the opposing aromatic cluster on TM-VI and TM-VII leads either to agonism, i.e. in a superficial binding mode, or it leads to inverse agonism, i.e. in a more profound binding mode. This relationship between different binding modes and opposite efficacy is in accordance with the Global Toggle Switch model for 7TM receptor activation.	Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Univ Leipzig, Inst Biochem, Fac Biosci Pharm & Psychol, D-04103 Leipzig, Germany; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen; Leipzig University	Holst, B (corresponding author), Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	b.holst@molpharm.dk	Nygaard, Rie/B-7351-2013; Mokrosinski, Jacek/M-1963-2019; Brandt, Erik/AHI-7905-2022; Mokrosinski, Jacek/J-9506-2012	Mokrosinski, Jacek/0000-0001-5008-0457; Brandt, Erik/0000-0001-7051-0784; Mokrosinski, Jacek/0000-0003-1710-1679; Frimruer, Thomas/0000-0002-9682-8245; Holst, Birgitte/0000-0001-7432-097X; Schwartz, Thue W./0000-0002-0261-6904				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Behr B, 2006, J BIOL CHEM, V281, P18120, DOI 10.1074/jbc.M601791200; Buck E, 2005, P NATL ACAD SCI USA, V102, P2719, DOI 10.1073/pnas.0500016102; Buck E, 2005, J BIOL CHEM, V280, P4009, DOI 10.1074/jbc.C400500200; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; DEL CR, 2004, MOL PHARM, V66, P356; Elling CE, 2006, J BIOL CHEM, V281, P17337, DOI 10.1074/jbc.M512510200; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; HOFMANN KP, 1999, NOVART FDN SYMP, V224, P175; Hoist B, 2006, J CLIN INVEST, V116, P637, DOI 10.1172/JCI27999; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2005, MOL ENDOCRINOL, V19, P2400, DOI 10.1210/me.2005-0059; Holst B, 2006, MOL PHARMACOL, V70, P936, DOI 10.1124/mol.106.024422; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; Lang MJ, 2004, J MED CHEM, V47, P1153, DOI 10.1021/jm030982t; Lewis JW, 2000, BIOCHEMISTRY-US, V39, P599, DOI 10.1021/bi991860z; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Muccioli G, 1998, J ENDOCRINOL, V157, P99, DOI 10.1677/joe.0.1570099; Muccioli G, 2001, J ENDOCRINOL INVEST, V24, pRC7, DOI 10.1007/BF03343831; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pantel J, 2006, J CLIN INVEST, V116, P760, DOI 10.1172/JCI25303; Rueda M, 2007, P NATL ACAD SCI USA, V104, P796, DOI 10.1073/pnas.0605534104; Schwartz T.W., 2002, TXB RECEPTOR PHARM, P81; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shen CP, 2006, EUR J PHARMACOL, V531, P41, DOI 10.1016/j.ejphar.2005.12.026; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Wang HJ, 2004, J CLIN ENDOCR METAB, V89, P157, DOI 10.1210/jc.2003-031395	37	70	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15799	15811		10.1074/jbc.M609796200	http://dx.doi.org/10.1074/jbc.M609796200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17371869	hybrid			2022-12-25	WOS:000246589600055
J	Kim, MJ; Park, SH; Opella, SJ; Marsilje, TH; Michellys, PY; Seidel, HM; Tian, SS				Kim, Min-Ju; Park, Sang Ho; Opella, Stanley J.; Marsilje, Thomas H.; Michellys, Pierre-Yves; Seidel, H. Martin; Tian, Shin-Shay			NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; HIGH-RESOLUTION NMR; ERYTHROPOIETIN RECEPTOR; MEMBRANE-PROTEINS; DIPOLAR COUPLINGS; LIGAND; MEGAKARYOCYTOPOIESIS; OLIGOMERIZATION; DIMERIZATION; SENSITIVITY	Thrombopoietin (Tpo) is a glycoprotein growth factor that supports hematopoietic stem cell survival and expansion and is the principal regulator of megakaryocyte growth and differentiation. Several small, nonpeptidyl molecules have been identified as selective human Tpo receptor (hTpoR) agonists. To understand how the small molecule Tpo mimic SB394725 interacts and activates hTpoR, we performed receptor domain swap and mutagenesis studies. The results suggest that SB394725 interacts specifically with the extracellular juxtamembrane region (JMR) and the transmembrane (TM) domain of hTpoR. Solution and solid-state NMR structural studies using a peptide containing the JMR-TM sequences showed that this region of hTpoR, unexpectedly, consists of two alpha-helices separated by a few nonhelical residues. SB394725 interacts specifically with His-499 in the TM domain and a few distinct residues in the JMR-TM region and affects several specific C-terminal TM domain residues. The unique structural information provided by these studies both sheds light on the distinctive mechanism of action of SB394725 and provides valuable insight into the mechanism of ligand-induced cytokine receptor activation.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Novartis; University of California System; University of California San Diego	Tian, SS (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	stian@gnf.org	Park, Sang Ho/AAK-3432-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066978] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41 EB002031] Funding Source: Medline; NIGMS NIH HHS [R01 GM066978] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boger DL, 2001, BIOORGAN MED CHEM, V9, P557, DOI 10.1016/S0968-0896(00)00276-5; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; De Angelis AA, 2004, J AM CHEM SOC, V126, P15340, DOI 10.1021/ja045631y; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deng BJ, 1998, BLOOD, V92, P1981, DOI 10.1182/blood.V92.6.1981.418k15_1981_1988; Ding KY, 2003, J MAGN RESON, V163, P208, DOI 10.1016/S1090-7807(03)00081-8; Doyle ML, 2003, J BIOL CHEM, V278, P9426, DOI 10.1074/jbc.M209220200; Duffy KJ, 2001, J MED CHEM, V44, P3730, DOI 10.1021/jm010283l; Erickson-Miller CL, 2005, EXP HEMATOL, V33, P85, DOI 10.1016/j.exphem.2004.09.006; ERICKSONMILLER CL, 2004, AM SOC HEM 46 ANN M, V104, pA796; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; FASSI A, 1996, BLOOD, V88, P1399; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Ishii Y, 2001, J BIOMOL NMR, V21, P141, DOI 10.1023/A:1012417721455; Kaushansky K, 2002, ONCOGENE, V21, P3359, DOI 10.1038/sj.onc.1205323; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Kuter DJ, 2002, BLOOD, V100, P3457, DOI 10.1182/blood.V100.10.3457; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Lu XH, 2006, J BIOL CHEM, V281, P7002, DOI 10.1074/jbc.M512638200; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nakamura T, 2006, BLOOD, V107, P4300, DOI 10.1182/blood-2005-11-4433; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Park SH, 2005, J MOL BIOL, V350, P310, DOI 10.1016/j.jmb.2005.05.004; Park SH, 2003, J MOL BIOL, V333, P409, DOI 10.1016/j.jmb.2003.08.048; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; STAUBER DJ, 2003, HDB CELL SIGNALING, V1, P251	31	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14253	14261		10.1074/jbc.M611616200	http://dx.doi.org/10.1074/jbc.M611616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369254	hybrid			2022-12-25	WOS:000246245800036
J	Malmquist, NA; Baldwin, J; Phillips, MA				Malmquist, Nicholas A.; Baldwin, Jeffrey; Phillips, Margaret A.			Detergent-dependent kinetics of truncated Plasmodium falciparum dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDATE PHOSPHATASE-ACTIVITY; YEAST SACCHAROMYCES-CEREVISIAE; CRITICAL MICELLE CONCENTRATION; MALARIA PARASITE; TRITON X-100; PHOSPHATIDYLINOSITOL 4-KINASE; TITRATION CALORIMETRY; ESCHERICHIA-COLI; MIXED MICELLES; MEMBRANE	The survival of the malaria parasite Plasmodium falciparum is dependent upon the de novo biosynthesis of pyrimidines. P. falciparum dihydroorotate dehydrogenase ( PfDHODH) catalyzes the fourth step in this pathway in an FMN-dependent reaction. The full-length enzyme is associated with the inner mitochondrial membrane, where ubiquinone ( CoQ) serves as the terminal electron acceptor. The lipophilic nature of the co-substrate suggests that electron transfer to CoQ occurs at the two-dimensional lipid-solution interface. Here we show that PfDHODH associates with liposomes even in the absence of the N-terminal transmembrane-spanning domain. The association of a series of ubiquinone substrates with detergent micelles was studied by isothermal titration calorimetry, and the data reveal that CoQ analogs with long decyl ( CoQ(D)) or geranyl ( CoQ(2)) tails partition into detergent micelles, whereas that with a short prenyl tail ( CoQ(1)) remains in solution. PfDHODH-catalyzed reduction of CoQD and CoQ2, but not CoQ(1), is stimulated as detergent concentrations ( Tween 80 or Triton X-100) are increased up to their critical micelle concentrations, beyond which activity declines. Steady-state kinetic data acquired for the reaction with CoQ(D) and CoQ(2) in substrate-detergent mixed micelles fit well to a surface dilution kinetic model. In contrast, the data for CoQ(1) as a substrate were well described by solution steady-state kinetics. Our results suggest that the partitioning of lipophilic ubiquinone analogues into detergent micelles needs to be an important consideration in the kinetic analysis of enzymes that utilize these substrates.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	margaret.phillips@utsouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245	NIAID NIH HHS [R01 AI053680, R01-AI053680] Funding Source: Medline; NIGMS NIH HHS [T32-GM008203] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin J, 2005, J BIOL CHEM, V280, P21847, DOI 10.1074/jbc.M501100200; Baldwin J, 2002, J BIOL CHEM, V277, P41827, DOI 10.1074/jbc.M206854200; Boa AN, 2005, BIOORGAN MED CHEM, V13, P1945, DOI 10.1016/j.bmc.2005.01.017; Breman JG, 2001, AM J TROP MED HYG, V64, P1; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; de Macedo CS, 2002, FEMS MICROBIOL LETT, V207, P13, DOI 10.1111/j.1574-6968.2002.tb11021.x; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Deems RA, 2000, ANAL BIOCHEM, V287, P1, DOI 10.1006/abio.2000.4766; ENGEL WD, 1980, BIOCHIM BIOPHYS ACTA, V592, P211, DOI 10.1016/0005-2728(80)90182-6; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; Hansen M, 2004, PROTEIN SCI, V13, P1031, DOI 10.1110/ps.03533004; Heerklotz H, 1996, J PHYS CHEM-US, V100, P6764, DOI 10.1021/jp9523534; Heerklotz H, 2000, BIOPHYS J, V78, P2435, DOI 10.1016/S0006-3495(00)76787-7; Heerklotz H, 2000, BBA-BIOMEMBRANES, V1508, P69, DOI 10.1016/S0304-4157(00)00009-5; Heikkila T, 2006, BIOORG MED CHEM LETT, V16, P88, DOI 10.1016/j.bmcl.2005.09.045; Hurt DE, 2006, BIOORG MED CHEM LETT, V16, P1610, DOI 10.1016/j.bmcl.2005.12.029; Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Karibian D, 1978, Methods Enzymol, V51, P58; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nara T, 2000, GENE, V257, P209, DOI 10.1016/S0378-1119(00)00411-X; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; Norager S, 2002, STRUCTURE, V10, P1211, DOI 10.1016/S0969-2126(02)00831-6; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Rawls J, 2000, EUR J BIOCHEM, V267, P2079, DOI 10.1046/j.1432-1327.2000.01213.x; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; SEELIG J, 1991, BIOCHEMISTRY-US, V30, P9354, DOI 10.1021/bi00102a031; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Ullrich A, 2001, EUR J BIOCHEM, V268, P1861, DOI 10.1046/j.1432-1033.2001.02061.x; Vial HJ, 2003, MOL BIOCHEM PARASIT, V126, P143, DOI 10.1016/S0166-6851(02)00281-5; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	48	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12678	12686		10.1074/jbc.M609893200	http://dx.doi.org/10.1074/jbc.M609893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329250	hybrid			2022-12-25	WOS:000245942800037
J	Tsuiji, H; Xu, L; Schwartz, K; Gumbiner, BM				Tsuiji, Hitomi; Xu, Liang; Schwartz, Kathleen; Gumbiner, Barry M.			Cadherin conformations associated with dimerization and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; C-CADHERIN; N-CADHERIN; MORPHOGENESIS; EXPRESSION; CALCIUM; HOMOASSOCIATION; ECTODOMAIN; INTERFACE; MECHANISM	To investigate conformations of C-cadherin associated with functional activity and physiological regulation, we generated monoclonal antibodies (mAbs) that bind differentially to monomeric or dimeric forms. These mAbs recognize conformational epitopes at multiple sites along the C-cadherin ectodomain aside from the well known Trp-2-mediated dimer interface in the N-terminal EC1 domain. Group 1 mAbs, which bind monomer better than dimer and the Trp-2-mutated protein (W2A) better than wild type, recognize epitopes in EC4 or EC5. Dimerization of the W2A mutant protein via a C-terminal immunoglobulin Fc domain restored the dimeric mAb-binding properties to EC4-5 and partial homophilic binding activity but did not restore full cell adhesion activity. Group 2 and Group 3 mAbs, which bind dimer better than monomer and wild type better than W2A, recognize epitopes in EC1 and the interface between EC1 and EC2, respectively. None of the mAbs could distinguish between different physiological states of C-cadherin at the cell surface of either Xenopus embryonic cells or Colo 205 cultured cells, demonstrating that changes in dimerization do not underlie regulation of adhesion activity. On the cell surface the EC3-EC5 domains are much less accessible to mAb binding than EC1 EC2, suggesting that they are masked by the state of cadherin organization or by other molecules. Thus, the EC2-EC5 domains either reflect, or are involved in, cadherin dimerization and organization at the cell surface.	Univ Virginia, Dept Cell Biol, Sch Med, Charlottesville, VA 22903 USA	University of Virginia	Gumbiner, BM (corresponding author), Univ Virginia, Dept Cell Biol, Sch Med, 1300 Jefferson Pk Ave, Charlottesville, VA 22903 USA.	gumbiner@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052717] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Birely J, 2005, DEV BIOL, V280, P162, DOI 10.1016/j.ydbio.2005.01.012; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DU XP, 1993, J BIOL CHEM, V268, P23087; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Harrison OJ, 2005, J CELL SCI, V118, P711, DOI 10.1242/jcs.01665; Haussinger D, 2004, EMBO J, V23, P1699, DOI 10.1038/sj.emboj.7600192; Haussinger D, 2002, J MOL BIOL, V324, P823, DOI 10.1016/S0022-2836(02)01137-3; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Leckband D, 2006, ANNU REV BIOMED ENG, V8, P259, DOI 10.1146/annurev.bioeng.8.061505.095753; Masai I, 2003, DEVELOPMENT, V130, P2479, DOI 10.1242/dev.00465; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P237; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351	36	19	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12871	12882		10.1074/jbc.M611725200	http://dx.doi.org/10.1074/jbc.M611725200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347145	hybrid			2022-12-25	WOS:000245942800059
J	Wada, T; Hata, K; Yamaguchi, K; Shiozaki, K; Koseki, K; Moriya, S; Miyagi, T				Wada, T.; Hata, K.; Yamaguchi, K.; Shiozaki, K.; Koseki, K.; Moriya, S.; Miyagi, T.			A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells	ONCOGENE			English	Article						sialidase; apoptosis; cancer; gangliosides; Ras; EGFR	GROWTH-FACTOR RECEPTOR; GANGLIOSIDE SIALIDASE; MOLECULAR-CLONING; GM3; GLYCOSYLATION; EXPRESSION; PHOSPHORYLATION; APOPTOSIS; NEU3; OVEREXPRESSION	Human plasma membrane-associated sialidase (NEU3), a key enzyme for ganglioside degradation, is markedly upregulated in human cancers, leading to apoptosis suppression. To de. ne molecular mechanisms and the possible target for NEU3, its encoding gene was silenced by small interference RNA (siRNA) or overexpressed in human cells. NEU3 siRNA-induced apoptosis with no special stimuli in HeLa cells, accompanied with decreased Bcl-xL and increased mda7 and GM3 synthase mRNA levels, whereas overexpression resulted in the opposite. Carcinoma HT-29 and MCF-7 cells appeared to be similarly affected, but normal cell lines demonstrated no significant changes. NEU3 siRNA was found to inhibit and NEU3 overexpression to stimulate Ras activation with consequent influence on extracellular signal-regulated kinases and Akt. Ras activation by NEU3 was abrogated by PP2 (src inhibitor) or AG1478 (epidermal growth factor receptor (EGFR) inhibitor), and NEU3 actually enhanced EGF-stimulated tyrosine-phosphorylation of EGFR, suggesting that the upstream targets might be tyrosine kinases including src and EGFR, and the subsequent stimulation of Ras cascade leads to the inhibition of cell apoptosis. Glycolipid changes observed seemed to be one of the causes of the cell effects. NEU3 may thus be an essential gene for cancer cell survival and siRNAs targeting this protein could have utility for gene-based therapy of human cancers.	Miyagi Canc Ctr, Inst Res, Div Biochem, Natori, Miyagi 9811293, Japan	Miyagi Cancer Center	Miyagi, T (corresponding author), Miyagi Canc Ctr, Inst Res, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Shiozaki, Kazuhiro/0000-0002-0523-838X				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; LI K, 1992, J CHROMATOGR-BIOMED, V579, P209, DOI 10.1016/0378-4347(92)80384-3; MACALA LJ, 1983, J LIPID RES, V24, P1243; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; Miura Y, 2004, P NATL ACAD SCI USA, V101, P16204, DOI 10.1073/pnas.0407297101; Miyagi T, 2004, TRENDS GLYCOSCI GLYC, V16, P371, DOI 10.4052/tigg.16.371; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; Sohn H, 2006, FASEB J, V20, P1248, DOI 10.1096/fj.05-4911fje; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Watanabe R, 2002, CANCER RES, V62, P3850; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017	35	81	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2483	2490		10.1038/sj.onc.1210341	http://dx.doi.org/10.1038/sj.onc.1210341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17334392				2022-12-25	WOS:000245831000008
J	Morgan, MJ; McEwan, W; Solomon, J				Morgan, Michael J.; McEwan, William; Solomon, Joshua			The Lingering Effects of an Artificial Blind Spot	PLOS ONE			English	Article								Background. When steady fixation is maintained on the centre of a large patch of texture, holes in the periphery of the texture rapidly fade from awareness, producing artificial scotomata (i.e., invisible areas of reduced vision, like the natural 'blind spot'). There has been considerable controversy about whether this apparent 'filling in' depends on a low-level or high-level visual process. Evidence for an active process is that when the texture around the scotomata is suddenly removed, phantasms of the texture appear within the previous scotomata. Methodology. To see if these phantasms were equivalent to real low-level signals, we measured contrast discrimination for real dynamic texture patches presented on top of the phantasms. Principal Findings. Phantasm intensity varied with adapting contrast. Contrast discrimination depended on both (real) pedestal contrast and phantasm intensity, in a manner indicative of a common sensory threshold. The phantasms showed inter-ocular transfer, proving that their effects are cortical rather than retinal. Conclusions. We show that this effect is consistent with a tonic spreading of the adapting texture into the scotomata, coupled with some overall loss of sensitivity. Our results support the view that 'filling in' happens at an early stage of visual processing, quite possibly in primary visual cortex (V1).	[Morgan, Michael J.; McEwan, William; Solomon, Joshua] City Univ London, Dept Optometry & Visual Sci, Henry Wellcome Vis Labs, London, England	City University London	Morgan, MJ (corresponding author), City Univ London, Dept Optometry & Visual Sci, Henry Wellcome Vis Labs, London, England.	m.morgan@city.ac.uk		McEwan, William/0000-0002-4408-0407	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The Wellcome Trust (UK registered charity)	BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; Boynton GM, 1999, VISION RES, V39, P257, DOI 10.1016/S0042-6989(98)00113-8; BRADLEY A, 1988, VISION RES, V28, P841, DOI 10.1016/0042-6989(88)90031-4; CAMPBELL FW, 1966, J PHYSIOL-LONDON, V187, P437, DOI 10.1113/jphysiol.1966.sp008101; DEWEERD P, 1995, NATURE, V377, P731, DOI 10.1038/377731a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Kohn A, 2003, NEURON, V39, P681, DOI 10.1016/S0896-6273(03)00438-0; LEGGE GE, 1987, J OPT SOC AM A, V4, P391, DOI 10.1364/JOSAA.4.000391; Lou LG, 1999, PERCEPTION, V28, P519, DOI 10.1068/p2816; NACHMIAS J, 1974, VISION RES, V14, P1039, DOI 10.1016/0042-6989(74)90175-8; PELLI DG, 1985, J OPT SOC AM A, V2, P1508, DOI 10.1364/JOSAA.2.001508; Pessoa L, 1998, BEHAV BRAIN SCI, V21, P723; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; Reich LN, 2000, VISION RES, V40, P805, DOI 10.1016/S0042-6989(99)00215-1; TROXLER D, 1804, OPHTHALMOLOGISCHES B, V2, P51	15	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e256	10.1371/journal.pone.0000256	http://dx.doi.org/10.1371/journal.pone.0000256			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327917	gold, Green Submitted, Green Published, Green Accepted			2022-12-25	WOS:000207444600016
J	Zhang, GC; Assadi, AH; McNeil, RS; Beffert, U; Wynshaw-Boris, A; Herz, J; Clark, GD; D'Arcangelo, G				Zhang, Guangcheng; Assadi, Amir H.; McNeil, Robert S.; Beffert, Uwe; Wynshaw-Boris, Anthony; Herz, Joachim; Clark, Gary D.; D'Arcangelo, Gabriella			The Pafah1b Complex Interacts with the Reelin Receptor VLDLR	PLOS ONE			English	Article								Reelin is an extracellular protein that directs the organization of cortical structures of the brain through the activation of two receptors, the very low-density lipoprotein receptor (VLDLR) and the apolipoprotein E receptor 2 (ApoER2), and the phosphorylation of Disabled-1 (Dab1). Lis1, the product of the Pafah1b1 gene, is a component of the brain platelet-activating factor acetylhydrolase 1b (Pafah1b) complex, and binds to phosphorylated Dab1 in response to Reelin. Here we investigated the involvement of the whole Pafah1b complex in Reelin signaling and cortical layer formation and found that catalytic subunits of the Pafah1b complex, Pafah1b2 and Pafah1b3, specifically bind to the NPxYL sequence of VLDLR, but not to ApoER2. Compound Pafah1b1(+/-); Apoer2(-/-) mutant mice exhibit a reeler-like phenotype in the forebrain consisting of the inversion of cortical layers and hippocampal disorganization, whereas double Pafah1b1(+/-); Vldlr(-/-) mutants do not. These results suggest that a cross-talk between the Pafah1b complex and Reelin occurs downstream of the VLDLR receptor.	[Zhang, Guangcheng; Assadi, Amir H.; McNeil, Robert S.; Clark, Gary D.; D'Arcangelo, Gabriella] Texas Childrens Hosp, Cain Fdn Labs, Houston, TX 77030 USA; [Zhang, Guangcheng; Assadi, Amir H.; McNeil, Robert S.; Clark, Gary D.; D'Arcangelo, Gabriella] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Clark, Gary D.; D'Arcangelo, Gabriella] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Clark, Gary D.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [D'Arcangelo, Gabriella] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [D'Arcangelo, Gabriella] Baylor Coll Med, Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Beffert, Uwe; Herz, Joachim] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [Wynshaw-Boris, Anthony] Univ Calif San Diego, Sch Med, Dept Pediat & Med, La Jolla, CA 92093 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	D'Arcangelo, G (corresponding author), Texas Childrens Hosp, Cain Fdn Labs, Houston, TX 77030 USA.	gangelo@bcm.tmc.edu		D'Arcangelo, Gabriella/0000-0003-1575-1010	National Institute of Disorders and Stroke/NIH [R01 NS042616]; NIH [HL20948, HL63762, NS43408]; Perot Family Foundation; Humboldt Foundation; Mental Retardation and Developmental Disabilities Research Center (MRDDRC); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408, R01NS042616] Funding Source: NIH RePORTER	National Institute of Disorders and Stroke/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Perot Family Foundation; Humboldt Foundation(Alexander von Humboldt Foundation); Mental Retardation and Developmental Disabilities Research Center (MRDDRC); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by a grant from the National Institute of Disorders and Stroke/NIH R01 NS042616 (G.D.), NIH grants HL20948, HL63762, NS43408, the Perot Family Foundation and the Humboldt Foundation (J.H.) and by the Mental Retardation and Developmental Disabilities Research Center (MRDDRC) at Baylor College of Medicine.	Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Andersen OM, 2003, J BIOL CHEM, V278, P23989, DOI 10.1074/jbc.M302157200; Assadi AH, 2003, NAT GENET, V35, P270, DOI 10.1038/ng1257; Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Benhayon D, 2003, MOL BRAIN RES, V112, P33, DOI 10.1016/S0169-328X(03)00032-9; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Boycott KM, 2005, AM J HUM GENET, V77, P477, DOI 10.1086/444400; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 2005, INT REV NEUROBIOL, P383; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Gambello MJ, 2003, J NEUROSCI, V23, P1719; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Huang YC, 2004, BIOCHEM BIOPH RES CO, V318, P204, DOI 10.1016/j.bbrc.2004.04.023; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Koizumi H, 2003, J BIOL CHEM, V278, P12489, DOI 10.1074/jbc.M211836200; Kuo G, 2005, J NEUROSCI, V25, P8578, DOI 10.1523/JNEUROSCI.1656-05.2005; Niu S, 2004, NEURON, V41, P71, DOI 10.1016/S0896-6273(03)00819-5; Nothwang HG, 2001, HUM MOL GENET, V10, P797, DOI 10.1093/hmg/10.8.797; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tsai JW, 2005, J CELL BIOL, V170, P935, DOI 10.1083/jcb.200505166; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Yan W, 2003, P NATL ACAD SCI USA, V100, P7189, DOI 10.1073/pnas.1236145100	42	36	40	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e252	10.1371/journal.pone.0000252	http://dx.doi.org/10.1371/journal.pone.0000252			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330141	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444600012
J	Kamimura, K; Mishima, Y; Obata, M; Endo, T; Aoyagi, Y; Kominami, R				Kamimura, K.; Mishima, Y.; Obata, M.; Endo, T.; Aoyagi, Y.; Kominami, R.			Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages	ONCOGENE			English	Article						DNA replication stress; Chk1; p27; apoptosis; Bcl11b tumor suppressor	CELL-DEATH; TRANSCRIPTIONAL REPRESSION; CHECKPOINT KINASE-1; THYMIC LYMPHOMAS; T-LYMPHOCYTES; GENE; MICE; CHK1; PATHWAY; MOUSE	Bcl11b/Rit1 is involved in T-cell development and undergoes chromosomal rearrangements in human T-cell leukemias. Thymocytes of Bcl11b(-/-) newborn mice exhibit apoptosis at a certain developmental stage when thymocytes re-enter into the cell-cycle. Here, we show that Bcl11b-knockdown T-cell lines, when exposed to growth stimuli, exhibited a poptosis at the S phase with concomitant decreases in a cell-cycle inhibitor, p27 and an antiapoptotic protein, Bcl-xL, owing to transcriptional repression. This repression was a likely consequence of the impairment of Sirt1, a nicotinamide adenine dinucleotide-dependent deacetylase associating with Bcl11b. Activation of the apoptotic process cleaved the mediator protein, Claspin, and inhibited phosphorylation of cell-cycle checkpoint kinase 1 ( Chk1) that plays a central role in sensing and responding to incomplete replication. Bcl11b(-/-) thymocytes also failed to phosphorylate Chk1 when UV irradiated. These results implicate Bcl11b in the remedy for DNA replication stress and maintenance of genomic integrity.	Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; Niigata Univ, Ctr Trandisciplinary Res, Niigata 9518510, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Asahimachi 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019					Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Clarke CAL, 2005, J BIOL CHEM, V280, P35337, DOI 10.1074/jbc.M506460200; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Eguchi-Ishimae M, 2001, BLOOD, V97, P737, DOI 10.1182/blood.V97.3.737; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagel S, 2003, CANCER RES, V63, P5329; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Takai H, 2000, GENE DEV, V14, P1439; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5840	5850		10.1038/sj.onc.1210388	http://dx.doi.org/10.1038/sj.onc.1210388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369851				2022-12-25	WOS:000249123100002
J	Matsumoto, S; Iwakawa, R; Takahashi, K; Kohno, T; Nakanishi, Y; Matsuno, Y; Suzuki, K; Nakamoto, M; Shimizu, E; Minna, JD; Yokota, J				Matsumoto, S.; Iwakawa, R.; Takahashi, K.; Kohno, T.; Nakanishi, Y.; Matsuno, Y.; Suzuki, K.; Nakamoto, M.; Shimizu, E.; Minna, J. D.; Yokota, J.			Prevalence and specificity of LKB1 genetic alterations in lung cancers	ONCOGENE			English	Article						LKB1; lung cancer mutation; deletion; smoking; poor differentiation	PEUTZ-JEGHERS-SYNDROME; FREQUENT EGFR MUTATIONS; SOMATIC MUTATIONS; TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; LKB1/STK11; STK11/LKB1; CARCINOMA; INDUCTION; DELETIONS	Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma ( AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines ( 21/70, 30%), especially in non-small cell lung cancers ( NSCLCs) ( 20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven ( 8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 1040045, Japan; Natl Canc Ctr, Diagnost Pathol Div, Tokyo, Japan; Natl Canc Ctr, Thorac Surg Div, Tokyo, Japan; Tottori Univ, Fac Med, Div Med Oncol & Mol Respirol, Tottori 680, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp			NCI NIH HHS [P50 CA 70907, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Bignell GR, 1998, CANCER RES, V58, P1384; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Fujita T, 1999, INT J ONCOL, V15, P927; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; GUDLBERG P, 1999, ONCOGENE, V18, P1777; Hearle NCM, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-38; Hearle NCM, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036830; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kishimoto M, 2005, CLIN CANCER RES, V11, P512; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Matsumoto S, 2006, INT J CANCER, V118, P2498, DOI 10.1002/ijc.21670; Matsumoto S, 2006, INT J CANCER, V119, P1491, DOI 10.1002/ijc.21940; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Upadhyay S, 2006, CANCER RES, V66, P7870, DOI 10.1158/0008-5472.CAN-05-2902; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Zhong DS, 2006, LUNG CANCER, V53, P285, DOI 10.1016/j.lungcan.2006.05.018	31	209	225	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5911	5918		10.1038/sj.onc.1210418	http://dx.doi.org/10.1038/sj.onc.1210418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384680	Green Accepted			2022-12-25	WOS:000249123100008
J	Miquel, C; Jacob, S; Grandjouan, S; Aime, A; Viguier, J; Sabourin, JC; Sarasin, A; Duval, A; Praz, F				Miquel, C.; Jacob, S.; Grandjouan, S.; Aime, A.; Viguier, J.; Sabourin, J-C; Sarasin, A.; Duval, A.; Praz, F.			Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability	ONCOGENE			English	Article						colorectal cancer; MSI phenotype; DNA repair; DNA damage signalling; chemotherapy	MONONUCLEOTIDE REPEATS; DEFICIENT CANCERS; MRE11 EXPRESSION; TARGET GENES; MUTATIONS; SEQUENCES; CARCINOGENESIS; PATHOGENESIS	Accumulation of frameshift mutations at genes containing coding mononucleotide repeats is thought to be the major molecular mechanism by which mismatch repair-deficient cells accumulate functional alterations. These mutations resulting from microsatellite instability ( MSI) can affect genes involved in pathways with a putative oncogenic role, but may also arise in genes without any expected role in MSI carcinogenesis because of the high mutation background of these tumours. We here screened 39 MSI colorectal tumours for the presence of mutations in 25 genes involved in DNA damage signalling and repair pathways. Using a maximum likelihood statistical method, these genes were divided into two different groups that differed significantly in their mutation frequencies, and likely represent mutations that do or do not provide selective pressure during MSI tumour progression. Interestingly, the so-called real-target mutational events were found to be distributed among genes involved in different functional pathways of the DNA metabolism, for example, DNA damage signalling ( DNA-PKcs, ATR), double-strand break ( DSB) repair ( DNA-PKcs, RAD50), mismatch repair ( MSH3, MSH6, MBD4) and replication ( POLD3). In particular, mutations in MRE11 and/or RAD50 were observed in the vast majority of the tumours and resulted in the concomitant loss of immunohistochemical expression of both proteins. These data might explain why MSI colorectal cancers ( CRC) behave differently in response to a wide variety of chemotherapeutic agents, notably those targeting DNA. More generally, they give further insights into how MSI leads to functional changes with synergistic effects in oncogenic pathways.	Univ Paris 06, U762, INSERM, CEPH, F-75010 Paris, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France; Hop Cochin, Serv Oncogenet Digest, F-75674 Paris, France; CNRS Genet Instabil & Canc, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Praz, F (corresponding author), Univ Paris 06, U762, INSERM, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.	praz@cephb.fr	miquel, catherine/B-5536-2013; PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Fallik D, 2003, CANCER RES, V63, P5738; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Li HR, 2004, CANCER RES, V64, P4760, DOI 10.1158/0008-5472.CAN-04-0975; Mori Y, 2001, CANCER RES, V61, P6046; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Suzuki K, 2002, CANCER RES, V62, P1961; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yanamadala S, 2003, MOL CANCER RES, V1, P747	22	94	96	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5919	5926		10.1038/sj.onc.1210419	http://dx.doi.org/10.1038/sj.onc.1210419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384679				2022-12-25	WOS:000249123100009
J	Dahl, E; Wiesmann, F; Woenckhaus, M; Stoehr, R; Wild, PJ; Veeck, J; Knuechell, R; Klopocki, E; Sauter, G; Simon, R; Wieland, WF; Walter, B; Denzinger, S; Hartmann, A; Hammerschmied, CG				Dahl, E.; Wiesmann, F.; Woenckhaus, M.; Stoehr, R.; Wild, P. J.; Veeck, J.; Knuechell, R.; Klopocki, E.; Sauter, G.; Simon, R.; Wieland, W. F.; Walter, B.; Denzinger, S.; Hartmann, A.; Hammerschmied, C. G.			Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma	ONCOGENE			English	Article						loss of SFRP1 in human tumours; renal cell carcinoma; tumour suppressor gene; Wnt pathway; SFRP1 methylation; tissue microarray	WNT ANTAGONIST SFRP1; BETA-CATENIN; EPIGENETIC INACTIVATION; BREAST-CANCER; GENES; TARGET; IDENTIFICATION; NONPAPILLARY; PROGRESSION; SUPPRESSOR	Oncogenic wingless-related mouse mammary tumour virus (Wnt) signalling, caused by epigenetic inactivation of specific pathway regulators like the putative tumour suppressor secreted frizzled-related protein 1 (SFRP1), may be causally involved in the carcinogenesis of many human solid tumours including breast, colon and kidney cancer. To evaluate the incidence of SFRP1 deficiency in human tumours, we performed a large-scale SFRP1 expression analysis using immunohistochemistry on a comprehensive tissue microarray (TMA) comprising 3448 tumours from 36 organs. This TMA contained 132 different tumour subtypes as well as 26 different normal tissues. Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours. We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis. Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours. We performed expression, mutation and methylation analysis in RCC and their matching normal kidney tissues. SFRP1 promoter methylation was frequently found in RCC (68%, n=38) and was correlated with loss of SFRP1 mRNA expression ( p < 0.05). Although loss of heterozygosity was found in 16% of RCC, structural mutations in the coding or promoter region of the SFRP1 gene were not observed. Our results indicate that loss of SFRP1 expression is a very common event in human cancer, arguing for a fundamental role of aberrant Wnt signalling in the development of solid tumours. In RCC, promoter hypermethylation seems to be the predominant mechanism of SFRP1 gene silencing and may contribute to initiation and progression of this disease.	Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany; Univ Regensburg, Dept Urol, D-8400 Regensburg, Germany; Univ Zurich, Inst Pathol, Zurich, Switzerland; Univ Med Berlin, Charite, Inst Med Genet, Berlin, Germany; Univ Hamburg Hosp, Inst Pathol, D-2000 Hamburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; University of Regensburg; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Klopocki, Eva/B-6823-2017; Veeck, Jürgen/B-9256-2008; Stoehr, Christine/N-6637-2018; Stoehr, Robert/D-7504-2011	Klopocki, Eva/0000-0003-1438-2081; Veeck, Jürgen/0000-0002-2952-6159; Stoehr, Christine/0000-0001-7501-4886; 				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bohm M, 1997, UROL RES, V25, P161; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoei-Hansen CE, 2004, MOL HUM REPROD, V10, P423, DOI 10.1093/molehr/gah059; HUGHSON MD, 1993, MODERN PATHOL, V6, P449; Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098; Kim YS, 2000, PATHOL INT, V50, P725, DOI 10.1046/j.1440-1827.2000.01111.x; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Li CH, 2006, J DENT RES, V85, P374, DOI 10.1177/154405910608500418; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; MANCILLAJIMENEZ R, 1976, CANCER, V38, P2469, DOI 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; ORTMANN M, 1991, VIRCHOWS ARCH B, V61, P123; Presti JC, 2002, J UROLOGY, V167, P1464, DOI 10.1016/S0022-5347(05)65346-3; Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987; SCHLEGEL J, 1995, VIRCHOWS ARCH, V426, P223; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; STORKEL S, 1989, VIRCHOWS ARCH B, V56, P237; Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Watanabe H, 2006, PANCREAS, V32, P382, DOI 10.1097/01.mpa.0000221617.89376.38; Zafrakas M, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-88; ZANG T, 2000, CHINESE SCI BULL, V45, P1703; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	112	118	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5680	5691		10.1038/sj.onc.1210345	http://dx.doi.org/10.1038/sj.onc.1210345			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353908				2022-12-25	WOS:000248801900015
J	Marzec, M; Kasprzycka, M; Liu, X; El-Salem, M; Halasa, K; Raghunath, PN; Bucki, R; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; El-Salem, M.; Halasa, K.; Raghunath, P. N.; Bucki, R.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); mammalian target of rapamycin (mTOR); mitogen-activated protein kinase pathway (MAPK); protein kinase B (PKB/Akt)	TRANSFORMED B-LYMPHOCYTES; NON-HODGKINS-LYMPHOMA; T-CELL LYMPHOMA; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; ANAPLASTIC LYMPHOMA; S6 KINASE; MEDIATED LYMPHOMAGENESIS; AMINO-ACIDS; IN-VITRO	The mechanisms of cell transformation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are only partially understood. Here, we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma display persistent activation of mammalian target of rapamycin ( mTOR) as determined by phosphorylation of mTOR targets S6rp and 4E-binding protein 1 (4E-BP1). The mTOR activation is serum growth factor-independent but nutrient-dependent. It is also dependent on the expression and enzymatic activity of NPM/ALK as demonstrated by cell transfection with wild-type and functionally deficient NPM/ALK, small interfering RNA (siRNA)-mediated NPM/ALK depletion and kinase activity suppression using the inhibitor WHI-P154. The NPM/ALK-induced mTOR activation is transduced through the mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway and, to a much lesser degree, through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway. Accordingly, whereas the low-dose PI3K inhibitor wortmannin and Akt inhibitor III profoundly inhibited Akt phosphorylation, they had a very modest effect on S6rp and 4E-BP1 phosphorylation. In turn, MEK inhibitors U0126 and PD98059 and siRNA-mediated depletion of either ERK1 or ERK2 inhibited S6rp phosphorylation much more effectively. Finally, the mTOR inhibitor rapamycin markedly decreased proliferation and increased the apoptotic rate of ALK+TCL cells. These findings identify mTOR as a novel key target of NPM/ALK and suggest that mTOR inhibitors may prove effective in therapy of ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Bucki, Robert/0000-0001-7664-9226; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01 CA96856] Funding Source: Medline; NIDCR NIH HHS [R01-DE-017337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19; Majewski M, 2000, P NATL ACAD SCI USA, V97, P4285, DOI 10.1073/pnas.080068597; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sekulic A, 2000, CANCER RES, V60, P3504; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018; WASIK MA, 2002, J CLIN PATHOL S, V118, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	41	76	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5606	5614		10.1038/sj.onc.1210346	http://dx.doi.org/10.1038/sj.onc.1210346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353907				2022-12-25	WOS:000248801900006
J	Gershon, E; Hourvitz, A; Reikhav, S; Maman, E; Dekel, N				Gershon, Eran; Hourvitz, Ariel; Reikhav, Sharon; Maman, Ettie; Dekel, Nava			Low expression of COX-2, reduced cumulus expansion, and impaired ovulation in SULT1E1-deficient mice	FASEB JOURNAL			English	Article						estrogen sulfotransferase; cyclooxygenase-2	HUMAN CHORIONIC-GONADOTROPIN; MESSENGER-RIBONUCLEIC-ACID; ESTROGEN-RECEPTOR-BETA; GENE-EXPRESSION; PREOVULATORY FOLLICLES; GRANULOSA-CELLS; CYTOSOLIC SULFOTRANSFERASES; STEROID SULFOTRANSFERASES; TARGETED DISRUPTION; MENSTRUAL-CYCLE	The SULT1E1-encoded estrogen sulfotransferase ( EST) catalyzes sulfation of estrogen, resulting in its inactivation. Reduced fertility observed in SULT1E1 knockout ( KO) female mice has previously been attributed to the deleterious effect of chronic exposure to high levels of circulating estrogen on placental function. We herein suggest that, in addition to placental dysfunction, this phenotype demonstrates that an excess of estrogen impairs ovulation. The role of SULT1E1 in ovulation is suggested by the substantially low ovulatory response in hCG- treated SULT1E1 KO mice; a similar effect was observed when 17 beta-estradiol was administered to wild-type (WT) females. The normal rate of ovulation in SULT1E1 KO females may be restored by PGE2. Along this line, ovaries of human Chorionic Gonadotropin (hCG)-treated SULT1E1 KO mice expressed low levels of cyclooxygenase-2 (COX- 2) and its downstream TSG6; moreover, their ovaries contained a reduced number of expanded cumuli. Our results demonstrate, for the first time, that estrogen inactivation may allow the expression of COX- 2 and subsequent cumulus expansion, enabling normal ovulation. Our findings may be applied to novel treatments of human ovulatory failure.-Gershon, E., Hourvitz, A., Reikhav, S., Maman, E., Dekel, N. Low expression of COX- 2, reduced cumulus expansion, and impaired ovulation in SULT1E1- deficient mice.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Obstet & Gynecol, In Vitro Fertilizat Unit, Ramat Gan, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center	Dekel, N (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, POB 26, IL-76100 Rehovot, Israel.	nava.dekel@weizmann.ac.il	DEKEL, NAVA/R-8817-2019		NICHD NIH HHS [HD 4276] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JB, 1991, BIOCHIM BIOPHYS ACTA, V1076, P282, DOI 10.1016/0167-4838(91)90279-9; Breivik K, 2002, SCI TOTAL ENVIRON, V290, P181, DOI 10.1016/S0048-9697(01)01075-0; Brown KA, 2006, ENDOCRINOLOGY, V147, P4222, DOI 10.1210/en.2006-0420; BUIRCHELL BJ, 1975, J STEROID BIOCHEM, V6, P1489, DOI 10.1016/0022-4731(75)90202-2; Coughtrie M. W. H., 2002, Pharmacogenomics Journal, V2, P297; Dallinga JW, 2002, HUM REPROD, V17, P1973, DOI 10.1093/humrep/17.8.1973; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Espey LL, 2000, BIOL REPROD, V62, P390, DOI 10.1095/biolreprod62.2.390; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; Falany CN, 1997, FASEB J, V11, P1; Falany JL, 1996, CANCER RES, V56, P1551; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P2581, DOI 10.1210/en.140.6.2581; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Gaytan F, 2003, BIOL REPROD, V69, P99, DOI 10.1095/biolreprod.102.013755; Hernandez-Gonzalez I, 2006, MOL ENDOCRINOL, V20, P1300, DOI 10.1210/me.2005-0420; Hertrampf T, 2005, MOL CELL ENDOCRINOL, V243, P51, DOI 10.1016/j.mce.2005.08.007; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; HOBKIRK R, 1983, BIOCHEM J, V216, P451, DOI 10.1042/bj2160451; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; HORI T, 1970, ENDOCRINOL JAPON, V17, P489; Hourvitz A, 2006, J ENDOCRINOL, V188, P531, DOI 10.1677/joe.1.06231; Jefferson WN, 2000, BIOL REPROD, V62, P310, DOI 10.1095/biolreprod62.2.310; Jo MS, 2004, ENDOCRINOLOGY, V145, P5384, DOI 10.1210/en.2004-0407; KATZ Y, 1976, ENDOCRINOLOGY, V99, P1442, DOI 10.1210/endo-99-6-1442; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Luu-The V, 2005, J STEROID BIOCHEM, V93, P269, DOI 10.1016/j.jsbmb.2005.01.003; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; Qian YM, 1999, ENDOCRINOLOGY, V140, P1048, DOI 10.1210/en.140.3.1048; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Richards JS, 2005, MOL CELL ENDOCRINOL, V234, P75, DOI 10.1016/j.mce.2005.01.004; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Rosselli M, 2000, HUM REPROD UPDATE, V6, P332, DOI 10.1093/humupd/6.4.332; Rubin GL, 1999, MOL HUM REPROD, V5, P995, DOI 10.1093/molehr/5.11.995; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Schirman-Hildesheim TD, 2005, ENDOCRINOLOGY, V146, P3401, DOI 10.1210/en.2005-0240; SINGER SS, 1976, ENDOCRINOLOGY, V99, P1346, DOI 10.1210/endo-99-5-1346; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Song WC, 1997, ENDOCRINOLOGY, V138, P5006, DOI 10.1210/en.138.11.5006; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Spano M, 2005, HUM REPROD, V20, P3488, DOI 10.1093/humrep/dei297; Takehara K, 2001, ARCH BIOCHEM BIOPHYS, V394, P201, DOI 10.1006/abbi.2001.2545; Tong MH, 2005, NAT MED, V11, P153, DOI 10.1038/nm1184; Tong MH, 2004, ENDOCRINOLOGY, V145, P2487, DOI 10.1210/en.2003-1237; Tong MH, 2002, ENDOCRINOLOGY, V143, P3144, DOI 10.1210/en.143.8.3144	49	35	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1893	1901		10.1096/fj.06-7688com	http://dx.doi.org/10.1096/fj.06-7688com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341680				2022-12-25	WOS:000246866500030
J	Klinge, L; Laval, S; Keers, S; Haldane, F; Straub, V; Barresi, R; Bushby, K				Klinge, Lars; Laval, Steve; Keers, Sharon; Haldane, Faye; Straub, Volker; Barresi, Rita; Bushby, Kate			From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis	FASEB JOURNAL			English	Article						membrane repair; muscular dystrophy; T-tubulogenesis	GIRDLE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MEMBRANE REPAIR; TRANSVERSE TUBULES; MIYOSHI MYOPATHY; SYSTEM FORMATION; CAVEOLIN-3; PROTEIN; CELLS; GENE	The dysferlin gene is mutated in limb-girdle muscular dystrophy type 2B, Miyoshi myopathy, and distal anterior compartment myopathy. In mature skeletal muscle, dysferlin is located predominantly at the sarcolemma, where it plays a role in membrane fusion and repair. To investigate the role of dysferlin during early muscle differentiation, its localization was studied at high resolution in a muscle cell line. This demonstrated that dysferlin is not expressed at the plasmalemma of myotubes but mostly localizes to the T-tubule network. However, dysferlin translocated to the site of injury and toward the plasma membrane in a Ca2+- dependent fashion in response to a newly designed in vitro wounding assay. This reaction was specific to the full-length protein, as heterologously expressed deletion mutants of distinct C2 domains of dysferlin did not show this response. These results shed light on the dynamics of muscle membrane repair and are highly indicative of a specific role of dysferlin in this process in early myogenesis.-Klinge, L., Laval, S., Keers, S., Haldane, F., Straub, V., Barresi, R., Bushby, K. From T- tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis.	Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	Newcastle University - UK	Bushby, K (corresponding author), Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Ctr Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	kate.bushby@ncl.ac.uk	Barresi, Rita/AAB-9569-2022	Barresi, Rita/0000-0001-7351-959X; Straub, Volker/0000-0001-9046-3540				Achanzar WE, 1997, J CELL SCI, V110, P1073; Ampong Beryl N, 2005, Acta Myol, V24, P134; Anderson LVB, 2000, NEUROMUSCULAR DISORD, V10, P553, DOI 10.1016/S0960-8966(00)00143-7; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bushby KMD, 2000, ACTA NEUROL BELG, V100, P142; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; de Luna N, 2006, J BIOL CHEM, V281, P17092, DOI 10.1074/jbc.M601885200; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; Engel A.G., 2004, MYOLOGY; FLUCHER BE, 1993, DEV BIOL, V160, P135, DOI 10.1006/dbio.1993.1292; FLUCHER BE, 1991, DEV BIOL, V145, P77, DOI 10.1016/0012-1606(91)90214-N; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Hernandez-Deviez DJ, 2006, HUM MOL GENET, V15, P129, DOI 10.1093/hmg/ddi434; HUANG Y, 2006, FASEB J; Huang YC, 2005, EUR J HUM GENET, V13, P721, DOI 10.1038/sj.ejhg.5201414; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; ISHIKAWA H, 1968, J CELL BIOL, V38, P51, DOI 10.1083/jcb.38.1.51; Laval SH, 2004, NEUROPATH APPL NEURO, V30, P91, DOI 10.1111/j.1365-2990.2004.00555.x; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuda C, 2005, J NEUROPATH EXP NEUR, V64, P334, DOI 10.1093/jnen/64.4.334; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; MCNEIL PL, 1987, J CELL SCI, V88, P669; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SCHIAFFINO S, 1977, TISSUE CELL, V9, P437, DOI 10.1016/0040-8166(77)90004-0; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; Washington NL, 2006, J CELL SCI, V119, P2552, DOI 10.1242/jcs.02980; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	47	72	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1768	1776		10.1096/fj.06-7659com	http://dx.doi.org/10.1096/fj.06-7659com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17363620				2022-12-25	WOS:000246866500019
J	Howell, KA; Cheng, K; Murcha, MW; Jenkin, LE; Millar, AH; Whelan, J				Howell, Katharine A.; Cheng, Kim; Murcha, Monika W.; Jenkin, Linne E.; Millar, A. Harvey; Whelan, James			Oxygen initiation of respiration and mitochondrial biogenesis in rice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CYTOPLASMIC MALE-STERILITY; PROCESSING PEPTIDASE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; CHEMOSTAT CULTURES; PLANT-MITOCHONDRIA; GENE-EXPRESSION; MESSENGER-RNA	Rice growth under aerobic and anaerobic conditions allowed aspects of mitochondrial biogenesis to be identified as dependent on or independent of an oxygen signal. Analysis of transcripts encoding mitochondrial components found that a subset of these genes respond to oxygen ( defined as aerobic), whereas others are relatively unaffected by oxygen availability. Mitochondria formed during growth in anaerobic conditions had reduced protein levels of tricarboxylic acid cycle components and cytochrome-containing complexes of the respiratory chain and repressed respiratory functionality. In general, the capacity of the general import pathway was found to be significantly lower in mitochondria isolated from tissue grown under anaerobic conditions, whereas the carrier import pathway capacity was not affected by changes in oxygen availability. Transcript levels of genes encoding components of the protein import apparatus were generally not affected by the absence of oxygen, and their protein abundance was severalfold higher in mitochondria isolated from anaerobically grown tissue. However, both transcript and protein abundances of the subunits of the mitochondrial processing peptidase, which in plants is integrated into the cytochrome bc(1) complex, were repressed under anaerobic conditions. Therefore, in this system, an increase in import capacity is correlated with an increase in the abundance of the cytochrome bc(1) complex, which is ultimately dependent on the presence of oxygen, providing a link between the respiratory chain and protein import apparatus.	Univ Western Australia, ARC Ctr Excellence Plant Energy Biol, Perth, WA 6009, Australia	University of Western Australia	Whelan, J (corresponding author), Univ Western Australia, ARC Ctr Excellence Plant Energy Biol, M316 MCS Bldg,35 Stirling Hwy, Perth, WA 6009, Australia.	seamus@cyllene.uwa.edu.au	Murcha, Monika W/C-3834-2011; Millar, A. Harvey/A-5452-2008; Whelan, James/F-6402-2011; Murcha, Monika W/H-5495-2014; Howell, Katharine A/A-4973-2010	Millar, A. Harvey/0000-0001-9679-1473; Whelan, James/0000-0001-5754-025X; Murcha, Monika W/0000-0002-3689-6158; Howell, Katharine A/0000-0002-5044-0034				Bellaoui M, 1997, EMBO J, V16, P5057, DOI 10.1093/emboj/16.16.5057; Binder S, 2003, PHILOS T R SOC B, V358, P181, DOI 10.1098/rstb.2002.1179; BRAUN HP, 1995, PLANTA, V195, P396, DOI 10.1007/BF00202597; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; Burke PV, 1997, J BIOL CHEM, V272, P14705, DOI 10.1074/jbc.272.23.14705; Cornah JE, 2003, TRENDS PLANT SCI, V8, P224, DOI 10.1016/S1360-1385(03)00064-5; COUEE I, 1992, PLANT PHYSIOL, V98, P411, DOI 10.1104/pp.98.2.411; Dessi P, 2000, PLANT J, V24, P637, DOI 10.1046/j.1365-313x.2000.00910.x; Eads BD, 2003, J EXP BIOL, V206, P3681, DOI 10.1242/jeb.00595; FOX TC, 1991, PLANTA, V184, P510, DOI 10.1007/BF00197900; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Giege P, 2000, EMBO REP, V1, P164, DOI 10.1093/embo-reports/kvd024; Giege P, 2005, PLANT CELL, V17, P1497, DOI 10.1105/tpc.104.030254; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; Grelet J, 2005, PLANT PHYSIOL, V137, P157, DOI 10.1104/pp.104.052480; GROOT GSP, 1975, NATURE, V255, P238, DOI 10.1038/255238a0; Howell KA, 2006, PLANT MOL BIOL, V60, P201, DOI 10.1007/s11103-005-3688-7; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Millar AH, 2004, J BIOL CHEM, V279, P39471, DOI 10.1074/jbc.M406015200; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Murcha MW, 2005, J MOL BIOL, V351, P16, DOI 10.1016/j.jmb.2005.06.004; Murcha MW, 2004, J MOL BIOL, V344, P443, DOI 10.1016/j.jmb.2004.09.045; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; Murcha MW, 1999, FEBS LETT, V464, P53, DOI 10.1016/S0014-5793(99)01674-9; Mustroph A, 2003, PHYSIOL PLANTARUM, V117, P508, DOI 10.1034/j.1399-3054.2003.00051.x; Pavlov PF, 1999, BIOCHEM J, V341, P95, DOI 10.1042/0264-6021:3410095; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; PLATTNER H, 1970, P NATL ACAD SCI USA, V66, P1252, DOI 10.1073/pnas.66.4.1252; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Rajjou L, 2004, PLANT PHYSIOL, V134, P1598, DOI 10.1104/pp.103.036293; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Rosenfeld E, 2004, ANTON LEEUW INT J G, V85, P9, DOI 10.1023/B:ANTO.0000020268.55350.54; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SHIBASAKA M, 1988, PLANT PHYSIOL, V86, P1008, DOI 10.1104/pp.86.4.1008; SMITH MK, 1994, ARCH BIOCHEM BIOPHYS, V313, P235, DOI 10.1006/abbi.1994.1382; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanudji M, 2001, PLANT MOL BIOL, V45, P317, DOI 10.1023/A:1006456115140; Taylor NL, 2003, FEBS LETT, V547, P125, DOI 10.1016/S0014-5793(03)00691-4; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Tsuji H, 2000, FEBS LETT, V471, P201, DOI 10.1016/S0014-5793(00)01411-3; UEDA K, 1971, PROTOPLASMA, V73, P203, DOI 10.1007/BF01275595; van der Laan M, 2006, CURR BIOL, V16, P2271, DOI 10.1016/j.cub.2006.10.025; Vartapetian BB, 2003, ANN BOT-LONDON, V91, P155, DOI 10.1093/aob/mcf244; VARTAPETIAN BB, 1975, PLANT SCI LETT, V4, P1, DOI 10.1016/0304-4211(75)90067-X; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; Wang WX, 2003, PLANTA, V218, P1, DOI 10.1007/s00425-003-1105-5; Whelan J, 1996, BBA-MOL CELL RES, V1312, P48, DOI 10.1016/0167-4889(96)00014-6; WHELAN J, 1995, PLANT MOL BIOL, V27, P769, DOI 10.1007/BF00020229; WHELAN J, 1993, PLANT PHYSIOL, V103, P1481, DOI 10.1104/pp.103.4.1481; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	59	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15619	15631		10.1074/jbc.M609866200	http://dx.doi.org/10.1074/jbc.M609866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383966	hybrid			2022-12-25	WOS:000246589600039
J	Schroeder-Gloeckler, JM; Rahman, SM; Janssen, RC; Qiao, LP; Shao, JH; Roper, M; Fischer, SJ; Lowe, E; Orlicky, DJ; McManaman, JL; Palmer, C; Gitomer, WL; Huang, W; O'Doherty, RM; Becker, TC; Klemm, DJ; Jensen, DR; Pulawa, LK; Eckel, RH; Friedman, JE				Schroeder-Gloeckler, Jill M.; Rahman, Shaikh Mizanoor; Janssen, Rachel C.; Qiao, Liping; Shao, Jianhua; Roper, Michael; Fischer, Stephanie J.; Lowe, Erin; Orlicky, David J.; McManaman, James L.; Palmer, Carol; Gitomer, William L.; Huang, Wan; O'Doherty, Robert M.; Becker, Thomas C.; Klemm, Dwight J.; Jensen, Dalan R.; Pulawa, Leslie K.; Eckel, Robert H.; Friedman, Jacob E.			CCAAT/Enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; TRANSCRIPTIONAL INHIBITORY PROTEIN; HEPATOCELLULAR GLUCOSE-PRODUCTION; GTP GENE-TRANSCRIPTION; C/EBP-BETA; FATTY-ACID; INSULIN-RESISTANCE; X-RECEPTOR; ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTORS	CCAAT/enhancer-binding protein beta (C/EBP beta) plays a key role in initiation of adipogenesis in adipose tissue and gluconeogenesis in liver; however, the role of C/ EBP beta in hepatic lipogenesis remains undefined. Here we show that C/EBP beta inactivation in Leprdb/ db mice attenuates obesity, fatty liver, and diabetes. In addition to impaired adipogenesis, livers from C/EB beta(-/-) x Lepr(db/db) mice had dramatically decreased triglyceride content and reduced lipogenic enzyme activity. C/EBP beta deletion in Lepr(db/db) mice down-regulated peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) and stearoyl-CoA desaturase-1 and up-regulated PPAR alpha independent of SREBP1c. Conversely, C/EBP beta overexpression in wild-type mice increased PPAR gamma 2 and stearoyl-CoA desaturase-1 mRNA and hepatic triglyceride content. In FAO cells, overexpression of the liver inhibiting form of C/EBP beta or C/EBP beta RNA interference attenuated palmitate-induced triglyceride accumulation and reduced PPAR gamma 2 and triglyceride levels in the liver in vivo. Leptin and the anti-diabetic drug metformin acutely down-regulated C/EBP beta expression in hepatocytes, whereas fatty acids up-regulate C/EBP beta expression. These data provide novel evidence linking C/EBP beta expression to lipogenesis and energy balance with important implications for the treatment of obesity and fatty liver disease.	UCDHSC, Dept Pediat, Aurora, CO 80045 USA; UCDHSC, Dept Pathol, Aurora, CO 80045 USA; UCDHSC, Dept Obstet & Gynecol, Aurora, CO 80045 USA; UCDHSC, Dept Physiol & Biophys, Aurora, CO 80045 USA; UCDHSC, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; UCDHSC, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA; Vet Affairs Med Ctr, Renal Sect, Denver, CO 80220 USA; Vet Affairs Med Ctr, Pulm Sect, Res Serv, Denver, CO 80220 USA; Univ Pittsburgh, Dept Med, Div Endocrinol, Pittsburgh, PA 15261 USA; Duke Univ, Med Ctr, Div Metab Endocrinol & Nutr, Durham, NC 27704 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University	Friedman, JE (corresponding author), UCDHSC, Dept Pediat, Mail Stop F-8106,POB 6511, Aurora, CO 80045 USA.	jed.friedman@uchsc.edu	Rahman, Shaikh Mizanoor/GLN-7518-2022	Rahman, Shaikh Mizanoor/0000-0002-4879-2663	NICHD NIH HHS [R01 HD045965, HD-38129, U10 HD045962, P01 HD038129, HD-045962] Funding Source: Medline; NIDDK NIH HHS [DK59767, DK-26356, R01 DK059767, DK-53969, R01 DK053969, DK-072162, P30 DK048520, R01 DK072162, DK-058855, U01-DK-56047, R01 DK058855, R01 DK026356, P30-DK-48520] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129, R01HD045965] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD045962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520, R01DK026356, R13DK056047, R01DK059767, R01DK058855, R01DK072162, R01DK053969] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbud RA, 2004, ENDOCRINOLOGY, V145, P867, DOI 10.1210/en.2003-0897; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Barbour LA, 2002, AM J OBSTET GYNECOL, V186, P512, DOI 10.1067/mob.2002.121256; Beaven SW, 2006, ANNU REV MED, V57, P313, DOI 10.1146/annurev.med.57.121304.131428; Benton CR, 2006, J PHYSIOL-LONDON, V573, P199, DOI 10.1113/jphysiol.2006.106013; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURTON BT, 1985, INT J OBESITY, V9, P155; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Chen JS, 2004, NEUROPSYCHOPHARMACOL, V29, P23, DOI 10.1038/sj.npp.1300289; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Chinetti-Gbaguidi G, 2005, CURR OPIN PHARMACOL, V5, P177, DOI 10.1016/j.coph.2004.11.004; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI 10.1016/j.paid.2005.05.008; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; CORRIGAN AP, 1983, BIOCHEM J, V214, P299, DOI 10.1042/bj2140299; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Forcheron F, 2002, DIABETES, V51, P3486, DOI 10.2337/diabetes.51.12.3486; Friedman JM, 1998, NUTR REV, V56, pS38; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Haugen BR, 2004, ENDOCRINOLOGY, V145, P3679, DOI 10.1210/en.2003-1401; Huang W, 2004, J BIOL CHEM, V279, P21695, DOI 10.1074/jbc.M401546200; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Lund EG, 2006, BIOCHEM PHARMACOL, V71, P453, DOI 10.1016/j.bcp.2005.11.004; Marchesini G, 2006, Minerva Cardioangiol, V54, P229; Matsusue K, 2004, MOL ENDOCRINOL, V18, P2751, DOI 10.1210/me.2004-0213; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; Millward CA, 2007, DIABETES, V56, P161, DOI 10.2337/db06-0310; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Miyazaki M, 2004, J BIOL CHEM, V279, P35017, DOI 10.1074/jbc.M405327200; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Nepokroeff C M, 1975, Methods Enzymol, V35, P37, DOI 10.1016/0076-6879(75)35136-7; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; Perdomo G, 2004, J BIOL CHEM, V279, P27177, DOI 10.1074/jbc.M403566200; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Qiao LP, 2006, ENDOCRINOLOGY, V147, P3060, DOI 10.1210/en.2005-1507; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rao MS, 2004, HEPATOLOGY, V40, P783, DOI 10.1002/hep.20453; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shao JH, 2005, DIABETES, V54, P976, DOI 10.2337/diabetes.54.4.976; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Sugden MC, 2002, BIOCHEM J, V364, P361, DOI 10.1042/BJ20011699; Sztalryd C, 2006, J BIOL CHEM, V281, P34341, DOI 10.1074/jbc.M602497200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yang JQ, 2005, J BIOL CHEM, V280, P38689, DOI 10.1074/jbc.M503486200; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	88	103	106	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15717	15729		10.1074/jbc.M701329200	http://dx.doi.org/10.1074/jbc.M701329200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17387171	Green Accepted, hybrid			2022-12-25	WOS:000246589600048
J	Lecine, P; Esmiol, S; Metais, JY; Nicoletti, C; Nourry, C; McDonald, C; Nunez, G; Hugot, JP; Borg, JP; Ollendorff, V				Lecine, Patrick; Esmiol, Sophie; Metais, Jean-Yves; Nicoletti, Cendrine; Nourry, Claire; McDonald, Christine; Nunez, Gabriel; Hugot, Jean-Pierre; Borg, Jean-Paul; Ollendorff, Vincent			The NOD2-RICK complex signals from the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURAMYL DIPEPTIDE RECOGNITION; INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; IMMUNE-RESPONSES; NOD2 VARIANTS; ACTIVATION; RECEPTOR; ERBIN	NOD2 plays an important role in the innate immunity of the intestinal tract. By sensing the muramyl dipeptide (MDP), a bacterial wall component, NOD2 triggers the NF-kappa B signaling pathway and promotes the release of proinflammatory cytokines such as interleukin-8. Mutations in Nod2 (1007FS, R702W, G908R) impinge on NOD2 functions and are associated with the pathogenesis of Crohn disease, a chronic inflammatory bowel disease. Although NOD2 is usually described as a cytosolic receptor for MDP, the protein is also localized at the plasma membrane, and the 1007FS mutation delocalizes NOD2 to the cytoplasm (Barnich, N., Aguirre, J. E., Reinecker, H. C., Xavier, R., and Podolsky, D. K. (2005) J. Cell Biol. 170, 21 - 26; McDonald, C., Chen, F. F., Ollendorff, V., Ogura, Y., Marchetto, S., Lecine, P., Borg, J. P., and Nunez, G. (2005) J. Biol. Chem. 280, 40301 - 40309). In this study, we demonstrate that membrane-bound versions of NOD2 and Crohn disease-associated mutants R702W and G908R are capable of responding to MDP and activating the NF-kappa B pathway from this location. In contrast, the 1007FS mutant remains unable to respond to MDP from the plasma membrane. We also show that NOD2 promotes the membrane recruitment of RICK, a serine-threonine kinase involved in NF-kappa B activation downstream of NOD2. Furthermore, the artificial attachment of RICK at the plasma membrane provokes a constitutive and strong activation of the NF-kappa B pathway and secretion of interleukin-8 showing that optimal RICK activity depends upon its subcellular localization. Finally, we show that endogenous RICK localizes at the plasma membrane in the THP1 cell line. Thus, our data suggest that NOD2 is responsible for the membrane recruitment of RICK to induce a regulated NF-kappa B signaling and production of proinflammatory cytokines.	Univ Paul Cezanne Fac St Jerome Serv, IMRN, INRA, UMR 1111, F-13397 Marseille 20, France; Univ Aix Marseille 2, INSERM, UMR 599, Inst J Paoli I Calmettes,Ctr Rech Cancerol Marsei, F-13009 Marseille, France; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Paris 07, Assistance Publ Hop Paris, Hop Robert Debre, INSERM U763,UFR Med Denis Diderot, F-75019 Paris, France	INRAE; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Ollendorff, V (corresponding author), Univ Paul Cezanne Fac St Jerome Serv, IMRN, INRA, UMR 1111, 342 Ave Escadrille Normandie Niemen, F-13397 Marseille 20, France.	vincent.ollendorff@univ-cezanne.fr	Nuñez, Gabriel/A-7160-2014; Lecine, Patrick/H-9338-2016; Hugot, Jean-Pierre/F-6594-2012; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Ollendorff, Vincent/0000-0001-9751-2202; Hugot, Jean-Pierre/0000-0002-8446-6056; Lecine, Patrick/0000-0002-8091-7286; McDonald, Christine/0000-0002-6745-9487				Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barnich N, 2005, J BIOL CHEM, V280, P19021, DOI 10.1074/jbc.M413776200; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Dai PG, 2006, J BIOL CHEM, V281, P927, DOI 10.1074/jbc.M507360200; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eckmann L, 2005, IMMUNITY, V22, P661, DOI 10.1016/j.immuni.2005.06.004; Economou M, 2004, AM J GASTROENTEROL, V99, P2393, DOI 10.1111/j.1572-0241.2004.40304.x; Gaya DR, 2006, LANCET, V367, P1271, DOI 10.1016/S0140-6736(06)68345-1; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; KOLCH W, 2003, SCI STKE, pPE37; Kufer TA, 2006, INFECT IMMUN, V74, P3115, DOI 10.1128/IAI.00035-06; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; McDonald C, 2005, J BIOL CHEM, V280, P40301, DOI 10.1074/jbc.M508538200; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Russell RK, 2004, CURR OPIN GENET DEV, V14, P264, DOI 10.1016/j.gde.2004.04.004; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	44	93	97	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15197	15207		10.1074/jbc.M606242200	http://dx.doi.org/10.1074/jbc.M606242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355968	Green Published, hybrid			2022-12-25	WOS:000246589000059
J	Ashworth, R; Devogelaere, B; Fabes, J; Tunwell, RE; Koh, KR; De Smedt, H; Patel, S				Ashworth, Rachel; Devogelaere, Benoit; Fabes, Jez; Tunwell, Richard E.; Koh, Kevin R.; De Smedt, Humbert; Patel, Sandip			Molecular and functional characterization of inositol trisphosphate receptors during early zebrafish development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; 1,4,5-TRISPHOSPHATE RECEPTOR; IP3 RECEPTOR; CALCIUM-RELEASE; ENDOPLASMIC-RETICULUM; CA2+ RELEASE; 2-AMINOETHOXYDIPHENYL BORATE; TYROSINE PHOSPHORYLATION; INTRACELLULAR CALCIUM; EMBRYONIC-DEVELOPMENT	Fluctuations in cytosolic Ca2+ are crucial for a variety of cellular processes including many aspects of development. Mobilization of intracellular Ca2+ stores via the production of inositol trisphosphate (IP3) and the consequent activation of IP3-sensitive Ca2+ channels is a ubiquitous means by which diverse stimuli mediate their cellular effects. Although IP3 receptors have been well studied at fertilization, information regarding their possible involvement during subsequent development is scant. In the present study we examined the role of IP3 receptors in early development of the zebrafish. We report the first molecular analysis of zebrafish IP3 receptors which indicates that, like mammals, the zebrafish genome contains three distinct IP3 receptor genes. mRNA for all isoforms was detectable at differing levels by the 64 cell stage, and IP3-induced Ca2+ transients could be readily generated (by flash photolysis) in a controlled fashion throughout the cleavage period in vivo. Furthermore, we show that early blastula formation was disrupted by pharmacological blockade of IP3 receptors or phospholipase C, by molecular inhibition of the former by injection of IRBIT (IP3 receptor-binding protein released with IP3) and by depletion of thapsigargin-sensitive Ca2+ stores after completion of the second cell cycle. Inhibition of Ca2+ entry or ryanodine receptors, however, had little effect. Our work defines the importance of IP3 receptors during early development of a genetically and optically tractable model vertebrate organism.	Queen Mary Univ London, Sch Biol & Chem Sci, London E1 4NS, England; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; UCL, Dept Physiol, London WC1E 6BT, England	University of London; Queen Mary University London; KU Leuven; University of London; University College London	Ashworth, R (corresponding author), Queen Mary Univ London, Sch Biol & Chem Sci, Mile End Rd, London E1 4NS, England.	r.ashworth@qmul.ac.uk	Zebrafish, UCL/A-3125-2009; Patel, Sandip/O-9591-2015	Patel, Sandip/0000-0001-7247-2013	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Ando H, 2006, MOL CELL, V22, P795, DOI 10.1016/j.molcel.2006.05.017; Ashworth R, 2004, CELL CALCIUM, V35, P393, DOI 10.1016/j.ceca.2004.01.002; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boulware MJ, 2005, CURR BIOL, V15, P765, DOI 10.1016/j.cub.2005.02.065; CHANG DC, 1995, J CELL BIOL, V131, P1539, DOI 10.1083/jcb.131.6.1539; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Cooper BJ, 2006, J BIOL CHEM, V281, P22471, DOI 10.1074/jbc.M602520200; Creton R, 1998, J CELL SCI, V111, P1613; Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200; Devogelaere B, 2006, BIOCHEM BIOPH RES CO, V343, P49, DOI 10.1016/j.bbrc.2006.02.119; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Field SJ, 2005, CURR BIOL, V15, P1407, DOI 10.1016/j.cub.2005.06.059; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FitzHarris G, 2003, MOL BIOL CELL, V14, P288, DOI 10.1091/mbc.E02-07-0431; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; He CL, 1999, BIOL REPROD, V61, P935, DOI 10.1095/biolreprod61.4.935; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kume S, 1997, MECH DEVELOP, V66, P157, DOI 10.1016/S0925-4773(97)00101-9; Kume S, 1997, SCIENCE, V278, P1940, DOI 10.1126/science.278.5345.1940; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Lee B, 2006, DEVELOPMENT, V133, P4355, DOI 10.1242/dev.02624; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; Lee KW, 2006, ZYGOTE, V14, P143, DOI 10.1017/S0967199406003637; Lee KW, 2003, INT J DEV BIOL, V47, P411; Li XG, 2005, J IMMUNOL, V175, P6205, DOI 10.4049/jimmunol.175.9.6205; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MEHLMANN LM, 1994, BIOL REPROD, V51, P1088, DOI 10.1095/biolreprod51.6.1088; Mehlmann LM, 1996, DEV BIOL, V180, P489, DOI 10.1006/dbio.1996.0322; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; Muto A, 1996, J CELL BIOL, V135, P181, DOI 10.1083/jcb.135.1.181; Nojima H, 2004, MECH DEVELOP, V121, P371, DOI 10.1016/j.mod.2004.02.003; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Szlufcik K, 2006, CELL CALCIUM, V39, P325, DOI 10.1016/j.ceca.2005.11.007; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Webb SE, 2000, BIOESSAYS, V22, P113, DOI 10.1002/(SICI)1521-1878(200002)22:2<113::AID-BIES3>3.0.CO;2-L; Webb SE, 1997, DEV BIOL, V192, P78, DOI 10.1006/dbio.1997.8724; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Westfall TA, 2003, DEV BIOL, V259, P380, DOI 10.1016/S0012-1606(03)00209-4; Whitaker M, 2006, PHYSIOL REV, V86, P25, DOI 10.1152/physrev.00023.2005; Wong R, 2005, CURR BIOL, V15, P1401, DOI 10.1016/j.cub.2005.06.060; Xu Z, 2003, DEV BIOL, V254, P163, DOI 10.1016/S0012-1606(02)00049-0; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Zimprich F, 1998, PFLUG ARCH EUR J PHY, V436, P489, DOI 10.1007/s004240050662	74	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13984	13993		10.1074/jbc.M700940200	http://dx.doi.org/10.1074/jbc.M700940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17331947	hybrid			2022-12-25	WOS:000246245800008
J	Huang, G; Kim, JY; Dehoff, M; Mizuno, Y; Kamm, KE; Worley, PF; Muallem, S; Zeng, W				Huang, Guojin; Kim, Joo Young; Dehoff, Marlin; Mizuno, Yusuke; Kamm, Kristine E.; Worley, Paul F.; Muallem, Shmuel; Zeng, Weizhong			Ca2+ signaling in microdomains - Homer1 mediates the interaction between RyR2 and Cav1.2 to regulate excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; SMOOTH-MUSCLE; RYANODINE RECEPTOR-TYPE-1; PROTEINS; SKELETAL; CHANNELS; CELLS; ACTIVATION; COMPLEXES; CA(V)1.2	Excitation-contraction (E-C) coupling and Ca2+-induced Ca2+ release in smooth and cardiac muscles is mediated by the L-type Ca2+ channel isoform Ca(v)1.2 and the ryanodine receptor isoform RyR2. Although physical coupling between Ca(v)1.1 and RyR1 in skeletal muscle is well established, it is generally assumed that Ca(v)1.2 and RyR2 do not directly communicate either passively or dynamically during E-C coupling. In the present work, we re-examined this assumption by studying E-C coupling in the detrusor muscle of wild type and Homer1(-/-) mice and by demonstrating a Homer1-mediated dynamic interaction between Ca(v)1.2 and RyR2 using the split green fluorescent protein technique. Deletion of Homer1 in mice (but not of Homer2 or Homer3) resulted in impaired urinary bladder function, which was associated with higher sensitivity of the detrusor muscle to muscarinic stimulation and membrane depolarization. This was not due to an altered expression or function of RyR2 and Ca(v)1.2. Most notably, expression of Ca(v)1.2 and RyR2 tagged with the complementary C- and N- terminal halves of green fluorescent protein and in the presence and absence of Homer1 isoforms revealed that H1a and H1b/c reciprocally modulates a dynamic interaction between Ca(v)1.2 and RyR2 to regulate the intensity of Ca2+-induced Ca2+ release and its dependence on membrane depolarization. These findings define the molecular basis of a "two-state" model of E-C coupling by Ca(v)1.2 and RyR2. In one state, Ca(v)1.2 couples to RyR2 by H1b/c, which results in reduced responsiveness to membrane depolarization and in the other state H1a uncouples Ca(v)1.2 and RyR2 to enhance responsiveness to membrane depolarization. These findings reveal an unexpected and novel mode of interaction and communication between Ca(v)1.2 and RyR2 with important implications for the regulation of smooth and possibly cardiac muscle E-C coupling.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Program Biochem Cellular & Mol Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Program Biochem Cellular & Mol Biol, Baltimore, MD 21205 USA.	pworley@jhmi.edu; Shmuel.muallem@utsouthwestern.edu	Huang, Guojin/ABB-1091-2021	Huang, Guojin/0000-0001-7020-5528	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010309, R01DA010309, P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10309, DA00266] Funding Source: Medline; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline; NIMH NIH HHS [MH068830] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bers DM, 2004, J MOL CELL CARDIOL, V37, P417, DOI 10.1016/j.yjmcc.2004.05.026; Cabantous S, 2005, NAT BIOTECHNOL, V23, P102, DOI 10.1038/nbt1044; Collier ML, 2000, J GEN PHYSIOL, V115, P653, DOI 10.1085/jgp.115.5.653; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Franzini-Armstrong C, 2004, BIOL RES, V37, P507; Huang GJ, 2006, J CELL SCI, V119, P153, DOI 10.1242/jcs.02731; Hwang SY, 2003, CELL CALCIUM, V34, P177, DOI 10.1016/S0143-4160(03)00082-4; Isotani E, 2004, P NATL ACAD SCI USA, V101, P6279, DOI 10.1073/pnas.0308742101; Ji GJ, 2004, J GEN PHYSIOL, V123, P377, DOI 10.1085/jgp.200308999; Kammermeier PJ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-1; Kiselyov K, 2005, PFLUG ARCH EUR J PHY, V451, P116, DOI 10.1007/s00424-005-1442-2; Kiselyov K, 2002, ADV EXP MED BIOL, V506, P175; Kotlikoff MI, 2003, PROG BIOPHYS MOL BIO, V83, P171, DOI 10.1016/S0079-6107(03)00056-7; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Ozawa T, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni032; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; Sgambato-Faure V, 2006, BIOCHEM BIOPH RES CO, V343, P630, DOI 10.1016/j.bbrc.2006.03.020; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002; Ward CW, 2004, J BIOL CHEM, V279, P5781, DOI 10.1074/jbc.M311422200; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Wehrens XHT, 2005, ANNU REV PHYSIOL, V67, P69, DOI 10.1146/annurev.physiol.67.040403.114521; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Wray S, 2005, CELL CALCIUM, V38, P397, DOI 10.1016/j.ceca.2005.06.018; Yamamoto K, 2005, EUR J NEUROSCI, V22, P1338, DOI 10.1111/j.1460-9568.2005.04278.x; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang H, 2006, EUR J NEUROSCI, V23, P2297, DOI 10.1111/j.1460-9568.2006.04734.x; Zhang SF, 2004, CELL, V119, P137, DOI 10.1016/j.cell.2004.09.012	31	34	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14283	14290		10.1074/jbc.M611529200	http://dx.doi.org/10.1074/jbc.M611529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355963	hybrid			2022-12-25	WOS:000246245800039
J	Penet, MF; Kober, F; Confort-Gouny, S; Le Fur, Y; Dalmasso, C; Coltel, N; Liprandi, A; Gulian, JM; Grau, GE; Cozzone, PJ; Viola, A				Penet, Marie-France; Kober, Frank; Confort-Gouny, Sylviane; Le Fur, Yann; Dalmasso, Christiane; Coltel, Nicolas; Liprandi, Agnes; Gulian, Jean-Marc; Grau, Georges E.; Cozzone, Patrick J.; Viola, Angele			Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; BLOOD-STAGE MALARIA; ACUTE LIVER-FAILURE; AMINO-ACIDS; FALCIPARUM-MALARIA; IN-VIVO; PATHOGENESIS; AMMONIA; ENCEPHALOPATHY; HEMOZOIN	Malaria is a major cause of morbidity and mortality with an annual death toll exceeding one million. Severe malaria is a complex multisystem disorder, including one or more of the following complications: cerebral malaria, anemia, acidosis, jaundice, respiratory distress, renal insufficiency, coagulation anomalies, and hyperparasitemia. Using a combined in vivo/in vitro metabolic-based approach, we investigated the putative pathogenic effects of Plasmodium berghei ANKA on brain, in a mouse strain developing malaria but resistant to cerebral malaria. The purpose was to determine whether the infection could cause a brain dysfunction distinct from the classic cerebral syndrome. Mice resistant to cerebral malaria were infected with P. berghei ANKA and explored during both the symptomless and the severe stage of the disease by using in vivo brain magnetic resonance imaging and spectroscopy. The infected mice did not present the lesional and metabolic hallmarks of cerebral malaria. However, brain dysfunction caused by anemia, parasite burden, and hepatic damage was evidenced. We report an increase in cerebral blood flow, a process allowing temporary maintenance of oxygen supply to brain despite anemia. Besides, we document metabolic anomalies affecting choline-derived compounds, myo-inositol, glutamine, glycine, and alanine. The choline decrease appears related to parasite proliferation. Glutamine, myo-inositol, glycine, and alanine variations together indicate a hepatic encephalopathy, a finding in agreement with the liver damage detected in mice, which is also a feature of the human disease. These results reveal the vulnerability of brain to malaria infection at the severe stage of the disease even in the absence of cerebral malaria.	Univ Aix Marseille 2, Fac Med Timone, CNRS, UMR 6612,Ctr Resonance Magnet Biol & Med, F-13005 Marseille, France; Univ Aix Marseille 2, Fac Med Timone, Unite Rickettsies & Pathogenes Emergents, UMR 6020,Inst Federat Rech,CNRS, F-13005 Marseille, France; Hop Enfants La Timone, Serv Anat Pathol & Neuropathol, F-13005 Marseille, France; Hop Enfants La Timone, Biochim Lab, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Viola, A (corresponding author), Univ Aix Marseille 2, Fac Med Timone, CNRS, UMR 6612,Ctr Resonance Magnet Biol & Med, 27 Blvd Jean Moulin, F-13005 Marseille, France.	viola@medecine.univ-mrs.fr	Penet, Marie-France/AGZ-6991-2022; Kober, Frank/L-8737-2013; Grau, Georges/AGR-7139-2022	Kober, Frank/0000-0002-7869-3615; Grau, Georges/0000-0002-0442-0462				Anand AC, 2005, J GASTROEN HEPATOL, V20, P1322, DOI 10.1111/j.1440-1746.2005.03884.x; Biagini GA, 2004, BLOOD, V104, P3372, DOI 10.1182/blood-2004-03-1084; Bluml S, 1998, J NEUROCHEM, V71, P1564; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Carney CK, 2006, J BIOL INORG CHEM, V11, P917, DOI 10.1007/s00775-006-0147-0; Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008; Chang KH, 2004, J INFECT DIS, V189, P735, DOI 10.1086/381458; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; Cordoba J, 1996, HEPATOLOGY, V24, P919, DOI 10.1002/hep.510240427; Cordoba J, 2002, METAB BRAIN DIS, V17, P415, DOI 10.1023/A:1021926405944; De-Oliveira ACAX, 2006, EXP PARASITOL, V113, P256, DOI 10.1016/j.exppara.2006.01.013; DEKOSSODO S, 1993, J IMMUNOL, V151, P4811; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; Freeman JJ, 1996, LIFE SCI, V58, P1921, DOI 10.1016/0024-3205(96)00181-6; Gerardin P, 2002, ARCH PEDIATRIE, V9, P1260, DOI 10.1016/S0929-693X(02)00127-6; Green MD, 1996, MOL BIOCHEM PARASIT, V83, P183, DOI 10.1016/S0166-6851(96)02769-7; Guerra CA, 2006, TRENDS PARASITOL, V22, P353, DOI 10.1016/j.pt.2006.06.006; Hansen DS, 2003, IMMUNITY, V18, P391, DOI 10.1016/S1074-7613(03)00052-9; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Icke G, 2005, PLOS MED, V2, P108, DOI 10.1371/journal.pmed.0020011; Jacobs T, 2004, EUR J IMMUNOL, V34, P972, DOI 10.1002/eji.200324477; Kennan RP, 2004, MAGN RESON MED, V51, P525, DOI 10.1002/mrm.20014; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; Kober F, 2004, MAGN RESON MED, V51, P62, DOI 10.1002/mrm.10676; Kochar DK, 2003, QJM-INT J MED, V96, P505, DOI 10.1093/qjmed/hcg091; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006; Malaguarnera L, 2002, LANCET INFECT DIS, V2, P472, DOI 10.1016/S1473-3099(02)00344-4; MANS AM, 1994, J NEUROCHEM, V63, P1829; Martiney JA, 2000, INFECT IMMUN, V68, P2259, DOI 10.1128/IAI.68.4.2259-2267.2000; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Mohanty N, 2004, T ROY SOC TROP MED H, V98, P753, DOI 10.1016/S0035-9203(03)00023-3; Mordmuller B, 1998, CLIN INFECT DIS, V26, P850, DOI 10.1086/513926; Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; Saywell W, 2006, BIOCHEM BIOPH RES CO, V340, P776, DOI 10.1016/j.bbrc.2005.12.080; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Schwarzer E, 2003, BLOOD, V101, P722, DOI 10.1182/blood-2002-03-0979; Shawcross D, 2005, CELL MOL LIFE SCI, V62, P2295, DOI 10.1007/s00018-005-5089-0; Shawcross DL, 2004, AM J PHYSIOL-GASTR L, V287, pG503, DOI 10.1152/ajpgi.00104.2004; Singh RP, 2002, J IMMUNOL, V168, P4674, DOI 10.4049/jimmunol.168.9.4674; Srivastava P, 2000, ECOTOX ENVIRON SAFE, V46, P19, DOI 10.1006/eesa.1999.1867; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; Tofteng F, 2006, J CEREBR BLOOD F MET, V26, P21, DOI 10.1038/sj.jcbfm.9600168; Tofteng F, 2004, METAB BRAIN DIS, V19, P207, DOI 10.1023/B:MEBR.0000043970.34533.04; Turner G, 1997, BRAIN PATHOL, V7, P569, DOI 10.1111/j.1750-3639.1997.tb01075.x; Viola A, 2004, MAGN RESON MATER PHY, V17, P47, DOI 10.1007/s10334-004-0044-x; Wichmann O, 2003, INFECTION, V31, P260, DOI 10.1007/s15010-002-3143-5; Zwingmann C, 2005, NEUROCHEM INT, V47, P39, DOI 10.1016/j.neuint.2005.04.005; Zwingmann C, 2002, METAB BRAIN DIS, V17, P263, DOI 10.1023/A:1021997532352; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	57	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14505	14514		10.1074/jbc.M608035200	http://dx.doi.org/10.1074/jbc.M608035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369263	hybrid			2022-12-25	WOS:000246245800064
J	Stanne, TM; Pojidaeva, E; Andersson, FI; Clarke, AK				Stanne, Tara M.; Pojidaeva, Elena; Andersson, Fredrik I.; Clarke, Adrian K.			Distinctive types of ATP-dependent Clp proteases in cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; GENE-TRANSFER; CHLOROPLAST; ARABIDOPSIS; SUBUNIT; COMPLEX; ACCLIMATION; DEGRADATION; IDENTIFICATION	Cyanobacteria are the only prokaryotes that perform oxygenic photosynthesis and are thought to be ancestors to plant chloroplasts. Like chloroplasts, cyanobacteria possess a diverse array of proteolytic enzymes, with one of the most prominent being the ATP-dependent Ser-type Clp protease. The model Clp protease in Escherichia coli consists of a single ClpP proteolytic core flanked on one or both ends by a HSP100 chaperone partner. In comparison, cyanobacteria have multiple ClpP paralogs plus a ClpP variant (ClpR), which lacks the catalytic triad typical of Ser-type proteases. In this study, we reveal that two distinct soluble Clp proteases exist in the unicellular cyanobacterium Synechococcus elongatus. Each protease consists of a unique proteolytic core comprised of two separate Clp subunits, one with ClpP1 and ClpP2, the other with ClpP3 and ClpR. Each core also associates with a particular HSP100 chaperone partner, ClpC in the case of the ClpP3/R core, and ClpX for the ClpP1/P2 core. The two adaptor proteins, ClpS1 and ClpS2 also interact with the ClpC chaperone protein, likely increasing the range of protein substrates targeted by the Clp protease in cyanobacteria. We also reveal the possible existence of a third Clp protease in Synechococcus, one which associates with the internal membrane network. Altogether, we show that presence of several distinctive Clp proteases in cyanobacteria, a feature which contrasts from that in most other organisms.	Univ Gothenburg, Dept Plant & Environm Sci, S-40530 Gothenburg, Sweden	University of Gothenburg	Clarke, AK (corresponding author), Univ Gothenburg, Dept Plant & Environm Sci, Box 461, S-40530 Gothenburg, Sweden.	adrian.clarke@dpes.gu.se		Pojidaeva, Elena/0000-0002-5106-5707				Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; Andersson FI, 2006, J BIOL CHEM, V281, P5468, DOI 10.1074/jbc.M509661200; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; CAMPBELL D, 1995, EMBO J, V14, P5457, DOI 10.1002/j.1460-2075.1995.tb00232.x; Clarke AK, 1999, ANN BOT-LONDON, V83, P593, DOI 10.1006/anbo.1999.0878; CLARKE AK, 1992, PLANT PHYSIOL, V100, P2081, DOI 10.1104/pp.100.4.2081; Clarke AK, 1998, PLANT MOL BIOL, V37, P791, DOI 10.1023/A:1006016302074; Desimone M, 1997, BOT ACTA, V110, P234, DOI 10.1111/j.1438-8677.1997.tb00634.x; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Erbse A, 2006, NATURE, V439, P753, DOI 10.1038/nature04412; Fu GK, 1997, J BIOL CHEM, V272, P534; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Herrmann RG, 1997, EUKARYOTISM SYMBIOSI, P73, DOI [10.1007/978-3-642-60885-8_7, DOI 10.1007/978-3-642-60885-8_7]; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Kim KI, 1999, J MOL BIOL, V294, P1363, DOI 10.1006/jmbi.1999.3320; Koussevitzky S, 2007, PLANT MOL BIOL, V63, P85, DOI 10.1007/s11103-006-9074-2; Kuroda H, 2003, NATURE, V425, P86, DOI 10.1038/nature01909; Li C, 2000, J BACTERIOL, V182, P6630, DOI 10.1128/JB.182.23.6630-6637.2000; Majeran W, 2005, FEBS J, V272, P5558, DOI 10.1111/j.1742-4658.2005.04951.x; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; Peltier JB, 2001, J BIOL CHEM, V276, P16318, DOI 10.1074/jbc.M010503200; Pojidaeva E, 2004, J BACTERIOL, V186, P3991, DOI 10.1128/JB.186.12.3991-3999.2004; Porankiewicz J, 1997, J BACTERIOL, V179, P5111, DOI 10.1128/jb.179.16.5111-5117.1997; Porankiewicz J, 1998, MOL MICROBIOL, V29, P275, DOI 10.1046/j.1365-2958.1998.00928.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rudella A, 2006, PLANT CELL, V18, P1704, DOI 10.1105/tpc.106.042861; Schelin J, 2002, MICROBIOL-SGM, V148, P2255, DOI 10.1099/00221287-148-7-2255; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Sjogren LLE, 2006, PLANT CELL, V18, P2635, DOI 10.1105/tpc.106.044594; Sokolenko A, 2002, CURR GENET, V41, P291, DOI 10.1007/s00294-002-0309-8; Sokolenko A, 1998, PLANTA, V207, P286, DOI 10.1007/s004250050485; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; YOO SJ, 1994, BIOCHEM BIOPH RES CO, V203, P798, DOI 10.1006/bbrc.1994.2253; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zheng B, 2006, PLANTA, V224, P1103, DOI 10.1007/s00425-006-0292-2; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	50	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14394	14402		10.1074/jbc.M700275200	http://dx.doi.org/10.1074/jbc.M700275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371875	hybrid			2022-12-25	WOS:000246245800052
J	Doerner, JF; Gisselmann, G; Hatt, H; Wetzel, CH				Doerner, Julia F.; Gisselmann, Guenter; Hatt, Hanns; Wetzel, Christian H.			Transient receptor potential channel a1 is directly gated by calcium ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; TRP CHANNEL; BINDING PROTEINS; EF-HANDS; ACTIVATION; CALMODULIN; COLD; TRANSDUCTION; PEPTIDES; NEURONS	Members of the superfamily of transient receptor potential (TRP) channels are proposed to play important roles in sensory physiology. As an excitatory ion channel TRPA1 is robustly activated by pungent irritants in mustard and garlic and is suggested to mediate the inflammatory actions of environmental irritants and proalgesic agents. Here, we demonstrate that, in addition to pungent natural compounds, Ca2+ directly gates heterologously expressed TRPA1 in whole-cell and excised-patch recordings with an apparent EC50 of 905 nM. Pharmacological experiments and site-directed mutagenesis indicate that the N-terminal EF-hand calcium-binding domain of the channel is involved in Ca2+-dependent activation. Furthermore, we determine Ca2+ as prerequisite for icilin activity on TRPA1.	Ruhr Univ Bochum, Fak Biol, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany	Ruhr University Bochum	Wetzel, CH (corresponding author), Ruhr Univ Bochum, Fak Biol, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany.	Christian.Wetzel@rub.de	Wetzel, Christian/F-1366-2018; Wetzel, Christian H/N-9880-2017; Wetzel, Christian/C-2501-2009	Wetzel, Christian H/0000-0002-5762-0003; Wetzel, Christian/0000-0002-5762-0003				Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Drake SK, 1997, J GEN PHYSIOL, V110, P173, DOI 10.1085/jgp.110.2.173; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Houtman R, 2001, J IMMUNOL, V166, P861, DOI 10.4049/jimmunol.166.2.861; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Lupinsky DA, 2006, J PHYSIOL-LONDON, V575, P491, DOI 10.1113/jphysiol.2006.105833; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j.cub.2005.04.018; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Watanabe H, 2003, CELL CALCIUM, V33, P489, DOI 10.1016/S0143-4160(03)00064-2; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P9335, DOI 10.1073/pnas.90.20.9335	29	236	240	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13180	13189		10.1074/jbc.M607849200	http://dx.doi.org/10.1074/jbc.M607849200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353192	hybrid			2022-12-25	WOS:000246060300006
J	Correia, JD; Miranda, Y; Leonard, N; Ulevitch, RJ				Correia, Jean da Silva; Miranda, Yvonne; Leonard, Nikki; Ulevitch, Richard J.			The subunit CSN6 of the COP9 signalosome is cleaved during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-LIGASE; CELL-DEATH; BACTERIAL PEPTIDOGLYCAN; CASPASE ACTIVATION; CYCLIN-E; NOD1; PROTEASOME; DEGRADATION; SUBSTRATE	The COP9 signalosome is a large multiprotein complex that consists of eight subunits termed CSN1-CSN8. The diverse functions of the COP9 complex include regulation of several important intracellular pathways, including the ubiquitin/proteasome system, DNA repair, cell cycle, developmental changes, and some aspects of immune responses. Nod1 is also thought to be an important cytoplasmic receptor involved in innate immune responses. It detects specific motifs of bacterial peptidoglycan, and this results in activation of multiple signaling pathways and changes in cell function. In this report, we performed a yeast two-hybrid screening and discovered that Nod1 interacts with several components of the COP9 signalosome through its CARD domain. Moreover, we observed that activation of the Nod1 apoptotic pathway leads to specific cleavage of the subunit CSN6. This cleavage is concomitant with caspase processing and generates a short amino-terminal peptide of 3 kDa. A complete inhibition of this cleavage was achieved in the presence of the broad spectrum pharmacological inhibitor of apoptosis, Z-VAD. Furthermore, overexpression of CLARP, a specific caspase 8 inhibitor, completely blocked cleavage of CSN6. Taken together, these results suggest a critical role of caspase 8 in the processing of CSN6. Moreover, these findings suggest that CSN6 cleavage may result in modifications of functions of the COP9 complex that are involved in apoptosis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ulevitch, RJ (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ulevitch@scripps.edu	Ulevitch, Richard J/Q-3393-2017		NIAID NIH HHS [AI15136, U54 AI54523] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI054523, R01AI015136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Correia JD, 2007, CELL DEATH DIFFER, V14, P830, DOI 10.1038/sj.cdd.4402070; Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Fischer U, 2006, ONCOGENE, V25, P152, DOI 10.1038/sj.onc.1209015; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fulda S, 1997, CANCER RES, V57, P3823; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Giri K, 2003, FEBS LETT, V555, P380, DOI 10.1016/S0014-5793(03)01294-8; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Opitz B, 2005, CIRC RES, V96, P319, DOI 10.1161/01.RES.0000155721.83594.2c; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Schwechheimer C, 2002, PLANT CELL, V14, P2553, DOI 10.1105/tpc.003434; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Welter-Stahl L, 2006, CELL MICROBIOL, V8, P1047, DOI 10.1111/j.1462-5822.2006.00686.x; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	54	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12557	12565		10.1074/jbc.M609587200	http://dx.doi.org/10.1074/jbc.M609587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337451	hybrid			2022-12-25	WOS:000245942800024
J	Cosen-Binker, LI; Lam, PPL; Binker, MG; Reeve, J; Pandol, S; Gaisano, HY				Cosen-Binker, Laura I.; Lam, Patrick P. L.; Binker, Marcelo G.; Reeve, Joseph; Pandol, Stephen; Gaisano, Herbert Y.			Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocytosis is mediated by protein kinase C alpha phosphorylation of Munc18c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ALCOHOLIC PANCREATITIS; REGULATED EXOCYTOSIS; MEMBRANE-FUSION; PLASMA-MEMBRANE; PKC-DELTA; CELLS; CHOLECYSTOKININ; MECHANISMS; MACHINERY	The pancreatic acinus is the functional unit of the exocrine pancreas whose role is to secrete zymogens into the gut lumen for food digestion via apical exocytosis. We previously reported that supramaximal CCK induced apical blockade and redirected exocytosis to ectopic sites on the basolateral plasma membrane (BPM) of this polarized cell, leading to pancreatitis. Basolateral exocytosis was mediated by protein kinase C phosphorylation of BPM Munc18c, causing its displacement into the cytosol and activation of BPM-bound Syntaxin-4 to form aSNARE complex. To mimic the conditions of alcoholic pancreatitis, we now examined whether 20 mM alcohol followed by submaximal CCK might mimic supramaximal CCK in inducing these pathologic exocytotic events. We show that a non-secretory but clinically relevant alcohol concentration (20 mM) inhibited submaximal CCK (50 pM)-stimulated amylase secretion by blocking apical exocytosis and redirecting exocytosis to less efficient BPM, indeed mimicking supramaximal CCK (10 nM) stimulation. We further demonstrate that basolateral exocytosis caused by both stimulation protocols is mediated by PKC alpha-induced phosphorylation of Munc18c: 1) PKC alpha is activated, which binds and induces phosphorylation of PM-Munc18c at a Thr site, and these events can be inhibited by PKC alpha blockade; 2) PKC alpha inhibition blocks Munc18c displacement from the BPM; 3) PKC alpha inhibition prevents basolateral exocytosis but does not rescue apical exocytosis. We conclude that 20 mM alcohol/submaximal CCK as well supramaximal CCK stimulation can trigger pathologic basolateral exocytosis in pancreatic acinar cells via PKC alpha-mediated activation of Munc18c, which enables Syntaxin-4 to become receptive in forming a SNARE complex in the BPM; and we further postulate this to be an underlying mechanism contributing to alcoholic pancreatitis.	Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Univ Hlth Network, Dept Physiol, Toronto, ON M5S 1A8, Canada; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Gaisano, HY (corresponding author), Univ Toronto, Univ Hlth Network, Dept Med, Rm 7226,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA015579] Funding Source: NIH RePORTER; NIAAA NIH HHS [R21 AA015579-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Bedford D, 2006, Ir Med J, V99, P80; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fujita H, 1998, BIOCHEM J, V329, P527, DOI 10.1042/bj3290527; Gaisano HY, 2000, PANCREAS, V20, P217, DOI 10.1097/00006676-200004000-00001; Gaisano HY, 2004, PANCREAS, V28, P395, DOI 10.1097/00006676-200405000-00008; GAISANO HY, 1992, BIOCHEM BIOPH RES CO, V187, P498, DOI 10.1016/S0006-291X(05)81522-0; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Gorelick FS, 2003, PANCREAS, V27, P305, DOI 10.1097/00006676-200311000-00006; Gukovskaya AS, 2004, AM J PHYSIOL-GASTR L, V286, pG204, DOI 10.1152/ajpgi.00088.2003; Hanck C, 2004, GASTROENTEROL CLIN N, V33, P751, DOI 10.1016/j.gtc.2004.07.002; James DE, 2005, J CLIN INVEST, V115, P219, DOI 10.1172/JCI200524158; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; LI C, 2000, AM J PHYSIOL-GASTR L, V287, pG764; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MURPHY JA, 2006, PANCREAS, V33, P485; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Oh E, 2005, DIABETES, V54, P638, DOI 10.2337/diabetes.54.3.638; Pandol SJ, 2003, PANCREAS, V27, P297, DOI 10.1097/00006676-200311000-00004; Pickett JA, 2005, J BIOL CHEM, V280, P1506, DOI 10.1074/jbc.M411967200; Purohit V, 2003, PANCREAS, V27, P281, DOI 10.1097/00006676-200311000-00001; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Saluja AK, 2003, PANCREAS, V27, P327, DOI 10.1097/00006676-200311000-00010; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; STEER M, 1998, NEW ENGL J MED, V316, P144; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	35	53	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13047	13058		10.1074/jbc.M611132200	http://dx.doi.org/10.1074/jbc.M611132200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324928	hybrid			2022-12-25	WOS:000245942800074
J	Novoselov, SV; Kryukov, GV; Xu, XM; Carlson, BA; Hatfield, DL; Gladyshev, VN				Novoselov, Sergey V.; Kryukov, Gregory V.; Xu, Xue-Ming; Carlson, Bradley A.; Hatfield, Dolph L.; Gladyshev, Vadim N.			Selenoprotein H is a nucleolar thioredoxin-like protein with a unique expression pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER-RNAS; EUKARYOTIC SECIS ELEMENTS; GENE-EXPRESSION; MAMMALIAN SELENOPROTEIN; GLUTATHIONE-PEROXIDASE; UGA CODONS; INSERTION; BINDING; MUSCLE; FORM	The human selenoproteome consists of 25 known selenoproteins, but functions of many of these proteins are not known. Selenoprotein H ( SelH) is a recently discovered 14-kDa mammalian protein with no sequence homology to functionally characterized proteins. By sensitive sequence and structure analyses, we identified SelH as a thioredoxin fold-like protein in which a conserved CXXU motif ( cysteine separated by two other residues from selenocysteine) corresponds to the CXXC motif in thioredoxins. These data suggest a redox function of SelH. Indeed, a recombinant SelH shows significant glutathione peroxidase activity. In addition, SelH has a conserved RKRK motif in the N-terminal sequence. We cloned wild-type and cysteine mutant forms of SelH either upstream or downstream of green fluorescent protein ( GFP) and localized this fusion protein to the nucleus in transfected mammalian cells, whereas mutations in the RKRK motif resulted in the cytosolic protein. Interestingly, the full-length SelH-GFP fusion protein localized specifically to nucleoli, whereas the N-terminal sequence of SelH fused to GFP had a diffuse nucleoplasm location. Northern blot analyses revealed low expression levels of SelH mRNA in various mouse tissues, but it was elevated in the early stages of embryonic development. In addition, SelH mRNA was overexpressed in human prostate cancer LNCaP and mouse lung cancer LCC1 cells. Down-regulation of SelH by RNA interference made LCC1 cells more sensitive to hydrogen peroxide but not to other peroxides tested. Overall, these data establish SelH as a novel nucleolar oxidoreductase and suggest that some functions in this compartment are regulated by redox and dependent on the trace element selenium.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Kryukov, Gregory V/A-9592-2008; Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016; Novoselov, Sergey/0000-0003-0104-6492; Kryukov, Gregory/0000-0002-6131-9483	NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aumann KD, 1997, BIOMED ENVIRON SCI, V10, P136; Beilstein MA, 1996, J INORG BIOCHEM, V61, P117, DOI 10.1016/0162-0134(95)00045-3; BERRIOS M, 1997, NUCL STRUCTURE FUNCT, P6; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Burk Raymond F, 2002, Nutr Clin Care, V5, P75, DOI 10.1046/j.1523-5408.2002.00006.x; BUSCH H, 1963, EXP CELL RES, P150; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Chavatte L, 2005, NAT STRUCT MOL BIOL, V12, P408, DOI 10.1038/nsmb922; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2003, GENE, V312, P17, DOI 10.1016/S0378-1119(03)00588-2; Copeland PR, 2001, BIOFACTORS, V14, P11, DOI 10.1002/biof.5520140103; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; Ferguson AD, 2006, J BIOL CHEM, V281, P3536, DOI 10.1074/jbc.M511386200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Granneman S, 2005, CURR OPIN CELL BIOL, V17, P281, DOI 10.1016/j.ceb.2005.04.001; Gu QP, 1999, ARCH BIOCHEM BIOPHYS, V361, P25, DOI 10.1006/abbi.1998.0949; Gu QP, 2000, MOL CELL BIOCHEM, V204, P49, DOI 10.1023/A:1007065829068; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; Hatfield D.L., 2002, SELENIUM ITS MOL BIO, V36, P235, DOI 10.1080/10715760290006394; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; Howard MT, 2005, EMBO J, V24, P1596, DOI 10.1038/sj.emboj.7600642; Hubert N, 1996, BIOCHIMIE, V78, P590, DOI 10.1016/S0300-9084(96)80005-8; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobson MR, 1995, J CELL BIOL, V131, P1649, DOI 10.1083/jcb.131.6.1649; Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kinch LN, 2003, PROTEINS, V52, P323, DOI 10.1002/prot.10425; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; Martin GW, 1998, RNA, V4, P65; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mekhail K, 2005, J CELL BIOL, V170, P733, DOI 10.1083/jcb.200506030; Mekhail K, 2004, CELL CYCLE, V3, P1027; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Olson MOJ, 2002, INT REV CYTOL, V219, P199; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Park SI, 1997, BIOMED ENVIRON SCI, V10, P116; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Raska I, 2006, CURR OPIN CELL BIOL, V18, P325, DOI 10.1016/j.ceb.2006.04.008; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Senger M, 1998, BIOINFORMATICS, V14, P452, DOI 10.1093/bioinformatics/14.5.452; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Thisse C, 2003, GENE EXPR PATTERNS, V3, P525, DOI 10.1016/S1567-133X(03)00054-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Whanger PD, 2000, CELL MOL LIFE SCI, V57, P1846, DOI 10.1007/PL00000666; Xu XM, 2005, J BIOL CHEM, V280, P41568, DOI 10.1074/jbc.M506696200	70	89	96	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11960	11968		10.1074/jbc.M701605200	http://dx.doi.org/10.1074/jbc.M701605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17337453	Green Submitted, hybrid			2022-12-25	WOS:000245941900039
J	Ferdinands, JM; Mannino, DM; Gwinn, ML; Bray, MS				Ferdinands, Jill M.; Mannino, David M.; Gwinn, Marta L.; Bray, Molly S.			ADRB2 Arg16Gly Polymorphism, Lung Function, and Mortality: Results from the Atherosclerosis Risk in Communities Study	PLOS ONE			English	Article							BETA-AGONIST USE; BETA(2)-ADRENERGIC RECEPTOR; ASTHMA; ASSOCIATION; ALBUTEROL; GENOTYPE; METAANALYSIS; HAPLOTYPE; DEATH	Background. Growing evidence suggests that the Arg16Arg genotype of the beta-2 adrenergic receptor gene may be associated with adverse effects of beta-agonist therapy. We sought to examine the association of beta-agonist use and the Arg16Gly polymorphism with lung function and mortality among participants in the Atherosclerosis Risk in Communities study. Methodology and Principal Findings. We genotyped study participants and analyzed the association of the Arg16Gly polymorphism and beta-agonist use with lung function at baseline and clinical examination three years later and with all-cause mortality during 10 years of follow-up. Lung function was characterized by percent-predicted forced expiratory volume in 1 second. Associations were examined separately for blacks and whites. Black beta-agonist users with the Arg/Arg genotype had better lung function at baseline and at the second clinical visit than those with Arg/Gly and Gly/Gly genotypes. Adjusted mean percent-predicted FEV1 was 21% higher in Arg/Arg subjects compared to Gly/Gly at baseline (p = 0.01) and 20% higher than Gly/Gly at visit 2 (p = 0.01). Arg/Gly subjects had adjusted percent-predicted FEV1 17% lower than Arg/Arg at baseline but were similar to Arg/Arg subjects at visit 2. Although black beta-agonist users with the Arg/Arg genotype appeared to have better crude survival rates, the association between genotype and all-cause mortality was inconclusive. We found no difference in lung function or mortality by genotype among blacks who did not use beta-agonists or among whites, regardless of beta-agonist use. Conclusions. Black beta-agonist users with the ADRB2 Arg16Arg genotype had better lung function, and, possibly, better overall survival compared to black beta-agonist users with the Gly16Gly genotype. Our findings highlight the need for additional studies of sufficient size and statistical power to allow examination of outcomes among beta-agonist users of different races and genotypes.	[Ferdinands, Jill M.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; [Mannino, David M.] Univ Kentucky, Coll Med, Div Pulm Crit Care & Sleep Med, Lexington, KY USA; [Gwinn, Marta L.] Ctr Dis Control & Prevent, Natl Off Publ Hlth Genom, Atlanta, GA USA; [Bray, Molly S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Centers for Disease Control & Prevention - USA; University of Kentucky; Centers for Disease Control & Prevention - USA; Baylor College of Medicine	Ferdinands, JM (corresponding author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.	zdn5@cdc.gov		Mannino, David/0000-0003-3646-7828	National Heart, Lung, and Blood Institute [1R01HL073366-01, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC55020, N01-HC-55021, N01-HC-55022]; Centers for Disease Control and Prevention [UR6/CCU617218]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055021, N01HC055020, N01HC055019, N01HC055015, N01HC055022, N01HC055016, N01HC055018] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R41HL055019, R42HL055018, R41HL055018, R01HL073366] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants 1R01HL073366-01 from the National Heart, Lung, and Blood Institute and UR6/CCU617218 from the Centers for Disease Control and Prevention. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC55020, N01-HC-55021, and N01-HC-55022.	Belfer I, 2005, EUR J HUM GENET, V13, P341, DOI 10.1038/sj.ejhg.5201313; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Israel E, 2005, J ALLERGY CLIN IMMUN, V115, pS532, DOI 10.1016/j.jaci.2005.01.029; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Joos L, 2002, CURR OPIN PULM MED, V8, P9, DOI 10.1097/00063198-200201000-00003; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; PAUWELS RA, 2001, AM J RESP CRIT CARE, V163, P1276; Raby BA, 2001, CURR OPIN MOL THER, V3, P554; Ramsay CE, 1999, CLIN EXP ALLERGY, V29, P1195; SEARS MR, 1994, DRUG SAFETY, V11, P259, DOI 10.2165/00002018-199411040-00005; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Summerhill E, 2000, AM J RESP CRIT CARE, V162, P599, DOI 10.1164/ajrccm.162.2.9910108; Tantisira KG, 2005, CURR OPIN MOL THER, V7, P209; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Taylor DR, 2000, J ASTHMA, V37, P691, DOI 10.3109/02770900009087308; TAYLOR M, 2006, PHARMACOGENOMICS J, P1; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; Turner SW, 2004, CLIN EXP ALLERGY, V34, P1043, DOI 10.1111/j.1365-2222.2004.02001.x; Wechsler ME, 2005, AM J RESP CRIT CARE, V172, P12, DOI 10.1164/rccm.200412-1635OE; WEISS ST, 2006, PHARMACOGENOMICS J; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; ARCH INTERN MED, V158, P1855	32	12	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e289	10.1371/journal.pone.0000289	http://dx.doi.org/10.1371/journal.pone.0000289			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356698	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444800012
J	Hullin, R; Matthes, J; von Vietinghoff, S; Bodi, I; Rubio, M; D'Souza, K; Khan, IF; Rottlander, D; Hoppe, UC; Mohacsi, P; Schmitteckert, E; Gilsbach, R; Bunemann, M; Hein, L; Schwartz, A; Herzig, S				Hullin, Roger; Matthes, Jan; von Vietinghoff, Sibylle; Bodi, Ilona; Rubio, Marta; D'Souza, Karen; Khan, Ismail Friedrich; Rottlaender, Dennis; Hoppe, Uta C.; Mohacsi, Paul; Schmitteckert, Eva; Gilsbach, Ralf; Buenemann, Moritz; Hein, Lutz; Schwartz, Arnold; Herzig, Stefan			Increased Expression of the Auxiliary beta(2)-subunit of Ventricular L-type Ca(2+) Channels Leads to Single-Channel Activity Characteristic of Heart Failure	PLOS ONE			English	Article								Background. Increased activity of single ventricular L-type Ca(2+)-channels (L-VDCC) is a hallmark in human heart failure. Recent findings suggest differential modulation by several auxiliary beta-subunits as a possible explanation. Methods and Results. By molecular and functional analyses of human and murine ventricles, we find that enhanced L-VDCC activity is accompanied by altered expression pattern of auxiliary L-VDCC beta-subunit gene products. In HEK293-cells we show differential modulation of single L-VDCC activity by coexpression of several human cardiac beta-subunits: Unlike beta(1) or beta(3) isoforms, beta(2a) and beta(2b) induce a high-activity channel behavior typical of failing myocytes. In accordance, beta(2)-subunit mRNA and protein are up-regulated in failing human myocardium. In a model of heart failure we find that mice overexpressing the human cardiac Ca(V)1.2 also reveal increased single-channel activity and sarcolemmal beta(2) expression when entering into the maladaptive stage of heart failure. Interestingly, these animals, when still young and non-failing ("Adaptive Phase''), reveal the opposite phenotype, viz: reduced single-channel activity accompanied by lowered beta(2) expression. Additional evidence for the cause-effect relationship between beta(2)-subunit expression and single L-VDCC activity is provided by newly engineered, double-transgenic mice bearing both constitutive Ca(V)1.2 and inducible beta(2) cardiac overexpression. Here in non-failing hearts induction of beta(2)-subunit overexpression mimicked the increase of single L-VDCC activity observed in murine and human chronic heart failure. Conclusions. Our study presents evidence of the pathobiochemical relevance of beta(2)-subunits for the electrophysiological phenotype of cardiac L-VDCC and thus provides an explanation for the single L-VDCC gating observed in human and murine heart failure.	[Hullin, Roger; Mohacsi, Paul] Univ Hosp Bern, Swiss Heart Ctr Bern, Dept Cardiol, CH-3010 Bern, Switzerland; [Matthes, Jan; Khan, Ismail Friedrich; Rottlaender, Dennis; Herzig, Stefan] Univ Cologne, Dept Pharmacol, Cologne, Germany; [von Vietinghoff, Sibylle; Schmitteckert, Eva; Buenemann, Moritz; Hein, Lutz] Univ Wurzburg, Dept Pharmacol, Wurzburg, Germany; [von Vietinghoff, Sibylle] Fac Med Charite, Franz Volhard Clin, Nephrol Hypertens Sect, Berlin, Germany; [Bodi, Ilona; Rubio, Marta; D'Souza, Karen; Schwartz, Arnold] Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH USA; [Khan, Ismail Friedrich; Hoppe, Uta C.; Herzig, Stefan] Univ Cologne, Ctr Mol Med, Cologne, Germany; [Gilsbach, Ralf; Hein, Lutz] Univ Freiburg, Dept Expt & Clin Pharmacol & Toxicol, Freiburg, Germany	University of Bern; University Hospital of Bern; University of Cologne; University of Wurzburg; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Ohio; University of Cincinnati; University of Cologne; University of Freiburg	Hullin, R (corresponding author), Univ Hosp Bern, Swiss Heart Ctr Bern, Dept Cardiol, CH-3010 Bern, Switzerland.	roger.hullin@insel.ch; schwara@email.uc.edu; stefan.herzig@uni-koeln.de	Matthes, Jan/AAF-1229-2020; Hein, Lutz/GRJ-8644-2022	Matthes, Jan/0000-0003-2754-1555; Gilsbach, Ralf/0000-0002-0895-1535; Herzig, Stefan/0000-0001-8107-5204	DFG [HE1578/13-1, SFB355 TPC10]; ZMMK [A5]; NIH (NHLBI) [R01 HL079599-01, T32-HL07382-30]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079599, T32HL007382] Funding Source: NIH RePORTER	DFG(German Research Foundation (DFG)); ZMMK; NIH (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Grant Support: Herzig S, DFG HE1578/13-1, ZMMK A5; Schwartz A, NIH (NHLBI), R01 HL079599-01; Schwartz A., Bodi I. T32-HL07382-30; Hullin R, Schweizer Herzstiftung, Katharina Huber-Steiner Stiftung; Hein L, DFG SFB355 TPC10.	Bodi I, 2005, J CLIN INVEST, V115, P3306, DOI 10.1172/JCI27167; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; Dalton S, 2005, J PHYSIOL-LONDON, V567, P757, DOI 10.1113/jphysiol.2005.093195; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Figulla HR, 1996, CIRCULATION, V94, P346, DOI 10.1161/01.CIR.94.3.346; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Foerster K, 2003, P NATL ACAD SCI USA, V100, P14475, DOI 10.1073/pnas.1936026100; Ganesan AN, 2006, CIRC RES, V98, pE11, DOI 10.1161/01.RES.0000202692.23001.e2; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Groner F, 2004, BIOCHEM BIOPH RES CO, V314, P878, DOI 10.1016/j.bbrc.2003.12.174; Grueter CE, 2006, MOL CELL, V23, P641, DOI 10.1016/j.molcel.2006.07.006; Haase H, 2000, J CELL BIOCHEM, V76, P695, DOI 10.1002/(SICI)1097-4644(20000315)76:4<695::AID-JCB17>3.0.CO;2-Q; Haase H, 1996, J MOL MED-JMM, V74, P99; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126, DOI 10.1152/ajpheart.2000.278.1.H126; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Klugbauer N, 1999, J NEUROSCI, V19, P684; Matthes J, 2004, J MOL CELL CARDIOL, V36, P241, DOI 10.1016/j.yjmcc.2003.11.013; Mukherjee R, 1998, J MOL CELL CARDIOL, V30, P1899, DOI 10.1006/jmcc.1998.0755; Murakami M, 2003, J BIOL CHEM, V278, P43261, DOI 10.1074/jbc.M211380200; Muth JN, 1999, J BIOL CHEM, V274, P21503, DOI 10.1074/jbc.274.31.21503; Muth JN, 2001, CIRCULATION, V103, P140; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Schotten U, 2003, J MOL CELL CARDIOL, V35, P437, DOI 10.1016/S0022-2828(03)00012-9; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Serikov V, 2002, BIOCHEM BIOPH RES CO, V293, P1405, DOI 10.1016/S0006-291X(02)00396-0; Shannon TR, 2004, ANN NY ACAD SCI, V1015, P28, DOI 10.1196/annals.1302.003; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Song LS, 2002, CIRC RES, V90, P174, DOI 10.1161/hh0202.103230; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175	44	49	50	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e292	10.1371/journal.pone.0000292	http://dx.doi.org/10.1371/journal.pone.0000292			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356701	gold, Green Published, Green Accepted			2022-12-25	WOS:000207444800015
J	Gilbert, MTP; Moore, W; Melchior, L; Worobey, M				Gilbert, M. Thomas P.; Moore, Wendy; Melchior, Linea; Worobey, Michael			DNA Extraction from Dry Museum Beetles without Conferring External Morphological Damage	PLOS ONE			English	Article							COLEOPTERA	Background. A large number of dry-preserved insect specimens exist in collections around the world that might be useful for genetic analyses. However, until now, the recovery of nucleic acids from such specimens has involved at least the partial destruction of the specimen. This is clearly undesirable when dealing with rare species or otherwise important specimens, such as type specimens. Methodology. We describe a method for the extraction of PCR-amplifiable mitochondrial and nuclear DNA from dry insects without causing external morphological damage. Using PCR to amplify approximate to 220 bp of the mitochondrial gene cytochrome c oxidase I, and 250-345 bp fragments of the multi-copy, nuclear 28s ribosomal DNA gene, we demonstrate the efficacy of this method on beetles collected up to 50 years ago. Conclusions. This method offers a means of obtaining useful genetic information from rare insects without conferring external morphological damage.	[Gilbert, M. Thomas P.; Melchior, Linea; Worobey, Michael] Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; [Gilbert, M. Thomas P.] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; [Moore, Wendy] Calif Acad Sci, Dept Entomol, San Francisco, CA 94118 USA; [Melchior, Linea] Univ Copenhagen, Inst Forens Med, Res Lab, Copenhagen, Denmark	University of Arizona; University of Copenhagen; Niels Bohr Institute; California Academy of Sciences; University of Copenhagen	Gilbert, MTP (corresponding author), Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.	mtpgilbert@gmail.com	Gilbert, Marcus TP/A-8936-2013	Gilbert, Marcus TP/0000-0002-5805-7195; Moore, Wendy/0000-0003-4441-6203	University of Arizona	University of Arizona	The University of Arizona is acknowledged for funding the research.	Blaxter ML, 2004, PHILOS T R SOC B, V359, P669, DOI 10.1098/rstb.2003.1447; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Hillis David M., 1996, P321; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Maddison DR, 1999, SYST ENTOMOL, V24, P103, DOI 10.1046/j.1365-3113.1999.00088.x; Pfeiffer I, 2004, FORENSIC SCI INT, V141, P149, DOI 10.1016/j.forsciint.2004.01.016; PHILLIPS AJ, 1995, ANN ENTOMOL SOC AM, V88, P281, DOI 10.1093/aesa/88.3.281; Rohland N, 2004, BIOTECHNIQUES, V36, P814, DOI 10.2144/04365ST05; Sambrook J., 1989, MOL CLONING LAB MANU; VOGLER AP, 1993, ANN ENTOMOL SOC AM, V86, P142, DOI 10.1093/aesa/86.2.142	10	180	197	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e272	10.1371/journal.pone.0000272	http://dx.doi.org/10.1371/journal.pone.0000272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342206	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444700007
J	Hook, BA; Goldstrohm, AC; Seay, DJ; Wickens, M				Hook, Brad A.; Goldstrohm, Aaron C.; Seay, Daniel J.; Wickens, Marvin			Two yeast PUF proteins negatively regulate a single mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEADENYLASE COMPLEX; BINDING PROTEINS; RECRUITMENT; HOMOLOG; FAMILY; DECAY; LOCALIZATION; SENSITIVITY; TRANSCRIPT; MICRORNAS	mRNA stability and translation are regulated by protein repressors that bind 3'-untranslated regions. PUF proteins provide a paradigm for these regulatory molecules: like other repressors, they inhibit translation, enhance mRNA decay, and promote poly( A) removal. Here we show that a single mRNA in Saccharomyces cerevisiae, encoding the HO endonuclease, is regulated by two distinct PUF proteins, Puf4p and Mpt5p. These proteins bind to adjacent sites and can co-occupy the mRNA. Both proteins are required for full repression and deadenylation in vivo; their removal dramatically stabilizes the mRNA. The two proteins act through overlapping but non-identical mechanisms: repression by Puf4p is dependent on deadenylation, whereas repression by Mpt5p can occur through additional mechanisms. Combinatorial action of the two regulatory proteins may allow responses to specific environmental cues and be common in 3'-untranslated region-mediated control.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	wickens@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050942] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50942] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Bernstein D, 2005, RNA, V11, P447, DOI 10.1261/rna.7255805; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chen TS, 1997, MOL CELL BIOL, V17, P3429, DOI 10.1128/MCB.17.6.3429; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Colegrove-Otero LJ, 2005, CRIT REV BIOCHEM MOL, V40, P21, DOI 10.1080/10409230590918612; Crittenden SL, 2002, NATURE, V417, P660, DOI 10.1038/nature754; Duttagupta R, 2003, MOL CELL BIOL, V23, P2623, DOI 10.1128/MCB.23.8.2623-2632.2003; Eckmann CR, 2002, DEV CELL, V3, P697, DOI 10.1016/S1534-5807(02)00322-2; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Goldstrohm AC, 2007, J BIOL CHEM, V282, P109, DOI 10.1074/jbc.M609413200; Goldstrohm AC, 2006, NAT STRUCT MOL BIOL, V13, P533, DOI 10.1038/nsmb1100; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Hook B, 2005, RNA, V11, P227, DOI 10.1261/rna.7202705; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jackson JS, 2004, RNA, V10, P1625, DOI 10.1261/rna.7270204; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Luitjens C, 2000, GENE DEV, V14, P2596, DOI 10.1101/gad.831700; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Moraes KCM, 2006, RNA, V12, P1084, DOI 10.1261/rna.59606; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Roush SF, 2006, ACS CHEM BIOL, V1, P132, DOI 10.1021/cb600138j; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103	38	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15430	15438		10.1074/jbc.M611253200	http://dx.doi.org/10.1074/jbc.M611253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389596	hybrid			2022-12-25	WOS:000246589600018
J	Fredriksson, J; Anevski, D; Almgren, P; Sjogren, M; Lyssenko, V; Carlson, J; Isomaa, B; Taskinen, MR; Groop, L; Orho-Melander, M				Fredriksson, Jenny; Anevski, Dragi; Almgren, Peter; Sjogren, Marketa; Lyssenko, Valeriya; Carlson, Joyce; Isomaa, Bo; Taskinen, Marja-Riitta; Groop, Leif; Orho-Melander, Marju		Botnia Study Grp	Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality	PLOS ONE			English	Article							GLYCOGEN-SYNTHASE GENE; APOLIPOPROTEIN-E POLYMORPHISM; WIDE LINKAGE SCANS; SUSCEPTIBILITY LOCUS; INSULIN-RESISTANCE; DIABETES-MELLITUS; GENOME SCAN; TRAITS; RISK; METAANALYSIS	Background. The muscle glycogen synthase gene (GYS1) has been associated with type 2 diabetes (T2D), the metabolic syndrome (MetS), male myocardial infarction and a defective increase in muscle glycogen synthase protein in response to exercise. We addressed the questions whether polymorphism in GYS1 can predict cardiovascular (CV) mortality in a high-risk population, if this risk is influenced by gender or physical activity, and if the association is independent of genetic variation in nearby apolipoprotein E gene (APOE). Methodology/Principal Findings. Polymorphisms in GYS1 (XbaIC>T) and APOE (-219G>T, epsilon 2/epsilon 3/epsilon 4) were genotyped in 4,654 subjects participating in the Botnia T2D-family study and followed for a median of eight years. Mortality analyses were performed using Cox proportional-hazards regression. During the follow-up period, 749 individuals died, 409 due to CV causes. In males the GYS1 XbaI T-allele (hazard ratio (HR) 1.9 [1.2-2.9]), T2D (2.5 [1.7-3.8]), earlier CV events (1.7 [1.2-2.5]), physical inactivity (1.9 [1.2-2.9]) and smoking (1.5 [1.0-2.3]) predicted CV mortality. The GYS1 XbaI T-allele predicted CV mortality particularly in physically active males (HR 1.7 [1.3-2.0]). Association of GYS1 with CV mortality was independent of APOE (219TT/epsilon 4), which by its own exerted an effect on CV mortality risk in females (2.9 [1.9-4.4]). Other independent predictors of CV mortality in females were fasting plasma glucose (1.2 [1.1-1.2]), high body mass index (BMI) (1.0 [1.0-1.1]), hypertension (1.9 [1.2-3.1]), earlier CV events (1.9 [1.3-2.8]) and physical inactivity (1.9 [1.2-2.8]). Conclusions/Significance. Polymorphisms in GYS1 and APOE predict CV mortality in T2D families in a gender-specific fashion and independently of each other. Physical exercise seems to unmask the effect associated with the GYS1 polymorphism, rendering carriers of the variant allele less susceptible to the protective effect of exercise on the risk of CV death, which finding could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this polymorphism.	[Fredriksson, Jenny; Anevski, Dragi; Almgren, Peter; Sjogren, Marketa; Lyssenko, Valeriya; Carlson, Joyce; Groop, Leif; Orho-Melander, Marju] Lund Univ, Dept Clin Sci Malmo, Clin Res Ctr, Malmo, Sweden; [Anevski, Dragi] Chalmers Univ Technol, Dept Math Sci, S-41296 Gothenburg, Sweden; [Isomaa, Bo] Helsinki & Malmska Municipal Hlth Care Ctr & Hosp, Biomedicum, Folkhalsan Res Ctr, Folkhalsan Inst Genet, Pietarsaari, Finland; [Taskinen, Marja-Riitta; Groop, Leif] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; [Groop, Leif] Univ Helsinki, Res Program Mol Med, Helsinki, Finland	Lund University; Chalmers University of Technology; Folkhalsan Research Center; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Orho-Melander, M (corresponding author), Lund Univ, Dept Clin Sci Malmo, Clin Res Ctr, Malmo, Sweden.	marju.orho-melander@med.lu.se	Taskinen, Marja-Riitta/AAN-5432-2020	Taskinen, Marja-Riitta/0000-0002-6229-3588	Diabetes Program at Lund University (DPLU); Foundation for Strategic Research through the National Network for Cardiovascular Research; Swedish Medical Research Council; Swedish Foundation for the Study of Diabetes; Albert Pahlssons Foundation; Malmo University Hospital Foundation; Crafoord Foundation; Lundberg Foundation; Novo Nordisk Foundation; Swedish Heart and Lung Foundation; Medical Faculty of Lund University; EXGENESIS [CT-2004-005272]; Sigrid Juselius Foundation; Academy of Finland; Finnish Diabetes Research Foundation; Folkhalsan Research Foundation; Viktor Ollqvist Foundation	Diabetes Program at Lund University (DPLU); Foundation for Strategic Research through the National Network for Cardiovascular Research; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Foundation for the Study of Diabetes; Albert Pahlssons Foundation; Malmo University Hospital Foundation; Crafoord Foundation; Lundberg Foundation(European Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Medical Faculty of Lund University; EXGENESIS(European Commission); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Finnish Diabetes Research Foundation; Folkhalsan Research Foundation; Viktor Ollqvist Foundation	This work was supported by grants from the Diabetes Program at Lund University (DPLU), the Foundation for Strategic Research through the National Network for Cardiovascular Research, the Swedish Medical Research Council, the Swedish Foundation for the Study of Diabetes, the Albert Pahlssons Foundation, Malmo University Hospital Foundation, Crafoord Foundation, the Lundberg Foundation, the Novo Nordisk Foundation, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University and EXGENESIS CT-2004-005272. The Botnia Study is principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation, and the Viktor Ollqvist Foundation.	Adeyemo AA, 2005, ATHEROSCLEROSIS, V181, P389, DOI 10.1016/j.atherosclerosis.2004.12.049; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; An P, 2005, DIABETOLOGIA, V48, P1142, DOI 10.1007/s00125-005-1769-4; An P, 2005, DIABETES, V54, P909, DOI 10.2337/diabetes.54.3.909; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Beekman M, 2003, EUR J HUM GENET, V11, P845, DOI 10.1038/sj.ejhg.5201053; Bell CG, 2004, DIABETES, V53, P1857, DOI 10.2337/diabetes.53.7.1857; Bosse Y, 2004, J LIPID RES, V45, P419, DOI 10.1194/jlr.M300401-JLR200; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; CASELLA G, 1990, STAT INFERENCE, P360; DUPONT W, POWER SAMPLE SIZE CA; EHNHOLM C, 1986, J LIPID RES, V27, P227; FEITOSA MF, 2005, ATHEROSCLEROSIS; Fenger M, 2000, DIABETIC MED, V17, P735, DOI 10.1046/j.1464-5491.2000.00377.x; Groop L, 1996, DIABETES, V45, P1585, DOI 10.2337/diabetes.45.11.1585; GROOP LC, 1993, NEW ENGL J MED, V328, P10, DOI 10.1056/NEJM199301073280102; Heijmans BT, 2005, EUR J HUM GENET, V13, P1143, DOI 10.1038/sj.ejhg.5201466; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; KADOWAKI T, 1993, NEW ENGL J MED, V328, P1568; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mori Y, 2002, DIABETES, V51, P1247, DOI 10.2337/diabetes.51.4.1247; *NAT HEART LUNG BL, 2002, NHLBI MORB MORT CHAR; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Orho-Melander M, 1999, DIABETOLOGIA, V42, P1138, DOI 10.1007/s001250051282; Panhuysen CIM, 2003, DIABETOLOGIA, V46, P579, DOI 10.1007/s00125-003-1066-z; Pollin TI, 2004, ATHEROSCLEROSIS, V173, P89, DOI 10.1016/j.atherosclerosis.2003.11.012; Pratley RE, 1998, J CLIN INVEST, V101, P1757, DOI 10.1172/JCI1850; Rinn JL, 2005, TRENDS GENET, V21, P298, DOI 10.1016/j.tig.2005.03.005; Rissanen J, 1997, DIABETOLOGIA, V40, P1313, DOI 10.1007/s001250050826; SchalinJantti C, 1996, HYPERTENSION, V27, P67, DOI 10.1161/01.HYP.27.1.67; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; Shephard RJ, 2000, CAN J APPL PHYSIOL, V25, P19, DOI 10.1139/h00-002; SING CF, 1985, AM J HUM GENET, V37, P268; Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013; St-Onge J, 2001, DIABETES, V50, P195, DOI 10.2337/diabetes.50.1.195; van Tilburg JHO, 2003, J CLIN ENDOCR METAB, V88, P2223, DOI 10.1210/jc.2002-021252; Watanabe RM, 2000, AM J HUM GENET, V67, P1186; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; Ye S, 2003, EUR J HUM GENET, V11, P437, DOI 10.1038/sj.ejhg.5200983; ZOUALI H, 1993, NEW ENGL J MED, V328, P1568; 1999, JAMA, V269, P3015	44	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e285	10.1371/journal.pone.0000285	http://dx.doi.org/10.1371/journal.pone.0000285			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356695	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444800008
J	Kumar, R; Qiu, J; Joshi, T; Valliyodan, B; Xu, D; Nguyen, HT				Kumar, Rajesh; Qiu, Jing; Joshi, Trupti; Valliyodan, Babu; Xu, Dong; Nguyen, Henry T.			Single Feature Polymorphism Discovery in Rice	PLOS ONE			English	Article								The discovery of nucleotide diversity captured as single feature polymorphism (SFP) by using the expression array is a high-throughput and effective method in detecting genome-wide polymorphism. The efficacy of such method was tested in rice, and the results presented in the paper indicate high sensitivity in predicting SFP. The sensitivity of polymorphism detection was further demonstrated by the fact that no biasness was observed in detecting SFP with either single or multiple nucleotide polymorphisms. The high density SFP data that can be generated quite effectively by the current method has promise for high resolution genetic mapping studies, as physical location of features are well-defined on rice genome.	[Kumar, Rajesh; Valliyodan, Babu; Nguyen, Henry T.] Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA; [Qiu, Jing] Univ Missouri, Dept Stat, Columbia, MO 65211 USA; [Joshi, Trupti; Xu, Dong] Univ Missouri, Dept Comp Sci, Columbia, MO USA; [Joshi, Trupti; Xu, Dong] Univ Missouri, Christopher S Bond Life Sci Ctr, Columbia, MO USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Kumar, R (corresponding author), Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA.	kumarr@missouri.edu; nguyenhenry@missouri.edu		Joshi, Trupti/0000-0001-8944-4924; Valliyodan, Babu/0000-0001-9457-9508	USDA-NRI; USDA-CSREES [2004-35317-14867]	USDA-NRI(United States Department of Agriculture (USDA)); USDA-CSREES(United States Department of Agriculture (USDA)National Institute of Food and Agriculture)	This work was conducted under RiceCAP project (www.uark.edu/ua/ricecap/) entitled "A coordinated research, education, and extension project for the application of genomics discoveries to improve rice in the United States.'' The multi-institutional RiceCAP project was supported by the USDA-NRI Competitive Grants Program and funding was from the USDA-CSREES (2004-35317-14867) to HTN.	Aluko G, 2004, THEOR APPL GENET, V109, P630, DOI 10.1007/s00122-004-1668-y; Bevan M, 1999, TRENDS GENET, V15, P211, DOI 10.1016/S0168-9525(99)01744-8; BOREVITZ J, 2005, ARRAY GENOTYPING MAP; Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; Buckler ES, 2002, CURR OPIN PLANT BIOL, V5, P107, DOI 10.1016/S1369-5266(02)00238-8; Cui XP, 2005, BIOINFORMATICS, V21, P3852, DOI 10.1093/bioinformatics/bti640; Feltus FA, 2004, GENOME RES, V14, P1812, DOI 10.1101/gr.2479404; Garris AJ, 2005, GENETICS, V169, P1631, DOI 10.1534/genetics.104.035642; Hazen SP, 2003, TRENDS PLANT SCI, V8, P413, DOI 10.1016/S1360-1385(03)00186-9; Hazen SP, 2005, PLANT PHYSIOL, V138, P990, DOI 10.1104/pp.105.061408; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Kim S, 2006, GENETICS, V173, P1125, DOI 10.1534/genetics.105.052720; Lu H, 2005, CROP SCI, V45, P66, DOI 10.2135/cropsci2005.0066; Lukowitz W, 2000, PLANT PHYSIOL, V123, P795, DOI 10.1104/pp.123.3.795; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Ni J, 2002, CROP SCI, V42, P601, DOI 10.2135/cropsci2002.0601; Rostoks N, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r54; Shen YJ, 2004, PLANT PHYSIOL, V135, P1198, DOI 10.1104/pp.103.038463; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Werner JD, 2005, GENETICS, V170, P1197, DOI 10.1534/genetics.104.036533; Winzeler EA, 2003, GENETICS, V163, P79; Wolyn DJ, 2004, GENETICS, V167, P907, DOI 10.1534/genetics.103.024810; 2005, IRGSP RELEASES BUILD; 2003, SUPERSCAFFOLD STAT O; SUPPLEMENTARY DATA S	25	52	54	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e284	10.1371/journal.pone.0000284	http://dx.doi.org/10.1371/journal.pone.0000284			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372626	gold, Green Published			2022-12-25	WOS:000207444800007
J	Traulsen, A; Nowak, MA				Traulsen, Arne; Nowak, Martin A.			Chromodynamics of Cooperation in Finite Populations	PLOS ONE			English	Article							EVOLUTIONARY GAME DYNAMICS; INDIRECT RECIPROCITY; KIN-SELECTION; GREEN BEARD; ALTRUISM; LATTICE; NETWORKS; SIGNALS; CYCLES; RULES	Background. The basic idea of tag-based models for cooperation is that individuals recognize each other via arbitrary signals, so-called tags. If there are tags of different colors, then cooperators can always establish new signals of recognition. The resulting "chromodynamics'' is a mechanism for the evolution of cooperation. Cooperators use a secret tag until they are discovered by defectors who then destroy cooperation based on this tag. Subsequently, a fraction of the population manages to establish cooperation based on a new tag. Methodology/Principal Findings. We derive a mathematical description of stochastic evolutionary dynamics of tag-based cooperation in populations of finite size. Benefit and cost of cooperation are given by b and c. We find that cooperators are more abundant than defectors if b/c > 1+2u/v, where u is the mutation rate changing only the strategy and v is the mutation rate changing strategy and tag. We study specific assumptions for u and v in two genetic models and one cultural model. Conclusions/Significance. In a genetic model, tag-based cooperation only evolves if a gene encodes both strategy and tag. In a cultural model with equal mutation rates between all possible phenotypes (tags and behaviors), the crucial condition is b/c > (K+1)/(K21), where K is the number of tags. A larger number of tags requires a smaller benefit-to-cost ratio. In the limit of many different tags, the condition for cooperators to have a higher average abundance than defectors becomes b > c.	[Traulsen, Arne; Nowak, Martin A.] Harvard Univ, Dept Organism & Evolutionary Biol, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA	Harvard University	Traulsen, A (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA.	traulsen@fas.harvard.edu	Nowak, Martin A/A-6977-2008; Traulsen, Arne/A-4955-2009	Traulsen, Arne/0000-0002-0669-5267	Deutsche Akademie der Naturforscher Leopoldina [BMBF-LPD 9901/8-134]; John Templeton foundation; NSF/NIH [1R01GM078986-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078986] Funding Source: NIH RePORTER	Deutsche Akademie der Naturforscher Leopoldina; John Templeton foundation; NSF/NIH(National Science Foundation (NSF)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Support from the Deutsche Akademie der Naturforscher Leopoldina (Grant No. BMBF-LPD 9901/8-134), the John Templeton foundation and the NSF/NIH joint program in mathematical biology (NIH grant 1R01GM078986-01) is gratefully acknowledged. The Program for Evolutionary Dynamics at Harvard University is sponsored by Jeffrey Epstein.	AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R, 2004, EVOLUTION, V58, P1833; Bernhard H, 2006, NATURE, V442, P912, DOI 10.1038/nature04981; Binmore K., 2007, PLAYING REAL TEXT GA, DOI [10.1093/acprof:oso/9780195300574.001.0001, DOI 10.1093/ACPROF:OSO/9780195300574.001.0001]; BLUME LE, 1993, GAME ECON BEHAV, V5, P387, DOI 10.1006/game.1993.1023; Brandt H, 2004, J THEOR BIOL, V231, P475, DOI 10.1016/j.jtbi.2004.06.032; Dawkins R, 1976, SELFISH GENE; Durrett R, 2005, J ECON BEHAV ORGAN, V57, P267, DOI 10.1016/j.jebo.2003.09.017; Frank S. A., 1998, FDN SOCIAL EVOLUTION, DOI DOI 10.1515/9780691206820; Fudenberg D, 2006, THEOR POPUL BIOL, V70, P352, DOI 10.1016/j.tpb.2006.07.006; GRAFEN A, 1990, ANIM BEHAV, V39, P42, DOI 10.1016/S0003-3472(05)80724-9; Grafen A, 2006, J THEOR BIOL, V238, P541, DOI 10.1016/j.jtbi.2005.06.009; Haig D, 1996, P NATL ACAD SCI USA, V93, P6547, DOI 10.1073/pnas.93.13.6547; Hales D, 2005, IEEE T SYST MAN CY A, V35, P385, DOI 10.1109/TSMCA.2005.846399; HALES D, 2004, LECT NOTES ARTIF INT, V3415, P89; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90039-6; Hartvigsen G., 2000, Complexity, V5, P14, DOI 10.1002/(SICI)1099-0526(200001/02)5:3<14::AID-CPLX3>3.0.CO;2-Q; Hauert C, 2005, AM J PHYS, V73, P405, DOI 10.1119/1.1848514; Hauert C, 2004, NATURE, V428, P643, DOI 10.1038/nature02360; Imhof LA, 2005, P NATL ACAD SCI USA, V102, P10797, DOI 10.1073/pnas.0502589102; Jansen VAA, 2006, NATURE, V440, P663, DOI 10.1038/nature04387; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Killingback T, 1998, J THEOR BIOL, V191, P335, DOI 10.1006/jtbi.1997.0602; MASUDA N, 2006, P ROY SOC LOND B BIO, V274, P689; MAYNARDSMITH J, 1976, Q REV BIOL, V51, P277; Nakamaru M, 2005, EVOL ECOL RES, V7, P853; Nakamaru M, 1997, J THEOR BIOL, V184, P65, DOI 10.1006/jtbi.1996.0243; Nowak MA, 2005, NATURE, V437, P1291, DOI 10.1038/nature04131; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Nowak MA, 2004, NATURE, V428, P646, DOI 10.1038/nature02414; Nowak MA, 2006, EVOLUTIONARY DYNAMIC; Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755; Ohtsuki H, 2004, J THEOR BIOL, V231, P107, DOI 10.1016/j.jtbi.2004.06.005; Ohtsuki H, 2006, NATURE, V441, P502, DOI 10.1038/nature04605; Pfeiffer T, 2006, CURR BIOL, V16, pR946, DOI 10.1016/j.cub.2006.10.011; Queller DC, 2003, SCIENCE, V299, P105, DOI 10.1126/science.1077742; Riolo RL, 2001, NATURE, V414, P441, DOI 10.1038/35106555; Roberts G, 2002, NATURE, V418, P499, DOI 10.1038/418499b; Rousset F, 2000, J EVOLUTION BIOL, V13, P814, DOI 10.1046/j.1420-9101.2000.00219.x; Sigmund K, 2001, NATURE, V414, P403, DOI 10.1038/35106672; Sinervo B, 2006, P NATL ACAD SCI USA, V103, P7372, DOI 10.1073/pnas.0510260103; SLATKIN M, 1978, P NATL ACAD SCI USA, V75, P3531, DOI 10.1073/pnas.75.7.3531; Summers K, 2005, P ROY SOC B-BIOL SCI, V272, P643, DOI 10.1098/rspb.2004.2890; Szabo G, 1998, PHYS REV E, V58, P69, DOI 10.1103/PhysRevE.58.69; Taylor C, 2004, B MATH BIOL, V66, P1621, DOI 10.1016/j.bulm.2004.03.004; Taylor PD, 1996, J THEOR BIOL, V180, P27, DOI 10.1006/jtbi.1996.0075; Traulsen A, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.046129; Traulsen A, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.046128; Traulsen A, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.011909; Traulsen A, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.021905; Traulsen A, 2006, P NATL ACAD SCI USA, V103, P10952, DOI 10.1073/pnas.0602530103; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; van Baalen M, 1998, J THEOR BIOL, V193, P631, DOI 10.1006/jtbi.1998.0730; van Baalen M, 2003, P ROY SOC B-BIOL SCI, V270, P69, DOI 10.1098/rspb.2002.2151; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0; West SA, 2001, NATURE, V409, P510, DOI 10.1038/35054057; WILSON DS, 1975, P NATL ACAD SCI USA, V72, P143, DOI 10.1073/pnas.72.1.143	58	84	85	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e270	10.1371/journal.pone.0000270	http://dx.doi.org/10.1371/journal.pone.0000270			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342204	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444700005
J	George, RE; Attiyeh, EF; Li, SL; Moreau, LA; Neuberg, D; Li, C; Fox, EA; Meyerson, M; Diller, L; Fortina, P; Look, AT; Maris, JM				George, Rani E.; Attiyeh, Edward F.; Li, Shuli; Moreau, Lisa A.; Neuberg, Donna; Li, Cheng; Fox, Edward A.; Meyerson, Matthew; Diller, Lisa; Fortina, Paolo; Look, A. Thomas; Maris, John M.			Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays	PLOS ONE			English	Article								Background. Neuroblastomas are characterized by chromosomal alterations with biological and clinical significance. We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array. Findings. Multiple areas of LOH and copy number gain were seen. The most commonly observed area of LOH was on chromosome arm 11q (15/22 samples; 68%). Chromosome 11q LOH was highly associated with occurrence of chromosome 3p LOH: 9 of the 15 samples with 11q LOH had concomitant 3p LOH (P = 0.016). Chromosome 1p LOH was seen in one-third of cases. LOH events on chromosomes 11q and 1p were generally accompanied by copy number loss, indicating hemizygous deletion within these regions. The one exception was on chromosome 11p, where LOH in all four cases was accompanied by normal copy number or diploidy, implying uniparental disomy. Gain of copy number was most frequently observed on chromosome arm 17q (21/22 samples; 95%) and was associated with allelic imbalance in six samples. Amplification of MYCN was also noted, and also amplification of a second gene, ALK, in a single case. Conclusions. This analysis demonstrates the power of SNP arrays for high-resolution determination of LOH and DNA copy number change in neuroblastoma, a tumor in which specific allelic changes drive clinical outcome and selection of therapy.	[George, Rani E.; Moreau, Lisa A.; Diller, Lisa; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Attiyeh, Edward F.; Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA; [Li, Shuli; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Li, Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Fox, Edward A.] Dana Farber Canc Inst, Microarray Core Facil, Boston, MA 02115 USA; [Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Fortina, Paolo] Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA	Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Jefferson University	George, RE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	rani_george@dfci.harvard.edu	Fortina, Paolo/ABE-8350-2020; George, Rani/AAG-7635-2019; Meyerson, Matthew L/E-7123-2012	Fortina, Paolo/0000-0002-5898-2081	NIH/NINDS [K08NS047983]; Young Investigator Awards; American Society of Clinical Oncology; Children's Oncology Group; NIH [R01 CA104605, R33-CA83220, R01-CA87847, U01-CA98543]; NATIONAL CANCER INSTITUTE [R01CA104605, R01CA087847, U10CA098543, R33CA083220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS047983] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Young Investigator Awards; American Society of Clinical Oncology; Children's Oncology Group; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH/NINDS Grant K08NS047983 (to R. E. G.), Young Investigator Awards, American Society of Clinical Oncology and Children's Oncology Group (to R. E. G.), NIH R01 CA104605 (A. T. L.), R33-CA83220 (to P. F., J.M.M.), R01-CA87847 (to J.M.M.) and U01-CA98543 (to the Children's Oncology Group).	Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Breen CJ, 2000, CANCER GENET CYTOGEN, V120, P44, DOI 10.1016/S0165-4608(99)00252-6; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Janoueix-Lerosey I, 2000, GENE CHROMOSOME CANC, V28, P276, DOI 10.1002/1098-2264(200007)28:3<276::AID-GCC5>3.0.CO;2-P; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Maris JM, 2005, GENOME RES, V15, P1168, DOI 10.1101/gr.3865305; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Mathew P, 2001, NEOPLASIA, V3, P105, DOI 10.1038/sj.neo.7900146; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Morowitz M, 2003, MODERN PATHOL, V16, P1248, DOI 10.1097/01.MP.0000097364.64566.81; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Murthy SK, 2002, MODERN PATHOL, V15, P1241, DOI 10.1097/01.MP.0000032535.62750.D1; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Plantaz D, 1997, AM J PATHOL, V150, P81; Raghavan M, 2005, CANCER RES, V65, P375; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Stallings RL, 2003, CANCER GENET CYTOGEN, V140, P133, DOI 10.1016/S0165-4608(02)00681-7; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WONG KK, 2004, NUCLEIC ACIDS RES, V32, P69; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	33	91	98	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e255	10.1371/journal.pone.0000255	http://dx.doi.org/10.1371/journal.pone.0000255			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327916	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444600015
J	van der Kuyl, AC; van den Burg, R; Zorgdrager, F; Groot, F; Berkhout, B; Cornelissen, M				van der Kuyl, Antoinette C.; van den Burg, Remco; Zorgdrager, Fokla; Groot, Fedde; Berkhout, Ben; Cornelissen, Marion			Sialoadhesin (CD169) Expression in CD14+Cells Is Upregulated Early after HIV-1 Infection and Increases during Disease Progression	PLOS ONE			English	Article								Background. Sialoadhesin (CD169, siglec-1 or Sn) is an activation marker seen on macrophages in chronic inflammatory diseases and in tumours, and on subsets of tissue macrophages. CD169 is highly expressed by macrophages present in AIDS-related Kaposi's sarcoma lesions. It is also increased on blood monocytes of HIV-1 infected patients with a high viral load despite antiretroviral treatment. Methodology/Principal Findings. We investigated expression of sialoadhesin in untreated HIV-1 and HHV-8 infected patients, by real-time PCR and FACS analysis to establish its expression in relation to infection and disease progression. Patients analysed were either HIV-1 seroconverters (n = 7), in the chronic phase of HIV-1 infection (n = 21), or in the AIDS stage (n = 58). Controls were HHV-8 infected, but otherwise healthy individuals (n = 20), and uninfected men having sex with men (n = 24). Sialoadhesin mRNA was significantly elevated after HIV-1, but not HHV-8 infection, and a further increase was seen in AIDS patients. Samples obtained around HIV-1 seroconversion indicated that sialoadhesin levels go up early in infection. FACS analysis of PBMCs showed that sialoadhesin protein was expressed at high levels by approximately 90% of CD14(+) and CD14(+)CD16(+) cells of HIV-1(+) patients with a concomitant 10-fold increase in sialoadhesin protein/cell compared with uninfected controls. Conclusions/Significance. We have shown that sialoadhesin is induced to high levels on CD14(+) cells early after HIV-1 infection in vivo. The phenotype of the cells is maintained during disease progression, suggesting that it could serve as a marker for infection and probably contributes to the severe dysregulation of the immune system seen in AIDS.	[van der Kuyl, Antoinette C.; van den Burg, Remco; Zorgdrager, Fokla; Groot, Fedde; Berkhout, Ben; Cornelissen, Marion] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam, Dept Med Microbiol,Lab Expt Virol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van der Kuyl, AC (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam, Dept Med Microbiol,Lab Expt Virol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.c.vanderkuyl@amc.uva.nl	Van der Kuyl, Antoinette/T-9369-2019					ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Avril T, 2006, BIOCHEM SOC T, V34, P1024, DOI 10.1042/BST0341024; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Cornelissen M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-7; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; Crocker PR, 1997, GLYCOCONJUGATE J, V14, P601, DOI 10.1023/A:1018588526788; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Decrion AZ, 2005, CURR HIV RES, V3, P243, DOI 10.2174/1570162054368057; Delputte PL, 2004, J VIROL, V78, P8094, DOI 10.1128/JVI.78.15.8094-8101.2004; Draude G, 1999, AM J PHYSIOL-HEART C, V276, pH1144, DOI 10.1152/ajpheart.1999.276.4.H1144; FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; GEYER H, 1988, J BIOL CHEM, V263, P11760; Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288; Kirchberger S, 2005, J IMMUNOL, V175, P1145, DOI 10.4049/jimmunol.175.2.1145; LOCHER C, 1994, CLIN EXP IMMUNOL, V98, P115, DOI 10.1111/j.1365-2249.1994.tb06616.x; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; Meroni L, 2005, JAIDS-J ACQ IMM DEF, V38, P310; Miller LS, 2001, AIDS RES HUM RETROV, V17, P443, DOI 10.1089/088922201750102544; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; NOCKHER WA, 1994, CLIN EXP IMMUNOL, V98, P369, DOI 10.1111/j.1365-2249.1994.tb05499.x; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Polstra AM, 2003, J CLIN MICROBIOL, V41, P5488, DOI 10.1128/JCM.41.12.5488-5491.2003; Pulliam L, 2004, J NEUROIMMUNOL, V157, P93, DOI 10.1016/j.jneuroim.2004.08.039; Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018; Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232; van der Meijden M, 1998, CELL IMMUNOL, V190, P156, DOI 10.1006/cimm.1998.1387; Vanderheijden N, 2003, J VIROL, V77, P8207, DOI 10.1128/JVI.77.15.8207-8215.2003; Weeks BS, 1998, INT J MOL MED, V1, P361	33	57	58	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e257	10.1371/journal.pone.0000257	http://dx.doi.org/10.1371/journal.pone.0000257			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330143	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444600017
J	Li, Y; Huang, J; Zhao, YL; He, J; Wang, W; Davies, KE; Nose, V; Xiao, S				Li, Y.; Huang, J.; Zhao, Y-L; He, J.; Wang, W.; Davies, K. E.; Nose, V.; Xiao, S.			UTRN on chromosome 6q24 is mutated in multiple tumors	ONCOGENE			English	Article						tumor suppressor; UTRN; functional screening	DUCHENNE MUSCULAR-DYSTROPHY; SUPPRESSOR GENE; BREAST-CANCER; TERMINAL DOMAIN; UTROPHIN GENE; CELL-LINES; ARM 6Q; TUMORIGENICITY; DELETION; HETEROZYGOSITY	Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN ( which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.	Harbin Inst Technol, Harbin, Peoples R China; Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Cornell Univ, Microarray Core Facility, Ithaca, NY USA; Univ Oxford, Dept Biochem, Oxford OX1 2JD, England	Harbin Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; University of Oxford	Xiao, S (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	sxiao@rics.bwh.harvard.edu						Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.0.CO;2-Y; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Atkin NB, 1996, CANCER GENET CYTOGEN, V92, P87, DOI 10.1016/S0165-4608(96)00131-8; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Biroccio A, 2003, ONCOGENE, V22, P6579, DOI 10.1038/sj.onc.1206812; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Brault E, 2001, J CELL SCI, V114, P1901; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hoffman PJ, 2004, FERTIL STERIL, V82, P639, DOI 10.1016/j.fertnstert.2004.01.047; Hu J, 2001, ONCOGENE, V20, P8042, DOI 10.1038/sj.onc.1204961; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Jensen RH, 2003, ANTICANCER RES, V23, P2281; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Mertens F, 1997, CANCER RES, V57, P2765; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MOSER H, 1984, HUM GENET, V66, P17, DOI 10.1007/BF00275183; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; Pozzoli U, 2002, GENETICS, V160, P793; Qu XY, 1998, DNA SEQUENCE, V9, P189, DOI 10.3109/10425179809105206; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roque L, 2003, GENE CHROMOSOME CANC, V36, P292, DOI 10.1002/gcc.10146; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 2001, CLIN CANCER RES, V7, P3404; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141	37	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6220	6228		10.1038/sj.onc.1210432	http://dx.doi.org/10.1038/sj.onc.1210432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17384672				2022-12-25	WOS:000249401300013
J	Brien, G; Trescol-Bierriont, MC; Bonnefoy-Berard, N				Brien, G.; Trescol-Bierriont, M-C; Bonnefoy-Berard, N.			Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis	ONCOGENE			English	Article						bcl-2; bfl-1; apoptosis; B lymphoma	NF-KAPPA-B; ELDERLY-PATIENTS; UP-REGULATION; R-CHOP; BCL-X; LYMPHOMA; SURVIVAL; GENE; CHEMOTHERAPY; A1/BFL-1	Elevated expression of the antiapoptotic protein Bfl-1 (A1) was previously reported in several cancer cell lines. Recently, molecular profiling of large B-cell lymphoma identified Bfl-1 as a gene signature in 'OxPhos' diffuse large B-cell lymphoma subtype and in primary mediastinal large B-cell lymphoma, suggesting that in addition to Bcl-2, Bcl-xL and Mcl-1, Bfl-1 may be a relevant target in the design of new strategies for cancer therapy. Using short hairpin RNA strategy, we show here that Bfl-1 silencing in one lymphoblastoid B-cell line and in two diffuse large B-cell lymphoma cell lines potently induces their apoptosis and sensitizes those cell lines to anti-CD20 (Rituximab)-mediated cell death as well as to apoptosis induced by chemotherapeutic molecules such as doxorubicin, vincristine, cisplatin and fludarabine. These results demonstrate for the first time that Bfl-1 is an essential protein for survival of malignant B cells and suggest Bfl-1 may represent a potential target for future drug development against B cell lymphoma.	INSERM, U 503, Lab Homeostasie Lymphocytaire, F-69007 Lyon, France; Univ Lyon 1, F-69003 Lyon, France; IFR128, F-69007 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bonnefoy-Berard, N (corresponding author), INSERM, U 503, Lab Homeostasie Lymphocytaire, 21 Ave Tony Garnier, F-69007 Lyon, France.	bonnefoy@cervi-lyon.inserm.fr	Bonnefoy, Nathalie/J-2536-2012	Bonnefoy, Nathalie/0000-0003-4814-6722				Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Cottalorda A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Mounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Trescol-Biemont MC, 2004, BIOCHIMIE, V86, P287, DOI 10.1016/j.biochi.2004.04.001; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	25	67	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5828	5832		10.1038/sj.onc.1210363	http://dx.doi.org/10.1038/sj.onc.1210363			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353899				2022-12-25	WOS:000248885100015
J	Tong, Y; Tan, Y; Zhou, C; Melmed, S				Tong, Y.; Tan, Y.; Zhou, C.; Melmed, S.			Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition	ONCOGENE			English	Article						PTTG1; pituitary; cell cycle	TRANSCRIPTIONAL ACTIVATION FUNCTION; BREAST-CANCER CELLS; CYCLE PROGRESSION; POTENTIAL ROLE; GROWTH-FACTOR; C-MYC; EXPRESSION; PTTG; MICE; IDENTIFICATION	Pituitary tumor transforming gene (PTTG1) was isolated from rat pituitary tumor cells, and subsequently identified as a securin protein as well as a transcription factor. We show here a global transcriptional effect of PTTG1 in human choriocarcinoma JEG-3 cells by simultaneously assessing 20 000 gene promoters using chromatin immunoprecipitation (ChIP)-on-Chip experiments. Seven hundred and forty-six gene promoters (P < 0.001) were found enriched, with functions relating to cell cycle, metabolic control and signal transduction. Significant interaction between PTTG1 and Sp1 (P < 0.000001) was found by transcriptional pattern analysis of ChIP data and further confirmed by immunoprecipitation and pull-down assays. PTTG1 acts coordinately with Sp1 to induce cyclin D3 expression similar to threefold, and promotes G1/S-phase transition independently of p21. PTTG1 deletion was also protective for anchorage-independent cell colony formation. The results show that PTTG1 exhibits properties of a global transcription factor, and specifically modulates the G1/S-phase transition by interacting with Sp1. This novel signaling pathway may be required for PTTG1 transforming activity.	Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Acad Affairs, Room 2015,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	melmed@csmc.edu	Zhou, Cuiqi/B-1568-2010		NATIONAL CANCER INSTITUTE [R01CA075979, K99CA138914] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075979, K99 CA138914, R01 CA075979-09, CA 75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Clem AL, 2003, GENE, V322, P113, DOI 10.1016/j.gene.2003.08.012; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Honda S, 2003, ANTICANCER RES, V23, P3775; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	29	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5596	5605		10.1038/sj.onc.1210339	http://dx.doi.org/10.1038/sj.onc.1210339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353909	Green Accepted			2022-12-25	WOS:000248801900005
J	Adams, VH; McBryant, SJ; Wade, PA; Woodcock, CL; Hansen, JC				Adams, Valerie H.; McBryant, Steven J.; Wade, Paul A.; Woodcock, Christopher L.; Hansen, Jeffrey C.			Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING PROTEIN; SEDIMENTATION-VELOCITY ANALYSIS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; RETT-SYNDROME; CHROMOSOMAL-PROTEIN; DNA METHYLATION; CHROMATIN; SEQUENCE; ASSOCIATION	To probe the tertiary structure and domain organization of native methyl CpG-binding protein 2 ( MeCP2), the recombinant human e2 isoform was purified to homogeneity and characterized by analytical ultracentrifugation, CD, and protease digestion. The location of intrinsic disorder in the MeCP2 sequence was predicted using the FoldIndex algorithm. MeCP2 was found to be monomeric in low and high salt and over a nearly 1000-fold concentration range. CD indicated that the MeCP2 monomer was nearly 60% unstructured under conditions where it could preferentially recognize CpG dinucleotides and condense chromatin. Protease digestion experiments demonstrate that MeCP2 is composed of at least six structurally distinct domains, two of which correspond to the well characterized methyl DNA binding domain and transcriptional repression domain. These domains collectively are organized into a tertiary structure with coil-like hydrodynamic properties, reflecting the extensive disorder in the MeCP2 sequence. When expressed as individual fragments, the methyl DNA binding domain and transcriptional repression domain both could function as nonspecific DNA binding domains. The unusual structural features of MeCP2 provide a basis for understanding MeCP2 multifunctionality in vitro and in vivo. These studies also establish an experimental paradigm for characterizing the tertiary structures of other highly disordered proteins.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	Colorado State University; University of Massachusetts System; University of Massachusetts Amherst; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hansen, JC (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 1870 Campus Delivery, Ft Collins, CO 80523 USA.	Jeffrey.C.Hansen@colostate.edu	Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM45916, GM70897, GM66834] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066834, R29GM045916, R01GM045916, R01GM070897] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Brero A, 2005, J CELL BIOL, V169, P733, DOI 10.1083/jcb.200502062; Brunner E, 2000, J BIOMOL NMR, V17, P175, DOI 10.1023/A:1008394831749; Buschdorf JP, 2004, J MOL MED, V82, P135, DOI 10.1007/s00109-003-0497-9; Carro S, 2004, J BIOL CHEM, V279, P25623, DOI 10.1074/jbc.M402571200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Demeler B, 2004, ANAL BIOCHEM, V335, P279, DOI 10.1016/j.ab.2004.08.039; Demeler B, 2000, METHOD ENZYMOL, V321, P38; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Hansen JC, 2006, J BIOL CHEM, V281, P1853, DOI 10.1074/jbc.R500022200; Harikrishnan KN, 2006, NAT GENET, V38, P964, DOI 10.1038/ng0906-964; Haynes C, 2006, PLOS COMPUT BIOL, V2, P890, DOI 10.1371/journal.pcbi.0020100; Heitmann B, 2003, EUR J BIOCHEM, V270, P3263, DOI 10.1046/j.1432-1033.2003.03714.x; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Hu KP, 2006, NAT GENET, V38, P962, DOI 10.1038/ng0906-962; Huppke P, 2005, J CHILD NEUROL, V20, P732, DOI 10.1177/08830738050200090601; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kato Y, 2004, J BIOL CHEM, V279, P31833, DOI 10.1074/jbc.M404719200; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klose RJ, 2004, J BIOL CHEM, V279, P46490, DOI 10.1074/jbc.M408284200; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kriaucionis S, 2004, NUCLEIC ACIDS RES, V32, P1818, DOI 10.1093/nar/gkh349; Laccone F, 2001, HUM MUTAT, V17, P183, DOI 10.1002/humu.3; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liu JG, 2006, BIOCHEMISTRY-US, V45, P6873, DOI 10.1021/bi0602718; Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979; McBryant SJ, 2006, BIOCHEMISTRY-US, V45, P15941, DOI 10.1021/bi061693k; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nikitina T, 2007, MOL CELL BIOL, V27, P864, DOI 10.1128/MCB.01593-06; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wade PA, 2004, BIOESSAYS, V26, P217, DOI 10.1002/bies.20018; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Young JI, 2005, P NATL ACAD SCI USA, V102, P17551, DOI 10.1073/pnas.0507856102; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172	53	101	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15057	15064		10.1074/jbc.M700855200	http://dx.doi.org/10.1074/jbc.M700855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371874	hybrid			2022-12-25	WOS:000246589000045
J	Hatherley, D; Harlos, K; Dunlop, DC; Stuart, DI; Barclay, AN				Hatherley, Deborah; Harlos, Karl; Dunlop, D. Cameron; Stuart, David I.; Barclay, A. Neil			The structure of the macrophage signal regulatory protein alpha (SIRP alpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; ADHESION MOLECULE CD2; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; ANTIGEN RECOGNITION; MYELOID CELLS; MHC LIGAND; CLASS-I; COMPLEX; FAMILY	Signal regulatory protein ( SIRP) alpha is a membrane receptor that sends inhibitory signals to myeloid cells by engagement of CD47. The high resolution x-ray structure of the N-terminal ligand binding domain shows it to have a distinctive immunoglobulin superfamily V-like fold. Site-directed mutagenesis suggests that CD47 is bound at a surface involving the BC, FG, and DE loops, which distinguishes it from other immunoglobulin superfamily surface proteins that use the faces of the fold, but resembles antigen receptors. The SIRP interaction is confined to a single domain, and its use of an extended DE loop strengthens the similarity with T cell receptor binding and the suggestion that they are closely related in evolution. The employment of loops to form the CD47-binding surface provides a mechanism for small sequence changes to modulate binding specificity, explaining the different binding properties of SIRP family members.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford Prot Prod Facil, Oxford OX3 7BN, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Wellcome Centre for Human Genetics	Barclay, AN (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.	neil.barclay@path.ox.ac.uk		Stuart, David/0000-0002-3426-4210	Medical Research Council [G0500365, G0400808] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0500365, G0400808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Bamford DH, 2005, CURR OPIN STRUC BIOL, V15, P655, DOI 10.1016/j.sbi.2005.10.012; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BARCLAY AN, 1997, LEUCOCYTE ANTIGEN FA, P1; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao E, 2006, IMMUNITY, V25, P559, DOI 10.1016/j.immuni.2006.06.020; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Dong XH, 2006, J BIOL CHEM, V281, P10610, DOI 10.1074/jbc.M513459200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Hatherley D, 2005, J IMMUNOL, V175, P2469, DOI 10.4049/jimmunol.175.4.2469; Hatherley D, 2004, EUR J IMMUNOL, V34, P1688, DOI 10.1002/eji.200425080; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu Y, 2005, J BIOL CHEM, V280, P36132, DOI 10.1074/jbc.M506419200; Liu Y, 2007, J MOL BIOL, V365, P680, DOI 10.1016/j.jmb.2006.09.079; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Piccio L, 2005, BLOOD, V105, P2421, DOI 10.1182/blood-2004-07-2823; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Tomasello E, 2005, EUR J IMMUNOL, V35, P1670, DOI 10.1002/eji.200425932; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; van den Berg TK, 2005, J IMMUNOL, V175, P7788, DOI 10.4049/jimmunol.175.12.7788; van den Berg TK, 2004, TRENDS IMMUNOL, V25, P11, DOI 10.1016/j.it.2003.11.006; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Zhang XW, 2001, ACTA CRYSTALLOGR D, V57, P898, DOI 10.1107/S0907444901005777	65	51	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14567	14575		10.1074/jbc.M611511200	http://dx.doi.org/10.1074/jbc.M611511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369261	hybrid			2022-12-25	WOS:000246245800070
J	Yeh, YH; Kesavulu, MM; Li, HM; Wu, SZ; Sun, YJ; Konozy, EHE; Hsiao, CD				Yeh, Yi-Hung; Kesavulu, Muppuru M.; Li, Hsou-min; Wu, Shu-Zon; Sun, Yuh-Ju; Konozy, Emadeldin H. E.; Hsiao, Chwan-Deng			Dimerization is important for the GTPase activity of chloroplast translocon components at Toc33 and psToc159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; PREPROTEIN RECEPTOR; BINDING; DOMAIN; INSERTION; ATTOC159; ENVELOPE; MUTANT; TOC159	Arabidopsis Toc33 (atToc33) is a GTPase and a member of the Toc (translocon at the outer-envelope membrane of chloroplasts) complex that associates with precursor proteins during protein import into chloroplasts. By inference from the crystal structure of psToc34, a homologue in pea, the arginine at residue 130 (Arg(130)) has been implicated in the formation of the atToc33 dimer and in intermolecular GTPase activation within the dimer. Here we report the crystal structure at 3.2-angstrom resolution of an atToc33 mutant, atToc33(R130A), in which Arg130 was mutated to alanine. Both in solution and in crystals, atToc33(R130A) was present in its monomeric form. In contrast, both wild-type atToc33 and another pea Toc GTPase homologue, pea Toc159 (psToc159), were able to form dimers in solution. Dimeric atToc33 and psToc159 had significantly higher GTPase activity than monomeric atToc33, psToc159, and atToc33(R130A). Molecular modeling using the structures of psToc34 and atToc33(R130A) suggests that, in an architectural dimer of atToc33, Arg130 from one monomer interacts with the beta-phosphate of GDP and several other amino acids of the other monomer. These results indicate that Arg130 is critical for dimer formation, which is itself important for GTPase activity. Activation of GTPase activity by dimer formation is likely to be a critical regulatory step in protein import into chloroplasts.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	hsiao@gate.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Kesavulu, Muppuru/G-4344-2013; Hsiao, Chwan-Deng/D-7327-2013; Li, Hsou-min/AAZ-8011-2021	Hsiao, Chwan-Deng/0000-0002-7012-1532; Kesavulu, Muppuru/0000-0002-3557-4739; Li, Hsou-min/0000-0002-0211-7339				Aronsson H, 2003, FEBS LETT, V544, P79, DOI 10.1016/S0014-5793(03)00478-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; Constan D, 2004, PLANT J, V38, P93, DOI 10.1111/j.1365-313X.2004.02024.x; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; Hillebrand S, 2005, ANAL BIOANAL CHEM, V383, P92, DOI 10.1007/s00216-005-3375-1; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Li HM, 1997, J BIOL CHEM, V272, P10968; MANNE V, 1985, BIOCHEM BIOPH RES CO, V128, P1440, DOI 10.1016/0006-291X(85)91101-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Scrima A, 2006, EMBO J, V25, P2940, DOI 10.1038/sj.emboj.7601171; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Tsai LY, 1999, J BIOL CHEM, V274, P18735, DOI 10.1074/jbc.274.26.18735; Wallas TR, 2003, J BIOL CHEM, V278, P44289, DOI 10.1074/jbc.M307873200; Weibel P, 2003, J BIOL CHEM, V278, P37321, DOI 10.1074/jbc.M305946200; Young ME, 1999, PLANT PHYSIOL, V121, P237, DOI 10.1104/pp.121.1.237	33	38	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13845	13853		10.1074/jbc.M608385200	http://dx.doi.org/10.1074/jbc.M608385200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337454	hybrid			2022-12-25	WOS:000246060300074
J	Plumet, S; Herschke, F; Bourhis, JM; Valentin, H; Longhi, S; Gerlier, D				Plumet, Sebastien; Herschke, Florence; Bourhis, Jean-Marie; Valentin, Helene; Longhi, Sonia; Gerlier, Denis			Cytosolic 5 '-Triphosphate Ended Viral Leader Transcript of Measles Virus as Activator of the RIG I-Mediated Interferon Response	PLOS ONE			English	Article								Background. Double stranded RNA (dsRNA) is widely accepted as an RNA motif recognized as a danger signal by the cellular sentries. However, the biology of non-segmented negative strand RNA viruses, or Mononegavirales, is hardly compatible with the production of such dsRNA. Methodology and Principal Findings. During measles virus infection, the IFN-beta gene transcription was found to be paralleled by the virus transcription, but not by the virus replication. Since the expression of every individual viral mRNA failed to activate the IFN-beta gene, we postulated the involvement of the leader RNA, which is a small not capped and not polyadenylated RNA firstly transcribed by Mononegavirales. The measles virus leader RNA, synthesized both in vitro and in vivo, was efficient in inducing the IFN-beta expression, provided that it was delivered into the cytosol as a 5'-trisphosphate ended RNA. The use of a human cell line expressing a debilitated RIG-I molecule, together with overexpression studies of wild type RIG-I, showed that the IFN-beta induction by virus infection or by leader RNA required RIG-I to be functional. RIG-I binds to leader RNA independently from being 5-trisphosphate ended; while a point mutant, Q299A, predicted to establish contacts with the RNA, fails to bind to leader RNA. Since the 5'-triphosphate is required for optimal RIG-I activation but not for leader RNA binding, our data support that RIG-I is activated upon recognition of the 5'-triphosphate RNA end. Conclusions/Significance. RIG-I is proposed to recognize Mononegavirales transcription, which occurs in the cytosol, while scanning cytosolic RNAs, and to trigger an IFN response when encountering a free 5'-triphosphate RNA resulting from a mislocated transcription activity, which is therefore considered as the hallmark of a foreign invader.	[Plumet, Sebastien; Herschke, Florence; Gerlier, Denis] Univ Lyon 1, CNRS, Fac Med, RTH Laennec, F-69365 Lyon, France; [Bourhis, Jean-Marie; Longhi, Sonia] Univ Aix Marseille 1, CNRS, UMR 6098, Marseille, France; [Bourhis, Jean-Marie; Longhi, Sonia] Univ Aix Marseille 2, F-13284 Marseille 07, France; [Valentin, Helene] Univ Lyon 1, INSERM, Immunol Fondamentale & Clin, Biosci Lyon Gerland IFR128,UMR 6098, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gerlier, D (corresponding author), Univ Lyon 1, CNRS, Fac Med, RTH Laennec, F-69365 Lyon, France.	denis.gerlier@univ-lyon1.fr	Gerlier, Denis/L-6094-2014; LONGHI, Sonia/M-5305-2014; Valentin, Helene/AAA-4265-2020	Gerlier, Denis/0000-0001-5539-456X; LONGHI, Sonia/0000-0002-6829-6771; 	Delegation Generale de l'Armement; MNERT; ANR-MIME	Delegation Generale de l'Armement; MNERT; ANR-MIME(French National Research Agency (ANR))	S. P. is an engineer supported by the Delegation Generale de l'Armement and F. H. is supported by an MNERT fellowship. The work was supported by a grant from ANR-MIME.	ABRAHAM G, 1975, CELL, V5, P51, DOI 10.1016/0092-8674(75)90091-4; Albertini AAV, 2006, SCIENCE, V313, P360, DOI 10.1126/science.1125280; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Baens M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000054; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; CASTANEDA SJ, 1990, J VIROL, V64, P222, DOI 10.1128/JVI.64.1.222-230.1990; CASTANEDA SJ, 1989, J VIROL, V63, P2977, DOI 10.1128/JVI.63.7.2977-2986.1989; Childs K, 2007, VIROLOGY, V359, P190, DOI 10.1016/j.virol.2006.09.023; Cortay JC, 2006, J VIROL METHODS, V131, P16, DOI 10.1016/j.jviromet.2005.06.021; Dhib-Jalbut S, 1999, J IMMUNOL, V162, P4024; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Garcin D, 2004, J VIROL, V78, P8799, DOI 10.1128/JVI.78.16.8799-8811.2004; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Green TJ, 2006, SCIENCE, V313, P357, DOI 10.1126/science.1126953; HEFTI E, 1975, J VIROL, V15, P90, DOI 10.1128/JVI.15.1.90-96.1975; Helin E, 2001, VIROLOGY, V290, P1, DOI 10.1006/viro.2001.1174; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; HORIKAMI SM, 1991, J VIROL, V65, P5342, DOI 10.1128/JVI.65.10.5342-5347.1991; Hornung V, 2006, SCIENCE; Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; KAWAI T, 2005, NAT IMMUNOL; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolakofsky D, 2004, VIROLOGY, V318, P463, DOI 10.1016/j.virol.2003.10.031; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LEPPERT M, 1978, J VIROL, V25, P427, DOI 10.1128/JVI.25.1.427-432.1978; LYNCH S, 1978, J VIROL, V28, P584, DOI 10.1128/JVI.28.2.584-589.1978; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MOYER SA, 1975, CELL, V5, P59, DOI 10.1016/0092-8674(75)90092-6; Nishino T, 2005, STRUCTURE, V13, P143, DOI 10.1016/j.str.2004.11.008; PERRY RP, 1981, J CELL BIOL, V91, pS28, DOI 10.1083/jcb.91.3.28s; Plumet S, 2005, J VIROL METHODS, V128, P79, DOI 10.1016/j.jviromet.2005.03.020; Plumet S, 2005, J VIROL, V79, P6900, DOI 10.1128/JVI.79.11.6900-6908.2005; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Reis e Sousa A, 2006, SCIENCE; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; VIDAL S, 1989, J VIROL, V63, P1951, DOI 10.1128/JVI.63.5.1951-1958.1989; Vidalain PO, 2002, J VIROL, V76, P6415, DOI 10.1128/JVI.76.13.6415-6424.2002; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	55	153	161	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e279	10.1371/journal.pone.0000279	http://dx.doi.org/10.1371/journal.pone.0000279			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356690	gold, Green Published			2022-12-25	WOS:000207444800002
J	Yuli, C; Shao, N; Rao, R; Aysola, P; Reddy, V; Oprea-llies, G; Lee, L; Okoli, J; Partridge, E; Reddy, ESP; Rao, VN				Yuli, C.; Shao, N.; Rao, R.; Aysola, P.; Reddy, V.; Oprea-llies, G.; Lee, L.; Okoli, J.; Partridge, E.; Reddy, E. S. P.; Rao, V. N.			BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers	ONCOGENE			English	Article						BRCA1a/1b; ovarian cancers; prostate cancer; tumor suppressor; estrogen receptor; triple-negative breast cancers	MAMMARY EPITHELIAL-CELLS; SPLICE VARIANTS; GENE BRCA1; EXPRESSION; P53; SUPPRESSION; INHIBITION; INTERACTS; DISTINCT; RNA	Breast cancer gene 1 ( BRCA1) mutations predispose women to breast and ovarian cancers and men to increased risks for prostate cancer. We have previously showed BRCA1 splice variant BRCA1a/p110 to induce apoptosis of human breast cancer cells. In the current study, stable expression of BRCA1a/p110 resulted in inhibition of growth of estrogen receptor ( ER)- positive and triple-negative ( TN) human breast, ovarian, prostate and colon cancer cells and mouse fibroblast cells. Similar to wildtype BRCA1, only those cells with wild- type Rb were sensitive to BRCA1a-induced growth suppression and the status of p53 did not affect the ability of BRCA1a to suppress growth of tumor cells. BRCA1a also significantly inhibited tumor mass in nude mice bearing human CAL- 51 TN breast cancer, ES- 2 ovarian cancer and PC- 3 prostate cancer xenografts. These results suggest that the majority of exon 11 sequences ( residues 263 - 1365) are not required for the tumor suppressor function of BRCA1 proteins. This is the first report demonstrating antitumor activity of BRCA1a in human ER- positive and TN breast, hormone-independent ovarian and prostate cancer cells. Currently, there are no effective treatments against TN breast cancers and results from these studies will provide new treatments for one of the biggest needs in breast cancer research.	Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, Atlanta, GA 30303 USA; Drexel Univ, Dept Biochem, Program Canc Genet, Philadelphia, PA 19104 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Sci Applicat Int Corp, Frederick, MD USA; Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Surg, Atlanta, GA USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Gynecol Oncol, Birmingham, AL USA	Morehouse School of Medicine; Drexel University; Emory University; Science Applications International Corporation (SAIC); Morehouse School of Medicine; University of Alabama System; University of Alabama Birmingham	Rao, VN (corresponding author), Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, 80 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	vrao@msm.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011104, G12RR003034] Funding Source: NIH RePORTER; NCRR NIH HHS [SP20RR11104, G-12-RR03034] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Grunberg E, 2000, TUMOR BIOL, V21, P211, DOI 10.1159/000030127; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Lu ML, 1996, CANCER RES, V56, P4578; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Marot D, 2006, GENE THER, V13, P235, DOI 10.1038/sj.gt.3302637; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Orban TI, 2001, BIOCHEM BIOPH RES CO, V280, P32, DOI 10.1006/bbrc.2000.4068; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; SHAO Q, 1996, CARDIOVASC PATHOBIOL, V1, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tait DL, 2000, GYNECOL ONCOL, V79, P471, DOI 10.1006/gyno.2000.5969; THEILE M, 1995, ONCOGENE, V10, P439; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Wang G, 2002, INT J CAST METAL RES, V15, P143; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	28	23	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6031	6037		10.1038/sj.onc.1210420	http://dx.doi.org/10.1038/sj.onc.1210420			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384678				2022-12-25	WOS:000249277200006
J	Bieler, G; Hasmim, M; Monnier, Y; Imaizumi, N; Ameyar, M; Bamat, J; Ponsonnet, L; Choualb, S; Grell, M; Goodman, SL; Lejeune, F; Ruegg, C				Bieler, G.; Hasmim, M.; Monnier, Y.; Imaizumi, N.; Ameyar, M.; Bamat, J.; Ponsonnet, L.; Choualb, S.; Grell, M.; Goodman, S. L.; Lejeune, F.; Rueegg, C.			Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappa B activation and endothelial cell survival	ONCOGENE			English	Article						endothelium; cell death; cancer; signaling; angiogenesis	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; PROTEIN-KINASE B/AKT; SHEAR-STRESS; CANCER CELLS; IFN-GAMMA; DEATH; INTERFERON; INHIBITION; PATHWAY	Tumor necrosis factor (TNF) is a pro-inflammatory cytokine exerting pleiotropic effects on endothelial cells. Depending on the vascular context it can induce endothelial cell activation and survival or death. The microenvironmental cues determining whether endothelial cells will survive or die, however, have remained elusive. Here we report that integrin ligation acts permissive for TNF-induced protein kinase B (PKB/Akt) but not nuclear factor (NF)-kappa B activation. Concomitant activation of PKB/Akt and NF-kappa B is essential for the survival of endothelial cells exposed to TNF. Active PKB/Akt strengthens integrin-dependent endothelial cell adhesion, whereas disruption of actin stress fibers abolishes the protective effect of PKB/Akt. Integrin-mediated adhesion also represses TNF-induced JNK activation, but JNK activity is not required for cell death. The alpha V beta 3/alpha V beta 5 integrin inhibitor EMD121974 sensitizes endothelial cells to TNF-dependent cytotoxicity and active PKB/ Akt attenuates this effect. Interferon gamma synergistically enhanced TNF-induced endothelial cell death in all conditions tested. Taken together, these observations reveal a novel permissive role for integrins in TNF-induced PKB/ Akt activation and prevention of TNF-induced death distinct of NF-kappa B, and implicate the actin cytoskeleton in PKB/Akt-mediated cell survival. The sensitizing effect of EMD121974 on TNF cytotoxicity may open new perspectives to the therapeutic use of TNF as anticancer agent.	Lausanne Canc Ctr, Div Expt Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; Inst Gustave Roussy, INSERM, UNIT U487, F-94805 Villejuif, France; Merck KGaA, Preclin Res Oncol, Darmstadt, Germany	Swiss Institute Experimental Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Merck KGaA	Ruegg, C (corresponding author), Lwoff Inst, CNRS, FRE 2944, 7 Rue Guy Moquet, F-94801 Villejuif, France.	curzio.ruegg@isrec.ch	Chouaib, Salem/F-7939-2016	Goodman, Simon L./0000-0002-3480-1346; Hasmim, Meriem/0000-0002-7920-2443				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BALKWILL FR, 1987, CANCER RES, V47, P4755; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 2002, INT REV CYTOL, V214, P225; Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chen JX, 2004, AM J PHYSIOL-HEART C, V287, pH187, DOI 10.1152/ajpheart.01058.2003; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Imose M, 2003, LIVER INT, V23, P386, DOI 10.1034/j.1478-3231.2003.00867.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Laird SM, 1998, CELL SIGNAL, V10, P473, DOI 10.1016/S0898-6568(97)00173-3; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; MAREEL M, 1988, INT J CANCER, V42, P470, DOI 10.1002/ijc.2910420327; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NOLOP KB, 1990, AM J PHYSIOL, V259, P123; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Pober JS, 1998, PATHOL BIOL, V46, P159; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SCANLON M, 1989, P NATL ACAD SCI USA, V86, P182, DOI 10.1073/pnas.86.1.182; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Spagnuolo R, 2004, BLOOD, V103, P3005, DOI 10.1182/blood-2003-07-2459; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Yilmaz A, 1998, INT J CANCER, V77, P592; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548	40	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5722	5732		10.1038/sj.onc.1210354	http://dx.doi.org/10.1038/sj.onc.1210354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369858				2022-12-25	WOS:000248885100004
J	Hu, B; Guo, P; Bar-Joseph, I; Imanishi, Y; Jarzynka, MJ; Bogler, O; Mikkelsen, T; Hirose, T; Nishikawa, R; Cheng, SY				Hu, B.; Guo, P.; Bar-Joseph, I.; Imanishi, Y.; Jarzynka, M. J.; Bogler, O.; Mikkelsen, T.; Hirose, T.; Nishikawa, R.; Cheng, S. Y.			Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway	ONCOGENE			English	Article						neuropilin-1; HGF/SF; c-Met; glioma	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; CANCER CELLS; EXPRESSION; RECEPTORS; INDUCTION	Neuropilin-1 (NRP1) functions as a coreceptor through interaction with plexin A1 or vascular endothelial growth factor (VEGF) receptor during neuronal development and angiogenesis. NRP1 potentiates the signaling pathways stimulated by semaphorin 3A and VEGF-A in neuronal and endothelial cells, respectively. In this study, we investigate the role of tumor cell-expressed NRP1 in glioma progression. Analyses of human glioma specimens (WHO grade I-IV tumors) revealed a significant correlation of NRP1 expression with glioma progression. In tumor xenografts, overexpression of NRP1 by U87MG gliomas strongly promoted tumor growth and angiogenesis. Overexpression of NRP1 by U87MG cells stimulated cell survival through the enhancement of autocrine hepatocyte growth factor/scatter factor (HGF/SF)/c-Met signaling. NRP1 not only potentiated the activity of endogenous HGF/SF on glioma cell survival but also enhanced HGF/SF-promoted cell proliferation. Inhibition of HGF/SF, c-Met and NRP1 abrogated NRP1-potentiated autocrine HGF/SF stimulation. Furthermore, increased phosphorylation of c-Met correlated with glioma progression in human glioma biopsies in which NRP1 is upregulated and in U87MG NRP1-overexpressing tumors. Together, these data suggest that tumor cell-expressed NRP1 promotes glioma progression through potentiating the activity of the HGF/SF autocrine c-Met signaling pathway, in addition to enhancing angiogenesis, suggesting a novel mechanism of NRP1 in promoting human glioma progression.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Res Pavil Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA; Saitama Med Univ, Dept Pathol, Saitama, Japan; Saitama Med Univ, Dept Neurosurg, Saitama, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital; Saitama Medical University; Saitama Medical University	Cheng, SY (corresponding author), Univ Pittsburgh, Inst Canc, Suite 2-26,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	hub@upmc.edu; chengs@upmc.edu	Imanishi, Yorihisa/AAL-3018-2021	Imanishi, Yorihisa/0000-0003-0047-7987; Bogler, Oliver/0000-0002-3700-0480	NATIONAL CANCER INSTITUTE [R24CA095809, R01CA130966, R01CA102011] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA130966-01A1, CA102011, R01 CA130966, R24 CA095809, R01 CA102011-04, R01 CA102011-02, R01 CA102011, CA095809, R01 CA102011-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Bachelder RE, 2003, CANCER RES, V63, P5230; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Guo P, 2001, CANCER RES, V61, P8569; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663	17	140	145	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5577	5586		10.1038/sj.onc.1210348	http://dx.doi.org/10.1038/sj.onc.1210348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369861	Green Accepted			2022-12-25	WOS:000248801900003
J	Shemesh, Y; Cohen, M; Bloch, G				Shemesh, Yair; Cohen, Mira; Bloch, Guy			Natural plasticity in circadian rhythms is mediated by reorganization in the molecular clockwork in honeybees	FASEB JOURNAL			English	Article						social behavior; clock gene; Apis mellifera	DIVISION-OF-LABOR; LOCOMOTOR BEHAVIOR; PERIOD EXPRESSION; GENE-EXPRESSION; ORGANIZATION; COLONY; LIGHT; CHRONOBIOLOGY; TIMELESS; BRAIN	Various animals naturally switch to considerable periods of around-the-clock activity with no apparent ill effects. Such plasticity in overt circadian rhythms might be observed because the clock is masked by the influence of external factors, is uncoupled from behavioral outputs, or results from genuine plasticity in the clock machinery. We studied honeybees in which plasticity in circadian rhythms is socially modulated and associated with the division of labor. We confirm that "nurse" bees care for the brood around-the-clock even when experiencing a light: dark illumination regime. However, nurses transferred from the hive to individual cages in constant conditions have robust circadian rhythms in locomotor activity with an onset of activity at the subjective morning. These data indicate that circadian rhythmicity in nurses depends on their environment, and suggest that some clockwork components were entrained even in nurses active around the clock while in the hive. Brain oscillations in transcript abundance for the putative clock genes Period, Cryptochrome-m, Cycle, and Timeout were attenuated or totally suppressed in nurses as compared to behaviorally rhythmic foragers, irrespective of the illumination regime. These findings provide the first support for the hypothesis that natural plasticity in circadian rhythms is associated with reorganization of the internal clock-work.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Bloch, G (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, Berman 114,Givat Ram Campus, IL-91904 Jerusalem, Israel.	bloch@vms.huji.ac.il	Bloch, Guy/I-5861-2019	Bloch, Guy/0000-0003-1624-4926				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Barnes JW, 2003, SCIENCE, V302, P439, DOI 10.1126/science.1086593; Bloch G, 2004, INSECT BIOCHEM MOLEC, V34, P879, DOI 10.1016/j.ibmb.2004.05.004; Bloch G, 2001, NATURE, V410, P1048, DOI 10.1038/35074183; Bloch G, 2001, J BIOL RHYTHM, V16, P444, DOI 10.1177/074873001129002123; Bloch G, 2007, J COMP PHYSIOL A, V193, P181, DOI 10.1007/s00359-006-0179-5; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Grima B, 2004, NATURE, V431, P869, DOI 10.1038/nature02935; Lin Y, 2004, J NEUROSCI, V24, P7951, DOI 10.1523/JNEUROSCI.2370-04.2004; Lyamin O, 2005, NATURE, V435, P1177, DOI 10.1038/4351177a; Menaker M, 2006, P NATL ACAD SCI USA, V103, P3015, DOI 10.1073/pnas.0600360103; Moore D, 2001, J INSECT PHYSIOL, V47, P843, DOI 10.1016/S0022-1910(01)00057-9; Moore D, 1998, BEHAV ECOL SOCIOBIOL, V43, P147, DOI 10.1007/s002650050476; Ohta H, 2005, NAT NEUROSCI, V8, P267, DOI 10.1038/nn1395; PAGE RE, 1988, ANIM BEHAV, V36, P944, DOI 10.1016/S0003-3472(88)80181-7; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Rubin EB, 2006, GENOME RES, V16, P1352, DOI 10.1101/gr.5094806; Stoleru D, 2005, NATURE, V438, P238, DOI 10.1038/nature04192; Stoleru D, 2004, NATURE, V431, P862, DOI 10.1038/nature02926; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Toma DP, 2000, P NATL ACAD SCI USA, V97, P6914, DOI 10.1073/pnas.97.12.6914; van der Veen DR, 2006, P NATL ACAD SCI USA, V103, P3393, DOI 10.1073/pnas.0507825103; van Oort BEH, 2005, NATURE, V438, P1095, DOI 10.1038/4381095a; von Frisch K., 1967, DANCE LANGUAGE ORIEN; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yerushalmi S, 2006, J EXP BIOL, V209, P1044, DOI 10.1242/jeb.02125; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	33	53	55	1	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2304	2311		10.1096/fj.06-8032com	http://dx.doi.org/10.1096/fj.06-8032com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17360847				2022-12-25	WOS:000248454400005
J	Maillet, EL; Pellegrini, N; Valant, C; Bucher, B; Hibert, M; Bourguignon, JJ; Galzi, JL				Maillet, Emeline L.; Pellegrini, Nadia; Valant, Celine; Bucher, Bernard; Hibert, Marcel; Bourguignon, Jean-Jacques; Galzi, Jean-Luc			A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties	FASEB JOURNAL			English	Article						allosterism; signal transduction; GPCR; neurokinin; drug discovery	PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL HYDROLYSIS; DOPAMINE-RECEPTOR; AGONIST; ACTIVATION; RESPONSES; ANTAGONIST; MULTIPLE; MUTATION; CALCIUM	The orthosteric agonist neurokinin A (NKA) interacts with the tachykinin NK2 receptors (NK2Rs) via an apparent sequential binding process, which stabilizes the receptor in at least two different active conformations (A1L and A2L). The A1L conformation exhibits fast NKA dissociation kinetics and triggers intracellular calcium elevation; the A2L conformation exhibits slow NKA dissociation kinetics and triggers cAMP production. The new compound LPI805 is a partial and noncompetitive inhibitor of NKA binding to NK2Rs. Analysis of NKA dissociation in the presence of LPI805 suggests that LPI805 decreases the number of NKA-NK2R complexes in A2L conformation while increasing those in the A1L conformation. Analysis of signaling pathways of NK2Rs shows that LPI805 dramatically inhibits the NKA-induced cAMP response while slightly enhancing the NKA-induced calcium response. Analysis of NKA association kinetics reveals that LPI805 promotes strong and specific destabilization of the NKA-NK2R complexes in the A2L conformation whereas access of NKA to the A1L conformations is unchanged. Thus, to our knowledge, LPI805 is the first example of a conformation-specific allosteric antagonist of a G-protein-coupled receptor. This work establishes the use of allosteric modulators in order to promote functional selectivity on certain agonist-receptor interactions.	Univ Strasbourg, CNRS, UMR 7175, Inst Gilbert Laustriat, Strasbourg, France; ESBS, Dept Recepteurs & Prot Membraines, Illkirch Graffenstaden, France; Fac Pharm, Dept Pharmacol & Physicochim Interact Cellulaires, Illkirch Graffenstaden, France; Fac Pharm, Dept Pharmacochim Commun Cellulaire, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maillet, EL (corresponding author), Mt Sinai Sch Med, Dept Neurosci, 1425 Madison Ave,Box 1065, New York, NY 10029 USA.	emeline.maillet@mssm.edu	maillet, emeline/G-5177-2012	maillet, emeline/0000-0003-0129-6328; Valant, Celine/0000-0002-2509-7465				Bartl FJ, 2005, J BIOL CHEM, V280, P34259, DOI 10.1074/jbc.M505260200; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Ciucci A, 1997, FEBS LETT, V416, P335, DOI 10.1016/S0014-5793(97)01236-2; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Durocher Y, 2000, ANAL BIOCHEM, V284, P316, DOI 10.1006/abio.2000.4698; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; EMONDSALT X, 1992, LIFE SCI, V50, pPL101, DOI 10.1016/0024-3205(92)90352-P; Evans PD, 1995, PROG BRAIN RES, V106, P259; GALZI J, 2000, Patent No. 2005059036; GALZI JL, 2003, Patent No. 03107004; Gao ZG, 2006, DRUG DISCOV TODAY, V11, P191, DOI 10.1016/S1359-6446(05)03689-5; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; HEIDMANN T, 1980, BIOCHEM BIOPH RES CO, V97, P889, DOI 10.1016/0006-291X(80)91460-6; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Ilien B, 2003, J NEUROCHEM, V85, P768, DOI 10.1046/j.1471-4159.2003.01717.x; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; MAGGI CA, 1991, J PHARMACOL EXP THER, V257, P1172; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Rees S, 2002, RECEPTOR CHANNEL, V8, P261, DOI 10.1080/10606820214640; Riitano D, 1997, J BIOL CHEM, V272, P7646, DOI 10.1074/jbc.272.12.7646; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wiens BL, 1998, MOL PHARMACOL, V54, P435, DOI 10.1124/mol.54.2.435	39	66	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2124	2134		10.1096/fj.06-7683com	http://dx.doi.org/10.1096/fj.06-7683com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17371796				2022-12-25	WOS:000247500300022
J	Song, Y; Cone, RD				Song, Youngsup; Cone, Roger D.			Creation of a genetic model of obesity in a teleost	FASEB JOURNAL			English	Article						melanocortin receptor; zebrafish; AgRP; energy homeostasis	AGOUTI-RELATED PROTEIN; MELANOCORTIN-4 RECEPTOR; FRAMESHIFT MUTATION; MORBID-OBESITY; DANIO-RERIO; FOOD-INTAKE; ZEBRAFISH; GHRELIN; BRAIN; MOUSE	The adipostat is the mechanism by which the brain detects and maintains constant levels of energy stored in adipocytes in the form of lipids. Key elements of the adipostat include the adipocyte-derived hormone leptin that is expressed in proportion to energy levels and serves to communicate this information to the central nervous system and the central circuits, which sense and respond to leptin. Blockade of one of these circuits, the central melanocortin system, disrupts leptin action and causes a distinct obesity syndrome in mice and humans, characterized by increased adiposity as well as increased linear growth. We show here that transgenic zebrafish overexpressing the endogenous melanocortin antagonist agouti-related protein (AgRP) also exhibit obesity, increased linear growth, and adipocyte hypertrophy. These findings demonstrate that key elements of the adipostat originated before the evolution of mammals. Furthermore, transgenic overexpression of AgRP in zebrafish yields a new model system for the genetic analysis of energy homeostasis in a simple vertebrate system.	Oregon Hlth & Sci Univ, Ctr Study Weight Regulat & Associated Disorders, Portland, OR 97239 USA	Oregon Health & Science University	Cone, RD (corresponding author), Oregon Hlth & Sci Univ, Ctr Study Weight Regulat & Associated Disorders, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	cone@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK075721] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56DK075721] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi H, 2004, ZOOL SCI, V21, P841, DOI 10.2108/zsj.21.841; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P2336, DOI 10.1210/en.2002-0213; Cerda-Reverter JM, 2003, ENDOCRINOLOGY, V144, P4552, DOI 10.1210/en.2003-0453; Chiba A, 2001, GEN COMP ENDOCR, V122, P287, DOI 10.1006/gcen.2001.7628; DORES RM, 1990, PROG CLIN BIOL RES, V342, P22; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Hansen IA, 2003, BIOCHEM BIOPH RES CO, V303, P1121, DOI 10.1016/S0006-291X(03)00475-3; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Howard V., 2005, UNBIASED STEREOLOGY; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Kurokawa T, 2005, PEPTIDES, V26, P745, DOI 10.1016/j.peptides.2004.12.017; Logan DW, 2003, GENOMICS, V81, P184, DOI 10.1016/S0888-7543(02)00037-x; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ringholm A, 2002, J NEUROCHEM, V82, P6, DOI 10.1046/j.1471-4159.2002.00934.x; Song Y, 2003, ENDOCRINE, V22, P257, DOI 10.1385/ENDO:22:3:257; TAKAHASHI A, 1995, BIOCHEM BIOPH RES CO, V213, P490, DOI 10.1006/bbrc.1995.2158; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; VOLFOFF H, 2003, BRAIN RES, V972, P90; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	141	145	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2042	2049		10.1096/fj.06-7503com	http://dx.doi.org/10.1096/fj.06-7503com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341684				2022-12-25	WOS:000247500300014
J	Luo, K; Ehrlich, E; Xiao, ZX; Zhang, WY; Ketner, G; Yu, XF				Luo, Kun; Ehrlich, Elana; Xiao, Zuoxiang; Zhang, Wenyan; Ketner, Gary; Yu, Xiao-Fang			Adenovirus E4orF6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53	FASEB JOURNAL			English	Article						proteasomal degradation; substrate receptor; virology	ZINC-BINDING DOMAIN; SOCS-BOX; E1B 55-KILODALTON; COMPLEX; PROTEINS; DEGRADATION; ONCOPROTEINS; CONJUGATION; EXPRESSION; INACTIVATE	The adenovirus protein E4orf6 targets p53 for polyubiquitination and proteasomal degradation and is known to form a complex with the Cul5-ElonginB- ElonginC E3 ubiquitin ligase. However, whether Cul5 is directly responsible for the E4orf6-mediated degradation of p53 remains unclear. By using a dominant-negative mutant of Cul5 and silencing Cul5 expression through RNA interference, we have now demonstrated that E4orf6- mediated p53 degradation requires Cul5. Furthermore, we have identified a lentiviral Vif-like BC-box motif in E4orf6 that is highly conserved among adenoviruses from multiple species. More importantly, we have shown that this Vif-like BC- box is essential for the recruitment of Cul5-ElonginB-ElonginC E3 ubiquitin ligase by E4orf6 and is also required for E4orf6- mediated p53 degradation. E4orf6 selectively recruited Cul5 despite the lack of either a Cul5-box, which is used by cellular substrate receptors to recruit Cul5, or a newly identified HCCH zinc-binding motif, which is used by primate lentiviral Vif to recruit Cul5. Therefore, adenovirus E4orf6 molecules represent a novel family of viral BC- box proteins the cellular ancestor of which is as yet unknown.-Luo, K., Ehrlich, E., Xiao, Z., Zhang, W., Ketner, G., Yu, X-F. Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Microbiol & Immunol, Baltimore, MD 21205 USA; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Zhejiang, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	xfyu@jhsph.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI062644, R01AI062644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI062644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STEEGE MW, 1998, PROVEN PRACTICE PREV, V1, P4; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06; Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204	39	43	44	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1742	1750		10.1096/fj.06-7241com	http://dx.doi.org/10.1096/fj.06-7241com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17351129				2022-12-25	WOS:000246866500016
J	Andra, J; Monreal, D; de Tejada, GM; Olak, C; Brezesinski, G; Gomez, SS; Goldmann, T; Bartels, R; Brandenburg, K; Moriyon, I				Andrae, Joerg; Monreal, Daniel; de Tejada, Guillermo Martinez; Olak, Claudia; Brezesinski, Gerald; Sanchez Gomez, Susana; Goldmann, Torsten; Bartels, Rainer; Brandenburg, Klaus; Moriyon, Ignacio			Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against gram-negative pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; PORE-FORMING PEPTIDE; MEMBRANE SELECTIVITY; HYDROPHOBIC MOMENT; CATIONIC PEPTIDES; MODEL MEMBRANES; MOLECULAR-BASIS; ANTIBACTERIAL; SEQUENCE	The peptide NK-2 is an effective antimicrobial agent with low hemolytic and cytotoxic activities and is thus a promising candidate for clinical applications. It comprises the alpha-helical, cationic core region of porcine NK-lysin a homolog of human granulysin and of amoebapores of pathogenic amoeba. Here we visualized the impact of NK-2 on Escherichia coli by electron microscopy and used NK-2 as a template for sequence variations to improve the peptide stability and activity and to gain insight into the structure/function relationships. We synthesized 18 new peptides and tested their activities on seven Gram-negative and one Gram-positive bacterial strains, human erythrocytes, and HeLa cells. Although all peptides appeared unordered in buffer, those active against bacteria adopted an alpha-helical conformation in membrane-mimetic environments like trifluoroethanol and negatively charged phosphatidylglycerol (PG) liposomes that mimick the cytoplasmic membrane of bacteria. This conformation was not observed in the presence of liposomes consisting of zwitterionic phosphatidylcholine (PC) typical for the human cell plasma membrane. The interaction was paralleled by intercalation of these peptides into PG liposomes as determined by FRET spectroscopy. A comparative analysis between biological activity and the calculated peptide parameters revealed that the decisive factor for a broad spectrum activity is not the peptide overall hydrophobicity or amphipathicity, but the possession of a minimal positive net charge plus a highly amphipathic anchor point of only seven amino acid residues (two helical turns).	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Navarra, Dept Microbiol, E-31008 Pamplona, Spain; Max Planck Inst Colloids & Interfaces, D-14476 Potsdam, Germany	Forschungszentrum Borstel; University of Navarra; Max Planck Society	Andra, J (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, Pk Allee 10, D-23845 Borstel, Germany.	jandrae@fz-borstel.de	Moriyon, Ignacio/N-4764-2016; Goldmann, Torsten/E-5906-2010; Martinez-de-Tejada, Guillermo/H-3849-2017; Martinez-de-Tejada, Guillermo/AAT-8535-2020	Moriyon, Ignacio/0000-0002-4288-0195; Goldmann, Torsten/0000-0002-1621-560X; Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Brezesinski, Gerald/0000-0002-7880-0492; Lazaro-Anton, Leticia/0000-0001-7720-5627				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Andra J, 2005, BIOCHEM J, V385, P135, DOI 10.1042/BJ20041270; Andra J, 2004, ANTIMICROB AGENTS CH, V48, P1593, DOI 10.1128/AAC.48.5.1593-1599.2004; Andra J, 1999, MED MICROBIOL IMMUN, V188, P117, DOI 10.1007/s004300050113; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DETEJADA GM, 1995, INFECT IMMUN, V63, P3054; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Falla T. J., 2004, Mammalian host defense peptides, P69; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GRIFFITH OH, 1972, P NATL ACAD SCI USA, V69, P561, DOI 10.1073/pnas.69.3.561; Gutsmann T, 2005, J ENDOTOXIN RES, V11, P167, DOI 10.1179/096805105X37330; Gutsmann T, 2001, BIOPHYS J, V80, P2935, DOI 10.1016/S0006-3495(01)76259-5; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; Lohner K., 2001, DEV NOVEL ANTIMICROB; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Meng FG, 2001, BIOCHIMIE, V83, P953, DOI 10.1016/S0300-9084(01)01340-2; Miteva M, 1999, FEBS LETT, V462, P155, DOI 10.1016/S0014-5793(99)01520-3; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Monreal D, 2003, INFECT IMMUN, V71, P3261, DOI 10.1128/IAI.71.6.3261-3271.2003; MUNFORD RS, 1995, J LIPID RES, V36, P1653; Norrby SR, 2005, LANCET INFECT DIS, V5, P115, DOI 10.1016/S1473-3099(05)01283-1; Papo N, 2005, J BIOL CHEM, V280, P10378, DOI 10.1074/jbc.M412865200; Papo N, 2004, BIOCHEMISTRY-US, V43, P6393, DOI 10.1021/bi049944h; Pena SV, 1997, J IMMUNOL, V158, P2680; Peschel A, 2006, NAT REV MICROBIOL, V4, P529, DOI 10.1038/nrmicro1441; Powers JPS, 2006, ANTIMICROB AGENTS CH, V50, P1522, DOI 10.1128/AAC.50.4.1522-1524.2006; Schroder-Borm H, 2003, BBA-BIOMEMBRANES, V1612, P164, DOI 10.1016/S0005-2736(03)00115-9; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Toke O, 2005, BIOPOLYMERS, V80, P717, DOI 10.1002/bip.20286; Wang Z, 2000, J IMMUNOL, V165, P1486, DOI 10.4049/jimmunol.165.3.1486; WAYNE PA, 2000, M7A5 NAT COMM CLIN L; Willumeit R, 2005, BBA-BIOMEMBRANES, V1669, P125, DOI 10.1016/j.bbamem.2005.01.011; Yang ST, 2003, FEBS LETT, V540, P229, DOI 10.1016/S0014-5793(03)00266-7; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	72	76	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14719	14728		10.1074/jbc.M608920200	http://dx.doi.org/10.1074/jbc.M608920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389605	hybrid			2022-12-25	WOS:000246589000007
J	Brucet, M; Querol-Audi, J; Serra, M; Ramirez-Espain, X; Bertlik, K; Ruiz, L; Lloberas, J; Macias, MJ; Fita, I; Celada, A				Brucet, Marina; Querol-Audi, Jordi; Serra, Maria; Ramirez-Espain, Ximena; Bertlik, Kamila; Ruiz, Lidia; Lloberas, Jorge; Macias, Maria J.; Fita, Ignacio; Celada, Antonio			Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; 3' TERMINI; PROTEIN; RECOGNITION; EXPRESSION; MECHANISM; 3'->5'-EXONUCLEASE; IDENTIFICATION; REPLICATION; MACROPHAGE	TREX1 is the most abundant mammalian 3' -> 5' DNA exonuclease. It has been described to form part of the SET complex and is responsible for the Aicardi-Goutieres syndrome in humans. Here we show that the exonuclease activity is correlated to the binding preferences toward certain DNA sequences. In particular, we have found three motifs that are selected, GAG, ACA, and CTGC. To elucidate how the discrimination occurs, we determined the crystal structures of two murine TREX1 complexes, with a nucleotide product of the exonuclease reaction, and with a single-stranded DNA substrate. Using confocal microscopy, we observed TREX1 both in nuclear and cytoplasmic subcellular compartments. Remarkably, the presence of TREX1 in the nucleus requires the loss of a C-terminal segment, which we named leucine-rich repeat 3. Furthermore, we detected the presence of a conserved proline-rich region on the surface of TREX1. This observation points to interactions with proline-binding domains. The potential interacting motif "PPPVPRPP" does not contain aromatic residues and thus resembles other sequences that select SH3 and/or Group 2 WW domains. By means of nuclear magnetic resonance titration experiments, we show that, indeed, a polyproline peptide derived from the murine TREX1 sequence interacted with the WW2 domain of the elongation transcription factor CA150. Co-immunoprecipitation studies confirmed this interaction with the full-length TREX1 protein, thereby suggesting that TREX1 participates in more functional complexes than previously thought.	Univ Barcelona, Inst Biomed Res, Macrophage Biol Grp, E-08028 Barcelona, Spain; CSIC, Inst Biol Mol Barcelona, Biomed Res Inst, E-08028 Barcelona, Spain; ICREA, Inst Biomed Res, Prot NMR Spect, Barcelona 08028, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Celada, A (corresponding author), Josep Samitier 1-5, E-08028 Barcelona, Spain.	acelada@ub.edu	Serra, Maria/AAA-9222-2020; Querol-Audí, Jordi/AAJ-9259-2021; Macias, Maria J/K-3898-2014; Lloberas, Jorge/D-4303-2014; Fita, Ignasi/R-4515-2019; Celada, Antonio/I-1714-2016; Ruiz, Lidia/ABF-9720-2021	Macias, Maria J/0000-0002-6915-963X; Lloberas, Jorge/0000-0001-7075-4201; Fita, Ignasi/0000-0002-7521-2679; Querol-Audi, Jordi/0000-0003-2892-7599; Serra, Maria/0000-0002-1559-250X; Ruiz Sainz, Lidia/0000-0002-8918-9158; Celada, Antonio/0000-0003-3883-2171	ICREA Funding Source: Custom	ICREA(ICREA)		Agrawal V, 2002, PROTEIN PEPTIDE LETT, V9, P185, DOI 10.2174/0929866023408760; Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; DESILVA U, 2007, J BIOL CHEM     0209; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Horio T, 2004, FEBS LETT, V577, P111, DOI 10.1016/j.febslet.2004.09.074; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Kato Y, 2004, J BIOL CHEM, V279, P31833, DOI 10.1074/jbc.M404719200; Kay JN, 2005, DEVELOPMENT, V132, P2573, DOI 10.1242/dev.01831; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; Pires JR, 2005, J MOL BIOL, V348, P399, DOI 10.1016/j.jmb.2005.02.056; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Shevelev Igor V., 2002, TheScientificWorldJOURNAL, V2, P275; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Tang WN, 2003, J BIOL CHEM, V278, P28154, DOI 10.1074/jbc.M212976200; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Yang DH, 2004, J GEN VIROL, V85, P3569, DOI 10.1099/vir.0.80592-0; Yang XC, 2006, J BIOL CHEM, V281, P30447, DOI 10.1074/jbc.M602947200; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	39	33	36	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14547	14557		10.1074/jbc.M700236200	http://dx.doi.org/10.1074/jbc.M700236200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355961	hybrid			2022-12-25	WOS:000246245800068
J	Caines, MEC; Vaughan, MD; Tarling, CA; Hancock, SM; Warren, RAJ; Withers, SG; Strynadka, NCJ				Caines, Matthew E. C.; Vaughan, Mark D.; Tarling, Chris A.; Hancock, Susan M.; Warren, R. Antony J.; Withers, Stephen G.; Strynadka, Natalie C. J.			Structural and mechanistic analyses of endo-glycoceramidase II, a membrane-associated family 5 glycosidase in the Apo and G(M3) ganglioside-bound forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BETA-GLUCOSIDASE; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; CERAMIDE-GLYCANASE; CRYSTALLOGRAPHIC STRUCTURE; GM1 GANGLIOSIDE; MOLECULAR-BASIS; HUMAN CD1B; GLYCOSPHINGOLIPIDS; PROTEIN	endo-Glycoceramidase, a membrane-associated family 5 glycosidase, deviates from the typical polysaccharide substrate specificity of other soluble members of the family, preferentially hydrolyzing glycosidic linkages between the oligosaccharide and ceramide moieties of gangliosides. Here we report the first x-ray crystal structures of an endo-glycoceramidase from Rhodococcus sp., in the apo form, in complex with the ganglioside G(M3) ( Svennerholm ganglioside nomenclature (Svennerholm, L. (1964) J. Lipid Res. 5, 145 - 155)), and trapped as a glycosyl-enzyme intermediate. These snapshots provide the first molecular insight into enzyme recognition and association with gangliosides, revealing the structural adaptations necessary for glycosidase-catalyzed hydrolysis and detailing a novel ganglioside binding topology. Consistent with the chemical duality of the substrate, the active site of endo-glycoceramidase is split into a wide, polar cavity to bind the polyhydroxylated oligosaccharide moiety and a narrow, hydrophobic tunnel to bind the ceramide lipid chains. The specific interactions with the ceramide polar head group manifest a surprising aglycone specificity, an observation substantiated by our kinetic analyses. Collectively, the reported structural and kinetic data provide insight toward rational redesign of the synthetic glycosynthase mutant of endo-glycoceramidase to enable facile synthesis of nonnatural, therapeutically useful gangliosides.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca	Withers, Stephen G/I-7229-2019	Withers, Stephen G/0000-0002-6722-5701				Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; Airenne TT, 2006, J MOL BIOL, V355, P224, DOI 10.1016/j.jmb.2005.10.031; Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; Batuwangala T, 2004, J IMMUNOL, V172, P2382, DOI 10.4049/jimmunol.172.4.2382; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Giabbai B, 2005, J IMMUNOL, V175, P977, DOI 10.4049/jimmunol.175.2.977; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hancock SM, 2006, CURR OPIN CHEM BIOL, V10, P509, DOI 10.1016/j.cbpa.2006.07.015; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; Horibata Y, 2004, J BIOL CHEM, V279, P33379, DOI 10.1074/jbc.M401460200; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; Itoh M, 2001, GLYCOBIOLOGY, V11, P125, DOI 10.1093/glycob/11.2.125; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Larson SB, 2003, BIOCHEMISTRY-US, V42, P8411, DOI 10.1021/bi034144c; LEATHERBARROW RJ, 2004, GRAFIT VERSION 4 0 2; Lemieux MJ, 2006, J MOL BIOL, V359, P913, DOI 10.1016/j.jmb.2006.04.004; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Matsuoka Y, 2003, J NEUROSCI, V23, P29; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nojiri H, 2002, CANCER DETECT PREV, V26, P114, DOI 10.1016/S0361-090X(02)00033-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pope-Coleman A, 1998, RESTOR NEUROL NEUROS, V12, P255; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sulzenbacher G, 2004, J BIOL CHEM, V279, P13119, DOI 10.1074/jbc.M313783200; Svennerholm L, 2002, DEMENT GERIATR COGN, V14, P128, DOI 10.1159/000063604; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tettamanti G, 2003, GLYCOCONJUGATE J, V20, P301, DOI 10.1023/B:GLYC.0000033627.02765.cc; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vaughan MD, 2006, J AM CHEM SOC, V128, P6300, DOI 10.1021/ja058469n; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; Wu D, 2006, P NATL ACAD SCI USA, V103, P3972, DOI 10.1073/pnas.0600285103; Zajonc DM, 2005, NAT IMMUNOL, V6, P810, DOI 10.1038/ni1224; Zajonc DM, 2005, IMMUNITY, V22, P209, DOI 10.1016/j.immuni.2004.12.009; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zajonc DM, 2005, J EXP MED, V202, P1517, DOI 10.1084/jem.20051625; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; ZHOU B, 1989, J BIOL CHEM, V264, P12272	65	39	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14300	14308		10.1074/jbc.M611455200	http://dx.doi.org/10.1074/jbc.M611455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17329247	hybrid			2022-12-25	WOS:000246245800041
J	Liu, C; Fei, EK; Jia, NL; Wang, HF; Tao, RS; Iwata, A; Nukina, N; Zhou, JN; Wang, GH				Liu, Chao; Fei, Erkang; Jia, Nali; Wang, Hongfeng; Tao, Ruisong; Iwata, Atsushi; Nukina, Nobuyuki; Zhou, Jiangning; Wang, Guanghui			Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha- synuclein implies Lewy body biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; INCLUSION FORMATION; POLYUBIQUITIN CHAINS; ALZHEIMERS-DISEASE; PROTEIN; BODIES; SYNPHILIN-1; MUTATION; MODEL; NEURODEGENERATION	alpha-Synuclein (alpha-syn) and ubiquitin (Ub) are major protein components deposited in Lewy bodies (LBs) and Lewy neurites, which are pathologic hallmarks of idiopathic Parkinson disease (PD). Almost 90% of alpha-syn in LBs is phosphorylated at serine 129 (Ser(129)). However, the role of Ser(129)-phosphorylated alpha-syn in the biogenesis of LBs remains unclear. Here, we show that compared with coexpression of wild type(WT) alpha-syn and Ub, coexpression of phospho-mimic mutant alpha-syn (S129D) and Ub in neuro2a cells results in an increase of Ub-conjugates and the formation of ubiquitinated inclusions. Furthermore, S129D alpha-syn fails to increase the Ub-conjugates and form ubiquitinated inclusions in the presence of a K63R mutant Ub. In addition, as compared with WT alpha-syn, S129D alpha-syn increased cytoplasmic and neuritic aggregates of itself in neuro2a cells treated with H2O2 and serum deprivation. These results suggest that the contribution of Ser(129)-phosphorylated alpha-syn to the Lys(63)-linked Ub-conjugates and aggregation of itself may be involved in the biogenesis of LBs in Parkinson disease and other related synucleinopathies.	Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Neurobiol, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, GH (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wghui@ustc.edu.cn	Zhou, JiangNing/N-3374-2013; liu, chao/G-3544-2011; Wang, Guanghui/U-3979-2017; Nukina, Nobuyuki/GPP-6265-2022; Iwata, Atsushi/AAH-8924-2019; Iwata, Atsushi/A-9598-2013; FEI, Erkang/AAI-9825-2021	Wang, Guanghui/0000-0001-8551-6468; Iwata, Atsushi/0000-0001-7308-5314; Iwata, Atsushi/0000-0001-7308-5314; FEI, Erkang/0000-0002-3581-9521				Amerik AY, 1997, EMBO J, V16, P4826; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; Chen QH, 2005, J BIOL CHEM, V280, P30009, DOI 10.1074/jbc.M501308200; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Eriksen JL, 2003, NEURON, V40, P453, DOI 10.1016/S0896-6273(03)00684-6; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jellinger KA, 2003, MOVEMENT DISORD, V18, pS2, DOI 10.1002/mds.10557; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Layfield R, 2003, AGEING RES REV, V2, P343, DOI 10.1016/S1568-1637(03)00025-4; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Sakamoto M, 2002, EXP NEUROL, V177, P88, DOI 10.1006/exnr.2002.7961; Sato S, 2006, EMBO J, V25, P211, DOI 10.1038/sj.emboj.7600774; Shults CW, 2006, P NATL ACAD SCI USA, V103, P1661, DOI 10.1073/pnas.0509567103; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Snyder H, 2004, J MOL NEUROSCI, V24, P425, DOI 10.1385/JMN:24:3:425; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; von Coelln R, 2006, J NEUROSCI, V26, P3685, DOI 10.1523/JNEUROSCI.0414-06.2006; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yamada M, 2004, J NEUROCHEM, V91, P451, DOI 10.1111/j.1471-4159.2004.02728.x; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	53	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14558	14566		10.1074/jbc.M700422200	http://dx.doi.org/10.1074/jbc.M700422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360705	hybrid			2022-12-25	WOS:000246245800069
J	Liu, HY; Collins, QF; Xiong, Y; Moukdar, F; Lupo, EG; Liu, ZQ; Cao, WH				Liu, Hui-Yu; Collins, Qu Fan; Xiong, Yan; Moukdar, Fatiha; Lupo, Edgar G., Jr.; Liu, Zhenqi; Cao, Wenhong			Prolonged treatment of primary Hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; HEPATIC GLUCOSE-PRODUCTION; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; INDUCED INHIBITION; POTENTIAL ROLE; IKK-BETA; MECHANISMS; OBESITY; GLUCONEOGENESIS	Free fatty acid (FFA) is believed to be a major environmental factor linking obesity to Type II diabetes. We have recently reported that FFA can induce gluconeogenesis in hepatocytes through p38 mitogen-activated protein kinase (p38). In this study, we have investigated the role of p38 in oleate-induced hepatic insulin resistance. Our results show that a prolonged treatment of primary hepatocytes with oleate blunted insulin suppression of hepatic gluconeogenesis, and decreased insulin-induced phosphorylation of Akt in a p38-dependent manner. Reduction of the insulin-induced Akt phosphorylation by oleate correlated with activation of p38. In the presence of p38 inhibition, prolonged exposure of hepatocytes to oleate failed to reduce insulin-stimulated phosphorylation of Akt. An siRNA against p38 alpha prevented oleate suppression of the insulin-induced phosphorylation of Akt. Furthermore, a prolonged exposure of hepatocytes to oleate decreased insulin-induced tyrosine phosphorylation of IRS1/2, while slightly increasing serine phosphorylation of IRS. The decrease of insulin-stimulated tyrosine phosphorylation of IRS1/2 in hepatocytes by oleate was reversed by the inhibition of p38. We further show that a prolonged exposure of primary hepatocytes to oleate elevated the protein level of the phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) gene in a p38-dependent manner, but had no effect on the mRNA level of PTEN. Knocking down the PTEN gene prevented oleate to inhibit insulin activation of Akt and insulin suppression of gluconeogenesis. Together, results from this study demonstrate a critical role for p38 in oleate-induced hepatic insulin resistance.	Hammer Inst Hlth Sci, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Endocrinol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27708 USA	The Hamner Institutes for Health Sciences; Central South University; University of Virginia; Duke University	Cao, WH (corresponding author), Hammer Inst Hlth Sci, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@thehamner.org						Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Baldeweg SE, 2000, EUR J CLIN INVEST, V30, P45; BEVILACQUA S, 1987, METABOLISM, V36, P502, DOI 10.1016/0026-0495(87)90051-5; Bloch-Damti A, 2005, ANTIOXID REDOX SIGN, V7, P1553, DOI 10.1089/ars.2005.7.1553; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Boden G, 2003, LIFE SCI, V72, P977, DOI 10.1016/S0024-3205(02)02350-0; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Bolinder J, 2000, DIABETES, V49, P797, DOI 10.2337/diabetes.49.5.797; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; Bysted A, 2005, EUR J CLIN NUTR, V59, P24, DOI 10.1038/sj.ejcn.1602028; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chen S, 2006, BIOCHEM BIOPH RES CO, V346, P931, DOI 10.1016/j.bbrc.2006.05.190; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Almeida IT, 2002, CLIN NUTR, V21, P219, DOI 10.1054/clnu.2001.0529; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hirsch IB, 2005, J DIABETES COMPLICAT, V19, P178, DOI 10.1016/j.jdiacomp.2004.10.001; Ju HS, 2003, J PHARMACOL EXP THER, V307, P932, DOI 10.1124/jpet.103.057422; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Qiao LP, 2006, J BIOL CHEM, V281, P24390, DOI 10.1074/jbc.M603038200; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Shen YH, 2006, J BIOL CHEM, V281, P7727, DOI 10.1074/jbc.M511105200; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang XL, 2006, DIABETES, V55, P2301, DOI 10.2337/db05-1574; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wiesenthal SR, 1999, DIABETES, V48, P766, DOI 10.2337/diabetes.48.4.766; Xiong Y, 2007, J BIOL CHEM, V282, P4975, DOI 10.1074/jbc.M606742200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhou H, 2005, BIOCHEM BIOPH RES CO, V338, P793, DOI 10.1016/j.bbrc.2005.10.007	54	59	70	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14205	14212		10.1074/jbc.M609701200	http://dx.doi.org/10.1074/jbc.M609701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17384440	hybrid			2022-12-25	WOS:000246245800031
J	Montaudon, D; Palle, K; Rivory, LP; Robert, J; Douat-Casassus, C; Quideau, S; Bjornsti, MA; Pourquier, P				Montaudon, Daniele; Palle, Komaraiah; Rivory, Laurent P.; Robert, Jacques; Douat-Casassus, Celine; Quideau, Stephane; Bjornsti, Mary-Ann; Pourquier, Philippe			Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds - Importance of vicinal cysteines 504 and 505	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAPACHONE-INDUCED APOPTOSIS; DNA TOPOISOMERASES; BETA-LAPACHONE; EUKARYOTIC TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; CAMPTOTHECIN RESISTANCE; CRYSTAL-STRUCTURES; 3T3-L1 ADIPOCYTES; HYDROGEN-PEROXIDE; SULFHYDRYL-GROUPS	DNA topoisomerase I (Top1) is a nuclear enzyme that plays a crucial role in the removal of DNA supercoiling associated with replication and transcription. It is also the target of the anticancer agent, camptothecin (CPT). Top1 contains eight cysteines, including two vicinal residues (504 and 505), which are highly conserved across species. In this study, we show that thiol-reactive compounds such as N-ethylmaleimide and phenylarsine oxide can impair Top1 catalytic activity. We demonstrate that in contrast to CPT, which inhibits Top1-catalyzed religation, thiolation of Top1 inhibited the DNA cleavage step of the reaction. This inhibition was more pronounced when Top1 was preincubated with the thiol-reactive compound and could be reversed in the presence of dithiothreitol. We also established that phenylarsine oxide-mediated inhibition of Top1 cleavage involved the two vicinal cysteines 504 and 505, as this effect was suppressed when cysteines were mutated to alanines. Interestingly, mutation of Cys-505 also altered Top1 sensitivity to CPT, even in the context of the double Cys-504 to Cys-505 mutant, which relaxed supercoiled DNA with a comparable efficiency to that of wild-type Top1. This indicates that cysteine 505, which is located in the lower Lip domain of human Top1, is critical for optimal poisoning of the enzyme by CPT and its analogs. Altogether, our results suggest that conserved vicinal cysteines 504 and 505 of human Top1 play a critical role in enzyme catalytic activity and are the target of thiol-reactive compounds, which may be developed as efficient Top1 catalytic inhibitors.	Univ Bordeaux 2, Mol Pharmacol Grp, INSERM, E347, F-33076 Bordeaux, France; Univ Bordeaux 2, Inst Bergonie, F-33076 Bordeaux, France; St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Johnson & Johnson Res Pty Ltd, Preclin Dev Team, Eveleigh, NSW 1430, Australia; Inst Europeen Chim & Biol, F-33607 Pessac, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; St Jude Children's Research Hospital; Johnson & Johnson	Pourquier, P (corresponding author), Univ Bordeaux 2, Mol Pharmacol Grp, INSERM, E347, 229 Cours Argonne,146 Rue Leo Saignat, F-33076 Bordeaux, France.	pourquier@bergonie.org	Quideau, Stéphane/AAG-5686-2019; Robert, Jacques/B-2179-2008; Pourquier, Philippe/O-8030-2018; Robert, Jacques/AAS-3923-2020; Douat, Celine/H-8671-2013	Robert, Jacques/0000-0003-4380-1476; Pourquier, Philippe/0000-0001-5326-3005; Rivory, Laurent/0000-0002-1734-7882; Douat, Celine/0000-0003-2678-1047	NATIONAL CANCER INSTITUTE [R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailly C, 1997, BIOCHEMISTRY-US, V36, P3917, DOI 10.1021/bi9624898; Bailly C, 2000, CURR MED CHEM, V7, P39, DOI 10.2174/0929867003375489; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHAMPOUX JJ, 1990, MECH ASPECTS TYPE 1, P217; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; DURNFORD JM, 1978, J BIOL CHEM, V253, P1086; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; FROST SC, 1985, J BIOL CHEM, V260, P2646; Frydman B, 1997, CANCER RES, V57, P620; Gerhard R, 2003, MOL PHARMACOL, V63, P1349, DOI 10.1124/mol.63.6.1349; GOTO T, 1984, J BIOL CHEM, V259, P422; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Haas R, 1998, FRESEN J ANAL CHEM, V361, P313, DOI 10.1007/s002160050892; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; KUTSUMI H, 1995, BLOOD, V85, P2559, DOI 10.1182/blood.V85.9.2559.bloodjournal8592559; Leppard JB, 2005, CHROMOSOMA, V114, P75, DOI 10.1007/s00412-005-0345-5; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; LI CJ, 1993, J BIOL CHEM, V268, P2263; LIAO K, 1991, J BIOL CHEM, V266, P6544; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Neder K, 1998, CELL MOL BIOL, V44, P465; Niu P, 2002, BBA-PROTEIN STRUCT M, V1594, P364, DOI 10.1016/S0167-4838(01)00329-6; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Pardee AB, 2002, CURR CANCER DRUG TAR, V2, P227, DOI 10.2174/1568009023333854; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; PLOUX O, 1995, BIOCHEMISTRY-US, V34, P4159, DOI 10.1021/bi00013a003; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Portela MPM, 1996, BIOCHEM PHARMACOL, V52, P1875; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SAMANTA AK, 1993, J BIOL CHEM, V268, P6147; Shiah SG, 1999, CANCER RES, V59, P391; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Tirumalai RS, 1996, J BIOL CHEM, V271, P29599, DOI 10.1074/jbc.271.47.29599; van Waardenburg RCAM, 2006, MOL CELL BIOL, V26, P4958, DOI 10.1128/MCB.00160-06; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200	57	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14403	14412		10.1074/jbc.M611673200	http://dx.doi.org/10.1074/jbc.M611673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355975	hybrid			2022-12-25	WOS:000246245800053
J	Pochynyuk, O; Staruschenko, A; Bugaj, V; LaGrange, L; Stockand, JD				Pochynyuk, Oleh; Staruschenko, Alexander; Bugaj, Vladislav; LaGrange, Lila; Stockand, James D.			Quantifying RhoA facilitated trafficking of the epithelial Na+ channel toward the plasma membrane with total internal reflection fluorescence- fluorescence recovery after photobleaching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; SUBUNIT STOICHIOMETRY; SECRETORY GRANULES; POTASSIUM CHANNEL; MAMMALIAN-CELLS; EXOCYTOSIS; TRANSLOCATION; TRANSPORT; PROTEINS; LOCALIZATION	The epithelial Na+ channel ( ENaC) plays a central role in control of epithelial surface hydration and vascular volume. Similar to other ion channels, ENaC activity is set, in part, by its membrane levels. The small G protein RhoA increases ENaC activity by increasing the membrane levels of this channel. We hypothesize that RhoA increases ENaC activity by promoting channel trafficking to the plasma membrane. Few experimental methods are available to directly visualize trafficking of ion channels to the plasma membrane. Here we combine electrophysiology with two complementary imaging methods, total internal reflection fluorescence microscopy and fluorescence recovery after photobleaching, to study the mechanistic basis of RhoA actions on ENaC. Patch clamp results demonstrate that RhoA increases ENaC activity in an additive manner with dominant-negative dynamin. This is consistent with a mechanism of increased ENaC trafficking to the membrane. Direct visualization of ENaC movement near the plasma membrane with total internal reflection fluorescence-fluorescence recovery after photobleaching revealed that RhoA accelerates ENaC trafficking toward the membrane. RhoA-facilitated movement of the channel was sensitive to disrupting the endomembrane system. Moreover, facilitating retrieval decreased ENaC activity but not trafficking toward the membrane. ENaC at the plasma membrane clustered and was laterally immobile suggesting that the cytoskeleton tethers or corrals membrane resident channels or membrane-directed vesicles containing ENaC. Disrupting microtubules but not microfilaments led to reorganization of ENaC clusters and slowed trafficking toward the membrane. The cytoskeleton is an established target for RhoA signaling. We conclude that RhoA, likely through effects on the cytoskeleton, promotes ENaC trafficking to the plasma membrane to increase channel membrane levels and activity.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594, R01DK070571] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK59594, R01 DK070571] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; BURGHARDT TP, 1981, BIOPHYS J, V33, P455, DOI 10.1016/S0006-3495(81)84906-5; Cao H, 2000, J CELL SCI, V113, P1993; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Hofer D, 1998, ANN NY ACAD SCI, V859, P75, DOI 10.1111/j.1749-6632.1998.tb11112.x; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Johns LM, 2001, J CELL BIOL, V153, P177, DOI 10.1083/jcb.153.1.177; Jones SVP, 2003, MOL PHARMACOL, V64, P987, DOI 10.1124/mol.64.4.987; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lorenz H, 2006, NAT METHODS, V3, P205, DOI 10.1038/nmeth857; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Pochynyuk O, 2006, J BIOL CHEM, V281, P26520, DOI 10.1074/jbc.M603716200; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; THOMPSON NL, 1981, BIOPHYS J, V33, P435, DOI 10.1016/S0006-3495(81)84905-3; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; YATANI A, 1991, J BIOL CHEM, V266, P22222	42	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14576	14585		10.1074/jbc.M701348200	http://dx.doi.org/10.1074/jbc.M701348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376773	hybrid			2022-12-25	WOS:000246245800071
J	Sinha-Datta, U; Datta, A; Ghorbel, S; Dodon, MD; Nicot, C				Sinha-Datta, Uma; Datta, Abhik; Ghorbel, Sofiane; Dodon, Madeleine Duc; Nicot, Christophe			Human T-cell lymphotrophic virus type I Rex and p30 interactions govern the switch between virus latency and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS; BINDING-PROTEIN; TAX; HTLV; RNA; ONCOPROTEIN; EXPRESSION; REGULATOR; COMPLEX; CREB	Human T-cell lymphotrophic virus type I Rex and p30 are both RNA binding regulatory proteins. Rex is a protein that interacts with a responsive element and stimulates nuclear export of incompletely spliced viral RNAs thereby increasing production of virus particles. In contrast, p30 is involved in the nuclear retention of the tax/rex mRNA leading to inhibition of virus expression and possible establishment of viral latency. How these two proteins, with apparent opposite functions, integrate in the viral replication cycle is unknown. Here, we demonstrate that Rex and p30 form ribonucleoprotein ternary complexes onto specific viral mRNA. Our results explain the selective nuclear retention of tax/rex but not other viral mRNAs by p30. Whereas p30 suppresses Rex expression, it did not affect Rex-mediated nuclear export of RNA containing the Rex response element. In contrast, Rex was able to counteract p30-mediated suppression of viral expression and restore cytoplasmic tax/rex mRNA and Tax protein expression. Together, our data demonstrate a complex regulatory mechanism of antagonizing post-transcriptional regulators evolved by human T-cell lymphotrophic virus type I to allow a vigilant control of viral gene expression.	Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; Ecole Normale Super Lyon, INSERM, U758, F-69364 Lyon 07, France	University of Kansas; University of Kansas Medical Center; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	cnicot@kumc.edu	Duc-Dodon, Madeleine/I-6580-2016	Datta, Abhik/0000-0002-3442-5774; Ghorbel, Sofiane/0000-0001-8793-4882	NIAID NIH HHS [R01 AI058944, AI058944] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Ghorbel S, 2006, J BIOL CHEM, V281, P37150, DOI 10.1074/jbc.M603981200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Hamaia S, 1997, J VIROL, V71, P8514, DOI 10.1128/JVI.71.11.8514-8521.1997; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemoine FJ, 2002, ONCOGENE, V21, P7230, DOI 10.1038/sj.onc.1205898; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	31	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14608	14615		10.1074/jbc.M611219200	http://dx.doi.org/10.1074/jbc.M611219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360706	hybrid			2022-12-25	WOS:000246245800074
J	Tu, SJ; Bulloch, EMM; Yang, LH; Ren, C; Huang, WC; Hsu, PH; Chen, CH; Liao, CL; Yu, HM; Lo, WS; Freitas, MA; Tsai, MD				Tu, Shengjiang; Bulloch, Esther M. M.; Yang, Lanhao; Ren, Chen; Huang, Wei-Chieh; Hsu, Pang-Hung; Chen, Chein-Hung; Liao, Chung-Lin; Yu, Hui-Ming; Lo, Wan-Sheng; Freitas, Michael A.; Tsai, Ming-Daw			Identification of histone demethylases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LYSINE METHYLATION; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION ELONGATION; OXIDATIVE DEMETHYLATION; ANDROGEN-RECEPTOR; ESCHERICHIA-COLI; FISSION YEAST; DNA-DAMAGE; H3	Based on the prediction that histone lysine demethylases may contain the JmjC domain, we examined the methylation patterns of five knock-out strains (ecm5 Delta, gis1 Delta, rph1 Delta, jhd1 Delta, and jhd2 Delta (yjr119c Delta)) of Saccharomyces cerevisiae. Mass spectrometry (MS) analyses of histone H3 showed increased modifications in all mutants except ecm5 Delta. High-resolution MS was used to unequivocally differentiate trimethylation from acetylation in various tryptic fragments. The relative abundance of specific fragments indicated that histones K36me3 and K4me3 accumulate in rph1 Delta and jhd2 Delta strains, respectively, whereas both histone K36me2 and K36me accumulate in gis1 Delta and jhd1 Delta strains. Analyses performed with strains overexpressing the JmjC proteins yielded changes in methylation patterns that were the reverse of those obtained in the complementary knock-out strains. In vitro enzymatic assays confirmed that the JmjC domain of Rph1 specifically demethylates K36me3 primarily and K36me2 secondarily. Overexpression of RPH1 generated a growth defect in response to UV irradiation. The demethylase activity of Rph1 is responsible for the phenotype. Collectively, in addition to Jhd1, our results identified three novel JmjC domain-containing histone demethylases and their sites of action in budding yeast S. cerevisiae. Furthermore, the methodology described here will be useful for identifying histone demethylases and their target sites in other organisms.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	National Taiwan University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Academia Sinica - Taiwan	Lo, WS (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan.	sunnylo@ha.mc.ntu.edu.tw; Freitas.5@osu.edu; Tsai.7@osu.edu	Tu, Shengjiang/K-7868-2012; Hsu, Pang-Hung/C-5587-2018; Freitas, Michael/C-8953-2009; Tsai, Ming-Daw/G-4689-2019	Tu, Shengjiang/0000-0003-3616-3242; Hsu, Pang-Hung/0000-0001-6873-6434; Freitas, Michael/0000-0002-3103-8410; Tsai, Ming-Daw/0000-0003-1374-0414; Bulloch, Esther/0000-0002-4262-1791	NCI NIH HHS [R01 CA107106-03, R21 CA110496, CA110496, R01 CA107106-04, CA69472, R01 CA069472, R01 CA107106-01, R01 CA107106, R01 CA107106-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069472, R21CA110496, R01CA107106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Brachmann CB, 1998, YEAST, V14, P115; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fingerman IM, 2005, J BIOL CHEM, V280, P28761, DOI 10.1074/jbc.C500097200; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jung J, 2005, J BIOL CHEM, V280, P30916, DOI 10.1074/jbc.M414482200; Kamakaka RT, 1998, GENETICS, V149, P903; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kubicek S, 2004, CELL, V119, P903, DOI 10.1016/j.cell.2004.12.006; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Lo WS, 2004, METHOD ENZYMOL, V377, P130; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Ouspenski II, 1999, NUCLEIC ACIDS RES, V27, P3001, DOI 10.1093/nar/27.15.3001; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Ren C, 2005, J AM SOC MASS SPECTR, V16, P1641, DOI 10.1016/j.jasms.2005.06.001; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Shahbazian MD, 2005, MOL CELL, V19, P271, DOI 10.1016/j.molcel.2005.06.010; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wysocki R, 2005, MOL CELL BIOL, V25, P8430, DOI 10.1128/MCB.25.19.8430-8443.2005; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027	55	80	84	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14262	14271		10.1074/jbc.M609900200	http://dx.doi.org/10.1074/jbc.M609900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369256	hybrid, Green Accepted			2022-12-25	WOS:000246245800037
J	Chernyavsky, AI; Arredondo, J; Kitajima, Y; Sato-Nagai, M; Grando, SA				Chernyavsky, Alex I.; Arredondo, Juan; Kitajima, Yasuo; Sato-Nagai, Miki; Grando, Sergei A.			Desmoglein versus non-desmoglein signaling in pemphigus acantholysis - Characterization of novel signaling pathways downstream of pemphigus vulgaris antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; NECROSIS-FACTOR-ALPHA; BASAL-CELL SHRINKAGE; HUMAN KERATINOCYTES; CULTURED KERATINOCYTES; CHOLINERGIC CONTROL; EPITHELIAL-CELLS; FAS-LIGAND; IGG; PHOSPHORYLATION	Although it is accepted that pemphigus antibody binding to keratinocytes (KCs) evokes an array of intracellular biochemical events resulting in cell detachment and death, the triggering events remain obscure. It has been postulated that the binding of pemphigus vulgaris IgG (PVIgG) to KCs induces "desmosomal" signaling. Because in contrast to integrins and classical cadherins, desmoglein (Dsg) molecules are not known to elicit intracellular signaling, and because PV patients also produce non-Dsg autoantibodies, we investigated the roles of both Dsg and non-desmoglein PV antigens. The time course studies of KCs treated with PVIgG demonstrated that the activity of Src peaked at 30 min, EGF receptor kinase (EGFRK) at 60 min, and p38MAPK at 240 min. The Src inhibitor PP2 decreased EGFRK and p38 activities by similar to 45 and 30%, respectively, indicating that in addition to Src, PVIgG evokes other triggering events. The shrinkage of KCs (cell volume reduction) became significant at 120 min, keratin aggregation at 240 min, and an increase of TUNEL positivity at 360 min. Pretreatment of KCs with PP2 blocked PVIgG-dependent cell shrinkage and keratin aggregation by similar to 50% and TUNEL positivity by similar to 25%. The p38 MAPK inhibitor PD169316 inhibited these effects by similar to 15, 20, and 70%, respectively. Transfection of KCs with small interfering RNAs that silenced expression of Dsg1 and/or Dsg3 proteins, blocked similar to 50% of p38 MAPK activity but did not significantly alter the PVIgG-dependent rise in Src and EGFRK activities. These results indicate that activation of p38 MAPK is a late signaling step associated with collapse of the cytoskeleton and disassembly of desmosomes caused by upstream events involving Src and EGFRK. Therefore, the early acantholytic events are triggered by non-Dsg antibodies.	Univ Calif Davis, Ctr Med, Dept Dermatol, Sacramento, CA 95816 USA; Gifu Univ, Sch Med, Gifu, Japan	University of California System; University of California Davis; Gifu University	Grando, SA (corresponding author), Univ Calif Davis, Ctr Med, Dept Dermatol, 3301 C St,Suite 1400, Sacramento, CA 95816 USA.	sagrando@ucdavis.edu						Amagai M, 2006, EXP DERMATOL, V15, P815, DOI 10.1111/j.1600-0625.2006.00499.x; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Arredondo J, 2005, AM J PATHOL, V167, P1531, DOI 10.1016/S0002-9440(10)61239-4; BARLOW Y, 1991, J ORAL PATHOL MED, V20, P241, DOI 10.1111/j.1600-0714.1991.tb00427.x; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Billet SE, 2006, AUTOIMMUNITY, V39, P617, DOI 10.1080/08916930600972099; Bystryn JC, 2006, J AM ACAD DERMATOL, V54, P513, DOI 10.1016/j.jaad.2005.12.003; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; Chernyavsky AI, 2005, J BIOL CHEM, V280, P39220, DOI 10.1074/jbc.M504407200; D'Alessandro M, 2002, J CELL SCI, V115, P4341, DOI 10.1242/jcs.00120; Farley N, 2006, MOL CELL BIOL, V26, P2118, DOI 10.1128/MCB.26.6.2118-2129.2006; Frusic-Zlotkin M, 2006, AUTOIMMUNITY, V39, P563, DOI 10.1080/08916930600971836; Garmyn M, 2001, J INVEST DERMATOL, V117, P1290, DOI 10.1046/j.0022-202x.2001.01553.x; Goodwin M, 2004, J MOL HISTOL, V35, P839, DOI 10.1007/s10735-004-1833-2; Grando SA, 2006, EXP DERMATOL, V15, P265, DOI 10.1111/j.0906-6705.2006.00410.x; GRANDO SA, 1993, J INVEST DERMATOL, V101, P32, DOI 10.1111/1523-1747.ep12358588; Grando SA, 2000, DERMATOLOGY, V201, P290, DOI 10.1159/000051540; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HU CH, 1978, AM J PATHOL, V90, P345; Kawasaki H, 2006, J INVEST DERMATOL, V126, P2621, DOI 10.1038/sj.jid.5700450; Kawasaki Y, 2006, AUTOIMMUNITY, V39, P587, DOI 10.1080/08916930600971943; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; Kitajima Y, 2003, ARCH DERMATOL RES, V295, pS17, DOI 10.1007/s00403-002-0368-1; KITAJIMA Y, IN PRESS CLIN REV AL; Kurzen H, 2006, AUTOIMMUNITY, V39, P549, DOI 10.1080/08916930600971554; Lanza A, 2006, J CUTAN PATHOL, V33, P401, DOI 10.1111/j.0303-6987.2006.00523.x; LEVER WF, 1953, MEDICINE, V32, P1; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; MORLEY SN, 1995, J CELL SCI, V108, P3463; Nguyen VT, 2004, ARCH DERMATOL, V140, P327, DOI 10.1001/archderm.140.3.327; Nguyen VT, 2004, J BIOL CHEM, V279, P2135, DOI 10.1074/jbc.M309000200; Orlov MD, 2006, AUTOIMMUNITY, V39, P557, DOI 10.1080/08916930600971729; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Sanchez-Carpintero I, 2004, BRIT J DERMATOL, V151, P565, DOI 10.1111/j.1365-2133.2004.06147.x; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; Toivola DM, 1997, J CELL SCI, V110, P23; Udey MC, 1999, JAMA-J AM MED ASSOC, V282, P572, DOI 10.1001/jama.282.6.572; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; WILGRAM GF, 1961, J INVEST DERMATOL, V36, P373, DOI 10.1038/jid.1961.58; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224; Yoneda K, 2004, J BIOL CHEM, V279, P7296, DOI 10.1074/jbc.M307242200	48	107	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13804	13812		10.1074/jbc.M611365200	http://dx.doi.org/10.1074/jbc.M611365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344213	hybrid			2022-12-25	WOS:000246060300070
J	Higashitsuji, H; Higashitsuji, H; Masuda, T; Liu, Y; Itoh, K; Fujita, J				Higashitsuji, Hisako; Higashitsuji, Hiroaki; Masuda, Tomoko; Liu, Yu; Itoh, Katsuhiko; Fujita, Jun			Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HISTONE DEACETYLASE-1; HEPATOCELLULAR CARCINOMAS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IN-VIVO; ACETYLATION; STABILITY; DEGRADATION; CELLS	HSCO ( hepatoma subtracted- cDNA library clone one, also called ETHE1) was originally identified by its frequent overexpression in hepatocellular carcinomas. HSCO inhibits function of NF-kappa B by binding to RelA and accelerating its export from the nucleus. We show here that HSCO exhibits anti-apoptotic activity in cells exposed to DNA-damaging agents by suppressing transcriptional activity of p53. Induction of pro-apoptotic genes, Noxa, Perp, PIG3, and Bax were suppressed in cells overexpressing HSCO. By increasing ubiquitylation and degradation of p53, HSCO reduces p53 protein levels. HSCO specifically associates with histone deacetylase 1 (HDAC1) independently of Mdm2 and facilitates deacetylation of p53 at Lys-373/382 by HDAC1. The metallo-beta-lactamase family consensus sequence in HSCO is important for its effect on p53 deacetylation. Co-immunoprecipitation and immunofluorescence studies suggested that HSCO, HDAC1, and p53 form a complex in the nucleus. Thus, HSCO is a cofactor that increases the deacetylase activity of HDAC1 toward p53, leading to suppression of apoptosis. Treatment of hepatocellular carcinomas that retain wildtype p53 and overexpress HSCO with anti-HSCO agents might re-establish the p53 response and revert chemoresistance.	Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, Kyoto 6068507, Japan	Kyoto University	Higashitsuji, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	hhigashi@virus.kyoto-u.ac.jp						Bandyopadhyay D, 2004, CANCER RES, V64, P7706, DOI 10.1158/0008-5472.CAN-03-3897; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gotoh K, 2004, FEBS LETT, V560, P19, DOI 10.1016/S0014-5793(04)00034-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kawaguchi Y, 2006, J BIOL CHEM, V281, P1394, DOI 10.1074/jbc.M505772200; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196; Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653; Treiber G, 2001, DIGEST DIS, V19, P311, DOI 10.1159/000050698; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	46	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13716	13725		10.1074/jbc.M609751200	http://dx.doi.org/10.1074/jbc.M609751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353187	hybrid			2022-12-25	WOS:000246060300061
J	Reig, N; del Rio, C; Casagrande, F; Ratera, M; Gelpi, JL; Torrents, D; Henderson, PJF; Xie, H; Baldwin, SA; Zorzano, A; Fotiadis, D; Palacin, M				Reig, Nuria; del Rio, Cesar; Casagrande, Fabio; Ratera, Merce; Gelpi, Josep Lluis; Torrents, David; Henderson, Peter J. F.; Xie, Hao; Baldwin, Stephen A.; Zorzano, Antonio; Fotiadis, Dimitrios; Palacin, Manuel			Functional and structural characterization of the first prokaryotic member of the L-amino acid transporter (LAT) family - A model for APC transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINURIC PROTEIN INTOLERANCE; MULTIPLE SEQUENCE ALIGNMENT; ESCHERICHIA-COLI; LIGHT SUBUNIT; THIOL MODIFICATION; LACTOSE PERMEASE; GENOME SEQUENCE; SYSTEM X(C)(-); IDENTIFICATION; CYSTINE	We have identified YkbA from Bacillus subtilis as a novel member of the L-amino acid transporter (LAT) family of amino acid transporters. The protein is similar to 30% identical in amino acid sequence to the light subunits of human heteromeric amino acid transporters. Purified His-tagged YkbA from Escherichia coli membranes reconstituted in proteoliposomes exhibited sodium-independent, obligatory exchange activity for L-serine and L-threonine and also for aromatic amino acids, albeit with less activity. Thus, we propose that YkbA be renamed SteT(Ser/Thr exchanger transporter). Kinetic analysis supports a sequential mechanism of exchange for SteT. Freeze-fracture analysis of purified, functionally active SteT in proteoliposomes, together with blue native polyacrylamide gel electrophoresis and transmission electron microscopy of detergent-solubilized purified SteT, suggest that the transporter exists in a monomeric form. Freeze-fracture analysis showed spherical particles with a diameter of 7.4 nm. Transmission electron microscopy revealed elliptical particles (diameters 6 x 7 nm) with a distinct central depression. To our knowledge, this is the first functional characterization of a prokaryotic member of the LAT family and the first structural data on an APC (amino acids, polyamines, and choline for organocations) transporter. SteT represents an excellent model to study the molecular architecture of the light subunits of heteromeric amino acid transporters and other APC transporters.	Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Univ Barcelona, Fac Biol, Inst Res Biomed, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Res Biomed, E-08028 Barcelona, Spain; Inst Catalana Recerca & Estudis Avancats, Barcelona Supercomp Ctr, Life Sci Program, E-08034 Barcelona, Spain; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; CIBERER, E-08028 Barcelona, Spain	University of Basel; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; Universitat Politecnica de Catalunya; Barcelona Supercomputer Center (BSC-CNS); University of Leeds; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Fotiadis, D (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland.	dimitrios.fotiadis@unibas.ch; mpalacin@pcb.ub.es	Henderson, Peter JF/Q-1907-2018; Gelpí, Josep Ll./M-6401-2013; Zorzano, Antonio/R-5479-2018; Torrents, David/G-5785-2015	Gelpí, Josep Ll./0000-0002-0566-7723; Henderson, Peter/0000-0002-9187-0938; Palacin, Manuel/0000-0002-8670-293X; Ratera, Merce/0000-0001-5224-9172; Torrents, David/0000-0002-6086-9037	ICREA Funding Source: Custom	ICREA(ICREA)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Chang AB, 2004, MOL MEMBR BIOL, V21, P171, DOI 10.1080/09687680410001720830; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Habermeier A, 2003, J BIOL CHEM, V278, P19492, DOI 10.1074/jbc.M210254200; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Hu LYA, 1999, BIOCHEM J, V339, P649, DOI 10.1042/0264-6021:3390649; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kaleeba JAR, 2006, SCIENCE, V311, P1921, DOI 10.1126/science.1120878; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lopez O, 1998, FEBS LETT, V426, P314, DOI 10.1016/S0014-5793(98)00363-9; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Palacin M, 2005, PHYSIOLOGY, V20, P112, DOI 10.1152/physiol.00051.2004; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Riley M, 2006, NUCLEIC ACIDS RES, V34, P1, DOI 10.1093/nar/gkj405; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Torras-Llort M, 2001, J MEMBRANE BIOL, V180, P213, DOI 10.1007/s002320010072; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Turk E, 2000, J BIOL CHEM, V275, P25711, DOI 10.1074/jbc.M003127200; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Xie H, 2004, MOL MEMBR BIOL, V21, P323, DOI 10.1080/09687860400003941; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059	46	34	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13270	13281		10.1074/jbc.M610695200	http://dx.doi.org/10.1074/jbc.M610695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344220	hybrid			2022-12-25	WOS:000246060300015
J	Wright, JF; Guo, YJ; Quazi, A; Luxenberg, DP; Bennett, F; Ross, JF; Qiu, YC; Whitters, MJ; Tomkinson, KN; Dunussi-Joannopoulos, K; Carreno, BM; Collins, M; Wolfman, NM				Wright, Jill F.; Guo, Yongjing; Quazi, Amira; Luxenberg, Deborah P.; Bennett, Frann; Ross, John F.; Qiu, Yongchang; Whitters, Matthew J.; Tomkinson, Kathleen N.; Dunussi-Joannopoulos, Kyri; Carreno, Beatriz M.; Collins, Mary; Wolfman, Neil M.			Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; NERVE GROWTH-FACTOR; T-CELLS; INFLAMMATORY RESPONSES; CRYSTAL-STRUCTURE; CUTTING EDGE; BONE EROSION; CYTOKINE; IL-17F	IL-17F and IL-17A are members of the IL-17 pro-inflammatory cytokine family. IL-17A has been implicated in the pathogenesis of autoimmune diseases. IL-17F is a disulfide-linked dimer that contains a cysteine-knot motif. We hypothesized that IL-17F and IL-17A could form a heterodimer due to their sequence homology and overlapping pattern of expression. We evaluated the structure of recombinant IL-17F and IL-17A proteins, as well as that of natural IL-17F and IL-17A derived from activated human CD4(+) T cells, by enzyme-linked immunosorbent assay, immunoprecipitation followed by Western blotting, and mass spectrometry. We find that both IL-17F and IL-17A can form both homodimeric and heterodimeric proteins when expressed in a recombinant system, and that all forms of the recombinant proteins have in vitro functional activity. Furthermore, we find that in addition to the homodimers of IL-17F and IL-17A, activated human CD4+ T cells also produce the IL-17F/ IL-17A heterodimer. These data suggest that the IL-17F/ IL-17A heterodimer may contribute to the T cell-mediated immune responses.	Wyeth Res, Dept Inflammat, Cambridge, MA 02140 USA; Wyeth Res, Dept Biol Technol, Cambridge, MA 02140 USA	Pfizer; Pfizer	Wright, JF (corresponding author), 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jwright@wyeth.com						Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Bessis N, 2001, JOINT BONE SPINE, V68, P477, DOI 10.1016/S1297-319X(01)00310-4; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Dumont FJ, 2003, EXPERT OPIN THER PAT, V13, P287, DOI 10.1517/13543776.13.3.287; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; Lubberts E, 2004, ARTHRITIS RHEUM-US, V50, P650, DOI 10.1002/art.20001; Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Reinhardt RL, 2006, CURR OPIN IMMUNOL, V18, P271, DOI 10.1016/j.coi.2006.03.003; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Veldhoen M, 2006, TRENDS IMMUNOL, V27, P358, DOI 10.1016/j.it.2006.06.001; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Witowski J, 2004, CELL MOL LIFE SCI, V61, P567, DOI 10.1007/s00018-003-3228-z; YOO ZB, 1995, J IMMUNOL, V155, P5483	36	233	262	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13447	13455		10.1074/jbc.M700499200	http://dx.doi.org/10.1074/jbc.M700499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355969	hybrid			2022-12-25	WOS:000246060300034
J	Isoo, N; Sato, C; Miyashita, H; Shinohara, M; Takasugi, N; Morohashi, Y; Tsuji, S; Tomita, T; Iwatsubo, T				Isoo, Noriko; Sato, Chihiro; Miyashita, Hiroyuki; Shinohara, Mitsuru; Takasugi, Nobumasa; Morohashi, Yuichi; Tsuji, Shoji; Tomita, Taisuke; Iwatsubo, Takeshi			A beta 42 overproduction associated with structural changes in the catalytic pore of gamma-secretase - Common effects of Pen-2 N-terminal elongation and fenofibrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOIDOGENIC A-BETA-42; TRANSMEMBRANE DOMAIN-4; C-TERMINUS; PRESENILIN; COMPLEX; STABILIZATION; SITE; ENDOPROTEOLYSIS; CLEAVAGE	gamma-Secretase is an atypical aspartyl protease that cleaves amyloid beta-precursor protein to generate A beta peptides that are causative for Alzheimer disease. gamma-Secretase is a multimeric membrane protein complex composed of presenilin ( PS), nicastrin, Aph-1, and Pen-2. Pen-2 directly binds to transmembrane domain 4 of PS and confers proteolytic activity on gamma-secretase, although the mechanism of activation and its role in catalysis remain unknown. Here we show that an addition of amino acid residues to the N terminus of Pen-2 specifically increases the generation of A beta 42, the longer and more aggregable species of A beta. The effect of the N- terminal elongation of Pen- 2 on A beta 42 generation was independent of the amino acid sequences, the expression system and the presenilin species. In vitro gamma-secretase assay revealed that Pen-2 directly affects the A beta 42- generating activity of gamma-secretase. The elongation of Pen-2N terminus caused a reduction in the water accessibility of the luminal side of the catalytic pore of PS1 in a similar manner to that caused by an A beta 42- raising gamma-secretase modulator, fenofibrate, as determined by substituted cysteine accessibility method. These data suggest a unique mechanism of A beta 42 overproduction associated with structural changes in the catalytic pore of presenilins caused commonly by the N-terminal elongation of Pen-2 and fenofibrate.	Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Neurol, Div Neurosci, Grad Sch Med,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp	Naganawa, Shinji/I-1572-2012; Tomita, Taisuke/L-5427-2015	Naganawa, Shinji/0000-0002-0214-613X; Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082; Sato, Chihiro/0000-0002-7639-8727				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Berezovska O, 2005, J NEUROSCI, V25, P3009, DOI 10.1523/JNEUROSCI.0364-05.2005; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Kim SH, 2005, J BIOL CHEM, V280, P41953, DOI 10.1074/jbc.M509070200; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Morohashi Y, 2006, J BIOL CHEM, V281, P14670, DOI 10.1074/jbc.M513012200; Niimura M, 2005, J BIOL CHEM, V280, P12967, DOI 10.1074/jbc.M409829200; Ogura T, 2006, BIOCHEM BIOPH RES CO, V343, P525, DOI 10.1016/j.bbrc.2006.02.158; Okochi M, 2006, J BIOL CHEM, V281, P7890, DOI 10.1074/jbc.M513250200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Prokop S, 2005, J NEUROCHEM, V94, P57, DOI 10.1111/j.1471-4159.2005.03165.x; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Sato C, 2006, J NEUROSCI, V26, P12081, DOI 10.1523/JNEUROSCI.3614-06.2006; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shiraishi H, 2004, J NEUROCHEM, V90, P1402, DOI 10.1111/j.1471-4159.2004.02597.x; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tomita T, 2006, CURR PHARM DESIGN, V12, P661, DOI 10.2174/138161206775474206; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Watanabe N, 2005, J BIOL CHEM, V280, P41967, DOI 10.1074/jbc.M509066200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	42	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12388	12396		10.1074/jbc.M611549200	http://dx.doi.org/10.1074/jbc.M611549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329245	hybrid			2022-12-25	WOS:000245942800007
J	Sanchez-Tillo, E; Comalada, M; Xaus, J; Farrera, C; Valledor, AF; Caelles, C; Lloberas, J; Celada, A				Sanchez-Tillo, Ester; Comalada, Monica; Xaus, Jordi; Farrera, Consol; Valledor, Annabel F.; Caelles, Carme; Lloberas, Jorge; Celada, Antonio			JNK1 is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; SIGNAL-REGULATED KINASE; INNATE IMMUNE-RESPONSES; N-TERMINAL KINASE; C-JUN; TRANSCRIPTION FACTORS; PATHWAY; CELLS; SPECIFICITY; RECEPTOR	Macrophages proliferate in the presence of their growth factor, macrophage colony-stimulating factor ( M-CSF), in a process that is dependent on early and short ERK activation. Lipopolysaccharide ( LPS) induces macrophage activation, stops proliferation, and delays ERK phosphorylation, thereby triggering an inflammatory response. Proliferating or activating responses are balanced by the kinetics of ERK phosphorylation, the inactivation of which correlates with Mkp1 induction. Here we show that the transcriptional induction of this phosphatase by M-CSF or LPS depends on JNK but not on the other MAPKs, ERK and p38. The lack of Mkp1 induction caused by JNK inhibition prolonged ERK-1/2 and p38 phosphorylation. The two JNK genes, jnk1 and jnk2, are constitutively expressed in macrophages. However, only the JNK1 isoform was phosphorylated and, as determined in single knock-out mice, was necessary for Mkp1 induction by M-CSF or LPS. JNK1 was also required for pro-inflammatory cytokine biosynthesis ( tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6) and LPS-induced NO production. This requirement is independent of Mkp1 expression, as shown in Mkp1 knock-out mice. Our results demonstrate a critical role for JNK1 in the regulation of Mkp1 induction and in LPS- dependent macrophage activation.	Inst Biomed Res, Macrophage Biol Grp, E-08028 Barcelona, Spain; Inst Biomed Res, Cell Signaling Grp, E-08028 Barcelona, Spain; Univ Barcelona, E-08028 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Celada, A (corresponding author), Inst Biomed Res, Macrophage Biol Grp, Barcelona Sci Pk,C Josep Samitier 1-5, E-08028 Barcelona, Spain.	acelada@ub.edu	Valledor, Annabel/H-5653-2015; Lloberas, Jorge/D-4303-2014; Celada, Antonio/I-1714-2016	Valledor, Annabel/0000-0003-4232-2633; Lloberas, Jorge/0000-0001-7075-4201; Farrera, Consol/0000-0002-4214-9597; Celada, Antonio/0000-0003-3883-2171				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CELADA A, 1989, EUR J IMMUNOL, V19, P205, DOI 10.1002/eji.1830190134; CELADA A, 1992, J IMMUNOL, V148, P1102; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Comalada M, 2003, EUR J IMMUNOL, V33, P3091, DOI 10.1002/eji.200324074; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dorfman K, 1996, ONCOGENE, V13, P925; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Herrero C, 2001, J CLIN INVEST, V107, P485, DOI 10.1172/JCI11696; Huber M, 2006, EUR J IMMUNOL, V36, P701, DOI 10.1002/eji.200535593; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Marques L, 2004, J IMMUNOL, V173, P1103, DOI 10.4049/jimmunol.173.2.1103; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Nishina H, 2004, J BIOCHEM, V136, P123, DOI 10.1093/jb/mvh117; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sanchez-Tillo E, 2006, J IMMUNOL, V176, P6594, DOI 10.4049/jimmunol.176.11.6594; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Stawowy P, 2003, BIOCHEM BIOPH RES CO, V303, P74, DOI 10.1016/S0006-291X(03)00301-2; Teng DHF, 1997, CANCER RES, V57, P4177; Triantafilou M, 2005, J ENDOTOXIN RES, V11, P5, DOI 10.1179/096805105225006641; Valledor AF, 1999, J IMMUNOL, V163, P2452; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794; Zhu JZ, 2005, J BIOL CHEM, V280, P8617, DOI 10.1074/jbc.M413539200	61	51	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12566	12573		10.1074/jbc.M609662200	http://dx.doi.org/10.1074/jbc.M609662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337450	hybrid			2022-12-25	WOS:000245942800025
J	Peskin, AV; Low, FM; Paton, LN; Maghzal, GJ; Hampton, MB; Winterbourn, CC				Peskin, Alexander V.; Low, Felicia M.; Paton, Louise N.; Maghzal, Ghassan J.; Hampton, Mark B.; Winterbourn, Christine C.			The high reactivity of peroxiredoxin 2 with H2O2 is not reflected in its reaction with other oxidants and thiol reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; HYPOCHLOROUS ACID; MAMMALIAN PEROXIREDOXIN; TAURINE CHLORAMINE; OXIDATION; PROTEIN; CELL; MYELOPEROXIDASE; METHIONINE; THIOREDOXIN	Peroxiredoxin 2 is a member of the mammalian peroxiredoxin family of thiol proteins that is important in antioxidant defense and redox signaling. We have examined its reactivity with various biological oxidants, in order to assess its ability to act as a direct physiological target for these species. Human erythrocyte peroxiredoxin 2 was oxidized stoichiometrically to its disulfide-bonded homodimer by hydrogen peroxide, as monitored electrophoretically under nonreducing conditions. The protein was highly susceptible to oxidation by adventitious peroxide, which could be prevented by treating buffers with low concentrations of catalase. However, this did not protect peroxiredoxin 2 against oxidation by added H2O2. Experiments measuring inhibition of dimerization indicated that at pH 7.4 catalase and peroxiredoxin 2 react with hydrogen peroxide at comparable rates. A rate constant of 1.3 x 107 M-1 s(-1) for the peroxiredoxin reaction was obtained from competition kinetic studies with horseradish peroxidase. This is 100-fold faster than is generally assumed. It is sufficiently high for peroxiredoxin to be a favored cellular target for hydrogen peroxide, even in competition with catalase or glutathione peroxidase. Reactions of t-butyl and cumene hydroperoxides with peroxiredoxin were also fast, but amino acid chloramines reacted much more slowly. This contrasts with other thiol compounds that react many times faster with chloramines than with hydrogen peroxide. The alkylating agent iodoacetamide also reacted extremely slowly with peroxiredoxin 2. These results demonstrate that peroxiredoxin 2 has a tertiary structure that facilitates reaction of the active site thiol with hydrogen peroxide while restricting its reactivity with other thiol reagents.	Univ Otago, Dept Pathol, Free Rad Res Grp, Christchurch, New Zealand	University of Otago	Peskin, AV (corresponding author), Univ Otago, Dept Pathol, Free Rad Res Grp, POB 4345, Christchurch, New Zealand.	alexander.peskin@chmeds.ac.nz	Peskin, alexander/R-6457-2019; maghzal, ghassan/A-9692-2015; LOW, FELICIA/GRF-2704-2022; Hampton, Mark B/A-8490-2008	Hampton, Mark B/0000-0002-7349-3729; peskin, alexander/0000-0001-9890-6043; Paton, Louise N/0000-0002-7055-5170				Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DUNFORD HB, 1999, HEME PEROXIDASES, P439; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Johnson RM, 2005, FREE RADICAL BIO MED, V39, P1407, DOI 10.1016/j.freeradbiomed.2005.07.002; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Kim JA, 2005, ANAL BIOCHEM, V338, P216, DOI 10.1016/j.ab.2004.12.008; Landar A, 2006, FREE RADICAL BIO MED, V40, P459, DOI 10.1016/j.freeradbiomed.2005.08.046; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Midwinter RG, 2004, J BIOL CHEM, V279, P32205, DOI 10.1074/jbc.M402070200; Midwinter RG, 2006, BIOCHEM J, V396, P71, DOI 10.1042/BJ20052026; Moon EY, 2006, FREE RADICAL BIO MED, V40, P2103, DOI 10.1016/j.freeradbiomed.2006.02.007; Moon EY, 2004, EUR J IMMUNOL, V34, P2119, DOI 10.1002/eji.200424962; MOORE RB, 1991, J BIOL CHEM, V266, P18964; MUNDAY R, 1985, J APPL TOXICOL, V5, P402, DOI 10.1002/jat.2550050613; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Ogusucu R, 2007, FREE RADICAL BIO MED, V42, P326, DOI 10.1016/j.freeradbiomed.2006.10.042; Parsonage D, 2005, BIOCHEMISTRY-US, V44, P10583, DOI 10.1021/bi050448i; Pattison DI, 2006, CURR MED CHEM, V13, P3271, DOI 10.2174/092986706778773095; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Peskin AV, 2006, FREE RADICAL BIO MED, V40, P45, DOI 10.1016/j.freeradbiomed.2005.08.019; Peskin AV, 2003, FREE RADICAL BIO MED, V35, P1252, DOI 10.1016/S0891-5849(03)00502-1; Puchades M, 1999, RAPID COMMUN MASS SP, V13, P344; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; SVENSSON BE, 1988, BIOCHEM J, V256, P751, DOI 10.1042/bj2560751; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	34	296	306	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11885	11892		10.1074/jbc.M700339200	http://dx.doi.org/10.1074/jbc.M700339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329258	hybrid			2022-12-25	WOS:000245941900031
J	Kasehagen, LJ; Mueller, I; Kiniboro, B; Bockarie, MJ; Reeder, JC; Kazura, JW; Kastens, W; McNamara, DT; King, CH; Whalen, CC; Zimmerman, PA				Kasehagen, Laurin J.; Mueller, Ivo; Kiniboro, Benson; Bockarie, Moses J.; Reeder, John C.; Kazura, James W.; Kastens, Will; McNamara, David T.; King, Charles H.; Whalen, Christopher C.; Zimmerman, Peter A.			Reduced Plasmodium vivax Erythrocyte Infection in PNG Duffy-Negative Heterozygotes	PLOS ONE			English	Article								Background. Erythrocyte Duffy blood group negativity reaches fixation in African populations where Plasmodium vivax (Pv) is uncommon. While it is known that Duffy-negative individuals are highly resistant to Pv erythrocyte infection, little is known regarding Pv susceptibility among heterozygous carriers of a Duffy-negative allele(+/-). Our limited knowledge of the selective advantages or disadvantages associated with this genotype constrains our understanding of the effect that interventions against Pv may have on the health of people living in malaria-endemic regions. Methods and Findings. We conducted cross-sectional malaria prevalence surveys in Papua New Guinea (PNG), where we have previously identified a new Duffy-negative allele among individuals living in a region endemic for all four human malaria parasite species. We evaluated infection status by conventional blood smear light microscopy and semi-quantitative PCR-based strategies. Analysis of a longitudinal cohort constructed from our surveys showed that Duffy heterozygous (+/-) individuals were protected from Pv erythrocyte infection compared to those homozygous for wild-type alleles (+/+) (log-rank tests: LM, p = 0.049; PCR, p = 0.065). Evaluation of Pv parasitemia, determined by semi-quantitative PCR-based methods, was significantly lower in Duffy +/-vs. +/+ individuals (Mann-Whitney U: p = 0.023). Overall, we observed no association between susceptibility to P. falciparum erythrocyte infection and Duffy genotype. Conclusions. Our findings provide the first evidence that Duffy-negative heterozygosity reduces erythrocyte susceptibility to Pv infection. As this reduction was not associated with greater susceptibility to Pf malaria, our in vivo observations provide evidence that Pv-targeted control measures can be developed safely.	[Kasehagen, Laurin J.; Kazura, James W.; Kastens, Will; McNamara, David T.; King, Charles H.; Zimmerman, Peter A.] Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA; [Mueller, Ivo; Kiniboro, Benson; Bockarie, Moses J.; Reeder, John C.] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; [Whalen, Christopher C.] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA	Case Western Reserve University; PNG Institute Of Medical Research; Case Western Reserve University	Zimmerman, PA (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA.	paz@case.edu	Bockarie, Moses/AAV-4578-2020; Mueller, Ivo/C-7251-2013; Bockarie, Moses/AAW-3130-2021	Mueller, Ivo/0000-0001-6554-6889; King, Charles/0000-0001-8349-9270; Reeder, John/0000-0003-1395-1289	National Institutes of Health [AI36478-04S1, AI46919]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036478, U01AI036478, R01AI046919] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by grants from the National Institutes of Health (AI36478-04S1 and AI46919). The funding agency played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beg MA, 2002, AM J TROP MED HYG, V67, P230, DOI 10.4269/ajtmh.2002.67.230; Boyd MF., 1949, MALARIOLOGY, P3; Bruce MC, 2000, SCIENCE, V287, P845, DOI 10.1126/science.287.5454.845; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; GENTON B, 1995, ANN TROP MED PARASIT, V89, P359, DOI 10.1080/00034983.1995.11812965; Haldane J.B.S., 1949, HEREDITAS, V35, P267; Iwamoto S, 1996, BIOCHEM BIOPH RES CO, V222, P852, DOI 10.1006/bbrc.1996.0833; Kasehagen LJ, 2006, AM J TROP MED HYG, V75, P588, DOI 10.4269/ajtmh.2006.75.588; Kish L, 1965, SURVEY SAMPLING; Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519; Luxemburger C, 1997, T ROY SOC TROP MED H, V91, P256, DOI 10.1016/S0035-9203(97)90066-3; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Mayxay M, 2004, TRENDS PARASITOL, V20, P233, DOI 10.1016/j.pt.2004.03.006; McNamara DT, 2006, AM J TROP MED HYG, V74, P413, DOI 10.4269/ajtmh.2006.74.413; McNamara DT, 2004, J CLIN MICROBIOL, V42, P2403, DOI 10.1128/JCM.42.6.2403-2410.2004; Mehlotra RK, 2002, AM J TROP MED HYG, V67, P555, DOI 10.4269/ajtmh.2002.67.555; Mgone CS, 1996, T ROY SOC TROP MED H, V90, P228, DOI 10.1016/S0035-9203(96)90223-0; Michon P, 2001, FEBS LETT, V495, P111, DOI 10.1016/S0014-5793(01)02370-5; Muller I, 2003, TRENDS PARASITOL, V19, P253, DOI 10.1016/S1471-4922(03)00091-6; Oron-Karni V, 1998, AM J HEMATOL, V58, P306, DOI 10.1002/(SICI)1096-8652(199808)58:4<306::AID-AJH10>3.0.CO;2-5; Patel SS, 2001, BLOOD, V98, P3489, DOI 10.1182/blood.V98.12.3489; Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004; Price RN, 2001, AM J TROP MED HYG, V65, P614, DOI 10.4269/ajtmh.2001.65.614; Ross A, 2006, AM J TROP MED HYG, V75, P63, DOI 10.4269/ajtmh.2006.75.63; Rothman K, 1986, MODERN EPIDEMIOLOGY; Smith T, 2001, AM J TROP MED HYG, V64, P262, DOI 10.4269/ajtmh.2001.64.262; Snounou G, 2004, TRENDS PARASITOL, V20, P262, DOI 10.1016/j.pt.2004.03.008; TOURNAMILLE C, 1995, HUM GENET, V95, P407, DOI 10.1007/BF00208965; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Twisk JWR, 2003, APPL LONGITUDINAL DA; WEATHERALL DJ, 1987, ANN TROP MED PARASIT, V81, P539, DOI 10.1080/00034983.1987.11812155; Williams TN, 1996, NATURE, V383, P522, DOI 10.1038/383522a0; ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406; Zimmerman PA, 1999, P NATL ACAD SCI USA, V96, P13973, DOI 10.1073/pnas.96.24.13973; Zimmerman PA, 2004, TRENDS PARASITOL, V20, P440, DOI 10.1016/j.pt.2004.07.004; Zimmerman PA, 2004, INFECTIOUS DISEASE AND HOST-PATHOGEN EVOLUTION, P141, DOI 10.1017/CBO9780511546259.007; 2000, PAPUA NEW GUINEA MIN	38	59	60	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e336	10.1371/journal.pone.0000336	http://dx.doi.org/10.1371/journal.pone.0000336			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389925	Green Published, gold			2022-12-25	WOS:000207445200019
J	Glaser, T; Pollard, SM; Smith, A; Brustle, O				Glaser, Tamara; Pollard, Steven M.; Smith, Austin; Bruestle, Oliver			Tripotential Differentiation of Adherently Expandable Neural Stem (NS) Cells	PLOS ONE			English	Article								Background. A recent study has shown that pure neural stem cells can be derived from embryonic stem (ES) cells and primary brain tissue. In the presence of fibroblast growth factor 2 (FGF2) and epidermal growth factor (EGF), this population can be continuously expanded in adherent conditions. In analogy to continuously self-renewing ES cells, these cells were termed 'NS' cells (Conti et al., PLoS Biol 3: e283, 2005). While NS cells have been shown to readily generate neurons and astrocytes, their differentiation into oligodendrocytes has remained enigmatic, raising concerns as to whether they truly represent tripotential neural stem cells. Methodology/Principal Findings. Here we provide evidence that NS cells are indeed tripotent. Upon proliferation with FGF2, platelet-derived growth factor (PDGF) and forskolin, followed by differentiation in the presence of thyroid hormone (T3) and ascorbic acid NS cells efficiently generate oligodendrocytes (similar to 20%) alongside astrocytes (similar to 40%) and neurons (similar to 10%). Mature oligodendroglial differentiation was confirmed by transplantation data showing that NS cell-derived oligodendrocytes ensheath host axons in the brain of myelin-deficient rats. Conclusions/Significance. In addition to delineating NS cells as a potential donor source for myelin repair, our data strongly support the view that these adherently expandable cells represent bona fide tripotential neural stem cells.	[Glaser, Tamara; Bruestle, Oliver] Univ Bonn, Inst Reconstruct Neurobiol, LIFE & BRAIN Ctr, D-5300 Bonn, Germany; [Glaser, Tamara; Bruestle, Oliver] Hertie Fdn, Bonn, Germany; [Pollard, Steven M.; Smith, Austin] Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Cambridge, England	University of Bonn; University of Cambridge	Brustle, O (corresponding author), Univ Bonn, Inst Reconstruct Neurobiol, LIFE & BRAIN Ctr, D-5300 Bonn, Germany.	brustle@uni-bonn.de	; Pollard, Steven/B-7966-2010	Smith, Austin/0000-0002-3029-4682; Pollard, Steven/0000-0001-6428-0492	EuroStemCell; BBRSC; Institute of Multiple Sclerosis Research (IMSF); Hertie Foundation; Biotechnology and Biological Sciences Research Council [G15381/2] Funding Source: researchfish; Medical Research Council [G9806702] Funding Source: researchfish; MRC [G9806702] Funding Source: UKRI	EuroStemCell(European Commission); BBRSC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Institute of Multiple Sclerosis Research (IMSF); Hertie Foundation; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by EuroStemCell, the BBRSC, the Institute of Multiple Sclerosis Research (IMSF) in Gottingen and the Hertie Foundation.	BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Glaser T, 2004, FASEB J, V18, P112, DOI 10.1096/fj.04-1931fje; Goldman S, 2003, TRENDS NEUROSCI, V26, P590, DOI 10.1016/j.tins.2003.09.011; Gotz M, 2003, GLIA, V43, P1, DOI 10.1002/glia.10251; Gotz M, 2003, NEUROSCIENTIST, V9, P379, DOI 10.1177/1073858403257138; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Klein D, 2006, GENE THER, V13, P1686, DOI 10.1038/sj.gt.3302834; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pollard SM, 2006, CEREB CORTEX, V16, pI112, DOI 10.1093/cercor/bhj167; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Watanabe M, 2006, J NEUROSCI RES, V84, P525, DOI 10.1002/jnr.20950; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weiss S, 1996, J NEUROSCI, V16, P7599; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780	41	86	88	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e298	10.1371/journal.pone.0000298	http://dx.doi.org/10.1371/journal.pone.0000298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356704	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444800021
J	Clausen, T; Ribbeck, K				Clausen, Thomas; Ribbeck, Katharina			Self-Organization of Anastral Spindles by Synergy of Dynamic Instability, Autocatalytic Microtubule Production, and a Spatial Signaling Gradient	PLOS ONE			English	Article								Assembly of the mitotic spindle is a classic example of macromolecular self-organization. During spindle assembly, microtubules (MTs) accumulate around chromatin. In centrosomal spindles, centrosomes at the spindle poles are the dominating source of MT production. However, many systems assemble anastral spindles, i.e., spindles without centrosomes at the poles. How anastral spindles produce and maintain a high concentration of MTs in the absence of centrosome-catalyzed MT production is unknown. With a combined biochemistry-computer simulation approach, we show that the concerted activity of three components can efficiently concentrate microtubules (MTs) at chromatin: (1) an external stimulus in form of a RanGTP gradient centered on chromatin, (2) a feed-back loop where MTs induce production of new MTs, and (3) continuous reorganization of MT structures by dynamic instability. The mechanism proposed here can generate and maintain a dissipative MT super-structure within a RanGTP gradient.	[Clausen, Thomas; Ribbeck, Katharina] European Mol Biol Lab, Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Ribbeck, K (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	Katharina_Ribbeck@hms.harvard.edu			EMBL; BioMS	EMBL; BioMS	This project was funded by EMBL and BioMS.	BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Caudron M, 2005, SCIENCE, V309, P1373, DOI 10.1126/science.1115964; Cramer J.S, 2003, LOGIT MODELS EC OTHE, DOI 10.1017/CBO9780511615412.002; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; Desai A, 1997, P NATL ACAD SCI USA, V94, P12378, DOI 10.1073/pnas.94.23.12378; Desai A, 1999, METHOD CELL BIOL, V61, P385; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Mahoney NM, 2006, CURR BIOL, V16, P564, DOI 10.1016/j.cub.2006.01.053; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pearl R, 1920, P NATL ACAD SCI USA, V6, P275, DOI 10.1073/pnas.6.6.275; Srayko M, 2006, CURR BIOL, V16, P1944, DOI 10.1016/j.cub.2006.08.029; Tirnauer JS, 2004, MOL BIOL CELL, V15, P1776, DOI 10.1091/mbc.E03-11-0824; Verhulst P. F., 1838, CORRES MATH PHYS, V10, P113, DOI DOI 10.1007/BF02309004; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; ZHENG Y, 2004, ANN REV CELL DEV BIO	25	33	33	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e244	10.1371/journal.pone.0000244	http://dx.doi.org/10.1371/journal.pone.0000244			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330139	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444600004
J	Schonenberger, E; Schnapauff, D; Teige, F; Laule, M; Hamm, B; Dewey, M				Schoenenberger, Eva; Schnapauff, Dirk; Teige, Florian; Laule, Michael; Hamm, Bernd; Dewey, Marc			Patient Acceptance of Noninvasive and Invasive Coronary Angiography	PLOS ONE			English	Article								Background. Noninvasive angiography using multislice computed tomography (MSCT) is superior to magnetic resonance imaging (MRI) for detection of coronary stenoses. We compared patient acceptance of these two noninvasive diagnostic tests and invasive conventional coronary angiography (Angio). Methods and Findings. A total of 111 consecutive patients with suspected coronary artery disease underwent MSCT, MRI, and Angio. Subsequently, patient acceptance of the three tests was evaluated with questionnaires in all patients. The main acceptance variables were preparation and information prior to the test, degree of concern, comfort, degree of helplessness, pain (on visual analog scales), willingness to undergo the test again, and overall satisfaction. Preparation for each test was not rated significantly differently, whereas patients were significantly more concerned about Angio than the two noninvasive tests (p < 0.001). No pain during MSCT, MRI, and Angio as assessed on visual analog scales (0 to 100) was reported by 99, 93, and 31 patients, respectively. Among the 82 patients who felt pain during at least one procedure, both CT (0.9 +/- 4.5) and MRI (5.2 +/- 16.6) were significantly less painful than Angio (24.6 +/- 23.4, both p < 0.001). MSCT was considered significantly more comfortable (1.49 +/- 0.64) than MRI (1.75 +/- 0.81, p < 0.001). In both the no-revascularization (55 patients) and the revascularization group (56 patients), the majority of the patients (73 and 71%) would prefer MSCT to MRI and Angio for future imaging of the coronary arteries. None of the patients indicated to be unwilling to undergo MSCT again. The major advantages patients attributed to MSCT were its fast, uncomplicated, noninvasive, and painless nature. Conclusions. Noninvasive coronary angiography with MSCT is considered more comfortable than MRI and both MSCT and MRI are less painful than Angio. Patient preference for MSCT might tip the scales in favor of this test provided that the diagnostic accuracy of MSCT can be shown to be high enough for clinical application.	[Schnapauff, Dirk; Teige, Florian; Hamm, Bernd; Dewey, Marc] Humboldt Univ, Charite, Dept Radiol, Berlin, Germany; [Schoenenberger, Eva] Hannover Med Sch, Dept Med, D-30623 Hannover, Germany; [Laule, Michael] Humboldt Univ, Charite, Dept Cardiol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Dewey, M (corresponding author), Humboldt Univ, Charite, Dept Radiol, Berlin, Germany.	marc.dewey@charite.de	Laule, Michael E/A-6548-2013	Dewey, Marc/0000-0002-4402-2733; Laule, Michael/0000-0002-7579-295X	GE Healthcare Biosciences	GE Healthcare Biosciences(General Electric)	Dr. Dewey and Dr. Hamm have received grant support from GE Healthcare Biosciences ( formerly: Amersham Buchler) for this study. The funding source had no role in the collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.	*AM HEART ASS, 2004, HEART DIS STROK STAT; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; Bogaert J, 2003, RADIOLOGY, V226, P707, DOI 10.1148/radiol.2263011750; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Coles DR, 2006, J AM COLL CARDIOL, V47, P1840, DOI 10.1016/j.jacc.2005.11.078; Cooper R, 2000, CIRCULATION, V102, P3137; Dewey M, 2006, ROFO-FORTSCHR RONTG, V178, P600, DOI 10.1055/s-2006-926755; Dewey M, 2006, J MAGN RESON IMAGING, V23, P674, DOI 10.1002/jmri.20568; Dewey M, 2006, INVEST RADIOL, V41, P400, DOI 10.1097/01.rli.0000201233.42994.9b; Dewey M, 2004, INVEST RADIOL, V39, P223, DOI 10.1097/01.rli.0000115201.27096.6e; DEWEY M, 2006, EUR RADIOL; Dewey M, 2006, ANN INTERN MED, V145, P407, DOI 10.7326/0003-4819-145-6-200609190-00004; Garcia MJ, 2006, JAMA-J AM MED ASSOC, V296, P403, DOI 10.1001/jama.296.4.403; Gerber TC, 2005, INVEST RADIOL, V40, P556, DOI 10.1097/01.rli.0000170628.69792.cb; Greenland P, 2006, ANN INTERN MED, V145, P466, DOI 10.7326/0003-4819-145-6-200609190-00012; Herborn CU, 2003, RADIOLOGY, V229, P217, DOI 10.1148/radiol.2291021033; Hoffmann MHK, 2005, JAMA-J AM MED ASSOC, V293, P2471, DOI 10.1001/jama.293.20.2471; Kim WY, 2001, NEW ENGL J MED, V345, P1863, DOI 10.1056/NEJMoa010866; Kondo C, 2005, J COMPUT ASSIST TOMO, V29, P694, DOI 10.1097/01.rct.0000173844.89988.37; Leber AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/j.jacc.2005.03.071; Lefere PA, 2002, RADIOLOGY, V224, P393, DOI 10.1148/radiol.2241011222; Leschka S, 2005, EUR HEART J, V26, P1482, DOI 10.1093/eurheartj/ehi261; Martuscelli E, 2004, EUR HEART J, V25, P1043, DOI 10.1016/j.ehj.2004.03.024; Menon K, 2001, AM J GASTROENTEROL, V96, P2646; Mollet NR, 2004, J AM COLL CARDIOL, V43, P2265, DOI 10.1016/j.jacc.2004.03.032; Mollet NR, 2005, CIRCULATION, V112, P2318, DOI 10.1161/CIRCULATIONAHA.105.533471; Nieman K, 2002, CIRCULATION, V106, P2051, DOI 10.1161/01.CIR.0000037222.58317.3D; Niendorf T, 2006, ROFO-FORTSCHR RONTG, V178, P15, DOI 10.1055/s-2005-858686; NOTO TJ, 1991, CATHETER CARDIO DIAG, V24, P75, DOI 10.1002/ccd.1810240202; Raff GL, 2005, J AM COLL CARDIOL, V46, P552, DOI 10.1016/j.jacc.2005.05.056; Ropers D, 2006, AM J CARDIOL, V97, P343, DOI 10.1016/j.amjcard.2005.08.050; Ropers D, 2003, CIRCULATION, V107, P664, DOI 10.1161/01.CIR.0000055738.31551.A9; Schoenhagen P, 2004, RADIOLOGY, V232, P7, DOI 10.1148/radiol.2321021803; Schoepf UJ, 2004, RADIOLOGY, V232, P18, DOI 10.1148/radiol.2321030636; Schuijf JD, 2006, AM HEART J, V151, P404, DOI 10.1016/j.ahj.2005.03.022; Schuijf JD, 2006, AM J CARDIOL, V98, P145, DOI 10.1016/j.amjcard.2006.01.092; Stamm G, 2002, ROFO-FORTSCHR RONTG, V174, P1570, DOI 10.1055/s-2002-35937; Stiebellehner L, 2002, WIEN KLIN WOCHENSCHR, V114, P847; Svensson MH, 2002, RADIOLOGY, V222, P337, DOI 10.1148/radiol.2222010669; Taupitz M, 2001, MAGN RESON MED, V46, P932, DOI 10.1002/mrm.1279; Trabold T, 2003, ROFO-FORTSCHR RONTG, V175, P1051; U-King-Im JM, 2004, CLIN RADIOL, V59, P358, DOI 10.1016/j.crad.2003.08.015; van Gelder RE, 2004, RADIOLOGY, V233, P328, DOI 10.1148/radiol.2331031208	43	36	36	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e246	10.1371/journal.pone.0000246	http://dx.doi.org/10.1371/journal.pone.0000246			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327910	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444600006
J	Kurabe, N; Katagiri, K; Komiya, Y; Ito, R; Sugiyama, A; Kawasaki, Y; Tashiro, F				Kurabe, N.; Katagiri, K.; Komiya, Y.; Ito, R.; Sugiyama, A.; Kawasaki, Y.; Tashiro, F.			Deregulated expression of a novel component of TFTC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: possible implication for the oncogenic potential of c-Myc	ONCOGENE			English	Article						c-Myc; metastasis; STAGA; transcription control; tumorigenicity	ACETYLASE COMPLEX; ORNITHINE-DECARBOXYLASE; NUCLEOSOME ACETYLATION; ESSENTIAL COFACTOR; IN-VIVO; IDENTIFICATION; MACHINERY; TRRAP; ONCOPROTEINS; INVOLVEMENT	c-Myc N-terminal conserved domains, MbI and MbII, are essential for c-Myc-mediated transformation and transactivation. These domains recruit the STAGA (SPT3-TAF9-GCN5-acetyltransferase) coactivator complex, but not TFTC (TATA-binding protein-free TAF-containing) to the target gene promoter. Although components of this complex are well conserved between yeast and mammals, four mammalian orthologs of yeast SPT8, SPT20, SGF11 and SGF29 remain to be identified. Here, we isolated a rat ortholog of yeast SGF29, a component of yeast SAGA (SPT-ADA-GCN5-acetyltransferase) complex. Both rat (r) SGF29 and c-myc mRNAs were overexpressed in five out of the eight tested rodent tumor cells. rSGF29 directly interacted with rADA3 and co-immunoprecipitated with two other TFTC/STAGA components, rGCN5 and rSPT3. rSGF29 was recruited to the c-Myc target gene promoters together with c-Myc, and it activated c-Myc target gene expressions. Downregulation of rSGF29 suppressed the expression of c-Myc target genes and inhibited anchorage-independent growth and tumorigenicity and lung metastasis of rat hepatoma K2 cells when injected into nude mice. These results show that rSGF29 is a novel component of TFTC/STAGA complexes and could be involved in the c-Myc-mediated malignant transformation.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Yamazaki 2641, Noda, Chiba 2788510, Japan.	ftashir@rs.noda.tus.ac.jp						Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PENA A, 1993, J BIOL CHEM, V268, P27277; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Urano Y, 2006, J BIOL CHEM, V281, P7498, DOI 10.1074/jbc.M510881200; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	24	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5626	5634		10.1038/sj.onc.1210349	http://dx.doi.org/10.1038/sj.onc.1210349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334388				2022-12-25	WOS:000248801900008
J	Wang, YC; Szczesna-Cordary, D; Craig, R; Diaz-Perez, Z; Guzman, G; Miller, T; Potter, JD				Wang, Yingcai; Szczesna-Cordary, Danuta; Craig, Roger; Diaz-Perez, Zoraida; Guzman, Georgianna; Miller, Todd; Potter, James D.			Fast skeletal muscle regulatory light chain is required for fast and slow skeletal muscle development	FASEB JOURNAL			English	Article						RLC-f; knock-out mouse; myofibril structure; histology	MYOSIN HEAVY-CHAIN; GROWTH-FACTOR RECEPTOR-3; INDIRECT FLIGHT-MUSCLE; GENE; EXPRESSION; HEART; CONTRACTION; DROSOPHILA; FREQUENCY; DEFICITS	In skeletal muscle, the myosin molecule contains two sets of noncovalently attached low molecular weight proteins, the regulatory (RLC) and essential (ELC) light chains. To assess the functional and developmental significance of the fast skeletal isoform of the RLC (RLC-f), the murine fast skeletal RLC gene (Mylpf) was disrupted by homologous recombination. Heterozygotes containing an intronic neo cassette (RLC-/+) had approximately one-half of the amount of the RLC-f mRNA compared to wild-type (WT) mice but their muscles were histologically normal in both adults and neonates. In contrast, homozygous mice (RLC-/+) had no RLC-f mRNA or protein and completely lacked both fast and slow skeletal muscle. This was likely due to interference with mRNA processing in the presence of the neo cassette. These RLC-f null mice died immediately after birth, presumably due to respiratory failure since their diaphragms lacked skeletal muscle. The body weight of newborn RLC-f null mice was decreased 30% compared to heterozygous or WT newborn mice. The lack of skeletal muscle formation in the null mice did not affect the development of other organs including the heart. In addition, we found that WT mice did not express the ventricular/slow skeletal RLC isoform (RLC-v/s) until after birth, while it was expressed normally in the embryonic heart. The lack of skeletal muscle formation observed in RLC-f null mice indicates the total dependence of skeletal muscle development on the presence of RLC-f during embryogenesis. This observation, along with the normal function of the RLC-v/s in the heart, implicates a coupled, diverse pathway for RLC-v/s and RLC-f during embryogenesis, where RLC-v/s is responsible for heart development and RLC-f is necessary for skeletal muscle formation. In conclusion, in this study we demonstrate that the Mylpf gene is critically important for fast and slow skeletal muscle development.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA USA	University of Miami; University of Massachusetts System; University of Massachusetts Worcester	Szczesna-Cordary, D (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Rm 6085A RMSB,1600 NW 10th Ave, Miami, FL 33136 USA.	dszczesna@med.miami.edu; jdpotter@miami.edu			NHLBI NIH HHS [R01 HL071778-01A1, R01 HL071778-04, R01 HL071778, HL-071778] Funding Source: Medline; NIAMS NIH HHS [AR-034711, AR-45183] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034711, R01AR045183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Crawford K, 2002, MOL CELL BIOL, V22, P5887, DOI 10.1128/MCB.22.16.5887-5896.2002; DEFREITAS F, 2006, BIOPHYS J, pA421; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; FAERMAN A, 1993, DEVELOPMENT, V118, P919; FAERMAN A, 1993, DEV DYNAM, V196, P165, DOI 10.1002/aja.1001960303; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LOUGHNA PT, 1990, DEVELOPMENT, V109, P217; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MACERA MJ, 1992, GENOMICS, V13, P829, DOI 10.1016/0888-7543(92)90161-K; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; PERIASAMY M, 1985, J BIOL CHEM, V260, P5856; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; Rottbauer W, 2006, CIRC RES, V99, P323, DOI 10.1161/01.RES.0000234807.16034.fe; SZCESNA D, 1996, BIOPHYS J, V70, pA380; Szczesna Danuta, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P187, DOI 10.2174/1568006033481474; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; Zhi G, 2005, P NATL ACAD SCI USA, V102, P17519, DOI 10.1073/pnas.0506846102	25	28	30	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2205	2214		10.1096/fj.06-7538com	http://dx.doi.org/10.1096/fj.06-7538com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356007				2022-12-25	WOS:000247500300029
J	Meriin, AB; Zhang, X; Alexandrov, IM; Salnikova, AB; Ter-Avanesian, MD; Chernoff, YO; Sherman, MY				Meriin, Anatoli B.; Zhang, XiaoQian; Alexandrov, Ilya M.; Salnikova, Alexandra B.; Ter-Avanesian, Michael D.; Chernoff, Yury O.; Sherman, Michael Y.			Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains	FASEB JOURNAL			English	Article						Huntington's disease	YEAST PSI+ PRION; SACCHAROMYCES-CEREVISIAE; MUTANT HUNTINGTIN; ACTIN CYTOSKELETON; ARP2/3 COMPLEX; BUDDING YEAST; DYNAMICS; LOCALIZATION; DEGRADATION; ASSOCIATION	The cell's failure to refold or break down abnormal polypeptides often leads to their aggregation, which could cause toxicity and various pathologies. Here we investigated cellular factors involved in protein aggregation in yeast and mammalian cells using model polypeptides containing polyglutamine domains. In yeast, a number of mutations affecting the complex responsible for formation of the endocytic vesicle reduced the aggregation. Components of the endocytic complex (EC) Sla1, Sla2, and Pan1 were seen as clusters in the polyglutamine aggregates. These proteins associate with EC at the later stages of its maturation. In contrast, Ede1 and Ent1, the elements of EC at the earlier stages, were not found in the aggregates, suggesting that late ECs are involved in polyglutamine aggregation. Indeed, stabilization of the late complexes by inhibition of actin polymerization enhanced aggregation of polypeptides with polyglutamine domains. Similarly, in mammalian cells, inhibitors of actin polymerization, as well as depletion of a mediator of actin polymerization, Arp2, strongly enhanced the aggregation. In contrast, destabilization of EC by depletion or inhibition of a scaffolding protein N-WASP effectively suppressed the aggregation. Therefore, EC appears to play a pivotal role in aggregation of cytosolic polypeptides with polyglutamine domains in both yeast and mammalian cells.-Meriin, A. B., Zhang, X., Alexandrov, I. M., Salnikova, A. B., Ter-Avanesian, M. D., Chernoff, Y. O., Sherman, M. Y. Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains.	Boston Univ, Sch Med, Dept Biochem, Boston, MA USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA USA; Georgia Inst Technol, Sch Biol, Atlanta, GA USA; Cardiol Res Ctr, Moscow, Russia	Boston University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; National Medical Research Center of Cardiology	Sherman, MY (corresponding author), 715 Albany St K323, Boston, MA 02118 USA.	sherma1@bu.edu	Chernoff, Yury O/J-2833-2014	Meriin, Anatoli/0000-0003-0087-814X; Sherman, Michael/0000-0003-3345-073X; Chernoff, Yury/0000-0002-8934-9051				Aguilar RC, 2003, J BIOL CHEM, V278, P10737, DOI 10.1074/jbc.M211622200; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ayscough KR, 2004, CURR BIOL, V14, pR124, DOI 10.1016/j.cub.2004.01.021; Bailleul PA, 1999, GENETICS, V153, P81; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Gagny B, 2000, J CELL SCI, V113, P3309; Ganusova EE, 2006, MOL CELL BIOL, V26, P617, DOI 10.1128/MCB.26.2.617-629.2006; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Pollitt SK, 2003, NEURON, V40, P685, DOI 10.1016/S0896-6273(03)00697-4; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimohata T, 2002, NEUROSCI LETT, V323, P215, DOI 10.1016/S0304-3940(02)00162-3; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Smith MG, 2001, J CELL SCI, V114, P1505; Takahashi J, 2003, NEUROBIOL DIS, V13, P230, DOI 10.1016/S0969-9961(03)00080-9; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Vidair CA, 1996, INT J HYPERTHER, V12, P681, DOI 10.3109/02656739609027676; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wigley WC, 1999, J CELL BIOL, V145, P481; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	52	57	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1915	1925		10.1096/fj.06-6878com	http://dx.doi.org/10.1096/fj.06-6878com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341688				2022-12-25	WOS:000246866500032
J	Banerjee, R; Schleicher, E; Meier, S; Viana, RM; Pokorny, R; Ahmad, M; Bittl, R; Batschauer, A				Banerjee, Roopa; Schleicher, Erik; Meier, Stefan; Viana, Rafael Munoz; Pokorny, Richard; Ahmad, Margaret; Bittl, Robert; Batschauer, Alfred			The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT PHOTORECEPTORS; CRYSTAL-STRUCTURE; DNA PHOTOLYASE; GREEN LIGHT; SINAPIS-ALBA; THALIANA; INDUCTION; DOMAIN	Cryptochrome ( Cry) photoreceptors share high sequence and structural similarity with DNA repair enzyme DNA-photolyase and carry the same flavin cofactor. Accordingly, DNA-photolyase was considered a model system for the light activation process of cryptochromes. In line with this view were recent spectroscopic studies on cryptochromes of the CryDASH subfamily that showed photoreduction of the flavin adenine dinucleotide ( FAD) cofactor to its fully reduced form. However, CryDASH members were recently shown to have photolyase activity for cyclobutane pyrimidine dimers in single-stranded DNA, which is absent for other members of the cryptochrome/photolyase family. Thus, CryDASH may have functions different from cryptochromes. The photocycle of other members of the cryptochrome family, such as Arabidopsis Cry1 and Cry2, which lack DNA repair activity but control photomorphogenesis and flowering time, remained elusive. Here we have shown that Arabidopsis Cry2 undergoes a photocycle in which semireduced flavin ( FADH(.)) accumulates upon blue light irradiation. Green light irradiation of Cry2 causes a change in the equilibrium of flavin oxidation states and attenuates Cry2-controlled responses such as flowering. These results demonstrate that the active form of Cry2 contains FADH(.) ( whereas catalytically active photolyase requires fully reduced flavin ( FADH(.))) and suggest that cryptochromes could represent photoreceptors using flavin redox states for signaling differently from DNA-photolyase for photorepair.	Univ Marburg, FB Biol Pflanzenphysiol, D-35032 Marburg, Germany; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; Univ Paris 06, UMR 7632, CNRS, F-75252 Paris 05, France; Penn State Univ, Dept Biol, Media, PA 19063 USA	Philipps University Marburg; Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Batschauer, A (corresponding author), Univ Marburg, FB Biol Pflanzenphysiol, Karl von Frisch Str 8, D-35032 Marburg, Germany.	batschau@staff.uni-marburg.de	Schleicher, Erik/C-9951-2010; Bittl, Robert/I-8149-2013	Bittl, Robert/0000-0003-4103-3768; Schleicher, Erik/0000-0003-2953-050X; Ahmad, Margaret/0000-0003-4524-5813				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Briggs W. R., 2006, PHOTOMORPHOGENESIS P, P171; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Corbesier L, 1996, PLANT J, V9, P947, DOI 10.1046/j.1365-313X.1996.9060947.x; Daiyasu H, 2004, GENES CELLS, V9, P479, DOI 10.1111/j.1356-9597.2004.00738.x; Dhingra A, 2006, PLANT PHYSIOL, V142, P1256, DOI 10.1104/pp.106.088351; EHRENBERG A, 1968, BIOL OXIDATIONS, P239; ELASSAL SED, 2003, PLANT PHYSIOL, V133, P1; Folta KM, 2004, PLANT PHYSIOL, V135, P1407, DOI 10.1104/pp.104.038893; Frechilla S, 2004, PLANT CELL PHYSIOL, V45, P1709, DOI 10.1093/pcp/pch197; Gindt YM, 1999, BIOCHEMISTRY-US, V38, P3857, DOI 10.1021/bi981191+; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HANKE J, 1969, PLANTA, V86, P235, DOI 10.1007/BF00386456; Huang YH, 2006, P NATL ACAD SCI USA, V103, P17701, DOI 10.1073/pnas.0608554103; Imaizumi T, 2003, NATURE, V426, P302, DOI 10.1038/nature02090; Klar T, 2007, J MOL BIOL, V366, P954, DOI 10.1016/j.jmb.2006.11.066; Kleiner O, 1999, PLANT J, V19, P289, DOI 10.1046/j.1365-313X.1999.00535.x; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; LIN C, 1995, P NATL ACAD SCI USA, V92, P8423, DOI 10.1073/pnas.92.18.8423; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Mancinelli Alberto L., 1994, P211; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Mockler TC, 1999, DEVELOPMENT, V126, P2073; MOZLEY D, 1995, J EXP BOT, V46, P173, DOI 10.1093/jxb/46.2.173; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Powles, 1981, CARNEGIE I WASHINGTO, V80, P59; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Sang Y, 2005, PLANT CELL, V17, P1569, DOI 10.1105/tpc.104.029645; Saxena C, 2005, J AM CHEM SOC, V127, P7984, DOI 10.1021/ja0421607; Schamiloglu E., 2006, Proceedings of the 27th International Power Modulator Symposium and 2006 High Voltage Workshop (IEEE Cat No. 06CH37746C), DOI 10.1007/1-4020-3811-9_1; Selby CP, 2006, P NATL ACAD SCI USA, V103, P17696, DOI 10.1073/pnas.0607993103; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Talbott LD, 2006, PLANT CELL PHYSIOL, V47, P332, DOI 10.1093/pcp/pci249; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Weber S, 2005, CHEMPHYSCHEM, V6, P292, DOI 10.1002/cphc.200400377; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	50	197	205	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14916	14922		10.1074/jbc.M700616200	http://dx.doi.org/10.1074/jbc.M700616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355959	hybrid			2022-12-25	WOS:000246589000029
J	Cai, ML; Huang, Y; Suh, JY; Louis, JM; Ghirlando, R; Craigie, R; Clore, GM				Cai, Mengli; Huang, Ying; Suh, Jeong-Yong; Louis, John M.; Ghirlando, Rodolfo; Craigie, Robert; Clore, G. Marius			Solution NMR structure of the barrier-to-autointegration factor-emerin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MEMBRANE PROTEIN; DIPOLAR COUPLINGS; LEM-DOMAIN; 3-DIMENSIONAL STRUCTURES; STRUCTURE REFINEMENT; RETROVIRAL DNA; BAF; BINDING; MACROMOLECULES; RESTRAINTS	The barrier-to-autointegration factor BAF binds to the LEM domain (Em(LEM)) of the nuclear envelope protein emerin and plays an essential role in the nuclear architecture of metazoan cells. In addition, the BAF(2) dimer bridges and compacts double-stranded DNA nonspecifically via two symmetry-related DNA binding sites. In this article we present biophysical and structural studies on a complex of BAF(2) and EmLEM. Light scattering, analytical ultracentrifugation, and NMR indicate a stoichiometry of one molecule of EmLEM bound per BAF(2) dimer. The equilibrium dissociation constant (K-d) for the interaction of the BAF(2) dimer and Em(LEM), determined by isothermal titration calorimetry, is 0.59 +/- 0.03 mu M. Z-exchange spectroscopy between corresponding cross-peaks of the magnetically non-equivalent subunits of the BAF(2) dimer in the complex yields a dissociation rate constant of 78 +/- 2 s(-1). The solution NMR structure of the BAF(2)-Em(LEM) complex reveals that the LEM and DNA binding sites on BAF(2) are non-overlapping and that both subunits of the BAF(2) dimer contribute approximately equally to the EmLEM binding site. The relevance of the implications of the structural and biophysical data on the complex in the context of the interaction between the BAF(2) dimer and EmLEM at the nuclear envelope is discussed.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008; Ghirlando, Rodolfo/A-8880-2009	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036171, Z01DK029043, ZIADK033007, Z01DK036171, Z01DK029023, Z01DK033007, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bradley CM, 2005, NAT STRUCT MOL BIOL, V12, P935, DOI 10.1038/nsmb989; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; CHANCE EM, 1979, R8775 AT EN RES EST; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; CLORE GM, 1991, J AM CHEM SOC, V113, P4350, DOI 10.1021/ja00011a059; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Furukawa K, 1999, J CELL SCI, V112, P2485; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Haraguchi T, 2001, J CELL SCI, V114, P4575; Iwahara J, 2006, J AM CHEM SOC, V128, P404, DOI 10.1021/ja056786o; Jacque JM, 2006, NATURE, V441, P641, DOI 10.1038/nature04682; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee KK, 2001, J CELL SCI, V114, P4567; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7	55	64	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14525	14535		10.1074/jbc.M700576200	http://dx.doi.org/10.1074/jbc.M700576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355960	hybrid			2022-12-25	WOS:000246245800066
J	Hashemy, SI; Johansson, C; Berndt, C; Lillig, CH; Holmgren, A				Hashemy, Seyed Isaac; Johansson, Catrine; Berndt, Carsten; Lillig, Christopher Horst; Holmgren, Arne			Oxidation and S-nitrosylation of cysteines in human cytosolic and mitochondrial glutaredoxins - Effects on structure and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; NMR SOLUTION STRUCTURE; RED-BLOOD-CELLS; NF-KAPPA-B; ESCHERICHIA-COLI; THIOLTRANSFERASE GLUTAREDOXIN; CATALYTIC MECHANISM; HUMAN THIOREDOXIN	Glutathione (GSH) is the major intracellular thiol present in 1-10-mM concentrations in human cells. However, the redox potential of the 2GSH/GSSG ( glutathione disulfide) couple in cells varies in association with proliferation, differentiation, or apoptosis from -260 mV to -200 or -170 mV. Hydrogen peroxide is transiently produced as second messenger in receptor-mediated growth factor signaling. To understand oxidation mechanisms by GSSG or nitric oxide-related nitrosylation we studied effects on glutaredoxins (Grx), which catalyze GSH-dependent thiol-disulfide redox reactions, particularly reversible glutathionylation of protein sulfhydryl groups. Human Grx1 and Grx2 contain Cys-Pro-Tyr-Cys and Cys-Ser-Tyr-Cys active sites and have three and two additional structural Cys residues, respectively. We analyzed the redox state and disulfide pairing of Cys residues upon GSSG oxidation and S-nitrosylation. Cytosolic/nuclear Grx1 was partly inactivated by both S-nitrosylation and oxidation. Inhibition by nitrosylation was reversible under anaerobic conditions; aerobically it was stronger and irreversible, indicating inactivation by nitration. Oxidation of Grx1 induced a complex pattern of disulfide-bonded dimers and oligomers formed between Cys-8 and either Cys-79 or Cys-83. In addition, an intramolecular disulfide between Cys-79 and Cys-83 was identified, predicted to have a profound effect on the three-dimensional structure. In contrast, mitochondrial Grx2 retains activity upon oxidation, did not form disulfide-bonded dimers or oligomers, and could not be S-nitrosylated. The dimeric iron sulfur cluster-coordinating inactive form of Grx2 dissociated upon nitrosylation, leading to activation of the protein. The striking differences between Grx1 and Grx2 reflect their diverse regulatory functions in vivo and also adaptation to different subcellular localization.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden; Univ Marburg, Dept Clin Cytobiol & Cytopathol, DE-35037 Marburg, Germany	Karolinska Institutet; Philipps University Marburg	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se	Lillig, Christopher Horst/AAD-7098-2019; Berndt, Carsten/X-6260-2018; Hashemy, Seyed Isaac/A-2693-2017	Lillig, Christopher Horst/0000-0003-2509-5117; Berndt, Carsten/0000-0001-8583-7966; Hashemy, Seyed Isaac/0000-0002-1323-5250				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Aykac-Toker G, 2001, HUM EXP TOXICOL, V20, P373, DOI 10.1191/096032701680350578; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Berndt C, 2007, ANTIOXID REDOX SIGN, V9, P151, DOI 10.1089/ars.2007.9.151; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; GAN ZR, 1986, J BIOL CHEM, V261, P996; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; HOPPER S, 1989, J BIOL CHEM, V264, P20438; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Johansson C, 2007, J BIOL CHEM, V282, P3077, DOI 10.1074/jbc.M608179200; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2004, BIOCHEM BIOPH RES CO, V319, P801, DOI 10.1016/j.bbrc.2004.04.199; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Moriarty-Craige SE, 2004, ANNU REV NUTR, V24, P481, DOI 10.1146/annurev.nutr.24.012003.132208; Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P2688, DOI 10.1073/pnas.041624998; Padilla CA, 1996, FEBS LETT, V378, P69; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Qiao FY, 2001, INVEST OPHTH VIS SCI, V42, P743; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Russell WK, 2001, ANAL CHEM, V73, P2682, DOI 10.1021/ac001332p; SAGEMARK J, 2007, IN PRESS PROTEINS; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; Sumbayev VV, 2003, ARCH BIOCHEM BIOPHYS, V415, P133, DOI 10.1016/S0003-9861(03)00199-1; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; YANG YF, 1991, J BIOL CHEM, V266, P12766; YANG YF, 1991, J BIOL CHEM, V266, P12759; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	67	80	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14428	14436		10.1074/jbc.M700927200	http://dx.doi.org/10.1074/jbc.M700927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355958	hybrid			2022-12-25	WOS:000246245800056
J	Ren, J; Sainsbury, S; Combs, SE; Capper, RG; Jordan, PW; Berrow, NS; Stammers, DK; Saunders, NJ; Owens, RJ				Ren, Jingshan; Sainsbury, Sarah; Combs, Susan E.; Capper, Richard G.; Jordan, Philip W.; Berrow, Nick S.; Stammers, David K.; Saunders, Nigel J.; Owens, Raymond J.			The structure and transcriptional analysis of a global regulator from Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NANOLITRE CRYSTALLIZATION EXPERIMENTS; THERMAL SHIFT ASSAYS; ESCHERICHIA-COLI LRP; CRYSTAL-STRUCTURE; PROTEIN LRP; BINDING; IDENTIFICATION; METABOLISM; CLUSTER; FORMS	Neisseria meningitidis, a causative agent of bacterial meningitis, has a relatively small repertoire of transcription factors, including NMB0573 (annotated AsnC), a member of the Lrp-AsnC family of regulators that are widely expressed in both Bacteria and Archaea. In the present study we show that NMB0573 binds to L-leucine and L-methionine and have solved the structure of the protein with and without bound amino acids. This has shown, for the first time that amino acid binding does not induce significant conformational changes in the structure of an AsnC/Lrp regulator although it does appear to stabilize the octameric assembly of the protein. Transcriptional profiling of wild-type and NMB0573 knock-out strains of N. meningitidis has shown that NMB0573 is associated with an adaptive response to nutrient poor conditions reflected in a reduction in major surface protein expression. On the basis of its structure and the transcriptional response, we propose that NMB0573 is a global regulator in Neisseria controlling responses to nutrient availability through indicators of general amino acid abundance: leucine and methionine.	Univ Oxford, Oxford Prot Prod Facil, Oxford OX3 7BN, England; Univ Oxford, Div Struct Biol, Henry Wellcome Bldg Genom Med, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Bacterial Pathogenesis & Funct Genom Grp, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford	Owens, RJ (corresponding author), Univ Oxford, Oxford Prot Prod Facil, Roosevelt Dr, Oxford OX3 7BN, England.	ray@strubi.ox.ac.uk	Saunders, Nigel J/W-6745-2019; Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Saunders, Nigel/0000-0002-0160-4573; Owens, Ray/0000-0002-3705-2993; Berrow, Nick/0000-0002-6104-4117; Scott, Susan Combs/0000-0002-1797-1685	MRC [G0400717] Funding Source: UKRI; Medical Research Council [G0400717] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berrow NS, 2006, ACTA CRYSTALLOGR D, V62, P1218, DOI 10.1107/S0907444906031337; BERROW NS, 2007, NUCLEIC ACIDS RES, V47, P1; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; Chen S, 2002, J MOL BIOL, V318, P1031, DOI 10.1016/S0022-2836(02)00187-0; Chen S, 2001, J MOL BIOL, V312, P625, DOI 10.1006/jmbi.2001.4955; Chen SL, 2005, J MOL BIOL, V345, P251, DOI 10.1016/j.jmb.2004.10.047; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; DEWIND N, 1985, NUCLEIC ACIDS RES, V13, P8797, DOI 10.1093/nar/13.24.8797; Ettema TJG, 2002, J BIOL CHEM, V277, P37464, DOI 10.1074/jbc.M206063200; Francis F, 2000, GENE, V251, P141, DOI 10.1016/S0378-1119(00)00200-6; Gunesekere IC, 2006, J BACTERIOL, V188, P4769, DOI 10.1128/JB.01807-05; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karp PD, 2005, NUCLEIC ACIDS RES, V33, P6083, DOI 10.1093/nar/gki892; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Koike H, 2004, P NATL ACAD SCI USA, V101, P2840, DOI 10.1073/pnas.0400109101; KOLLING R, 1985, J BACTERIOL, V164, P310; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031; Minezaki Y, 2005, DNA RES, V12, P269, DOI 10.1093/dnares/dsi016; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; Ren JS, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-13; Saal LH, 2002, GENOME BIOL, V3; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Snyder LAS, 2005, MICROBIOL-SGM, V151, P4005, DOI 10.1099/mic.0.27925-0; Snyder LAS, 2003, MOL MICROBIOL, V47, P431, DOI 10.1046/j.1365-2958.2003.03204.x; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thaw P, 2006, NUCLEIC ACIDS RES, V34, P1439, DOI 10.1093/nar/gkl009; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997	37	33	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14655	14664		10.1074/jbc.M701082200	http://dx.doi.org/10.1074/jbc.M701082200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374605	hybrid			2022-12-25	WOS:000246245800079
J	West, M; Hedges, JB; Lo, KY; Johnson, AW				West, Matthew; Hedges, John B.; Lo, Kai-Yin; Johnson, Arlen W.			Novel interaction of the 60S ribosomal subunit export adapter Nmd3 at the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; LEPTOMYCIN B; IN-VIVO; YEAST; PROTEIN; CRM1; NUCLEOPORIN; REQUIRES	Nuclear export of the large (60S) ribosomal subunit depends on the adapter protein Nmd3 to provide a nuclear export signal (NES). The leucine-rich NES is recognized by the export receptor Crm1 to mediate export via interaction with the nuclear pore complex (NPC). Here, we show that certain mutant Nmd3 proteins that are impaired for binding to the 60S subunit accumulate at the nuclear envelope. These mutant proteins also show enhanced binding to Crm1, both in vivo and in vitro. Although their interaction with the NPC is dependent on recognition of the NES by Crm1, their interaction with Crm1 is not strictly dependent on RanGTP. Using a collection of GFP-tagged nucleoporin mutants, we identified several nucleoporins, including components of the Nup82 complex that copurified with the mutant Nmd3. The Nup82 complex is on the cytoplasmic face of the NPC and has previously been shown to be important as a terminal binding site for Crm1-mediated export. Mutations in the Nup82 complex led to accumulation of wild-type Nmd3 in the nucleoplasm, suggesting that the interaction of mutant Nmd3 with the Nup82 complex reflects a defect in the bona fide export pathway for the 60S subunit. These results suggest that in the absence of the ribosome, Nmd3 is not efficiently released from Crm1 at the NPC.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Johnson, AW (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn,A5000, Austin, TX 78712 USA.	arlen@mail.utexas.edu		Johnson, Arlen/0000-0002-4742-085X; LO, KAI-YIN/0000-0003-0440-6836	NIGMS NIH HHS [GM53655] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Bernad R, 2006, J BIOL CHEM, V281, P19378, DOI 10.1074/jbc.M512585200; Del Priore V, 1997, J CELL SCI, V110, P2987; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fornerod Maarten, 2002, Results Probl Cell Differ, V35, P67; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Hedges J, 2006, J BIOL CHEM, V281, P36579, DOI 10.1074/jbc.M606798200; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Ho JHN, 2000, RNA, V6, P1625, DOI 10.1017/S1355838200001291; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; LUND E, 2001, SMALL GTPASE RAN, P59; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Trotta CR, 2003, EMBO J, V22, P2841, DOI 10.1093/emboj/cdg249; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	45	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14028	14037		10.1074/jbc.M700256200	http://dx.doi.org/10.1074/jbc.M700256200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347149	hybrid			2022-12-25	WOS:000246245800012
J	Witkowski, A; Joshi, AK; Smith, S				Witkowski, Andrzej; Joshi, Anil K.; Smith, Stuart			Coupling of the de Novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; RAT-LIVER MITOCHONDRIA; LIPOIC ACID; ESCHERICHIA-COLI; LONG-CHAIN; SACCHAROMYCES-CEREVISIAE; SYNTHASE; CLONING; IDENTIFICATION; ARABIDOPSIS	The objective of this study was to identify the products and possible role of a putative pathway for de novo fatty acid synthesis in mammalian mitochondria. Bovine heart mitochondrial matrix preparations were prepared free from contamination by proteins from other subcellular components and, using a combination of radioisotopic labeling and mass spectrometry, were shown to contain all of the enzymes required for the extension of a 2-carbon precursor by malonyl moieties to saturated acyl-ACP thioesters containing up to 14 carbon atoms. A major product was octanoyl-ACP and, in the presence of the apo-H-protein of the glycine cleavage complex, the newly synthesized octanoyl moieties were translocated to the lipoylation site on the acceptor protein. These studies demonstrate that one of the functions of the de novo fatty acid biosynthetic pathway in mammalian mitochondria is to provide the octanoyl precursor required for the essential protein lipoylation pathway.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Smith, S (corresponding author), 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	ssmith@chori.org		Witkowski, Andrzej/0000-0002-0442-4586	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRON EJ, 1966, BIOCHIM BIOPHYS ACTA, V116, P425, DOI 10.1016/0005-2760(66)90113-5; BRADY RO, 1958, P NATL ACAD SCI USA, V44, P993, DOI 10.1073/pnas.44.10.993; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; CHRIST EJV, 1968, BIOCHIM BIOPHYS ACTA, V152, P50, DOI 10.1016/0005-2760(68)90007-6; Cronan JE, 2005, FEBS LETT, V579, P4892, DOI 10.1016/j.febslet.2005.07.077; DUPRE S, 1980, ARCH BIOCHEM BIOPHYS, V202, P361, DOI 10.1016/0003-9861(80)90438-5; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; HARLAN WR, 1963, J BIOL CHEM, V238, P3216; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; HOWARD CF, 1968, BIOCHIM BIOPHYS ACTA, V164, P448, DOI 10.1016/0005-2760(68)90176-8; HULSMANN WC, 1962, BIOCHIM BIOPHYS ACTA, V58, P417, DOI 10.1016/0006-3002(62)90052-5; Joshi AK, 2005, BIOCHEMISTRY-US, V44, P4100, DOI 10.1021/bi047856r; Kataoka H, 1997, METHOD ENZYMOL, V279, P166; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; Olsen JG, 2004, FEBS LETT, V577, P170, DOI 10.1016/j.febslet.2004.10.007; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; QUAGLIARIELLO E, 1968, BIOCHIM BIOPHYS ACTA, V164, P12, DOI 10.1016/0005-2760(68)90066-0; REED LJ, 1951, SCIENCE, V114, P93, DOI 10.1126/science.114.2952.93; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; RUTKOSKI A, 1978, ANAL BIOCHEM, V91, P370, DOI 10.1016/0003-2697(78)90854-0; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SEUBERT W, 1957, ANGEW CHEM INT EDIT, V69, P359, DOI 10.1002/ange.19570691103; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stephens JL, 2007, J BIOL CHEM, V282, P4427, DOI 10.1074/jbc.M609037200; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Wada M, 2001, PLANT CELL PHYSIOL, V42, P650, DOI 10.1093/pcp/pce081; WAKIL SJ, 1958, J AM CHEM SOC, V80, P6465, DOI 10.1021/ja01556a086; WAKIL SJ, 1960, J BIOL CHEM, V235, P31; WHEREAT AF, 1969, J BIOL CHEM, V244, P6498; Witkowski A, 2004, BIOCHEMISTRY-US, V43, P10458, DOI 10.1021/bi048988n; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935; Yasuno R, 2004, J BIOL CHEM, V279, P8242, DOI 10.1074/jbc.M308894200; Yi XW, 2005, MOL CELL BIOL, V25, P8387, DOI 10.1128/MCB.25.18.8387-8392.2005; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016	46	59	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14178	14185		10.1074/jbc.M701486200	http://dx.doi.org/10.1074/jbc.M701486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374604	hybrid			2022-12-25	WOS:000246245800028
J	Kasahara, T; Maeda, M; Ishiguro, M; Kasahara, M				Kasahara, Toshiko; Maeda, Mari; Ishiguro, Masaji; Kasahara, Michihiro			Identification by comprehensive chimeric analysis of a key residue responsible for high affinity glucose transport by yeast HXT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MAJOR FACILITATOR SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE RECOGNITION; GAL2 TRANSPORTER; FAMILY; MECHANISM; VII	Hxt2 and Hxt1 are, respectively, high affinity and low affinity facilitative glucose transporter paralogs of Saccharomyces cerevisiae. We have previously investigated which amino acid residues of Hxt2 are important for high affinity transport activity. Studies with all the possible combinations of 12 transmembrane segments (TMs) of Hxt2 and Hxt1 revealed that TMs 1, 5, 7, and 8 of Hxt2 are necessary for high affinity transport. Systematic shuffling of the 20 amino acid residues that differ between Hxt2 and Hxt1 in these TMs subsequently identified 5 residues as important for such activity: Leu(59) and Leu(61) (TM1), Leu(201) (TM5), Asn(331) (TM7), and Phe(366) (TM8). We have now studied the relative importance of these 5 residues by individually replacing them with each of the other 19 residues. Replacement of Asn(331) yielded transporters with various affinities, with those of the Ile(331), Val(331), and Cys(331) mutants being higher than that of the wild type. Replacement of the Hxt2 residues at the other four sites yielded transporters with affinities similar to that of the wild type but with various capacities. A working homology model of the chimeric transporters containing Asn(331) or its 19 replacement residues indicated that those residues at this site that yield high affinity transporters (Ile(331), Val(331), Cys(331)) face the central cavity and are within van der Waals distances of Phe(208) (TM5), Leu(357) ( TM8), and Tyr(427) (TM10). Interactions via these residues of the four TMs, which compose a half of the central pore, may thus play a pivotal role in formation of a core structure for high affinity transport.	Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan; Teikyo Univ, Sch Med, Genome Res Ctr, Tokyo 1920395, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Biol Chem Lab, Niigata 9568603, Japan	Teikyo University; Teikyo University; Suntory Holdings Ltd; Niigata University	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBERG DC, 2005, METHODS YEAST GENETI, P200; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Ding J, 2006, J BIOL CHEM, V281, P29817, DOI 10.1074/jbc.M606152200; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 2004, J BIOL CHEM, V279, P30274, DOI 10.1074/jbc.M403762200; Kasahara T, 2003, BIOCHEM J, V372, P247, DOI 10.1042/BJ20030044; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 2000, J BIOL CHEM, V275, P4422, DOI 10.1074/jbc.275.6.4422; Kasahara T, 2006, J BIOL CHEM, V281, P18532, DOI 10.1074/jbc.M602123200; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Manolescu A, 2005, J BIOL CHEM, V280, P42978, DOI 10.1074/jbc.M508678200; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999; Yin Y, 2006, SCIENCE, V312, P741, DOI 10.1126/science.1125629	22	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13146	13150		10.1074/jbc.C700041200	http://dx.doi.org/10.1074/jbc.C700041200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17369259	hybrid			2022-12-25	WOS:000246060300002
J	Kearney, A; Avramovic, A; Castro, MAA; Carmo, AM; Davis, SJ; van der Merwe, PA				Kearney, Alice; Avramovic, Adam; Castro, Monica A. A.; Carmo, Alexandre M.; Davis, Simon J.; van der Merwe, P. Anton			The contribution of conformational adjustments and long-range electrostatic forces to the CD2/CD58 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; T-CELL-ACTIVATION; ISOTHERMAL TITRATION CALORIMETRY; ADHESION MOLECULE CD2; VANT-HOFF; BINDING-SITE; SIGNIFICANT DISCREPANCIES; CD58 LFA-3; ANTIGEN RECOGNITION; MUTATIONAL ANALYSIS	CD2 is a T cell surface molecule that enhances T and natural killer cell function by binding its ligands CD58 (humans) and CD48 (rodents) on antigen-presenting or target cells. Here we show that the CD2/CD58 interaction is enthalpically driven and accompanied by unfavorable entropic changes. Taken together with structural studies, this indicates that binding is accompanied by energetically significant conformational adjustments. Despite having a highly charged binding interface, neither the affinity nor the rate constants of the CD2/CD58 interaction were affected by changes in ionic strength, indicating that long-range electrostatic forces make no net contribution to binding.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Nuffield Dept Clin Med, Weatherall Inst Mol Med, Med Res Council Human Immunol Unit, Oxford OX3 9DS, England; Univ Porto, Grp Cell Activat & Gene Express, Inst Biol Mol & Celular, P-4099002 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099002 Oporto, Portugal	University of Oxford; University of Oxford; Universidade do Porto; Universidade do Porto	van der Merwe, PA (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	vandermerwe@path.ox.ac.uk	van der Merwe, P. Anton/F-8539-2011; Carmo, Alexandre/B-5191-2011	Carmo, Alexandre/0000-0002-2508-9799	Medical Research Council [G9722488, G19/31] Funding Source: Medline; Wellcome Trust [081894] Funding Source: Medline; MRC [G9722488] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; Atkins, 1998, PHYS CHEM, P830; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Bayas MV, 2007, J BIOL CHEM, V282, P5589, DOI 10.1074/jbc.M607968200; BIERER BE, 1989, IMMUNOL REV, V111, P267, DOI 10.1111/j.1600-065X.1989.tb00549.x; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Chaires JB, 1997, BIOPHYS CHEM, V64, P15, DOI 10.1016/S0301-4622(96)02205-3; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P157; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; GUTFREUND H, 1995, KINETICS LIFE SCI RE, P231; Horn JR, 2001, BIOCHEMISTRY-US, V40, P1774, DOI 10.1021/bi002408e; Horn JR, 2002, BIOCHEMISTRY-US, V41, P7501, DOI 10.1021/bi025626b; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Kim M, 2001, J MOL BIOL, V312, P711, DOI 10.1006/jmbi.2001.4980; Kitao A, 2000, P NATL ACAD SCI USA, V97, P2064, DOI 10.1073/pnas.030540397; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; LIU YF, 1995, PROTEIN SCI, V4, P2559, DOI 10.1002/pro.5560041212; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Wyss DF, 1997, PROTEIN SCI, V6, P534; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	54	10	10	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13160	13166		10.1074/jbc.M700829200	http://dx.doi.org/10.1074/jbc.M700829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344209	Green Accepted, hybrid			2022-12-25	WOS:000246060300004
J	Larson, HN; Zhou, JZ; Chen, ZQ; Stamler, JS; Weiner, H; Hurley, TD				Larson, Heather N.; Zhou, Jianzhong; Chen, Zhiqiang; Stamler, Jonathan S.; Weiner, Henry; Hurley, Thomas D.			Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde dehydrogenase - Roles of residues 475 and 487	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGLYCERIN; INTERFACE; MECHANISM; SUBUNIT; MODEL; SITE	The common mitochondrial aldehyde dehydrogenase (ALDH2) ALDH2*2 polymorphism is associated with impaired ethanol metabolism and decreased efficacy of nitroglycerin treatment. These physiological effects are due to the substitution of Lys for Glu-487 that reduces the k(cat) for these processes and increases the K-m for NAD(+), as compared with ALDH2. In this study, we sought to understand the nature of the interactions that give rise to the loss of structural integrity and low activity in ALDH2*2 even when complexed with coenzyme. Consequently, we have solved the crystal structure of ALDH2*2 complexed with coenzyme to 2.5 angstrom. We have also solved the structures of a mutated form of ALDH2 where Arg-475 is replaced by Gln (R475Q). The structural and functional properties of the R475Q enzyme are intermediate between those of wild-type and the ALDH2*2 enzymes. In both cases, the binding of coenzyme restores most of the structural deficits observed in the apoenzyme structures. The binding of coenzyme to the R475Q enzyme restores its structure and catalytic properties to near wild-type levels. In contrast, the disordered helix within the coenzyme binding pocket of ALDH2*2 is reordered, but the active site is only partially reordered. Consistent with the structural data, ALDH2*2 showed a concentration-dependent increase in esterase activity and nitroglycerin reductase activity upon addition of coenzyme, but the levels of activity do not approach those of the wild-type enzyme or that of the R475Q enzyme. The data presented shows that Glu-487 maintains a critical function in linking the structure of the coenzyme-binding site to that of the active site through its interactions with Arg-264 and Arg-475, and in doing so, creates the stable structural scaffold conducive to catalysis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Howard Hughes Medical Institute; Duke University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hurley, TD (corresponding author), 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		Stamler, Jonathan/0000-0002-6866-1572; HURLEY, THOMAS/0000-0002-5942-1163	NIAAA NIH HHS [R01 AA11982, R01 AA011982] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011982] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], 2004, PERS VIS RAYTR VERS; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FUNG HL, 1994, CARDIOVASC DRUG THER, V8, P489, DOI 10.1007/BF00877927; GOEDDE HW, 1979, HUM GENET, V51, P331; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; HIGUCHI S, 1992, J STUD ALCOHOL, V53, P170, DOI 10.15288/jsa.1992.53.170; Ho KK, 2005, BIOCHEMISTRY-US, V44, P8022, DOI 10.1021/bi050038u; Hurley TD, 2001, CHEM-BIOL INTERACT, V130, P3, DOI 10.1016/S0009-2797(00)00217-9; Hurley TD, 1999, ADV EXP MED BIOL, V463, P15; Hurley TD, 2002, PHARMACOGENOMICS SEA, P417, DOI DOI 10.1002/3527600752; Ignarro LJ, 2002, P NATL ACAD SCI USA, V99, P7816, DOI 10.1073/pnas.132271799; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Larson HN, 2005, J BIOL CHEM, V280, P30550, DOI 10.1074/jbc.M502345200; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng GS, 1999, PHARMACOGENETICS, V9, P463; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Seitz HK, 2001, ALCOHOL CLIN EXP RES, V25, p137S, DOI 10.1097/00000374-200105051-00024; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Wei BX, 2000, BIOCHEMISTRY-US, V39, P5295, DOI 10.1021/bi000028n; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x; Zhou JZ, 2000, BIOCHEMISTRY-US, V39, P12019, DOI 10.1021/bi001221k	36	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12940	12950		10.1074/jbc.M607959200	http://dx.doi.org/10.1074/jbc.M607959200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327228	Green Accepted, hybrid			2022-12-25	WOS:000245942800065
J	Oberstein, A; Jeffrey, PD; Shi, YG				Oberstein, Adam; Jeffrey, Philip D.; Shi, Yigong			Crystal structure of the Bcl-X-L-beclin 1 peptide complex - Beclin 1 is a novel BH3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR; MOLECULAR-MECHANISMS; 3-KINASE COMPLEX; AUTOPHAGY GENE; X-RAY; APOPTOSIS; BCL-2; TUMORIGENESIS; MACROAUTOPHAGY	Bcl-2 family proteins are key regulators of apoptosis and have recently been shown to modulate autophagy. The tumor suppressor Beclin 1 has been proposed to coordinate both apoptosis and autophagy through direct interaction with anti-apoptotic family members Bcl-2 and/or Bcl-X-L. However, the molecular basis for this interaction remains enigmatic. Here we report that Beclin 1 contains a conserved BH3 domain, which is both necessary and sufficient for its interaction with Bcl-X-L. We also report the crystal structure of a Beclin BH3 peptide in complex with Bcl-X-L at 2.5 angstrom resolution. Reminiscent of previously determined Bcl-X-L-BH3 structures, the amphipathic BH3 helix of Beclin 1 bound to a conserved hydrophobic groove of Bcl-X-L. These results define Beclin 1 as a novel BH3-only protein, implying that Beclin 1 may have a direct role in initiating apoptotic signaling. We propose that this putative apoptotic function may be linked to the ability of Beclin 1 to suppress tumor formation in mammals.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	ygshi@princeton.edu		Jeffrey, Philip/0000-0002-4351-5341; Shi, Yigong/0000-0003-2030-168X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bursch W, 2004, FEMS YEAST RES, V5, P101, DOI 10.1016/j.femsyr.2004.07.006; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fletcher JI, 2006, CELL DEATH DIFFER, V13, P1268, DOI 10.1038/sj.cdd.4401995; Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kundu M, 2005, CELL DEATH DIFFER, V12, P1484, DOI 10.1038/sj.cdd.4401780; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Thuduppathy GR, 2006, PROTEIN SCI, V15, P248, DOI 10.1110/ps.051807706; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wyllie A H, 1974, J Clin Pathol Suppl (R Coll Pathol), V7, P35; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	62	479	507	2	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13123	13132		10.1074/jbc.M700492200	http://dx.doi.org/10.1074/jbc.M700492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337444	hybrid			2022-12-25	WOS:000245942800080
J	Fijolek, A; Hofer, A; Thelander, L				Fijolek, Artur; Hofer, Anders; Thelander, Lars			Expression, purification, characterization, and in vivo targeting of trypanosome CTP synthetase for treatment of African sleeping sickness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE-TRIPHOSPHATE SYNTHETASE; ANTI-TUMOR AGENT; PHASE-I; CEREBROSPINAL-FLUID; ACID; ACIVICIN; GLUTAMINE; BRUCEI; ANTICANCER; METABOLISM	African sleeping sickness is a fatal disease caused by two parasite subspecies: Trypanosoma brucei gambiense and T.b. rhodesiense. We previously reported that trypanosomes have extraordinary low CTP pools compared with mammalian cells. Trypanosomes also lack salvage of cytidine/cytosine making the parasite CTP synthetase a potential target for treatment of the disease. In this study, we have expressed and purified recombinant T. brucei CTP synthetase. The enzyme has a higher K-m value for UTP than the mammalian CTP synthetase, which in combination with a lower UTP pool may account for the low CTP pool in trypanosomes. The activity of the trypanosome CTP synthetase is irreversibly inhibited by the glutamine analogue acivicin, a drug extensively tested as an antitumor agent. There is a rapid uptake of acivicin in mice both given intraperitoneally and orally by gavage. Daily injection of acivicin in trypanosome-infected mice suppressed the infection up to one month without any significant loss of weight. Experiments with cultured bloodstream T. brucei showed that acivicin is trypanocidal if present at 1 mu M concentration for at least 4 days. Therefore, acivicin may qualify as a drug with "desirable" properties, i.e. cure within 7 days, according to the current Target Product Profiles of WHO and DNDi.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Fijolek, A (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	artur.fijolek@medchem.umu.se		Hofer, Anders/0000-0003-2890-2957				AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I; Bacher G, 2001, J MASS SPECTROM, V36, P1038, DOI 10.1002/jms.208; Berrang-Ford L, 2006, EMERG INFECT DIS, V12, P813; Brun R, 2006, CURR OPIN INFECT DIS, V19, P415, DOI 10.1097/01.qco.0000244045.93016.b1; CHIKHALE EG, 1995, BIOCHEM PHARMACOL, V49, P941, DOI 10.1016/0006-2952(95)00005-K; Chittur SV, 2001, BIOCHEMISTRY-US, V40, P876, DOI 10.1021/bi0014047; COONEY DA, 1974, CANCER CHEMOTH REP 1, V58, P793; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; EARHART RH, 1983, CANCER TREAT REP, V67, P683; EARHART RH, 1985, ADV ENZYME REGUL, V24, P179, DOI 10.1016/0065-2571(85)90076-7; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; FISCHER PH, 1984, CANCER RES, V44, P3355; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; HANKA LJ, 1973, ANTIMICROB AGENTS CH, V3, P425, DOI 10.1128/AAC.3.3.425; Hatse S, 1999, BIOCHEM PHARMACOL, V58, P539, DOI 10.1016/S0006-2952(99)00035-0; HICKMAN CP, 1997, INTEGRATED PRINCIPLE, P225; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Hofer A, 2001, P NATL ACAD SCI USA, V98, P6412, DOI 10.1073/pnas.111139498; Huang M, 2003, CELL MOL LIFE SCI, V60, P321, DOI 10.1007/s000180300027; HURLBERT RB, 1960, J BIOL CHEM, V235, P443; Kaufman SL, 1998, ANAL BIOCHEM, V259, P195, DOI 10.1006/abio.1998.2644; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kursula P, 2006, ACTA CRYSTALLOGR F, V62, P613, DOI 10.1107/S1744309106018136; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; Livingston R B, 1970, Adv Pharmacol Chemother, V8, P57; LONG CW, 1970, J BIOL CHEM, V245, P80; LONG CW, 1967, J BIOL CHEM, V242, P4715; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; MCGOVREN JP, 1981, J PHARMACOL EXP THER, V216, P433; MCGOVREN JP, 1982, CANCER TREAT REP, V66, P1333; MCPARTLAND RP, 1976, J BIOL CHEM, V251, P4372; Neil G L, 1978, Adv Enzyme Regul, V17, P375; NEIL GL, 1979, CANCER RES, V39, P852; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; PYE IF, 1978, ANAL CHEM, V50, P951, DOI 10.1021/ac50029a031; ROBERTSON JG, 1995, BIOCHEMISTRY-US, V34, P7533, DOI 10.1021/bi00022a029; Rofougaran R, 2006, J BIOL CHEM, V281, P27705, DOI 10.1074/jbc.M605573200; SAVAGE CR, 1970, J BIOL CHEM, V245, P2529; SULLIVAN MP, 1988, CANCER CHEMOTH PHARM, V21, P78, DOI 10.1007/BF00262746; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; WEISS GR, 1982, CANCER RES, V42, P3892; Welburn SC, 2006, TRENDS PARASITOL, V22, P123, DOI 10.1016/j.pt.2006.01.011; WHO Expert Comm, 1998, WHO TECH REP SER, V881, P1	47	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11858	11865		10.1074/jbc.M611580200	http://dx.doi.org/10.1074/jbc.M611580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331943	hybrid			2022-12-25	WOS:000245941900028
J	Ghosh, S; Pendurthi, UR; Steinoe, A; Esmon, CT; Rao, LVM				Ghosh, Samit; Pendurthi, Usha R.; Steinoe, Anne; Esmon, Charles T.; Rao, L. Vijaya Mohan			Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; ACTIVATED FACTOR-VII; FACTOR-XA; BINDING; COAGULATION; EXPRESSION; PHARMACOKINETICS; INDIVIDUALS; GENERATION; TURNOVER	Although factor VII/factor VIIa ( FVII/FVIIa) is known to interact with many non-vascular cells, activated monocytes, and endothelial cells via its binding to tissue factor ( TF), the interaction of FVII/FVIIa with unperturbed endothelium and the role of this interaction in clearing FVII/FVIIa from the circulation are unknown. To investigate this, in the present study we examined the binding of radiolabeled FVIIa to endothelial cells and its subsequent internalization. I-125-FVIIa bound to non-stimulated human umbilical vein endothelial cells ( HUVEC) in time- and dose-dependent manner. The binding is specific and independent of TF and negatively charged phospholipids. Protein C and monoclonal antibodies to endothelial cell protein C receptor ( EPCR) blocked effectively I-125-FVIIa binding to HUVEC. FVIIa binding to EPCR is confirmed by demonstrating a marked increase in I-125-FVIIa binding to CHO cells that had been stably transfected with EPCR compared with the wild-type. Binding analysis revealed that FVII, FVIIa, protein C, and activated protein C(APC) bound to EPCR with similar affinity. FVIIa binding to EPCR failed to accelerate FVIIa activation of factor X or protease-activated receptors. FVIIa binding to EPCR was shown to facilitate FVIIa endocytosis. Pharmacological concentrations of FVIIa were found to impair partly the EPCR-dependent protein C activation and APC-mediated cell signaling. Overall, the present data provide convincing evidence that EPCR serves as a cellular binding site for FVII/FVIIa. Further studies are needed to evaluate the pathophysiological consequences and relevance of FVIIa binding to EPCR.	Univ Texas Hlth Ctr, Biomed Res Div, Tyler, TX 75708 USA; Univ Oklahoma, Hlth Sci Ctr, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Rao, LVM (corresponding author), Univ Texas Hlth Ctr, Biomed Res Div, 11937 US HWY 271, Tyler, TX 75708 USA.	Vijay.Rao@uthct.edu	Ghosh, Samit/F-1772-2015	Ghosh, Samit/0000-0002-3536-3077	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065500, R01HL058869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58869, HL 65500, R01 HL065500, R01 HL058869, R01 HL058869-08, R01 HL065500-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bjorkman S, 2001, CLIN PHARMACOKINET, V40, P815; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Erhardtsen E, 2000, SEMIN THROMB HEMOST, V26, P385, DOI 10.1055/s-2000-8457; FAIR DS, 1983, BLOOD, V62, P784; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Ghosh S, 2007, J THROMB HAEMOST, V5, P336, DOI 10.1111/j.1538-7836.2007.02308.x; Hackeng TM, 2006, P NATL ACAD SCI USA, V103, P3106, DOI 10.1073/pnas.0504240103; HASSELBACK R, 1960, J APPL PHYSIOL, V15, P945, DOI 10.1152/jappl.1960.15.5.945; Hjortoe G, 2005, J THROMB HAEMOST, V3, P2264, DOI 10.1111/j.1538-7836.2005.01542.x; Iakhiaev A, 2001, J BIOL CHEM, V276, P45895, DOI 10.1074/jbc.M107603200; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; LE DT, 1992, J BIOL CHEM, V267, P15447; LOELIGER EA, 1960, THROMB DIATH HAEMOST, V4, P196, DOI 10.1055/s-0038-1654496; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; NICOLAISEN EM, 1992, FEBS LETT, V306, P157, DOI 10.1016/0014-5793(92)80989-T; OREILLY RA, 1963, J CLIN INVEST, V42, P1542, DOI 10.1172/JCI104839; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; Preston RJS, 2006, J BIOL CHEM, V281, P28850, DOI 10.1074/jbc.M604966200; Qu D, 2006, J THROMB HAEMOST, V4, P229, DOI 10.1111/j.1538-7836.2005.01676.x; RAO LVM, 1988, BLOOD, V71, P791; Rao LVM, 2003, MOL CELL BIOCHEM, V253, P131, DOI 10.1023/A:1026004208822; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; REUNING U, 1993, THROMB HAEMOSTASIS, V69, P197; Riewald M, 2003, J ENDOTOXIN RES, V9, P317, DOI 10.1179/096805103225002584; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; RODGERS GM, 1984, BLOOD, V63, P434; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SELIGSOHN U, 1979, BLOOD, V53, P828; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STENFLO J, 1984, SEMIN THROMB HEMOST, V10, P109, DOI 10.1055/s-2007-1004413; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611	37	122	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11849	11857		10.1074/jbc.M609283200	http://dx.doi.org/10.1074/jbc.M609283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327234	Green Accepted, hybrid			2022-12-25	WOS:000245941900027
J	Lian, HY; Zhang, H; Zhang, ZR; Loovers, HM; Jones, GW; Rowling, PJE; Itzhaki, LS; Zhou, JM; Perrett, S				Lian, Hui-Yong; Zhang, Hong; Zhang, Zai-Rong; Loovers, Harriet M.; Jones, Gary W.; Rowling, Pamela J. E.; Itzhaki, Laura S.; Zhou, Jun-Mei; Perrett, Sarah			Hsp40 interacts directly with the native state of the yeast prion protein Ure2 and inhibits formation of amyloid-like fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; DNAJ HOMOLOG; IN-VITRO; ATPASE ACTIVITY; HSP70; DOMAIN; PROPAGATION; AGGREGATION; GLUTATHIONE	Ure2 is the protein determinant of the [ URE3] prion phenotype in Saccharomyces cerevisiae and consists of a flexible N-terminal prion-determining domain and a globular C-terminal glutathione transferase-like domain. Overexpression of the type I Hsp40 member Ydj1 in yeast cells has been found to result in the loss of [ URE3]. However, the mechanism of prion curing by Ydj1 remains unclear. Here we tested the effect of overexpression of Hsp40 members Ydj1, Sis1, and Apj1 and also Hsp70 co-chaperones Cpr7, Cns1, Sti1, and Fes1 in vivo and found that only Ydj1 showed a strong curing effect on [ URE3]. We also investigated the interaction of Ydj1 with Ure2 in vitro. We found that Ydj1 was able to suppress formation of amyloid-like fibrils of Ure2 by delaying the process of fibril formation, as monitored by thioflavin T binding and atomic force microscopy imaging. Controls using bovine serum albumin, Sis1, or the human Hsp40 homologues Hdj1 or Hdj2 showed no significant inhibitory effect. Ydj1 was only effective when added during the lag phase of fibril formation, suggesting that it interacts with Ure2 at an early stage in fibril formation and delays the nucleation process. Using surface plasmon resonance and size exclusion chromatography, we demonstrated a direct interaction between Ydj1 and both wild type and N-terminally truncated Ure2. In contrast, Hdj2, which did not suppress fibril formation, did not show this interaction. The results suggest that Ydj1 inhibits Ure2 fibril formation by binding to the native state of Ure2, thus delaying the onset of oligomerization.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Natl Univ Ireland Maynooth, Dept Biol, Maynooth, Kildare, Ireland; Hutchison Med Res Council, Res Ctr, Canc Cell Unit, Cambridge CB2 0XZ, England; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Maynooth University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Perrett, S (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	sarah.perrett@iname.com	Perrett, Sarah/AAS-9483-2020; Zhang, Zairong/G-1030-2013	Perrett, Sarah/0000-0003-0137-0997; ?, ??/0000-0003-0168-9201; Jones, Gary/0000-0002-7565-934X; ZHANG, ZAIRONG/0000-0001-9768-0548	Medical Research Council [MC_U105370180] Funding Source: Medline; MRC [MC_U105370180] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Catharino S, 2005, BIOL CHEM, V386, P633, DOI 10.1515/BC.2005.074; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Galani D, 2002, J MOL BIOL, V315, P213, DOI 10.1006/jmbi.2001.5234; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Hainzl O, 2004, J BIOL CHEM, V279, P23267, DOI 10.1074/jbc.M402189200; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Johnson SM, 2005, ACCOUNTS CHEM RES, V38, P911, DOI 10.1021/ar020073i; Jones GW, 2005, BIOESSAYS, V27, P823, DOI 10.1002/bies.20267; Kryndushkin DS, 2002, J BIOL CHEM, V277, P23702, DOI 10.1074/jbc.M111547200; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lian HY, 2006, BBA-PROTEINS PROTEOM, V1764, P535, DOI 10.1016/j.bbapap.2005.11.016; Loovers HM, 2007, GENETICS, V175, P621, DOI 10.1534/genetics.106.066019; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Minami Y, 1999, GENES CELLS, V4, P721, DOI 10.1046/j.1365-2443.1999.00299.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Roberts BT, 2004, YEAST, V21, P107, DOI 10.1002/yea.1062; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; SILVER JM, 1969, BIOCHEM BIOPH RES CO, V34, P301, DOI 10.1016/0006-291X(69)90831-6; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhu L, 2003, J MOL BIOL, V328, P235, DOI 10.1016/S0022-2836(03)00249-3	63	52	52	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11931	11940		10.1074/jbc.M606856200	http://dx.doi.org/10.1074/jbc.M606856200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324933	hybrid			2022-12-25	WOS:000245941900036
J	Chen, C; Tang, JQ; Dong, W; Wang, CJ; Feng, YJ; Wang, J; Zheng, F; Pan, XZ; Liu, D; Li, M; Song, YJ; Zhu, XX; Sun, HB; Feng, T; Guo, ZB; Ju, AP; Ge, JC; Dong, YQ; Sun, W; Jiang, YQ; Wang, J; Yan, JH; Yang, HM; Wang, XN; Gao, GF; Yang, RF; Wang, J; Yu, J				Chen, Chen; Tang, Jiaqi; Dong, Wei; Wang, Changjun; Feng, Youjun; Wang, Jing; Zheng, Feng; Pan, Xiuzhen; Liu, Di; Li, Ming; Song, Yajun; Zhu, Xinxing; Sun, Haibo; Feng, Tao; Guo, Zhaobiao; Ju, Aiping; Ge, Junchao; Dong, Yaqing; Sun, Wen; Jiang, Yongqiang; Wang, Jun; Yan, Jinghua; Yang, Huanming; Wang, Xiaoning; Gao, George F.; Yang, Ruifu; Wang, Jian; Yu, Jun			A Glimpse of Streptococcal Toxic Shock Syndrome from Comparative Genomics of S-suis 2 Chinese Isolates	PLOS ONE			English	Article								Background. Streptococcus suis serotype 2 (SS2) is an important zoonotic pathogen, causing more than 200 cases of severe human infection worldwide, with the hallmarks of meningitis, septicemia, arthritis, etc. Very recently, SS2 has been recognized as an etiological agent for streptococcal toxic shock syndrome (STSS), which was originally associated with Streptococcus pyogenes (GAS) in Streptococci. However, the molecular mechanisms underlying STSS are poorly understood. Methods and Findings. To elucidate the genetic determinants of STSS caused by SS2, whole genome sequencing of 3 different Chinese SS2 strains was undertaken. Comparative genomics accompanied by several lines of experiments, including experimental animal infection, PCR assay, and expression analysis, were utilized to further dissect a candidate pathogenicity island (PAI). Here we show, for the first time, a novel molecular insight into Chinese isolates of highly invasive SS2, which caused two large-scale human STSS outbreaks in China. A candidate PAI of similar to 89 kb in length, which is designated 89K and specific for Chinese SS2 virulent isolates, was investigated at the genomic level. It shares the universal properties of PAIs such as distinct GC content, consistent with its pivotal role in STSS and high virulence. Conclusions. To our knowledge, this is the first PAI candidate from S. suis worldwide. Our finding thus sheds light on STSS triggered by SS2 at the genomic level, facilitates further understanding of its pathogenesis and points to directions of development on some effective strategies to combat highly pathogenic SS2 infections.	[Tang, Jiaqi; Wang, Changjun; Zheng, Feng; Pan, Xiuzhen; Li, Ming; Ju, Aiping; Ge, Junchao; Dong, Yaqing; Sun, Wen] Res Inst Med Nanjing Command, Dept Epidemiol, Nanjing, Peoples R China; [Chen, Chen; Dong, Wei; Wang, Jing; Zhu, Xinxing; Sun, Haibo; Feng, Tao; Wang, Jun; Yang, Huanming; Wang, Jian; Yu, Jun] Chinese Acad Sci, Beijing Genom Inst, Beijing, Peoples R China; [Song, Yajun; Guo, Zhaobiao; Jiang, Yongqiang; Yang, Ruifu] Acad Mil Med Sci, Inst Microbiol & Epidemiol, Beijing, Peoples R China; [Feng, Youjun; Liu, Di; Yan, Jinghua; Gao, George F.] Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing, Peoples R China; [Chen, Chen; Dong, Wei; Wang, Jing; Zhu, Xinxing; Sun, Haibo; Feng, Tao; Wang, Jun; Yang, Huanming; Wang, Jian; Yu, Jun] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Xiaoning] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China; [Wang, Jun] Univ Aarhus, Inst Human Genet, Aarhus, Denmark; [Feng, Youjun; Liu, Di; Yan, Jinghua; Gao, George F.] Chinese Acad Sci, Inst Microbiol, China Japan Joint Lab Mol Immunol & Mol Microbiol, Beijing, Peoples R China; [Feng, Youjun] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China	Beijing Genomics Institute (BGI); Chinese Academy of Sciences; Academy of Military Medical Sciences - China; Chinese Academy of Sciences; Institute of Microbiology, CAS; Zhejiang University; South China University of Technology; Aarhus University; Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Tang, JQ (corresponding author), Res Inst Med Nanjing Command, Dept Epidemiol, Nanjing, Peoples R China.	tjq85@hotmail.com; xnwang@21cn.net; gaof@im.ac.cn; yangrf@nic.bmi.ac.cn; wangjian@genomics.org.cn; junyu@genomics.org.cn	Gao, George Fu/ABD-5229-2021; CHEN, CHEN/HDM-6657-2022; Song, Yajun/F-3714-2011; 郑, 征/C-8514-2011; Song, Yajun/GQQ-0476-2022; Liu, Di/G-6135-2014; chen, chen/AAQ-1805-2021; Feng, Youjun/E-8386-2010; Feng, Youjun/I-4134-2012; Liu, Di/ABD-2729-2021; Wang, Jun/C-8434-2016; Wang, Jun/B-9503-2016	Song, Yajun/0000-0002-6628-2747; Song, Yajun/0000-0002-6628-2747; Liu, Di/0000-0003-3693-2726; chen, chen/0000-0003-1765-8899; Liu, Di/0000-0003-3693-2726; Wang, Jun/0000-0002-8540-8931; Wang, Jun/0000-0002-2113-5874	Beijing Institute of Genomics; Chinese Academy of Sciences, National Basic Research Program (973) of China [KSCX2-SW-331, 2006CB504400]; National Natural Science Foundation of China [30670105, 30600533]; High-Tech Research&Development Project [2005AA219070]; National Basic Research Program (973) of China [2005CB523001]; National Key Technologies RD Program [2006BAD06A04]; Natural Science Foundation of Jiangsu Province, China [BK2006014]; Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology); National Natural Science Foundation of China (NSFC) [30525010]	Beijing Institute of Genomics; Chinese Academy of Sciences, National Basic Research Program (973) of China(National Basic Research Program of ChinaChinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High-Tech Research&Development Project; National Basic Research Program (973) of China(National Basic Research Program of China); National Key Technologies RD Program(National Key Technology R&D Program); Natural Science Foundation of Jiangsu Province, China(Natural Science Foundation of Jiangsu Province); Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by institutional grant at the Beijing Institute of Genomics and a grant to JY (KSCX2-SW-331) from Chinese Academy of Sciences, National Basic Research Program (973) of China (2006CB504400), a grant from National Natural Science Foundation of China (30670105) and High-Tech Research&Development Project 863 (2005AA219070) to JT, National Basic Research Program (973) of China (2005CB523001) to GFG, National Key Technologies R&D Program (2006BAD06A04) to JY, and a grant from National Natural Science Foundation of China (30600533) and a grant from Natural Science Foundation of Jiangsu Province, China (BK2006014) to CW. The China-Japan Joint Laboratory of Molecular Immunology and Molecular Microbiology is, in part, supported by Japan MEXT (Ministry of Education, Culture, Sports, Science and Technology). GFG is a distinguished young investigator of National Natural Science Foundation of China (NSFC) (Grant No. 30525010). The authors declare no competing financial interests.	Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; Beier D, 2006, CURR OPIN MICROBIOL, V9, P143, DOI 10.1016/j.mib.2006.01.005; Bentley SD, 2003, LANCET, V361, P637, DOI 10.1016/S0140-6736(03)12597-4; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; Brandt CM, 2005, INT J MED MICROBIOL, V295, P539, DOI 10.1016/j.ijmm.2005.07.013; Brown EJ, 2004, NEW ENGL J MED, V350, P2093, DOI 10.1056/NEJMcibr040657; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; Cabello F, 1997, TRENDS MICROBIOL, V5, P431, DOI 10.1016/S0966-842X(97)01150-5; CHESNEY PJ, 1983, INFECTION, V11, P181, DOI 10.1007/BF01641192; Desvaux M, 2006, FEMS MICROBIOL REV, V30, P774, DOI 10.1111/j.1574-6976.2006.00035.x; Dobrindt U, 2004, NAT REV MICROBIOL, V2, P414, DOI 10.1038/nrmicro884; Fitzgerald JR, 2001, J BACTERIOL, V183, P63, DOI 10.1128/JB.183.1.63-70.2001; Gal-Mor O, 2006, CELL MICROBIOL, V8, P1707, DOI 10.1111/j.1462-5822.2006.00794.x; Gottschalk M, 2000, VET MICROBIOL, V76, P259, DOI 10.1016/S0378-1135(00)00250-9; Hacker J., 2003, Acta Microbiologica et Immunologica Hungarica, V50, P321, DOI 10.1556/AMicr.50.2003.4.1; Hacker J, 2001, EMBO REP, V2, P376, DOI 10.1093/embo-reports/kve097; Hashikawa S, 2004, J CLIN MICROBIOL, V42, P186, DOI 10.1128/JCM.42.1.186-192.2004; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Lindsay JA, 1998, MOL MICROBIOL, V29, P527, DOI 10.1046/j.1365-2958.1998.00947.x; McCluskey J, 2004, MOL MICROBIOL, V51, P1661, DOI 10.1111/j.1365-2958.2003.03917.x; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; Middendorf B, 2001, J INFECT DIS, V183, pS17, DOI 10.1086/318843; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; Nallapareddy SR, 2005, J BACTERIOL, V187, P5709, DOI 10.1128/JB.187.16.5709-5718.2005; Ochman H, 1996, INFECT IMMUN, V64, P5410, DOI 10.1128/IAI.64.12.5410-5412.1996; Qian W, 2005, GENOME RES, V15, P757, DOI 10.1101/gr.3378705; Sachse S, 2002, FEMS IMMUNOL MED MIC, V34, P159, DOI 10.1016/S0928-8244(02)00373-5; Schmidt H, 2004, CLIN MICROBIOL REV, V17, P14, DOI 10.1128/CMR.17.1.14-56.2004; Sitkiewicz I, 2006, INFECT IMMUN, V74, P1339, DOI 10.1128/IAI.74.2.1339-1351.2006; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; Sriskandan S, 2006, PLOS MED, V3, P595, DOI 10.1371/journal.pmed.0030187; Staats JJ, 1997, VET RES COMMUN, V21, P381, DOI 10.1023/A:1005870317757; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; TANG J, 2006, PLOS MED, V3; Tang XY, 2006, MOL PLANT MICROBE IN, V19, P1159, DOI 10.1094/MPMI-19-1159; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; Tyler BM, 2006, SCIENCE, V313, P1261, DOI 10.1126/science.1128796; Ubeda C, 2003, MOL MICROBIOL, V49, P193, DOI 10.1046/j.1365-2958.2003.03577.x; WOOD TF, 1993, ANN SURG, V217, P109, DOI 10.1097/00000658-199302000-00003; Yu HJ, 2006, EMERG INFECT DIS, V12, P914, DOI 10.3201/eid1206.051194	42	217	749	3	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e315	10.1371/journal.pone.0000315	http://dx.doi.org/10.1371/journal.pone.0000315			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375201	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445100017
J	van Opijnen, T; de Ronde, A; Boerlijst, MC; Berkhout, B				van Opijnen, Tim; de Ronde, Anthony; Boerlijst, Maarten C.; Berkhout, Ben			Adaptation of HIV-1 Depends on the Host-Cell Environment	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE MUTATIONS; LONG TERMINAL REPEAT; DELETERIOUS MUTATIONS; REVERSE-TRANSCRIPTASE; EXPERIMENTAL EVOLUTION; BENEFICIAL MUTATIONS; BACKGROUND SELECTION; DIMINISHING RETURNS; TYPE-1 VARIANTS	Many viruses have the ability to rapidly develop resistance against antiviral drugs and escape from the host immune system. To which extent the host environment affects this adaptive potential of viruses is largely unknown. Here we show that for HIV-1, the host-cell environment is key to the adaptive potential of the virus. We performed a large-scale selection experiment with two HIV-1 strains in two different T-cell lines (MT4 and C8166). Over 110 days of culture, both virus strains adapted rapidly to the MT4 T-cell line. In contrast, when cultured on the C8166 T-cell line, the same strains did not show any increase in fitness. By sequence analyses and infections with viruses expressing either yellow or cyan fluorescent protein, we were able to show that the absence of adaptation was linked to a lower recombination rate in the C8166 T-cell line. Our findings suggest that if we can manipulate the host-cellular factors that mediate viral evolution, we may be able to significantly retard viral adaptability.	[van Opijnen, Tim; de Ronde, Anthony; Berkhout, Ben] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; [van Opijnen, Tim; Boerlijst, Maarten C.] Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Sect Populat Biol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam	van Opijnen, T (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	Tim.van_Opijnen@tufts.edu		van Opijnen, Tim/0000-0001-6895-6795	NWO-ALW [811.35.001]; ZonMw; NWO-CW	NWO-ALW(Netherlands Organization for Scientific Research (NWO)); ZonMw(Netherlands Organization for Health Research and Development); NWO-CW(Netherlands Organization for Scientific Research (NWO))	This research was supported by NWO-ALW, project number 811.35.001, as well as by ZonMw (vici-grant) and NWO-CW (TOP-grant).	Althaus CL, 2005, J VIROL, V79, P13572, DOI 10.1128/JVI.79.21.13572-13578.2005; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BARTON NH, 1995, GENETICS, V140, P821; Beck Z, 2003, J MED VIROL, V71, P94, DOI 10.1002/jmv.10447; Berkhout B, 1999, J BIOMED SCI, V6, P298, DOI 10.1159/000025401; Bleiber G, 2001, J VIROL, V75, P3291, DOI 10.1128/JVI.75.7.3291-3300.2001; Bocharov G, 2005, J GEN VIROL, V86, P3109, DOI 10.1099/vir.0.81138-0; Boerlijst MC, 1996, P ROY SOC B-BIOL SCI, V263, P1577, DOI 10.1098/rspb.1996.0231; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BUTCHER D, 1995, GENETICS, V141, P431; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; CHARLESWORTH D, 1995, GENETICS, V141, P1619; Charpentier C, 2006, J VIROL, V80, P2472, DOI 10.1128/JVI.80.5.2472-2482.2006; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Clementi M, 2004, MICROBIOLOGICA, V27, P207; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Doyon L, 1998, J VIROL, V72, P6146, DOI 10.1128/JVI.72.7.6146-6150.1998; Ebert D, 1998, SCIENCE, V282, P1432, DOI 10.1126/science.282.5393.1432; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; ESHEL I, 1970, Theoretical Population Biology, V1, P88, DOI 10.1016/0040-5809(70)90043-2; Fisher R.A., 1930, GENETICAL THEORY NAT; Frenkel LM, 2001, NEW ENGL J MED, V344, P520, DOI 10.1056/NEJM200102153440710; FU YX, 1993, GENETICS, V133, P693; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Gessler DDG, 1995, GENET RES, V66, P241, DOI 10.1017/S0016672300034686; Gordo I, 2000, GENETICS, V156, P2137; GU ZX, 1995, J GEN VIROL, V76, P2601, DOI 10.1099/0022-1317-76-10-2601; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Hemonnot B, 2004, J BIOL CHEM, V279, P32426, DOI 10.1074/jbc.M313137200; Hey J, 1998, GENETICS, V149, P2089; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Kauffman S.A., 1993, ORIGINS ORDER; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Keulen W, 1996, ANTIVIR RES, V31, P45, DOI 10.1016/0166-3542(96)00944-8; Kim Y, 2003, GENETICS, V164, P389; KONDRASHOV AS, 1984, GENET RES, V44, P199, DOI 10.1017/S0016672300026392; KORTHALS A, 2006, P BIOL SCI, V273, P1697; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; LEITNER T, 1995, VIROLOGY, V209, P136, DOI 10.1006/viro.1995.1237; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Maree AFM, 2000, J VIROL, V74, P11067, DOI 10.1128/JVI.74.23.11067-11072.2000; Matsuo Yoshinobu, 2004, Hum Cell, V17, P85; Miralles R, 1999, SCIENCE, V285, P1745, DOI 10.1126/science.285.5434.1745; Miralles R, 2000, J VIROL, V74, P3566, DOI 10.1128/JVI.74.8.3566-3571.2000; Mohapatra S, 2003, CANCER RES, V63, P8523; Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; Orr HA, 2000, GENETICS, V155, P961; Otto SP, 1997, GENETICS, V147, P879; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; PECK JR, 1994, GENETICS, V137, P597; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Rice WR, 1998, GENETICA, V102-3, P71, DOI 10.1023/A:1017055429755; Rice WR, 2002, NAT REV GENET, V3, P241, DOI 10.1038/nrg760; Rodrigo AG, 1999, P NATL ACAD SCI USA, V96, P2187, DOI 10.1073/pnas.96.5.2187; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Rouzine IM, 2005, GENETICS, V170, P7, DOI 10.1534/genetics.104.029926; ROZAS J, DNA POLYMORPHISM ANA; SABINO E, 1994, AIDS, V8, P901, DOI 10.1097/00002030-199407000-00006; SERVIENE E, 2005, P NATL ACAD SCI US; SMITH JM, 1968, AM NAT, V102, P469, DOI 10.1086/282559; SMITH JM, 1978, EVOLUTION SEX; SMITH SD, 1984, CANCER RES, V44, P5657; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Valdez H, 2002, AIDS, V16, P1113, DOI 10.1097/00002030-200205240-00004; van Opijnen T, 2005, REV MED VIROL, V15, P219, DOI 10.1002/rmv.472; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; VANOPIJNEN T, 2006, J VIROL IN PRESS; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356; Zaccarelli M, 2004, CURR HIV RES, V2, P283, DOI 10.2174/1570162043351192	84	14	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e271	10.1371/journal.pone.0000271	http://dx.doi.org/10.1371/journal.pone.0000271			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342205	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444700006
J	Lau, WM; Ho, TH; Hui, KM				Lau, W. M.; Ho, T. H.; Hui, K. M.			p16(INK4A)-silencing augments DNA damage-induced apoptosis in cervical cancer cells	ONCOGENE			English	Article						p16; RNAi; cervical cancer; DNA damage; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; G(1) ARREST; POSTTRANSLATIONAL MODIFICATION; GROWTH ARREST; P53 PROTEIN; EXPRESSION; DEGRADATION; GENE; RNA; E6	p16(INK4A) ( p16) has been suggested to be an early biomarker for the detection of cervical cancer. However, its functional role in cervical cancer is not well characterized. In this study, we reported the consistent and significant upregulation of p16 in cervical cancer tissues when compared to both matched non-tumourous tissues of the same patient and normal cervical tissues from non- cancer patients. We have employed p16 small interfering RNA ( siRNA) to dissect the role of p16 in cervical carcinogenesis. Although the silencing of p16 was accompanied by the upregulation of p53, p21 and RB in the p16 siRNA- transfected cells, no significant effect on cell cycle progression was observed. When the p16 siRNA-silenced cells were subjected to DNA damage stress including ultraviolet-irradiation and cisplatin treatments, a significantly higher percentage of apoptotic cells could be observed in the p16- siRNA silenced cells compared to control siRNA- treated cells. Moreover, induction of apoptosis was associated with the activation of p53 through phosphorylation, and this process, when studied by gene pro. ling experiments, involved both the intrinsic and extrinsic apoptotic pathways. The observation that silencing of p16 expression augments DNA damage-induced apoptosis in cervical cancer cells offers alternative strategies for anti-cancer therapies for human cervical cancer.	Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Singapore, Singapore; KK Womens & Childrens Hosp, Gynaecol Oncol Unit, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; KK Women's & Children's Hospital	Hui, KM (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com.sg	Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Andersson S, 2006, INT J ONCOL, V29, P705; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BUTZ K, 1995, ONCOGENE, V10, P927; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu W, 2006, CANCER GENE THER, V13, P1023, DOI 10.1038/sj.cgt.7700971; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ishikawa M, 2006, INT J GYNECOL CANCER, V16, P347, DOI 10.1111/j.1525-1438.2006.00355.x; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanao H, 2004, CANCER LETT, V213, P31, DOI 10.1016/j.canlet.2004.03.030; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Lee YS, 2006, J PHARMACOL EXP THER, V317, P202, DOI 10.1124/jpet.105.096719; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MUNGER K, 1992, CANCER SURV, V12, P197; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Putral LN, 2005, MOL PHARMACOL, V68, P1311, DOI 10.1124/mol.105.014191; Queiroz C, 2006, PATHOL RES PRACT, V202, P77, DOI 10.1016/j.prp.2005.08.012; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yamamoto A, 2003, INT J CANCER, V106, P301, DOI 10.1002/ijc.11219; Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008-5472.CAN-06-1594; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	17	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6050	6060		10.1038/sj.onc.1210405	http://dx.doi.org/10.1038/sj.onc.1210405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369842				2022-12-25	WOS:000249277200008
J	Wu, YH; Chang, JHT; Cheng, YW; Wu, TC; Chen, CY; Lee, H				Wu, Y-H; Chang, J-H Tsai; Cheng, Y-W; Wu, T-C; Chen, C-Y; Lee, H.			Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers	ONCOGENE			English	Article						xeroderma pigmentosum group C (XPC); promoter methylation; p53 mutation; non-small cell; lung cancer	NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; HEPATOCELLULAR-CARCINOMA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; MUTANT MICE; TOBACCO-SMOKE; DAMAGED DNA; CPG ISLANDS; GROUP-A; XPC	Reduced DNA repair capability is associated with developing lung cancer, especially in nonsmokers. XPC participates in the initial recognition of DNA damage during the DNA nucleotide excision repair process. We hypothesize that inactivation of XPC by promoter hypermethylation may play an important role in the reduction of DNA repair capability to cause p53 mutation during lung carcinogenesis. In this report we demonstrate that hypermethylation of 17 CpG islands between - 175 and - 1 of the XPC promoter correlates very well with XPC expression levels in eight lung cancer cell lines. When cells with hypermethylated XPC promoters were treated with the demethylating agent 5-aza-20-deoxycytidine, XPC expression was de-repressed. Interestingly, XPC hypermethylation was found in 4 of 5 (80%) lung cancer cell lines harbored p53 mutation, but not observed in two lung cancer cells which had a wild- type p53 gene. Among the analysis of the hypermethylation status of 158 lung tumors, XPC hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P = 0.010). Additionally, XPC hypermethylation is more often with G -> T or G -> C mutations in the p53 gene. To verify whether XPC inactivation is involved in the occurrence of p53 mutation, XPC gene of A549 cells was knockdown by a small interference RNA and then XPC-inactivated cells were treated with benzo[a] pynrene for different passages. Surprisingly, G-T mutation in p53 gene at codon 215 was indeed detected in XPC-inactivated A549 cells of passages 15 and confirmed by loss of transcription activity of mdm2. These results show that hypermethylation of the XPC promoter may play a crucial role in XPC inactivation, which may partly contribute to the occurrence of p53 mutations during lung tumorigenesis, especially nonsmokers.	Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, Taichung, Taiwan; Chung Shan Med Univ, Inst Med, Taichung, Taiwan; Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan; Chung Shan Med Univ, Lung Canc Res Ctr, Taichung, Taiwan; China Med Univ, Dept Thorac Surg, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; China Medical University Taiwan	Lee, H (corresponding author), Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, 110,Sec 1,Chien Kuo N Rd, Taichung, Taiwan.	hl@csmu.edu.tw	Lee, Huei/B-2664-2010					Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; ALAIN S, 2001, CANCER RES, V61, P2480; Azzam EI, 2002, J INVEST DERMATOL, V119, P1350, DOI 10.1046/j.1523-1747.2002.19628.x; Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091; Chang JT, 2004, ANAL BIOCHEM, V334, P199, DOI 10.1016/j.ab.2004.07.018; Chang MY, 2005, CANCER LETT, V222, P195, DOI 10.1016/j.canlet.2004.11.020; Cheo DL, 1999, CANCER RES, V59, P771; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Esteller M, 2000, CANCER RES, V60, P2368; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gao WM, 2003, LUNG CANCER-J IASLC, V40, P141, DOI 10.1016/S0169-5002(03)00035-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hollander MC, 2005, P NATL ACAD SCI USA, V102, P13200, DOI 10.1073/pnas.0503133102; Hu ZB, 2005, INT J CANCER, V115, P478, DOI 10.1002/ijc.20911; Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779; Janicijevic A, 2003, DNA REPAIR, V2, P325, DOI 10.1016/S1568-7864(02)00222-7; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Kim DH, 2001, CANCER RES, V61, P3419; Ko JL, 2002, DNA REPAIR, V1, P755, DOI 10.1016/S1568-7864(02)00094-0; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551; Marin MS, 2004, CANCER EPIDEM BIOMAR, V13, P1788; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; Mellon I, 2002, DNA REPAIR, V1, P531, DOI 10.1016/S1568-7864(02)00053-8; Nahari D, 2004, DNA REPAIR, V3, P379, DOI 10.1016/j.dnarep.2003.03.001; Neumann AS, 2005, MOL CARCINOGEN, V42, P65, DOI 10.1002/mc.20069; Nutt CL, 1999, CARCINOGENESIS, V20, P2361, DOI 10.1093/carcin/20.12.2361; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P993; Pavanello S, 2005, CARCINOGENESIS, V26, P169, DOI 10.1093/carcin/bgh303; Piao CQ, 1999, CARCINOGENESIS, V20, P1529, DOI 10.1093/carcin/20.8.1529; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Reis AM, 2000, CANCER RES, V60, P1571; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; RYK C, 2006, CANC LETT, V8, P142; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Shen HB, 2003, INT J CANCER, V107, P84, DOI 10.1002/ijc.11346; Soria JC, 2002, CANCER RES, V62, P351; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Suk R, 2005, CLIN CANCER RES, V11, P1534, DOI 10.1158/1078-0432.CCR-04-1953; Tapias A, 2004, J BIOL CHEM, V279, P19074, DOI 10.1074/jbc.M312611200; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vodicka P, 2004, ENVIRON MOL MUTAGEN, V44, P283, DOI 10.1002/em.20055; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wolf P, 2001, CANCER RES, V61, P8113; Wu MF, 2005, INT J CANCER, V113, P440, DOI 10.1002/ijc.20597; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852	49	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4761	4773		10.1038/sj.onc.1210284	http://dx.doi.org/10.1038/sj.onc.1210284			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17325666				2022-12-25	WOS:000248170400002
J	Sennvik, K; Boekhoorn, K; Lasrado, R; Terwel, D; Verhaeghe, S; Korr, H; Schmitz, C; Tomiyama, T; Mori, H; Krugers, H; Joels, M; Ramakers, GJA; Lucassen, PJ; Van Leuven, F				Sennvik, Kristina; Boekhoorn, Karin; Lasrado, Reena; Terwel, Dick; Verhaeghe, Steven; Korr, Hubert; Schmitz, Christoph; Tomiyama, Takami; Mori, Hiroshi; Krugers, Harm; Joels, Marian; Ramakers, Ger J. A.; Lucassen, Paul J.; Van Leuven, Fred			Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice	FASEB JOURNAL			English	Article						transgenic mice; neurogenesis; cognition; primary cultures	LONG-TERM POTENTIATION; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; ALZHEIMERS-DISEASE; DENTATE GYRUS; CULTURED NEURONS; ISOFORMS; BRAIN; NEUROGENESIS; HYPERPHOSPHORYLATION	Differential isoform expression and phosphorylation of protein tau are believed to regulate the assembly and stabilization of microtubuli in fetal and adult neurons. To define the functions of tau in the developing and adult brain, we generated transgenic mice expressing the human tau-4R/2N (htau-4R) isoform on a murine tau null background, by a knockout/knockin approach (tau-KOKI). The main findings in these mice were the significant increases in hippocampal volume and neuronal number, which were sustained throughout adult life and paralleled by improved cognitive functioning. The increase in hippocampal size was found to be due to increased neurogenesis and neuronal survival. Proliferation and neuronal differentiation were further analyzed in primary hippocampal cultures from tau-KOKI mice, before and after htau-4R expression onset. In absence of tau, proliferation increased and both neurite and axonal outgrowth were reduced. Htau-4R expression suppressed proliferation, promoted neuronal differentiation, and restored neurite and axonal outgrowth. We suggest that the tau-4R isoform essentially contributes to hippocampal development by controlling proliferation and differentiation of neuronal precursors.	Katholieke Univ Leuven, Expt Genet Grp, Dept Human Genet, B-3000 Louvain, Belgium; Swammerdam Inst Life Sci, Neurobiol Sect, Amsterdam, Netherlands; Univ Aachen, Rhein Westfal TH Aachen, Dept Anat & Cell Biol, D-5100 Aachen, Germany; Sch Med, Dept Neurosci, Osaka, Japan; Netherlands Inst Brain Res, Amsterdam, Netherlands	KU Leuven; University of Amsterdam; RWTH Aachen University; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Van Leuven, F (corresponding author), Katholieke Univ Leuven, Expt Genet Grp, Dept Human Genet, Campus Gasthuisberg ON1-06-602, B-3000 Louvain, Belgium.	fredvl@med.kuleuven.be	Lucassen, Paul/ABA-3113-2020; Joëls, Marian/P-6415-2016	Lucassen, Paul/0000-0001-9708-9133; Verhaeghe, Sofie/0000-0002-2063-5033; Joels, Marian/0000-0002-4826-6209				Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Andorfer CA, 2000, DEV NEUROSCI-BASEL, V22, P303, DOI 10.1159/000017454; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Dawson HN, 2001, J CELL SCI, V114, P1179; Dewachter I, 2002, J NEUROSCI, V22, P3445; Goedert M, 1996, ANN NY ACAD SCI, V777, P121, DOI 10.1111/j.1749-6632.1996.tb34410.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; LARCHER JC, 1992, DEV BIOL, V154, P195, DOI 10.1016/0012-1606(92)90059-P; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Liu CWA, 1999, CELL MOTIL CYTOSKEL, V43, P232, DOI 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7; Lucassen PJ, 2004, BIOL PSYCHIAT, V55, P789, DOI 10.1016/j.biopsych.2003.12.014; Ramakers GJA, 1998, DEV BRAIN RES, V108, P205, DOI 10.1016/S0165-3806(98)00050-9; Schmitz C, 2000, EXP GERONTOL, V35, P429, DOI 10.1016/S0531-5565(00)00094-2; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Takuma H, 2003, DEV BRAIN RES, V142, P121, DOI 10.1016/S0165-3806(03)00056-7; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Umans L, 1999, NEUROSCIENCE, V94, P315, DOI 10.1016/S0306-4522(99)00242-0; Utton MA, 2001, J BIOL CHEM, V276, P34288, DOI 10.1074/jbc.M011384200; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	33	51	52	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2149	2161		10.1096/fj.06-7735com	http://dx.doi.org/10.1096/fj.06-7735com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341679				2022-12-25	WOS:000247500300024
J	Han, J; Goldstein, LA; Hou, W; Rabinowich, H				Han, Jie; Goldstein, Leslie A.; Hou, Wen; Rabinowich, Hannah			Functional linkage between NOXA and Bim in mitochondrial apoptotic events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; GAMMA-SECRETASE-INHIBITOR; CELL-DEATH; BH3-ONLY PROTEINS; MYELOMA CELLS; GRANZYME-B; MCL-1; SURVIVAL; PERMEABILITY; INDUCTION	NOXA is a BH3-only protein whose expression is induced by certain p53-depenent or independent apoptotic stimuli. Both NOXA and Bim are avid binders of Mcl-1, but a functional linkage between these BH3-only proteins has not yet been reported. In this study, we demonstrate that Mcl-1 binding of endogenously induced NOXA interferes with the ability of Mcl-1 to efficiently sequester endogenous Bim, as Bim is displaced from its complex with Mcl- 1. Induced NOXA significantly enhances the UV sensitivity of cells, and the ensuing mitochondrial depolarization is entirely abrogated by Bim knockdown. These results demonstrate a Mcl-1-mediated cross-talk between endogenous NOXA and Bim that occurs upstream of the Bak/Bax-dependent execution of UV-induced mitochondrial depolarization. The current findings demonstrate that the mitochondrial response to an induced expression ofNOXAis executed by endogenous Bim and suggest a plausible mechanism for the observed NOXA-Bim linkage.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavill,Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NCI NIH HHS [R01 CA109285, R01 CA111786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111786, R01CA109285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gentile M, 2003, NUCLEIC ACIDS RES, V31, P4779, DOI 10.1093/nar/gkg675; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Johnson DE, 2000, CANCER RES, V60, P1818; Kang JH, 2005, EUR J IMMUNOL, V35, P2982, DOI 10.1002/eji.200526242; Lucken-Ardjomande S, 2005, CR BIOL, V328, P616, DOI 10.1016/j.crvi.2005.05.002; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Qin JZ, 2004, MOL CANCER THER, V3, P895; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	37	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16223	16231		10.1074/jbc.M611186200	http://dx.doi.org/10.1074/jbc.M611186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17374615	hybrid			2022-12-25	WOS:000246794300030
J	Addison, WN; Azari, F; Sorensen, ES; Kaartinen, MT; Mckee, MD				Addison, William N.; Azari, Fereshteh; Sorensen, Esben S.; Kaartinen, Mari T.; McKee, Marc D.			Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE ANKYLOSIS GENE; MUSCLE-CELL CALCIFICATION; O-GLYCOSYLATION SITES; INORGANIC PYROPHOSPHATE; IN-VITRO; HYDROXYAPATITE FORMATION; INFANTILE HYPOPHOSPHATASIA; BETA-GLYCEROPHOSPHATE; EXTRACELLULAR-MATRIX; MC3T3-E1 CELLS	Inorganic pyrophosphate (PPi) produced by cells inhibits mineralization by binding to crystals. Its ubiquitous presence is thought to prevent "soft" tissues from mineralizing, whereas its degradation to P-i in bones and teeth by tissue-nonspecific alkaline phosphatase (Tnap, Tnsalp, Alp1, Akp2) may facilitate crystal growth. Whereas the crystal binding properties of PPi are largely understood, less is known about its effects on osteoblast activity. We have used MC3T3-E1 osteoblast cultures to investigate the effect of PPi on osteoblast function and matrix mineralization. Mineralization in the cultures was dose-dependently inhibited by PPi. This inhibition could be reversed by Tnap, but not if PPi was bound to mineral. PPi also led to increased levels of osteopontin (Opn) induced via the Erk1/2 and p38 MAPK signaling pathways. Opn regulation by PPi was also insensitive to foscarnet (an inhibitor of phosphate uptake) and levamisole (an inhibitor of Tnap enzymatic activity), suggesting that increased Opn levels did not result from changes in phosphate. Exogenous OPN inhibited mineralization, but dephosphorylation by Tnap reversed this effect, suggesting that OPN inhibits mineralization via its negatively charged phosphate residues and that like PPi, hydrolysis by Tnap reduces its mineral inhibiting potency. Using enzyme kinetic studies, we have shown that PPi inhibits Tnap-mediated P-i release from beta-glycerophosphate (a commonly used source of organic phosphate for culture mineralization studies) through a mixed type of inhibition. In summary, PPi prevents mineralization in MC3T3-E1 osteoblast cultures by at least three different mechanisms that include direct binding to growing crystals, induction of Opn expression, and inhibition of Tnap activity.	McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; McGill Univ, Fac Med, Dept Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University; Aarhus University; McGill University; McGill University	Mckee, MD (corresponding author), McGill Univ, Fac Dent, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	marc.mckee@mcgill.ca	McKee, Marc D/E-2187-2011	McKee, Marc D/0000-0001-8349-965X; Kaartinen, Mari/0000-0003-2999-6502; Sorensen, Esben Skipper/0000-0002-7050-3354				Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169-6009(92)90707-K; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; Boskey AL, 2005, CELLS TISSUES ORGANS, V181, P144, DOI 10.1159/000091376; Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223-001-1121-z; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; CHUCK AJ, 1989, ANN RHEUM DIS, V48, P571, DOI 10.1136/ard.48.7.571; CHUNG CH, 1992, CALCIFIED TISSUE INT, V51, P305, DOI 10.1007/BF00334492; Coburn SP, 1998, J CLIN ENDOCR METAB, V83, P3951, DOI 10.1210/jc.83.11.3951; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014; ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639; Ehara A, 2003, BIOMATERIALS, V24, P831, DOI 10.1016/S0142-9612(02)00411-8; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0; FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671; Foster BL, 2006, CALCIFIED TISSUE INT, V78, P103, DOI 10.1007/s00223-005-0184-7; Garimella R, 2006, BONE, V38, P811, DOI 10.1016/j.bone.2005.11.027; Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223-004-1288-1; Gurley KA, 2006, J BONE MINER RES, V21, P1238, DOI 10.1359/JBMR.060515; Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Hoyer JR, 2001, KIDNEY INT, V60, P77, DOI 10.1046/j.1523-1755.2001.00772.x; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; Hui MZ, 1998, ANAT REC, V253, P91; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413; Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994; Johnson KA, 2000, AM J PHYSIOL-REG I, V279, pR1365, DOI 10.1152/ajpregu.2000.279.4.R1365; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; Kananovich S. Zh., 2003, Journal of Applied Spectroscopy, V70, P765, DOI 10.1023/B:JAPS.0000008876.07758.08; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; Kawazoe Y, 2004, J DENT RES, V83, P613, DOI 10.1177/154405910408300806; Kornberg A., 1962, HORIZONS BIOCH, P251; Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7; LUNN JE, 1993, BIOCHEM J, V290, P375, DOI 10.1042/bj2900375; MANSUROVA SE, 1989, BIOCHIM BIOPHYS ACTA, V977, P237, DOI 10.1016/S0005-2728(89)80078-7; MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749-6632.1995.tb44629.x; McKee MD, 2000, OSTEOPOROSIS PRIMER, P46; MEYER JL, 1973, CALC TISS RES, V13, P295, DOI 10.1007/BF02015419; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; MOSS DW, 1967, BIOCHEM J, V102, P53, DOI 10.1042/bj1020053; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097-0177(199703)208:3<432::AID-AJA13>3.0.CO;2-1; Nociti FH, 2002, J DENT RES, V81, P817, DOI 10.1177/154405910208101204; Nurnberg P, 2001, NAT GENET, V28, P37, DOI 10.1038/ng0501-37; Orimo H, 2006, MOL CELL BIOCHEM, V282, P101, DOI 10.1007/s11010-006-1520-6; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589; Ryan LM, 2003, CURR OPIN RHEUMATOL, V15, P311, DOI 10.1097/00002281-200305000-00020; SAKAMOTO M, 1994, PATHOL INT, V44, P420, DOI 10.1111/j.1440-1827.1994.tb01705.x; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SORENSEN ES, 1993, J DAIRY RES, V60, P189, DOI 10.1017/S0022029900027503; TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756-3282(92)90205-B; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; Tesch W, 2003, J BONE MINER RES, V18, P117, DOI 10.1359/jbmr.2003.18.1.117; VILLIOTTE PJ, 1991, FEMS MICROBIOL LETT, V78, P293; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang W, 2005, MOL CELL BIOL, V25, P312, DOI 10.1128/MCB.25.1.312-323.2005; WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Zaka R, 2005, OSTEOARTHR CARTILAGE, V13, P745, DOI 10.1016/j.joca.2005.04.006	75	259	284	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15872	15883		10.1074/jbc.M701116200	http://dx.doi.org/10.1074/jbc.M701116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383965	hybrid			2022-12-25	WOS:000246589600062
J	Edlich, F; Erdmann, F; Jarczowski, F; Moutty, MC; Weiwad, M; Fischer, G				Edlich, Frank; Erdmann, Frank; Jarczowski, Franziska; Moutty, Marie-Christine; Weiwad, Matthias; Fischer, Gunter			The Bcl-2 regulator FKBP38-calmodulin-Ca2+ is inhibited by Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HEAT-SHOCK PROTEINS; HSP90-BINDING IMMUNOPHILINS; CALMODULIN; BINDING; DOMAIN; RECEPTOR; FKBP38; ACTIVATION; APOPTOSIS	FKBP38 is a negative effector of the anti-apoptotic Bcl-2 protein in neuroblastoma cells. The interaction with Bcl-2 and the enzyme activity of FKBP38 depend on prior binding of calmodulin-Ca2+ (CaM-Ca2+) at high Ca2+ concentrations. The FKBP38 protein structure contains three tetratricopeptide repeat (TPR) motifs corresponding to the Hsp90 interaction sites of other immunophilins. In this study we show that the TPR domain of FKBP38 interacts with the C-terminal domain of Hsp90, but only if the FKBP38-CaM-Ca2+ complex is preformed. Hence, FKBP38 is the first example of a TPR-containing immunophilin that interacts cofactor-dependently with Hsp90. In the ternary Hsp90-FKBP38-CaM-Ca2+ complex the active site of FKBP38 is blocked, thus preventing interactions with Bcl-2. The dual control of the active site cleft of FKBP38 by CaM-Ca2+ and Hsp90 highlights the importance of the enzyme activity of the FKBP38-CaM-Ca2+ complex in the regulation of programmed cell death.	Max Planck Res Unit Enzymol Prot Folding, D-66120 Halle, Germany	Max Planck Society	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-66120 Halle, Germany.	fischer@enzyme-halle.mpg.de	Erdmann, Frank/AAF-1091-2021	Erdmann, Frank/0000-0001-5261-0984				Barker CR, 2006, NUCLEIC ACIDS RES, V34, P1148, DOI 10.1093/nar/gkj516; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Cambiazo V, 1999, FEBS LETT, V457, P343, DOI 10.1016/S0014-5793(99)01070-4; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Cliff MJ, 2005, J MOL BIOL, V346, P717, DOI 10.1016/j.jmb.2004.12.017; Cliff MJ, 2006, STRUCTURE, V14, P415, DOI 10.1016/j.str.2005.12.009; Compton SA, 2006, MOL CELL BIOL, V26, P1452, DOI 10.1128/MCB.26.4.1452-1462.2006; Crackower MA, 2003, SCIENCE, V300, P1291, DOI 10.1126/science.1083022; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Edlich F, 2006, J BIOL CHEM, V281, P14961, DOI 10.1074/jbc.M600452200; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Guo ZH, 2001, J NEUROCHEM, V79, P361, DOI 10.1046/j.1471-4159.2001.00564.x; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Jiang BM, 2005, CELL STRESS CHAPERON, V10, P252, DOI 10.1379/CSC-124R.1; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Okamoto T, 2006, EMBO J, V25, P5015, DOI 10.1038/sj.emboj.7601367; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Papapetropoulos A, 2004, MOL PHARMACOL, V65, P407, DOI 10.1124/mol.65.2.407; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Wang JD, 2006, FEBS LETT, V580, P4392, DOI 10.1016/j.febslet.2006.07.002; Weiwad M, 2005, FEBS LETT, V579, P1591, DOI 10.1016/j.febslet.2004.12.098; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	47	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15341	15348		10.1074/jbc.M611594200	http://dx.doi.org/10.1074/jbc.M611594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17379601	hybrid			2022-12-25	WOS:000246589600009
J	Morrison, BH; Bauer, JA; Lupica, JA; Tang, Z; Schmidt, H; DiDonato, JA; Lindner, DJ				Morrison, Bei H.; Bauer, Joseph A.; Lupica, Joseph A.; Tang, Zhuo; Schmidt, Heidi; DiDonato, Joseph A.; Lindner, Daniel J.			Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL HEXAKISPHOSPHATE KINASE-2; OVARIAN-CARCINOMA CELLS; IKK-ALPHA; DNA-PK; TRAF2; DEATH; TNF; PYROPHOSPHATES; BETA; PHOSPHORYLATION	We previously showed that inositol hexakisphosphate kinase 2 (IHPK2) functions as a growth-suppressive and apoptosis-enhancing kinase during cell stress. Overexpression of IHPK2 sensitized ovarian carcinoma cell lines to the growth-suppressive and apoptotic effects of interferon beta (IFN-beta), IFN-alpha 2, and gamma-irradiation. Expression of a kinase-dead mutant abrogated 50% of the apoptosis induced by IFN-beta. Because the kinase-dead mutant retained significant response to cell stressors, we hypothesized that a portion of the death-promoting function of IHPK2 was independent of its kinase activity. We now demonstrate that IHPK2 binds to tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2 and interferes with phosphorylation of transforming growth factor beta-activated kinase 1 (TAK1), thereby inhibiting NF-kappa B signaling. IHPK2 contains two sites required for TRAF2 binding, Ser-347 and Ser-359. Compared with wild type IHPK2-transfected cells, cells expressing S347A and S359A mutations displayed 3.5-fold greater TAK1 activation following TNF-alpha. This mutant demonstrated a 6-10-fold increase in NF-kappa B DNA binding following TNF-alpha compared with wild type IHPK2-expressing cells in which NF-kappa B DNA binding was inhibited. Cells transfected with wild type IHPK2 or IHPK2 mutants that lacked S347A and S359A mutations displayed enhanced terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling staining following TNF-alpha. We believe that IHPK2-TRAF2 binding leads to attenuation of TAK1- and NF-kappa B-mediated signaling and is partially responsible for the apoptotic activity of IHPK2.	Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland State University	Lindner, DJ (corresponding author), Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Taussig Canc Ctr, 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@ccf.org	Hazen, Stanley L/ABD-5845-2021; Lindner, Daniel/ABB-5440-2020	Lupica, Joseph/0000-0003-1476-037X; Bauer, Joseph/0000-0003-4972-6008	NATIONAL CANCER INSTITUTE [R01CA095020] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095020-01A1, CA095020, R01 CA095020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Byrum J, 2004, NUCLEIC ACIDS RES, V32, P2776, DOI 10.1093/nar/gkh592; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Davies CC, 2005, MOL CELL BIOL, V25, P9806, DOI 10.1128/MCB.25.22.9806-9819.2005; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MA Y, 2002, J BIOL CHEM, V30, P30; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Ozes ON, 1999, NATURE, V401, P82; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	31	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15349	15356		10.1074/jbc.M700156200	http://dx.doi.org/10.1074/jbc.M700156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17379600	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000246589600010
J	Namslauer, A; Lepp, H; Branden, M; Jasaitis, A; Verkhovsky, MI; Brzezinski, P				Namslauer, Andreas; Lepp, Hakan; Branden, Magnus; Jasaitis, Audrius; Verkhovsky, Michael I.; Brzezinski, Peter			Plasticity of proton pathway structure and water coordination in cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS ELECTRON-TRANSFER; SITE-DIRECTED MUTAGENESIS; HEME-COPPER OXIDASES; RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; MOLECULAR-DYNAMICS; BIOLOGICAL-SYSTEMS; R-SPHAEROIDES; GLUTAMATE 286; ACTIVE-SITE	Cytochrome c oxidase (CytcO) is a redox-driven, membrane-bound proton pump. One of the proton transfer pathways of the enzyme, the D pathway, used for the transfer of both substrate and pumped protons, accommodates a network of hydrogen-bonded water molecules that span the distance between an aspartate (Asp(132)), near the protein surface, and glutamate Glu(286), which is an internal proton donor to the catalytic site. To investigate how changes in the environment around Glu(286) affect the mechanism of proton transfer through the pathway, we introduced a non-hydrogen-bonding (Ala) or an acidic residue (Asp) at position Ser(197) (S197A or S197D), located similar to 7 angstrom from Glu(286). Although Ser(197) is hydrogen- bonded to a water molecule that is part of the D pathway "proton wire," replacement of the Ser by an Ala did not affect the proton transfer rate. In contrast, the S197D mutant CytcO displayed a turnover activity of similar to 35% of that of the wild-type CytcO, and the O-2 reduction reaction was not linked to proton pumping. Instead, a fraction of the substrate protons was taken from the positive ("incorrect") side of the membrane. Furthermore, the pH dependence of the proton transfer rate was altered in the mutant CytcO. The results indicate that there is plasticity in the water coordination of the proton pathway, but alteration of the electrostatic potential within the pathway results in uncoupling of the proton translocation machinery.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, FIN-00014 Helsinki, Finland	Stockholm University; University of Helsinki	Brzezinski, P (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	peterb@dbb.su.se						Aagaard A, 2002, BBA-BIOENERGETICS, V1555, P133, DOI 10.1016/S0005-2728(02)00268-2; Aagaard A, 2000, BIOCHEMISTRY-US, V39, P15847, DOI 10.1021/bi0012641; Adelroth P, 1998, BIOCHEMISTRY-US, V37, P2470, DOI 10.1021/bi971813b; Adelroth P, 1997, BIOCHEMISTRY-US, V36, P13824, DOI 10.1021/bi9629079; ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P2844; Adelroth P, 1998, BBA-BIOENERGETICS, V1367, P107, DOI 10.1016/S0005-2728(98)00142-X; Adelroth P, 2000, BBA-BIOENERGETICS, V1459, P533, DOI 10.1016/S0005-2728(00)00194-8; Adelroth P, 2006, BBA-BIOENERGETICS, V1757, P867, DOI 10.1016/j.bbabio.2006.08.011; Behr J, 2000, BIOCHEMISTRY-US, V39, P1356, DOI 10.1021/bi991504g; Branden G, 2005, BIOCHEMISTRY-US, V44, P10466, DOI 10.1021/bi0502745; Branden G, 2006, BBA-BIOENERGETICS, V1757, P1052, DOI 10.1016/j.bbabio.2006.05.020; Branden M, 2001, P NATL ACAD SCI USA, V98, P5013, DOI 10.1073/pnas.081088398; Brzezinski P, 2004, TRENDS BIOCHEM SCI, V29, P380, DOI 10.1016/j.tibs.2004.05.008; Brzezinski P, 1998, J BIOENERG BIOMEMBR, V30, P99, DOI 10.1023/A:1020567729941; BRZEZINSKI P, 1985, FEBS LETT, V187, P111, DOI 10.1016/0014-5793(85)81224-2; Brzezinski P, 2006, CURR OPIN STRUC BIOL, V16, P465, DOI 10.1016/j.sbi.2006.06.012; Burykin A, 2003, BIOPHYS J, V85, P3696, DOI 10.1016/S0006-3495(03)74786-9; DRACHEV LA, 1979, ANAL BIOCHEM, V96, P250, DOI 10.1016/0003-2697(79)90580-3; Dutton P L, 1978, Methods Enzymol, V54, P411; Faxen K, 2005, NATURE, V437, P286, DOI 10.1038/nature03921; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Gilderson G, 2002, BIOPHYS CHEM, V98, P105, DOI 10.1016/S0301-4622(02)00088-1; Han D, 2006, BIOCHEMISTRY-US, V45, P14064, DOI 10.1021/bi061465q; Hosler JP, 1996, BIOCHEMISTRY-US, V35, P10776, DOI 10.1021/bi9606511; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Iwaki M, 2003, BIOCHEMISTRY-US, V42, P8809, DOI 10.1021/bi034522d; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Junemann S, 1997, BIOCHEMISTRY-US, V36, P14456, DOI 10.1021/bi971458p; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P14664, DOI 10.1021/bi0013748; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P6850, DOI 10.1021/bi992719t; Karpefors M, 1998, P NATL ACAD SCI USA, V95, P13606, DOI 10.1073/pnas.95.23.13606; Karpefors M, 1999, ISRAEL J CHEM, V39, P427; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Mills DA, 2000, BBA-BIOENERGETICS, V1458, P180, DOI 10.1016/S0005-2728(00)00067-0; Mills DA, 2002, BBA-BIOENERGETICS, V1555, P96, DOI 10.1016/S0005-2728(02)00261-X; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P13089, DOI 10.1021/bi961416l; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1101, P188, DOI 10.1016/S0005-2728(05)80016-7; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Namslauer A, 2004, FEBS LETT, V567, P103, DOI 10.1016/j.febslet.2004.04.027; Namslauer A, 2003, P NATL ACAD SCI USA, V100, P15543, DOI 10.1073/pnas.2432106100; Namslauer A, 2003, BIOCHEMISTRY-US, V42, P1488, DOI 10.1021/bi026524o; Olkhova E, 2004, BIOPHYS J, V86, P1873, DOI 10.1016/S0006-3495(04)74254-X; Olsson MHM, 2006, P NATL ACAD SCI USA, V103, P6500, DOI 10.1073/pnas.0510860103; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; PADDOCK ML, 1994, BIOCHEMISTRY-US, V33, P734, DOI 10.1021/bi00169a015; Pawate AS, 2002, BIOCHEMISTRY-US, V41, P13417, DOI 10.1021/bi026582+; Pfitzner U, 2000, BIOCHEMISTRY-US, V39, P6756, DOI 10.1021/bi992235x; Pomes R, 1998, BBA-BIOENERGETICS, V1365, P255, DOI 10.1016/S0005-2728(98)00077-2; Popovic DM, 2004, FEBS LETT, V566, P126, DOI 10.1016/j.febslet.2004.04.016; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Puustinen A, 1999, P NATL ACAD SCI USA, V96, P35, DOI 10.1073/pnas.96.1.35; Salomonsson L, 2005, P NATL ACAD SCI USA, V102, P17624, DOI 10.1073/pnas.0505431102; Smirnova IA, 1999, BIOCHEMISTRY-US, V38, P6826, DOI 10.1021/bi982865j; Sucheta A, 1997, BIOCHEMISTRY-US, V36, P554, DOI 10.1021/bi962422k; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Szundi I, 2003, BIOCHEMISTRY-US, V42, P5074, DOI 10.1021/bi020483e; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Verkhovsky MI, 1997, BBA-BIOENERGETICS, V1318, P6, DOI 10.1016/S0005-2728(96)00147-8; Wikstrom M, 2003, BBA-BIOENERGETICS, V1604, P61, DOI 10.1016/S0005-2728(03)00041-0; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; Wikstrom M, 2000, BBA-BIOENERGETICS, V1459, P514, DOI 10.1016/S0005-2728(00)00191-2; Xu JC, 2006, BBA-BIOENERGETICS, V1757, P852, DOI 10.1016/j.bbabio.2006.05.028; Zaslavsky D, 2000, BBA-BIOENERGETICS, V1458, P164, DOI 10.1016/S0005-2728(00)00066-9	67	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15148	15158		10.1074/jbc.M700348200	http://dx.doi.org/10.1074/jbc.M700348200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363369	hybrid			2022-12-25	WOS:000246589000054
J	Saito, K; Williams, S; Bulankina, A; Honing, S; Mustelin, T				Saito, Kan; Williams, Scott; Bulankina, Anna; Honing, Stefan; Mustelin, Tomas			Association of protein-tyrosine phosphatase MEG2 via its Sec14p homology domain with vesicle-trafficking proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; T-CELLS; INTERACTING PROTEIN; LOCALIZATION; BINDING; TIP47; POLYPHOSPHOINOSITIDES; RECOGNITION; ACTIVATION; EXPRESSION	The protein-tyrosine phosphatase PTPMEG2 is located on the cytoplasmic face of the enclosing membrane of secretory vesicles, where it regulates vesicle size by promoting homotypic vesicle fusion by dephosphorylating N-ethylmaleimide-sensitive factor, a key regulator of vesicle fusion. Here we address the question of how PTPMEG2 is targeted to this subcellular location. Using a series of deletion mutants, we pinpointed the N-terminal Sec14p homology ( SEC14) domain of PTPMEG2, residues 1 - 261, as the region containing the secretory vesicle targeting signal. This domain, alone or appended to a heterologous protein, was localized to intracellular vesicle membranes. Yeast two-hybrid screening identified a number of secretory vesicle proteins that interacted directly with the SEC14 domain of PTPMEG2, providing a mechanism for PTPMEG2 targeting to secretory vesicles. Two such proteins, mannose 6-phosphate receptor-interacting protein TIP47 and Arfaptin2, were found to alter PTPMEG2 localization when overexpressed, and elimination of TIP47 resulted in loss of PTPMEG2 function. Weconclude that the N terminus of PTPMEG2 is necessary for the targeting of this phosphatase to the secretory vesicle compartment by association with other proteins involved in intracellular transport.	Burnham Inst Med Res, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, Ctr Canc, La Jolla, CA 92037 USA; Burnham Inst Med Res, Ctr Canc, Program Signal Transduct, La Jolla, CA 92037 USA; Univ Cologne, Inst Biochem 1, D-50931 Cologne, Germany	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of Cologne	Mustelin, T (corresponding author), Burnham Inst Med Res, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, Ctr Canc, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org		Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI55741] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055741] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Burguete AS, 2005, METHOD ENZYMOL, V403, P357, DOI 10.1016/S0076-6879(05)03031-4; Cherfils J, 2001, FEBS LETT, V507, P280, DOI 10.1016/S0014-5793(01)02970-2; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Hayess K, 1998, J CELL BIOCHEM, V69, P304, DOI 10.1002/(SICI)1097-4644(19980601)69:3<304::AID-JCB8>3.3.CO;2-U; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Huse M, 2006, NAT IMMUNOL, V7, P247, DOI 10.1038/ni1304; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Huynh H, 2003, J IMMUNOL, V171, P6661, DOI 10.4049/jimmunol.171.12.6661; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Kruger JM, 2002, J BIOL CHEM, V277, P2620, DOI 10.1074/jbc.M104550200; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Mustelin T, 2004, MOL IMMUNOL, V41, P687, DOI 10.1016/j.molimm.2004.04.015; Nair P, 2003, J BIOL CHEM, V278, P24753, DOI 10.1074/jbc.M300174200; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Page LJ, 1998, BBA-MOL CELL RES, V1401, P146, DOI 10.1016/S0167-4889(97)00138-9; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Pettersson M, 2000, GENOMICS, V68, P351, DOI 10.1006/geno.2000.6278; Roche PA, 1999, IMMUNITY, V11, P391, DOI 10.1016/S1074-7613(00)80114-4; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Wang YC, 2005, J EXP MED, V202, P1587, DOI 10.1084/jem.20051108; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zhao RX, 2003, J BIOL CHEM, V278, P22609, DOI 10.1074/jbc.M301560200	31	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15170	15178		10.1074/jbc.M608682200	http://dx.doi.org/10.1074/jbc.M608682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387180	hybrid			2022-12-25	WOS:000246589000056
J	Sinha, KM; Stephanou, NC; Gao, F; Glickman, MS; Shuman, S				Sinha, Krishna Murari; Stephanou, Nicolas C.; Gao, Feng; Glickman, Michael S.; Shuman, Stewart			Mycobacterial UvrD1 is a Ku-dependent DNA helicase that plays a role in multiple DNA repair events, including double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; FUNCTIONAL INTERACTION; LIGASE-D; PSEUDOMONAS-AERUGINOSA; POLYMERASE COMPONENT; GENE-EXPRESSION; IDENTIFICATION; TUBERCULOSIS; HETERODIMER; COMPLEX	Mycobacterium tuberculosis and other bacterial pathogens have a Ku-dependent nonhomologous end joining pathway of DNA double-strand break repair. Here we identify mycobacterial UvrD1 as a novel interaction partner for Ku in a genome-wide yeast two-hybrid screen. UvrD1 per se is a vigorous DNA-dependent ATPase but a feeble DNA helicase. Ku stimulates UvrD1 to catalyze ATP-dependent unwinding of 3'-tailed DNAs. UvrD1, Ku, and DNA form a stable ternary complex in the absence of ATP. The Ku binding determinants are located in the distinctive C-terminal segment of UvrD1. A second mycobacterial paralog, UvrD2, is a vigorous Ku-independent DNA helicase. Ablation of UvrD1 sensitizes Mycobacterium smegmatis to killing by ultraviolet and ionizing radiation and to a single chromosomal break generated by I-SceI endonuclease. The physical and functional interactions of bacterial Ku and UvrD1 highlight the potential for cross-talk between components of nonhomologous end joining and nucleotide excision repair pathways.	Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Infect Dis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Glickman, MS (corresponding author), Sloan Kettering Inst, Program Immunol, 1275 York Ave, New York, NY 10021 USA.	glickmam@MSKCC.ORG		Glickman, Michael S/0000-0001-7918-5164	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064693] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI064693, R01 AI064693-03, AI64693] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cadman CJ, 2006, J MOL BIOL, V362, P18, DOI 10.1016/j.jmb.2006.06.032; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; Cooper MP, 2000, GENE DEV, V14, P907; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; Glickman MS, 2003, J BIOL CHEM, V278, P7844, DOI 10.1074/jbc.M212458200; GOLEMIS E, 1999, CURRENT PROTOCOLS MO; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Korycka-Machala M, 2006, FEMS MICROBIOL LETT, V258, P83, DOI 10.1111/j.1574-6968.2006.00199.x; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2005, NUCLEIC ACIDS RES, V33, P6861, DOI 10.1093/nar/gki984; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li BM, 2002, NUCLEIC ACIDS RES, V30, P3653, DOI 10.1093/nar/gkf488; Lieber MR, 2006, DNA REPAIR, V5, P1234, DOI 10.1016/j.dnarep.2006.05.013; Mackintosh SG, 2006, NUCLEIC ACIDS RES, V34, P4154, DOI 10.1093/nar/gkl501; Matson SW, 2006, NUCLEIC ACIDS RES, V34, P4089, DOI 10.1093/nar/gkl450; MATSON SW, 1986, J BIOL CHEM, V261, P169; MINB, 2005, P NATL ACAD SCI US, V101, P8906; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; PANG PP, 1983, J BACTERIOL, V153, P1172, DOI 10.1128/JB.153.3.1172-1179.1983; Pitcher RS, 2006, MOL CELL, V23, P743, DOI 10.1016/j.molcel.2006.07.009; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; So S, 2004, J BIOL CHEM, V279, P55433, DOI 10.1074/jbc.M409827200; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Yakovleva L, 2006, J BIOL CHEM, V281, P25026, DOI 10.1074/jbc.M603302200; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	38	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15114	15125		10.1074/jbc.M701167200	http://dx.doi.org/10.1074/jbc.M701167200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376770	hybrid			2022-12-25	WOS:000246589000051
J	Jeon, SH; Yoon, JY; Park, YN; Jeong, WJ; Kim, S; Jho, EH; Surh, YJ; Choi, KY				Jeon, Soung Hoo; Yoon, Ju-Yong; Park, Young-Nyun; Jeong, Woo-Jeong; Kim, Sewoon; Jho, Eek-Hoon; Surh, Young-Joon; Choi, Kang-Yell			Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR CARCINOMAS; TYROSINE PHOSPHORYLATION; GENETIC ALTERATIONS; COLORECTAL-CANCER; TUMOR-DEVELOPMENT; ONCOGENIC RAS; COLON-CANCER; ACTIVATION; EXPRESSION; MUTATIONS	Interactions between the Wnt/beta-catenin and the extracellular signal-regulated kinase (ERK) pathways have been posited, but the molecular mechanisms and cooperative roles of such interaction in carcinogenesis are poorly understood. In the present study, the Raf-1, MEK, and ERK activities were concomitantly decreased in fibroblasts, which inhibit morphological transformation and proliferation by Axin induction. The inhibition of the components of the ERK pathway by Axin occurred in cells retaining wild-type beta-catenin, including primary hepatocytes, but not in cells retaining non-degradable mutant beta-catenin. Axin inhibits cellular proliferation and ERK pathway activation induced by either epidermal growth factor or Ras, indicating a role of Axin in the regulation of growth induced by ERK pathway activation. ERK pathway regulation by Axin occurs at least partly via reduction of the protein level of Ras. Both wild-type and mutant Ras proteins are subjected to regulation by Axin, which occurs in cells retaining wild-type but not mutant beta-catenin gene. The role of beta-catenin in the regulation of the Ras-ERK pathway was further confirmed by Ras reduction and subsequent inhibitions of the ERK pathway components by knock down of mutated form of beta-catenin. The Ras regulation by Axin was blocked by treatment of leupeptin, an inhibitor of the lysosomal protein degradation machinery. Overall, Axin inhibits proliferation of cells at least partly by reduction of Ras protein level via beta-catenin. This study provides evidences for the role of the Ras-ERK pathway in carcinogenesis caused by mutations of the Wnt/beta-catenin pathway components.	Yonsei Univ, Natl Res Lab Mol Complex Control, Seoul 120749, South Korea; Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea; Yonsei Univ, Dept Pathol, Ctr Chron Metab Dis, Project Med Sci BK21,Coll Med, Seoul 120749, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea	Yonsei University; Yonsei University; Yonsei University; Yonsei University Health System; University of Seoul; Seoul National University (SNU)	Choi, KY (corresponding author), Yonsei Univ, Natl Res Lab Mol Complex Control, Seoul 120749, South Korea.	kychoi@yonsei.ac.kr		Park, Young Nyun/0000-0003-0357-7967; Jho, Eek-hoon/0000-0003-2414-6234				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; JEN J, 1994, CANCER RES, V54, P5523; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lyu J, 2003, J BIOL CHEM, V278, P13487, DOI 10.1074/jbc.M300591200; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Woodcroft KJ, 1999, BIOCHEM BIOPH RES CO, V266, P304, DOI 10.1006/bbrc.1999.1817; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	43	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14482	14492		10.1074/jbc.M611129200	http://dx.doi.org/10.1074/jbc.M611129200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374607	hybrid			2022-12-25	WOS:000246245800062
J	Masud, A; Mohapatra, A; Lakhani, SA; Ferrandino, A; Hakem, R; Flavell, RA				Masud, Ali; Mohapatra, Alexander; Lakhani, Saquib A.; Ferrandino, Anthony; Hakem, Razqallah; Flavell, Richard A.			Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; CASPASE ACTIVATION; ER STRESS; CROSS-TALK; EXPRESSION; MECHANISM; PROGRAM; INFLAMMATION; MICE	Members of the caspase family are essential for many apoptotic programs. We studied mouse embryonic fibroblasts (MEFs) deficient in caspases 3 and 7 and in caspase 9 to determine the role of these proteases in endoplasmic reticulum (ER) stress-induced apoptosis. Both caspase 3(-/-)/caspase 7(-/-) and caspase 9(-/-) MEFs were resistant to cytotoxicity induced via ER stress and failed to exhibit apoptotic morphology. Specifically, apoptosis induced by increased intracellular calcium was shown to depend only on caspases 3 and 9, whereas apoptosis induced by disruption of ER function depended additionally on caspase 7. Caspase 3(-/-)/caspase 7(-/-) and caspase 9(-/-) MEFs also exhibited decreased loss of mitochondrial membrane potential, which correlated with altered caspase 9 processing, increased induction of procaspase 11, and decreased processing of caspase 12 in caspase 3(-/-)/caspase 7(-/-) cells. Furthermore, disruption of ER function was sufficient to induce accumulation of cleaved caspase 3 and 7 in a heavy membrane compartment, suggesting a potential mechanism for caspase 12 processing and its role as an amplifier in the death pathway. Caspase 8(-/-) MEFs were not resistant to ER stress-induced cytotoxicity, and processing of caspase 8 was not observed upon induction of ER stress. This study thus demonstrates a requirement for caspases 3 and 9 and a key role for the intrinsic pathway in ER stress-induced apoptosis.	Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, Dept Immunobiol, Howard Hughes Med Inst, New Haven, CT 06520 USA; Shady Grove Adventist Hosp, Rockville, MD 20850 USA; Univ Toronto, Ontario Canc Inst, Div Cellular & Mol Biol, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Yale University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Immunobiol, 300 Cedar St,TAC S-569A, New Haven, CT 06519 USA.	richard.flavell@yale.edu	Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Lakhani, Saquib/0000-0003-3235-3460; Hakem, Razqallah/0000-0001-5948-7931				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheung HH, 2006, EXP CELL RES, V312, P2347, DOI 10.1016/j.yexcr.2006.03.027; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Darios F, 2003, J NEUROCHEM, V84, P643, DOI 10.1046/j.1471-4159.2003.01590.x; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Groenendyk J, 2005, ACTA BIOCHIM POL, V52, P381; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansell EJ, 1995, BIOCHEM CELL BIOL, V73, P373, DOI 10.1139/o95-045; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Liu N, 2006, VIROLOGY, V348, P398, DOI 10.1016/j.virol.2006.01.002; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	34	81	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14132	14139		10.1074/jbc.M700077200	http://dx.doi.org/10.1074/jbc.M700077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371867	hybrid			2022-12-25	WOS:000246245800023
J	Ventura, C; Cantoni, S; Bianchi, F; Lionetti, V; Cavallini, C; Scarlata, I; Foroni, L; Maioli, M; Bonsi, L; Alviano, F; Fossati, V; Bagnara, GP; Pasquinelli, G; Recchia, FA; Perbellini, A				Ventura, Carlo; Cantoni, Silvia; Bianchi, Francesca; Lionetti, Vincenzo; Cavallini, Claudia; Scarlata, Ignazio; Foroni, Laura; Maioli, Margherita; Bonsi, Laura; Alviano, Francesco; Fossati, Valentina; Bagnara, Gian Paolo; Pasquinelli, Gianandrea; Recchia, Fabio A.; Perbellini, Alberto			Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IN-VITRO; EXPRESSION; TRANSPLANTATION; VEGF; NEOVASCULARIZATION; DIFFERENTIATION; CARDIOGENESIS; MYOCARDIUM; PROTECTION	We have developed a mixed ester of hyaluronan with butyric and retinoic acid (HBR) that acted as a novel cardiogenic/vasculogenic agent in human mesenchymal stem cells isolated from bone marrow, dental pulp, and fetal membranes of term placenta (FMhMSCs). HBR remarkably enhanced vascular endothelial growth factor (VEGF), KDR, and hepatocyte growth factor (HGF) gene expression and the secretion of the angiogenic, mitogenic, and antiapoptotic factors VEGF and HGF, priming stem cell differentiation into endothelial cells. HBR also increased the transcription of the cardiac lineage-promoting genes GATA-4 and Nkx-2.5 and the yield of cardiac marker-expressing cells. These responses were notably more pronounced in FMhMSCs. FMhMSC transplantation into infarcted rat hearts was associated with increased capillary density, normalization of left ventricular function, and significant decrease in scar tissue. Transplantation of HBR-preconditioned FMhMSCs further enhanced capillary density and the yield of human vWF-expressing cells, additionally decreasing the infarct size. Some engrafted, HBR-pretreated FMhMSCs were also positive for connexin 43 and cardiac troponin I. Thus, the beneficial effects of HBR-exposed FMhMSCs may be mediated by a large supply of angiogenic and antiapoptotic factors, and FMhMSC differentiation into vascular cells. These findings may contribute to further development in cell therapy of heart failure.	Univ Bologna, Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, Inst Cardiol, I-40138 Bologna, Italy; Univ Bologna, Dept Expt Pathol, I-40138 Bologna, Italy; Univ Bologna, Dept Histol Embryol & Appl Biol, I-40138 Bologna, Italy; Scuola Super Sant Anna, CNR, Inst Clin Physiol, Sector Med, I-56124 Pisa, Italy; New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	University of Bologna; University of Bologna; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; New York Medical College; University of Sassari	Ventura, C (corresponding author), Univ Bologna, Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, S Orsola Malpighi Hosp, Pavill 21,Via Massarenti 9, I-40138 Bologna, Italy.	cvent@libero.it	Lionetti, Vincenzo/G-9528-2014; Bianchi, Francesca/M-2205-2016; Lionetti, Vincenzo/AAN-1994-2020; Pasquinelli, Gianandrea/I-7088-2012; Ventura, Carlo/AAV-3658-2020; Recchia, Fabio/F-2315-2010; Lionetti, Vincenzo/AAH-9503-2020; Cantoni, Silvia/H-3938-2011	Bianchi, Francesca/0000-0001-6732-0533; Lionetti, Vincenzo/0000-0002-0640-8651; Pasquinelli, Gianandrea/0000-0003-1506-1829; Cavallini, Claudia/0000-0002-8079-9697; fossati, valentina/0000-0003-1825-9371; Scarlata, Ignazio/0000-0002-5490-7834; MAIOLI, Margherita/0000-0003-0187-4968; Cantoni, Silvia/0000-0002-3866-3307; Ventura, Carlo/0000-0001-9333-0321				Bailo M, 2004, TRANSPLANTATION, V78, P1439, DOI 10.1097/01.TP.0000144606.84234.49; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barry F, 2001, BIOCHEM BIOPH RES CO, V289, P519, DOI 10.1006/bbrc.2001.6013; Barry FP, 1999, BIOCHEM BIOPH RES CO, V265, P134, DOI 10.1006/bbrc.1999.1620; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kim BO, 2005, CIRCULATION, V112, pI96, DOI 10.1161/01.CIRCULATIONAHA.105.524678; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Li YW, 2003, CIRCULATION, V107, P2499, DOI 10.1161/01.CIR.0000065579.19126.B8; Makkar RR, 2005, J CARDIOVASC PHARM T, V10, P225, DOI 10.1177/107424840501000403; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Matsumoto R, 2005, ARTERIOSCL THROM VAS, V25, P1168, DOI 10.1161/01.ATV.0000165696.25680.ce; Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Rangappa S, 2003, J THORAC CARDIOV SUR, V126, P124, DOI 10.1016/S0022-5223(03)00074-6; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007; Tang YL, 2004, REGUL PEPTIDES, V117, P3, DOI 10.1016/j.regpep.2003.09.005; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Ventura C, 2004, J BIOL CHEM, V279, P23574, DOI 10.1074/jbc.M401869200; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433	44	138	173	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14243	14252		10.1074/jbc.M609350200	http://dx.doi.org/10.1074/jbc.M609350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363374	hybrid, Green Published			2022-12-25	WOS:000246245800035
J	Zhao, YT; Kalari, SK; Usatyuk, PV; Gorshkova, I; He, DH; Watkins, T; Brindley, DN; Sun, CD; Bittman, R; Garcia, JGN; Berdyshev, EV; Natarajan, V				Zhao, Yutong; Kalari, Satish K.; Usatyuk, Peter V.; Gorshkova, Irina; He, Donghong; Watkins, Tonya; Brindley, David N.; Sun, Chaode; Bittman, Robert; Garcia, Joe G. N.; Berdyshev, Evgeni V.; Natarajan, Viswanathan			Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells - Role of lipid phosphate phosphatase-1 and sphingosine kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; FUNCTIONAL-CHARACTERIZATION; LYSOPHOSPHATIDIC ACID; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; MOLECULAR-CLONING; ACTIVATION; SURVIVAL; METABOLISM; RECEPTORS	Sphingosine 1-phosphate (S1P) regulates diverse cellular functions through extracellular ligation to S1P receptors, and it also functions as an intracellular second messenger. Human pulmonary artery endothelial cells (HPAECs) effectively utilized exogenous S1P to generate intracellular S1P. We, therefore, examined the role of lipid phosphate phosphatase (LPP)-1 and sphingosine kinase-1 (SphK1) in converting exogenous S1P to intracellular S1P. Exposure of P-32-labeled HPAECs to S1P or sphingosine (Sph) increased the intracellular accumulation of [P-32]S1P in a dose- and time-dependent manner. The S1P formed in the cells was not released into the medium. The exogenously added S1P did not stimulate the sphingomyelinase pathway; however, added [H-3]S1P was hydrolyzed to [H-3]Sph in HPAECs, and this was blocked by XY-14, an inhibitor of LPPs. HPAECs expressed LPP1-3, and overexpression of LPP-1 enhanced the hydrolysis of exogenous [H-3]S1P to [H-3]Sph and increased intracellular S1P production by 2-3-fold compared with vector control cells. Down-regulation of LPP-1 by siRNA decreased intracellular S1P production from extracellular S1P but had no effect on the phosphorylation of Sph to S1P. Knockdown of SphK1, but not SphK2, by siRNA attenuated the intracellular generation of S1P. Overexpression of wild type SphK1, but not SphK2 wild type, increased the accumulation of intracellular S1P after exposure to extracellular S1P. These studies provide the first direct evidence for a novel pathway of intracellular S1P generation. This involves the conversion of extracellular S1P to Sph by LPP-1, which facilitates Sph uptake, followed by the intracellular conversion of Sph to S1P by SphK1.	Univ Chicago, Dept Med, Ctr Integrat Sci Bldg, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Chicago; Johns Hopkins University; University of Alberta; City University of New York (CUNY) System; Queens College NY (CUNY)	Natarajan, V (corresponding author), Univ Chicago, Dept Med, Ctr Integrat Sci Bldg, Sect Pulm & Crit Care Med, Rm 408B,929 E 57th St, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010; Kalari, Satish/C-6967-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079396] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079396, R01 HL079396-02, R01 HL803187, R01 HL79396] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Aoki S, 2005, J BIOCHEM, V138, P47, DOI 10.1093/jb/mvi100; Argraves KM, 2002, ADV EXP MED BIOL, V507, P439; Berdyshev EV, 2006, CELL SIGNAL, V18, P1779, DOI 10.1016/j.cellsig.2006.01.018; Bernatchez PN, 2003, J CELL BIOCHEM, V90, P719, DOI 10.1002/jcb.10686; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Chin TY, 2002, MOL PHARMACOL, V61, P486, DOI 10.1124/mol.61.3.486; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Giussani P, 2006, MOL CELL BIOL, V26, P5055, DOI 10.1128/MCB.02107-05; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kariya Y, 2005, GENES CELLS, V10, P605, DOI 10.1111/j.1365-2443.2005.00862.x; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Le Stunff H, 2004, J BIOL CHEM, V279, P34290, DOI 10.1074/jbc.M404907200; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood-2004-02-0452; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Long J, 2005, BIOCHEM J, V391, P25, DOI 10.1042/BJ20050342; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; Mechtcheriakova D, 2007, CELL SIGNAL, V19, P748, DOI 10.1016/j.cellsig.2006.09.004; Misasi R, 2001, FASEB J, V15, P467, DOI 10.1096/fj.00-0217com; Mulders ACM, 2006, ARTERIOSCL THROM VAS, V26, P2043, DOI 10.1161/01.ATV.0000237569.95046.b9; Nanjundan M, 2001, AM J PHYSIOL-LUNG C, V281, pL1484, DOI 10.1152/ajplung.2001.281.6.L1484; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Prestwich GD, 2005, BIOCHEM SOC T, V33, P1357, DOI 10.1042/BST0331357; Pyne S, 2005, BIOCHEM SOC T, V33, P1370, DOI 10.1042/BST0331370; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Smyth SS, 2003, J BIOL CHEM, V278, P43214, DOI 10.1074/jbc.M306709200; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sun CD, 2004, J ORG CHEM, V69, P7694, DOI 10.1021/jo0487404; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Usatyuk PV, 2005, AM J PHYSIOL-LUNG C, V289, pL999, DOI 10.1152/ajplung.00211.2005; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160; Zhi L, 2006, J CELL PHYSIOL, V208, P109, DOI 10.1002/jcp.20646; ZUHERINGDORF DM, 2003, FEBS LETT, V554, P443	65	107	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14165	14177		10.1074/jbc.M701279200	http://dx.doi.org/10.1074/jbc.M701279200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379599	Green Accepted, hybrid			2022-12-25	WOS:000246245800027
J	Cottrell, JW; Kuzmin, YI; Fedor, MJ				Cottrell, Joseph W.; Kuzmin, Yaroslav I.; Fedor, Martha J.			Functional analysis of hairpin ribozyme active site architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERTIARY STRUCTURE STABILITY; GUANOSINE REQUIREMENT; CRYSTAL-STRUCTURE; HYDROGEN-BONDS; RNA; CLEAVAGE; ENERGETICS; CATALYSIS; SECONDARY; STABILIZATION	The hairpin ribozyme is a small catalytic motif found in plant satellite RNAs where it catalyzes a reversible self-cleavage reaction during processing of replication intermediates. Crystallographic studies of hairpin ribozymes have provided high resolution views of the RNA functional groups that comprise the active site and stimulated biochemical studies that probed the contributions of nucleobase functional groups to catalytic chemistry. The dramatic loss of activity that results from perturbation of active site architecture points to the importance of positioning and orientation in catalytic rate acceleration. The current study focuses on the network of noncovalent interactions that align nucleophilic and leaving group oxygens in the orientation required for the S(N)2-type reaction mechanism and orient the active site nucleobases near the reactive phosphate to facilitate catalytic chemistry. Nucleotide modifications that alter or eliminate individual hydrogen bonding partners had different effects on the activation barrier to catalysis, the stability of ribozyme complexes in the ground state, and the internal equilibrium between cleavage and ligation of bound products. Furthermore, substitution of hydrogen bond donors and acceptors with seemingly equivalent pairs sometimes had very different functional consequences. These biochemical analyses augment high resolution structural information to provide insights into the functional significance of active site architecture.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Fedor, MJ (corresponding author), Scripps Res Inst, Dept Biol Mol, 10550 N Torrey Pines Rd,MB35, La Jolla, CA 92037 USA.	mfedor@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046422] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam S, 2005, BIOCHEMISTRY-US, V44, P14396, DOI 10.1021/bi051550i; Canny MD, 2007, BIOCHEMISTRY-US, V46, P3826, DOI 10.1021/bi062077r; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; De la Pena M, 2003, EMBO J, V22, P5561, DOI 10.1093/emboj/cdg530; Donahue CP, 2000, J MOL BIOL, V295, P693, DOI 10.1006/jmbi.1999.3380; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; Fedor Martha J, 2004, Methods Mol Biol, V252, P19; Fedor MJ, 1999, BIOCHEMISTRY-US, V38, P11040, DOI 10.1021/bi991069q; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Fedor MJ, 2005, NAT REV MOL CELL BIO, V6, P399, DOI 10.1038/nrm1647; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRASBY JA, 1995, BIOCHEMISTRY-US, V34, P4068, DOI 10.1021/bi00012a025; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HEGG LA, 1995, BIOCHEMISTRY-US, V34, P15813, DOI 10.1021/bi00048a027; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Khvorova A, 2003, NAT STRUCT BIOL, V10, P708, DOI 10.1038/nsb959; Klostermeier D, 2002, BIOCHEMISTRY-US, V41, P14095, DOI 10.1021/bi025551b; Klostermeier D, 2001, BIOCHEMISTRY-US, V40, P11211, DOI 10.1021/bi010773f; Kuzmin YI, 2005, J MOL BIOL, V349, P989, DOI 10.1016/j.jmb.2005.04.005; Kuzmin YI, 2004, J MOL BIOL, V340, P233, DOI 10.1016/j.jmb.2004.04.067; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Martick M, 2006, CELL, V126, P309, DOI 10.1016/j.cell.2006.06.036; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Murchie AIH, 1998, MOL CELL, V1, P873, DOI 10.1016/S1097-2765(00)80086-6; Nesbitt SM, 1999, J MOL BIOL, V286, P1009, DOI 10.1006/jmbi.1999.2543; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Ryder SP, 1999, J MOL BIOL, V291, P295, DOI 10.1006/jmbi.1999.2959; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; Salter J, 2006, BIOCHEMISTRY-US, V45, P686, DOI 10.1021/bi051887k; Schmidt S, 1996, NUCLEIC ACIDS RES, V24, P573, DOI 10.1093/nar/24.4.573; Shippy R, 1998, BIOCHEMISTRY-US, V37, P564, DOI 10.1021/bi9721288; Silverman SK, 1999, BIOCHEMISTRY-US, V38, P8691, DOI 10.1021/bi9906118; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; Walter NG, 1999, NAT STRUCT BIOL, V6, P544; Wilson TJ, 2001, BIOCHEMISTRY-US, V40, P2291, DOI 10.1021/bi002644p; Yadava RS, 2001, J MOL BIOL, V309, P893, DOI 10.1006/jmbi.2001.4713; Zhao ZY, 2000, RNA, V6, P1833, DOI 10.1017/S1355838200001230	43	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13498	13507		10.1074/jbc.M700451200	http://dx.doi.org/10.1074/jbc.M700451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17351263	hybrid			2022-12-25	WOS:000246060300039
J	Hamik, A; Lin, ZY; Kumar, A; Balcells, M; Sinha, S; Katz, J; Feinberg, MW; Gerzsten, RE; Edelman, ER; Jain, MK				Hamik, Anne; Lin, Zhiyong; Kumar, Ajay; Balcells, Mercedes; Sinha, Sumita; Katz, Jonathan; Feinberg, Mark W.; Gerzsten, Robert E.; Edelman, Elazer R.; Jain, Mukesh K.			Kruppel-like factor 4 regulates endothelial inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; NITRIC-OXIDE SYNTHASE; FINGER TRANSCRIPTION FACTOR; CELL-ADHESION MOLECULE-1; GROWTH-FACTOR-BETA; NF-KAPPA-B; GENE-EXPRESSION; SHEAR-STRESS; MICE LACKING; PROTEIN-C	The vascular endothelium plays a critical role in vascular homeostasis. Inflammatory cytokines and non-laminar blood flow induce endothelial dysfunction and confer a pro-adhesive and pro-thrombotic phenotype. Therefore, identification of factors that mediate the effects of these stimuli on endothelial function is of considerable interest. Kruppel-like factor 4 expression has been documented in endothelial cells, but a function has not been described. In this communication we describe the expression in vitro and in vivo of Kruppel-like factor 4 in human and mouse endothelial cells. Furthermore, we demonstrate that endothelial Kruppel-like factor 4 is induced by pro-inflammatory stimuli and shear stress. Overexpression of Kruppel-like factor 4 induces expression of multiple anti-inflammatory and anti-thrombotic factors including endothelial nitric-oxide synthase and thrombomodulin, whereas knockdown of Kruppel-like factor 4 leads to enhancement of tumor necrosis factor alpha-induced vascular cell adhesion molecule-1 and tissue factor expression. The functional importance of Kruppel-like factor 4 is verified by demonstrating that Kruppel-like factor 4 expression markedly decreases inflammatory cell adhesion to the endothelial surface and prolongs clotting time under inflammatory states. Kruppel-like factor 4 differentially regulates the promoter activity of pro- and anti-inflammatory genes in a manner consistent with its anti-inflammatory function. These data implicate Kruppel-like factor 4 as a novel regulator of endothelial activation in response to pro-inflammatory stimuli.	Case Western Reserve Univ, Cardiovasc Res Inst, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Cambridge, MA 02138 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Ctr Immunol & Inflammatory Dis, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA	Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Pennsylvania	Jain, MK (corresponding author), Case Western Reserve Univ, Cardiovasc Res Inst, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	mukesh.jain2@case.edu		Balcells, Mercedes/0000-0002-2532-0516; Feinberg, Mark/0000-0001-9523-3859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069477, R01HL076754, P01HL048743, R01HL075427, R01HL072952] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250; Balcells M, 2005, J CELL PHYSIOL, V204, P329, DOI 10.1002/jcp.20281; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; BYERS SW, 1995, J CELL SCI, V108, P2053; Cadroy Y, 1997, ARTERIOSCL THROM VAS, V17, P520, DOI 10.1161/01.ATV.17.3.520; Calnek DS, 1998, EXP CELL RES, V238, P294, DOI 10.1006/excr.1997.3812; Cenni E, 2002, BIOMATERIALS, V23, P2159, DOI 10.1016/S0142-9612(01)00347-7; Chiambaretta F, 2004, MOL VIS, V10, P901; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; GIMBRONE MA, 1990, ANN NY ACAD SCI, V598, P77, DOI 10.1111/j.1749-6632.1990.tb42279.x; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; Grey ST, 1996, J IMMUNOL, V156, P2256; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heeringa P, 2000, AM J PATHOL, V156, P879, DOI 10.1016/S0002-9440(10)64957-7; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Koedel U, 2001, J NEUROPATH EXP NEUR, V60, P1041, DOI 10.1093/jnen/60.11.1041; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lamprecht P, 2005, AUTOIMMUN REV, V4, P28, DOI 10.1016/j.autrev.2004.06.001; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004-07-2681; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Lin ZY, 2006, ARTERIOSCL THROM VAS, V26, P1185, DOI 10.1161/01.ATV.0000215638.53414.99; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Liuzzo G, 2001, Rays, V26, P221; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Lowe GDO, 2003, PATHOPHYSIOL HAEMO T, V33, P455, DOI 10.1159/000083845; Martinez JM, 2002, TOXICOL SCI, V69, P409, DOI 10.1093/toxsci/69.2.409; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Michel T, 1999, BRAZ J MED BIOL RES, V32, P1361, DOI 10.1590/S0100-879X1999001100006; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NEWMAN KM, 1994, CONNECT TISSUE RES, V30, P265, DOI 10.3109/03008209409015042; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; PERKINS AC, 1995, NATURE, V375, P318; Rose SL, 2005, J BIOMED MATER RES A, V72A, P269, DOI 10.1002/jbm.a.30222; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sasaki M, 2003, J PHARMACOL EXP THER, V305, P78, DOI 10.1124/jpet.102.044099; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sonveaux P, 2003, CANCER RES, V63, P1012; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stone PH, 2003, CURR OPIN CARDIOL, V18, P458, DOI 10.1097/00001573-200311000-00007; TAKADA Y, 1994, BIOCHEM BIOPH RES CO, V205, P1345, DOI 10.1006/bbrc.1994.2813; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	86	271	278	1	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13769	13779		10.1074/jbc.M700078200	http://dx.doi.org/10.1074/jbc.M700078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339326	hybrid			2022-12-25	WOS:000246060300067
J	Kim, JA; Formoso, G; Li, YH; Potenza, MA; Marasciulo, FL; Montagnani, M; Quon, MJ				Kim, Jeong-a; Formoso, Gloria; Li, Yunhua; Potenza, Maria A.; Marasciulo, Flora L.; Montagnani, Monica; Quon, Michael J.			Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; SPONTANEOUSLY HYPERTENSIVE-RATS; INSULIN-STIMULATED PRODUCTION; MUSCLE GLUCOSE-UPTAKE; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; MICROVASCULAR RECRUITMENT; TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1	Green tea consumption is associated with reduced cardiovascular mortality in some epidemiological studies. Epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, mimics metabolic actions of insulin to inhibit gluconeogenesis in hepatocytes. Because signaling pathways regulating metabolic and vasodilator actions of insulin are shared in common, we hypothesized that EGCG may also have vasodilator actions to stimulate production of nitric oxide (NO) from endothelial cells. Acute intra-arterial administration of EGCG to mesenteric vascular beds isolated ex vivo from WKY rats caused dose-dependent vasorelaxation. This was inhibitable by L-NAME (NO synthase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), or PP2 (Src family kinase inhibitor). Treatment of bovine aortic endothelial cells (BAEC) with EGCG (50 mu m) acutely stimulated production of NO(assessed with NO-specific fluorescent dye DAF-2) that was inhibitable by L-NAME, wortmannin, or PP2. Stimulation of BAEC with EGCG also resulted in dose- and time-dependent phosphorylation of eNOS that was inhibitable by wortmannin or PP2 (but not by MEK inhibitor PD98059). Specific knockdown of Fyn (but not Src) with small interfering RNA inhibited both EGCG-stimulated phosphorylation of Akt and eNOS as well as production of NO in BAEC. Treatment of BAEC with EGCG generated intracellular H2O2 ( assessed with H2O2-specific fluorescent dye CM-H2DCF-DA), whereas treatment with N-acetylcysteine inhibited EGCG-stimulated phosphorylation of Fyn, Akt, and eNOS. We conclude that EGCG has endothelial-dependent vasodilator actions mediated by intracellular signaling pathways requiring reactive oxygen species and Fyn that lead to activation of phosphatidylinositol 3-kinase, Akt, and eNOS. This mechanism may explain, in part, beneficial vascular and metabolic health effects of green tea consumption.	NCCAM, Diabet Unit, Bethesda, MD 20892 USA; Univ Bari, Dept Pharmacol & Human Physiol, I-70124 Bari, Italy	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Universita degli Studi di Bari Aldo Moro	Quon, MJ (corresponding author), Bldg 10,Room 6C-205, Bethesda, MD 20892 USA.	quonm@nih.gov	Montagnani, Monica/AAV-2057-2020; Quon, Michael/B-1970-2008	Montagnani, Monica/0000-0002-5697-8185; Potenza, Maria Assunta/0000-0002-9995-1468; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000001, ZIAAT000001, Z02AT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Anter E, 2005, CIRC RES, V96, P1072, DOI 10.1161/01.RES.0000168807.63013.56; Anter E, 2004, J BIOL CHEM, V279, P46637, DOI 10.1074/jbc.M405547200; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baron AD, 2000, DIABETES, V49, P768, DOI 10.2337/diabetes.49.5.768; Chou MT, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-32; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Formoso G, 2006, MOL ENDOCRINOL, V20, P1153, DOI 10.1210/me.2005-0266; Fujimura Y, 2005, BIOCHEM BIOPH RES CO, V336, P674, DOI 10.1016/j.bbrc.2005.08.146; Goldstein BJ, 2005, ANTIOXID REDOX SIGN, V7, P1021, DOI 10.1089/ars.2005.7.1021; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109; Kim JA, 2006, CIRCULATION, V113, P1888, DOI 10.1161/CIRCULATIONAHA.105.563213; Kim JA, 2005, J BIOL CHEM, V280, P23173, DOI 10.1074/jbc.M501439200; Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mather K, 2000, AM J PHYSIOL-ENDOC M, V279, pE1264, DOI 10.1152/ajpendo.2000.279.6.E1264; MAY JM, 1979, J BIOL CHEM, V254, P2214; McVeigh Gary E, 2003, Curr Diab Rep, V3, P87, DOI 10.1007/s11892-003-0059-0; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Mochizuki M, 2002, BBA-GEN SUBJECTS, V1569, P35, DOI 10.1016/S0304-4165(01)00230-6; Mochizuki Y, 2002, J CELL SCI, V115, P175; Montagnani M, 2002, MOL ENDOCRINOL, V16, P1931, DOI 10.1210/me.2002-0074; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potenza MA, 2005, AM J PHYSIOL-HEART C, V289, pH813, DOI 10.1152/ajpheart.00092.2005; POTENZA MA, 2007, IN PRESS AM J PHYSL; Potenza MA, 2006, DIABETES, V55, P3594, DOI 10.2337/db06-0667; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Rhee S G, 2000, Sci STKE, V2000, ppe1; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Sano J, 2004, CIRC J, V68, P665, DOI 10.1253/circj.68.665; Stangl V, 2006, MOL NUTR FOOD RES, V50, P218, DOI 10.1002/mnfr.200500118; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tian WX, 2004, LIFE SCI, V74, P2389, DOI 10.1016/j.lfs.2003.09.064; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Vincent MA, 2003, AM J PHYSIOL-ENDOC M, V285, pE123, DOI 10.1152/ajpendo.00021.2003; Vincent MA, 2004, DIABETES, V53, P1418, DOI 10.2337/diabetes.53.6.1418; Vincent Michelle A, 2003, Curr Diab Rep, V3, P279, DOI 10.1007/s11892-003-0018-9; Vinson JA, 2000, BIOFACTORS, V13, P127, DOI 10.1002/biof.5520130121; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200; Werdich XQ, 2006, ANGIOGENESIS, V8, P315; Widlansky ME, 2005, FREE RADICAL BIO MED, V38, P499, DOI 10.1016/j.freeradbiomed.2004.11.013; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	66	173	178	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13736	13745		10.1074/jbc.M609725200	http://dx.doi.org/10.1074/jbc.M609725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363366	hybrid			2022-12-25	WOS:000246060300063
J	Lee, JH; Kim, SY; Kil, IS; Park, JW				Lee, Jin Hyup; Kim, Sung Youl; Kil, In Sup; Park, Jeen-Woo			Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP(+)-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-DEATH; PERMEABILITY TRANSITION; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; FREE-RADICALS; HYDROPEROXIDE; THIOREDOXIN; ANTIOXIDANT	Ionizing radiation induces the production of reactive oxygen species, which play an important causative role in apoptotic cell death. By supplying NADPH for antioxidant systems, we recently demonstrated that the control of mitochondrial redox balance and the cellular defense against oxidative damage are some of the primary functions of mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm). In this study, we demonstrate that modulation of IDPm activity in U937 cells regulates ionizing radiation-induced apoptosis. When we examined the regulatory role of IDPm against ionizing radiation-induced apoptosis in U937 cells transfected with the cDNA for mouse IDPm in sense and antisense orientations, a clear inverse relationship was observed between the amount of IDPm expressed in target cells and their susceptibility to apoptosis. Upon exposure to 2 gray gamma-irradiation, there was a distinct difference between the IDPm transfectant cells in regard to the morphological evidence of apoptosis, DNA fragmentation, cellular redox status, oxidative damage to cells, mitochondrial function, and the modulation of apoptotic marker proteins. In addition, transfection of HeLa cells with an IDPm small interfering RNA decreased the activity of IDPm, enhancing the susceptibility of radiation-induced apoptosis. Taken together, these results indicate that IDPm may play an important role in regulating the apoptosis induced by ionizing radiation, and the effect of IDPm small interfering RNA on HeLa cells offers the possibility of developing a modifier of radiation therapy.	Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea	Kyungpook National University	Park, JW (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea.	parkjw@knu.ac.kr						Akerboom T P, 1981, Methods Enzymol, V77, P373; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Buege J A, 1978, Methods Enzymol, V52, P302; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; EWING D, 1987, ARCH BIOCHEM BIOPHYS, V254, P53, DOI 10.1016/0003-9861(87)90080-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1999, FREE RADICAL BIO MED, P267; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KASTAN MB, 1991, CANCER RES, V51, P6304; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KONO Y, 1982, J BIOL CHEM, V257, P5751; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANE DP, 1992, NATURE, V358, P16; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; REPINE JE, 1981, P NATL ACAD SCI-BIOL, V78, P1001, DOI 10.1073/pnas.78.2.1001; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; YAMAGUCHI S, 1994, FREE RADICAL BIO MED, V17, P389, DOI 10.1016/0891-5849(94)90165-1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	45	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13385	13394		10.1074/jbc.M700303200	http://dx.doi.org/10.1074/jbc.M700303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350954	hybrid			2022-12-25	WOS:000246060300027
J	Diaz-Martinez, LA; Gimenez-Abian, JF; Clarke, DJ				Diaz-Martinez, Laura A.; Gimenez-Abian, Juan F.; Clarke, Duncan J.			Cohesin Is Dispensable for Centromere Cohesion in Human Cells	PLOS ONE			English	Article							SISTER-CHROMATID COHESION; VERTEBRATE COHESIN; MEDIATED COHESION; CHROMOSOME; TOPOISOMERASE; SEPARATION; ANAPHASE; CHECKPOINT; SHUGOSHIN; COMPLEX	Background. Proper regulation of the cohesion at the centromeres of human chromosomes is essential for accurate genome transmission. Exactly how cohesion is maintained and is then dissolved in anaphase is not understood. Principal Findings. We have investigated the role of the cohesin complex at centromeres in human cells both by depleting cohesin subunits using RNA interference and also by expressing a non-cleavable version of the Rad21 cohesin protein. Rad21 depletion results in aberrant anaphase, during which the sister chromatids separate and segregate in an asynchronous fashion. However, centromere cohesion was maintained before anaphase in Rad21-depleted cells, and the primary constrictions at centromeres were indistinguishable from those in control cells. Expression of non-cleavable Rad21 (NC-Rad21), in which the sites normally cleaved by separase are mutated, resulted in delayed sister chromatid resolution in prophase and prometaphase, and a blockage of chromosome arm separation in anaphase, but did not impede centromere separation. Conclusions. These data indicate that cohesin complexes are dispensable for sister cohesion in early mitosis, yet play an important part in the fidelity of sister separation and segregation during anaphase. Cleavage at the separase-sensitive sites of Rad21 is important for arm separation, but not for centromere separation.	[Diaz-Martinez, Laura A.; Gimenez-Abian, Juan F.; Clarke, Duncan J.] Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; [Gimenez-Abian, Juan F.] CSIC, Ctr Invest Biol, Madrid, Spain	University of Minnesota System; University of Minnesota Twin Cities; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Clarke, DJ (corresponding author), Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	Duncan.J.Clarke-2@umn.edu	Díaz-Martínez, Laura/A-5357-2010; Abián, Juan F Giménez/E-6372-2015	Abián, Juan F Giménez/0000-0002-9220-286X; Diaz-Martinez, Laura/0000-0002-7226-7068; Clarke, Duncan/0000-0002-7795-3294	NIH [CA099033]; MEC-Spain DGI; CONACyT; NATIONAL CANCER INSTITUTE [R01CA099033] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MEC-Spain DGI; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by NIH grant CA099033 (D. J. C.) and J. F. G. A was partly supported by MEC-Spain DGI and L. A. D. M. by CONACyT.	Bailis JM, 2003, NAT CELL BIOL, V5, P1111, DOI 10.1038/ncb1069; Bailis JM, 2003, CELL CYCLE, V2, P303, DOI 10.4161/cc.2.4.434; Baumann C, 2007, CELL, V128, P101, DOI 10.1016/j.cell.2006.11.041; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; CLARKE DJ, 1993, J CELL SCI, V105, P563; Clarke DJ, 2006, CELL CYCLE, V5, P1925, DOI 10.4161/cc.5.17.3200; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Flemming W., 1882, ZELLSUBSTANZ KERN ZE; Gimenez-Abian JF, 2005, CELL CYCLE, V4, P1576, DOI 10.4161/cc.4.11.2147; Gimenez-Abian JF, 2005, CELL CYCLE, V4, P1561, DOI 10.4161/cc.4.11.2146; Gimenez-Abian JF, 2002, EUR J CELL BIOL, V81, P9, DOI 10.1078/0171-9335-00226; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Huang CE, 2005, PHILOS T ROY SOC B, V360, P537, DOI 10.1098/rstb.2004.1609; Huang J, 2004, MOL CELL, V13, P739, DOI 10.1016/S1097-2765(04)00103-0; Huang JA, 2004, CELL CYCLE, V3, P973; Kenney RD, 2006, J CELL SCI, V119, P5057, DOI 10.1242/jcs.03277; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; Kumada K, 2006, J CELL BIOL, V172, P835, DOI 10.1083/jcb.200511126; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2005, J CELL SCI, V118, P2133, DOI 10.1242/jcs.02355; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Nasmyth K, 2005, PHILOS T R SOC B, V360, P483, DOI 10.1098/rstb.2004.1604; Noble D, 2006, CELL CYCLE, V5, P2528, DOI 10.4161/cc.5.21.3405; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Vagnarelli P, 2004, EMBO REP, V5, P167, DOI 10.1038/sj.embor.7400077; Watanabe Y, 2005, PHILOS T ROY SOC B, V360, P515, DOI 10.1098/rstb.2004.1607; Watrin E, 2006, CURR BIOL, V16, P863, DOI 10.1016/j.cub.2006.03.049; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; WOLF F, 2006, EMBO J; Yalon M, 2004, J CELL SCI, V117, P1961, DOI 10.1242/jcs.01032; Yu HT, 2005, CELL CYCLE, V4, P262; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	53	25	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e318	10.1371/journal.pone.0000318	http://dx.doi.org/10.1371/journal.pone.0000318			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389909	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445200001
J	Demeny, MA; Soutoglou, E; Nagy, Z; Scheer, E; Janoshazi, A; Richardot, M; Argentini, M; Kessler, P; Tora, L				Demeny, Mate A.; Soutoglou, Evi; Nagy, Zita; Scheer, Elisabeth; Janoshazi, Agnes; Richardot, Magalie; Argentini, Manuela; Kessler, Pascal; Tora, Laszlo			Identification of a Small TAF Complex and Its Role in the Assembly of TAF-Containing Complexes	PLOS ONE			English	Article							RNA-POLYMERASE-II; HISTONE FOLD; TRANSCRIPTION; COMPONENTS; BINDING; SAGA; DISTINCT; PROTEIN; CHROMATIN; PROMOTER	TFIID plays a role in nucleating RNA polymerase II preinitiation complex assembly on protein-coding genes. TFIID is a multisubunit complex comprised of the TATA box binding protein (TBP) and 14 TBP-associated factors (TAFs). Another class of multiprotein transcriptional regulatory complexes having histone acetyl transferase (HAT) activity, and containing TAFs, includes TFTC, STAGA and the PCAF/GCN5 complex. Looking for as yet undiscovered subunits by a proteomic approach, we had identified TAF8 and SPT7L in human TFTC preparations. Subsequently, however, we demonstrated that TAF8 was not a stable component of TFTC, but that it is present in a small TAF complex (SMAT), containing TAF8, TAF10 and SPT7L, that co-purified with TFTC. Thus, TAF8 is a subunit of both TFIID and SMAT. The latter has to be involved in a pathway of complex formation distinct from the other known TAF complexes, since these three histone fold (HF)-containing proteins (TAF8, TAF10 and SPT7L) can never be found together either in TFIID or in STAGA/TFTC HAT complexes. Here we show that TAF8 is absolutely necessary for the integration of TAF10 in a higher order TFIID core complex containing seven TAFs. TAF8 forms a heterodimer with TAF10 through its HF and proline rich domains, and also interacts with SPT7L through its C-terminal region, and the three proteins form a complex in vitro and in vivo. Thus, the TAF8-TAF10 and TAF10-SPT7L HF pairs, and also the SMAT complex, seem to be important regulators of the composition of different TFIID and/or STAGA/TFTC complexes in the nucleus and consequently may play a role in gene regulation.	[Demeny, Mate A.; Soutoglou, Evi; Nagy, Zita; Scheer, Elisabeth; Janoshazi, Agnes; Richardot, Magalie; Argentini, Manuela; Kessler, Pascal; Tora, Laszlo] Univ Strasbourg, INSERM, U596, IGBMC,CNRS,UMR 7104, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), Univ Strasbourg, INSERM, U596, IGBMC,CNRS,UMR 7104, Strasbourg, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; Soutoglou, Evi/0000-0002-3724-5613	European Community [HPRN-CT-2000-00088, PRN-CT 00504228, STREP LSHG-CT-2004-502950]; ARC [05-BLAN-0396-01]; EU-RTN MC [HPRN-CT 00504228]; CNRS; INSERM; Universite Louis Pasteur; Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale; Fond National de La Science ACI; INTAS; AICR [03-084]	European Community(European Commission); ARC(Australian Research Council); EU-RTN MC; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Louis Pasteur; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fond National de La Science ACI; INTAS(INTASEuropean Commission); AICR	M. A. Demeny was supported by a fellowship from the European Community grant (HPRN-CT-2000-00088) and a fellowship from the ARC, E. Soutoglou was supported by an EMBO fellowship and Z. Nagy was supported by a EU-RTN MC grant (HPRN-CT 00504228). This work was supported by funds from CNRS, INSERM, Universite Louis Pasteur, Association pour la Recherche sur le Cancer, the Fondation pour la Recherche Medicale, the Fond National de La Science ACI, ANR (05-BLAN-0396-01; Regulome), European Community (HPRN-CT 00504228 and STREP LSHG-CT-2004-502950), INTAS and AICR (03-084) grants.	Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Davidson I, 2003, TRENDS BIOCHEM SCI, V28, P391, DOI 10.1016/S0968-0004(03)00117-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Frontini M, 2005, MOL CELL BIOL, V25, P4638, DOI 10.1128/MCB.25.11.4638-4649.2005; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Gangloff YG, 2001, MOL CELL BIOL, V21, P5109, DOI 10.1128/MCB.21.15.5109-5121.2001; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guermah M, 2003, MOL CELL, V12, P991, DOI 10.1016/S1097-2765(03)00396-4; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Hernandez-Hernandez A, 2001, MOL CELL BIOL, V21, P614, DOI 10.1128/MCB.21.2.614-623.2001; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Lebedeva LA, 2005, P NATL ACAD SCI USA, V102, P18087, DOI 10.1073/pnas.0509063102; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mohan WS, 2003, MOL CELL BIOL, V23, P4307, DOI 10.1128/MCB.23.12.4307-4318.2003; Nishizaka S, 2000, CANCER RES, V60, P4830; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Shao HS, 2005, MOL CELL BIOL, V25, P206, DOI 10.1128/MCB.25.1.206-219.2005; Soutoglou E, 2005, MOL CELL BIOL, V25, P4092, DOI 10.1128/MCB.25.10.4092-4104.2005; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Voss AK, 2000, DEVELOPMENT, V127, P5449; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wright KJ, 2006, P NATL ACAD SCI USA, V103, P12347, DOI 10.1073/pnas.0605499103; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	47	44	48	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e316	10.1371/journal.pone.0000316	http://dx.doi.org/10.1371/journal.pone.0000316			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375202	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445100018
J	Diaz, S; Amaro, F; Rico, D; Campos, V; Benitez, L; Martin-Gonzalez, A; Hamilton, EP; Orias, E; Gutierrez, JC				Diaz, Silvia; Amaro, Francisco; Rico, Daniel; Campos, Virginia; Benitez, Laura; Martin-Gonzalez, Ana; Hamilton, Eileen P.; Orias, Eduardo; Gutierrez, Juan C.			Tetrahymena Metallothioneins Fall into Two Discrete Subfamilies	PLOS ONE			English	Article							STRESS INDUCIBLE METALLOTHIONEIN; METAL-BINDING FEATURES; IN-VITRO; HEAVY-METALS; ALPHA-DOMAIN; CADMIUM; GENE; PROTEIN; COPPER; EXPRESSION	Background. Metallothioneins are ubiquitous small, cysteine-rich, multifunctional proteins which can bind heavy metals. Methodology/Principal Findings. We report the results of phylogenetic and gene expression analyses that include two new Tetrahymena thermophila metallothionein genes (MTT3 and MTT5). Sequence alignments of all known Tetrahymena metallothioneins have allowed us to rationalize the structure of these proteins. We now formally subdivide the known metallothioneins from the ciliate genus Tetrahymena into two well defined subfamilies, 7a and 7b, based on phylogenetic analysis, on the pattern of clustering of Cys residues, and on the pattern of inducibility by the heavy metals Cd and Cu. Sequence alignment also reveals a remarkably regular, conserved and hierarchical modular structure of all five subfamily 7a MTs, which include MTT3 and MTT5. The former has three modules, while the latter has only two. Induction levels of the three T. thermophila genes were determined using quantitative real time RT-PCR. Various stressors (including heavy metals) brought about dramatically different fold-inductions for each gene; MTT5 showed the highest fold-induction. Conserved DNA motifs with potential regulatory significance were identified, in an unbiased way, upstream of the start codons of subfamily 7a MTs. EST evidence for alternative splicing in the 3' UTR of the MTT5 mRNA with potential regulatory activity is reported. Conclusion/Significance. The small number and remarkably regular structure of Tetrahymena MTs, coupled with the experimental tractability of this model organism for studies of in vivo function, make it an attractive system for the experimental dissection of the roles, structure/function relationships, regulation of gene expression, and adaptive evolution of these proteins, as well as for the development of biotechnological applications for the environmental monitoring of toxic substances.	[Hamilton, Eileen P.; Orias, Eduardo] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Diaz, Silvia; Amaro, Francisco; Rico, Daniel; Campos, Virginia; Benitez, Laura; Martin-Gonzalez, Ana; Gutierrez, Juan C.] Univ Complutense, Fac Biol, Dept Microbiol 3, Madrid, Spain	University of California System; University of California Santa Barbara; Complutense University of Madrid	Hamilton, EP (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.		MARTIN, ANA/ABG-7710-2020; Amaro, Francisco/Y-5610-2019; Rico, Daniel/I-2049-2013	Amaro, Francisco/0000-0002-0061-477X; Rico, Daniel/0000-0002-6561-2310; Gutierrez, Juan Carlos/0000-0003-0909-3349	CAM [07M/0029/2002]; Del AMO project (UCM-University of California); NIH [RR-09231]; Ministerio de Educacion y Ciencia; Complutense University; UC-UCM EAP;  [BOS2002-01067 MCYT (1+ D)];  [CGL2005-00548]; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009231] Funding Source: NIH RePORTER	CAM; Del AMO project (UCM-University of California)(University of California System); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministerio de Educacion y Ciencia(Spanish Government); Complutense University; UC-UCM EAP; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was partially supported by the following grants: BOS2002-01067 MCYT (1+ D) to A. M. G., CAM (07M/0029/2002) and CGL2005-00548 to J.C.G., Del AMO project (UCM-University of California) to J.C.G. and E.O., NIH grant RR-09231 to E.O., Ph.D. scholarship from Ministerio de Educacion y Ciencia to S. D. and V. C., Ph.D. scholarship from Complutense University (UCM) to F. A. and UC-UCM EAP scholarship to D. R.	BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Binz PA, 1999, METALLOTHIONEIN IV, P7; Boldrin F, 2006, EUKARYOT CELL, V5, P422, DOI 10.1128/EC.5.2.422-425.2006; Boldrin F, 2002, PROTIST, V153, P283, DOI 10.1078/1434-4610-00105; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chabanon Herve, 2004, Briefings in Functional Genomics & Proteomics, V3, P240; Cheung, 2005, BBA-GENE STRUCT EXPR, V1731, P191, DOI [10.1016/j.bbaexp.2005.09.006, 10.1016/j.bbaexp.2005.9.006]; CHURCH HJ, 1993, J INORG BIOCHEM, V49, P55, DOI 10.1016/0162-0134(93)80048-E; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; CODY CW, 1994, BIOCHEM BIOPH RES CO, V202, P954, DOI 10.1006/bbrc.1994.2022; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dondero F, 2005, GENE, V345, P259, DOI 10.1016/j.gene.2004.11.031; Dondero F, 2004, PROTIST, V155, P157, DOI 10.1078/143446104774199565; Egli D, 2006, MOL CELL BIOL, V26, P2286, DOI 10.1128/MCB.26.6.2286-2296.2006; Egli D, 2006, GENES CELLS, V11, P647, DOI 10.1111/j.1365-2443.2006.00971.x; Eisen JA, 2006, PLOS BIOL, V4, P1620, DOI 10.1371/journal.pbio.0040286; Emoto T, 1996, BIOCHEM GENET, V34, P239, DOI 10.1007/BF02407022; Erk M, 2001, ANAL CHIM ACTA, V442, P165, DOI 10.1016/S0003-2670(01)01130-8; Fu CJ, 2006, PROTIST, V157, P193, DOI 10.1016/j.protis.2006.02.006; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Gaertig J, 1999, NAT BIOTECHNOL, V17, P462, DOI 10.1038/8638; Gutierrez JC, 2003, EUR J PROTISTOL, V39, P461, DOI 10.1078/0932-4739-00021; Hamilton EP, 2000, METHOD CELL BIOL, V62, P265; Hamilton EP, 2000, METHOD CELL BIOL, V62, P219; Haq F, 2003, MUTAT RES-FUND MOL M, V533, P211, DOI 10.1016/j.mrfmmm.2003.07.014; Henkel G, 2004, CHEM REV, V104, P801, DOI 10.1021/cr020620d; Hughes S, 2007, ENVIRON POLLUT, V145, P395, DOI 10.1016/j.envpol.2006.06.003; IKEBUCHI H, 1986, BIOCHEM J, V233, P541, DOI 10.1042/bj2330541; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KANEY AR, 1983, EXP CELL RES, V143, P461, DOI 10.1016/0014-4827(83)90074-5; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Klaassen CD, 1998, ENVIRON HEALTH PERSP, V106, P297, DOI 10.2307/3433930; KOJIMA Y, 1976, P NATL ACAD SCI USA, V73, P3413, DOI 10.1073/pnas.73.10.3413; Kondrashov FA, 2006, J THEOR BIOL, V239, P141, DOI 10.1016/j.jtbi.2005.08.033; Kovalchuk I, 2005, MUTAT RES-FUND MOL M, V570, P149, DOI 10.1016/j.mrfmmm.2004.10.004; Li WH, 2005, TRENDS GENET, V21, P602, DOI 10.1016/j.tig.2005.08.006; Liu J, 1996, FUND APPL TOXICOL, V29, P294, DOI 10.1006/faat.1996.0034; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luporini P, 2005, ACTA PROTOZOOL, V44, P89; Martin-Gonzalez A, 2006, RES MICROBIOL, V157, P108, DOI 10.1016/j.resmic.2005.06.005; Martin-Gonzalez A., 1999, Recent Research Developments in Microbiology, V3, P93; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICELI C, 1992, P NATL ACAD SCI USA, V89, P1988, DOI 10.1073/pnas.89.5.1988; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; NILSSON JR, 1989, EUR J PROTISTOL, V25, P2, DOI 10.1016/S0932-4739(89)80074-4; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Nury D, 2005, BIOCHEM J, V387, P419, DOI 10.1042/BJ20040630; Ohno S., 1970, EVOLUTION GENE DUPLI; OLAFSON RW, 1988, BIOCHEM J, V251, P691, DOI 10.1042/bj2510691; PAN PK, 1994, BIOCHEM BIOPH RES CO, V202, P621, DOI 10.1006/bbrc.1994.1973; Park JD, 2001, TOXICOLOGY, V163, P93, DOI 10.1016/S0300-483X(01)00375-4; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Peterson DS, 2002, MOL BIOCHEM PARASIT, V122, P119, DOI 10.1016/S0166-6851(02)00079-8; Piccinni E, 1999, GENE, V234, P51, DOI 10.1016/S0378-1119(99)00181-X; PICCINNI E, 1994, EUR J BIOCHEM, V226, P853, DOI 10.1111/j.1432-1033.1994.t01-1-00853.x; Robinson NJ, 2001, ADV MICROB PHYSIOL, V44, P183, DOI 10.1016/S0065-2911(01)44014-8; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rozen S, 2000, Methods Mol Biol, V132, P365; Santovito G, 2001, PROTIST, V152, P219, DOI 10.1078/1434-4610-00061; Santovito G, 2000, EUR J PROTISTOL, V36, P437, DOI 10.1016/S0932-4739(00)80049-8; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Shang YH, 2002, P NATL ACAD SCI USA, V99, P3734, DOI 10.1073/pnas.052016199; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smith JJ, 2004, NUCLEIC ACIDS RES, V32, P4313, DOI 10.1093/nar/gkh771; Tanguy A, 2001, GENE, V273, P123, DOI 10.1016/S0378-1119(01)00577-7; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Tio L, 2004, J BIOL CHEM, V279, P24403, DOI 10.1074/jbc.M401346200; Turkewitz AP, 2002, TRENDS GENET, V18, P35, DOI 10.1016/S0168-9525(01)02560-4; Valls M, 2001, J BIOL CHEM, V276, P32835, DOI 10.1074/jbc.M102151200; Verstrepen KJ, 2005, NAT GENET, V37, P986, DOI 10.1038/ng1618; Viarengo A, 2000, CELL MOL BIOL, V46, P407; Vidal F, 1993, ZYGOTE, V1, P225, DOI 10.1017/S0967199400001507; Villarreal L, 2006, FEBS J, V273, P523, DOI 10.1111/j.1742-4658.2005.05086.x; WAALKES MP, 1984, TOXICOL LETT, V20, P33, DOI 10.1016/0378-4274(84)90179-6; Wong L, 2000, GENETICS, V155, P1119; WU AL, 1993, J BIOL CHEM, V268, P18850; Wuitschick JD, 1999, J EUKARYOT MICROBIOL, V46, P239, DOI 10.1111/j.1550-7408.1999.tb05120.x; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	83	68	75	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e291	10.1371/journal.pone.0000291	http://dx.doi.org/10.1371/journal.pone.0000291			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356700	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444800014
J	Sakamoto, S; Iijima, K; Mochizuki, D; Nakamura, K; Teshigawara, K; Kobayashi, J; Matsuura, S; Tauchi, H; Komatsu, K				Sakamoto, S.; Iijima, K.; Mochizuki, D.; Nakamura, K.; Teshigawara, K.; Kobayashi, J.; Matsuura, S.; Tauchi, H.; Komatsu, K.			Homologous recombination repair is regulated by domains at the N- and C-terminus of NBS1 and is dissociated with ATM functions	ONCOGENE			English	Article						NBS1; ATM; MRE11; homologous recombination; FHA/BRCT domains	FORKHEAD-ASSOCIATED DOMAIN; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; IONIZING-RADIATION; CELLULAR-RESPONSE; GAMMA-H2AX FOCI; MRE11 COMPLEX; HISTONE H2AX; CELLS; PATHWAY	The proteins responsible for radiation sensitive disorders, NBS1, kinase ataxia- telangiectasia-( A- T)- mutated ( ATM) and MRE11, interact through the C- terminus of NBS1 in response to the generation of DNA double- strand breaks ( DSBs) and are all implicated in checkpoint regulation and DSB repair, such as homologous recombination ( HR). We measured the ability of several NBS1 mutant clones and A- T cells to regulate HR repair using the DR- GFP or SCneo systems. ATM deficiency did not reduce the HR repair frequency of an induced DSB, and it was confirmed by findings that HR frequencies are only slightly affected by deletion of ATM- binding site at the extreme C-terminus of NBS1. In contrast, The HR- regulating ability is dramatically reduced by deletion of the MRE11- binding domain at the C- terminus of NBS1 and markedly inhibited by mutations in the FHA/ BRCT domains at the N- terminus. This impaired capability in HR is consistent with a failure to observe MRE11 foci formation. Furthermore, normal HR using sister chromatid was completely inhibited by the absence of FHA/ BRCT domains. These results suggested that the N- and C- terminal domains of NBS1 are the major regulatory domains for HR pathways, very likely through the recruitment and retention of the MRE11 nuclease to DSB sites in an ATM-independent fashion.	Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan; Kyoto Univ, Ctr Radiat Biol, Dept Radiat Repair Dynam, Kyoto, Japan; Ibaraki Univ, Dept Environm Sci, Ibaraki, Japan; Lymphocyte Bank Co Ltd, Kyoto, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Hiroshima, Japan	Ibaraki University; Kyoto University; Ibaraki University; Hiroshima University	Tauchi, H (corresponding author), Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan.	htauchi@mx.ibaraki.ac.jp; komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Sakamoto, Shuichi/0000-0001-9396-9475; Nakamura, Kyosuke/0000-0003-1809-639X				Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	27	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6002	6009		10.1038/sj.onc.1210428	http://dx.doi.org/10.1038/sj.onc.1210428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384674				2022-12-25	WOS:000249277200003
J	Mouri, A; Noda, Y; Hara, H; Mizoguchi, H; Tabira, T; Nabeshima, T				Mouri, Akihiro; Noda, Yukihiro; Hara, Hideo; Mizoguchi, Hiroyuki; Tabira, Takeshi; Nabeshima, Toshitaka			Oral vaccination with a viral vector containing A beta cDNA attenuates age-related A beta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model	FASEB JOURNAL			English	Article						A beta-peptide; cognitive dysfunction	ADENOASSOCIATED VIRUS VECTOR; AMYLOID PRECURSOR PROTEIN; NITRIC-OXIDE SYNTHASE; TRANSGENIC MICE; DISEASE; IMMUNIZATION; PEPTIDE; IMPAIRMENT; GENE; MICROGLIA	Immunotherapy with A beta is expected to bring great improvement for Alzheimer disease (AD). However, clinical trials have been suspended because of meningoencephalitics, which accompanied lymphocytic infiltration. We have developed an oral vaccine for AD with a recombinant adeno-associated viral vector carrying A beta cDNA (AAV/A beta). The vaccine reduces the amount of A beta deposited without lymphocytic infiltration in APP transgenic (Tg2576) mice. In the present study, Tg2576 mice showed progressive cognitive impairments in the novel object recognition test, Y-maze test, water maze test, and contextual conditioned fear learning test. A single oral administration of AAV/A beta to Tg2576 mice at the age of 10 months alleviated progressive cognitive impairment with decreased A beta deposition, insoluble A beta, soluble A beta oligomer (A beta*56), microglial attraction, and synaptic degeneration induced in the brain regions at the age of 13 months. A histological analysis with hematoxylin and eosin and an immunohistochemical analysis with antibodies against CD3, CD4, CD8, and CD19 suggested there was no lymphocytic infiltration or microhemorrhage in the brain of AAV/A beta-vaccinated Tg2576 mice at 13 months of age. Taken together, these results suggest that immunotherapy with AAV/A beta is a safe and effective treatment for AD.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Meijo Univ, Fac Pharm, Div Clin Sci & Neuropsychopharmacol, Nagoya, Aichi 468, Japan; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, Morioka, Obu, Japan	Nagoya University; Meijo University; National Center for Geriatrics & Gerontology	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp						Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Berns K I, 1979, Adv Virus Res, V25, P407, DOI 10.1016/S0065-3527(08)60574-6; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Combs CK, 2001, J NEUROSCI, V21, P1179; DICKSON DW, 1988, AM J PATHOL, V132, P86; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Enomoto T, 2005, MOL PHARMACOL, V68, P1765, DOI 10.1124/mol.105.011304; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Furlan R, 2003, BRAIN, V126, P285, DOI 10.1093/brain/awg031; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hara H, 2004, J ALZHEIMERS DIS, V6, P483; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kensil C R, 1995, Pharm Biotechnol, V6, P525; Kobayashi K, 2000, J NEUROSCI, V20, P2418; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Mamiya T, 2000, NEUROPHARMACOLOGY, V39, P2391, DOI 10.1016/S0028-3908(00)00078-2; Manabe T, 1998, NATURE, V394, P577, DOI 10.1038/29073; Matsubara E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/j.1471-4159.2003.01654.x; Maurice T, 1999, BRIT J PHARMACOL, V127, P335, DOI 10.1038/sj.bjp.0702553; Monsonego A, 2006, P NATL ACAD SCI USA, V103, P5048, DOI 10.1073/pnas.0506209103; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagai T, 2002, FASEB J, V16, P50, DOI 10.1096/fj.02-0448fje; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Ribaut-Barassin C, 2003, NEUROSCIENCE, V120, P405, DOI 10.1016/S0306-4522(03)00332-4; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Winters BD, 2005, J NEUROSCI, V25, P4243, DOI 10.1523/JNEUROSCI.0480-05.2005; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xie Z, 2002, J NEUROSCI, V22, P3484; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	48	126	142	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2135	2148		10.1096/fj.06-7685com	http://dx.doi.org/10.1096/fj.06-7685com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341681				2022-12-25	WOS:000247500300023
J	Sogaard, TMM; Svejstrup, JQ				Sogaard, T. Max M.; Svejstrup, Jesper Q.			Hyperphosphorylation of the C-terminal repeat domain of RNA polymerase II facilitates dissociation of its complex with mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING-KINASE; UBIQUITIN-PROTEIN LIGASE; SACCHAROMYCES-CEREVISIAE; FCP1 PHOSPHATASE; GENE-EXPRESSION; FISSION YEAST; LARGE SUBUNIT; IN-VITRO; TRANSCRIPTION; HOLOENZYME	The Mediator complex associates with RNA polymerase II (RNAPII) at least partly via the RNAPII C-terminal repeat domain (CTD). This association greatly stimulates the CTD kinase activity of general transcription factor TFIIH, and subsequent CTD phosphorylation is involved in triggering promoter clearance. Here, highly purified proteins and a protein dissociation assay were used to investigate whether the RNAPII.Mediator complex (holo-RNAPII) can be disrupted by CTD phosphorylation, thereby severing one of the bonds that stabilize promoter-associated initiation complexes. We report that CTD phosphorylation by the serine 5-specific TFIIH complex, or its kinase module TFIIK, is indeed sufficient to dissociate holo-RNAPII. Surprisingly, phosphorylation by the CTD serine 2-specific kinase CTDK1 also results in dissociation. Moreover, the Mediator-induced stimulation of CTD phosphorylation previously reported for TFIIH is also observed with CTDK1 kinase. An unrelated CTD-binding protein, Rsp5, is capable of stimulating this CTD kinase activity as well. These data shed new light on mechanisms that drive the RNAPII transcription cycle and suggest a mechanism for the enhancement of CTD kinase activity by the Mediator complex.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Sogaard, Teit Max Moscote/0000-0001-6224-4818; Svejstrup, Jesper/0000-0003-4964-6147				Andrau JC, 2006, MOL CELL, V22, P179, DOI 10.1016/j.molcel.2006.03.023; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Guidi BW, 2004, J BIOL CHEM, V279, P29114, DOI 10.1074/jbc.M404426200; Hallberg M, 2004, P NATL ACAD SCI USA, V101, P3370, DOI 10.1073/pnas.0400221101; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; Jones JC, 2004, J BIOL CHEM, V279, P24957, DOI 10.1074/jbc.M402218200; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kong SE, 2005, J BIOL CHEM, V280, P4299, DOI 10.1074/jbc.M411071200; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee KM, 2005, MOL BIOL CELL, V16, P2734, DOI 10.1091/mbc.E04-11-0982; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Pei Y, 2006, MOL CELL BIOL, V26, P777, DOI 10.1128/MCB.26.3.777-788.2006; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; SOMESH BP, 2007, IN PRESS CELL; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 2004, BBA-GENE STRUCT EXPR, V1677, P64, DOI 10.1016/j.bbaexp.2003.10.012; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Takagi Y, 2006, MOL CELL, V23, P355, DOI 10.1016/j.molcel.2006.06.007; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zhu XF, 2006, MOL CELL, V22, P169, DOI 10.1016/j.molcel.2006.03.032	51	86	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14113	14120		10.1074/jbc.M701345200	http://dx.doi.org/10.1074/jbc.M701345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376774	hybrid			2022-12-25	WOS:000246245800021
J	Ao, ZJ; Huang, GY; Yao, H; Xu, ZK; Labine, M; Cochrane, AW; Yao, XJ				Ao, Zhujun; Huang, Guanyou; Yao, Han; Xu, Zaikun; Labine, Meaghan; Cochrane, Alan W.; Yao, Xiaojian			Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL DNA FLAP; HIV-1 INTEGRASE; REVERSE TRANSCRIPTION; LOCALIZATION SIGNAL; NONDIVIDING CELLS; VIRION INCORPORATION; GENETIC ANALYSES; MATRIX PROTEIN; INFECTION; BETA	Similar to all other viruses, human immunodeficiency virus type 1 ( HIV-1) depends heavily on cellular factors for its successful replication. In this study we have investigated the interaction of HIV-1 integrase (IN) with several host nuclear import factors using co-immunoprecipitation assays. Our results indicate that IN interacts specifically with host importin 7 (Imp7) in vivo, but does not interact with importin 8 (Imp8) or importin alpha(Rch1). In contrast, another HIV-1 karyophilic protein MAp17, which is capable of binding Rch1, fails to interact with Imp7, suggesting that IN and Map17 may interact with different cellular pathways during HIV-1 replication. Genetic analysis revealed that the C-terminal domain of IN is the region responsible for interaction between IN with Imp7, and an IN mutant (K240A, K244A/ R263A, K264A) disrupted the Imp7 binding ability of the protein, indicating that both regions ((235)WKGPAKLLWKG and (262)RRKAK) within the C-terminal domain of IN are required for efficient IN/Imp7 interaction. Using a vesicular stomatitis virus G glycoprotein pseudotyped HIV single-cycle replication system, we showed that the IN/Imp7 interaction-deficient mutant was unable to mediate viral replication and displayed impairment at both viral reverse transcription and nuclear import steps. Moreover, transient knockdown of Imp7 in both HIV-1 producing and target cells resulted in a 2.5 - 3.5-fold inhibition of HIV infection. Altogether, our results indicate that HIV-1 IN specifically interacts with Imp7, and this viral/cellular protein interaction contributes to efficient HIV-1 infection.	Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB R3E 0W3, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3G 1J4, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Manitoba; Universite de Montreal; University of Toronto	Yao, XJ (corresponding author), Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB R3E 0W3, Canada.	yao2@cc.umanitoba.ca		Yao, Xiaojian/0000-0002-5022-1309				Ao Z, 2004, J VIROL, V78, P3170, DOI 10.1128/JVI.78.6.3170-3177.2004; Ao ZJ, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-62; Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Bukrinsky M, 2004, MOL MED, V10, P1; Bukrinsky MI, 1998, MOL MED, V4, P138, DOI 10.1007/BF03401911; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Busschots K, 2005, J BIOL CHEM, V280, P17841, DOI 10.1074/jbc.M411681200; Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; Dean KA, 2001, J CELL SCI, V114, P3479; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fridell RA, 1997, J CELL SCI, V110, P1325; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hearps AC, 2006, BIOCHEM J, V398, P475, DOI 10.1042/BJ20060466; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Ikeda T, 2004, J VIROL, V78, P11563, DOI 10.1128/JVI.78.21.11563-11573.2004; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lu R, 2005, J VIROL, V79, P10356, DOI 10.1128/JVI.79.16.10356-10368.2005; Lu R, 2004, J VIROL, V78, P12735, DOI 10.1128/JVI.78.23.12735-12746.2004; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nakajima N, 2001, J VIROL, V75, P7944, DOI 10.1128/JVI.75.17.7944-7955.2001; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pluymers Wim, 2001, Current Drug Targets - Infectious Disorders, V1, P133, DOI 10.2174/1568005014606044; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Sirven A, 2000, BLOOD, V96, P4103; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vandegraaff N, 2006, VIROLOGY, V346, P415, DOI 10.1016/j.virol.2005.11.022; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Vodicka Marie A., 2001, Somatic Cell and Molecular Genetics, V26, P35, DOI 10.1023/A:1021022629126; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004; Zielske SP, 2005, J VIROL, V79, P11541, DOI 10.1128/JVI.79.17.11541-11546.2005	58	85	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13456	13467		10.1074/jbc.M610546200	http://dx.doi.org/10.1074/jbc.M610546200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360709	hybrid			2022-12-25	WOS:000246060300035
J	Gerbino, A; Fistetto, G; Colella, M; Hofer, AM; Debellis, L; Caroppo, R; Curci, S				Gerbino, Andrea; Fistetto, Gregorio; Colella, Matilde; Hofer, Aldebaran M.; Debellis, Lucantonio; Caroppo, Rosa; Curci, Silvana			Real time measurements of water flow in amphibian gastric glands - Modulation via the extracellular Ca2+-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CHANNEL-RELATED PROTEIN; ACID-SECRETION; PARIETAL-CELLS; ALKALINE SECRETION; APICAL MEMBRANE; OXYNTIC CELLS; K+ CHANNEL; OXYNTOPEPTIC CELLS; OSMOTIC FLOW	The mechanisms for the formation of the osmotic gradient driving water movements in the gastric gland and its modulation via the extracellular Ca2+-sensing receptor (CaR) were investigated. Real time measurements of net water flux in the lumen of single gastric glands of the intact amphibian stomach were performed using ion-selective double-barreled microelectrodes. Water movement was measured by recording changes in the concentration of impermeant TEA(+) ions ([TEA(+)](gl)) with TEA(+)-sensitive microelectrodes inserted in the lumen of individual gastric glands. Glandular K+ (K-gl(+)) and H+ (pH(gl)) were also measured by using K+- and H+-sensitive microelectrodes, respectively. Stimulation with histamine significantly decreased [TEA](gl), indicating net water flow toward the gland lumen. This response was inhibited by the H+/K+- ATPase inhibitor, SCH 28080. Histamine also elicited a significant and reversible increase in [K+](gl) that was blocked by chromanol 293B, a blocker of KCQN1 K+ channels. Histamine failed to induce net water flow in the presence of chromanol 293B. In the "resting state," stimulation of CaR with diverse agonists resulted in significant increase in [TEA](gl). CaR activation also significantly reduced histamine-induced water secretion and apical K+ transport. Our data validate the strong link between histamine-stimulated acid secretion and water transport. We also show that cAMP-dependent [K+](gl) elevation prior to the onset of acid secretion generates the osmotic gradient initially driving water into the gastric glands and that CaR activation inhibits this process, probably through reduction of intracellular cAMP levels.	Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, W Roxbury, MA 02132 USA; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Universita degli Studi di Bari Aldo Moro	Curci, S (corresponding author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	scurci@rics.bwh.harvard.edu	Gerbino, Andrea/Y-6526-2018; Colella, Matilde/G-9246-2011	Gerbino, Andrea/0000-0002-2839-0130; Colella, Matilde/0000-0002-9584-7030; Debellis, Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985				BERGLINDH T, 1980, AM J PHYSIOL, V238, P165; Bijvelds MJC, 2005, AM J PHYSIOL-GASTR L, V289, pG870, DOI 10.1152/ajpgi.00226.2005; Bleich M, 1997, PFLUG ARCH EUR J PHY, V434, P499, DOI 10.1007/s004240050427; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; Caroppo R, 2004, J CELL BIOL, V166, P111, DOI 10.1083/jcb.200310145; Caroppo R, 2001, EMBO J, V20, P6316, DOI 10.1093/emboj/20.22.6316; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; CHEBABO SR, 1995, J PHYSIOL-LONDON, V487, P685, DOI 10.1113/jphysiol.1995.sp020910; CHEW CS, 1980, AM J PHYSIOL, V238, P312; CUPPOLETTI J, 1993, AM J PHYSIOL, V264, pC1609, DOI 10.1152/ajpcell.1993.264.6.C1609; CUPPOLETTI J, 1984, J BIOL CHEM, V259, P4952; DEBELLIS L, 1990, AM J PHYSIOL, V258, pG631, DOI 10.1152/ajpgi.1990.258.4.G631; DEBELLIS L, 1994, PFLUG ARCH EUR J PHY, V428, P655, DOI 10.1007/BF00374590; Debellis L, 2001, AM J PHYSIOL-GASTR L, V281, pG1440, DOI 10.1152/ajpgi.2001.281.6.G1440; DEBELLIS L, 1992, PFLUG ARCH EUR J PHY, V422, P253, DOI 10.1007/BF00376210; Debellis L, 1998, J PHYSIOL-LONDON, V513, P235, DOI 10.1111/j.1469-7793.1998.235by.x; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; DURBIN RP, 1979, AM J PHYSIOL, V236, pE63, DOI 10.1152/ajpendo.1979.236.1.E63; DURBIN RP, 1956, J GEN PHYSIOL, V39, P535, DOI 10.1085/jgp.39.4.535; FINKELSTEIN A, 1987, DISTINGUISHED LECTUR, V4, P1; FLEMSTROM G, 1977, AM J PHYSIOL, V233, pE1, DOI 10.1152/ajpendo.1977.233.1.E1; FLEMSTROM G, 1982, AM J PHYSIOL, V242, P183; FORTE JG, 1975, J PHYSIOL-LONDON, V244, P33, DOI 10.1113/jphysiol.1975.sp010783; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; FORTE JG, 1980, ANNU REV PHYSIOL, V42, P111, DOI 10.1146/annurev.ph.42.030180.000551; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; Fujiwara K, 1996, HISTOCHEM CELL BIOL, V106, P465, DOI 10.1007/s004180050065; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015; HEINZ E, 1954, PHYSIOL REV, V34, P643, DOI 10.1152/physrev.1954.34.4.643; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hofer AM, 2005, J CELL SCI, V118, P855, DOI 10.1242/jcs.01705; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; HOGBEN CAM, 1955, AM J PHYSIOL, V180, P641; HOLM L, 1990, J INTERN MED S, V732, P91; Lambrecht NWG, 2005, PHYSIOL GENOMICS, V21, P81, DOI 10.1152/physiolgenomics.00212.2004; LOGSDON CD, 1982, AM J PHYSIOL, V242, pG388, DOI 10.1152/ajpgi.1982.242.4.G388; MALINOWSKA DH, 1983, AM J PHYSIOL, V245, pG573, DOI 10.1152/ajpgi.1983.245.4.G573; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MALINOWSKA DH, 2004, AM J PHYSIOL, V286, pG495; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; McDaniel N, 2005, AM J PHYSIOL-GASTR L, V289, pG550, DOI 10.1152/ajpgi.00095.2005; Mizukawa Y, 2002, AM J PHYSIOL-CELL PH, V282, pC786, DOI 10.1152/ajpcell.00239.2001; MOODY FG, 1969, AM J PHYSIOL, V217, P255, DOI 10.1152/ajplegacy.1969.217.1.255; Nakahari T, 1997, EXP PHYSIOL, V82, P55, DOI 10.1113/expphysiol.1997.sp004015; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; NICHOLSON C, 1993, J NEUROSCI METH, V48, P199, DOI 10.1016/0165-0270(93)90092-6; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; Ochi Y, 2005, LIFE SCI, V77, P2040, DOI 10.1016/j.lfs.2005.04.006; OKADA Y, 1984, J PHYSIOL-LONDON, V354, P109, DOI 10.1113/jphysiol.1984.sp015366; ORKAND RK, 1984, NEUROSCI LETT, V45, P273, DOI 10.1016/0304-3940(84)90238-6; POWELL DW, 1964, AM J PHYSIOL, V207, P868, DOI 10.1152/ajplegacy.1964.207.4.868; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; REENSTRA WW, 1990, AM J PHYSIOL, V259, pG850, DOI 10.1152/ajpgi.1990.259.5.G850; REHM WS, 1970, J THEOR BIOL, V27, P433, DOI 10.1016/S0022-5193(70)80008-X; REHM WS, 1953, AM J PHYSIOL, V175, P473, DOI 10.1152/ajplegacy.1953.175.3.473; Richter C, 1998, BIOCHEM J, V335, P481, DOI 10.1042/bj3350481; RUIZ MC, 1993, AM J PHYSIOL, V265, pG934, DOI 10.1152/ajpgi.1993.265.5.G934; SACHS G, 1976, J BIOL CHEM, V251, P7690; Sachs G, 1997, ANNU REV PHYSIOL, V59, P243, DOI 10.1146/annurev.physiol.59.1.243; Schubert ML, 2005, CURR OPIN GASTROEN, V21, P636, DOI 10.1097/01.mog.0000181713.89281.14; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; UEDA S, 1989, BIOCHIM BIOPHYS ACTA, V1012, P254, DOI 10.1016/0167-4889(89)90105-5; VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776; VILLEGAS L, 1971, AM J PHYSIOL, V220, P1282, DOI 10.1152/ajplegacy.1971.220.5.1282; VILLEGAS L, 1982, BIOCHIM BIOPHYS ACTA, V685, P249, DOI 10.1016/0005-2736(82)90064-5; VILLEGAS L, 1974, AM J PHYSIOL, V226, P1338, DOI 10.1152/ajplegacy.1974.226.6.1338; VILLEGAS L, 1968, AM J PHYSIOL, V214, P997, DOI 10.1152/ajplegacy.1968.214.5.997; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; Wang KS, 2000, AM J PHYSIOL-GASTR L, V279, pG448, DOI 10.1152/ajpgi.2000.279.2.G448; WOLOSIN JM, 1984, AM J PHYSIOL, V246, pG537; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; ZEUTHEN T, 1994, J PHYSIOL-LONDON, V478, P203, DOI 10.1113/jphysiol.1994.sp020243; ZHNG EB, 1996, GASTROINTESTINAL HEP, P91	82	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13477	13486		10.1074/jbc.M610585200	http://dx.doi.org/10.1074/jbc.M610585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363364	hybrid			2022-12-25	WOS:000246060300037
J	Gorner, K; Holtorf, E; Waak, J; Pham, TT; Vogt-Weisenhorn, DM; Wurst, W; Haass, C; Kahle, PJ				Goerner, Karin; Holtorf, Eve; Waak, Jens; Pham, Thu-Trang; Vogt-Weisenhorn, Daniela M.; Wurst, Wolfgang; Haass, Christian; Kahle, Philipp J.			Structural determinants of the C-terminal helix-kink-helix motif essential for protein stability and survival promoting activity of DJ-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PARKINSONS-DISEASE; RESOLUTION CRYSTAL-STRUCTURE; EARLY-ONSET PARKINSONISM; TUMOR-SUPPRESSOR PTEN; OXIDATIVE STRESS; DROSOPHILA DJ-1; CELL-DEATH; ESCHERICHIA-COLI; ALPHA-SYNUCLEIN; APOPTOSIS	Mutations in the PARK7 gene encoding DJ-1 cause autosomal recessive Parkinson disease. The most deleterious point mutation is the L166P substitution, which resides in a structure motif comprising two alpha-helices (G and H) separated by a kink. Here we subjected the C-terminal helix-kink-helix motif to systematic site-directed mutagenesis, introducing helix-incompatible proline residues as well as conservative substitutions into the helical interface. Furthermore, we generated deletion mutants lacking the H-helix, the kink, and the entire C terminus. When transfected into neural and non-neural cell lines, steady-state levels of G-helix breaking and kink deletion mutants were dramatically lower than wildtype DJ-1. The effects of H-helix breakers were comparably smaller, and the non-helix breaking mutants only slightly destabilized DJ-1. The decreased steady-state levels were due to accelerated protein degradation involving in part the proteasome. G-helix breaking DJ-1 mutations abolished dimer formation. These structural perturbations had functional consequences on the cytoprotective activities of DJ-1. The destabilizing mutations conferred reduced cytoprotection against H2O2 in transiently retransfected DJ-1 knock-out mouse embryonic fibroblasts. The loss of survival promoting activity of the DJ-1 mutants with destabilizing C-terminal mutations correlated with impaired anti-apoptotic signaling. We found that wild-type, but not mutant DJ-1 facilitated the Akt pathway and simultaneously blocked the apoptosis signal-regulating kinase 1, with which DJ-1 interacted in a redox-dependent manner. Thus, the G-helix and kink are critical determinants of the C-terminal helix-kink-helix motif, which is absolutely required for stability and the regulation of survival-promoting redox signaling of the Parkinson disease-associated protein DJ-1.	Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Dev Genet, D-85764 Neuherberg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kahle, PJ (corresponding author), Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, Otfried Muller Str 27, D-72076 Tubingen, Germany.	Philipp.Kahle@uni-tuebingen.de		Wurst, Wolfgang/0000-0003-4422-7410; Vogt Weisenhorn, Daniela/0000-0002-4566-6506				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Bandyopadhyay S, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-6; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Cookson MR, 2003, P NATL ACAD SCI USA, V100, P9111, DOI 10.1073/pnas.1633722100; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Heales SJR, 2004, NEUROCHEM RES, V29, P513, DOI 10.1023/B:NERE.0000014822.69384.0f; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li HM, 2005, FREE RADICAL RES, V39, P1091, DOI 10.1080/10715760500260348; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lockhart PJ, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011106; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Menzies FM, 2005, CURR BIOL, V15, P1578, DOI 10.1016/j.cub.2005.07.036; Meulener M, 2005, CURR BIOL, V15, P1572, DOI 10.1016/j.cub.2005.07.064; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Nishinaga H, 2005, NEUROSCI LETT, V390, P54, DOI 10.1016/j.neulet.2005.07.053; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Ooe H, 2005, TOXICOL SCI, V88, P114, DOI 10.1093/toxsci/kfi278; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shinbo YM, 2005, INT J ONCOL, V26, P641; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Wilson MA, 2005, J MOL BIOL, V353, P678, DOI 10.1016/j.jmb.2005.08.033; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.jmb.2005.12.030; Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200	52	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13680	13691		10.1074/jbc.M609821200	http://dx.doi.org/10.1074/jbc.M609821200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17331951	hybrid			2022-12-25	WOS:000246060300058
J	Granier, S; Kim, S; Shafer, AM; Ratnala, VRP; Fung, JJ; Zare, RN; Kobilka, B				Granier, Sebastien; Kim, Samuel; Shafer, Aaron M.; Ratnala, Venkata R. P.; Fung, Juan Jose; Zare, Richard N.; Kobilka, Brian			Structure and conformational changes in the C-terminal domain of the beta(2)-adrenoceptor - Insights from fluorescence resonance energy transfer studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT CHANGES; BETA-2-ADRENERGIC RECEPTOR; PALMITOYLATION SITES; CYTOPLASMIC END; LIVING CELLS; HELIX VII; ACTIVATION; RHODOPSIN	The C terminus of the beta(2)-adrenoceptor (AR) interacts with G protein-coupled receptor kinases and arrestins in an agonist-dependent manner, suggesting that conformational changes induced by ligands in the transmembrane domains are transmitted to the C terminus. We used fluorescence resonance energy transfer (FRET) to examine ligand-induced structural changes in the distance between two positions on the beta(2)-AR C terminus and cysteine 265 (Cys-265) at the cytoplasmic end of transmembrane domain 6. The donor fluorophore FlAsH ( Fluorescein Arsenical Helix binder) was attached to a CCPGCC motif introduced at position 351-356 in the proximal C terminus or at the distal C terminus. An acceptor fluorophore, Alexa Fluor 568, was attached to Cys-265. FRET analyses revealed that the average distances between Cys-265 and the proximal and distal FlAsH sites were 57 and 62 A, respectively. These relatively large distances suggest that the C terminus is in an extended, relatively unstructured conformation. Nevertheless, we observed ligand-specific changes in FRET. All ligands induced an increase in FRET between the proximal C-terminal FlAsH site and Cys-265. Ligands that have been shown to induce arrestin-dependent ERK activation, including the catecholamine agonists and the inverse agonist ICI118551, led to a decrease in FRET between the distal FlAsH site and Cys-265, whereas other ligands had no effect or induced a small increase in FRET. Taken together the results provide new insight into the structure of the C terminus of the beta(2)-AR as well as ligand-induced conformational changes that may be relevant to arrestin-dependent regulation and signaling.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Kobilka, B (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Rm B157 Beckman Ctr,279 Campus Dr, Stanford, CA 94305 USA.	kobilka@stanford.edu	Kim, Samuel C/ABF-6326-2021; Granier, Sebastien/J-1089-2016; Zare, Richard N./A-8410-2009	Kim, Samuel C/0000-0001-5237-6358; Zare, Richard/0000-0001-5266-4253; Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [R37NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CHEN RF, 1965, SCIENCE, V150, P1593, DOI 10.1126/science.150.3703.1593; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Ha TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/pnas.96.3.893; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, V2nd, DOI 10.1007/978-0-387-46312-4; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Magde D, 2002, PHOTOCHEM PHOTOBIOL, V75, P327, DOI 10.1562/0031-8655(2002)075<0327:FQYATR>2.0.CO;2; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801	31	134	141	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13895	13905		10.1074/jbc.M611904200	http://dx.doi.org/10.1074/jbc.M611904200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347144	Green Submitted, hybrid			2022-12-25	WOS:000246060300079
J	Schaub, MC; Lopez, SR; Caputi, M				Schaub, Michael C.; Lopez, Suzette R.; Caputi, Massimo			Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP-H; TAT EXON-2; REGULATORY ELEMENTS; A/B PROTEINS; SR PROTEINS; BINDING; SILENCER; A1; CLEAVAGE	In this study we analyzed members of the heterogeneous nuclear ribonucleoprotein ( hnRNP) H protein family to determine their RNA binding specificities and roles in splicing regulation. Our data indicate that hnRNPs H, H', F, 2H9, and GRSF-1 bind the consensus motif DGGGD (where D is U, G, or A) and aggregate in a multimeric complex. We analyzed the role of these proteins in the splicing of a substrate derived from the HIV-1 tat gene and have shown that hnRNP H family members are required for efficient splicing of this substrate. The hnRNP H protein family members activated splicing of the viral substrate by promoting the formation of ATP-dependent spliceosomal complexes. Mutational analysis of six consensus motifs present within the intron of the substrate indicated that only one of these motifs acts as an intronic splicing enhancer.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University	Caputi, M (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	mcaputi@fau.edu			NIAID NIH HHS [R01AI052820] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052820] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkan SA, 2006, BIOCHEM J, V393, P361, DOI 10.1042/BJ20050538; AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; Buratti E, 2004, NUCLEIC ACIDS RES, V32, P4224, DOI 10.1093/nar/gkh752; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 2004, J VIROL, V78, P6517, DOI 10.1128/JVI.78.12.6517-6526.2004; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Das R, 1999, RNA, V5, P1504, DOI 10.1017/S1355838299991501; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Gamberi C, 1997, MOL CELL BIOL, V17, P2587, DOI 10.1128/MCB.17.5.2587; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Hallay H, 2006, J BIOL CHEM, V281, P37159, DOI 10.1074/jbc.M603864200; Han K, 2005, PLOS BIOL, V3, P843, DOI 10.1371/journal.pbio.0030158; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Honore B, 2004, EXP CELL RES, V294, P199, DOI 10.1016/j.yexcr.2003.11.011; House AE, 2006, NAT STRUCT MOL BIOL, V13, P937, DOI 10.1038/nsmb1149; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kim DH, 2005, NUCLEIC ACIDS RES, V33, P3866, DOI 10.1093/nar/gki698; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MARCUCCI R, 2006, NUCL ACIDS RES; Martinez-Contreras R, 2006, PLOS BIOL, V4, P172, DOI 10.1371/journal.pbio.0040021; Mayeda A, 1999, METH MOL B, V118, P309; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Park YW, 1999, P NATL ACAD SCI USA, V96, P6694, DOI 10.1073/pnas.96.12.6694; Sharma S, 2005, MOL CELL, V19, P485, DOI 10.1016/j.molcel.2005.07.014; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Tange TO, 2001, EMBO J, V20, P5748; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Yeo G, 2004, P NATL ACAD SCI USA, V101, P15700, DOI 10.1073/pnas.0404901101; Yoshida T, 1999, GENES CELLS, V4, P707, DOI 10.1046/j.1365-2443.1999.00295.x; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zhang YZ, 2000, GENE, V257, P33, DOI 10.1016/S0378-1119(00)00372-3; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	44	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13617	13626		10.1074/jbc.M700774200	http://dx.doi.org/10.1074/jbc.M700774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337441	hybrid			2022-12-25	WOS:000246060300051
J	Basler, M; Knapp, O; Masin, J; Fiser, R; Maier, E; Benz, R; Sebo, P; Osicka, R				Basler, Marek; Knapp, Oliver; Masin, Jiri; Fiser, Radovan; Maier, Elke; Benz, Roland; Sebo, Peter; Osicka, Radim			Segments crucial for membrane translocation and pore-forming activity of Bordetella adenylate cyclase toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-INVASIVE ACTIVITY; ESCHERICHIA-COLI; HEMOLYTIC ACTIVITIES; FATTY-ACYLATION; TARGET-CELLS; PERTUSSIS; CALMODULIN; IDENTIFICATION; SECRETION; PROTEIN	Bordetella adenylate cyclase toxin-hemolysin ( CyaA, AC-Hly, or ACT) permeabilizes cell membranes by forming small cation-selective ( hemolytic) pores and subverts cellular signaling by delivering into host cells an adenylate cyclase ( AC) enzyme that converts ATP to cAMP. Both AC delivery and pore formation were previously shown to involve a predicted amphipathic alpha-helix(502-522) containing a pair of negatively charged Glu(509) and Glu(516) residues. Another predicted transmembrane alpha-helix(565-591) comprises a Glu(570) and Glu(581) pair. We examined the roles of these glutamates in the activity of CyaA. Substitutions of Glu(516) increased specific hemolytic activity of CyaA by two different molecular mechanisms. Replacement of Glu(516) by positively charged lysine residue ( E516K) increased the propensity of CyaA to form pores, whereas proline ( E516P) or glutamine ( E516Q) substitutions extended the lifetime of open single pore units. All three substitutions also caused a drop of pore selectivity for cations. Substitutions of Glu(570) and Glu(581) by helix-breaking proline or positively charged lysine residue reduced ( E570K, E581P) or ablated ( E570P, E581K) AC membrane translocation. Moreover, E570P, E570K, and E581P substitutions down-modulated also the specific hemolytic activity of CyaA. In contrast, the E581K substitution enhanced the hemolytic activity of CyaA 4 times, increasing both the frequency of formation and lifetime of toxin pores. Negative charge at position 570, but not at position 581, was found to be essential for cation selectivity of the pore, suggesting a role of Glu(570) in ion filtering inside or close to pore mouth. The pairs of glutamate residues in the predicted transmembrane segments of CyaA thus appear to play a key functional role in membrane translocation and pore-forming activities of CyaA.	Acad Sci Czech Republ, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, CZ-12844 Prague 2, Czech Republic; Univ Wurzburg, Theodor Boveri Inst, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Charles University Prague; University of Wurzburg	Osicka, R (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	osicka@biomed.cas.cz	Osicka, Radim/H-6776-2014; Basler, Marek/A-3559-2012; Fiser, Radovan/E-4908-2012; SEBO, Peter/F-7423-2011; Masin, Jiri/H-3125-2014; SEBO, Peter/N-2043-2019	Osicka, Radim/0000-0003-2626-5456; Basler, Marek/0000-0001-5414-2088; Fiser, Radovan/0000-0003-4516-0086; SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Masin, Jiri/0000-0001-6258-4599; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P239; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1989, J BIOL CHEM, V264, P14792; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; LADANT D, 1988, J BIOL CHEM, V263, P2612; MASURE HR, 1990, BIOCHEMISTRY-US, V29, P140, DOI 10.1021/bi00453a017; Osickova A, 1999, J BIOL CHEM, V274, P37644; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SZABO G, 1994, J BIOL CHEM, V269, P22496; WEISS J, 1986, BIOCHEM BIOPH RES CO, V136, P463, DOI 10.1016/0006-291X(86)90463-8; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	41	58	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12419	12429		10.1074/jbc.M611226200	http://dx.doi.org/10.1074/jbc.M611226200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347146	hybrid			2022-12-25	WOS:000245942800010
J	Iwai, M; Michikawa, T; Bosanac, I; Ikura, M; Mikoshiba, K				Iwai, Miwako; Michikawa, Takayuki; Bosanac, Ivan; Ikura, Mitsuhiko; Mikoshiba, Katsuhiko			Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR DOMAIN; XENOPUS OOCYTES; CALCIUM; SITE; SEQUENCE; COMPLEX; TYPE-3; CELLS	Three isoforms of the inositol 1,4,5-trisphosphate ( IP3) receptor ( IP3R), IP(3)R1, IP(3)R2, and IP(3)R3, have different IP3-binding affinities and cooperativities. Here we report that the amino-terminal 604 residues of three mouse IP3R types exhibited K-d values of 49.5 +/- 10.5, 14.0 +/- 3.5, and 163.0 +/- 44.4 nM, which are close to the intrinsic IP3-binding affinity previously estimated from the analysis of full-length IP(3)Rs. In contrast, residues 224-604 of IP(3)R1 and IP(3)R2 and residues 225-604 of IP(3)R3, which contain the IP3-binding core domain but not the suppressor domain, displayed an almost identical IP3-binding affinity with a K-d value of similar to 2 nM. Addition of 100-fold excess of the suppressor domain did not alter the IP3-binding affinity of the IP3-binding core domain. Artificial chimeric proteins in which the suppressor domain was fused to the IP3-binding core domain from different isoforms exhibited IP3-binding affinity significantly different from those of the proteins composed of the native combination of the suppressor domain and the IP3-binding core domain. Systematic mutagenesis analyses showed that amino acid residues critical for type-3 receptor-specific IP3-binding affinity are involved in Glu-39, Ala-41, Asp-46, Met-127, Ala-154, Thr-155, Leu-162, Trp-168, Asn-173, Asn-176, and Val-179. These results indicate that the IP3-binding affinity of IP(3)Rs is specifically tuned through the intramolecular attenuation of IP3-binding affinity of the IP3-binding core domain by the aminoterminal suppressor domain. Moreover, the functional diversity in ligand sensitivity among IP3R isoforms originates from at least the structural difference identified on the suppressor domain.	Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Div Signaling Biol, Toronto, ON M5G 1L7, Canada	University of Tokyo; RIKEN; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Michikawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takamich@ims.u-tokyo.ac.jp; mikosiba@ims.u-tokyo.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015	Ikura, Mitsuhiko/0000-0002-9524-1303				BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iwai M, 2005, J BIOL CHEM, V280, P10305, DOI 10.1074/jbc.M413824200; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; Matsu-ura T, 2006, J CELL BIOL, V173, P755, DOI 10.1083/jcb.200512141; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Szlufcik K, 2006, CELL CALCIUM, V39, P325, DOI 10.1016/j.ceca.2005.11.007; Taylor Colin W., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	24	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12755	12764		10.1074/jbc.M609833200	http://dx.doi.org/10.1074/jbc.M609833200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327232	hybrid			2022-12-25	WOS:000245942800046
J	Pucci, B; De Felice, M; Rocco, M; Esposito, F; De Falco, M; Esposito, L; Rossi, M; Pisani, FM				Pucci, Biagio; De Felice, Mariarita; Rocco, Monia; Esposito, Francesco; De Falco, Mariarosaria; Esposito, Luca; Rossi, Mose; Pisani, Francesca M.			Modular organization of the Sulfolobus solfataricus mini-chromosome maintenance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITY; MCM HELICASE; BIOCHEMICAL-ANALYSIS; ARCHAEAL MCM; COMPLEX; POLYMORPHISM	Mini-chromosome maintenance ( MCM) proteins form ring-like hexameric complexes that are commonly believed to act as the replicative DNA helicase at the eukaryotic/archaeal DNA replication fork. Because of their simplified composition with respect to the eukaryotic counterparts, the archaeal MCM complexes represent a good model system to use in analyzing the structural/functional relationships of these important replication factors. In this study the domain organization of the MCM-like protein from Sulfolobus solfataricus ( Sso MCM) has been dissected by trypsin partial proteolysis. Three truncated derivatives of Sso MCM corresponding to protease-resistant domains were produced as soluble recombinant proteins and purified: the N-terminal domain ( N-ter, residues 1-268); a fragment comprising the AAA+ and C-terminal domains ( AAA+-C-ter, residues 269-686); and the C-terminal domain ( C-ter, residues 504-686). All of the purified recombinant proteins behaved as monomers in solution as determined by analytical gel filtration chromatography, suggesting that the polypeptide chain integrity is required for stable oligomerization of Sso MCM. However, the AAA+-C-ter derivative, which includes the AAA+ motor domain and retains ATPase activity, was able to form dimers in solution when ATP was present, as analyzed by size exclusion chromatography and glycerol gradient sedimentation analyses. Interestingly, the AAA+-C-ter protein could displace oligonucleotides annealed to M13 single-stranded DNA although with a reduced efficiency in comparison with the full-sized Sso MCM. The implications of these findings for understanding the DNA helicase mechanism of the MCM complex are discussed.	CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	fm.pisani@ibp.cnr.it	Pisani, Francesca M./AAX-4025-2020; Pucci, Biagio/AAS-7502-2021; pucci, biagio/AAA-9268-2020	pucci, biagio/0000-0003-4502-1748				Barry ER, 2007, NUCLEIC ACIDS RES, V35, P988, DOI 10.1093/nar/gkl1117; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Costa A, 2006, NUCLEIC ACIDS RES, V34, P5829, DOI 10.1093/nar/gkl708; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; ERZBERGER JP, 2006, ANNU REV BIOPH BIOM, V85, P91; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; GABROWSKI B, 2003, ANNU REV MICROBIOL, V57, P487; Gomez-Llorente Y, 2005, J BIOL CHEM, V280, P40909, DOI 10.1074/jbc.M509760200; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kasiviswanathan R, 2004, J BIOL CHEM, V279, P28358, DOI 10.1074/jbc.M403202200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McGeoch AT, 2005, NAT STRUCT MOL BIOL, V12, P756, DOI 10.1038/nsmb974; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pucci B, 2004, J BIOL CHEM, V279, P49222, DOI 10.1074/jbc.M408967200; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	31	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12574	12582		10.1074/jbc.M610953200	http://dx.doi.org/10.1074/jbc.M610953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337732	hybrid			2022-12-25	WOS:000245942800026
J	Zhang, AS; Anderson, SA; Meyers, KR; Hernandez, C; Eisenstein, RS; Enns, CA				Zhang, An-Sheng; Anderson, Sheila A.; Meyers, Kathrin R.; Hernandez, Catalina; Eisenstein, Richard S.; Enns, Caroline A.			Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; MORPHOGENETIC PROTEIN CORECEPTOR; JUVENILE HEMOCHROMATOSIS; EXPRESSION PATTERN; RAT-LIVER; MOUSE; GENE; HEPCIDIN; RGM; METABOLISM	Hemojuvelin ( HJV), encoded by the gene HFE2, is a critical upstream regulator of hepcidin expression. Hepcidin, the central iron regulatory hormone, is secreted from hepatocytes, whereas HFE2 is highly expressed in skeletal muscle and liver. Previous studies demonstrated that HJV is a GPI-anchored protein, binds the proteins neogenin and bone morphogenetic proteins ( BMP2 and BMP4), and can be released from the cell membrane ( shedding). In this study, we investigated the physiological significance and the underlying mechanism of HJV shedding. In acutely iron-deficient rats with markedly suppressed hepatic hepcidin expression, we detected an early phase increase of serum HJV with no significant change of either HFE2 mRNA or protein levels in gastrocnemius muscle. Studies in both C2C12 ( a mouse myoblast cell line) and HepG2 ( a human hepatoma cell line) cells showed active HJV shedding, implying that both skeletal muscle and liver could be the source of serum HJV. In agreement with the observations in iron-deficient rats, HJV shedding in these cell lines was down-regulated by holo-transferrin in a concentration-dependent manner. Our present study showing that knockdown of endogenous neogenin, a HJV receptor, in C2C12 cells suppresses HJV shedding and that overexpression of neogenin in HEK293 cells markedly enhances this process, suggests that membrane HJV shedding is mediated by neogenin. The finding that neither BMP4 nor its antagonist, noggin, was able to alter HJV shedding support the lack of involvement of BMP signaling pathway in this process.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, Portland, OR 97239 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison	Zhang, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhanga@ohsu.edu			NIDDK NIH HHS [DK066600, DK54488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK066600, R37DK054488, R01DK066600, R01DK054488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Fairbanks VF, 1994, MODERN NUTR HLTH DIS, P185; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang FW, 2005, J CLIN INVEST, V115, P2187, DOI 10.1172/JCI25049; Johnson MB, 2004, BLOOD, V104, P4287, DOI 10.1182/blood-2004-06-2477; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Kuninger D, 2004, GENOMICS, V84, P876, DOI 10.1016/j.ygeno.2004.07.013; Kuninger D, 2006, J CELL SCI, V119, P3273, DOI 10.1242/jcs.03074; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2005, J BIOL CHEM, V280, P33885, DOI 10.1074/jbc.M506207200	42	94	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12547	12556		10.1074/jbc.M608788200	http://dx.doi.org/10.1074/jbc.M608788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331953	hybrid			2022-12-25	WOS:000245942800023
J	Gendra, E; Colgan, DF; Meany, B; Konarska, MM				Gendra, Elisenda; Colgan, Diana F.; Meany, Brendan; Konarska, Maria M.			A sequence motif in the simian virus 40 (SV40) early core promoter affects alternative splicing of transcribed mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; SITE SELECTION; IN-VIVO; ELONGATION-FACTORS; GENE-EXPRESSION; FACT COMPLEX; U6 SNRNA; INITIATION; PROTEIN; DNA	To identify new sequence elements in the promoter that affect splicing patterns of pre-mRNAs, we analyzed effects of different promoters on alternative splicing of model reporter genes. We compared the E1a alternative splicing pattern in transcripts expressed from the full-length cytomegalovirus, SV40 early, or a hybrid cytomegalovirus/SV40 early promoter and found that the hybrid promoter improved selection of the suboptimal E1a 5'SS-1. Expressing RNA from the hybrid promoter also enhanced selection of suboptimal splice sites in other alternatively spliced reporter genes, demonstrating the generality of this effect. Unlike previously defined promoter elements shown to affect alternative splicing, which were located in the enhancer/upstream activating sequences, the motif identified in this work is positioned within the core promoter; it is comprised of eight T-residues directly upstream of the SV40 early TATA box. This motif was previously implicated in DNA bending and negative regulation of transcription. Together, these results suggest that the identity of transcription complex assembled in the core promoter-dependent fashion can affect splice site selection during pre-mRNA splicing, perhaps by influencing the processivity of transcription elongation.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Konarska, MM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	konarsk@mail.rockefeller.edu	Konarska, Maria/ABG-6405-2020; Konarska, Maria M./AAT-2572-2021	Konarska, Maria M./0000-0001-9235-1702	NCI NIH HHS [T32 CA009673] Funding Source: Medline; NIGMS NIH HHS [GM49044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Biswas D, 2005, MOL CELL BIOL, V25, P5812, DOI 10.1128/MCB.25.14.5812-5822.2005; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Calvo O, 2005, EMBO J, V24, P1009, DOI 10.1038/sj.emboj.7600575; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; HERTZ GZ, 1987, J VIROL, V61, P2322, DOI 10.1128/JVI.61.7.2322-2325.1987; Hirose Y, 2000, GENE DEV, V14, P1415; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Pagani F, 2003, J BIOL CHEM, V278, P1511, DOI 10.1074/jbc.M209676200; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; Prather D, 2005, MOL CELL BIOL, V25, P10122, DOI 10.1128/MCB.25.22.10122-10135.2005; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Robson-Dixon ND, 2004, J BIOL CHEM, V279, P29075, DOI 10.1074/jbc.M312747200; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Rosonina E, 2005, MOL CELL, V20, P167, DOI 10.1016/j.molcel.2005.10.004; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Takahara T, 2005, MOL CELL, V18, P245, DOI 10.1016/j.molcel.2005.03.018; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Ujvari A, 2004, J BIOL CHEM, V279, P49773, DOI 10.1074/jbc.M409087200; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029	65	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11648	11657		10.1074/jbc.M611126200	http://dx.doi.org/10.1074/jbc.M611126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331949	hybrid			2022-12-25	WOS:000245941900006
J	Lowe, AW; Olsen, M; Hao, Y; Lee, SP; Lee, KT; Chen, X; van de Rijn, M; Brown, PO				Lowe, Anson W.; Olsen, Mari; Hao, Ying; Lee, Sum P.; Lee, Kyu Taek; Chen, Xin; van de Rijn, Matt; Brown, Patrick O.			Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues	PLOS ONE			English	Article								Background. Cancers of the pancreas originate from both the endocrine and exocrine elements of the organ, and represent a major cause of cancer-related death. This study provides a comprehensive assessment of gene expression for pancreatic tumors, the normal pancreas, and nonneoplastic pancreatic disease. Methods/Results. DNA microarrays were used to assess the gene expression for surgically derived pancreatic adenocarcinomas, islet cell tumors, and mesenchymal tumors. The addition of normal pancreata, isolated islets, isolated pancreatic ducts, and pancreatic adenocarcinoma cell lines enhanced subsequent analysis by increasing the diversity in gene expression profiles obtained. Exocrine, endocrine, and mesenchymal tumors displayed unique gene expression profiles. Similarities in gene expression support the pancreatic duct as the origin of adenocarcinomas. In addition, genes highly expressed in other cancers and associated with specific signal transduction pathways were also found in pancreatic tumors. Conclusion. The scope of the present work was enhanced by the inclusion of publicly available datasets that encompass a wide spectrum of human tissues and enabled the identification of candidate genes that may serve diagnostic and therapeutic goals.	[Lowe, Anson W.; Hao, Ying] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; [Brown, Patrick O.] Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; [van de Rijn, Matt] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lowe, Anson W.; Brown, Patrick O.] Stanford Univ, Med Ctr, Stanford Digest Dis Ctr, Stanford, CA 94305 USA; [Olsen, Mari; Brown, Patrick O.] Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Lee, Sum P.] Vet Adm Puget Sound Hlth Care Syst, Seattle, WA USA; [Lee, Kyu Taek] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea; [Chen, Xin] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Sungkyunkwan University (SKKU); Samsung Medical Center; University of California System; University of California San Francisco	Lowe, AW (corresponding author), Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA.	lowe@stanford.edu	Lee, Sum Ping/C-4333-2009	van de Rijn, Matt/0000-0002-1909-9739	Susan E. Riley Family Foundation; Lustgarten Foundation; NCI [CA77097]; HHMI; General Medical Research Service; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER	Susan E. Riley Family Foundation; Lustgarten Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); HHMI(Howard Hughes Medical Institute); General Medical Research Service; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Susan E. Riley Family Foundation (AWL and POB), The Lustgarten Foundation (AWL), NCI grant CA77097 and HHMI (POB), General Medical Research Service of the Department of Veterans Affairs (SPL). POB is an investigator of the Howard Hughes Medical Institute. The study sponsors had no role in the study design, data collection, analysis, interpretation of the data, writing of the paper, or the decision to submit for publication.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Argani P, 2001, CANCER RES, V61, P4320; Argani P, 2001, CLIN CANCER RES, V7, P3862; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; DICHN M, 2006, PLOS GENET, V2, pE11; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Dilley WG, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-9; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Friess H, 1999, ANN SURG, V230, P767, DOI 10.1097/00000658-199912000-00005; Hansel DE, 2004, CLIN CANCER RES, V10, P6152, DOI 10.1158/1078-0432.CCR-04-0285; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kern S, 2001, CANCER RES, V61, P4923; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Logsdon CD, 2003, CANCER RES, V63, P2649; Lowy AM, 2003, ANN SURG ONCOL, V10, P284, DOI 10.1245/ASO.2003.05.003; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maitra A, 2003, CLIN CANCER RES, V9, P5988; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Oda D, 1998, IN VITRO CELL DEV-AN, V34, P211; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ryu B, 2002, CANCER RES, V62, P819; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Shyamsundar R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r22; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stumpf E, 2000, GENE CHROMOSOME CANC, V29, P83, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1011>3.0.CO;2-Z; Sun WS, 2003, ANN ONCOL, V14, P898, DOI 10.1093/annonc/mdg257; Sweet Ian R, 2002, Diabetes Technol Ther, V4, P67, DOI 10.1089/15209150252924111; Terris B, 1998, GENE CHROMOSOME CANC, V22, P50, DOI 10.1002/(SICI)1098-2264(199805)22:1<50::AID-GCC7>3.0.CO;2-6; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; Wang XC, 2004, ENDOCR-RELAT CANCER, V11, P295, DOI 10.1677/erc.0.0110295; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187	46	79	85	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e323	10.1371/journal.pone.0000323	http://dx.doi.org/10.1371/journal.pone.0000323			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389914	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200006
J	Isaac, NJB; Turvey, ST; Collen, B; Waterman, C; Baillie, JEM				Isaac, Nick J. B.; Turvey, Samuel T.; Collen, Ben; Waterman, Carly; Baillie, Jonathan E. M.			Mammals on the EDGE: Conservation Priorities Based on Threat and Phylogeny	PLOS ONE			English	Article							QUANTIFYING BIODIVERSITY; DIVERSITY; EXTINCTION; HOTSPOTS; INFORMATION; MODELS	Conservation priority setting based on phylogenetic diversity has frequently been proposed but rarely implemented. Here, we define a simple index that measures the contribution made by different species to phylogenetic diversity and show how the index might contribute towards species-based conservation priorities. We describe procedures to control for missing species, incomplete phylogenetic resolution and uncertainty in node ages that make it possible to apply the method in poorly known clades. We also show that the index is independent of clade size in phylogenies of more than 100 species, indicating that scores from unrelated taxonomic groups are likely to be comparable. Similar scores are returned under two different species concepts, suggesting that the index is robust to taxonomic changes. The approach is applied to a near-complete species-level phylogeny of the Mammalia to generate a global priority list incorporating both phylogenetic diversity and extinction risk. The 100 highest-ranking species represent a high proportion of total mammalian diversity and include many species not usually recognised as conservation priorities. Many species that are both evolutionarily distinct and globally endangered (EDGE species) do not benefit from existing conservation projects or protected areas. The results suggest that global conservation priorities may have to be reassessed in order to prevent a disproportionately large amount of mammalian evolutionary history becoming extinct in the near future.	[Isaac, Nick J. B.; Turvey, Samuel T.; Collen, Ben; Waterman, Carly; Baillie, Jonathan E. M.] Zool Soc London, Inst Zool, London NW1 4RY, England	Zoological Society of London	Isaac, NJB (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.	nick.isaac@ioz.ac.uk	Collen, Ben/D-5055-2011; Isaac, Nick/C-2716-2011; Collen, Ben/F-2543-2016	Isaac, Nick/0000-0002-4869-8052; Collen, Ben/0000-0003-2564-4243	Natural Environment Research Council [CEH010021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Agapow PM, 2004, Q REV BIOL, V79, P161, DOI 10.1086/383542; Averianov Alexander O., 2000, Contributions from the Zoological Institute St Petersburg, V3, P1; Barker GM, 2002, BIOL J LINN SOC, V76, P165, DOI 10.1111/j.1095-8312.2002.tb02081.x; Bininda-Emonds ORP, 2004, TRENDS ECOL EVOL, V19, P315, DOI 10.1016/j.tree.2004.03.015; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; BININDAEMONDS ORP, 2007, NATURE IN PRESS, DOI DOI 10.1038/NATURE05634; Briggs DEG, 2001, PALAEOBIOLOGY, VII; Brooks TM, 2005, CONSERV BIOL SER, V8, P267; Butchart SHM, 2004, PLOS BIOL, V2, P2294, DOI 10.1371/journal.pbio.0020383; Crozier RH, 1997, ANNU REV ECOL SYST, V28, P243, DOI 10.1146/annurev.ecolsys.28.1.243; Diniz JAF, 2004, CONSERV BIOL, V18, P698; Dudgeon D, 2005, AQUAT CONSERV, V15, P105, DOI 10.1002/aqc.687; Entwistle A., 2000, HAS PANDA HAD ITS DA; ERWIN TL, 1991, SCIENCE, V253, P750, DOI 10.1126/science.253.5021.750; Faith DP, 2002, CONSERV BIOL, V16, P248, DOI 10.1046/j.1523-1739.2002.00503.x; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Flannery TF, 1998, MAMMALIA, V62, P367, DOI 10.1515/mamm.1998.62.3.367; Groves CP, 2001, PRIMATE TAXONOMY; Hallam A., 1997, MASS EXTINCTIONS THE; Hartmann K, 2007, RECONSTRUCTING EVOLU; Heard SB, 2000, P ROY SOC B-BIOL SCI, V267, P613, DOI 10.1098/rspb.2000.1046; Isaac NJB, 2004, TRENDS ECOL EVOL, V19, P464, DOI 10.1016/j.tree.2004.06.004; *IUCN, 2006, 2006 IUCN RED LIST T; IUCN Red List Standards and Petitions Subcommittee, 2006, GUID US IUCN RED LIS; Kemp TS., 1999, FOSSILS EVOLUTION; KRAJEWSKI C, 1991, SCIENCE, V254, P918, DOI 10.1126/science.254.5034.918-a; Leader-Williams N, 2000, HAS PANDA HAD ITS DA, P53; Mace Georgina M., 2002, V7, P61, DOI 10.1017/CBO9780511606304.005; Mace GM, 2003, SCIENCE, V300, P1707, DOI 10.1126/science.1085510; MACE GM, 2005, MILLENNIUM ECOSYSTEM, V1, pCH4; MacPhee R.D.E., 1999, P333; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; McKinney ML, 1998, ANIM CONSERV, V1, P159, DOI 10.1111/j.1469-1795.1998.tb00024.x; Musser G G, 1993, MAMMAL SPECIES WORLD; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Nee S, 1997, SCIENCE, V278, P692, DOI 10.1126/science.278.5338.692; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; Orme CDL, 2005, NATURE, V436, P1016, DOI 10.1038/nature03850; Owens IPF, 2000, CONSERV BIOL, V14, P1014, DOI 10.1046/j.1523-1739.2000.98509.x; Pavoine S, 2005, ECOL LETT, V8, P579, DOI 10.1111/j.1461-0248.2005.00752.x; Peterson AT, 1999, CONSERV BIOL, V13, P427, DOI 10.1046/j.1523-1739.1999.013002427.x; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Purvis A, 2005, CONSERV BIOL SER, V8, P295; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; Redding DW, 2006, CONSERV BIOL, V20, P1670, DOI 10.1111/j.1523-1739.2006.00555.x; Rodrigues ASL, 2002, BIOL CONSERV, V105, P103, DOI 10.1016/S0006-3207(01)00208-7; Rodrigues ASL, 2004, NATURE, V428, P640, DOI 10.1038/nature02422; Sechrest W, 2002, P NATL ACAD SCI USA, V99, P2067, DOI 10.1073/pnas.251680798; Soutullo A, 2005, ANIM CONSERV, V8, P249, DOI 10.1017/S136794300500226X; Stattersfield Alison J., 1998, Birdlife Conservation Series, V7, P1; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Weitzman ML, 1998, ECONOMETRICA, V66, P1279, DOI 10.2307/2999617; Wilson DE, 1993, MAMMAL SPECIES WORLD; WITTING L, 1995, BIOL CONSERV, V71, P205, DOI 10.1016/0006-3207(94)00041-N	56	597	623	4	171	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e296	10.1371/journal.pone.0000296	http://dx.doi.org/10.1371/journal.pone.0000296			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17375184	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444800019
J	Li, L; Wang, XF; Sasidharan, R; Stolc, V; Deng, W; He, H; Korbel, J; Chen, XW; Tongprasit, W; Ronald, P; Chen, RS; Gerstein, M; Deng, XW				Li, Lei; Wang, Xiangfeng; Sasidharan, Rajkumar; Stolc, Viktor; Deng, Wei; He, Hang; Korbel, Jan; Chen, Xuewei; Tongprasit, Waraporn; Ronald, Pamela; Chen, Runsheng; Gerstein, Mark; Deng, Xing Wang			Global Identification and Characterization of Transcriptionally Active Regions in the Rice Genome	PLOS ONE			English	Article							ANTISENSE TRANSCRIPTS; MESSENGER-RNA; DRAFT SEQUENCE; EXPRESSION; MICROARRAYS; ANNOTATION; PREDICTION; PAIR	Genome tiling microarray studies have consistently documented rich transcriptional activity beyond the annotated genes. However, systematic characterization and transcriptional profiling of the putative novel transcripts on the genome scale are still lacking. We report here the identification of 25,352 and 27,744 transcriptionally active regions (TARs) not encoded by annotated exons in the rice (Oryza. sativa) subspecies japonica and indica, respectively. The non-exonic TARs account for approximately two thirds of the total TARs detected by tiling arrays and represent transcripts likely conserved between japonica and indica. Transcription of 21,018 (83%) japonica non-exonic TARs was verified through expression profiling in 10 tissue types using a re-array in which annotated genes and TARs were each represented by five independent probes. Subsequent analyses indicate that about 80% of the japonica TARs that were not assigned to annotated exons can be assigned to various putatively functional or structural elements of the rice genome, including splice variants, uncharacterized portions of incompletely annotated genes, antisense transcripts, duplicated gene fragments, and potential non-coding RNAs. These results provide a systematic characterization of non-exonic transcripts in rice and thus expand the current view of the complexity and dynamics of the rice transcriptome.	[Li, Lei; Wang, Xiangfeng; Stolc, Viktor; Deng, Xing Wang] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Wang, Xiangfeng; Deng, Wei; He, Hang] Natl Inst Biol Sci, Beijing, Peoples R China; [Wang, Xiangfeng] Peking Univ, Coll Life Sci, Peking Yale Joint Res Ctr Plant Mol Genet & Agrob, Beijing 100871, Peoples R China; [Sasidharan, Rajkumar; Korbel, Jan; Gerstein, Mark] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA; [Stolc, Viktor] NASA, Ames Res Ctr, Genome Res Facil, Moffett Field, CA 94035 USA; [Deng, Wei; He, Hang; Chen, Runsheng] Chinese Acad Sci, Inst Biophys, Bioinformat Lab, Beijing 100080, Peoples R China; [Chen, Xuewei; Ronald, Pamela] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; [Tongprasit, Waraporn] Eloret Corp, Sunnyvale, CA USA	Yale University; National Institute of Biological Sciences, Beijing; Peking University; Yale University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of California System; University of California Davis	Deng, XW (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	xingwang.deng@yale.edu	Ronald, Pamela/AAK-7664-2020; Korbel, Jan O/G-6470-2012; Deng, Wei/I-1280-2012; Deng, Xing Wang/ABF-4107-2020; He, Hang/ABF-4074-2020; Chen, Runsheng/S-9834-2017	Korbel, Jan O/0000-0002-2798-3794; Chen, Runsheng/0000-0001-6049-8347; Wang, Xiangfeng/0000-0002-6406-5597; He, Hang/0000-0003-3165-283X; Deng, Wei/0000-0001-7561-9172	NSF [DBI-0421675]	NSF(National Science Foundation (NSF))	This work was supported by a grant from the NSF Plant Genome Program (DBI-0421675).	Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Borsani O, 2005, CELL, V123, P1279, DOI 10.1016/j.cell.2005.11.035; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Deng W, 2006, GENOME RES, V16, P20, DOI 10.1101/gr.4139206; FARRELL CM, 1995, J BIOL CHEM, V270, P3400, DOI 10.1074/jbc.270.7.3400; Feng Q, 2002, NATURE, V420, P316, DOI 10.1038/nature01183; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Haas BJ, 2003, NUCLEIC ACIDS RES, V31, P5654, DOI 10.1093/nar/gkg770; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Jabbari K, 2004, TRENDS PLANT SCI, V9, P281, DOI 10.1016/j.tplants.2004.04.006; Jiang N, 2004, NATURE, V431, P569, DOI 10.1038/nature02953; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Juretic N, 2005, GENOME RES, V15, P1292, DOI 10.1101/gr.4064205; Juretic N, 2004, BIOINFORMATICS, V20, P155, DOI 10.1093/bioinformatics/bth019; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KAUFFMAN HE, 1973, PLANT DIS REP, V57, P537; KIKUCHI S, 2003, SCIENCE, V300, P1566; Kitagawa N, 2005, BIOINFORMATICS, V21, P1758, DOI 10.1093/bioinformatics/bti253; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Li L, 2006, NAT GENET, V38, P124, DOI 10.1038/ng1704; Li L, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r52; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Matsumura H, 1999, PLANT J, V20, P719, DOI 10.1046/j.1365-313X.1999.00640.x; Matsumura H, 2006, NAT METHODS, V3, P469, DOI 10.1038/NMETH882; Mockler TC, 2005, GENOMICS, V85, P1, DOI 10.1016/j.ygeno.2004.10.005; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; Nakano M, 2006, NUCLEIC ACIDS RES, V34, pD731, DOI 10.1093/nar/gkj077; Osato N, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2003-5-1-r5; *RIC CHROM 10 SEQ, 2003, SCIENCE NEW YORK NY, V0300; Ronemus M, 2006, PLANT CELL, V18, P1559, DOI 10.1105/tpc.106.042127; Rouillard JM, 2003, NUCLEIC ACIDS RES, V31, P3057, DOI 10.1093/nar/gkg426; Royce TE, 2005, TRENDS GENET, V21, P466, DOI 10.1016/j.tig.2005.06.007; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Selinger DW, 2000, NAT BIOTECHNOL, V18, P1262, DOI 10.1038/82367; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Wang H, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r92; Wang XF, 2006, BIOINFORMATICS, V22, P2955, DOI 10.1093/bioinformatics/btl525; Wang XJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r30; Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yu J, 2005, PLOS BIOL, V3, P266, DOI 10.1371/journal.pbio.0030038; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Yuan QP, 2005, PLANT PHYSIOL, V138, P17, DOI 10.1104/pp.104.059063	48	60	64	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e294	10.1371/journal.pone.0000294	http://dx.doi.org/10.1371/journal.pone.0000294			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372628	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444800017
J	Estrugo, D; Fischer, A; Hess, F; Scherthan, H; Belka, C; Cordes, N				Estrugo, Doris; Fischer, Alexander; Hess, Franziska; Scherthan, Harry; Belka, Claus; Cordes, Nils			Ligand Bound beta 1 Integrins Inhibit Procaspase-8 for Mediating Cell Adhesion-Mediated Drug and Radiation Resistance in Human Leukemia Cells	PLOS ONE			English	Article								Background. Chemo- and radiotherapeutic responses of leukemia cells are modified by integrin-mediated adhesion to extracellular matrix. To further characterize the molecular mechanisms by which beta 1 integrins confer radiation and chemoresistance, HL60 human acute promyelocytic leukemia cells stably transfected with beta 1 integrin and A3 Jurkat T-lymphoma cells deficient for Fas-associated death domain protein or procaspase-8 were examined. Methodology/Principal Findings. Upon exposure to X-rays, Ara-C or FasL, suspension and adhesion (fibronectin (FN), laminin, collagen-1; 5-100 mu g/cm(2) coating concentration) cultures were processed for measurement of apoptosis, mitochondrial transmembrane potential (MTP), caspase activation, and protein analysis. Overexpression of beta 1 integrins enhanced the cellular sensitivity to X-rays and Ara-C, which was counteracted by increasing concentrations of matrix proteins in association with reduced caspase-3 and -8 activation and MTP breakdown. Usage of stimulatory or inhibitory anti beta 1 integrin antibodies, pharmacological caspase or phosphatidylinositol-3 kinase (PI3K) inhibitors, coprecipitation experiments and siRNA-mediated beta 1 integrin silencing provided further data showing an interaction between FN-ligated beta 1 integrin and PI3K/Akt for inhibiting procaspase-8 cleavage. Conclusions/Significance. The presented data suggest that the ligand status of beta 1 integrins is critical for their antiapoptotic effect in leukemia cells treated with Ara-C, FasL or ionizing radiation. The antiapoptotic actions involve formation of a beta 1 integrin/Akt complex, which signals to prevent procaspase-8-mediated induction of apoptosis in a PI3K-dependent manner. Antagonizing agents targeting beta 1 integrin and PI3K/Akt signaling in conjunction with conventional therapies might effectively reduce radiation-and drug-resistant tumor populations and treatment failure in hematological malignancies.	[Cordes, Nils] Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, D-8027 Dresden, Germany; [Estrugo, Doris; Fischer, Alexander; Hess, Franziska; Scherthan, Harry; Cordes, Nils] Bundeswehr Inst Radiobiol, Munich, Germany; [Belka, Claus] Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Eberhard Karls University of Tubingen	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, D-8027 Dresden, Germany.	Nils.Cordes@Oncoray.de		Cordes, Nils/0000-0001-5684-629X	Federal Ministry of Education and Research, Germany, BMBF [03ZIK041]	Federal Ministry of Education and Research, Germany, BMBF(Federal Ministry of Education & Research (BMBF))	This research was in part supported by the Federal Ministry of Education and Research, Germany, BMBF contract 03ZIK041 to N.C.	Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Belka C, 2006, ONCOGENE, V25, P969, DOI 10.1038/sj.onc.1209175; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; GRENMAN R, 1989, INT J CANCER, V44, P131, DOI 10.1002/ijc.2910440123; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; HESS F, 2006, ONCOGENE        0828, DOI DOI 10.1038/SJ.ONC.1209947;2006; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Ilic D, 1998, J CELL BIOL, V143, P547; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lu B, 2006, J IMMUNOL, V176, P6785, DOI 10.4049/jimmunol.176.11.6785; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; Wu RC, 2004, CELL MOL LIFE SCI, V61, P2071, DOI 10.1007/s00018-004-4165-1; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	44	57	59	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e269	10.1371/journal.pone.0000269	http://dx.doi.org/10.1371/journal.pone.0000269			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342203	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444700004
J	Ringach, DL				Ringach, Dario L.			On the Origin of the Functional Architecture of the Cortex	PLOS ONE			English	Article							PRIMARY VISUAL-CORTEX; LATERAL GENICULATE-NUCLEUS; OCULAR-DOMINANCE COLUMNS; CYTOCHROME-OXIDASE BLOBS; PRIMATE STRIATE CORTEX; CORTICAL MAGNIFICATION FACTOR; SPATIAL RESOLVING POWER; ISO-ORIENTATION DOMAINS; SIMPLE RECEPTIVE-FIELDS; RETINAL GANGLION-CELLS	The basic structure of receptive fields and functional maps in primary visual cortex is established without exposure to normal sensory experience and before the onset of the critical period. How the brain wires these circuits in the early stages of development remains unknown. Possible explanations include activity-dependent mechanisms driven by spontaneous activity in the retina and thalamus, and molecular guidance orchestrating thalamo-cortical connections on a fine spatial scale. Here I propose an alternative hypothesis: the blueprint for receptive fields, feature maps, and their inter-relationships may reside in the layout of the retinal ganglion cell mosaics along with a simple statistical connectivity scheme dictating the wiring between thalamus and cortex. The model is shown to account for a number of experimental findings, including the relationship between retinotopy, orientation maps, spatial frequency maps and cytochrome oxidase patches. The theory's simplicity, explanatory and predictive power makes it a serious candidate for the origin of the functional architecture of primary visual cortex.	Univ Calif Los Angeles, Dept Psychol & Neurobiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Ringach, DL (corresponding author), Univ Calif Los Angeles, Dept Psychol & Neurobiol, Los Angeles, CA 90095 USA.	dario@ucla.edu			NIH [EY-12816]; DARPA [FA8650-06-C-7633]; NATIONAL EYE INSTITUTE [R01EY012816] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work has been supported by NIH EY-12816 and DARPA FA8650-06-C-7633.	Adams DL, 2003, J NEUROSCI, V23, P5984, DOI 10.1523/JNEUROSCI.23-14-05984.2003; Adams DL, 2003, J NEUROSCI, V23, P3771; AHMED B, 1991, EXP BRAIN RES, V84, P676; ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; Alonso JM, 2001, J NEUROSCI, V21, P4002, DOI 10.1523/JNEUROSCI.21-11-04002.2001; Andrade MA, 1997, NEURAL NETWORKS, V10, P1037, DOI 10.1016/S0893-6080(97)00003-8; BARTFELD E, 1992, P NATL ACAD SCI USA, V89, P11905, DOI 10.1073/pnas.89.24.11905; Bartsch AP, 2001, BIOL CYBERN, V84, P41, DOI 10.1007/s004220170003; Basole A, 2003, NATURE, V423, P986, DOI 10.1038/nature01721; Bednar JA, 2006, NEUROCOMPUTING, V69, P1272, DOI 10.1016/j.neucom.2005.12.090; Blasdel G, 2001, J NEUROSCI, V21, P8286, DOI 10.1523/JNEUROSCI.21-20-08286.2001; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; Blumenfeld B, 2006, J COMPUT NEUROSCI, V20, P219, DOI 10.1007/s10827-006-6307-y; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 2002, NAT NEUROSCI, V5, P874, DOI 10.1038/nn908; BOYCOTT BB, 1974, J PHYSIOL-LONDON, V240, P397, DOI 10.1113/jphysiol.1974.sp010616; Buzas P, 2003, EUR J NEUROSCI, V18, P957, DOI 10.1046/j.1460-9568.2003.02808.x; Carandini M, 2000, J NEUROSCI, V20, P470, DOI 10.1523/JNEUROSCI.20-01-00470.2000; Chapman B, 2000, J NEUROSCI, V20, P1922; Chklovskii DB, 2004, ANNU REV NEUROSCI, V27, P369, DOI 10.1146/annurev.neuro.27.070203.144226; Chklovskii DB, 2000, PHYSICA A, V284, P318, DOI 10.1016/S0378-4371(00)00219-3; CLELAND BG, 1985, J PHYSIOL-LONDON, V369, P249, DOI 10.1113/jphysiol.1985.sp015899; CLELAND BG, 1971, NATURE-NEW BIOL, V231, P191, DOI 10.1038/newbio231191a0; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1997, J NEUROPHYSIOL, V77, P3381, DOI 10.1152/jn.1997.77.6.3381; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Crair MC, 2001, J COMP NEUROL, V430, P235, DOI 10.1002/1096-9861(20010205)430:2<235::AID-CNE1028>3.0.CO;2-P; Crowley JC, 2000, SCIENCE, V290, P1321, DOI 10.1126/science.290.5495.1321; Crowley JC, 2002, CURR OPIN NEUROBIOL, V12, P104, DOI 10.1016/S0959-4388(02)00297-0; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; DANIELS JD, 1978, J NEUROPHYSIOL, V41, P1373, DOI 10.1152/jn.1978.41.6.1373; Das A, 1997, NATURE, V387, P594, DOI 10.1038/42461; Dayan P, 2003, J PHYSIOL-PARIS, V97, P475, DOI 10.1016/j.jphysparis.2004.01.006; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; Eglen SJ, 2005, VISUAL NEUROSCI, V22, P859, DOI 10.1017/S0952523805226147; Eglen SJ, 2006, MATH MED BIOL, V23, P79, DOI 10.1093/imammb/dql003; Ernst U, 1999, NEURAL COMPUT, V11, P375, DOI 10.1162/089976699300016692; Ernst UA, 2001, NAT NEUROSCI, V4, P431, DOI 10.1038/86089; Erwin E, 1998, J NEUROSCI, V18, P9870; EVERSON R, 1995, INVEST OPHTH VIS SCI, V36, pS873; FERSTER D, 1978, J COMP NEUROL, V182, P923, DOI 10.1002/cne.901820510; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; GOODHILL GJ, 1994, NEURAL COMPUT, V6, P615, DOI 10.1162/neco.1994.6.4.615; Goodhill GJ, 1997, P ROY SOC B-BIOL SCI, V264, P649, DOI 10.1098/rspb.1997.0092; Goodhill GJ, 2000, NETWORK-COMP NEURAL, V11, P153, DOI 10.1088/0954-898X/11/2/303; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Horton JC, 2005, PHILOS T R SOC B, V360, P837, DOI 10.1098/rstb.2005.1623; HORTON JC, 1984, PHILOS T ROY SOC B, V304, P199, DOI 10.1098/rstb.1984.0021; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; Hubener M, 2000, EUR J NEUROSCI, V12, P194; Hubener M, 1997, J NEUROSCI, V17, P9270; HUMPHREY AL, 1985, J COMP NEUROL, V233, P190, DOI 10.1002/cne.902330204; IKEDA H, 1978, EXP BRAIN RES, V31, P193; IKEDA H, 1978, ARCH ITAL BIOL, V116, P375; Issa NP, 2000, J NEUROSCI, V20, P8504, DOI 10.1523/JNEUROSCI.20-22-08504.2000; JONES DG, 1991, J NEUROSCI, V11, P3794; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; Kanold PO, 2003, SCIENCE, V301, P521, DOI 10.1126/science.1084152; Kaschube M, 2002, J NEUROSCI, V22, P7206; Kayser AS, 2002, NEURON, V33, P131, DOI 10.1016/S0896-6273(01)00570-0; KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288; Kohonen T, 1985, J OPT SOC AM A, V2, pP16; Landisman CE, 2002, J NEUROPHYSIOL, V87, P3126, DOI 10.1152/jn.2002.87.6.3126; LEVENTHAL AG, 1983, J COMP NEUROL, V220, P465, DOI 10.1002/cne.902200408; Li Y, 2006, NAT NEUROSCI, V9, P676, DOI 10.1038/nn1684; Maldonado PE, 1997, SCIENCE, V276, P1551, DOI 10.1126/science.276.5318.1551; MALSBURG CV, 1973, KYBERNETIK, V14, P85, DOI 10.1007/BF00288907; MALSBURG CV, 1973, PFLUG ARCH EUR J PHY, V339, P95; Marino J, 2005, NAT NEUROSCI, V8, P194, DOI 10.1038/nn1391; Matsuda Y, 2000, NEUROREPORT, V11, P3337, DOI 10.1097/00001756-200010200-00015; McLaughlin D, 2003, J PHYSIOL-PARIS, V97, P237, DOI 10.1016/j.jphysparis.2003.09.019; MILLER KD, 1992, NEUROREPORT, V3, P73, DOI 10.1097/00001756-199201000-00019; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; Miller KD, 2003, CEREB CORTEX, V13, P73, DOI 10.1093/cercor/13.1.73; MILLER KD, 1994, J NEUROSCI, V14, P409; Miller KD, 2001, VISUAL NEUROSCI, V18, P821, DOI 10.1017/S0952523801185159; MILLER KD, 1994, PROG BRAIN RES, V102, P303; Miller KD, 1998, NEURAL COMPUT, V10, P529, DOI 10.1162/089976698300017647; Miller KD, 1999, J NEUROBIOL, V41, P44, DOI 10.1002/(SICI)1097-4695(199910)41:1<44::AID-NEU7>3.0.CO;2-V; Mooser F, 2004, NAT NEUROSCI, V7, P872, DOI 10.1038/nn1287; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; Muller T, 2000, NEURAL COMPUT, V12, P2573, DOI 10.1162/089976600300014854; MURPHY KM, 1995, J NEUROSCI, V15, P4196; MURPHY KM, 1991, INVEST OPHTH VIS SCI, V32, P1116; Murphy KM, 2001, CEREB CORTEX, V11, P122, DOI 10.1093/cercor/11.2.122; NAEGELE JR, 1988, J COMP NEUROL, V277, P593, DOI 10.1002/cne.902770411; NIEBUR E, 1994, NEURAL COMPUT, V6, P602, DOI 10.1162/neco.1994.6.4.602; Obermayer K, 1997, NEURAL COMPUT, V9, P555, DOI 10.1162/neco.1997.9.3.555; OBERMAYER K, 1995, BEHAV BRAIN RES, V66, P161, DOI 10.1016/0166-4328(94)00136-4; OBERMAYER K, 1992, PHYS REV A, V45, P7568, DOI 10.1103/PhysRevA.45.7568; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Ohki K, 2006, NATURE, V442, P925, DOI 10.1038/nature05019; Ohshiro T, 2006, NAT NEUROSCI, V9, P1541, DOI 10.1038/nn1799; Ohzawa I, 1996, J NEUROPHYSIOL, V75, P1779, DOI 10.1152/jn.1996.75.5.1779; Olshausen BA, 1996, NETWORK-COMP NEURAL, V7, P333, DOI 10.1088/0954-898X/7/2/014; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; Price DJ, 2006, EUR J NEUROSCI, V23, P910, DOI 10.1111/j.1460-9568.2006.04620.x; PURVES D, 1992, TRENDS NEUROSCI, V15, P362, DOI 10.1016/0166-2236(92)90180-G; Rao SC, 1997, J COMP NEUROL, V387, P358; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; Ringach DL, 2002, J NEUROPHYSIOL, V88, P455, DOI 10.1152/jn.2002.88.1.455; Ringach DL, 2004, J NEUROPHYSIOL, V92, P468, DOI 10.1152/jn.01202.2003; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SAKITT B, 1982, VISION RES, V22, P417, DOI 10.1016/0042-6989(82)90158-4; Sasaki Y, 2006, NEURON, V51, P661, DOI 10.1016/j.neuron.2006.07.021; SCHALL JD, 1986, BRAIN RES, V368, P18, DOI 10.1016/0006-8993(86)91037-1; SCHALL JD, 1987, J COMP NEUROL, V257, P149, DOI 10.1002/cne.902570202; Schmidt KF, 2006, NEUROSCIENCE, V141, P1525, DOI 10.1016/j.neuroscience.2006.04.056; Schmidt KF, 2006, NEUROIMAGE, V29, P439, DOI 10.1016/j.neuroimage.2005.07.031; Schummers J, 2004, J PHYSIOL-PARIS, V98, P429, DOI 10.1016/j.jphysparis.2005.09.017; Schummers J, 2002, NEURON, V36, P969, DOI 10.1016/S0896-6273(02)01012-7; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SHATZ CJ, 1994, INT J DEV NEUROSCI, V12, P531, DOI 10.1016/0736-5748(94)90061-2; SHERK H, 1976, J NEUROPHYSIOL, V39, P63, DOI 10.1152/jn.1976.39.1.63; Shmuel A, 2000, P NATL ACAD SCI USA, V97, P5568, DOI 10.1073/pnas.97.10.5568; Shmuel A, 1996, J NEUROSCI, V16, P6945; Shoham D, 1997, NATURE, V385, P529, DOI 10.1038/385529a0; Skaliora I, 2000, J NEUROSCI, V20, P3650, DOI 10.1523/JNEUROSCI.20-10-03650.2000; SOODAK RE, 1987, P NATL ACAD SCI USA, V84, P3936, DOI 10.1073/pnas.84.11.3936; SOODAK RE, 1991, VISUAL NEUROSCI, V6, P507, DOI 10.1017/S0952523800001358; Stein JJ, 1996, J COMP NEUROL, V372, P597, DOI 10.1002/(SICI)1096-9861(19960902)372:4<597::AID-CNE8>3.0.CO;2-#; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; SWINDALE NV, 1990, TRENDS NEUROSCI, V13, P487, DOI 10.1016/0166-2236(90)90082-L; Swindale NV, 2000, CEREB CORTEX, V10, P633, DOI 10.1093/cercor/10.7.633; SWINDALE NV, 1991, BIOL CYBERN, V65, P415, DOI 10.1007/BF00204654; Swindale NV, 2004, NETWORK-COMP NEURAL, V15, P217, DOI 10.1088/0954-898X/15/4/001; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; Swindale NV, 2003, CEREB CORTEX, V13, P225, DOI 10.1093/cercor/13.3.225; Swindale NV, 2000, NAT NEUROSCI, V3, P822, DOI 10.1038/77731; Tavazoie SF, 2000, NAT NEUROSCI, V3, P608, DOI 10.1038/75786; Thomas PJ, 2006, MATH MED BIOL, V23, P119, DOI 10.1093/imammb/dql006; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; Usrey WM, 1999, J NEUROPHYSIOL, V82, P3527, DOI 10.1152/jn.1999.82.6.3527; Van Hooser SD, 2005, J NEUROSCI, V25, P19, DOI 10.1523/JNEUROSCI.4042-04.2005; WASSLE H, 1981, PROC R SOC SER B-BIO, V212, P157, DOI 10.1098/rspb.1981.0032; WASSLE H, 1989, NATURE, V341, P643, DOI 10.1038/341643a0; WASSLE H, 1981, PROC R SOC SER B-BIO, V212, P177, DOI 10.1098/rspb.1981.0033; Weliky M, 1999, J NEUROBIOL, V41, P25, DOI 10.1002/(SICI)1097-4695(199910)41:1<25::AID-NEU5>3.0.CO;2-#; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; Weng C, 2005, J NEUROPHYSIOL, V93, P3537, DOI 10.1152/jn.00847.2004; Wimbauer S, 1997, BIOL CYBERN, V77, P453, DOI 10.1007/s004220050405; Wolf F, 1996, NATURE, V382, P306, DOI 10.1038/382306a0; Wolf F, 2000, J PHYSIOLOGY-PARIS, V94, P525, DOI 10.1016/S0928-4257(00)01104-9; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; Xiao YP, 2003, NATURE, V421, P535, DOI 10.1038/nature01372; Xing DJ, 2004, J PHYSIOL-LONDON, V557, P923, DOI 10.1113/jphysiol.2004.062026; Yeh CI, 2003, J NEUROPHYSIOL, V90, P1852, DOI 10.1152/jn.00417.2003; Yu H, 2005, NEURON, V47, P267, DOI 10.1016/j.neuron.2005.06.011; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8; Zhan XJ, 2000, VISUAL NEUROSCI, V17, P23, DOI 10.1017/S0952523800171032	159	53	55	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e251	10.1371/journal.pone.0000251	http://dx.doi.org/10.1371/journal.pone.0000251			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330140	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444600011
J	Falagas, ME; Karydis, I; Kostogiannou, I				Falagas, Matthew E.; Karydis, Ioannis; Kostogiannou, Ilektra			Percutaneous Exposure Incidents of the Health Care Personnel in a Newly Founded Tertiary Hospital: A Prospective Study	PLOS ONE			English	Article								Background. Percutaneous exposure incidents (PEIs) and blood splashes on the skin of health care workers are a major concern, since they expose susceptible employees to the risk of infectious diseases. We undertook this study in order to estimate the overall incidence of such injuries in a newly founded tertiary hospital, and to evaluate possible changes in their incidence over time. Methodology/Principal Findings. We prospectively studied the PEIs and blood splashes on the skin of employees in a newly founded (October 2000) tertiary hospital in Athens, Greece, while a vaccination program against hepatitis B virus, as well as educational activities for avoidance of injuries, were taking place. The study period ranged from October 1, 2002 to February 28, 2005. Serologic studies for hepatitis B (HBV) and C virus (HCV) as well as human immunodeficiency virus (HIV) were performed in all injured employees and the source patients, when known. High-titer immunoglobulin (250 IU anti-HBs intramuscularly) and HBV vaccination were given to non-vaccinated or previously vaccinated but serologically non-responders after exposure. Statistical analysis of the data was performed using Mc Nemar's and Fisher's tests. 60 needlestick, 11 sharp injuries, and two splashes leading to exposure of the skin or mucosa to blood were reported during the study period in 71 nurses and two members of the cleaning staff. The overall incidence (percutaneous injuries and splashes) per 100 full-time employment-years (100 FTEYs) for high-risk personnel (nursing, medical, and cleaning staff) was 3.48, whereas the incidence of percutaneous injuries (needlestick and sharp injuries) alone per 100 FTEYs was 3.38. A higher incidence of injuries was noted during the first than in the second half of the study period (4.67 versus 2.29 per 100 FTEYs, p = 0.005). No source patient was found positive for HCV or HIV. The use of high-titer immunoglobulin after adjustment for the incidence of injuries was higher in the first than in the second half of the study period, although the difference was not statistically significant [9/49 (18.37%) vs 1/24 (4.17%), p = 0.15]. Conclusions/Significance. Our data show that nurses are the healthcare worker group that reports most of PEIs. Doctors did not report such injuries during the study period in our setting. However, the possibility of even relatively frequent PEIs in doctors cannot be excluded. This is due to underreporting of such events that has been previously described for physicians and surgeons. A decrease of the incidence of PEIs occurred during the operation of this newly founded hospital.	[Falagas, Matthew E.; Karydis, Ioannis] Alfa Inst Biomed Sci, Athens, Greece; [Falagas, Matthew E.] Henry Dunant Hosp, Employee Hlth Clin, Athens, Greece; [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Kostogiannou, Ilektra] Henry Dunant Hosp, Dept Nursing, Athens, Greece	Alfa Institute Of Biomedical Sciences; Henry Dunant Hospital; Tufts University; Henry Dunant Hospital	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, Athens, Greece.	m.falagas@aibs.gr						AGERTON TB, 1995, INFECT CONT HOSP EP, V16, P287; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; Babcock HM, 2003, INFECT CONT HOSP EP, V24, P731, DOI 10.1086/502121; Beekmann SE, 2001, INFECT CONT HOSP EP, V22, P73, DOI 10.1086/501867; BOLYARD E, 2001, INFECT CONTROL REFER, P1105; Dement JM, 2004, AM J IND MED, V46, P637, DOI 10.1002/ajim.20106; Doebbeling BN, 2003, CLIN INFECT DIS, V37, P1006, DOI 10.1086/377535; Foley M, 2004, AM J NURS, V104, P96, DOI 10.1097/00000446-200408000-00049; Lee Jennifer M, 2005, AAOHN J, V53, P117; MALLON DFJ, 1992, MED J AUSTRALIA, V157, P592, DOI 10.5694/j.1326-5377.1992.tb137397.x; Merchant RC, 2006, ANN EMERG MED, V47, P492, DOI 10.1016/j.annemergmed.2006.02.013; Murphy E, 2000, OCCUP MED-OXFORD, V50, P383, DOI 10.1093/occmed/50.6.383; Nash G, 2001, BRIT MED J, V323, P169, DOI 10.1136/bmj.323.7305.169; Pournaras S, 1999, OCCUP MED-OXFORD, V49, P423, DOI 10.1093/occmed/49.7.423; Puro V, 2001, INFECT CONT HOSP EP, V22, P206, DOI 10.1086/501890; ROUDOTTHORAVAL F, 2000, INFECT CONT HOSP EP, V21, P494; Shiao JSC, 1999, AM J INFECT CONTROL, V27, P254, DOI 10.1053/ic.1999.v27.a97006; Tan L, 2001, ARCH INTERN MED, V161, P929, DOI 10.1001/archinte.161.7.929; Trape-Cardoso M, 2004, AM J INFECT CONTROL, V32, P301, DOI 10.1016/j.ajic.2003.12.003; Whitby RM, 2002, MED J AUSTRALIA, V177, P405	20	27	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e194	10.1371/journal.pone.0000194	http://dx.doi.org/10.1371/journal.pone.0000194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17332844	Green Published, gold			2022-12-25	WOS:000207444300007
J	Pulukuri, SM; Patibandla, S; Patel, J; Estes, N; Rao, JS				Pulukuri, S. M.; Patibandla, S.; Patel, J.; Estes, N.; Rao, J. S.			Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors	ONCOGENE			English	Article						CpG methylation; TIMP-2; MeCP2; prostate cancer	IN-VIVO; TRANSCRIPTIONAL REPRESSION; CANCER STATISTICS; DNA METHYLATION; GELATINASE-A; EXPRESSION; INVASION; CELLS; HYPERMETHYLATION; ANGIOGENESIS	Gene silencing via CpG island methylation in the promoter region is one of the mechanisms by which tumor suppressor genes are inactivated in human cancers. Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, which is an endogenous inhibitor of matrix metalloproteinases involved in cell invasion and tumorigenesis, is downregulated or silenced in a variety of human cancer cell lines. Here, we investigated the mechanism underlying TIMP-2 expression in prostate cancer cell lines and primary prostate tumor samples. We observed a strong correlation between promoter hypermethylation and lost expression of TIMP-2 gene, which was supported by other results demonstrating that promoter demethylation by 5-aza-2'-deoxycytidine and trichostatin A reactivated TIMP-2 and restored its expression in TIMP-2-silenced metastatic prostate cell lines. These results were further substantiated by a chromatin immunoprecipitation assay, showing the preferential binding of MeCP2 to methylated CpG island in TIMP-2-silenced metastatic prostate cell lines. In vitro Matrigel invasion assays showed that re-expression of TIMP- 2 after a combined treatment with 5-aza and trichostatin-A in metastatic prostate cells resulted in a significant reduction of tumor cell invasion. Furthermore, CpG methylation of TIMP- 2 promoter was also shown in primary prostate tumors that expressed decreased TIMP-2 protein levels. These results suggest that the downregulation of the TIMP- 2 gene is associated with promoter methylation and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Box-1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA075557, CA75557, CA116708, CA95058, R01 CA116708, CA92393, R01 CA092393, R01 CA095058] Funding Source: Medline; NINDS NIH HHS [R01 NS047699, NS57529, NS47699, R01 NS057529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA092393, R01CA095058, R01CA116708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057529, R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bachman KE, 1999, CANCER RES, V59, P798; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DECLERCK YA, 1992, CANCER RES, V52, P701; Esteller M, 2001, CANCER RES, V61, P3225; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Gokaslan ZL, 1998, CLIN EXP METASTAS, V16, P721, DOI 10.1023/A:1006580728338; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hegeman Robert B, 2004, Clin Prostate Cancer, V3, P150, DOI 10.3816/CGC.2004.n.025; Imren S, 1996, CANCER RES, V56, P2891; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; Nagase H, 1998, Cell Res, V8, P179; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Yamamoto M, 1996, CANCER RES, V56, P384; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201	27	70	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5229	5237		10.1038/sj.onc.1210329	http://dx.doi.org/10.1038/sj.onc.1210329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325663	Green Accepted			2022-12-25	WOS:000248674200006
J	Thirunarayanan, N; Cifire, F; Fichtner, I; Posner, S; Benga, J; Relterer, P; Krernmer, E; Koble, K; Lipp, M				Thirunarayanan, N.; Cifire, F.; Fichtner, I.; Posner, S.; Benga, J.; Relterer, P.; Krernmer, E.; Koeble, K.; Lipp, M.			Enhanced tumorigenicity of fibroblasts transformed with human herpesvirus 8 chemokine receptor vGPCR by successive passage in nude and immunocompetent mice	ONCOGENE			English	Article						chemokine receptor; vGPCR; Kaposi's sarcoma; animal model; HHV-8	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; KAPOSIS-SARCOMA; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; INFECTION; ORF74; MODEL	The human herpes virus 8 (HHV-8)-encoded G protein-coupled chemokine receptor (vGPCR) has been implicated in the pathogenesis of Kaposi's sarcoma (KS), particularly because of its high constitutive signaling activity. Here, we used retroviral transduction to generate vGPCR-expressing 3T3 fibroblasts that are tumorigenic in nude mice, but as expected fail to induce tumors in their immunocompetent counterparts. However, tumor fragments obtained from nude mice grow progressively in immunocompetent BALB/c mice. Unexpectedly, vGPCR-expressing cells established from grafted tumor fragments gave rise to tumors in immunocompetent mice. These tumors exhibit a striking histological resemblance to KS including plump spindle cell morphology, a high degree of vascularization and brisk mitotic activity. High expression of vGPCR was confirmed in the cell lines and tumors using a newly developed vGPCR-specific monoclonal antibody. Finally, short interfering RNA directed at vGPCR abrogated or significantly delayed tumorigenesis in mice, demonstrating that the tumor development is specifically driven by vGPCR. This novel model for vGPCR-mediated oncogenesis will contribute to our understanding of the role of vGPCR in the pathogenesis of HHV-8 and may even be important in identifying critical molecular and epigenetic changes during tumor progression in vivo.	Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Expt Pharmacol, D-13125 Berlin, Germany; GSF Munich, Res Ctr, Inst Mol Immunol, Munich, Germany; Univ Klinikum Charite, Inst Pathol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lipp, M (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, Robert Rossle Str 10, D-13125 Berlin, Germany.	mLIPP@mdc-berlin.de	Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Brekken RA, 2001, J CONTROL RELEASE, V74, P173, DOI 10.1016/S0168-3659(01)00333-9; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; EMRICH T, 1993, BIOCHEM BIOPH RES CO, V197, P214, DOI 10.1006/bbrc.1993.2463; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Forster R, 1998, J IMMUNOL, V160, P1522; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Hopken UE, 2004, EUR J IMMUNOL, V34, P461, DOI 10.1002/eji.200324690; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; Kolble K, 1999, LAB INVEST, V79, P1145; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller G, 2001, BIOL CHEM, V382, P1387, DOI 10.1515/BC.2001.171; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; QIN ZH, 1995, CANCER RES, V55, P4747; Quan N, 1999, CANCER RES, V59, P1080; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samaniego F, 2002, CELL GROWTH DIFFER, V13, P387; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	34	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5702	5712		10.1038/sj.onc.1210357	http://dx.doi.org/10.1038/sj.onc.1210357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353903				2022-12-25	WOS:000248885100002
J	Jousse, C; Deval, C; Maurin, AC; Parry, L; Cherasse, Y; Chaveroux, C; Lefloch, R; Lenormand, P; Bruhat, A; Fafournoux, P				Jousse, Celine; Deval, Christiane; Maurin, Anne-Catherine; Parry, Laurent; Cherasse, Yoan; Chaveroux, Cedric; Lefloch, Renaud; Lenormand, Philippe; Bruhat, Alain; Fafournoux, Pierre			TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DEPRIVATION; SENSING RESPONSE PATHWAY; TRANSLATIONAL CONTROL; INSULIN-RESISTANCE; EIF2-ALPHA KINASE; TRIBBLES HOMOLOG; PROTEIN; EXPRESSION; CHOP; BINDING	The integrated stress response (ISR) is defined as a highly conserved response to several stresses that converge to the induction of the activating transcription factor 4 (ATF4). Because an uncontrolled response may have deleterious effects, cells have elaborated several negative feedback loops that attenuate the ISR. In the present study, we describe how induction of the human homolog of Drosophila tribbles (TRB3) attenuates the ISR by a negative feedback mechanism. To investigate the role of TRB3 in the control of the ISR, we used the regulation of gene expression by amino acid limitation as a model. The enhanced production of ATF4 upon amino acid starvation results in the induction of a large number of target genes like CHOP (CAAT/enhancer-binding protein-homologous protein), asparagine synthetase (ASNS), or TRB3. We demonstrate that TRB3 overexpression inhibits the transcriptional induction of CHOP and ASNS whereas TRB3 silencing induces the expression of these genes both under normal and stressed conditions. In addition, transcriptional profiling experiments show that TRB3 affects the expression of many ISR-regulated genes. Our results also suggest that TRB3 and ATF4 belong to the same protein complex bound to the sequence involved in the ATF4-dependent regulation of gene expression by amino acid limitation. Collectively, our data identify TRB3 as a negative feedback regulator of the ATF4-dependent transcription and participates to the fine regulation of the ISR.	INRA, UMR 1019, Unite Nutr Humaine, F-63122 St Genes Champanelle, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06100 Nice, France	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Fafournoux, P (corresponding author), INRA, UMR 1019, Unite Nutr Humaine, F-63122 St Genes Champanelle, France.	fpierre@clermont.inra.fr	Lenormand, Philippe/N-5996-2018; Cherasse, Yoan/F-8915-2010; Cherasse, Yoan/AAD-6442-2020	Cherasse, Yoan/0000-0002-6139-8193; Chaveroux, Cedric/0000-0002-4116-3354				Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BRUHAT A, 2007, NUCL ACIDS RES; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran CA, 2005, CANCER BIOL THER, V4, P1063, DOI 10.4161/cbt.4.10.2205; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Matsushima R, 2006, J BIOL CHEM, V281, P29719, DOI 10.1074/jbc.M511636200; Maurin AC, 2005, CELL METAB, V1, P273, DOI 10.1016/j.cmet.2005.03.004; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2005, BIOCHEM BIOPH RES CO, V330, P210, DOI 10.1016/j.bbrc.2005.02.149; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Prudente S, 2005, DIABETES, V54, P2807, DOI 10.2337/diabetes.54.9.2807; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rorth P, 2000, MOL CELL, V6, P23; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sok J, 1999, MOL CELL BIOL, V19, P495; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	41	122	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15851	15861		10.1074/jbc.M611723200	http://dx.doi.org/10.1074/jbc.M611723200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369260	Green Published, hybrid			2022-12-25	WOS:000246589600060
J	Matsumura, S; Toyoshima, F; Nishida, E				Matsumura, Shigeru; Toyoshima, Fumiko; Nishida, Eisuke			Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; SPINDLE-CHECKPOINT PROTEINS; MITOTIC CHECKPOINT; CENP-E; BOX DOMAIN; AURORA-B; KINETOCHORE LOCALIZATION; BINDING DOMAIN; HUMAN-CELLS; HELA-CELLS	Plk1, an evolutionarily conserved M phase kinase, associates with not only spindle poles but also kinetochores during prometaphase. However, the role of Plk1 at kinetochores has been poorly understood. Here we show that BubR1 mediates the action of Plk1 at kinetochores for proper chromosome alignment. Our results show that BubR1 colocalizes with Plk1 at kinetochores of unaligned chromosomes and physically interacts with Plk1 in prometaphase cells. Down-regulation of Plk1 by small interfering RNA abolished the mobility-shifted, hyperphosphorylated form of BubR1 in the prometaphase-arrested cells. In addition, BubR1 was phosphorylated by Plk1 in vitro at two Plk1 consensus sites in the kinase domain of BubR1. The add-back of either wild-type BubR1 or BubR1 2E, in which the two Plk1 phosphorylation sites were replaced by glutamic acids, but not that of BubR1 2A, an unphosphorylatable mutant, rescued the chromosome alignment defects in BubR1-deficient cells. Moreover, when both Plk1 and BubR1 were down-regulated, the add-back of BubR1 2E, but not that of wild-type BubR1, rescued the chromosome alignment defects. These results taken together suggest that Plk1 facilitates chromosome alignment during prometaphase through BubR1.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp		Toyoshima, Fumiko/0000-0002-3698-0034				Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; King JM, 2000, J CELL SCI, V113, P3815; Kline-Smith SL, 2005, CURR OPIN CELL BIOL, V17, P35, DOI 10.1016/j.ceb.2004.12.009; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Liu JJ, 2005, ONCOGENE, V24, P238, DOI 10.1038/sj.onc.1208220; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 2001, J CELL SCI, V114, P4385; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wong OK, 2005, J CELL BIOL, V170, P709, DOI 10.1083/jcb.200502163; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	46	75	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15217	15227		10.1074/jbc.M611053200	http://dx.doi.org/10.1074/jbc.M611053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376779	hybrid			2022-12-25	WOS:000246589000061
J	Beuret, L; Flori, E; Denoyelle, C; Bille, K; Busca, R; Picardo, M; Bertolotto, C; Ballotti, R				Beuret, Laurent; Flori, Enrica; Denoyelle, Christophe; Bille, Karine; Busca, Roser; Picardo, Mauro; Bertolotto, Corine; Ballotti, Robert			Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA GENE-PRODUCT; TRANSCRIPTION FACTOR MITF; NF-KAPPA-B; C-MET; FACTOR/SCATTER FACTOR; MALIGNANT-MELANOMA; LINEAGE SURVIVAL; INVASIVE GROWTH; CARCINOMA-CELLS; DOWN-REGULATION	The MET proto-oncogene encodes for the hepatocyte growth factor (HGF) receptor, a plasma membrane tyrosine kinase that is involved in melanocyte growth and melanoma development. In mouse melanoma cells, Met expression is increased by alpha MSH via the activation of the cAMP pathway. However, the mechanism by which cAMP regulates MET and the biological consequences of this increase were not known. In the present report, we show that alpha MSH regulates MET expression in both human melanocytes and mouse melanoma cells through a transcriptional mechanism that requires MITF. Furthermore, the adenovirus driven expression of MITF is sufficient to increase MET in melanoma cells. Functional analysis of the MET promoter allows us to identify an E-box motif conserved in both human and mouse promoter that mediates the effect of MITF. Interestingly, up-regulation of MET expression by cAMP leads to an exacerbated HGF signaling and allows HGF to protect melanocytes and melanoma cells from apoptosis. Thus, physiological stimuli or pathological events that would induce MITF expression may lead to increased MET expression thereby favoring melanoma survival. These observations strengthen the roles of MITF and MET in melanoma development.	INSERM, U597, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice, France; Univ Nice Sophia Antipolis, UFR Med, Nice, France; IRCCS, Lab Fisiopatol Cutanea, Ist Dermatol San Gallicano, I-00144 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Ballotti, R (corresponding author), INSERM, U597, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice, France.	ballotti@unice.fr	Picardo, Mauro/A-6978-2011; Bertolotto-Ballotti, Corine/O-2155-2016; DENOYELLE, Christophe CD/K-6205-2015; BALLOTTI, Robert/F-8825-2013; Flori, Enrica/H-4417-2014; Bertolotto, Corine/AAF-6634-2021	Picardo, Mauro/0000-0003-4899-6639; DENOYELLE, Christophe CD/0000-0001-7153-8826; Flori, Enrica/0000-0002-9275-1041; Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bolanos-Garcia VM, 2005, MOL CELL BIOCHEM, V276, P149, DOI 10.1007/s11010-005-3696-6; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen QY, 1997, HEPATOLOGY, V26, P59; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cruz J, 2003, ONCOLOGY-BASEL, V65, P72, DOI 10.1159/000071207; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Gaggioli C, 2003, PIGM CELL RES, V16, P374, DOI 10.1034/j.1600-0749.2003.00057.x; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Hamasuna R, 1999, INT J CANCER, V82, P274, DOI 10.1002/(SICI)1097-0215(19990719)82:2<274::AID-IJC19>3.0.CO;2-2; Kankuri E, 2005, CANCER RES, V65, P9914, DOI 10.1158/0008-5472.CAN-05-1559; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Noonan FP, 2000, CANCER RES, V60, P3738; Otsuka T, 1998, CANCER RES, V58, P5157; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Recio JA, 2003, CANCER RES, V63, P1576; Rusciano D, 1999, J CELL SCI, V112, P623; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Wu M, 2000, GENE DEV, V14, P301; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF82, DOI 10.1152/ajprenal.00200.2002	41	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14140	14147		10.1074/jbc.M611563200	http://dx.doi.org/10.1074/jbc.M611563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371876	hybrid			2022-12-25	WOS:000246245800024
J	Davis, AJ; Im, YJ; Dubin, JS; Tomer, KB; Boss, WF				Davis, Amanda J.; Im, Yang Ju; Dubin, Joshua S.; Tomer, Kenneth B.; Boss, Wendy F.			RETRACTED: Arabidopsis phosphatidylinositol phosphate kinase 1 binds F-actin and recruits phosphatidylinositol 4-kinase beta 1 to the actin cytoskeleton (Retracted article. See vol. 284, pg. 16060, 2009)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							PLECKSTRIN HOMOLOGY DOMAIN; POLLEN-TUBE GROWTH; ROOT HAIR-CELLS; PHOSPHOINOSITIDE METABOLISM; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; 5-KINASE; PROTEIN; ORGANIZATION; CYCLODEXTRINS	The actin cytoskeleton can be influenced by phospholipids and lipid-modifying enzymes. In animals the phosphatidylinositol phosphate kinases (PIPKs) are associated with the cytoskeleton through a scaffold of proteins; however, in plants such an interaction was not clear. Our approach was to determine which of the plant PIPKs interact with actin and determine whether the PIPK-actin interaction is direct. Our results indicate that AtPIPK1 interacts directly with actin and that the binding is mediated through a predicted linker region in the lipid kinase. AtPIPK1 also recruits AtPI4K beta 1 to the cytoskeleton. Recruitment of AtPI4K beta 1 to F-actin was dependent on the C-terminal catalytic domain of phosphatidylinositol-4-phosphate 5-kinase but did not require the presence of the N-terminal 251 amino acids, which includes 7 putative membrane occupation and recognition nexus motifs. In vivo studies confirm the interaction of plant lipid kinases with the cytoskeleton and suggest a role for actin in targeting PIPKs to the membrane.	N Carolina State Univ, Raleigh, NC 27695 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Boss, WF (corresponding author), N Carolina State Univ, Box 7649, Raleigh, NC 27695 USA.	wendy_boss@ncsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050171, Z01ES050171] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABE S, 1992, J EXP BOT, V43, P941, DOI 10.1093/jxb/43.7.941; Boss Wendy E., 2006, V39, P181; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC, P47; Davis AJ, 2004, J LIPID RES, V45, P1783, DOI 10.1194/jlr.D400005-JLR200; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dowd PE, 2006, PLANT CELL, V18, P1438, DOI 10.1105/tpc.106.041582; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Fauvelle F, 1997, J PHARM SCI, V86, P935, DOI 10.1021/js9602453; Gubbels MJ, 2006, J CELL SCI, V119, P2236, DOI 10.1242/jcs.02949; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; Heilmann I, 1999, PLANT PHYSIOL, V119, P1331, DOI 10.1104/pp.119.4.1331; Helling D, 2006, PLANT CELL, V18, P3519, DOI 10.1105/tpc.106.047373; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Im YJ, 2007, J BIOL CHEM, V282, P5443, DOI 10.1074/jbc.M611342200; Javierre I, 2002, J COLLOID INTERF SCI, V254, P120, DOI 10.1006/jcis.2002.8545; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; KARUPPIAH N, 1995, BIOCHEM BIOPH RES CO, V211, P60, DOI 10.1006/bbrc.1995.1778; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; Kovar DR, 2000, PLANT CELL, V12, P583, DOI 10.1105/tpc.12.4.583; Kusner DJ, 2003, ARCH BIOCHEM BIOPHYS, V412, P231, DOI 10.1016/S0003-9861(03)00052-3; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Perera IY, 2005, FEBS LETT, V579, P3427, DOI 10.1016/j.febslet.2005.05.018; Preuss ML, 2006, J CELL BIOL, V172, P991, DOI 10.1083/jcb.200508116; Preuss ML, 2004, PLANT CELL, V16, P1589, DOI 10.1105/tpc.021634; Shimada H, 2004, PLANT CELL PHYSIOL, V45, P960, DOI 10.1093/pcp/pch130; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Staiger CJ, 2006, CURR OPIN PLANT BIOL, V9, P554, DOI 10.1016/j.pbi.2006.09.013; Staiger CJ, 1997, TRENDS PLANT SCI, V2, P275, DOI 10.1016/S1360-1385(97)86350-9; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Stevenson-Paulik J, 2003, PLANT PHYSIOL, V132, P1053, DOI 10.1104/pp.103.021758; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Van Gestel K, 2002, J EXP BOT, V53, P659, DOI 10.1093/jexbot/53.369.659; Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074; Westergren T, 2001, BIOCHEM J, V359, P583, DOI 10.1042/0264-6021:3590583; XU P, 1992, PLANT CELL, V4, P941, DOI 10.1105/tpc.4.8.941; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhong RQ, 2004, PLANT CELL, V16, P3242, DOI 10.1105/tpc.104.027466	47	15	15	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14121	14131		10.1074/jbc.M611728200	http://dx.doi.org/10.1074/jbc.M611728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379598	hybrid			2022-12-25	WOS:000246245800022
J	Han, JH; Zhou, H; Li, ZZ; Xu, RM; Zhang, ZG				Han, Junhong; Zhou, Hui; Li, Zhizhong; Xu, Rui-Ming; Zhang, Zhiguo			The Rtt109-Vps75 histone acetyltransferase complex acetylates non-nucleosomal histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; H3K56 ACETYLATION; CELL-CYCLE; LYSINE-56; DNA; CHROMATIN; TRANSCRIPTION; REPLICATION; STABILITY; INTEGRITY	Acetylation of lysine 56 of histone H3 (H3-Lys-56) occurs in S phase and disappears during G(2)/M phase of the cell cycle. However, it is not clear how this modification is regulated during the progression of the cell cycle. We and others have shown that the histone acetyltransferase (AT) Rtt109 is the primary HAT responsible for acetylating H3-Lys-56 in budding yeast. Here we show that Rtt109 forms a complex with Vps75 and that both recombinant Rtt109-Vps75 complexes and native complexes purified from yeast cells acetylate H3 present in H3/H4/H2A/H2B core histones but not other histones. In addition, both recombinant and native Rtt109-Vps75 HAT complexes exhibited no detectable activity toward nucleosomal H3, suggesting that H3-Lys-56 acetylation is at least in part regulated by the inability of Rtt109-Vps75 complexes to acetylate nucleosomal H3 during G(2)/M phase of the cell cycle. Further, Rtt109 bound mutant H3/H4 tetramers composed of histones lacking their N-terminal tail domains less efficiently than wild-type H3/H4 tetramers, and Rtt109-Vps75 complexes displayed reduced HAT activity toward these mutant H3/H4 tetramers. Thus, the N termini of H3/H4 tetramers are required for efficient acetylation of H3 by the Rtt109-Vps75 complex. Taken together, these studies provide insights into how H3-Lys-56 acetylation is regulated during the cell cycle.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; NYU, Sch Med, Helen L & Martin S Kimmel Ctr Biol & Med, Skirball Inst Biomed,Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Mayo Clinic; New York University; New York University	Zhang, ZG (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	Zhang.Zhiguo@mayo.edu	xu, rui/GRX-5734-2022; Han, Junhong/L-5264-2013	Han, Junhong/0000-0002-3371-8698				AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; van Holde KE., 1989, SPRINGER SERIES MOL; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	28	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14158	14164		10.1074/jbc.M700611200	http://dx.doi.org/10.1074/jbc.M700611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369253	hybrid			2022-12-25	WOS:000246245800026
J	Scherner, O; Meurer, SK; Tihaa, L; Gressner, AM; Weiskirchen, R				Scherner, Olaf; Meurer, Steffen K.; Tihaa, Lidia; Gressner, Axel M.; Weiskirchen, Ralf			Endoglin differentially modulates antagonistic transforming growth factor-beta 1 and BMP-7 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; BONE MORPHOGENETIC PROTEIN-7; HEPATIC STELLATE CELLS; I RECEPTORS; OSTEOGENIC PROTEIN-1; ENDOTHELIAL-CELLS; OSTEOBLAST DIFFERENTIATION; MYOGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX	Transforming growth factor-beta 1 (TGF-beta 1) and BMP-7 (bone morphogenetic protein-7; OP-1) play central, antagonistic roles in kidney fibrosis, a setting in which the expression of endoglin (CD105), an accessory TGF-beta type III receptor, is increased. So far, endoglin is known as a negative regulator of TGF-beta/ALK-5 signaling. Here we analyzed the effect of BMP-7 on TGF-beta 1 signaling and the role of endoglin for both pathways in endoglin-deficient L6E9 cells. In this myoblastic cell line, TGF-beta 1 and BMPs are opposing cytokines, interfering with myogenic differentiation. Both induce specific target genes of which Id1 (for BMPs) and collagen I (for TGF-beta 1) are two examples. TGF-beta 1 activated two distinct type I receptors, ALK-5 and ALK-1, in these cells. Although the ALK-5/Smad3 signaling pathway mediated collagen I expression, ALK-1/Smad1/Smad5 signaling mediated a transient Id1 up-regulation. In contrast, BMP-7 exclusively activated Smad1/Smad5 resulting in a more prolonged Id1 expression. Although BMP-7 had no impact on collagen I abundance, it antagonized TGF-beta 1-induced collagen I expression and (CAGA) 12-MLP-Luc activity, effects that are mediated by the ALK-5/Smad3 pathway. Finally, we found that the transient overexpression of endoglin, previously shown to inhibit TGF-beta 1-induced ALK-5/Smad3 signaling, enhanced the BMP-7/Smad1/Smad5 pathway.	RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Weiskirchen, R (corresponding author), RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany.	rweiskirchen@ukaachen.de	Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Aoki H, 2001, J CELL SCI, V114, P1483; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebisawa T, 1999, J CELL SCI, V112, P3519; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Gu K, 2004, CELLS TISSUES ORGANS, V176, P28, DOI 10.1159/000075025; Guo BQ, 2004, ANTICANCER RES, V24, P1337; HEINO J, 1990, J BIOL CHEM, V265, P10181; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Izumi N, 2006, AM J PHYSIOL-LUNG C, V290, pL120, DOI 10.1152/ajplung.00171.2005; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KINOSHITA K, 2006, GUT; Kollias HD, 2006, MOL CELL BIOL, V26, P6248, DOI 10.1128/MCB.00384-06; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Meurer SK, 2005, J BIOL CHEM, V280, P3078, DOI 10.1074/jbc.M405411200; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newfeld SJ, 1999, GENETICS, V152, P783; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Obreo J, 2004, CELL PHYSIOL BIOCHEM, V14, P301, DOI 10.1159/000080340; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Rodriguez-Barbero A, 2001, BIOCHEM BIOPH RES CO, V282, P142, DOI 10.1006/bbrc.2001.4526; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sorensen LK, 2003, DEV BIOL, V261, P235, DOI 10.1016/S0012-1606(03)00158-1; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303-7207(03)00151-5; Vinals F, 2004, J BIOL CHEM, V279, P45766, DOI 10.1074/jbc.M408059200; Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200; Weiskirchen R, 2000, BIOCHEM BIOPH RES CO, V274, P655, DOI 10.1006/bbrc.2000.3187; Wiercinska E, 2006, HEPATOLOGY, V43, P1032, DOI 10.1002/hep.21135; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	65	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13934	13943		10.1074/jbc.M611062200	http://dx.doi.org/10.1074/jbc.M611062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376778	hybrid			2022-12-25	WOS:000246245800003
J	St-Jean, M; Izard, T; Sygusch, J				St-Jean, Miguel; Izard, Tina; Sygusch, Jurgen			A hydrophobic pocket in the active site of glycolytic aldolase mediates interactions with Wiskott-Aldrich syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; F-ACTIN; N-WASP; WASP/SCAR PROTEINS; BINDING; POLYMERIZATION; ACTIVATION; ENZYMES; MUSCLE; MECHANISM	Aldolase plays essential catalytic roles in glycolysis and gluconeogenesis. However, aldolase is a highly abundant protein that is remarkably promiscuous in its interactions with other cellular proteins. In particular, aldolase binds to highly acidic amino acid sequences, including the C terminus of the Wiskott-Aldrich syndrome protein, an actin nucleation-promoting factor. Here we report the crystal structure of tetrameric rabbit muscle aldolase in complex with a C-terminal peptide of Wiskott-Aldrich syndrome protein. Aldolase recognizes a short, four-residue DEWD motif (residues 498 - 501), which adopts a loose hairpin turn that folds around the central aromatic residue, enabling its tryptophan side chain to fit into a hydrophobic pocket in the active site of aldolase. The flanking acidic residues in this binding motif provide further interactions with conserved aldolase active site residues Arg-42 and Arg-303, aligning their side chains and forming the sides of the hydrophobic pocket. The binding of Wiskott-Aldrich syndrome protein to aldolase precludes intramolecular interactions of its C terminus with its active site and is competitive with substrate as well as with binding by actin and cortactin. Finally, based on this structure, a novel naphthol phosphate-based inhibitor of aldolase was identified, and its structure in complex with aldolase demonstrated mimicry of the Wiskott-Aldrich syndrome protein-aldolase interaction. The data support a model whereby aldolase exists in distinct forms that regulate glycolysis or actin dynamics.	Univ Montreal, Stn Ctr Ville, Dept Biochem, Montreal, PQ H3C 3J7, Canada; St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA	Universite de Montreal; St Jude Children's Research Hospital	Sygusch, J (corresponding author), Univ Montreal, Stn Ctr Ville, Dept Biochem, CP 6128, Montreal, PQ H3C 3J7, Canada.	Jurgen.Sygusch@UMontreal.CA		Sygusch, Jurgen/0000-0002-6629-2128	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071596] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antunes N, 2006, KIDNEY INT, V69, P68, DOI 10.1038/sj.ki.5000013; ARNOLD H, 1971, EUR J BIOCHEM, V22, P121, DOI 10.1111/j.1432-1033.1971.tb01522.x; ARNOLD H, 1968, EUR J BIOCHEM, V6, P163, DOI 10.1111/j.1432-1033.1968.tb00434.x; Atkinson SJ, 2004, J BIOL CHEM, V279, P5194, DOI 10.1074/jbc.M306973200; BARANOWSKI T, 1949, J BIOL CHEM, V180, P543; BERSHADSKY AD, 1983, CELL BIOL INT REP, V7, P173, DOI 10.1016/0309-1651(83)90218-7; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; CLARKE FM, 1976, BIOCHEM J, V159, P797, DOI 10.1042/bj1590797; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; KUHNE W, 1993, AM J PHYSIOL, V264, pH1599, DOI 10.1152/ajpheart.1993.264.5.H1599; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Lundmark R, 2004, J BIOL CHEM, V279, P42694, DOI 10.1074/jbc.M407430200; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Maughan DW, 2005, MOL CELL PROTEOMICS, V4, P1541, DOI 10.1074/mcp.M500053-MCP200; Meyerhof O, 1936, BIOCHEM Z, V286, P301; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; Navarro-Lerida I, 2004, PROTEOMICS, V4, P339, DOI 10.1002/pmic.200300528; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; PENHOET E, 1967, BIOCHEMISTRY-US, V6, P2040; Pimentel G.C., 1960, HYDROGEN BOND; RACKER E, 1947, J BIOL CHEM, V167, P843; ROSE IA, 1965, J BIOL CHEM, V240, P1758; Schindler R, 2001, BIOCHEM CELL BIOL, V79, P719, DOI 10.1139/bcb-79-6-719; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; St-Jean M, 2005, J BIOL CHEM, V280, P27262, DOI 10.1074/jbc.M502413200; STRAPAZON E, 1976, BIOCHEMISTRY-US, V15, P1421, DOI 10.1021/bi00652a011; Sukumvanich P, 2004, CELL MOTIL CYTOSKEL, V59, P141, DOI 10.1002/cm.20030; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8; Wang J, 1997, EXP CELL RES, V237, P445, DOI 10.1006/excr.1997.3811; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	52	23	25	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14309	14315		10.1074/jbc.M611505200	http://dx.doi.org/10.1074/jbc.M611505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17329259	hybrid			2022-12-25	WOS:000246245800042
J	Koziczak-Holbro, M; Joyce, C; Gluck, A; Kinzel, B; Muller, M; Tschopp, C; Mathison, JC; Davis, CN; Gram, H				Koziczak-Holbro, Magdalena; Joyce, Claire; Glueck, Anton; Kinzel, Bernd; Mueller, Matthias; Tschopp, Claude; Mathison, John C.; Davis, Christopher N.; Gram, Hermann			IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; TOLL-LIKE RECEPTORS; NF-KAPPA-B; BACTERIAL-INFECTIONS; INNATE IMMUNITY; ACTIVATION; COMPLEX; FAMILY; AUTOPHOSPHORYLATION; PHOSPHORYLATION	IRAK-4 is an essential component of the signal transduction complex downstream of the IL-1- and Toll-like receptors. Although regarded as the first kinase in the signaling cascade, the role of IRAK-4 kinase activity versus its scaffold function is still controversial. To investigate the role of IRAK-4 kinase function in vivo, "knock- in" mice were generated by replacing the wild type IRAK-4 gene with a mutant gene encoding kinase-deficient IRAK-4 protein (IRAK-4 KD). IRAK-4 kinase was rendered inactive by mutating the conserved lysine residues in the ATP pocket essential for coordinating ATP. Analyses of embryonic fibroblasts and macrophages obtained from IRAK-4 KD mice demonstrate lack of cellular responsiveness to stimulation with IL-1 beta or a Toll- like receptor 7 (TLR7) agonist. IRAK-4 kinase deficiency prevents the recruitment of IRAK-1 to the IL-1 receptor complex and its subsequent phosphorylation and degradation. IRAK-4 KD cells are severely impaired in NF kappa B, JNK, and p38 activation in response to IL-1 beta or TLR7 ligand. As a consequence, IL-1 receptor/TLR7-mediated production of cytokines and chemokines is largely absent in these cells. Additionally, microarray analysis identified IL-1 beta response genes and revealed that the induction of IL-1 beta-responsive mRNAs is largely ablated in IRAK-4KDcells. In summary, our results suggest that IRAK-4 kinase activity plays a critical role in IL-1 receptor (IL-1R)/TLR7-mediated induction of inflammatory responses.	Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Novartis; Scripps Research Institute	Gram, H (corresponding author), Novartis Inst BioMed Res, Kohlenstr 10,Bldg 386-9-27, CH-4002 Basel, Switzerland.	hermann.gram@novartis.com						Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Cheng H, 2007, BIOCHEM BIOPH RES CO, V352, P609, DOI 10.1016/j.bbrc.2006.11.068; Comalada N, 2003, AM J PHYSIOL-CELL PH, V285, pC1235, DOI 10.1152/ajpcell.00228.2003; Davis CN, 2006, J NEUROCHEM, V98, P1379, DOI 10.1111/j.1471-4159.2006.03951.x; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medvedev AE, 2005, J IMMUNOL, V174, P6587, DOI 10.4049/jimmunol.174.11.6587; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Suzuki N, 2006, SCIENCE, V311, P1927, DOI 10.1126/science.1124256; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang ZL, 2006, STRUCTURE, V14, P1835, DOI 10.1016/j.str.2006.11.001; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	64	87	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13552	13560		10.1074/jbc.M700548200	http://dx.doi.org/10.1074/jbc.M700548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337443	hybrid			2022-12-25	WOS:000246060300044
J	Rizwan, AN; Krick, W; Burckhardt, G				Rizwan, Ahsan N.; Krick, Wolfgang; Burckhardt, Gerhard			The chloride dependence of the human organic anion transporter 1 (hOAT1) is blunted by mutation of a single amino acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; FUNCTIONAL-CHARACTERIZATION; CATION TRANSPORTERS; EXPRESSION CLONING; MOLECULAR-CLONING; LACTOSE PERMEASE; RAT-KIDNEY; OAT1; POLYMORPHISMS; SPECIFICITY	Organic anion transporter 1 (OAT1) is key for the secretion of organic anions in renal proximal tubules. These organic anions comprise endogenous as well as exogenous compounds including frequently used drugs of various chemical structures. The molecular basis for the polyspecificity of OAT1 is not known. Here we mutated a conserved positively charged arginine residue (Arg(466)) in the 11(th) transmembrane helix of human OAT1. The replacement by the positively charged lysine (R466K) did not impair expression of hOAT1 at the plasma membrane of Xenopus laevis oocytes but decreased the transport of p-aminohippurate (PAH) considerably. Extracellular glutarate inhibited and intracellular glutarate trans-stimulated wild type and mutated OAT1, suggesting for the mutant R466K an unimpaired interaction with dicarboxylates. However, when Arg(466) was replaced by the negatively charged aspartate (R466D), glutarate no longer interacted with the mutant. PAH uptake by wild type hOAT1 was stimulated in the presence of chloride, whereas the R466K mutant was chloride-insensitive. Likewise, the uptake of labeled glutarate or ochratoxin A was chloride-dependent in the wild type but not in R466K. Kinetic experiments revealed that chloride did not alter the apparent K-m for PAH but influenced V-max in wild type OAT1-expressing oocytes. In R466K mutants the apparent Km for PAH was similar to that of the wild type, but V-max was not changed by chloride removal. We conclude that Arg(466) influences the binding of glutarate, but not interaction with PAH, and interacts with chloride, which is a major determinant in substrate translocation.	Univ Gottingen, Abt Vegetat Physiol & Pathophysiol, Zentrum Physiol & Pathophysiol, D-37073 Gottingen, Germany	University of Gottingen	Burckhardt, G (corresponding author), Univ Gottingen, Abt Vegetat Physiol & Pathophysiol, Zentrum Physiol & Pathophysiol, Humboldtallee 23, D-37073 Gottingen, Germany.	gburckh@gwdg.de						Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; Anzai N, 2006, J PHARMACOL SCI, V100, P411, DOI 10.1254/jphs.CRJ06006X; Bahn A, 2005, AM J PHYSIOL-CELL PH, V289, pC1075, DOI 10.1152/ajpcell.00619.2004; Bahn A, 2004, DRUG METAB DISPOS, V32, P424, DOI 10.1124/dmd.32.4.424; Bahn A, 2004, BIOCHIMIE, V86, P133, DOI 10.1016/j.biochi.2003.12.001; Bleasby K, 2005, J PHARMACOL EXP THER, V314, P923, DOI 10.1124/jpet.105.084301; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; Fujita Tomoe, 2005, Pharmacogenet Genomics, V15, P201, DOI 10.1097/01213011-200504000-00003; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Hagos Y, 2007, J AM SOC NEPHROL, V18, P430, DOI 10.1681/ASN.2006040415; Hong M, 2004, J BIOL CHEM, V279, P31478, DOI 10.1074/jbc.M404686200; Hong M, 2007, BIOCHEM J, V401, P515, DOI 10.1042/BJ20061171; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Kimura H, 2002, J PHARMACOL EXP THER, V301, P293, DOI 10.1124/jpet.301.1.293; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; Perry JL, 2006, J BIOL CHEM, V281, P38071, DOI 10.1074/jbc.M608834200; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tanaka K, 2004, BIOCHEM J, V380, P283, DOI 10.1042/BJ20031724; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Uwai Y, 1998, FEBS LETT, V438, P321, DOI 10.1016/S0014-5793(98)01328-3; Wolff NA, 2003, J AM SOC NEPHROL, V14, P1959, DOI 10.1097/01.ASN.0000079040.55124.25; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; Wolff NA, 2001, J AM SOC NEPHROL, V12, P2012, DOI 10.1681/ASN.V12102012; Xu G, 2005, KIDNEY INT, V68, P1491, DOI 10.1111/j.1523-1755.2005.00612.x; Xu W, 2006, J BIOL CHEM, V281, P31178, DOI 10.1074/jbc.M605664200; Zhang XH, 2005, J BIOL CHEM, V280, P34813, DOI 10.1074/jbc.M506342200	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13402	13409		10.1074/jbc.M609849200	http://dx.doi.org/10.1074/jbc.M609849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353191	hybrid			2022-12-25	WOS:000246060300029
J	Saxena, NK; Vertino, PM; Anania, FA; Sharma, D				Saxena, Neeraj K.; Vertino, Paula M.; Anania, Frank A.; Sharma, Dipali			Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED KINASE; FEMALE MICE; D1; TRANSCRIPTION; EXPRESSION; INDUCTION; OVEREXPRESSION; TRANSFORMATION; REQUIREMENT; TRANSDUCER	Numerous epidemiological studies documented that obesity is a risk factor for breast cancer development in postmenopausal women. Leptin, the key player in the regulation of energy balance and body weight control also acts as a growth factor on certain organs in both normal and disease state. In this study, we analyzed the role of leptin and the molecular mechanism(s) underlying its action in breast cancer cells that express both short and long isoforms of leptin receptor. Leptin increased MCF7 cell population in the S-phase of the cell cycle along with a robust increase in CYCLIN D1 expression. Also, leptin induced Stat3-phosphorylation-dependent proliferation of MCF7 cells as blocking Stat3 phosphorylation with a specific inhibitor, AG490, abolished leptin-induced proliferation. Using deletion constructs of CYCLIN D1 promoter and chromatin immunoprecipitation assay, we show that leptin induced increase in CYCLIN D1 promoter activity is mediated through binding of activated Stat3 at the Stat binding sites and changes in histone acetylation and methylation. We also show specific involvement of coactivator molecules, histone acetyltransferase SRC1, and mediator complex in leptin-mediated regulation of CYCLIN D1 promoter. Importantly, silencing of SRC1 and Med1 abolished the leptin induced increase in CYCLIN D1 expression and MCF7 cell proliferation. Intriguingly, recruitment of both SRC1 and Med1 was dependent on phosphorylated Stat3 as AG490 treatment inhibited leptin-induced recruitment of these coactivators to CYCLIN D1 promoter. Our data suggest that CYCLIN D1 may be a target gene for leptin mediated growth stimulation of breast cancer cells and molecular mechanisms involve activated Stat3-mediated recruitment of distinct coactivator complexes.	Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Digest Dis, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Sharma, D (corresponding author), 1701 Uppergate Dr, Atlanta, GA 30322 USA.	dsharma@emory.edu			NATIONAL CANCER INSTITUTE [R01CA077337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062092, R01DK062092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA012933] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077337-07, R01 CA077337-06A1, R01 CA077337] Funding Source: Medline; NIAAA NIH HHS [AA 12933, R21 AA012933, R21 AA012933-02] Funding Source: Medline; NIDDK NIH HHS [R56 DK062092, DK 062092, R01 DK062092, R01 DK062092-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2004, PHYSIOL BEHAV, V81, P223, DOI 10.1016/j.physbeh.2004.02.014; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Bahrenberg G, 2002, MOL ENDOCRINOL, V16, P859, DOI 10.1210/me.16.4.859; Berclaz G, 2004, ANN ONCOL, V15, P875, DOI 10.1093/annonc/mdh222; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burdelya L, 2002, MOL CANCER THER, V1, P893; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cleary MP, 2004, EXP BIOL MED, V229, P182, DOI 10.1177/153537020422900207; Cleary MP, 2003, BREAST CANCER RES TR, V77, P205, DOI 10.1023/A:1021891825399; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Dizdar O, 2004, MED HYPOTHESES, V63, P790, DOI 10.1016/j.mehy.2004.01.046; Flajollet S, 2006, J BIOL CHEM, V281, P20338, DOI 10.1074/jbc.M603023200; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Gertler A, 2006, TRENDS ENDOCRIN MET, V17, P372, DOI 10.1016/j.tem.2006.09.006; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Han SW, 2003, ONCOL REP, V10, P141; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; Housa D, 2006, PHYSIOL RES, V55, P233, DOI 10.33549/physiolres.930848; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Misra P, 2002, J BIOL CHEM, V277, P48745, DOI 10.1074/jbc.M208829200; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Palamara Kerri L, 2006, Cardiol Rev, V14, P238, DOI 10.1097/01.crd.0000233903.57946.fd; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Saxena NK, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1847fje; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; SHARMA D, 2006, ENDOCR-RELAT CANCER, V13, P1; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sulkowska M, 2006, PATHOL ONCOL RES, V12, P69, DOI 10.1007/BF02893446; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316	55	159	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13316	13325		10.1074/jbc.M609798200	http://dx.doi.org/10.1074/jbc.M609798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344214	Green Accepted, hybrid			2022-12-25	WOS:000246060300019
J	Xia, SH; Forman, LW; Faller, DV				Xia, Shuhua; Forman, Lora W.; Faller, Douglas V.			Protein kinase C delta is required for survival of cells expressing activated p21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-INDUCED APOPTOSIS; CANCER CELLS; SIGNALING PATHWAYS; PREMATURE SENESCENCE; MEDIATED APOPTOSIS; PKC ISOFORMS; T-CELLS; INHIBITION; GROWTH; PHOSPHORYLATION	Inhibition of protein kinase C (PKC) activity in transformed cells and tumor cells containing activated p21(RAS) results in apoptosis. To investigate the pro-apoptotic pathway induced by the p21RAS oncoprotein, we first identified the specific PKC isozyme necessary to prevent apoptosis in the presence of activated p21(RAS). Dominant-negative mutants of PKC, short interfering RNA vectors, and PKC isozyme-specific chemical inhibitors directed against the PKC delta isozyme demonstrated that PKC delta plays a critical role in p21(RAS)- mediated apoptosis. An activating p21(RAS) mutation, or activation of the phosphatidylinositol 3-kinase (PI3K) Ras effector pathway, increased the levels of PKC delta protein and activity in cells, whereas inhibition of p21RAS activity decreased the expression of the PKC delta protein. Activation of the Akt survival pathway by oncogenic Ras required PKC delta activity. Akt activity was dramatically decreased after PKC delta suppression in cells containing activated p21(RAS). Conversely, constitutively activated Akt rescued cells from apoptosis induced by PKC delta inhibition. Collectively, these findings demonstrate that p21(RAS), through its downstream effector PI3K, induces PKC delta expression and that this increase in PKC delta activity, acting through Akt, is required for cell survival. The p21RAS effector molecule responsible for the initiation of the apoptotic signal after suppression of PKC delta activity was also determined to be PI3K. PI3K (p110(CAAX), where AA is aliphatic amino acid) was sufficient for induction of apoptosis after PKC delta inhibition. Thus, the same p21(RAS) effector, PI3K, is responsible for delivering both a pro-apoptotic signal and a survival signal, the latter being mediated by PKC delta and Akt. Selective suppression of PKC delta activity and consequent induction of apoptosis is a potential strategy for targeting of tumor cells containing an activated p21(RAS).	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, K-701,715 Albany St, Boston, MA 02118 USA.	dfaller@bu.edu			NCI NIH HHS [R41 CA141908, CA108100, CA112102, R41 CA108100, R01 CA112102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112102, R41CA141908, R41CA108100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Chou CK, 2006, LIFE SCI, V78, P1823, DOI 10.1016/j.lfs.2005.08.039; Clark AS, 2003, CANCER RES, V63, P780; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Hiraragi H, 2005, J VIROL, V79, P9449, DOI 10.1128/JVI.79.15.9449-9457.2005; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jung JW, 2005, CANCER LETT, V225, P199, DOI 10.1016/j.canlet.2004.11.029; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kiley SC, 1999, CANCER RES, V59, P3230; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liou JS, 2004, J CELL PHYSIOL, V198, P277, DOI 10.1002/jcp.10409; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Majumder S., 1997, Indian Journal of Experimental Biology, V35, P162; McCracken MA, 2003, MOL CANCER THER, V2, P273; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Okhrimenko H, 2005, J BIOL CHEM, V280, P23643, DOI 10.1074/jbc.M501374200; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Stice LL, 2002, EXP CELL RES, V275, P17, DOI 10.1006/excr.2002.5482; SUN C, 2000, J STOMATOLOGY, V18, P237; Thimmaiah KN, 2003, CANCER RES, V63, P364; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Whang YE, 2004, VITAM HORM, V67, P409; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zhang JD, 2005, J CELL BIOCHEM, V96, P522, DOI 10.1002/jcb.20535	62	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13199	13210		10.1074/jbc.M610225200	http://dx.doi.org/10.1074/jbc.M610225200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350960	hybrid, Green Accepted			2022-12-25	WOS:000246060300008
J	Yohe, ME; Rossman, KL; Gardner, OS; Karnoub, AE; Snyder, JT; Gershburg, S; Graves, LM; Der, CJ; Sondek, J				Yohe, Marielle E.; Rossman, Kent L.; Gardner, Olivia S.; Karnoub, Antoine E.; Snyder, Jason T.; Gershburg, Svetlana; Graves, Lee M.; Der, Channing J.; Sondek, John			Auto-inhibition of the Dbl family protein tim by an N-terminal helical motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; TYROSINE PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; SIGNALING PATHWAY; GDP/GTP EXCHANGE; STRUCTURAL BASIS; RATIONAL DESIGN; ACTIVATION; VAV	Dbl-related oncoproteins are guanine nucleotide exchange factors specific for Rho-family GTPases and typically possess tandem Dbl homology (DH) and pleckstrin homology domains that act in concert to catalyze exchange. Because the ability of many Dbl-family proteins to catalyze exchange is constitutively activated by truncations N-terminal to their DH domains, it has been proposed that the activity of Dbl-family proteins is regulated by auto-inhibition. However, the exact mechanisms of regulation of Dbl- family proteins remain poorly understood. Here we show that the Dbl- family protein, Tim, is auto-inhibited by a short, helical motif immediately N-terminal to its DH domain, which directly occludes the catalytic surface of the DH domain to prevent GTPase activation. Similar to the distantly related Vav isozymes, auto-inhibition of Tim is relieved by truncation, mutation, or phosphorylation of the auto-inhibitory helix. A peptide comprising the helical motif inhibits the exchange activity of Tim in vitro. Furthermore, substitutions within the most highly conserved surface of the DH domain designed to disrupt interactions with the auto-inhibitory helix also activate the exchange process.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sondek, J (corresponding author), CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	Sondek@med.unc.edu	Graves, Lee/AAG-5470-2021	Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA92240, CA063071] Funding Source: Medline; NIGMS NIH HHS [GM62299, GM65533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092240, R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, P01GM065533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; CHAN AML, 1994, ONCOGENE, V9, P1057; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Debily MA, 2004, HUM MOL GENET, V13, P323, DOI 10.1093/hmg/ddh024; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deprez C, 2005, J MOL BIOL, V346, P1047, DOI 10.1016/j.jmb.2004.12.028; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; Rojas RJ, 2003, COMB CHEM HIGH T SCR, V6, P409; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; Schiller MR, 2006, CELL SIGNAL, V18, P1834, DOI 10.1016/j.cellsig.2006.01.022; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; TAKAI S, 1995, CANCER GENET CYTOGEN, V83, P87, DOI 10.1016/S0165-4608(95)00017-8; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xie XZ, 2005, CELL SIGNAL, V17, P461, DOI 10.1016/j.cellsig.2004.09.012; Yamauchi J, 2002, BIOCHEM BIOPH RES CO, V296, P85, DOI 10.1016/S0006-291X(02)00839-2; Yoshizuka N, 2004, J BIOL CHEM, V279, P43998, DOI 10.1074/jbc.M406082200; Zeeh JC, 2006, J BIOL CHEM, V281, P11805, DOI 10.1074/jbc.M600149200; Zenke FT, 2004, J BIOL CHEM, V279, P18392, DOI 10.1074/jbc.M400084200; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	51	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13813	13823		10.1074/jbc.M700185200	http://dx.doi.org/10.1074/jbc.M700185200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337446	Green Published, hybrid			2022-12-25	WOS:000246060300071
J	Selth, L; Svejstrup, JQ				Selth, Luke; Svejstrup, Jesper Q.			Vps75, a new yeast member of the NAP histone chaperone family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; SACCHAROMYCES-CEREVISIAE; DNA; ACETYLATION; SCREEN; H2B	Homologues of nucleosome assembly protein 1 ( NAP1) are found throughout eukaryotes. Here we identify and characterize a new NAP family histone chaperone from budding yeast, named Vps75. Purified Vps75 preferentially binds histone H3/H4 tetramers and is capable of assembling nucleosomes in vitro. In vivo, Vps75 is associated with the chromatin of both active and inactive genes and telomeres. Others have previously reported that Vps75 forms a complex with Rtt109, required for acetylation of histone H3 lysine 56 ( H3 Lys- 56). Cells lacking RTT109 are sensitive to hydroxyurea, pointing to a role in replication. We show that VPS75 is not required for H3 Lys- 56 acetylation and that vps75 Delta cells are insensitive to hydroxyurea, suggesting that although Rtt109 and Vps75 associate and are likely to be functionally connected, they also have separate roles.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk	Selth, Luke/AAH-4823-2021	Selth, Luke/0000-0002-4686-1418; Svejstrup, Jesper/0000-0003-4964-6147				Askree SH, 2004, P NATL ACAD SCI USA, V101, P8658, DOI 10.1073/pnas.0401263101; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; Mosammaparast N, 2002, EMBO J, V21, P6527, DOI 10.1093/emboj/cdf647; NELSON T, 1979, P NATL ACAD SCI USA, V76, P5510, DOI 10.1073/pnas.76.11.5510; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2006, BIOCHEM CELL BIOL, V84, P549, DOI 10.1139/O06-088; Ricke RM, 2005, BIOL PROCED ONLINE, V7, P60, DOI 10.1251/bpo106; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Wittmeyer J, 2004, METHOD ENZYMOL, V377, P322; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011	21	62	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12358	12362		10.1074/jbc.C700012200	http://dx.doi.org/10.1074/jbc.C700012200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344218	hybrid			2022-12-25	WOS:000245942800003
J	Law, FBF; Chen, YW; Wong, KY; Ying, J; Tao, Q; Langford, C; Lee, PY; Law, S; Cheung, RWL; Chui, CH; Tsao, SW; Lam, KY; Wong, J; Srivastava, G; Tang, JCO				Law, F. B. F.; Chen, Y. W.; Wong, K. Y.; Ying, J.; Tao, Q.; Langford, C.; Lee, P. Y.; Law, S.; Cheung, R. W. L.; Chui, C. H.; Tsao, S. W.; Lam, K. Y.; Wong, J.; Srivastava, G.; Tang, J. C. O.			Identifcation of a novel tumor transforming gene GAEC1 at 7q22 which encodes a nuclear protein and is frequently amplified and overexpressed in esophageal squamous cell carcinoma	ONCOGENE			English	Article						gene amplifcation; overexpression; transforming gene; esophageal cancer; 7q22	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL IMBALANCES; KINASE-C; LINES; AMPLIFICATION; ABERRATIONS; MULTIPLE; SEQUENCE; CANCER; PCR	By comparative DNA. fingerprinting, we identified a 357-bp DNA fragment frequently amplified in esophageal squamous cell carcinomas ( ESCC). This fragment overlaps with an expressed sequence tag mapped to 7q22. Further 5' and 3'-rapid amplification of cDNA ends revealed that it is part of a novel, single-exon gene with full-length mRNA of 2052 bp and encodes a nuclear protein of 109 amino acids ( similar to 15 kDa). This gene, designated as gene amplified in esophageal cancer 1 ( GAEC1), was located within a 1-2 Mb amplicon at 7q22.1 identified by high-resolution 1 Mb array-comparative genomic hybridization in 6/10 ESCC cell lines. GAEC1 was ubiquitously expressed in normal tissues including esophageal and gastrointestinal organs; with amplification and overexpression in 6/10 ( 60%) ESCC cell lines and 34/99 ( 34%) primary tumors. Overexpression of GAEC1 in 3T3 mouse. broblasts caused foci formation and colony formation in soft agar, comparable to H-ras and injection of GAEC1-transfected 3T3 cells into athymic nude mice formed undifferentiated sarcoma in vivo, indicating that GAEC1 is a transforming oncogene. Although no significant correlation was observed between GAEC1 amplification and clinicopathological parameters and prognosis, our study demonstrated that overexpressed GAEC1 has tumorigenic potential and suggest that overexpressed GAEC1 may play an important role in ESCC pathogenesis.	Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China; Griffith Univ, Dept Pathol, Nathan, Qld 4111, Australia; Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Lo Ka Chung Ctr Nat Anti Canc Drug Dev, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong Canc Inst, Sir YK Pao Ctr Canc, Dept Clin Oncol,State Key Lab Oncol S China,Canc, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Griffith University; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; Wellcome Trust Sanger Institute; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Tang, JCO (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.	gopesh@pathology.hku.hk; bccotang@polyu.edu.hk	Law, Simon/C-4324-2009; Tang, Johnny Cheuk-on/W-7214-2019; Tsao, George/C-4422-2009; Tang, Johnny C. O./M-9639-2014; Lam, Alfred/C-1652-2008; Tao, Qian/T-4743-2018; Law, Fian/C-4692-2009	Law, Simon/0000-0002-6518-5806; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Tang, Johnny C. O./0000-0002-4261-3206; Lam, Alfred/0000-0003-2771-564X; Tao, Qian/0000-0001-5383-4808; 	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed MN, 2000, CANCER GENET CYTOGEN, V116, P10, DOI 10.1016/S0165-4608(99)00103-X; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Forozan F, 2000, CANCER RES, V60, P4519; Fujibe T, 2006, BIOSCI BIOTECH BIOCH, V70, P1827, DOI 10.1271/bbb.50673; Glockner G, 1998, GENOME RES, V8, P1060; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Ince N, 2000, CANCER RES, V60, P1261; Kang KF, 1996, J IMMUNOL, V156, P1402; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; NOWELL PC, 1989, SEMIN ONCOL, V16, P116; SolinasToldo S, 1996, CANCER RES, V56, P3803; Tang JCO, 2001, CLIN CANCER RES, V7, P1539; Watters DJ, 1999, BIOCHEM PHARMACOL, V58, P383, DOI 10.1016/S0006-2952(99)00063-5; YANG DY, 2000, J KOREAN SOC PRECISI, V17, P5; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154	23	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5877	5888		10.1038/sj.onc.1210390	http://dx.doi.org/10.1038/sj.onc.1210390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384685	Green Accepted			2022-12-25	WOS:000249123100005
J	Perks, CM; Vernon, EG; Rosendahl, AH; Tonge, D; Holly, JMP				Perks, C. M.; Vernon, E. G.; Rosendahl, A. H.; Tonge, D.; Holly, J. M. P.			IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells	ONCOGENE			English	Article						IGF-II; IGFBP-2; PTEN	FACTOR-BINDING PROTEIN-2; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-I; EPITHELIAL-CELLS; MAP KINASE; EXPRESSION; PHOSPHATASE; INHIBITION; PROLIFERATION; TUMORIGENESIS	The dual-function phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II ( IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein ( IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our. findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.	Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England; Lund Univ, Dept Oncol Clin Sci, Lund, Sweden; AstraZeneca UK, Macclesfield, Cheshire, England	Southmead Hospital; University of Bristol; Lund University; AstraZeneca	Perks, CM (corresponding author), Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England.	Claire.m.perks@bristol.ac.uk		Perks, Claire/0000-0003-1562-891X; Vernon, Ellen/0000-0002-8344-1025				Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Clark AS, 2002, MOL CANCER THER, V1, P707; Clark MA, 2005, INT J CANCER, V116, P506, DOI 10.1002/ijc.21029; COULSON VJ, 1991, GROWTH REGULAT, V1, P119; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUBOIS V, 1995, EUR J BIOCHEM, V232, P47, DOI 10.1111/j.1432-1033.1995.tb20779.x; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hoeflich A, 2001, CANCER RES, V61, P8601; Hwang PH, 2005, EXP MOL MED, V37, P391, DOI 10.1038/emm.2005.49; Kang-Park S, 2003, FEBS LETT, V545, P203, DOI 10.1016/S0014-5793(03)00535-0; Levitt RJ, 2005, BIOCHEM BIOPH RES CO, V336, P1056, DOI 10.1016/j.bbrc.2005.08.229; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liu XJ, 2001, J BIOL CHEM, V276, P32419, DOI 10.1074/jbc.C100299200; Maile LA, 1999, ENDOCRINOLOGY, V140, P4040, DOI 10.1210/en.140.9.4040; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Schmid AC, 2004, FEBS LETT, V566, P35, DOI 10.1016/j.febslet.2004.03.102; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stokoe D, 2005, P NATL ACAD SCI USA, V102, P2677, DOI 10.1073/pnas.0500089102; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967	32	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5966	5972		10.1038/sj.onc.1210397	http://dx.doi.org/10.1038/sj.onc.1210397			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369847				2022-12-25	WOS:000249123100014
J	Macpherson, IR; Hooper, S; Serrels, A; McGarry, L; Ozanne, BW; Harrington, K; Frame, MC; Sahai, E; Brunton, VG				Macpherson, I. R.; Hooper, S.; Serrels, A.; McGarry, L.; Ozanne, B. W.; Harrington, K.; Frame, M. C.; Sahai, E.; Brunton, V. G.			p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism	ONCOGENE			English	Article						p120; E-cadherin; invasion; phosphorylation	EPIDERMAL-GROWTH-FACTOR; MEDIATED TRANSCRIPTIONAL REPRESSION; E-CADHERIN EXPRESSION; RHO-FAMILY GTPASES; P120 CATENIN; NUCLEAR-LOCALIZATION; TYROSINE KINASES; COLON-CARCINOMA; BREAST-CANCER; TUMOR-CELLS	Loss of E-cadherin-mediated cell-cell junctions has been correlated with cancer cell invasion and poor patient survival. p120-catenin has emerged as a key player in promoting E-cadherin stability and adherens junction integrity and has been proposed as a potential invasion suppressor by preventing release of cells from the constraints imposed by cadherin-mediated cell-cell adhesion. However, it has been proposed that tyrosine phosphorylation of p120 may contribute to cadherin-dependent junction disassembly during invasion. Here, we use small interfering RNA ( siRNA) in A431 cells to show that knockdown of p120 promotes two-dimensional migration of cells. In contrast, p120 knockdown impairs epidermal growth factor-induced A431 invasion into three-dimensional matrix gels or in organotypic culture, whereas re-expression of siRNA-resistant p120, or a p120 isoform that cannot be phosphorylated on tyrosine, restores the collective mode of invasion employed by A431 cells in vitro. Thus, p120 promotes A431 cell invasion in a phosphorylation-independent manner. We show that the collective invasion of A431 cells depends on the presence of cadherin-mediated (P- and E-cadherin) cell-cell contacts, which are lost in cells where p120 expression is knocked down. Furthermore, membranous p120 is maintained in invasive squamous cell carcinomas in tumours suggesting that p120 may be important for the collective invasion of tumours cells in vivo.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Canc Res UK London Res Inst, London, England; Inst Canc Res, London SW3 6JB, England	Beatson Institute; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Brunton, VG (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	v.brunton@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Harrington, Kevin/0000-0002-6014-348X; Macpherson, Iain/0000-0003-4295-8885; Sahai, Erik/0000-0002-3932-5086				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Ardern H, 2006, CELL MOTIL CYTOSKEL, V63, P6, DOI 10.1002/cm.20101; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Grosheva I, 2001, J CELL SCI, V114, P695; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jensen PJ, 1997, CELL TISSUE RES, V288, P307, DOI 10.1007/s004410050816; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Lim YP, 2003, MOL CANCER THER, V2, P1369; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MCLEAN GW, 1991, J IMMUNOL METHODS, V137, P149, DOI 10.1016/0022-1759(91)90019-C; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ozawa M, 2001, J CELL SCI, V114, P503; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PLUMB JA, 1989, CANCER RES, V49, P4435; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shibata T, 2004, AM J PATHOL, V164, P2269, DOI 10.1016/S0002-9440(10)63783-2; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022	50	44	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5214	5228		10.1038/sj.onc.1210334	http://dx.doi.org/10.1038/sj.onc.1210334			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334396				2022-12-25	WOS:000248674200005
J	Saenz-Robles, MT; Toma, D; Cantalupo, P; Zhou, J; Gong, H; Edwards, C; Pipas, JM; Xie, W				Saenz-Robles, M. T.; Toma, D.; Cantalupo, P.; Zhou, J.; Gong, H.; Edwards, C.; Pipas, J. M.; Xie, W.			Repression of intestinal drug metabolizing enzymes by the SV40 large T antigen	ONCOGENE			English	Article						cytochrome P450; SV40 T antigen; retinoblastoma	VILLUS-ASSOCIATED ENTEROCYTES; NUCLEAR RECEPTOR; TRANSGENIC MICE; CELL-CYCLE; BILE-ACIDS; EXPRESSION; PROTEIN; CYTOCHROME-P450; TRANSFORMATION; TRANSPORTER	Toxic compounds such as carcinogens are removed from the body by the action of a series of detoxifying enzymes and transporters expressed in the liver and the small intestine. We have found that intestinal epithelial cells expressing the SV40 large T antigen ( TAg) contain significantly lower levels of mRNAs, encoding several drug metabolizing/ detoxifying enzymes and transporters compared to their non- transgenic littermates. In addition, TAg blocks the induction of these mRNAs by xenobiotics. The repression depends on an intact LXCXE motif in TAg, suggesting that inactivation of the retinoblastoma ( Rb) family of tumor suppressors plays a role in the process. These results imply that a functional Rb pathway in the intestine is necessary for the expression of the detoxification system used to clear carcinogens, and suggest that loss of this tumor suppressor might alter susceptibility to chemical injury. In addition, the effect of TAg on the detoxification pathway appears to be tissuespecific, as its ectopic expression in the liver failed to suppress the P450 enzymes. The TAg- mediated suppression of drug metabolizing/ detoxifying enzymes may have broad implications in the metabolism and mechanism of action of both carcinogens and prescription drugs.'	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, 578 Crawford Hall, Pittsburgh, PA 15260 USA.	pipas@pitt.edu; wex6@pitt.edu	Xie, Wen/M-1768-2016		NATIONAL CANCER INSTITUTE [R01CA040586, R37CA040586, R01CA098956, R01CA107011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012479] Funding Source: NIH RePORTER; NCI NIH HHS [CA40586, CA098956, CA107011] Funding Source: Medline; NIEHS NIH HHS [ES012479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Kim RB, 2003, EUR J CLIN INVEST, V33, P1, DOI 10.1046/j.1365-2362.33.s2.5.x; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kullak-Ublick GA, 2003, J HEPATOL, V39, P628, DOI 10.1016/S0168-8278(03)00397-0; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; McFadyen MCE, 2001, BIOCHEM PHARMACOL, V62, P207, DOI 10.1016/S0006-2952(01)00643-8; Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1; Oyama T, 2004, FRONT BIOSCI-LANDMRK, V9, P1967, DOI 10.2741/1378; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Renton KW, 2004, CURR DRUG METAB, V5, P235, DOI 10.2174/1389200043335559; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; Saini SPS, 2005, HEPATOLOGY, V41, P497, DOI 10.1002/hep.20570; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Uppal H, 2005, HEPATOLOGY, V41, P168, DOI 10.1002/hep.20512; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2004, DRUG DISCOV TODAY, V9, P442, DOI 10.1016/S1359-6446(04)03061-2	31	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5124	5131		10.1038/sj.onc.1210310	http://dx.doi.org/10.1038/sj.onc.1210310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334401				2022-12-25	WOS:000248487400011
J	Rodrigues, S; De Wever, O; Bruyneel, E; Rooney, RJ; Gespach, C				Rodrigues, S.; De Wever, O.; Bruyneel, E.; Rooney, R. J.; Gespach, C.			Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis	ONCOGENE			English	Article						adenosine A2B receptors; src; apoptosis; caspase-8; hypoxia; cDNA microarrays	NETRIN-1-MEDIATED AXON OUTGROWTH; UBIQUITIN-PROTEASOME PATHWAY; ADENOSINE A2B RECEPTOR; COLORECTAL-CANCER; ACTIVATION; ADHESION; KINASE; GENE; TUMORIGENESIS; EXPRESSION	Deleted in colon cancer (DCC) and UNC5 function as netrin dependence receptors by inducing apoptosis in the absence of their ligand and accordingly were recently designated as putative conditional tumor suppressors. Herein, we determined whether netrin-1 and its receptors are implicated in cancer cell invasion and tumor progression. Expression of DCC, UNC5 and adenosine A2B-receptors (A2B-Rs) was investigated by reverse transcription polymerase chain reaction in human colon cancer cells. The impact of DCC restitution and netrin-1 was evaluated on collagen type I invasion, tumor growth and metastasis in nude mice, cancer cell survival and gene expression pro. ling. Flow cytometry, poly(ADP-ribose)-polymerase-1 and caspase-8 activation were used to evaluate the impact of DCC on cell death. Both netrin-1 and A2B-R activation induced the invasive phenotype through the Rho-Rho kinase axis in DCC-deficient human colorectal cancer cells. Restitution of wild-type DCC blocked invasion induced by netrin-1, A2B-R agonist and other agents. Ectopic expression of netrin-1 led to increased growth of human colon tumor xenografts in athymic mice. Conversely, introduction of wt-DCC in kidney MDCKts. src-ggl cells strongly inhibited metastasis in lymph nodes and lungs and increased sensitivity to apoptosis in hypoxia. DNA microarrays revealed that netrin and DCC had common and divergent impacts on gene expression linked to cell cycle, survival, surface signaling and adhesion. Our findings underscore that netrin is a potent invasion and tumor growth-promoting agent and that DCC is a metastasis suppressor gene targeting both proinvasive and survival pathways in a cumulative manner.	INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Genome Explorat Inc, Memphis, TN USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), INSERM, U673, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bouchard JF, 2004, J NEUROSCI, V24, P3040, DOI 10.1523/JNEUROSCI.4934-03.2004; Chen L, 2005, FEBS J, V272, P2746, DOI 10.1111/j.1742-4658.2005.04694.x; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Grider JR, 2006, GASTROENTEROLOGY, V130, P771, DOI 10.1053/j.gastro.2005.12.026; Hebrok M, 2004, TRENDS CELL BIOL, V14, P153, DOI 10.1016/j.tcb.2004.02.005; Hill A, 2006, ONCOGENE, V25, P6079, DOI 10.1038/sj.onc.1209628; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Hucho TB, 2005, J NEUROSCI, V25, P6119, DOI 10.1523/JNEUROSCI.0285-05.2005; Kadono Y, 1998, CANCER RES, V58, P2240; Kim TH, 2005, J NEUROCHEM, V95, P1, DOI 10.1111/j.1471-4159.2005.03314.x; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lahti JM, 2006, CANCER RES, V66, P5981, DOI 10.1158/0008-5472.CAN-06-0131; Linden J, 1999, MOL PHARMACOL, V56, P705; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Martin M, 2006, EUR J CELL BIOL, V85, P769, DOI 10.1016/j.ejcb.2006.02.013; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIYAKI M, 1990, CANCER RES, V50, P7166; Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103; Nguyen QD, 2005, ONCOGENE, V24, P8240, DOI 10.1038/sj.onc.1208990; Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Tan EY, 2006, AM J PHYSIOL-CELL PH, V291, pC433, DOI 10.1152/ajpcell.00238.2005; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Xie Y, 2006, J BIOL CHEM, V281, P2605, DOI 10.1074/jbc.M512767200; Yebra M, 2003, DEV CELL, V5, P695, DOI 10.1016/S1534-5807(03)00330-7	40	80	90	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5615	5625		10.1038/sj.onc.1210347	http://dx.doi.org/10.1038/sj.onc.1210347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334389				2022-12-25	WOS:000248801900007
J	Davies, SL; Ozawa, A; McCormick, WD; Dvorak, MM; Ward, DT				Davies, Sarah L.; Ozawa, Ai; McCormick, Wanda D.; Dvorak, Melita M.; Ward, Donald T.			Protein kinase C-mediated phosphorylation of the calcium-sensing receptor is stimulated by receptor activation and attenuated by calyculin-sensitive phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; CA2+-SENSING RECEPTOR; CA-0(2+)-SENSING RECEPTOR; CAR; EXPRESSION; SECRETION; RELEASE; CLONING; POTENT	The agonist sensitivity of the calcium-sensing receptor ( CaR) can be altered by protein kinase C ( PKC), with CaR residue Thr(888) contributing significantly to this effect. To determine whether CaRT888 is a substrate for PKC and whether receptor activation modulates such phosphorylation, a phospho-specific antibody against this residue was raised ( CaRpT888). In HEK-293 cells stably expressing CaR ( CaR-HEK), but not in cells expressing the mutant receptor CaRT888A, phorbol ester ( PMA) treatment increased CaRp(T888) immunoreactivity as observed by immunoblotting and immunofluorescence. Raising extracellular Ca2+ concentration from 0.5 to 2.5 mM increased CaRT888 phosphorylation, an effect that was potentiated stereoselectively by the calcimimetic NPS R-467. These responses were mimicked by 5 mM extracellular Ca2+ and abolished by the calcilytic NPS-89636 and also by PKC inhibition or chronic PMA pretreatment. Whereas CaRT888A did exhibit increased apparent agonist sensitivity, by converting intracellular Ca2+ ( Ca-i(2+)) oscillations to sustained plateau responses in some cells, we still observed Ca-i(2+) oscillations in a significant number of cells. This suggests that CaRT888 contributes significantly to CaR regulation but is not the exclusive determinant of CaR-induced Ca-i(2+) oscillations. Finally, dephosphorylation of CaRT888 was blocked by the protein phosphatase 1/2A inhibitor calyculin, a treatment that also inhibited Ca-i(2+) oscillations. In addition, calyculin/PMA cotreatment increased CaRT888 phosphorylation in bovine parathyroid cells. Therefore, CaRT888 is a substrate for receptor-induced, PKC-mediated feedback phosphorylation and can be dephosphorylated by a calyculin-sensitive phosphatase.	Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England; Univ Calif San Francisco, Dept Endocrinol, San Francisco, CA 94121 USA	University of Manchester; University of California System; University of California San Francisco	Ward, DT (corresponding author), Univ Manchester, Core Technol Facil, Floor 2,46 Grafton St, Manchester M13 9NT, Lancs, England.	d.ward@manchester.ac.uk		McCormick, Wanda/0000-0002-6287-7321; Ward, Donald/0000-0003-1342-9458	Biotechnology and Biological Sciences Research Council [BBS/B/04986] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; CHARTIER L, 1991, CELL MOTIL CYTOSKEL, V18, P26, DOI 10.1002/cm.970180104; Davies SL, 2006, AM J PHYSIOL-CELL PH, V290, pC1543, DOI 10.1152/ajpcell.00482.2005; Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HOSOYA N, 1993, J CELL SCI, V105, P883; Jiang YF, 2002, J BIOL CHEM, V277, P50543, DOI 10.1074/jbc.M205798200; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; MEMBRENO L, 1989, ENDOCRINOLOGY, V124, P789, DOI 10.1210/endo-124-2-789; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE RFK, 1994, BIOCHEM BIOPH RES CO, V267, pE429; Sakwe AM, 2004, EXP CELL RES, V297, P560, DOI 10.1016/j.yexcr.2004.03.039; Tanaka M, 2004, BIOORG MED CHEM LETT, V14, P5171, DOI 10.1016/j.bmcl.2004.07.061; Ward DT, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015623.73739.B8; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200	23	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15048	15056		10.1074/jbc.M607469200	http://dx.doi.org/10.1074/jbc.M607469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376781	hybrid			2022-12-25	WOS:000246589000044
J	Kim, JG; Son, YJ; Yun, CH; Kim, YI; Nam-Goong, IS; Park, JH; Park, SK; Ojeda, SR; D'Elia, AV; Damante, G; Lee, BJ				Kim, Jae Geun; Son, Young June; Yun, Chang Ho; Kim, Young Il; Nam-Goong, Il Seong; Park, Jun Heon; Park, Sang Kyu; Ojeda, Sergio R.; D'Elia, Angela Valentina; Damante, Giuseppe; Lee, Byung Ju			Thyroid transcription factor-1 facilitates cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONICITY-RESPONSIVE ELEMENT; DNA-BINDING PROTEINS; CHOROID-PLEXUS; THYROGLOBULIN PROMOTER; GENE-TRANSCRIPTION; LUNG MORPHOGENESIS; AQP1 EXPRESSION; WATER CHANNELS; TTF-1; HOMEODOMAIN	In the brain, aquaporin-1 ( AQP-1), a water channel for high osmotic water permeability, is mainly expressed in the apical membrane of the ventricular choroid plexus and regulates formation of cerebrospinal fluid ( CSF). Although the physiology of AQP-1 has been the subject of several publications, much less is known about the trans-acting factors involved in the control of AQP-1 gene expression. Here we report that TTF-1, a homeodomain-containing transcriptional regulator, is coexpressed with AQP-1 in the rat brain choroid plexus and enhances AQP-1 gene transcription by binding to conserved core TTF-1-binding motifs in the 5'-flanking region of the AQP-1 gene. Intracerebroventricular administration of an antisense TTF-1 oligodeoxynucleotide significantly decreased AQP-1 synthesis and reduced CSF formation. In addition, blockade of TTF-1 synthesis increased survival of the animals following acute water intoxication-induced brain edema. These results suggest that TTF-1 is physiologically involved in the transcriptional control of AQP-1, which is required for CSF formation.	Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea; Ulsan Univ Hosp, Dept Internal Med, Ulsan 682060, South Korea; Ulsan Univ Hosp, Dept Pediat, Ulsan 682060, South Korea; Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Ulsan; University of Ulsan; Ulsan University Hospital; University of Ulsan; Ulsan University Hospital; Oregon Health & Science University; Oregon National Primate Research Center; University of Udine	Lee, BJ (corresponding author), Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea.	bjlee@ulsan.ac.kr	Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009; NAM-GOONG, IL SEONG/0000-0002-0492-0467	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD018185, R01HD025123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD25123, U54 HD18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Cadnapaphornchai MA, 2000, AM J MED, V109, P688, DOI 10.1016/S0002-9343(00)00622-7; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAVSON H, 1982, J NEUROBIOL, V13, P293, DOI 10.1002/neu.480130402; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Gunnarson E, 2004, NEUROSCIENCE, V129, P947, DOI 10.1016/j.neuroscience.2004.08.022; Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624; Han ZQ, 2000, BIOCHEM BIOPH RES CO, V273, P328, DOI 10.1006/bbrc.2000.2944; Johanson CE, 1999, AM J PHYSIOL-CELL PH, V276, pC82, DOI 10.1152/ajpcell.1999.276.1.C82; Kim MS, 2002, J BIOL CHEM, V277, P36863, DOI 10.1074/jbc.M206443200; Kramer SG, 1999, DEVELOPMENT, V126, P191; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Masseguin C, 2000, J APPL PHYSIOL, V88, P843, DOI 10.1152/jappl.2000.88.3.843; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Nakamura K, 2001, DEV BRAIN RES, V130, P159, DOI 10.1016/S0165-3806(01)00226-7; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Oshio K, 2003, ACT NEUR S, V86, P525; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Son YJ, 2003, J BIOL CHEM, V278, P27043, DOI 10.1074/jbc.M303157200; Speake T, 2003, BBA-BIOMEMBRANES, V1609, P80, DOI 10.1016/S0005-2736(02)00658-2; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V293, P913, DOI 10.1016/S0006-291X(02)00316-9; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Wu Q, 1998, AM J PHYSIOL-CELL PH, V275, pC1565, DOI 10.1152/ajpcell.1998.275.6.C1565; Zhang CL, 2006, NUCLEIC ACIDS RES, V34, P2238, DOI 10.1093/nar/gkl248; Zhang D, 2002, J GEN PHYSIOL, V119, P561, DOI 10.1085/jgp.20028597	44	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14923	14931		10.1074/jbc.M701411200	http://dx.doi.org/10.1074/jbc.M701411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371871	hybrid			2022-12-25	WOS:000246589000030
J	Pagan, JK; Arnold, J; Hanchard, KJ; Kumar, R; Bruno, T; Jones, MJK; Richard, DJ; Forrest, A; Spurdle, A; Verdin, E; Crossley, M; Fanciulli, M; Chenevix-Trench, G; Young, DB; Khanna, KK				Pagan, Julia K.; Arnold, Jeremy; Hanchard, Kim J.; Kumar, Raman; Bruno, Tiziana; Jones, Mathew J. K.; Richard, Derek J.; Forrest, Alistair; Spurdle, Amanda; Verdin, Eric; Crossley, Merlin; Fanciulli, Maurizio; Chenevix-Trench, Georgia; Young, David B.; Khanna, Kum Kum			A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; TERMINAL-BINDING-PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITIONS; CO-REPRESSOR; E-CADHERIN; ANKYRIN-REPEAT; ACETYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION	Corepressors play a crucial role in negative gene regulation and are defective in several diseases. BCoR is a corepressor for the BCL6 repressor protein. Here we describe and functionally characterize BCoR-L1, a homolog of BCoR. When tethered to a heterologous promoter, BCoR-L1 is capable of strong repression. Like other corepressors, BCoR-L1 associates with histone deacetylase ( HDAC) activity. Specifically, BCoR-L1 coprecipitates with the Class II HDACs, HDAC4, HDAC5, and HDAC7, suggesting that they are involved in its role as a transcriptional repressor. BCoR-L1 also interacts with the CtBP corepressor through a CtBP-interacting motif in its amino terminus. Abrogation of the CtBP binding site within BCoR-L1 partially relieves BCoR-L1-mediated transcriptional repression. Furthermore, BCoR-L1 is located on the E-cadherin promoter, a known CtBP-regulated promoter, and represses the E-cadherin promoter activity in a reporter assay. The inhibition of BCoR-L1 expression by RNA-mediated interference results in derepression of E-cadherin in cells that do not normally express E-cadherin, indicating that BCoR-L1 contributes to the repression of an authentic endogenous CtBP target.	Queensland Inst Med Res, Herston, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Sch Med, Cent Clin Div, Herston, Qld 4029, Australia; Inst Med & Vet Sci, Hanson Inst, Breast Canc Genet Grp, Adelaide, SA 5000, Australia; Regina Elena Inst Canc Res, I-00158 Rome, Italy; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Queensland; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Sydney	Khanna, KK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4029, Australia.		Chenevix-Trench, Georgia/AAV-2014-2020; Pagan, Julia/O-1929-2016; Khanna, Kum Kum/I-1747-2013; Spurdle, Amanda B/A-4978-2011; Verdin, Eric/AAB-7999-2019; Richard, Derek/J-1338-2012; bruno, tiziana/AAC-4913-2022; Kumar, Raman/AHE-0538-2022; fanciulli, maurizio/ABH-6745-2020; Crossley, Merlin/D-7888-2011; Forrest, Alistair/A-6597-2008	Chenevix-Trench, Georgia/0000-0002-1878-2587; Pagan, Julia/0000-0002-7079-6388; Spurdle, Amanda B/0000-0003-1337-7897; Richard, Derek/0000-0002-4839-8471; bruno, tiziana/0000-0003-0352-4523; Kumar, Raman/0000-0001-7976-8386; Crossley, Merlin/0000-0003-2057-3642; Forrest, Alistair/0000-0003-4543-1675; Khanna, Kum Kum/0000-0001-8650-5381; Jones, Mathew/0000-0003-2714-8411; Kumar, Raman Krishna/0000-0003-4343-0951; Verdin, Eric/0000-0003-3703-3183				Alpatov R, 2004, MOL CELL BIOL, V24, P10223, DOI 10.1128/MCB.24.23.10223-10235.2004; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Gabellini D, 2004, CURR OPIN GENET DEV, V14, P301, DOI 10.1016/j.gde.2004.04.010; Gabellini D, 2003, CURR OPIN GENET DEV, V13, P239, DOI 10.1016/S0959-437X(03)00050-9; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Huynh KD, 2000, GENE DEV, V14, P1810; Jardin F, 2005, HEMATOLOGY, V10, P115, DOI 10.1080/10245330400026105; Jepsen K, 2002, J CELL SCI, V115, P689; Joo JH, 2005, MOL VIS, V11, P133; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; McKinsey TA, 2006, MOL BIOL CELL, V17, P438, DOI 10.1091/mbc.E05-07-0612; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thio SSC, 2004, NUCLEIC ACIDS RES, V32, P1836, DOI 10.1093/nar/gkh344; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Voss TC, 2005, J CELL SCI, V118, P3277, DOI 10.1242/jcs.02450; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	71	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15248	15257		10.1074/jbc.M700246200	http://dx.doi.org/10.1074/jbc.M700246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17379597	Green Published, hybrid			2022-12-25	WOS:000246589000064
J	Takeuchi, K; Takahashi, H; Kawano, S; Shimada, I				Takeuchi, Koh; Takahashi, Hideo; Kawano, Seiko; Shimada, Ichio			Identification and characterization of the slowly exchanging pH-dependent conformational rearrangement in KcsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL KCSA; LIVIDANS K+ CHANNEL; SELECTIVITY FILTER; CRYSTAL-STRUCTURE; MEMBRANE-PROTEIN; STRUCTURAL BASIS; VOLTAGE-SENSOR; ION PERMEATION; ACTIVATION; STOICHIOMETRY	Gating of ion channels is strictly regulated by physiological conditions as well as intra/extracellular ligands. To understand the underlying structures mediating ion channel gating, we investigated the pH-dependent gating of the K+ channel KcsA under near-physiological conditions, using solution-state NMR. In a series of (HN)-H-1-N-15-TROSY HSQC (transverse relaxation optimized spectroscopy-heteronuclear single quantum coherence) spectra measured at various pH values, significant chemical shift changes were detected between pH 3.9 and 5.2, reflecting a conformational rearrangement associated with the gating. The pH-dependent chemical shift changes were mainly observed for the resonances from the residues near the intracellular helix bundle, which has been considered to form the primary gate in the K+ channel, as well as the intracellular extension of the inner helix. The substitution of His-25 by Ala abolished this pH-dependent conformational rearrangement, indicating that the residue serves as a "pH-sensor" for the channel. Although the electrophysiological open probability of KcsA is less than 10%, the conformations of the intracellular helix bundle between the acidic and neutral conditions seem to be remarkably different. This supports the recently proposed "dual gating" properties of the K+ channel, in which the activation-coupled inactivation at the selectivity filter determines the channel open probability of the channel. Indeed, a pH-dependent chemical shift change was also observed for the signal from the Trp-67 indole, which is involved in a hydrogen bond network related to the activation-coupled inactivation. The slow kinetic parameter obtained for the intracellular bundle seems to fit better into the time scale for burst duration than very fast fluctuations within a burst period, indicating the existence of another gating element with faster kinetic properties.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Koto Ku, Biol Informat Res Ctr, Tokyo 1350064, Japan; Tokyo Med & Dent Univ, Dept Cardiovasc Dis, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Medical & Dental University (TMDU)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Takeuchi, Koh/B-4971-2010	Takeuchi, Koh/0000-0002-6227-4627				Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Chill JH, 2006, PROTEIN SCI, V15, P684, DOI 10.1110/ps.051954706; Cordero-Morales JF, 2006, NAT STRUCT MOL BIOL, V13, P311, DOI 10.1038/nsmb1069; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 2004, BIOPHYS J, V86, P2101, DOI 10.1016/S0006-3495(04)74269-1; Fiaux J, 2004, J BIOMOL NMR, V29, P289, DOI 10.1023/B:JNMR.0000032523.00554.38; Gao LZ, 2005, P NATL ACAD SCI USA, V102, P17630, DOI 10.1073/pnas.0505158102; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kelly BL, 2003, NAT STRUCT BIOL, V10, P280, DOI 10.1038/nsb908; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Lohr F, 2003, J BIOMOL NMR, V25, P291, DOI 10.1023/A:1023084605308; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; Oxenoid K, 2001, BIOCHEMISTRY-US, V40, P5111, DOI 10.1021/bi0029090; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Takeuchi K, 2003, STRUCTURE, V11, P1381, DOI 10.1016/j.str.2003.10.003; Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yokogawa M, 2005, J AM CHEM SOC, V127, P12021, DOI 10.1021/ja0511772; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	36	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15179	15186		10.1074/jbc.M608264200	http://dx.doi.org/10.1074/jbc.M608264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17360718	hybrid			2022-12-25	WOS:000246589000057
J	Kindrachuk, J; Potter, JE; Brownlie, R; Ficzycz, AD; Griebel, PJ; Mookherjee, N; Mutwiri, GK; Babiuk, LA; Napper, S				Kindrachuk, Jason; Potter, Jean E.; Brownlie, Robert; Ficzycz, Andrew D.; Griebel, Philip J.; Mookherjee, Neeloffer; Mutwiri, George K.; Babiuk, Lorne A.; Napper, Scott			Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CPG-DNA; PATHOGEN RECOGNITION; CUTTING EDGE; IMMUNE CELLS; TLR9; BINDING; LEUKOCYTES; INDUCTION; BOVINE; MOTIFS	Toll-like receptor 9 (TLR9) activates the innate immune system in response to microbial DNA or mimicking oligodeoxynucleotides. Although cell stimulation experiments demonstrate the preferential activation of TLR9 by CpG-containing nucleic acids, direct binding investigations have reached contradictory conclusions with respect to the ability of this receptor to bind nucleic acids in a sequence-specific manner. To address this apparent discrepancy, we report the purification of the soluble ectodomain of human TLR9 with characterization of its ligand binding properties. We observe that TLR9 has a high degree of specificity in its ability to bind nucleic acids that contain CpG dinucleotides as well as higher order motifs that mediate species-specific activation. However, TLR9 is also functionally influenced by nucleic acids in a sequence-independent fashion as both stimulatory and nonstimulatory nucleic acids sensitize TLR9 for in vitro ligand binding as well as in vivo activation. We propose a model in which receptor activation is achieved in a sequence-dependent manner, and sensitivity is modulated by the absolute concentration of nucleic acids in a sequence-independent fashion. This model bears resemblance to that recently proposed for Toll in that activation is a two-step process in which formation of a ligand-bound monomer precedes formation of the activated dimer. In each model receptor sensitivity is determined within the second step with the crucial distinction that Toll undergoes negative cooperativity, whereas TLR9 is sensitized through a positive cooperative effect.	Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of Saskatchewan; University of British Columbia	Napper, S (corresponding author), Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada.	scott.napper@usask.ca		Kindrachuk, Jason/0000-0002-3305-7084; Mookherjee, Neeloffer/0000-0002-9350-4157				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cornelie S, 2004, J BIOL CHEM, V279, P15124, DOI 10.1074/jbc.M313406200; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; GILKESON GS, 1995, J CLIN INVEST, V95, P1398, DOI 10.1172/JCI117793; GILKESON GS, 1993, CLIN IMMUNOL IMMUNOP, V68, P283, DOI 10.1006/clin.1993.1129; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hallman M, 2001, PEDIATR RES, V50, P315, DOI 10.1203/00006450-200109000-00004; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ioannou XP, 2003, ANTISENSE NUCLEIC A, V13, P157, DOI 10.1089/108729003768247628; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Jurk M, 2006, CHEMMEDCHEM, V1, P1007, DOI 10.1002/cmdc.200600064; Kirk P, 2005, IMMUNITY, V23, P347, DOI 10.1016/j.immuni.2005.09.008; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; KOWALSKI J, 1993, VACCINE, V11, P1100, DOI 10.1016/0264-410X(93)90069-A; Krieg AM, 1999, PHARMACOL THERAPEUT, V84, P113, DOI 10.1016/S0163-7258(99)00023-6; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lazarczyk M, 2005, EXPERT OPIN BIOL TH, V5, P525, DOI 10.1517/14712598.5.4.525; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Mena A, 2003, OLIGONUCLEOTIDES, V13, P245, DOI 10.1089/154545703322460621; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; Roberts TL, 2005, J IMMUNOL, V174, P605, DOI 10.4049/jimmunol.174.2.605; ROUAS R, 2002, CANCER GENE THER, V9, P1; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sester DP, 2000, J IMMUNOL, V165, P4165, DOI 10.4049/jimmunol.165.8.4165; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032; Wagner H, 2006, J EXP MED, V203, P265, DOI 10.1084/jem.20052191; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Yasuda K, 2006, EUR J IMMUNOL, V36, P431, DOI 10.1002/eji.200535210	47	25	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13944	13953		10.1074/jbc.M608089200	http://dx.doi.org/10.1074/jbc.M608089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355967	hybrid			2022-12-25	WOS:000246245800004
J	Visser, F; Sun, LJ; Damaraju, V; Tackaberry, T; Peng, YS; Robins, MJ; Baldwin, SA; Young, JD; Cass, CE				Visser, Frank; Sun, Lijie; Damaraju, Vijaya; Tackaberry, Tracey; Peng, Yunshan; Robins, Morris J.; Baldwin, Stephen A.; Young, James D.; Cass, Carol E.			Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE-GUANOSINE TRANSPORTER; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; INTRACELLULAR MEMBRANES; LEISHMANIA-DONOVANI; RECOMBINANT HUMAN; BINDING-SITES; S-6-(4-NITROBENZYL)-MERCAPTOPURINE RIBOSIDE; NITROBENZYLTHIOINOSINE BINDING; NUCLEOBASE TRANSPORT	Equilibrative nucleoside transporters (ENTs) are important for the metabolic salvage of nucleosides and the cellular uptake of antineoplastic and antiviral nucleoside analogs. Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Random mutagenesis and screening by functional complementation for inhibitor-resistant mutants in yeast revealed mutations at Phe334 and Asn-338. Both residues are predicted to lie in transmembrane segment 8 (TM 8), which contains residues that are highly conserved in the ENT family. F334Y displayed increased V-max values that were attributed to increased rates of catalytic turnover, and N338Q and N338C displayed altered membrane distributions that appeared to be because of protein folding defects. Mutations of Phe-334 or Asn-338 impaired interactions with dilazep and dipyridamole, whereas mutations of Asn-338 impaired interactions with draflazine and soluflazine. A helical wheel projection of TM 8 predicted that Phe-334 and Asn-338 lie in close proximity to other highly conserved and/or hydrophilic residues, suggesting that they form part of a structurally important region that influences interactions with inhibitors, protein folding, and rates of conformational change during the transport cycle.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Edmonton, AB, Canada; Univ Alberta, Dept Oncol, Edmonton, AB, Canada; Univ Alberta, Dept Physiol, Edmonton, AB, Canada; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Brigham Young University; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca	Cass, Carol E/F-5861-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Arastu-Kapur S, 2005, J BIOL CHEM, V280, P2213, DOI 10.1074/jbc.M408224200; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; BARCLAY BJ, 1982, CAN J BIOCHEM CELL B, V60, P172, DOI 10.1139/o82-023; Barnes K, 2006, CIRC RES, V99, P510, DOI 10.1161/01.RES.0000238359.18495.42; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Endres CJ, 2005, MOL PHARMACOL, V67, P837, DOI 10.1124/mol.104.008102; Endres CJ, 2004, BIOCHEM J, V380, P131, DOI 10.1042/BJ20031880; GATI WP, 1989, MOL PHARMACOL, V36, P134; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greener A, 1996, Methods Mol Biol, V57, P375, DOI 10.1385/0-89603-332-5:375; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; GRIFFITH DA, 1990, BIOCHEM PHARMACOL, V40, P2297, DOI 10.1016/0006-2952(90)90726-2; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1991, MOL PHARMACOL, V39, P771; Hammond JR, 2000, N-S ARCH PHARMACOL, V361, P373, DOI 10.1007/s002100000214; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; IJZERMAN AP, 1989, EUR J PHARM-MOLEC PH, V172, P273, DOI 10.1016/0922-4106(89)90057-6; JAMIESON GP, 1993, CYTOMETRY, V14, P32, DOI 10.1002/cyto.990140107; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; Jennings LL, 1998, DRUG DEVELOP RES, V45, P277, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<277::AID-DDR26>3.0.CO;2-7; JONES KW, 1993, EUR J PHARM-MOLEC PH, V246, P97, DOI 10.1016/0922-4106(93)90085-N; King KM, 2006, MOL PHARMACOL, V69, P346, DOI 10.1124/mol.105.015768; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; KOREN R, 1983, BIOCHEM J, V216, P299, DOI 10.1042/bj2160299; SenGupta DJ, 2004, BIOCHEM PHARMACOL, V67, P453, DOI 10.1016/j.bcp.2003.09.018; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; Spratlin J, 2004, CLIN CANCER RES, V10, P6956, DOI 10.1158/1078-0432.CCR-04-0224; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Valdes R, 2006, J BIOL CHEM, V281, P22647, DOI 10.1074/jbc.M602366200; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 2004, NUCLEOS NUCLEOT NUCL, V23, P361, DOI 10.1081/NCN-120028333; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Visser F, 2005, J BIOL CHEM, V280, P11025, DOI 10.1074/jbc.M410348200; Visser F, 2005, MOL PHARMACOL, V67, P1291, DOI 10.1124/mol.104.005884; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476; Zhang J, 2003, MOL PHARMACOL, V64, P1512, DOI 10.1124/mol.64.6.1512	55	34	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14148	14157		10.1074/jbc.M701735200	http://dx.doi.org/10.1074/jbc.M701735200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379602	hybrid			2022-12-25	WOS:000246245800025
J	Zhu, SM; Si, ML; Wu, HL; Mo, YY				Zhu, Shuomin; Si, Min-Liang; Wu, Hailong; Mo, Yin-Yuan			MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER; RT-PCR; EXPRESSION; CELLS; RNA; PROTEIN; CDNA; RAS; ORGANIZATION	MicroRNAs are small noncoding RNA molecules that control expression of target genes. Our previous studies show that mir-21 is overexpressed in tumor tissues compared with the matched normal tissues. Moreover, suppression of mir-21 by antisense oligonucleotides inhibits tumor cell growth both in vitro and in vivo. However, it remains largely unclear as to how mir-21 affects tumor growth, because our understanding of mir-21 targets is limited. In this study, we performed two-dimensional differentiation in-gel electrophoresis of tumors treated with anti-mir-21 and identified the tumor suppressor tropomyosin 1 (TPM1) as a potential mir-21 target. In agreement with this, there is a putative mir-21 binding site at the 3'-untranslated region (3'-UTR) of TPM1 variants V1 and V5. Thus, we cloned the 3'-UTR of TPM1 into a luciferase reporter and found that although mir-21 down-regulated the luciferase activity, anti-mir-21 up-regulated it. Moreover, deletion of the mir-21 binding site abolished the effect of mir-21 on the luciferase activity, suggesting that this mir-21 binding site is critical. Western blot with the cloned TPM1-V1 plus the 3'-UTR indicated that TPM1 protein level was also regulated by mir-21, whereas real-time quantitative reverse transcription-PCR revealed no difference at the mRNA level, suggesting translational regulation. Finally, overexpression of TPM1 in breast cancer MCF-7 cells suppressed anchor-age-independent growth. Thus, down-regulation of TPM1 by mir-21 may explain, at least in part, why suppression of mir-21 can inhibit tumor growth, further supporting the notion that mir-21 functions as an oncogene.	So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 801 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/B-6141-2011; zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/R-8255-2019; Vickers, Michael M/E-4095-2010		NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102630, CA102630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen GA, 2004, J PATHOL, V202, P321, DOI 10.1002/path.1524; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; FINLAY TH, 1993, ENDOCRINOLOGY, V133, P996, DOI 10.1210/en.133.3.996; Fitzgerald K, 2005, CURR OPIN DRUG DISC, V8, P557; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Sanvito F, 2000, CANCER RES, V60, P510; SI ML, 2006, IN PRESS ONCOGENE; Smalheiser Neil R., 2006, V342, P115, DOI 10.1385/1-59745-123-1:115; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444	47	868	991	3	77	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14328	14336		10.1074/jbc.M611393200	http://dx.doi.org/10.1074/jbc.M611393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363372	hybrid			2022-12-25	WOS:000246245800044
J	de Oliveira, SK; Hoffmeister, M; Gambaryan, S; Muller-Esterl, W; Guimaraes, JA; Smolenski, AP				de Oliveira, Simone Kobe; Hoffmeister, Meike; Gambaryan, Stepan; Mueller-Esterl, Werner; Guimaraes, Jorge A.; Smolenski, Albert P.			Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; PROTEIN; CAMP; CGMP; BINDING; TRANSACTIVATION; ACTIVATION; DETERMINANTS; LOCALIZATION; MECHANISMS	Phosphodiesterase type 2A (PDE2A) hydrolyzes cyclic nucleotides cAMP and cGMP, thus efficiently controlling cAMP-dependent signaling pathways. PDE2A is composed of an amino-terminal region, two regulatory GAF domains, and a catalytic domain. Cyclic nucleotide hydrolysis is known to be activated by cGMP binding to GAF-B; however, other mechanisms may operate to fine-tune local cyclic nucleotide levels. In a yeast two-hybrid screening we identified XAP2, a crucial component of the aryl hydrocarbon receptor (AhR) complex, as a major PDE2A-interacting protein. We mapped the XAP2 binding site to the GAF-B domain of PDE2A. PDE assays with purified proteins showed that XAP2 binding does not change the enzymatic activity of PDE2A. To analyze whether PDE2A could affect the function of XAP2, we studied nuclear translocation of AhR, i.e. the master transcription factor controlling the expression of multiple detoxification genes. Notably, regulation of AhR target gene expression is initiated by tetrachlorodibenzodioxin (TCDD) binding to AhR and by a poorly understood cAMP-dependent pathway followed by the translocation of AhR from the cytosol into the nucleus. Binding of PDE2A to XAP2 inhibited TCDD- and cAMP-induced nuclear translocation of AhR in Hepa1c1c7 hepatocytes. Furthermore, PDE2A attenuated TCDD- induced transcription in reporter gene assays. We conclude that XAP2 targets PDE2A to the AhR complex, thereby restricting AhR mobility, possibly by a local reduction of cAMP levels. Our results provide first insights into the elusive cAMP-dependent regulation of AhR.	Univ Frankfurt Klinikum, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Fed Rio Grande do Sul, Ctr Biotechnol, BR-91501970 Porto Alegre, RS, Brazil; Univ Wurzburg, Ins Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Russian Acad Sci, Sechenov Inst Evolut Physiol & Biochem, St Petersburg 194223, Russia	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universidade Federal do Rio Grande do Sul; University of Wurzburg; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry	Smolenski, AP (corresponding author), Univ Frankfurt Klinikum, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	smolenski@biochem2.de	Gambaryan, Stepan/I-3940-2016	Gambaryan, Stepan/0000-0002-1470-0791; Guimaraes, Jorge A./0000-0001-6354-6789; Smolenski, Albert/0000-0001-9210-9406				Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Bentley JK, 2001, J NEUROCHEM, V76, P1252, DOI 10.1046/j.1471-4159.2001.00133.x; Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Froidevaux MSC, 2006, EMBO REP, V7, P1035, DOI 10.1038/sj.embor.7400778; Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162; Gross-Langenhoff M, 2006, J BIOL CHEM, V281, P2841, DOI 10.1074/jbc.M511468200; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; Iffland A, 2005, BIOCHEMISTRY-US, V44, P8312, DOI 10.1021/bi047313h; Kashuba EV, 2006, J BIOL CHEM, V281, P1215, DOI 10.1074/jbc.M509036200; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Ma Q, 1997, J BIOL CHEM, V272, P8878; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Meurer S, 2005, J BIOL CHEM, V280, P33149, DOI 10.1074/jbc.M507565200; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mongillo M, 2006, CIRC RES, V98, P226, DOI 10.1161/01.RES.0000200178.34179.93; Oesch-Bartlomowicz B, 2005, P NATL ACAD SCI USA, V102, P9218, DOI 10.1073/pnas.0503488102; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Ramadoss P, 2005, BIOCHEMISTRY-US, V44, P11148, DOI 10.1021/bi050948b; Ramadoss Preeti, 2005, Expert Opin Drug Metab Toxicol, V1, P9, DOI 10.1517/17425255.1.1.9; Rosman GJ, 1997, GENE, V191, P89, DOI 10.1016/S0378-1119(97)00046-2; Schultess J, 2005, BLOOD, V105, P3185, DOI 10.1182/blood-2004-09-3605; Seybold J, 2005, BLOOD, V105, P3569, DOI 10.1182/blood-2004-07-2729; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Zaccolo M, 2006, BIOCHEM SOC T, V34, P495, DOI 10.1042/BST0340495	34	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13656	13663		10.1074/jbc.M610942200	http://dx.doi.org/10.1074/jbc.M610942200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17329248	Green Submitted, hybrid			2022-12-25	WOS:000246060300055
J	Li, DL; Sinha, KK; Hay, MA; Rinaldi, CR; Saunthararajah, Y; Nucifora, G				Li, Donglan; Sinha, Kislay K.; Hay, Maher A.; Rinaldi, Ciro R.; Saunthararajah, Yogen; Nucifora, Giuseppina			RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; AML1 GENE; MYELOID-LEUKEMIA; MYELODYSPLASTIC SYNDROME; TRANSCRIPTION FACTORS; FUSION PROTEIN; CBF-BETA; REPRESSION	RUNX1 (AML1, CBF alpha 2, PEBP2 alpha B) is a transcription factor essential for the establishment of the hematopoietic stem cell. It is generally thought that RUNX1 exists as a monomer that regulates hematopoietic differentiation by interacting with tissue-specific factors and its DNA consensus through its N terminus. RUNX1 is frequently altered in human leukemia by gene fusions or point mutations. In general, these alterations do not affect the N terminus of the protein, and it is unclear how they consistently lead to hematopoietic transformation and leukemia. Here we report that RUNX1 homodimerizes through a mechanism involving C terminus-C terminus interaction. This RUNX1-RUNX1 interaction regulates the activity of the protein in reporter gene assays and modulates its ability to induce hematopoietic differentiation of hematopoietic cell lines. The promoters of genes regulated by RUNX1 often contain multiple RUNX1 binding sites. This arrangement suggests that RUNX1 could homodimerize to bring and hold together distant chromatin sites and factors and that if the dimerization region is removed by gene fusions or is altered by point mutations, as observed in leukemia, the ability of RUNX1 to regulate differentiation could be impaired.	Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Med, Coll Med Res Bldg,M-C 737,909 S Wolcott Ave, Chicago, IL 60612 USA.	nucifora@uic.edu		Sinha, Kislay/0000-0002-6978-4611; Abdul-Hay, Maher/0000-0003-1041-7689	NCI NIH HHS [CA96448] Funding Source: Medline; NHLBI NIH HHS [R01 HL72691, HL79580, HL 082935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082935, R01HL079580, R01HL072691] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chi YQ, 2003, J BIOL CHEM, V278, P49806, DOI 10.1074/jbc.M309645200; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; Gutierrez S, 2004, J BIOL CHEM, V279, P43581, DOI 10.1074/jbc.M408335200; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; McLean TW, 1996, BLOOD, V88, P4252; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niini T, 2000, HAEMATOLOGICA, V85, P362; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PEPLING ME, 1995, P NATL ACAD SCI USA, V92, P9087, DOI 10.1073/pnas.92.20.9087; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Saunthararajah Y, 2006, CRIT REV EUKAR GENE, V16, P183, DOI 10.1615/CritRevEukarGeneExpr.v16.i2.60; Senyuk V, 2005, CANCER RES, V65, P7603, DOI 10.1158/0008-5472.CAN-05-0412; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Soulier J, 2003, LEUKEMIA, V17, P1679, DOI 10.1038/sj.leu.2403000; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Uchida H, 1997, J IMMUNOL, V158, P2251; Vradii D, 2005, P NATL ACAD SCI USA, V102, P7174, DOI 10.1073/pnas.0502130102; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	57	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13542	13551		10.1074/jbc.M700074200	http://dx.doi.org/10.1074/jbc.M700074200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355962	hybrid			2022-12-25	WOS:000246060300043
J	Pino, MF; Kim, KA; Shelton, KD; Lindner, J; Odili, S; Li, CH; Collins, HW; Shiota, M; Matschinsky, FM; Magnuson, MA				Pino, Maria F.; Kim, Kyoung-Ah; Shelton, Kathy D.; Lindner, Jill; Odili, Stella; Li, Changhong; Collins, Heather W.; Shiota, Masakazu; Matschinsky, Franz M.; Magnuson, Mark A.			Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL GLUCOKINASE; YOUNG TYPE-2 MODY-2; DIABETES-MELLITUS; LIVER GLUCOKINASE; TRANSGENIC MICE; FRUCTOSE 1-PHOSPHATE; INSULIN-SECRETION; RAT-LIVER; GENE; HOMEOSTASIS	To better understand how glucokinase (GK) missense mutations associated with human glycemic diseases perturb glucose homeostasis, we generated and characterized mice with either an activating (A456V) or inactivating (K414E) mutation in the gk gene. Animals with these mutations exhibited alterations in their blood glucose concentration that were inversely related to the relative activity index of GK. Moreover, the threshold for glucose-stimulated insulin secretion from islets with either the activating or inactivating mutation were left- or right-shifted, respectively. However, we were surprised to find that mice with the activating mutation had markedly reduced amounts of hepatic GK activity. Further studies of bacterially expressed mutant enzymes revealed that GK(A456V) is as stable as the wild type enzyme, whereas GK(K414E) is thermolabile. However, the ability of GK regulatory protein to inhibit GK(A456V) was found to be less than that of the wild type enzyme, a finding consistent with impaired hepatic nuclear localization. Taken together, this study indicates that it is necessary to have knowledge of both thermolability and the interactions of mutant GK enzymes with GK regulatory protein when attempting to predict in vivo glycemic phenotypes based on the measurement of enzyme kinetics.	Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Nashville, TN 37232 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Diabet, Philadelphia, PA 19104 USA	Vanderbilt University; Vanderbilt University; University of Pennsylvania; University of Pennsylvania	Magnuson, MA (corresponding author), Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Dept Physiol & Mol Biophys, 802 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	mark.magnuson@vanderbilt.edu	Lindner, Jill/K-5511-2012; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Lindner, Jill/0000-0002-8897-7494; Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022122, R01DK022122] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42502, DK 22122] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; Brocklehurst KJ, 2004, BIOCHEM J, V378, P693, DOI 10.1042/BJ20031414; Burke CV, 1999, BIOCHEM J, V342, P345, DOI 10.1042/0264-6021:3420345; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Christesen HBT, 2002, DIABETES, V51, P1240, DOI 10.2337/diabetes.51.4.1240; Cuesta-Munoz AL, 2004, DIABETES, V53, P2164, DOI 10.2337/diabetes.53.8.2164; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Gloyn AL, 2003, HUM MUTAT, V22, P353, DOI 10.1002/humu.10277; Gloyn AL, 2005, J BIOL CHEM, V280, P14105, DOI 10.1074/jbc.M413146200; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Grimsby J, 2000, J BIOL CHEM, V275, P7826, DOI 10.1074/jbc.275.11.7826; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; Heredia VV, 2006, J BIOL CHEM, V281, P40201, DOI 10.1074/jbc.M607987200; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kesavan P, 1997, BIOCHEM J, V322, P57, DOI 10.1042/bj3220057; LABOSKY PA, 1994, CIBA F SYMP, V182, P157; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Miller SP, 1999, DIABETES, V48, P1645, DOI 10.2337/diabetes.48.8.1645; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Sagen JV, 2006, DIABETES, V55, P1713, DOI 10.2337/db05-1513; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Toyoda Y, 2001, HORM METAB RES, V33, P329, DOI 10.1055/s-2001-15418; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1992, BIOCHEM J, V286, P253, DOI 10.1042/bj2860253; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; Velho G, 1997, DIABETOLOGIA, V40, P217, DOI 10.1007/s001250050666; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Zelent D, 2006, DIABETES, V55, P1923, DOI 10.2337/db06-0151	55	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13906	13916		10.1074/jbc.M610094200	http://dx.doi.org/10.1074/jbc.M610094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353190	hybrid			2022-12-25	WOS:000246060300080
J	Zhang, F; Yim, YI; Scarselletta, S; Norton, M; Eisenberg, E; Greene, LE				Zhang, Fang; Yim, Yang-In; Scarselletta, Sarah; Norton, Mark; Eisenberg, Evan; Greene, Lois E.			Clathrin adaptor GGA1 polymerizes clathrin into tubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; VHS DOMAINS; ENDOSOME TRANSPORT; GAMMA-ADAPTIN; PROTEINS; AP-1; TGN; LOCALIZATION; TRAFFICKING; RECEPTORS	GGAs, a class of monomeric clathrin adaptors, are involved in the sorting of cargo at the trans-Golgi network of eukaryotic cells. They are modular structures consisting of the VHS, the GAT, hinge, and GAEdomains, which have been shown to interact directly with cargo, ARF, clathrin, and accessory proteins, respectively. Previous studies have shown that GGAs interact with clathrin both in solution and in the cell, but it has yet been shown whether they assemble clathrin. We find that GGA1 promoted assembly of clathrin with complete assembly achieved when one GGA1 molecule is bound per heavy chain. In the presence of excess GGA1, we obtained the unusual stoichiometry of five GGA1s per heavy chain, and even at this stoichiometry the binding was not saturated. The assembled structures were mostly baskets, but similar to 10% of the structures were tubular with an average length of 180 similar to 40 nm and width of similar to 50 nm. The truncated GGA1 fragment consisting of the hinge+GAE domains bound to clathrin with similar affinity as the full-length molecule and polymerized clathrin into baskets. Unlike the full-length molecule, this fragment saturated the lattices at one molecule per heavy chain and assembled clathrin only into baskets. The separated hinge and GAE domains bound much weaker to clathrin than the intact molecule, and these domains do not significantly polymerize clathrin into baskets. We conclude that clathrin adaptor GGA1 is a clathrin assembly protein, but it is unique in its ability to polymerize clathrin into tubules.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Greene, LE (corresponding author), NHLBI, Cell Biol Lab, NIH, 50 S Dr,Rm 2737,MSC 8017, Bethesda, MD 20892 USA.	greenel@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516, ZIAHL000516] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bai HD, 2004, J BIOL CHEM, V279, P17411, DOI 10.1074/jbc.M401158200; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2001, MOL BIOL CELL, V12, P3573, DOI 10.1091/mbc.12.11.3573; Knuehl C, 2006, TRAFFIC, V7, P1688, DOI 10.1111/j.1600-0854.2006.00499.x; Ma YC, 2002, J BIOL CHEM, V277, P49267, DOI 10.1074/jbc.M203695200; Nakayama K, 2003, CELL STRUCT FUNCT, V28, P431, DOI 10.1247/csf.28.431; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Polishchuk RS, 2006, TRAFFIC, V7, P1092, DOI 10.1111/j.1600-0854.2006.00453.x; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Zhao XH, 2001, J CELL SCI, V114, P353; Zhu YX, 2001, METHOD ENZYMOL, V329, P379	28	12	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13282	13289		10.1074/jbc.M700936200	http://dx.doi.org/10.1074/jbc.M700936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344219	hybrid			2022-12-25	WOS:000246060300016
J	Xie, HQ; Choi, RCY; Leung, KW; Siow, NL; Kong, LW; Lau, FTC; Peng, HB; Tsim, KWK				Xie, Heidi Q.; Choi, Roy C. Y.; Leung, K. Wing; Siow, Nina L.; Kong, Ling W.; Lau, Faye T. C.; Peng, H. Benjamin; Tsim, Karl W. K.			Regulation of a transcript encoding the proline-rich membrane anchor of globular muscle acetylcholinesterase - The suppressive roles of myogenesis and innervating nerves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; FAST-TWITCH MUSCLE; CYCLIC-AMP; NEUROMUSCULAR-JUNCTION; CHICK MYOTUBES; COLLAGEN COLQ; T-PEPTIDE; EXPRESSION; SLOW; EXERCISE	The transcriptional regulation of proline-rich membrane anchor ( PRiMA), an anchoring protein of tetrameric globular form acetylcholinesterase ( G(4) AChE), was revealed in muscle during myogenic differentiation under the influence of innervation. During myotube formation of C2C12 cells, the expression of AChE(T) protein and the enzymatic activity were dramatically increased, but the level of G(4) AChE was relatively decreased. This G(4) AChE in C2C12 cells was specifically recognized by anti-PRiMA antibody, suggesting the association of this enzyme with PRiMA. Reverse transcription-PCR analysis revealed that the level of PRiMA mRNA was reduced during the myogenic differentiation of C2C12 cells. Overexpression of PRiMA in C2C12 myotubes significantly increased the production of G(4) AChE. The oligomerization of G(4) AChE, however, did not require the intracellular cytoplasmic tail of PRiMA. After overexpressing the muscle regulatory factors, myogenin and MyoD, the expressions of PRiMA and G(4) AChE in cultured myotubes were markedly reduced. In addition, calcitonin gene-related peptide, a known motor neuron-derived factor, and muscular activity were able to suppress PRiMA expression in muscle; the suppression was mediated by the phosphorylation of a cAMP-responsive element-binding protein. In accordance with the in vitro results, sciatic nerve denervation transiently increased the expression of PRiMA mRNA and decreased the phosphorylation of cAMP-responsive element-binding protein as well as its activator calcium/calmodulin-dependent protein kinase II in muscles. Our results suggest that the expression of PRiMA, as well as PRiMA-associated G(4) AChE, in muscle is suppressed by muscle regulatory factors, muscular activity, and nerve-derived trophic factor(s).	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Hong Kong, Hong Kong, Peoples R China.	BOTSIM@UST.HK		Leung, Ka Wing/0000-0002-6137-3877; Tsim, Karl/0000-0003-4808-1674				Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; BACOU F, 1982, NATURE, V296, P661, DOI 10.1038/296661a0; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dvir H, 2004, EMBO J, V23, P4394, DOI 10.1038/sj.emboj.7600425; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Falasca C, 2005, J BIOL CHEM, V280, P878, DOI 10.1074/jbc.M409201200; FERNANDEZ HL, 1994, NEUROCHEM RES, V19, P1369, DOI 10.1007/BF00972465; Fernandez HL, 1996, J APPL PHYSIOL, V80, P357, DOI 10.1152/jappl.1996.80.1.357; FERNANDEZ HL, 1988, J APPL PHYSIOL, V65, P2245, DOI 10.1152/jappl.1988.65.5.2245; GISIGER V, 1994, EUR J NEUROSCI, V6, P673, DOI 10.1111/j.1460-9568.1994.tb00979.x; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; HODGESSAVOLA CA, 1991, J NEUROCHEM, V56, P1423, DOI 10.1111/j.1471-4159.1991.tb11441.x; Inestrosa NC, 1998, J PHYSIOLOGY-PARIS, V92, P341, DOI 10.1016/S0928-4257(99)80002-3; JASMIN BJ, 1990, J NEUROSCI, V10, P1444; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; Lee HHC, 2004, J BIOL CHEM, V279, P27098, DOI 10.1074/jbc.M402596200; Liang D, 2003, NEUROSCIENCE, V121, P999, DOI 10.1016/S0306-4522(03)00483-4; Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Massoulie J, 2005, CHEM-BIOL INTERACT, V157, P3, DOI 10.1016/j.cbi.2005.10.002; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2003, EUR J NEUROSCI, V18, P1837, DOI 10.1046/j.1460-9568.2003.02914.x; Pick M, 2004, ANN NY ACAD SCI, V1018, P85, DOI 10.1196/annals.1296.010; Rossi SG, 2003, J BIOL CHEM, V278, P24994, DOI 10.1074/jbc.M211379200; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; Ting AKL, 2005, CHEM-BIOL INTERACT, V157, P63, DOI 10.1016/j.cbi.2005.10.009; Tsim KWK, 1997, J NEUROCHEM, V68, P479; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	40	48	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11765	11775		10.1074/jbc.M608265200	http://dx.doi.org/10.1074/jbc.M608265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324938	hybrid			2022-12-25	WOS:000245941900019
J	Ball, T; Rahm, B; Eickhoff, SB; Schulze-Bonhage, A; Speck, O; Mutschler, I				Ball, Tonio; Rahm, Benjamin; Eickhoff, Simon B.; Schulze-Bonhage, Andreas; Speck, Oliver; Mutschler, Isabella			Response Properties of Human Amygdala Subregions: Evidence Based on Functional MRI Combined with Probabilistic Anatomical Maps	PLOS ONE			English	Article							NEURAL REPRESENTATIONS; PREFRONTAL CORTEX; MUSIC CORRELATE; ACTIVATION; EMOTION; FEAR; HABITUATION; INTENSITY; CIRCUITS; VALENCE	The human amygdala is thought to play a pivotal role in the processing of emotionally significant sensory information. The major subdivisions of the human amygdala-the laterobasal group (LB), the superficial group (SF), and the centromedial group (CM)-have been anatomically delineated, but the functional response properties of these amygdala subregions in humans are still unclear. We combined functional MRI with cyto-architectonically defined probabilistic maps to analyze the response characteristics of amygdala subregions in subjects presented with auditory stimuli. We found positive auditory stimulation-related signal changes predominantly in probabilistically defined LB, and negative responses predominantly in SF and CM. In the left amygdala, mean response magnitude in the core area of LB with 90-100% assignment probability was significantly larger than in the core areas of SF and CM. These differences were observed for pleasant and unpleasant stimuli. Our findings reveal that the probabilistically defined anatomical subregions of the human amygdala show distinctive fMRI response patterns. The stronger auditory responses in LB as compared with SF and CM may reflect a predominance of auditory inputs to human LB, similar to many animal species in which the majority of sensory, including auditory, afferents project to this subdivision of the amygdala. Our study indicates that the intrinsic functional differentiation of the human amygdala may be probed using fMRI combined with probabilistic anatomical maps.	[Ball, Tonio; Schulze-Bonhage, Andreas; Mutschler, Isabella] Univ Hosp Freiburg, Epilepsy Ctr, Freiburg, Germany; [Ball, Tonio; Mutschler, Isabella] Heidelberg Acad Sci & Humanities, Heidelberg, Germany; [Ball, Tonio; Schulze-Bonhage, Andreas] Bernstein Ctr Computat Neurosci Freiburg, Freiburg, Germany; [Rahm, Benjamin] Univ Basel, Dept Cognit Psychol & Methodol, Basel, Switzerland; [Rahm, Benjamin] Goethe Univ Frankfurt, Inst Med Psychol, Frankfurt, Germany; [Eickhoff, Simon B.] Res Ctr Julich, Inst Med, Julich, Germany; [Eickhoff, Simon B.] Univ Dusseldorf, C&O Inst Brain Res, Dusseldorf, Germany; [Speck, Oliver] Univ Magdeburg, Inst Expt Phys, Dept Biomed Magnet Resonance, D-39106 Magdeburg, Germany	University of Freiburg; University of Basel; Goethe University Frankfurt; Helmholtz Association; Research Center Julich; Heinrich Heine University Dusseldorf; Otto von Guericke University	Ball, T (corresponding author), Univ Hosp Freiburg, Epilepsy Ctr, Freiburg, Germany.	tonio.ball@uniklinik-freiburg.de	Schulze-Bonhage, Andreas/AAJ-3107-2020; Eickhoff, Simon B./K-2061-2013; Speck, Oliver/F-1406-2013	Eickhoff, Simon B./0000-0001-6363-2759; Speck, Oliver/0000-0002-6019-5597; Mutschler Collins, Isabella/0000-0003-2738-5943	Heidelberg Academy of Science and Humanities; University of Freiburg; YAMAHA Stiftung 100 Jahre e. V., Germany	Heidelberg Academy of Science and Humanities; University of Freiburg; YAMAHA Stiftung 100 Jahre e. V., Germany	This research was supported by the Heidelberg Academy of Science and Humanities, the University of Freiburg, and the 'YAMAHA Stiftung 100 Jahre e. V.', Germany.	Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5; Anderson AK, 2003, NAT NEUROSCI, V6, P196, DOI 10.1038/nn1001; [Anonymous], 2000, SER AFFECTIVE SCI; Baas D, 2004, BRAIN RES REV, V45, P96, DOI 10.1016/j.brainresrev.2004.02.004; Birbaumer N, 1998, NEUROREPORT, V9, P1223, DOI 10.1097/00001756-199804200-00048; Birbaumer N, 2005, ARCH GEN PSYCHIAT, V62, P799, DOI 10.1001/archpsyc.62.7.799; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; BORDI F, 1992, J NEUROSCI, V12, P2493; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; Collins DR, 1999, J NEUROSCI, V19, P836; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Fischer H, 2003, BRAIN RES BULL, V59, P387, DOI 10.1016/S0361-9230(02)00940-1; GONZALEZLIMA F, 1986, BRAIN RES, V363, P239, DOI 10.1016/0006-8993(86)91009-7; Heimer L., 1999, PRIMATE NERVOUS SY 3, P57, DOI DOI 10.1016/S0924-8196(99)80024-4; Khalfa S, 2005, NEUROREPORT, V16, P1981, DOI 10.1097/00001756-200512190-00002; Kim H, 2003, NEUROREPORT, V14, P2317, DOI 10.1097/00001756-200312190-00006; Kim H, 2004, J COGNITIVE NEUROSCI, V16, P1730, DOI 10.1162/0898929042947865; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Krishnan S, 2006, NEUROIMAGE, V31, P560, DOI 10.1016/j.neuroimage.2005.12.061; LEDOUX J, 2000, SER AFFECTIVE SCI, P129; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liberzon I, 2003, NEUROPSYCHOPHARMACOL, V28, P726, DOI 10.1038/sj.npp.1300113; McDonald AJ, 2003, ANN NY ACAD SCI, V985, P1; McDonald AJ, 1998, PROG NEUROBIOL, V55, P257, DOI 10.1016/S0301-0082(98)00003-3; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; Merboldt KD, 2001, NEUROIMAGE, V14, P253, DOI 10.1006/nimg.2001.0802; MERKSZ M, 1978, ACTA MORPHOL HUNG, V26, P139; Morris JS, 2001, NEUROIMAGE, V13, P1044, DOI 10.1006/nimg.2000.0721; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Phillips ML, 2001, HUM BRAIN MAPP, V12, P193, DOI 10.1002/1097-0193(200104)12:4<193::AID-HBM1015>3.0.CO;2-A; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Price JL, 2003, ANN NY ACAD SCI, V985, P50; Robinson S, 2004, NEUROIMAGE, V22, P203, DOI 10.1016/j.neuroimage.2003.12.048; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Sander D, 2003, REV NEUROSCIENCE, V14, P303, DOI 10.1515/REVNEURO.2003.14.4.303; Sander K, 2005, J COGNITIVE NEUROSCI, V17, P1519, DOI 10.1162/089892905774597227; Seifritz E, 2003, BIOL PSYCHIAT, V54, P1367, DOI 10.1016/S0006-3223(03)00697-8; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Small DM, 2003, NEURON, V39, P701, DOI 10.1016/S0896-6273(03)00467-7; Turner R, 2002, NEUROIMAGE, V16, P1062, DOI 10.1006/nimg.2002.1082; Veit R, 2002, NEUROSCI LETT, V328, P233, DOI 10.1016/S0304-3940(02)00519-0; Vuilleumier P, 2005, TRENDS COGN SCI, V9, P585, DOI 10.1016/j.tics.2005.10.011; Whalen PJ, 2001, EMOTION, V1, P70, DOI 10.1037/1528-3542.1.1.70; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2; Winston JS, 2005, J NEUROSCI, V25, P8903, DOI 10.1523/JNEUROSCI.1569-05.2005; Wright CI, 2001, NEUROREPORT, V12, P379, DOI 10.1097/00001756-200102120-00039; Zaitsev M, 2004, MAGNET RESON MED, V52, P1156, DOI 10.1002/mrm.20261; Zald DH, 2003, BRAIN RES REV, V41, P88, DOI 10.1016/S0165-0173(02)00248-5	53	123	124	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e307	10.1371/journal.pone.0000307	http://dx.doi.org/10.1371/journal.pone.0000307			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375193	Green Published, Green Accepted, gold, Green Submitted			2022-12-25	WOS:000207445100009
J	Foligne, B; Zoumpopoulou, G; Dewulf, J; Ben Younes, A; Chareyre, F; Sirard, JC; Pot, B; Grangette, C				Foligne, Benoit; Zoumpopoulou, Georgia; Dewulf, Joelle; Ben Younes, Amena; Chareyre, Fabrice; Sirard, Jean-Claude; Pot, Bruno; Grangette, Corinne			A Key Role of Dendritic Cells in Probiotic Functionality	PLOS ONE			English	Article							REGULATORY T-CELLS; MURINE COLITIS; CUTTING EDGE; KAPPA-B; IMMUNE-RESPONSES; INHIBITION; INTERLEUKIN-10; INFLAMMATION; TOLERANCE; BACTERIA	Background. Disruption of the intestinal homeostasis and tolerance towards the resident microbiota is a major mechanism involved in the development of inflammatory bowel disease. While some bacteria are inducers of disease, others, known as probiotics, are able to reduce inflammation. Because dendritic cells (DCs) play a central role in regulating immune responses and in inducing tolerance, we investigated their role in the anti-inflammatory potential of probiotic lactic acid bacteria. Methodology/Principal Findings. Selected LAB strains, while efficiently taken up by DCs in vitro, induced a partial maturation of the cells. Transfer of probiotic-treated DCs conferred protection against 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Protection was associated with a reduction of inflammatory scores and colonic expression of proinflammatory genes, while a high local expression of the immunoregulatory enzyme indolamine 2, 3 dioxgenase (IDO) was observed. The preventive effect of probiotic-pulsed DCs required not only MyD88-, TLR2- and NOD2-dependent signaling but also the induction of CD4+ CD25+ regulatory cells in an IL-10-independent pathway. Conclusions/Significance. Altogether, these results suggest that selected probiotics can stimulate DC regulatory functions by targeting specific pattern-recognition receptors and pathways. The results not only emphasize the role of DCs in probiotic immune interactions, but indicate a possible role in immune-intervention therapy for IBD.	[Foligne, Benoit; Zoumpopoulou, Georgia; Dewulf, Joelle; Pot, Bruno; Grangette, Corinne] Inst Biol Lille, Inst Pasteur Lille, Lab Bacteries Lact & Immunite Muqueuses, Lille, France; [Foligne, Benoit; Sirard, Jean-Claude] Inst Biol Lille, Inst Pasteur Lille, INSERM, U801, Lille, France; [Ben Younes, Amena] Inst Biol Lille, Inst Pasteur Lille, IFR142, Lille, France; [Chareyre, Fabrice] CEPH, Fdn Jean Dausset, INSERM, U674, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Grangette, C (corresponding author), Inst Biol Lille, Inst Pasteur Lille, Lab Bacteries Lact & Immunite Muqueuses, Lille, France.	Corinne.grangette@ibl.fr	Zoumpopoulou, Georgia/AAQ-6419-2021; Sirard, Jean-Claude/B-5932-2011; Foligne, Benoit/B-2754-2014; Pot, Bruno DF/I-6645-2012	Sirard, Jean-Claude/0000-0001-9854-4652; Foligne, Benoit/0000-0001-9263-9706; 	Institut Pasteur de Lille; foundation Aupetit, Paris	Institut Pasteur de Lille; foundation Aupetit, Paris	This work was supported by the Institut Pasteur de Lille and the foundation Aupetit, Paris.	Bibiloni R, 2005, AM J GASTROENTEROL, V100, P1539, DOI 10.1111/j.1572-0241.2005.41794.x; Braat H, 2004, AM J CLIN NUTR, V80, P1618, DOI 10.1093/ajcn/80.6.1618; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Cong YZ, 2005, J IMMUNOL, V174, P2787, DOI 10.4049/jimmunol.174.5.2787; Corinti S, 1999, J IMMUNOL, V163, P3029; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; Elson CO, 1996, J IMMUNOL, V157, P2174; Fiorucci S, 2004, P NATL ACAD SCI USA, V101, P15736, DOI 10.1073/pnas.0404722101; Foligne B, 2006, DIGEST DIS SCI, V51, P390, DOI 10.1007/s10620-006-3143-x; Foligne B, 2005, GUT, V54, P727; Foligne B, 2007, WORLD J GASTROENTERO, V13, P236, DOI 10.3748/wjg.v13.i2.236; GASSON MJ, 1983, J BACTERIOL, V154, P1; Grangette C, 2005, P NATL ACAD SCI USA, V102, P10321, DOI 10.1073/pnas.0504084102; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hackstein H, 2004, NAT REV IMMUNOL, V4, P24, DOI 10.1038/nri1256; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Hollenbach E, 2005, J BIOL CHEM, V280, P14981, DOI 10.1074/jbc.M500966200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Lammers KM, 2005, INFLAMM BOWEL DIS, V11, P447, DOI 10.1097/01.mpa.0000160302.40931.7b; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Madsen KL, 1999, GASTROENTEROLOGY, V116, P1107, DOI 10.1016/S0016-5085(99)70013-2; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Nishihara T, 2006, GASTROENTEROLOGY, V131, P853, DOI 10.1053/j.gastro.2006.06.015; Noel C, 2003, PARASITOL RES, V89, P487, DOI 10.1007/s00436-002-0811-4; Oldenhove G, 2003, J EXP MED, V198, P259, DOI 10.1084/jem.20030654; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sartor RB, 2004, GASTROENTEROLOGY, V126, P1620, DOI 10.1053/j.gastro.2004.03.024; Sheil B, 2004, GUT, V53, P694, DOI 10.1136/gut.2003.027789; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Stephens LA, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tan PH, 2005, J IMMUNOL, V174, P7633, DOI 10.4049/jimmunol.174.12.7633; Torok HP, 2004, GASTROENTEROLOGY, V127, P365, DOI 10.1053/j.gastro.2004.05.051; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; van Heel DA, 2005, GUT, V54, P1553, DOI 10.1136/gut.2005.065888; Vandenbroucke K, 2004, GASTROENTEROLOGY, V127, P502, DOI 10.1053/j.gastro.2004.05.020; Velde AAT, 2006, INFLAMM BOWEL DIS, V12, P995, DOI 10.1097/01.mib.0000227817.54969.5e; WALLACE JL, 1989, GASTROENTEROLOGY, V96, P29, DOI 10.1016/0016-5085(89)90760-9; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wolf AM, 2004, CLIN IMMUNOL, V113, P47, DOI 10.1016/j.clim.2004.05.004; Zelenay S, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036-a; Zhu M, 2003, WORLD J GASTROENTERO, V9, P2509	54	218	231	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e313	10.1371/journal.pone.0000313	http://dx.doi.org/10.1371/journal.pone.0000313			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375199	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445100015
J	Chen, L; Shen, RL; Ye, Y; Pu, XA; Liu, XL; Duan, WR; Wen, J; Zimmerer, J; Wang, Y; Liu, Y; Lasky, LC; Heerema, NA; Perrotti, D; Ozato, K; Kuramochi-Miyagawa, S; Nakano, T; Yates, AJ; Carson, WE; Lin, HF; Barsky, SH; Gao, JX				Chen, Li; Shen, Rulong; Ye, Yin; Pu, Xin-An; Liu, Xingluo; Duan, Wenrui; Wen, Jing; Zimmerer, Jason; Wang, Ying; Liu, Yan; Lasky, Larry C.; Heerema, Nyla A.; Perrotti, Danilo; Ozato, Keiko; Kuramochi-Miyagawa, Satomi; Nakano, Toru; Yates, Allen J.; Carson, William E., III; Lin, Haifan; Barsky, Sanford H.; Gao, Jian-Xin			Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; SELF-RENEWAL; GENE-EXPRESSION; CANCER; IDENTIFICATION; RECEPTOR; TUMORS; SUBPOPULATION; MAINTENANCE; HIERARCHY	Cancer stem cells (CSCs) have been identified in hematopoietic and solid tumors. However, their precursors-namely, precancerous stem cells (pCSCs) -have not been characterized. Here we experimentally define the pCSCs that have the potential for both benign and malignant differentiation, depending on environmental cues. While clonal pCSCs can develop into various types of tissue cells in immunocompetent mice without developing into cancer, they often develop, however, into leukemic or solid cancers composed of various types of cancer cells in immunodeficient mice. The progress of the pCSCs to cancers is associated with the up-regulation of c-kit and Sca-1, as well as with lineage markers. Mechanistically, the pCSCs are regulated by the PIWI/AGO family gene called piwil2. Our results provide clear evidence that a single clone of pCSCs has the potential for both benign and malignant differentiation, depending on the environmental cues. We anticipate pCSCs to be a novel target for the early detection, prevention, and therapy of cancers.	[Chen, Li; Shen, Rulong; Ye, Yin; Wang, Ying; Liu, Yan; Lasky, Larry C.; Heerema, Nyla A.; Yates, Allen J.; Barsky, Sanford H.; Gao, Jian-Xin] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Liu, Xingluo; Duan, Wenrui; Wen, Jing; Zimmerer, Jason; Heerema, Nyla A.; Perrotti, Danilo; Carson, William E., III; Gao, Jian-Xin] Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Pu, Xin-An] Ohio State Univ, Med Ctr, Ctr Mol Neurobiol, Columbus, OH 43210 USA; [Lasky, Larry C.] Ctr Stem Cell & Regenerat Med, Cleveland, OH USA; [Lin, Haifan] Yale Univ, Sch Med, Yale Stem Cell Ctr, New Haven, CT USA; [Ozato, Keiko] NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; [Kuramochi-Miyagawa, Satomi; Nakano, Toru] Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Osaka, Japan	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Yale University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Osaka University	Gao, JX (corresponding author), Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA.	Jian-Xin.Gao@osumc.edu	Carson, William E/E-2846-2011; Perrotti, Danilo/E-3852-2011; Shen, Rulong/E-4079-2011	Carson, III, William E./0000-0001-7024-7533; duan, wenrui/0000-0001-6512-7350	Department of Pathology; Ohio State University (OSU); Strategy Initiative [2005/2006]; American Cancer Society [IRG-112367]; Immunology Program; Davis/Bremer Medical Research; National Cancer Institute [CA095512]; United States Army; Chronic Myelogenous Leukemia (CML) Research Program [DAMD17-03-1-0184]; National Institute of Child and Human Development [HD42012]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008815] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042012, Z01HD008815] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA095512] Funding Source: NIH RePORTER	Department of Pathology; Ohio State University (OSU)(Ohio State University); Strategy Initiative; American Cancer Society(American Cancer Society); Immunology Program; Davis/Bremer Medical Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); United States Army(United States Department of DefenseUnited States Army); Chronic Myelogenous Leukemia (CML) Research Program; National Institute of Child and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work is supported from the Grants of Start-up funding, Department of Pathology, Ohio State University (OSU) (JXG); Strategy Initiative Grant (SIG) 2005/2006, OSU (JXG); American Cancer Society grant IRG-112367 (JXG); Immunology Program Award 2007 (OSU) (JXG); Davis/Bremer Medical Research Grant, OSU (RS); Strategy Initiative Grant (SIG) 2006, OSU (SHB); National Cancer Institute CA095512 (D. P.); the United States Army, Chronic Myelogenous Leukemia (CML) Research Program DAMD17-03-1-0184 (D. P.); and National Institute of Child and Human Development HD42012 (H. L.).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brownie J, 1997, NUCLEIC ACIDS RES, V25, P3235, DOI 10.1093/nar/25.16.3235; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Casserly IP, 2002, CELL MOL LIFE SCI, V59, P478, DOI 10.1007/s00018-002-8440-8; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Constantinescu S, 2003, J CELL MOL MED, V7, P103, DOI 10.1111/j.1582-4934.2003.tb00209.x; Cotter FE, 2004, SEMIN ONCOL, V31, P18, DOI 10.1053/j.seminoncol.2004.10.014; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Demetri GD, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.29181; Drexler HG, 2004, GROWTH FACTORS, V22, P71, DOI 10.1080/08977190410001700989; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gao JX, 2003, J IMMUNOL, V170, P5927, DOI 10.4049/jimmunol.170.12.5927; Gao JX, 2000, CELL IMMUNOL, V202, P41, DOI 10.1006/cimm.2000.1656; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Ishikawa T, 2001, DEVELOPMENT, V128, P25; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kawase Y, 2001, CONTEMP TOP LAB ANIM, V40, P31; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Lau NC, 2006, SCIENCE, V313, P363, DOI 10.1126/science.1130164; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; Massung RF, 1998, J CLIN MICROBIOL, V36, P1090, DOI 10.1128/JCM.36.4.1090-1095.1998; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; Nagy A., 2003, MANIPULATING MOUSE E; Nakamura Y, 1998, EXP HEMATOL, V26, P1105; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Palmqvist L, 2005, STEM CELLS, V23, P663, DOI 10.1634/stemcells.2004-0157; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Potti Anil, 2005, J Carcinog, V4, P8, DOI 10.1186/1477-3163-4-8; Raaphorst FM, 2003, TRENDS IMMUNOL, V24, P522, DOI 10.1016/S1471-4906(03)00241-2; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skea D, 1999, J HEMATOTHER, V8, P129, DOI 10.1089/106161299320406; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Wang HY, 2004, FRONT BIOSCI-LANDMRK, V9, P1043, DOI 10.2741/1310; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; YILMAZ OH, 2006, NATURE	64	94	97	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e293	10.1371/journal.pone.0000293	http://dx.doi.org/10.1371/journal.pone.0000293			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356702	Green Published, gold			2022-12-25	WOS:000207444800016
J	Kraeva, RI; Krastev, DB; Roguev, A; Ivanova, A; Nedelcheva-Veleva, MN; Stoynov, SS				Kraeva, Rayna I.; Krastev, Dragomir B.; Roguev, Assen; Ivanova, Anna; Nedelcheva-Veleva, Marina N.; Stoynov, Stoyno S.			Stability of mRNA/DNA and DNA/DNA Duplexes Affects mRNA Transcription	PLOS ONE			English	Article								Nucleic acids, due to their structural and chemical properties, can form double-stranded secondary structures that assist the transfer of genetic information and can modulate gene expression. However, the nucleotide sequence alone is insufficient in explaining phenomena like intron-exon recognition during RNA processing. This raises the question whether nucleic acids are endowed with other attributes that can contribute to their biological functions. In this work, we present a calculation of thermodynamic stability of DNA/DNA and mRNA/DNA duplexes across the genomes of four species in the genus Saccharomyces by nearest-neighbor method. The results show that coding regions are more thermodynamically stable than introns, 3'-untranslated regions and intergenic sequences. Furthermore, open reading frames have more stable sense mRNA/DNA duplexes than the potential antisense duplexes, a property that can aid gene discovery. The lower stability of the DNA/DNA and mRNA/DNA duplexes of 3'-untranslated regions and the higher stability of genes correlates with increased mRNA level. These results suggest that the thermodynamic stability of DNA/DNA and mRNA/DNA duplexes affects mRNA transcription.	[Kraeva, Rayna I.; Nedelcheva-Veleva, Marina N.; Stoynov, Stoyno S.] Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria	Bulgarian Academy of Sciences	Stoynov, SS (corresponding author), Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria.	stoynov@obzor.bio21.bas.bg		Krastev, Dragomir/0000-0003-4298-7272; Stoynov, Stoyno/0000-0002-7004-1081	Alexander von Humboldt Foundation; NATO [EAP.RIG.981642]	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); NATO(NATO (North Atlantic Treaty Organisation))	The research of S. S. S. has been supported by an Alexander von Humboldt Foundation Return Fellowship and NATO Grant EAP.RIG.981642.	Ak P, 2005, PLOS COMPUT BIOL, V1, P41, DOI 10.1371/journal.pcbi.0010007; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; DOVE WF, 1962, J MOL BIOL, V5, P467, DOI 10.1016/S0022-2836(62)80119-3; Dye MJ, 2006, MOL CELL, V21, P849, DOI 10.1016/j.molcel.2006.01.032; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Graber JH, 2002, NUCLEIC ACIDS RES, V30, P1851, DOI 10.1093/nar/30.8.1851; Graber JH, 1999, NUCLEIC ACIDS RES, V27, P888, DOI 10.1093/nar/27.3.888; Greive SJ, 2005, NAT REV MOL CELL BIO, V6, P221, DOI 10.1038/nrm1588; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang YL, 2003, NUCLEIC ACIDS RES, V31, P3819, DOI 10.1093/nar/gkg562; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Kellis M, 2004, J COMPUT BIOL, V11, P319, DOI 10.1089/1066527041410319; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; SCHILDKRAUT C, 1965, BIOPOLYMERS, V3, P195, DOI 10.1002/bip.360030207; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; van Helden J, 2000, NUCLEIC ACIDS RES, V28, P1000; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032	30	17	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e290	10.1371/journal.pone.0000290	http://dx.doi.org/10.1371/journal.pone.0000290			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356699	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444800013
J	Seo, H; Sonntag, KC; Kim, W; Cattaneo, E; Isacson, O				Seo, Hyemyung; Sonntag, Kai-Christian; Kim, Woori; Cattaneo, Elena; Isacson, Ole			Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells	PLOS ONE			English	Article								In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system ( UPS) is reduced in the brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin. We determined how to enhance UPS function and influence catalytic protein degradation and cell survival in HD. Proteasome activators involved in either the ubiquitinated or the non-ubiquitinated proteolysis were overexpressed in HD patients' skin fibroblasts or mutant huntingtin-expressing striatal neurons. Following compromise of the UPS, overexpression of the proteasome activator subunit PA28 gamma, but not subunit S5a, recovered proteasome function in the HD cells. PA28 gamma also improved cell viability in mutant huntingtin-expressing striatal neurons exposed to pathological stressors, such as the excitotoxin quinolinic acid and the reversible proteasome inhibitor MG132. These results demonstrate the specific functional enhancements of the UPS that can provide neuroprotection in HD cells.	[Seo, Hyemyung; Sonntag, Kai-Christian; Isacson, Ole] McLean Hosp, Ctr Neuroregenerat Res, Neuroregenerat Labs, Belmont, MA 02178 USA; [Seo, Hyemyung; Sonntag, Kai-Christian; Isacson, Ole] Harvard Univ, Sch Med, Belmont, MA 02178 USA; [Seo, Hyemyung; Kim, Woori] Hanyang Univ, Dept Mol & Life Sci, Gyeonggi Do, South Korea; [Cattaneo, Elena] Univ Milan, Ctr Neurodegenerat Dis, Milan, Italy	Harvard University; McLean Hospital; Harvard University; Hanyang University; University of Milan	Seo, H (corresponding author), McLean Hosp, Ctr Neuroregenerat Res, Neuroregenerat Labs, 115 Mill St, Belmont, MA 02178 USA.	hseo@hanyang.ac.kr; isacson@hms.harvard.edu	Kim, Woori/AAL-4146-2021; Sonntag, Kai-Christian/AAU-6921-2021	Isacson, Ole/0000-0001-8091-8302; Kim, Woori/0000-0002-7951-9280; CATTANEO, ELENA/0000-0002-0755-4917; Sonntag, Kai-Christian/0000-0001-7979-8171	NIH [NS-30064]; Vaughan Foundation; Korean Government (MOEHRD) [KRF-2005-202-C00230]; Hanyang University [HY-2005]; BK21 fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030064] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vaughan Foundation; Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); Hanyang University; BK21 fellowship(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was primarily supported by NIH NS-30064 (to OI), the Vaughan Foundation (to OI), and in part by a KRF Grant funded by the Korean Government (MOEHRD) (KRF-2005-202-C00230) (to HS), Hanyang University (HY-2005) (to HS) and BK21 fellowship (to WK).	Bae Y, 2006, P NATL ACAD SCI USA, V103, P3405, DOI 10.1073/pnas.0511316103; Barton LF, 2004, J IMMUNOL, V172, P3948, DOI 10.4049/jimmunol.172.6.3948; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1988, J NEUROSCI, V8, P3901; Bett JS, 2006, HUM MOL GENET, V15, P33, DOI 10.1093/hmg/ddi423; Bowman AB, 2005, HUM MOL GENET, V14, P679, DOI 10.1093/hmg/ddi064; Brouillet E, 2005, J NEUROCHEM, V95, P1521, DOI 10.1111/j.1471-4159.2005.03515.x; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; de Pril R, 2004, HUM MOL GENET, V13, P1803, DOI 10.1093/hmg/ddh188; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Demasi M, 2003, FEBS LETT, V542, P89, DOI 10.1016/S0014-5793(03)00353-3; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DIAZHERNANDEZ M, 2006, J NEUROCHEM; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groll M, 2005, METHOD ENZYMOL, V398, P329, DOI 10.1016/S0076-6879(05)98027-0; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Hansson O, 1999, P NATL ACAD SCI USA, V96, P8727, DOI 10.1073/pnas.96.15.8727; Jacquard C, 2006, FASEB J, V20, P1021, DOI 10.1096/fj.05-5085fje; Kaytor MD, 2004, J NEUROCHEM, V89, P962, DOI 10.1111/j.1471-4159.2004.02376.x; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Layfield R, 2005, ESSAYS BIOCHEM, V41, P157, DOI 10.1042/EB0410157; Lee HG, 2003, BRAIN PATHOL, V13, P630; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Metere A, 2006, J NEUROCHEM, V97, P1327, DOI 10.1111/j.1471-4159.2006.03814.x; Myers Richard H, 2004, NeuroRx, V1, P255, DOI 10.1007/BF03206609; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Petrucelli L, 2004, ANN MED, V36, P315, DOI 10.1080/07853890410031948; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; ROBERTS RC, 1989, SYNAPSE, V3, P363, DOI 10.1002/syn.890030410; Ruan QM, 2004, HUM MOL GENET, V13, P669, DOI 10.1093/hmg/ddh082; Seo H, 2004, ANN NEUROL, V56, P319, DOI 10.1002/ana.20207; SEO H, 2005, ANN C SOC NEUR; SIMPSON JR, 1993, EXP NEUROL, V121, P57, DOI 10.1006/exnr.1993.1071; Sipione S, 2002, HUM MOL GENET, V11, P1953, DOI 10.1093/hmg/11.17.1953; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yamamoto A, 2006, J CELL BIOL, V172, P719, DOI 10.1083/jcb.200510065; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; YEE WM, 1993, EXP BRAIN RES, V94, P193; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	50	95	97	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e238	10.1371/journal.pone.0000238	http://dx.doi.org/10.1371/journal.pone.0000238			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327906	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444600001
J	Raho, G; Miranda, C; Tamborini, E; Pierotti, MA; Greco, A				Raho, G.; Miranda, C.; Tamborini, E.; Pierotti, M. A.; Greco, A.			Detection of novel mRNA splice variants of human ING4 tumor suppressor gene	ONCOGENE			English	Article						ING4; alternative splicing; PHD domain	PHD-FINGER; CANCER; EXPRESSION; PROTEINS; APOPTOSIS; FAMILY; DOMAIN; P53; TRANSCRIPTION; ACETYLATION	Inhibitor of growth (ING) 4, member of a gene family encoding potential tumor suppressors, is implicated as a repressor of angiogenesis and tumor growth and suppresses loss of contact inhibition in vitro. Here, we report that ING4 undergoes alternative splicing. Expression analysis identified novel ING4 spliced variant mRNAs encoding proteins devoid of different portions. The ING4 variants were detected in both normal and tumor tissues. The existence of ING4 variants was confirmed by several approaches, including reverse transcriptase-polymerase chain reaction, real-time PCR and in silico experiments. To investigate the functional consequences of alternative splicing the ING4 variant cDNAs were expressed in mammalian cells. Our studies indicated that (i) the ING4 variants do not differ from wild-type in their nuclear localization, interaction with p53 and association to HBO1 complex; and (ii) the ING4-Delta Ex6A variant, devoid of the C-terminal portion, loses the capability to inhibit NF-kappa B. On the whole our data suggest that alternative splicing could modulate the activity of ING4 tumor suppressor protein.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol Expt Mol Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; angela.greco@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Tamborini, Elena/0000-0002-3819-8687; Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349				Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Huiping C, 2002, EUR J CANCER, V38, P728, DOI 10.1016/S0959-8049(01)00432-4; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kataoka H, 2003, CANCER RES, V63, P5785; Kaufmann D, 2002, CANCER RES, V62, P1503; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Okano T, 2006, ONCOL REP, V15, P545; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Tsai KW, 2006, GENOMICS, V88, P855, DOI 10.1016/j.ygeno.2006.07.004; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner MJ, 2005, GEN COMP ENDOCR, V144, P38, DOI 10.1016/j.ygcen.2005.04.008; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhou MI, 2005, P NATL ACAD SCI USA, V102, P11035, DOI 10.1073/pnas.0500757102	33	33	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5247	5257		10.1038/sj.onc.1210335	http://dx.doi.org/10.1038/sj.onc.1210335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325660				2022-12-25	WOS:000248674200008
J	Li, JX; Zhang, C; Xu, XQ; Wang, J; Yu, HN; Lai, R; Gong, WM				Li, Jianxu; Zhang, Cheng; Xu, Xueqing; Wang, Jie; Yu, Haining; Lai, Ren; Gong, Weimin			Trypsin inhibitory loop is an excellent lead structure to design serine protease inhibitors and antimicrobial peptides	FASEB JOURNAL			English	Article						trypsin resistance	PROTEINASE-INHIBITOR; MOLECULAR-CLONING; SKIN SECRETIONS; SUNFLOWER SEEDS; BACTERIA	The disulfide-bridged hendecapeptide ( CWTKSIPPKPC) loop, derived from an amphibian skin peptide, is found to have strong trypsin inhibitory capability. This loop, called the trypsin inhibitory loop ( TIL), appears to be the smallest serine protease inhibitor known. A series of synthetic peptides derived from this loop also exhibits trypsin inhibitory activity; some peptides even exhibit both antimicrobial and trypsin inhibitory activities. Antimicrobial peptides are attractive candidates for producing novel antibiotics, but their sensitivity to trypsin-like proteases appreciably limits their application. Bifunctional peptides with both antimicrobial and trypsin inhibitory activities could be ideal candidates for clinical antibiotics, since these reported synthetic peptides have shown resistance against trypsin. The crystal structure of a complex of trypsin with one TIL derivative is solved. The concept of TIL is introduced in this paper. Novel trypsin inhibitors or antimicrobial peptides can be designed readily on the basis of the TIL. Furthermore, functional analysis and a precursor comparison suggest that serine protease inhibitors may have a common ancestor with antimicrobial peptides.	Chinese Acad Sci, Kunming Inst Zool, Biotoxin Unit, Key Lab Anim Models & Human Dis, Kunming 650223, Peoples R China; Chinese Acad Sci, Inst Biophys, Beijing, Peoples R China; Nanjing Agr Univ, Life Sci Coll, Minist Agr, Key Lab Microbiol Engn Agr Environm, Nanjing, Peoples R China; Heibei Normal Univ, Coll Life Sci, Hebei, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Institute of Biophysics, CAS; Ministry of Agriculture & Rural Affairs; Nanjing Agricultural University; Hebei Normal University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Lai, R (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Biotoxin Unit, Key Lab Anim Models & Human Dis, Kunming 650223, Peoples R China.	rlai@mail.kiz.ac.cn; wgong@ibp.ac.cn	Zhang, Cheng/O-4372-2015; Li, Jianxu/I-5723-2013	Zhang, Cheng/0000-0001-9042-4007; 				BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Christeller JT, 2005, FEBS J, V272, P5710, DOI 10.1111/j.1742-4658.2005.04975.x; Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P153; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Lai R, 2002, PEPTIDES, V23, P427, DOI 10.1016/S0196-9781(01)00641-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prakash B, 1996, J MOL EVOL, V42, P560, DOI 10.1007/BF02352286; Qi RF, 2005, ACTA BIOCH BIOPH SIN, V37, P283, DOI 10.1111/j.1745-7270.2005.00048.x; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246	21	57	64	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2466	2473		10.1096/fj.06-7966com	http://dx.doi.org/10.1096/fj.06-7966com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384140				2022-12-25	WOS:000248454400021
J	Offer, T; Ames, BN; Bailey, SW; Sabens, EA; Nozawa, M; Ayling, JE				Offer, Tal; Ames, Bruce N.; Bailey, Steven W.; Sabens, Elizabeth A.; Nozawa, Mamoru; Ayling, June E.			5-Methyltetrahydrofolate inhibits photosensitization reactions and strand breaks in DNA	FASEB JOURNAL			English	Article						folate; folic acid; ultraviolet radiation; singlet oxygen; supercoiled DNA	FOLIC-ACID; MOLECULAR-OXYGEN; ULTRAVIOLET; FOLATE; PHOTOLYSIS; RADIATION; DAMAGE; SKIN; PHOTOOXIDATION; GENERATION	The known functions of folate are to support one-carbon metabolism and to serve as photoreceptors for cryptochromes and photolyases. We demonstrate that 5-methyltetrahydrofolate (5-MTHF, the predominant folate in plasma) is also a potent, near diffusion limited, scavenger of singlet oxygen and quencher of excited photosensitizers. Both pathways result in decomposition of 5-MTHF, although ascorbate can protect against this loss. In the absence of photosensitizers, 5-MTHF is directly decomposed only very slowly by UVA or UVB. Although synthetic folic acid can promote DNA damage by UVA, submicromolar 5-MTHF inhibits photosensitization-induced strand breaks. These observations suggest a new role for reduced folate in protection from ultraviolet damage and have bearing on the hypothesis that folate photodegradation influenced the evolution of human skin color.	Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA; CHORI, Nutr & Metab Ctr, Oakland, CA USA	University of South Alabama; Children's Hospital Oakland Research Institute	Ayling, JE (corresponding author), Univ S Alabama, Dept Pharmacol, Rm 3370,MSB,307 N Univ Blvd, Mobile, AL 36688 USA.	jayling@jaguar1.usouthal.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K05AT001323] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068165] Funding Source: NIH RePORTER; NCCIH NIH HHS [K05 AT001323] Funding Source: Medline; NHLBI NIH HHS [HL068165] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; BLAZEK ER, 1989, PHOTOCHEM PHOTOBIOL, V49, P607, DOI 10.1111/j.1751-1097.1989.tb08431.x; BRANDA RF, 1978, SCIENCE, V201, P625, DOI 10.1126/science.675247; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CABRERIZO FM, 2007, IN PRESS PHOTOCHEM P; CHOU PT, 1983, BIOCHEM BIOPH RES CO, V115, P932, DOI 10.1016/S0006-291X(83)80024-2; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; Fenech M, 2001, MUTAT RES-FUND MOL M, V475, P57, DOI 10.1016/S0027-5107(01)00079-3; FIEL RJ, 1981, CANCER RES, V41, P3543; FIEL RJ, 1982, BIOCHEM BIOPH RES CO, V107, P1067, DOI 10.1016/0006-291X(82)90630-1; Gregory JF, 2001, J NUTR, V131, P1928, DOI 10.1093/jn/131.7.1928; Higgins JR, 2000, BRIT J OBSTET GYNAEC, V107, P1149, DOI 10.1111/j.1471-0528.2000.tb11115.x; Hirakawa K, 2003, ARCH BIOCHEM BIOPHYS, V410, P261, DOI 10.1016/S0003-9861(02)00722-1; Hughes MC, 2006, INT J CANCER, V119, P1953, DOI 10.1002/ijc.22061; Huovinen P, 2006, PHOTOCHEM PHOTOBIOL, V82, P515, DOI 10.1562/2005-07-05-RA-601; Ito K, 1997, BIOL CHEM, V378, P1307; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Kelly P, 1997, AM J CLIN NUTR, V65, P1790, DOI 10.1093/ajcn/65.6.1790; Kift R, 2006, PHOTOCHEM PHOTOBIOL, V82, P579, DOI 10.1562/2005-04-20-RA-494; LEE PCC, 1987, PHOTOCHEM PHOTOBIOL, V45, P79, DOI 10.1111/j.1751-1097.1987.tb08407.x; LIPMAN RSA, 1995, BIOCHEMISTRY-US, V34, P11217, DOI 10.1021/bi00035a030; LOWRY OH, 1949, J BIOL CHEM, V180, P389; Mahns A, 2003, FREE RADICAL RES, V37, P391, DOI 10.1080/1071576031000064702; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Off MK, 2005, J PHOTOCH PHOTOBIO B, V80, P47, DOI 10.1016/j.jphotobiol.2005.03.001; Partch CL, 2005, METHOD ENZYMOL, V393, P726, DOI 10.1016/S0076-6879(05)93038-3; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; STUDER SL, 1989, J AM CHEM SOC, V111, P7643, DOI 10.1021/ja00201a071; Thomas AH, 2000, J PHOTOCH PHOTOBIO A, V135, P147, DOI 10.1016/S1010-6030(00)00304-X; Thomas AH, 2003, PHOTOCH PHOTOBIO SCI, V2, P245, DOI 10.1039/b209993d; Tucker KL, 2005, AM J CLIN NUTR, V82, P627; Vorobey P, 2006, PHOTOCHEM PHOTOBIOL, V82, P817, DOI 10.1562/2005-11-23-RA-739; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8	36	39	39	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2101	2107		10.1096/fj.06-7513com	http://dx.doi.org/10.1096/fj.06-7513com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341682				2022-12-25	WOS:000247500300019
J	Sudo, H; Maru, Y				Sudo, Haruka; Maru, Yoshiro			LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin	FASEB JOURNAL			English	Article						tetraploid; central spindle; microtubule; Fps; MKLP1	TYROSINE KINASE; SPINDLE POLE; BCR-ABL; PROTEIN; CANCER; CELLS; GROWTH; INTERACTS; MITOSIS; PHOSPHORYLATION	Prostate cancer is one of the most common cancers in men, with more than 500,000 new worldwide cases reported annually, resulting in 200,000 deaths of mainly older men in developed countries. Existing treatments have not proved very effective in managing prostate cancer, and continuing efforts therefore are ongoing to explore novel targets and strategies for future therapies. LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown. We report here that LAPSER1 colocalizes to the centrosomes and midbodies in mitotic cells with gamma-tubulin, MKLP1, and p80 katanin, and is involved in cytokinesis. Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle. Significantly, the enhanced expression of LAPSER1 induces binucleation and renders the cells resistant to oncogenic transformation. In cells transformed by the v-Fps oncogene, overexpressed LAPSER1 induces abortive cytokinesis, followed by mitotic catastrophe in a p80 katanin-dependent manner. Cells that are rescued from this apoptotic pathway with Z-VAD-fmk display karyokinesis. These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.	Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp	Sudo, Haruka/GWC-9919-2022					ARIIZUMI K, 1985, J VIROL, V55, P660, DOI 10.1128/JVI.55.3.660-669.1985; Buster D, 2002, J CELL SCI, V115, P1083; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Errico A, 2004, HUM MOL GENET, V13, P2121, DOI 10.1093/hmg/ddh223; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898; Karabay A, 2004, J NEUROSCI, V24, P5778, DOI 10.1523/JNEUROSCI.1382-04.2004; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Konno D, 2002, J CELL SCI, V115, P4695, DOI 10.1242/jcs.00127; Kuriyama R, 2002, J CELL BIOL, V156, P783, DOI 10.1083/jcb.200109090; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; McNally KP, 2000, J CELL SCI, V113, P1623; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Rajaraman R, 2005, CELL BIOL INT, V29, P1084, DOI 10.1016/j.cellbi.2005.10.003; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Takahashi S, 2003, J BIOL CHEM, V278, P49129, DOI 10.1074/jbc.C300289200; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Vinogradov AE, 2001, GENOME, V44, P350, DOI 10.1139/gen-44-3-350; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yu WQ, 2005, J NEUROSCI, V25, P5573, DOI 10.1523/JNEUROSCI.0834-05.2005	31	31	34	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2086	2100		10.1096/fj.06-7254com	http://dx.doi.org/10.1096/fj.06-7254com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17351128				2022-12-25	WOS:000247500300018
J	Mahadevan, D; Cooke, L; Riley, C; Swart, R; Simons, B; Della Croce, K; Wisner, L; Iorio, M; Shakalya, K; Garewal, H; Nagle, R; Bearss, D				Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bearss, D.			A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors	ONCOGENE			English	Article						tyrosine kinases; morphological change; Kit mutations; GIST	CELL-ADHESION MOLECULE; C-KIT; CRYSTAL-STRUCTURE; GROWTH; MICROENVIRONMENT; IDENTIFICATION; INHIBITOR; MUTATIONS; INVASION; BIOLOGY	KIT or alpha-platelet-derived growth factor receptor (alpha-PDGFR) activating mutations are the pathogenic mechanisms that characterize gastrointestinal stromal tumors (GIST). Despite excellent responses to imatinib mesylate (IM), patients are relapsing. We developed an IM-resistant GIST cell line (GIST-R) from the IM-sensitive GIST882 cell line (GIST-S) by growing these cells in IM. Gene expression pro. ling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance. Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor tyrosine kinase-AXL-in a kinase switch'. Further, the two IM resistant GIST patients express AXL and not c-Kit, seen by immunohistochemistry (IHC). Real time reverse transcriptase-polymerase chain reaction and Western blotting of the GIST-S and GIST-R cells confirmed the switch from Kit to AXL. In GIST-R, AXL is tyrosine phosphorylated and its ligand growth-arrest-specific gene 6 is overexpressed implying autocrine activation. The kinase switch is associated with a morphological change from spindle to epithelioid. Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/ AXL kinase inhibitor. MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Supergen Pharmaceut, Salt Lake City, UT USA	Arizona Center Cancer Care; University of Arizona; Radboud University Nijmegen	Mahadevan, D (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	dmahadevan@azcc.arizona.edu	Bearss, David/Q-9141-2019	Riley, Christopher/0000-0001-7930-1495; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NCI NIH HHS [CA23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BAUER S, 2005, ASCO9034, V23, pS824; Buchholz M, 2003, CANCER RES, V63, P4945; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chen Lei L, 2005, Curr Oncol Rep, V7, P293, DOI 10.1007/s11912-005-0053-6; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; DeMatteo RP, 2002, HUM PATHOL, V33, P466, DOI 10.1053/hupa.2002.124122; Duffaud F, 2003, ONCOLOGY-BASEL, V65, P187, DOI 10.1159/000074470; Haldar S, 1997, CANCER RES, V57, P229; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y; Kristiansen G, 2004, J MOL HISTOL, V35, P255; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; MAHADEVAN D, 2005, 96 ANN M APR 16 20 2; McLean SR, 2005, MOL CANCER THER, V4, P2008, DOI 10.1158/1535-7163.MCT-05-0070; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; PEREZATAYDE AR, 1993, AM J SURG PATHOL, V17, P706, DOI 10.1097/00000478-199307000-00008; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Theou N, 2005, CLIN CANCER RES, V11, P7593, DOI 10.1158/1078-0432.CCR-05-0710; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989	38	213	238	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3909	3919		10.1038/sj.onc.1210173	http://dx.doi.org/10.1038/sj.onc.1210173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17325667				2022-12-25	WOS:000247144500001
J	Batkai, S; Osei-Hyiaman, D; Pan, H; El-Assal, O; Rajesh, M; Mukhopadhyay, P; Hong, F; Harvey-White, J; Jafri, A; Hasko, G; Huffman, JW; Gao, B; Kunos, G; Pacher, P				Batkai, Sandor; Osei-Hyiaman, Douglas; Pan, Hao; El-Assal, Osama; Rajesh, Mohanraj; Mukhopadhyay, Partha; Hong, Feng; Harvey-White, Judith; Jafri, Anjum; Hasko, Gyorgy; Huffman, John W.; Gao, Bin; Kunos, George; Pacher, Pal			Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury	FASEB JOURNAL			English	Article						endocannabinoids; anandamide; 2-arachidonoylglycerol; peroxynitrite; oxidative stress	ENDOCANNABINOID SYSTEM; CB2 RECEPTOR; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; N-ACYLETHANOLAMINES; HEMODYNAMIC PROFILE; ADHESION MOLECULES; LIVER-INJURY; ANANDAMIDE; ACTIVATION	Hepatic ischemia-reperfusion (I/R) injury continues to be a fatal complication that can follow liver surgery or transplantation. We have investigated the involvement of the endocannabinoid system in hepatic I/R injury using an in vivo mouse model. Here we report that I/R triggers several-fold increases in the hepatic levels of the endocannabinoids anandamide and 2-arachidonoylglycerol, which originate from hepatocytes, Kupffer, and endothelial cells. The I/R-induced increased tissue endocannabinoid levels positively correlate with the degree of hepatic damage and serum TNF- alpha, MIP- 1 alpha, and MIP- 2 levels. Furthermore, a brief exposure of hepatocytes to various oxidants (H2O2 and peroxynitrite) or inflammatory stimuli (endotoxin and TNF-alpha) also increases endocannabinoid levels. Activation of CB2 cannabinoid receptors by JWH133 protects against I/R damage by decreasing inflammatory cell infiltration, tissue and serum TNF-alpha, MIP-1 alpha and MIP- 2 levels, tissue lipid peroxidation, and expression of adhesion molecule ICAM- 1 in vivo. JWH133 also attenuates the TNF-alpha-induced ICAM-1 and VCAM- 1 expression in human liver sinusoidal endothelial cells (HLSECs) and the adhesion of human neutrophils to HLSECs in vitro. Consistent with the protective role of CB2 receptor activation, CB2-/- mice develop increased I/R-induced tissue damage and proinflammatory phenotype. These findings suggest that oxidative/nitrosative stress and inflammatory stimuli may trigger endocannabinoid production, and indicate that targeting CB2 cannabinoid receptors may represent a novel protective strategy against I/R injury. We also demonstrate that CB2-/- mice have a normal hemodynamic profile.-Batkai, S., Osei-Hyiaman, D., Pan, H., El-Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey-White, J., Jafri, A., Hasko, G., Huffman, J. W., Gao, B., Kunos, G., Pacher, P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/ reperfusion injury.	NIAAA, Sect Oxidat Stress & Tissue Injury, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Dept Surg, New Jersey Med Sch, Newark, NJ 07103 USA; Clemson Univ, Howard L Hunter Chem Lab, Clemson, SC 29631 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Clemson University	Pacher, P (corresponding author), NIAAA, Sect Oxidat Stress & Tissue Injury, Lab Physiol Studies, NIH, 5625 Fishers Lane,MSC-9413, Bethesda, MD 20892 USA.	pacher@mail.nih.gov	MUKHOPADHYAY, PARTHA/G-3890-2010; Mohanraj, Rajesh/L-1798-2019; Batkai, Sandor/G-3889-2010; Batkai, Sandor/H-7983-2014; Pacher, Pal/B-6378-2008	MUKHOPADHYAY, PARTHA/0000-0002-1178-1274; Pacher, Pal/0000-0001-7036-8108; Mohanraj, Rajesh/0000-0003-2660-2184; Osei-Hyiaman, Douglas/0000-0002-2725-5519; Pan, Hao/0000-0001-9925-0752	Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NIDA NIH HHS [R01 DA003590, DA03590] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000369, Z01AA000351, Z01AA000368, Z01AA000375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003590] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arai T, 1998, CIRC RES, V82, P540, DOI 10.1161/01.RES.82.5.540; Batkai S, 2004, CIRCULATION, V110, P1996, DOI 10.1161/01.CIR.0000143230.23252.D2; Batkai S, 2004, AM J PHYSIOL-HEART C, V287, pH595, DOI 10.1152/ajpheart.00184.2004; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; CARLOS TM, 1994, BLOOD, V84, P2068; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Elmes SJR, 2005, PAIN, V118, P327, DOI 10.1016/j.pain.2005.09.005; Elmes SJR, 2004, EUR J NEUROSCI, V20, P2311, DOI 10.1111/j.1460-9568.2004.03690.x; Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838; Fan CG, 1999, J MOL MED, V77, P577, DOI 10.1007/s001099900029; Gabbay E, 2005, LIVER INT, V25, P921, DOI 10.1111/j.1478-3231.2005.01180.x; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Hayakawa K, 2004, NEUROREPORT, V15, P2381, DOI 10.1097/00001756-200410250-00016; Huffman JW, 2005, MINI-REV MED CHEM, V5, P641, DOI 10.2174/1389557054368844; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Husted Thomas L, 2005, Curr Opin Investig Drugs, V6, P508; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jaeschke H, 1997, AM J PHYSIOL-GASTR L, V273, pG602, DOI 10.1152/ajpgi.1997.273.3.G602; Jaeschke H, 2006, AM J PHYSIOL-GASTR L, V290, pG1083, DOI 10.1152/ajpgi.00568.2005; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kimball ES, 2006, AM J PHYSIOL-GASTR L, V291, pG364, DOI 10.1152/ajpgi.00407.2005; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Kunos G, 2006, NAT MED, V12, P607, DOI 10.1038/nm0606-608; Kupiec-Weglinski JW, 2005, TRANSPL P, V37, P1653, DOI 10.1016/j.transproceed.2005.03.134; Lamontagne D, 2006, ARCH MAL COEUR VAISS, V99, P242; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Liaudet L, 2002, INFECT IMMUN, V70, P192, DOI 10.1128/IAI.70.1.192-198.2002; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Louw DF, 2000, BRAIN RES, V857, P183, DOI 10.1016/S0006-8993(99)02422-1; Mallat A, 2006, J Endocrinol Invest, V29, P58; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Massa F, 2005, J MOL MED, V83, P944, DOI 10.1007/s00109-005-0698-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Nagayama T, 1999, J NEUROSCI, V19, P2987; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Ohkohchi N, 1999, TRANSPLANT P, V31, P1055, DOI 10.1016/S0041-1345(98)01902-2; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pacher P, 2005, HANDB EXP PHARMACOL, V168, P599; Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6; Pacher P, 2005, BRIT J PHARMACOL, V146, P313, DOI 10.1038/sj.bjp.0706332; Pacher P, 2005, NEUROPHARMACOLOGY, V48, P1130, DOI 10.1016/j.neuropharm.2004.12.005; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Pacher P, 2004, J PHYSIOL-LONDON, V558, P647, DOI 10.1113/jphysiol.2004.064824; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1; Schabitz WR, 2002, STROKE, V33, P2112, DOI 10.1161/01.STR.0000023491.63693.18; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Siegmund SV, 2006, J BIOL CHEM, V281, P10431, DOI 10.1074/jbc.M509706200; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Szabo Gabor, 2005, Current Vascular Pharmacology, V3, P215, DOI 10.2174/1570161054368599; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Zamora-Valdes Daniel, 2005, Ann Hepatol, V4, P248	67	194	219	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1788	1800		10.1096/fj.06-7451com	http://dx.doi.org/10.1096/fj.06-7451com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327359	Green Accepted			2022-12-25	WOS:000246866500021
J	Norgett, EE; Borthwick, KJ; Al-Lamki, RS; Su, Y; Smith, AN; Karet, FE				Norgett, Elizabeth E.; Borthwick, Katherine J.; Al-Lamki, Rafia S.; Su, Ya; Smith, Annabel N.; Karet, Fiona E.			V-1 and V-0 domains of the human H+-ATPase are linked by an interaction between the G and a subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; V-ATPASE; MOLECULAR-CLONING; COATED VESICLE; C-SUBUNIT; G VMA10P; VACUOLAR; KIDNEY; MUTATIONS; ISOFORMS	The specialized H+-ATPases found in the inner ear and acid-handling cells in the renal collecting duct differ from those at other sites, as they contain tissue-specific subunits, such as a4 and B1, and in the kidney, C2, d2, and G3 as well. These subunits replace the ubiquitously expressed forms. Previously, we have shown that, in major organs of both mouse and man, G3 subunit expression is limited to the kidney. Here we have shown widespread transcription of murine G3 in specific segments of microdissected nephron, and demonstrated additional G3 expression in epithelial fragments from human inner ear. We raised a polyclonal G3-specific antibody, which specifically detects G3 from human, mouse, and rat kidney lysates, and displays no cross-reactivity with G1 or G2. However, immunolocalization using this antibody on human and mouse kidney sections was unachievable, suggesting epitope masking. Phage display analysis and subsequent enzyme-linked immunosorbent assay, using the G3 antibody epitope peptide as bait, identified a possible interaction between the G3 subunit and the a4 subunit of the H+-ATPase. This interaction was verified by successfully using purified, immobilized full-length G3 to pull down the a4 subunit from human kidney membrane preparations. This confirms that a4 and G3 are component subunits of the same proton pump and explains the observed epitope masking. This interaction was also found to be a more general feature of human H+-ATPases, as similar G1/a1, G3/a1, and G1/a4 interactions were also demonstrated. These interactions represent a novel link between the V-1 and V-0 domains in man, which is known to be required for H+-ATPase assembly and regulation.	Univ Cambridge, Dept Med Genet, Cambridge CB2 0XY, England; Univ Cambridge, Dept Med, Cambridge CB2 0XY, England; Univ Cambridge, Div Renal Med, Cambridge CB2 0XY, England	University of Cambridge; University of Cambridge; University of Cambridge	Karet, FE (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Box 139, Cambridge CB2 0XY, England.	fek1000@cam.ac.uk		Karet, Fiona/0000-0002-2457-2869	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arata Y, 2002, BBA-BIOENERGETICS, V1555, P71, DOI 10.1016/S0005-2728(02)00257-8; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; HO MN, 1993, J BIOL CHEM, V268, P18286; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; KANE PM, 1995, J BIOL CHEM, V270, P17025; Karet FE, 1999, AM J HUM GENET, V65, P1656, DOI 10.1086/302679; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Pietrement C, 2006, BIOL REPROD, V74, P185, DOI 10.1095/biolreprod.105.043752; Smith AN, 2005, J AM SOC NEPHROL, V16, P1245, DOI 10.1681/ASN.2004090761; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Sun-Wada GH, 2003, J BIOL CHEM, V278, P44843, DOI 10.1074/jbc.M307197200; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200	27	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14421	14427		10.1074/jbc.M701226200	http://dx.doi.org/10.1074/jbc.M701226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360703	hybrid			2022-12-25	WOS:000246245800055
J	Wozniak, RJ; Boyer, ME; Grass, JA; Lee, Y; Bresnick, EH				Wozniak, Ryan J.; Boyer, Meghan E.; Grass, Jeffrey A.; Lee, Youngsook; Bresnick, Emery H.			Context-dependent gata factor function - Combinatorial requirements for transcriptional control in hematopoietic and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GENE-EXPRESSION; ADHESION MOLECULE-1; BINDING PROTEINS; FACTOR INTERPLAY; ACTIVATION; MECHANISMS; COMPLEX; HEMANGIOBLAST; SCL/TAL-1	GATA factors are fundamental components of developmentally important transcriptional networks. By contrast to common mechanisms in which transacting factors function directly at promoters, the hematopoietic GATA factors GATA-1 and GATA-2 often assemble dispersed complexes over broad chromosomal regions. For example, GATA-1 and GATA-2 occupy five conserved regions over similar to 100 kb of the Gata2 locus in the transcriptionally repressed and active states, respectively, in erythroid cells. Since it is unknown whether the individual complexes exert qualitatively distinct or identical functions to regulate Gata2 transcription in vivo, we compared the activity of the -3.9 and +9.5 kb sites of the Gata2 locus in transgenic mice. The +9.5 site functioned as an autonomous enhancer in the endothelium and fetal liver of embryonic day 11 embryos, whereas the -3.9 site lacked such activity. Mechanistic studies demonstrated critical requirements for a GATA motif and a neighboring E-box within the +9.5 site for enhancer activity in endothelial and hematopoietic cells. Surprisingly, whereas this GATA-E-box composite motif was sufficient for enhancer activity in an erythroid precursor cell line, its enhancer function in primary human endothelial cells required additional regulatory modules. These results identify the first molecular determinant of Gata2 transcription in vascular endothelium, composed of a core enhancer module active in both endothelial and hematopoietic cells and regulatory modules preferentially required in endothelial cells.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067050, T32HL007936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068634, R56DK068634] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07936, HL67050] Funding Source: Medline; NIDDK NIH HHS [DK68634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bresnick EH, 2005, J CELL PHYSIOL, V205, P1, DOI 10.1002/jcp.20393; Bresnick EH, 2006, PROG NUCLEIC ACID RE, V81, P435, DOI 10.1016/S0079-6603(06)81011-1; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; Choi K, 1998, DEVELOPMENT, V125, P725; Craven SE, 2004, DEVELOPMENT, V131, P1165, DOI 10.1242/dev.01024; D'Souza SL, 2005, BLOOD, V105, P3862, DOI 10.1182/blood-2004-09-3611; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Friedle H, 2002, J BIOL CHEM, V277, P23872, DOI 10.1074/jbc.M201831200; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Ikonomi P, 2000, GENE, V261, P277, DOI 10.1016/S0378-1119(00)00510-2; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kobayashi-Osaki M, 2005, MOL CELL BIOL, V25, P7005, DOI 10.1128/MCB.25.16.7005-7020.2005; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEONARD M, 1993, BLOOD, V82, P1071; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Mann RS, 2002, CURR OPIN GENET DEV, V12, P592, DOI 10.1016/S0959-437X(02)00344-1; Martowicz ML, 2005, J BIOL CHEM, V280, P1724, DOI 10.1074/jbc.M406038200; McGrath KE, 2005, EXP HEMATOL, V33, P1021, DOI 10.1016/j.exphem.2005.06.012; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; MIKKOLA HK, 2005, NATURE, V421, P547; Minami T, 2004, J BIOL CHEM, V279, P20626, DOI 10.1074/jbc.M308730200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; NG YK, 1994, DEVELOPMENT, V120, P3257; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; Vyas P, 1999, DEVELOPMENT, V126, P2799; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; ZON LI, 1993, BLOOD, V81, P3234	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14665	14674		10.1074/jbc.M700792200	http://dx.doi.org/10.1074/jbc.M700792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347142	hybrid			2022-12-25	WOS:000246245800080
J	Lu, CY; Egawa, T; Wainwright, LM; Poole, RK; Yeh, SR				Lu, Changyuan; Egawa, Tsuyoshi; Wainwright, Laura M.; Poole, Robert K.; Yeh, Syun-Ru			Structural and functional properties of a truncated hemoglobin from a food-borne pathogen Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; DIMERIC BACTERIAL HEMOGLOBIN; LIGAND-BINDING PROPERTIES; HYDROGEN-BOND NETWORK; AMINO-ACID-SEQUENCE; DISTAL HEME POCKET; MYCOBACTERIUM-TUBERCULOSIS; OXYGEN-BINDING; CARBON-MONOXIDE; VITREOSCILLA HEMOGLOBIN	Campylobacter jejuni contains two hemoglobins, Cgb and Ctb. Cgb has been suggested to perform an NO detoxification reaction to protect the bacterium against NO attack. On the other hand, the physiological function of Ctb, a class III truncated hemoglobin, remains unclear. By using CO as a structural probe, resonance Raman data show that the distal heme pocket of Ctb exhibits a positive electrostatic potential. In addition, two ligand-related vibrational modes, v(Fe-O2) and v(O-O), were identified in the oxy derivative, with frequencies at 542 and 1132 cm(-1), respectively, suggesting the presence of an intertwined H-bonding network surrounding the heme-bound ligand, which accounts for its unusually high oxygen affinity ( 222 mu m(-1)). Mutagenesis studies of various distal mutants suggest that the heme-bound dioxygen is stabilized by H-bonds donated from the Tyr(B10) and Trp(G8) residues, which are highly conserved in the class III truncated hemoglobins; furthermore, an additional H-bond donated from the His(E7) to the Tyr(B10) further regulates these H-bonding interactions by restricting the conformational freedom of the phenolic side chain of the Tyr( B10). Taken together, the data suggest that it is the intricate balance of the H-bonding interactions that determines the unique ligand binding properties of Ctb. The extremely high oxygen affinity of Ctb makes it unlikely to function as an oxygen transporter; on the other hand, the distal heme environment of Ctb is surprisingly similar to that of cytochrome c peroxidase, suggesting a role of Ctb in performing a peroxidase or P450-type of oxygen chemistry.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Yeshiva University; Albert Einstein College of Medicine; University of Sheffield	Yeh, SR (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	syeh@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	Biotechnology and Biological Sciences Research Council [BB/E010504/1] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; BBSRC [BB/E010504/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Dikshit KL, 1998, ARCH BIOCHEM BIOPHYS, V349, P161, DOI 10.1006/abbi.1997.0432; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Egawa T, 2005, J INORG BIOCHEM, V99, P72, DOI 10.1016/j.jinorgbio.2004.10.017; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Elvers KT, 2004, J BACTERIOL, V186, P5332, DOI 10.1128/JB.186.16.5332-5341.2004; Elvers KT, 2005, MOL MICROBIOL, V57, P735, DOI 10.1111/j.1365-2958.2005.04723.x; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Giangiacomo L, 2005, J BIOL CHEM, V280, P9192, DOI 10.1074/jbc.M407267200; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; Kaur R, 2002, APPL ENVIRON MICROB, V68, P152, DOI 10.1128/AEM.68.1.152-160.2002; Kundu S, 2004, BIOCHEMISTRY-US, V43, P6241, DOI 10.1021/bi049848g; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Nardini M, 2006, J BIOL CHEM, V281, P37803, DOI 10.1074/jbc.M607254200; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Park KW, 2002, J BIOL CHEM, V277, P33334, DOI 10.1074/jbc.M203820200; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Pesce A, 2004, J BIOL CHEM, V279, P33662, DOI 10.1074/jbc.M403597200; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Takaya N, 1997, FEBS LETT, V414, P545, DOI 10.1016/S0014-5793(97)01069-7; Tarricone C, 1997, PROTEINS, V27, P154, DOI 10.1002/(SICI)1097-0134(199701)27:1<154::AID-PROT15>3.0.CO;2-M; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; Wainwright LM, 2006, BIOCHEMISTRY-US, V45, P6003, DOI 10.1021/bi052247k; Wajcman H, 2002, CR BIOL, V325, P1159, DOI 10.1016/S1631-0691(02)01537-8; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wang J., 1996, METHODS NITRIC OXIDE, P427; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; WEBSTER DA, 1966, J BIOL CHEM, V241, P3308; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	80	58	60	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13627	13636		10.1074/jbc.M609397200	http://dx.doi.org/10.1074/jbc.M609397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339325	hybrid			2022-12-25	WOS:000246060300052
J	Duca, L; Blanchevoye, C; Cantarelli, B; Ghoneim, C; Dedieu, S; Delacoux, F; Hornebeck, W; Hinek, A; Martiny, L; Debelle, L				Duca, Laurent; Blanchevoye, Charlotte; Cantarelli, Benoit; Ghoneim, Christelle; Dedieu, Stephane; Delacoux, Frederic; Hornebeck, William; Hinek, Aleksander; Martiny, Laurent; Debelle, Laurent			The elastin receptor complex transduces signals through the catalytic activity of its Neu-1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; LYSOSOMAL MULTIENZYME COMPLEX; BINDING-PROTEIN; BETA-GALACTOSIDASE; CULTURED FIBROBLASTS; ENDOTHELIAL-CELLS; HUMAN-LEUKOCYTES; PLASMA-MEMBRANE; GENE-EXPRESSION	The binding of elastin peptides on the elastin receptor complex leads to the formation of intracellular signals but how this is achieved remains totally unknown. Using pharmacological inhibitors of the enzymatic activities of its subunits, we show here that the elastin peptide-driven ERK1/2 activation and subsequent pro-MMP-1 production, observed in skin fibroblasts when they are cultured in the presence of these peptides, rely on a membrane-bound sialidase activity. As lactose blocked this effect, the elastin receptor sialidase subunit, Neu-1, seemed to be involved. The use of a catalytically inactive form of Neu-1 and the small interfering RNA-mediated decrease of Neu-1 expression strongly support this view. Finally, we report that N-acetyl neuraminic acid can reproduce the effects of elastin peptides on both ERK1/2 activation and pro-MMP-1 production. Altogether, our results indicate that the enzymatic activity of the Neu-1 subunit of the elastin receptor complex is responsible for its signal transduction, presumably through sialic acid generation from undetermined substrates.	CNRS, Fac Sci, UMR 6198, IFR 53,Lab Biochim, F-51687 Reims 2, France; Univ Toronto, Hosp Sick Children, Lab Med & Pathobiol, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Debelle, L (corresponding author), CNRS, Fac Sci, UMR 6198, IFR 53,Lab Biochim, Moulin Housse,BP 1039, F-51687 Reims 2, France.	laurent.debelle@univ-reims.fr	MARTINY, Laurent/ABI-5531-2020; Hinek, Aleksander/V-8790-2019	DUCA, Laurent/0000-0002-6035-4906; Dedieu, Stephane/0000-0003-1447-5640				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Caciotti A, 2005, AM J PATHOL, V167, P1689, DOI 10.1016/S0002-9440(10)61251-5; Caciotti A, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9475; Callahan JW, 1999, BBA-MOL BASIS DIS, V1455, P85, DOI 10.1016/S0925-4439(99)00075-7; Chen XP, 1997, J IMMUNOL, V158, P3070; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Duca L, 2005, MOL PHARMACOL, V67, P1315, DOI 10.1124/mol.104.002725; Duca L, 2004, CRIT REV ONCOL HEMAT, V49, P235, DOI 10.1016/j.critrevonc.2003.09.007; Duca L, 2002, FEBS LETT, V524, P193, DOI 10.1016/S0014-5793(02)03057-0; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; Faury G, 1998, CIRC RES, V82, P328, DOI 10.1161/01.RES.82.3.328; GROSSO LE, 1993, MATRIX, V13, P157, DOI 10.1016/S0934-8832(11)80074-0; Hauck M, 1995, BIOCHEM MOL BIOL INT, V37, P45; HINEK A, 1995, EXP CELL RES, V220, P312, DOI 10.1006/excr.1995.1321; Hinek A, 2006, J BIOL CHEM, V281, P3698, DOI 10.1074/jbc.M508736200; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; Hinek A, 1996, BIOL CHEM, V377, P471; ITOH K, 1993, J BIOL CHEM, V268, P1180; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; Jin L, 2002, J EXP MED, V195, P1199, DOI 10.1084/jem.20011796; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Kielty CM, 2002, J CELL SCI, V115, P2817; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; LONG MM, 1989, J CELL PHYSIOL, V140, P512, DOI 10.1002/jcp.1041400316; LONG MM, 1988, BIOCHIM BIOPHYS ACTA, V968, P300, DOI 10.1016/0167-4889(88)90021-3; Lukong KE, 2000, HUM MOL GENET, V9, P1075, DOI 10.1093/hmg/9.7.1075; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 2001, J BIOL CHEM, V276, P17286, DOI 10.1074/jbc.M100460200; Malvagia S, 2004, MOL GENET METAB, V82, P48, DOI 10.1016/j.ymgme.2004.02.007; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Mizuno T, 2005, AM J PHYSIOL-HEART C, V288, pH2819, DOI 10.1152/ajpheart.00862.2004; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; MORREAU H, 1989, J BIOL CHEM, V264, P20655; OGURA K, 1992, EXP CELL RES, V199, P169, DOI 10.1016/0014-4827(92)90475-N; OOYAMA T, 1987, ARTERIOSCLEROSIS, V7, P593, DOI 10.1161/01.ATV.7.6.593; Ostuni A, 2002, INT J BIOCHEM CELL B, V34, P130, DOI 10.1016/S1357-2725(01)00115-7; Peterszegi G, 1999, EUR J CLIN INVEST, V29, P166, DOI 10.1046/j.1365-2362.1999.00423.x; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; Stamatos NM, 2004, J LEUKOCYTE BIOL, V75, P307, DOI 10.1189/jlb.0503241; Tajima S, 1997, ARCH DERMATOL RES, V289, P489, DOI 10.1007/s004030050227; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; USUKI S, 1988, J BIOL CHEM, V263, P10595; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; WACHI H, 1995, FEBS LETT, V368, P215, DOI 10.1016/0014-5793(95)00641-L	58	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12484	12491		10.1074/jbc.M609505200	http://dx.doi.org/10.1074/jbc.M609505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327233	hybrid			2022-12-25	WOS:000245942800017
J	Yang, DH; Cai, KQ; Roland, IH; Smith, ER; Xu, XX				Yang, Dong-Hua; Cai, Kathy Q.; Roland, Isabelle H.; Smith, Elizabeth R.; Xu, Xiang-Xi			Disabled-2 is an epithelial surface positioning gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; PRIMITIVE ENDODERM; SIGNALING PATHWAY; VISCERAL ENDODERM; PARIETAL ENDODERM; RETINOIC ACID; CELL-ADHESION; MOUSE; DAB2; OVARIAN	The formation of the primitive endoderm layer on the surface of the inner cell mass is one of the earliest epithelial morphogenesis in mammalian embryos. In mouse embryos deficient of Disabled2 (Dab2), the primitive endoderm cells lose the ability to position on the surface, resulting in defective morphogenesis. Embryonic stem cells lacking Dab2 are also unable to position on the surface of cell aggregates and fail to form a primitive endoderm outer layer in the embryoid bodies. The cellular function of Dab2, a cargo-selective adaptor, in mediating endocytic trafficking of clathrin-coated vesicles is well established. We show here that Dab2 mediates directional trafficking and polarized distribution of cell surface proteins such as megalin and E-cadherin and propose that loss of polarity is the underlying mechanism for the loss of epithelial cell surface positioning in Dab2-deficient embryos and embryoid bodies. Thus, the findings indicate that Dab2 is a surface positioning gene and suggest a novel mechanism of epithelial cell surface targeting.	Fox Chase Canc Ctr, Ovarian Canc & Tumor Cell Biol Programs, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc & Tumor Cell Biol Programs, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Xiangxi.Xu@fccc.edu			NCI NIH HHS [CA75389, CA79716, CA006927, R01 CA095071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, P30CA006927, R01CA095071, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1979, CELL, V16, P953, DOI 10.1016/0092-8674(79)90110-7; Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bielinska M, 1999, INT J DEV BIOL, V43, P183; BIRCHMEIER W, 1999, EPITHELIAL MORPHOGEN; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Capo-chichi CD, 2005, DEV BIOL, V286, P574, DOI 10.1016/j.ydbio.2005.07.037; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; CLARK WH, 1995, ACTA ONCOL, V34, P3, DOI 10.3109/02841869509093632; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FOWLER KJ, 1990, EXP CELL RES, V191, P194, DOI 10.1016/0014-4827(90)90005-U; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GUETHHALLONET C, 1994, DEVELOPMENT, V120, P3289; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Kamikura DM, 2003, GENE DEV, V17, P2798, DOI 10.1101/gad.1136103; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Liebl EC, 2003, DEVELOPMENT, V130, P3217, DOI 10.1242/dev.00545; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Matthews P, 2000, SIGHT SOUND, V10, P42; Maurer ME, 2005, J CELL SCI, V118, P5345, DOI 10.1242/jcs.02650; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Nagai J, 2005, AM J PHYSIOL-RENAL, V289, pF569, DOI 10.1152/ajprenal.00292.2004; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Rice DS, 1998, DEVELOPMENT, V125, P3719; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Rossant J, 2003, PHILOS T ROY SOC B, V358, P1341, DOI 10.1098/rstb.2003.1329; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wolpert L., 2002, PRINCIPLES DEV; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13114	13122		10.1074/jbc.M611356200	http://dx.doi.org/10.1074/jbc.M611356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339320	hybrid			2022-12-25	WOS:000245942800079
J	Wong, ESP; Tan, JMM; Wang, C; Zhang, ZS; Tay, SP; Zaiden, N; Ko, HS; Dawson, VL; Dawson, TM; Lim, KL				Wong, Esther S. P.; Tan, Jeanne M. M.; Wang, Cheng; Zhang, Zhenshui; Tay, Shiam-Peng; Zaiden, Norazean; Ko, Han Seok; Dawson, Valina L.; Dawson, Ted M.; Lim, Kah-Leong			Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; MUTATIONS; DOMAIN; DOPAMINE; ASSOCIATION; COMPLEX; GENE; RING	Loss of parkin function is a predominant cause of familial Parkinsonism. Emerging evidence also suggests that parkin expression variability may confer a risk for sporadic Parkinson disease. We have recently demonstrated that a wide variety of Parkinson disease-linked stressors, including dopamine ( DA), induce parkin solubility alterations and promote its aggregation within the cell, a phenomenon that may underlie the progressive susceptibility of the brain to degeneration. The vulnerability of parkin to stress-induced modification is likely due to its abundance of cysteine residues. Here, we performed a comprehensive mutational analysis and demonstrate that Cys residues residing both within and outside of the RING-IBR ( (i) under barn (b) under bar etween (R) under bar ING fingers)-RING domain of parkin are important in maintaining its solubility. The majority of these Cys residues are highly conserved in parkin across different species and potentially fulfil important structural roles. Further, we found that both parkin and HHARI ( human homologue of Drosophila ariadne), another RING-IBR-RING- type ubiquitin ligase, are comparably more susceptible to solubility alterations induced by oxidative and nitrosative stress when compared with other non RING-IBR-RING Cys-containing enzymes. However, parkin appears to be uniquely sensitive to DA-mediated stress, the specificity of which is likely due to DA modification of 2 Cys residues on parkin ( Cys-268 and Cys-323) that are distinct from other RING-IBR-RING members.	Natl Inst Neurosci, Neurodegenerat Res Lab, Singapore 308433, Singapore; Natl Inst Neurosci, Parkinsons Dis & Movement Disorders Ctr, Singapore 308433, Singapore; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Natl Univ Singapore, Dept Sci Biol, Singapore 119077, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 119077, Singapore	National Neuroscience Institute (NNI); National Neuroscience Institute (NNI); Johns Hopkins University; Johns Hopkins University; National University of Singapore; National University of Singapore	Lim, KL (corresponding author), Natl Inst Neurosci, Neurodegenerat Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	Kah_Leong_Lim@nni.com.sg	Tan, Jeanne/GQI-3612-2022; Lim, Kah/L-5426-2019; Wong, Esther/E-1344-2011; Lim, Kah-Leong/AAY-3308-2020; Dawson, Valina/Y-9757-2019	Lim, Kah-Leong/0000-0002-5440-2588; Dawson, Valina/0000-0002-2915-3970; Wong, Esther/0000-0003-2421-7346	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377, R01NS048206] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377, R01 NS048206, P50 NS038377, NS48206] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Capili AD, 2004, J MOL BIOL, V340, P1117, DOI 10.1016/j.jmb.2004.05.035; Cookson MR, 2003, CURR BIOL, V13, pR522, DOI 10.1016/S0960-9822(03)00446-9; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Klein C, 2003, ANN NEUROL, V54, P415, DOI 10.1002/ana.10737; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Lim KL, 2003, ANN NY ACAD SCI, V991, P80; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Savitt JM, 2006, J CLIN INVEST, V116, P1744, DOI 10.1172/JCI29178; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Wang C, 2005, HUM MOL GENET, V14, P3885, DOI 10.1093/hmg/ddi413; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; West AB, 2002, HUM MOL GENET, V11, P2787, DOI 10.1093/hmg/11.22.2787; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	22	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12310	12318		10.1074/jbc.M609466200	http://dx.doi.org/10.1074/jbc.M609466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329252	hybrid			2022-12-25	WOS:000245941900073
J	Tester, AM; Cox, JH; Connor, AR; Starr, AE; Dean, RA; Puente, XS; Lopez-Otin, C; Overall, CM				Tester, Angus M.; Cox, Jennifer H.; Connor, Andrea R.; Starr, Amanda E.; Dean, Richard A.; Puente, Xose S.; Lopez-Otin, Carlos; Overall, Christopher M.			LPS Responsiveness and Neutrophil Chemotaxis In Vivo Require PMN MMP-8 Activity	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; CXC CHEMOKINES; POTENTIAL ROLE; TUMOR-CELLS; GRO-ALPHA; INTERLEUKIN-8; BINDING; VITRO; INFLAMMATION; PROTEIN-2	We identify matrix metalloproteinase (MMP)-8, the polymorphonuclear (PMN) leukocyte collagenase, as a critical mediator initiating lipopolysaccharide (LPS)-responsiveness in vivo. PMN infiltration towards LPS is abrogated in Mmp8-null mice. MMP-8 cleaves LPS-induced CXC chemokine (LIX) at Ser(4)similar to Val(5) and Lys(79)similar to Arg(80). LIX bioactivity is increased upon N-terminal cleavage, enhancing intracellular calcium mobilization and chemotaxis upon binding its cognate receptor, CXCR2. As there is no difference in PMN chemotaxis in Mmp8-null mice compared with wild-type mice towards synthetic analogues of MMP-8-cleaved LIX, MMP-8 is not essential for extravasation or cell migration in collagenous matrices in vivo. However, with biochemical redundancy between MMPs 1, 2, 9, and 13, which also cleave LIX at position 4 similar to 5, it was surprising to observe such a markedly reduced PMN infiltration towards LPS and LIX in Mmp8-/- mice. This lack of physiological redundancy in vivo identifies MMP-8 as a key mediator in the regulation of innate immunity. Comparable results were found with CXCL8/IL-8 and CXCL5/ENA-78, the human orthologues of LIX. MMP-8 cleaves CXCL8 at Arg(5)-Ser(6) and at Val(7)-Leu(8) in CXCL5 to activate respective chemokines. Hence, rather than collagen, these PMN chemoattractants are important MMP-8 substrates in vivo; PMN-derived MMP-8 cleaves and activates LIX to execute an in cis PMN-controlled feed-forward mechanism to orchestrate the initial inflammatory response and promote LPS responsiveness in tissue.	[Tester, Angus M.; Cox, Jennifer H.; Connor, Andrea R.; Starr, Amanda E.; Dean, Richard A.; Overall, Christopher M.] Univ British Columbia, Ctr Blood Res, Dept Oral Biol & Med Sci, Vancouver, BC V5Z 1M9, Canada; [Tester, Angus M.; Cox, Jennifer H.; Connor, Andrea R.; Starr, Amanda E.; Dean, Richard A.; Overall, Christopher M.] Univ British Columbia, Ctr Blood Res, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; [Puente, Xose S.; Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, Oviedo, Spain	University of British Columbia; University of British Columbia; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Overall, CM (corresponding author), Univ British Columbia, Ctr Blood Res, Dept Oral Biol & Med Sci, Vancouver, BC V5Z 1M9, Canada.	chris.overall@ubc.ca	Puente, Xosé S./ADB-0672-2022; López-Otín, Carlos/AAB-2106-2020	Puente, Xosé S./0000-0001-9525-1483; López-Otín, Carlos/0000-0001-6964-1904	Michael Smith Foundation for Health Research; Natural Sciences and Engineering Research Council of Canada; CIHR [STP-53877]; Canadian Institutes of Health Research; National Cancer Institute of Canada; Michael Smith Research Foundation	Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Michael Smith Research Foundation(Michael Smith Foundation for Health Research)	This work was supported by the Michael Smith Foundation for Health Research (JHC), Natural Sciences and Engineering Research Council of Canada (JHC and AES), CIHR Strategic Training Program STP-53877 (JHC and AES). CMO is a Canada Research Chair in Metalloproteinase Proteomics and Systems Biology, and has research grants from the Canadian Institutes of Health Research, the National Cancer Institute of Canada, and a Centre Grant from the Michael Smith Research Foundation (UBC Centre for Blood Research).	Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Arcaroli J, 2002, CHEST, V121, p76S, DOI 10.1378/chest.121.3_suppl.76S; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303, DOI 10.1165/ajrcmb.20.6.3558; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; Butler GS, 2002, J BIOL CHEM, V277, P17511, DOI 10.1074/jbc.M201461200; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DEAN RA, 2007, MOL CELL PROTEOMICS; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HASTY KA, 1987, J BIOL CHEM, V262, P10048; Houghton AM, 2006, CANCER RES, V66, P6149, DOI 10.1158/0008-5472.CAN-04-0297; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; LEE J, 1995, J IMMUNOL, V155, P2158; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; Madri J A, 2000, Dev Immunol, V7, P103, DOI 10.1155/2000/79045; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Olszyna DP, 2001, INFECT IMMUN, V69, P2736, DOI 10.1128/IAI.69.4.2736-2738.2001; Overall Christopher M, 2004, Biochem J, V383, pe5; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Park JE, 2004, AM J SURG, V187, p11S, DOI 10.1016/S0002-9610(03)00296-4; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Pelman GR, 2005, J BIOL CHEM, V280, P2370, DOI 10.1074/jbc.M409603200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; Smith JB, 1997, J LEUKOCYTE BIOL, V62, P598, DOI 10.1002/jlb.62.5.598; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tateda K, 2001, INFECT IMMUN, V69, P2017, DOI 10.1128/IAI.69.4.2017-2024.2001; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Van Lint P, 2005, J IMMUNOL, V175, P7642, DOI 10.4049/jimmunol.175.11.7642; VANDAMME J, 1990, EUR J IMMUNOL, V20, P2113, DOI 10.1002/eji.1830200933; Vergote D, 2006, P NATL ACAD SCI USA, V103, P19182, DOI 10.1073/pnas.0604678103; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wuyts A, 1998, EUR J BIOCHEM, V255, P67, DOI 10.1046/j.1432-1327.1998.2550067.x; Wuyts A, 1999, J IMMUNOL, V163, P6155; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; Wuyts A, 1996, J IMMUNOL, V157, P1736; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	61	171	176	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e312	10.1371/journal.pone.0000312	http://dx.doi.org/10.1371/journal.pone.0000312			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375198	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445100014
J	Chien, CV				Chien, Colleen V.			HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?	PLOS ONE			English	Article							ANTIRETROVIRAL DRUGS; ACCESS; TRADE	Background. Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. Methodology/Principal Findings. An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of first line drugs, which were provided mostly by generic firms, while the remaining 4%, of second line drugs, was sourced primarily from brand companies. 85% of the generic drugs in the sample were manufactured in India, where the majority of the drugs procured were ineligible for patent protection. The remaining 15% was manufactured in South Africa, mostly under voluntary licenses provided by brand companies to a single generic company. In Sub-Saharan African countries, four first line drugs in the dataset were widely patented, however no general deterrent to generic purchasing based on a patent was detected. Conclusions/Significance. Generic and brand companies have played distinct roles in increasing the availability of ARVs in Sub-Saharan Africa. Generic companies provided most of the drugs studied, at prices below those charged by brand companies, and until now, almost exclusively supplied several fixed-dose combination drugs. Brand companies have supplied almost all second line drugs, signed voluntary licenses with generic companies, and are not strictly enforcing patents in certain countries. Further investigation into how price reductions in second line drugs can be achieved and the cheapest drugs can actually be procured is warranted.	Fenwick & W LLP, Oakland, CA USA		Chien, CV (corresponding author), Fenwick & W LLP, Oakland, CA USA.	colleenchien@gmail.com			Stanford Center for Law and the Biosciences at Stanford Law School	Stanford Center for Law and the Biosciences at Stanford Law School	This paper was written with the generous support of the Stanford Center for Law and the Biosciences at Stanford Law School, at which the author was a Fellow during its writing. The Center played no role in any part of the conception, analysis, or approval of the manuscript.	Abbott FM, 2005, AM J INT LAW, V99, P317, DOI 10.2307/1562501; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; *AVERT, 2006, PRES EM PLAN AIDS RE; Bartram D, 2006, COMPUTER-BASED TESTING AND THE INTERNET: ISSUES AND ADVANCES, P13; BOULET P, 2006, PATENT STATUS HIV AI; Butler D, 2005, NATURE, V436, P156, DOI 10.1038/436156a; CAMP R, 2006, ANTIRETROVIRALS PIPE; Cohen JC, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-17; *FOOD DRUG ADM, 2005, FDA CONSUM, V39, P3; Ford N, 2006, LANCET, V367, P794, DOI 10.1016/S0140-6736(06)68313-X; *GLAXOSMITHKLINE, 2006, GSK PAT PAT APPL COM; *GLOB FUND FIGHT A, 2006, DISTR FUND 5 ROUNDS; Grace C, 2004, EFFECT CHANGING INTE; HAMILTON D, 2006, GOOD DEED AIDS DRUG; *HOFFMANLAROCHE, 2004, REM BARR INCR ACC RO; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; KULLINAN K, 2006, ASPENS GENERICS ENSU; *LAW COLL HIV AIDS, 2006, ACC MED POSTTRIPS RE; Lee K, 2004, JAMA-J AM MED ASSOC, V291, P2636, DOI 10.1001/jama.291.21.2636; Medecins Sans Frontieres, 2006, UNT WEB PRIC RED PRI; THOEN E, 2003, DRUG PATENTS SPOTLIG; UNAIDS, 2006, REP GLOB AIDS EP; Vasan A, 2006, B WORLD HEALTH ORGAN, V84, P393, DOI 10.2471/BLT.05.025684; Westerhaus M, 2006, PLOS MED, V3, P1230, DOI 10.1371/journal.pmed.0030332; *WHO, 2006, REP WHO UNA IN PRESS; *WHO, 2006, GLOB PRIC REP MECH; *WHO, 2006, WEIGHT AV PRIC ARVS; *WHO, 2006, AIDS MED DIAGN SERV; WHO, 2004, SCAL ANT THER RES LI; *WORLD COMM ADV BO, 2005, WORLD COMM ADV BOARD; World Health Organization, 2006, ANT THER HIV INF AD; 2006, EC TIMES        0905; 2006, MED NEWS TODAY  1206	33	46	48	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e278	10.1371/journal.pone.0000278	http://dx.doi.org/10.1371/journal.pone.0000278			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372625	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444800001
J	Seebacher, F; Murray, SA				Seebacher, Frank; Murray, Shauna A.			Transient Receptor Potential Ion Channels Control Thermoregulatory Behaviour in Reptiles	PLOS ONE			English	Article							BODY-TEMPERATURE; MELATONIN; MECHANISMS; EVOLUTION; RESPONSES; SELECTION; FALLACY; MODEL	Biological functions are governed by thermodynamics, and animals regulate their body temperature to optimise cellular performance and to avoid harmful extremes. The capacity to sense environmental and internal temperatures is a prerequisite for the evolution of thermoregulation. However, the mechanisms that enable ectothermic vertebrates to sense heat remain unknown. The recently discovered thermal characteristics of transient receptor potential ion channels (TRP) render these proteins suitable to act as temperature sensors. Here we test the hypothesis that TRPs are present in reptiles and function to control thermoregulatory behaviour. We show that the hot-sensing TRPV1 is expressed in a crocodile (Crocodylus porosus), an agamid (Amphibolurus muricatus) and a scincid (Pseudemoia entrecasteauxii) lizard, as well as in the quail and zebrafinch (Coturnix chinensis and Poephila guttata). The TRPV1 genes from all reptiles form a unique clade that is delineated from the mammalian and the ancestral Xenopus sequences by an insertion of two amino acids. TRPV1 and the cool-sensing TRPM8 are expressed in liver, muscle (transversospinalis complex), and heart tissues of the crocodile, and have the potential to act as internal thermometer and as external temperatures sensors. Inhibition of TRPV1 and TRPM8 in C. porosus abolishes the typically reptilian shuttling behaviour between cooling and heating environments, and leads to significantly altered body temperature patterns. Our results provide the proximate mechanism of thermal selection in terrestrial ectotherms, which heralds a fundamental change in interpretation, because TRPs provide the mechanism for a tissue-specific input into the animals' thermoregulatory response.	[Seebacher, Frank; Murray, Shauna A.] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Seebacher, F (corresponding author), Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia.	fseebach@bio.usyd.edu.au	Murray, Shauna/K-5781-2015	Murray, Shauna/0000-0001-7096-1307; Seebacher, Frank/0000-0002-2281-9311	Australian Research Council	Australian Research Council(Australian Research Council)	This work was supported by the Australian Research Council. The authors have no financial interest in this manuscript.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BOGERT CM, 1949, EVOLUTION, V3, P195, DOI 10.2307/2405558; Boulant JA, 2006, J APPL PHYSIOL, V100, P1347, DOI 10.1152/japplphysiol.01064.2005; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cooper KE, 2002, J APPL PHYSIOL, V92, P1717, DOI 10.1152/japplphysiol.01051.2001; DiMicco JA, 2007, AM J PHYSIOL-REG I, V292, pR47, DOI 10.1152/ajpregu.00498.2006; Egan GF, 2005, P NATL ACAD SCI USA, V102, P5262, DOI 10.1073/pnas.0409753102; GILCHRIST GW, 1995, AM NAT, V146, P252, DOI 10.1086/285797; Glanville EJ, 2006, J EXP BIOL, V209, P4869, DOI 10.1242/jeb.02585; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; HAMMEL HT, 1967, SCIENCE, V156, P1260, DOI 10.1126/science.156.3779.1260; HERTZ PE, 1993, AM NAT, V142, P796, DOI 10.1086/285573; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; HUEY RB, 1976, Q REV BIOL, V51, P363, DOI 10.1086/409470; HUEY RB, 1991, AM NAT, V137, pS91, DOI 10.1086/285141; Incropera F.P., 1996, FUNDAMENTALS HEAT MA; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Lee H, 2005, PFLUG ARCH EUR J PHY, V451, P160, DOI 10.1007/s00424-005-1438-y; Lutterschmidt DI, 2002, HORM BEHAV, V41, P41, DOI 10.1006/hbeh.2001.1721; Lutterschmidt DI, 2003, CAN J ZOOL, V81, P1, DOI 10.1139/Z02-189; Lutterschmidt DI, 1997, COMP BIOCHEM PHYS C, V118, P271, DOI 10.1016/S0742-8413(97)00106-0; MCKEMY DD, 2007, ARCH EUR J IN PRESS; Nealen ML, 2003, J NEUROPHYSIOL, V90, P515, DOI 10.1152/jn.00843.2002; NELSON DO, 1984, AM ZOOL, V24, P791; Nilius B, 2005, PFLUG ARCH EUR J PHY, V451, P1, DOI 10.1007/s00424-005-1462-y; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RIVKEES SA, 1989, P NATL ACAD SCI USA, V86, P3882, DOI 10.1073/pnas.86.10.3882; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; Seebacher F, 2006, P ROY SOC B-BIOL SCI, V273, P565, DOI 10.1098/rspb.2005.3333; Seebacher F, 2004, J COMP PHYSIOL B, V174, P577, DOI 10.1007/s00360-004-0446-0; Seebacher F, 2004, PHYSIOL BIOCHEM ZOOL, V77, P688, DOI 10.1086/422052; Seebacher F, 1999, PHYSIOL BIOCHEM ZOOL, V72, P57, DOI 10.1086/316638; Tosini G, 1997, ETHOL ECOL EVOL, V9, P313, DOI 10.1080/08927014.1997.9522875; Weil A, 2005, MOL PHARMACOL, V68, P518, DOI 10.1124/mol.105.012146	40	38	40	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e281	10.1371/journal.pone.0000281	http://dx.doi.org/10.1371/journal.pone.0000281			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356692	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444800004
J	Martin, JR; Rogers, KL; Chagneau, C; Brulet, P				Martin, Jean-Rene; Rogers, Kelly L.; Chagneau, Carine; Brulet, Philippe			In vivo Bioluminescence Imaging of Ca2+ Signalling in the Brain of Drosophila	PLOS ONE			English	Article							MUSHROOM BODY; LOCOMOTOR-ACTIVITY; CENTRAL COMPLEX; NEURONS; BODIES; DUNCE; GENE; PHOSPHODIESTERASE; MELANOGASTER; ARCHITECTURE	Many different cells' signalling pathways are universally regulated by Ca2+ concentration [Ca2+] rises that have highly variable amplitudes and kinetic properties. Optical imaging can provide the means to characterise both the temporal and spatial aspects of Ca2+ signals involved in neurophysiological functions. New methods for in vivo imaging of Ca2+ signalling in the brain of Drosophila are required for probing the different dynamic aspects of this system. In studies here, whole brain Ca2+ imaging was performed on transgenic flies with targeted expression of the bioluminescent Ca2+ reporter GFP-aequorin (GA) in different neural structures. A photon counting based technique was used to undertake continuous recordings of cytosolic [Ca2+] over hours. Time integrals for reconstructing images and analysis of the data were selected offline according to the signal intensity. This approach allowed a unique Ca2+ response associated with cholinergic transmission to be identified by whole brain imaging of specific neural structures. Notably, [Ca2+] transients in the Mushroom Bodies (MBs) following nicotine stimulation were accompanied by a delayed secondary [Ca2+] rise (up to 15 min. later) in the MB lobes. The delayed response was sensitive to thapsigargin, suggesting a role for intra-cellular Ca2+ stores. Moreover, it was reduced in dunce mutant flies, which are impaired in learning and memory. Bioluminescence imaging is therefore useful for studying Ca2+ signalling pathways and for functional mapping of neurophysiological processes in the fly brain.	[Martin, Jean-Rene] CNRS, Unite UPR 9040, Equipe Bases Neurales Comportements Chez Drosophi, Neurobiol Cellulaire & Mol Lab, Gif Sur Yvette, France; [Rogers, Kelly L.; Brulet, Philippe] Inst Pasteur, CNRS, URA 2578, Unite Embryol Mol, Paris, France; [Chagneau, Carine] Univ Paris 11, CNRS, UMR 8620, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Martin, JR (corresponding author), CNRS, Unite UPR 9040, Equipe Bases Neurales Comportements Chez Drosophi, Neurobiol Cellulaire & Mol Lab, Gif Sur Yvette, France.	jean-rene.martin@inaf.cnrs-gif.fr; pbrulet@pasteur.fr		Rogers, Kelly L./0000-0002-6755-0221	CNRS; ANR; Pasteur Institute	CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR(French National Research Agency (ANR)); Pasteur Institute	This work was supported by Grants from CNRS and ANR (Neuroscience) to J-R Martin, and from Pasteur Institute and CNRS to P. Brulet.	Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Besson M, 2005, J NEUROBIOL, V62, P386, DOI 10.1002/neu.20111; BRAND AH, 1993, DEVELOPMENT, V118, P401; Crittenden JR, 1998, LEARN MEMORY, V5, P38; CURIE T, 2007, MOL IMAGING IN PRESS; Davis RL, 2005, ANNU REV NEUROSCI, V28, P275, DOI 10.1146/annurev.neuro.28.061604.135651; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; Fiala A, 2002, CURR BIOL, V12, P1877, DOI 10.1016/S0960-9822(02)01239-3; FIALA A, 2003, SCI STKE, V174, pPL6; Gorokhovatsky AY, 2004, BIOCHEM BIOPH RES CO, V320, P703, DOI 10.1016/j.bbrc.2004.06.014; HANESCH U, 1989, CELL TISSUE RES, V257, P343, DOI 10.1007/BF00261838; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Hou JM, 2004, J NEUROBIOL, V60, P249, DOI 10.1002/neu.20021; Ito K, 1998, LEARN MEMORY, V5, P52; KAUVAR LM, 1982, J NEUROSCI, V2, P1347; Kim YJ, 2006, CURR BIOL, V16, P1395, DOI 10.1016/j.cub.2006.06.027; Lee T, 1999, DEVELOPMENT, V126, P4065; Martin JR, 1999, J COMP PHYSIOL A, V185, P277, DOI 10.1007/s003590050387; Martin JR, 1998, LEARN MEMORY, V5, P179; MARTIN JR, 2002, J NEUROGENET, V15, P1; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Rogers KL, 2005, EUR J NEUROSCI, V21, P597, DOI 10.1111/j.1460-9568.2005.03871.x; Rosay P, 2001, NEURON, V30, P759, DOI 10.1016/S0896-6273(01)00323-3; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; STRAUSS R, 1993, J NEUROSCI, V13, P1852, DOI 10.1523/jneurosci.13-05-01852.1993; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Wang YL, 2004, J NEUROSCI, V24, P6507, DOI 10.1523/JNEUROSCI.3727-03.2004; YANG MY, 1995, NEURON, V15, P45; Yasuyama K, 1999, MICROSC RES TECHNIQ, V45, P65, DOI 10.1002/(SICI)1097-0029(19990415)45:2<65::AID-JEMT2>3.0.CO;2-0; Yu DH, 2003, J NEUROSCI, V23, P64	33	58	58	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e275	10.1371/journal.pone.0000275	http://dx.doi.org/10.1371/journal.pone.0000275			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342209	gold, Green Published			2022-12-25	WOS:000207444700010
J	D'Angiolella, V; Palazzo, L; Santarpia, C; Costanzo, V; Grieco, D				D'Angiolella, Vincenzo; Palazzo, Luca; Santarpia, Concetta; Costanzo, Vincenzo; Grieco, Domenico			Role for Non-Proteolytic Control of M-phase Promoting Factor Activity at M-phase Exit	PLOS ONE			English	Article								M-phase Promoting Factor (MPF; the cyclin B-cdk 1 complex) is activated at M-phase onset by removal of inhibitory phosphorylation of cdk1 at thr-14 and tyr-15. At M-phase exit, MPF is destroyed by ubiquitin-dependent cyclin proteolysis. Thus, control of MPF activity via inhibitory phosphorylation is believed to be particularly crucial in regulating transition into, rather than out of, M-phase. Using the in vitro cell cycle system derived form Xenopus eggs, here we show, however, that inhibitory phosphorylation of cdk1 contributes to control MPF activity during M-phase exit. By sampling extracts at very short intervals during both meiotic and mitotic exit, we found that cyclin B1-associated cdk1 underwent transient inhibitory phosphorylation at tyr-15 and that cyclin B1-cdk1 activity fell more rapidly than the cyclin B1 content. Inhibitory phosphorylation of MPF correlated with phosphorylation changes of cdc25C, the MPF phosphatase, and physical interaction of cdk1 with wee1, the MPF kinase, during M-phase exit. MPF down-regulation required Ca++/calmodulin-dependent kinase II (CaMKII) and cAMP-dependent protein kinase (PKA) activities at meiosis and mitosis exit, respectively. Treatment of M-phase extracts with a mutant cyclin B1-cdk1AF complex, refractory to inhibition by phosphorylation, impaired binding of the Anaphase Promoting Complex/Cyclosome (APC/C) to its co-activator Cdc20 and altered M-phase exit. Thus, timely M-phase exit requires a tight coupling of proteolysis-dependent and proteolysis-independent mechanisms of MPF inactivation.	[D'Angiolella, Vincenzo; Palazzo, Luca; Santarpia, Concetta; Grieco, Domenico] Univ Naples Federico 2, Fac Biotechnol Sci, Naples, Italy; [D'Angiolella, Vincenzo; Palazzo, Luca; Santarpia, Concetta; Grieco, Domenico] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; [Palazzo, Luca; Santarpia, Concetta; Grieco, Domenico] CEINGE Biotecnol Avanzate, Naples, Italy; [D'Angiolella, Vincenzo] NYU, Dept Pathol, New York, NY 10016 USA; [Costanzo, Vincenzo] London Res Inst, Clare Hall Labs, London, England	University of Naples Federico II; University of Naples Federico II; CEINGE Biotecnologie Avanzate; New York University	Grieco, D (corresponding author), Univ Naples Federico 2, Fac Biotechnol Sci, Naples, Italy.	domenico.grieco@unina.it	Palazzo, Luca/Q-1084-2017	Palazzo, Luca/0000-0002-5556-5549; Costanzo, Vincenzo/0000-0002-2920-9508; GRIECO, Domenico/0000-0002-7131-5742	Associazione Italiana per la Ricerca sul Cancro (AIRC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)	Arnaoutov A, 2003, DEV CELL, V5, P99, DOI 10.1016/S1534-5807(03)00194-1; Ciliberto A, 2005, CELL CYCLE, V4, P1107; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; D'Angiolella V, 2004, CELL CYCLE, V3, P132; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harvey SL, 2005, CELL, V122, P407, DOI 10.1016/j.cell.2005.05.029; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hutchins JRA, 2003, MOL BIOL CELL, V14, P4003, DOI 10.1091/mbc.E03-02-0061; Kim SY, 2005, MOL CELL BIOL, V25, P10580, DOI 10.1128/MCB.25.23.10580-10590.2005; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pomerening JR, 2005, CELL, V122, P565, DOI 10.1016/j.cell.2005.06.016; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Stanford JS, 2005, MOL BIOL CELL, V16, P5749, DOI 10.1091/mbc.E05-06-0541; Stumpff J, 2005, CURR BIOL, V15, P1525, DOI 10.1016/j.cub.2005.07.031; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Wolfe BA, 2004, CELL CYCLE, V3, P601; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622	26	22	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e247	10.1371/journal.pone.0000247	http://dx.doi.org/10.1371/journal.pone.0000247			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327911	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444600007
J	Unneberg, P; Claverie, JM				Unneberg, Per; Claverie, Jean-Michel			Tentative Mapping of Transcription-Induced Interchromosomal Interaction using Chimeric EST and mRNA Data	PLOS ONE			English	Article								Recent studies on chromosome conformation show that chromosomes colocalize in the nucleus, bringing together active genes in transcription factories. This spatial proximity of actively transcribing genes could provide a means for RNA interaction at the transcript level. We have screened public databases for chimeric EST and mRNA sequences with the intent of mapping transcription-induced interchromosomal interactions. We suggest that chimeric transcripts may be the result of close encounters of active genes, either as functional products or "noise'' in the transcription process, and that they could be used as probes for chromosome interactions. We have found a total of 5,614 chimeric ESTs and 587 chimeric mRNAs that meet our selection criteria. Due to their higher quality, the mRNA findings are of particular interest and we hope that they may serve as food for thought for specialists in diverse areas of molecular biology.	[Unneberg, Per; Claverie, Jean-Michel] CNRS, UPR 2589, Inst Biol Struct & Microbiol, Struct & Genom Informat Lab, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Unneberg, P (corresponding author), CNRS, UPR 2589, Inst Biol Struct & Microbiol, Struct & Genom Informat Lab, Marseille, France.	per.unneberg@igs.cnrs-mrs.fr	Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019	Claverie, Jean-Michel/0000-0003-1424-0315; Unneberg, Per/0000-0001-5735-3315	Swedish Research Council	Swedish Research Council(Swedish Research CouncilEuropean Commission)	Per Unneberg was supported by the Swedish Research Council.	Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; Chen JJ, 2004, NUCLEIC ACIDS RES, V32, P4812, DOI 10.1093/nar/gkh818; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Chuang CH, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-237; Claverie JM, 2005, SCIENCE, V309, P1529, DOI 10.1126/science.1116800; Dahary D, 2005, GENOME RES, V15, P364, DOI 10.1101/gr.3308405; Dixon RJ, 2005, NUCLEIC ACIDS RES, V33, P5904, DOI 10.1093/nar/gki893; Finta C, 2002, J BIOL CHEM, V277, P5882, DOI 10.1074/jbc.M109175200; Frith MC, 2006, PLOS GENET, V2, P504, DOI 10.1371/journal.pgen.0020023; Frith MC, 2006, PLOS GENET, V2, P515, DOI 10.1371/journal.pgen.0020052; Hahn Y, 2004, P NATL ACAD SCI USA, V101, P13257, DOI 10.1073/pnas.0405490101; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kim N, 2006, NUCLEIC ACIDS RES, V34, pD21, DOI 10.1093/nar/gkj019; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Parra G, 2006, GENOME RES, V16, P37, DOI 10.1101/gr.4145906; Romani A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng017; Smalheiser NR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-403; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zhang C, 2003, DNA CELL BIOL, V22, P303, DOI 10.1089/104454903322216653	28	17	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e254	10.1371/journal.pone.0000254	http://dx.doi.org/10.1371/journal.pone.0000254			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330142	Green Published, gold			2022-12-25	WOS:000207444600014
J	Tikkinen, KAO; Tammela, TLJ; Rissanen, AM; Valpas, A; Huhtala, H; Auvinen, A				Tikkinen, Kari A. O.; Tammela, Teuvo L. J.; Rissanen, Aila M.; Valpas, Antti; Huhtala, Heini; Auvinen, Anssi			Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland	PLOS ONE			English	Article							URINARY-TRACT SYMPTOMS; INCONTINENCE; WOMEN; NOCTURIA; MEN	Background. In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions. Methodology/Principal Findings. The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003-2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18-79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. Conclusions/Significance. Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies, occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low participation.	[Tikkinen, Kari A. O.; Tammela, Teuvo L. J.] Tampere Univ Hosp, Dept Urol, Tampere, Finland; [Tikkinen, Kari A. O.; Tammela, Teuvo L. J.] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Tikkinen, Kari A. O.; Huhtala, Heini; Auvinen, Anssi] Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland; [Rissanen, Aila M.] Univ Helsinki, Cent Hosp, Obes Res Unit, Helsinki, Finland; [Valpas, Antti] S Karelian Cent Hosp, Dept Obstet & Gynecol, Lappeenranta, Finland	Tampere University; Tampere University Hospital; Tampere University; Tampere University; University of Helsinki; Helsinki University Central Hospital	Tikkinen, KAO (corresponding author), Tampere Univ Hosp, Dept Urol, Tampere, Finland.	kari.tikkinen@fimnet.fi	Auvinen, Anssi/AAL-2111-2020; Auvinen, Anssi/AAD-9311-2020; Tikkinen, Kari/L-3632-2018	Auvinen, Anssi/0000-0003-1125-4818; Tikkinen, Kari/0000-0002-1389-8214	Medical Research Fund of the Tampere University Hospital; Emil Aaltonen Foundation; Lilly Foundation; Research Foundation of Orion Corporation; Tampere University Foundation	Medical Research Fund of the Tampere University Hospital; Emil Aaltonen Foundation; Lilly Foundation; Research Foundation of Orion Corporation; Tampere University Foundation	The study was funded by a grant from the Medical Research Fund of the Tampere University Hospital, and an unrestricted grant was accepted from Pfizer to cover the mailing and printing costs of questionnaires. The work of the corresponding author was funded by unrestricted grants from the Emil Aaltonen Foundation, the Lilly Foundation, the Medical Research Fund of the Tampere University Hospital, the Research Foundation of Orion Corporation, and the Tampere University Foundation. The funding sources had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. The authors' work was independent of the funders. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; ARMSTRONG BK, 1992, PRINCIPLES EXPOSURE, P190; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Chen GD, 2003, NEUROUROL URODYNAM, V22, P109, DOI 10.1002/nau.10010; Corcos Jacques, 2004, Can J Urol, V11, P2278; dos Santos Silva I, 1999, CANC EPIDEMIOLOGY PR; Homma Y, 2005, BJU INT, V96, P1314, DOI 10.1111/j.1464-410X.2005.05835.x; Hu TW, 2005, BJU INT, V96, P43, DOI 10.1111/j.1464-410X.2005.05654.x; *IMS, 2006, IMS WORLD REV; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019; Khan MS, 2004, BJOG-INT J OBSTET GY, V111, P468, DOI 10.1111/j.1471-0528.2004.00126.x; Lapitan MC, 2001, INT UROGYNECOL J PEL, V12, P226, DOI 10.1007/s001920170043; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; Moller LA, 2000, BMJ-BRIT MED J, V320, P1429, DOI 10.1136/bmj.320.7247.1429; Moorthy P, 2004, BJU INT, V93, P528, DOI 10.1111/j.1464-410X.2003.04682.x; Moynihan R, 2006, PLOS MED, V3, P425, DOI 10.1371/journal.pmed.0030191; Nabi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003781.pub2; Ouslander JG, 2004, NEW ENGL J MED, V350, P786, DOI 10.1056/NEJMra032662; Parazzini F, 2002, J FAM PRACTICE, V51, P1072; *POP REG CTR, 2004, TASK FICKF 2004; SCHOU J, 1993, SCAND J UROL NEPHROL, V27, P489, DOI 10.3109/00365599309182282; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Swithinbank LV, 1999, BRIT J GEN PRACT, V49, P897; Teloken C, 2006, EUR UROL, V49, P1087, DOI 10.1016/j.eururo.2006.01.026; Temml C, 2005, EUR UROL, V48, P622, DOI 10.1016/j.eururo.2005.04.026; Tikkinen KAO, 2006, J UROLOGY, V175, P596, DOI 10.1016/S0022-5347(05)00245-4; Tikkinen KAO, 2006, AM J EPIDEMIOL, V163, P1003, DOI 10.1093/aje/kwj139; Yu HJ, 2006, UROL INT, V77, P327, DOI 10.1159/000096337; Zhang WJ, 2006, NEUROUROL URODYNAM, V25, P717, DOI 10.1002/nau.20293	30	49	49	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e195	10.1371/journal.pone.0000195	http://dx.doi.org/10.1371/journal.pone.0000195			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17332843	Green Published, gold			2022-12-25	WOS:000207444300008
J	Jacobs, AMF; Nicol, SM; Hislop, RG; Jaffray, EG; Hay, RT; Fuller-Pace, FV				Jacobs, A-M F.; Nicol, S. M.; Hislop, R. G.; Jaffray, E. G.; Hay, R. T.; Fuller-Pace, F. V.			SUMO modifcation of the DEAD box protein p68modulates its transcriptional activity and promotes its interaction with HDAC1	ONCOGENE			English	Article						p68; DEAD box protein; SUMO modifcation; transcriptional activity	P68 RNA HELICASE; ACTIVATION; UBIQUITIN; NUCLEAR; P53; COACTIVATOR; IDENTIFICATION; BINDING; ACTS	The nuclear protein p68 ( also known as Ddx5) is a prototypic member of the 'DEAD box' family of RNA helicases, which has been shown to be abnormally expressed and modified in colorectal tumors and to function as an important transcriptional regulator. Here, we show that p68 is modified in vivo on a single site ( K53) by the small ubiquitin-like modifier-2 ( SUMO-2). We demonstrate that the SUMO E3 ligase PIAS1 interacts with p68 and enhances its SUMO modi. cation in vivo. To determine the functional consequences of SUMO modi. cation, we compared the transcriptional activity of p68 and a K53R mutant that could not be SUMO-modified. Our data show that SUMO modi. cation enhances p68 transcriptional repression activity and inhibits the ability of p68 to function as a coactivator of p53. These findings may be explained by the ability of wild type, but not K53R p68, to alter the modification state of chromatin by recruitment of histone deacetylase 1 ( HDAC1).	Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Epxress, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Ninewells Dr, Dundee DD1 9SY, Scotland.	f.v.fullerpace@dundee.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bond AT, 2001, MOL CELL BIOL, V21, P7366, DOI 10.1128/MCB.21.21.7366-7379.2001; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu G, 2006, BIOCHEM BIOPH RES CO, V349, P360, DOI 10.1016/j.bbrc.2006.08.049; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	40	58	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5866	5876		10.1038/sj.onc.1210387	http://dx.doi.org/10.1038/sj.onc.1210387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369852				2022-12-25	WOS:000249123100004
J	Castilho, RM; Squarize, CH; Patel, V; Millar, SE; Zheng, Y; Molinolo, A; Gutkind, JS				Castilho, R. M.; Squarize, C. H.; Patel, V.; Millar, S. E.; Zheng, Y.; Molinolo, A.; Gutkind, J. S.			Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells	ONCOGENE			English	Article						epithelial stem cells; hair follicle; Rho GTPases; Rac1; epidermal regeneration	LABEL-RETAINING CELLS; EPIDERMAL PROLIFERATIVE UNIT; POPULATIONS; SKIN; BIOLOGY	Epithelial stem cells in the bulge region within the hair follicle maintain the cyclic hair growth, but whether these stem cells also contribute to the epidermal renewal remains unclear. Here, we observed that the conditional deletion of the Rac1 gene in the mouse skin, including the potential follicular and epidermal stem cell compartments, results in alopecia owing to defective hair development. Surprisingly, mice lacking the expression of this Rho GTPase do not display major alterations in the interfollicular skin. Furthermore, Rac1 excision from primary epithelial keratinocytes results in the inability to reconstitute hair follicles and sebaceous glands when grafted onto mice, but epithelial cells lacking Rac1 can nonetheless form a healthy epidermi s. Together, these findings support the emerging view that the epidermis and the hair follicles are maintained by different epithelial stem cells, and provide evidence that the requirement for Rac1 function can distinguish these distinct stem cells populations.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Zheng, Yi/J-7235-2015; Castilho, Rogerio M/E-4987-2010; Gutkind, J. Silvio/J-1201-2016	Zheng, Yi/0000-0001-7089-6074; Castilho, Rogerio M/0000-0001-5358-612X; Gutkind, J. Silvio/0000-0002-5150-4482; Millar, Sarah/0000-0001-8792-6890; Squarize, Cristiane/0000-0002-6782-3429	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; BICKENBACH JR, 1986, CELL TISSUE KINET, V19, P325, DOI 10.1111/j.1365-2184.1986.tb00684.x; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Squarize CH, 2002, J ORAL PATHOL MED, V31, P379, DOI 10.1034/j.1600-0714.2002.00142.x; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x	25	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5078	5085		10.1038/sj.onc.1210322	http://dx.doi.org/10.1038/sj.onc.1210322			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334398				2022-12-25	WOS:000248487400006
J	Covey, TM; Edes, K; Fitzpatrick, FA				Covey, T. M.; Edes, K.; Fitzpatrick, F. A.			Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor	ONCOGENE			English	Article						Akt; PTEN; cyclooxygenase-2; 5-lipoxygenase; tumor suppressor	SIGNALING PATHWAY; REDOX REGULATION; PHOSPHOINOSITIDE 3-KINASE; CANCER; KINASE; EXPRESSION; AKT/PKB; TARGETS; CELLS; SERUM	Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes are overexpressed during inflammation and multistage tumor progression in many neoplastic disorders including lung, breast and pancreatic cancers. Here we report that the tumor suppressor phosphatase and tensin homolog (PTEN) is oxidized and inactivated during arachidonic acid (AA) metabolism in pancreatic cancer cell lines expressing COX-2 or 5-LOX. Oxidation of PTEN decreases its phosphatase activity, favoring increased phosphatidylinositol 3,4,5-triphosphate production, activation of Akt and phosphorylation of downstream Akt targets including GSK-3 beta and S6K. These effects are recapitulated with pancreatic phospholipase A(2), which hydrolyses the release of membrane-bound AA. Interference with PTEN's physiological antagonism of signals from growth factors, insulin and oncogenes may confer risk for hypertrophic or neoplastic diseases associated with chronic inflammation or unwarranted oxidative metabolism of essential fatty acids.	Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Med Chem & Oncol Sci, 200 Circle Hope, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu			NCI NIH HHS [T32 CA093247, P01 CA73992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992, T32CA093247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bianchi M, 2005, BIOCHEM J, V391, P359, DOI 10.1042/BJ20050282; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding XZ, 2001, PANCREATOLOGY, V1, P291, DOI 10.1159/000055827; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; Goriely A, 2001, J NONLINEAR SCI, V11, P3, DOI 10.1007/s003320010009; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; Hughes-Fulford M, 2006, CANCER RES, V66, P1427, DOI 10.1158/0008-5472.CAN-05-0914; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li F, 2005, AM J PHYSIOL-HEART C, V288, pH2306, DOI 10.1152/ajpheart.00571.2004; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; NEVALAINEN TJ, 1985, CLIN CHEM, V31, P1116; Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.E04-05-0369; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VINOKUROVA LV, 2001, ROSS GASTROENETEROL, V2, P72; Wagner TM, 2006, J BIOL CHEM, V281, P2598, DOI 10.1074/jbc.M509723200; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wildroudt ML, 2006, BBA-MOL CELL BIOL L, V1761, P11, DOI 10.1016/j.bbalip.2005.11.009; Xiong HQ, 2004, CANCER CHEMOTH PHARM, V54, pS69, DOI 10.1007/s00280-004-0890-2; YAMASHITA S, 1994, CLIN CHIM ACTA, V228, P91, DOI 10.1016/0009-8981(94)90280-1; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	37	75	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5784	5792		10.1038/sj.onc.1210391	http://dx.doi.org/10.1038/sj.onc.1210391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369849				2022-12-25	WOS:000248885100010
J	Clements, A; Tull, D; Jenney, AW; Farn, JL; Kim, SH; Bishop, RE; McPhee, JB; Hancock, REW; Hartland, EL; Pearse, MJ; Wijburg, OLC; Jackson, DC; McConville, MJ; Strugnell, RA				Clements, Abigail; Tull, Dedreia; Jenney, Adam W.; Farn, Jacinta L.; Kim, Sang-Hyun; Bishop, Russell E.; McPhee, Joseph B.; Hancock, Robert E. W.; Hartland, Elizabeth L.; Pearse, Martin J.; Wijburg, Odilia L. C.; Jackson, David C.; McConville, Malcolm J.; Strugnell, Richard A.			Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; GRAM-NEGATIVE BACILLI; OUTER-MEMBRANE STABILITY; INTENSIVE-CARE UNITS; LIPID-A COMPONENT; O SIDE-CHAIN; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-AERUGINOSA; BACTERIAL-RESISTANCE	Klebsiella pneumoniae is an important cause of nosocomial Gram-negative sepsis. Lipopolysaccharide (LPS) is considered to be a major virulence determinant of this encapsulated bacterium and most mutations to the lipid A anchor of LPS are conditionally lethal to the bacterium. We studied the role of LPS acylation in K. pneumoniae disease pathogenesis by using a mutation of lpxM (msbB/waaN), which encodes the enzyme responsible for late secondary acylation of immature lipid A molecules. A K. pneumoniae B5055 (K2:O1) lpxM mutant was found to be attenuated for growth in the lungs in a mouse pneumonia model leading to reduced lethality of the bacterium. B5055 Delta lpxM exhibited similar sensitivity to phagocytosis or complement-mediated lysis than B5055, unlike the non-encapsulated mutant B5055nm. In vitro, B5055 Delta lpxM showed increased permeability of the outer membrane and an increased susceptibility to certain antibacterial peptides suggesting that in vivo attenuation may be due in part to sensitivity to antibacterial peptides present in the lungs of BALB/c mice. These data support the view that lipopolysaccharide acylation plays a important role in providing Gram-negative bacteria some resistance to structural and innate defenses and especially the antibacterial properties of detergents (e. g. bile) and cationic defensins.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, CRC Vaccine Technol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; CSL Ltd, Parkville, Vic 3052, Australia; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada; Monash Univ, Dept Microbiol, CRC Vaccine Technol, Clayton, Vic 3800, Australia; Univ Melbourne, Australian Bacterial Pathogenesis Program, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne; University of Melbourne; CSL; University of Toronto; University of British Columbia; Monash University; University of Melbourne	Strugnell, RA (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.	rastru@unimelb.edu.au	Hancock, Robert E. W./E-1145-2013; McPhee, Joseph/AAG-5382-2019; Hartland, Elizabeth/O-2569-2014	Hancock, Robert E. W./0000-0001-5989-8503; Hartland, Elizabeth/0000-0003-4254-2863; Strugnell, Richard/0000-0003-0614-5641; Clements, Abigail/0000-0003-2285-777X; Tull, Dedreia/0000-0003-2546-6707; McPhee, Joseph/0000-0002-6844-755X; Jackson, David/0000-0001-7255-270X	Canadian Institutes of Health Research [84329-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Alvarez D, 2000, INFECT IMMUN, V68, P953, DOI 10.1128/IAI.68.2.953-955.2000; Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; BENNER SA, 1994, J MOL BIOL, V235, P926, DOI 10.1006/jmbi.1994.1049; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Campos MA, 2004, INFECT IMMUN, V72, P7107, DOI 10.1128/IAI.72.12.7107-7114.2004; Cortes G, 2002, INFECT IMMUN, V70, P2583, DOI 10.1128/IAI.70.5.2583-2590.2002; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Frirdich E, 2005, J ENDOTOXIN RES, V11, P133, DOI 10.1179/096805105X46592; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hanberger H, 1999, JAMA-J AM MED ASSOC, V281, P67, DOI 10.1001/jama.281.1.67; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hancock REW, 1997, J MED MICROBIOL, V46, P1; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HIGHSMITH AK, 1985, INFECT CONT HOSP EP, V6, P75, DOI 10.1017/S0195941700062640; Jia WY, 2004, J BIOL CHEM, V279, P44966, DOI 10.1074/jbc.M404963200; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; KOHASHI O, 1992, MICROBIOL IMMUNOL, V36, P369, DOI 10.1111/j.1348-0421.1992.tb02036.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, IMMUNOLOGY, V89, P307; LEHMANN V, 1978, EUR J BIOCHEM, V86, P487, DOI 10.1111/j.1432-1033.1978.tb12332.x; Maneval WE, 1941, STAIN TECHNOL, V16, P13, DOI 10.3109/10520294109106189; Manterola L, 2005, J BACTERIOL, V187, P5631, DOI 10.1128/JB.187.16.5631-5639.2005; McManus MC, 1997, AM J HEALTH-SYST PH, V54, P1420, DOI 10.1093/ajhp/54.12.1420; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MERINO S, 1992, INFECT IMMUN, V60, P2529, DOI 10.1128/IAI.60.6.2529-2535.1992; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; Murray SR, 2001, J BACTERIOL, V183, P5554, DOI 10.1128/JB.183.19.5554-5561.2001; Nesper J, 2001, INFECT IMMUN, V69, P435, DOI 10.1128/IAI.69.1.435-445.2001; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; Post DMB, 2003, INFECT IMMUN, V71, P647, DOI 10.1128/IAI.71.2.647-655.2003; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Regue M, 2005, J BACTERIOL, V187, P4198, DOI 10.1128/JB.187.12.4198-4206.2005; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Sforza S, 2004, J MASS SPECTROM, V39, P378, DOI 10.1002/jms.598; Shankar-Sinha S, 2004, INFECT IMMUN, V72, P1423, DOI 10.1128/IAI.72.3.1423-1430.2004; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; SIMOONSSMIT AM, 1984, J MED MICROBIOL, V17, P67, DOI 10.1099/00222615-17-1-67; Somerville JE, 1999, INFECT IMMUN, V67, P6583; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; THARANATHAN RN, 1978, EUR J BIOCHEM, V84, P385, DOI 10.1111/j.1432-1033.1978.tb12179.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; WEISS J, 1982, INFECT IMMUN, V38, P1149, DOI 10.1128/IAI.38.3.1149-1153.1982; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLIAMS P, 1983, J GEN MICROBIOL, V129, P2181; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yin N, 2003, J AM CHEM SOC, V125, P2426, DOI 10.1021/ja0284456; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	61	86	88	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15569	15577		10.1074/jbc.M701454200	http://dx.doi.org/10.1074/jbc.M701454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17371870	Green Accepted, hybrid			2022-12-25	WOS:000246589600034
J	Nyalendo, C; Michaud, M; Beaulieu, E; Roghi, C; Murphy, G; Gingras, D; Beliveau, R				Nyalendo, Carine; Michaud, Marisol; Beaulieu, Edith; Roghi, Christian; Murphy, Gilian; Gingras, Denis; Beliveau, Richard			Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573 - Role in endothelial and tumor cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE; MT1-MMP; CAVEOLAE; CANCER; SURFACE; OLIGOMERIZATION; ANGIOGENESIS; LOCALIZATION; PROTEOLYSIS; INHIBITION	Membrane type 1 matrix metalloproteinase (MT1-MMP) is a transmembrane MMP that plays important roles in migratory processes underlying tumor invasion and angiogenesis. In addition to its matrix degrading activity, MT1-MMP also contains a short cytoplasmic domain whose involvement in cell locomotion seems important but remains poorly understood. In this study, we show that MT1-MMP is phosphorylated on the unique tyrosine residue located within this cytoplasmic sequence (Tyr(573)) and that this phosphorylation requires the kinase Src. Using phosphospecific antibodies recognizing MT1-MMP phosphorylated on Tyr(573), we observed that tyrosine phosphorylation of the enzyme is rapidly induced upon stimulation of tumor and endothelial cells with the platelet-derived chemoattractant sphingosine-1-phosphate, suggesting a role in migration triggered by this lysophospholipid. Accordingly, overexpression of a nonphosphorylable MT1-MMP mutant (Y573F) blocked sphingosine-1-phosphate-induced migration of Human umbilical vein endothelial cells and HT-1080 (human fibrosarcoma) cells and failed to stimulate migration of cells lacking the enzyme (bovine aortic endothelial cells). Altogether, these findings strongly suggest that the Src-dependent tyrosine phosphorylation of MT1-MMP plays a key role in cell migration and further emphasize the importance of the cytoplasmic domain of the enzyme in this process.	Univ Quebec, Ctr Cancerol Charles Bruneau, Mol Med Lab, Hop St Justine, Montreal, PQ H3T 1C5, Canada; Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Universite de Montreal; University of Quebec; University of Quebec Montreal; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Beliveau, R (corresponding author), St Justine UQAM, Ctr Cancerol Charles Bruneau, Mol Med Lab, 3175,Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	molmed@recherche-ste-justine.qc.ca	Roghi, Christian/F-3228-2012	Roghi, Christian/0000-0002-4109-6382				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Follows ER, 2001, BIOCHEM J, V359, P427, DOI 10.1042/0264-6021:3590427; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Haas TL, 2005, CAN J PHYSIOL PHARM, V83, P1, DOI 10.1139/Y04-120; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koo HM, 2002, MOL CELLS, V13, P118; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Mandell JW, 2003, AM J PATHOL, V163, P1687, DOI 10.1016/S0002-9440(10)63525-0; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pilorget A, 2005, J CEREBR BLOOD F MET, V25, P1171, DOI 10.1038/sj.jcbfm.9600117; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Uekita T, 2004, J BIOL CHEM, V279, P12734, DOI 10.1074/jbc.M309957200; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	46	107	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15690	15699		10.1074/jbc.M608045200	http://dx.doi.org/10.1074/jbc.M608045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389600	hybrid			2022-12-25	WOS:000246589600045
J	Banchio, C; Lingrell, S; Vance, DE				Banchio, Claudia; Lingrell, Susanne; Vance, Dennis E.			Sp-1 binds promoter elements that are regulated by retinoblastoma and regulate CTP: Phosphocholine cytidylyltransferase-alpha transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE SYNTHESIS; GENE-PRODUCT; S-PHASE; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE; FATTY-ACIDS; RB PROTEIN; CELL-CYCLE; RAT-LIVER; EXPRESSION	The retinoblastoma (Rb) protein is implicated in transcriptional regulation of at least five cellular genes. Co-transfection of Rb and truncated promoter constructs has defined a discrete element (retinoblastoma control element (RCE)) within the promoters of each of these genes as being necessary for Rb-mediated transcriptional control. In the present report we demonstrate that two RCEs identified within the CTP: phosphocholine cytidylyltransferase-alpha (CT alpha) proximal promoter are essential to promote transcription. Mutations that abolished each RCE markedly decreased CT alpha transcription. Co-transfection of Rb and truncated promoter constructs demonstrated that Rb regulates CT alpha expression by different mechanisms depending on the phase of the cell cycle. The regulation of CT alpha expression by Rb required both the Sp1 and the RCEs. Maximal expression occurred when both Rb and Sp1 were overexpressed. Moreover, RCEs were required for Rb association with the DNA. This regulatory mechanism alters CT alpha activity and thereafter changes PC availability and cell physiology. This is the first report demonstrating not only that surrounding Sp1 binding sites alter regulation mediated by Rb, but also that the expression of a gene involved in PC biosynthesis shares a common regulatory pathway with genes responsible for cell growth and differentiation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol,Biol Div, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst M, RA-2002 Rosario, Argentina	University of Alberta; University of Alberta; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	Banchio, C (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.	banchio@ibr.gov.ar; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Banchio C, 2004, J BIOL CHEM, V279, P40220, DOI 10.1074/jbc.M406468200; Banchio C, 2006, J BIOL CHEM, V281, P10010, DOI 10.1074/jbc.M513503200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREAGH SC, 1990, PHYS REV A, V42, P1907, DOI 10.1103/PhysRevA.42.1907; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Hellwinkel OJC, 2005, J GENE MED, V7, P407, DOI 10.1002/jgm.684; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Sabah M, 2006, APPL IMMUNOHISTO M M, V14, P397, DOI 10.1097/01.pai.0000190176.06200.68; Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Simpson D, 2000, MOL VIS, V6, P178; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WEINBERG RA, 1992, CANCER SURV, V12, P43	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14827	14835		10.1074/jbc.M700527200	http://dx.doi.org/10.1074/jbc.M700527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17384411	hybrid			2022-12-25	WOS:000246589000018
J	Ellyard, JI; Simson, L; Bezos, A; Johnston, K; Freeman, C; Parish, CR				Ellyard, Julia I.; Simson, Ljubov; Bezos, Anna; Johnston, Kellie; Freeman, Craig; Parish, Christopher R.			Eotaxin selectively binds heparin - An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED EOSINOPHIL INFILTRATION; PLASMINOGEN-PLASMIN SYSTEM; MOLECULAR-WEIGHT HEPARIN; MAST-CELL TRYPTASE; ALLERGIC INFLAMMATION; GLYCOSAMINOGLYCAN BINDING; SULFATE PROTEOGLYCANS; RECEPTOR-BINDING; GUINEA-PIGS; CHEMOKINES	An important feature of chemokines is their ability to bind to the glycosaminoglycan (GAG) side chains of proteoglycans, predominately heparin and heparan sulfate. To date, all chemokines tested bind to immobilized heparin in vitro, as well as cell surface heparan sulfate in vitro and in vivo. These interactions play an important role in modulating the action of chemokines by facilitating the formation of stable chemokine gradients within the vascular endothelium and directing leukocyte migration, by protecting chemokines from proteolysis, by inducing chemokine oligomerization, and by facilitating transcytosis. Despite the importance of eotaxin in eosinophil differentiation and recruitment being well established, little is known about the interaction between eotaxin and GAGs and the functional consequences of such an interaction. Here we report that eotaxin binds selectively to immobilized heparin with high affinity ( Kd = 1.23 x 10(-8) M), but not to heparan sulfate or a range of other GAGs. The interaction of eotaxin with heparin does not promote eotaxin oligomerization but protects eotaxin from proteolysis directly by plasmin and indirectly by cathepsin G and elastase. In vivo, co-administration of eotaxin and heparin is able to significantly enhance eotaxin-mediated eosinophil recruitment in a mouse air-pouch model. Furthermore, when heparin is coadministered with eotaxin at a concentration that does not normally result in eosinophil infiltration, eosinophil recruitment occurs. In contrast, heparin does not enhance eotaxin-mediated eosinophil chemotaxis in vitro, suggesting protease protection or haptotactic gradient formation as the mechanism by which heparin enhances eotaxin action in vivo. These results suggest a role for mast cell-derived heparin in the recruitment of eosinophils, reinforcing Th2 polarization of inflammatory responses.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Bldg 54,Garran Rd, Acton, ACT 0200, Australia.	christopher.parish@anu.edu.au	Simson, Ljubov/C-2954-2009	Parish, Christopher/0000-0001-7740-0430				Abraham WM, 2002, AM J PHYSIOL-LUNG C, V282, pL193, DOI 10.1152/ajplung.00429.2001; Ahmed T, 1997, AM J RESP CRIT CARE, V155, P1848, DOI 10.1164/ajrccm.155.6.9196085; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Buckland KF, 2003, BRIT J PHARMACOL, V140, P1117, DOI 10.1038/sj.bjp.0705530; Conroy DM, 2001, RESP RES, V2, P150, DOI 10.1186/rr52; Cook EB, 2004, ANN ALLERG ASTHMA IM, V92, P65, DOI 10.1016/S1081-1206(10)61712-7; Crown SE, 2006, J BIOL CHEM, V281, P25438, DOI 10.1074/jbc.M601518200; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Culley FJ, 2003, EUR J IMMUNOL, V33, P1302, DOI 10.1002/eji.200323509; Das AM, 1998, J LEUKOCYTE BIOL, V64, P156, DOI 10.1002/jlb.64.2.156; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Ferland C, 2004, J IMMUNOL, V173, P4417, DOI 10.4049/jimmunol.173.7.4417; Ferland C, 2001, J LEUKOCYTE BIOL, V69, P772; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Freeman C, 2005, J BIOL CHEM, V280, P8842, DOI 10.1074/jbc.M410769200; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 2004, ACTA PHARMACOL SIN, V25, P1677; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Johnson Z, 2005, CYTOKINE GROWTH F R, V16, P625, DOI 10.1016/j.cytogfr.2005.04.006; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LAWMAN MJP, 1984, J IMMUNOL METHODS, V69, P197, DOI 10.1016/0022-1759(84)90318-1; Ley K, 2003, MICROCIRCULATION, V10, P289, DOI 10.1038/sj.mn.7800194; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Mattes J, 2003, J EXP MED, V197, P387, DOI 10.1084/jem.20021683; Middleton J, 2002, BLOOD, V100, P3853, DOI 10.1182/blood.V100.12.3853; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Oliveira SHP, 2002, BLOOD, V100, P4291, DOI 10.1182/blood.V100.13.4291; Pang LH, 2006, J IMMUNOL, V176, P3788, DOI 10.4049/jimmunol.176.6.3788; Parish CR, 2006, NAT REV IMMUNOL, V6, P633, DOI 10.1038/nri1918; PARISH CR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P56, DOI 10.1016/0304-4165(91)90182-G; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Piliponsky AM, 2002, MOL IMMUNOL, V38, P1369, DOI 10.1016/S0161-5890(02)00090-1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; Seeds EAM, 1995, PULM PHARMACOL, V8, P97, DOI 10.1006/pulp.1995.1012; Seeds EAM, 2001, PULM PHARMACOL THER, V14, P111, DOI 10.1006/pupt.2000.0277; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Simson L, 2007, J IMMUNOL, V178, P4222, DOI 10.4049/jimmunol.178.7.4222; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Teran LM, 2000, IMMUNOL TODAY, V21, P235, DOI 10.1016/S0167-5699(00)01634-0; Tomimori Y, 2002, LAB INVEST, V82, P789, DOI 10.1097/01.LAB.0000018827.78602.F4; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Wang QL, 2000, JPN J PHARMACOL, V82, P326; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9; Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200	66	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15238	15247		10.1074/jbc.M608046200	http://dx.doi.org/10.1074/jbc.M608046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17384413	hybrid			2022-12-25	WOS:000246589000063
J	Johannessen, M; Delghandi, MP; Rykx, A; Dragset, M; Vandenheede, JR; Van Lint, J; Moens, U				Johannessen, Mona; Delghandi, Marit Pedersen; Rykx, An; Dragset, Marte; Vandenheede, Jackie R.; Van Lint, Johan; Moens, Ugo			Protein kinase D induces transcription through direct phosphorylation of the cAMP-response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATION LOOP PHOSPHORYLATION; SOMATOSTATIN GENE-TRANSCRIPTION; SIGNAL-TRANSDUCTION PATHWAY; C-MU; PROTEOLYTIC CLEAVAGE; CARDIAC-HYPERTROPHY; NUCLEAR EXPORT; NIH 3T3-CELLS; PHORBOL ESTER	Protein kinase D (PKD), a family of serine/threonine kinases, can be activated by a multitude of stimuli in a protein kinase C-dependent or -independent manner. PKD is involved in signal transduction pathways controlling cell proliferation, apoptosis, motility, and protein trafficking. Despite its versatile functions, few genuine in vivo substrates for PKD have been identified. In this study we demonstrate that the transcription factor cAMP-response element-binding protein (CREB) is a direct substrate for PKD. PKD1 and CREB interact in cells, and activated PKD1 provokes CREB phosphorylation at Ser-133 both in vitro and in vivo. A constitutive active mutant of PKD1 stimulates GAL4-CREB- mediated transcription in a Ser-133-dependent manner, activates CRE-responsive promoters, and increases the expression of CREB target genes. PKD1 also enhances transcription mediated by two other members of the CREB family, ATF-1 and CREM. Our results describe a novel mechanism for PKD-induced signaling through activation of the transcription factor CREB and suggest that stimulus-induced phosphorylation of CREB, reported to be mediated by protein kinase C, may involve downstream activated PKD.	Univ Tromso, Inst Med Biol, Dept Microbiol & Virol, N-9037 Tromso, Norway; Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, B-3000 Louvain, Belgium	UiT The Arctic University of Tromso; KU Leuven	Moens, U (corresponding author), Univ Tromso, Inst Med Biol, Dept Microbiol & Virol, N-9037 Tromso, Norway.	ugom@fagmed.uit.no	Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				Anel AMD, 2005, J CELL BIOL, V169, P83, DOI 10.1083/jcb.200412089; Arnold R, 2005, MOL CELL BIOL, V25, P2364, DOI 10.1128/MCB.25.6.2364-2383.2005; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Elliott MR, 2003, J IMMUNOL, V171, P3636, DOI 10.4049/jimmunol.171.7.3636; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; FOSS KB, 1994, EUR J BIOCHEM, V220, P217, DOI 10.1111/j.1432-1033.1994.tb18617.x; Ghanekar Y, 2005, TRENDS CELL BIOL, V15, P511, DOI 10.1016/j.tcb.2005.08.001; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Guha S, 2002, CANCER RES, V62, P1632; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Haworth RS, 2004, CIRC RES, V95, P1091, DOI 10.1161/01.RES.0000149299.34793.3c; Hurd C, 2003, BIOCHEM BIOPH RES CO, V302, P800, DOI 10.1016/S0006-291X(03)00268-7; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Jaggi M, 2005, CANCER RES, V65, P483; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Johannessen M, 2004, CELL SIGNAL, V16, P1187, DOI 10.1016/j.cellsig.2004.03.009; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moens MJU, 2007, FRONT BIOSCI-LANDMRK, V12, P1814; Montminy M, 1996, METABOLISM, V45, P4, DOI 10.1016/S0026-0495(96)90068-2; Morel E, 2005, CIRC RES, V97, P1296, DOI 10.1161/01.RES.0000194325.31359.86; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAGANO JS, 1969, PROG IMMUNOBIOL STAN, V3, P152; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Romero DG, 2006, ENDOCRINOLOGY, V147, P6046, DOI 10.1210/en.2006-0794; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shiga H, 2005, J NEUROSCI RES, V80, P767, DOI 10.1002/jnr.20513; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vantus T, 2004, CELL SIGNAL, V16, P703, DOI 10.1016/j.cellsig.2003.11.009; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Wang Y, 2004, J BIOL CHEM, V279, P53674, DOI 10.1074/jbc.M410331200; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	79	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14777	14787		10.1074/jbc.M610669200	http://dx.doi.org/10.1074/jbc.M610669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389598	hybrid			2022-12-25	WOS:000246589000013
J	Saether, T; Berge, T; Ledsaak, M; Matre, V; Alm-Kristiansen, AH; Dahle, O; Aubry, F; Gabrielsen, OS				Saether, Thomas; Berge, Tone; Ledsaak, Marit; Matre, Vilborg; Alm-Kristiansen, Anne Hege; Dahle, Oyvind; Aubry, Florence; Gabrielsen, Odd Stokke			The chromatin remodeling factor Mi-2 alpha acts as a novel co-activator for human c-Myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RET FINGER PROTEIN; T-CELL DEVELOPMENT; V-MYB; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; MI-2 AUTOANTIGEN; GENE-EXPRESSION; HISTONE H3; COMPLEX	The c-Myb protein belongs to a group of early hematopoietic transcription factors that are important for progenitor generation and proliferation. These factors have been hypothesized to participate in establishing chromatin patterns specific for hematopoietic genes. In a two-hybrid screening we identified the chromatin remodeling factor Mi-2 alpha as an interaction partner for human c-Myb. The main interacting domains were mapped to the N-terminal region of Mi-2 alpha and the DNA-binding domain of c-Myb. Surprisingly, functional analysis revealed that Mi-2 alpha, previously studied as a subunit in the NuRD corepressor complex, enhanced c-Myb-dependent reporter activation. Consistently, knock-down of endogenous Mi-2 alpha in c-Myb-expressing K562 cells, led to down-regulation of the c-Myb target genes NMU and ADA. When wild-type and helicase-dead Mi-2 alpha were compared, the Myb-Mi-2 alpha co-activation appeared to be independent of the ATPase/DNA helicase activity of Mi-2 alpha. The rationale for the unexpected co-activator function seems to lie in a dual function of Mi-2 alpha, by which this factor is able to repress transcription in a helicase-dependent and activate in a helicase-independent fashion, as revealed by Gal4-tethering experiments. Interestingly, desumoylation of c-Myb potentiated the Myb-Mi-2 alpha transactivational co-operation, as did co-transfection with p300.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Rennes 1, INSERM, U625, GERHM, F-35042 Rennes, France	University of Oslo; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041, N-0316 Oslo, Norway.	o.s.gabrielsen@imbv.uio.no	Aubry, Florence/I-2746-2015					Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Andersson KB, 2003, J BIOL CHEM, V278, P3816, DOI 10.1074/jbc.M209404200; Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brackertz M, 2006, NUCLEIC ACIDS RES, V34, P397, DOI 10.1093/nar/gkj437; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Matre V, 2003, BIOCHEM J, V372, P851, DOI 10.1042/BJ20030057; Miranda GA, 2002, MOL IMMUNOL, V38, P1151, DOI 10.1016/S0161-5890(02)00007-X; Mo XM, 2005, GENE DEV, V19, P2447, DOI 10.1101/gad.355405; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shimono K, 2005, J BIOL CHEM, V280, P39436, DOI 10.1074/jbc.M507356200; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Thomas MD, 2005, IMMUNITY, V23, P275, DOI 10.1016/j.immuni.2005.08.005; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	60	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13994	14005		10.1074/jbc.M700755200	http://dx.doi.org/10.1074/jbc.M700755200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17344210	hybrid			2022-12-25	WOS:000246245800009
J	Jeong, CH; Lee, HJ; Cha, JH; Kim, JH; Kim, KR; Kim, JH; Yoon, DK; Kim, KW				Jeong, Chul-Ho; Lee, Hyo-Jong; Cha, Jong-Ho; Kim, Jeong Hun; Kim, Kwang Rok; Kim, Ji-Hye; Yoon, Dae-Kwan; Kim, Kyu-Won			Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; EXPRESSION; DIFFERENTIATION; HIF-1-ALPHA; PLURIPOTENCY; ACTIVATION; APOPTOSIS; NANOG	During mammalian embryogenesis, the early embryo grows in a relatively hypoxic environment due to a restricted supply of oxygen. The molecular mechanisms underlying modulation of self-renewal and differentiation of mouse embryonic stem cells (mESCs) under such hypoxic conditions remain to be established. Here, we show that hypoxia inhibits mESC self-renewal and induces early differentiation in vitro, even in the presence of leukemia inhibitory factor (LIF). These effects are mediated by down-regulation of the LIF-STAT3 signaling pathway. Under conditions of hypoxia, hypoxia-inducible factor-1 alpha (HIF-1 alpha) suppresses transcription of LIF-specific receptor (LIFR) by directly binding to the reverse hypoxia-responsive element located in the LIFR promoter. Ectopic expression and small interference RNA knockdown of HIF-1 alpha verified the inhibitory effect on LIFR transcription. Our findings collectively suggest that hypoxia-induced in vitro differentiation of mESCs is triggered, at least in part, by the HIF-1 alpha-mediated suppression of LIF-STAT3 signaling.	Seoul Natl Univ, Coll Pharm, ResInst Pharmaceut Sci, Neurovasc Coordinat Res Ctr, Seoul 151742, South Korea; Seoul Natl Univ Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Seoul Artificial eye Ctr, Clin Res Inst, Seoul 110744, South Korea; Korea Res Inst Chem Technol, Div Med Sci, Taejon 305600, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Korea Research Institute of Chemical Technology (KRICT)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, ResInst Pharmaceut Sci, Neurovasc Coordinat Res Ctr, Seoul 151742, South Korea.	qwonkim@plaza.snu.ac.kr	Kim, Jeong Hun/J-2748-2012; Kim, Kyu Won/AAJ-7213-2020	Lee, Hyo-Jong/0000-0003-4826-7954				Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 1997, BIOCHEM J, V328, P879, DOI 10.1042/bj3280879; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061; Duval D, 2004, CELL DEATH DIFFER, V11, P331, DOI 10.1038/sj.cdd.4401337; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; FICHER P, 1993, J REPROD FERTIL, V99, P673; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Pampfer S, 1999, CELL DEATH DIFFER, V6, P533, DOI 10.1038/sj.cdd.4400516; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Smith A G, 1992, Semin Cell Biol, V3, P385, DOI 10.1016/1043-4682(92)90010-S; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tighe AP, 2004, J CELL PHYSIOL, V198, P223, DOI 10.1002/jcp.10424; Viswanathan S, 2003, BIOTECHNOL BIOENG, V84, P505, DOI 10.1002/bit.10799; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje	34	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13672	13679		10.1074/jbc.M700534200	http://dx.doi.org/10.1074/jbc.M700534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360716	hybrid			2022-12-25	WOS:000246060300057
J	Fufezan, C; Gross, CM; Sjodin, M; Rutherford, AW; Krieger-Liszkay, A; Kirilovsky, D				Fufezan, Christian; Gross, Christine M.; Sjodin, Martin; Rutherford, A. William; Krieger-Liszkay, Anja; Kirilovsky, Diana			Influence of the redox potential of the primary quinone electron acceptor on photoinhibition in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM THERMOSYNECHOCOCCUS-ELONGATUS; PHOTOSYNTHETIC OXYGEN EVOLUTION; CHARGE RECOMBINATION; REACTION CENTERS; SINGLET OXYGEN; D1 PROTEIN; THERMOLUMINESCENCE BANDS; RHODOPSEUDOMONAS-VIRIDIS; LOW-TEMPERATURE; LOW-LIGHT	We report the characterization of the effects of the A249S mutation located within the binding pocket of the primary quinone electron acceptor, Q(A), in the D-2 subunit of photosystem II in Thermosynechococcus elongatus. This mutation shifts the redox potential of Q(A) by similar to-60 mV. This mutant provides an opportunity to test the hypothesis, proposed earlier from herbicide-induced redox effects, that photoinhibition ( light-induced damage of the photosynthetic apparatus) is modulated by the potential of Q(A). Thus the influence of the redox potential of Q(A) on photoinhibition was investigated in vivo and in vitro. Compared with the wild-type, the A249S mutant showed an accelerated photoinhibition and an increase in singlet oxygen production. Measurements of thermoluminescence and of the fluorescence yield decay kinetics indicated that the charge-separated state involving Q(A) was destabilized in the A249S mutant. These findings support the hypothesis that a decrease in the redox potential of Q(A) causes an increase in singlet oxygen-mediated photoinhibition by favoring the back-reaction route that involves formation of the reaction center chlorophyll triplet. The kinetics of charge recombination are interpreted in terms of a dynamic structural heterogeneity in photosystem II that results in high and low potential forms of Q(A). The effect of the A249S mutation seems to reflect a shift in the structural equilibrium favoring the low potential form.	CEA Saclay, Serv Bioenerget, Dept Biol, CNRS,Unite Rech Associe 2096, F-91191 Gif Sur Yvette, France; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Freiburg	Fufezan, C (corresponding author), CUNY City Coll, Dept Phys J419, 160 Convent Ave, New York, NY 10031 USA.	christian@fufezan.net	Rutherford, Alfred W/A-7831-2019; Kirilovsky, Diana/I-2359-2014	Rutherford, Alfred W/0000-0002-3124-154X; Fufezan, Christian/0000-0002-7048-6822; Krieger-Liszkay, Anja/0000-0001-7141-4129; Kirilovsky, Diana/0000-0003-2146-3103				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BOUGESBOCQUET B, 1973, BIOCHIM BIOPHYS ACTA, V314, P250, DOI 10.1016/0005-2728(73)90140-0; Boussac A, 2004, J BIOL CHEM, V279, P22809, DOI 10.1074/jbc.M401677200; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Cuni A, 2004, PHYS CHEM CHEM PHYS, V6, P4825, DOI 10.1039/b407511k; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; El Bissati K, 2000, BBA-BIOENERGETICS, V1457, P229, DOI 10.1016/S0005-2728(00)00104-3; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Fufezan C, 2005, BIOCHEMISTRY-US, V44, P12780, DOI 10.1021/bi051000k; Fufezan C, 2005, BIOCHEMISTRY-US, V44, P5931, DOI 10.1021/bi050055j; Fufezan C, 2002, FEBS LETT, V532, P407, DOI 10.1016/S0014-5793(02)03724-9; GOPHER A, 1985, BIOPHYS J, V48, P311, DOI 10.1016/S0006-3495(85)83784-X; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Gunner M.R., 1982, FUNCTION QUINONES EN, P265; Hakala M, 2005, BBA-BIOENERGETICS, V1706, P68, DOI 10.1016/j.bbabio.2004.09.001; HIDEG E, 1994, BBA-BIOENERGETICS, V1186, P143, DOI 10.1016/0005-2728(94)90173-2; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; JOLIOT A, 1964, CR HEBD ACAD SCI, V258, P4622; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KANAZAWA A, 1992, RES PHOTOSYNTHESIS, V2, P131; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KEREN N, 1995, J BIOL CHEM, V270, P806, DOI 10.1074/jbc.270.2.806; Kirilovsky D, 2004, J BIOL CHEM, V279, P52869, DOI 10.1074/jbc.M408206200; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Komenda J, 2000, PHOTOSYNTH RES, V63, P135, DOI 10.1023/A:1006307417977; KRIEGER A, 1993, PHOTOSYNTH RES, V37, P117, DOI 10.1007/BF02187470; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAVERGNE J, 1995, BIOPHYS J, V68, P2474, DOI 10.1016/S0006-3495(95)80429-7; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MIRANDA T, 1995, PHOTOSYNTH RES, V43, P251, DOI 10.1007/BF00029938; Nakajima Y, 1996, PLANT CELL PHYSIOL, V37, P673, DOI 10.1093/oxfordjournals.pcp.a028997; Olesen K, 2003, BIOCHEMISTRY-US, V42, P2025, DOI 10.1021/bi026175y; PALLETT KE, 1980, J EXP BOT, V31, P1051, DOI 10.1093/jxb/31.4.1051; PAROT P, 1987, BIOCHIM BIOPHYS ACTA, V893, P534, DOI 10.1016/0005-2728(87)90105-8; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; Rappaport F, 2005, BIOPHYS J, V88, P1948, DOI 10.1529/biophysj.104.050237; Rappaport F, 2002, BIOCHEMISTRY-US, V41, P8518, DOI 10.1021/bi025725p; Roncel M, 2003, J BIOL INORG CHEM, V8, P206, DOI 10.1007/s00775-002-0406-7; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P648, DOI 10.1016/S0968-0004(01)01953-3; RUTHERFORD AW, 1981, BIOCHIM BIOPHYS ACTA, V635, P205, DOI 10.1016/0005-2728(81)90020-7; SCHOEPP B, 1992, NATO ADV SCI INST SE, V237, P331; SEBBAN P, 1989, BIOCHIM BIOPHYS ACTA, V974, P54, DOI 10.1016/S0005-2728(89)80165-3; SEBBAN P, 1991, BIOCHIM BIOPHYS ACTA, V1057, P109, DOI 10.1016/S0005-2728(05)80090-8; SEBBAN P, 1988, BIOCHIM BIOPHYS ACTA, V936, P128; SHOPES RJ, 1987, BIOCHIM BIOPHYS ACTA, V893, P409, DOI 10.1016/0005-2728(87)90093-4; Sugiura M, 1999, PLANT CELL PHYSIOL, V40, P1219, DOI 10.1093/oxfordjournals.pcp.a029510; Trebst A, 2002, FEBS LETT, V516, P156, DOI 10.1016/S0014-5793(02)02526-7; VANGORKOM HJ, 1985, PHOTOSYNTH RES, V6, P97, DOI 10.1007/BF00032785; VANMIEGHEM F, 1995, BIOCHEMISTRY-US, V34, P4798, DOI 10.1021/bi00014a038; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VELTHUYS BR, 1974, BIOCHIM BIOPHYS ACTA, V333, P85, DOI 10.1016/0005-2728(74)90165-0; VELTHUYS BR, 1981, FEBS LETT, V126, P277, DOI 10.1016/0014-5793(81)80260-8; Wincencjusz H, 1999, BIOCHEMISTRY-US, V38, P3719, DOI 10.1021/bi982295n; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4; WRAIGHT CA, 1981, ISRAEL J CHEM, V21, P348	68	67	68	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12492	12502		10.1074/jbc.M610951200	http://dx.doi.org/10.1074/jbc.M610951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327225	hybrid			2022-12-25	WOS:000245942800018
J	Sanz-Rodriguez, CE; Concepcion, JL; Pekerar, S; Oldfield, E; Urbina, JA				Sanz-Rodriguez, Carlos E.; Concepcion, Juan L.; Pekerar, Sara; Oldfield, Eric; Urbina, Julio A.			Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase - Kinetic and metabolic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAGAS-DISEASE; SCHIZOTRYPANUM CRUZI; IN-VITRO; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOKINASE ACTIVATORS; FUMARATE REDUCTASE; ENERGY-METABOLISM; DIABETES THERAPY; EPIMASTIGOTES; GROWTH	Trypanosoma cruzi, the etiologic agent of Chagas disease, has an unusual ATP-dependent hexokinase (TcHK) that is not affected by D-glucose 6-phosphate, but is non-competitively inhibited by inorganic pyrophosphate (PPi), suggesting a heterotropic modulator effect. In a previous study we identified a novel family of bisphosphonates, metabolically stable analogs of PPi, which are potent and selective inhibitors of TcHK as well as the proliferation of the clinically relevant intracellular amastigote form of the parasite in vitro ( Hudock, M. P., Sanz-Rodriguez, C. E., Song, Y., Chan, J. M., Zhang, Y., Odeh, S., Kosztowski, T., Leon-Rossell, A., Concepcion, J. L., Yardley, V., Croft, S. L., Urbina, J. A., and Oldfield, E. ( 2006) J. Med. Chem. 49, 215 - 223). In this work, we report a detailed kinetic analysis of the effects of three of these bisphosphonates on homogeneous TcHK, as well as on the enzyme in purified intact glycosomes, peroxisome-like organelles that contain most of the glycolytic pathway enzymes in this organism. We also investigated the effects of the same compounds on glucose consumption by intact and digitonin-permeabilized T. cruzi epimastigotes, and on the growth of such cells in liver-infusion tryptose medium. The bisphosphonates investigated were several orders of magnitude more active than PPi as non-competitive or mixed inhibitors of TcHK and blocked the use of glucose by the epimastigotes, inducing a metabolic shift toward the use of amino acids as carbon and energy sources. Furthermore, there was a significant correlation between the IC50 values for TcHK inhibition and those for epi-mastigote growth inhibition for the 12 most potent compounds of this series. Finally, these bisphosphonates did not affect the sterol composition of the treated cells, indicating that they do not act as inhibitors of farnesyl diphosphate synthase. Taken together, our results suggest that these novel bisphosphonates act primarily as specific inhibitors of TcHK and may represent a novel class of selective anti-T. cruzi agents.	Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020, Venezuela; Univ Los Andes, Fac Ciencias, Dept Biol, Lab Enzimol Parasitos, Merida 5101, Venezuela; Inst Venezolano Invest Cient, Ctr Quim, Caracas 1020, Venezuela; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	Venezuelan Institute Science Research; University of Los Andes Venezuela; Venezuelan Institute Science Research; University of Illinois System; University of Illinois Urbana-Champaign	Urbina, JA (corresponding author), Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020, Venezuela.	jurbina@mac.com	Sanz-Rodriguez, Carlos/AAF-6746-2020	Sanz-Rodriguez, Carlos/0000-0002-6759-1955	NIGMS NIH HHS [GM-65307] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065307] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta H, 2004, COMP BIOCHEM PHYS B, V138, P347, DOI 10.1016/j.cbpc.2004.04.017; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Caceres AJ, 2003, MOL BIOCHEM PARASIT, V126, P251, DOI 10.1016/S0166-6851(02)00294-3; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Cazzulo Juan Jose, 1992, V18, P235; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; de Maio A., 1984, Acta Cientifica Venezolana, V35, P136; Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074-02762002000500002; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo Roberto, 2001, Current Drug Targets - Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191; FRYDMAN B, 1990, EUR J BIOCHEM, V192, P363, DOI 10.1111/j.1432-1033.1990.tb19235.x; Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Hudock MP, 2006, J MED CHEM, V49, P215, DOI 10.1021/jm0582625; HUDSON L, 1983, T ROY SOC TROP MED H, V77, P416, DOI 10.1016/0035-9203(83)90176-1; Kita K, 2003, CURR MED CHEM, V10, P2535, DOI 10.2174/0929867033456549; KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010; Leighton B, 2005, BIOCHEM SOC T, V33, P371, DOI 10.1042/BST0330371; Lemercier G, 2004, J BIOL CHEM, V279, P3420, DOI 10.1074/jbc.M309974200; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; Matschinsky FM, 2006, DIABETES, V55, P1; Moreno B, 2002, FEBS LETT, V523, P207, DOI 10.1016/S0014-5793(02)02977-0; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Quinones W, 2004, EXP PARASITOL, V106, P135, DOI 10.1016/j.exppara.2004.03.006; RACAGNI GE, 1983, MOL BIOCHEM PARASIT, V9, P181, DOI 10.1016/0166-6851(83)90108-1; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rodrigues CO, 2001, J EUKARYOT MICROBIOL, V48, P588, DOI 10.1111/j.1550-7408.2001.tb00195.x; TAYLOR M, 1986, FEBS LETT, V201, P262, DOI 10.1016/0014-5793(86)80620-2; TAYLOR MB, 1987, EXP PARASITOL, V63, P84, DOI 10.1016/0014-4894(87)90081-6; Turrens JF, 1999, FEMS MICROBIOL LETT, V175, P217, DOI 10.1111/j.1574-6968.1999.tb13623.x; URBINA JA, 1984, MOL BIOCHEM PARASIT, V11, P241, DOI 10.1016/0166-6851(84)90069-0; URBINA JA, 1984, MOL BIOCHEM PARASIT, V11, P225, DOI 10.1016/0166-6851(84)90068-9; URBINA JA, 1994, PARASITOL TODAY, V10, P107, DOI 10.1016/0169-4758(94)90010-8; Urbina JA, 2003, INT J ANTIMICROB AG, V21, P39, DOI 10.1016/S0924-8579(02)00274-1; Urbina JA, 2003, INT J ANTIMICROB AG, V21, P27, DOI 10.1016/S0924-8579(02)00273-X; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001; URBINA JA, 1987, ARCH BIOCHEM BIOPHYS, V258, P186, DOI 10.1016/0003-9861(87)90335-3; URBINA JA, 1990, ARCH BIOCHEM BIOPHYS, V282, P91, DOI 10.1016/0003-9861(90)90091-C; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; [No title captured]	49	55	57	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12377	12387		10.1074/jbc.M607286200	http://dx.doi.org/10.1074/jbc.M607286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329254	hybrid			2022-12-25	WOS:000245942800006
J	Addo, MM; Draenert, R; Rathod, A; Verrill, CL; Davis, BT; Gandhi, RT; Robbins, GK; Basgoz, NO; Stone, DR; Cohen, DE; Johnston, MN; Flynn, T; Wurcel, AG; Rosenberg, ES; Altfeld, M; Walker, BD				Addo, Marylyn M.; Draenert, Rika; Rathod, Almas; Verrill, Cori L.; Davis, Benjamin T.; Gandhi, Rajesh T.; Robbins, Gregory K.; Basgoz, Nesli O.; Stone, David R.; Cohen, Daniel E.; Johnston, Mary N.; Flynn, Theresa; Wurcel, Alysse G.; Rosenberg, Eric S.; Altfeld, Marcus; Walker, Bruce D.			Fully Differentiated HIV-1 Specific CD8+T Effector Cells Are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection	PLOS ONE			English	Article								Background. CD8+ T cells impact control of viral infections by direct elimination of infected cells and secretion of a number of soluble factors. In HIV-1 infection, persistent HIV-1 specific IFN-gamma+ CD8+ T cell responses are detected in the setting of disease progression, consistent with functional impairment in vivo. Recent data suggest that impaired maturation, as defined by the lineage markers CD45RA and CCR7, may contribute to a lack of immune control by these responses. Methodology/Principal Findings. We investigated the maturation phenotype of epitope-specific CD8+ T cell responses directed against HIV-1 in 42 chronically infected, untreated individuals, 22 of whom were "Controllers'' (median 1140 RNA copies/ml plasma, range, 50 to 2520), and 20 "progressors'' of whom had advanced disease and high viral loads (median 135,500 RNA copies/ml plasma, range 12100 to >750000). Evaluation of a mean of 5 epitopes per person revealed that terminally differentiated CD8+ T cells directed against HIV-1 are more often seen in HIV-1 Controllers (16/22; 73%) compared to HIV-1 progressors (7/20; 35%)(p = 0.015), but the maturation state of epitope-specific responses within a given individual was quite variable. Maturation phenotype was independent of the HLA restriction or the specificity of a given CD8+ T cell response and individual epitopes associated with slow disease progression were not more likely to be terminally differentiated. Conclusions/Significance. These data indicate that although full maturation of epitope-specific CD8+ T cell responses is associated with viral control, the maturation status of HIV-1 specific CD8+ T cell responses within a given individual are quite heterogeneous, suggesting epitope-specific influences on CD8+ T cell function.	[Draenert, Rika; Verrill, Cori L.; Walker, Bruce D.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Boston, MA 02114 USA; [Addo, Marylyn M.; Draenert, Rika; Rathod, Almas; Verrill, Cori L.; Davis, Benjamin T.; Gandhi, Rajesh T.; Robbins, Gregory K.; Basgoz, Nesli O.; Johnston, Mary N.; Flynn, Theresa; Wurcel, Alysse G.; Rosenberg, Eric S.; Altfeld, Marcus; Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Addo, Marylyn M.; Draenert, Rika; Rathod, Almas; Verrill, Cori L.; Davis, Benjamin T.; Gandhi, Rajesh T.; Robbins, Gregory K.; Basgoz, Nesli O.; Johnston, Mary N.; Flynn, Theresa; Wurcel, Alysse G.; Rosenberg, Eric S.; Altfeld, Marcus; Walker, Bruce D.] Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA; [Stone, David R.; Wurcel, Alysse G.] Lemuel Shattuck Hosp, Boston, MA USA; [Cohen, Daniel E.] Fenway Community Hlth Ctr, Boston, MA USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Boston, MA 02114 USA.	Bwalker@partners.org	Addo, Marylyn M./GNP-2548-2022; Robbins, Gregory/F-7988-2011; Wurcel, Alysse/AAZ-6132-2020; Wurcel, Alysse/AAC-5372-2019; Altfeld, Marcus/AAE-7306-2019	Wurcel, Alysse/0000-0002-8255-8387; Altfeld, Marcus/0000-0001-5972-2997; Robbins, Gregory/0000-0001-7545-5817; Addo, Marylyn/0000-0003-2836-9224	National Institutes of Health [RO1 AI28568, AI054178-01, NO1-A1-15442]; Deutsche Forschungsgemeinschaft [DR424/1-1]; Howard Hughes Medical Institute; Doris Duke Charitable Foundation (BDW); Partners/Fenway/Shattuck CFAR; Claflin Distinguished Scholar Award (MMA); Concerned Parents for AIDS Research (CPFA); AmfAR [70577-31-RFT]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028568, R01AI054178, R56AI054178] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation (BDW)(Doris Duke Charitable Foundation (DDCF)); Partners/Fenway/Shattuck CFAR; Claflin Distinguished Scholar Award (MMA); Concerned Parents for AIDS Research (CPFA); AmfAR; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (RO1 AI28568 and AI054178-01, contract # NO1-A1-15442), the Deutsche Forschungsgemeinschaft DR424/1-1 (RD), the Howard Hughes Medical Institute (RD and BDW), the Doris Duke Charitable Foundation (BDW), the Partners/Fenway/Shattuck CFAR, the Claflin Distinguished Scholar Award (MMA), Concerned Parents for AIDS Research (CPFA) (MMA) and AmfAR (70577-31-RFT) (MMA).	Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781; Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borroto R J, 1997, Rev Panam Salud Publica, V1, P3; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; Draenert R, 2004, INFECTION, V32, P250, DOI 10.1007/s15010-004-6404-7; Draenert R, 2004, J VIROL, V78, P630, DOI 10.1128/JVI.78.2.630-641.2004; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; FRAHM N, 2002, HIV MOL IMMUNOLOGY; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; KIEPIELA P, 2004, NATURE IN PRESS; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341; Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; van Baarle D, 2002, TRENDS IMMUNOL, V23, P586, DOI 10.1016/S1471-4906(02)02326-8	34	83	92	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e321	10.1371/journal.pone.0000321	http://dx.doi.org/10.1371/journal.pone.0000321			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389912	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200004
J	Goldreich, D				Goldreich, Daniel			A Bayesian Perceptual Model Replicates the Cutaneous Rabbit and Other Tactile Spatiotemporal Illusions	PLOS ONE			English	Article							SOMATOSENSORY CORTEX; TEMPORAL-ORDER; ELECTROCUTANEOUS STIMULATION; BODY SITE; SPACE; TIME; SALTATION; DISTANCE; TAU; DISCRIMINATION	Background. When brief stimuli contact the skin in rapid succession at two or more locations, perception strikingly shrinks the intervening distance, and expands the elapsed time, between consecutive events. The origins of these perceptual space-time distortions are unknown. Methodology/Principal Findings. Here I show that these illusory effects, which I term perceptual length contraction and time dilation, are emergent properties of a Bayesian observer model that incorporates prior expectation for speed. Rapidly moving stimuli violate expectation, provoking perceptual length contraction and time dilation. The Bayesian observer replicates the cutaneous rabbit illusion, the tau effect, the kappa effect, and other spatiotemporal illusions. Additionally, it shows realistic tactile temporal order judgment and spatial attention effects. Conclusions/Significance. The remarkable explanatory power of this simple model supports the hypothesis, first proposed by Helmholtz, that the brain biases perception in favor of expectation. Specifically, the results suggest that the brain automatically incorporates prior expectation for speed in order to overcome spatial and temporal imprecision inherent in the sensorineural signal.	McMaster Univ, Dept Psychol Neurosci & Behaviour, Hamilton, ON, Canada	McMaster University	Goldreich, D (corresponding author), McMaster Univ, Dept Psychol Neurosci & Behaviour, Hamilton, ON, Canada.	goldrd@mcmaster.ca		Goldreich, Daniel/0000-0002-5104-2185	Natural Sciences and Engineering Research Council of Canada (NSERC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	Supported by an individual Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC).	Adams WJ, 2004, NAT NEUROSCI, V7, P1057, DOI 10.1038/nn1312; Blankenburg F, 2006, PLOS BIOL, V4, P459, DOI 10.1371/journal.pbio.0040069; Braun C, 2002, NEUROIMAGE, V17, P1451, DOI 10.1006/nimg.2002.1277; BRIGNER WL, 1984, PERCEPT MOTOR SKILL, V59, P359, DOI 10.2466/pms.1984.59.2.359; BRIGNER WL, 1988, PERCEPT MOTOR SKILL, V66, P637, DOI 10.2466/pms.1988.66.2.637; Burton H, 2000, SOMATOSENS MOT RES, V17, P213; Cholewiak RW, 1999, PERCEPTION, V28, P851, DOI 10.1068/p2873; Cholewiak RW, 2000, PERCEPT PSYCHOPHYS, V62, P1220, DOI 10.3758/BF03212124; COHEN J, 1953, NATURE, V172, P901, DOI 10.1038/172901a0; COLLYER CE, 1976, PERCEPT PSYCHOPHYS, V19, P47, DOI 10.3758/BF03199384; COLLYER CE, 1977, PERCEPT PSYCHOPHYS, V21, P357, DOI 10.3758/BF03199487; Craig JC, 2003, PERCEPT PSYCHOPHYS, V65, P81, DOI 10.3758/BF03194785; DARIANSMITH I, 1980, J PHYSIOL-LONDON, V309, P147, DOI 10.1113/jphysiol.1980.sp013500; Eimer M, 2005, PERCEPT PSYCHOPHYS, V67, P458, DOI 10.3758/BF03193324; Essick GK, 1998, ADV PSYCHOL, V127, P1; Flach R, 2006, J EXP PSYCHOL HUMAN, V32, P717, DOI 10.1037/0096-1523.32.3.717; Foffani G, 2004, J NEUROSCI, V24, P7266, DOI 10.1523/JNEUROSCI.2523-04.2004; GELDARD FA, 1972, SCIENCE, V178, P178, DOI 10.1126/science.178.4057.178; GELDARD FA, 1982, PSYCHOL BULL, V92, P136, DOI 10.1037/0033-2909.92.1.136; GREEN BG, 1982, PERCEPT PSYCHOPHYS, V31, P315, DOI 10.3758/BF03202654; Helmholtz H., 1925, TREATISE PHYSL OPTIC, V3; Helson H, 1930, Science, V71, P536, DOI 10.1126/science.71.1847.536; Helson H, 1931, J EXP PSYCHOL, V14, P202, DOI 10.1037/h0071164; HIRSH IJ, 1961, J EXP PSYCHOL, V62, P423, DOI 10.1037/h0045283; Iguchi Y, 2005, CLIN NEUROPHYSIOL, V116, P1077, DOI 10.1016/j.clinph.2004.12.005; JOHANSSON RS, 1979, J PHYSIOL-LONDON, V286, P283, DOI 10.1113/jphysiol.1979.sp012619; JOHNSON KO, 1981, J NEUROPHYSIOL, V46, P1177, DOI 10.1152/jn.1981.46.6.1177; JONES B, 1982, PSYCHOL BULL, V91, P128, DOI 10.1037/0033-2909.91.1.128; JONES FN, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484; KILGARD MP, 1995, NATURE, V373, P663, DOI 10.1038/373663a0; KLEFFNER DA, 1992, PERCEPT PSYCHOPHYS, V52, P18, DOI 10.3758/BF03206757; Knill DC, 1996, PERCEPTION BAYESIAN; Lawson R.W, 1952, RELATIVITY SPECIAL G; LECHELT EC, 1977, B PSYCHONOMIC SOC, V10, P191; MARKS LE, 1982, PERCEPT PSYCHOPHYS, V32, P537, DOI 10.3758/BF03204207; MARKS LE, 1982, PERCEPT PSYCHOPHYS, V32, P529, DOI 10.3758/BF03204206; Pouget A, 2003, ANNU REV NEUROSCI, V26, P381, DOI 10.1146/annurev.neuro.26.041002.131112; SHERRICK CE, 1970, IEEE T MAN MACHINE, VMM11, P25, DOI 10.1109/TMMS.1970.299957; Shore DI, 2005, PERCEPTION, V34, P1251, DOI 10.1068/p3313; Shore DI, 1998, J ACOUST SOC AM, V103, P3730, DOI 10.1121/1.423093; Stocker AA, 2006, NAT NEUROSCI, V9, P578, DOI 10.1038/nn1669; Suto Y., 1952, JAPANESE J PSYCHOL, V22, P45; WASSLE H, 1990, VISION RES, V30, P1897, DOI 10.1016/0042-6989(90)90166-I; Weber EH., 1978, EH WEBER SENSE TOUCH; WEINSTEIN SIDNEY, 1968, P195; Weiss Y, 2002, NAT NEUROSCI, V5, P598, DOI 10.1038/nn858; WHITSEL BL, 1986, SOMATOSENS MOT RES, V3, P185, DOI 10.3109/07367228609144583; WIELAND BA, 1960, AM J PSYCHOL, V73, P248, DOI 10.2307/1419901; Wiemer J, 2000, BIOL CYBERN, V82, P173, DOI 10.1007/s004220050017	49	71	71	3	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e333	10.1371/journal.pone.0000333	http://dx.doi.org/10.1371/journal.pone.0000333			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389923	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445200016
J	Hein, G; Alink, A; Kleinschmidt, A; Muller, NG				Hein, Grit; Alink, Arjen; Kleinschmidt, Andreas; Mueller, Notger G.			Competing Neural Responses for Auditory and Visual Decisions	PLOS ONE			English	Article								Why is it hard to divide attention between dissimilar activities, such as reading and listening to a conversation? We used functional magnetic resonance imaging (fMRI) to study interference between simple auditory and visual decisions, independently of motor competition. Overlapping activity for auditory and visual tasks performed in isolation was found in lateral prefrontal regions, middle temporal cortex and parietal cortex. When the visual stimulus occurred during the processing of the tone, its activation in prefrontal and middle temporal cortex was suppressed. Additionally, reduced activity was seen in modality-specific visual cortex. These results paralleled impaired awareness of the visual event. Even without competing motor responses, a simple auditory decision interferes with visual processing on different neural levels, including prefrontal cortex, middle temporal cortex and visual regions.	[Hein, Grit; Mueller, Notger G.] Goethe Univ Frankfurt, Cognit Neurol Unit, Frankfurt, Germany; [Hein, Grit; Alink, Arjen; Mueller, Notger G.] Brain Imaging Ctr, Frankfurt, Germany; [Hein, Grit] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Alink, Arjen] Max Planck Inst Brain Res, Dept Neurophysiol, D-60496 Frankfurt, Germany; [Kleinschmidt, Andreas] INSERM, U562, Gif Sur Yvette, France; [Kleinschmidt, Andreas] CEA, Life Sci Div DSV, Gif Sur Yvette, France	Goethe University Frankfurt; University of California System; University of California Berkeley; Max Planck Society; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Hein, G (corresponding author), Goethe Univ Frankfurt, Cognit Neurol Unit, Frankfurt, Germany.	ghein@berkeley.edu	Houghton, Peter/E-3265-2011; Hein, Grit/AAF-7964-2019	Mueller, Notger/0000-0002-5483-6423; Alink, Arjen/0000-0001-6468-5449	Volkswagen foundation; German Research Foundation [HE 4566/1-1]	Volkswagen foundation(Volkswagen); German Research Foundation(German Research Foundation (DFG))	Funding was obtained from the Volkswagen foundation (A. K., G. H.) and the German Research Foundation (HE 4566/1-1, G. H.).	ALLPORT DA, 1980, COGNITIVE PSYCHOL NE, P112; Badre D, 2005, NEURON, V47, P907, DOI 10.1016/j.neuron.2005.07.023; Baier B, 2006, J NEUROSCI, V26, P12260, DOI 10.1523/JNEUROSCI.1457-06.2006; Barbas H, 2005, CEREB CORTEX, V15, P1356, DOI 10.1093/cercor/bhi018; Barber AD, 2005, CEREB CORTEX, V15, P899, DOI 10.1093/cercor/bhh189; Barcelo F, 2000, NAT NEUROSCI, V3, P399, DOI 10.1038/73975; Beauchamp MS, 2004, NEURON, V41, P809, DOI 10.1016/S0896-6273(04)00070-4; Bourke PA, 1996, Q J EXP PSYCHOL-A, V49, P525, DOI 10.1080/027249896392487; Brass M, 2005, J COGNITIVE NEUROSCI, V17, P1367, DOI 10.1162/0898929054985400; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Calvert GA, 2001, CEREB CORTEX, V11, P1110, DOI 10.1093/cercor/11.12.1110; Chao LL, 1997, CEREB CORTEX, V7, P63, DOI 10.1093/cercor/7.1.63; Coull JT, 1998, J NEUROSCI, V18, P7426; Culham JC, 2006, CURR OPIN NEUROBIOL, V16, P205, DOI 10.1016/j.conb.2006.03.005; Dehaene S, 2001, NAT NEUROSCI, V4, P752, DOI 10.1038/89551; Dehaene S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/pnas.1332574100; Duncan J, 2001, NAT REV NEUROSCI, V2, P820, DOI 10.1038/35097575; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Dux PE, 2006, NEURON, V52, P1109, DOI 10.1016/j.neuron.2006.11.009; Erickson KI, 2005, NEUROIMAGE, V28, P967, DOI 10.1016/j.neuroimage.2005.06.047; Feinstein JS, 2004, CONSCIOUS COGN, V13, P323, DOI 10.1016/j.concog.2003.10.004; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Herath P, 2001, CEREB CORTEX, V11, P796, DOI 10.1093/cercor/11.9.796; Jiang YH, 2004, PSYCHOL SCI, V15, P390, DOI 10.1111/j.0956-7976.2004.00690.x; Johnson JA, 2005, CEREB CORTEX, V15, P1609, DOI 10.1093/cercor/bhi039; Johnson JA, 2006, NEUROIMAGE, V31, P1673, DOI 10.1016/j.neuroimage.2006.02.026; Jolicoeur P, 1999, PSYCHON B REV, V6, P87, DOI 10.3758/BF03210813; Kourtzi Z, 2000, J NEUROSCI, V20, P3310, DOI 10.1523/JNEUROSCI.20-09-03310.2000; KRANCZIOCH C, 2004, NEUROIMAGE, V24, P707; Marcantoni WS, 2003, BRAIN COGNITION, V53, P318, DOI 10.1016/S0278-2626(03)00134-9; Marois R, 2000, NEURON, V28, P299, DOI 10.1016/S0896-6273(00)00104-5; Marois R, 2005, TRENDS COGN SCI, V9, P296, DOI 10.1016/j.tics.2005.04.010; Marois R, 2004, NEURON, V41, P465, DOI 10.1016/S0896-6273(04)00012-1; Martens S, 2006, J COGNITIVE NEUROSCI, V18, P1423, DOI 10.1162/jocn.2006.18.9.1423; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MULLER NG, 2006, J COGN NEUR IN PRESS; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; Schubert T, 2003, COGNITIVE BRAIN RES, V17, P733, DOI 10.1016/S0926-6410(03)00198-8; Shomstein S, 2004, J NEUROSCI, V24, P10702, DOI 10.1523/JNEUROSCI.2939-04.2004; Stelzel C, 2006, PSYCHOL RES-PSYCH FO, V70, P514, DOI 10.1007/s00426-005-0013-7; Strayer DL, 2001, PSYCHOL SCI, V12, P462, DOI 10.1111/1467-9280.00386; Szameitat AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195; Szameitat AJ, 2006, PSYCHOL RES-PSYCH FO, V70, P541, DOI 10.1007/s00426-005-0015-5; Wojciulik E, 1999, NEURON, V23, P747, DOI 10.1016/S0896-6273(01)80033-7; Zaitsev M, 2004, MAGNET RESON MED, V52, P1156, DOI 10.1002/mrm.20261	45	16	16	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e320	10.1371/journal.pone.0000320	http://dx.doi.org/10.1371/journal.pone.0000320			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389911	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200003
J	Han, X; Boyden, ES				Han, Xue; Boyden, Edward S.			Multiple-Color Optical Activation, Silencing, and Desynchronization of Neural Activity, with Single-Spike Temporal Resolution	PLOS ONE			English	Article								The quest to determine how precise neural activity patterns mediate computation, behavior, and pathology would be greatly aided by a set of tools for reliably activating and inactivating genetically targeted neurons, in a temporally precise and rapidly reversible fashion. Having earlier adapted a light-activated cation channel, channelrhodopsin-2 (ChR2), for allowing neurons to be stimulated by blue light, we searched for a complementary tool that would enable optical neuronal inhibition, driven by light of a second color. Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light. We show that trains of yellow and blue light pulses can drive high-fidelity sequences of hyperpolarizations and depolarizations in neurons simultaneously expressing yellow light-driven Halo and blue light-driven ChR2, allowing for the first time manipulations of neural synchrony without perturbation of other parameters such as spiking rates. The Halo/ChR2 system thus constitutes a powerful toolbox for multichannel photoinhibition and photostimulation of virally or transgenically targeted neural circuits without need for exogenous chemicals, enabling systematic analysis and engineering of the brain, and quantitative bioengineering of excitable cells.	[Han, Xue; Boyden, Edward S.] MIT, Media Lab, Cambridge, MA 02139 USA; [Han, Xue] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Massachusetts Institute of Technology (MIT); Stanford University	Boyden, ES (corresponding author), MIT, Media Lab, Cambridge, MA 02139 USA.	esb@media.mit.edu			MIT Media Lab; Helen Hay Whitney Foundation	MIT Media Lab; Helen Hay Whitney Foundation	This work was funded by an anonymous donor and the MIT Media Lab (E. S. B.), and the Helen Hay Whitney Foundation (X. H.).	Ango F, 2004, CELL, V119, P257, DOI 10.1016/j.cell.2004.10.004; BAMBERG E, 1993, P NATL ACAD SCI USA, V90, P639, DOI 10.1073/pnas.90.2.639; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; Cerbai E, 2001, J MOL CELL CARDIOL, V33, P441, DOI 10.1006/jmcc.2000.1316; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Chung Jin Mo, 2002, Pain Pract, V2, P87, DOI 10.1046/j.1533-2500.2002.02011.x; Cohen MR, 2004, CURR OPIN NEUROBIOL, V14, P169, DOI 10.1016/j.conb.2004.03.016; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Donoghue JP, 1998, J NEUROPHYSIOL, V79, P159, DOI 10.1152/jn.1998.79.1.159; DUSCHL A, 1990, J BIOL CHEM, V265, P1261; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; Froemke RC, 2002, NATURE, V416, P433, DOI 10.1038/416433a; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Gershon AA, 2003, AM J PSYCHIAT, V160, P835, DOI 10.1176/appi.ajp.160.5.835; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Graziano MSA, 2002, NEURON, V34, P841, DOI 10.1016/S0896-6273(02)00698-0; Huang CJ, 2006, NAT BIOTECHNOL, V24, P439, DOI 10.1038/nbt1194; IACONO RP, 1995, ACTA NEUROCHIR, V137, P106, DOI 10.1007/BF02188792; Ishizuka T, 2006, NEUROSCI RES, V54, P85, DOI 10.1016/j.neures.2005.10.009; Johns DC, 1999, J NEUROSCI, V19, P1691; Jung JC, 2004, J NEUROPHYSIOL, V92, P3121, DOI 10.1152/jn.00234.2004; Kandel E., 2000, PRINCIPLES NEURAL SC; Karpova AY, 2005, NEURON, V48, P727, DOI 10.1016/j.neuron.2005.11.015; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; Kim JM, 2005, BIOCHEMISTRY-US, V44, P2284, DOI 10.1021/bi048328i; Koch Christof, 2004, QUEST CONSCIOUSNESS; Koller WC, 1999, J NEUROL SCI, V167, P1, DOI 10.1016/S0022-510X(99)00139-2; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1986, ANNU REV BIOPHYS BIO, V15, P11, DOI 10.1146/annurev.bb.15.060186.000303; Lechner HAE, 2002, J NEUROSCI, V22, P5287; Leone M, 2003, NEUROL SCI, V24, pS143; Li P, 2002, FEBS LETT, V528, P77, DOI 10.1016/S0014-5793(02)03245-3; Li X, 2005, P NATL ACAD SCI USA, V102, P17816, DOI 10.1073/pnas.0509030102; Loebrich S, 2006, EMBO J, V25, P987, DOI 10.1038/sj.emboj.7600995; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Milanesi R, 2006, NEW ENGL J MED, V354, P151, DOI 10.1056/NEJMoa052475; Moore T, 2003, NATURE, V421, P370, DOI 10.1038/nature01341; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nagel G, 2005, CURR BIOL, V15, P2279, DOI 10.1016/j.cub.2005.11.032; Nuss HB, 1999, J CLIN INVEST, V103, P889, DOI 10.1172/JCI5073; OESTERHELT D, 1985, EMBO J, V4, P2351, DOI 10.1002/j.1460-2075.1985.tb03938.x; Poolos Nicholas P, 2006, Epilepsy Curr, V6, P88, DOI 10.1111/j.1535-7511.2006.00107.x; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; ROMANSKI LM, 1992, J NEUROSCI, V12, P4501; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SCHRODERLANG S, 2006, NAT METHODS; Schroll C, 2006, CURR BIOL, V16, P1741, DOI 10.1016/j.cub.2006.07.023; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shaw BK, 1999, J NEUROPHYSIOL, V82, P1114, DOI 10.1152/jn.1999.82.3.1114; Shoham S, 2005, NAT METHODS, V2, P837, DOI 10.1038/nmeth793; Slimko EM, 2003, J NEUROSCI METH, V124, P75, DOI 10.1016/S0165-0270(02)00362-X; Slimko EM, 2002, J NEUROSCI, V22, P7373; Svoboda K, 2006, NEURON, V50, P823, DOI 10.1016/j.neuron.2006.05.019; Tse HF, 2006, CIRCULATION, V114, P1000, DOI 10.1161/CIRCULATIONAHA.106.615385; Uhhaas PJ, 2006, NEURON, V52, P155, DOI 10.1016/j.neuron.2006.09.020; Volgraf M, 2006, NAT CHEM BIOL, V2, P47, DOI 10.1038/nchembio756; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yamamoto M, 2003, J NEUROSCI, V23, P6759; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Yu CR, 2004, NEURON, V42, P553, DOI 10.1016/S0896-6273(04)00224-7	70	430	490	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e299	10.1371/journal.pone.0000299	http://dx.doi.org/10.1371/journal.pone.0000299			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375185	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445100001
J	Schmitt, E; Beauchemin, M; Bertrand, R				Schmitt, E.; Beauchemin, M.; Bertrand, R.			Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) duringG(2)/M cell-cycle checkpoint	ONCOGENE			English	Article						bcl-xL; cdk1(cdc2); apoptosis; cell cycle; senescence; DNA damage	DNA TOPOISOMERASE-I; PROTEIN-KINASE; CYTOCHROME-C; MITOCHONDRIAL CONTROL; REGULATED KINASE; HL-60 CELLS; G2 ARREST; S-PHASE; PHOSPHORYLATION; APOPTOSIS	In response to cancer chemotherapeutic drugs, cells rapidly trigger the apoptotic program or undergo growth arrest and senescence at specific phases of the cell cycle. Mitochondrial bcl-xL plays a central role in preventing alteration of mitochondrial dysfunction, cytochrome c release, caspase activation, DNA fragmentation and apoptosis. However, its pleitropic function depends on its subcellular localization. Here, we show that in addition to its mitochondrial effect that delays apoptosis, bcl-xL colocalizes and binds to cdk1( cdc2) during G(2)/M cell-cycle checkpoint and its overexpression stabilizes a G(2)/M-arrest senescence program in surviving cells after DNA damage. Bcl-xL potently inhibits cdk1( cdc2) kinase activity, which is reversible by a synthetic peptide between the 41st amino acid and 60th amino acid surrounding of the Thr47 and Ser62 phosphorylation sites, and Asn52 deamidation site, within the. exible loop domain of bcl-xL. A mutant deleted of this region does not alter the antiapoptotic function of bcl-xL, but impedes its effect on cdk1( cdc2) activity and on the G(2)/M-arrest senescence program after DNA damage. The nuclear interaction of bcl-xL and cdk1( cdc2) suggests that bcl-xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis.	Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; Canc Montreal, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, 1560 Sherbrooke St E Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Barboule N, 2005, CELL CYCLE, V4, P590; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BERTRAND R, 1992, EUR J CANCER, V28A, P743, DOI 10.1016/0959-8049(92)90107-D; Blagosklonny MV, 1997, CANCER RES, V57, P130; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chang BD, 1999, CANCER RES, V59, P3761; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Fan MY, 2000, CANCER RES, V60, P6403; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; HOLM C, 1989, CANCER RES, V49, P6365; Jamil S, 2005, BIOCHEM J, V387, P659, DOI 10.1042/BJ20041596; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1992, CANCER RES, V52, P1817; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1993, CANCER RES, V53, P4776; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt E, 2002, RRD CANCER, V4, P453; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU T, 1995, CANCER RES, V55, P228; TSAO YP, 1992, CANCER RES, V52, P1823; Vairo G, 1996, ONCOGENE, V13, P1511; Vander Heiden MG, 1999, MOL CELL, V3, P159; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang NC, 2004, ANAL BIOCHEM, V325, P337, DOI 10.1016/j.ab.2003.11.012; Yao SL, 1996, CANCER RES, V56, P4551; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	71	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5851	5865		10.1038/sj.onc.1210396	http://dx.doi.org/10.1038/sj.onc.1210396			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369848				2022-12-25	WOS:000249123100003
J	Ehtesham, M; Sarangi, A; Valadez, JG; Chanthaphaychith, S; Becher, MW; Abel, TW; Thompson, RC; Cooper, MK				Ehtesham, M.; Sarangi, A.; Valadez, J. G.; Chanthaphaychith, S.; Becher, M. W.; Abel, T. W.; Thompson, R. C.; Cooper, M. K.			Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells	ONCOGENE			English	Article						brain tumor; glioma; Hedgehog; cancer stem; cell; Olig2; patched	NEURAL STEM-CELLS; SONIC-HEDGEHOG; BRAIN-TUMORS; NERVOUS-SYSTEM; IN-VIVO; GROWTH; CANCER; GLIOBLASTOMA; INHIBITION; DISEASE	The hedgehog (Hh) signaling pathway regulates progenitor cells during embryogenesis and tumorigenesis in multiple organ systems. We have investigated the activity of this pathway in adult gliomas, and demonstrate that the Hh pathway is operational and activated within grade II and III gliomas, but not grade IV de novo glioblastoma multiforme. Furthermore, our studies reveal that pathway activity and responsiveness is confined to progenitor cells within these tumors. Additionally, we demonstrate that Hh signaling in glioma progenitor cells is ligand-dependent and provide evidence documenting the in vivo source of Sonic hedgehog protein. These findings suggest a regulatory role for the Hh pathway in progenitor cells within grade II and III gliomas, and the potential clinical utility of monitoring and targeting this pathway in these primary brain tumors.	Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Cooper, MK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, MRBIII,Rm 6140,465 21st Ave S, Nashville, TN 37232 USA.	michael.cooper@vanderbilt.edu			NINDS NIH HHS [R01 NS051557, K08 NS02133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557, K08NS002133] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; American Cancer Society, 2004, CANC FACTS FIG; Azzarelli B, 2004, J NEUROPATH EXP NEUR, V63, P170, DOI 10.1093/jnen/63.2.170; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Katayama M, 2002, J NEURO-ONCOL, V59, P107, DOI 10.1023/A:1019660421216; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Oh S, 2005, DEV DYNAM, V234, P489, DOI 10.1002/dvdy.20422; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493	33	112	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5752	5761		10.1038/sj.onc.1210359	http://dx.doi.org/10.1038/sj.onc.1210359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353902				2022-12-25	WOS:000248885100007
J	Matsumura, K; Higashida, K; Ishida, H; Hata, Y; Yamamoto, K; Shigeta, M; Mizuno-Horikawa, Y; Wang, XC; Miyoshi, E; Gu, JG; Taniguchi, N				Matsumura, Kengo; Higashida, Katsuya; Ishida, Hiroki; Hata, Yoji; Yamamoto, Kenji; Shigeta, Masaki; Mizuno-Horikawa, Yoko; Wang, Xiangchun; Miyoshi, Eiji; Gu, Jianguo; Taniguchi, Naoyuki			Carbohydrate binding specificity of a fucose-specific lectin from aspergillus oryzae - A novel probe for core fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-III; ALEURIA-AURANTIA LECTIN; HEPATOCELLULAR-CARCINOMA; RALSTONIA-SOLANACEARUM; CRYSTAL-STRUCTURE; FUNGAL LECTIN; CELL-LINES; RECOGNITION; HEPATOMA; PHYTOHEMAGGLUTININ	The alpha 1,6-fucosyl residue (core fucose) of glycoproteins is widely distributed in mammalian tissues and is altered under pathological conditions. A probe that specifically detects core fucose is important for understanding the role of this oligosaccharide structure. Aleuria aurantia lectin (AAL) and Lens culimaris agglutinin-A (LCA) have been often used as carbohydrate probes for core fucose in glycoproteins. Here we show, by using surface plasmon resonance (SPR) analysis, that Aspergillus oryzae L-fucose-specific lectin (AOL) has strongest preference for the alpha 1,6-fucosylated chain among alpha 1,2-, alpha 1,3-, alpha 1,4-, and alpha 1,6-fucosylated pyridylaminated (PA)-sugar chains. These results suggest that AOL is a novel probe for detecting core fucose in glycoproteins on the surface of animal cells. A comparison of the carbohydrate-binding specificity of AOL, AAL, and LCA by SPR showed that the irreversible binding of AOL to the alpha 1,2-fucosylated PA-sugar chain (H antigen) relative to the alpha 1,6-fucosylated chain was weaker than that of AAL, and that the interactions of AOL and AAL with alpha 1,6- fucosylated glycopeptide (FGP), which is considered more similar to in vivo glycoproteins than PA-sugar chains, were similar to their interactions with the alpha 1,6-fucosylated PA-sugar chain. Furthermore, positive staining of AOL, but not AAL, was completely abolished in the cultured embryo fibroblast (MEF) cells obtained from alpha 1,6- fucosyltransferase (Fut8) knock-out mice, as assessed by cytological staining. Taken together, these results suggest that AOL is more suitable for detecting core fucose than AAL or LCA.	Gekkeikan Sake Co Ltd, Inst Res, Fushimi Ku, Kyoto 6128361, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Dis Glycom, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University; Tohoku Medical & Pharmaceutical University; Osaka University	Matsumura, K (corresponding author), Gekkeikan Sake Co Ltd, Inst Res, Fushimi Ku, 300 Katahara Cho, Kyoto 6128361, Japan.	kengo@gekkeikan.co.jp	Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fujihashi M, 2003, BIOCHEMISTRY-US, V42, P11093, DOI 10.1021/bi034983z; FUKUMORI F, 1990, J BIOCHEM-TOKYO, V107, P190, DOI 10.1093/oxfordjournals.jbchem.a123024; HUTCHINSON WL, 1991, HEPATOLOGY, V13, P683, DOI 10.1002/hep.1840130412; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Ishida H, 2002, BIOSCI BIOTECH BIOCH, V66, P1002, DOI 10.1271/bbb.66.1002; KOCHIBE N, 1980, BIOCHEMISTRY-US, V19, P2841, DOI 10.1021/bi00554a004; Kostlanova N, 2005, J BIOL CHEM, V280, P27839, DOI 10.1074/jbc.M505184200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; Noda K, 2003, CANCER RES, V63, P6282; Oda Y, 2003, J BIOL CHEM, V278, P32439, DOI 10.1074/jbc.M305181200; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; PEREIRA MEA, 1974, BIOCHEMISTRY-US, V13, P3184, DOI 10.1021/bi00712a029; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; Stelck S, 1999, GLYCOBIOLOGY, V9, P1171, DOI 10.1093/glycob/9.11.1171; STEPHAN EB, 1996, GLYCOCONJ J, V13, P585; Sudakevitz D, 2002, J BIOCHEM, V132, P353, DOI 10.1093/oxfordjournals.jbchem.a003230; TOYOSHIMA S, 1970, BIOCHIM BIOPHYS ACTA, V221, P514, DOI 10.1016/0005-2795(70)90222-9; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; Wimmerova M, 2003, J BIOL CHEM, V278, P27059, DOI 10.1074/jbc.M302642200; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688	26	140	149	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15700	15708		10.1074/jbc.M701195200	http://dx.doi.org/10.1074/jbc.M701195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383961	hybrid			2022-12-25	WOS:000246589600046
J	Zhu, TN; He, HJ; Kole, S; D'Souza, T; Agarwal, R; Morin, PJ; Bernier, M				Zhu, Tie-Nian; He, Hua-Jun; Kole, Sutapa; D'Souza, Theresa; Agarwal, Rachana; Morin, Patrice J.; Bernier, Michel			Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MATRIX METALLOPROTEINASE-2 AND-9; GTPASE-ACTIVATING PROTEIN; DEPENDENT ACTIVATION; GENE-EXPRESSION; METASTATIC MELANOMA; KINASE ACTIVATION; CANCER CELLS; GELATINASE-B; KAPPA-B	The actin-binding protein filamin A (FLNa) is associated with diverse cellular processes such as cell motility and signaling through its scaffolding properties. Here we examine the effect of FLNa on the regulation of signaling pathways that control the expression of matrix metalloproteinases (MMPs). The lack of FLNa in human M2 melanoma cells was associated with constitutive and phorbol ester-induced expression and secretion of active MMP-9 in the absence of MMP-2 up-regulation. M2 cells displayed stronger MMP-9 production and activity than their M2A7 counterparts where FLNa had been stably reintroduced. Using an MMP-9 promoter construct (pMMP-9-Luc), in vitro kinase assays, and genetic and pharmacological approaches, we demonstrate that FLNa mediated transcriptional down-regulation of pMMP-9-Luc by suppressing the constitutive hyperactivity of the Ras/MAPK extracellular signal-regulated kinase (ERK) cascade. Experimental evidence indicated that this phenomenon was associated with destabilization and ubiquitylation of Ras-GRF1, a guanine nucleotide exchange factor that activates H-Ras by facilitating the release of GDP. Ectopic expression of Ras-GRF1 was accompanied by ERK activation and elevated levels of MMP-9 in M2A7 cells, whereas a catalytically inactive dominant negative Ras-GRF1, which prevented ERK activation, reduced MMP-9 expression in M2 cells. Our results indicate that expression of FLNa regulates constitutive activation of the Ras/ERK pathway partly through a Ras-GRF1 mechanism to modulate the production of MMP-9.	NIA, Diabet Sect, NIH, Clin Invest Lab, Baltimore, MD 21224 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bernier, M (corresponding author), NIA, Diabet Sect, NIH, Clin Invest Lab, Box 23,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Bernierm@mail.nih.gov	Bernier, Michel/AAO-3983-2021; Bernier, Michel/Y-7139-2019	Bernier, Michel/0000-0002-5948-368X; 	NATIONAL INSTITUTE ON AGING [Z01AG000512, ZIAAG000395, Z01AG000892, Z01AG000395, ZIAAG000892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Anilkumar G, 2003, CANCER RES, V63, P2645; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Forlani G, 2006, FEBS J, V273, P2127, DOI 10.1111/j.1742-4658.2006.05226.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; Gollob JA, 2005, CANCER RES, V65, P8869, DOI 10.1158/0008-5472.CAN-05-1387; Guerrero C, 1996, ONCOGENE, V12, P1097; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Ho LL, 2002, EUR J PHARMACOL, V453, P149, DOI 10.1016/S0014-2999(02)02340-3; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Johansson N, 2000, HISTOL HISTOPATHOL, V15, P225, DOI 10.14670/HH-15.225; Kaneda A, 2002, CANCER RES, V62, P6645; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato Y, 2005, J BIOL CHEM, V280, P10938, DOI 10.1074/jbc.M411313200; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; La Porta CAM, 1998, ANTICANCER RES, V18, P2591; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Leaner VD, 2005, MOL CELL BIOL, V25, P3324, DOI 10.1128/MCB.25.8.3324-3337.2005; Liabakk NB, 1996, CANCER RES, V56, P190; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lypowy J, 2005, J BIOL CHEM, V280, P25717, DOI 10.1074/jbc.M414266200; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MacDougall JR, 1999, BRIT J CANCER, V80, P504, DOI 10.1038/sj.bjc.6690385; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Palmer HG, 2003, CANCER RES, V63, P7799; Parrini E, 2006, BRAIN, V129, P1892, DOI 10.1093/brain/awl125; Parsons SL, 1998, BRIT J CANCER, V78, P1495, DOI 10.1038/bjc.1998.712; Popp O, 2003, BIOL CHEM, V384, P951, DOI 10.1515/BC.2003.107; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; SATO H, 1993, ONCOGENE, V8, P395; Satyamoorthy K, 2003, CANCER RES, V63, P756; Scott MGH, 2006, MOL CELL BIOL, V26, P3432, DOI 10.1128/MCB.26.9.3432-3445.2006; Spallarossa P, 2006, CARDIOVASC RES, V69, P736, DOI 10.1016/j.cardiores.2005.08.009; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Tsubokawa T, 2006, STROKE, V37, P1888, DOI 10.1161/01.STR.0000227259.15506.24; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Woo CH, 2004, J IMMUNOL, V173, P6973, DOI 10.4049/jimmunol.173.11.6973; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	72	48	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14816	14826		10.1074/jbc.M611430200	http://dx.doi.org/10.1074/jbc.M611430200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389601	hybrid			2022-12-25	WOS:000246589000017
J	Hammond, CL; Marchan, R; Krance, SM; Ballatori, N				Hammond, Christine L.; Marchan, Rosemarie; Krance, Suzanne M.; Ballatori, Nazzareno			Glutathione export during apoptosis requires functional multidrug resistance-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; REDUCED GLUTATHIONE; GSH EXTRUSION; OUTWARD TRANSLOCATION; ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; EXECUTION PHASE; LEUKOTRIENE C-4; P-GLYCOPROTEIN; CELLS	GSH is released in cells undergoing apoptosis, and the present study indicates that the multidrug resistance-associated proteins (MRPs/ABCC) are responsible for this GSH release. Jurkat cells released similar to 75-80% of their total intracellular GSH during both Fas antibody- and staurosporine-induced apoptosis. In contrast, Raji cells, a lymphocyte cell line that is deficient in phosphatidylserine externalization, did not release GSH during apoptosis, and other apoptotic features appeared more slowly in these cells. Jurkat and Raji cell lines expressed comparable MRP and OATP/SLCO (organic anion-transporting polypeptide) mRNA levels, and MRP1 protein levels; however, differences existed in MRP1 localization and function. In Jurkat cells, MRP1 was largely localized to the plasma membrane, and these cells exported the MRP substrate calcein. Calcein release was enhanced during apoptosis. In contrast, Raji cells had little MRP1 at the plasma membrane and did not export calcein under basal or apoptotic conditions, indicating that these cells lack functional MRPs at the plasma membrane. GSH release in Jurkat cells undergoing apoptosis was inhibited by the organic anion transport inhibitors MK571, sulfinpyrazone, and probenecid, supporting a role for the MRP transporters in this process. Furthermore, when MRP1 expression was decreased with RNA interference, GSH release was lower under both basal and apoptotic conditions, providing direct evidence that MRP1 is involved in GSH export.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	University of Rochester	Ballatori, N (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, 575 Elmwood Ave,Box EHSC, Rochester, NY 14642 USA.	Ned_Ballatori@urmc.rochester.edu		Marchan, Rosemarie/0000-0003-4414-1633	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823, R01DK067214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES006484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48823, DK067214] Funding Source: Medline; NIEHS NIH HHS [ES01247, ES06484, ES07026] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMQUIST KC, 1995, CANCER RES, V55, P102; Ballatori N, 2005, TOXICOL APPL PHARM, V204, P238, DOI 10.1016/j.taap.2004.09.008; Briz O, 2006, J BIOL CHEM, V281, P30326, DOI 10.1074/jbc.M602048200; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; De Nicola M, 2006, BIOCHEM PHARMACOL, V72, P1405, DOI 10.1016/j.bcp.2006.06.009; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; FELLER N, 1995, FEBS LETT, V368, P385, DOI 10.1016/0014-5793(95)00677-2; Forsberg AJ, 2004, ANTIOXID REDOX SIGN, V6, P203, DOI 10.1089/152308604322899279; Franco R, 2006, J BIOL CHEM, V281, P29542, DOI 10.1074/jbc.M602500200; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Gennuso F, 2004, P NATL ACAD SCI USA, V101, P2470, DOI 10.1073/pnas.0308452100; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GRANT CE, 1994, CANCER RES, V54, P357; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hammond CL, 2004, TOXICOL APPL PHARM, V195, P12, DOI 10.1016/j.taap.2003.10.008; Hammond CL, 2001, J HEPATOL, V34, P946, DOI 10.1016/S0168-8278(01)00037-X; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; LEIER I, 1994, J BIOL CHEM, V269, P27807; Letschert K, 2005, J PHARMACOL EXP THER, V313, P549, DOI 10.1124/jpet.104.081224; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Masuda S, 1999, MOL PHARMACOL, V55, P743; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Sohnius A, 2003, MOL MEMBR BIOL, V20, P299, DOI 10.1080/0968768031000114033; Sugiyama D, 2001, J PHARMACOL EXP THER, V298, P316; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Van Luyn MJA, 1998, INT J CANCER, V76, P55, DOI 10.1002/(SICI)1097-0215(19980330)76:1<55::AID-IJC10>3.3.CO;2-O; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Versantvoort CHM, 1995, INT J CANCER, V63, P855, DOI 10.1002/ijc.2910630617; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Woehlecke H, 2003, BIOCHEM J, V376, P489, DOI 10.1042/BJ20030886	51	88	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14337	14347		10.1074/jbc.M611019200	http://dx.doi.org/10.1074/jbc.M611019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374608	hybrid			2022-12-25	WOS:000246245800045
J	Meary, F; Metral, S; Ferreira, C; Eladari, D; Colin, Y; Lecomte, MC; Nicolas, G				Meary, Fleur; Metral, Sylvain; Ferreira, Chrystophe; Eladari, Dominique; Colin, Yves; Lecomte, Marie-Christine; Nicolas, Gael			A mutant alpha II-spectrin designed to resist calpain and caspase cleavage questions the functional importance of this process in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROAGGREGATIVE ESCHERICHIA-COLI; DEPENDENT PROTEASE-I; MEMBRANE SKELETON; CALMODULIN-BINDING; BRAIN SPECTRIN; APOPTOSIS; FODRIN; CALCIUM; SITE; PHOSPHORYLATION	alpha- and beta-spectrins are components of molecular scaffolds located under the lipid bilayer and named membrane skeletons. Disruption of these scaffolds through mutations in spectrins demonstrated that they are involved in the membrane localization or the maintenance of proteins associated with them. The ubiquitous alpha II-spectrin chain bears in its central region a unique domain that is sensitive to several proteases such as calpains or caspases. The conservation of this region in vertebrates suggests that the proteolysis of alpha II-spectrin by these enzymes could be involved in important functions. To assess the role of alpha II-spectrin cleavage in vivo, we generated a murine model in which the exons encoding the region defining this cleavage sensitivity were disrupted by gene targeting. Surprisingly, homozygous mice expressing this mutant alpha II-spectrin appeared healthy, bred normally, and had no histological anomaly. Remarkably, the mutant alpha II-spectrin assembles correctly into the membrane skeleton, thus challenging the notion that this region is required for the stable biogenesis of the membrane skeleton in nonerythroid cells. Our finding also argues against a critical role of this particular alpha II-spectrin cleavage in either major cellular functions or in normal development.	Inst Natl Transfus Sanguine, INSERM, U665, F-75015 Paris, France; Univ Paris 07, F-75005 Paris, France; Univ Paris 07, Inst Fed Rech Claude Bernard, F-75018 Paris, France; INSERM, U652, F-75006 Paris, France; Hop Necker Enfants Malad, Dept Physiol, AP HP, F-75006 Paris, France; Univ Paris 05, Fac Med Rene Descartes, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Nicolas, G (corresponding author), Inst Natl Transfus Sanguine, INSERM, U665, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	gnicolas@idf.inserm.fr	METRAL, Sylvain/P-5833-2017; NICOLAS, Gaël/X-9555-2019; NICOLAS, Gaël/D-7611-2013; colin, yves/O-1910-2017	METRAL, Sylvain/0000-0001-6244-8546; NICOLAS, Gaël/0000-0002-1671-8274; NICOLAS, Gaël/0000-0002-1671-8274; colin, yves/0000-0001-5196-4254; Ferreira, Chrystophe/0000-0002-1990-278X; Meary, Fleur/0000-0002-5356-4649; Eladari, Dominique/0000-0003-1067-0844				Bignone PA, 2003, BIOCHEM J, V374, P613, DOI 10.1042/BJ20030507; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; Canizalez-Roman A, 2003, MOL MICROBIOL, V48, P947, DOI 10.1046/j.1365-2958.2003.03492.x; Chen HQ, 2007, J BIOL CHEM, V282, P4124, DOI 10.1074/jbc.M610231200; Delaunay J, 2007, BLOOD REV, V21, P1, DOI 10.1016/j.blre.2006.03.005; FOWLER VM, 1992, J CELL BIOL, V119, P1559, DOI 10.1083/jcb.119.6.1559; GEDDES JW, 1995, NEUROBIOL AGING, V16, P651, DOI 10.1016/0197-4580(95)00062-J; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Ikeda Y, 2006, NAT GENET, V38, P184, DOI 10.1038/ng1728; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Leneuve P, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng021; LETO TL, 1989, J BIOL CHEM, V264, P5826; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; Lynch G, 2007, NEUROPHARMACOLOGY, V52, P12, DOI 10.1016/j.neuropharm.2006.07.027; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mohindas N, 2006, TRANSFUS CLIN BIOL, V13, P29, DOI 10.1016/j.tracli.2006.02.017; Navarro-Garcia F, 2004, INFECT IMMUN, V72, P3609, DOI 10.1128/IAI.72.6.3609-3621.2004; Nedrelow JH, 2003, J BIOL CHEM, V278, P7735, DOI 10.1074/jbc.M210988200; Nicolas G, 2002, MOL CELL BIOL, V22, P3527, DOI 10.1128/MCB.22.10.3527-3536.2002; Norman KR, 2002, J CELL BIOL, V157, P665, DOI 10.1083/jcb.200111051; Ozkan ED, 1997, P NATL ACAD SCI USA, V94, P4137, DOI 10.1073/pnas.94.8.4137; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Praitis V, 2005, DEV BIOL, V283, P157, DOI 10.1016/j.ydbio.2005.04.002; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Rubera I, 2004, J AM SOC NEPHROL, V15, P2050, DOI 10.1097/01.ASN.0000133023.89251.01; Simonovic M, 2006, J BIOL CHEM, V281, P34333, DOI 10.1074/jbc.M604613200; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Williams ST, 2003, APOPTOSIS, V8, P353, DOI 10.1023/A:1024168901003; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	38	19	19	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14226	14237		10.1074/jbc.M700028200	http://dx.doi.org/10.1074/jbc.M700028200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374614	hybrid			2022-12-25	WOS:000246245800033
J	Little, R; Martinez-Argudo, I; Perry, S; Dixon, R				Little, Richard; Martinez-Argudo, Isabel; Perry, Susan; Dixon, Ray			Role of the H domain of the histidine kinase-like protein NifL in signal transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NIFL; NITROGEN REGULATOR-II; TERMINAL GAF DOMAIN; FUNCTIONAL DISSECTION; FIXATION; REDOX; MUTATIONS; ACTIVATOR; SYSTEM; 2-OXOGLUTARATE	The NifL protein from Azotobacter vinelandii senses both the redox and fixed nitrogen status to regulate nitrogen fixation by controlling the activity of the transcriptional activator NifA. NifL has a domain architecture similar to that of the cytoplasmic histidine protein kinases. It contains two N-terminal PAS domains and a C-terminal transmitter region containing a conserved histidine residue ( H domain) and a nucleotide binding GHKL domain corresponding to the catalytic core of the histidine kinases. Despite these similarities, NifL does not exhibit kinase activity and regulates its partner NifA by direct protein-protein interactions rather than phosphorylation. NifL senses the redox status via a FAD co-factor located within the PAS1 domain and responds to the nitrogen status by interaction with the signal transduction protein GlnK, which binds to the GHKL domain. The ability of NifL to inhibit NifA is antagonized by the binding of 2-oxoglutarate to the N-terminal GAF domain of NifA. In this study we have performed site-directed mutagenesis of the H domain of NifL to examine its role in signal transmission. Our results suggest that this domain plays a major role in transmission of signals perceived by the PAS1 and GHKL domains to ensure that NifL achieves the required conformation necessary to inhibit the 2-oxoglutarate-bound form of NifA. Some of the substitutions discriminate the redox and fixed nitrogen sensing functions of NifL implying that the conformational requirements and/or domain interactions necessary for NifA inhibition differ with respect to the signal input.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dixon, R (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	ray.dixon@bbsrc.ac.uk	Martinez, Isabel/R-4803-2019	Martinez, Isabel/0000-0001-5067-1791; Dixon, Ray/0000-0002-6348-639X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Hefti MH, 2001, ANAL BIOCHEM, V295, P180, DOI 10.1006/abio.2001.5214; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Jiang P, 2000, BIOCHEMISTRY-US, V39, P13433, DOI 10.1021/bi000794u; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; Kramer G, 1999, P NATL ACAD SCI USA, V96, P604, DOI 10.1073/pnas.96.2.604; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; Marina A, 2005, EMBO J, V24, P4247, DOI 10.1038/sj.emboj.7600886; Martinez-Argudo I, 2004, P NATL ACAD SCI USA, V101, P16316, DOI 10.1073/pnas.0405312101; Martinez-Argudo I, 2004, MOL MICROBIOL, V52, P1731, DOI 10.1111/j.1365-2958.2004.04089.x; Martinez-Argudo I, 2004, J BACTERIOL, V186, P601, DOI 10.1128/JB.186.3.601-610.2004; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Perry S, 2005, J MOL BIOL, V346, P935, DOI 10.1016/j.jmb.2004.12.033; Qin L, 2003, J BACTERIOL, V185, P3429, DOI 10.1128/JB.185.11.3429-3435.2003; Reyes-Ramirez F, 2002, J BACTERIOL, V184, P6777, DOI 10.1128/JB.184.24.6777-6785.2002; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; Soderback E, 1998, MOL MICROBIOL, V28, P179, DOI 10.1046/j.1365-2958.1998.00788.x; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wolanin PM, 2002, GENOME BIOL, V3; WOODLEY P, 1994, MOL MICROBIOL, V13, P619, DOI 10.1111/j.1365-2958.1994.tb00456.x; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	34	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13429	13437		10.1074/jbc.M610827200	http://dx.doi.org/10.1074/jbc.M610827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355964	hybrid			2022-12-25	WOS:000246060300032
J	Dai, QY; Sheng, ZY; Geiger, JH; Castellino, FJ; Prorok, M				Dai, Qiuyun; Sheng, Zhenyu; Geiger, James H.; Castellino, Francis J.; Prorok, Mary			Helix-helix interactions between homo- and heterodimeric gamma-carboxyglutamate-containing conantokin peptides and their derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR ANTAGONIST; COILED-COILS; CALCIUM; BINDING	The conantokins are a family of small, naturally occurring gamma-carboxyglutamate ( Gla)-rich peptides that specifically antagonize the N-methyl-D-aspartate ( NMDA) subtype of ionotropic glutamate receptor. One member of this family, conantokin-G ( con-G), undergoes Ca2+-mediated self-assembly to form an antiparallel helical dimer. Subunit interactions in this complex are incumbent upon intermolecular Ca2+ bridging of Gla residues spaced at i, i + 4, i + 7, i + 11 intervals within the monomer. Herein, we further probe the molecular determinants governing such helix-helix interactions. Select variants were synthesized to evaluate the contributions of non-Gla residues to conantokin self-association. Con-G dimerization was shown to be exothermic and accompanied by positive heat capacity changes. Using positional Gla variants of conantokin-R ( con-R), a non-dimerizing conantokin, i, i + 4, i + 7, i + 11 Gla spacing alone was shown to be insufficient for self-assembly. The Ca2+-dependent antiparallel heterodimerization of con-G and con-T( K7 gamma), two peptides that harbor optimal Gla spacing, was established. Last, the effects of covalently constrained con-G dipeptides on NMDA-evoked current in HEK293 cells expressing combinations of NR1a, NR1b, NR2A, and NR2B subunits of the NMDA receptor were investigated. The antiparallel dipeptide was unique in its ability to potentiate current at NR1a/2A receptors and, like monomeric con-G, was inhibitory at NR1a/2B and NR1b/2B combinations. In contrast, the parallel species was completely inactive at all subunit combinations tested. These results suggest that, under physiological Ca2+ concentrations, equilibrium levels of con-G dimer most likely exist in an antiparallel orientation and exert effects on NMDA receptor activity that differ from the monomer.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Wm Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	University of Notre Dame; University of Notre Dame; Michigan State University	Prorok, M (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 230 Raclin Carmichael Hall, Notre Dame, IN 46556 USA.	mprorok@nd.edu		Dai, Qiuyun/0000-0003-2062-8332; Geiger, James/0000-0002-9443-4488	NHLBI NIH HHS [HL019982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blandl T, 1999, J PEPT RES, V53, P453, DOI 10.1034/j.1399-3011.1999.00042.x; Buczek O, 2005, CELL MOL LIFE SCI, V62, P3067, DOI 10.1007/s00018-005-5283-0; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chen ZG, 1998, J BIOL CHEM, V273, P16248, DOI 10.1074/jbc.273.26.16248; Cnudde SE, 2007, J AM CHEM SOC, V129, P1586, DOI 10.1021/ja065722q; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; Dai QY, 2004, BIOCHEMISTRY-US, V43, P13225, DOI 10.1021/bi048796s; Dai QY, 2004, J MOL BIOL, V336, P731, DOI 10.1016/j.jmb.2003.12.027; De Crescenzo G, 2003, BIOCHEMISTRY-US, V42, P1754, DOI 10.1021/bi0268450; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Jimenez EC, 2002, EPILEPSY RES, V51, P73, DOI 10.1016/S0920-1211(02)00101-8; Klein RC, 2001, J BIOL CHEM, V276, P26860, DOI 10.1074/jbc.M102428200; Klein RC, 1999, NEUROPHARMACOLOGY, V38, P1819, DOI 10.1016/S0028-3908(99)00065-9; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; McClain DL, 2001, J MOL BIOL, V313, P371, DOI 10.1006/jmbi.2001.5044; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; Prorok M, 2001, CURR DRUG TARGETS, V2, P313, DOI 10.2174/1389450013348542; Ragnarsson L, 2006, J NEUROCHEM, V96, P283, DOI 10.1111/j.1471-4159.2005.03574.x; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Rishavy MA, 2005, J BIOL CHEM, V280, P34870, DOI 10.1074/jbc.M504345200; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; White HS, 2000, J PHARMACOL EXP THER, V292, P425	31	20	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12641	12649		10.1074/jbc.M609087200	http://dx.doi.org/10.1074/jbc.M609087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347154	hybrid			2022-12-25	WOS:000245942800033
J	Guo, BC; Cheng, GH				Guo, Beichu; Cheng, Genhong			Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEPATITIS-C VIRUS; MEDIATED SIGNAL-TRANSDUCTION; INDUCIBLE GENE-I; RIG-I; IKK-EPSILON; VIRAL-INFECTION; ACTIVATION; PATHWAY; KINASE	Induction of type I interferons can be triggered by viral components through Toll-like receptors or intracellular viral receptors such as retinoic acid-inducible gene I. Here, we demonstrate that the TRAF ( tumor necrosis factor receptor-associated factor) family member-associated NF-kappa B activator ( TANK) plays an important role in interferon induction through both retinoic acid-inducible gene I- and Toll-like receptor-dependent pathways. TANK forms complexes with both upstream signal mediators, such as Cardif/MAVS/IPS-1/VISA, TRIF ( Toll-interleukin-1 receptor domain-containing adaptor inducing interferon-beta), and TRAF3 and downstream mediators TANK-binding kinase 1, inducible I kappa B kinase, and interferon regulatory factor 3. In addition, it synergizes with these signaling components in interferon induction. Specific knockdown of TANK results in reduced type I interferon production, increased viral titers, and enhanced cell sensitivity to viral infection. Thus, TANK may be a critical adaptor that regulates the assembly of the TANK-binding kinase 1-inducible I kappa B kinase complex with upstream signaling molecules in multiple antiviral pathways.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 8-240 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	genhongc@microbio.ucla.edu			NATIONAL CANCER INSTITUTE [T32CA009120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069120, R01AI056154] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA009120] Funding Source: Medline; NIAID NIH HHS [R01 AI069120, R01 AI056154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chin AID, 1999, MOL CELL BIOL, V19, P6665; Chung JY, 2002, J CELL SCI, V115, P679; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Heim MH, 2005, J HEPATOL, V42, P431, DOI 10.1016/j.jhep.2004.12.016; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jefferies CA, 2005, TRENDS MOL MED, V11, P403, DOI 10.1016/j.molmed.2005.07.006; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Le Page C, 2000, Rev Immunogenet, V2, P374; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Nomura F, 2000, GENES CELLS, V5, P191; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Sasai M, 2005, J IMMUNOL, V174, P27, DOI 10.4049/jimmunol.174.1.27; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	48	163	167	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11817	11826		10.1074/jbc.M700017200	http://dx.doi.org/10.1074/jbc.M700017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327220	hybrid			2022-12-25	WOS:000245941900024
J	Suzan-Monti, M; La Scola, B; Barrassi, L; Espinosa, L; Raoult, D				Suzan-Monti, Marie; La Scola, Bernard; Barrassi, Lina; Espinosa, Leon; Raoult, Didier			Ultrastructural Characterization of the Giant Volcano-like Virus Factory of Acanthamoeba polyphaga Mimivirus	PLOS ONE			English	Article								Acanthamoeba polyphaga Mimivirus is a giant double-stranded DNA virus defining a new genus, the Mimiviridae, among the Nucleo-Cytoplasmic Large DNA Viruses (NCLDV). We used utrastructural studies to shed light on the different steps of the Mimivirus replication cycle: entry via phagocytosis, release of viral DNA into the cell cytoplasm through fusion of viral and vacuolar membranes, and finally viral morphogenesis in an extraordinary giant cytoplasmic virus factory (VF). Fluorescent staining of the AT-rich Mimivirus DNA showed that it enters the host nucleus prior to the generation of a cytoplasmic independent replication centre that forms the core of the VF. Assembly and filling of viral capsids were observed within the replication centre, before release into the cell cytoplasm where progeny virions accumulated. 3D reconstruction from fluorescent and differential contrast interference images revealed the VF emerging from the cell surface as a volcano-like structure. Its size dramatically grew during the 24 h infectious lytic cycle. Our results showed that Mimivirus replication is an extremely efficient process that results from a rapid takeover of cellular machinery, and takes place in a unique and autonomous giant assembly centre, leading to the release of a large number of complex virions through amoebal lysis.	[Suzan-Monti, Marie; La Scola, Bernard; Barrassi, Lina; Espinosa, Leon; Raoult, Didier] Univ Aix Marseille 2, Fac Med, CNRS, Unite Rickettsies,UMR 6020,IFR 48, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Suzan-Monti, M (corresponding author), Univ Aix Marseille 2, Fac Med, CNRS, Unite Rickettsies,UMR 6020,IFR 48, Marseille, France.	marie.suzan@medecine.univ-mrs.fr; Didier.Raoult@medecine.univ-mrs.fr	RAOULT, Didier/A-8434-2008; LA SCOLA, Bernard/P-6477-2016; Espinosa, Leon/V-8410-2017	RAOULT, Didier/0000-0002-0633-5974; LA SCOLA, Bernard/0000-0001-8006-7704; 	Centre National de la Recherche Scientifique (CNRS)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	Centre National de la Recherche Scientifique (CNRS)	Andres G, 1997, J VIROL, V71, P2331; Berger P, 2006, EMERG INFECT DIS, V12, P248; Brookes SM, 1998, VIROLOGY, V249, P175, DOI 10.1006/viro.1998.9308; Brookes SM, 1996, VIROLOGY, V224, P84, DOI 10.1006/viro.1996.0509; GARCIABEATO R, 1992, VIROLOGY, V188, P637, DOI 10.1016/0042-6822(92)90518-T; Greub G, 2004, CLIN MICROBIOL REV, V17, P413, DOI 10.1128/CMR.17.2.413-433.2004; Heath CM, 2001, J CELL BIOL, V153, P449, DOI 10.1083/jcb.153.3.449; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; La Scola B, 2005, EMERG INFECT DIS, V11, P449, DOI 10.3201/eid1103.040538; La Scola B, 2003, SCIENCE, V299, P2033; MOSS B, 2001, FIELDS VIROLOGY, P2637; Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058; Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485; Raoult D, 2006, ANN INTERN MED, V144, P702, DOI 10.7326/0003-4819-144-9-200605020-00025; Renesto P, 2006, J VIROL, V80, P11678, DOI 10.1128/JVI.00940-06; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; ROWBOTHAM TJ, 1980, J CLIN PATHOL, V33, P1179, DOI 10.1136/jcp.33.12.1179; Suzan-Monti M, 2006, VIRUS RES, V117, P145, DOI 10.1016/j.virusres.2005.07.011; Valdecasas AG, 2001, MICRON, V32, P559, DOI 10.1016/S0968-4328(00)00061-5; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; Van Etten JL, 2002, ARCH VIROL, V147, P1479, DOI 10.1007/s00705-002-0822-6; Williams T, 2005, ADV VIRUS RES, V65, P173, DOI 10.1016/S0065-3527(05)65006-3; Williams T, 1996, ADV VIRUS RES, V46, P345, DOI 10.1016/S0065-3527(08)60076-7; Xiao CA, 2005, J MOL BIOL, V353, P493, DOI 10.1016/j.jmb.2005.08.060	26	112	114	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e328	10.1371/journal.pone.0000328	http://dx.doi.org/10.1371/journal.pone.0000328			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389919	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445200011
J	Wuchty, S				Wuchty, Stefan			Rich-Club Phenomenon in the Interactome of P. falciparum-Artifact or Signature of a Parasitic Life Style?	PLOS ONE			English	Article							PROTEINS; TOPOLOGY; VIRULENCE; DATABASE; BIOLOGY	Recent advances have provided a first experimental protein interaction map of the human malaria parasite P. falciparum, which appears to be remotely related to interactomes of other eukaryotes. Here, we present a comparative topological analysis of this experimentally determined web with a network of conserved interactions between proteins in S. cerevisiae, C. elegans and D. melanogaster that have an ortholog in Plasmodium. Focusing on experimental interactions, we find a significant presence of a "rich-club,'' a topological characteristic that features an "oligarchy'' of highly connected proteins being intertwined with one another. In complete contrast, the network of interologs and particularly the web of evolutionary-conserved interactions in P. falciparum lack this feature. This observation prompts the question of whether this result points to a topological signature of the parasite's biology, since experimentally obtained interactions widely cover parasite-specific functions. Significantly, hub proteins that appear in such an oligarchy revolve around invasion functions, shaping an island of parasite-specific activities in a sea of evolutionary inherited interactions. This presence of a biologically unprecedented network feature in the human malaria parasite might be an artifact of the quality and the methods to obtain interaction data in this organism. Yet, the observation that rich-club proteins have distinctive and statistically significant functions that revolve around parasite-specific activities point to a topological signature of a parasitic life style.	Northwestern Univ, NW Inst Complex, Evanston, IL 60208 USA	Northwestern University	Wuchty, S (corresponding author), Northwestern Univ, NW Inst Complex, Evanston, IL 60208 USA.	s-wuchty@northwest-ern.edu	li, lingxuan/F-7033-2010		Northwestern Institute of Complexity	Northwestern Institute of Complexity	The Northwestern Institute of Complexity supported this study.	Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Colizza V, 2006, NAT PHYS, V2, P110, DOI 10.1038/nphys209; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Han JDJ, 2005, NAT BIOTECHNOL, V23, P839, DOI 10.1038/nbt1116; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stumpf MPH, 2005, P NATL ACAD SCI USA, V102, P4221, DOI 10.1073/pnas.0501179102; Suthram S, 2005, NATURE, V438, P108, DOI 10.1038/nature04135; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Winzeler EA, 2006, NAT REV MICROBIOL, V4, P145, DOI 10.1038/nrmicro1327; Wuchty S, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-8; Wuchty S, 2003, NAT GENET, V35, P176, DOI 10.1038/ng1242; Wuchty S, 2004, GENOME RES, V14, P1310, DOI 10.1101/gr.2300204; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303	26	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e335	10.1371/journal.pone.0000335	http://dx.doi.org/10.1371/journal.pone.0000335			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389924	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200018
J	Daksis, JI; Erikson, GH				Daksis, Jasmine I.; Erikson, Glen H.			Heteropolymeric Triplex-Based Genomic Assay (R) to Detect Pathogens or Single-Nucleotide Polymorphisms in Human Genomic Samples	PLOS ONE			English	Article							HELIX FORMATION; MAJOR GROOVE; DNA; SEQUENCE; RECOGNITION; ELONGATION; RESISTANCE; MUTATION; BINDING	Human genomic samples are complex and are considered difficult to assay directly without denaturation or PCR amplification. We report the use of a base-specific heteropolymeric triplex, formed by native duplex genomic target and an oligonucleotide third strand probe, to assay for low copy pathogen genomes present in a sample also containing human genomic duplex DNA, or to assay human genomic duplex DNA for Single Nucleotide Polymorphisms (SNP), without PCR amplification. Wild-type and mutant probes are used to identify triplexes containing FVL G1691A, MTHFR C677T and CFTR mutations. The specific triplex structure forms rapidly at room temperature in solution and may be detected without a separation step. YOYO-1, a fluorescent bis-intercalator, promotes and signals the formation of the specific triplex. Genomic duplexes may be assayed homogeneously with single base pair resolution. The specific triple-stranded structures of the assay may approximate homologous recombination intermediates, which various models suggest may form in either the major or minor groove of the duplex. The bases of the stable duplex target are rendered specifically reactive to the bases of the probe because of the activity of intercalated YOYO-1, which is known to decondense duplex locally 1.3 fold. This may approximate the local decondensation effected by recombination proteins such as RecA in vivo. Our assay, while involving triplex formation, is sui generis, as it is not homopurine sequence-dependent, as are "canonical triplexes''. Rather, the base pair-specific heteropolymeric triplex of the assay is conformation-dependent. The highly sensitive diagnostic assay we present allows for the direct detection of base sequence in genomic duplex samples, including those containing human genomic duplex DNA, thereby bypassing the inherent problems and cost associated with conventional PCR based diagnostic assays.	[Daksis, Jasmine I.; Erikson, Glen H.] Ingeneus Res, Mississauga, ON, Canada		Daksis, JI (corresponding author), Ingeneus Res, Mississauga, ON, Canada.	jasmine@ingeneus.net			Ingeneus Inc.	Ingeneus Inc.	Ingeneus Inc.	BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Bertucat G, 2000, J BIOMOL STRUCT DYN, P147, DOI 10.1080/07391102.2000.10506615; Birch L, 2004, CLIN CHEM, V50, P1553, DOI 10.1373/clinchem.2003.029454; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; CHENG AJ, 1994, NUCLEIC ACIDS RES, V22, P4742, DOI 10.1093/nar/22.22.4742; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Daksis JI, 2005, GENET TEST, V9, P111, DOI 10.1089/gte.2005.9.111; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; FRANKKAMENETSKI.MD, 1990, DNA TOPOLOGY ITS BIO, P185; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Grody Wayne W., 2001, Genetics in Medicine, V3, P149, DOI 10.1097/00125817-200103000-00010; HELENE C, 1992, ANN NY ACAD SCI, V660, P27, DOI 10.1111/j.1749-6632.1992.tb21054.x; Johansen F, 1998, J BIOMOL STRUCT DYN, V16, P205, DOI 10.1080/07391102.1998.10508240; KIM MG, 1995, J MOL BIOL, V247, P874, DOI 10.1006/jmbi.1994.0187; Kosikov KM, 1999, J MOL BIOL, V289, P1301, DOI 10.1006/jmbi.1999.2798; Leitner D, 2000, J BIOMOL STRUCT DYN, V17, P993, DOI 10.1080/07391102.2000.10506587; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; Malkov VA, 2000, J MOL BIOL, V299, P629, DOI 10.1006/jmbi.2000.3770; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Raggi CC, 2003, CLIN CHEM, V49, P782, DOI 10.1373/49.5.782; Seidman MM, 2003, J CLIN INVEST, V112, P487, DOI 10.1172/JCI200319552; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; STASIAK A, 1981, J MOL BIOL, V151, P557, DOI 10.1016/0022-2836(81)90010-3; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Titus SA, 1997, J NEUROSCI, V17, P875; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023; Zhang Y, 2005, BIOPHYS J, V89, P2950, DOI 10.1529/biophysj.104.058552; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	33	5	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e305	10.1371/journal.pone.0000305	http://dx.doi.org/10.1371/journal.pone.0000305			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375191	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445100007
J	Frak, V; Croteau, I; Bourbonnais, D; Duval, C; Duclos, C; Cohen, H				Frak, Victor; Croteau, Isabelle; Bourbonnais, Daniel; Duval, Christian; Duclos, Cyril; Cohen, Henri			Simulation Modifies Prehension: Evidence for a Conjoined Representation of the Graspable Features of an Object and the Action of Grasping It	PLOS ONE			English	Article							MAGNETIC STIMULATION; MOTOR IMAGERY; HAND; MOVEMENTS; BRAIN; MECHANISMS; ARM; ORIENTATION; INHIBITION; DORSAL	Movement formulas, engrams, kinesthetic images and internal models of the body in action are notions derived mostly from clinical observations of brain-damaged subjects. They also suggest that the prehensile geometry of an object is integrated in the neural circuits and includes the object's graspable characteristics as well as its semantic properties. In order to determine whether there is a conjoined representation of the graspable characteristics of an object in relation to the actual grasping, it is necessary to separate the graspable (low-level) from the semantic (high-level) properties of the object. Right-handed subjects were asked to grasp and lift a smooth 300-g cylinder with one hand, before and after judging the level of difficulty of a "grasping for pouring'' action, involving a smaller cylinder and using the opposite hand. The results showed that simulated grasps with the right hand exert a direct influence on actual motor acts with the left hand. These observations add to the evidence that there is a conjoined representation of the graspable characteristics of the object and the biomechanical constraints of the arm.	[Frak, Victor; Duval, Christian] Univ Quebec, Dept Kinanthropol, Montreal, PQ H3C 3P8, Canada; [Frak, Victor; Croteau, Isabelle; Bourbonnais, Daniel; Duclos, Cyril] Univ Quebec, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Inst Readaptat Montreal, Montreal, PQ H3C 3P8, Canada; [Cohen, Henri] Clin St Anne, Quebec Memory & Motor Skill Disorders Res Ctr, CNRS Paris Descartes, Psychol & Cognit Neurosci Lab, Quebec City, PQ, Canada	University of Quebec; University of Quebec Montreal; Universite de Montreal; University of Quebec; University of Quebec Montreal	Frak, V (corresponding author), Univ Quebec, Dept Kinanthropol, Montreal, PQ H3C 3P8, Canada.	frak.victor@uqam.ca	Duclos, Cyril/C-4060-2014	Duclos, Cyril/0000-0002-5788-2396; Frak, Victor/0000-0002-3311-777X	PAFARC-Universite du Quebec a Montreal	PAFARC-Universite du Quebec a Montreal	PAFARC-Universite du Quebec a Montreal: publication fee.	AIZAWA H, 1990, EXP BRAIN RES, V82, P219; ANQUETIL T, 2007, BRAIN RES IN PRESS; Bastian H.C., 1887, BRAIN, V10, P1, DOI [10.1093/brain/10.1.1, DOI 10.1093/BRAIN/10.1.1]; Bernstein N.A., 1967, COORDINATION REGULAT; BRINKMAN J, 1973, BRAIN, V96, P653, DOI 10.1093/brain/96.4.653; Carson RG, 2005, BRAIN RES REV, V49, P641, DOI 10.1016/j.brainresrev.2005.03.005; CERNACEK J, 1961, ARCH NEUROL-CHICAGO, V4, P165, DOI 10.1001/archneur.1961.00450080047005; Daprati E, 2006, TRENDS COGN SCI, V10, P265, DOI 10.1016/j.tics.2006.04.005; Daskalakis ZJ, 2002, J PHYSIOL-LONDON, V543, P317, DOI 10.1113/jphysiol.2002.017673; Dettmers C, 1996, J APPL PHYSIOL, V81, P596, DOI 10.1152/jappl.1996.81.2.596; Donchin O, 2002, J NEUROPHYSIOL, V88, P3498, DOI 10.1152/jn.00335.2001; Farne A, 2003, NEUROPSYCHOLOGIA, V41, P739, DOI 10.1016/S0028-3932(02)00177-X; Frak V, 2006, THESCIENTIFICWORLDJO, V6, P1805, DOI 10.1100/tsw.2006.291; Frak V, 2004, NEUROREPORT, V15, P1489, DOI 10.1097/01.wnr.0000132429.68206.48; Frak V, 2001, EXP BRAIN RES, V136, P120, DOI 10.1007/s002210000583; Gallagher S, 2002, J CONSCIOUSNESS STUD, V9, P3; Gentili R, 2006, NEUROSCIENCE, V137, P761, DOI 10.1016/j.neuroscience.2005.10.013; Glover S, 2004, EXP BRAIN RES, V154, P103, DOI 10.1007/s00221-003-1659-2; HESS CW, 1986, NEUROSCI LETT, V71, P235, DOI 10.1016/0304-3940(86)90565-3; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Jeannerod M, 2006, MOTOR COGNITION WHAT, DOI 10.1093/acprof:oso/9780198569657.001.0001/acprof-9780198569657; Johnson SH, 2000, COGNITION, V74, P33, DOI 10.1016/S0010-0277(99)00063-3; Kleist K., 1934, GEHIRNPATHOLOGIE; Liepmann H, 1900, MON PSYCHIATR NEUROL, V8, P15; Morton SM, 2001, EXP BRAIN RES, V141, P438, DOI 10.1007/s002210100889; NAPIER JR, 1956, J BONE JOINT SURG BR, V38, P902, DOI 10.1302/0301-620X.38B4.902; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; Parsons LM, 1998, J NEUROSCI, V18, P6539; Paulignan Y, 1997, EXP BRAIN RES, V114, P226, DOI 10.1007/PL00005631; Rossetti Y, 2002, ATTENTION PERFORM, V19, P62; SAKATA H, 1995, CEREB CORTEX, V5, P429, DOI 10.1093/cercor/5.5.429; Schnitzler A, 1996, EXP BRAIN RES, V112, P381; Tanne-Gariepy J, 2002, EXP BRAIN RES, V145, P91, DOI 10.1007/s00221-002-1078-9	34	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e311	10.1371/journal.pone.0000311	http://dx.doi.org/10.1371/journal.pone.0000311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375197	Green Accepted, gold, Green Published, Green Submitted			2022-12-25	WOS:000207445100013
J	Lafay, B; Burdon, JJ				Lafay, Benedicte; Burdon, Jeremy J.			Molecular Diversity of Legume Root-Nodule Bacteria in Kakadu National Park, Northern Territory, Australia	PLOS ONE			English	Article								Background. Symbiotic relationships between leguminous plants (family Fabaceae) and nodule-forming bacteria in Australia native ecosystems remain poorly characterized despite their importance. Most studies have focused on temperate parts of the country, where the use of molecular approaches have already revealed the presence of Bradyrhizobium, Ensifer (formerly Sinorhizobium), Mesorhizobium and Rhizobium genera of legume root-nodule bacteria. We here provide the first molecular characterization of nodulating bacteria from tropical Australia. Methodology/Principal Findings. 45 nodule-forming bacterial strains, isolated from eight native legume hosts at eight locations in Kakadu National Park, Northern Territory, Australia, were examined for their genetic diversity and phylogenetic position. Using SSU rDNA PCR-RFLPs and phylogenetic analyses, our survey identified nine genospecies, two of which, Bradyrhizobium genospp. B and P, had been previously identified in south-eastern Australia and one, Mesorhizobium genospecies AA, in southern France. Three of the five newly characterized Bradyrhizobium genospecies were more closely related to B. japonicum USDA110, whereas the other two belonged to the B. elkanii group. All five were each more closely related to strains sampled in various tropical areas outside Australia than to strains known to occur in Australia. We also characterized an entirely novel nodule-forming lineage, phylogenetically distant from any previously described rhizobial and non-rhizobial legume-nodulating lineage within the Rhizobiales. Conclusions/Significance. Overall, the present results support the hypothesis of tropical areas being centres of biodiversity and diversification for legume root-nodule bacteria and confirm the widespread occurrence of Bradyrhizobium genosp. B in continental Australia.	[Lafay, Benedicte; Burdon, Jeremy J.] Commonwealth Sci & Ind Res Org Plant Ind, Ctr Plant Biodivers Res, Canberra, ACT, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Lafay, B (corresponding author), Ctr IRD, CNRS, UMR IRD 2724, Montpellier, France.	blafay@mpl.ird.fr	Lafay, Bénédicte/D-8359-2011; Burdon, Jeremy J/B-9913-2009	Lafay, Bénédicte/0000-0001-5783-5269; 				BARNET YM, 1991, PLANT SOIL, V135, P109, DOI 10.1007/BF00014783; BARNET YM, 1985, AUST J BOT, V33, P595, DOI 10.1071/BT9850595; Benhizia Y, 2004, SYST APPL MICROBIOL, V27, P462, DOI 10.1078/0723202041438527; Bowen G. D., 1956, Od. J. agric. Sci., V13, P47; BOWEN G. D., 1959, Queensland Journal of Agricultural Science, V16, P253; BOWEN GD, 1959, QLD J AGR SCI, V16, P267; Chen WM, 2001, INT J SYST EVOL MICR, V51, P1729, DOI 10.1099/00207713-51-5-1729; DAVIDSON BR, 1993, LEGUMES AUSTR EXPERI, P47; Euzeby JP, 1997, INT J SYST BACTERIOL, V47, P590, DOI 10.1099/00207713-47-2-590; Felsenstein J., 2004, PHYLIP PHYLOGENETIC; Jaftha JB, 2002, SYST APPL MICROBIOL, V25, P440, DOI 10.1078/0723-2020-00124; Lafay B, 2006, J APPL MICROBIOL, V100, P1228, DOI 10.1111/j.1365-2672.2006.02902.x; Lafay B, 1998, APPL ENVIRON MICROB, V64, P3989; Lafay B, 2001, APPL ENVIRON MICROB, V67, P396, DOI 10.1128/AEM.67.1.396-402.2001; LAGUERRE G, 1994, APPL ENVIRON MICROB, V60, P56, DOI 10.1128/AEM.60.1.56-63.1994; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P351; LANGE RT, 1961, J GEN MICROBIOL, V61, P351; LANGKAMP PJ, 1982, AUST J BOT, V30, P87, DOI 10.1071/BT9820087; LANGKAMP PJ, 1981, AUST J BOT, V29, P1, DOI 10.1071/BT9810001; LAWRIE AC, 1983, APPL ENVIRON MICROB, V45, P1822, DOI 10.1128/AEM.45.6.1822-1828.1983; Marsudi NDS, 1999, SOIL BIOL BIOCHEM, V31, P1229, DOI 10.1016/S0038-0717(99)00032-2; MCINNES A, 1996, COLLECTION ISOLATION; McKNIGHT T., 1949, QUEENSLAND JOUR AGRIC SCI, V6, P61; MOREIRA FMS, 1993, SYST APPL MICROBIOL, V16, P135, DOI 10.1016/S0723-2020(11)80258-4; Moreira FMS, 1998, MOL ECOL, V7, P889, DOI 10.1046/j.1365-294x.1998.00411.x; Moulin L, 2001, NATURE, V411, P948, DOI 10.1038/35082070; Murray B. R., 2001, Ecological Management & Restoration, V2, P213, DOI 10.1046/j.1442-8903.2001.00086.x; Ngom A, 2004, J GEN APPL MICROBIOL, V50, P17, DOI 10.2323/jgam.50.17; Nick G, 1999, INT J SYST BACTERIOL, V49, P1359, DOI 10.1099/00207713-49-4-1359; NORRIS DO, 1956, EMPIRE J EXPER AGR, V24, P245; POHILL RM, 1981, ADV LEGUME SYSTEMA 1; PRIN Y, 1993, BOIS FOR TROP, V238, P5; REDDELL P, 1992, AUST J BOT, V40, P223, DOI 10.1071/BT9920223; Rivas R, 2002, APPL ENVIRON MICROB, V68, P5217, DOI 10.1128/AEM.68.11.5217-5222.2002; Sawada H, 2003, J GEN APPL MICROBIOL, V49, P155, DOI 10.2323/jgam.49.155; SPRENT JI, 1994, PLANT SOIL, V161, P1, DOI 10.1007/BF02183080; SRITHARAN V, 1991, MOL CELL PROBE, V5, P385, DOI 10.1016/S0890-8508(06)80011-3; Sy A, 2001, J BACTERIOL, V183, P214, DOI 10.1128/JB.183.1.214-220.2001; THOMPSON SC, 1984, AUSTR I AGR SCI OCCA, V12, P27; Thrall PH, 2005, J APPL ECOL, V42, P740, DOI 10.1111/j.1365-2664.2005.01058.x; van Berkum P, 2003, J BACTERIOL, V185, P2988, DOI 10.1128/JB.185.10.2988-2998.2003; van Berkum P, 2002, APPL ENVIRON MICROB, V68, P1132, DOI 10.1128/AEM.68.3.1132-1136.2002; Vandamme P, 2002, SYST APPL MICROBIOL, V25, P507, DOI 10.1078/07232020260517634; Vincent J., 1970, INT BIOL PROGRAMME H, V15; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991	45	23	25	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e277	10.1371/journal.pone.0000277	http://dx.doi.org/10.1371/journal.pone.0000277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17356689	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444700012
J	Davey, RE; Onishi, K; Mahdavi, A; Zandstra, PW				Davey, Ryan E.; Onishi, Kento; Mahdavi, Alborz; Zandstra, Peter W.			LIF-mediated control of embryonic stem cell self-renewal emerges due to an autoregulatory loop	FASEB JOURNAL			English	Article						positive feedback; cell signaling; Jak-STAT; threshold; systems biology	RESPONSIVE ELEMENT-BINDING; EARLY MOUSE EMBRYOGENESIS; ES CELLS; SIGNALING PATHWAYS; STAT3; DIFFERENTIATION; EXPRESSION; PLURIPOTENCY; INDUCTION; PROTEINS	Stem cells convert graded stimuli into all-or-nothing cell-fate responses. We investigated how embryonic stem cells (ESCs) convert leukemia inhibitory factor (LIF) concentration into an all-or-nothing cell-fate decision (self-renewal). Using a combined experimental/computational approach we demonstrate unexpected switch-like (on/off) signaling in response to LIF. This behavior emerges over time due to a positive feedback loop controlling transcriptional expression of LIF signaling pathway components. The autoregulatory loop maintains robust pathway responsiveness ("on") at sufficient concentrations of exogenous LIF, while autocrine signaling and low concentrations of exogenous LIF cause ESCs to adopt the weakly responsive ("off") state of differentiated cells. We demonstrate that loss of ligand responsiveness is reversible and precedes loss of the ESC transcription factors Oct4 and Nanog, suggesting an early step in the hierarchical control of differentiation. While endogenously produced ligands were insufficient to sustain the "on" state, they buffer it, influencing the timing of differentiation. These results demonstrate a novel switch-like behavior, which establishes the LIF threshold for ESC self-renewal.	Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada	University of Toronto; University of Toronto	Zandstra, PW (corresponding author), Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, 160 Coll St,11th Floor, Toronto, ON M5S 3E1, Canada.	peter.zandstra@utoronto.ca						Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bader A, 2000, CIRC RES, V86, P787, DOI 10.1161/01.RES.86.7.787; Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang KH, 2004, BIOTECHNOL BIOENG, V88, P287, DOI 10.1002/bit.20242; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Davey RE, 2006, STEM CELLS, V24, P2538, DOI 10.1634/stemcells.2006-0216; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Gadue P, 2005, EXP HEMATOL, V33, P955, DOI 10.1016/j.exphem.2005.06.009; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; Guo Y, 2006, STEM CELLS, V24, P850, DOI 10.1634/stemcells.2005-0457; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440; HICKARMANE V, 2006, PLOS COMPUT BIOL, V2, pE123; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Ko SY, 2006, CELL STRUCT FUNCT, V31, P53, DOI 10.1247/csf.31.53; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nashta AAF, 2004, J ENDOCRINOL, V181, P477, DOI 10.1677/joe.0.1810477; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; SAITO M, 1992, J IMMUNOL, V148, P4066; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Viswanathan S, 2005, BIOTECHNOL APPL BIOC, V42, P119, DOI 10.1042/BA20040207; Viswanathan S, 2002, STEM CELLS, V20, P119, DOI 10.1634/stemcells.20-2-119; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhan M, 2005, CELL BIOCHEM BIOPHYS, V43, P379, DOI 10.1385/CBB:43:3:379	46	58	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2020	2032		10.1096/fj.06-7852com	http://dx.doi.org/10.1096/fj.06-7852com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356004				2022-12-25	WOS:000247500300012
J	Shimizu, R; Trainor, CD; Nishikawa, K; Kobayashi, M; Ohneda, K; Yamamoto, M				Shimizu, Ritsuko; Trainor, Cecelia D.; Nishikawa, Keizo; Kobayashi, Makoto; Ohneda, Kinuko; Yamamoto, Masayuki			GATA-1 self-association controls erythroid development in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; DNA-BINDING; ZINC-FINGER; HEMATOPOIETIC TRANSCRIPTION; GENE; DIFFERENTIATION; ACETYLATION; DOMAIN; EXPRESSION	GATA-1 is the key transcription factor for the development of the erythroid, megakaryocytic, eosinophilic, and mast cell lineages. GATA-1 possesses the ability to self-associate, and this characteristic has been suggested to be important for GATA-1 function. To elucidate the roles self-associated GATA-1 plays during hematopoietic cell development in vivo, in this study we prepared GATA-1 mutants in which three lysine residues potentially contributing to the self-association (Lys-245, Lys-246, and Lys-312) are substituted in combination with alanines. Of the mutants, 3KA harboring alanine substitutions in all three lysines showed reduced self-association activity without considerable interference in the modification of GATA-1 by acetylation. We generated transgenic mouse lines that express these GATA-1 mutants utilizing the Gata1 hematopoietic regulatory domain, and crossed the mice to Gata1 knockdown (GATA-1.05) mutant mice. Although NKA (K245A and K246A) and CKA (K312A) mutants almost fully rescued the GATA-1.05 mice from anemia and embryonic lethality, the 3KA mutant only partially rescued the GATA-1.05 mutant mice. Even with the higher than endogenous level expression, GATA-1.05/Y::3KA embryos were prone to die at various stages in mid-to-late gestation. Live birth and an anemic phenotype were restored in some embryos depending on the expression level of the 3KA transgene. The expression of the transferrin receptor and heme biosynthesis enzymes was impaired in the yolk sac and liver of the 3KA-rescued embryos. Immature erythroid cells with insufficient expression of the transferrin receptor accumulated in the livers of 3KA-rescued embryos. These results provide the first convincing line of evidence that the self-association of GATA-1 is important for proper mammalian erythroid development in vivo.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Japan Sci & Technol Agcy, Explorat Res Adv Technol Environm Response Projec, Tsukuba, Ibaraki 3058577, Japan; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yamamoto, M (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	masi@tara.tsukuba.ac.jp	Kobayashi, Makoto/B-2537-2008; Shimizu, Ritsuko/A-4877-2010; Ohneda, Kinuko/AAC-8822-2019; Yamamoto, Masayuki/A-4873-2010	Kobayashi, Makoto/0000-0001-6660-450X; Shimizu, Ritsuko/0000-0001-6672-7606; Yamamoto, Masayuki/0000-0002-9073-9436	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011005, ZIADK011005] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Hung HL, 1999, MOL CELL BIOL, V19, P3496; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Ito T, 2000, GENE DEV, V14, P1899; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; Newton A, 2001, J BIOL CHEM, V276, P35794, DOI 10.1074/jbc.M106256200; Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295-8305.2003; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Ohneda K, 2002, GENES CELLS, V7, P1243, DOI 10.1046/j.1365-2443.2002.00595.x; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Shimizu R, 2005, SEMIN CELL DEV BIOL, V16, P129, DOI 10.1016/j.semcdb.2004.11.001; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Shimizu R, 2004, BLOOD, V103, P2560, DOI 10.1182/blood-2003-07-2514; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Suzuki N, 2003, BLOOD, V102, P3575, DOI 10.1182/blood-2003-04-1154; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wassarman P. M., 1993, METHODS ENZYMOLOGY G, V225, P747; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Zhang P, 2000, BLOOD, V96, P2641	47	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15862	15871		10.1074/jbc.M701936200	http://dx.doi.org/10.1074/jbc.M701936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17374603	hybrid			2022-12-25	WOS:000246589600061
J	Graham, ME; Anggono, V; Bache, N; Larsen, MR; Craft, GE; Robinson, PJ				Graham, Mark E.; Anggono, Victor; Bache, Nicolai; Larsen, Martin R.; Craft, George E.; Robinson, Phillip J.			The in vivo phosphorylation sites of rat brain dynamin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; MEDIATED ENDOCYTOSIS; MASS-SPECTROMETRY; SH3 DOMAIN; DEPOLARIZATION; SYNAPTOSOMES; CDK5; MICROCOLUMNS	Dynamin I (dynI) is phosphorylated in synaptosomes at Ser(774) and Ser(778) by cyclin-dependent kinase 5 to regulate recruitment of syndapin I for synaptic vesicle endocytosis, and in PC12 cells on Ser(857). Hierarchical phosphorylation of Ser(774) precedes phosphorylation of Ser(778). In contrast, Thr(780) phosphorylation by cdk5 has been reported as the sole site (Tomizawa, K., Sunada, S., Lu, Y. F., Oda, Y., Kinuta, M., Ohshima, T., Saito, T., Wei, F. Y., Matsushita, M., Li, S. T., Tsutsui, K., Hisanaga, S. I., Mikoshiba, K., Takei, K., and Matsui, H. (2003) J. Cell Biol. 163, 813-824). To resolve the discrepancy and to better understand the biological roles of dynI phosphorylation, we undertook a systematic identification of all phosphorylation sites in rat brain nerve terminal dynI. Using phosphoamino acid analysis, exclusively phospho-serine residues were found. Thr(780) phosphorylation was not detectable. Mutation of Ser(774), Ser(778), and Thr(780) confirmed that Thr(780) phosphorylation is restricted to in vitro conditions. Mass spectrometry of P-32-labeled phosphopeptides separated by two-dimensional mapping revealed seven in vivo phosphorylation sites: Ser(774), Ser(778), Ser(822), Ser(851), Ser(857), Ser(512), and Ser(347). Quantification of P-32 radiation in each phosphopeptide showed that Ser(774) and Ser(778) were the major sites (up to 69% of the total), followed by Ser(851) and Ser(857) (12%), and Ser(853) (2%). Phosphorylation of Ser(851) and Ser(857) was restricted to the long tail splice variant dynIxa and was not hierarchical. Co-purified, P-32- labeled dynIII was phosphorylated at Ser(759), Ser(763), and Ser(853). Ser(853) is homologous to Ser(851) in dynIxa. The results identify all major and several minor phosphorylation sites in dynI and provide the first measure of their relative abundance and relative responses to depolarization. The multiple phospho-sites suggest subtle regulation of synaptic vesicle endocytosis by new protein kinases and new protein-protein interactions. The homologous dynI and dynIII phosphorylation indicates a high mechanistic similarity. The results suggest a unique role for the long splice variants of dynI and dynIII in nerve terminals.	Childrens Med Res Inst, Cell Signaling Unit, Wentworthville, NSW 2145, Australia; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Children's Medical Research Institute - Australia; University of Southern Denmark	Robinson, PJ (corresponding author), Childrens Med Res Inst, Cell Signaling Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	probinson@cmri.com.au	Graham, Mark E/A-6480-2014; Robinson, Phillip J/G-4008-2011; Anggono, Victor/J-2750-2013; Larsen, Martin Rossel/F-1411-2015	Graham, Mark E/0000-0002-7290-1217; Robinson, Phillip J/0000-0002-7878-0313; Anggono, Victor/0000-0002-4062-4884; Larsen, Martin Rossel/0000-0001-6203-0123				Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Anggono V, 2006, NAT NEUROSCI, V9, P752, DOI 10.1038/nn1695; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Gray NW, 2003, CURR BIOL, V13, P510, DOI 10.1016/S0960-9822(03)00136-2; HOSOYA H, 1994, BIOCHEM BIOPH RES CO, V202, P1127, DOI 10.1006/bbrc.1994.2045; Huang Y, 2004, BIOCHEMISTRY-US, V43, P10173, DOI 10.1021/bi036060+; Kapp EA, 2003, ANAL CHEM, V75, P6251, DOI 10.1021/ac034616t; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Larsen MR, 2004, MOL CELL PROTEOMICS, V3, P456, DOI 10.1074/mcp.M300105-MCP200; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MEISENHELDER J, 1999, CURRENT PROTOCOLS PR; Nguyen C, 2003, J CELL BIOL, V163, P697, DOI 10.1083/jcb.200310038; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; Ramachandran R, 2007, EMBO J, V26, P559, DOI 10.1038/sj.emboj.7601491; ROBINSON PJ, 1983, NEUROSCI LETT, V43, P85, DOI 10.1016/0304-3940(83)90133-7; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SAKAMOTO Y, 1988, J CHROMATOGR, V442, P69, DOI 10.1016/S0021-9673(00)94457-1; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; SIHRA TS, 1993, J NEUROCHEM, V61, P1220, DOI 10.1111/j.1471-4159.1993.tb13612.x; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4	29	42	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14695	14707		10.1074/jbc.M609713200	http://dx.doi.org/10.1074/jbc.M609713200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376771	hybrid			2022-12-25	WOS:000246589000005
J	Chan, SJ; Nakagawa, S; Steiner, DF				Chan, Shu Jin; Nakagawa, Satoe; Steiner, Donald F.			Complementation analysis demonstrates that insulin cross-links both alpha subunits in a truncated insulin receptor dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING DOMAIN; EXTRACELLULAR DOMAIN; STRUCTURAL BASIS; LIGAND-BINDING; AFFINITY; EPITOPES; FRAGMENT; KINASE	The insulin receptor is a homodimer composed of two alpha beta half receptors. Scanning mutagenesis studies have identified key residues important for insulin binding in the L1 domain (amino acids 1-150) and C-terminal region (amino acids 704 - 719) of the alpha subunit. However, it has not been shown whether insulin interacts with these two sites within the same alpha chain or whether it cross-links a site from each alpha subunit in the dimer to achieve high affinity binding. Here we have tested the contralateral binding mechanism by analyzing truncated insulin receptor dimers (midi-hIRs) that contain complementary mutations in each alpha subunit. Midi-hIRs containing Ala(14), Ala(64), or Gly(714) mutations were fused with Myc or FLAG epitopes at the C terminus and were expressed separately by transient transfection. Immunoblots showed that R14A + FLAG, F64A + FLAG, and F714G+Myc mutant midi-hIRs were expressed in the medium but insulin binding activity was not detected. However, after co-transfection with R14A+FLAG/ F714G+Myc or F64A + FLAG/ F714G+Myc, hybrid dimers were obtained with a marked increase in insulin binding activity. Competitive displacement assays revealed that the hybrid mutant receptors bound insulin with the same affinity as wild type and also displayed curvilinear Scatchard plots. In addition, when hybrid mutant midi-hIR was covalently cross-linked with I-125(A14)-insulin and reduced, radiolabeled monomer was immunoprecipitated only with anti-FLAG, demonstrating that insulin was bound asymmetrically. These results demonstrate that a single insulin molecule can contact both alpha subunits in the insulin receptor dimer during high affinity binding and this property may be an important feature for receptor signaling.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Dept Med, 5820 E 58th St, Chicago, IL 60637 USA.	dfsteine@uchicago.edu			NIDDK NIH HHS [P60 DK020595, R01 DK013914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Brandt J, 2001, J BIOL CHEM, V276, P12378, DOI 10.1074/jbc.M009402200; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; De Meyts P, 2004, BIOESSAYS, V26, P1351, DOI 10.1002/bies.20151; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106; OSIGO H, 2002, CELL, V110, P775; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SHAFFER L, 1994, EUR J BIOCHEM, V221, P1127; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Whittaker J, 2005, J BIOL CHEM, V280, P20932, DOI 10.1074/jbc.M411320200; Whittaker J, 2002, J BIOL CHEM, V277, P47380, DOI 10.1074/jbc.M208371200	21	30	34	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13754	13758		10.1074/jbc.M700724200	http://dx.doi.org/10.1074/jbc.M700724200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339314	hybrid			2022-12-25	WOS:000246060300065
J	Wang, GY; Strang, C; Pfaffinger, PJ; Covarrubias, M				Wang, Guangyu; Strang, Candace; Pfaffinger, Paul J.; Covarrubias, Manuel			Zn2+-dependent redox switch in the intracellular T1-T1 interface of a Kv channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SULFENIC ACIDS; DEPENDENT K+ CURRENTS; NITRIC-OXIDE; OXIDATIVE MODULATION; ZINC HOMEOSTASIS; CYSTEINE; COMPLEX; KCHIP3; ZN2+	The thiol-based redox regulation of proteins plays a central role in cellular signaling. Here, we investigated the redox regulation at the Zn2+ binding site (HX5CX20CC) in the intracellular T1-T1 inter-subunit interface of a Kv4 channel. This site undergoes conformational changes coupled to voltage-dependent gating, which may be sensitive to oxidative stress. The main results show that internally applied nitric oxide (NO) inhibits channel activity profoundly. This inhibition is reversed by reduced glutathione and suppressed by intracellular Zn2+, and at least two Zn2+ site cysteines are required to observe the NO-induced inhibition (Cys-110 from one subunit and Cys-132 from the neighboring subunit). Biochemical evidence suggests strongly that NO induces a disulfide bridge between Cys-110 and Cys-132 in intact cells. Finally, further mutational studies suggest that intra-subunit Zn2+ coordination involving His-104, Cys-131, and Cys-132 protects against the formation of the inhibitory disulfide bond. We propose that the interfacial T1 Zn2+ site of Kv4 channels acts as a Zn2+-dependent redox switch that may regulate the activity of neuronal and cardiac A-type K+ currents under physiological and pathological conditions.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Jefferson University; Baylor College of Medicine	Wang, GY (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Lucust St,JAH241, Philadelphia, PA 19107 USA.	Guang-yu.Wang@jefferson.edu; Manuel.Covarrubias@jefferson.edu		Wang, Guangyu/0000-0002-5581-6926; Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [T32 AA007463, T32 AA07463] Funding Source: Medline; NINDS NIH HHS [R01 NS032337, R01 NS032337-06, R01 NS032337-12, R01 NS032337-07, R01 NS032337-08, R01 NS032337-09A1, P01 NS037444, R01 NS032337-10, R01 NS032337-11] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS037444, R01NS032337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akar FG, 2004, AM J PHYSIOL-HEART C, V286, pH602, DOI 10.1152/ajpheart.00673.2003; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Capasso M, 2005, J ALZHEIMERS DIS, V8, P93; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Colvin RA, 2003, EUR J PHARMACOL, V479, P171, DOI 10.1016/j.ejphar.2003.08.067; Crane EJ, 1997, BIOCHEMISTRY-US, V36, P8611, DOI 10.1021/bi9707990; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Gow A, 2002, AM J PHYSIOL-LUNG C, V282, pL183, DOI 10.1152/ajplung.00424.2001; Han NLR, 2006, J NEUROPHYSIOL, V95, P2167, DOI 10.1152/jn.01185.2004; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; HEINEMANN SH, 2006, SCI STKE, pE33; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Ilbert M, 2006, ANTIOXID REDOX SIGN, V8, P835, DOI 10.1089/ars.2006.8.835; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; Jahng AW, 2002, J BIOL CHEM, V277, P47885, DOI 10.1074/jbc.M208416200; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jerng HH, 2005, J PHYSIOL-LONDON, V568, P767, DOI 10.1113/jphysiol.2005.087858; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Knipp M, 2003, J BIOL CHEM, V278, P3410, DOI 10.1074/jbc.M209088200; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Maret W, 2006, ANTIOXID REDOX SIGN, V8, P1419, DOI 10.1089/ars.2006.8.1419; Muller W, 2002, J NEUROPHYSIOL, V87, P2990, DOI 10.1152/jn.00790.2001; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nanao MH, 2003, P NATL ACAD SCI USA, V100, P8670, DOI 10.1073/pnas.1432840100; Neculai AM, 2005, J BIOL CHEM, V280, P2826, DOI 10.1074/jbc.C400517200; Noguchi T, 2003, BIOCHEMISTRY-US, V42, P11642, DOI 10.1021/bi035260i; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Pioletti M, 2006, NAT STRUCT MOL BIOL, V13, P987, DOI 10.1038/nsmb1164; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Prasad M, 2004, AM J PHYSIOL-CELL PH, V286, pC671, DOI 10.1152/ajpcell.00137.2003; Rozanski GJ, 2002, J MOL CELL CARDIOL, V34, P1623, DOI 10.1006/jmcc.2002.2112; Rozanski GJ, 2002, AM J PHYSIOL-HEART C, V282, pH2346, DOI 10.1152/ajpheart.00894.2001; Ruschenschmidt C, 2006, EUR J NEUROSCI, V23, P675, DOI 10.1111/j.1460-9568.2006.04608.x; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Takeda A, 2001, BIOMETALS, V14, P343, DOI 10.1023/A:1012982123386; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Wang GY, 2006, J GEN PHYSIOL, V127, P391, DOI 10.1085/jgp.200509442; Wang GY, 2005, J GEN PHYSIOL, V126, P55, DOI 10.1085/jgp.200509288; Wang HY, 2007, NAT NEUROSCI, V10, P32, DOI 10.1038/nn1822; Wilcox DE, 2001, ANTIOXID REDOX SIGN, V3, P549, DOI 10.1089/15230860152542925; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821	53	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13637	13647		10.1074/jbc.M609182200	http://dx.doi.org/10.1074/jbc.M609182200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17331952	Green Accepted, hybrid			2022-12-25	WOS:000246060300053
J	Dehennaut, V; Lefebvre, T; Sellier, C; Leroy, Y; Gross, B; Walker, S; Cacan, R; Michalski, JC; Vilain, JP; Bodart, JF				Dehennaut, Vanessa; Lefebvre, Tony; Sellier, Chantal; Leroy, Yves; Gross, Benjamin; Walker, Suzanne; Cacan, Rene; Michalski, Jean-Claude; Vilain, Jean-Pierre; Bodart, Jean-Francois			O-linked N-acetylglucosaminyltransferase inhibition prevents G(2)/M transition in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC MATURATION; CELL-CYCLE; PROTEIN-KINASE; REDOX REGULATION; RANA PIPIENS; MAP KINASE; GLCNAC; PHOSPHORYLATION; ACTIVATION; MPF	Full-grown Xenopus oocytes are arrested at the prophase of the first meiotic division in a G(2)-like state. Progesterone triggers meiotic resumption also called the G(2)/M transition. This event is characterized by germinal vesicle breakdown ( GVBD) and by a burst in phosphorylation level that reflects activation of M-phase-promoting factor ( MPF) and MAPK pathways. Besides phosphorylation and ubiquitin pathways, increasing evidence has suggested that the cytosolic and nucleus-specific O-GlcNAc glycosylation also contributes to cell cycle regulation. To investigate the relationship between O-GlcNAc and cell cycle, Xenopus oocyte, in which most of the M-phase regulators have been discovered, was used. Alloxan, an O-GlcNAc transferase inhibitor, blocked G(2)/M transition in a concentration-dependent manner. Alloxan prevented GVBD and both MPF and MAPK activations, either triggered by progesterone or by egg cytoplasm injection. The addition of detoxifying enzymes ( SOD and catalase) did not rescue GVBD, indicating that the alloxan effect did not occur through reactive oxygen species production. These results were strengthened by the use of a benzoxazolinone derivative ( XI), a new O-GlcNAc transferase inhibitor. Conversely, injection of O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate, an O-GlcNAcase inhibitor, accelerated the maturation process. Glutamine: fructose-6-phosphate amidotransferase inhibitors, azaserine and 6-diazo-5-ox-onorleucine, failed to prevent GVBD. Such a strategy appeared to be inefficient; indeed, UDP-GlcNAc assays in mature and immature oocytes revealed a constant pool of the nucleotide sugar. Finally, we observed that cyclin B2, the MPF regulatory subunit, was associated with an unknown O-GlcNAc partner. The present work underlines a crucial role for O-GlcNAc in G(2)/M transition and strongly suggests that its function is required for cell cycle regulation.	Univ Sci & Technol Lille, EA 4020, Lab Regulat Signaux Div, SN3,IFR147, F-59655 Villeneuve Dascq, France; CNRS, Unite Glycobiol Struct & Fonct, UMR 8576, IFR147, F-59655 Villeneuve Dascq, France; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Harvard University; Harvard Medical School	Bodart, JF (corresponding author), Univ Sci & Technol Lille, EA 4020, Lab Regulat Signaux Div, SN3,IFR147, F-59655 Villeneuve Dascq, France.	jean-francois.bodart@univ-lille1.fr	Bodart, Jean-François Laurent/AAZ-2075-2021; Lefebvre, Tony/AAW-9169-2021; dehennaut, vanessa/I-7435-2018; Lefebvre, Tony/AAZ-1724-2021	Bodart, Jean-François Laurent/0000-0002-6113-7700; dehennaut, vanessa/0000-0001-6421-0793; Lefebvre, Tony/0000-0001-9883-2240				Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Baert F, 2003, J BIOL CHEM, V278, P49714, DOI 10.1074/jbc.M308067200; Bodart JFL, 2005, DEV BIOL, V283, P373, DOI 10.1016/j.ydbio.2005.04.031; Bodart JFL, 2002, DEV BIOL, V245, P348, DOI 10.1006/dbio.2002.0647; Cakir Y, 2005, ANTIOXID REDOX SIGN, V7, P726, DOI 10.1089/ars.2005.7.726; Champattanachai V, 2007, AM J PHYSIOL-CELL PH, V292, pC178, DOI 10.1152/ajpcell.00162.2006; Chesnel F, 1997, DEV BIOL, V188, P122, DOI 10.1006/dbio.1997.8631; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; DWORKIN MB, 1992, MOL REPROD DEV, V32, P354, DOI 10.1002/mrd.1080320408; DWORKIN MB, 1989, DEV BIOL, V132, P512, DOI 10.1016/0012-1606(89)90246-7; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Fisher DL, 1999, DEVELOPMENT, V126, P4537; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Iyer SPN, 2003, BIOCHEMISTRY-US, V42, P2493, DOI 10.1021/bi020685a; Kim YH, 2006, J CELL PHYSIOL, V207, P689, DOI 10.1002/jcp.20609; Konrad RJ, 2002, BIOCHEM BIOPH RES CO, V293, P207, DOI 10.1016/S0006-291X(02)00200-0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lefebvre T, 2004, J CELL BIOCHEM, V93, P999, DOI 10.1002/jcb.20242; Liu J, 2006, J MOL CELL CARDIOL, V40, P303, DOI 10.1016/j.yjmcc.2005.11.003; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; Masui Y, 2001, DIFFERENTIATION, V69, P1, DOI 10.1046/j.1432-0436.2001.690101.x; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; Rudolph J, 2005, ANTIOXID REDOX SIGN, V7, P761, DOI 10.1089/ars.2005.7.761; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schmitt A, 2002, J CELL SCI, V115, P2457; Slawson C, 2006, J CELL BIOCHEM, V97, P71, DOI 10.1002/jcb.20676; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Slawson C, 2002, BBA-GEN SUBJECTS, V1573, P121, DOI 10.1016/S0304-4165(02)00369-0; SMITH LD, 1968, DEV BIOL, V17, P627, DOI 10.1016/0012-1606(68)90010-9; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Szkudelski T, 2001, PHYSIOL RES, V50, P537; Walsh S, 2003, MOL CANCER RES, V1, P280; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wu G, 2006, BIOCHEMISTRY-US, V45, P5319, DOI 10.1021/bi0601149; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	47	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12527	12536		10.1074/jbc.M700444200	http://dx.doi.org/10.1074/jbc.M700444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329255	hybrid			2022-12-25	WOS:000245942800021
J	Li, J; Machius, M; Chuang, JL; Wynn, RM; Chuang, DT				Li, Jun; Machius, Mischa; Chuang, Jacinta L.; Wynn, R. Max; Chuang, David T.			The two active sites in human branched-chain alpha-keto acid dehydrogenase operate independently without an obligatory alternating-site mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PYRUVATE DECARBOXYLASE; THIAMIN DIPHOSPHATE BINDING; PHOSPHORYLATION SITES; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; TRANSKETOLASE; RECONSTITUTION; REACTIVITY; SUBUNIT; ENZYMES	A long standing controversy is whether an alternating active-site mechanism occurs during catalysis in thiamine diphosphate ( ThDP)-dependent enzymes. We address this question by investigating the ThDP-dependent decarboxylase/dehydrogenase ( E1b) component of the mitochondrial branched-chain alpha-keto acid dehydrogenase complex ( BCKDC). Our crystal structure reveals that conformations of the two active sites in the human E1b heterotetramer harboring the reaction intermediate are identical. Acidic residues in the core of the E1b heterotetramer, which align with the proton-wire residues proposed to participate in active-site communication in the related pyruvate dehydrogenase from Bacillus stearothermophilus, are mutated. Enzyme kinetic data show that, except in a few cases because of protein misfolding, these alterations are largely without effect on overall activity of BCKDC, ruling out the requirement of a proton-relay mechanism in E1b. BCKDC overall activity is nullified at 50% phosphorylation of E1b, but it is restored to nearly half of the pre-phosphorylation level after dissociation and reconstitution of BCKDC with the same phosphorylated E1b. The results suggest that the abolition of overall activity likely results from the specific geometry of the half-phosphorylated E1b in the BCKDC assembly and not due to a disruption of the alternating active-site mechanism. Finally, we show that a mutant E1b containing only one functional active site exhibits half of the wild-type BCKDC activity, which directly argues against the obligatory communication between active sites. The above results provide evidence that the two active sites in the E1b heterotetramer operate independently during the ThDP-dependent decarboxylation reaction.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK26758, DK62306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062306, R01DK026758, R56DK062306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chang CF, 2006, J BIOL CHEM, V281, P28345, DOI 10.1074/jbc.M605005200; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; EGAN RM, 1981, J BIOL CHEM, V256, P4877; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Jordan F, 2005, ACCOUNTS CHEM RES, V38, P755, DOI 10.1021/ar040244e; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KOCHETOV GA, 1976, BIOCHEM BIOPH RES CO, V69, P839, DOI 10.1016/0006-291X(76)90450-2; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; Kovina MV, 1998, FEBS LETT, V440, P81, DOI 10.1016/S0014-5793(98)01423-9; Kovina MV, 1997, FEBS LETT, V418, P11, DOI 10.1016/S0014-5793(97)01331-8; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; Machius M, 2006, STRUCTURE, V14, P287, DOI 10.1016/j.str.2005.10.009; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Meshalkina L, 1997, EUR J BIOCHEM, V244, P646, DOI 10.1111/j.1432-1033.1997.t01-1-00646.x; Milne JLS, 2002, EMBO J, V21, P5587, DOI 10.1093/emboj/cdf574; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Seifert F, 2006, BIOCHEMISTRY-US, V45, P12775, DOI 10.1021/bi061582l; Sergienko EA, 2000, BIOCHEMISTRY-US, V39, P13862, DOI 10.1021/bi001214w; Sergienko EA, 2002, BIOCHEMISTRY-US, V41, P6164, DOI 10.1021/bi0121712; Song JL, 2001, J BIOL CHEM, V276, P40241, DOI 10.1074/jbc.M107242200; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Wynn RM, 2003, J BIOL CHEM, V278, P43402, DOI 10.1074/jbc.M306204200; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; ZHAO Y, 1994, J BIOL CHEM, V269, P18583; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	41	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11904	11913		10.1074/jbc.M610843200	http://dx.doi.org/10.1074/jbc.M610843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329260	hybrid			2022-12-25	WOS:000245941900033
J	Nicholson, KE; Harmon, LJ; Losos, JB				Nicholson, Kirsten E.; Harmon, Luke J.; Losos, Jonathan B.			Evolution of Anolis Lizard Dewlap Diversity	PLOS ONE			English	Article							VISUAL SIGNAL-DESIGN; MALE MATING SUCCESS; SPECIES-RECOGNITION; MORPHOLOGY; PATTERNS; DISPLAY; SIZE; CONSTRAINTS; ADAPTATION; DIMORPHISM	Background. The dewlaps of Anolis lizards provide a classic example of a complex signaling system whose function and evolution is poorly understood. Dewlaps are flaps of skin beneath the chin that are extended and combined with head and body movements for visual signals and displays. They exhibit extensive morphological variation and are one of two cladistic features uniting anoles, yet little is known regarding their function and evolution. We quantified the diversity of anole dewlaps, investigated whether dewlap morphology was informative regarding phylogenetic relationships, and tested two separate hypotheses: (A) similar Anolis habitat specialists possess similar dewlap configurations (Ecomorph Convergence hypothesis), and (B) sympatric species differ in their dewlap morphologies to a greater extent than expected by chance (Species Recognition hypothesis). Methodology/Principal Findings. We found that dewlap configurations (sizes, patterns and colors) exhibit substantial diversity, but that most are easily categorized into six patterns that incorporate one to three of 13 recognizable colors. Dewlap morphology is not phylogenetically informative and, like other features of anoles, exhibits convergence in configurations. We found no support for the Ecomorph Convergence hypothesis; species using the same structural habitat were no more similar in dewlap configuration than expected by chance. With one exception, all sympatric species in four communities differ in dewlap configuration. However, this provides only weak support for the Species Recognition hypothesis because, due to the great diversity in dewlap configurations observed across each island, few cases of sympatric species with identical dewlaps would be expected to co-occur by chance alone. Conclusions/Significance. Despite previous thought, most dewlaps exhibit easily characterizable patterns and colorations. Nevertheless, dewlap variation is extensive and explanations for the origin and evolution of this diversity are lacking. Our data do not support two hypothesized explanations for this diversity, but others such as sexual selection remain to be tested.	[Nicholson, Kirsten E.] Cent Michigan Univ, Dept Biol, Mt Pleasant, MI 48859 USA; [Harmon, Luke J.] Univ British Columbia, Biodivers Ctr, Vancouver, BC V5Z 1M9, Canada; [Losos, Jonathan B.] Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; [Losos, Jonathan B.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Central Michigan University; University of British Columbia; Harvard University; Harvard University	Nicholson, KE (corresponding author), Cent Michigan Univ, Dept Biol, Mt Pleasant, MI 48859 USA.	kirsten.nicholson@cmich.edu	Harmon, Luke/A-8225-2012	Harmon, Luke/0000-0002-4985-5750	NSF [DEB-9982736]	NSF(National Science Foundation (NSF))	This project was supported by NSF grant DEB-9982736.	Ashton R. E., 1991, HDB REPTILES AMPHI 2; BELS VL, 1990, J MORPHOL, V206, P225, DOI 10.1002/jmor.1052060209; Beuttell K, 1999, HERPETOL MONOGR, V13, P1, DOI 10.2307/1467059; Bohning-Gaese K, 2003, J EVOLUTION BIOL, V16, P956, DOI 10.1046/j.1420-9101.2003.00605.x; Butler MA, 2000, EVOLUTION, V54, P259, DOI 10.1111/j.0014-3820.2000.tb00026.x; Butler MA, 2002, ECOL MONOGR, V72, P541, DOI 10.1890/0012-9615(2002)072[0541:MSDSSA]2.0.CO;2; CASGRAIN P, 2001, PERMUTEL VERS 3 4 AL; COOPER WE, 1992, BIOL REPTILIA HORMON, P578; DAWKINS MS, 1993, PHILOS T ROY SOC B, V340, P251, DOI 10.1098/rstb.1993.0065; ECHELLE A A, 1971, Herpetologica, V27, P271; ENDLER JA, 1993, PHILOS T R SOC B, V340, P215, DOI 10.1098/rstb.1993.0060; ERHARDT HC, 2002, ACOUSTIC COMMUNICATI; Espmark Y., 2000, ANIMAL SIGNALS SIGNA; FITCH H S, 1987, Amphibia-Reptilia, V8, P69, DOI 10.1163/156853887X00063; FITCH HS, 1984, COPEIA, P315, DOI 10.2307/1445187; Fleishman Leo J., 2000, P209; FLEISHMAN LJ, 1993, NATURE, V365, P397, DOI 10.1038/365397a0; FLEISHMAN LJ, 1992, AM NAT, V139, pS36, DOI 10.1086/285304; Fleishman LK, 2001, J EXP BIOL, V204, P1559; FONT E, 1990, J MORPHOL, V206, P245, DOI 10.1002/jmor.1052060210; Greenfield MD, 2002, SIGNALERS RECEIVERS; Harmon LJ, 2005, EVOLUTION, V59, P409; Jackman TR, 1999, SYST BIOL, V48, P254, DOI 10.1080/106351599260283; JENSSEN TA, 1977, AM ZOOL, V17, P203; Kolbe JJ, 2004, NATURE, V431, P177, DOI 10.1038/nature02807; Leal M, 2004, AM NAT, V163, P26, DOI 10.1086/379794; Leal M, 2002, P ROY SOC B-BIOL SCI, V269, P351, DOI 10.1098/rspb.2001.1904; Leal M, 1997, BIOTROPICA, V29, P372, DOI 10.1111/j.1744-7429.1997.tb00440.x; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; Losos JB, 1998, COPEIA, P430, DOI 10.2307/1447437; LOSOS JB, 1985, COPEIA, P905, DOI 10.2307/1445240; LOSOS JB, 2004, ADAPTIVE SPECIATION, P335; MACEDONIA JM, 1994, ETHOLOGY, V98, P246; MACEDONIA JM, 1994, ANIM BEHAV, V47, P1220, DOI 10.1006/anbe.1994.1163; Martins EP, 2004, ANIM BEHAV, V68, P453, DOI 10.1016/j.anbehav.2003.08.026; MOERMOND TC, 1979, ECOLOGY, V60, P152, DOI 10.2307/1936477; Nicholson JC, 2002, BRIT J NEUROSURG, V16, P93, DOI 10.1080/02688690220131688; Nicholson KE, 2005, J BIOGEOGR, V32, P929, DOI 10.1111/j.1365-2699.2004.01222.x; Ord TJ, 2002, BIOL J LINN SOC, V76, P145, DOI 10.1046/j.1095-8312.2002.00058.x; Ord TJ, 2002, BIOL J LINN SOC, V77, P127, DOI 10.1046/j.1095-8312.2002.00100.x; Persons MH, 1999, J COMP PHYSIOL A, V184, P585, DOI 10.1007/s003590050358; Poe S, 2004, HERPETOL MONOGR, V18, P37, DOI 10.1655/0733-1347(2004)018[0037:POA]2.0.CO;2; RAMBAUT A, 2001, TREEEDIT V 1 08; RAND A S, 1970, American Naturalist, V104, P99, DOI 10.1086/282643; Rivero J.A., 1978, AMPHIBIANS REPTILES; Rodrigues Miguel Trefaut, 2002, Pap. Avulsos Zool. (São Paulo), V42, P363, DOI 10.1590/S0031-10492002001600001; Rodriguez-Schettino L., 1999, IGUANID LIZARDS CUBA; Sanderson MJ, 2003, BIOINFORMATICS, V19, P301, DOI 10.1093/bioinformatics/19.2.301; SCHWARTZ A., 1991, AMPHIBIANS REPTILES; SMITHE F.B., 1981, NATURALISTS COLOR GU; SMOUSE PE, 1986, SYST ZOOL, V35, P627, DOI 10.2307/2413122; Tokarz RR, 2005, J HERPETOL, V39, P174, DOI 10.1670/0022-1511(2005)039[0174:IODDIM]2.0.CO;2; Tokarz RR, 2003, COPEIA, P502, DOI 10.1643/00-170; Tokarz RR, 2002, HERPETOLOGICA, V58, P87, DOI 10.1655/0018-0831(2002)058[0087:AETOTI]2.0.CO;2; Williams E.E., 1983, LIZARD ECOLOGY STUDI, P326, DOI DOI 10.4159/HARVARD.9780674183384.C18; WILLIAMS EE, 1977, AM ZOOL, V17, P261; Williams EE., 1972, EVOL BIOL, V6, P47, DOI [DOI 10.1007/978-1-4684-9063-3_3, 10. 1007/978-1-4684-9063-3]; [No title captured]	58	101	111	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e274	10.1371/journal.pone.0000274	http://dx.doi.org/10.1371/journal.pone.0000274			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342208	Green Published, gold			2022-12-25	WOS:000207444700009
J	Howe, PDL; Livingstone, MS				Howe, Piers D. L.; Livingstone, Margaret S.			The Use of the Cancellation Technique to Quantify the Hermann Grid Illusion	PLOS ONE			English	Article								When observers view a grid of mid-gray lines superimposed on a black background, they report seeing illusory dark gray smudges at the grid intersections, an effect known as the Hermann grid illusion. The strength of the illusion is often measured using the cancellation technique: A white disk is placed over one of these intersections and the luminance of the disk is reduced until the disk disappears. Its luminance at this point, i.e., the disk's detection threshold, is taken to be a measure of the strength of the illusion. Our experiments showed that some distortions of the Hermann grid, which were sufficient to completely disrupt the illusion, did not reduce the disk's detection threshold. This showed that the cancellation technique is not a valid method for measuring the strength of the Hermann grid illusion. Those studies that attempted to use this technique inadvertently studied a different effect known as the blanking phenomenon. We conclude by presenting an explanation for the latter effect.	[Howe, Piers D. L.; Livingstone, Margaret S.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Howe, PDL (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	phowe@hms.harvard.edu		Livingstone, Margaret/0000-0002-1950-0123; Howe, Piers/0000-0001-6171-1381	Helen Hay Whitney Foundation; NIH [EY 13135]; ARO [46961]; NATIONAL EYE INSTITUTE [R01EY013135] Funding Source: NIH RePORTER	Helen Hay Whitney Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARO; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by a Helen Hay Whitney Foundation grant to P. H., and an NIH grant EY 13135 and an ARO grant 46961 to M. L. None of these sponsors played any role in the any part of the experiment or the manuscript preparation.	de Lafuente V, 2004, EXP BRAIN RES, V154, P255, DOI 10.1007/s00221-003-1700-5; Dresp B, 1999, SPATIAL VISION, V12, P129, DOI 10.1163/156856899X00085; Garcia-Perez MA, 1998, VISION RES, V38, P1861, DOI 10.1016/S0042-6989(97)00340-4; Hermann L., 1870, ARCHIV FR GESAMTE PH, V3, P13, DOI DOI 10.1007/BF01855743; McAnany JJ, 2005, VISION RES, V45, P193, DOI 10.1016/j.visres.2004.08.003; McAnany JJ, 2004, VISION RES, V44, P993, DOI 10.1016/j.visres.2003.11.010; Schrauf M, 1997, VISION RES, V37, P1033, DOI 10.1016/S0042-6989(96)00255-6; Solomon JA, 2000, VISION RES, V40, P279, DOI 10.1016/S0275-5408(99)00059-9; TROSCIANKO T, 1982, VISION RES, V22, P485, DOI 10.1016/0042-6989(82)90197-3; TROSCIANKO T, 1982, VISION RES, V22, P1363, DOI 10.1016/0042-6989(82)90226-7	10	4	4	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e265	10.1371/journal.pone.0000265	http://dx.doi.org/10.1371/journal.pone.0000265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327924	Green Published, gold			2022-12-25	WOS:000207444600025
J	Sengupta, K; Upender, MB; Barenboim-Stapleton, L; Nguyen, QT; Wincovitch, SM; Garfield, SH; Difilippantonio, MJ; Ried, T				Sengupta, Kundan; Upender, Madhvi B.; Barenboim-Stapleton, Linda; Nguyen, Quang Tri; Wincovitch, Stephen M., Sr.; Garfield, Susan H.; Difilippantonio, Michael J.; Ried, Thomas			Artificially Introduced Aneuploid Chromosomes Assume a Conserved Position in Colon Cancer Cells	PLOS ONE			English	Article								Background. Chromosomal aneuploidy is a defining feature of carcinomas. For instance, in colon cancer, an additional copy of Chromosome 7 is not only observed in early pre-malignant polyps, but is faithfully maintained throughout progression to metastasis. These copy number changes show a positive correlation with average transcript levels of resident genes. An independent line of research has also established that specific chromosomes occupy a well conserved 3D position within the interphase nucleus. Methodology/Principal Findings. We investigated whether cancer-specific aneuploid chromosomes assume a 3D-position similar to that of its endogenous homologues, which would suggest a possible correlation with transcriptional activity. Using 3D-FISH and confocal laser scanning microscopy, we show that Chromosomes 7, 18, or 19 introduced via microcell-mediated chromosome transfer into the parental diploid colon cancer cell line DLD-1 maintain their conserved position in the interphase nucleus. Conclusions. Our data is therefore consistent with the model that each chromosome has an associated zip code (possibly gene density) that determines its nuclear localization. Whether the nuclear localization determines or is determined by the transcriptional activity of resident genes has yet to be ascertained.	[Sengupta, Kundan; Upender, Madhvi B.; Barenboim-Stapleton, Linda; Nguyen, Quang Tri; Difilippantonio, Michael J.; Ried, Thomas] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Wincovitch, Stephen M., Sr.; Garfield, Susan H.] NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ried, T (corresponding author), NCI, Genet Branch, NIH, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	Difilippantonio, Michael/AAF-2839-2021	Difilippantonio, Michael/0000-0002-4676-7034	NIH; National Cancer Institute; NATIONAL CANCER INSTITUTE [Z01BC010835] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200348] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This research was supported by the intramural research program of the NIH, National Cancer Institute.	Bolzer A, 2005, PLOS BIOL, V3, P826, DOI 10.1371/journal.pbio.0030157; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Cook PR, 2002, NAT GENET, V32, P347, DOI 10.1038/ng1102-347; Cremer M, 2003, J CELL BIOL, V162, P809, DOI 10.1083/jcb.200304096; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Goldberg M, 1999, P NATL ACAD SCI USA, V96, P2852, DOI 10.1073/pnas.96.6.2852; GRADE M, 2006, CANC RES IN PRESS; Grade M, 2006, CELL ONCOL, V28, P71; Habermann JK, 2007, GENE CHROMOSOME CANC, V46, P10, DOI 10.1002/gcc.20382; Hyman E, 2002, CANCER RES, V62, P6240; Macville M, 1997, HISTOCHEM CELL BIOL, V108, P299, DOI 10.1007/s004180050169; Mayer R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-44; Parada LA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r44; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schrock E, 1996, GENE CHROMOSOME CANC, V15, P199, DOI 10.1002/(SICI)1098-2264(199604)15:4<199::AID-GCC1>3.0.CO;2-X; Tanabe H, 2002, P NATL ACAD SCI USA, V99, P4424, DOI 10.1073/pnas.072618599; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Upender MB, 2004, CANCER RES, V64, P6941, DOI 10.1158/0008-5472.CAN-04-0474; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Williams RRE, 2002, EXP CELL RES, V272, P163, DOI 10.1006/excr.2001.5400; Zinner R, 2006, HISTOCHEM CELL BIOL, V125, P3, DOI 10.1007/s00418-005-0049-1	25	21	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e199	10.1371/journal.pone.0000199	http://dx.doi.org/10.1371/journal.pone.0000199			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17332847	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444300011
J	Woo, Y; Wright, SM; Maas, SA; Alley, TL; Caddle, LB; Kamdar, S; Affourtit, J; Foreman, O; Akeson, EC; Shaffer, D; Bronson, RT; Morse, HC; Roopenian, D; Mills, KD				Woo, Y.; Wright, S. M.; Maas, S. A.; Alley, T. L.; Caddle, L. B.; Kamdar, S.; Affourtit, J.; Foreman, O.; Akeson, E. C.; Shaffer, D.; Bronson, R. T.; Morse, H. C., III; Roopenian, D.; Mills, K. D.			The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity	ONCOGENE			English	Article						nonhomologous end joining; RS-SCID; Artemis; loss of heterozygosity; p53	QUANTITATIVE GENE-EXPRESSION; DNA BREAKS; P53; IMMUNODEFICIENCY; TRANSLOCATIONS; REPAIR; AMPLIFICATION; INSTABILITY; LYMPHOCYTE; DEFICIENT	Nonhomologous end joining ( NHEJ) is a critical DNA repair pathway, with proposed tumor suppression functions in many tissues. Mutations in the NHEJ factor ARTEMIS cause radiation- sensitive severe combined immunodeficiency in humans and may increase susceptibility to lymphoma in some settings. We now report that deficiency for Artemis (encoded by Dclre1c/Art in mouse) accelerates tumorigenesis in several tissues in a Trp53 heterozygous setting, revealing tumor suppression roles for NHEJ in lymphoid and non- lymphoid cells. We also show that B- lineage lymphomas in these mice undergo loss of Trp53 heterozygosity by allele replacement, but arise by mechanisms distinct from those in Art Trp53 double null mice. These findings demonstrate a general tumor suppression function for NHEJ, and reveal that interplay between NHEJ and Trp53 loss of heterozygosity influences the sequence of multi-hit oncogenesis. We present a model where p53 status at the time of tumor initiation is a key determinant of subsequent oncogenic mechanisms. Because Art deficient mice represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest that these patients maybe at risk for both lymphoid and non- lymphoid cancers.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Maine, Functional Genom PhD Program, Orono, ME USA; Bar Harbor Biotechnol, Trenton, NJ USA; Tufts Univ, Sch Vet Med, Cummings Sch, Dept Biomed Sci, North Grafton, MA 01536 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; NIAID, Immunopathol Lab, Rockville, MD USA	Jackson Laboratory; University of Maine System; University of Maine Orono; Tufts University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mills, KD (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	kevin.mills@jax.org		Morse, Herbert/0000-0002-9331-3705	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007065] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA115665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA115665] Funding Source: Medline; NICHD NIH HHS [T32 HD07065-27, T32 HD007065] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akeson EC, 2006, GENOMICS, V87, P311, DOI 10.1016/j.ygeno.2005.09.022; Akeson EC, 2001, CYTOGENET CELL GENET, V93, P270, DOI 10.1159/000056997; Akilesh S, 2003, GENOME RES, V13, P1719, DOI 10.1101/gr.533003; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Churchill GA, 2004, BIOTECHNIQUES, V37, P173, DOI 10.2144/04372TE01; de Villartay JP, 2003, CURR OPIN IMMUNOL, V15, P592, DOI 10.1016/S0952-7915(03)00101-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Eilers PHC, 2005, BIOINFORMATICS, V21, P1146, DOI 10.1093/bioinformatics/bti148; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Hart GT, 2004, INFECT IMMUN, V72, P4471, DOI 10.1128/IAI.72.8.4471-4479.2004; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Kerr M K, 2001, Biostatistics, V2, P183, DOI 10.1093/biostatistics/2.2.183; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Olivier M, 2003, CANCER RES, V63, P6643; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; WU H, 2003, ANAL GENE EXPRESSION; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	37	18	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6010	6020		10.1038/sj.onc.1210430	http://dx.doi.org/10.1038/sj.onc.1210430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384673				2022-12-25	WOS:000249277200004
J	Pollice, A; Sepe, M; Villella, V; Tolino, F; Vivo, M; Calabro, V; La Mantia, G				Pollice, A.; Sepe, M.; Villella, V. R.; Tolino, F.; Vivo, M.; Calabro, V.; La Mantia, G.			TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation	ONCOGENE			English	Article						p14ARF; TBP-1; proteasome; N-terminal ubiquitination	ARF TUMOR-SUPPRESSOR; TAT-BINDING PROTEIN-1; 26S PROTEASOME; PROTEOLYSIS; NUCLEOLAR; INK4A/ARF; NUCLEOPHOSMIN; STABILITY; P14(ARF); SUBUNIT	The p14ARF tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer. The mechanisms that regulate alternative reading frame (ARF) turnover have been obscure for longtime, being ARF a relatively stable protein. Recently, it has been described that its degradation depends, at least in part, on the proteasome and that it can be subjected to N- terminal ubiquitination. We have previously reported that ARF protein levels are regulated by TBP- 1 (Tat- Binding Protein 1), a multifunctional protein, component of the regulatory subunit of the proteasome, involved in different cellular processes. Here we demonstrate that the stabilization effect exerted by TBP- 1 requires an intact N- terminal 39 amino acids in ARF and occurs independently from N- terminal ubiquitination of the protein. Furthermore, we observed that ARF can be degraded in vitro by the 20S proteasome, in the absence of ubiquitination and this effect can be counteracted by TBP- 1. These observations seem relevant in the comprehension of the regulation of ARF metabolism as, among the plethora of cellular ARF's interactors already identifi. ed, only NPM/B23 and TBP- 1 appear to be involved in the control of ARF intracellular levels.	Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy.	lamantia@unina.it	Vivo, Maria/S-3390-2017; Calabro, Viola/H-6156-2013	Vivo, Maria/0000-0003-2458-4226; Calabro, Viola/0000-0002-6508-8889	Telethon [GGP030326] Funding Source: Medline	Telethon(Fondazione Telethon)		Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000	27	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5154	5162		10.1038/sj.onc.1210313	http://dx.doi.org/10.1038/sj.onc.1210313			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334400				2022-12-25	WOS:000248487400014
J	Ostler, K; Davis, E; Payne, S; Gosalia, B; Exposito-Cespedes, J; Le Beau, MM; Godley, LA				Ostler, K. R.; Davis, E. M.; Payne, S. L.; Gosalia, B. B.; Exposito-Cespedes, J.; Le Beau, M. M.; Godley, L. A.			Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins	ONCOGENE			English	Article						DNA methylation; DNMT3B; aberrant mRNA splicing; epigenetics	DNA METHYLTRANSFERASES DNMT3A; CHROMOSOMAL INSTABILITY; PROMOTER METHYLATION; CPG METHYLATION; MESSENGER-RNA; GENE; CHROMATIN; HYPOMETHYLATION; 3B; HYPERMETHYLATION	Cancer cells display an altered distribution of DNA methylation relative to normal cells. Certain tumor suppressor gene promoters are hypermethylated and transcriptionally inactivated, whereas repetitive DNA is hypomethylated and transcriptionally active. Little is understood about how the abnormal DNA methylation patterns of cancer cells are established and maintained. Here, we identify over 20 DNMT3B transcripts from many cancer cell lines and primary acute leukemia cells that contain aberrant splicing at the 50 end of the gene, encoding truncated proteins lacking the C-terminal catalytic domain. Many of these aberrant transcripts retain intron sequences. Although the aberrant transcripts represent a minority of the DNMT3B transcripts present, Western blot analysis demonstrates truncated DNMT3B isoforms in the nuclear protein extracts of cancer cells. To test if expression of a truncated DNMT3B protein could alter the DNA methylation patterns within cells, we expressed DNMT3B7, the most frequently expressed aberrant transcript, in 293 cells. DNMT3B7-expressing 293 cells have altered gene expression as identified by microarray analysis. Some of these changes in gene expression correlate with altered DNA methylation of corresponding CpG islands. These results suggest that truncated DNMT3B proteins could play a role in the abnormal distribution of DNA methylation found in cancer cells.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ostler, K (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	lgodley@medicine.bsd.uchicago.edu		Raimondi, Stacey/0000-0001-7667-6814	NCI NIH HHS [P01 CA040046, CA 40046, R01 CA129831-01A1, R01 CA129831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040046, R01CA129831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chan AOO, 2006, WORLD J GASTROENTERO, V12, P199, DOI 10.3748/wjg.v12.i2.199; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Parolini O, 2003, IMMUNOGENETICS, V55, P116, DOI 10.1007/s00251-003-0557-x; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Ueda Y, 2006, DEVELOPMENT, V133, P1183, DOI 10.1242/dev.02293; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031; Wang L, 2006, INT J ONCOL, V29, P201; Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	52	108	114	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5553	5563		10.1038/sj.onc.1210351	http://dx.doi.org/10.1038/sj.onc.1210351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353906	Green Accepted			2022-12-25	WOS:000248801900001
J	Ramer, R; Eichele, K; Hinz, B				Ramer, R.; Eichele, K.; Hinz, B.			Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells	ONCOGENE			English	Article						cisplatin; matrigel cell invasion; tissue inhibitor of matrix metalloproteinases-1; matrix metalloproteinase-2; human cervical cancer cells; human lung; carcinoma cells	PROMOTES INVASION; INDUCED APOPTOSIS; EPITHELIAL-CELLS; TUMOR INVASION; KAPPA-B; P38; ACTIVATION; EXPRESSION; STRESS; TIMP-1	Cancer cell invasion is one of the crucial events in local spreading, growth and metastasis of tumors. The present study investigates the mechanism underlying the antiinvasive action of the chemotherapeutic cisplatin. In human cervical carcinoma cells (HeLa), cisplatin caused a time- and concentration-dependent suppression of cell invasion through Matrigel. Inhibition of invasion was accompanied by upregulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), whereas levels of matrix metalloproteinase-2 (MMP-2), MMP-9 and TIMP-2 remained unchanged. Cisplatin's effects on TIMP-I expression and invasion were associated with phosphorylations of p38 and p42/44 mitogen-activated protein kinases and were abrogated by specific inhibitors of both pathways. The impact of TIMP-I in the anti-invasive action of cisplatin was proven by transfecting cells with small interfering RNA targeting TIMP-1, which completely reversed suppression of invasion by cisplatin. A functional relevance of TIMP-1 upregulation was substantiated by findings showing a concentration-dependent inhibition of Matrigel invasion by recombinant TIMP-1. The essential role of TIMP-1 in the anti-invasive action of cisplatin was confirmed using another human cervical carcinoma cell line (C33A) and human lung carcinoma cells (A549). Altogether, our data demonstrate a hitherto unknown mechanism by which cisplatin exerts its antimetastatic properties on highly invasive cancer cells.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-eriangen.de						Biroccio A, 2004, NEOPLASIA, V6, P195, DOI 10.1593/neo.03370; Chan VYW, 2005, REGUL PEPTIDES, V127, P87, DOI 10.1016/j.regpep.2004.10.016; Chintala SK, 1997, CLIN EXP METASTAS, V15, P361, DOI 10.1023/A:1018442003163; Choi J, 2005, CANCER RES, V65, P5554, DOI 10.1158/0008-5472.CAN-04-4570; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Han R, 2005, J IMMUNOL, V174, P3072, DOI 10.4049/jimmunol.174.5.3072; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/14656566.4.6.889; Hinz B, 2005, FASEB J, V19, P1929, DOI 10.1096/fj.04-3626fje; HONG JH, 2006, CHEM REV, V99, P2467; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LOCHRER PJ, 1984, ANN INTERN MED, V100, P704; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Morikawa T, 1995, Nihon Ika Daigaku Zasshi, V62, P320; Park MJ, 2005, J CELL BIOCHEM, V95, P955, DOI 10.1002/jcb.20452; Razzaque MS, 1999, HISTOCHEM CELL BIOL, V111, P359, DOI 10.1007/s004180050368; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Villedieu M, 2006, GYNECOL ONCOL, V101, P507, DOI 10.1016/j.ygyno.2005.11.017; Zhang QX, 2005, WORLD J GASTROENTERO, V11, P4451, DOI 10.3748/wjg.v11.i29.4451	22	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5822	5827		10.1038/sj.onc.1210358	http://dx.doi.org/10.1038/sj.onc.1210358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369856				2022-12-25	WOS:000248885100014
J	Rozenfeld, R; Devi, LA				Rozenfeld, Raphael; Devi, Lakshmi A.			Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers	FASEB JOURNAL			English	Article						G-protein-coupled receptors; morphine; oligomerization; 7TM receptors; enkephalin; narcotic addiction	BETA-ARRESTIN; MORPHINE-TOLERANCE; REGULATED KINASES; PROTEIN-KINASE; CELLS; ANALGESIA; MICE; OPIATE; PHOSPHORYLATION; DEPENDENCE	Opiates are analgesics of choice in the treatment of chronic pain, but their long-term use leads to the development of physiological tolerance. Thus, understanding the mechanisms modulating the response of their receptor, the mu opioid receptor (mu OR), is of great clinical relevance. Here we show that heterodimerization of mu OR with delta opioid receptors (delta OR) leads to a constitutive recruitment of beta-arrestin2 to the receptor complex resulting in changes in the spatiotemporal regulation of ERK1/2 signaling. The involvement of beta-arrestin2 is further supported by studies using beta-arrestin2 siRNA in cells endogenously expressing the heterodimers. The association of beta-rrestin2 with the heterodimer can be altered by treatment with a combination of mu OR agonist (DAMGO) and delta OR antagonist (Tipp psi), and this leads to a shift in the pattern of ERK1/2 phosphorylation to the pattern observed with mu OR alone. These data indicate that, in the naive state, mu OR- delta OR heterodimers are in a conformation conducive to beta-arrestin-mediated signaling. Destabilization of this conformation by cotreatment with mu OR and delta OR ligands leads to a switch to a non-beta-arrestin- mediated signaling. Taken together, these results show for the first time that mu OR- delta OR heterodimers, by differentially recruiting beta-arrestin, modulate the spatio-temporal dynamics of opioid receptor signaling.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 19-84 Anenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, R37DA008863, R01DA008863, K05DA019521] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA095823] Funding Source: Medline; NIDA NIH HHS [K05 DA019521-08, R56 DA008863, R01 DA008863-17, R37 DA008863, R01 DA008863, DA08863, K05 DA019521, DA019521] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bilecki W, 2005, CELL MOL LIFE SCI, V62, P2369, DOI 10.1007/s00018-005-5277-y; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Charles AC, 2003, MOL PHARMACOL, V63, P89, DOI 10.1124/mol.63.1.89; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Dai Y, 2002, J NEUROSCI, V22, P7737; Fan T, 2005, J BIOL CHEM, V280, P38478, DOI 10.1074/jbc.M505644200; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guan JS, 2005, CELL, V122, P619, DOI 10.1016/j.cell.2005.06.010; Herz A., 1993, OPIOIDS; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Morinville A, 2003, J NEUROSCI, V23, P4888; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Riba P, 2002, J PHARMACOL EXP THER, V300, P265, DOI 10.1124/jpet.300.1.265; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yuen JWF, 2004, NEUROREPORT, V15, P1431, DOI 10.1097/01.wnr.0000130433.90962.6e; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	33	165	172	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2455	2465		10.1096/fj.06-7793com	http://dx.doi.org/10.1096/fj.06-7793com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384143	Green Accepted			2022-12-25	WOS:000248454400020
J	Sumi, T; Tsuneyoshi, N; Nakatsuji, N; Suemori, H				Sumi, T.; Tsuneyoshi, N.; Nakatsuji, N.; Suemori, H.			Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc	ONCOGENE			English	Article						c-Myc; human ES cells; self-renewal; differentiation	SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; P53-DEPENDENT APOPTOSIS; CASPASE-3 ACTIVITY; MOUSE EMBRYOS; CANCER CELLS; ES CELLS; IN-VIVO; PLURIPOTENCY; MAINTENANCE	Embryonic stem (ES) cells are self-renewing, pluripotent cell lines, characterized by their potential to differentiate into all cell types. The proto-oncogene product c-Myc has a crucial role in the self-renewal of mouse ES (mES) cells, but its role in human ES (hES) cells is unknown. To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. In contrast to its role in mES cells, activation of c-MycER in hES cells induced apoptosis and differentiation into extraembryonic endoderm and trophectoderm lineages concomitant with reduced expression of the pluripotent markers Oct4 and Nanog. Neither inhibition of caspase activity nor knockdown of p53 by RNA interference impaired the induction of differentiation markers induced by c-Myc activation. In addition, differentiation induced by c-Myc activation was associated with downregulation of alpha 6 integrin expression, suggesting an important role for the integrin/extracellular matrix interaction in the regulation of ES cell behavior. None of these effects occurred with deletion of the c-Myc transactivation domain, indicating that c-Myc promotes both apoptosis and differentiation in a transcriptional activity-dependent manner. Together, our results provide new insights into the c-Myc functions regulating hES cell fate.	Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Dev & Differentiat, Kyoto, Japan	Kyoto University; Kyoto University	Suemori, H (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, 53 Kawahara Cho,Shogoin, Kyoto 6068507, Japan.	hsuemori@frontier.kyoto-u.ac.jp						Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen S.-C., 2000, KLUW INT S ADV DATA, V21; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Duval D, 2006, CELL DEATH DIFFER, V13, P564, DOI 10.1038/sj.cdd.4401789; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fujioka T, 2004, INT J DEV BIOL, V48, P1149, DOI 10.1387/ijdb.041852tf; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Selvakumaran M, 1996, BLOOD, V88, P1248, DOI 10.1182/blood.V88.4.1248.bloodjournal8841248; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suemori H, 2006, BIOCHEM BIOPH RES CO, V345, P926, DOI 10.1016/j.bbrc.2006.04.135; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Yamane T, 2005, P NATL ACAD SCI USA, V102, P3312, DOI 10.1073/pnas.0500167102; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	63	75	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5564	5576		10.1038/sj.onc.1210353	http://dx.doi.org/10.1038/sj.onc.1210353			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369859				2022-12-25	WOS:000248801900002
J	Waha, A; Koch, A; Hartmann, W; Milde, U; Felsberg, J; Hubner, A; Mikeska, T; Goodyer, CG; Sorensen, N; Lindberg, I; Wiestler, OD; Pietsch, T; Waha, A				Waha, A.; Koch, A.; Hartmann, W.; Milde, U.; Felsberg, J.; Huebner, A.; Mikeska, T.; Goodyer, C. G.; Soerensen, N.; Lindberg, I.; Wiestler, O. D.; Pietsch, T.; Waha, A.			SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas	ONCOGENE			English	Article						medulloblastoma; SGNE1/7B2; methylation; DMH; cRT-PCR	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; COMPARATIVE GENOMIC HYBRIDIZATION; NEUROENDOCRINE PROTEIN 7B2; NH2-TERMINAL SEQUENCE; PITUITARY POLYPEPTIDE; CONVERTASE PC2; CELL-GROWTH; IN-VIVO; EXPRESSION	In a genome-wide screen using differential methylation hybridization (DMH), we have identified a CpG island within the 50 region and untranslated first exon of the secretory granule neuroendocrine protein 1 gene (SGNE1/7B2) that showed hypermethylation in medulloblastomas compared to fetal cerebellum. Bisulfite sequencing and combined bisulfite restriction assay were performed to confirm the methylation status of this CpG island in primary medulloblastomas and medulloblastoma cell lines. Hypermethylation was detected in 16/23 (70%) biopsies and 7/8 (87%) medulloblastoma cell lines, but not in nonneoplastic fetal (n=8) cerebellum. Expression of SGNE1 was investigated by semi-quantitative competitive reverse transcription-polymerase chain reaction and found to be significantly downregulated or absent in all, but one primary medulloblastomas and all cell lines compared to fetal cerebellum. After treatment of medulloblastoma cell lines with 5-aza-2'-deoxycytidine, transcription of SGNE1 was restored. No mutation was found in the coding region of SGNE1 by single-strand conformation polymorphism analysis. Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation. In summary, we have identified SGNE1 as a novel epigenetically silenced gene in medulloblastomas. Its frequent inactivation, as well as its inhibitory effect on tumor cell proliferation and focus formation strongly argues for a significant role in medulloblastoma development.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; Univ Wurzburg, Dept Pediat Neurosurg, D-97070 Wurzburg, Germany; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Bonn; McGill University; University of Wurzburg; Louisiana State University System; Helmholtz Association; German Cancer Research Center (DKFZ)	Waha, A (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	awaha1@uni-bonn.de	Lindberg, Iris/Q-3825-2019; Hartmann, Wolfgang/G-1893-2017; Mikeska, Thomas/B-4876-2008	Hartmann, Wolfgang/0000-0002-7609-5021; Mikeska, Thomas/0000-0003-1318-0859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1990, CANCER RES, V50, P2347; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Braks JAM, 1996, EUR J BIOCHEM, V236, P60, DOI 10.1111/j.1432-1033.1996.00060.x; Cassidy SB, 1997, J MED GENET, V34, P917, DOI 10.1136/jmg.34.11.917; Collini P, 1998, VIRCHOWS ARCH, V432, P505, DOI 10.1007/s004280050198; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1984, NEUROENDOCRINOLOGY, V39, P453, DOI 10.1159/000124020; Jeannotte R, 1997, DNA CELL BIOL, V16, P1175, DOI 10.1089/dna.1997.16.1175; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kobayashi I, 2003, ENDOCRINE, V22, P285, DOI 10.1385/ENDO:22:3:285; KOCH KR, 1996, ALLG VERMESS NACHR, V1, P1; Krause RM, 2001, ASM NEWS, V67, P15; Lindsey Janet C, 2005, Neurosurg Focus, V19, pE10, DOI 10.3171/foc.2005.19.5.11; MATTEI MG, 1990, GENOMICS, V6, P436, DOI 10.1016/0888-7543(90)90473-8; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; PIETSCH T, 1994, CANCER RES, V54, P3278; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Reardon DA, 1997, CANCER RES, V57, P4042; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Schmidt G, 2006, DIABETES, V55, P452, DOI 10.2337/diabetes.55.02.06.db05-0733; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Uziel T, 2006, CELL CYCLE, V5, P363, DOI 10.4161/cc.5.4.2475; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; Waha A, 1998, BRAIN PATHOL, V8, P13; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yan PS, 2001, CANCER RES, V61, P8375; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	38	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5662	5668		10.1038/sj.onc.1210338	http://dx.doi.org/10.1038/sj.onc.1210338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334394				2022-12-25	WOS:000248801900012
J	Herbert, AP; Deakin, JA; Schmidt, CQ; Blaum, BS; Egan, C; Ferreira, VP; Pangburn, MK; Lyon, M; Uhrin, D; Barlow, PN				Herbert, Andrew P.; Deakin, Jon A.; Schmidt, Christoph Q.; Blaum, Barbel S.; Egan, Claire; Ferreira, Viviana P.; Pangburn, Michael K.; Lyon, Malcolm; Uhrin, Dusan; Barlow, Paul N.			Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; HEPARIN-BINDING DOMAIN; SHORT CONSENSUS REPEAT; ALTERNATIVE PATHWAY; STRONG ASSOCIATION; NMR-SPECTROSCOPY; VARIANT; COMMON; Y402H	A common single nucleotide polymorphism in the factor H gene predisposes to age-related macular degeneration. Factor H blocks the alternative pathway of complement on self-surfaces bearing specific polyanions, including the glycosaminoglycan chains of proteoglycans. Factor H also binds C-reactive protein, potentially contributing to noninflammatory apoptotic processes. The at risk sequence contains His ( rather than Tyr) at position 402 (384 in the mature protein), in the seventh of the 20 complement control protein (CCP) modules (CCP7) of factor H. We expressed both His402 and Tyr(402) variants of CCP7, CCP7,8, and CCP6-8. We determined structures of His(402) and Tyr(402) CCP7 and showed them to be nearly identical. The side chains of His/Tyr(402) have similar, solvent-exposed orientations far from interfaces with CCP6 and -8. Tyr(402) CCP7 bound significantly more tightly than His(402) CCP7 to a heparin affinity column as well as to defined-length sulfated heparin oligosaccharides employed in gel mobility shift assays. This observation is consistent with the position of the 402 side chain on the edge of one of two glycosaminoglycan-binding surface patches on CCP7 that we inferred on the basis of chemical shift perturbation studies with a sulfated heparin tetrasaccharide. According to surface plasmon resonance measurements, Tyr(402) CCP6-8 binds significantly more tightly than His(402) CCP6-8 to immobilized C-reactive protein. The data support a causal link between H402Y and age-related macular degeneration in which variation at position 402 modulates the response of factor H to age-related changes in the glycosaminoglycan composition and apoptotic activity of the macula.	Univ Edinburgh, Sch Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Manchester, Paterson Inst Canc Res, Canc Res Uk Glyco Oncol Grp, Manchester M20 4BX, Lancs, England; Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75703 USA	University of Edinburgh; University of Edinburgh; Paterson Institute for Cancer Research; University of Manchester; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Barlow, PN (corresponding author), Univ Edinburgh, Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Barlow, Paul N/G-2853-2011; Herbert, Andrew P/C-4755-2008; Herbert, Andy P/F-6693-2010	Herbert, Andrew P/0000-0002-4549-6965; Herbert, Andy P/0000-0002-4549-6965; Ferreira, Viviana/0000-0001-8923-5671; Blaum, Baerbel/0000-0003-4312-8912; Lyon, Malcolm/0000-0001-9575-6879	Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH HHS [DK35081] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200; Cordier F, 2003, J AM CHEM SOC, V125, P15750, DOI 10.1021/ja038616m; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Habeck Michael, 2004, Methods Mol Biol, V278, P379; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Jarva H, 1999, J IMMUNOL, V163, P3957; Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9; Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KUHN S, 1995, J IMMUNOL, V155, P5663; Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831; Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871; Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269; Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nabuurs SB, 2003, J AM CHEM SOC, V125, P12026, DOI 10.1021/ja035440f; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Nowak JZ, 2006, PHARMACOL REP, V58, P353; Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103; Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x; Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012; ORMSBY RJ, 2007, MOL IMMUNOL, V44, P224; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Provis Jan M, 2005, Clin Exp Optom, V88, P269; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Sue SC, 2004, J MOL BIOL, V343, P1365, DOI 10.1016/j.jmb.2004.09.014; Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426; Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149	62	90	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18960	18968		10.1074/jbc.M609636200	http://dx.doi.org/10.1074/jbc.M609636200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17360715	hybrid			2022-12-25	WOS:000247475300038
J	Kikkawa, Y; Sasaki, T; Nguyen, MT; Nomizu, M; Mitaka, T; Miner, JH				Kikkawa, Yamato; Sasaki, Takako; Nguyen, Mai Tuyet; Nomizu, Motoyoshi; Mitaka, Toshihiro; Miner, Jeffrey H.			The LG1-3 tandem of laminin alpha 5 harbors the binding sites of lutheran/basal cell adhesion molecule and alpha 3 beta 1/alpha 6 beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP GLYCOPROTEIN; GLOMERULAR-BASEMENT-MEMBRANE; IN-VIVO; ENDOTHELIAL-CELLS; G-DOMAIN; DYSTROGLYCAN-BINDING; GLOBULAR DOMAIN; HUMAN TISSUES; LG MODULES; B-CAM	The laminin-type globular (LG) domains of laminin alpha chains have been implicated in various cellular interactions that are mediated through receptors such as integrins, alpha-dystroglycan, syndecans, and the Lutheran blood group glycoprotein (Lu). Lu, an Ig superfamily transmembrane receptor specific for laminin alpha 5, is also known as basal cell adhesion molecule (B-CAM). Although Lu/B-CAM binds to the LG domain of laminin alpha 5, the binding site has not been precisely defined. To better delineate this binding site, we produced a series of recombinant laminin trimers containing modified alpha chains, such that all or part of alpha 5LG was replaced with analogous segments of human laminin alpha 1LG. In solid phase binding assays using a soluble Lu (Lu-Fc) composed of the Lu extracellular domain and human IgG1 Fc, we found that Lu bound to Mr5G3, a recombinant laminin containing alpha 5 domains LN through LG3 fused to human laminin alpha 1LG4-5. However, Lu/B-CAM did not bind other recombinant laminins containing alpha 5LG3 unless alpha 5LG1-2 was also present. A recombinant alpha 5LG1-3 tandem lacking the laminin coiled coil (LCC) domain did not reproduce the activity of Lu/B-CAM binding. Therefore, proper structure of the alpha 5LG1-3 tandem with the LCC domain was essential for the binding of Lu/BCAM to laminin alpha 5. Our results also suggest that the binding site for Lu/B-CAM on laminin alpha 5 may overlap with that of integrins alpha 3 beta 1 and alpha 6 beta 1.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Biochem, Hachioji, Tokyo 1920392, Japan; Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Pathophysiol, Sapporo, Hokkaido 0608556, Japan; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Tokyo University of Pharmacy & Life Sciences; Washington University (WUSTL); Washington University (WUSTL); Sapporo Medical University; Max Planck Society	Kikkawa, Y (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Biochem, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	kikkawa@ps.toyaku.ac.jp	Kikkawa, Yamato/D-1503-2010; Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871	NIDDK NIH HHS [R01DK064687] Funding Source: Medline; NIGMS NIH HHS [R01GM060432] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060432] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernemann TM, 2000, J CUTAN PATHOL, V27, P108, DOI 10.1034/j.1600-0560.2000.027003108.x; Bolcato-Bellemin AL, 2003, DEV BIOL, V260, P376, DOI 10.1016/S0012-1606(03)00254-9; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; ELION EA, 1998, CURRENT PROTOCOLS MO, V1; Eyler CE, 2006, TRANSFUSION, V46, P668, DOI 10.1111/j.1537-2995.2006.00779.x; Fukumoto S, 2006, J BIOL CHEM, V281, P5008, DOI 10.1074/jbc.M509295200; Garbe JHO, 2002, BIOCHEM J, V362, P213, DOI 10.1042/0264-6021:3620213; Gauthier E, 2005, J BIOL CHEM, V280, P30055, DOI 10.1074/jbc.M503293200; Hasenson S, 2005, EXP EYE RES, V81, P415, DOI 10.1016/j.exer.2005.02.015; Hines PC, 2003, BLOOD, V101, P3281, DOI 10.1182/blood-2001-12-0289; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Ido H, 2006, MATRIX BIOL, V25, P112, DOI 10.1016/j.matbio.2005.10.003; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Kikkawa Y, 2005, CONNECT TISSUE RES, V46, P193, DOI 10.1080/03008200500344074; Kikkawa Y, 2003, J CELL BIOL, V161, P187, DOI 10.1083/jcb.200211121; Kikkawa Y, 2002, J BIOL CHEM, V277, P44864, DOI 10.1074/jbc.M208731200; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kikkawa Y, 2006, DEV BIOL, V296, P265, DOI 10.1016/j.ydbio.2006.04.463; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Murphy MM, 2005, BLOOD, V105, P3322, DOI 10.1182/blood-2004-07-2881; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; Nguyet NM, 2005, DEV BIOL, V282, P111, DOI 10.1016/j.ydbio.2005.02.031; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Schon M, 2000, J INVEST DERMATOL, V115, P1047, DOI 10.1046/j.1523-1747.2000.00189.x; Shannon MB, 2006, J AM SOC NEPHROL, V17, P1913, DOI 10.1681/ASN.2005121298; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; Sterk LMT, 2002, J CELL SCI, V115, P1161; Suzuki N, 2005, CONNECT TISSUE RES, V46, P142, DOI 10.1080/03008200591008527; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Vainionpaa N, 2006, AM J PHYSIOL-CELL PH, V290, pC764, DOI 10.1152/ajpcell.00285.2005; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	46	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14853	14860		10.1074/jbc.M611706200	http://dx.doi.org/10.1074/jbc.M611706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17383963	hybrid			2022-12-25	WOS:000246589000021
J	Xhemalce, B; Miller, KM; Driscoll, R; Masumoto, H; Jackson, SP; Kouzarides, T; Verreault, A; Arcangioli, B				Xhemalce, Blerta; Miller, Kyle M.; Driscoll, Robert; Masumoto, Hiroshi; Jackson, Stephen P.; Kouzarides, Tony; Verreault, Alain; Arcangioli, Benoit			Regulation of histone H3 lysine 56 acetylation in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ASSEMBLY FACTOR ASF1; SACCHAROMYCES-CEREVISIAE; S-PHASE; FISSION YEAST; H3K56 ACETYLATION; CELL-CYCLE; H3; CHROMATIN; REPAIR	In Saccharomyces cerevisiae, acetylation of lysine 56 ( Lys-56) in the globular domain of histone H3 plays an important role in response to genotoxic agents that interfere with DNA replication. However, the regulation and biological function of this modification are poorly defined in other eukaryotes. Here we show that Lys-56 acetylation in Schizosaccharomyces pombe occurs transiently during passage through S-phase and is normally removed in G2. Genotoxic agents that cause DNA double strand breaks during replication elicit a delay in deacetylation of histone H3 Lys-56. In addition, mutant cells that cannot acetylate Lys-56 are acutely sensitive to genotoxic agents that block DNA replication. Moreover, we show that Spbc342.06cp, a previously uncharacterized open reading frame, encodes the functional homolog of S. cerevisiae Rtt109, and that this protein acetylates H3 Lys-56 both in vitro and in vivo. Altogether, our results indicate that both the regulation of histone H3 Lys-56 acetylation by its histone acetyltransferase and histone deacetylase and its role in the DNA damage response are conserved among two distantly related yeast model organisms.	Inst Pasteur, Unite Dynam Genome, F-75724 Paris 15, France; Univ Montreal, Inst Rech Immunol & Cancerol, Montreal, PQ H3C 3J7, Canada; Wellcome Trust & Canc Res, Cambridge CB2 1QN, England; Dept Pathol, Cambridge CB2 1QN, England; Univ Cambridge, Wellcome Trust & Canc Res, Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England; Osaka Univ, Grad Sch Frontier Sci, Labs Biomol Networks, Suita, Osaka 5650871, Japan	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Montreal; University of Cambridge; University of Cambridge; Osaka University	Arcangioli, B (corresponding author), Inst Pasteur, Unite Dynam Genome, 25 Rue Dr Roux, F-75724 Paris 15, France.	barcan@pasteur.fr	Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Xhemalce, Blerta/0000-0002-0517-9607; Miller, Kyle/0000-0002-4544-0013; Kouzarides, Tony/0000-0002-8918-4162				Adkins MW, 2007, J BIOL CHEM, V282, P1334, DOI 10.1074/jbc.M608025200; Arcangioli B, 2000, EMBO REP, V1, P145, DOI 10.1093/embo-reports/kvd023; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Djupedal I, 2005, GENE DEV, V19, P2301, DOI 10.1101/gad.344205; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Freeman-Cook LL, 1999, MOL BIOL CELL, V10, P3171, DOI 10.1091/mbc.10.10.3171; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Holmes AM, 2005, MOL CELL BIOL, V25, P303, DOI 10.1128/MCB.25.1.303-311.2005; Hu FH, 2001, GENE DEV, V15, P1061, DOI 10.1101/gad.873201; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Kats ES, 2006, P NATL ACAD SCI USA, V103, P3710, DOI 10.1073/pnas.0511102103; Kaykov A, 2004, CURR BIOL, V14, P1924, DOI 10.1016/j.cub.2004.10.026; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lewis LK, 2005, NUCLEIC ACIDS RES, V33, P4928, DOI 10.1093/nar/gki806; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Miller KM, 2006, CELL CYCLE, V5, P2561, DOI 10.4161/cc.5.22.3501; MORENO S, 1989, J CELL SCI, P1; Nakayama J, 2001, EMBO J, V20, P2857, DOI 10.1093/emboj/20.11.2857; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Ozdemir A, 2006, CELL CYCLE, V5, P2602, DOI 10.4161/cc.5.22.3473; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Redon C, 2006, GENETICS, V172, P67, DOI 10.1534/genetics.105.046128; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Tomschik M, 2005, P NATL ACAD SCI USA, V102, P3278, DOI 10.1073/pnas.0500189102; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Vengrova S, 2004, GENE DEV, V18, P794, DOI 10.1101/gad.289404; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Ye JX, 2005, MOL CELL, V18, P123, DOI 10.1016/j.molcel.2005.02.031; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	50	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15040	15047		10.1074/jbc.M701197200	http://dx.doi.org/10.1074/jbc.M701197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17369611	hybrid			2022-12-25	WOS:000246589000043
J	Funa, N; Awakawa, T; Horinouchi, S				Funa, Nobutaka; Awakawa, Takayoshi; Horinouchi, Sueharu			Pentaketide resorcylic acid synthesis by type III polyketide synthase from Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-ORYZAE; BIOSYNTHESIS; METABOLITES; IDENTIFICATION; SUPERFAMILY; FAMILY	Type III polyketide synthases (PKSs) are responsible for aromatic polyketide synthesis in plants and bacteria. Genome analysis of filamentous fungi has predicted the presence of fungal type III PKSs, although none have thus far been functionally characterized. In the genome of Neurospora crassa, a single open reading frame, NCU04801.1, annotated as a type III PKS was found. In this report, we demonstrate that NCU04801.1 is a novel type III PKS catalyzing the synthesis of pentaketide alkylresorcylic acids. NCU04801.1, hence named 2'-oxoalkylresorcylic acid synthase (ORAS), preferred stearoyl-CoA as a starter substrate and condensed four molecules of malonyl-CoA to give a pentaketide intermediate. For ORAS to yield pentaketide alkylresorcylic acids, aldol condensation and aromatization of the intermediate, which is still attached to the enzyme, are presumably followed by hydrolysis for release of the product as a resorcylic acid. ORAS is the first type III PKS that synthesizes pentaketide resorcylic acids.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp						Austin MB, 2004, CHEM BIOL, V11, P1179, DOI 10.1016/j.chembiol.2004.05.024; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Eckermann C, 2003, PHYTOCHEMISTRY, V62, P271, DOI 10.1016/S0031-9422(02)00554-X; Filip P, 2002, Z NATURFORSCH C, V57, P1004; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2006, P NATL ACAD SCI USA, V103, P6356, DOI 10.1073/pnas.0511227103; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Keller NP, 2005, NAT REV MICROBIOL, V3, P937, DOI 10.1038/nrmicro1286; KUSHWAHA SC, 1976, LIPIDS, V11, P778, DOI 10.1007/BF02533055; Langfelder K, 2003, FUNGAL GENET BIOL, V38, P143, DOI 10.1016/S1087-1845(02)00526-1; Machida M, 2005, NATURE, V438, P1157, DOI 10.1038/nature04300; Ninomiya Y, 2004, P NATL ACAD SCI USA, V101, P12248, DOI 10.1073/pnas.0402780101; Saeed A, 2003, HELV CHIM ACTA, V86, P377, DOI 10.1002/hlca.200390038; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SEITZ LM, 1992, J AGR FOOD CHEM, V40, P1541, DOI 10.1021/jf00021a014; Seshime Y, 2005, BIOCHEM BIOPH RES CO, V331, P253, DOI 10.1016/j.bbrc.2005.03.160; Shen B, 2003, CURR OPIN CHEM BIOL, V7, P285, DOI 10.1016/S1367-5931(03)00020-6; Suzuki Y, 1998, PHYTOCHEMISTRY, V47, P1247, DOI 10.1016/S0031-9422(97)00720-6; Sweeney MJ, 1999, FEMS MICROBIOL LETT, V175, P149, DOI [10.1016/S0378-1097(99)00103-2, 10.1111/j.1574-6968.1999.tb13614.x]; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Yang SW, 2006, J ANTIBIOT, V59, P190, DOI 10.1038/ja.2006.27; Zarnowski R, 2000, Z NATURFORSCH C, V55, P846	24	103	107	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14476	14481		10.1074/jbc.M701239200	http://dx.doi.org/10.1074/jbc.M701239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374612	hybrid			2022-12-25	WOS:000246245800061
J	McCole, DF; Truong, A; Bunz, M; Barrett, KE				McCole, Declan F.; Truong, Anh; Bunz, Michael; Barrett, Kim E.			Consequences of direct Versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CHLORIDE SECRETION; FACTOR-ALPHA BIND; EGF-RECEPTOR; TRANSFORMING GROWTH; COLON-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-MECHANISM; COUPLED RECEPTORS; PHOSPHOLIPASE-C; ERBB RECEPTORS	The epidermal growth factor receptor (EGFR) is an integral regulator of many cellular functions. EGFR also acts as a central conduit for extracellular signals involving direct activation of the receptor by EGFR ligands or indirect activation by G protein-coupled receptor (GPCR)-stimulated transactivation of the EGFR. We have previously shown that EGFR negatively regulates epithelial chloride secretion as a result of transforming growth factor-alpha-mediated EGFR transactivation in response to muscarinic GPCR activation. Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Moreover, we demonstrate that this differential signaling and its consequences depend on protein-tyrosine phosphatase 1B activity. Thus protein-tyrosine phosphatase 1B governs differential recruitment of signaling pathways involved in EGFR regulation of epithelial ion transport. Our findings furthermore establish how divergent signaling outcomes can arise from the activation of a single receptor.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	McCole, DF (corresponding author), Univ Calif San Diego, Div Gastroenterol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dmccole@ucsd.edu	McCole, Declan/AAL-2454-2020; Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARTLIDGE SA, 1989, BRIT J CANCER, V60, P657, DOI 10.1038/bjc.1989.334; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Darmoul D, 2004, MOL CANCER RES, V2, P514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DeYulia GJ, 2005, BIOCHEM BIOPH RES CO, V334, P38, DOI 10.1016/j.bbrc.2005.06.056; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; LABURTHE M, 1989, AM J PHYSIOL, V256, pG443, DOI 10.1152/ajpgi.1989.256.3.G443; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Lenferink AEG, 1998, BIOCHEM J, V336, P147, DOI 10.1042/bj3360147; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; McCole DF, 2005, GASTROENTEROLOGY, V129, P591, DOI 10.1053/j.gastro.2005.06.004; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MILARSKI KL, 1993, J BIOL CHEM, V268, P26364; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Playford RJ, 1996, GUT, V39, P262, DOI 10.1136/gut.39.2.262; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHAWISAN R, 1986, J PHARM PHARMACOL, V38, P150, DOI 10.1111/j.2042-7158.1986.tb04533.x; Wang DG, 2002, ONCOGENE, V21, P2785, DOI 10.1038/sj.onc.1205375; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386	52	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13303	13315		10.1074/jbc.M700424200	http://dx.doi.org/10.1074/jbc.M700424200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339316	hybrid			2022-12-25	WOS:000246060300018
J	Shi, R; Lamb, SS; Bhat, S; Sulea, T; Wright, GD; Matte, A; Cygler, M				Shi, Rong; Lamb, Sherry S.; Bhat, Sathesh; Sulea, Traian; Wright, Gerard D.; Matte, Allan; Cygler, Miroslaw			Crystal structure of StaL, a glycopeptide antibiotic sulfotransferase from Streptomyces toyocaensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFICITY; MOLECULAR-BASIS; MODEL; BIOSYNTHESIS; SUBSTRATE; SULFATION; REFINEMENT; GENERATION; DOPAMINE; PROTEINS	Over the past decade, antimicrobial resistance has emerged as a major public health crisis. Glycopeptide antibiotics such as vancomycin and teicoplanin are clinically important for the treatment of Gram-positive bacterial infections. StaL is a 3'-phosphoadenosine 5'-phosphosulfate-dependent sulfotransferase capable of sulfating the cross-linked heptapeptide substrate both in vivo and in vitro, yielding the product A47934, a unique teicoplanin-class glycopeptide antibiotic. The sulfonation reaction catalyzed by StaL constitutes the final step in A47934 biosynthesis. Here we report the crystal structure of StaL and its complex with the cofactor product 3'-phosphoadenosine 5'-phosphate. This is only the second prokaryotic sulfotransferase to be structurally characterized. StaL belongs to the large sulfotransferase family and shows higher similarity to cytosolic sulfotransferases (ST) than to the bacterial ST (Stf0). StaL has a novel dimerization motif, different from any other STs that have been structurally characterized. We have also applied molecular modeling to investigate the binding mode of the unique substrate, desulfo-A47934. Based on the structural analysis and modeling results, a series of residues was mutated and kinetically characterized. In addition to the conserved residues (Lys(12), His(67), and Ser(98)), molecular modeling, fluorescence quenching experiments, and mutagenesis studies identified several other residues essential for substrate binding and/or activity, including Trp(34), His(43), Phe(77), Trp(13)2, and Glu(205).	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McMaster Univ, Dept Biochem & Biomed Sci, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	National Research Council Canada; McGill University; McMaster University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				Bal AM, 2005, EXPERT OPIN PHARMACO, V6, P2257, DOI 10.1517/14656566.6.13.2257; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhat S, 2006, PROTEINS, V62, P244, DOI 10.1002/prot.20682; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; BOECK LD, 1986, J ANTIBIOT, V39, P1533, DOI 10.7164/antibiotics.39.1533; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chang HJ, 2004, J BIOL CHEM, V279, P2689, DOI 10.1074/jbc.M310446200; Chapman E, 2004, ANGEW CHEM INT EDIT, V43, P3526, DOI 10.1002/anie.200300631; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Dombrovski L, 2006, PROTEINS, V64, P1091, DOI 10.1002/prot.21048; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gamage NU, 2003, J BIOL CHEM, V278, P7655, DOI 10.1074/jbc.M207246200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanin M, 1997, MOL MICROBIOL, V24, P1119, DOI 10.1046/j.1365-2958.1997.3981777.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kahne D, 2005, CHEM REV, V105, P425, DOI 10.1021/cr030103a; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Lamb SS, 2006, CHEM BIOL, V13, P171, DOI 10.1016/j.chembiol.2005.12.003; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lehrer S S, 1978, Methods Enzymol, V49, P222; Lu JH, 2005, BIOCHEM BIOPH RES CO, V335, P417, DOI 10.1016/j.bbrc.2005.07.091; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McGann MR, 2003, BIOPOLYMERS, V68, P76, DOI 10.1002/bip.10207; Moon AF, 2004, J BIOL CHEM, V279, P45185, DOI 10.1074/jbc.M405013200; Mougous JD, 2002, CHEM BIOL, V9, P767, DOI 10.1016/S1074-5521(02)00175-8; Mougous JD, 2006, P NATL ACAD SCI USA, V103, P4258, DOI 10.1073/pnas.0510861103; Mougous JD, 2004, NAT STRUCT MOL BIOL, V11, P721, DOI 10.1038/nsmb802; Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Petrotchenko EV, 2001, FEBS LETT, V490, P39, DOI 10.1016/S0014-5793(01)02129-9; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; Purisima EO, 1998, J COMPUT CHEM, V19, P1494, DOI 10.1002/(SICI)1096-987X(199810)19:13<1494::AID-JCC6>3.0.CO;2-L; Rath VL, 2004, DRUG DISCOV TODAY, V9, P1003, DOI 10.1016/S1359-6446(04)03273-8; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Schafer M, 1996, HELV CHIM ACTA, V79, P1916, DOI 10.1002/hlca.19960790714; Smith DW, 2004, PROTEINS, V57, P854, DOI 10.1002/prot.20258; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Townsend GE, 2006, J BACTERIOL, V188, P8560, DOI 10.1128/JB.01035-06; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZMIJEWSKI MJ, 1987, ANTIMICROB AGENTS CH, V31, P1497, DOI 10.1128/AAC.31.10.1497	58	19	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13073	13086		10.1074/jbc.M611912200	http://dx.doi.org/10.1074/jbc.M611912200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329243	hybrid			2022-12-25	WOS:000245942800076
J	Rodriguez-Molina, VM; Aertsen, A; Heck, DH				Rodriguez-Molina, Victor M.; Aertsen, Ad; Heck, Detlef H.			Spike Timing and Reliability in Cortical Pyramidal Neurons: Effects of EPSC Kinetics, Input Synchronization and Background Noise on Spike Timing	PLOS ONE			English	Article								In vivo studies have shown that neurons in the neocortex can generate action potentials at high temporal precision. The mechanisms controlling timing and reliability of action potential generation in neocortical neurons, however, are still poorly understood. Here we investigated the temporal precision and reliability of spike firing in cortical layer V pyramidal cells at near-threshold membrane potentials. Timing and reliability of spike responses were a function of EPSC kinetics, temporal jitter of population excitatory inputs, and of background synaptic noise. We used somatic current injection to mimic population synaptic input events and measured spike probability and spike time precision (STP), the latter defined as the time window (Delta t) holding 80% of response spikes. EPSC rise and decay times were varied over the known physiological spectrum. At spike threshold level, EPSC decay time had a stronger influence on STP than rise time. Generally, STP was highest (<= 2.45 ms) in response to synchronous compounds of EPSCs with fast rise and decay kinetics. Compounds with slow EPSC kinetics (decay time constants>6 ms) triggered spikes at lower temporal precision (>= 6.58 ms). We found an overall linear relationship between STP and spike delay. The difference in STP between fast and slow compound EPSCs could be reduced by incrementing the amplitude of slow compound EPSCs. The introduction of a temporal jitter to compound EPSCs had a comparatively small effect on STP, with a tenfold increase in jitter resulting in only a five fold decrease in STP. In the presence of simulated synaptic background activity, precisely timed spikes could still be induced by fast EPSCs, but not by slow EPSCs.	[Heck, Detlef H.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Rodriguez-Molina, Victor M.; Aertsen, Ad] Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, D-7800 Freiburg, Germany; [Rodriguez-Molina, Victor M.] Univ Autonoma Estado Morelos, Fac Med, Cuernavaca, Morelos, Mexico; [Aertsen, Ad] Univ Freiburg, Bernstein Ctr Computat Neurosci, Freiburg, Germany	University of Tennessee System; University of Tennessee Health Science Center; University of Freiburg; Universidad Autonoma del Estado de Morelos; University of Freiburg	Heck, DH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.	dheck@utmem.edu	Heck, Detlef/GPS-4854-2022	Heck, Detlef/0000-0003-2438-4064	German Research Foundation [DFG-SFB505]; German Academic Exchange Service (DAAD)	German Research Foundation(German Research Foundation (DFG)); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD))	Funding for this study was provided by the German Research Foundation (DFG-SFB505); V. M. R. was supported by the German Academic Exchange Service (DAAD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Anderson JS, 2000, SCIENCE, V290, P1968, DOI 10.1126/science.290.5498.1968; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Azouz R, 1999, J NEUROSCI, V19, P2209; Bacci A, 2006, NEURON, V49, P119, DOI 10.1016/j.neuron.2005.12.014; Berger T, 2001, J NEUROPHYSIOL, V85, P855, DOI 10.1152/jn.2001.85.2.855; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; Boucsein C, 2005, J NEUROPHYSIOL, V94, P2948, DOI 10.1152/jn.00245.2005; Cash S, 1999, NEURON, V22, P383, DOI 10.1016/S0896-6273(00)81098-3; COPE TC, 1987, J PHYSIOL-LONDON, V390, P161, DOI 10.1113/jphysiol.1987.sp016692; DAYHOFF JE, 1983, J NEUROPHYSIOL, V49, P1334, DOI 10.1152/jn.1983.49.6.1334; Destexhe A, 1999, J NEUROPHYSIOL, V81, P1531, DOI 10.1152/jn.1999.81.4.1531; Destexhe A, 2000, NEUROCOMPUTING, V32, P113, DOI 10.1016/S0925-2312(00)00151-X; Diesmann M, 1999, NATURE, V402, P529, DOI 10.1038/990101; FETZ EE, 1983, J PHYSIOL-LONDON, V341, P387, DOI 10.1113/jphysiol.1983.sp014812; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; Grande LA, 2004, J NEUROSCI, V24, P1839, DOI 10.1523/JNEUROSCI.3500-03.2004; GUSTAFSSON B, 1984, J PHYSIOL-LONDON, V347, P431, DOI 10.1113/jphysiol.1984.sp015074; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; Holt GR, 1996, J NEUROPHYSIOL, V75, P1806, DOI 10.1152/jn.1996.75.5.1806; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; JACK JJB, 1971, J PHYSIOL-LONDON, V215, P283, DOI 10.1113/jphysiol.1971.sp009472; Kara P, 2000, NEURON, V27, P635, DOI 10.1016/S0896-6273(00)00072-6; Kuhn A, 2004, J NEUROSCI, V24, P2345, DOI 10.1523/JNEUROSCI.3349-03.2004; Leger JF, 2005, J NEUROPHYSIOL, V93, P281, DOI 10.1152/jn.00067.2003; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; Magee JC, 2000, NAT NEUROSCI, V3, P895, DOI 10.1038/78800; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Margulis M, 1998, J NEUROPHYSIOL, V79, P2809, DOI 10.1152/jn.1998.79.5.2809; Marom S, 1998, J MEMBRANE BIOL, V161, P105, DOI 10.1007/s002329900318; NICOLL A, 1993, J PHYSIOL-LONDON, V468, P693, DOI 10.1113/jphysiol.1993.sp019795; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; Poliakov AV, 1997, J PHYSIOL-LONDON, V504, P401, DOI 10.1111/j.1469-7793.1997.401be.x; Powers RK, 2000, J NEUROPHYSIOL, V83, P483, DOI 10.1152/jn.2000.83.1.483; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; ROBINSON HPC, 1993, J NEUROSCI METH, V49, P157, DOI 10.1016/0165-0270(93)90119-C; Schiller J, 2000, NATURE, V404, P285, DOI 10.1038/35005094; Schneidman E, 1998, NEURAL COMPUT, V10, P1679, DOI 10.1162/089976698300017089; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1998, J NEUROSCI, V18, P3870; SHARP AA, 1993, J NEUROPHYSIOL, V69, P992, DOI 10.1152/jn.1993.69.3.992; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Stevens CF, 1998, NAT NEUROSCI, V1, P210, DOI 10.1038/659; Stricker C, 1996, J PHYSIOL-LONDON, V490, P419, DOI 10.1113/jphysiol.1996.sp021155; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Stuart G, 1998, J NEUROSCI, V18, P3501; Toib A, 1998, J NEUROSCI, V18, P1893; Urban NN, 1998, P NATL ACAD SCI USA, V95, P11450, DOI 10.1073/pnas.95.19.11450; van Rossum MCW, 2003, J NEUROPHYSIOL, V89, P2406, DOI 10.1152/jn.01106.2002; VILLA AEP, 1990, BRAIN RES, V509, P325, DOI 10.1016/0006-8993(90)90558-S; Williams SR, 2002, SCIENCE, V295, P1907, DOI 10.1126/science.1067903; Zsiros V, 2005, J NEUROPHYSIOL, V93, P3248, DOI 10.1152/jn.01027.2004	59	38	38	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e319	10.1371/journal.pone.0000319	http://dx.doi.org/10.1371/journal.pone.0000319			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389910	Green Published, gold			2022-12-25	WOS:000207445200002
J	Noble, CG; Song, HW				Noble, Christian G.; Song, Haiwei			MLN51 Stimulates the RNA-Helicase Activity of eIF4AIII	PLOS ONE			English	Article								The core of the exon-junction complex consists of Y14, Magoh, MLN51 and eIF4AIII, a DEAD-box RNA helicase. MLN51 stimulates the ATPase activity of eIF4AIII, whilst the Y14-Magoh complex inhibits it. We show that the MLN51-dependent stimulation increases both the affinity of eIF4AIII for ATP and the rate of enzyme turnover; the KM is decreased by an order of magnitude and k(cat) increases 30 fold. Y14-Magoh do inhibit the MLN51-stimulated ATPase activity, but not back to background levels. The ATP-bound form of the eIF4AIII-MLN51 complex has a 100-fold higher affinity for RNA than the unbound form and ATP hydrolysis reduces this affinity. MLN51 stimulates the RNA-helicase activity of eIF4AIII, suggesting that this activity may be functionally important.	[Noble, Christian G.; Song, Haiwei] Natl Univ Singapore, Inst Mol & Cell Biol, Lab Macromol Struct, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Song, HW (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Lab Macromol Struct, 10 Kent Ridge Crescent, Singapore 117548, Singapore.	haiwei@imcb.a-star.edu.sg	song, haiwei/H-6082-2011		Agency for Science Technology and Research (A*-Star), Singapore	Agency for Science Technology and Research (A*-Star), Singapore(Agency for Science Technology & Research (A*STAR))	This research was funded by the Agency for Science Technology and Research (A*-Star), Singapore.	Andersen CBF, 2006, SCIENCE, V313, P1968, DOI 10.1126/science.1131981; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Bono F, 2006, CELL, V126, P713, DOI 10.1016/j.cell.2006.08.006; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Degot S, 2002, ONCOGENE, V21, P4422, DOI 10.1038/sj.onc.1205611; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002; Li QY, 1999, MOL CELL BIOL, V19, P7336; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Noble CG, 2004, NUCLEIC ACIDS RES, V32, P3364, DOI 10.1093/nar/gkh664; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Shi H, 2003, GENE DEV, V17, P971, DOI 10.1101/gad.260403; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012	21	40	43	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e303	10.1371/journal.pone.0000303	http://dx.doi.org/10.1371/journal.pone.0000303			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375189	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445100005
J	Prinz, S; Aldridge, C; Ramsey, SA; Taylor, RJ; Galitski, T				Prinz, Susanne; Aldridge, Christine; Ramsey, Stephen A.; Taylor, R. James; Galitski, Timothy			Control of Signaling in a MAP-kinase Pathway by an RNA-Binding Protein	PLOS ONE			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FEEDBACK-REGULATION; MESSENGER-RNAS; PUF FAMILY; YEAST; GROWTH; GENE; RECOVERY; PUMILIO	Signaling-protein mRNAs tend to have long untranslated regions (UTRs) containing binding sites for RNA-binding proteins regulating gene expression. Here we show that a PUF-family RNA-binding protein, Mpt5, represses the yeast MAP-kinase pathway controlling differentiation to the filamentous form. Mpt5 represses the protein levels of two pathway components, the Ste7 MAP-kinase kinase and the Tec1 transcriptional activator, and negatively regulates the kinase activity of the Kss1 MAP kinase. Moreover, Mpt5 specifically inhibits the output of the pathway in the absence of stimuli, and thereby prevents inappropriate cell differentiation. The results provide an example of what may be a genome-scale level of regulation at the interface of signaling networks and protein-RNA binding networks.	[Prinz, Susanne; Aldridge, Christine; Ramsey, Stephen A.; Taylor, R. James; Galitski, Timothy] Inst Syst Biol, Seattle, WA USA; [Taylor, R. James; Galitski, Timothy] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Institute for Systems Biology (ISB); University of British Columbia	Galitski, T (corresponding author), Inst Syst Biol, Seattle, WA USA.	tgalitski@system-sbiology.org			NIH [P50 GM076547, U54 AI054523R]; Michael Smith Foundation; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI054523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076547] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Smith Foundation(Michael Smith Foundation for Health Research); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported by grant P50 GM076547 from NIH. S. A. Ramsey was supported by grant U54 AI054523R from NIH. R.J. Taylor was supported by a junior graduate studentship from the Michael Smith Foundation for Health Research. T. Galitski is a recipient of a Burroughs Wellcome Fund Career Award in the Biomedical Sciences.	Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Chen TS, 1997, MOL CELL BIOL, V17, P3429, DOI 10.1128/MCB.17.6.3429; Chou S, 2006, MOL CELL BIOL, V26, P4794, DOI 10.1128/MCB.02053-05; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Gerber AP, 2006, P NATL ACAD SCI USA, V103, P4487, DOI 10.1073/pnas.0509260103; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Goldstrohm AC, 2006, NAT STRUCT MOL BIOL, V13, P533, DOI 10.1038/nsmb1100; Gu W, 2004, GENE DEV, V18, P1452, DOI 10.1101/gad.1189004; Guthrie C, 1991, GUIDE YEAST GENETICS; Heikkinen HL, 2003, NUCLEIC ACIDS RES, V31, P4006, DOI 10.1093/nar/gkg474; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Hurowitz EH, 2004, GENOME BIOL, V5; Kaeberlein M, 2002, GENETICS, V160, P83; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIKUCHI Y, 1994, MOL GEN GENET, V245, P107, DOI 10.1007/BF00279756; LASKO P, 2003, SCI STKE, pRE6; Lin HF, 1997, DEVELOPMENT, V124, P2463; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Maleri S, 2004, MOL CELL BIOL, V24, P9221, DOI 10.1128/MCB.24.20.9221-9238.2004; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Ohkuni K, 2006, MOL GENET GENOMICS, V275, P81, DOI 10.1007/s00438-005-0064-x; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Prinz S, 2004, GENOME RES, V14, P380, DOI 10.1101/gr.2020604; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rives AW, 2003, P NATL ACAD SCI USA, V100, P1128, DOI 10.1073/pnas.0237338100; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Spassov DS, 2003, IUBMB LIFE, V55, P359, DOI 10.1080/15216540310001603093; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STEWART MS, 2006, MPT5P STRESS TOLERAN; Storici F, 2006, METHOD ENZYMOL, V409, P329, DOI 10.1016/S0076-6879(05)09019-1; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; Xu BE, 2001, GENETICS, V159, P1559	43	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e249	10.1371/journal.pone.0000249	http://dx.doi.org/10.1371/journal.pone.0000249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327913	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444600009
J	McCabe, NP; De, S; Vasanji, A; Brainard, J; Byzova, TV				McCabe, N. P.; De, S.; Vasanji, A.; Brainard, J.; Byzova, T. V.			Prostate cancer specific integrin alpha v beta 3 modulates bone metastatic growth and tissue remodeling	ONCOGENE			English	Article						prostate cancer; metastasis; bone; integrins	BREAST-CANCER; TUMOR-GROWTH; INTEGRIN; ACTIVATION; EXPRESSION; MUTATION; PLATELET; DOMAIN; IIIA	The management of pain and morbidity due to the spreading and growth of cancer within bone remains to be a paramount problem in clinical care. Cancer cells actively transform bone, however, the molecular requirements and mechanisms of this process remain unclear. This study shows that functional modulation of the alpha v beta 3 integrin receptor in prostate cancer cells is required for progression within bone and determines tumor-induced bone tissue transformation. Using histology and quantitative microCT analysis, we show that avb3 integrin is required not only for tumor growth within the bone but for tumor-induced bone gain, a response resembling bone lesions in prostate cancer patients. Expression of normal, fully functional avb3 enabled tumor growth in bone ( incidence: 4/4), whereas avb3 (-), inactive or constitutively active mutants of alpha v beta 3 did not ( incidence: 0/4, 0/6 and 1/7, respectively) within a 35-day-period. This response appeared to be bone-specific in comparison to the subcutis where tumor incidence was greater than 60% for all groups. Interestingly, bone residing prostate cancer cells expressing normal or dis-regulated alpha v beta 3 ( either inactive of constitutively active), but not those lacking beta 3 promoted bone gain or afforded protection from bone loss in the presence or absence of histologically detectable tumor 35 days following implantation. As bone is replete with ligands for beta 3 integrin, we next demonstrated that avb3 integrin activation on tumor cells is essential for the recognition of key bone-specific matrix proteins. As a result, prostate cancer cells expressing fully functional but not dis-regulated avb3 integrin are able to control their own adherence and migration to bone matrix, functions that facilitate tumor growth and control bone lesion development.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Educ Fdn, Dept Biomed Engn, Cleveland, OH USA; Cleveland Clin Educ Fdn, Dept Anat & Pathol, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X	NCI NIH HHS [R01 CA126847-05A1, CA1172462, R01 CA126847, R01 CA126847-06] Funding Source: Medline; NIAMS NIH HHS [1P30 AR-050953, P30 AR050953] Funding Source: Medline; NIDDK NIH HHS [DK060933, R01 DK060933-04, R01 DK060933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA126847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090-4295(83)90147-4; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Latson L, 2003, P ANN INT IEEE EMBS, V25, P1058, DOI 10.1109/IEMBS.2003.1279427; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Nemeth JA, 2003, CLIN EXP METASTAS, V20, P413, DOI 10.1023/A:1025461507027; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2; Takayama S, 2005, ANTICANCER RES, V25, P79	23	150	154	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6238	6243		10.1038/sj.onc.1210429	http://dx.doi.org/10.1038/sj.onc.1210429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17369840	Green Accepted			2022-12-25	WOS:000249401300015
J	Ohi, H; Mishima, Y; Kamimura, K; Maruyama, M; Sasai, K; Kominami, R				Ohi, H.; Mishima, Y.; Kamimura, K.; Maruyama, M.; Sasai, K.; Kominami, R.			Multi-step lymphomagenesis deduced from DNA changes in thymic lymphomas and atrophic thymuses at various times after gamma-irradiation	ONCOGENE			English	Article						multistep lymphomagenesis; gamma-ray; atrophic thymuses; clonal growth; Bcl11b	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL DEVELOPMENT; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DEFICIENT MICE; HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; NOTCH1 MUTATIONS; POINT MUTATIONS; TRANSGENIC MICE	Whole-body gamma-irradiation to mice causes thymic atrophy where a population of precancerous cells with mutation can be found. Thus, clonal growth and DNA changes at Bcl11b, Ikaros, Pten, Notch1 and Myc were examined in not only thymic lymphomas but also in atrophic thymuses at various times after irradiation. Clonal expansion was detected from the distinct patterns of rearrangements at the TCR beta receptor locus in a fraction of atrophic thymuses at as early as 30 days after irradiation. This expansion may be in part owing to the rearranged TCR beta signaling because the transfer of bone marrow cells with the rearrangement and the wild-type locus into severe-combined immunodeficiency mice showed preferential growth of the rearranged thymocytes in atrophic thymus. Loss of heterozygosity (LOH) at Bcl11b and trisomy of Myc were found at high frequencies in both lymphomas and atrophic thymuses, and in contrast, LOH at Ikaros and Pten were rare in atrophic thymuses but prevalent in lymphomas. Notch1 activation was detected in lymphomas and in atrophic thymuses only at a late stage. Similar patterns of DNA changes were found in atrophic thymuses induced in Bcl11b(+/-) mice. These results suggest the order of genetic changes during lymphomagenesis, Bcl11b and Myc being at the early stage; whereas Ikaros, Pten and Notch1 at the late stage.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Niigata 9518510, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Asahimachi Doori 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019	Maruyama, Masaki/0000-0002-9534-4652				ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; BRATHWAITE O, 1992, CANCER RES, V52, P3791; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; Gray DHD, 2005, CURR OPIN IMMUNOL, V17, P137, DOI 10.1016/j.coi.2005.02.001; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kakinuma S, 2002, RADIAT RES, V157, P331, DOI 10.1667/0033-7587(2002)157[0331:SOZIIA]2.0.CO;2; KAMIMURA K, IN PRESS BIOCH BIOPH; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; Kawamoto H, 2003, EUR J IMMUNOL, V33, P606, DOI 10.1002/eji.200323461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; LUDWIG FC, 1968, LAB INVEST, V19, P240; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUTO M, 1987, CANCER RES, V47, P3469; Nagel S, 2003, CANCER RES, V63, P5329; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Ruiz A, 2004, BRIT J HAEMATOL, V125, P31, DOI 10.1111/j.1365-2141.2004.04854.x; SADO T, 1991, J RADIAT RES, V32, P168, DOI 10.1269/jrr.32.SUPPLEMENT2_168; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tsuji H, 2004, CANCER RES, V64, P8882, DOI 10.1158/0008-5472.CAN-03-1163; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350	58	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5280	5289		10.1038/sj.onc.1210325	http://dx.doi.org/10.1038/sj.onc.1210325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325664				2022-12-25	WOS:000248674200011
J	Lucas, PC; Kuffa, P; Gu, S; Kohrt, D; Kim, DSL; Siu, K; Jin, X; Swenson, J; McAllister-Lucas, LM				Lucas, P. C.; Kuffa, P.; Gu, S.; Kohrt, D.; Kim, D. S. L.; Siu, K.; Jin, X.; Swenson, J.; McAllister-Lucas, L. M.			A dual role for the API2 moiety in API2-MALT1-dependent NF-kappa B activation: heterotypic oligomerization and TRAF2 recruitment	ONCOGENE			English	Article						MALT lymphoma; cIAP2; MALT1; NF-kappa B	HELICOBACTER-PYLORI ERADICATION; LYMPHOID-TISSUE LYMPHOMA; RECEPTOR-ASSOCIATED FACTOR-2; GASTRIC MALT LYMPHOMAS; CELL LYMPHOMA; UBIQUITIN LIGASE; BIR DOMAINS; FUSION; APOPTOSIS; BCL10	Mucosa-associated lymphoid tissue ( MALT) lymphoma is the most common extranodal lymphoid neoplasm. Chromosomal translocation t(11; 18)(q21, q21) is found in 30% of gastric MALT lymphomas and is associated with a failure to respond to standard treatment and a tendency to disseminate. This translocation generates a chimeric protein composed of N-terminal sequences of Inhibitor of Apoptosis 2 (API2, also known as BIRC3 and cIAP2) fused to C-terminal sequences of MALT1. API2-MALT1 promotes cell survival and proliferation via activation of nuclear factor-kappa B(NF-kappa B). Here, we investigate the mechanism by which the API2 moiety contributes to NF-kappa B stimulation. We find that the API2 moiety mediates oligomerization of API2-MALT1 as well as interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2). Surprisingly, oligomerization does not occur via homotypic interaction; rather, the API2 moiety of one monomer interacts with the MALT1 moiety of another monomer. Further, the specific region of the API2 moiety responsible for mediating oligomerization is distinct from that mediating TRAF2 binding. Although deletion or mutation of the TRAF2 binding site does not inhibit oligomerization, it does lead to dramatically decreased NF-kappa B activation. Deletion of both TRAF2 binding and oligomerization regions results in near-complete loss of NF-kappa B activation. Thus, API2 moiety-mediated heterotypic oligomerization and TRAF2 binding both contribute to maximal API2-MALT1-dependent NF-kappa B stimulation.	Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McAllister-Lucas, LM (corresponding author), Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, 3520D MSRB 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	lindaluc@umich.edu		Lucas, Peter/0000-0003-4880-7172	NCI NIH HHS [5K08 CA097986, 5K08 CA094920] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA094920, K08CA097986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Inagaki H, 2004, AM J SURG PATHOL, V28, P1560, DOI 10.1097/00000478-200412000-00003; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; Iwano M, 2004, J GASTROENTEROL, V39, P739, DOI 10.1007/s00535-004-1382-1; Levy M, 2005, J CLIN ONCOL, V23, P5061, DOI 10.1200/JCO.2005.05.660; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Luque LE, 2002, BIOCHEMISTRY-US, V41, P13663, DOI 10.1021/bi0263964; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Okabe M, 2003, AM J PATHOL, V162, P1113, DOI 10.1016/S0002-9440(10)63908-9; Penas EMM, 2003, LEUKEMIA, V17, P2225, DOI 10.1038/sj.leu.2403122; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sakugawa ST, 2003, MODERN PATHOL, V16, P1232, DOI 10.1097/01.MP.0000097283.47637.58; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Senyuk V, 2005, CANCER RES, V65, P7603, DOI 10.1158/0008-5472.CAN-05-0412; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Turner SD, 2006, LEUKEMIA, V20, P572, DOI 10.1038/sj.leu.2404125; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251; Ye HT, 2003, BLOOD, V101, P2547, DOI 10.1182/blood-2002-10-3167; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zucca E, 2000, BLOOD, V96, P410	47	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5643	5654		10.1038/sj.onc.1210342	http://dx.doi.org/10.1038/sj.onc.1210342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334391				2022-12-25	WOS:000248801900010
J	Caprio, M; Feve, B; Claes, A; Viengchareun, S; Lombes, M; Zennaro, MC				Caprio, Massimiliano; Feve, Bruno; Claes, Aurelie; Viengchareun, Say; Lombes, Marc; Zennaro, Maria-Christina			Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis	FASEB JOURNAL			English	Article						adipocyte differentiation; aldosterone; glucocorticoids; nuclear receptors	ADIPOSE CONVERSION; GLUCOCORTICOID RECEPTOR; VISCERAL OBESITY; BROWN ADIPOCYTES; GENE-EXPRESSION; 3T3-L1 CELLS; DIFFERENTIATION; DEHYDROGENASE; ACTIVATION; COREPRESSOR	In addition to their role in controlling water and salt homeostasis, recent work suggests that aldosterone and mineralocorticoid receptors (MR) may be involved in adipocyte biology. This is of particular relevance given the role of MR as a high-affinity receptor for both mineralocorticoids and glucocorticoids. We have thus examined the effect of aldosterone and MR on white adipose cell differentiation. When cells are cultured in a steroid-free medium, aldosterone promotes acquisition of the adipose phenotype of 3T3-L1 and 3T3-F442A cells in a time-, dose-, and MR-dependent manner. In contrast, late and long-term exposure to dexamethasone inhibits adipocyte terminal maturation. The aldosterone effect on adipose maturation was accompanied by induction of PPAR gamma mRNA expression, which was blocked by the MR antagonist spironolactone. Under permissive culture conditions, specific MR down-regulation by siRNAs markedly inhibited 3T3-L1 differentiation by interfering with the transcriptional control of adipogenesis, an effect not mimicked by specific inactivation of the glucocorticoid receptor. These results demonstrate that MR represents an important proadipogenic transcription factor that may mediate both aldosterone and glucocorticoid effects on adipose tissue development. MR thus may be of pathophysiological relevance to the development of obesity and the metabolic syndrome.	Coll France, INSERM, U7721, F-75005 Paris, France; INSERM, U693, Fac Med Paris Sud, Le Kremlin Bicetre, France; Univ Paris 11, Orsay, France; Univ Roma Tor Vergata, Chair Endocrinol, Dept Internal Med, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Rome Tor Vergata	Zennaro, MC (corresponding author), Coll France, INSERM, U7721, 11,Pl M Berthelot, F-75005 Paris, France.	maria-christina.zennaro@college-de-france.fr	Caprio, Massimiliano/J-3020-2012; Viengchareun, Say/GOV-6812-2022; Lombes, Marc/L-5933-2018; Zennaro, Maria-Christina/G-2841-2013; Viengchareun, Say/M-6612-2017	Caprio, Massimiliano/0000-0003-0722-7163; Lombes, Marc/0000-0003-3189-023X; Zennaro, Maria-Christina/0000-0001-5449-9191; Feve, Bruno/0000-0001-6577-9009; viengchareun, say/0000-0003-4280-3250				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Bridgham JT, 2006, SCIENCE, V312, P97, DOI 10.1126/science.1123348; Ehrhart-Bornstein M, 2003, P NATL ACAD SCI USA, V100, P14211, DOI 10.1073/pnas.2336140100; Fallo F, 2006, J CLIN ENDOCR METAB, V91, P454, DOI 10.1210/jc.2005-1733; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1989, MOL CELL ENDOCRINOL, V67, P17, DOI 10.1016/0303-7207(89)90226-8; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Funder JW, 2005, HEART FAIL REV, V10, P15, DOI 10.1007/s10741-005-2344-2; Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Hellal-Levy C, 1999, FEBS LETT, V464, P9, DOI 10.1016/S0014-5793(99)01667-1; Hu X, 2006, MOL ENDOCRINOL, V20, P1471, DOI 10.1210/me.2005-0247; Kershaw EE, 2005, DIABETES, V54, P1023, DOI 10.2337/diabetes.54.4.1023; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Morton NM, 2004, DIABETES, V53, P931, DOI 10.2337/diabetes.53.4.931; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; RONDINONE CM, 1993, ENDOCRINOLOGY, V132, P2421, DOI 10.1210/en.132.6.2421; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Viengchareun S, 2001, AM J PHYSIOL-ENDOC M, V280, pE640, DOI 10.1152/ajpendo.2001.280.4.E640; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; Zennaro MC, 2001, MOL ENDOCRINOL, V15, P1586, DOI 10.1210/me.15.9.1586	36	238	256	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2185	2194		10.1096/fj.06-7970com	http://dx.doi.org/10.1096/fj.06-7970com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384139				2022-12-25	WOS:000247500300027
J	Gloster, TM; Ibatullin, FM; Macauley, K; Eklof, JM; Roberts, S; Turkenburg, JP; Bjornvad, ME; Jorgensen, PL; Danielsen, S; Johansen, KS; Borchert, TV; Wilson, KS; Brumer, H; Davies, GJ				Gloster, Tracey M.; Ibatullin, Farid M.; Macauley, Katherine; Eklof, Jens M.; Roberts, Shirley; Turkenburg, Johan P.; Bjornvad, Mads E.; Jorgensen, Per Lina; Danielsen, Steffen; Johansen, Katja S.; Borchert, Torben V.; Wilson, Keith S.; Brumer, Harry; Davies, Gideon J.			Characterization and three-dimensional structures of two distinct bacterial xyloglucanases from families GH5 and GH12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL COMPOSITION; CELLULOSE SURFACES; CRYSTAL-STRUCTURES; ENDOGLUCANASE; OLIGOSACCHARIDES; CLONING; REVEAL; BIOSYNTHESIS; EXPRESSION; SUBSTRATE	The plant cell wall is a complex material in which the cellulose microfibrils are embedded within a mesh of other polysaccharides, some of which are loosely termed "hemicellulose." One such hemicellulose is xyloglucan, which displays a beta-1,4-linked D-glucose backbone substituted with xylose, galactose, and occasionally fucose moieties. Both xyloglucan and the enzymes responsible for its modification and degradation are finding increasing prominence, reflecting both the drive for enzymatic biomass conversion, their role in detergent applications, and the utility of modified xyloglucans for cellulose fiber modification. Here we present the enzymatic characterization and three-dimensional structures in ligand free and xyloglucan- oligosaccharide complexed forms of two distinct xyloglucanases from glycoside hydrolase families GH5 and GH12. The enzymes, Paenibacillus pabuli XG5 and Bacillus licheniformis XG12, both display open active center grooves grafted upon their respective (beta/alpha)(8) and beta-jelly roll folds, in which the side chain decorations of xyloglucan may be accommodated. For the beta-jelly roll enzyme topology of GH12, binding of xylosyl and pendant galactosyl moieties is tolerated, but the enzymeis similarly competent in the degradation of unbranched glucans. In the case of the (beta/alpha)(8) GH5 enzyme, kinetically productive interactions are made with both xylose and galactose substituents, as reflected in both a high specific activity on xyloglucan and the kinetics of a series of aryl glycosides. The differential strategies for the accommodation of the side chains of xyloglucan presumably facilitate the action of these microbial hydrolases in milieus where diverse and differently substituted substrates may be encountered.	AlbaNova Univ Ctr, Sch Biotechnol, Royal Inst Technol, S-10691 Stockholm, Sweden; Novozymes A S, DK-2880 Bagsvaerd, Denmark	Royal Institute of Technology; Novozymes	Brumer, H (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	harry@biotech.kth.se; davies@ysbl.york.ac.uk	Ibatullin, Farid/B-2705-2012; Davies, Gideon J/A-9042-2011; Johansen, Katja/J-7939-2016; Johansen, Katja/E-9740-2013	Davies, Gideon J/0000-0002-7343-776X; Johansen, Katja/0000-0002-7587-5990; Ibatullin, Farid/0000-0002-7660-4172; Wilson, Keith/0000-0002-3581-2194; McAuley, Katherine/0000-0002-9545-072X; Turkenburg, Johan/0000-0001-6992-6838	Biotechnology and Biological Sciences Research Council [BB/D522511/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanco A, 1998, APPL MICROBIOL BIOT, V50, P48, DOI 10.1007/s002530051255; Brumer H, 2004, J AM CHEM SOC, V126, P5715, DOI 10.1021/ja0316770; Brummell DA, 2006, FUNCT PLANT BIOL, V33, P103, DOI 10.1071/FP05234; Buckeridge MS, 1997, CARBOHYD RES, V303, P233, DOI 10.1016/S0008-6215(97)00161-4; Buckeridge MS, 2000, PLANT PHYSIOL BIOCH, V38, P141, DOI 10.1016/S0981-9428(00)00162-5; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; Chanliaud E, 2004, PLANT J, V38, P27, DOI 10.1111/j.1365-313X.2004.02018.x; CLAEYSSENS M, 1992, BIORESOURCE TECHNOL, V39, P143, DOI 10.1016/0960-8524(92)90133-I; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Crennell SJ, 2002, J MOL BIOL, V320, P883, DOI 10.1016/S0022-2836(02)00446-1; DAPRANO A, 1968, P NATL ACAD SCI USA, V61, P1183, DOI 10.1073/pnas.61.4.1183; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005; DUCROS V, 1995, STRUCTURE, V3, P939, DOI 10.1016/S0969-2126(01)00228-3; Ducros VMA, 2003, CHEM BIOL, V10, P619, DOI 10.1016/S1074-5521(03)00143-1; Dunand C, 2000, PLANT SCI, V151, P183, DOI 10.1016/S0168-9452(99)00217-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Faure R, 2006, J ORG CHEM, V71, P5151, DOI 10.1021/jo0525682; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; Greffe L, 2005, GLYCOBIOLOGY, V15, P437, DOI 10.1093/glycob/cwi013; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hoffman M, 2005, CARBOHYD RES, V340, P1826, DOI 10.1016/j.carres.2005.04.016; Jia ZH, 2005, CARBOHYD RES, V340, P1818, DOI 10.1016/j.carres.2005.04.015; Johansson P, 2004, PLANT CELL, V16, P874, DOI 10.1105/tpc.020065; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lonnberg H, 2006, BIOMACROMOLECULES, V7, P2178, DOI 10.1021/bm060178z; Martinez-Fleites C, 2006, J BIOL CHEM, V281, P24922, DOI 10.1074/jbc.M603583200; Miyazaki S, 1998, J CONTROL RELEASE, V56, P75, DOI 10.1016/S0168-3659(98)00079-0; Miyazaki S, 2003, DRUG DEV IND PHARM, V29, P113, DOI 10.1081/DDC-120016718; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson N, 1944, J BIOL CHEM, V153, P375; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YW, 1997, BIOCHEM BIOPH RES CO, V241, P636, DOI 10.1006/bbrc.1997.7747; Pauly M, 1999, PLANT J, V20, P629, DOI 10.1046/j.1365-313X.1999.00630.x; Pauly M, 1999, GLYCOBIOLOGY, V9, P93, DOI 10.1093/glycob/9.1.93; Popper ZA, 2004, NEW PHYTOL, V164, P165, DOI 10.1111/j.1469-8137.2004.01146.x; Popper ZA, 2003, ANN BOT-LONDON, V91, P1, DOI 10.1093/aob/mcg013; Rao P S, 1973, IND GUMS; Reiter WD, 2002, CURR OPIN PLANT BIOL, V5, P536, DOI 10.1016/S1369-5266(02)00306-0; SAARILAHTI HT, 1990, GENE, V90, P9, DOI 10.1016/0378-1119(90)90433-R; Sandgren M, 2004, J MOL BIOL, V342, P1505, DOI 10.1016/j.jmb.2004.07.098; Scheible WR, 2004, CURR OPIN PLANT BIOL, V7, P285, DOI 10.1016/j.pbi.2004.03.006; Shankaracharya NB, 1998, J FOOD SCI TECH MYS, V35, P193; Shirakawa M, 1998, FOOD HYDROCOLLOID, V12, P25, DOI 10.1016/S0268-005X(98)00052-6; Sims IM, 1996, CARBOHYD RES, V293, P147, DOI 10.1016/0008-6215(96)00142-5; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Stiernstedt J, 2006, BIOMACROMOLECULES, V7, P2147, DOI 10.1021/bm060100i; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Thompson DS, 2005, J EXP BOT, V56, P2275, DOI 10.1093/jxb/eri247; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; Vargas-Rechia C, 1998, PLANT PHYSIOL, V116, P1013, DOI 10.1104/pp.116.3.1013; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vincken JP, 1997, CARBOHYD RES, V298, P299, DOI 10.1016/S0008-6215(96)00325-4; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; Vincken JP, 1996, CARBOHYD POLYM, V29, P75, DOI 10.1016/0144-8617(95)00149-2; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; Yaoi K, 2005, APPL ENVIRON MICROB, V71, P7670, DOI 10.1128/AEM.71.12.7670-7678.2005; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Zhou Q, 2006, CARBOHYD POLYM, V63, P449, DOI 10.1016/j.carbpol.2005.09.015; Zhou Q, 2005, MACROMOLECULES, V38, P3547, DOI 10.1021/ma047712k	68	92	92	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19177	19189		10.1074/jbc.M700224200	http://dx.doi.org/10.1074/jbc.M700224200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17376777	hybrid			2022-12-25	WOS:000247475300059
J	Papadopulos, A; Vehring, S; Lopez-Montero, I; Kutschenko, L; Stockl, M; Devaux, PF; Kozlov, M; Pomorski, T; Herrmann, A				Papadopulos, Andreas; Vehring, Stefanie; Lopez-Montero, Ivan; Kutschenko, Lara; Stoeckl, Martin; Devaux, Philippe F.; Kozlov, Michael; Pomorski, Thomas; Herrmann, Andreas			Flippase activity detected with unlabeled lipids by shape changes of giant unilamellar vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; RAPID TRANSBILAYER MOVEMENT; SPIN-LABELED LIPIDS; PHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-VESICLES; CYTOPLASMIC MEMBRANE; PROTEINS; ASYMMETRY; TRANSLOCATION; FLOP	Transbilayer movement of phospholipids in biological membranes is mediated by energy-dependent and energy-independent flippases. Available methods for detection of flippase mediated transversal flip-flop are essentially based on spin-labeled or fluorescent lipid analogues. Here we demonstrate that shape change of giant unilamellar vesicles (GUVs) can be used as a new tool to study the occurrence and time scale of flippase-mediated transbilayer movement of unlabeled phospholipids. Insertion of lipids into the external leaflet created an area difference between the two leaflets that caused the formation of a bud-like structure. Under conditions of negligible flip-flop, the bud was stable. Upon reconstitution of the energy-independent flippase activity of the yeast endoplasmic reticulum into GUVs, the initial bud formation was reversible, and the shapes were recovered. This can be ascribed to a rapid flip-flop leading to relaxation of the monolayer area difference. Theoretical analysis of kinetics of shape changes provides self-consistent determination of the flip-flop rate and further kinetic parameters. Based on that analysis, the half-time of phospholipid flip-flop in the presence of endoplasmic reticulum proteins was found to be on the order of few minutes. In contrast, GUVs reconstituted with influenza virus protein formed stable buds. The results argue for the presence of specific membrane proteins mediating rapid flip-flop.	Humboldt Univ, Mat Nat Wissensch Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany; Inst Biol Physicochim, F-75005 Paris, France; Tel Aviv Univ, Dept Physiol & Pharmacol, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Humboldt University of Berlin; Tel Aviv University; Sackler Faculty of Medicine	Pomorski, T (corresponding author), Humboldt Univ, Mat Nat Wissensch Fak 1, Inst Biol Biophys, Invalidenstr 42, D-10115 Berlin, Germany.	thomas.pomorski@rz.hu-berlin.de; andreas.herrmann@rz.hu-berlin.de	López-Montero, Iván/A-5263-2017; Stöckl, Martin T/I-6554-2016; Pomorski, Thomas Günther/G-4804-2014; Stöckl, Martin/AAM-6743-2020	López-Montero, Iván/0000-0001-8131-6063; Stöckl, Martin T/0000-0001-7986-9291; Pomorski, Thomas Günther/0000-0002-4889-0829; Stöckl, Martin/0000-0001-7986-9291; Papadopulos, Andreas/0000-0002-3376-1979				ADAMSON AW, 1990, PHYS CHEM SURFACES, P548; ALBERTY RA, 1983, PHYS CHEM, P275; ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; BERNDL K, 1990, EUROPHYS LETT, V13, P659, DOI 10.1209/0295-5075/13/7/015; BHAMIDIPATI SP, 1995, BIOCHEMISTRY-US, V34, P5666, DOI 10.1021/bi00016a043; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN SD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P13, DOI 10.1016/0005-2760(93)90260-G; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; DEKRUYFF B, 1977, BIOCHIM BIOPHYS ACTA, V465, P443, DOI 10.1016/0005-2736(77)90263-2; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; Eckford PDW, 2005, BIOCHEM J, V389, P517, DOI 10.1042/BJ20050047; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; Fellmann P, 1994, Methods Mol Biol, V27, P161; Girard P, 2004, BIOPHYS J, V87, P419, DOI 10.1529/biophysj.104.040360; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; HOPE MJ, 1989, BIOCHEMISTRY-US, V28, P4181, DOI 10.1021/bi00436a009; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; Kol MA, 2004, BIOCHEMISTRY-US, V43, P2673, DOI 10.1021/bi036200f; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; Lopez-Montero I, 2005, J BIOL CHEM, V280, P25811, DOI 10.1074/jbc.M412052200; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MUI BLS, 1995, BIOPHYS J, V69, P930, DOI 10.1016/S0006-3495(95)79967-2; Nicolson T, 2000, FEBS LETT, V476, P277, DOI 10.1016/S0014-5793(00)01684-7; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROUSER G, 1970, LIPIDS, V5, P496; Tanaka T, 2004, LANGMUIR, V20, P9526, DOI 10.1021/la049481g; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Vishwakarma RA, 2005, ORG BIOMOL CHEM, V3, P1275, DOI 10.1039/b500300h; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	38	47	47	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15559	15568		10.1074/jbc.M604740200	http://dx.doi.org/10.1074/jbc.M604740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369612	hybrid			2022-12-25	WOS:000246589600033
J	Su, G; Blaine, SA; Qiao, DH; Friedl, A				Su, Gui; Blaine, Stacy A.; Qiao, Dianhua; Friedl, Andreas			Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROSTATE EPITHELIAL-CELLS; GROWTH-FACTOR; SOLUBLE SYNDECAN-1; TUMOR MICROENVIRONMENT; MITOGENIC ACTIVITY; PROGNOSTIC-FACTOR; INTEGRIN ACTIVITY; CARCINOMA CELLS; CORE PROTEIN	The cell surface heparan sulfate proteoglycan syndecan-1 is induced in stromal fibroblasts of breast carcinomas and participates in a reciprocal feedback loop, which stimulates carcinoma cell growth in vitro and in vivo. To define the molecular mechanism of carcinoma growth stimulation, a three-dimensional co-culture model was developed that combines T47D breast carcinoma cells with immortalized human mammary fibroblasts in collagen gels. By silencing endogenous syndecan-1 induction with short interfering RNA and expressing mutant murine syndecan-1 constructs, it was determined that carcinoma cell mitogenesis required proteolytic shedding of syndecan-1 from the fibroblast surface. The paracrine growth signal was mediated by the syndecan-1 heparan sulfate chains rather than the ectodomain of the core protein and required fibroblast growth factor 2 and stroma-derived factor 1. This paracrine pathway may provide an opportunity for the therapeutic disruption of stroma-epithelial signaling.	Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4812, Madison, WI 53792 USA; Dept Vet Affairs Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4812, 600 Highland Ave, Madison, WI 53792 USA.	afriedl@wisc.edu			NATIONAL CANCER INSTITUTE [R01CA107012] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA107012-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Baba F, 2006, BREAST CANCER RES TR, V98, P91, DOI 10.1007/s10549-005-9135-2; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BROUTYBOYE D, 1993, ANTICANCER RES, V13, P1087; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Burbach BJ, 2003, MATRIX BIOL, V22, P163, DOI 10.1016/S0945-053X(03)00009-X; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Dillon C, 2004, J MAMMARY GLAND BIOL, V9, P207, DOI 10.1023/B:JOMG.0000037163.56461.1e; Ding K, 2005, J CELL BIOL, V171, P729, DOI 10.1083/jcb.200508010; Elenius V, 2004, J BIOL CHEM, V279, P41928, DOI 10.1074/jbc.M404506200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Feng SJ, 1997, CANCER RES, V57, P5369; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gudjonsson T, 2002, J CELL SCI, V115, P39; Hornby A E, 1995, EXS, V74, P249; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Joensuu H, 2002, CANCER RES, V62, P5210; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Langford JK, 2005, J BIOL CHEM, V280, P3467, DOI 10.1074/jbc.M412451200; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; Lee PHA, 2004, J BIOL CHEM, V279, P48640, DOI 10.1074/jbc.M407241200; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lovell R, 2005, BRIT J HAEMATOL, V130, P542, DOI 10.1111/j.1365-2141.2005.05647.x; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; MALI M, 1994, J BIOL CHEM, V269, P27795; Mathe M, 2006, ORAL ONCOL, V42, P493, DOI 10.1016/j.oraloncology.2005.10.003; McQuade KJ, 2006, J CELL SCI, V119, P2445, DOI 10.1242/jcs.02970; Mukunyadzi P, 2003, MODERN PATHOL, V16, P796, DOI 10.1097/01.MP.0000081731.17549.53; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shimazu A, 1999, J DENT RES, V78, P1791, DOI 10.1177/00220345990780120501; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Wang ZH, 2005, BIOCHEMISTRY-US, V44, P12355, DOI 10.1021/bi050620i; Wozniak MA, 2005, BIOL PROCED ONLINE, V7, P144, DOI 10.1251/bpo112; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Yu HM, 2005, LAB CHIP, V5, P1089, DOI 10.1039/b504403k	56	98	100	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14906	14915		10.1074/jbc.M611739200	http://dx.doi.org/10.1074/jbc.M611739200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17344212	hybrid			2022-12-25	WOS:000246589000028
J	Kilpatrick, EL; Hildebrandt, JD				Kilpatrick, Eric L.; Hildebrandt, John D.			Sequence dependence and differential expression of G gamma 5 subunit isoforms of the heterotrimeric G proteins variably processed after prenylation in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA DIMERS; RAS; INHIBITORS	Between 1 and 2% of proteins coded for in the human genome, including all G protein gamma subunits, are predicted to be prenylated. Subsequently, prenylated proteins are proteolytically cleaved at the C terminus and carboxymethylated. These reactions are generally obligatory events required for functional expression of prenylated proteins. The biological role of prenyl substrates has made these reactions significant targets for anticancer drug development. Understanding the enzymology of this pathway will be key to success for this strategy. When G gamma 1, -2, -4, -10, -11, -12, and -13 were expressed in HEK293 cells they were completely processed according to the current understanding of the prenylation reaction. In contrast, G gamma 5 was processed to two forms; a minor one, fully processed as predicted, and a major one that was prenylated without further processing. When the Ca(1)a(2)X motif of G gamma 5, CSFL, was exchanged for that of G gamma 2, CAIL, G gamma 5 was completely processed. Conversely, G gamma 2-SFL was incompletely processed. Differential processing of G gamma 5 was found due to the presence of an aromatic amino acid in its Ca(1)a(2)X motif. Retrieving endogenous G gamma subunits from HEK293 or Neuro-2a cells with FLAG-G beta constructs identified multiple G gamma subunits by mass spectrometry in either cell, but in both cases the most prominent one was G gamma 5 expressed without C-terminal processing after prenylation. This work indicates that post-prenylation reactions can generate multiple products determined by the C-terminal Ca(1)a(2)X motif. Within the human genome 10% of predicted prenylated proteins have aromatic amino acids in their Ca(1)a(2)X sequence and would likely generate the prenylation pattern described here.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29464 USA	Medical University of South Carolina	Hildebrandt, JD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29464 USA.	hildebjd@musc.edu			NIDDK NIH HHS [DK37219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Cook LA, 2006, MOL CELL PROTEOMICS, V5, P671, DOI 10.1074/mcp.M500223-MCP200; Cook LA, 1998, BIOCHEMISTRY-US, V37, P12280, DOI 10.1021/bi980230e; Cook LA, 2001, PROTEIN SCI, V10, P2548, DOI 10.1110/ps.ps.26401; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HORI Y, 1991, ONCOGENE, V6, P515; Jang GF, 1998, BIOCHEMISTRY-US, V37, P4473, DOI 10.1021/bi972289b; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; McIntire WE, 2006, BIOCHEMISTRY-US, V45, P11616, DOI 10.1021/bi0604882; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Morgan MA, 2003, LEUKEMIA, V17, P1482, DOI 10.1038/sj.leu.2403024; Morishita R, 1999, J NEUROCHEM, V73, P2369, DOI 10.1046/j.1471-4159.1999.0732369.x; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006-291X(03)00323-1; Rowinsky EK, 2006, J CLIN ONCOL, V24, P2981, DOI 10.1200/JCO.2006.05.9808; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WILCOX MD, 1995, BIOCHEM BIOPH RES CO, V212, P367, DOI 10.1006/bbrc.1995.1979; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	42	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14038	14047		10.1074/jbc.M701338200	http://dx.doi.org/10.1074/jbc.M701338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353195	hybrid			2022-12-25	WOS:000246245800013
J	Lagergren, A; Mansson, R; Zetterblad, J; Smith, E; Basta, B; Bryder, D; Akerblad, P; Sigvardsson, M				Lagergren, Anna; Mansson, Robert; Zetterblad, Jenny; Smith, Emma; Basta, Barbro; Bryder, David; Akerblad, Peter; Sigvardsson, Mikael			The Cxcl12, Periostin, and Ccl9 genes are direct targets for early B-cell factor in OP-9 stroma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTORS; INTERLEUKIN-7 RECEPTOR; MICE LACKING; NEURONAL DIFFERENTIATION; LYMPHOCYTE EXPANSION; HEMATOPOIETIC STEM; EXPRESSION; PROMOTER; EBF	The development of blood cells from hematopoietic stem cells in the bone marrow is dependent on communication with bone marrow stroma cells, making these cells central for the appropriate regulation of hematopoiesis. To identify transcription factors that may play a role in gene regulation in stroma cells, we performed comparative gene expression analysis of fibroblastic NIH3T3 cells, unable to support hematopoiesis in vitro, and OP-9 stroma cells, highly efficient in this regard. These experiments revealed that transcription factors of the early B cell factor (EBF) family were highly expressed in OP-9 cells as compared with the NIH3T3 cells. To identify potential targets genes for EBF proteins in stroma cells, we overexpressed EBF in fibroblasts and analyzed the pattern of induced genes by microarray analysis. This revealed that EBF was able to up-regulate expression of among others the Cxcl12, Ccl9, and Periostin genes. The identification of relevant promoters revealed that they all contained functional EBF binding sites able to interact with EBF in OP-9 cells. Furthermore, ectopic expression of a dominant negative EBF protein or antisense EBF-1 RNA in OP-9 stroma cells resulted in reduced expression of these target genes. These data suggest that EBF proteins might have dual roles in hematopoiesis acting both as intrinsic regulators of B-lymphopoiesis and as regulators of genes in bone marrow stroma cells.	Lund Univ, Lund Stemcell Ctr, Dept Hematopoet Stem Cell Biol, S-22184 Lund, Sweden; AstraZeneca R&D, Dept Mol Pharmacol, S-43183 Molndal, Sweden; Linkoping Univ, Univ Hlth Sci, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Lund University; AstraZeneca; Linkoping University	Sigvardsson, M (corresponding author), Lund Univ, Lund Stemcell Ctr, Dept Hematopoet Stem Cell Biol, BMC B12, S-22184 Lund, Sweden.	mikael.sigvardsson@stemcell.lu.se	Mansson, Robert/D-4372-2014; Bryder, David/Q-6292-2019	Mansson, Robert/0000-0003-0738-0328; Bryder, David/0000-0002-8761-4237; Smith, Emma/0000-0003-0609-4864; Sigvardsson, Mikael/0000-0001-8527-7276				Akerblad P, 2005, PHYSIOL GENOMICS, V23, P206, DOI 10.1152/physiolgenomics.00015.2005; Akerblad P, 1999, MOL CELL BIOL, V19, P392; Akerblad P, 2002, MOL CELL BIOL, V22, P8015, DOI 10.1128/MCB.22.22.8015-8025.2002; Akerblad P, 1999, J IMMUNOL, V163, P5453; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Corradi A, 2003, DEVELOPMENT, V130, P401, DOI 10.1242/dev.00215; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dubois L, 2001, MECH DEVELOP, V108, P3, DOI 10.1016/S0925-4773(01)00486-5; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Garcia-Dominguez M, 2003, DEVELOPMENT, V130, P6013, DOI 10.1242/dev.00840; Garel S, 1999, DEVELOPMENT, V126, P5285; Garel S, 1997, DEV DYNAM, V210, P191, DOI 10.1002/(SICI)1097-0177(199711)210:3<191::AID-AJA1>3.0.CO;2-B; Gisler R, 2002, J IMMUNOL, V168, P5130, DOI 10.4049/jimmunol.168.10.5130; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Jimenez MA, 2007, MOL CELL BIOL, V27, P743, DOI 10.1128/MCB.01557-06; Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009; Kieusseian A, 2006, BLOOD, V107, P492, DOI 10.1182/blood-2005-02-0529; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Lagergren A, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-80; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liberg D, 2002, MOL CELL BIOL, V22, P8389, DOI 10.1128/MCB.22.24.8389-8397.2002; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Mansson R, 2004, J BIOL CHEM, V279, P17905, DOI 10.1074/jbc.M400589200; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; SALCEDO R, 1995, CELL IMMUNOL, V160, P165, DOI 10.1016/0008-8749(95)80023-C; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Sicurella C, 2001, BLOOD CELL MOL DIS, V27, P470, DOI 10.1006/bcmd.2001.0407; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Sitnicka E, 2003, J EXP MED, V198, P1495, DOI 10.1084/jem.20031152; Smith EMK, 2005, BLOOD, V106, P1995, DOI 10.1182/blood-2004-12-4744; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Vieira Paulo, 2004, Methods Mol Biol, V271, P67; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wang SS, 2002, MOL CELL NEUROSCI, V20, P404, DOI 10.1006/mcne.2002.1138; Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	52	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14454	14462		10.1074/jbc.M610263200	http://dx.doi.org/10.1074/jbc.M610263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374609	hybrid			2022-12-25	WOS:000246245800059
J	Tanaka, S; Narita, S; Tokuda, H				Tanaka, Shin-ya; Narita, Shin-ichiro; Tokuda, Hajime			Characterization of the Pseudomonas aeruginosa Lol system as a lipoprotein sorting mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE LOCALIZATION; ABC TRANSPORTER; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; CELL-ENVELOPE; TRANSLOCATION; DETACHMENT; RELEASE; PEPTIDOGLYCAN	Escherichia coli lipoproteins are localized to either the inner or the outer membrane depending on the residue that is present next to the N- terminal acylated Cys. Asp at position 2 causes the retention of lipoproteins in the inner membrane. In contrast, the accompanying study ( 9) revealed that the residues at positions 3 and 4 determine the membrane specificity of lipoproteins in Pseudomonas aeruginosa. Since the five Lol proteins involved in the sorting of E. coli lipoproteins are conserved in P. aeruginosa, we examined whether or not the Lol proteins of P. aeruginosa are also involved in lipoprotein sorting but utilize different signals. The genes encoding LolCDE, LolA, and LolB homologues were cloned and expressed. The LolCDE homologue thus purified was reconstituted into proteoliposomes with lipoproteins. When incubated in the presence of ATP and a LolA homologue, the reconstituted LolCDE homologue released lipoproteins, leading to the formation of a LolA-lipoprotein complex. Lipoproteins were then incorporated into the outer membrane depending on a LolB homologue. As revealed in vivo, lipoproteins with Lys and Ser at positions 3 and 4, respectively, remained in proteoliposomes. On the other hand, E. coli LolCDE released lipoproteins with this signal and transferred them to LolA of not only E. coli but also P. aeruginosa. These results indicate that Lol proteins are responsible for the sorting of lipoproteins to the outer membrane of P. aeruginosa, as in the case of E. coli, but respond differently to inner membrane retention signals.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp		Narita, Shin-ichiro/0000-0001-9425-2943				Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; Ikegami A, 2005, BIOSCI BIOTECH BIOCH, V69, P1595, DOI 10.1271/bbb.69.1595; Ito Y, 2006, MOL MICROBIOL, V62, P1064, DOI 10.1111/j.1365-2958.2006.05378.x; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; Narita S, 2006, FEBS LETT, V580, P1164, DOI 10.1016/j.febslet.2005.10.038; Narita SI, 2007, J BIOL CHEM, V282, P13372, DOI 10.1074/jbc.M611839200; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Schulze RJ, 2006, MOL MICROBIOL, V59, P1473, DOI 10.1111/j.1365-2958.2006.05039.x; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; TANI K, 1990, J BIOL CHEM, V265, P17341; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995; YOKOTA N, 1999, J BIOL CHEM, V279, P25939; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506	31	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13379	13384		10.1074/jbc.M611840200	http://dx.doi.org/10.1074/jbc.M611840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350955	hybrid			2022-12-25	WOS:000246060300026
J	Fuller, GLJ; Williams, JAE; Tomlinson, MG; Eble, JA; Hanna, SL; Pohlmann, S; Suzuki-Inoue, K; Ozaki, Y; Watson, SP; Pearce, AC				Fuller, Gemma L. J.; Williams, Jennifer A. E.; Tomlinson, Michael G.; Eble, Johannes A.; Hanna, Sheri L.; Pohlmann, Stefan; Suzuki-Inoue, Katsue; Ozaki, Yukio; Watson, Steve P.; Pearce, Andrew C.			The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; IMMUNODEFICIENCY-VIRUS TYPE-1; TANDEM SH2 DOMAINS; ANTIGEN-RECEPTOR; PLATELET ACTIVATION; INTEGRIN ALPHA(2)BETA(1); PHOSPHOLIPASE C-GAMMA-2; GLYCOPROTEIN-VI; ZAP-70 BIND; SYK	The two lectin receptors, CLEC-2 and Dectin-1, have been shown to signal through a Syk-dependent pathway, despite the presence of only a single YXXL in their cytosolic tails. In this study, we show that stimulation of CLEC-2 in platelets and in two mutant cell lines is dependent on the YXXL motif and on proteins that participate in signaling by immunoreceptor tyrosine-based activation motif receptors, including Src, Syk, and Tec family kinases, and on phospholipase C gamma. Strikingly, mutation of either Src homology (SH) 2 domain of Syk blocks signaling by CLEC-2 despite the fact that it has only a single YXXL motif. Furthermore, signaling by CLEC-2 is only partially dependent on the BLNK/ SLP-76 family of adapter proteins in contrast to that of immunoreceptor tyrosinebased activation motif receptors. The C-type lectin receptor, Dectin-1, which contains a YXXL motif preceded by the same four amino acids as for CLEC-2 ( DEDG), signals like CLEC-2 and also requires the two SH2 domains of Syk and is only partially dependent on the BLNK/SLP-76 family of adapters. In marked contrast, the C-type lectin receptor, DCSIGN, which has a distinct series of amino acids preceding a single YXXL, signals independent of this motif. A mutational analysis of the DEDG sequence of CLEC-2 revealed that the glycine residue directly upstream of the YXXL tyrosine is important for CLEC-2 signaling. These results demonstrate that CLEC-2 and Dectin-1 signal through a single YXXL motif that requires the tandem SH2 domains of Syk but is only partially dependent on the SLP- 76/ BLNK family of adapters.	Univ Birmingham, Biomed Res Inst, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Yamanashi Univ, Dept Clin Lab & Med, Yamanashi 4093898, Japan	University of Birmingham; University of Munster; University of Pennsylvania; University of Erlangen Nuremberg; University of Yamanashi	Pearce, AC (corresponding author), Univ Birmingham, Biomed Res Inst, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England.	a.c.pearce@bham.ac.uk	Pöhlmann, Stefan/H-2395-2011; Watson, Stephen P/Q-6292-2016	Pöhlmann, Stefan/0000-0001-6086-9136; Watson, Stephen P/0000-0002-7846-7423; Tomlinson, Michael/0000-0002-1189-0091	MRC [G0400247] Funding Source: UKRI; British Heart Foundation [PG/02/036/13595] Funding Source: Medline; Medical Research Council [G0400247] Funding Source: Medline; Wellcome Trust [073107] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; Bori-Sanz T, 2003, J BIOL CHEM, V278, P35914, DOI 10.1074/jbc.M301826200; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252; Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06; Chung CH, 2001, BIOCHEM BIOPH RES CO, V285, P689, DOI 10.1006/bbrc.2001.5228; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Colonna M, 2000, EUR J IMMUNOL, V30, P697; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Drickamer K, 2002, BIOCHEM SOC SYMP, V69, P59; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Levi M, 2005, HEMATOLOGY, V10, P129, DOI 10.1080/10245330512331390177; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Lin J, 2001, J CELL SCI, V114, P243; Liu HH, 2006, ACTA PHYS-CHIM SIN, V22, P868, DOI 10.3866/PKU.WHXB20060720; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Pao LI, 1998, J IMMUNOL, V160, P3305; Pearce AC, 2004, J BIOL CHEM, V279, P53955, DOI 10.1074/jbc.M410355200; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Qi RM, 1999, BBA-MOL CELL RES, V1451, P353, DOI 10.1016/S0167-4889(99)00105-6; Quek LS, 2000, BLOOD, V96, P4246; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Scaradavou A, 2002, BLOOD REV, V16, P73, DOI 10.1054/blre.2001.0188; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Suzuki-Inoue K, 2006, BLOOD, V107, P542, DOI 10.1182/blood-2005-05-1994; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wang LD, 2003, IMMUNOLOGY, V110, P411, DOI 10.1111/j.1365-2567.2003.01756.x; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538-7836.2005.01429.x; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413	64	165	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12397	12409		10.1074/jbc.M609558200	http://dx.doi.org/10.1074/jbc.M609558200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339324	Green Accepted, hybrid			2022-12-25	WOS:000245942800008
J	Li, SY; Gruschow, S; Dordick, JS; Sherman, DH				Li, Shengying; Gruschow, Sabine; Dordick, Jonathan S.; Sherman, David H.			Molecular analysis of the role of tyrosine 224 in the active site of Streptomyces coelicolor RppA, a bacterial type III polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; CHALCONE SYNTHASE; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-FLUORESCENS; BIOSYNTHESIS; PATHWAY; ANTIBIOTICS; MANIPULATION; SUPERFAMILY; METABOLITES	Streptomyces coelicolor RppA (Sc-RppA), a bacterial type III polyketide synthase, utilizes malonyl-CoA as both starter and extender unit substrate to form 1,3,6,8-tetrahydroxynaphthalene (THN) (therefore RppA is also known as THN synthase (THNS)). The significance of the active site Tyr224 for substrate specificity has been established previously, and its aromatic ring is believed to be essential for RppA to select malonyl-CoA as starter unit. Herein, we describe a series of Tyr224 mutants of Sc-RppA including Y224F, Y224L, Y224C, Y224M, and Y224A that were able to catalyze a physiological assembly of THN, albeit with lower efficiency, challenging the necessity for the Tyr224 aromatic ring. Steady-state kinetics and radioactive substrate binding analysis of the mutant enzymes corroborated these unexpected results. Functional examination of the Tyr224 series of RppA mutants using diverse unnatural acyl-CoA substrates revealed the unique role of malonyl-CoA as starter unit substrate for RppA, leading to the development of a novel steric-electronic constraint model.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Rensselaer Polytechnic Institute	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	davidhs@umich.edu			PHS HHS [M66712] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe I, 2005, J AM CHEM SOC, V127, P12709, DOI 10.1021/ja053945v; Abe I, 2005, J AM CHEM SOC, V127, P1362, DOI 10.1021/ja0431206; Abe I, 2004, FEBS LETT, V562, P171, DOI 10.1016/S0014-5793(04)00230-3; Achkar J, 2005, J AM CHEM SOC, V127, P5332, DOI 10.1021/ja042340g; Akiyama T, 1999, EUR J BIOCHEM, V263, P834, DOI 10.1046/j.1432-1327.1999.00562.x; Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bangera MG, 1999, J BACTERIOL, V181, P3155, DOI 10.1128/JB.181.10.3155-3163.1999; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, J BIOL CHEM, V277, P4628, DOI 10.1074/jbc.M110357200; Funa N, 2002, BIOCHEM J, V367, P781, DOI 10.1042/BJ20020953; Gerth K, 2003, J BIOTECHNOL, V106, P233, DOI 10.1016/j.jbiotec.2003.07.015; Gross F, 2006, ARCH MICROBIOL, V185, P28, DOI 10.1007/s00203-005-0059-3; HAHLBROCK K, 1972, H-S Z PHYSIOL CHEM, V353, P1522; HELARIUTTA Y, 1995, PLANT MOL BIOL, V28, P47, DOI 10.1007/BF00042037; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; Jeong JC, 2005, J AM CHEM SOC, V127, P64, DOI 10.1021/ja0441559; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; Jez JM, 2001, BIOCHEMISTRY-US, V40, P14829, DOI 10.1021/bi015621z; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Li TL, 2001, CHEM COMMUN, P2156, DOI 10.1039/b106638b; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Paniego NB, 1999, EUR J BIOCHEM, V262, P612, DOI 10.1046/j.1432-1327.1999.00444.x; Pfeifer V, 2001, J BIOL CHEM, V276, P38370, DOI 10.1074/jbc.M106580200; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; Seshime Y, 2005, BIOCHEM BIOPH RES CO, V331, P253, DOI 10.1016/j.bbrc.2005.03.160; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tseng CC, 2004, BIOCHEMISTRY-US, V43, P970, DOI 10.1021/bi035714b; Zha WJ, 2006, J BIOL CHEM, V281, P32036, DOI 10.1074/jbc.M606500200	33	14	15	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12765	12772		10.1074/jbc.M700393200	http://dx.doi.org/10.1074/jbc.M700393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331946	hybrid			2022-12-25	WOS:000245942800047
J	Bhat, R; Watzl, C				Bhat, Rauf; Watzl, Carsten			Serial Killing of Tumor Cells by Human Natural Killer Cells - Enhancement by Therapeutic Antibodies	PLOS ONE			English	Article								Background. Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell cytotoxicity. Methodology/Principal Findings. We observe that IL-2 activated human NK cells can serially hit multiple targets. Using functional assays, we demonstrate that on an average, a single IL-2 activated NK cell can kill four target cells. Data using live video microscopy suggest that an individual NK cell can make serial contacts with multiple targets and majority of contacts lead to lysis of target cells. Serial killing is associated with a loss of Perforin and Granzyme B content. A large majority of NK cells survive serial killing, and IL-2 can replenish their granular stock and restore the diminished cytotoxicity of 'exhausted' NK cells. IL-2 and IL-15 are equally effective in enhancing the killing frequency of resting NK cells. Significantly, Rituximab, a therapeutic monoclonal antibody increases the killing frequency of both resting and IL-2 activated NK cells. Conclusion/Significance. Our data suggest that NK cell-based therapies for overcoming tumors rely on their serial killing ability. Therefore, strategies augmenting the killing ability of NK cells can boost the immune system and enhance the effectiveness of monoclonal antibody-based therapies.	[Bhat, Rauf; Watzl, Carsten] Heidelberg Univ, Inst Immunol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Watzl, C (corresponding author), Heidelberg Univ, Inst Immunol, Neuenheimer Feld 305, D-6900 Heidelberg, Germany.	Carsten.watzl@urz.uni-heidelberg.de	Watzl, Carsten/B-4911-2013; Bhat, Rauf/AGI-1900-2022	Watzl, Carsten/0000-0001-5195-0995; Bhat, Rauf/0000-0001-8503-2447	Deutsche Forschungsgemeinschaft (DFG) [SFB405, A9, A13]; Deutsche Krebshilfe; BioFuture Program of the BMBF	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); BioFuture Program of the BMBF	This work was supported by the Deutsche Forschungsgemeinschaft (DFG, SFB405, A9, A13), the Deutsche Krebshilfe and the BioFuture Program of the BMBF. Other than financial support, these funders had no impact in this study.	Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Eisenbeis CF, 2004, CLIN CANCER RES, V10, P6101, DOI 10.1158/1078-0432.CCR-04-0525; Gluck WL, 2004, CLIN CANCER RES, V10, P2253, DOI 10.1158/1078-0432.CCR-1087-3; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; Jewett A, 1996, J IMMUNOL, V156, P907; JEWETT A, 1995, CELL IMMUNOL, V160, P91, DOI 10.1016/0008-8749(95)80013-9; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; MARTZ E, 1976, TRANSPLANTATION, V21, P5, DOI 10.1097/00007890-197601000-00002; PERELSON AS, 1982, J IMMUNOL, V129, P2796; PERELSON AS, 1984, J IMMUNOL, V132, P2190; Sandusky MM, 2006, EUR J IMMUNOL, V36, P3268, DOI 10.1002/eji.200636146; THORN RM, 1976, J IMMUNOL, V117, P2213; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Wiedemann A, 2006, P NATL ACAD SCI USA, V103, P10985, DOI 10.1073/pnas.0600651103; Wulfing C, 2003, P NATL ACAD SCI USA, V100, P7767, DOI 10.1073/pnas.1336920100	22	176	182	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e326	10.1371/journal.pone.0000326	http://dx.doi.org/10.1371/journal.pone.0000326			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389917	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200009
J	Lu, XY; Shaw, CA; Patel, A; Li, JZ; Cooper, ML; Wells, WR; Sullivan, CM; Sahoo, T; Yatsenko, SA; Bacino, CA; Stankiewicz, P; Ou, ZS; Chinault, AC; Beaudet, AL; Lupski, JR; Cheung, SW; Ward, PA				Lu, Xinyan; Shaw, Chad A.; Patel, Ankita; Li, Jiangzhen; Cooper, M. Lance; Wells, William R.; Sullivan, Cathy M.; Sahoo, Trilochan; Yatsenko, Svetlana A.; Bacino, Carlos A.; Stankiewicz, Pawel; Ou, Zhishu; Chinault, A. Craig; Beaudet, Arthur L.; Lupski, James R.; Cheung, Sau W.; Ward, Patricia A.			Clinical Implementation of Chromosomal Microarray Analysis: Summary of 2513 Postnatal Cases	PLOS ONE			English	Article								Background. Array Comparative Genomic Hybridization (a-CGH) is a powerful molecular cytogenetic tool to detect genomic imbalances and study disease mechanism and pathogenesis. We report our experience with the clinical implementation of this high resolution human genome analysis, referred to as Chromosomal Microarray Analysis (CMA). Methods and Findings. CMA was performed clinically on 2513 postnatal samples from patients referred with a variety of clinical phenotypes. The initial 775 samples were studied using CMA array version 4 and the remaining 1738 samples were analyzed with CMA version 5 containing expanded genomic coverage. Overall, CMA identified clinically relevant genomic imbalances in 8.5% of patients: 7.6% using V4 and 8.9% using V5. Among 117 cases referred for additional investigation of a known cytogenetically detectable rearrangement, CMA identified the majority (92.5%) of the genomic imbalances. Importantly, abnormal CMA findings were observed in 5.2% of patients (98/1872) with normal karyotypes/FISH results, and V5, with expanded genomic coverage, enabled a higher detection rate in this category than V4. For cases without cytogenetic results available, 8.0% (42/524) abnormal CMA results were detected; again, V5 demonstrated an increased ability to detect abnormality. Improved diagnostic potential of CMA is illustrated by 90 cases identified with 51 cryptic microdeletions and 39 predicted apparent reciprocal microduplications in 13 specific chromosomal regions associated with 11 known genomic disorders. In addition, CMA identified copy number variations (CNVs) of uncertain significance in 262 probands; however, parental studies usually facilitated clinical interpretation. Of these, 217 were interpreted as familial variants and 11 were determined to be de novo; the remaining 34 await parental studies to resolve the clinical significance. Conclusions. This large set of clinical results demonstrates the significantly improved sensitivity of CMA for the detection of clinically relevant genomic imbalances and highlights the need for comprehensive genetic counseling to facilitate accurate clinical correlation and interpretation.	[Lu, Xinyan; Shaw, Chad A.; Patel, Ankita; Li, Jiangzhen; Cooper, M. Lance; Wells, William R.; Sullivan, Cathy M.; Sahoo, Trilochan; Yatsenko, Svetlana A.; Bacino, Carlos A.; Stankiewicz, Pawel; Ou, Zhishu; Chinault, A. Craig; Beaudet, Arthur L.; Lupski, James R.; Cheung, Sau W.; Ward, Patricia A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Cheung, SW (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	scheung@bcm.tmc.edu	Stankiewicz, Paweł/AAP-7906-2021; Patel, Ankita/D-3247-2013	Stankiewicz, Paweł/0000-0002-6456-7490; Shaw, Chad/0000-0001-7267-5398				Baldocchi RA, 2005, CYTOM PART A, V67A, P129, DOI 10.1002/cyto.a.20161; Bejjani BA, 2005, AM J MED GENET A, V134A, P259, DOI 10.1002/ajmg.a.30621; Biesecker LG, 2002, AM J MED GENET, V107, P263, DOI 10.1002/ajmg.10160.abs; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Cheung SW, 2005, GENET MED, V7, P422, DOI 10.1097/01.GIM.0000170992.63691.32; CHEUNG SW, 2007, AM J MED GE IN PRESS; Ciccone R, 2005, HUM GENET, V117, P571, DOI 10.1007/s00439-005-1324-x; de Vries BBA, 2005, AM J HUM GENET, V77, P606, DOI 10.1086/491719; del Gaudio D, 2006, GENET MED, V8, P784, DOI 10.1097/01.gim.0000250502.28516.3c; Dhami P, 2005, AM J HUM GENET, V76, P750, DOI 10.1086/429588; Fauth C, 2006, HUM GENET, V119, P145, DOI 10.1007/s00439-005-0103-z; Friedman JM, 2006, AM J HUM GENET, V79, P500, DOI 10.1086/507471; Goidts V, 2006, HUM GENET, V119, P185, DOI 10.1007/s00439-005-0130-9; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; Gribble SM, 2004, CHROMOSOME RES, V12, P35, DOI 10.1023/B:CHRO.0000009325.69828.83; Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158; Hwang KS, 2005, AM J MED GENET A, V137A, P88, DOI 10.1002/ajmg.a.30858; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Inoue K, 2002, ANNU REV GENOM HUM G, V3, P199, DOI 10.1146/annurev.genom.3.032802.120023; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Kireeva N, 2004, J CELL BIOL, V166, P775, DOI 10.1083/jcb.200406049; Koolen DA, 2005, EUR J HUM GENET, V13, P1019, DOI 10.1038/sj.ejhg.5201456; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; LE CC, 2005, AM J MED GENET A, V132, P175; Lee JA, 2005, PRENATAL DIAG, V25, P1188, DOI 10.1002/pd.1308; LENNON PA, 2007, AM J MED GE IN PRESS; Lu XY, 2002, LEUKEMIA, V16, P2222, DOI 10.1038/sj.leu.2402662; Lupski J.R., 2006, GENOMIC DISORDERS TH; Lupski JR, 2006, NAT GENET, V38, P974, DOI 10.1038/ng0906-974; Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Lupski JR, 1998, MOL MED, V4, P3, DOI 10.1007/BF03401724; LUPSKI JR, 2007, N ENGL J MED UNPUB; Menten B, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039453; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Miura S, 2006, J HUM GENET, V51, P412, DOI 10.1007/s10038-006-0376-7; Peng HH, 2006, J REPROD MED, V51, P438; Pinkel D, 2005, ANNU REV GENOM HUM G, V6, P331, DOI 10.1146/annurev.genom.6.080604.162140; POTOCKI L, 2007, AM J HUM GE IN PRESS; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Ravnan JB, 2006, J MED GENET, V43, P478, DOI 10.1136/jmg.2005.036350; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Rickman L, 2005, EUR J MED GENET, V48, P232, DOI 10.1016/j.ejmg.2005.03.003; Rickman L, 2006, J MED GENET, V43, P353, DOI 10.1136/jmg.2005.037648; Rosenberg C, 2005, HUM GENET, V116, P390, DOI 10.1007/s00439-004-1248-x; Sahoo T, 2006, GENET MED, V8, P719, DOI 10.1097/01.gim.0000245576.47154.63; Schulz R, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl461; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S; Shaffer LG, 2000, ANNU REV GENET, V34, P297, DOI 10.1146/annurev.genet.34.1.297; Shaffer UG, 2006, J PEDIATR-US, V149, P98, DOI 10.1016/j.jpeds.2006.02.006; Shaw CJ, 2004, J MED GENET, V41, P113, DOI 10.1136/jmg.2003.012831; Shaw-Smith C, 2004, J MED GENET, V41, P241, DOI 10.1136/jmg.2003.017731; Shopland LS, 2006, J CELL BIOL, V174, P27, DOI 10.1083/jcb.200603083; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Speicher MR, 2005, NAT REV GENET, V6, P782, DOI 10.1038/nrg1692; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Tyson C, 2005, AM J MED GENET A, V139A, P173, DOI 10.1002/ajmg.a.31015; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; Vermeesch JR, 2005, J HISTOCHEM CYTOCHEM, V53, P413, DOI 10.1369/jhc.4A6436.2005; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; Vissers LELM, 2005, HUM MOL GENET, V14, pR215, DOI 10.1093/hmg/ddi268; Wilson GM, 2006, GENOME RES, V16, P173, DOI 10.1101/gr.4456006; Yu W, 2003, HUM MOL GENET, V12, P2145, DOI 10.1093/hmg/ddg230	66	173	176	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e327	10.1371/journal.pone.0000327	http://dx.doi.org/10.1371/journal.pone.0000327			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389918	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445200010
J	Gu, XXJ; Yue, FY; Kovacs, CM; Ostrowski, MA				Gu, Xiao Xiao Jenny; Yue, Feng Yun; Kovacs, Colin M.; Ostrowski, Mario A.			The Role of Cytokines which Signal through the Common gamma Chain Cytokine Receptor in the Reversal of HIV Specific CD4(+) and CD8(+) T Cell Anergy	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMARY IMMUNE-RESPONSE; LYMPHOCYTE RESPONSE; CROSS-LINKING; INTERLEUKIN-2; INFECTION; MEMORY; IL-2; PROLIFERATION; PROGRESSION	Background. HIV specific T cells are putatively anergic in vivo. IL-2, a member of a class of cytokines that binds to receptors containing the common gamma chain (gamma c) has been shown to reverse anergy. We examined the role of gamma c cytokines in reversing HIV specific T cell anergy. Methods. PBMC from untreated HIV-infected individuals were briefly exposed to a panel of gamma c cytokines, and frequencies of gag specific T cells were enumerated by intracellular IFN-gamma flow cytometry. Results. Of the gamma c cytokines, brief exposure to IL-2, IL-15, or combined IL-15/IL-7 significantly enhanced (range 2-7 fold) the CD4(+) and CD8(+) T cell IFN-gamma responses to HIV gag, with IL-15 giving the greatest enhancement. The effects of cytokines were not due to enhanced proliferation of pre-existing antigen specific cells, but were due to a combination of enhanced cytokine production from antigen specific T cells plus activation of non-epitope specific T cells. Conclusions. These observations support the notion that a significant number of HIV specific T cells are circulating in an anergic state. IL-2, IL-7 and particularly IL-15 as an immune modulator to reverse HIV-1 specific T cell anergy should be investigated, with the caveat that non-specific activation of T cells may also be induced.	[Gu, Xiao Xiao Jenny; Yue, Feng Yun; Kovacs, Colin M.; Ostrowski, Mario A.] Univ Toronto, Div Clin Sci, Toronto, ON, Canada; [Ostrowski, Mario A.] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Kovacs, Colin M.] CIRC, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Ostrowski, MA (corresponding author), Univ Toronto, Div Clin Sci, Toronto, ON, Canada.	m.ostrowski@utoronto.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Ontario HIV Treatment Network, Canadian Institutes of Health Research	Arno A, 1999, J INFECT DIS, V180, P56, DOI 10.1086/314831; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; Biglino A, 1996, CLIN IMMUNOL IMMUNOP, V78, P61, DOI 10.1006/clin.1996.0009; Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866; Calarota SA, 2003, J IMMUNOL METHODS, V279, P55, DOI 10.1016/S0022-1759(03)00246-1; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Chitnis V, 2003, CLIN IMMUNOL, V107, P36, DOI 10.1016/S1521-6616(02)00051-7; Clark S J, 1993, Semin Immunol, V5, P149, DOI 10.1006/smim.1993.1018; Collins KL, 2003, CURR HIV RES, V1, P31, DOI 10.2174/1570162033352138; Dybul M, 2002, J INFECT DIS, V185, P61, DOI 10.1086/338123; Gea-Banacloche JC, 2000, J IMMUNOL, V165, P1082, DOI 10.4049/jimmunol.165.2.1082; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Goepfert PA, 2000, J VIROL, V74, P10249, DOI 10.1128/JVI.74.21.10249-10255.2000; Iyasere C, 2003, J VIROL, V77, P10900, DOI 10.1128/JVI.77.20.10900-10909.2003; Jennes W, 2002, J IMMUNOL METHODS, V270, P99, DOI 10.1016/S0022-1759(02)00275-2; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Lane C, 1997, AIDS Treat News, P1; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Liu KB, 2002, P NATL ACAD SCI USA, V99, P6192, DOI 10.1073/pnas.092675799; McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598; MIGUELES SA, 2002, NAT IMMUNOL, V7, P7; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Reusser P, 1999, J INFECT DIS, V180, P247, DOI 10.1086/314879; ROOS MTL, 1994, AIDS, V8, P1533, DOI 10.1097/00002030-199411000-00003; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenberg ES, 1999, IMMUNOL LETT, V66, P89, DOI 10.1016/S0165-2478(98)00165-5; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Scriba TJ, 2005, J CLIN INVEST, V115, P443, DOI 10.1172/JCI200523084; Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101; Vogel TU, 2001, J VIROL, V75, P2458, DOI 10.1128/JVI.75.5.2458-2461.2001; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Yue FY, 2004, J IMMUNOL, V172, P2476, DOI 10.4049/jimmunol.172.4.2476	39	24	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e300	10.1371/journal.pone.0000300	http://dx.doi.org/10.1371/journal.pone.0000300			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375186	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445100002
J	Coll, BA; Garcia, RA; Marmer, WN				Coll, Brian A.; Garcia, Rafael A.; Marmer, William N.			Diffusion of Protease into Meat & Bone Meal for Solubility Improvement and Potential Inactivation of the BSE Prion	PLOS ONE			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; ENZYME INFUSION; HYDROLYSIS; RELEVANT; NITRITE; NITRATE	Background. Government-imposed feed bans have created a need for new applications for meat & bone meal (MBM). Many potential new applications require MBM protein to be both soluble and free of infectious prion. Treatment with protease is generally effective in reducing insoluble, thermally-denatured proteins to soluble peptides. It has been reported in the literature that certain proteases, including Versazyme (TM), are able to degrade infectious prions in a system where the prions are readily accessible to proteolytic attack. Prions distributed within MBM, however, may conceivably be protected from proteases. Methodology/Principal Findings. The overall rate of proteolytic MBM digestion depends greatly on whether the protease can penetrate deep within individual particles, or if the protease can only act near the surface of the particle. This research examined the barriers to the diffusion of Versazyme (TM) into particles of MBM. Confocal microscopy demonstrated differences in the density distributions between the bone and the soft tissue particles of MBM. By tracking the diffusion of fluorescently labeled Versazyme (TM) through individual particles, it was found that bone particles show full Versazyme (TM) penetration within 30 minutes, while penetration of soft tissue particles can take up to four hours, depending on the particle's diameter. From the variety of normal proteins comprising MBM, a specific protein was chosen to serve as a prion surrogate based on characteristics including size, solubility, distribution and abundance. This surrogate was used to measure the effect of several factors on Versazyme (TM) diffusion. Conclusions/Significance. Results showed that surrogate distributed in bone particles was more susceptible to degradation than that in soft tissue particles. Three factors controllable by unit operations in an industrial-scale process were also tested. It was found that removing the lipid content and hydrating MBM prior to incubation both significantly increased the rate of surrogate degradation. In a test of particle size, the smallest collected diameter range demonstrated the largest degradation of the prion surrogate, suggesting milling would be beneficial.	[Coll, Brian A.; Garcia, Rafael A.; Marmer, William N.] ARS, USDA, Eastern Reg Res Ctr, Fats Oils & Anim Coprod Res Unit, Wyndmoor, PA USA; [Coll, Brian A.] Widener Univ, Dept Chem Engn, Chester, PA 19013 USA	United States Department of Agriculture (USDA); Widener University	Garcia, RA (corresponding author), ARS, USDA, Eastern Reg Res Ctr, Fats Oils & Anim Coprod Res Unit, Wyndmoor, PA USA.	Rafael.Garcia@ars.usda.gov	Garcia, Rafael A./D-2796-2009	Garcia, Rafael A./0000-0002-5452-3929	Fats and Proteins Research Foundation, Alexandria, VA	Fats and Proteins Research Foundation, Alexandria, VA	This research was supported in part by a grant from the Fats and Proteins Research Foundation, Alexandria, VA.	Baker RA, 1996, TRENDS FOOD SCI TECH, V7, P279, DOI 10.1016/0924-2244(96)10030-3; CAPARELLA T, 2006, RENDER, P32; CAPARELLA T, 2006, RENDER, P39; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; CHO HJ, 1983, CAN J COMP MED, V47, P494; Culver CA, 2000, J AGR FOOD CHEM, V48, P5933, DOI 10.1021/jf000094w; FOX JB, 1980, J FOOD SCI, V45, P1740, DOI 10.1111/j.1365-2621.1980.tb07601.x; Garcia RA, 2006, APPL ENG AGRIC, V22, P729; Heilemann M, 2002, DEUT TIERARZTL WOCH, V109, P354; Hui Z, 2004, BIOCHEM BIOPH RES CO, V321, P45, DOI 10.1016/j.bbrc.2004.06.100; Jung S, 2004, J AM OIL CHEM SOC, V81, P953, DOI 10.1007/s11746-004-1007-3; Kalambura S., 2005, Krmiva, V47, P97; Kasermann F, 2003, J GEN VIROL, V84, P3173, DOI 10.1099/vir.0.19355-0; Langeveld JPM, 2003, J INFECT DIS, V188, P1782, DOI 10.1086/379664; Matthews D, 2003, REV SCI TECH OIE, V22, P283, DOI 10.20506/rst.22.1.1393; NASH A, 1971, J FOOD SCI, V36, P930, DOI 10.1111/j.1365-2621.1971.tb15562.x; Novakofski J, 2005, J ANIM SCI, V83, P1455; Oidtmann B, 2003, ARCH LEBENSMITTELHYG, V54, P141; Park SK, 2000, J AM OIL CHEM SOC, V77, P1223, DOI 10.1007/s11746-000-0191-5; Pinotti A, 2002, J FOOD SCI, V67, P2165, DOI 10.1111/j.1365-2621.2002.tb09521.x; QUAGLIA GB, 1987, J SCI FOOD AGR, V38, P271, DOI 10.1002/jsfa.2740380311; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Struckmann P., 2004, VGB Powertech, V85, P72; Taylor DM, 2003, REV SCI TECH OIE, V22, P297, DOI 10.20506/rst.22.1.1400; Taylor MM, 2006, J AM LEATHER CHEM AS, V101, P169; Tsiroulnikov K, 2004, J AGR FOOD CHEM, V52, P6353, DOI 10.1021/jf0493324; Varzakas TH, 2005, LWT-FOOD SCI TECHNOL, V38, P239, DOI 10.1016/j.lwt.2004.05.009; WEBSTER JD, 1982, MEAT SCI, V7, P147, DOI 10.1016/0309-1740(82)90080-8; Whiteman MD, 2003, BIOPHARM INT, V16, P20; Yokoyama T, 2006, SOIL SCI PLANT NUTR, V52, P71, DOI 10.1111/j.1747-0765.2006.00011.x	30	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e245	10.1371/journal.pone.0000245	http://dx.doi.org/10.1371/journal.pone.0000245			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327909	gold, Green Published			2022-12-25	WOS:000207444600005
J	McConnell, JL; Gomez, RJ; McCorvey, LRA; Law, BK; Wadzinski, BE				McConnell, J. L.; Gomez, R. J.; McCorvey, L. R. A.; Law, B. K.; Wadzinski, B. E.			Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway	ONCOGENE			English	Article						PP2A; TIP; alpha4; ATM/ATR; Tip41; Tap42	CATALYTIC SUBUNIT; TOR PROTEINS; CELL-GROWTH; 2A PP2A; BINDING; FAMILY; PURIFICATION; TAP42; ATM; PHOSPHORYLATION	Protein serine/ threonine phosphatase 2A ( PP2A) activity must be tightly controlled to maintain cell homeostasis. Here, we report the identification of a previously uncharacterized mammalian protein, type 2A- interacting protein ( TIP), as a novel regulatory protein of PP2A and the PP2A- like enzymes PP4 and PP6. TIP is a ubiquitously express ed protein and parallels the distribution of the PP2A catalytic subunit. Unlike its role in yeast, TIP does not interact with the mammalian homolog of type 2A-associated protein of 42 kDa ( Tap42), alpha 4, but instead associates with PP2A, PP4 and PP6 catalytic subunits independently of mammalian target of rapamycin kinase activity. Interestingly, the 20 kDa TIP splice variant TIP_i2, which lacks amino acids 173-272 of TIP's C- terminus, does not interact with PP2A; this finding indicates that residues 173 - 272 are important for the assembly of the TIP. phosphatase complex. In contrast to purified PP2A holoenzymes, TIP. PP2A complexes are devoid of phosphatase activity. Furthermore, alterations in the cellular levels of TIP influence the phosphorylation state of a specific protein substrate of ataxia- telangiectasia mutated ( ATM)/ ATM- and Rad3-related ( ATR) kinases. Elevated levels of TIP result in an increase in the phosphorylation state of this protein substrate, whereas TIP- depleted cells exhibit a significant decrease in this protein's phosphorylation state, which is reversed by treatment with the PP2A inhibitor okadaic acid. These results indicate TIP is a novel inhibitory regulator of PP2A and implicate a role for TIP. PP2A complexes within the ATM/ ATR signaling pathway controlling DNA replication and repair.	Vanderbilt Univ, Ctr Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA	Vanderbilt University; State University System of Florida; University of Florida	Wadzinski, BE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu	Law, Brian/L-6043-2019		NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070787, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM051366] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK070787, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Luke MM, 1996, MOL CELL BIOL, V16, P2744; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strasser G, 1998, PHYSICA E, V2, P515, DOI 10.1016/S1386-9477(98)00106-4; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6	33	63	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6021	6030		10.1038/sj.onc.1210406	http://dx.doi.org/10.1038/sj.onc.1210406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384681				2022-12-25	WOS:000249277200005
J	van Wely, K; Meester-Smoor, MA; Janssen, MJFW; Aarnoudse, AJ; Grosveld, GC; Zwarthoff, EC				van Wely, Khm; Meester-Smoor, M. A.; Janssen, M. J. F. W.; Aarnoudse, A-J; Grosveld, G. C.; Zwarthoff, E. C.			The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; coactivator; mutant	HISTONE DEACETYLASE; CELL-GROWTH; DNA-BINDING; GENE; TRANSLOCATION; DEFECTS; SARCOMA; OVEREXPRESSION; COACTIVATORS; PATHWAYS	The translocation t(12;22)(p13;q11) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. MN1 is a transcription coactivator of the retinoic acid and vitamin D receptors, and TEL (ETV6) is a member of the E26-transform ation-specific family of transcription factors. In MN1-TEL, the transactivating domains of MN1 are combined with the DNA-binding domain of TEL. We show that MN1-TEL inhibits retinoic acid receptor (RAR)-mediated transcription, counteracts coactivators such as p160 and p300, and acts as a dominant-negative mutant of MN1. Compared to MN1 the same transactivation domains in MIN1-TEL are poorly stimulated by p160, p300 or histone deacetylase inhibitors, indicating that the block of RAR-mediated transcription by MN1-TEL is caused by dysfunctional transactivation domains rather than by recruitment of corepressors. The mechanism leading to myeloid leukemia in t(12;22) thus differs from the translocations that involve RAR itself.	Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	Erasmus University Rotterdam; Erasmus MC; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus MC, Josephine Nefkens Inst, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.zwarthoff@erasmusmc.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bohlander SK, 2005, SEMIN CANCER BIOL, V15, P162, DOI 10.1016/j.semcancer.2005.01.008; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BUIJS A, 1995, ONCOGENE, V10, P1511; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; BUIJS A, 1995, IN PRESS ONCOGENE, P809; Carella C, 2006, LEUKEMIA, V20, P1582, DOI 10.1038/sj.leu.2404298; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Kawagoe H, 2005, BLOOD, V106, P4269, DOI 10.1182/blood-2005-04-1679; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Meester-Smoor MA, 2005, MOL CELL BIOL, V25, P4229, DOI 10.1128/MCB.25.10.4229-4236.2005; Mercader N, 2000, DEVELOPMENT, V127, P3961; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sutton ALM, 2005, MOL ENDOCRINOL, V19, P2234, DOI 10.1210/me.2005-0081; van Wely KHM, 2003, ONCOGENE, V22, P699, DOI 10.1038/sj.onc.1206124; VANROOZENDAAL KEP, 1990, EXP CELL RES, V190, P137, DOI 10.1016/0014-4827(90)90155-4; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; Wang ZG, 1998, SCIENCE, V279, P1547; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	30	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5733	5740		10.1038/sj.onc.1210382	http://dx.doi.org/10.1038/sj.onc.1210382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369854				2022-12-25	WOS:000248885100005
J	Yan, Y; Yamada, K; Niwa, M; Nagai, T; Nitta, A; Nabeshima, T				Yan, Yijin; Yamada, Kiyofumi; Niwa, Minae; Nagai, Taku; Nitta, Atsumi; Nabeshima, Toshitaka			Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial cell line-derived neurotrophic factor mutant mice	FASEB JOURNAL			English	Article						GDNF mutant mice; METH self-administration; relapse	DELTA-FOSB; DRUG-ADDICTION; COCAINE; GDNF; ABUSE; ACQUISITION; EXTINCTION; RECEPTORS; DEGENERATION; STRIATUM	Genetic factors are considered to play an important role in drug dependence/addiction including the development of drug dependence and relapse. With the use of a model of drug self-administration in mutant mice, several specific genes and proteins have been identified as potentially important in the development of drug dependence. In contrast, little is known about the role of specific genes in enduring vulnerability to relapse, a clinical hallmark of drug addiction. Using a mouse model of reinstatement, which models relapse of drug-seeking behavior in addicts, we provide evidence that a partial reduction in the expression of the glial cell line-derived neurotrophic factor (GDNF) potentiates methamphetamine (METH) self-administration, enhances motivation to take METH, increases vulnerability to drug-primed reinstatement, and prolongs cue-induced reinstatement of extinguished METH-seeking behavior. In contrast, there was no significant difference in novelty responses, METH-stimulated hyperlocomotion and locomotor sensitization, food-reinforced operant behavior and motivation, or reinstatement of food-seeking behavior between GDNF heterozygous knockout mice and wild-type littermates. These findings suggest that GDNF may be associated with enduring vulnerability to reinstatement of METH-seeking behavior and a potential target in the development of therapies to control relapse.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Neuropsychopharmacol, Kanazawa, Ishikawa 920, Japan	Nagoya University; Kanazawa University	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp	Niwa, Minae/AAV-2639-2021; Sokabe, Masahiro/I-1565-2012; Nagai, Taku/I-7507-2014; Yan, Yijin/C-2733-2012; Yamada, Kiyofumi/I-7487-2014; Niwa, Minae/G-5469-2011; Nitta, Atsumi/AAF-4211-2019	Niwa, Minae/0000-0002-8784-7815; Nagai, Taku/0000-0001-5050-7748; Yamada, Kiyofumi/0000-0002-5280-5180; Niwa, Minae/0000-0002-8784-7815; 				Airavaara M, 2004, EUR J NEUROSCI, V20, P2336, DOI 10.1111/j.1460-9568.2004.03700.x; Caine SB, 2002, J NEUROSCI, V22, P2977, DOI 10.1523/JNEUROSCI.22-07-02977.2002; Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Colby CR, 2003, J NEUROSCI, V23, P2488; Elmer GI, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0004.2002; Epstein DH, 2006, PSYCHOPHARMACOLOGY, V189, P1, DOI 10.1007/s00213-006-0529-6; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; Green-Sadan T, 2005, EXP NEUROL, V194, P97, DOI 10.1016/j.expneurol.2005.01.020; Green-Sadan T, 2003, EUR J NEUROSCI, V18, P2093, DOI 10.1046/j.1460-9568.2003.02943.x; Griffin WC, 2006, BRAIN RES, V1068, P257, DOI 10.1016/j.brainres.2005.10.080; He DY, 2005, J NEUROSCI, V25, P619, DOI 10.1523/JNEUROSCI.3959-04.2005; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kendler KS, 2003, AM J PSYCHIAT, V160, P687, DOI 10.1176/appi.ajp.160.4.687; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583; Le AD, 2006, J NEUROSCI, V26, P1872, DOI 10.1523/JNEUROSCI.4895-05.2006; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X; Mizoguchi H, 2004, MOL PHARMACOL, V65, P1293, DOI 10.1124/mol.65.5.1293; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; NIWA M, IN PRESS BIOL PSYCHI; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Prescott CA, 1999, AM J PSYCHIAT, V156, P34, DOI 10.1176/ajp.156.1.34; ROBERTS DCS, 1993, PSYCHOPHARMACOLOGY, V111, P215, DOI 10.1007/BF02245526; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Self DW, 2004, NEUROPHARMACOLOGY, V47, P242, DOI 10.1016/j.neuropharm.2004.07.005; Stuber GD, 2005, NEURON, V46, P661, DOI 10.1016/j.neuron.2005.04.036; Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249; Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967; Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223; Ulery PG, 2006, J NEUROSCI, V26, P5131, DOI 10.1523/JNEUROSCI.4970-05.2006; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005; Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539; Yan YJ, 2007, BEHAV BRAIN RES, V177, P261, DOI 10.1016/j.bbr.2006.11.033; Yan YJ, 2006, BEHAV BRAIN RES, V168, P137, DOI 10.1016/j.bbr.2005.11.030; Zavala AR, 2003, BRAIN RES, V990, P157, DOI 10.1016/S0006-8993(03)03452-8	49	44	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1994	2004		10.1096/fj.06-7772com	http://dx.doi.org/10.1096/fj.06-7772com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17356005				2022-12-25	WOS:000247500300009
J	Yong, WD; Bao, SD; Chen, HY; Li, DP; Sanchez, ER; Shou, W				Yong, Weidong; Bao, Shideng; Chen, Hanying; Li, Dapei; Sanchez, Edwin R.; Shou, Weinian			Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT; DNA-DAMAGE; SERINE/THREONINE PHOSPHATASE; TPR DOMAIN; IN-VITRO; ACTIVATION; ATM; PP5; PROTEIN-PHOSPHATASE-5; IDENTIFICATION	Protein phosphatase 5 (Ppp5), a tetratricopeptide repeat domain protein, has been implicated in multiple cellular functions, including cellular proliferation, migration, differentiation and survival, and cell cycle checkpoint regulation via the ataxia telangiectasia mutated/ATM and Rad3-related (ATM/ATR) signal pathway. However, the physiological functions of Ppp5 have not been reported. To confirm the role of Ppp5 in cell cycle checkpoint regulation, we generated Ppp5-deficient mice and isolated mouse embryonic fibroblast (MEF) cells from Ppp5-deficient and littermate control embryos. Although Ppp5-deficient mice can survive through embryonic development and postnatal life and MEF cells from the Ppp5-deficient mice maintain normal replication checkpoint induced by hydroxyurea, Ppp5-deficient MEF cells display a significant defect in G(2)/M DNA damage checkpoint in response to ionizing radiation (IR). To determine whether this defect in IR-induced G(2)/M checkpoint is due to altered ATM-mediated signaling, we measured ATM kinase activity and ATM-mediated downstream events. Our data demonstrated that IR-induced ATM kinase activity is attenuated in Ppp5-deficient MEFs. Phosphorylation levels of two known ATM substrates, Rad17 and Chk2, were significantly reduced in Ppp5-deficient MEFs in response to IR. Furthermore, DNA damage-induced Rad17 nuclear foci were dramatically reduced in Ppp5-deficient MEFs. These results demonstrate a direct regulatory linkage between Ppp5 and activation of the ATM-mediated G(2)/M DNA damage check-point pathway in vivo.	Indiana Univ, Herman B Wells Ctr Pediat Res, Dept Pediat, Sect Pediat Cardiol,Sch Med, Indianapolis, IN 46202 USA; Univ Colorado, Hlth Sci Ctr, Dept Radiat Oncol, Aurora, CO 80011 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurosurg, Aurora, CO 80011 USA; Univ Toledo, Coll Med, Dept Physiol & Pharmacol, Toledo, OH 43614 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Ohio; University of Toledo	Shou, W (corresponding author), Indiana Univ, Herman B Wells Ctr Pediat Res, Dept Pediat, Sect Pediat Cardiol,Sch Med, R4-368,1044 W Walnut, Indianapolis, IN 46202 USA.	wshou@iupui.edu			NHLBI NIH HHS [R01 HL081092, R01 HL081092-01A2] Funding Source: Medline; NIDDK NIH HHS [R01 DK043867, R01 DK070127, R01 DK073402, DK73402, DK70127, DK43867, R01 DK073402-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073402, R01DK043867, R29DK043867, R01DK070127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; Gentile S, 2006, P NATL ACAD SCI USA, V103, P5202, DOI 10.1073/pnas.0600080103; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kobayashi M, 2004, GENES CELLS, V9, P291, DOI 10.1111/j.1356-9597.2004.00728.x; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Ramsey AJ, 2002, BIOCHEMISTRY-US, V41, P5625, DOI 10.1021/bi016090h; Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	30	45	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14690	14694		10.1074/jbc.C700019200	http://dx.doi.org/10.1074/jbc.C700019200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376776	Green Accepted, hybrid			2022-12-25	WOS:000246589000004
J	Tsuji, T; Sheehy, N; Gautier, VW; Hayakawa, H; Sawa, H; Hall, WW				Tsuji, Takahiro; Sheehy, Noreen; Gautier, Virginie W.; Hayakawa, Hitoshi; Sawa, Hirofumi; Hall, William W.			The nuclear import of the human T lymphotropic virus type I (HTLV-1) tax protein is carrier- and energy-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; NF-KAPPA-B; BETA-CATENIN; TRANSCRIPTION FACTOR; LOCALIZATION SIGNAL; PORE COMPLEX; NUCLEOCYTOPLASMIC TRAFFICKING; SUBCELLULAR-DISTRIBUTION; RECEPTOR; RAN	HTLV-1 is the etiologic agent of the adult T cell leukemia-lymphoma (ATLL). The viral regulatory protein Tax plays a central role in leukemogenesis as a transcriptional transactivator of both viral and cellular gene expression, and this requires Tax activity in both the cytoplasm and the nucleus. In the present study, we have investigated the mechanisms involved in the nuclear localization of Tax. Employing a GFP fusion expression system and a range of Tax mutants, we could confirm that the N-terminal 60 amino acids, and specifically residues within the zinc finger motif in this region, are important for nuclear localization. Using an in vitro nuclear import assay, it could be demonstrated that the transportation of Tax to the nucleus required neither energy nor carrier proteins. Specific and direct binding between Tax and p62, a nucleoporin with which the importin beta family of proteins have been known to interact was also observed. The nuclear import activity of wild type Tax and its mutants and their binding affinity for p62 were also clearly correlated, suggesting that the entry of Tax into the nucleus involves a direct interaction with nucleoporins within the nuclear pore complex (NPC). The nuclear export of Tax was also shown to be carrier independent. It could be also demonstrated that Tax it self may have a carrier function and that the NF-kappa B subunit p65 could be imported into the nucleus by Tax. These studies suggest that Tax could alter the nucleocytoplasmic distribution of cellular proteins, and this could contribute to the deregulation of cellular processes observed in HTLV-1 infection.	Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland; Hokkaido Univ, Res Ctr, Dept Mol Pathobiol, Sapporo, Hokkaido 0600818, Japan; Hokkaido Univ, Res Ctr, Century COE Program Zoonosis Control 21st, Kita Ku, Sapporo, Hokkaido 0600818, Japan	University College Dublin; Hokkaido University; Hokkaido University	Hall, WW (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland.	william.hall@ucd.ie	Sawa, Hirofumi/AAW-8816-2021; Gautier, virginie/K-4057-2012; Sawa, Hirofumi/F-6954-2012	Gautier, virginie/0000-0003-1862-2644; Sawa, Hirofumi/0000-0003-2569-2755; Sheehy, Noreen/0000-0001-5004-0228				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Alefantis T, 2005, J BIOL CHEM, V280, P17353, DOI 10.1074/jbc.M409851200; Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Asally M, 2005, EXP CELL RES, V308, P357, DOI 10.1016/j.yexcr.2005.05.011; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Delhaye S, 2004, J VIROL, V78, P4357, DOI 10.1128/JVI.78.8.4357-4362.2004; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatza ML, 2006, J VIROL, V80, P6657, DOI 10.1128/JVI.02270-05; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gustin KE, 2003, VIRUS RES, V95, P35, DOI 10.1016/S0168-1702(03)00165-5; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Koike M, 2004, J BIOL CHEM, V279, P34038, DOI 10.1074/jbc.M405821200; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Muranyi W, 2002, SCIENCE, V297, P854, DOI 10.1126/science.1071506; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Peloponese JM, 2006, IMMUNOL RES, V34, P1, DOI 10.1385/IR:34:1:1; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Stewart M, 2003, SCIENCE, V302, P1513, DOI 10.1126/science.1092863; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUZUKI T, 1994, ONCOGENE, V9, P3099; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; YAMADA S, 1995, CANCER RES, V55, P2524; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong HL, 2005, J BIOL CHEM, V280, P10675, DOI 10.1074/jbc.M412878200	80	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13875	13883		10.1074/jbc.M611629200	http://dx.doi.org/10.1074/jbc.M611629200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344183	hybrid			2022-12-25	WOS:000246060300077
J	Hrmova, M; Farkas, V; Lahnstein, J; Fincher, GB				Hrmova, Maria; Farkas, Vladimir; Lahnstein, Jelle; Fincher, Geoffrey B.			A barley xyloglucan xyloglucosyl transferase covalently links xyloglucan, cellulosic substrates, and (1,3;1,4)-beta-D-glucans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL WALL; CARBOHYDRATE-ACTIVE ENZYMES; HORDEUM-VULGARE L.; ENDOTRANSGLYCOSYLASE; BIOSYNTHESIS; ARABIDOPSIS; EXPRESSION; XTH; TRANSGLYCOSYLATION; OLIGOSACCHARIDES	Molecular interactions between wall polysaccharides, which include cellulose and a range of noncellulosic polysaccharides such as xyloglucans and (1,3;1,4)-beta-D-glucans, are fundamental to cell wall properties. These interactions have been assumed to be noncovalent in nature in most cases. Here we show that a highly purified barley xyloglucan xyloglucosyl transferase HvXET5 (EC 2.4.1.207), a member of the GH16 group of glycoside hydrolases, catalyzes the in vitro formation of covalent linkages between xyloglucans and cellulosic substrates and between xyloglucans and (1,3;1,4)-beta-D-glucans. The rate of covalent bond formation catalyzed by HvXET5 with hydroxyethylcellulose (HEC) is comparable with that on tamarind xyloglucan, whereas that with (1,3;1,4)-beta-D-glucan is significant but slower. Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analyses showed that oligosaccharides released from the fluorescent HEC:xyloglucan conjugate by a specific (1,4)-beta-Dglucan endohydrolase consisted of xyloglucan substrate with one, two, or three glucosyl residues attached. Ancillary peaks contained hydroxyethyl substituents (m/z 45) and confirmed that the parent material consisted of HEC covalently linked with xyloglucan. Similarly, partial hydrolysis of the (1,3;1,4)-beta-D-glucan:xyloglucan conjugate by a specific (1,3;1,4)-beta-Dglucan endohydrolase revealed the presence of a series of fluorescent oligosaccharides that consisted of the fluorescent xyloglucan acceptor substrate linked covalently with 2-6 glucosyl residues. These findings raise the possibility that xyloglucan endo-transglucosylases could link different polysaccharides in vivo and hence influence cell wall strength, flexibility, and porosity.	Univ Adelaide, Sch Agr Food & Wine, Glen Osmond, SA 5064, Australia; Univ Adelaide, Australian Ctr Plant Funct Genom, Glen Osmond, SA 5064, Australia; Slovak Acad Sci, Inst Chem, Ctr Excellence GLYCOBIOS, Bratislava 84538, Slovakia	University of Adelaide; University of Adelaide; Slovak Academy of Sciences	Fincher, GB (corresponding author), Univ Adelaide, Sch Agr Food & Wine, Waite Campus, Glen Osmond, SA 5064, Australia.	maria.hrmova@adelaide.edu.au; geoff.fincher@adelaide.edu.au	Hrmova, Maria/AAH-3951-2020	Farkas, Vladimir/0000-0002-8219-4288; Hrmova, Maria/0000-0002-3545-0605				Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Carpita NC, 2001, PLANT PHYSIOL, V127, P551, DOI 10.1104/pp.010146; Cohen A, 2004, J CHROMATOGR A, V1029, P87, DOI 10.1016/j.chroma.2003.12.010; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Coutinho PM, 1999, ROY SOC CH, P3; Cumming CM, 2005, PLANTA, V222, P546, DOI 10.1007/s00425-005-1560-2; FARKAS V, 1992, ARCH BIOCHEM BIOPHYS, V298, P365, DOI 10.1016/0003-9861(92)90423-T; Farkas V, 2005, PLANT PHYSIOL BIOCH, V43, P431, DOI 10.1016/j.plaphy.2005.03.006; Farrokhi N, 2006, PLANT BIOTECHNOL J, V4, P145, DOI 10.1111/j.1467-7652.2005.00169.x; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; Fry SC, 1997, PLANT J, V11, P1141, DOI 10.1046/j.1365-313X.1997.11051141.x; Geisler-Lee J, 2006, PLANT PHYSIOL, V140, P946, DOI 10.1104/pp.105.072652; Gibeaut DM, 2005, PLANTA, V221, P729, DOI 10.1007/s00425-005-1481-0; Gomez-Esquer F, 2004, MICROBIOL-SGM, V150, P3269, DOI 10.1099/mic.0.27314-0; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; Hrmova M, 2006, BIOCHEM J, V399, P77, DOI 10.1042/BJ20060170; Ishii T, 1999, J BIOL CHEM, V274, P13098, DOI 10.1074/jbc.274.19.13098; Jin ZF, 2006, BIOPOLYMERS, V83, P103, DOI 10.1002/bip.20533; Johansson P, 2004, PLANT CELL, V16, P874, DOI 10.1105/tpc.020065; Kallas AM, 2005, BIOCHEM J, V390, P105, DOI 10.1042/BJ20041749; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KEEGSTRA K, 1973, PLANT PHYSIOL, V51, P188, DOI 10.1104/pp.51.1.188; Kerr EM, 2003, PLANTA, V217, P327, DOI 10.1007/s00425-003-1027-2; Knogge W, 2002, MYCOTA, V11, P289; Mohand FA, 2006, CARBOHYD RES, V341, P577, DOI 10.1016/j.carres.2006.01.018; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P225; Popper ZA, 2005, ANN BOT-LONDON, V96, P91, DOI 10.1093/aob/mci153; Purugganan MM, 1997, PLANT PHYSIOL, V115, P181, DOI 10.1104/pp.115.1.181; Rose JKC, 2002, PLANT CELL PHYSIOL, V43, P1421, DOI 10.1093/pcp/pcf171; Saladie M, 2006, PLANT J, V47, P282, DOI 10.1111/j.1365-313X.2006.02784.x; Saura-Valls M, 2006, BIOCHEM J, V395, P99, DOI 10.1042/BJ20051396; Schroder R, 1998, PLANTA, V204, P242, DOI 10.1007/s004250050253; Schunmann PHD, 1997, PLANT CELL ENVIRON, V20, P1439, DOI 10.1046/j.1365-3040.1997.d01-49.x; Somerville C, 2004, SCIENCE, V306, P2206, DOI 10.1126/science.1102765; Steele NM, 1999, BIOCHEM J, V340, P207, DOI 10.1042/0264-6021:3400207; Strohmeier M, 2004, PROTEIN SCI, V13, P3200, DOI 10.1110/ps.04828404; Suurnakki A, 2000, CELLULOSE, V7, P189, DOI 10.1023/A:1009280109519; Thompson JE, 2000, PLANTA, V211, P275, DOI 10.1007/s004250000287; Trethewey JAK, 2002, NEW PHYTOL, V154, P347, DOI 10.1046/j.1469-8137.2002.00383.x; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; Yokoyama R, 2004, PLANT CELL PHYSIOL, V45, P1111, DOI 10.1093/pcp/pch151; Yokoyama R, 2004, PLANT PHYSIOL, V134, P1088, DOI 10.1104/pp.103.035261	46	121	125	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12951	12962		10.1074/jbc.M611487200	http://dx.doi.org/10.1074/jbc.M611487200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329246	hybrid			2022-12-25	WOS:000245942800066
J	Filomeni, G; Cerchiaro, G; Ferreira, AMD; De Martino, A; Pedersen, JZ; Rotilio, G; Ciriolo, MR				Filomeni, Giuseppe; Cerchiaro, Giselle; Da Costa Ferreira, Ana Maria; De Martino, Angelo; Pedersen, Jens Z.; Rotilio, Giuseppe; Ciriolo, Maria R.			Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; ANTICANCER DRUGS; CANCER-TREATMENT; KINASE PATHWAYS; CELLS; IRON; INHIBITION; BLEOMYCIN; TARGETS; DNA	We characterized the pro-apoptotic activity of two new synthesized isatin- Schiff base copper(II) complexes, obtained from isatin and 1,3- diaminopropane or 2-(2-aminoethyl)pyridine: (Cu(isapn)) and (Cu(isaepy)(2)), respectively. We demonstrated that these compounds trigger apoptosis via the mitochondrial pathway. The early induction of the p53/p21 system indicates a role for p53 in cell death, however, experiments carried out with small interfering RNA against p53, or with cells lacking p53, support that a p53-independent mechanism can also occur. The extent of apoptosis mirrors the kinetics of intracellular copper uptake. Particularly, Cu(isaepy())2 enters the cells more efficiently and specifically damages nuclei and mitochondria, as evidenced by atomic absorption analysis of copper content and by the extent of nuclear and mitochondrial integrity. Conversely, Cu(isapn), although less permeable, induces a widespread oxidative stress, as demonstrated by analyses of reactive oxygen species concentration, and oxidation of proteins and lipids. The increase of the antioxidant defense, through the overexpression of Cu,Zn-SOD, partially counteracts cell death; whereas retinoic acid-mediated differentiation completely rescues cells from apoptosis induced by both compounds. The activation of JNK- and Akt-mediated phosphorylative pathways has been found to be not functional for apoptosis induction. On the contrary, apoptosis significantly decreased when the analogous zinc complex was used or when Cu(isaepy)(2) was incubated in the presence of a copper chelator. Altogether, our data provide evidence for a dual role of these copper(II) complexes: they are able to vehicle copper into the cell, thus producing reactive oxygen species, and could behave as delocalized lipophilic cation-like molecules, thus specifically targeting organelles.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Sao Paulo, Inst Quim, Dept Quim Fundamental, BR-05513970 Sao Paulo, Brazil	University of Rome Tor Vergata; Universidade de Sao Paulo	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	ciriolo@bio.uniroma2.it	Da Costa Ferreira, Ana Maria/C-2244-2012; Ciriolo, Maria Rosa/K-6572-2016; Cerchiaro, Giselle/B-8424-2013	Da Costa Ferreira, Ana Maria/0000-0001-9898-1692; Ciriolo, Maria Rosa/0000-0002-7863-9029; Cerchiaro, Giselle/0000-0001-8606-5400; Filomeni, Giuseppe/0000-0002-2719-1412				ANTHOLINE WE, 1976, J MED CHEM, V19, P339, DOI 10.1021/jm00224a030; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Cerchiaro G, 2005, J INORG BIOCHEM, V99, P1433, DOI 10.1016/j.jinorgbio.2005.03.013; Cerchiaro G, 2004, J MOL CATAL A-CHEM, V221, P29, DOI 10.1016/j.molcata.2004.06.017; Chen D, 2005, FRONT BIOSCI-LANDMRK, V10, P2932, DOI 10.2741/1749; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; CIRIOLO MR, 1989, J BIOL CHEM, V264, P1443; Cleveland JL, 2000, NATURE, V407, P309, DOI 10.1038/35030277; Daniel KG, 2004, BIOCHEM PHARMACOL, V67, P1139, DOI 10.1016/j.bcp.2003.10.031; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798; Filomeni G, 2005, CELL DEATH DIFFER, V12, P1555, DOI 10.1038/sj.cdd.4401754; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Filomeni G, 2002, FASEB J, V16, P64, DOI 10.1096/fj.02-0105fje; Filomeni G, 2003, CANCER RES, V63, P5940; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Griguer CE, 2006, CANCER RES, V66, P2257, DOI 10.1158/0008-5472.CAN-05-3364; Harsch A, 2000, NUCLEIC ACIDS RES, V28, P1978, DOI 10.1093/nar/28.9.1978; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Katsaros N, 2002, CRIT REV ONCOL HEMAT, V42, P297, DOI 10.1016/S1040-8428(01)00222-0; Kotamraju S, 2004, METHOD ENZYMOL, V378, P362; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354; Miller RA, 2001, CLIN CANCER RES, V7, P3215; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITANO JS, 1987, CANCER RES, V47, P4361; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Radulovic S, 2002, CURR MED CHEM, V9, P1611, DOI 10.2174/0929867023369376; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rossi L, 2004, NATO SCI SER I LIFE, V358, P207; SARYAN LA, 1979, J MED CHEM, V22, P1218, DOI 10.1021/jm00196a013; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Townsend DM, 2005, METHOD ENZYMOL, V401, P287, DOI 10.1016/S0076-6879(05)01019-0; Wang T, 2006, CURR MED CHEM, V13, P525, DOI 10.2174/092986706776055742; Wilson L, 2004, J CHEMOTHERAPY, V16, P83, DOI 10.1179/joc.2004.16.Supplement-1.83	41	124	128	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12010	12021		10.1074/jbc.M610927200	http://dx.doi.org/10.1074/jbc.M610927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327230	hybrid			2022-12-25	WOS:000245941900043
J	Genini, D; Catapano, CV				Genini, Davide; Catapano, Carlo V.			Block of nuclear receptor ubiquitination - A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME SYSTEM CONTROLS; PPAR-DELTA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; COLON CARCINOGENESIS; COLORECTAL-CANCER; EPITHELIAL-CELLS; ADENOMA GROWTH; ROLES; ALPHA	Peroxisome proliferator-activated receptor delta ( PPAR delta) is a ligand-activated transcription factor involved in many physiological and pathological processes. PPAR delta is a promising therapeutic target for metabolic, chronic inflammatory, and neuro-degenerative disorders. However, limited information is available about the mechanisms that control the activity of this nuclear receptor. Here, we examined the role of the ubiquitin-proteasome system in PPAR delta turnover. The receptor was ubiquitinated and subject to rapid degradation by the 26 S proteasome. Unlike most nuclear receptors that are degraded upon ligand binding, PPAR delta ligands inhibited the ubiquitination of the receptor, thereby preventing its degradation. Ligand binding was required for inhibition of the ubiquitination since disruption of the ligand binding domain abolished the effect. Site-directed mutagenesis showed that the DNA binding domain was also required, indicating that ligands preferentially stabilized the DNA-bound receptor. In contrast, the activation function-2 domain and co-repressor binding site were not involved in ligand-induced stabilization. Block of ubiquitination by ligands may be an essential step to avoid rapid degradation of a receptor, like PPAR delta, with a very short half-life and sustain its transcriptional activity once it is engaged in transcriptional activation complexes.	Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland	Institute of Oncology Research (IOR)	Catapano, CV (corresponding author), Oncol Inst So Switzerland, Expt Oncol Lab, Via Vela 6, CH-6500 Bellinzona, Switzerland.	carlo.catapano@irb.unisi.ch		Catapano, Carlo V./0000-0002-7079-557X				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Blanquart C, 2004, BIOCHEM BIOPH RES CO, V319, P663, DOI 10.1016/j.bbrc.2004.05.035; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Cutler NS, 2003, CANCER RES, V63, P1748; Dennis AP, 2005, J STEROID BIOCHEM, V94, P337, DOI 10.1016/j.jsbmb.2004.11.009; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2005, J BIOL CHEM, V280, P38700, DOI 10.1074/jbc.M507782200; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Glinghammar B, 2003, BIOCHEM BIOPH RES CO, V308, P361, DOI 10.1016/S0006-291X(03)01384-6; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hirotani M, 2001, BIOCHEM BIOPH RES CO, V288, P106, DOI 10.1006/bbrc.2001.5739; Jaeckel EC, 2001, ARCH OTOLARYNGOL, V127, P1253, DOI 10.1001/archotol.127.10.1253; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; Rodriguez-Vilarino S, 2000, J BIOL CHEM, V275, P6592, DOI 10.1074/jbc.275.9.6592; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Shao JY, 2002, CANCER RES, V62, P3282; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tong BJ, 2000, NEOPLASIA, V2, P483, DOI 10.1038/sj.neo.7900119; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Yin YZ, 2005, CANCER RES, V65, P3950, DOI 10.1158/0008-5472.CAN-04-3990	46	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11776	11785		10.1074/jbc.M609149200	http://dx.doi.org/10.1074/jbc.M609149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324937	hybrid			2022-12-25	WOS:000245941900020
J	Min, XJ; Hickey, DA				Min, Xiang Jia; Hickey, Donal A.			DNA Barcodes Provide a Quick Preview of Mitochondrial Genome Composition	PLOS ONE			English	Article								DNA barcodes have achieved prominence as a tool for species-level identifications. Consequently, there is a rapidly growing database of these short sequences from a wide variety of taxa. In this study, we have analyzed the correlation between the nucleotide content of the short DNA barcode sequences and the genomes from which they are derived. Our results show that such short sequences can yield important, and surprisingly accurate, information about the composition of the entire genome. In other words, for unsequenced genomes, the DNA barcodes can provide a quick preview of the whole genome composition.	[Min, Xiang Jia; Hickey, Donal A.] Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Hickey, DA (corresponding author), Concordia Univ, Dept Biol, 1455 De Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	dhickey@alcor.concordia.ca	Min, Xiangjia Jack/O-9509-2014	Min, Xiangjia Jack/0000-0001-7978-0596	Natural Sciences and Engineering Research Council (Canada); Genome Canada to the Canadian Barcode of Life Network	Natural Sciences and Engineering Research Council (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Genome Canada to the Canadian Barcode of Life Network(Genome Canada)	This study was supported by grants from the Natural Sciences and Engineering Research Council (Canada) and Genome Canada to the Canadian Barcode of Life Network, and by a Discovery Grant to DAH from the Natural Sciences and Engineering Research Council (Canada).	Dellaporta SL, 2006, P NATL ACAD SCI USA, V103, P8751, DOI 10.1073/pnas.0602076103; Hajibabaei M, 2006, P NATL ACAD SCI USA, V103, P968, DOI 10.1073/pnas.0510466103; Hajibabaei M, 2007, TRENDS GENET, V23, P167, DOI 10.1016/j.tig.2007.02.001; Hebert PDN, 2004, PLOS BIOL, V2, P1657, DOI 10.1371/journal.pbio.0020312; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; NAYLOR GJP, 1995, NATURE, V373, P565, DOI 10.1038/373565b0; PERNA NT, 1995, J MOL EVOL, V41, P353, DOI 10.1007/BF01215182	7	41	45	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e325	10.1371/journal.pone.0000325	http://dx.doi.org/10.1371/journal.pone.0000325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389916	Green Submitted, Green Accepted, Green Published, gold			2022-12-25	WOS:000207445200008
J	Laponogov, I; Veselkov, DA; Sohi, MK; Pan, XS; Achari, A; Yang, C; Ferrara, JD; Fisher, LM; Sanderson, MR				Laponogov, Ivan; Veselkov, Dennis A.; Sohi, Maninder K.; Pan, Xiao-Su; Achari, Aniruddha; Yang, Cheng; Ferrara, Joseph D.; Fisher, L. Mark; Sanderson, Mark R.			Breakage-Reunion Domain of Streptococcus pneumoniae Topoisomerase IV: Crystal Structure of a Gram-Positive Quinolone Target	PLOS ONE			English	Article								The 2.7 angstrom crystal structure of the 55-kDa N-terminal breakage-reunion domain of topoisomerase (topo) IV subunit A (ParC) from Streptococcus pneumoniae, the first for the quinolone targets from a gram-positive bacterium, has been solved and reveals a 'closed' dimer similar in fold to Escherichia coli DNA gyrase subunit A (GyrA), but distinct from the 'open' gate structure of Escherichia coli ParC. Unlike GyrA whose DNA binding groove is largely positively charged, the DNA binding site of ParC exhibits a distinct pattern of alternating positively and negatively charged regions coincident with the predicted positions of the grooves and phosphate backbone of DNA. Based on the ParC structure, a new induced-fit model for sequence-specific recognition of the gate (G) segment by ParC has been proposed. These features may account for the unique DNA recognition and quinolone targeting properties of pneumococcal type II topoisomerases compared to their gram-negative counterparts.	[Pan, Xiao-Su; Fisher, L. Mark] Univ London, Div Basic Med Sci, Mol & Metab Signalling Ctr, Mol Genet Grp, London, England; [Laponogov, Ivan; Veselkov, Dennis A.; Sohi, Maninder K.; Achari, Aniruddha; Sanderson, Mark R.] Kings Coll London, Sch Biomed & Hlth Sci, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; [Yang, Cheng; Ferrara, Joseph D.] Rigaku Amer Corp, The Woodlands, TX USA	University of London; University of London; King's College London; Rigaku Corporation	Fisher, LM (corresponding author), Univ London, Div Basic Med Sci, Mol & Metab Signalling Ctr, Mol Genet Grp, London, England.	lfisher@sgul.ac.uk; mark.sanderson@kcl.ac.uk		Fisher, Larry Mark/0000-0002-2172-3369	Biotechnology and Biological Sciences Research Council of the United Kingdom [C16747]; School of Biomedical and Health Sciences; ORS Award; Biotechnology and Biological Sciences Research Council [BB/D01882X/1] Funding Source: researchfish; BBSRC [BB/D01882X/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council of the United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); School of Biomedical and Health Sciences; ORS Award; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Project Grant C16747 from the Biotechnology and Biological Sciences Research Council of the United Kingdom (to L. M. Fisher and M. R. Sanderson). I. Laponogov was supported by a scholarship from the School of Biomedical and Health Sciences and ORS Award. Xiao- Su Pan, Dennis A. Veselkov and this work were funded by Project Grant C16747 from the Biotechnology and Biological Sciences Research Council of the United Kingdom (to L. M. Fisher and M. R. Sanderson).	[Anonymous], ACTA CRYSTALLOGR D, V50, P760; Bates PA, 2001, PROTEINS, P39; Bates PA, 1999, PROTEINS, P47; Bellon S, 2004, ANTIMICROB AGENTS CH, V48, P1856, DOI 10.1128/AAC.48.5.1856-1864.2004; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Contreras-Moreira B, 2002, BIOINFORMATICS, V18, P1141, DOI 10.1093/bioinformatics/18.8.1141; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; Gadelle D, 2003, BIOESSAYS, V25, P232, DOI 10.1002/bies.10245; Huang W M, 1994, Adv Pharmacol, V29A, P201; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leo E, 2005, J BIOL CHEM, V280, P14252, DOI 10.1074/jbc.M500156200; Maxwell A, 1996, NAT STRUCT BIOL, V3, P109, DOI 10.1038/nsb0296-109; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan XS, 1999, ANTIMICROB AGENTS CH, V43, P1129, DOI 10.1128/AAC.43.5.1129; Pan XS, 1998, ANTIMICROB AGENTS CH, V42, P2810, DOI 10.1128/AAC.42.11.2810; Pan XS, 1997, ANTIMICROB AGENTS CH, V41, P471, DOI 10.1128/AAC.41.2.471; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Petrey D, 2003, METHOD ENZYMOL, V374, P492, DOI 10.1016/S0076-6879(03)74021-X; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; Richter SN, 2006, NUCLEIC ACIDS RES, V34, P1982, DOI 10.1093/nar/gkl127; Ruthenburg AJ, 2005, J BIOL CHEM, V280, P26177, DOI 10.1074/jbc.M502838200; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	52	31	34	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e301	10.1371/journal.pone.0000301	http://dx.doi.org/10.1371/journal.pone.0000301			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375187	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445100003
J	Seshasayee, ASN				Seshasayee, Aswin Sai Narain			An Assessment of the Role of DNA Adenine Methyltransferase on Gene Expression Regulation in E coli	PLOS ONE			English	Article								N6-Adenine methylation is an important epigenetic signal, which regulates various processes, such as DNA replication and repair and transcription. In gamma-proteobacteria, Dam is a stand-alone enzyme that methylates GATC sites, which are non-randomly distributed in the genome. Some of these overlap with transcription factor binding sites. This work describes a global computational analysis of a published Dam knockout microarray alongside other publicly available data to throw insights into the extent to which Dam regulates transcription by interfering with protein binding. The results indicate that DNA methylation by DAM may not globally affect gene transcription by physically blocking access of transcription factors to binding sites. Down-regulation of Dam during stationary phase correlates with the activity of TFs whose binding sites are enriched for GATC sites.	EMBL European Bioinformat Inst, Genom & Regulatory Syst Grp, Cambridge, England	European Molecular Biology Laboratory (EMBL)	Seshasayee, ASN (corresponding author), EMBL European Bioinformat Inst, Genom & Regulatory Syst Grp, Wellcome Trust Genome Campus, Cambridge, England.	aswin@ebi.ac.uk	Hide, Winston/R-3815-2019; Hide, Winston Hide/C-7217-2009; Hide, Winston A/V-2727-2017	Hide, Winston/0000-0002-8621-3271; Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271	Cambridge Commonwealth Trust	Cambridge Commonwealth Trust	This is an entirely independent project carried out by me without the aid of any funding agency. My studentship at the EMBL-EBI is partly covered by the Cambridge Commonwealth Trust.	Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glasner JD, 2003, NUCLEIC ACIDS RES, V31, P147, DOI 10.1093/nar/gkg125; Henaut A, 1996, J MOL BIOL, V257, P574, DOI 10.1006/jmbi.1996.0186; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Kouzminova EA, 2004, P NATL ACAD SCI USA, V101, P16262, DOI 10.1073/pnas.0405943101; Lobner-Olesen A, 2003, P NATL ACAD SCI USA, V100, P4672, DOI 10.1073/pnas.0538053100; Martinez-Antonio A, 2003, CURR OPIN MICROBIOL, V6, P482, DOI 10.1016/j.mib.2003.09.002; Oshima T, 2002, MOL MICROBIOL, V45, P673, DOI 10.1046/j.1365-2958.2002.03037.x; Ponder RG, 2005, MOL CELL, V19, P791, DOI 10.1016/j.molcel.2005.07.025; RASMUSSEN LJ, 1994, MOL MICROBIOL, V12, P631, DOI 10.1111/j.1365-2958.1994.tb01050.x; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Robbins-Manke JL, 2005, J BACTERIOL, V187, P7027, DOI 10.1128/JB.187.20.7027-7037.2005; Salgado H, 2006, NUCLEIC ACIDS RES, V34, pD394, DOI 10.1093/nar/gkj156; Sivaraman K, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-20; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Tjaden B, 2002, NUCLEIC ACIDS RES, V30, P3732, DOI 10.1093/nar/gkf505; VONHEYDEBRECK A, 2004, BIOCONDUCTOR PROJECT, V7; VONHEYDEBRECK A, 2004, BIOCONDUCTOR WORKING; Wion D, 2006, NAT REV MICROBIOL, V4, P183, DOI 10.1038/nrmicro1350; YAMANAKA K, 1995, FEMS MICROBIOL LETT, V133, P59, DOI 10.1111/j.1574-6968.1995.tb07861.x; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317	26	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e273	10.1371/journal.pone.0000273	http://dx.doi.org/10.1371/journal.pone.0000273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342207	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444700008
J	Aleksic, T; Bechtel, M; Krndija, D; von Wichert, G; Knobel, B; Giehl, K; Gress, TM; Michl, P				Aleksic, T.; Bechtel, M.; Krndija, D.; von Wichert, G.; Knobel, B.; Giehl, K.; Gress, T. M.; Michl, P.			CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation	ONCOGENE			English	Article						CUTL1; migration; Src; Csk; spreading	PROTEIN-TYROSINE KINASES; FAMILY KINASES; ACTIVATION; ADHESION; BETA; DISPLACEMENT; MODULATION; MECHANISMS; MOTILITY; INTEGRIN	Recently, we identified the homeodomain transcription factor CUTL1 as important mediator of cell migration and tumor invasion downstream of transforming growth factor beta ( TGFb). The molecular mechanisms and effectors mediating the pro-migratory and pro-invasive phenotype induced by CUTL1 have not been elucidated so far. Therefore, the aim of this study was to identify signaling pathways downstream of CUTL1 which are responsible for its effects on tumor cell migration. We found that the reduced motility seen after knock down of CUTL1 by RNA interference is accompanied by a delay in tumor cell spreading. This spreading defect is paralleled by a marked reduction of Src protein levels. We show that CUTL1 leads to Src protein stabilization and activation of Src-regulated downstream signaling molecules such as RhoA, Rac1, Cdc42 and ROCK. In addition, we demonstrate that CUTL1 decreases proteasome-mediated Src protein degradation, possibly via transcriptionally upregulating C-terminal Src kinase (Csk). Based on experiments using Src knockout cells ( SYF), we present evidence that Src plays a crucial role in CUTL1-induced tumor cell migration. In conclusion, our findings linking the pro-invasive transcription factor CUTL1 and the Src pathway provide important new insights in the molecular effector pathways mediating CUTL-induced migration and invasion.	Univ Marburg, Dept Internal Med, Div Gastroenterol & Endocrinol, D-35043 Marburg, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-7900 Ulm, Germany	Philipps University Marburg; Ulm University; Ulm University	Michl, P (corresponding author), Univ Marburg, Dept Internal Med, Div Gastroenterol, Baklingerstr, D-35043 Marburg, Germany.	michlp@med.uni-marburg.de	Krndija, Denis/AAR-5918-2020; Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021	Krndija, Denis/0000-0001-8686-7542; Gress, Thomas/0000-0002-9333-5461				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Kaido T, 2004, J BIOL CHEM, V279, P53762, DOI 10.1074/jbc.M411202200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	25	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5939	5949		10.1038/sj.onc.1210398	http://dx.doi.org/10.1038/sj.onc.1210398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369846				2022-12-25	WOS:000249123100011
J	Rose-Hellekant, TA; Schroeder, MD; Brockman, JL; Zhdankin, O; Bolstad, R; Chen, KS; Gould, MN; Schuler, LA; Sandgren, EP				Rose-Hellekant, T. A.; Schroeder, M. D.; Brockman, J. L.; Zhdankin, O.; Bolstad, R.; Chen, K. S.; Gould, M. N.; Schuler, L. A.; Sandgren, E. P.			Estrogen receptor-positive mammary tumorigenesis in TGF alpha transgenic mice progresses with progesterone receptor loss	ONCOGENE			English	Article						breast cancer; mammary cancer; TGF alpha; transgenic mice; estrogen receptor; progesterone receptor	GROWTH-FACTOR-ALPHA; BREAST-CANCER CELLS; C-MYC; MOUSE MAMMARY; EXPRESSION; PROLACTIN; OVEREXPRESSION; INDUCTION; PHENOTYPE; CARCINOMA	We characterized the novel NRL-transforming growth factor alpha (NRL-TGF alpha) transgenic mouse model in which growth factor - steroid receptor interactions were explored. The NRL promoter directs transgene expression to mammary ductal and alveolar cells and is nonresponsive to estrogen manipulations in vitro and in vivo. NRL-TGF alpha mice acquire proliferative hyperplasias as well as cystic and solid tumors. Quantitative transcript analysis revealed a progressive decrease in estrogen receptor alpha ( ER) and progesterone receptor (PR) mRNA levels with tumorigenesis. However, ER protein was evident in all lesion types and in surrounding stromal cells using immunohistochemistry. PR protein was identified in normal epithelial cells and in very few cells of small epithelial hyperplasias, but never in stromal or tumor cells. Prophylactic ovariectomy significantly delayed tumor development and decreased incidence. Finally, while heterozygous (+/- ) p53 mice did not acquire mammary lesions, p53 +/- mice carrying the NRL-TGF alpha transgene developed ER negative/PR negative undifferentiated carcinomas. These data demonstrate that unregulated TGF alpha expression in the mammary gland leads to oncogenesis that is dependent on ovarian steroids early in tumorigenesis. Resulting tumors resemble a clinical phenotype of ER+/ PR-, and when combined with a heterozygous p53 genotype, ER-/PR-.	Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Oncol, Madison, WI USA	University of Minnesota System; University of Minnesota Duluth; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rose-Hellekant, TA (corresponding author), Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA.	trosehel@d.umn.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA078312, R01CA058328, R01CA064843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312-03S2, R01-CA78312, R01 CA078312-03S1, R01 CA078312-03, R01-CA58328, R01-CA64843, R01 CA078312, R01 CA078312-04A1, R01 CA078312-02S1] Funding Source: Medline; NCRR NIH HHS [K01-RR00145] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAN RAH, 1992, J BIOL CHEM, V267, P3771; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Arendt LM, 2006, AM J PATHOL, V168, P1365, DOI 10.2353/ajpath.2006.050861; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GURURAJ AE, 2006, CLIN CANC RES, V12; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Hewitt SC, 2002, CANCER RES, V62, P2798; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medina D, 2003, CANCER RES, V63, P6140; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pierson-Mullany Lisa K, 2003, Breast Dis, V18, P21; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Stoesz SP, 1995, ONCOGENE, V11, P2233; Zhang XM, 2005, ONCOGENE, V24, P4220, DOI 10.1038/sj.onc.1208597	38	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5238	5246		10.1038/sj.onc.1210340	http://dx.doi.org/10.1038/sj.onc.1210340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334393	Green Accepted			2022-12-25	WOS:000248674200007
J	Marx, FP; Soehn, AS; Berg, D; Melle, C; Schiesling, C; Lang, M; Kautzmann, S; Strauss, KM; Franck, T; Engelender, S; Pahnke, J; Dawson, S; von Eggeling, F; Schulz, JB; Riess, O; Kruger, R				Marx, Frank P.; Soehn, Anne S.; Berg, Daniela; Melle, Christian; Schiesling, Carola; Lang, Mira; Kautzmann, Sabine; Strauss, Karsten M.; Franck, Thomas; Engelender, Simone; Pahnke, Jens; Dawson, Simon; von Eggeling, Ferdinand; Schulz, Joerg B.; Riess, Olaf; Krueger, Rejko			The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein - implications for Parkinson's disease	FASEB JOURNAL			English	Article						neurodegeneration; ubiquitin; alpha-synuclein; proteasome	LEWY-BODY FORMATION; ALPHA-SYNUCLEIN; AGGRESOMES; UBIQUITIN; BODIES; CHAINS; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; INCLUSIONS	Synphilin-1 is linked to Parkinson's disease ( PD), based on its role as an alpha-synuclein (PARK1)-interacting protein and substrate of the ubiquitin E3 ligase Parkin (PARK2) and because of its presence in Lewy bodies ( LB) in brains of PD patients. We found that overexpression of synphilin-1 in cells leads to the formation of ubiquitinated cytoplasmic inclusions supporting a derangement of the ubiquitin-proteasome system in PD. We report here a novel specific interaction of synphilin- 1 with the regulatory proteasomal protein S6 ATPase ( tbp7). Functional characterization of this interaction on a cellular level revealed colocalization of S6 and synphilin- 1 in aggresome- like intracytoplasmic inclusions. Overexpression of synphilin- 1 and S6 in cells caused reduced proteasomal activity associated with a significant increase in inclusion formation compared to cells expressing synphilin-1 alone. Steady-state levels of synphilin-1 in cells were not altered after cotransfection of S6 and colocalization of synphilin-1-positive inclusions with lysosomal markers suggests the presence of an alternative lysosomal degradation pathway. Subsequent immunohistochemical studies in brains of PD patients identified S6 ATPase as a component of LB. This is the first study investigating the physiological role of synphilin- 1 in the ubiquitin proteasome system. Our data suggest a direct interaction of synphilin- 1 with the regulatory complex of the proteasome modulating proteasomal function.-Marx, F. P., Soehn, A. S., Berg, D., Melle, C., Schiesling, C., Lang, M., Kautzmann, S., Strauss, K. M., Franck, T., Engelender, S., Pahnke, J., Dawson, S., von Eggeling, F., Schulz, J. B., Riess, O., Kruger, R. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson's disease.	Univ Tubingen, Ctr Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Genet, D-72076 Tubingen, Germany; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Univ Jena, Inst Human Genet & Anthropol, Core Unit Chip Applicat, D-6900 Jena, Germany; Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Friedrich Schiller University of Jena; University of Zurich; University Zurich Hospital; University of Nottingham	Kruger, R (corresponding author), Univ Tubingen, Ctr Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	rejko.krueger@uni-tuebingen.de	von Eggeling, Ferdinand/A-1645-2008; Pahnke, Jens/G-1757-2010; von Eggeling, Ferdinand/AAC-8349-2022; Schulz, Jörg B/D-9786-2012; Berg, Daniela/A-8728-2019; von Eggeling, Ferdinand/B-4033-2014	Pahnke, Jens/0000-0001-7355-4213; von Eggeling, Ferdinand/0000-0002-8062-6999; Schulz, Jörg B/0000-0002-8903-0593; Berg, Daniela/0000-0001-5796-5442; von Eggeling, Ferdinand/0000-0002-8062-6999; Melle, Christian/0000-0002-1870-9419; Engelender, Simone/0000-0001-7401-6855				Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fortun J, 2003, J NEUROSCI, V23, P10672; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 2002, TRENDS MOL MED, V8, P236, DOI 10.1016/S1471-4914(02)02333-X; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lee T., 2002, ACM T ASIAN LANGUAGE, V1, P83; Lehmann R, 2005, J PROTEOME RES, V4, P1717, DOI 10.1021/pr050163s; Lim KL, 2006, NEUROBIOL AGING, V27, P524, DOI 10.1016/j.neurobiolaging.2005.07.023; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Schulz JB, 1999, CURR OPIN NEUROL, V12, P433, DOI 10.1097/00019052-199908000-00010; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	37	40	41	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1759	1767		10.1096/fj.06-6734com	http://dx.doi.org/10.1096/fj.06-6734com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327361				2022-12-25	WOS:000246866500018
J	Kim, D; Kim, MA; Cho, IH; Kim, MS; Lee, S; Jo, EK; Choi, SY; Park, K; Kim, JS; Akira, S; Na, HS; Oh, SB; Lee, SJ				Kim, Donghoon; Kim, Myung Ah; Cho, Ik-Hyun; Kim, Mi Sun; Lee, Soojin; Jo, Eun-Kyeong; Choi, Se-Young; Park, Kyungpyo; Kim, Joong Soo; Akira, Shizuo; Na, Heung Sik; Oh, Seog Bae; Lee, Sung Joong			A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; ROOT GANGLION NEURONS; NEUROPATHIC PAIN; MECHANICAL ALLODYNIA; TACTILE ALLODYNIA; DORSAL-HORN; WALLERIAN DEGENERATION; ENDOGENOUS LIGAND; GENE-EXPRESSION	The activation of spinal cord glial cells has been implicated in the development of neuropathic pain upon peripheral nerve injury. The molecular mechanisms underlying glial cell activation, however, have not been clearly elucidated. In this study, we found that damaged sensory neurons induce the expression of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and inducible nitric-oxide synthase genes in spinal cord glial cells, which is implicated in the development of neuropathic pain. Studies using primary glial cells isolated from toll-like receptor 2 knock-out mice indicate that damaged sensory neurons activate glial cells via toll-like receptor 2. In addition, behavioral studies using toll-like receptor 2 knock-out mice demonstrate that the expression of toll-like receptor 2 is required for the induction of mechanical allodynia and thermal hyperalgesia due to spinal nerve axotomy. The nerve injury-induced spinal cord microglia and astrocyte activation is reduced in the toll-like receptor 2 knock-out mice. Similarly, the nerve injury-induced pro-inflammatory gene expression in the spinal cord is also reduced in the toll-like receptor 2 knock-out mice. These data demonstrate that toll-like receptor 2 contributes to the nerve injury-induced spinal cord glial cell activation and subsequent pain hypersensitivity.	Seoul Natl Univ, Program Mol & Cellular Neurosci, Dent Res Inst, BK21, Seoul 110749, South Korea; Seoul Natl Univ, Dept Oral Physiol, Sch Dent, Seoul 110749, South Korea; Korea Univ, Coll Med, Dept Physiol, Med Sci Res Ctr, Seoul 136705, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 301747, South Korea; Osaka Univ, Dept Host Def, Suita, Osaka 5650871, Japan	Seoul National University (SNU); Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine); Chungnam National University; Osaka University	Oh, SB (corresponding author), Seoul Natl Univ, Program Mol & Cellular Neurosci, Dent Res Inst, BK21, Seoul 110749, South Korea.	odolbae@snu.ac.kr; sjlee87@snu.ac.kr	Akira, Shizuo/C-3134-2009; OH, Seog Bae/AAQ-2478-2020; Cho, Ik-Hyun/A-9348-2014	Choi, Se-Young/0000-0001-7534-5167; Lee, Soojin/0000-0002-0383-5025; Eun-Kyeong, Jo/0000-0001-7191-0587				Aronica E, 2005, NEUROSCIENCE, V130, P927, DOI 10.1016/j.neuroscience.2004.10.024; Arruda JL, 2000, BRAIN RES, V879, P216, DOI 10.1016/S0006-8993(00)02807-9; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Broom DC, 2004, NEUROSCIENCE, V124, P891, DOI 10.1016/j.neuroscience.2004.01.003; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Coggeshall RE, 2001, J COMP NEUROL, V435, P276, DOI 10.1002/cne.1029; Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065; Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7; Coyle DE, 1998, GLIA, V23, P75; Csillik B, 2003, ANN ANAT, V185, P303, DOI 10.1016/S0940-9602(03)80050-X; DeLeo JA, 1996, J INTERF CYTOK RES, V16, P695, DOI 10.1089/jir.1996.16.695; ECCLESTON PA, 1984, DEV BRAIN RES, V16, P1, DOI 10.1016/0165-3806(84)90056-7; Falchi M, 2001, DRUG EXP CLIN RES, V27, P97; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; GARRISON CJ, 1991, BRAIN RES, V565, P1, DOI 10.1016/0006-8993(91)91729-K; Guo LH, 2005, J NEUROIMMUNOL, V163, P120, DOI 10.1016/j.jneuroim.2005.03.007; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Honore P, 2006, BEHAV BRAIN RES, V167, P355, DOI 10.1016/j.bbr.2005.09.024; Jin SX, 2003, J NEUROSCI, V23, P4017; Karanth S, 2006, EXP NEUROL, V202, P161, DOI 10.1016/j.expneurol.2006.05.024; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KNYIHARCSILLIK E, 1989, CELL TISSUE RES, V258, P515; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Levy D, 1998, EUR J NEUROSCI, V10, P1846, DOI 10.1046/j.1460-9568.1998.00186.x; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; Ma WY, 2002, BRAIN RES, V937, P94, DOI 10.1016/S0006-8993(02)02593-3; Milligan ED, 2004, EUR J NEUROSCI, V20, P2294, DOI 10.1111/j.1460-9568.2004.03709.x; Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Polgar E, 2005, J NEUROSCI, V25, P6658, DOI 10.1523/JNEUROSCI.1490-05.2005; Schafers M, 2003, J NEUROSCI, V23, P2517; Schenker M, 2003, EXP NEUROL, V184, P225, DOI 10.1016/S0014-4886(03)00255-3; Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005; Shi TJS, 2001, NEUROSCIENCE, V105, P249, DOI 10.1016/S0306-4522(01)00148-8; Sommer C, 2001, BRAIN RES, V913, P86, DOI 10.1016/S0006-8993(01)02743-3; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; SVENSSON M, 1993, J NEUROSCI RES, V35, P373, DOI 10.1002/jnr.490350404; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wilson ADH, 2003, BRIT J PLAST SURG, V56, P732, DOI 10.1016/j.bjps.2003.08.005; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	59	234	239	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14975	14983		10.1074/jbc.M607277200	http://dx.doi.org/10.1074/jbc.M607277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355971	hybrid			2022-12-25	WOS:000246589000036
J	Yatsenko, AS; Gray, EE; Shcherbata, HR; Patterson, LB; Sood, VD; Kucherenko, MM; Baker, D; Ruohola-Baker, H				Yatsenko, Andriy S.; Gray, Elizabeth E.; Shcherbata, Halyna R.; Patterson, Larissa B.; Sood, Vanita D.; Kucherenko, Mariya M.; Baker, David; Ruohola-Baker, Hannele			A putative Src homology 3 domain binding motif but not the C-terminal dystrophin WW domain binding motif is required for dystroglycan function in cellular polarity in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR AGGREGATION; CONGENITAL MUSCULAR-DYSTROPHIES; BETA-DYSTROGLYCAN; INTEGRIN ACTIVATION; TYROSINE PHOSPHORYLATION; NEUROMUSCULAR-JUNCTION; EPITHELIAL-CELLS; SKELETAL-MUSCLE; TALIN; COMPLEX	The conserved dystroglycan-dystrophin (Dg(.)Dys) complex connects the extracellular matrix to the cytoskeleton. In humans as well as Drosophila, perturbation of this complex results in muscular dystrophies and brain malformations and in some cases cellular polarity defects. However, the regulation of the Dg(.)Dys complex is poorly understood in any cell type. We now find that in loss-of-function and overexpression studies more than half (34 residues) of the Dg proline-rich conserved C-terminal regions can be truncated without significantly compromising its function in regulating cellular polarity in Drosophila. Notably, the truncation eliminates the WW domain binding motif at the very C terminus of the protein thought to mediate interactions with dystrophin, suggesting that a second, internal WW binding motif can also mediate this interaction. We confirm this hypothesis by using a sensitive fluorescence polarization assay to show that both WW domain binding sites of Dg bind to Dys in humans (K-d = 7.6 and 81 mu M, respectively) and Drosophila (K-d = 16 and 46 mu M, respectively). In contrast to the large deletion mentioned above, a single proline to an alanine point mutation within a predicted Src homology 3 domain (SH3) binding site abolishes Dg function in cellular polarity. This suggests that an SH3-containing protein, which has yet to be identified, functionally interacts with Dg.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Ivan Franko Natl Univ, UA-79005 Lvov, Ukraine	University of Washington; University of Washington Seattle; Ministry of Education & Science of Ukraine; Ivan Franko National University Lviv	Ruohola-Baker, H (corresponding author), Univ Washington, Dept Biochem, HSB-591,Box 357350, Seattle, WA 98195 USA.	hannele@u.washington.edu	Baker, David/K-8941-2012; Shcherbata, Halyna/J-5712-2017; Yatsenko, Andriy/D-1895-2018	Baker, David/0000-0001-7896-6217; Shcherbata, Halyna/0000-0002-3855-0345; Kucherenko, Mariya/0000-0002-8637-2037; Sood, Vanita/0000-0001-6714-3725; Yatsenko, Andriy/0000-0001-8730-5744				Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 2004, BIOCHEM SOC T, V32, P434, DOI 10.1042/BST0320434; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Cohn RD, 2005, NEUROMUSCULAR DISORD, V15, P207, DOI 10.1016/j.nmd.2004.11.005; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Heathcote RD, 2000, DEV BIOL, V227, P595, DOI 10.1006/dbio.2000.9906; Henry MD, 2001, HUM PATHOL, V32, P791, DOI 10.1053/hupa.2001.26468; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Kato Y, 2002, J BIOL CHEM, V277, P10173, DOI 10.1074/jbc.M110490200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Liu SC, 2000, J CELL SCI, V113, P3563; Martens P, 2003, GLOBAL ENVIRON CHANG, V13, P75, DOI 10.1016/S0959-3780(02)00089-4; Martin PT, 2003, J NEUROCYTOL, V32, P915, DOI 10.1023/B:NEUR.0000020632.41508.83; Martin-Rendon E, 2003, TRENDS PHARMACOL SCI, V24, P178, DOI 10.1016/S0165-6147(03)00050-6; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Muntoni F, 2004, CURR OPIN NEUROL, V17, P205, DOI 10.1097/00019052-200404000-00020; Muschler J, 2002, CANCER RES, V62, P7102; Pignoni F, 1997, DEVELOPMENT, V124, P271; Poulton JS, 2006, P NATL ACAD SCI USA, V103, P12775, DOI 10.1073/pnas.0603817103; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Schneider M, 2006, DEVELOPMENT, V133, P3805, DOI 10.1242/dev.02549; Sgambato A, 2005, J CELL PHYSIOL, V205, P163, DOI 10.1002/jcp.20411; Shcherbata HR, 2007, EMBO J, V26, P481, DOI 10.1038/sj.emboj.7601503; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TAPLEY P, 1989, ONCOGENE, V4, P325; Tracey WD, 2000, GENETICS, V154, P273; Tremblay MR, 2006, J BIOL CHEM, V281, P13365, DOI 10.1074/jbc.M600912200; van der Plas MC, 2006, J NEUROSCI, V26, P333, DOI 10.1523/JNEUROSCI.4069-05.2006; Van Doren M, 1998, CURR BIOL, V8, P243; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zhou YW, 2006, BIOCHEMISTRY-US, V45, P2042, DOI 10.1021/bi0519957	49	17	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15159	15169		10.1074/jbc.M608800200	http://dx.doi.org/10.1074/jbc.M608800200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355978	hybrid, Green Published			2022-12-25	WOS:000246589000055
J	Ji, ZY; Mei, FC; Xie, JW; Cheng, XD				Ji, Zhenyu; Mei, Fang C.; Xie, Jingwu; Cheng, Xiaodong			Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA RECEPTOR; K-RAS MUTATIONS; DUCTAL ADENOCARCINOMA; EPITHELIAL-CELLS; GENE-MUTATIONS; GLI PROTEINS; IN-VITRO; GROWTH; INHIBITION; EXPRESSION	Hedgehog (Hh) signaling is deregulated in multiple human cancers including pancreatic ductal adenocarcinoma (PDA). Because KRAS mutation represents one of the earliest genetic alterations and occurs almost universally in PDA, we hypothesized that oncogenic KRAS promotes pancreatic tumorigenesis in part through activation of the Hh pathway. Here, we report that oncogenic KRAS activates hedgehog signaling in PDA cells, utilizing a downstream effector pathway mediated by RAF/MEK/MAPK but not phosphatidylinositol 3-kinase (PI3K)/AKT. Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin. Inactivation of KRAS activity by a small interfering RNA specific for oncogenic KRAS inhibits GLI activity and GLI1 expression in PDA cell lines with activating KRAS mutation; the MEK inhibitors U0126 and PD98059 elicit a similar response. In addition, expression of the constitutively active form of BRAFE600, but not myr-AKT, blocks the inhibitory effects of KRAS knockdown on Hh signaling. Finally, suppressing GLI activity leads to a selective attenuation of the oncogenic transformation activity of mutant KRAS-expressing PDA cells. These results demonstrate that oncogenic KRAS, through RAF/MEK/MAPK signaling, is directly involved in the activation of the hedgehog pathway in PDA cells and that collaboration between these two signaling pathways may play an important role in PDA progression.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019	Cheng, Xiaodong/0000-0002-3479-1694	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; BOS JL, 1989, CANCER RES, V49, P4682; Brunner TB, 2005, CANCER RES, V65, P8433, DOI 10.1158/0008-5472.CAN-05-0158; CALDAS C, 1994, CANCER RES, V54, P3568; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; FRIESS H, 1993, CANCER RES, V53, P2704; Furukawa T, 1996, AM J PATHOL, V148, P1763; Goggins M, 1998, CANCER RES, V58, P5329; Goggins M, 1996, CANCER RES, V56, P5360; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kayed H, 2004, INT J CANCER, V110, P668, DOI 10.1002/ijc.20194; Klein WM, 2002, MODERN PATHOL, V15, P441, DOI 10.1038/modpathol.3880544; KLIMSTRA DS, 1994, AM J PATHOL, V145, P1547; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Luttges J, 1999, CANCER-AM CANCER SOC, V85, P1703; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Mei FC, 2005, FASEB J, V19, P497, DOI 10.1096/fj.05-4586fje; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moskaluk CA, 1997, CANCER RES, V57, P2140; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Sahin F, 2003, MODERN PATHOL, V16, P686, DOI 10.1097/01.MP.0000075645.97329.86; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	47	230	243	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14048	14055		10.1074/jbc.M611089200	http://dx.doi.org/10.1074/jbc.M611089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353198	hybrid			2022-12-25	WOS:000246245800014
J	Sasaki, M; Nie, LH; Maki, CG				Sasaki, Mark; Nie, Linghu; Maki, Carl G.			MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; CELL-CYCLE ARREST; MUTANT P53; IN-VIVO; MONOCLONAL-ANTIBODY; CANCER-THERAPY; UBIQUITINATION; STABILIZATION; MUTATIONS	p53 protein conformation is an important determinant of its localization and activity. Changes in p53 conformation can be monitored by reactivity with wild-type conformation-specific (pAb-1620) or mutant conformation-specific (pAb-240) p53 antibodies. Wild-type p53 accumulated in a mutant (pAb-240 reactive) form when its proteasome-dependent degradation was blocked during recovery from stress treatment and in cells co-expressing p53 and MDM2. This suggests that conformational change precedes wild-type p53 degradation by the proteasome. MDM2 binding to the p53 N terminus could induce a conformational change in wild-type p53. Interestingly, this conformational change was opposed by heat-shock protein 90 and did not require the MDM2 RING-finger domain and p53 ubiquitination. Finally, ubiquitinated p53 accumulated in a pAb-240 reactive form when p53 degradation was blocked by proteasome inhibition, and a p53-ubiquitin fusion protein displayed a mutant-only conformation in MDM2-null cells. These results support a model in which MDM2 binding induces a conformational change that is opposed by heat-shock protein 90 and precedes p53 ubiquitination. The covalent attachment of ubiquitin may "lock" p53 in a mutant conformation in the absence of MDM2-binding and prior to its degradation by the proteasome.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Rm G06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			NCI NIH HHS [R01 CA080918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016/j.canlet.2004.09.046; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Maki CG, 1996, CANCER RES, V56, P2649; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller P, 2005, J BIOL CHEM, V280, P6682, DOI 10.1074/jbc.M412767200; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Shimizu H, 2006, BIOCHEM J, V397, P355, DOI 10.1042/BJ20051521; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103	35	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14626	14634		10.1074/jbc.M610514200	http://dx.doi.org/10.1074/jbc.M610514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363365	hybrid			2022-12-25	WOS:000246245800076
J	Endo, M; Ohashi, K; Mizuno, K				Endo, Mitsuharu; Ohashi, Kazumasa; Mizuno, Kensaku			LIM kinase and slingshot are critical for neurite extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; GROWTH CONE MOTILITY; COFILIN PHOSPHORYLATION; NEURONAL DIFFERENTIATION; CYTOSKELETAL DYNAMICS; REGULATES COFILIN; PROTEIN-KINASE; PHOSPHATASE; FAMILY; CELLS	Cofilin and its closely related protein, actin-depolymerizing factor (ADF), are key regulators of actin cytoskeleton dynamics that have been implicated in growth cone motility and neurite extension. Cofilin/ADF are inactivated by LIM kinase (LIMK)catalyzed phosphorylation and reactivated by Slingshot (SSH)catalyzed dephosphorylation. Here we examined the roles of cofilin/ADF, LIMKs (LIMK1 and LIMK2), and SSHs (SSH1 and SSH2) in nerve growth factor (NGF)-induced neurite extension. Knockdown of cofilin/ADF by RNA interference almost completely inhibited NGF-induced neurite extension from PC12 cells, and double knockdown of SSH1/SSH2 significantly suppressed both NGF-induced cofilin/ADF dephosphorylation and neurite extension from PC12 cells, thus indicating that cofilin/ADF and their activating phosphatases SSH1/SSH2 are critical for neurite extension. Interestingly, NGF stimulated the activities of both LIMK1 and LIMK2 in PC12 cells, and suppression of LIMK1/LIMK2 expression or activity significantly reduced NGF-induced neurite extension from PC12 cells or chick dorsal root ganglion (DRG) neurons. Inhibition of LIMK1/LIMK2 activity reduced actin filament assembly in the peripheral region of the growth cone of chick DRG neurons. These results suggest that proper regulation of cofilin/ADF activities through control of phosphorylation by LIMKs and SSHs is critical for neurite extension and that LIMKs regulate actin filament assembly at the tip of the growth cone.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan	Tohoku University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; Birkenfeld J, 2001, J NEUROCHEM, V78, P924, DOI 10.1046/j.1471-4159.2001.00500.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Endo M, 2003, J NEUROSCI, V23, P2527; Gehler S, 2004, J NEUROSCI, V24, P10741, DOI 10.1523/JNEUROSCI.2836-04.2004; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Lee-Hoeflich ST, 2004, EMBO J, V23, P4792, DOI 10.1038/sj.emboj.7600418; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Nishita M, 2005, J CELL BIOL, V171, P349, DOI 10.1083/jcb.200504029; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosenblatt J, 1998, NATURE, V393, P739, DOI 10.1038/31597; Rosso S, 2004, MOL BIOL CELL, V15, P3433, DOI 10.1091/mbc.E03-05-0328; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Yang EJ, 2004, J BIOL CHEM, V279, P8903, DOI 10.1074/jbc.M311913200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	36	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13692	13702		10.1074/jbc.M610873200	http://dx.doi.org/10.1074/jbc.M610873200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360713	hybrid			2022-12-25	WOS:000246060300059
J	Lee, JH; Tate, CM; You, JS; Skalnik, DG				Lee, Jeong-Heon; Tate, Courtney M.; You, Jin-Sam; Skalnik, David G.			Identification and characterization of the human Set1B histone H3-Lys(4) methyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; H3 LYSINE-4; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; MLL GENE; METHYLATION; COMPASS	We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex ( Lee, J.- H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a similar to 450 kDa complex that contains all five noncatalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.	Indiana Univ, Sch Med, Wells Ctr Pediat Res, Sect Pediat Hematol Oncol,Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Ctr Appl Prot Sci, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Canc Res Bldg,Rm 327,1044 W Walnut St, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu			NIAID NIH HHS [T32 AI060519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	34	174	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13419	13428		10.1074/jbc.M609809200	http://dx.doi.org/10.1074/jbc.M609809200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355966	hybrid			2022-12-25	WOS:000246060300031
J	Sato, O; Li, XD; Ikebe, M				Sato, Osamu; Li, Xiang-dong; Ikebe, Mitsuo			Myosin Va becomes a low duty ratio motor in the inhibited form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; TAIL DOMAIN; UNCONVENTIONAL MYOSIN; MELANOSOME TRANSPORT; FLUORESCENT-PROBE; ATPASE ACTIVITY; ACTIN-BINDING; SMOOTH-MUSCLE; PROCESSIVITY; ACTOMYOSIN	Vertebrate myosin Va is a typical processive motor with high duty ratio. Recent studies have revealed that the actin-activated ATPase activity of the full-length myosin Va (M5aFull) is inhibited at a low [Ca2+], which is due to the formation of a folded conformation of M5aFull. To clarify the underlying inhibitory mechanism, we analyzed the actin-activated ATP hydrolysis mechanism of the M5aFull at the inhibited and the activated states, respectively. Marked differences were found in the hydrolysis, Pi release, and ADP release steps between the activated and the inhibited states. The kinetic constants of these steps of the activated state were similar to those of the unregulated S1 construct, in which the rate-limiting step was the ADP release step. On the other hand, the P-i release rate from acto-M5aFull was decreased in EGTA by > 1,000-fold, which makes this step the rate-limiting step for the actin-activated ATP hydrolysis cycle of M5aFull. The ADP off rate from acto-M5aFull was decreased by similar to 10-fold, and the equilibrium between the prehydrolysis state and the post hydrolysis state was shifted toward the former state in the inhibited state of M5aFull. Because of these changes, M5aFull spends a majority of the ATP hydrolysis cycling time in the weak actin binding state. The present results indicate that M5aFull molecules at a low [Ca2+] is inhibited as a cargo transporter not only due to the decrease in the cross-bridge cycling rate but also due to the decrease in the duty ratio thus being dissociated from actin.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41653, AR048526] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Evans LL, 1997, J CELL SCI, V110, P439; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Li XD, 2005, J BIOL CHEM, V280, P17815, DOI 10.1074/jbc.M413295200; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Li XD, 2006, J BIOL CHEM, V281, P21789, DOI 10.1074/jbc.M602957200; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Lu HL, 2006, J BIOL CHEM, V281, P31987, DOI 10.1074/jbc.M605181200; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Olivares AO, 2006, J BIOL CHEM, V281, P31326, DOI 10.1074/jbc.M603898200; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rodriguez OC, 2002, J CELL SCI, V115, P991; Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Thirumurugan K, 2006, NATURE, V442, P212, DOI 10.1038/nature04865; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v	52	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13228	13239		10.1074/jbc.M610766200	http://dx.doi.org/10.1074/jbc.M610766200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363376	hybrid			2022-12-25	WOS:000246060300011
J	Ahmed, AH; Loh, AP; Jane, DE; Oswald, RE				Ahmed, H. Ahmed; Loh, Adrienne P.; Jane, David E.; Oswald, Robert E.			Dynamics of the S1S2 glutamate binding domain of GluR2 measured using F-19 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PARTIAL AGONIST ACTION; GATED ION CHANNELS; AMPA RECEPTORS; CONFORMATIONAL-CHANGES; CHEMICAL EXCHANGE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; MECHANISM; CORE	Ionotropic glutamate receptors mediate the majority of vertebrate excitatory synaptic transmission. Although the structure of the GluR2 binding domain (S1S2) is well known (agonist binding site between two lobes), little is known about the time scales of conformational transitions or the relationship between dynamics and function. (FNMR)-F-19 (F-19-labeled tryptophan) spectroscopy was used to monitor motions in the S1S2 domain bound to ligands with varying efficacy and in the apo state. One tryptophan (Trp-671) undergoes chemical exchange in some but not all agonists, consistent with mu s-ms motion. The dynamics can be correlated to ligand affinity, and a likely source of the motion is a peptide bond capable of transiently forming hydrogen bonds across the lobe interface. Another tryptophan (Trp767) appears to monitor motions of the relative positions of the lobes and suggests that the relative orientation in the apo- and antagonist-bound forms can exchange between at least two conformations on the ms time scale.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Univ Wisconsin, Dept Chem, La Crosse, WI 54601 USA; Univ Bristol, Sch Med Sci, Ctr Synapt Plast, Dept Pharmacol, Bristol BS8 1TD, Avon, England	Cornell University; University of Wisconsin System; University of Bristol	Oswald, RE (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	reo1@cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068935] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM068935] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Armstrong N, 2006, CELL, V127, P85, DOI 10.1016/j.cell.2006.08.037; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; Asztely F, 1996, MOL NEUROBIOL, V12, P1, DOI 10.1007/BF02740744; Auerbach A, 2005, P NATL ACAD SCI USA, V102, P1408, DOI 10.1073/pnas.0406787102; CARVER JP, 1972, J MAGN RESON, V6, P89, DOI 10.1016/0022-2364(72)90090-X; DAVIS DG, 1994, J MAGN RESON SER B, V104, P266, DOI 10.1006/jmrb.1994.1084; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dingledine R, 1999, PHARMACOL REV, V51, P7; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holm MM, 2005, P NATL ACAD SCI USA, V102, P12053, DOI 10.1073/pnas.0505522102; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jane DE, 1997, J MED CHEM, V40, P3645, DOI 10.1021/jm9702387; JEN J, 1978, J MAGN RESON, V30, P111, DOI 10.1016/0022-2364(78)90229-9; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2005, J NEUROSCI, V25, P9027, DOI 10.1523/JNEUROSCI.2567-05.2005; Jin RS, 2003, BIOCHEMISTRY-US, V42, P5201, DOI 10.1021/bi020632t; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Kasper C, 2006, J MOL BIOL, V357, P1184, DOI 10.1016/j.jmb.2006.01.024; Lawrence JJ, 2003, MOL PHARMACOL, V64, P269, DOI 10.1124/mol.64.2.269; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUZ Z, 1963, J CHEM PHYS, V39, P366, DOI 10.1063/1.1734254; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Mayer ML, 2006, NATURE, V440, P456, DOI 10.1038/nature04709; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Oswald RE, 2004, ADV PROTEIN CHEM, V68, P313; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Ramanoudjame G, 2006, P NATL ACAD SCI USA, V103, P10473, DOI 10.1073/pnas.0603225103; REEVES LW, 1971, CAN J CHEMISTRY, V49, P3683, DOI 10.1139/v71-615; Robert A, 2005, J NEUROSCI, V25, P3752, DOI 10.1523/JNEUROSCI.0188-05.2005; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; Salopek-Sondi B, 2002, PROTEIN ENG, V15, P855, DOI 10.1093/protein/15.11.855; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Sutcliffe MJ, 1998, METHOD ENZYMOL, V293, P589; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Valentine ER, 2005, BIOCHEMISTRY-US, V44, P3410, DOI 10.1021/bi047984f; Weston MC, 2006, J NEUROSCI, V26, P7650, DOI 10.1523/JNEUROSCI.1519-06.2006; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; Zemsky J, 1999, PROTEINS, V37, P709	50	42	43	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12773	12784		10.1074/jbc.M610077200	http://dx.doi.org/10.1074/jbc.M610077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337449	hybrid			2022-12-25	WOS:000245942800048
J	Brinsmade, SR; Escalante-Semerena, JC				Brinsmade, Shaun R.; Escalante-Semerena, Jorge C.			In vivo and in vitro analyses of single-mino acid variants of the Salmonella enterica phosphotransacetylase enzyme provide insights into the function of its N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; RIBOSOMAL-PROTEIN MODIFICATION; ESCHERICHIA-COLI-B; SEROVAR TYPHIMURIUM; METHANOSARCINA-THERMOPHILA; DETHIOBIOTIN SYNTHETASE; LARGE-INTESTINE; MUTANT LACKING; GLOBAL SIGNAL; ACETATE	The function of the N-terminal domain ( similar to 350 residues) of the Pta ( phosphotransacetylase) enzyme of Salmonella enterica is unclear. Results from in vivo genetic and in vitro studies suggest that the N-terminal domain of Pta is a sensor for NADH and pyruvate. We isolated 10 single-amino acid variants of Pta that, unlike the wild-type protein, supported growth of a strain of S. enterica devoid of Acs ( acetyl-CoA synthetase; AMP-forming) activity on 10 mM acetate. All mutations were mapped within the N-terminal domain of the protein. Kinetic analyses of the wild type and three variant Pta proteins showed that two of the variant proteins were faster enzymes ( k(cat) 2.5-3-fold > k(cat) Pta(WT). Results from sedimentation equilibrium experiments are consistent with Pta(WT) being a trimer. Pta variants formed more hexamer than the Pta(WT) protein. NADH inhibited Pta(WT) activity by inducing a conformational change detectable by limited trypsin proteolysis; NADH did not inhibit variant protein Pta(R252H). Pyruvate stimulated Pta(WT) activity, and its effect was potentiated in the variants, being most pronounced on Pta(R252H).	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	escalante@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62203, R01 GM062203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLAS R, 1995, HDB MEDIA ENV MICROB, P5; Atteia A, 2006, J BIOL CHEM, V281, P9909, DOI 10.1074/jbc.M507862200; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinsmade SR, 2005, J BACTERIOL, V187, P8039, DOI 10.1128/JB.187.23.8039-8046.2005; Brinsmade SR, 2004, J BACTERIOL, V186, P1890, DOI 10.1128/JB.186.6.1890-1892.2004; BROWN TDK, 1977, J GEN MICROBIOL, V102, P327, DOI 10.1099/00221287-102-2-327; Canovas M, 2003, BIOTECHNOL BIOENG, V84, P686, DOI 10.1002/bit.10822; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; CLARK DP, 1996, CELLULAR MOL BIOL, P343; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; El-Mansi M, 2006, CURR OPIN MICROBIOL, V9, P173, DOI 10.1016/j.mib.2006.02.002; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Epelbaum S, 1998, J BACTERIOL, V180, P4056, DOI 10.1128/JB.180.16.4056-4067.1998; Fink Pamela S., 1993, P307; Frodyma M, 2000, J BACTERIOL, V182, P236, DOI 10.1128/JB.182.1.236-240.2000; Galperin MY, 2000, PROTEINS, V41, P238, DOI 10.1002/1097-0134(20001101)41:2<238::AID-PROT80>3.0.CO;2-L; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; Gupta S, 2005, BBA-PROTEINS PROTEOM, V1750, P112, DOI 10.1016/j.bbapap.2005.02.004; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HONG JS, 1971, P NATL ACAD SCI USA, V68, P3158, DOI 10.1073/pnas.68.12.3158; HOWARD BV, 1974, J BIOL CHEM, V249, P7912; HUANG WJ, 1995, BIOCHEMISTRY-US, V34, P10985, DOI 10.1021/bi00035a004; ISONO K, 1980, MOL GEN GENET, V177, P645; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; Ke J, 2000, PLANT PHYSIOL, V123, P497, DOI 10.1104/pp.123.2.497; Kimura S, 2001, J BIOCHEM, V130, P481, DOI 10.1093/oxfordjournals.jbchem.a003010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 2007, J BACTERIOL, V189, P1589, DOI 10.1128/JB.01151-06; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; Macfarlane GT, 1997, SCAND J GASTROENTERO, V32, P3, DOI 10.1080/00365521.1997.11720708; MARGOLIS SA, 1986, ANAL CHEM, V58, P2504, DOI 10.1021/ac00125a033; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; Palacios S, 2003, J BACTERIOL, V185, P2802, DOI 10.1128/JB.185.9.2802-2810.2003; Poot RA, 1997, FEBS LETT, V401, P175, DOI 10.1016/S0014-5793(96)01467-6; PRUSS BM, 1994, MOL MICROBIOL, V12, P973; Pruss BM, 1998, ARCH MICROBIOL, V170, P141, DOI 10.1007/s002030050626; RADIKA K, 1984, ARCH BIOCHEM BIOPHYS, V233, P272, DOI 10.1016/0003-9861(84)90626-X; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rubio A, 2002, J BACTERIOL, V184, P2827, DOI 10.1128/JB.184.10.2827-2832.2002; SASSE J, 1991, CURRENT PROTOCOLS MO; SCHEPPACH W, 1991, CLIN SCI, V80, P177, DOI 10.1042/cs0800177; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; Segel I.H., 1975, ENZYME KINETICS; SHAW WV, 1992, SCI PROGRESS-UK, V76, P565; SHIMIZU M, 1969, BIOCHIM BIOPHYS ACTA, V191, P550, DOI 10.1016/0005-2744(69)90348-9; Shivers RP, 2006, MOL MICROBIOL, V62, P811, DOI 10.1111/j.1365-2958.2006.05410.x; Shivers RP, 2005, MOL MICROBIOL, V56, P1549, DOI 10.1111/j.1365-2958.2005.04634.x; Starai VJ, 2004, CELL MOL LIFE SCI, V61, P2020, DOI 10.1007/s00018-004-3448-x; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; SUZUKI T, 1969, BIOCHIM BIOPHYS ACTA, V191, P559, DOI 10.1016/0005-2744(69)90349-0; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P822, DOI 10.1139/o79-102; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WINSTON SE, 1990, CURRENT PROTOCOLS MO; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Wolfe AJ, 2003, MOL MICROBIOL, V48, P977, DOI 10.1046/j.1365-2958.2003.03457.x	69	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12629	12640		10.1074/jbc.M611439200	http://dx.doi.org/10.1074/jbc.M611439200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339319	hybrid			2022-12-25	WOS:000245942800032
J	Fratti, RA; Wickner, W				Fratti, Rutilio A.; Wickner, William			Distinct targeting and fusion functions of the PX and SNARE domains of yeast vacuolar Vam7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEX RING DOMAIN; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; ALPHA-SNAP; DOCKING; PROTEIN; COMPLEX; SEC17P; PURIFICATION	Regulated membrane fusion requires organelle tethering, enrichment of selected proteins and lipids at the fusion site, bilayer distortion, and lipid rearrangement. Yeast vacuole homotypic fusion requires regulatory lipids (ergosterol, diacylglycerol, and phosphoinositides), the Rab family GTPase Ypt7p, the multisubunit Ypt7p-effector complex HOPS (homotypic fusion and vacuole protein sorting), and four SNAREs. One SNARE, Vam7p, has an N-terminal PX domain which binds to phosphatidylinositol 3-phosphate (PI(3)P) and to HOPS and a C-terminal SNARE domain but no apolar membrane anchor. We have exploited an in vitro reaction of vacuole fusion to analyze the functions of each domain, removing the PX domain or mutating it to abolish its PI(3) P affinity. Lowering the PI(3) P affinity of the PX domain, or even deleting the PX domain, affects the fusion K-m for Vam7p but not the maximal fusion rate. Fusion driven by the SNARE domain alone is strikingly enhanced by the PLC inhibitor U73122 through enhanced binding of Vam7p SNARE domain to vacuoles, and the further addition of Plc1p blocks this U73122 effect. The PX domain, through its affinities for phosphoinositides and HOPS, is thus exclusively required for enhancing the targeting of Vam7p rather than for execution of the Vam7p functions in HOPS.SNARE complex assembly and fusion.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu						Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Collins KM, 2005, EMBO J, V24, P1775, DOI 10.1038/sj.emboj.7600658; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Jun Y, 2006, EMBO J, V25, P5260, DOI 10.1038/sj.emboj.7601413; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551	30	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13133	13138		10.1074/jbc.M700584200	http://dx.doi.org/10.1074/jbc.M700584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347148	hybrid			2022-12-25	WOS:000245942800081
J	Shelton, MD; Kern, TS; Mieyal, JJ				Shelton, Melissa D.; Kern, Timothy S.; Mieyal, John J.			Glutaredoxin regulates nuclear factor kappa-B and intercellular adhesion molecule in Muller cells - Model of diabetic retinopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; OXIDATIVE STRESS; S-GLUTATHIONYLATION; REDOX REGULATION; GLIAL-CELLS; THIOLTRANSFERASE GLUTAREDOXIN; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; 20S PROTEASOME; COMPLEX-I	Reversible S-glutathionylation of proteins is a focal point of redox signaling and cellular defense against oxidative stress. This post-translational modification alters protein function, and its reversal ( deglutathionylation) is catalyzed specifically and efficiently by glutaredoxin ( GRx, thioltransferase), a thioldisulfide oxidoreductase. We hypothesized that changes in glutaredoxin might be important in the development of diabetic retinopathy, a condition characterized by oxidative stress. Indeed, GRx protein and activity were increased in retinal homogenates from streptozotocin-diabetic rats. Also, incubation of rat retinal Muller cells ( rMC-1) in normal glucose ( 5 mM) or diabetic-like glucose ( 25 mM) medium led to selective up-regulation of GRx in contrast to thioredoxin, the other thioldisulfide oxidoreductase system. Under analogous conditions, NF-kappa B ( p50-p65) translocated to the nucleus, and expression of ICAM-1 ( intercellular adhesion molecule-1), a transcriptional product of NF-kappa B, increased. Proinflammatory ICAM-1 is increased in diabetic retinae, and it is implicated in pathogenesis of retinopathy. To evaluate the role of GRx in mediating these changes, intracellular GRx content and activity in rMC-1cells were increased independently under normal glucose via infection with an adenoviral GRx1 construct ( Ad-GRx). rMC-1 cells exhibited adenovirus concentration-dependent increases in GRx and corresponding increases in NF-kappa B nuclear translocation, NF-kappa B luciferase reporter activity, and ICAM-1 expression. Blocking the increase in GRx1 via small interfering RNA in rMC-1 cells in high glucose prevented the increased ICAM-1 expression. These data suggest that redox regulation by glutaredoxin in retinal glial cells is perturbed by hyperglycemia, leading to NF-kappa B activation and a pro-inflammatory response. Thus, GRx may represent a novel therapeutic target to inhibit diabetic retinopathy.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Mieyal, JJ (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 2109 Adelbert Rd,WRT300-9, Cleveland, OH 44106 USA.	JJM5@case.edu			NEI NIH HHS [5 T32 EY07157] Funding Source: Medline; NIA NIH HHS [P01 AG15885, R01 AG024413] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024413, P01AG015885] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P681; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Biaglow JE, 2000, ANAL BIOCHEM, V281, P77, DOI 10.1006/abio.2000.4533; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gerhardinger C, 2005, INVEST OPHTH VIS SCI, V46, P349, DOI 10.1167/iovs.04-0860; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRAVINA SA, 1993, THESIS CASE W RESERV; Hamnell-Pamment Y, 2005, BIOCHEM BIOPH RES CO, V332, P362, DOI 10.1016/j.bbrc.2005.04.130; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jeon KI, 2003, EXP MOL MED, V35, P61, DOI 10.1038/emm.2003.9; Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kenchappa RS, 2003, FASEB J, V17, P717, DOI 10.1096/fj.02-0771fje; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Li X, 2005, AM J PHYSIOL-HEART C, V288, pH1417, DOI 10.1152/ajpheart.00559.2004; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034; Moorthy AK, 2006, EMBO J, V25, P1945, DOI 10.1038/sj.emboj.7601081; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Peltoniemi MJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-133; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; POW DV, 1995, NEUROSCI LETT, V193, P25, DOI 10.1016/0304-3940(95)11657-I; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sawada M, 2006, J NEURAL TRANSM-SUPP, P373; Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shrikant P, 1996, J IMMUNOL, V156, P1307; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; THOMSON JJ, 1903, CONDUCTION ELECT GAS, P258; Wang J, 2003, P NATL ACAD SCI USA, V100, P5103, DOI 10.1073/pnas.0931345100; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960	56	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12467	12474		10.1074/jbc.M610863200	http://dx.doi.org/10.1074/jbc.M610863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324929	hybrid			2022-12-25	WOS:000245942800015
J	Xu, L; Chong, YH; Hwang, IY; D'Onofrio, A; Amore, K; Beardsley, GP; Li, CL; Olson, AJ; Boger, DL; Wilson, IA				Xu, Lan; Chong, Youhoon; Hwang, Inkyu; D'Onofrio, Anthony; Amore, Kristen; Beardsley, G. Peter; Li, Chenglong; Olson, Arthur J.; Boger, Dale L.; Wilson, Ian A.			Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN AICAR TRANSFORMYLASE; IMP CYCLOHYDROLASE; RIBONUCLEOTIDE TRANSFORMYLASE; CATALYTIC MECHANISM; PURIFICATION; ENZYME; EXPRESSION; INSIGHTS; COMPLEX; BINDING	The inosine monophosphate cyclohydrolase (IMPCH) component (residues 1-199) of the bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR Tfase, residues 200-593)/IMPCH (ATIC) catalyzes the final step in the de novo purine biosynthesis pathway that produces IMP. As a potential target for antineoplastic intervention, we designed IMPCH inhibitors, 1,5-dihydroimidazo[4,5-c][1,2,6] thiadiazin-4(3H)-one 2,2-dioxide (heterocycle, 1), the corresponding nucleoside (2), and the nucleoside monophosphate (nucleotide) (3), as mimics of the tetrahedral intermediate in the cyclization reaction. All compounds are competitive inhibitors against IMPCH (K-i values = 0.13-0.23 mu M) with the simple heterocycle 1 exhibiting the most potent inhibition (K-i = 0.13 nM). Crystal structures of bifunctional ATIC in complex with nucleoside 2 and nucleotide 3 revealed IMPCH binding modes similar to that of the IMPCH feedback inhibitor, xanthosine 5'-monophosphate. Surprisingly, the simpler heterocycle 1 had a completely different IMPCH binding mode and was relocated to the phosphate binding pocket that was identified from previous xanthosine 5'-monophosphate structures. The aromatic imidazole ring interacts with a helix dipole, similar to the interaction with the phosphate moiety of 3. The crystal structures not only revealed the mechanism of inhibition of these compounds, but they now serve as a platform for future inhibitor improvements. Importantly, the nucleoside-complexed structure supports the notion that inhibitors lacking a negatively charged phosphate can still inhibit IMPCH activity with comparable potency to phosphate-containing inhibitors. Provocatively, the nucleotide inhibitor 3 also binds to the AICAR Tfase domain of ATIC, which now provides a lead compound for the design of inhibitors that simultaneously target both active sites of this bifunctional enzyme.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pediat & Pharmacol, New Haven, CT 06520 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Yale University	Boger, DL (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	boger@scripps.edu; wilson@scripps.edu	Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719; Hwang, Inkyu/0000-0001-8997-6090	NATIONAL CANCER INSTITUTE [P01CA063536, R24CA095830] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA063536, R24 CA95830, P01 CA63536] Funding Source: Medline; NCRR NIH HHS [P41 RR08605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEARDSLEY GP, 1997, PURINE PYRIMIDINE ME, P221; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulock KG, 2002, J BIOL CHEM, V277, P22168, DOI 10.1074/jbc.M111964200; Cheong CG, 2004, J BIOL CHEM, V279, P18034, DOI 10.1074/jbc.M313691200; Christopherson RI, 2002, ACCOUNTS CHEM RES, V35, P961, DOI 10.1021/ar0000509; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Efferth T, 2003, BIOCHEM PHARMACOL, V66, P613, DOI 10.1016/S0006-2952(03)00341-1; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IMAI KI, 1969, J ORG CHEM, V34, P1547, DOI 10.1021/jo01258a004; Jackson RC., 1981, NUCLEOSIDES CANC TRE, P18; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2004, J MED CHEM, V47, P6681, DOI 10.1021/jm049504o; MEYER RB, 1979, J MED CHEM, V22, P944, DOI 10.1021/jm00194a011; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JD, 2002, J MED CHEM, V45, P5295, DOI 10.1021/jm020258v; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Shim JH, 2001, J AM CHEM SOC, V123, P4687, DOI 10.1021/ja010014k; SRIVASTAVA PC, 1974, J MED CHEM, V17, P1207, DOI 10.1021/jm00257a600; SZABADOS E, 1994, BIOCHEMISTRY-US, V33, P14237, DOI 10.1021/bi00251a036; Szabados E, 1998, BIOCHEM MOL BIOL INT, V44, P617; Vergis JM, 2004, BIOCHEMISTRY-US, V43, P1184, DOI 10.1021/bi035139b; Wall M, 2000, BIOCHEMISTRY-US, V39, P11303, DOI 10.1021/bi0007268; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wolan DW, 2004, BIOCHEMISTRY-US, V43, P1171, DOI 10.1021/bi030162i; Wolan DW, 2003, BIOCHEMISTRY-US, V42, P10904, DOI 10.1021/bi030106h; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xu L, 2004, J BIOL CHEM, V279, P50555, DOI 10.1074/jbc.M406801200	35	16	16	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13033	13046		10.1074/jbc.M607293200	http://dx.doi.org/10.1074/jbc.M607293200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324932	hybrid			2022-12-25	WOS:000245942800073
J	Agaugue, S; Perrin-Cocon, L; Andre, P; Lotteau, V				Agaugue, Sophie; Perrin-Cocon, Laure; Andre, Patrice; Lotteau, Vincent			Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell	PLOS ONE			English	Article							LOW-DENSITY-LIPOPROTEIN; TOLL-LIKE RECEPTOR-4; ACTIVATED PROTEIN-KINASE; REAL-TIME PCR; PERIPHERAL-BLOOD; IMMUNE-RESPONSES; FATTY-ACIDS; MATURATION; EXPRESSION; ALPHA	Background. Hepatitis C virus (HCV) can be purified from serum of chronically-infected patients in the form of Lipo-Viro-Particles (LVP), which are triglycerid-rich lipoprotein-like particles containing viral RNA and proteins. Since LVP is a constant feature of chronically infected patients, we asked whether purified LVP could interfere with the immune response by acting directly on dendritic cell (DC) function. Methods and Findings. We have analyzed the impact of LVP on the maturation monocyte-derived DC induced by TLR3 or TLR4 ligands. Following incubation with LVP, immature DC supported weak transient HCV-RNA replication and type I IFN synthesis. This, however, did not lead to viral particle production nor to maturation of DC. LVP-treatment prior to TLR3 stimulation by polyI:C only enhanced the secretion of IL-12, IL-6 and TNF alpha yielding typical mature DC. In contrast, LVP-treated DC activated by the TLR4 ligand LPS yielded phenotypically mature DC with reduced capacity to secrete both pro-and anti-inflammatory cytokines. Their ability to stimulate allogeneic T lymphocytes was strongly affected since activated T cells produced IL-5 and IL-13 instead of IFN gamma. Addition of IFN alpha prevented the effect of LVP on DC function. Restoration of IFN gamma secretion by T cells was obtained by blocking ERK activation in DC, while induction of IL-5 and IL-13 secretion was inhibited by blocking the p38-MAPK pathway in DC. Conclusions. LVP can interfere with TLR4-triggered maturation of DC, inducing a shift in DC function that stimulates Th2 cells instead of Th1, by a mechanism that is ERK- and p38-MAPK-dependent. The effect of LVP on DC polarization was reversed by IFN alpha, providing an additional rationale for the interferon therapy of chronically-infected patients. By acting on TLR4 pathway with LVP, HCV may thus exploit a natural protective mechanism of the liver and the intestine normally used to control inflammation and immunity to commensal microorganisms.	[Agaugue, Sophie; Perrin-Cocon, Laure; Andre, Patrice; Lotteau, Vincent] INSERM, U851, F-69008 Lyon, France; [Agaugue, Sophie; Perrin-Cocon, Laure; Andre, Patrice; Lotteau, Vincent] Univ Lyon, Lyon, France; [Andre, Patrice; Lotteau, Vincent] Hop Croix Rousse, Hosp Civils Lyon, Virol Lab, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Lotteau, V (corresponding author), INSERM, U851, F-69008 Lyon, France.	lotteau@cervi-lyon.inserm.fr	Perrin-Cocon, Laure A/M-8099-2014; André, Patrice/M-8139-2014; lotteau, vincent/M-8143-2014	Perrin-Cocon, Laure A/0000-0003-0501-6733; André, Patrice/0000-0002-5834-7395; Lotteau, Vincent/0000-0003-0997-3282	Agence Nationale de Recherche sur le Sida [HC EP 05]; Institut National de la Sante et de la Recherche Medicale; Hospices Civils de Lyon	Agence Nationale de Recherche sur le Sida(ANRSFrench National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Hospices Civils de Lyon	This work was supported by the Agence Nationale de Recherche sur le Sida (grant HC EP 05), Institut National de la Sante et de la Recherche Medicale, and the Hospices Civils de Lyon. S. A. was first recipient of a Ligue Nationale Francaise contre le Cancer doctoral scholarship and then of a Association pour la Recherche sur le Cancer doctoral scholarship.	Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Andre P, 2005, SEMIN LIVER DIS, V25, P93, DOI 10.1055/s-2005-864785; Anthony DD, 2004, J IMMUNOL, V172, P4907, DOI 10.4049/jimmunol.172.8.4907; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bluml S, 2005, J IMMUNOL, V175, P501, DOI 10.4049/jimmunol.175.1.501; Bochkov VN, 2003, J MOL MED, V81, P613, DOI 10.1007/s00109-003-0467-2; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Coutant F, 2002, J IMMUNOL, V169, P1688, DOI 10.4049/jimmunol.169.4.1688; Coutant F, 2004, J IMMUNOL, V172, P54, DOI 10.4049/jimmunol.172.1.54; Deforges S, 2004, J GEN VIROL, V85, P2515, DOI 10.1099/vir.0.80071-0; Diaz O, 2006, J GEN VIROL, V87, P2983, DOI 10.1099/vir.0.82033-0; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; DUSSAIX E, 1985, ACTA NEUROL SCAND, V71, P504; Fang SH, 2001, J CLIN MICROBIOL, V39, P3895, DOI 10.1128/JCM.39.11.3895-3901.2001; Furnkranz A, 2004, CURR PHARM DESIGN, V10, P915, DOI 10.2174/1381612043452929; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Goodridge HS, 2004, IMMUNOLOGY, V113, P491, DOI 10.1111/j.1365-2567.2004.01993.x; Goutagny N, 2004, J INFECT DIS, V189, P1646, DOI 10.1086/383248; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; He XS, 1999, P NATL ACAD SCI USA, V96, P5692, DOI 10.1073/pnas.96.10.5692; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Jiang W, 2005, P NATL ACAD SCI USA, V102, P17077, DOI 10.1073/pnas.0504570102; Jude BA, 2003, NAT IMMUNOL, V4, P573, DOI 10.1038/ni926; Kanto T, 2005, INTERVIROLOGY, V49, P58, DOI 10.1159/000087264; Kanto T, 2004, J INFECT DIS, V190, P1919, DOI 10.1086/425425; Kanto T, 1999, J IMMUNOL, V162, P5584; Komurian-Pradel F, 2004, J VIROL METHODS, V116, P103, DOI 10.1016/j.jviromet.2003.10.004; Komurian-Pradel F, 2001, J VIROL METHODS, V95, P111, DOI 10.1016/S0166-0934(01)00300-7; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Larsson M, 2004, SEMIN IMMUNOL, V16, P147, DOI 10.1016/j.smim.2004.02.002; Lauer GM, 2004, GASTROENTEROLOGY, V127, P924, DOI 10.1053/j.gastro.2004.06.015; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Longman RS, 2005, J INFECT DIS, V192, P497, DOI 10.1086/431523; Longman RS, 2004, BLOOD, V103, P1026, DOI 10.1182/blood-2003-04-1339; Luo YK, 2004, J CARDIOVASC PHARM, V44, P381, DOI 10.1097/01.fjc.0000138164.88740.f8; Murakami H, 2004, CLIN EXP IMMUNOL, V137, P559, DOI 10.1111/j.1365-2249.2004.02550.x; Nielsen SU, 2006, J VIROL, V80, P2418, DOI 10.1128/JVI.80.5.2418-2428.2006; Nielsen SU, 2004, J GEN VIROL, V85, P1497, DOI 10.1099/vir.0.79967-0; Panther E, 2002, J IMMUNOL, V169, P4129, DOI 10.4049/jimmunol.169.8.4129; Perrin-Cocon L, 2006, VACCINE, V24, P1254, DOI 10.1016/j.vaccine.2005.09.036; Perrin-Cocon L, 2001, J IMMUNOL, V167, P3785, DOI 10.4049/jimmunol.167.7.3785; Piccioli D, 2005, J HEPATOL, V42, P61, DOI 10.1016/j.jhep.2004.09.014; Price DA, 2006, GUT, V55, P715, DOI 10.1136/gut.2005.079905; Puig-Kroger A, 2001, BLOOD, V98, P2175, DOI 10.1182/blood.V98.7.2175; Randall G, 2001, CURR OPIN INFECT DIS, V14, P743, DOI 10.1097/00001432-200112000-00013; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Schwarzer E, 2003, BLOOD, V101, P722, DOI 10.1182/blood-2002-03-0979; Shaw PX, 2004, ARCH IMMUNOL THER EX, V52, P225; Skorokhod OA, 2004, J IMMUNOL, V173, P4066, DOI 10.4049/jimmunol.173.6.4066; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Zeisel MB, 2006, J HEPATOL, V44, P436, DOI 10.1016/j.jhep.2005.11.031; Zeyda M, 2005, J BIOL CHEM, V280, P14293, DOI 10.1074/jbc.M410000200	60	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e330	10.1371/journal.pone.0000330	http://dx.doi.org/10.1371/journal.pone.0000330			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389921	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200013
J	Kaipainen, A; Kieran, MW; Huang, S; Butterfield, C; Bielenberg, D; Mostoslavsky, G; Mulligan, R; Folkman, J; Panigrahy, D				Kaipainen, Arja; Kieran, Mark W.; Huang, Sui; Butterfield, Catherine; Bielenberg, Diane; Mostoslavsky, Gustavo; Mulligan, Richard; Folkman, Judah; Panigrahy, Dipak			PPAR alpha Deficiency in Inflammatory Cells Suppresses Tumor Growth	PLOS ONE			English	Article								Inflammation in the tumor bed can either promote or inhibit tumor growth. Peroxisome proliferator-activated receptor (PPAR)alpha is a central transcriptional suppressor of inflammation, and may therefore modulate tumor growth. Here we show that PPAR alpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of the endogenous angiogenesis inhibitor thrombospondin-1 and prevents tumor growth. Bone marrow transplantation and granulocyte depletion show that PPAR alpha expressing granulocytes are necessary for tumor growth. Neutralization of thrombospondin-1 restores tumor growth in PPAR alpha-deficient mice. These findings suggest that the absence of PPAR alpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis.	[Kaipainen, Arja; Kieran, Mark W.; Huang, Sui; Butterfield, Catherine; Bielenberg, Diane; Folkman, Judah; Panigrahy, Dipak] Harvard Univ, Childrens Hosp, Sch Med, Dept Surg,Vasc Biol Program, Boston, MA 02115 USA; [Kieran, Mark W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Mostoslavsky, Gustavo; Mulligan, Richard] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Panigrahy, D (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg,Vasc Biol Program, Boston, MA 02115 USA.	dipak.panigrahy@childrens.harvard.edu		Kieran, Mark/0000-0003-2184-7692; Mostoslavsky, Gustavo/0000-0002-0784-2169	Stop & Shop Pediatric Brain Tumor Fund; C.J. Buckley Pediatric Brain Tumor Research Fund; Department of Defense Innovator Award [W81XWH-04-1-0316]; private philanthropic funds	Stop & Shop Pediatric Brain Tumor Fund; C.J. Buckley Pediatric Brain Tumor Research Fund; Department of Defense Innovator Award(United States Department of Defense); private philanthropic funds	This study was supported by the Stop & Shop Pediatric Brain Tumor Fund and the C.J. Buckley Pediatric Brain Tumor Research Fund ( M. K.) and Department of Defense Innovator Award #W81XWH-04-1-0316 and private philanthropic funds (J.F.).	Achilles EG, 2001, J NATL CANCER I, V93, P1075, DOI 10.1093/jnci/93.14.1075; Albo D, 1998, J SURG RES, V76, P86, DOI 10.1006/jsre.1998.5299; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Cattley RC, 1998, REGUL TOXICOL PHARM, V27, P47, DOI 10.1006/rtph.1997.1163; Celik I, 2005, CANCER RES, V65, P11044, DOI 10.1158/0008-5472.CAN-05-2617; Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101; Collett GP, 2000, CLIN CANCER RES, V6, P3241; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crawford SE, 1998, HUM PATHOL, V29, P1039, DOI 10.1016/S0046-8177(98)90410-5; CROMMELIN DJA, 2002, PHARM BIOTECHNOLOGY, P125; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015; Gonzalez FJ, 2002, MOL CELL ENDOCRINOL, V193, P71, DOI 10.1016/S0303-7207(02)00098-9; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hadley C, 2003, EMBO REP, V4, P924, DOI 10.1038/sj.embor.embor953; Hamano Y, 2004, CANCER RES, V64, P1570, DOI 10.1158/0008-5472.CAN-03-3126; Hays T, 2005, CARCINOGENESIS, V26, P219, DOI 10.1093/carcin/bgh285; Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9; Kammertoens T, 2005, TRENDS MOL MED, V11, P225, DOI 10.1016/j.molmed.2005.03.002; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lin EY, 2004, BRIT J CANCER, V90, P2053, DOI 10.1038/sj.bjc.6601705; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; Mehta R, 2001, CLIN CANCER RES, V7, P81; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Motegi K, 2002, HISTOCHEM J, V34, P411, DOI 10.1023/A:1023687505139; NATHAN FE, 1994, CANCER, V73, P2853, DOI 10.1002/1097-0142(19940601)73:11<2853::AID-CNCR2820731131>3.0.CO;2-9; Neve BP, 2000, BIOCHEM PHARMACOL, V60, P1245, DOI 10.1016/S0006-2952(00)00430-5; Ohta Y, 1999, CANCER, V85, P2570, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.3.CO;2-6; Oshiba G, 1999, ANTICANCER RES, V19, P4375; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; SJIN RMT, 2006, CANC GENE THER; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tanaka T, 2001, CANCER RES, V61, P2424; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; TUSZYNSKI GP, 1992, THROMB HAEMOSTASIS, V67, P607; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Wang TN, 1996, SURGERY, V120, P449, DOI 10.1016/S0039-6060(96)80322-9; Wang TN, 1996, J SURG RES, V63, P39, DOI 10.1006/jsre.1996.0219; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yamashita Y, 1998, CANCER, V82, P632, DOI 10.1002/(SICI)1097-0142(19980215)82:4<632::AID-CNCR3>3.0.CO;2-N; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	67	72	73	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e260	10.1371/journal.pone.0000260	http://dx.doi.org/10.1371/journal.pone.0000260			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327920	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444600020
J	Kanome, T; Itoh, N; Ishikawa, F; Mori, K; Kim-Kaneyama, JR; Nose, K; Shibanuma, M				Kanome, T.; Itoh, N.; Ishikawa, F.; Mori, K.; Kim-Kaneyama, J-R; Nose, K.; Shibanuma, M.			Characterization of Jumping translocation breakpoint (JTB) gene product isolated as a TGF-beta 1-inducible clone involved in regulation of mitochondrial function, cell growth and cell death	ONCOGENE			English	Article						JTB; mitochondria; TGF-beta	BETA-INDUCED APOPTOSIS; CANCER-CELLS; ACTIVATION; EXPRESSION; PATHWAY; PROTEIN; CHEMOTHERAPY; RESPIRATION; MUTATIONS; TARGET	Jumping translocation breakpoint ( JTB) is a gene located on human chromosome 1 at q21 that suffers an unbalanced translocation in various types of cancers, and potentially encodes a transmembrane protein of unknown function. The results of cancer pro. ling indicated that its expression was suppressed in many cancers from different organs, implying a role in the neoplastic transformation of cells. Recently, we isolated JTB as a TGF-beta 1-inducible clone by differential screening. In this study, we characterized its product and biological functions. We found that it was processed at the N- terminus and located mostly in mitochondria. When expressed in cells, JTB- induced clustering of mitochondria around the nuclear periphery and swelling of each mitochondrion. In those mitochondria, membrane potential, as monitored with a JC- 1 probe, was significantly reduced. Coinciding with these changes in mitochondria, JTB retarded the growth of the cells and conferred resistance to TGF-beta 1-induced apoptosis. These activities were dependent on the N- terminal processing and induced by wild- type JTB but not by a mutant resistant to cleavage. These findings raised the possibility that aberration of JTB in structure or expression induced neoplastic changes in cells through dysfunction of mitochondria leading to deregulated cell growth and/or death.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Shibanuma, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; Hatakeyama S, 1999, ONCOGENE, V18, P2085, DOI 10.1038/sj.onc.1202510; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Marchetti P, 2002, ANN BIOL CLIN-PARIS, V60, P391; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; WARBURG O, 1956, SCIENCE, V124, P269; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9	28	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					5991	6001		10.1038/sj.onc.1210423	http://dx.doi.org/10.1038/sj.onc.1210423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369841				2022-12-25	WOS:000249277200002
J	de Feraudy, S; Limoli, CL; Gledzinski, E; Karentz, D; Marti, TM; Feeney, L; Cleaver, JE				de Feraudy, S.; Limoli, C. L.; Gledzinski, E.; Karentz, D.; Marti, T. M.; Feeney, L.; Cleaver, J. E.			Pol eta is required for DNA replication during nucleotide deprivation by hydroxyurea	ONCOGENE			English	Article						pol eta; H2AX; hydroxyurea	DOUBLE-STRAND BREAKS; S PHASE CHECKPOINT; POLYMERASE-ETA; HOMOLOGOUS RECOMBINATION; HISTONE H2AX; ARREST; MECHANISM; PHOSPHORYLATION; SENSITIVITY; INHIBITION	Hydroxyurea reduces DNA replication by nucleotide deprivation, whereas UV damage generates DNA photoproducts that directly block replication fork progression. We show that the low fidelity class Y polymerase Pol eta is recruited to proliferating cell nuclear antigen at replication forks both by hydroxyurea and UV light. Under nucleotide deprivation, Pol I allows cells to accumulate at the G1/S boundary by facilitating slow S-phase progression and promotes apoptosis. Normal cells consequently enter apoptosis at a faster rate than Pol eta-deficient cells. Coincident with hydroxyurea-induced S-phase delay, Pol eta-deficient cells undergo more replication fork breakage and accumulate more foci of the Mre11/Rad50/Nbs1 complex and phosphorylated histone H2AX. We conclude that under conditions of nucleotide deprivation, Pol eta is required for S-phase progression but is proapoptotic. However, as Pol eta is reported to require higher nucleotide concentrations than class B replicative polymerases, its recruitment by hydroxyurea requires it to function under suboptimal conditions. Our results suggest that hydr-oxyurea-induced apoptosis occurs at the G1/S boundary and that initiation of the S-phase requires greater nucleotide concentrations than does S-phase progression.	Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, San Francisco, CA 94143 USA; Univ Calif Irvine, Dept Radiat Oncol, Irvine, CA USA; Univ Calif San Francisco, Dept Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; University of California System; University of California Irvine; University of California System; University of California San Francisco	Cleaver, JE (corresponding author), Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, Room N431, San Francisco, CA 94143 USA.	jcleaver@cc.ucsf.edu	Marti, Thomas/AAW-5232-2020; Limoli, Charles/AAW-1748-2020	Marti, Thomas/0000-0003-3005-220X; Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 RO1 ES 8061] Funding Source: Medline; NINDS NIH HHS [5R01NS052781] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052781] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaudeau C, 2000, MUTAT RES-DNA REPAIR, V461, P221, DOI 10.1016/S0921-8777(00)00052-5; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carter G L, 1989, Cancer Commun, V1, P13; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Halicka HD, 2005, CELL CYCLE, V4, P339; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Limoli CL, 2005, ONCOGENE, V24, P3708, DOI 10.1038/sj.onc.1208515; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Washington MT, 2003, MOL CELL BIOL, V23, P8316, DOI 10.1128/MCB.23.22.8316-8322.2003	25	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5713	5721		10.1038/sj.onc.1210385	http://dx.doi.org/10.1038/sj.onc.1210385			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369853				2022-12-25	WOS:000248885100003
J	Biteman, B; Hassan, IR; Walker, E; Leedom, AJ; Dunn, M; Seta, F; Laniado-Schwartzman, M; Gronert, K				Biteman, Benjamin; Hassan, Iram R.; Walker, Everald; Leedom, Alexander J.; Dunn, Michael; Seta, Francesca; Laniado-Schwartzman, Michal; Gronert, Karsten			Interdependence of lipoxin A(4) and heme-oxygenase in counter-regulating inflammation during corneal wound healing	FASEB JOURNAL			English	Article						lipid autacoids; resolution; neutrophil; 12/15-lipoxygenase	OCULAR IMMUNE PRIVILEGE; DOCOSAHEXAENOIC ACID; LIPID MEDIATORS; 12/15-LIPOXYGENASE; MACROPHAGES; RESOLUTION; MICE; 15-LIPOXYGENASE; PROTECTIN-D1; GENERATION	In the immune-privileged cornea, epithelial wounds heal rapidly with almost no scarring and, unlike in most other tissues, acute inflammation in the absence of infection is beneficial to healing. Molecular mechanisms, which account for this striking property, remain to be clearly defined, but they likely include autacoids that control leukocyte activation. Two prominent enzymes, 12/15-lipoxygenase (LOX), which generates antiinflammatory lipid autacoids, and heme-oxygenase (HO), which generates antioxidants and carbon monoxide, are highly expressed in human and mouse corneas. LXA(4), an endogenous 12/15-LOX product, proved to be a potent inhibitor of exacerbated inflammation and significantly increased re-epithelialization in corneal wounds. In vivo deletion of 12/15-LOX correlated with exacerbated inflammation and impaired wound healing in 12/15-LOX-/- mice, a phenotype that was rescued by treatment with LXA(4). More importantly, 12/15-LOX-/- mice demonstrated impaired induction of HO-1 in both acute and exacerbated inflammation. Topical LXA(4) restored HO-1 expression in 12/15-LOX-/- mice and amplified HO-1 gene expression in human corneal epithelial cells. HO-2(-/-) mice, which fail to induce HO-1, also demonstrated exacerbated inflammation in response to injury, a phenotype that, notably, correlated with a 50% reduction in endogenous LXA(4) formation. Collectively, results demonstrate a critical role for LXA(4) in inflammatory/ reparative responses and provide the first evidence that 12/15-LOX and HO systems function in concert to control inflammation.-Biteman, B., Hassan, I. R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado-Schwartzman, M., Gronert, K. Interdependence of lipoxin A(4) and heme-oxygenase in counterregulating inflammation during corneal wound healing.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Gronert, K (corresponding author), New York Med Coll, Dept Pharmacol, Basic Sci Bldg, Valhalla, NY 10595 USA.	karsten_gronert@nymc.edu	Seta, Francesca/ABB-1566-2020	Seta, Francesca/0000-0001-7985-5615	NATIONAL EYE INSTITUTE [R01EY016136, R01EY006513] Funding Source: NIH RePORTER; NEI NIH HHS [EY016136, EY06513, R01 EY016136-03, R01 EY016136] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Cao ZY, 2002, J BIOL CHEM, V277, P42299, DOI 10.1074/jbc.M200981200; Carlson EC, 2003, MOL VIS, V9, P615; Chang MS, 2005, INVEST OPHTH VIS SCI, V46, P849, DOI 10.1167/iovs.04-1166; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Emerson MR, 2004, BRAIN RES, V1021, P140, DOI 10.1016/j.brainres.2004.06.045; Fleiszig Suzanne M J, 2002, Clin Exp Optom, V85, P271; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gan L, 1999, INVEST OPHTH VIS SCI, V40, P575; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Gronert K, 2005, PROSTAG LEUKOTR ESS, V73, P221, DOI 10.1016/j.plefa.2005.05.009; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 1999, METH MOL B, V120, P119; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hanselmann C, 2001, BIOCHEM J, V353, P459, DOI 10.1042/0264-6021:3530459; Hazlett LD, 2005, OCUL IMMUNOL INFLAMM, V13, P133, DOI 10.1080/09273940490912362; Hegazi RAF, 2005, J EXP MED, V202, P1703, DOI 10.1084/jem.20051047; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Khatri S, 2002, INVEST OPHTH VIS SCI, V43, P2278; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Kumar V., 2004, ROBBINS COTRAN PATHO; LaniadoSchwartzman M, 1997, BIOCHEM PHARMACOL, V53, P1069, DOI 10.1016/S0006-2952(97)00080-4; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; Li ZJ, 2006, INVEST OPHTH VIS SCI, V47, P1947, DOI 10.1167/iovs.05-1193; LIMINGA M, 1994, BBA-LIPID LIPID MET, V1210, P288, DOI 10.1016/0005-2760(94)90231-3; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; McClellan SA, 2003, J IMMUNOL, V170, P5219, DOI 10.4049/jimmunol.170.10.5219; Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; SERHAN CN, 1989, FREE RADICAL RES COM, V7, P341, DOI 10.3109/10715768909087960; Seta F, 2006, AM J PATHOL, V169, P1612, DOI 10.2353/ajpath.2006.060555; Sharma GD, 2005, J BIOL CHEM, V280, P7917, DOI 10.1074/jbc.M408852200; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574; Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224; Turkseven S, 2007, J CELL BIOCHEM, V100, P815, DOI 10.1002/jcb.21138; Ueno M, 2005, INVEST OPHTH VIS SCI, V46, P4097, DOI 10.1167/iovs.05-0548; Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833	56	79	85	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2257	2266		10.1096/fj.06-7918com	http://dx.doi.org/10.1096/fj.06-7918com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384141				2022-12-25	WOS:000247500300034
J	Malester, B; Tong, X; Ghiu, I; Kontogeorgis, A; Gutstein, DE; Xu, J; Hendricks-Munoz, KD; Coetzee, WA				Malester, Brian; Tong, XiaoYong; Ghiu, Ioana; Kontogeorgis, Andrianos; Gutstein, David E.; Xu, Jie; Hendricks-Munoz, Karen D.; Coetzee, William A.			Transgenic expression of a dominant negative K-ATP channel subunit in the mouse endothelium: effects on coronary flow and endothelin-1 secretion	FASEB JOURNAL			English	Article						potassium channels; coronary vasculature; transgenic mouse	SENSITIVE POTASSIUM CHANNELS; VASCULAR SMOOTH-MUSCLE; PANCREATIC BETA-CELLS; GUINEA-PIG HEART; INSULIN-SECRETION; ION CHANNELS; SULFONYLUREA RECEPTOR-1; CAMP SENSOR; MICE; RELEASE	K-ATP channels are involved in regulating coronary function, but the contribution of endothelial KATP channels remains largely uncharacterized. We generated a transgenic mouse model to specifically target endothelial KATP channels by expressing a dominant negative Kir6.1 subunit only in the endothelium. These animals had no obvious overt phenotype and no early mortality. Histologically, the coronary endothelium in these animals was preserved. There was no evidence of increased susceptibility to ergonovine-induced coronary vasospasm. However, isolated hearts from these animals had a substantially elevated basal coronary perfusion pressure. The KATP channel openers, adenosine and levcromakalim, decreased the perfusion pressure whereas the KATP channel blocker glibenclamide failed to produce a vasoconstrictive response. The inducible endothelial nitric oxide pathway was intact, as evidenced by vasodilation caused by bradykinin. In contrast, basal endothelin-1 release was significantly elevated in the coronary effluent from these hearts. Treatment of mice with bosentan (endothelin-1 receptor antagonist) normalized the coronary perfusion pressure, demonstrating that the elevated endothelin-1 release was sufficient to account for the increased coronary perfusion pressure. Pharmacological blockade of KATP channels led to elevated endothelin-1 levels in the coronary effluent of isolated mouse and rat hearts as well as enhanced endothelin-1 secretion from isolated human coronary endothelial cells. These data are consistent with a role for endothelial KATP channels to control the coronary blood flow by modulating the release of the vasoconstrictor, endothelin-1.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Amer Cardiovasc Res Inst, Atlanta, GA USA	New York University; New York University; New York University; New York University; Boston University	Coetzee, WA (corresponding author), NYU, Sch Med, Dept Pediat, 560 1st Ave,TCH-521, New York, NY 10016 USA.	william.coetzee@med.nyu.edu	Tong, Xiaoyong/L-5791-2019	Coetzee, William/0000-0003-1522-8326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081336, R01HL064838] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 081336, HL64838, R01 HL081336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; AKAI K, 1995, J CARDIOVASC PHARM, V26, P541, DOI 10.1097/00005344-199510000-00006; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BELLONI FL, 1991, AM J PHYSIOL, V261, pH720, DOI 10.1152/ajpheart.1991.261.3.H720; Bolad I, 2005, CURR OPIN CARDIOL, V20, P270, DOI 10.1097/01.hco.0000167719.37700.1d; Brayden JE, 2002, CLIN EXP PHARMACOL P, V29, P312, DOI 10.1046/j.1440-1681.2002.03650.x; Bugiardini R, 2004, CIRCULATION, V109, P2518, DOI 10.1161/01.CIR.0000128208.22378.E3; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; DAUT J, 1994, CARDIOVASC RES, V28, P811, DOI 10.1093/cvr/28.6.811; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; ECKMAN DM, 1992, BRIT J PHARMACOL, V106, P9, DOI 10.1111/j.1476-5381.1992.tb14285.x; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Fisher TE, 2001, PROG BIOPHYS MOL BIO, V77, P269, DOI 10.1016/S0079-6107(01)00017-7; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Ghiu IA, 2004, BIOPHYS J, V86, p441A; Heron-Milhavet L, 2004, MOL CELL NEUROSCI, V25, P585, DOI 10.1016/j.mcn.2003.10.012; HUTCHESON IR, 1994, AM J PHYSIOL, V266, pH590, DOI 10.1152/ajpheart.1994.266.2.H590; Ishizaka H, 1997, AM J PHYSIOL-HEART C, V273, pH104, DOI 10.1152/ajpheart.1997.273.1.H104; JACKSON WF, 1993, AM J PHYSIOL, V265, pH1797, DOI 10.1152/ajpheart.1993.265.5.H1797; Jackson WF, 1998, MICROCIRCULATION, V5, P85, DOI 10.1038/sj.mn.7300025; Kakkar R, 2006, CIRC RES, V98, P682, DOI 10.1161/01.RES.0000207498.40005.e7; Kang GX, 2006, J PHYSIOL-LONDON, V573, P595, DOI 10.1113/jphysiol.2006.107391; Katnik C, 1997, AM J PHYSIOL-HEART C, V272, pH2507, DOI 10.1152/ajpheart.1997.272.5.H2507; KLIEBER HG, 1994, CARDIOVASC RES, V28, P823, DOI 10.1093/cvr/28.6.823; KOMARU T, 1991, CIRC RES, V69, P1146, DOI 10.1161/01.RES.69.4.1146; Kunz L, 2006, J CLIN ENDOCR METAB, V91, P1950, DOI 10.1210/jc.2005-2269; KUO L, 1995, AM J PHYSIOL-HEART C, V269, pH541, DOI 10.1152/ajpheart.1995.269.2.H541; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Morrissey Alison, 2005, BMC Physiol, V5, P1, DOI 10.1186/1472-6793-5-1; NAKASHIMA M, 1992, CIRC RES, V71, P859, DOI 10.1161/01.RES.71.4.859; Nenquin M, 2004, J BIOL CHEM, V279, P32316, DOI 10.1074/jbc.M402076200; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; NUSSDORFER GG, 1979, ANAT ANZEIGER, V145, P319; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Olsen HL, 2005, ENDOCRINOLOGY, V146, P4861, DOI 10.1210/en.2005-0800; ORourke ST, 1996, J CARDIOVASC PHARM, V27, P636, DOI 10.1097/00005344-199605000-00004; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; QUAYLE JM, 1994, CARDIOVASC RES, V28, P797, DOI 10.1093/cvr/28.6.797; Quesada I, 2004, CURR MED CHEM, V11, P2707, DOI 10.2174/0929867043364379; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; Remedi MS, 2004, DIABETES, V53, P3159, DOI 10.2337/diabetes.53.12.3159; Russell FD, 1999, BRIT J PHARMACOL, V126, P391, DOI 10.1038/sj.bjp.0702315; SAMAHA FF, 1992, AM J PHYSIOL, V262, pC1220, DOI 10.1152/ajpcell.1992.262.5.C1220; Schnitzler MMY, 2000, J PHYSIOL-LONDON, V525, P307, DOI 10.1111/j.1469-7793.2000.t01-1-00307.x; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; Theis JGW, 1997, CAN J PHYSIOL PHARM, V75, P1241, DOI 10.1139/cjpp-75-10-11-1241; Thevenod F, 2002, AM J PHYSIOL-CELL PH, V283, pC651, DOI 10.1152/ajpcell.00600.2001; Tong XY, 2006, AM J PHYSIOL-HEART C, V291, pH543, DOI 10.1152/ajpheart.00051.2006; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022	55	45	46	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2162	2172		10.1096/fj.06-7821com	http://dx.doi.org/10.1096/fj.06-7821com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341678				2022-12-25	WOS:000247500300025
J	Guo, ZF; Eisenberg, D				Guo, Zhefeng; Eisenberg, David			The mechanism of the amyloidogenic conversion of T7 endonuclease I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILITY; FIBRIL FORMATION; THERMODYNAMIC STABILITY; CONFORMATIONS; AGGREGATION; SOLUBILITY; MODULATION; PRECURSORS; DISEASE	Amyloid fibrils are associated with a range of human disorders. Understanding the conversion of amyloidogenic proteins from their soluble forms to amyloid fibrils is critical for developing effective therapeutics. Previously we showed that T7 endonuclease I forms amyloid-like fibrils. Here we study the mechanism of the amyloidogenic conversion of T7 endonuclease I. We show that T7 endonuclease I forms fibrils at pH 6.8, but not at pH 6.0 or 8.0. The amyloidogenicity at pH 6.8 is not correlated with thermodynamic stability, unfolding cooperativity, or solubility. Thermal melting experiments at various pH values show that the protein has a distinctive thermal transition at pH 6.8. The transition at pH 6.8 has a lower transition temperature than the unfolding transitions observed at pH 6.0 and 8.0 and leads to a beta-rich conformation instead of an unfolded state. Electron microscopy shows that the thermal transition at pH 6.8 results in fibril formation. The thermal transition at pH 6.8 leads to a protein state that is not accessible at pH 6.0 or 8.0, showing that the existence of the amyloidogenic conformation of T7 endonuclease I depends sensitively on solution conditions. Therefore, we propose that fibrillizing proteins need to be "prepared" for fibrillization. Preparation may consist of amino acid replacements or changing solution conditions and may require retention of some aspects of native structure. In this model, some amyloid-enhancing mutations decrease protein stability, whereas others have little effect.	Univ Calif Los Angeles, Howard Hughes Med Inst, DOE Inst Genom & Proteom, Inst Mol Biol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, DOE Inst Genom & Proteom, Inst Mol Biol, Box 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu	Guo, Zhefeng/A-2069-2013	Guo, Zhefeng/0000-0003-1992-7255				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; Calamai M, 2005, BIOPHYS J, V89, P4201, DOI 10.1529/biophysj.105.068726; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Chow MKM, 2004, J BIOL CHEM, V279, P47643, DOI 10.1074/jbc.M405799200; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Dumoulin M, 2005, J MOL BIOL, V346, P773, DOI 10.1016/j.jmb.2004.11.020; Eakin CM, 2006, NAT STRUCT MOL BIOL, V13, P202, DOI 10.1038/nsmb1068; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Guo ZF, 2006, P NATL ACAD SCI USA, V103, P8042, DOI 10.1073/pnas.0602607103; Hadden JM, 2001, NAT STRUCT BIOL, V8, P62; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morel B, 2006, J MOL BIOL, V356, P453, DOI 10.1016/j.jmb.2005.11.062; Pedersen JS, 2004, J MOL BIOL, V341, P575, DOI 10.1016/j.jmb.2004.06.020; Plakoutsi G, 2005, J MOL BIOL, V351, P910, DOI 10.1016/j.jmb.2005.06.043; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schmittschmitt JP, 2003, PROTEIN SCI, V12, P2374, DOI 10.1110/ps.03152903; Soldi G, 2005, BIOPHYS J, V89, P4234, DOI 10.1529/biophysj.105.067538; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Westermark P, 2005, FEBS J, V272, P5942, DOI 10.1111/j.1742-4658.2005.05024.x	37	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14968	14974		10.1074/jbc.M609514200	http://dx.doi.org/10.1074/jbc.M609514200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17360710	hybrid			2022-12-25	WOS:000246589000035
J	Nagle, CA; An, J; Shiota, M; Torres, TP; Cline, GW; Liu, ZX; Wang, SL; Catlin, RL; Shulman, GI; Newgard, CB; Coleman, RA				Nagle, Cynthia A.; An, Jie; Shiota, Masakazu; Torres, Tracy P.; Cline, Gary W.; Liu, Zhen-Xiang; Wang, Shuli; Catlin, ReEtta L.; Shulman, Gerald I.; Newgard, Christopher B.; Coleman, Rosalind A.			Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE-1; SKELETAL-MUSCLE; FATTY-ACIDS; GLYCOGEN-SYNTHESIS; SAFFLOWER OIL; FISH-OIL; LIVER; TRIACYLGLYCEROL; ACTIVATION	Fatty liver is commonly associated with insulin resistance and type 2 diabetes, but it is unclear whether triacylglycerol accumulation or an excess flux of lipid intermediates in the pathway of triacyglycerol synthesis are sufficient to cause insulin resistance in the absence of genetic or diet-induced obesity. To determine whether increased glycerolipid flux can, by itself, cause hepatic insulin resistance, we used an adenoviral construct to overexpress glycerol-sn-3-phosphate acyltransferase-1 (Ad-GPAT1), the committed step in de novo triacylglycerol synthesis. After 5-7 days, food intake, body weight, and fat pad weight did not differ between Ad-GPAT1 and Ad-enhanced green fluorescent protein control rats, but the chow-fed Ad-GPAT1 rats developed fatty liver, hyperlipidemia, and insulin resistance. Liver was the predominant site of insulin resistance; Ad-GPAT1 rats had 2.5-fold higher hepatic glucose output than controls during a hyperinsulinemic-euglycemic clamp. Hepatic diacylglycerol and lysophosphatidate were elevated in Ad-GPAT1 rats, suggesting a role for these lipid metabolites in the development of hepatic insulin resistance, and hepatic protein kinase C is an element of was activated, providing a potential mechanism for insulin resistance. Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation. Glycogen synthesis and uptake of 2-deoxyglucose were reduced in skeletal muscle, suggesting mild peripheral insulin resistance associated with a higher content of skeletal muscle triacylglycerol. These results indicate that increased flux through the pathway of hepatic de novo triacylglycerol synthesis can cause hepatic and systemic insulin resistance in the absence of obesity or a lipogenic diet.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Vanderbilt University; Howard Hughes Medical Institute; Yale University; Yale University	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Adiels, Martin/C-9278-2011; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R56DK056598, R56DK060667, R01DK060667, P01DK058398, P30DK056350, R01DK056598, R01DK040936, U24DK059635] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056598, P30 DK034987, R01 DK040936, DK56598, P30 DK34987, P01 DK058398, R56 DK056598, U24 DK059635, DK-58398, R56 DK060667, P30 DK056350, U24 DK59635, DK-40936, R01 DK056598-25, P30 DK056350-050001, R01 DK060667, DK60667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; BECKER TC, 2004, METHOD CELL BIOL, V43, P161; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cao JS, 2006, P NATL ACAD SCI USA, V103, P19695, DOI 10.1073/pnas.0609140103; Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e; DONNELLY R, 1994, ENDOCRINOLOGY, V1135, P874; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Goudriaan JR, 2003, J LIPID RES, V44, P2270, DOI 10.1194/jlr.M300143-JLR200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Haluzik M, 2004, ENDOCRINOLOGY, V145, P3258, DOI 10.1210/en.2004-0219; Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Ide T, 2004, MED SCI MONITOR, V10, pBR388; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Jucker BM, 1999, DIABETES, V48, P134, DOI 10.2337/diabetes.48.1.134; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Linden D, 2006, FASEB J, V20, P434, DOI 10.1096/fj.05-4568com; Man WC, 2006, J LIPID RES, V47, P1928, DOI 10.1194/jlr.M600172-JLR200; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; NEWGARD CB, 1984, J BIOL CHEM, V259, P6958; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Pedrini MT, 2005, DIABETOLOGIA, V48, P756, DOI 10.1007/s00125-005-1684-8; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; SAUEL VT, 2007, J CLIN INVEST, V117, P739; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	51	95	98	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14807	14815		10.1074/jbc.M611550200	http://dx.doi.org/10.1074/jbc.M611550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389595	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000246589000016
J	Kang, S; Bennett, CN; Gerin, I; Rapp, LA; Hankenson, KD; MacDougald, OA				Kang, Sona; Bennett, Christina N.; Gerin, Isabelle; Rapp, Lauren A.; Hankenson, Kurt D.; MacDougald, Ormond A.			Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; BROWN ADIPOCYTE DIFFERENTIATION; HIGH-BONE-MASS; BETA-CATENIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTES OSTEOGENESIS; 3T3-L1 CELLS; PPAR-GAMMA; IN-VITRO	Mesenchymal precursor cells have the potential to differentiate into several cell types, including adipocytes and osteoblasts. Activation of Wnt/beta-catenin signaling shifts mesenchymal cell fate toward osteoblastogenesis at the expense of adipogenesis; however, molecular mechanisms by which Wnt signaling alters mesenchymal cell fate have not been fully investigated. Our prior work indicates that multipotent precursors express adipogenic and osteoblastogenic transcription factors at physiological levels and that ectopic expression of Wnt10b in bipotential ST2 cells suppresses expression of CCAAT/enhancer-binding protein alpha (C/EBP alpha) and peroxisome proliferator-activated receptor gamma (PPAR gamma) and increases expression of Runx2, Dlx5, and osterix. Here, we demonstrate that transient activation of Wnt/beta-catenin signaling rapidly suppresses C/EBP alpha and PPAR gamma, followed by activation of osteoblastogenic transcription factors. Enforced expression of C/EBP alpha or PPAR gamma partially rescues lipid accumulation and decreases mineralization in ST2 cells expressing Wnt10b, suggesting that suppression of C/EBP alpha and PPAR gamma is required for Wnt/beta-catenin to alter cell fate. Furthermore, knocking down expression of C/EBP alpha, PPAR gamma, or both greatly reduces adipogenic potential and causes spontaneous osteoblastogenesis in ST2 cells and mouse embryonic fibroblasts, suggesting that Wnt signaling alters the fate of mesenchymal precursor cells primarily by suppressing C/EBP alpha and PPAR gamma.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Orthoped Surg, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Med Ctr, 1301 E Catherine Rd, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Hankenson, Kurt/AFS-9417-2022; Hankenson, Kurt/ABI-1547-2020	Hankenson, Kurt/0000-0001-6361-143X; MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062876, R56DK062876] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62876] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acampora D, 1999, DEVELOPMENT, V126, P3795; Akerblad P, 2002, MOL CELL BIOL, V22, P8015, DOI 10.1128/MCB.22.22.8015-8025.2002; Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Backesjo CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gummow BM, 2003, J BIOL CHEM, V278, P26572, DOI 10.1074/jbc.M212677200; Hankenson KD, 2002, J BONE MINER RES, V17, P415, DOI 10.1359/jbmr.2002.17.3.415; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200; Kanazawa A, 2005, DIABETOLOGIA, V48, P1315, DOI 10.1007/s00125-005-1797-0; Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272-1282.2005; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Khan E, 2003, J LAB CLIN MED, V142, P29, DOI 10.1016/S0022-2143(03)00058-1; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nanbu-Wakao R, 2002, MOL ENDOCRINOL, V16, P1565, DOI 10.1210/me.16.7.1565; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005-2226; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Soroceanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723; Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; ter Brugge PJ, 2003, CLIN ORAL IMPLAN RES, V14, P472, DOI 10.1034/j.1600-0501.2003.00886.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706-715.2005; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Wiesenthal V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj029; Wu JH, 2005, BIOCHEMISTRY-US, V44, P11098, DOI 10.1021/bi050166i; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	82	309	336	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14515	14524		10.1074/jbc.M700030200	http://dx.doi.org/10.1074/jbc.M700030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17351296	hybrid			2022-12-25	WOS:000246245800065
J	Marechal, A; Mattioli, TA; Stuehr, DJ; Santolini, J				Marechal, Amandine; Mattioli, Tony A.; Stuehr, Dennis J.; Santolini, Jerome			Activation of peroxynitrite by inducible nitric-oxide synthase - A direct source of nitrative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE NITRATION; CARBON-DIOXIDE; MEDIATED OXIDATION; NITROGEN MONOXIDE; MECHANISM; CHEMISTRY; INACTIVATION; MYOGLOBIN; PTERIN; HEME	In mammals, nitric oxide (NO) is an essential biological mediator that is exclusively synthesized by nitric-oxide synthases (NOSs). However, NOSs are also directly or indirectly responsible for the production of peroxynitrite, a well known cytotoxic agent involved in numerous pathophysiological processes. Peroxynitrite reactivity is extremely intricate and highly depends on activators such as hemoproteins. NOSs present, therefore, the unique ability to both produce and activate peroxynitrite, which confers upon them a major role in the control of peroxynitrite bioactivity. We report here the first kinetic analysis of the interaction between peroxynitrite and the oxygenase domain of inducible NOS (iNOSoxy). iNOSoxy binds peroxynitrite and accelerates its decomposition with a second order rate constant of 22 x 10(4) m(-1)s(-1) at pH 7.4. This reaction is pH-dependent and is abolished by the binding of substrate or product. Peroxynitrite activation is correlated with the observation of a new iNOS heme intermediate with specific absorption at 445 nm. iNOSoxy modifies peroxynitrite reactivity and directs it toward one-electron processes such as nitration or one-electron oxidation. Taken together our results suggest that, upon binding to iNOSoxy, peroxynitrite undergoes homolytic cleavage with build-up of an oxo-ferryl intermediate and concomitant release of a NO2. radical. Successive cycles of peroxynitrite activation were shown to lead to iNOSoxy autocatalytic nitration and inhibition. The balance between peroxynitrite activation and self-inhibition of iNOSoxy may determine the contribution of NOSs to cellular oxidative stress.	CEA Saclay, Lab Stress Oxydant & Detoxicat, iBiTec S, F-91191 Gif Sur Yvette, France; Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Cleveland Clinic Foundation	Santolini, J (corresponding author), CEA Saclay, Lab Stress Oxydant & Detoxicat, iBiTec S, F-91191 Gif Sur Yvette, France.	jerome.santolini@cea.fr	MARECHAL, Amandine/AAF-7931-2020	MARECHAL, Amandine/0000-0003-3460-3806; Santolini, Jerome/0000-0001-8919-112X				AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ANDERSEN HJ, 1992, J AGR FOOD CHEM, V40, P1741, DOI 10.1021/jf00022a004; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Bredt DS, 2003, J CELL SCI, V116, P9, DOI 10.1242/jcs.00183; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2004, BIOCHEM BIOPH RES CO, V317, P873, DOI 10.1016/j.bbrc.2004.03.122; Daiber A, 2002, METHOD ENZYMOL, V359, P379; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Goldstein S, 2005, CHEM REV, V105, P2457, DOI 10.1021/cr0307087; Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009; Herold S, 2005, BIOCHEMISTRY-US, V44, P6223, DOI 10.1021/bi0475929; Herold S, 2003, BIOCHEMISTRY-US, V42, P14036, DOI 10.1021/bi0350349; Herold S, 2003, CHEM RES TOXICOL, V16, P390, DOI 10.1021/tx025595l; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Herold S, 1998, FEBS LETT, V439, P85, DOI 10.1016/S0014-5793(98)01345-3; Herold S, 2001, J AM CHEM SOC, V123, P4085, DOI 10.1021/ja010111d; Huhmer AFR, 1996, CHEM RES TOXICOL, V9, P484, DOI 10.1021/tx950152l; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ishimura Y, 2005, BIOCHEM BIOPH RES CO, V338, P543, DOI 10.1016/j.bbrc.2005.07.202; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; Koppenol WH, 2001, REDOX REP, V6, P339, DOI 10.1179/135100001101536517; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; Lincoln J, 1997, NITRIC OXIDE HLTH DI; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1242/jcs.01166; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Meli R, 2002, J BIOL INORG CHEM, V7, P31, DOI 10.1007/s007750100262; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; NAKAJIMA R, 1985, BIOCHEM BIOPH RES CO, V128, P1, DOI 10.1016/0006-291X(85)91635-3; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Pasquet JPEE, 1996, BIOCHIMIE, V78, P785, DOI 10.1016/S0300-9084(97)82537-0; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Shimanovich R, 2001, ARCH BIOCHEM BIOPHYS, V387, P307, DOI 10.1006/abbi.2000.2247; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Titheradge MA, 1998, METH MOL B, V100, P83; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699	70	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14101	14112		10.1074/jbc.M609237200	http://dx.doi.org/10.1074/jbc.M609237200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369257	hybrid			2022-12-25	WOS:000246245800020
J	Pandey, SK; Yu, XX; Watts, LM; Michael, MD; Sloop, KW; Rivard, AR; Leedom, TA; Manchem, VP; Samadzadeh, L; Mckay, RA; Monia, BP; Bhanot, S				Pandey, Sanjay K.; Yu, Xing Xian; Watts, Lynnetta M.; Michael, M. Dodson; Sloop, Kyle W.; Rivard, Amber R.; Leedom, Thomas A.; Manchem, Vara Prasad; Samadzadeh, Laura; McKay, Robert A.; Monia, Brett P.; Bhanot, Sanjay			Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; LMW-PTP; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; NEGATIVE REGULATOR; GLYCOGEN-SYNTHESIS; DIABETIC MICE; HUMAN-DISEASE; RESISTANCE; GLUCOSE	To investigate the role of low molecular weight protein-tyrosine phosphatase (LMW-PTP) in glucose metabolism and insulin action, a specific antisense oligonucleotide ( ASO) was used to reduce its expression both in vitro and in vivo. Reduction of LMW-PTP expression with the ASO in cultured mouse hepatocytes and in liver and fat tissues of diet-induced obese (DIO) mice and ob/ob mice led to increased phosphorylation and activity of key insulin signaling intermediates, including insulin receptor-beta subunit, phosphatidylinositol 3-kinase, and Akt in response to insulin stimulation. The ASO-treated DIO and ob/ob animals showed improved insulin sensitivity, which was reflected by a lowering of both plasma insulin and glucose levels and improved glucose and insulin tolerance in DIO mice. The treatment did not decrease body weight or increase metabolic rate. These data demonstrate that LMW-PTP is a key negative regulator of insulin action and a potential novel target for the treatment of insulin resistance and type 2 diabetes.	ISIS Pharmaceut, Antisense Drug Discovery, Metab Dis Program, Carlsbad, CA 92008 USA; Lilly Res Labs, Endocrine Discovery, Indianapolis, IN 46285 USA	Isis Pharmaceuticals Inc; Eli Lilly	Pandey, SK (corresponding author), ISIS Pharmaceut, Antisense Drug Discovery, Metab Dis Program, 1896 Rutherford Rd, Carlsbad, CA 92008 USA.	spandey@isisph.com		Michael, Mervyn/0000-0002-0224-1065				Bazzano LA, 2005, J AM COLL NUTR, V24, P310, DOI 10.1080/07315724.2005.10719479; Bottini N, 2002, ARCH IMMUNOL THER EX, V50, P95; Bottini N, 2002, MOL GENET METAB, V77, P226, DOI 10.1016/S1096-7192(02)00120-8; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dean NM, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P319; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Iannaccone U, 2005, METABOLISM, V54, P891, DOI 10.1016/j.metabol.2005.02.002; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Magherini F, 1998, FEBS LETT, V437, P263, DOI 10.1016/S0014-5793(98)01241-1; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Pandey SK, 1998, BIOCHEMISTRY-US, V37, P7006, DOI 10.1021/bi9726786; Ramponi G, 1997, INT J BIOCHEM CELL B, V29, P279, DOI 10.1016/S1357-2725(96)00109-4; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Taddei ML, 2000, BIOCHEM BIOPH RES CO, V270, P564, DOI 10.1006/bbrc.2000.2456; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	32	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14291	14299		10.1074/jbc.M609626200	http://dx.doi.org/10.1074/jbc.M609626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353188	hybrid			2022-12-25	WOS:000246245800040
J	Ceccarelli, DFJ; Blasutig, IM; Goudreault, M; Li, ZQ; Ruston, J; Pawson, T; Sicheri, F				Ceccarelli, Derek F. J.; Blasutig, Ivan M.; Goudreault, Marilyn; Li, Zhiqin; Ruston, Julie; Pawson, Tony; Sicheri, Frank			Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH DOMAIN; STRUCTURAL BASIS; DIFFRACTION DATA; MEMBRANE; BINDING; RAC; RECOGNITION; COMPLEX; KINASE; IDENTIFICATION	Pleckstrin homology (PH) domains are phosphoinositide (PI)-binding modules that target proteins to membrane surfaces. Here we define a family of PH domain proteins, including Tiam1 and ArhGAP9, that demonstrates specificity for PI(4,5)P-2, as well as for PI(3,4,5) P-3 and PI(3,4)P-2, the products of PI 3-kinase. These PH domain family members utilize a noncanonical phosphoinositide binding pocket related to that employed by beta- spectrin. Crystal structures of the PH domain of ArhGAP9 in complex with the headgroups of Ins(1,3,4)P-3, Ins(1,4,5)P-3, and Ins(1,3,5)P-3 reveal how two adjacent phosphate positions in PI(3,4)P-2, PI(4,5)P-2, and PI(3,4,5)P-3 are accommodated through flipped conformations of the bound phospholipid. We validate the non-canonical site of phosphoinositide interaction by showing that binding pocket mutations, which disrupt phosphoinositide binding in vitro, also disrupt membrane localization of Tiam1 in cells. We posit that the diversity in PI interaction modes displayed by PH domains contributes to their versatility of use in biological systems.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Syst Biol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Syst Biol, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca; sicheri@mshri.on.ca	Sicheri, Frank/F-8856-2013; Pawson, Tony J/E-4578-2013	Blasutig, Ivan/0000-0001-7310-2647; Ceccarelli, Derek/0000-0002-2674-9234				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balla T, 2005, J CELL SCI, V118, P2093, DOI 10.1242/jcs.02387; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; Cronin TC, 2004, EMBO J, V23, P3711, DOI 10.1038/sj.emboj.7600388; Di Lello P, 2005, BIOCHEMISTRY-US, V44, P7678, DOI 10.1021/bi050099s; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DiNitto JP, 2006, BBA-MOL CELL BIOL L, V1761, P850, DOI 10.1016/j.bbalip.2006.04.008; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Furukawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P643, DOI 10.1006/bbrc.2001.5022; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Ten Klooster JP, 2006, BIOCHEM J, V397, P39, DOI 10.1042/BJ20051957; Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4	46	75	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13864	13874		10.1074/jbc.M700505200	http://dx.doi.org/10.1074/jbc.M700505200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339315	hybrid			2022-12-25	WOS:000246060300076
J	Grodnitzky, JA; Syed, N; Kimber, MJ; Day, TA; Donaldson, JG; Hsu, WH				Grodnitzky, Justin A.; Syed, Nasser; Kimber, Michael J.; Day, Tim A.; Donaldson, Julie G.; Hsu, Walter H.			Somatostatin receptors signal through EFA6A-ARF6 to activate phospholipase D in clonal beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NUCLEOTIDE EXCHANGE FACTOR; SMOOTH-MUSCLE-CELLS; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INSULIN-SECRETION; PLASMA-MEMBRANE; P115 RHOGEF; ARF6; STIMULATION	Somatostatin (SS) is a peptide hormone that inhibits insulin secretion in beta-cells by activating its G(i/o)-coupled receptors. Our previous work indicated that a beta gamma-dimer of G(i/o) coupled to SS receptors can activate phospholipase D1 ( PLD1) ( Cheng, H., Grodnitzky, J. A., Yibchok-anun, S., Ding, J., and Hsu, W. H. (2005) Mol. Pharmacol. 67, 2162-2172). The aim of the present study was to elucidate the mechanisms underlying SS-induced PLD activation. We demonstrated the presence of ADP-ribosylation factor Arf1 and Arf6 in clonal beta-cells, HIT-T15. We also determined that the activation of PLD1 was mediated through Arf6. Overexpression of dominant-negative (dn) Arf6 mutant, Arf6( T27N), and suppression of mRNA levels using siRNA, both abolished SS-induced PLD activation, while overexpression of wild type Arf6 further enhanced this PLD activation. In contrast, overexpression of dn-Arf1 mutant Arf1(T31N) or dn-Arf5 mutant Arf5(T31N) failed to reduce SS-induced PLD activation. These findings suggested that Arf6, but not Arf1 or Arf5, mediates the effect of SS. We further determined the involvement of the Arf6 guanine nucleotide exchange factor (GEF) EFA6A, a GEF previously thought to be found predominantly in the brain, in the activation of PLD1 in HIT-T15 cells. Using Northern and Western blot analyses, both mRNA and protein of EFA6A were found in these cells. Overexpression of dn-EFA6A mutant, EFA6A( E242K), and suppression of mRNA levels using siRNA, both abolished SS-induced PLD activation, whereas overexpression of dn-EFA6B mutant, EFA6B( E651K), failed to reduce SS-induced PLD activation. In addition, overexpression of dn-ARNO mutant, ARNO(E156K), another GEF of Arf6, had no effect on SS-induced activation of PLD. Taken together, these results suggest that SS signals through EFA6A to activate Arf6-PLD cascade.	Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Iowa State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hsu, WH (corresponding author), Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA.	whsu@iastate.edu		Day, Tim/0000-0002-9037-6540	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000517, Z01HL000517] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Andresen BT, 2001, HYPERTENSION, V37, P635, DOI 10.1161/01.HYP.37.2.635; ANGING WF, 2005, REV MED PHYSL, P85; Bhattacharya M, 2004, J NEUROSCI, V24, P8752, DOI 10.1523/JNEUROSCI.3155-04.2004; Bollag WB, 2002, MOL CELL ENDOCRINOL, V192, P7, DOI 10.1016/S0303-7207(02)00134-X; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Cheng H, 2005, MOL PHARMACOL, V67, P2162, DOI 10.1124/mol.104.010470; Cheng H, 2002, LIFE SCI, V71, P927, DOI 10.1016/S0024-3205(02)01774-5; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; Cui Y, 1997, J INVEST MED, V45, P388; Derrien V, 2002, J CELL SCI, V115, P2867; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Foster DA, 2003, MOL CANCER RES, V1, P789; GUPTA S, 1995, ENDOCRINOLOGY, V136, P3794, DOI 10.1210/en.136.9.3794; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; HOU CF, 1994, J BIOL CHEM, V269, P10357; HSU WH, 1991, J BIOL CHEM, V266, P837; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Karschin A, 1995, NEUROREPORT, V7, P121, DOI 10.1097/00001756-199512000-00029; Kato Y, 1997, PROSTAGLANDINS, V54, P475, DOI 10.1016/S0090-6980(97)00061-0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lee SD, 2000, NEUROSCI LETT, V294, P130, DOI 10.1016/S0304-3940(00)01563-9; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MIWA M, 1995, BIOCHEM CELL BIOL, V73, P191, DOI 10.1139/o95-023; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; Robertson DN, 2003, MOL PHARMACOL, V64, P1239, DOI 10.1124/mol.64.5.1239; Sakagami H, 2004, EUR J NEUROSCI, V19, P863, DOI 10.1111/j.0953-816X.2004.03195.x; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	63	7	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13410	13418		10.1074/jbc.M701940200	http://dx.doi.org/10.1074/jbc.M701940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353194	Green Submitted, hybrid			2022-12-25	WOS:000246060300030
J	Grosfeld, A; Stolze, IP; Cockman, ME; Pugh, CW; Edelmann, M; Kessler, B; Bullock, AN; Ratcliffe, PJ; Masson, N				Grosfeld, Alexandra; Stolze, Ineke P.; Cockman, Matthew E.; Pugh, Christopher W.; Edelmann, Mariola; Kessler, Benedikt; Bullock, Alex N.; Ratcliffe, Peter J.; Masson, Norma			Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; PROTEIN; COMPLEX; GROWTH; PVHL; HYDROXYPROLINE; UBIQUITYLATION; TUMORIGENESIS; ANGIOGENESIS; TRAFFICKING	The von Hippel-Lindau tumor suppressor (pVHL) targets hydroxylated alpha-subunits of hypoxia-inducible factor (HIF) for ubiquitin-mediated proteasomal destruction through direct interaction with the hydroxyproline binding pocket in its beta-domain. Although disruption of this process may contribute to VHL-associated tumor predisposition by up-regulation of HIF target genes, genetic and biochemical analyses support the existence of additional functions, including a role in the assembly of extracellular matrix. In an attempt to delineate these pathways, we searched for novel pVHL-binding proteins. Here we report a direct, hydroxylation-dependent interaction with alpha-chains of collagen IV. Interaction with pVHL was also observed with fibrillar collagen chains, but not the folded collagen triple helix. The interaction was suppressed by a wide range of tumor-associated mutations, including those that do not disturb the regulation of HIF, supporting a role in HIF- independent tumor suppressor functions.	Univ Oxford, Oxford OX3 7BN, England	University of Oxford	Masson, N (corresponding author), Univ Oxford, Henry Wellcome Bldg Mol Physiol, Oxford OX3 7BN, England.	nmasson@well.ox.ac.uk	Grosfeld, Alexandra/AAH-3510-2020; Cockman, Matthew/V-9619-2019; Kessler, Benedikt/AAY-8614-2021; Grosfeld, Alexandra/R-1404-2017	Cockman, Matthew/0000-0002-3310-4821; Kessler, Benedikt/0000-0002-8160-2446; Grosfeld, Alexandra/0000-0002-9508-036X; Pugh, Chris/0000-0002-5170-1662; Edelmann, Mariola/0000-0003-0459-7716; Ratcliffe, Peter/0000-0002-2853-806X	Medical Research Council [G116/127] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G116/127] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Batycka M, 2006, RAPID COMMUN MASS SP, V20, P2074, DOI 10.1002/rcm.2563; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; Gotkin MG, 2004, EXP CELL RES, V296, P307, DOI 10.1016/j.yexcr.2004.01.029; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Zimmer M, 2004, MOL CANCER RES, V2, P89	27	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13264	13269		10.1074/jbc.M611648200	http://dx.doi.org/10.1074/jbc.M611648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339318	hybrid			2022-12-25	WOS:000246060300014
J	Wang, ZX; Teh, CHL; Kueh, JLL; Lufkin, T; Robson, P; Stanton, LW				Wang, Zheng-Xu; Teh, Christina Hui-Leng; Kueh, Jacqueline L. L.; Lufkin, Thomas; Robson, Paul; Stanton, Lawrence W.			Oct4 and sox2 directly regulate expression of another pluripotency transcription factor, Zfp206, in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SELF-RENEWAL; ENHANCER; COMPLEX; NANOG; OCTAMER; OCT-3/4; SITES	It is well known that Oct4 and Sox2 play an important role in the maintenance of embryonic stem cell pluripotency. These transcription factors bind to regulatory regions within hundreds of target genes to control their expression. Zfp206 is a recently characterized transcription factor that has a role in maintaining stem cell pluripotency. We have demonstrated here that Zfp206 is a direct downstream target of Oct4 and Sox2. Two composite sox-oct binding sites have been identified within the first intron of Zfp206. We have demonstrated binding of Oct4 and Sox2 to this region. In addition, we have shown that Oct4 or Sox2 alone can activate transcription via one of these sox-oct elements, although the presence of both Oct4 and Sox2 gave rise to a synergistic effect. These studies extend our understanding of the transcriptional network that operates to regulate the differentiation potential of embryonic stem cells.	Genome Inst Singapore, Dept Stem Cell & Dev Biol, Singapore 138672, Singapore; Jin Cheng Hosp Lan Zhou, Dept Gen Surg, Lanzhou 730050, Gansu, Peoples R China; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Stanton, LW (corresponding author), Genome Inst Singapore, Dept Stem Cell & Dev Biol, 60 Biopolis St, Singapore 138672, Singapore.	stantonl@gis.a-star.edu.sg	Lufkin, Thomas/AAG-7476-2019; Robson, Paul/A-3464-2009; Lufkin, Thomas/B-5352-2011	Lufkin, Thomas/0000-0002-7902-4771; Robson, Paul/0000-0002-0191-3958; Lufkin, Thomas/0000-0002-7902-4771				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; Furusawa T, 2006, BIOL REPROD, V75, P555, DOI 10.1095/biolreprod.105.049502; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Matin MM, 2004, STEM CELLS, V22, P659, DOI 10.1634/stemcells.22-5-659; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Palmqvist L, 2005, STEM CELLS, V23, P663, DOI 10.1634/stemcells.2004-0157; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sharov AA, 2003, PLOS BIOL, V1, P410, DOI 10.1371/journal.pbio.0000074; Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang W, 2006, NUCLEIC ACIDS RES, V34, P4780, DOI 10.1093/nar/gkl631	30	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12822	12830		10.1074/jbc.M611814200	http://dx.doi.org/10.1074/jbc.M611814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344211	hybrid			2022-12-25	WOS:000245942800054
J	Jiang, SX; Seng, S; Avraham, HK; Fu, YG; Avraham, S				Jiang, Shuxian; Seng, Seyha; Avraham, Hava Karsenty; Fu, Yigong; Avraham, Shalom			Process elongation of oligodendrocytes is promoted by the kelch-related protein MRP2/KLHL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEIN; RAT OPTIC-NERVE; NEURITE OUTGROWTH; INTERACTION MOTIF; PRECURSOR CELLS; SPINAL-CORD; LINEAGE; DROSOPHILA; BINDING; EXPRESSION	Oligodendrocytes ( OLGs) are generated by progenitor cells that are committed to differentiating into myelin-forming cells of the central nervous system. Rearrangement of the cytoskeleton leading to the extension of cellular processes is essential for the myelination of axons by OLGs. Here, we have characterized a new member of the Kelch-related protein family termed MRP2 ( for Mayven-related protein 2) that is specifically expressed in brain. MRP2/KLHL1 is expressed in oligodendrocyte precursors and mature OLGs, and its expression is up-regulated during OLG differentiation. MRP2/KLHL1 expression was abundant during the specific stages of oligodendrocyte development, as identified by A2B5-, O4-, and O1-specific oligodendrocyte markers. MRP2/KLHL1 was localized in the cytoplasm and along the cell processes. Moreover, a direct endogenous association of MRP2/KLHL1 with actin was observed, which was significantly increased in differentiated OLGs compared with undifferentiated OLGs. Overexpression of MRP2/KLHL1 resulted in a significant increase in the process extension of rat OLGs, whereas MRP2/KLHL1 antisense reduced the process length of primary rat OLGs. Furthermore, murine OLGs isolated from MRP2/KLHL1 transgenic mice showed a significant increase in the process extension of OLGs compared with control wild-type murine OLGs. These studies provide insights into the role of MRP2/KLHL1, through its interaction with actin, in the process elongation of OLGs.	Harvard Univ, Sch Med, Div Expt Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER; NCI NIH HHS [CA 096805] Funding Source: Medline; NHLBI NIH HHS [K18 PAR-HL-02-069] Funding Source: Medline; NINDS NIH HHS [NS 39558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ARMSTRONG R, 1991, ANN NY ACAD SCI, V633, P520; AVRAHAM S, 2003, RECENT RES DEV BIOL, V1, P231; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1992, J NEUROBIOL, V23, P1221, DOI 10.1002/neu.480230912; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Barry C, 1996, DEV NEUROSCI-BASEL, V18, P233, DOI 10.1159/000111413; Benzow KA, 2002, MAMM GENOME, V13, P134, DOI 10.1007/s0033501-2105-2; Benzow KA, 2002, LEUKEMIA LYMPHOMA, V43, P1987, DOI 10.1080/1042819021000015943; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; GODT D, 1993, DEVELOPMENT, V119, P799; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; He Y, 2006, J NEUROSCI, V26, P9975, DOI 10.1523/JNEUROSCI.2595-06.2006; Jiang S, 2005, J NEUROCHEM, V92, P1191, DOI 10.1111/j.1471-4159.2004.02946.x; KENNEDY PGE, 1980, LAB INVEST, V43, P342; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 2005, J CELL SCI, V118, P5537, DOI 10.1242/jcs.02643; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; LEVITON A, 1973, J NEUROL SCI, V18, P53, DOI 10.1016/0022-510X(73)90020-8; Ludwin SK, 1997, J NEUROPATH EXP NEUR, V56, P111, DOI 10.1097/00005072-199702000-00001; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Nemes JP, 2000, HUM MOL GENET, V9, P1543, DOI 10.1093/hmg/9.10.1543; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Seng S, 2000, PARASITOL RES, V86, P263, DOI 10.1007/s004360050041; Seng S, 2006, MOL CELL BIOL, V26, P8371, DOI 10.1128/MCB.02167-05; Shi JY, 1998, J NEUROSCI, V18, P4627; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; TIMSIT S, 1995, J NEUROSCI, V15, P1012; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; WARF BC, 1991, J NEUROSCI, V11, P2477; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Williams SK, 2005, J NEUROSCI RES, V81, P622, DOI 10.1002/jnr.20588; WILSON R, 1989, J NEUROSCI RES, V22, P439, DOI 10.1002/jnr.490220409; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	45	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12319	12329		10.1074/jbc.M701019200	http://dx.doi.org/10.1074/jbc.M701019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324934	hybrid			2022-12-25	WOS:000245941900074
J	Miki, T; Takegami, Y; Okawa, K; Muraguchi, T; Noda, M; Takahashi, C				Miki, Takao; Takegami, Yujiro; Okawa, Katsuya; Muraguchi, Teruyuki; Noda, Makoto; Takahashi, Chiaki			The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase n and modulates their endocytic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HUMAN ENDOTHELIAL-CELLS; AMINOPEPTIDASE-N; DOWN-REGULATION; INHIBITOR RECK; LUNG-CANCER; LIPID RAFTS; MT1-MMP; CAVEOLAE; INVASION	The reversion-inducing cysteine-rich protein with Kazal motifs ( RECK) is anchored to the cell surface via glycosylphosphatidylinositol. This molecule antagonizes the function of membrane type 1 matrix metalloproteinase ( MT1-MMP) to promote proMMP-2 maturation. Here, we attempt to clarify the mechanism underlying RECK functions. First, we found that RECK forms a complex with MT1-MMP and inhibits its proteolytic activity. Notably, RECK increases the amount of MT1-MMP that associates with detergent-resistant membranes during sucrose gradient ultracentrifugation. Furthermore, perturbation of membrane cholesterol significantly affected the function of RECK in suppressing MT1-MMP function. These findings indicate that RECK possibly regulates MT1-MMP function by modulating its behavior on the cell surface as well as by enzymatic action; this prompted us to find another molecule whose behavior in detergent-resistant membranes is influenced by RECK. Subsequently, we found that RECK interacts with CD13/aminopeptidase N. Further, we found that RECK inhibits the proteolytic activity of CD13 in a cholesterol perturbation-sensitive manner. Finally, we examined whether RECK influences the behavior of MT1-MMP and CD13 during their internalization from the cell surface. In the absence of RECK, MT1-MMP and CD13 were internalized along with the markers of clathrin- or caveolae-dependent endocytosis. However, interestingly, in the presence of RECK these molecules were internalized preferentially with an endocytic marker that is neither clathrin- nor caveolae-dependent, indicating that RECK modulates endocytic pathways of MT1-MMP and CD13. This modulation was correlated with the accelerated internalization and decay of MT1-MMP and CD13. This study unveils the novel function and target molecules of RECK.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Format, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University	Takahashi, C (corresponding author), Kyoto Univ, Grad Sch Med, 21st Century COE Format, Sakyo Ku, Kyoto 6068501, Japan.	chtakaha@virus.kyoto-u.ac.jp						Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Aozuka Y, 2004, CANCER LETT, V216, P35, DOI 10.1016/j.canlet.2004.06.050; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bhagwat SV, 2003, BLOOD, V101, P1818, DOI 10.1182/blood-2002-05-1422; Bigg HF, 2001, CANCER RES, V61, P3610; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x; Chang YW, 2005, INT J CANCER, V116, P243, DOI 10.1002/ijc.21089; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Echizenya M, 2005, ONCOGENE, V24, P5850, DOI 10.1038/sj.onc.1208733; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; Oda A, 2005, BLOOD, V105, P3141, DOI 10.1182/blood-2003-04-1319; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Paulissen G, 2006, MOL MED, V12, P171, DOI 10.2119/2006-00028.Paulissen; Rabien A, 2007, EUR UROL, V51, P1259, DOI 10.1016/j.eururo.2006.05.050; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; van Lent PLEM, 2005, ANN RHEUM DIS, V64, P368, DOI 10.1136/ard.2004.027870; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhang Z, 2005, PEPTIDES, V26, P2182, DOI 10.1016/j.peptides.2005.03.049	42	70	74	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12341	12352		10.1074/jbc.M610948200	http://dx.doi.org/10.1074/jbc.M610948200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329256	hybrid			2022-12-25	WOS:000245941900076
J	Li, FM; Luo, ZM; Huang, WY; Lu, QS; Wilcox, CS; Jose, PA; Chen, SY				Li, Fengmin; Luo, Zaiming; Huang, Wenyan; Lu, Quansheng; Wilcox, Christopher S.; Jose, Pedro A.; Chen, Shiyou			Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; STEM-CELLS; IN-VITRO; ACTIN EXPRESSION; SMAD PROTEINS; CARG ELEMENTS; MYOCARDIN; TRANSCRIPTION; PROLIFERATION; ACTIVATION	We previously developed a robust in vitro model system for vascular smooth muscle cell ( VSMC) differentiation from neural crest cell line Monc-1 upon transforming growth factor-ss ( TGF-ss) induction. Further studies demonstrated that both Smad and RhoA signaling are critical for TGF-ss- induced VSMC development. To identify downstream targets, we performed Affymetrix cDNA array analysis of Monc-1 cells and identified a gene named response gene to complement 32 (RGC-32) to be important for the VSMC differentiation. RGC-32 expression was increased 5-fold after 2 h and 50- fold after 24 h of TGF-ss induction. Knockdown of RGC-32 expression in Monc-1 cells by small interfering RNA significantly inhibited the expression of multiple smooth muscle marker genes, including SM alpha-actin (alpha-SMA), SM22 alpha, and calponin. Of importance, the inhibition of RGC-32 expression correlated with the reduction of alpha-SMA while not inhibiting smooth muscle- unrelated c-fos gene expression, suggesting that RGC-32 is an important protein factor for VSMC differentiation from neural crest cells. Moreover, RGC-32 overexpression significantly enhanced TGF-ss-induced alpha-SMA, SM22 alpha, and SM myosin heavy chain promoter activities in both Monc-1 and C3H10T1/2 cells. The induction of VSMC gene promoters by RGC-32 appears to be CArG- dependent. These data suggest that RGC-32 controls VSMC differentiation by regulating marker gene transcription in a CArG- dependent manner. Further studies revealed that both Smad and RhoA signaling are important for RGC-32 activation.	Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20057 USA	Georgetown University; Georgetown University	Chen, SY (corresponding author), Georgetown Univ, Med Ctr, Dept Pediat, Bldg D,Room 363,4000 Reservoir Rd NW, Washington, DC 20057 USA.	sc229@georgetown.edu	Li, Fengmin/J-5721-2013; Li, Fengmin/K-8740-2012	Li, Fengmin/0000-0002-2144-3498	NHLBI NIH HHS [HL68686] Funding Source: Medline; NIDDK NIH HHS [DK52612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; Baldwin H. Scott, 1999, Current Opinion in Pediatrics, V11, P413, DOI 10.1097/00008480-199910000-00008; Brand-Saberi B, 2000, CURR TOP DEV BIOL, V48, P1; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Choudhary B, 2006, DEV BIOL, V289, P420, DOI 10.1016/j.ydbio.2005.11.008; Ding RB, 2004, STEM CELLS DEV, V13, P509, DOI 10.1089/1547328042417336; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Epstein J. A., 2001, TRENDS GENET, V17, pS13; Epstein JA, 2000, DEVELOPMENT, V127, P1869; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Fosbrink M, 2005, EXP MOL PATHOL, V78, P116, DOI 10.1016/j.yexmp.2004.11.001; Fosbrink M, 2005, IMMUNOL RES, V31, P37, DOI 10.1385/IR:31:1:37; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; Hagedorn L, 1999, DEVELOPMENT, V126, P3781; Hirschi KK, 2004, ANAT REC PART A, V276A, P22, DOI 10.1002/ar.a.10128; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Lilly B, 2001, DEV BIOL, V240, P531, DOI 10.1006/dbio.2001.0507; Liu CY, 2002, DEVELOPMENT, V129, P5081; Mack CP, 1999, CIRC RES, V84, P852; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; SCHWARTZ SM, 1983, P SOC EXP BIOL MED, V173, P1; Schwartz SM, 1998, ANNU REV MED, V49, P437; Schwartz SM, 1997, J CLIN INVEST, V100, P87; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Vitelli F, 2002, HUM MOL GENET, V11, P915, DOI 10.1093/hmg/11.8.915; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wu JL, 2003, TRENDS NEUROSCI, V26, P40, DOI 10.1016/S0166-2236(02)00011-5; Wurdak H, 2005, GENE DEV, V19, P530, DOI 10.1101/gad.317405; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhou JL, 2005, J BIOL CHEM, V280, P10861, DOI 10.1074/jbc.M411586200	57	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10133	10137		10.1074/jbc.C600225200	http://dx.doi.org/10.1074/jbc.C600225200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17327222	hybrid			2022-12-25	WOS:000245941000002
J	Kanazawa, T; Iwashita, T; Kommareddi, P; Nair, T; Misawa, K; Misawa, Y; Ueda, Y; Tono, T; Carey, TE				Kanazawa, T.; Iwashita, T.; Kommareddi, P.; Nair, T.; Misawa, K.; Misawa, Y.; Ueda, Y.; Tono, T.; Carey, T. E.			Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors	ONCOGENE			English	Article						g protein-coupled receptors; mitogen-activated protein kinase; cyclin-dependent kinase inhibitor; head and neck neoplasm	PROTEIN-KINASE; CANCER CELLS; HEAD; ARREST; 18Q; P27; EXPRESSION; RAS	Galanin receptor 1(GALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently inactivated by methylation. To investigate effects of GALR1 and its signaling pathways, we stably expressed hemaglutinin-tagged GALR1 in a human oral carcinoma cell line (UM-SCC-1-GALR1) that expresses no endogenous GALR1. In transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2 (ERK1/2) and suppressed proliferation. Galanin stimulation mediated decreased expression of cyclin D1 and increased expression of the cyclin-dependent kinase inhibitors (CKI), p27(Kip1) and p57(Kip2). Pretreatment with the ERK1/2-specitic inhibitor U0126 prevented these galanin-induced effects. Phosphatidylinositol 3-kinase (PI3K) pathway activation did not differ in UM-SCC-1-GALR1 and UM-SCC-1-mock cells after galanin treatment. Pertussis toxin and LY294002 inhibition demonstrated that galanin and GALR1 induce ERK1/2 activation via God, not the PI3K pathway-linked to the G beta gamma subunit. Galanin and GALR1 also inhibit colony formation and tumor growth in vivo. Our results implicate GALR1, a Gi protein-coupled receptor, as a tumor suppressor gene that inhibits cell proliferation via ERK1/2 activation.	Univ Michigan, Dept Otolaryngol Head & Neck Surg, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Ryukyus, Dept Otolaryngol Head & Neck Surg, Okinawa, Japan; Hamamatsu Univ Sch Med, Dept Otolaryngol, Hamamatsu, Shizuoka 43131, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Ryukyus; Hamamatsu University School of Medicine	Carey, TE (corresponding author), Univ Michigan, Dept Otolaryngol, 1301 E Ann St,6020 KHRI, Ann Arbor, MI 48109 USA.	careyte@umich.edu		Carey, Thomas/0000-0002-5202-7518	NATIONAL CANCER INSTITUTE [P50CA097248, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC005188] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97248, P30 CA46592] Funding Source: Medline; NIDCD NIH HHS [P30 DC005188, P30 DC05188] Funding Source: Medline; NIDCR NIH HHS [R01 DE12477] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akervall J, 2003, CLIN CANCER RES, V9, P1750; Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Cody JD, 1997, AM J MED GENET, V71, P420, DOI 10.1002/(SICI)1096-8628(19970905)71:4<420::AID-AJMG9>3.3.CO;2-A; Dixon BS, 2002, AM J PHYSIOL-CELL PH, V283, pC193, DOI 10.1152/ajpcell.00289.2001; Esposito V, 1997, CANCER RES, V57, P3381; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Han JH, 2005, J BIOL CHEM, V280, P31548, DOI 10.1074/jbc.M503431200; Henson BS, 2005, J BIOL CHEM, V280, P22564, DOI 10.1074/jbc.M414589200; Hoffmann MJ, 2005, INT J CANCER, V114, P406, DOI 10.1002/ijc.20749; Kong SM, 2000, CANCER RES, V60, P249; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Lu XY, 2005, NEUROPEPTIDES, V39, P165, DOI 10.1016/j.npep.2004.12.013; Massarelli E, 2005, CANCER-AM CANCER SOC, V103, P952, DOI 10.1002/cncr.20879; Masuda T, 2002, CANCER RES, V62, P3819; MISAWA K, 2004, P AM ASSOC CANC RES, V44, P4271; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Otis M, 2005, ENDOCRINOLOGY, V146, P633, DOI 10.1210/en.2004-0935; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Seufferlein T, 1996, CANCER RES, V56, P5758; Takebayashi S, 2000, CANCER RES, V60, P3397; Takebayashi S, 2004, GENE CHROMOSOME CANC, V41, P145, DOI 10.1002/gcc.20066; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102	32	50	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5762	5771		10.1038/sj.onc.1210384	http://dx.doi.org/10.1038/sj.onc.1210384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17384686				2022-12-25	WOS:000248885100008
J	Sims-Mourtada, J; Izzo, JG; Ajani, J; Chao, KSC				Sims-Mourtada, J.; Izzo, J. G.; Ajani, J.; Chao, K. S. C.			Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport	ONCOGENE			English	Article						hedgehog; multiple drug resistance; drug transport; chemoresistance	MULTIDRUG-RESISTANCE; STEM-CELLS; MUTATIONS; PTCH	A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATP-binding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.	Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chao, KSC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 97, Houston, TX 77030 USA.	cchao@mdanderson.org			NATIONAL CANCER INSTITUTE [P50CA097007, R01CA089198, R21CA121551] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97007, CA121551, CA89198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chintamani, 2005, WORLD J SURG ONCOL, V3, P61; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kubo A, 2004, AM J GASTROENTEROL, V99, P582, DOI 10.1111/j.1572-0241.2004.04131.x; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	17	177	185	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5674	5679		10.1038/sj.onc.1210356	http://dx.doi.org/10.1038/sj.onc.1210356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353904				2022-12-25	WOS:000248801900014
J	Robinet, A; Millart, H; Oszust, F; Hornebeck, W; Bellon, G				Robinet, Arnaud; Millart, Herve; Oszust, Floriane; Hornebeck, William; Bellon, Georges			Binding of elastin peptides to S-Gal protects the heart against ischemia/reperfusion injury by triggering the RISK pathway	FASEB JOURNAL			English	Article						preconditioning; postconditioning; cardioprotection; aging	NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION; SMOOTH-MUSCLE CELLS; UP-REGULATION; MATRIX METALLOPROTEINASE-1; MYOCARDIAL-INFARCTION; CHEMOTACTIC ACTIVITY; REPERFUSION INJURY; LAMININ RECEPTOR; VASCULAR WALL	Elastin peptides (EPs) generated by hydrolysis of elastic fibers by elastinolytic enzymes display a wide spectrum of biological activities. Here, we investigated their influence on rat heart ischemia-mediated injury using the Langendorff ex vivo model. EPs, i.e., kappa elastin, at 1.32- and 660-nM concentrations, when administered before the ischemia period, elicited a beneficial influence against ischemia by accelerating the recovery rate of heart contractile parameters and by decreasing significantly creatine kinase release and heart necrosis area when measured at the onset of the reperfusion. All effects were S-Gal-dependent, as being reproduced by (VGVAPG) 3 and as being inhibited by receptor antagonists, such as lactose and V14 peptide (VVGSPSAQDEASPL). EPs interaction with S-Gal triggered NO release and activation of PI3-kinase/Akt and ERK1/2 in human coronary endothelial cells (HCAECs) and rat neonatal cardiomyocytes (RCs). This signaling pathway, as designated as RISK, for reperfusion injury salvage kinase pathway, was shown to be responsible for the beneficial influence of EPs on ischemia/reperfusion injury on the basis of its inhibition by specific pharmacological inhibitors. EPs survival activity was attained at a concentration averaging that present into the blood circulation, supporting the contention that these matrikines might offer a natural protection against cardiac injury in young and adult individuals. Such protective effect might be lost with aging, since we found that hearts from 24-month-old rats did not respond to EPs.	Univ Reims, Fac Med, Lab Pharmacol Med, Reims, France; Univ Reims, Fac Med, Lab Biochim & Biol Mol, UMR 6198,CNRS, Reims, France	Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Hornebeck, W (corresponding author), Univ Reims, Biochim Lab, Fac Med, CNRS UMR 6 19, 51 Rue Cognacq Jay, F-51095 Reims, France.	william.hornebeck@univ-reims.fr	OSZUST, Floriane/B-7976-2012	OSZUST, Floriane/0000-0001-9742-3365				Adler A, 2004, AM J PHYSIOL-HEART C, V287, pH14, DOI 10.1152/ajpheart.01235.2003; Bizbiz L, 1997, ATHEROSCLEROSIS, V131, P73, DOI 10.1016/S0021-9150(97)06076-0; BLOOD CH, 1993, CANCER RES, V53, P2661; Bolli R, 1997, CIRC RES, V81, P42, DOI 10.1161/01.RES.81.1.42; Booms P, 2006, J MOL CELL CARDIOL, V40, P234, DOI 10.1016/j.yjmcc.2005.11.009; Boucher M, 2004, J CARDIOVASC PHARM, V43, P416, DOI 10.1097/00005344-200403000-00013; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Crisostomo PR, 2006, J AM COLL SURGEONS, V202, P797, DOI 10.1016/j.jamcollsurg.2005.12.002; Davidson SM, 2006, INT J BIOCHEM CELL B, V38, P414, DOI 10.1016/j.biocel.2005.09.017; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Debret R, 2006, J INVEST DERMATOL, V126, P1860, DOI 10.1038/sj.jid.5700337; Duca L, 2005, MOL PHARMACOL, V67, P1315, DOI 10.1124/mol.104.002725; Faury G, 1997, MECH AGEING DEV, V95, P31, DOI 10.1016/S0047-6374(96)01842-8; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; Faury G, 2003, J CLIN INVEST, V112, P1419, DOI 10.1172/JCI200319028; Faury G, 2003, BIOMED PHARMACOTHER, V57, P216, DOI 10.1016/S0753-3322(03)00053-2; Floquet N, 2004, BIOPOLYMERS, V76, P266, DOI 10.1002/bip.20029; Fulop T, 2001, PATHOL BIOL, V49, P339, DOI 10.1016/S0369-8114(01)00143-2; GHUYSENITARD AF, 1992, CR ACAD SCI III-VIE, V315, P473; Guo Y, 2005, AM J PHYSIOL-HEART C, V289, pH2251, DOI 10.1152/ajpheart.00341.2005; Haendeler J, 2006, EUR J CLIN PHARMACOL, V62, P137, DOI 10.1007/s00228-005-0008-8; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hinek A, 1996, BIOL CHEM, V377, P471; Hornebeck W, 2005, ANTICANCER RES, V25, P2617; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011; Liu YH, 2005, AM J PHYSIOL-HEART C, V289, pH2616, DOI 10.1152/ajpheart.00546.2005; Mizuno T, 2005, AM J PHYSIOL-HEART C, V288, pH2819, DOI 10.1152/ajpheart.00862.2004; MIZUNO T, 2005, J INVEST DERMATOL, V112, pI81; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2; Pezet Mylene, 2004, Journal de la Societe de Biologie, V198, P279; Qian HS, 2006, J CARDIOVASC PHARM, V47, P587, DOI 10.1097/01.fjc.0000211736.55583.5c; Razavi HM, 2005, PHARMACOL THERAPEUT, V106, P147, DOI 10.1016/j.pharmthera.2004.11.006; ROBERT L, 1989, PATHOL BIOL, V37, P736; Robert L, 2000, BIOGERONTOLOGY, V1, P123, DOI 10.1023/A:1010048014925; Robert L, 1996, ATHEROSCLEROSIS, V123, P169, DOI 10.1016/0021-9150(96)05804-2; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Saito M, 2002, EXP GERONTOL, V37, P937, DOI 10.1016/S0531-5565(02)00021-9; SATO S, 1983, J MOL CELL CARDIOL, V15, P261, DOI 10.1016/0022-2828(83)90281-X; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; Smith RS, 2005, LIFE SCI, V76, P2457, DOI 10.1016/j.lfs.2004.11.028; Strijdom H, 2006, FASEB J, V20, P314, DOI 10.1096/fj.05-4225fje; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe; Wang GW, 2005, AM J PHYSIOL-HEART C, V288, pH1290, DOI 10.1152/ajpheart.00796.2004; Wenzel D, 2006, CIRC RES, V98, P1203, DOI 10.1161/01.RES.0000219899.93384.ed	52	31	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					1968	1978		10.1096/fj.06-6477com	http://dx.doi.org/10.1096/fj.06-6477com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341689				2022-12-25	WOS:000247500300007
J	Chwatko, G; Boers, GHJ; Strauss, KA; Shih, DM; Jakubowski, H				Chwatko, Grazyna; Boers, Godfried H. J.; Strauss, Kevin A.; Shih, Diana M.; Jakubowski, Hieronim			Mutations in methylenetetrahydrofolate reductase or cystathionine beta-syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice	FASEB JOURNAL			English	Article						genetic hyperhomocysteinemia; dietary hyperhomocysteinemia; atherosclerosis	PROGRAMMED CELL-DEATH; PROTEIN HOMOCYSTEINYLATION; PLASMA HOMOCYSTEINE; PATHOLOGICAL CONSEQUENCES; N-HOMOCYSTEINYLATION; SYNTHASE DEFICIENCY; POSSIBLE MECHANISM; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; MOLECULAR-BASIS	Genetic disorders of homocysteine (Hcy) metabolism or a high-methionine diet lead to elevations of plasma Hcy levels. In humans, severe genetic hyperhomocysteinemia results in premature death from vascular complications whereas dietary hyperhomocysteinemia is often used to induce atherosclerosis in animal models. Hcy is mistakenly selected in place of methionine by methionyl-tRNA synthetase during protein biosynthesis, which results in the formation of Hcy-thiolactone and initiates a pathophysiological pathway that has been implicated in human vascular disease. However, whether genetic deficiencies in Hcy metabolism or a high-methionine diet affect Hcy-thiolactone levels in mammals has been unknown. Here we show that plasma Hcy-thiolactone is elevated 59-fold and 72-fold in human patients with hyperhomocysteinemia secondary to mutations in methylenetetrahydrofolate reductase and cystathionine beta-synthase genes, respectively. We also show that mice, like humans, eliminate Hcy-thiolactone by urinary excretion; in contrast to humans, however, mice also eliminate significant amounts of plasma total Hcy (similar to 38%) by urinary excretion. In mice, hyperhomocysteinemia secondary to a high-methionine diet leads to 3.7-fold and 25-fold increases in plasma and urinary Hcy-thiolactone levels, respectively. Thus, we conclude that hyperhomocysteinemia leads to significant increases in the atherogenic metabolite Hcy-thiolactone in humans and mice. Chwatko, G., Boers, G. H. J., Strauss, K. A., Shih, D. M., Jakubowski, H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta- syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; Clin Special Children, Strasburg, PA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-00901 Warsaw, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Radboud University Nijmegen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Chwatko, Grażyna/R-8757-2016; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409; Chwatko, Grazyna/0000-0001-9247-5131				BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; de las Casas CM, 2003, BIRTH DEFECTS RES A, V67, P35, DOI 10.1002/bdra.10014; Den Heijer M, 2005, J THROMB HAEMOST, V3, P292, DOI 10.1111/j.1538-7836.2005.01141.x; Endo N, 2006, BRIT J NUTR, V95, P1088, DOI 10.1079/BJN20061764; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Goyette P, 1996, AM J HUM GENET, V59, P1268; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2006, CHEM-EUR J, V12, P8039, DOI 10.1002/chem.200600785; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowsky H., 2005, AMINOACYL TRNA SYNTH, P384; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; Legendre C, 2002, BIOCHEM BIOPH RES CO, V295, P1052, DOI 10.1016/S0006-291X(02)00814-8; Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Perna AF, 2006, KIDNEY INT, V69, P869, DOI 10.1038/sj.ki.5000070; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Sauls DL, 2006, BIOCHEMISTRY-US, V45, P2480, DOI 10.1021/bi052076j; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Spence JD, 2005, STROKE, V36, P2404, DOI 10.1161/01.STR.0000185929.38534.f3; Tuite NL, 2005, J BACTERIOL, V187, P4362, DOI 10.1128/JB.187.13.4362-4371.2005; Uji Y, 2002, CLIN CHEM, V48, P941; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Undas A, 2006, THROMB HAEMOSTASIS, V96, P342, DOI 10.1160/TH06-04-0228; Undas A, 2006, ARTERIOSCL THROM VAS, V26, P1397, DOI 10.1161/01.ATV.0000219688.43572.75; van Guldener C, 1998, KIDNEY INT, V54, P166, DOI 10.1046/j.1523-1755.1998.00983.x; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zimny J, 2006, J BIOL CHEM, V281, P22485, DOI 10.1074/jbc.M603656200	43	90	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1707	1713		10.1096/fj.06-7435com	http://dx.doi.org/10.1096/fj.06-7435com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327360				2022-12-25	WOS:000246866500012
J	Lee, CK; Daniel, RM; Shepherd, C; Saul, D; Cary, SC; Danson, MJ; Eisenthal, R; Peterson, ME				Lee, Charles K.; Daniel, Roy M.; Shepherd, Charis; Saul, David; Cary, S. Craig; Danson, Michael J.; Eisenthal, Robert; Peterson, Michelle E.			Eurythermalism and the temperature dependence of enzyme activity	FASEB JOURNAL			English	Article						enzyme temperature optimum; Equilibrium Model; growth temperature; protein stability; temperature adaptation	ESCHERICHIA-COLI; THERMOTOGA-MARITIMA; PROTEIN THERMOSTABILITY; CATALASE; DENATURATION; ADAPTATION; RESISTANCE; FLEXIBILITY; DISRUPTION; STABILITY	The "Equilibrium Model" has provided new tools for describing and investigating enzyme thermal adaptation. It has been shown that the effect of temperature on enzyme activity is not only governed by Delta G double dagger(cat) and Delta G double dagger(inact) but also by two new intrinsic parameters, Delta H-eq and T-eq, which describe the enthalpy and midpoint, respectively, of a reversible equilibrium between active and inactive ( but not denatured) forms of enzyme. Twenty-one enzymes from organisms with a wide range of growth temperatures were characterized using the Equilibrium Model. Statistical analysis indicates that Teq is a better predictor of growth temperature than enzyme stability (Delta G double dagger(inact)). As expected from the Equilibrium Model, Delta H-eq correlates with catalytic temperature tolerance of enzymes and thus can be declared the first intrinsic and quantitative measure of enzyme eurythermalism. Other findings shed light on the evolution of psychrophilic and thermophilic enzymes. The findings suggest that the description of the Equilibrium Model of the effect of temperature on enzyme activity applies to all enzymes regardless of their temperature origins and that its associated parameters, Delta H-eq and T-eq, are intrinsic and necessary parameters for characterizing the thermal properties of enzymes and their temperature adaptation and evolution.-Lee, C. K., Daniel, R. M., Shepherd, C., Saul, D., Cary, S. C., Danson, M. J., Eisenthal, R., Peterson, M. E. Eurythermalism and the temperature dependence of enzyme activity.	Univ Waikato, Dept Sci Biol, Hamilton 3240, New Zealand; Univ Auckland, Sch Biol Sci, Auckland, New Zealand; Univ Delaware, Coll Marine & Earth Studies, Delaware, OH USA; Univ Bath, Dept Biol & Biochem, Bath, Avon, England; Univ Bath, Dept Biol & Biochem, Ctr Extremophile Res, Bath, Avon, England	University of Waikato; University of Auckland; University of Delaware; University of Bath; University of Bath	Daniel, RM (corresponding author), Univ Waikato, Dept Sci Biol, Hamilton 3240, New Zealand.	r.daniel@waikato.ac.nz	Lee, Charles/AAC-9417-2019; Peterson, Michelle E/C-2455-2009	Lee, Charles/0000-0002-6562-4733; Peterson, Michelle E/0000-0002-6413-322X; Cary, Stephen/0000-0002-2876-2387				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calera JA, 2000, FEBS LETT, V475, P117, DOI 10.1016/S0014-5793(00)01637-9; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; DANIEL RM, 1982, BIOCHEM J, V207, P641, DOI 10.1042/bj2070641; Daniel RM, 2003, ANNU REV BIOPH BIOM, V32, P69, DOI 10.1146/annurev.biophys.32.110601.142445; Daniel RM, 1996, BIOCHEM J, V317, P1, DOI 10.1042/bj3170001; Daniel RM, 2001, TRENDS BIOCHEM SCI, V26, P223, DOI 10.1016/S0968-0004(01)01803-5; Diaz A, 2001, FREE RADICAL BIO MED, V31, P1323, DOI 10.1016/S0891-5849(01)00637-2; Eisenthal R, 2006, TRENDS BIOTECHNOL, V24, P289, DOI 10.1016/j.tibtech.2006.05.004; FLINT KP, 1987, J APPL BACTERIOL, V63, P261, DOI 10.1111/j.1365-2672.1987.tb04945.x; Georlette D, 2003, J BIOL CHEM, V278, P37015, DOI 10.1074/jbc.M305142200; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Gerike U, 1997, EUR J BIOCHEM, V248, P49, DOI 10.1111/j.1432-1033.1997.00049.x; Gershenson A, 2000, BIOCHEMISTRY-US, V39, P4658, DOI 10.1021/bi992473s; HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335; Ichikawa JK, 1998, ARCH BIOCHEM BIOPHYS, V358, P222, DOI 10.1006/abbi.1998.0830; Johns GC, 2004, MOL BIOL EVOL, V21, P314, DOI 10.1093/molbev/msh021; LOPEZMEDRANO R, 1995, INFECT IMMUN, V63, P4774; Merz A, 1999, J MOL BIOL, V288, P753, DOI 10.1006/jmbi.1999.2709; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; NODA L, 1957, J BIOL CHEM, V226, P541; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; OWUSU RK, 1989, ENZYME MICROB TECH, V11, P568, DOI 10.1016/0141-0229(89)90084-7; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; Pappenberger G, 1997, J MOL BIOL, V274, P676, DOI 10.1006/jmbi.1997.1421; Peterson ME, 2004, J BIOL CHEM, V279, P20717, DOI 10.1074/jbc.M309143200; PETERSON ME, 2005, THESIS U WAIKATO HAM; Peterson ME, 2007, BIOCHEM J, V402, P331, DOI 10.1042/BJ20061143; Schwartzman DW, 2004, BIOCHEM SOC T, V32, P168, DOI 10.1042/BST0320168; Statsoft Inc., 2005, STATISTICA VERS 7 1; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; Switala J, 1999, BIOCHEMISTRY-US, V38, P3895, DOI 10.1021/bi982863z; Thomas TM, 1998, BIOCHEM J, V330, P1087; TSUBOI KK, 1975, J BIOL CHEM, V250, P132; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wachtershauser G, 1998, THERMOPHILES KEYS MO, P47; WASSERMAN BP, 1981, ARCH BIOCHEM BIOPHYS, V212, P385, DOI 10.1016/0003-9861(81)90379-9; Xu Y, 2003, J BACTERIOL, V185, P5519, DOI 10.1128/JB.185.18.5519-5526.2003; Xu Y, 2003, INT J SYST EVOL MICR, V53, P533, DOI 10.1099/ijs.0.02228-0	41	27	27	18	95	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1934	1941		10.1096/fj.06-7265com	http://dx.doi.org/10.1096/fj.06-7265com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341686				2022-12-25	WOS:000246866500034
J	Sudo, Y; Furutani, Y; Spudich, JL; Kandori, H				Sudo, Yuki; Furutani, Yuji; Spudich, John L.; Kandori, Hideki			Early photocycle structural changes in a bacteriorhodopsin mutant engineered to transmit photosensory signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY-RHODOPSIN-II; INTERNAL WATER-MOLECULES; PROTONATED SCHIFF-BASE; OUT-OF-PLANE; PHARAONIS PHOBORHODOPSIN; RETINAL CHROMOPHORE; PRIMARY PHOTOPRODUCT; CHARGED RESIDUES; HYDROGEN-BONDS; TRANSDUCER	Bacteriorhodopsin ( BR) and sensory rhodopsin II (SRII) function as a light-driven proton pump and a receptor for negative phototaxis in haloarchaeal membranes, respectively. SRII transmits light signals through changes in protein-protein interaction with its transducer HtrII. Recently, we converted BR by three mutations into a form capable of transmitting photosignals to HtrII to mediate phototaxis responses. The BR triple mutant (BR-T) provides an opportunity to identify structural changes necessary to activate HtrII by comparing light-induced infrared spectral changes of BR, BR-T, and SRII. The hydrogen out-of-plane (HOOP) vibrations of the BR-T were very similar to those of SRII, indicating that they are distributed more extensively along the retinal chromophore than in BR, as in SRII. On the other hand, the bands of the protein moiety in BR-T are similar to those of BR, indicating that they are not specific to photosensing. The alteration of the O-H stretching vibration of Thr-204 in SRII, which we had previously shown to be essential for signal relay to HtrII, occurs also in BR-T. In addition, 1670(+)/1664(-)cm(-1) bands attributable to a distorted alpha-helix were observed in BR-T in a HtrII-dependent manner, as is seen in SRII. Thus, we identified similarities and dissimilarities of BR-T to BR and SRII. The results suggest signaling function of the structural changes of the HOOP vibrations, the O-H stretching vibration of the Thr-215 residue, and a distorted alpha-helix for the signal generation. We also succeeded in measurements of L minus initial state spectra of BR- T, which are the first FTIR spectra of L intermediates among sensory rhodopsins.	Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Nagoya Inst Technol, Dept Mat Sci & Engn, Showa Ku, Nagoya, Aichi 4668555, Japan	University of Texas System; University of Texas Health Science Center Houston; Nagoya Institute of Technology	Spudich, JL (corresponding author), Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu; kandori@nitech.ac.jp	Furutani, Yuji/J-8337-2019; Sudo, Yuki/AGY-0493-2022	Furutani, Yuji/0000-0001-5284-8773; Sudo, Yuki/0000-0001-8155-9356	NIGMS NIH HHS [R37GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergo V, 2004, BIOCHEMISTRY-US, V43, P9075, DOI 10.1021/bi0361968; Bergo V, 2003, J BIOL CHEM, V278, P36556, DOI 10.1074/jbc.M303719200; Bergo VB, 2005, J BIOL CHEM, V280, P28365, DOI 10.1074/jbc.M505555200; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRIGGS W, 2004, HDB PHOTOSENSORY REC, P1; Furutani Y, 2005, PHOTOCH PHOTOBIO SCI, V4, P661, DOI 10.1039/b416698a; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2003, BIOCHEMISTRY-US, V42, P4837, DOI 10.1021/bi034317y; Furutani Y, 2006, BIOCHEMISTRY-US, V45, P11836, DOI 10.1021/bi0610597; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Kamada K, 2006, BIOCHEMISTRY-US, V45, P4859, DOI 10.1021/bi060047i; Kamo N, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1277, DOI 10.1023/A:1013187403599; Kandori H, 2000, P NATL ACAD SCI USA, V97, P4643, DOI 10.1073/pnas.080064797; Kandori H, 2002, J PHYS CHEM A, V106, P2091, DOI 10.1021/jp012447f; Kandori H, 2001, BIOCHEMISTRY-US, V40, P15693, DOI 10.1021/bi011621n; Kandori H, 2002, BIOCHEMISTRY-US, V41, P4554, DOI 10.1021/bi0120749; Kandori H, 2002, BIOCHEMISTRY-US, V41, P6026, DOI 10.1021/bi025585j; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kandori H, 2000, J AM CHEM SOC, V122, P11745, DOI 10.1021/ja0032069; Kandori H, 1999, BIOCHEMISTRY-US, V38, P9676, DOI 10.1021/bi990713y; Kandori H, 2000, BBA-BIOENERGETICS, V1460, P177, DOI 10.1016/S0005-2728(00)00138-9; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MAEDA A, 1991, PHOTOCHEM PHOTOBIOL, V54, P911, DOI 10.1111/j.1751-1097.1991.tb02111.x; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PALINGS I, 1989, BIOCHEMISTRY-US, V28, P1498, DOI 10.1021/bi00430a012; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; Shibata M, 2003, J AM CHEM SOC, V125, P13312, DOI 10.1021/ja037343s; Shibata N, 2005, BIOCHEMISTRY-US, V44, P7406, DOI 10.1021/bi050122+; Shimono K, 2003, BIOCHEMISTRY-US, V42, P7801, DOI 10.1021/bi034284m; SIEBERT F, 1983, EUR J BIOCHEM, V130, P565, DOI 10.1111/j.1432-1033.1983.tb07187.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Spudich JL, 2006, TRENDS MICROBIOL, V14, P480, DOI 10.1016/j.tim.2006.09.005; Sudo Y, 2006, J MOL BIOL, V357, P1274, DOI 10.1016/j.jmb.2006.01.061; Sudo Y, 2005, J AM CHEM SOC, V127, P16036, DOI 10.1021/ja056203a; Sudo Y, 2005, BIOCHEMISTRY-US, V44, P6144, DOI 10.1021/bi047573z; Sudo Y, 2004, BIOCHEMISTRY-US, V43, P13748, DOI 10.1021/bi048803c; Sudo Y, 2003, BIOCHEMISTRY-US, V42, P14166, DOI 10.1021/bi035678g; Sudo Y, 2002, BIOPHYS J, V83, P427, DOI 10.1016/S0006-3495(02)75180-1; Sudo Y, 2001, PHOTOCHEM PHOTOBIOL, V74, P489, DOI 10.1562/0031-8655(2001)074<0489:PPBTIC>2.0.CO;2; Sudo Y, 2006, P NATL ACAD SCI USA, V103, P16129, DOI 10.1073/pnas.0607467103; Sudo Y, 2006, J BIOL CHEM, V281, P34239, DOI 10.1074/jbc.M605907200; Tanimoto T, 2004, BIOCHEMISTRY-US, V43, P9439, DOI 10.1021/bi049368p; Tanimoto T, 2003, BIOCHEMISTRY-US, V42, P2300, DOI 10.1021/bi026990d; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Yamazaki Y, 1996, BIOCHEMISTRY-US, V35, P4063, DOI 10.1021/bi9524530; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200	49	26	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15550	15558		10.1074/jbc.M701271200	http://dx.doi.org/10.1074/jbc.M701271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17387174	hybrid			2022-12-25	WOS:000246589600032
J	Liscombe, DK; Facchini, PJ				Liscombe, David K.; Facchini, Peter J.			Molecular cloning and characterization of tetrahydroprotoberberine cis-N- methyltransferase, an enzyme involved in alkaloid biosynthesis in opium poppy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPAVER-SOMNIFERUM; CDNA CLONING; O-METHYLTRANSFERASE; SUSPENSION-CULTURES; CRYSTAL-STRUCTURES; GENE-EXPRESSION; ACCUMULATION; (S)-STYLOPINE; LOCALIZATION; PURIFICATION	S-Adenosyl-L-methionine: tetrahydroprotoberberine cis-N-methyltransferase (EC 2.1.1.122) catalyzes the conversion of (S)-stylopine to the quaternary ammonium alkaloid, (S)-cis-N-methylstylopine, as a key step in the biosynthesis of protopine and benzophenanthridine alkaloids in plants. A full-length cDNA encoding a protein exhibiting 45 and 48% amino acid identity with coclaurine N-methyltransferase from Papaver somniferum (opium poppy) and Coptis japonica, respectively, was identified in an elicitor-treated opium poppy cell culture expressed sequence tag data base. Phylogenetic analysis showed that the protein belongs to a unique clade of enzymes that includes coclaurine N-methyltransferase, the predicated translation products of the Arabidopsis thaliana genes, At4g33110 and At4g33120, and bacterial S-adenosyl-L-methionine-dependent cyclopropane fatty acid synthases. Expression of the cDNA in Escherichia coli produced a recombinant enzyme able to convert the protoberberine alkaloids stylopine, canadine, and tetrahydropalmatine to their corresponding N-methylated derivatives. However, the protoberberine alkaloids tetrahydroxyberbine and scoulerine, and simple isoquinoline, benzylisoquinoline, and pavine alkaloids were not accepted as substrates, demonstrating the strict specificity of the enzyme. The apparent K-m values for (R,S)-stylopine and S-adenosyl-L-methionine were 0.6 and 11.5 mu M, respectively. TNMT gene transcripts and enzyme activity were detected in opium poppy seedlings and all mature plant organs and were induced in cultured opium poppy cells after treatment with a fungal elicitor. The enzyme was detected in cell cultures of other members of the Papaveraceae but not in species of related plant families that do not accumulate protopine and benzophenanthridine alkaloids.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Facchini, PJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	pfacchin@ucalgary.ca		Facchini, Peter/0000-0002-7693-290X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anaya AL, 2006, FRONT BIOSCI-LANDMRK, V11, P2354, DOI 10.2741/1975; BATTERSBY AR, 1968, J CHEM SOC C, P2163, DOI 10.1039/j39680002163; BAUER W, 1989, TETRAHEDRON LETT, V30, P5257, DOI 10.1016/S0040-4039(01)93756-6; BAUER W, 1991, PHYTOCHEMISTRY, V30, P2953, DOI 10.1016/S0031-9422(00)98230-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERWOOD JM, 1971, PHYTOCHEMISTRY, V10, P682, DOI 10.1016/S0031-9422(00)94724-1; CASTILLO P, 1986, SYNTHESIS-STUTTGART, V10, P839; CHEN CY, 1968, CAN J CHEMISTRY, V46, P2501, DOI 10.1139/v68-410; Cheng SH, 1998, METH MOL B, V86, P27; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; Choi KB, 2001, PHYTOCHEMISTRY, V56, P649, DOI 10.1016/S0031-9422(00)00481-7; CHRZANOWSKA M, 1995, J NAT PRODUCTS, V58, P401, DOI 10.1021/np50117a008; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Facchini P, 2005, CAN J BOT, V83, P1189, DOI 10.1139/b05-094; Facchini Peter J., 2007, Phytochemistry Reviews, V6, P97, DOI 10.1007/s11101-006-9042-0; Facchini PJ, 2003, PHYTOCHEMISTRY, V64, P177, DOI 10.1016/S0031-9422(03)00292-9; Facchini PJ, 2001, ANNU REV PLANT PHYS, V52, P29, DOI 10.1146/annurev.arplant.52.1.29; Facchini PJ, 1996, PLANT PHYSIOL, V111, P687, DOI 10.1104/pp.111.3.687; FACCHINI PJ, 1994, J BIOL CHEM, V269, P26684; Ferrer JL, 2005, PLANT PHYSIOL, V137, P1009, DOI 10.1104/pp.104.048751; Frick S, 2005, J NAT PROD, V68, P666, DOI 10.1021/np0496643; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Huang FC, 2000, PHYTOCHEMISTRY, V53, P555, DOI 10.1016/S0031-9422(99)00600-7; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; Ikezawa N, 2003, J BIOL CHEM, V278, P38557, DOI 10.1074/jbc.M302470200; Larsson KAE, 2006, PHYTOCHEMISTRY, V67, P2002, DOI 10.1016/j.phytochem.2006.06.036; Liscombe DK, 2005, PHYTOCHEMISTRY, V66, P1374, DOI 10.1016/j.phytochem.2005.04.029; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MCOMIE JFW, 1968, TETRAHEDRON, V24, P2289, DOI 10.1016/0040-4020(68)88130-X; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; Morishige T, 2002, EUR J BIOCHEM, V269, P5659, DOI 10.1046/j.1432-1033.2002.03275.x; NARASIMHAN NS, 1983, TETRAHEDRON, V39, P1975, DOI 10.1016/S0040-4020(01)91915-5; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; OHASHI M, 1963, J AM CHEM SOC, V85, P2807, DOI 10.1021/ja00901a030; OKEEFE BR, 1994, PLANT PHYSIOL, V105, P395, DOI 10.1104/pp.105.1.395; Ounaroon A, 2003, PLANT J, V36, P808, DOI 10.1046/j.1365-313X.2003.01928.x; Paraskevas S, 2005, Int J Dent Hyg, V3, P162, DOI 10.1111/j.1601-5037.2005.00145.x; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; Raman SB, 2003, PLANT PHYSIOL, V132, P1642, DOI 10.1104/pp.103.020453; RUEFFER M, 1990, PHYTOCHEMISTRY, V29, P3727, DOI 10.1016/0031-9422(90)85321-6; RUEFFER M, 1987, TETRAHEDRON LETT, V28, P5307, DOI 10.1016/S0040-4039(00)96715-7; Samanani N, 2005, PLANT CELL, V17, P915, DOI 10.1105/tpc.104.028654; Samanani N, 2004, PLANT J, V40, P302, DOI 10.1111/j.1365-313X.2004.02210.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmeller T, 1997, PHYTOCHEMISTRY, V44, P257, DOI 10.1016/S0031-9422(96)00545-6; SCHUMACHER HM, 1988, PLANT CELL REP, V7, P43, DOI 10.1007/BF00272975; Suzuki K, 1999, PLANT CELL PHYSIOL, V40, P289, DOI 10.1093/oxfordjournals.pcp.a029540; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; TANAHASHI T, 1990, PHYTOCHEMISTRY, V29, P1113, DOI 10.1016/0031-9422(90)85414-B; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Ziegler J, 2005, PLANTA, V222, P458, DOI 10.1007/s00425-005-1550-4; Zubieta C, 2002, PLANT CELL, V14, P1265, DOI 10.1105/tpc.001412; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029; Zulak KG, 2007, PLANTA, V225, P1085, DOI 10.1007/s00425-006-0419-5	60	80	95	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14741	14751		10.1074/jbc.M611908200	http://dx.doi.org/10.1074/jbc.M611908200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389594	hybrid			2022-12-25	WOS:000246589000009
J	Taylor, RC; Brumatti, G; Ito, S; Hengartner, MO; Derry, WB; Martin, SJ				Taylor, Rebecca C.; Brumatti, Gabriela; Ito, Shu; Hengartner, Michael O.; Derry, W. Brent; Martin, Seamus J.			Establishing a blueprint for CED-3-dependent killing through identification of multiple substrates for this protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MYOSIN LIGHT-CHAIN; CAENORHABDITIS-ELEGANS; C-ELEGANS; GENE CED-3; GRANZYME-B; ROCK-I; APOPTOSIS; ACTIVATION; CALRETICULIN	Genetic studies have established that the cysteine protease CED-3 plays a central role in coordinating programmed cell death in Caenorhabditis elegans. However, it remains unclear how CED-3 activation results in cell death because few substrates for this protease have been described. We have used a global proteomics approach to seek substrates for CED-3 and have identified 22 worm proteins that undergo CED-3-dependent proteolysis. Proteins that were found to be substrates for CED-3 included the cytoskeleton proteins actin, myosin light chain, and tubulin, as well as proteins involved in ATP synthesis, cellular metabolism, and chaperone function. We estimate that similar to 3% of the C. elegans proteome is susceptible to CED-3-dependent proteolysis. Notably, the endoplasmic reticulum chaperone calreticulin, which has been implicated in the recognition of apoptotic cells by phagocytes, was cleaved by CED-3 and was also cleaved by human caspases during apoptosis. Inhibitors of caspase activity blocked the appearance of calreticulin on the surface of apoptotic cells, suggesting a mechanism for the surface display of calreticulin during apoptosis. Further analysis of these substrates is likely to yield important insights into the mechanism of killing by CED-3 and its human caspase counterparts.	Trinity Coll Dublin, Mol Cell Biol Lab, Smurfit Inst Genet, Dublin 2, Ireland; Univ Toronto, Program Dev Biol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON M5G 1X8, Canada; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Trinity College Dublin; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Zurich	Martin, SJ (corresponding author), Trinity Coll Dublin, Mol Cell Biol Lab, Smurfit Inst Genet, Dublin 2, Ireland.	martinsj@tcd.ie	Derry, Brent/CAF-4503-2022; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X; Derry, Brent/0000-0002-1977-8475; Taylor, Rebecca/0000-0003-3429-3123; Martin, Seamus/0000-0002-8539-3143				Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Kim SY, 2004, MOL BIOTECHNOL, V27, P1, DOI 10.1385/MB:27:1:01; Lettre G, 2006, NAT REV MOL CELL BIO, V7, P97, DOI 10.1038/nrm1836; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Moretti A, 2002, P NATL ACAD SCI USA, V99, P11860, DOI 10.1073/pnas.182373099; Moss DK, 2006, J CELL SCI, V119, P2362, DOI 10.1242/jcs.02959; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shaham S, 1999, GENETICS, V153, P1655; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Syntichaki P, 2005, CURR BIOL, V15, P1249, DOI 10.1016/j.cub.2005.05.057; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Won J, 2003, J BIOL CHEM, V278, P19347, DOI 10.1074/jbc.M213098200; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	35	29	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15011	15021		10.1074/jbc.M611051200	http://dx.doi.org/10.1074/jbc.M611051200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371877	Green Accepted, hybrid			2022-12-25	WOS:000246589000040
J	Ojima, K; Ono, Y; Doi, N; Yoshioka, K; Kawabata, Y; Labeit, S; Sorimachi, H				Ojima, Koichi; Ono, Yasuko; Doi, Naoko; Yoshioka, Katsuhide; Kawabata, Yukiko; Labeit, Siegfried; Sorimachi, Hiroyuki			Myogenic stage, sarcomere length, and protease activity modulate localization of muscle-specific calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHY TYPE 2A; ALPHA-ACTININ-BINDING; TITIN KINASE DOMAIN; Z-I-BODIES; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; Z-DISC; MOLECULAR-STRUCTURE; STRIATED-MUSCLE; TERMINAL REGION	p94/calpain 3 is a Ca2+-binding intracellular protease predominantly expressed in skeletal muscles. p94 binds to the N2A and M-line regions of connectin/titin and localizes in the Z-bands. Genetic evidence showing that compromised p94 proteolytic activity leads to muscular dystrophy (limb-girdle muscular dystrophy type 2A) indicates the importance of p94 function in myofibrils. Here we show that a series of p94 splice variants is expressed immediately after muscle differentiation and differentially change localization during myofibrillogenesis. We found that the endogenous N-terminal ( but not C-terminal) domain of p94 was not only localized in the Z-bands but also directly bound to sarcomeric alpha-actinin. These data suggest the incorporation of proteolytic N-terminal fragments of p94 into the Z-bands. In myofibrils localization of exogenously expressed p94 shifted from the M-line to N2A as the sarcomere lengthens beyond similar to 2.6 and 2.8 mu m for wild-type and protease-inactive p94, respectively. These data demonstrate for the first time that p94 proteolytic activity is involved in responses to muscle conditions, which may explain why p94 inactivation causes limb-girdle muscular dystrophy.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan; Japan Sci & Technol Agcy, JST, CREST, Kawaguchi 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68167 Mannheim, Germany	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); University of Tokyo; Ruprecht Karls University Heidelberg	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/Q-6956-2017; Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727; Ojima, Koichi/0000-0002-5973-1073				Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; Farkas A, 2003, BIOL CHEM, V384, P945, DOI 10.1515/BC.2003.106; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; GOLL DE, 1991, J BIOL CHEM, V266, P8501; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380; Haravuori H, 2001, NEUROLOGY, V56, P869, DOI 10.1212/WNL.56.7.869; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Holtzer H, 1997, CELL STRUCT FUNCT, V22, P83, DOI 10.1247/csf.22.83; Kawabata Y, 2003, FEBS LETT, V555, P623, DOI 10.1016/S0014-5793(03)01324-3; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kramerova I, 2005, HUM MOL GENET, V14, P2125, DOI 10.1093/hmg/ddi217; Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; MARUYAMA K, 1976, J BIOCHEM-TOKYO, V80, P405, DOI 10.1093/oxfordjournals.jbchem.a131291; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Obermann WMJ, 1997, EMBO J, V16, P211, DOI 10.1093/emboj/16.2.211; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; Ohtsuka H, 1997, FEBS LETT, V401, P65, DOI 10.1016/S0014-5793(96)01432-9; Ojima K, 1999, J CELL SCI, V112, P4101; Ojima K, 2004, BIOCHEM BIOPH RES CO, V321, P1050, DOI 10.1016/j.bbrc.2004.07.069; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Ono Y, 2006, J BIOL CHEM, V281, P18519, DOI 10.1074/jbc.M601029200; Poussard S, 1996, CELL GROWTH DIFFER, V7, P1461; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sato N, 2003, MOL CELL BIOL, V23, P6662, DOI 10.1128/MCB.23.18.6662-6671.2003; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Taveau M, 2003, MOL CELL BIOL, V23, P9127, DOI 10.1128/MCB.23.24.9127-9135.2003; TOKUYASU KT, 1987, J CELL BIOL, V105, P2795, DOI 10.1083/jcb.105.6.2795; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Trombitas K, 2003, BIOPHYS J, V85, P3142, DOI 10.1016/S0006-3495(03)74732-8; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; Wittt CC, 2004, J MOL BIOL, V336, P145, DOI 10.1016/j.jmb.2003.12.021; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807	48	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14493	14504		10.1074/jbc.M610806200	http://dx.doi.org/10.1074/jbc.M610806200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371879	hybrid			2022-12-25	WOS:000246245800063
J	Tringali, C; Lupo, B; Anastasia, L; Papini, N; Monti, E; Bresciani, R; Tettamanti, G; Venerando, B				Tringali, Cristina; Lupo, Barbara; Anastasia, Luigi; Papini, Nadia; Monti, Eugenio; Bresciani, Roberto; Tettamanti, Guido; Venerando, Bruno			Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MEMBRANE-ASSOCIATED SIALIDASE; ABL TRANSFORMING ACTIVITY; CHRONIC MYELOID-LEUKEMIA; B16 MELANOMA-CELLS; SRC FAMILY KINASES; MOLECULAR-BIOLOGY; CANCER-THERAPY; OVEREXPRESSION; GANGLIOSIDES	Chronic myeloid leukemia is a hematopoietic stem cell cancer, originated by the perpetually "switched on" activity of the tyrosine kinase Bcr-Abl, leading to uncontrolled proliferation and insensitivity to apoptotic stimuli. The genetic phenotype of myeloid leukemic K562 cells includes the suppression of cytosolic sialidase Neu2. Neu2 transfection in K562 cells induced a marked decrease (-30% and -80%) of the mRNA of the antiapoptotic factors Bcl-XL and Bcl-2, respectively, and an almost total disappearance of Bcl-2 protein. In addition, gene expression and activity of Bcr-Abl underwent a 35% diminution, together with a marked decrease of Bcr-Abl-dependent Src and Lyn kinase activity. Thus, the antiapoptotic axis Bcr-Abl, Src, and Lyn, which stimulates the formation of Bcl-XL and Bcl- 2, was remarkably weakened. The ultimate consequences of these modifications were an increased susceptibility to apoptosis of K562 cells and a marked reduction of their proliferation rate. The molecular link between Neu2 activity and Bcr-Abl signaling pathway may rely on the desialylation of some cytosolic glycoproteins. In fact, three cytosolic glycoproteins, in the range 45 - 66 kDa, showed a 50 - 70% decrease of their sialic acid content upon Neu2 expression, supporting their possible role as modulators of the Bcr-Abl complex.	Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, I-25153 Brescia, Italy	University of Milan; University of Brescia	Venerando, B (corresponding author), Univ Milan, Dept Med Chem Biochem & Biotechnol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	bruno.venerando@unimi.it	Tringali, Cristina Alessandra/Q-7259-2017; papini, nadia/M-2425-2017; Anastasia, Luigi/AAN-1964-2020; Bresciani, Roberto/AAA-9728-2020	Tringali, Cristina Alessandra/0000-0002-0632-6197; papini, nadia/0000-0003-4066-4955; Anastasia, Luigi/0000-0002-0712-2161; Bresciani, Roberto/0000-0002-7881-7550; Lupo, Barbara/0000-0002-4383-6882; MONTI, Eugenio/0000-0002-4742-7445				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bremer E, 2006, TRENDS MOL MED, V12, P382, DOI 10.1016/j.molmed.2006.06.002; CARTER HE, 1964, J BIOL CHEM, V239, P743; Chavas LMG, 2005, J BIOL CHEM, V280, P469, DOI 10.1074/jbc.M411506200; Chen R, 2006, CANCER RES, V66, P10959, DOI 10.1158/0008-5472.CAN-06-1216; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; Fanzani A, 2003, FEBS LETT, V547, P183, DOI 10.1016/S0014-5793(03)00709-9; Fernandez-Luna JL, 2000, APOPTOSIS, V5, P315, DOI 10.1023/A:1009623222534; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hakomori S, 1996, CANCER RES, V56, P5309; Inokuchi Koiti, 2006, Journal of Nippon Medical School, V73, P178, DOI 10.1272/jnms.73.178; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kato T, 2001, INT J CANCER, V92, P797, DOI 10.1002/ijc.1268; Lin CF, 2006, CURR MED CHEM, V13, P1609, DOI 10.2174/092986706777441986; Melo J, 2004, HEMATOL J, V5, pS183, DOI 10.1038/sj.thj.6200449; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Papadopoulos K, 2006, SEMIN ONCOL, V33, P449, DOI 10.1053/j.seminoncol.2006.04.008; Papini N, 2004, J BIOL CHEM, V279, P16989, DOI 10.1074/jbc.M400881200; Pasternak G, 1998, J CANCER RES CLIN, V124, P643, DOI 10.1007/s004320050228; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; Salesse S, 2003, MOL CANCER THER, V2, P173; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; SONNINO S, 1984, J LIPID RES, V25, P620; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; Tringali C, 2007, GLYCOCONJUGATE J, V24, P67, DOI 10.1007/s10719-006-9013-0; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Zhang YM, 2001, GLYCOCONJUGATE J, V18, P557, DOI 10.1023/A:1019682102486	53	46	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14364	14372		10.1074/jbc.M700406200	http://dx.doi.org/10.1074/jbc.M700406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374613	hybrid			2022-12-25	WOS:000246245800048
J	Fan, DP; Qiu, SF; Overton, CD; Yancey, PG; Swift, LL; Jerome, WG; Linton, MF; Fazio, S				Fan, Daping; Qiu, Shenfeng; Overton, Cheryl D.; Yancey, Patricia G.; Swift, Larry L.; Jerome, W. Gray; Linton, MacRae F.; Fazio, Sergio			Impaired secretion of apolipoprotein E2 from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; HUMAN-PLASMA-LIPOPROTEINS; APOE-DEFICIENT MICE; REDUCES ATHEROSCLEROSIS; CHOLESTEROL EFFLUX; GENE-TRANSFER; E ISOFORMS; A-I; EXPRESSION; PROTEIN	Human apoE is a multifunctional and polymorphic protein synthesized and secreted by liver, brain, and tissue macrophages. Here we show that apoE isoforms and mutants expressed through lentiviral transduction display cell-specific differences in secretion efficiency. Whereas apoE3, apoE4, and a natural mutant of apoE4 (apoE-Cys(142)) were efficiently secreted from macrophages, apoE2 and a non-natural apoE mutant (apoE-Cys(112)/Cys(142)) were retained in the perinuclear region and only minimally secreted. The secretory block for apoE2 in macrophages was not affected by the ablation of LDLR (low density lipoprotein receptor), ABCA-1, or SR-BI (scavenger receptor class B type I) but was released in the absence of low density lipoprotein receptor-related protein (LRP). In co-immunoprecipitation experiments, an anti-apoE antibody pulled down two times more LRP in apoE2-transduced macrophages than in apoE3-expressing macrophages. Non-reducing SDS-PAGE/Western blot analyses showed that macrophage apoE2 is mostly dimeric and multimeric, whereas apoE3 is predominantly monomeric. ApoE2 retention and multimer formation also occurred in human macrophages derived from the monocyte cell line THP-1. These results were specific for macrophages, as in transduced mouse primary hepatocytes: 1) ApoE2 was secreted as efficiently as apoE3 and apoE4; 2) all isoforms were exclusively in monomeric form; 3) there was no co-immunoprecipitation of apoE and LRP. A microsomal triglyceride transfer protein (MTP) inhibitor nearly deleted apoB100 secretion from hepatocytes without affecting apoE secretion. These data show that macrophages retain apoE2, a highly expressed protein carried by about 8% of the human population. Given the role of locally produced apoE in regulating cholesterol efflux, modulating inflammation, and controlling oxidative stress, this unique property of apoE2 may have important impacts on atherogenesis.	Vanderbilt Univ, Med Ctr, Atheroscelrosis Res Unit, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Cardiol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Fazio, S (corresponding author), Vanderbilt Univ, Med Ctr, Atheroscelrosis Res Unit, 2220 Pierce Ave,383 PRB, Nashville, TN 37232 USA.	sergio.fazio@vanderbilt.edu	Yancey, Patricia/ABB-5856-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-057986, R01 HL057986] Funding Source: Medline; NIDDK NIH HHS [DK59637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Braun NA, 2006, J LIPID RES, V47, P1176, DOI 10.1194/jlr.M500503-JLR200; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; Fazio S, 2002, J LIPID RES, V43, P1602, DOI 10.1194/jlr.M200108-JLR200; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Huang ZH, 2004, J BIOL CHEM, V279, P29195, DOI 10.1074/jbc.M402631200; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Kitajima K, 2006, ARTERIOSCL THROM VAS, V26, P1852, DOI 10.1161/01.ATV.0000231520.26490.54; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LaDu MJ, 2006, BIOCHEMISTRY-US, V45, P381, DOI 10.1021/bi051765s; Lin CY, 1999, J LIPID RES, V40, P1618; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Lucic D, 2007, J LIPID RES, V48, P366, DOI 10.1194/jlr.M600259-JLR200; Lund-Katz S, 2001, J LIPID RES, V42, P894; Mabile L, 2003, J CELL BIOCHEM, V90, P766, DOI 10.1002/jcb.10697; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Overton CD, 2007, CIRC RES, V100, P670, DOI 10.1161/01.RES.0000260204.40510.aa; Raffai RL, 2003, J BIOL CHEM, V278, P11670, DOI 10.1074/jbc.M212873200; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200; Tsukamoto K, 2000, MOL THER, V1, P189, DOI 10.1006/mthe.2000.0028; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VOGEL T, 1994, J CELL BIOCHEM, V54, P299, DOI 10.1002/jcb.240540306; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Yoshida H, 2001, CIRCULATION, V104, P2820, DOI 10.1161/hc4801.100034; Zhao YW, 1999, J LIPID RES, V40, P1029; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	64	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13746	13753		10.1074/jbc.M611754200	http://dx.doi.org/10.1074/jbc.M611754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17341585	hybrid			2022-12-25	WOS:000246060300064
J	Torres, M; Fernandez-Fuentes, N; Fiser, A; Casadevall, A				Torres, Marcela; Fernandez-Fuentes, Narcis; Fiser, Andras; Casadevall, Arturo			The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENTAL FLEXIBILITY; FINE SPECIFICITY; GENERATION; ISOTYPE; REPERTOIRE; DIVERSITY; RESIDUES; BINDING; RECOGNITION; ASSOCIATION	A central dogma in immunology is that antibody specificity is a function of the variable (V) region. However serological analysis of IgG(1), IgG(2a), and IgG(2b) switch variants of murine monoclonal antibody (mAb) 3E5 IgG(3) with identical V domains revealed apparent specificity differences for Cryptococcus neoformans glucuronoxylomannan (GXM). Kinetic and thermodynamic binding properties of mAbs 3E5 to a 12-mer peptide mimetic of GXM revealed differences in the affinity of these mAbs for a monovalent ligand, a result that implied that the constant (C) region affects the secondary structure of the antigen binding site, thus accounting for variations in specificity. Structural models of mAbs 3E5 suggested that isotype-related differences in binding resulted from amino acid sequence polymorphisms in the C region. This study implies that isotype switching is another mechanism for generating diversity in antigen binding and that isotype restriction of certain antibody responses may reflect structural constraints imposed by C region on V region binding. Furthermore, isotype affected the polyreactivity of V region identical antibodies, implying a role for C region in determining self-reactivity.	Albert Einstein Coll Med, Dept Immunol & Microbiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Casadevall, A (corresponding author), Albert Einstein Coll Med, Dept Immunol & Microbiol, 1300 Morris Pk Ave,Forchheimer Bldg,Rm 411, Bronx, NY 10461 USA.	casadeva@aecom.yu.edu		Fernandez-Fuentes, Narcis/0000-0002-6421-1080	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033774, R37AI033142, R01AI033142] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59842] Funding Source: Medline; NIAID NIH HHS [AI33142, AI33774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2004, J MOL BIOL, V344, P1135, DOI 10.1016/j.jmb.2004.10.055; Beck A, 2005, J CHROMATOGR B, V819, P203, DOI 10.1016/j.jchromb.2004.06.052; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boffey J, 2004, J NEUROIMMUNOL, V152, P98, DOI 10.1016/j.jneuroim.2004.04.002; CASADEVALL A, 1992, J INFECT DIS, V165, P1086, DOI 10.1093/infdis/165.6.1086; Chennubhotla C, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100075; Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330; COOPER LJN, 1993, J IMMUNOL, V150, P2231; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DAVIS ME, 1991, METHOD ENZYMOL, V202, P473; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GREENSPAN NS, 1995, IMMUNOL TODAY, V16, P226, DOI 10.1016/0167-5699(95)80164-2; GREENSPAN NS, 1989, FASEB J, V3, P2203, DOI 10.1096/fasebj.3.10.2666233; Hande S, 1997, MOL IMMUNOL, V34, P1281, DOI 10.1016/S0161-5890(98)00005-4; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JESKE DJ, 1984, J IMMUNOL, V133, P1090; KOZACK RE, 1995, BIOPHYS J, V68, P807, DOI 10.1016/S0006-3495(95)80257-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavoie TB, 1999, MOL IMMUNOL, V36, P1189, DOI 10.1016/S0161-5890(99)00130-3; Lipschultz CA, 2002, J MOL RECOGNIT, V15, P44, DOI 10.1002/jmr.559; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; Luger E, 2001, EUR J IMMUNOL, V31, P2319, DOI 10.1002/1521-4141(200108)31:8<2319::AID-IMMU2319>3.0.CO;2-T; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; McCloskey N, 1996, IMMUNOLOGY, V88, P169, DOI 10.1111/j.1365-2567.1996.tb00001.x; McLean GR, 2002, J IMMUNOL, V169, P1379, DOI 10.4049/jimmunol.169.3.1379; MORAHAN G, 1983, NATURE, V301, P720, DOI 10.1038/301720a0; Okamoto A, 1999, BIOCHEMISTRY-US, V38, P1176, DOI 10.1021/bi981921d; Pritsch O, 2000, EUR J IMMUNOL, V30, P3387, DOI 10.1002/1521-4141(2000012)30:12<3387::AID-IMMU3387>3.0.CO;2-K; Rai BK, 2006, BIOINFORMATICS, V22, P2691, DOI 10.1093/bioinformatics/btl449; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Reitan SK, 2002, P NATL ACAD SCI USA, V99, P7588, DOI 10.1073/pnas.052150899; Reitan SK, 2001, EUR J IMMUNOL, V31, P2143, DOI 10.1002/1521-4141(200107)31:7<2143::AID-IMMU2143>3.0.CO;2-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SPIRA G, 1992, J IMMUNOL METHODS, V148, P121, DOI 10.1016/0022-1759(92)90165-P; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres M, 2005, J IMMUNOL, V174, P2132, DOI 10.4049/jimmunol.174.4.2132; VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/0167-5699(91)90081-4	45	101	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13917	13927		10.1074/jbc.M700661200	http://dx.doi.org/10.1074/jbc.M700661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353196	hybrid			2022-12-25	WOS:000246060300081
J	Bera, AK; Kuhn, RJ; Smith, JL				Bera, Aloke K.; Kuhn, Richard J.; Smith, Janet L.			Functional characterization of cis and trans activity of the flavivirus NS2B-NS3 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST-NILE-VIRUS; YELLOW-FEVER VIRUS; SITE-DIRECTED MUTAGENESIS; NS3 SERINE-PROTEASE; NONSTRUCTURAL PROTEINS; VIRAL REPLICATION; CLEAVAGE SITE; IN-VITRO; DENGUE; DOMAIN	Flaviviruses are serious human pathogens for which treatments are generally lacking. The proteolytic maturation of the 375-kDa viral polyprotein is one target for antiviral development. The flavivirus serine protease consists of the N-terminal domain of the multifunctional nonstructural protein 3 (NS3) and an essential 40-residue cofactor (NS2B40) within viral protein NS2B. The NS2B-NS3 protease is responsible for all cytoplasmic cleavage events in viral polyprotein maturation. This study describes the first biochemical characterization of flavivirus protease activity using full-length NS3. Recombinant proteases were created by fusion of West Nile virus (WNV) NS2B40 to full-length WNV NS3. The protease catalyzed two autolytic cleavages. The NS2B/NS3 junction was cleaved before protein purification. A second site at Arg4592Gly460 within the C-terminal helicase region of NS3 was cleaved more slowly. Autolytic cleavage reactions also occurred in NS2B-NS3 recombinant proteins from yellow fever virus, dengue virus types 2 and 4, and Japanese encephalitis virus. Cis and trans cleavages were distinguished using a noncleavable WNV protease variant and two types of substrates as follows: an inactive variant of recombinant WNV NS2B-NS3, and cyan and yellow fluorescent proteins fused by a dodecamer peptide encompassing a natural cleavage site. With these materials, the autolytic cleavages were found to be intramolecular only. Autolytic cleavage of the helicase site was insensitive to protein dilution, confirming that autolysis is intramolecular. Formation of an active protease was found to require neither cleavage of NS2B from NS3 nor a free NS3 N terminus. Evidence was also obtained for product inhibition of the protease by the cleaved C terminus of NS2B.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Smith, JL (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	JanetSmith@umich.edu	Bera, Aloke Kumar/AAD-9541-2022; Kuhn, Richard/AAR-2722-2021	Kuhn, Richard/0000-0003-4148-1026	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI055672, P01 AI-055672] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; Beasley DWC, 2005, J VIROL, V79, P8339, DOI 10.1128/JVI.79.13.8339-8347.2005; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; Chappell KJ, 2006, J BIOL CHEM, V281, P38448, DOI 10.1074/jbc.M607641200; Chappell KJ, 2005, J BIOL CHEM, V280, P2896, DOI 10.1074/jbc.M409931200; Erbel P, 2006, NAT STRUCT MOL BIOL, V13, P372, DOI 10.1038/nsmb1073; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Ganesh VK, 2005, BIOORGAN MED CHEM, V13, P257, DOI 10.1016/j.bmc.2004.09.036; Khumthong R, 2002, J BIOCHEM MOL BIOL, V35, P206; Kuhn RJ, 2003, ADV PROTEIN CHEM, V64, P363; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Li J, 2005, J BIOL CHEM, V280, P28766, DOI 10.1074/jbc.M500588200; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; LIN C, 1993, VIROLOGY, V192, P596, DOI 10.1006/viro.1993.1076; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; Niyomrattanakit P, 2006, BIOCHEM J, V397, P203, DOI 10.1042/BJ20051767; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PUGACHEV KV, 1993, FEBS LETT, V328, P115, DOI 10.1016/0014-5793(93)80977-3; Shiryaev SA, 2006, BIOCHEM J, V393, P503, DOI 10.1042/BJ20051374; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; Wu JH, 2005, J VIROL, V79, P10268, DOI 10.1128/JVI.79.16.10268-10277.2005; Xu T, 2005, J VIROL, V79, P10278, DOI 10.1128/JVI.79.16.10278-10288.2005; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963	31	79	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12883	12892		10.1074/jbc.M611318200	http://dx.doi.org/10.1074/jbc.M611318200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337448	hybrid			2022-12-25	WOS:000245942800060
J	Guo, NX; Kanter, D; Funderburgh, ML; Mann, MM; Du, YQ; Funderburgh, JL				Guo, Naxin; Kanter, David; Funderburgh, Martha L.; Mann, Mary M.; Du, Yiqin; Funderburgh, James L.			A rapid transient increase in hyaluronan synthase-2 mRNA initiates secretion of hyaluronan by corneal keratocytes in response to transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TGF-BETA; INTRACELLULAR HYALURONAN; PROTEOGLYCAN EXPRESSION; ARTICULAR-CARTILAGE; ENDOTHELIAL-CELLS; ACCUMULATION; FIBROBLASTS; GENE; GROWTH-FACTOR-BETA-1	Keratocytes of the corneal stroma produce transparent extracellular matrix devoid of hyaluronan ( HA); however, in corneal pathologies and wounds, HA is abundant. We previously showed primary keratocytes cultured under serum-free conditions to secrete matrix similar to that of normal stroma, but serum and transforming growth factor beta ( TGF beta) induced secretion of fibrotic matrix components, including HA. This study found HA secretion by primary bovine keratocytes to increase rapidly in response to TGF beta, reaching a maximum in 12 h and then decreasing to < 5% of the maximum by 48 h. Cell-free biosynthesis of HAby cell extracts also exhibited a transient peak at 12 h after TGF beta treatment. mRNA for hyaluronan synthase enzymes HAS1 and HAS2 increased > 10- and > 50-fold, respectively, in 4-6 h, decreasing to near original levels after 24-48 h. Small interfering RNA against HAS2 inhibited the transient increase of HAS2 mRNA and completely blocked HA induction, but small interfering RNA to HAS1 had no effect on HA secretion. HAS2 mRNA was induced by a variety of mitogens, and TGF beta acted synergistically to induce HAS2 by as much as 150-fold. In addition to HA synthesis, treatment with TGF beta induced degradation of fluorescein-HA added to culture medium. These results show HA secretion by keratocytes to be initiated by a rapid transient increase in the HAS2 mRNA pool. The very rapid induction of HA expression in keratocytes suggests a functional role of this molecule in the fibrotic response of keratocytes to wound healing.	Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1009,Ophthalmol & Visual Sci Res C, Sch Med,UPMC Eye Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Funderburgh, JL (corresponding author), Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst 1009,Ophthalmol & Visual Sci Res C, Sch Med,UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu	Du, Yiqin/A-7727-2018; DU, YIQIN/AAO-1566-2020	DU, YIQIN/0000-0002-4330-0957	NEI NIH HHS [EY09368, R01 EY009368, P30 EY008098, R01 EY009368-15A1, P30-EY08098, P30 EY008098-179003] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008098, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Arici M, 2002, NEPHROL DIAL TRANSPL, V17, P1751, DOI 10.1093/ndt/17.10.1751; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; FITZSIMMONS TD, 1994, INVEST OPHTH VIS SCI, V35, P2774; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; Funderburgh ML, 2005, FASEB J, V19, P1371, DOI 10.1096/fj.04-2770fje; Haase HR, 2001, J PERIODONTOL, V72, P341, DOI 10.1902/jop.2001.72.3.341; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HAUBECK HD, 1995, ARTHRITIS RHEUM-US, V38, P669, DOI 10.1002/art.1780380515; Hirsch M, 2001, EXP EYE RES, V72, P123, DOI 10.1006/exer.2000.0935; Hiscock DRR, 2000, OSTEOARTHR CARTILAGE, V8, P120, DOI 10.1053/joca.1999.0280; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Jenkins RH, 2004, J BIOL CHEM, V279, P41453, DOI 10.1074/jbc.M401678200; Jia Y, 2004, EXP BIOL MED, V229, P676, DOI 10.1177/153537020422900712; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Meek KM, 2003, EYE, V17, P927, DOI 10.1038/sj.eye.6700574; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Nishida Y, 2000, OSTEOARTHR CARTILAGE, V8, P127, DOI 10.1053/joca.1999.0281; Oguchi T, 2004, CONNECT TISSUE RES, V45, P197, DOI 10.1080/03008200490523031; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Plaas A H, 2001, Methods Mol Biol, V171, P117; Recklies AD, 2001, BIOCHEM J, V354, P17, DOI 10.1042/0264-6021:3540017; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Shimabukuro Y, 2005, J CELL PHYSIOL, V203, P557, DOI 10.1002/jcp.20256; Spicer Andrew P, 2004, Birth Defects Res C Embryo Today, V72, P89, DOI 10.1002/bdrc.20006; Stephan JP, 2004, AM J NEPHROL, V24, P14, DOI 10.1159/000075347; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Stuhlmeier KM, 2004, RHEUMATOLOGY, V43, P164, DOI 10.1093/rheumatology/keh014; Suzuki K, 2003, JPN J OPHTHALMOL, V47, P557, DOI 10.1016/j.jjo.2003.09.001; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Usui T, 2003, BRIT J OPHTHALMOL, V87, P357, DOI 10.1136/bjo.87.3.357; Wilkinson TS, 2004, AM J RESP CELL MOL, V31, P92, DOI 10.1165/rcmb.2003-0380OC	40	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12475	12483		10.1074/jbc.M609280200	http://dx.doi.org/10.1074/jbc.M609280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327235	Green Accepted, hybrid			2022-12-25	WOS:000245942800016
J	Jones, BW; Song, GJ; Greuber, EK; Hinkle, PM				Jones, Brian W.; Song, Gyun Jee; Greuber, Emileigh K.; Hinkle, Patricia M.			Phosphorylation of the endogenous thyrotropin-releasing hormone receptor in pituitary GH3 cells and pituitary tissue revealed by phosphosite-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; A(3) ADENOSINE RECEPTOR; PROTEIN PHOSPHATASE 2A; BETA-ARRESTIN; DESENSITIZATION; KINASE; DEPHOSPHORYLATION; INTERNALIZATION; SITES; VISUALIZATION	To study phosphorylation of the endogenous type I thyrotropin-releasing hormone receptor in the anterior pituitary, generated phosphosite-specific polyclonal antibodies. The major phosphorylation site of receptor endogenously expressed in pituitary GH3 cells was Thr(365) in the receptor tail; distal sites were more phosphorylated in some heterologous models. beta-Arrestin 2 reduced thyrotropin-releasing hormone (TRH)-stimulated inositol phosphate production and accelerated internalization of the wild type receptor but not receptor mutants where the critical phosphosites were mutated to Ala. Phosphorylation peaked within seconds and was maximal at 100 nM TRH. Based on dominant negative kinase and small interfering RNA approaches, phosphorylation was mediated primarily by G protein-coupled receptor kinase 2. Phosphorylated receptor, visualized by immunofluorescence microscopy, was initially at the plasma membrane, and over 5-30 min it moved to intracellular vesicles in GH3 cells. Dephosphorylation was rapid (t(1/2) alpha 1 min) if agonist was removed while receptor was at the surface. Dephosphorylation was slower (t(1/2) similar to 4 min) if agonist was withdrawn after receptor had internalized. After agonist removal and dephosphorylation, a second pulse of agonist caused extensive rephosphorylation, particularly if most receptor was still on the plasma membrane. Phosphorylated receptor staining was visible in prolactin- and thyrotropin-producing cells in rat pituitary tissue from untreated rats and much stronger in tissue from animals injected with TRH. Our results show that the TRH receptor can rapidly cycle between a phosphorylated and nonphosphorylated state in response to changing agonist concentrations and that phosphorylation can be used as an indicator of receptor activity in vivo.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711, Rochester, NY 14642 USA.	Patricia_Hinkle@urmc.rochester.edu		Jones, Brian/0000-0002-3277-4735	NIDDK NIH HHS [DK19974, R01 DK019974] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams RA, 2003, BIOCHEM J, V374, P537, DOI 10.1042/BJ20030408; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Cook LB, 2004, ENDOCRINOLOGY, V145, P3095, DOI 10.1210/en.2004-0304; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; Du DY, 2005, MOL PHARMACOL, V68, P204, DOI 10.1124/mol.105.012641; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; HALPERN J, 1981, P NATL ACAD SCI-BIOL, V78, P587, DOI 10.1073/pnas.78.1.587; HINKLE PM, 1973, J BIOL CHEM, V248, P6180; IMAI A, 1985, J BIOL CHEM, V260, P536; Iyer V, 2006, BRIT J PHARMACOL, V147, P249, DOI 10.1038/sj.bjp.0706551; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Jones BW, 2005, J BIOL CHEM, V280, P38346, DOI 10.1074/jbc.M502918200; Kageyama K, 2006, ENDOCRINOLOGY, V147, P441, DOI 10.1210/en.2005-0376; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mao LM, 2005, J BIOL CHEM, V280, P12602, DOI 10.1074/jbc.M411709200; MARTIN TFJ, 1986, J BIOL CHEM, V261, P2918; McLaughlin JP, 2004, J BIOL CHEM, V279, P1810, DOI 10.1074/jbc.M305796200; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; Neill JD, 1998, ENDOCRINOLOGY, V139, P1781, DOI 10.1210/en.139.4.1781; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; PERRONE MH, 1978, J BIOL CHEM, V253, P5168; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pollok-Kopp B, 2003, J BIOL CHEM, V278, P2190, DOI 10.1074/jbc.M209844200; Pollok-Kopp B, 2007, J BIOL CHEM, V282, P4345, DOI 10.1074/jbc.M601317200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Rabeler R, 2004, MOL ENDOCRINOL, V18, P1450, DOI 10.1210/me.2004-0017; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Spurney RF, 2001, J PHARMACOL EXP THER, V296, P592; Tachibanaki S, 2005, P NATL ACAD SCI USA, V102, P9329, DOI 10.1073/pnas.0501875102; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Woerner BM, 2005, CANCER RES, V65, P11392, DOI 10.1158/0008-5472.CAN-05-0847; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yu R, 1998, THYROID, V8, P887, DOI 10.1089/thy.1998.8.887; Zhu CC, 2002, J BIOL CHEM, V277, P28228, DOI 10.1074/jbc.M204221200	52	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12893	12906		10.1074/jbc.M610854200	http://dx.doi.org/10.1074/jbc.M610854200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329249	hybrid			2022-12-25	WOS:000245942800061
J	Bhattacharyya, G; Grove, A				Bhattacharyya, Gargi; Grove, Anne			The N-terminal extensions of Deinococcus radiodurans Dps-1 mediate DNA major groove interactions as well as assembly of the dodecamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROTEIN; ESCHERICHIA-COLI DPS; BINDING PROTEIN; CRYSTAL-STRUCTURE; FERRITIN HOMOLOG; IRON; PROTECTION; STRATEGIES; REVEALS; SITE	Dps ( (D) under bar NA (p) under bar rotection during (s) under bar tarvation) proteins play an important role in the protection of prokaryotic macromolecules from damage by reactive oxygen species. Previous studies have suggested that the lysine-rich N-terminal tail of Dps proteins participates in DNA binding. In comparison with other Dps proteins, Dps-1 from Deinococcus radiodurans has an extended N terminus comprising 55 amino acids preceding the first helix of the 4-helix bundle monomer. In the crystal structure of Dps-1, the first similar to 30 N-terminal residues are invisible, and the remaining 25 residues form a loop that harbors a novel metal-binding site. We show here that deletion of the flexible N-terminal tail obliterates DNA/Dps-1 interaction. Surprisingly, deletion of the entire N terminus also abolishes dodecameric assembly of the protein. Retention of the N-terminal metal site is necessary for formation of the dodecamer, and metal binding at this site facilitates oligomerization of the protein. Electrophoretic mobility shift assays using DNA modified with specific major/minor groove reagents further show that Dps-1 interacts through the DNA major groove. DNA cyclization assays suggest that dodecameric Dps-1 does not wrap DNA about itself. A significant decrease in DNA binding affinity accompanies a reduction in duplex length from 22 to 18 bp, but only for dodecameric Dps-1. Our data further suggest that high affinity DNA binding depends on occupancy of the N-terminal metal site. Taken together, the mode of DNA interaction by dodecameric Dps-1 suggests interaction of two metal-anchored N-terminal tails in successive DNA major grooves, leading to DNA compaction by formation of stacked protein-DNA layers.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Grove, A (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	agrove@lsu.edu	Grove, Anne/O-5998-2015	Grove, Anne/0000-0002-4390-0354				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; BOYD D, 1985, J BIOL CHEM, V260, P1755; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Ceci P, 2005, J BIOL CHEM, V280, P34776, DOI 10.1074/jbc.M502343200; Ceci P, 2004, NUCLEIC ACIDS RES, V32, P5935, DOI 10.1093/nar/gkh915; Ceci P, 2003, J BIOL CHEM, V278, P20319, DOI 10.1074/jbc.M302114200; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; Frenkiel-Krispin D, 2004, MOL MICROBIOL, V51, P395, DOI 10.1046/j.1365-2958.2003.03855.x; Gauss GH, 2006, BIOCHEMISTRY-US, V45, P10815, DOI 10.1021/bi060782u; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Grove A, 2005, J MOL BIOL, V347, P495, DOI 10.1016/j.jmb.2005.01.055; Grove A, 2001, J MOL BIOL, V311, P491, DOI 10.1006/jmbi.2001.4763; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; Kim SG, 2006, J MOL BIOL, V361, P105, DOI 10.1016/j.jmb.2006.06.010; LATHAM KA, 1995, J BIOL CHEM, V270, P3765, DOI 10.1074/jbc.270.8.3765; Liu XF, 2006, J BIOL CHEM, V281, P27827, DOI 10.1074/jbc.M601398200; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; Romao CV, 2006, J BIOL INORG CHEM, V11, P891, DOI 10.1007/s00775-006-0142-5; Sabatini R, 2002, J BIOL CHEM, V277, P28150, DOI 10.1074/jbc.M201487200; Stillman TJ, 2005, MOL MICROBIOL, V57, P1101, DOI 10.1111/j.1365-2958.2005.04757.x; Surguladze N, 2004, J BIOL CHEM, V279, P14694, DOI 10.1074/jbc.M313348200; Theil EC, 2006, J BIOL INORG CHEM, V11, P803, DOI 10.1007/s00775-006-0125-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wilson DM, 2003, FRONT BIOSCI-LANDMRK, V8, pD963, DOI 10.2741/1109; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	37	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11921	11930		10.1074/jbc.M611255200	http://dx.doi.org/10.1074/jbc.M611255200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331944	Green Published, hybrid			2022-12-25	WOS:000245941900035
J	Byrnes, JE; Reynolds, PL; Stachowicz, JJ				Byrnes, Jarrett E.; Reynolds, Pamela L.; Stachowicz, John J.			Invasions and Extinctions Reshape Coastal Marine Food Webs	PLOS ONE			English	Article								The biodiversity of ecosystems worldwide is changing because of species loss due to human-caused extinctions and species gain through intentional and accidental introductions. Here we show that the combined effect of these two processes is altering the trophic structure of food webs in coastal marine systems. This is because most extinctions (similar to 70%) occur at high trophic levels (top predators and other carnivores), while most invasions are by species from lower trophic levels (70% macroplanktivores, deposit feeders, and detritivores). These opposing changes thus alter the shape of marine food webs from a trophic pyramid capped by a diverse array of predators and consumers to a shorter, squatter configuration dominated by filter feeders and scavengers. The consequences of the simultaneous loss of diversity at top trophic levels and gain at lower trophic levels is largely unknown. However, current research suggests that a better understanding of how such simultaneous changes in diversity can impact ecosystem function will be required to manage coastal ecosystems and forecast future changes.	[Byrnes, Jarrett E.; Stachowicz, John J.] Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA; [Reynolds, Pamela L.] Bodega Bay Marine Lab, Bodega Bay, CA USA	University of California System; University of California Davis	Byrnes, JE (corresponding author), Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA.	jebyrnes@ucdavis.edu		Byrnes, Jarrett/0000-0002-9791-9472; Reynolds, Pamela/0000-0002-0177-3537	NSF-DGE [0114432]; National Science Foundation [OCE 03-17778]	NSF-DGE(National Science Foundation (NSF)NSF - Directorate for STEM Education (EDU)); National Science Foundation(National Science Foundation (NSF))	Funding and other support for this study was provided by the UC Davis IGERT on Biological Invasions (NSF-DGE No. 0114432) and the National Science Foundation Biological Oceanography program (OCE 03-17778 to JJS).	*A WEGN I POL MAR, 2006, FLOR FAUN NO WADD SE; ALPINE AE, 1992, LIMNOL OCEANOGR, V37, P946, DOI 10.4319/lo.1992.37.5.0946; Aquilino KM, 2005, OIKOS, V108, P275, DOI 10.1111/j.0030-1299.2005.13418.x; Berlow EL, 1999, NATURE, V398, P330, DOI 10.1038/18672; Byrnes J, 2006, ECOL LETT, V9, P61, DOI 10.1111/j.1461-0248.2005.00842.x; Cardinale BJ, 2003, ECOL LETT, V6, P857, DOI 10.1046/j.1461-0248.2003.00508.x; Cardinale BJ, 2006, NATURE, V443, P989, DOI 10.1038/nature05202; Carlton J.T., 1995, NONINDIGENOUS AQUATI; CARPENTER SR, TROPHIC CASCADE LAKE; Duffy JE, 2006, MAR ECOL PROG SER, V311, P233, DOI 10.3354/meps311233; Duffy JE, 2005, ECOL LETT, V8, P301, DOI 10.1111/j.1461-0248.2005.00725.x; Duffy JE, 2003, ECOL LETT, V6, P680, DOI 10.1046/j.1461-0248.2003.00494.x; Duffy JE, 2003, ECOL LETT, V6, P637; Dulvy NK, 2003, FISH FISH, V4, P25, DOI 10.1046/j.1467-2979.2003.00105.x; Dyer LA, 2003, ECOL LETT, V6, P60, DOI 10.1046/j.1461-0248.2003.00398.x; ESTES JA, 1974, SCIENCE, V185, P1058, DOI 10.1126/science.185.4156.1058; Finke DL, 2005, ECOL LETT, V8, P1299, DOI 10.1111/j.1461-0248.2005.00832.x; Gamfeldt L, 2005, ECOL LETT, V8, P696, DOI 10.1111/j.1461-0248.2005.00765.x; HEWITT CL, 2002, NATL INTRO MARINE PE; Levin PS, 2002, ECOLOGY, V83, P3182, DOI 10.2307/3071852; Lotze HK, 2006, SCIENCE, V312, P1806, DOI 10.1126/science.1128035; Lotze HK, 2005, HELGOLAND MAR RES, V59, P84, DOI 10.1007/s10152-004-0209-z; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; NEHRING S, 2006, AQUATIC ALIEN SPECIE; Parker JD, 2006, SCIENCE, V311, P1459, DOI 10.1126/science.1121407; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Petchey OL, 1999, NATURE, V402, P69, DOI 10.1038/47023; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Sax DF, 2003, TRENDS ECOL EVOL, V18, P561, DOI 10.1016/S0169-5347(03)00224-6; Sax DF, 2002, AM NAT, V160, P766, DOI 10.1086/343877; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; Solan M, 2004, SCIENCE, V306, P1177, DOI 10.1126/science.1103960; Steneck RS, 2004, ECOSYSTEMS, V7, P323, DOI 10.1007/s10021-004-0240-6; Thebault E, 2006, ECOL RES, V21, P17, DOI 10.1007/s11284-005-0127-9; Wasson K, 2005, BIOL INVASIONS, V7, P935, DOI 10.1007/s10530-004-2995-2; Worm B, 2006, SCIENCE, V314, P787, DOI 10.1126/science.1132294; Zavaleta ES, 2004, SCIENCE, V306, P1175, DOI 10.1126/science.1102643	37	160	165	0	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e295	10.1371/journal.pone.0000295	http://dx.doi.org/10.1371/journal.pone.0000295			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356703	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444800018
J	Paoletti, M; Saupe, SJ; Clave, C				Paoletti, Mathieu; Saupe, Sven J.; Clave, Corinne			Genesis of a Fungal Non-Self Recognition Repertoire	PLOS ONE			English	Article								Conspecific allorecognition, the ability for an organism to discriminate its own cells from those of another individual of the same species, has been developed by many organisms. Allorecognition specificities are determined by highly polymorphic genes. The processes by which this extreme polymorphism is generated remain largely unknown. Fungi are able to form heterokaryons by fusion of somatic cells, and somatic non self-recognition is controlled by heterokaryon incompatibility loci (het loci). Herein, we have analyzed the evolutionary features of the het-d and het-e fungal allorecognition genes. In these het genes, allorecognition specificity is determined by a polymorphic WD-repeat domain. We found that het-d and het-e belong to a large gene family with 10 members that all share the WD-repeat domain and show that repeats of all members of the family undergo concerted evolution. It follows that repeat units are constantly exchanged both within and between members of the gene family. As a consequence, high mutation supply in the repeat domain is ensured due to the high total copy number of repeats. We then show that in each repeat four residues located at the protein/protein interaction surface of the WD-repeat domain are under positive diversifying selection. Diversification of het-d and het-e is thus ensured by high mutation supply, followed by reshuffling of the repeats and positive selection for favourable variants. We also propose that RIP, a fungal specific hypermutation process acting specifically on repeated sequences might further enhance mutation supply. The combination of these evolutionary mechanisms constitutes an original process for generating extensive polymorphism at loci that require rapid diversification.	[Paoletti, Mathieu] CNRS, Lab Genet Mol Champignons, UMR 5095, Bordeaux, France; Univ Bordeaux 2, F-33076 Bordeaux, France; IBGC, Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Paoletti, M (corresponding author), CNRS, Lab Genet Mol Champignons, UMR 5095, Bordeaux, France.	mathieu.paoletti@ibgc.u-bordeaux2.fr		saupe, sven/0000-0002-5589-721X	European commission [511983]	European commission(European CommissionEuropean Commission Joint Research Centre)	M. P. is funded by a European commission grant (Transdeath Contract 511983).	Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BEGUERET J, 1973, THESIS U BORDEAUX 2; BERNET J, 1967, CR ACAD SCI D NAT, V265, P1330; Biella S, 2002, P ROY SOC B-BIOL SCI, V269, P2269, DOI 10.1098/rspb.2002.2148; BOUCHERIE H, 1981, BIOCHIM BIOPHYS ACTA, V653, P18, DOI 10.1016/0005-2787(81)90100-3; Bouhouche K, 2004, GENETICS, V167, P151, DOI 10.1534/genetics.167.1.151; Braun FN, 2004, J MOL EVOL, V59, P97, DOI 10.1007/s00239-004-2608-9; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; De Tomaso AW, 2005, NATURE, V438, P454, DOI 10.1038/nature04150; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; Drake JW, 1998, GENETICS, V148, P1667; Espagne E, 1997, MOL GEN GENET, V256, P620, DOI 10.1007/s004380050610; Espagne E, 2002, GENETICS, V161, P71; ESPAGNE E, 2000, THESIS U BORDEAUX 2; Fedorova ND, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-177; Galagan JE, 2004, TRENDS GENET, V20, P417, DOI 10.1016/j.tig.2004.07.007; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Glass NL, 2003, EUKARYOT CELL, V2, P1, DOI 10.1128/EC.2.1.1-8.2003; Glass NL, 2000, ANNU REV GENET, V34, P165, DOI 10.1146/annurev.genet.34.1.165; GLASS NL, 2006, CURR OPIN MICROBIOL; Gout L, 2006, MOL MICROBIOL, V60, P67, DOI 10.1111/j.1365-2958.2006.05076.x; Hamann A, 2000, MOL GEN GENET, V263, P1061, DOI 10.1007/s004380050035; Kaneko I, 2006, GENETICS, V172, P1545, DOI 10.1534/genetics.105.051490; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kufer TA, 2005, TRENDS MICROBIOL, V13, P381, DOI 10.1016/j.tim.2005.06.004; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LABARERE J, 1973, CR ACAD SCI D NAT, V276, P1301; Lelpe DD, 2004, J MOL BIOL, V343, P1, DOI 10.1016/j.jmb.2004.08.023; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; Malakhova ML, 2005, J BIOL CHEM, V280, P26312, DOI 10.1074/jbc.M500481200; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Metzgar D, 2000, CELL, V101, P581, DOI 10.1016/S0092-8674(00)80869-7; Mondragon-Palomino M, 2005, MOL BIOL EVOL, V22, P2444, DOI 10.1093/molbev/msi241; Montiel MD, 2006, FUNGAL GENET BIOL, V43, P439, DOI 10.1016/j.fgb.2006.01.011; Nasrallah JB, 2005, TRENDS IMMUNOL, V26, P412, DOI 10.1016/j.it.2005.06.005; Nei M, 2005, MOL BIOL EVOL, V22, P2318, DOI 10.1093/molbev/msi242; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nei M, 1996, ANNU REV GENET, V30, P371, DOI 10.1146/annurev.genet.30.1.371; NEI M, 2005, ANN REV GENET; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Nuss DL, 2005, NAT REV MICROBIOL, V3, P632, DOI 10.1038/nrmicro1206; Paoletti M, 2006, MOL ECOL, V15, P249, DOI 10.1111/j.1365-294X.2005.02728.x; Pinan-Lucarre B, 2005, EUKARYOT CELL, V4, P1765, DOI 10.1128/EC.4.11.1765-1774.2005; Pinan-Lucarre R, 2003, MOL MICROBIOL, V47, P321, DOI 10.1046/j.1365-2958.2003.03208.x; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; Queller DC, 2002, SCIENCE, V296, P311, DOI 10.1126/science.1070671; Richman A, 2000, MOL ECOL, V9, P1953, DOI 10.1046/j.1365-294X.2000.01125.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAUPE S, 1995, CURR GENET, V27, P466, DOI 10.1007/BF00311217; SAUPE S, 1995, GENE, V162, P135, DOI 10.1016/0378-1119(95)00272-8; SAUPE S, 1994, P NATL ACAD SCI USA, V91, P5927, DOI 10.1073/pnas.91.13.5927; Saupe SJ, 2000, MICROBIOL MOL BIOL R, V64, P489, DOI 10.1128/MMBR.64.3.489-502.2000; Shiu PKT, 1999, GENETICS, V151, P545; Smith ML, 2000, GENETICS, V155, P1095; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Suzuki Y, 1999, MOL BIOL EVOL, V16, P1315, DOI 10.1093/oxfordjournals.molbev.a026042; Vallender EJ, 2006, HUM MOL GENET, V15, P3034, DOI 10.1093/hmg/ddl245; Wu J, 1998, P NATL ACAD SCI USA, V95, P12398, DOI 10.1073/pnas.95.21.12398	65	62	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e283	10.1371/journal.pone.0000283	http://dx.doi.org/10.1371/journal.pone.0000283			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356694	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444800006
J	Huber, R; Esser, SK; Ferrarelli, F; Massimini, M; Peterson, MJ; Tononi, G				Huber, Reto; Esser, Steve K.; Ferrarelli, Fabio; Massimini, Marcello; Peterson, Michael J.; Tononi, Giulio			TMS-Induced Cortical Potentiation during Wakefulness Locally Increases Slow Wave Activity during Sleep	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; LONG-TERM POTENTIATION; REPETITIVE TMS; CORTICOSPINAL EXCITABILITY; MOTOR CORTEX; HOMEOSTASIS; ACTIVATION; RESPONSES	Background. Sleep slow wave activity (SWA) is thought to reflect sleep need, increasing in proportion to the length of prior wakefulness and decreasing during sleep. However, the process responsible for SWA regulation is not known. We showed recently that SWA increases locally after a learning task involving a circumscribed brain region, suggesting that SWA may reflect plastic changes triggered by learning. Methodology/Principal Findings. To test this hypothesis directly, we used transcranial magnetic stimulation (TMS) in conjunction with high-density EEG in humans. We show that 5-Hz TMS applied to motor cortex induces a localized potentiation of TMS-evoked cortical EEG responses. We then show that, in the sleep episode following 5-Hz TMS, SWA increases markedly (+39.1 +/- 17.4%, p<0.01, n = 10). Electrode coregistration with magnetic resonance images localized the increase in SWA to the same premotor site as the maximum TMS-induced potentiation during wakefulness. Moreover, the magnitude of potentiation during wakefulness predicts the local increase in SWA during sleep. Conclusions/Significance. These results provide direct evidence for a link between plastic changes and the local regulation of sleep need.	[Huber, Reto; Esser, Steve K.; Ferrarelli, Fabio; Massimini, Marcello; Peterson, Michael J.; Tononi, Giulio] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Tononi, G (corresponding author), Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA.	gtononi@wisc.edu	ferrarelli, fabio/C-2945-2011; Ferrarelli, Fabio/D-3219-2019; Peterson, Michael J./A-8834-2009; Massimini, Marcello/T-8115-2017	Ferrarelli, Fabio/0000-0003-0560-0227; Peterson, Michael J./0000-0001-9181-1009; Massimini, Marcello/0000-0003-2271-957X	Swiss Foundation [LSHM-CT-2005-518189]; NRSA [1F31NS055553-01]; National Institutes of Health [1RO1 NS 055 185-01]; McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055185] Funding Source: NIH RePORTER	Swiss Foundation(Swiss National Science Foundation (SNSF)); NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the Swiss Foundation for Fellowships in Biology and Medicine to R. H., from LSHM-CT-2005-518189 to R. H., from a NRSA (1F31NS055553-01) to S. K. E., from a NIH Pioneer Award to G. T., from the National Institutes of Health (1RO1 NS 055 185-01) to G. T and from a McDonnell Foundation grant to G. T.	Bestmann S, 2004, EUR J NEUROSCI, V19, P1950, DOI 10.1111/j.1460-9568.2004.03277.x; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Borbely A A, 1982, Hum Neurobiol, V1, P195; Borbely A. A., 2000, PRINCIPLES PRACTICE, P377; Borbely AA, 2001, ARCH ITAL BIOL, V139, P53; Clapp WC, 2005, NEUROREPORT, V16, P1977, DOI 10.1097/00001756-200512190-00001; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; Di Lazzaro V, 2002, EXP BRAIN RES, V144, P549, DOI 10.1007/s00221-002-1106-9; Esser SK, 2006, BRAIN RES BULL, V69, P86, DOI 10.1016/j.brainresbull.2005.11.003; Esser SK, 2005, J NEUROPHYSIOL, V94, P622, DOI 10.1152/jn.01230.2004; Ferrarelli F, 2004, BRAIN RES BULL, V64, P103, DOI 10.1016/j.brainresbull.2004.04.020; Finelli LA, 2001, EUR J NEUROSCI, V13, P2282, DOI 10.1046/j.0953-816x.2001.01597.x; Fink GR, 1997, J NEUROPHYSIOL, V77, P2164, DOI 10.1152/jn.1997.77.4.2164; Frenkel MY, 2006, NEURON, V51, P339, DOI 10.1016/j.neuron.2006.06.026; Ghilardi MF, 2000, BRAIN RES, V871, P127, DOI 10.1016/S0006-8993(00)02365-9; Hill S, 2005, J NEUROPHYSIOL, V93, P1671, DOI 10.1152/jn.00915.2004; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huber R, 2000, NEUROREPORT, V11, P3321, DOI 10.1097/00001756-200010200-00012; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huber R, 2006, NAT NEUROSCI; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Kole MHP, 1999, BRAIN RES, V826, P309, DOI 10.1016/S0006-8993(99)01257-3; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Loo CK, 2005, J AFFECT DISORDERS, V88, P255, DOI 10.1016/j.jad.2005.08.001; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Matsunaga K, 2005, J PHYSIOL-LONDON, V562, P295, DOI 10.1113/jphysiol.2004.070755; MORECRAFT RJ, 1993, J COMP NEUROL, V337, P669, DOI 10.1002/cne.903370411; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Quartarone A, 2005, EXP BRAIN RES, V161, P114, DOI 10.1007/s00221-004-2052-5; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Siebner HR, 2000, NEUROLOGY, V54, P956, DOI 10.1212/WNL.54.4.956; Steriade M, 2003, FRONT BIOSCI-LANDMRK, V8, pD878, DOI 10.2741/1043; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Tegenthoff M, 2005, PLOS BIOL, V3, P2031, DOI 10.1371/journal.pbio.0030362; Teyler TJ, 2005, EUR J NEUROSCI, V21, P2045, DOI 10.1111/j.1460-9568.2005.04007.x; Tokuno H, 2000, CEREB CORTEX, V10, P58, DOI 10.1093/cercor/10.1.58; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; Vyazovskiy V, 2000, J SLEEP RES, V9, P367, DOI 10.1046/j.1365-2869.2000.00230.x; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Werth E, 1997, J SLEEP RES, V6, P102, DOI 10.1046/j.1365-2869.1997.d01-36.x; Ziemann U, 2004, REV NEUROSCIENCE, V15, P253	46	168	170	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e276	10.1371/journal.pone.0000276	http://dx.doi.org/10.1371/journal.pone.0000276			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342210	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444700011
J	Gutova, M; Najbauer, J; Gevorgyan, A; Metz, MZ; Weng, YH; Shih, CC; Aboody, KS				Gutova, Margarita; Najbauer, Joseph; Gevorgyan, Anna; Metz, Marianne Z.; Weng, Yehua; Shih, Chu-Chih; Aboody, Karen S.			Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung Cancer	PLOS ONE			English	Article								Background. The urokinase plasminogen activator (uPA) and its receptor (uPAR/CD87) are major regulators of extracellular matrix degradation and are involved in cell migration and invasion under physiological and pathological conditions. The uPA/uPAR system has been of great interest in cancer research because it is involved in the development of most invasive cancer phenotypes and is a strong predictor of poor patient survival. However, little is known about the role of uPA/uPAR in small cell lung cancer (SCLC), the most aggressive type of lung cancer. We therefore determined whether uPA and uPAR are involved in generation of drug resistant SCLC cell phenotype. Methods and Findings. We screened six human SCLC cell lines for surface markers for putative stem and cancer cells. We used fluorescence-activated cell sorting (FACS), fluorescence microscopy and clonogenic assays to demonstrate uPAR expression in a subpopulation of cells derived from primary and metastatic SCLC cell lines. Cytotoxic assays were used to determine the sensitivity of uPAR-positive and uPAR-negative cells to chemotherapeutic agents. The uPAR-positive cells in all SCLC lines demonstrated multi-drug resistance, high clonogenic activity and co-expression of CD44 and MDR1, putative cancer stem cell markers. Conclusions. These data suggest that uPAR-positive cells may define a functionally important population of cancer cells in SCLC, which are resistant to traditional chemotherapies, and could serve as critical targets for more effective therapeutic interventions in SCLC.	[Gutova, Margarita; Najbauer, Joseph; Gevorgyan, Anna; Metz, Marianne Z.; Weng, Yehua; Shih, Chu-Chih; Aboody, Karen S.] City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; [Gutova, Margarita; Najbauer, Joseph; Gevorgyan, Anna; Metz, Marianne Z.; Weng, Yehua; Shih, Chu-Chih; Aboody, Karen S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; [Aboody, Karen S.] City Hope Natl Med Ctr, Div Neurosci, Duarte, CA 91010 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope	Gutova, M (corresponding author), City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	mgutova@coh.org; kaboody@coh.org			Stop Cancer Foundation; Rosalinde and Arthur Gilbert Foundation; Marcus Foundation	Stop Cancer Foundation; Rosalinde and Arthur Gilbert Foundation; Marcus Foundation	This work was supported by Stop Cancer Foundation, The Rosalinde and Arthur Gilbert Foundation, and Marcus Foundation.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alfano D, 2005, THROMB HAEMOSTASIS, V93, P205, DOI 10.1160/TH04-09-0592; Alfano D, 2006, J BIOL CHEM, V281, P17758, DOI 10.1074/jbc.M601812200; Allgayer H, 2006, EUR J CANCER, V42, P811, DOI 10.1016/j.ejca.2006.01.018; Almasi CE, 2005, LUNG CANCER, V48, P349, DOI 10.1016/j.lungcan.2004.11.020; Aref S, 2003, Hematology, V8, P385, DOI 10.1080/10245330310001621323; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Foekens JA, 2000, CANCER RES, V60, P636; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gelder MEV, 2004, CANCER RES, V64, P4563, DOI 10.1158/0008-5472.CAN-03-3848; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; Lakka SS, 2001, INT J ONCOL, V18, P71; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Margheri F, 2005, GENE THER, V12, P702, DOI 10.1038/sj.gt.3302456; Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478; Montuori N, 2005, THROMB HAEMOSTASIS, V93, P192, DOI 10.1160/TH04-09-0580; MURALIKRISHNA PS, 2005, J BIOL CHEM; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pisick Evan, 2003, J Exp Ther Oncol, V3, P305, DOI 10.1111/j.1533-869X.2003.01103.x; Rao JS, 2005, MOL CANCER THER, V4, P1399, DOI 10.1158/1535-7163.MCT-05-0082; Rigolin GM, 2003, BRIT J HAEMATOL, V120, P953, DOI 10.1046/j.1365-2141.2003.04176.x; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Werle B, 2004, ANTICANCER RES, V24, P4147; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	36	114	118	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e243	10.1371/journal.pone.0000243	http://dx.doi.org/10.1371/journal.pone.0000243			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327908	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444600003
J	Oh, KB; Stanton, MJ; West, WW; Todd, GL; Wagner, KU				Oh, K. B.; Stanton, M. J.; West, W. W.; Todd, G. L.; Wagner, K-U			Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation	ONCOGENE			English	Article						Tsg101; breast cancer; mammary gland; transgenic; epidermal growth factor receptor	TUMOR SUSCEPTIBILITY GENE; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; RECEPTOR; PATHWAY; GROWTH; DIFFERENTIATION; PROLIFERATION; ABNORMALITIES	Previous studies reported that the Tumor Susceptibility Gene 101 ( TSG101) is upregulated in selected human malignancies, and the expression of exogenous Tsg101 was suggested to transform immortalized fibroblasts in culture. To date, the potential oncogenic properties of Tsg101 have not been examined in vivo owing to the lack of appropriate model systems. In this study, we show that Tsg101 is highly expressed in a subset of invasive human breast cancers. Based on this observation, we generated the first transgenic mouse model with a targeted overexpression of Tsg101 in the developing mammary gland to test whether exogenous Tsg101 is capable of initiating tumorigenesis. Normal functionality of exogenous Tsg101 was tested by rescuing the survival of Tsg101-deficient mammary epithelial cells in conditional knockout mice. The overexpression of Tsg101 resulted in increased phosphorylation of the epidermal growth factor receptor and downstream activation of MAP kinases. Despite an increase in the activation of these signal transducers, the mammary gland of females expressing exogenous Tsg101 developed normally throughout the reproductive cycle. In aging females, the overexpression of Tsg101 seemed to increase the susceptibility of mammary epithelia toward malignant transformation. However, owing to the long latency of tumor formation and the sporadic occurrence of bona. de mammary cancers, we conclude that the Tsg101 protein has only weak oncogenic properties. Instead of cancer initiation, it is therefore likely that Tsg101 plays a more predominant role in the progression of a subset of spontaneously arising breast cancers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Room 8009,986805, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [R01CA093797] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93797] Funding Source: Medline; NCRR NIH HHS [P20 RR 16469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BURDON T, 1991, J BIOL CHEM, V266, P6909; Carstens MJ, 2004, J BIOL CHEM, V279, P35984, DOI 10.1074/jbc.M400408200; Cerrito MG, 2004, J CELL PHYSIOL, V201, P244, DOI 10.1002/jcp.20077; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu RT, 2002, ONCOGENE, V21, P4830, DOI 10.1038/sj.onc.1205612; Lo YF, 2000, BREAST CANCER RES TR, V60, P259, DOI 10.1023/A:1006426400524; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2003, ONCOGENE, V22, P3742, DOI 10.1038/sj.onc.1206428	29	46	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5950	5959		10.1038/sj.onc.1210401	http://dx.doi.org/10.1038/sj.onc.1210401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369844				2022-12-25	WOS:000249123100012
J	Kamranvar, SA; Gruhne, B; Szeles, A; Masucci, MG				Kamranvar, S. A.; Gruhne, B.; Szeles, A.; Masucci, M. G.			Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; chromosome; aberrations; genomic instability	CELL-LINES; CHROMOSOMAL-ABERRATIONS; DNA-REPAIR; C-MYC; GENETIC INSTABILITY; B-CELLS; TELOMERASE; TRANSLOCATIONS; ABNORMALITIES; INFECTION	Epstein-Barr virus (EBV) has been implicated in the pathogenesis of human malignancies but the mechanisms of oncogenesis remain largely unknown. Genomic instability and chromosomal aberrations are hallmarks of malignant transformation. We report that EBV carriage promotes genomic instability in Burkitt's lymphoma (BL). Cytogenetic analysis of EBV-and EBV+ BL lines and their sublines derived by EBV conversion or spontaneous loss of the viral genome revealed a significant increase in dicentric chromosomes, chromosome fragments and chromatid gaps in EBV-carrying cells. Expression of EBV latency I was suf. ficient for this effect, whereas a stronger effect was observed in cells expressing latency III. Telomere analysis by. fluorescent in situ hybridization revealed an overall increase of telomere size and prevalence of telomere fusion and double strand-break fusion in dicentric chromosomes from EBV+ cells. Phosphorylated H2AX, a reporter of DNA damage and ongoing repair, was increased in virus-carrying cells in the absence of exogenous stimuli, whereas efficient activation of DNA repair was observed in both EBV + and EBV- cells following treatment withetopos ide. These. findings point to induction of telomere dysfunction and DNA damage as important mechanisms for EBV oncogenesis.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 275, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; Cao J, 2002, MUTAT RES-FUND MOL M, V504, P85, DOI 10.1016/S0027-5107(02)00082-9; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chan WY, 2002, DIAGN MOL PATHOL, V11, P127, DOI 10.1097/00019606-200209000-00001; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Chen F, 2005, INT J CANCER, V113, P284, DOI 10.1002/ijc.20594; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Dolcetti R, 2006, PROGRESS IN VIRUS RESEARCH, P191; Gualandi G, 2001, MUTAGENESIS, V16, P203, DOI 10.1093/mutage/16.3.203; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; Jox A, 1997, ANN ONCOL, V8, P131, DOI 10.1023/A:1008215207384; Karpova MB, 2006, INT J ONCOL, V28, P605; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; Raptis S, 2006, EXP SUPPL, V96, P303; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shao JY, 2001, ANTICANCER RES, V21, P3021; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; STOLLMANN B, 1985, BRIT J HAEMATOL, V60, P183, DOI 10.1111/j.1365-2141.1985.tb07399.x; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; ZattaraCannoni H, 1996, LEUKEMIA LYMPHOMA, V21, P515, DOI 10.3109/10428199609093453; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; Zimonjic DB, 2001, LEUKEMIA, V15, P1582, DOI 10.1038/sj.leu.2402281	36	77	80	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5115	5123		10.1038/sj.onc.1210324	http://dx.doi.org/10.1038/sj.onc.1210324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17325665				2022-12-25	WOS:000248487400010
J	Uemura, K; Kuzuya, A; Shimozono, Y; Aoyagi, N; Ando, K; Shimohama, S; Kinoshita, A				Uemura, Kengo; Kuzuya, Akira; Shimozono, Yoshiharu; Aoyagi, Nobuhisa; Ando, Koichi; Shimohama, Shun; Kinoshita, Ayae			GSK3 beta activity modifies the localization and function of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; BETA-CATENIN; N-CADHERIN; TAU-HYPERPHOSPHORYLATION; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; CLEAVAGE; ADHESION	Presenilin 1, a causative gene product of familial Alzheimer disease, has been reported to be localized mainly in the endoplasmic reticulum and Golgi membranes. However, endogenous Presenilin 1 also localizes at the plasma membrane as a biologically active molecule. Presenilin 1 interacts with N-cadherin/beta-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues ( serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3 beta. Here, we demonstrate that cell-surface expression of Presenilin 1/gamma-secretase is enhanced by N-cadherin-based cell-cell contact. Physical interaction between Presenilin 1 and N-cadherin/beta-catenin plays an important role in this process. Glycogen synthase kinase 3 beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression. Moreover, reduction of the Presenilin 1 center dot N-cadherin center dot beta-catenin complex formation leads to an impaired activation of contact-mediated phosphatidylinositol 3-kinase/Akt cell survival signaling. Furthermore, phosphorylation of Presenilin 1 hinders epsilon-cleavage of N-cadherin, whereas epsilon-cleavage of APP remained unchanged. This is the first report that clarifies the regulatory mechanism of Presenilin 1/gamma-secretase with respect to its subcellular distribution and its differential substrate cleavage. Because the cleavage of various membrane proteins by Presenilin 1/gamma-cleavage is involved in cellular signaling, glycogen synthase kinase 3 beta-mediated phosphorylation of Presenilin 1 should be deeply associated with signaling functions. Our findings indicate that the abnormal activation of glycogen synthase kinase 3 beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.	Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan; Sapporo Med Univ, Dept Neurol, Sapporo, Hokkaido 0608556, Japan	Kyoto University; Kyoto University; Kyoto University; Sapporo Medical University	Kinoshita, A (corresponding author), Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, 53 Shogoinkawahara Cho, Kyoto 6068507, Japan.	akinoshita@hs.med.kyoto-u.ac.jp		Shimozono, Yoshiharu/0000-0003-1422-530X				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471-4159.2004.02422.x; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deng Y, 2006, J NEUROSCI, V26, P3845, DOI 10.1523/JNEUROSCI.5384-05.2006; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Li BL, 2004, TRANSGENIC RES, V13, P385, DOI 10.1023/B:TRAG.0000040039.44899.6f; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Twomey C, 2006, FEBS LETT, V580, P4015, DOI 10.1016/j.febslet.2006.06.035; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Uemura K, 2003, J NEUROSCI RES, V73, P166, DOI 10.1002/jnr.10641; Uemura K, 2006, NEUROSCI LETT, V402, P278, DOI 10.1016/j.neulet.2006.04.018; Uemura K, 2006, BIOCHEM BIOPH RES CO, V345, P951, DOI 10.1016/j.bbrc.2006.04.157; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	35	65	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15823	15832		10.1074/jbc.M610708200	http://dx.doi.org/10.1074/jbc.M610708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389597	hybrid			2022-12-25	WOS:000246589600057
J	Dogra, C; Hall, SL; Wedhas, N; Linkhart, TA; Kumar, A				Dogra, Charu; Hall, Susan L.; Wedhas, Nia; Linkhart, Thomas A.; Kumar, Ashok			Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes - Evidence for tweak- independent functions of Fn14 during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; FIBROBLAST GROWTH FACTOR-INDUCIBLE-14; INHIBITS SKELETAL MYOGENESIS; NUCLEAR FACTOR-KAPPAB; NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAYS; STEM-CELLS; MUSCLE DIFFERENTIATION; TNF SUPERFAMILY; WEAK INDUCER	Fibroblast growth factor-inducible 14 ( Fn14), distantly related to tumor necrosis factor receptor superfamily and a receptor for TWEAK cytokine, has been implicated in several biological responses. In this study, we have investigated the role of Fn14 in skeletal muscle formation in vitro. Flow cytometric and Western blot analysis revealed that Fn14 is highly expressed on myoblastic cell line C2C12 and mouse primary myoblasts. The expression of Fn14 was decreased upon differentiation of myoblasts into myotubes. Suppression of Fn14 expression using RNA interference inhibited the myotube formation in both C2C12 and primary myoblast cultures. Fn14 was required for the transactivation of skeletal alpha-actin promoter and the expression of specific muscle proteins such as myosin heavy chain fast type and creatine kinase. RNA interference-mediated knockdown of Fn14 receptor in C2C12 myoblasts decreased the levels of myogenic regulatory factors MyoD and myogenin upon induction of differentiation. Conversely, overexpression of MyoD increased differentiation in Fn14-knockdown C2C12 cultures. Suppression of Fn14 expression in C2C12 myoblasts also inhibited the differentiation-associated increase in the activity of serum response factor and RhoA GTPase. In addition, our data suggest that the role of Fn14 during myogenic differentiation could be independent of TWEAK cytokine. Collectively, our study suggests that the Fn14 receptor is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes.	Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, Loma Linda, CA 92357 USA; Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA	Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, 11201 Benton St, Loma Linda, CA 92357 USA.	ashok.kumar2@va.gov		Kumar, Ashok/0000-0001-8571-2848	NIA NIH HHS [R01 AG029623, R01 AG029623-01, R01 AG129623] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; Dogra C, 2006, J BIOL CHEM, V281, P10327, DOI 10.1074/jbc.M511131200; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2003, FASEB J, V17, P1800, DOI 10.1096/fj.02-1148com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Miller SM, 1998, MOL BIOL CELL, V9, p292A; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Sartorelli V, 2005, CURR OPIN GENET DEV, V15, P528, DOI 10.1016/j.gde.2005.04.015; Schulze M, 2005, GENE DEV, V19, P1787, DOI 10.1101/gad.339305; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Tanabe K, 2003, J NEUROSCI, V23, P9675; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; WARNER DO, 1992, AM REV RESPIR DIS, V145, P553, DOI 10.1164/ajrccm/145.3.553; Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02-0187fje; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wilson EM, 2003, J BIOL CHEM, V278, P41109, DOI 10.1074/jbc.C300299200; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yepes M, 2005, AM J PATHOL, V166, P511, DOI 10.1016/S0002-9440(10)62273-0; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	62	68	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15000	15010		10.1074/jbc.M608668200	http://dx.doi.org/10.1074/jbc.M608668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17383968	hybrid, Green Accepted			2022-12-25	WOS:000246589000039
J	Lecuit, M; Sonnenburg, JL; Cossart, P; Gordon, JI				Lecuit, Marc; Sonnenburg, Justin L.; Cossart, Pascale; Gordon, Jeffrey I.			Functional genomic studies of the intestinal response to a foodborne enteropathogen in a humanized gnotobiotic mouse model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES; IMMUNE-RESPONSES; KAPPA-B; INTERNALIN; INFECTION; ACTIVATION; DIVERSITY	Members of the genus Listeria provide a model for defining host responses to invasive foodborne enteropathogens. Active translocation of Listeria monocytogenes across the gut epithelial barrier is mediated by interaction of bacterial internalin ( InlA) and its species-specific host receptor, E-cadherin, whereas translocation across Peyer's patches through M-cells is InlA-independent. To define microbial determinants and molecular correlates of the host response to translocation via these two routes, we colonized germ-free transgenic mice expressing the human enterocyte-associated E-cadherin receptor with wildtype ( WT) or mutant L. monocytogenes strains, or its nonpathogenic noninvasive relative Listeria innocua, or with Bacteroides thetaiotaomicron, a prominent gut symbiont. Mouse Gene-Chips, combined with Ingenuity Pathway software, were used to identify canonical signaling pathways that comprise the response to WT L. monocytogenes versus the other species. Gain- and loss-of-function experiments with L. innocua and L. monocytogenes, respectively, demonstrated that the 773-member transcriptional signature of the response to WT L. monocytogenes is largely conserved in the Delta inlA mutant. Internalin-dependent responses include down-regulation of gene networks involved in various aspects of lipid, amino acid, and energy metabolism and up-regulation of immunoinflammatory responses. The host response is markedly attenuated in a listeriolysin-deficient ( Delta hly) mutant despite its ability to be translocated to the lamina propria. Together, these studies establish that hly, rather than bacterial invasion of the lamina propria mediated by InlA, is a dominant determinant of the intensity of the host response to L. monocytogenes infection via the oral route.	Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA; Inst Pasteur, Bacteria Cell Interact Unit, INSERM U604, F-75015 Paris, France; INRA, USC2020, F-75015 Paris, France	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, 4444 Forest Pk Blvd,Campus 8510, St Louis, MO 63108 USA.	jgordon@wustl.edu	Lecuit, Marc/M-4126-2019; Lecuit, Marc/J-4073-2013	Lecuit, Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dramsi S, 1998, INFECT IMMUN, V66, P4461; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Glaser P, 2001, SCIENCE, V294, P849; Havell EA, 1999, IMMUNOBIOLOGY, V201, P164, DOI 10.1016/S0171-2985(99)80056-4; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Jacquet C, 2004, J INFECT DIS, V189, P2094, DOI 10.1086/420853; Kayal S, 1999, MOL MICROBIOL, V31, P1709, DOI 10.1046/j.1365-2958.1999.01305.x; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Lecuit M, 2004, P NATL ACAD SCI USA, V101, P6152, DOI 10.1073/pnas.0401434101; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Lecuit M, 1997, INFECT IMMUN, V65, P5309, DOI 10.1128/IAI.65.12.5309-5319.1997; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; Marco AJ, 1997, MICROB PATHOGENESIS, V23, P255, DOI 10.1006/mpat.1997.0144; Nishikawa S, 1998, MICROBIOL IMMUNOL, V42, P325, DOI 10.1111/j.1348-0421.1998.tb02290.x; Olier M, 2002, MICROBIOL-SGM, V148, P1855, DOI 10.1099/00221287-148-6-1855; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; Pentecost M, 2006, PLOS PATHOG, V2, P29, DOI 10.1371/journal.ppat.0020003; Pizarro-Cerda J, 2006, J PATHOL, V208, P215, DOI 10.1002/path.1888; Pron B, 1998, INFECT IMMUN, V66, P747, DOI 10.1128/IAI.66.2.747-755.1998; Sabet C, 2005, INFECT IMMUN, V73, P6912, DOI 10.1128/IAI.73.10.6912-6922.2005; Serbina NV, 2003, IMMUNITY, V19, P891, DOI 10.1016/S1074-7613(03)00330-3; Slaghuis J, 2004, J INFECT DIS, V189, P393, DOI 10.1086/381206; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Tang P, 1996, INFECT IMMUN, V64, P2359, DOI 10.1128/IAI.64.6.2359-2361.1996; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	36	60	63	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15065	15072		10.1074/jbc.M610926200	http://dx.doi.org/10.1074/jbc.M610926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389602	Green Published, hybrid			2022-12-25	WOS:000246589000046
J	Xu, R; Spencer, VA; Bissell, MJ				Xu, Ren; Spencer, Virginia A.; Bissell, Mina J.			Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BETA-CASEIN EXPRESSION; GLUCOCORTICOID-RECEPTOR; HISTONE ACETYLTRANSFERASE; STAT5; DIFFERENTIATION; ACTIVATION; INDUCTION; PROLACTIN; COMPLEXES	Extracellular cues play crucial roles in the transcriptional regulation of tissue-specific genes, but whether and how these signals lead to chromatin remodeling is not understood and subject to debate. Using chromatin immunoprecipitation assays and mammary-specific genes as models, we show here that extracellular matrix molecules and prolactin cooperate to induce histone acetylation and binding of transcription factors and the SWI/SNF complex to the beta- and gamma-casein promoters. Introduction of a dominant negative Brg1, an ATPase subunit of SWI/SNF complex, significantly reduced both beta- and gamma-casein expression, suggesting that SWI/SNF-dependent chromatin remodeling is required for transcription of mammary-specific genes. Chromatin immunoprecipitation analyses demonstrated that the ATPase activity of SWI/SNF is necessary for recruitment of RNA transcriptional machinery, but not for binding of transcription factors or for histone acetylation. Co-immunoprecipitation analyses showed that the SWI/SNF complex is associated with STAT5, CCAAT/enhancer-binding protein beta, and glucocorticoid receptor. Thus, extracellular matrix-and prolactin-regulated transcription of the mammary-specific casein genes requires the concerted action of chromatin remodeling enzymes and transcription factors.	Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Bissell, MJ (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd,MS 977R225A, Berkeley, CA 94720 USA.	MJBissell@lbl.gov		Xu, Ren/0000-0002-3591-9522	NCI NIH HHS [R01 CA057621-13, R01 CA057621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Carey M, 2005, MOL CELL, V17, P323, DOI 10.1016/j.molcel.2005.01.013; Chan HM, 2001, J CELL SCI, V114, P2363; Close MJ, 1997, J CELL SCI, V110, P2861; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; Farkas G, 2000, GENE, V253, P117, DOI 10.1016/S0378-1119(00)00240-7; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Hill DA, 2004, J CELL BIOCHEM, V91, P987, DOI 10.1002/jcb.20003; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Jolivet G, 2001, J CELL BIOCHEM, V82, P371, DOI 10.1002/jcb.1166; Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852; Kabotyanski EB, 2006, MOL ENDOCRINOL, V20, P2355, DOI 10.1210/me.2006-0160; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kolb AF, 2002, BBA-GENE STRUCT EXPR, V1579, P101, DOI 10.1016/S0167-4781(02)00533-X; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; LEE EYHP, 1985, P NATL ACAD SCI USA, V82, P1419, DOI 10.1073/pnas.82.5.1419; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pujuguet P, 2001, J CELL BIOCHEM, V83, P660, DOI 10.1002/jcb.1260; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Rijnkels M, 1997, MAMM GENOME, V8, P9, DOI 10.1007/s003359900338; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Rosen JM, 1999, ANNU REV NUTR, V19, P407, DOI 10.1146/annurev.nutr.19.1.407; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Sun JM, 2003, METHODS, V31, P12, DOI 10.1016/S1046-2023(03)00083-5; VanLint C, 1996, GENE EXPRESSION, V5, P245; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228	56	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14992	14999		10.1074/jbc.M610316200	http://dx.doi.org/10.1074/jbc.M610316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387179	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000246589000038
J	McNally, DJ; Aubry, AJ; Hui, JPM; Khieu, NH; Whitfield, D; Ewing, CP; Guerry, P; Brisson, JR; Logan, SM; Soo, EC				McNally, David J.; Aubry, Annie J.; Hui, Joseph P. M.; Khieu, Nam H.; Whitfield, Dennis; Ewing, Cheryl P.; Guerry, Patricia; Brisson, Jean-Robert; Logan, Susan M.; Soo, Evelyn C.			Targeted metabolomics analysis of Campylobacter coli VC167 reveals legionaminic acid derivatives as novel flagellar glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMOPHILA SEROGROUP-1 LIPOPOLYSACCHARIDE; O-CHAIN POLYSACCHARIDE; FUNCTIONAL-CHARACTERIZATION; LEGIONELLA-PNEUMOPHILA; NMR-SPECTROSCOPY; PSEUDAMINIC ACID; POSTTRANSLATIONAL MODIFICATION; HELICOBACTER-PYLORI; CHEMICAL STRUCTURES; ANTIBODY-RESPONSE	Glycosylation of Campylobacter flagellin is required for the biogenesis of a functional flagella filament. Recently, we used a targeted metabolomics approach using mass spectrometry and NMR to identify changes in the metabolic profile of wild type and mutants in the flagellar glycosylation locus, characterize novel metabolites, and assign function to genes to define the pseudaminic acid biosynthetic pathway in Campylobacter jejuni 81-176 (McNally, D. J., Hui, J. P., Aubry, A. J., Mui, K. K., Guerry, P., Brisson, J. R., Logan, S. M., and Soo, E. C. ( 2006) J. Biol. Chem. 281, 18489 - 18498). In this study, we use a similar approach to further define the glycome and metabolomic complement of nucleotide-activated sugars in Campylobacter coli VC167. Herein we demonstrate that, in addition to CMP-pseudaminic acid, C. coli VC167 also produces two structurally distinct nucleotide-activated nonulosonate sugars that were observed as negative ions at m/z 637 and m/z 651 (CMP-315 and CMP-329). Hydrophilic interaction liquid chromatography-mass spectrometry yielded suitable amounts of the pure sugar nucleotides for NMR spectroscopy using a cold probe. Structural analysis in conjunction with molecular modeling identified the sugar moieties as acetamidino and N-methylacetimidoyl derivatives of legionaminic acid (Leg5Am7Ac and Leg5AmNMe7Ac). Targeted metabolomic analyses of isogenic mutants established a role for the ptmA-F genes and defined two new ptm genes in this locus as legionaminic acid biosynthetic enzymes. This is the first report of legionaminic acid in Campylobacter sp. and the first report of legionaminic acid derivatives as modifications on a protein.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; USN, Med Res Ctr, Silver Spring, MD 20910 USA	National Research Council Canada; International Business Machines (IBM); National Research Council Canada; United States Department of Defense; United States Navy	Logan, SM (corresponding author), Natl Res Council Canada, Inst Biol Sci, Rm 3037,100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	susan.logan@nrc-cnrc.gc.ca; evelyn.soo@nrc-cnrc.gc.ca	Guerry, Patricia/A-8024-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043559] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43559] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM RA, 1992, J BACTERIOL, V174, P4230, DOI 10.1128/JB.174.13.4230-4238.1992; ASPINALL GO, 1995, EUR J BIOCHEM, V231, P570, DOI 10.1111/j.1432-1033.1995.0570d.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; Blaser M. J., 1997, J INFECT DIS S2, V176, P103; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; Brisson JR, 2002, CAN J CHEM, V80, P949, DOI 10.1139/V02-114; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Fouts DE, 2005, PLOS BIOL, V3, P72, DOI 10.1371/journal.pbio.0030015; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; GUERRY P, 1991, J BACTERIOL, V173, P4757, DOI 10.1128/jb.173.15.4757-4764.1991; Guerry P, 2006, MOL MICROBIOL, V60, P299, DOI 10.1111/j.1365-2958.2006.05100.x; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; HARRIS LA, 1987, J BACTERIOL, V169, P5066, DOI 10.1128/jb.169.11.5066-5071.1987; HERMANSSON K, 1993, EUR J BIOCHEM, V212, P801, DOI 10.1111/j.1432-1033.1993.tb17721.x; Kenne L, 1988, CARBOHYD RES, V180, P285, DOI 10.1016/0008-6215(88)80085-5; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Konkel ME, 2004, J BACTERIOL, V186, P3296, DOI 10.1128/JB.186.11.3296-3303.2004; Kooistra O, 2002, EUR J BIOCHEM, V269, P573, DOI 10.1046/j.0014-2956.2001.02684.x; Kooistra O, 2002, EUR J BIOCHEM, V269, P560, DOI 10.1046/j.0014-2956.2001.02683.x; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Luneberg E, 1998, J EXP MED, V188, P49, DOI 10.1084/jem.188.1.49; MARTIN PMV, 1989, INFECT IMMUN, V57, P2542, DOI 10.1128/IAI.57.8.2542-2546.1989; McNally DJ, 2006, J BIOL CHEM, V281, P18489, DOI 10.1074/jbc.M603777200; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; NACHAMKIN I, 1985, J CLIN MICROBIOL, V21, P33, DOI 10.1128/JCM.21.1.33-38.1985; Olivier NB, 2006, BIOCHEMISTRY-US, V45, P13659, DOI 10.1021/bi061456h; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; POWER ME, 1994, J BACTERIOL, V176, P3303, DOI 10.1128/jb.176.11.3303-3313.1994; Schirm M, 2005, ANAL CHEM, V77, P7774, DOI 10.1021/ac051316y; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, GLYCOBIOLOGY, V16, p8C, DOI 10.1093/glycob/cwl010; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Song YC, 2004, MOL MICROBIOL, V53, P541, DOI 10.1111/j.1365-2958.2004.04175.x; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; Tsvetkov YE, 2001, CARBOHYD RES, V335, P221, DOI 10.1016/S0008-6215(01)00235-X; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; VLIEGENTHART A, 1982, CELL BIOL MONOGR, P127; YAO RJ, 1993, GENE, V130, P127, DOI 10.1016/0378-1119(93)90355-7; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	47	96	100	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14463	14475		10.1074/jbc.M611027200	http://dx.doi.org/10.1074/jbc.M611027200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371878	hybrid			2022-12-25	WOS:000246245800060
J	Nie, LH; Sasaki, M; Maki, CG				Nie, Linghu; Sasaki, Mark; Maki, Carl G.			Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; MONOCLONAL-ANTIBODY; MUTANT P53; MDM2; PROTEIN; DEGRADATION; MUTATIONS; CELLS; EXCLUSION; LIGASE	Wild-type p53 is a conformationally labile protein that undergoes nuclear-cytoplasmic shuttling. MDM2-mediated ubiquitination promotes p53 nuclear export by exposing or activating a nuclear export signal (NES) in the C terminus of p53. We observed that cancer-derived p53s with a mutant ( primary antibody 1620-/pAb240+) conformation localized in the cytoplasm to a greater extent and displayed increased susceptibility to ubiquitination than p53s with a more wild-type ( primary antibody 1620+/pAb240-) conformation. The cytoplasmic localization of mutant p53s required the C-terminal NES and an intact ubiquitination pathway. Mutant p53 ubiquitination occurred at lysines in both the DNA-binding domain (DBD) and C terminus. Interestingly, Lys to Arg mutations that inhibited ubiquitination restored nuclear localization to mutant p53 but had no apparent effect on p53 conformation. Further studies revealed that wild-type p53, like mutant p53, is ubiquitinated by MDM2 in both the DBD and C terminus and that ubiquitination in both regions contributes to its nuclear export. MDM2 binding can induce a conformational change in wild-type p53, but this conformational change is insufficient to promote p53 nuclear export in the absence of MDM2 ubiquitination activity. Taken together, these results support a stepwise model for mutant and wild-type p53 nuclear export. In this model, the conformational change induced by either the cancer-derived mutation or MDM2 binding precedes p53 ubiquitination. The addition of ubiquitin to DBD and C-terminal lysines then promotes nuclear export via the C-terminal NES.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Rm G06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu	Bhattacharyya, Debnath/A-3144-2016; Bandyopadhyay, Samir Kumar/AAR-8919-2020	Bhattacharyya, Debnath/0000-0003-0140-9644; Bandyopadhyay, Samir Kumar/0000-0002-4868-3459	NCI NIH HHS [R01 CA080918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chan WM, 2006, MOL CANCER RES, V4, P15, DOI 10.1158/1541-7786.MCR-05-0097; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shimizu H, 2006, BIOCHEM J, V397, P355, DOI 10.1042/BJ20051521; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	39	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14616	14625		10.1074/jbc.M610515200	http://dx.doi.org/10.1074/jbc.M610515200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371868	hybrid			2022-12-25	WOS:000246245800075
J	Gong, Q; Weide, M; Huntsman, C; Xu, ZJ; Jan, LY; Ma, D				Gong, Qiang; Weide, Michael; Huntsman, Christopher; Xu, Zhuojin; Jan, Lily Y.; Ma, Dzwokai			Identification and characterization of a new class of trafficking motifs for controlling clathrin-independent internalization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; EXCHANGE FACTOR; K+ CHANNEL; CELLS; ARF6; PROTEINS; DISTINCT; EFA6; MACROPINOCYTOSIS	Plasma membrane proteins such as receptors and ion channels allow a cell to communicate with its environment and regulate many intracellular activities. Thus, the proper control of the surface number of these proteins is essential for maintaining the structural and functional homeostasis of a cell. Internalization and recycling plays a key role in determining the surface density of receptors and channels. Whereas the clathrin-mediated internalization and its associated recycling have been the focus of research in this field, recent studies have revealed that an increasing number of receptors and channels enter a cell via clathrin-independent pathways. However, little is known about the trafficking motifs involved in controlling clathrin-independent internalization and various associated recycling pathways. By using a potassium channel as a model system, we identified a class of trafficking motifs that function along a clathrin-independent pathway to increase the surface density of a membrane protein by preventing its rapid internalization and/or facilitating its recycling via the ADP-ribosylation factor 6-dependent recycling pathway. Moreover our data suggest that these motifs may enhance the association of membrane proteins with the EFA6 family of guanine nucleotide exchange factors for ADP-ribosylation factor	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ma, D (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	ma@lifesci.ucsb.edu	Gong, Qiang/D-5337-2009; Gong, Qiang/H-3234-2014	/0000-0002-6129-2938; Jan, Lily/0000-0003-3938-8498				Benmerah A, 1999, J CELL SCI, V112, P1303; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Cardelli J, 2001, TRAFFIC, V2, P311, DOI 10.1034/j.1600-0854.2001.002005311.x; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Decressac S, 2004, EMBO REP, V5, P1171, DOI 10.1038/sj.embor.7400292; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Derrien V, 2002, J CELL SCI, V115, P2867; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Dobrzynski H, 2001, J HISTOCHEM CYTOCHEM, V49, P1221, DOI 10.1177/002215540104901004; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Hu KL, 2003, NEURON, V38, P417, DOI 10.1016/S0896-6273(03)00256-3; Kass RS, 2005, J CLIN INVEST, V115, P1986, DOI 10.1172/JCI26011; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peters M, 2003, KIDNEY INT, V64, P923, DOI 10.1046/j.1523-1755.2003.00153.x; RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Richards DA, 2003, NEURON, V39, P529, DOI 10.1016/S0896-6273(03)00405-7; Rodman JS, 2000, J CELL SCI, V113, P183; Sakagami H, 2006, BRAIN RES, V1093, P1, DOI 10.1016/j.brainres.2006.02.058; SANDVIG K, 1991, CELL BIOL INT REP, V15, P3, DOI 10.1016/0309-1651(91)90077-V; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wilkinson RS, 2004, TRENDS NEUROSCI, V27, P171, DOI 10.1016/j.tins.2004.01.011; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	42	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13087	13097		10.1074/jbc.M700767200	http://dx.doi.org/10.1074/jbc.M700767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331948	hybrid			2022-12-25	WOS:000245942800077
J	McMillan, BJ; McMillan, SN; Glover, E; Bradfield, CA				McMillan, Brian J.; McMillan, Susanne N.; Glover, Ed; Bradfield, Christopher A.			2,3,7,8-Tetrachlorodibenzo-p-dioxin induces premature activation of the KLF2 regulon during thymocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; KRUPPEL-LIKE FACTOR-2; T-CELL QUIESCENCE; DEFICIENT MICE; AH-RECEPTOR; MOUSE; EXPRESSION; TRANSCRIPTION; TOXICITY; GENES	The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD, dioxin) causes numerous and diverse toxic events via activation of the aryl hydrocarbon receptor, including atrophy of the thymus. Exposure to TCDD induces acute thymocyte cell loss, which occurs concomitantly with proliferation arrest and premature emigration of triple negative ( TN; CD4(-), CD8(-), CD3(-)) T cell progenitors. In this report, we demonstrate that TCDD exposure results in dysregulation of KLF2 ( Kruppel-like factor 2) expression in developing thymocytes. The Klf2 gene encodes an Sp1-like zinc finger transcription factor that functions as a central regulator of T lymphocyte proliferation and trafficking. During normal thymocyte development, KLF2 is expressed exclusively in CD4 and CD8 single positive T cells and promotes a nonproliferative, promigratory phenotype. In mice exposed to TCDD, however, the Klf2 gene is prematurely expressed in TN thymocytes. Administration of a 100 mu g/kg dose of TCDD results in a similar to 15-fold induction of KLF2 as early as the TN2 ( CD44(+), CD25(+)) stage of development and immediately precedes acute cell loss in the TN3, TN4, and double positive ( CD4(+), CD8(+)) cell stages. Induction of KLF2 occurs within 12 h of TCDD exposure and is fully dependent on expression of the aryl hydrocarbon receptor. In addition, TCDD exposure alters the expression of several factors comprising the KLF2 regulon, including Edg1/S1P(1), beta(7)integrin, CD52, Cdkn2d( cyclin-dependent kinase inhibitor 2D), s100a4, and IL10R alpha. These findings indicate that the pollutant TCDD interferes with early thymopoeisis via ectopic expression of the KLF2 regulon.	Univ Wisconsin, McArdle Lab Canc Res, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Sch Med, 1400 Univ Ave, Madison, WI 53706 USA.	bradfield@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [T32CA009135, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005703, R01ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA009135, P30-CA014520] Funding Source: Medline; NIEHS NIH HHS [R01 ES005703, R37-ES05703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; BEATTY P, 1976, BIOCHEM BIOPH RES CO, V68, P197, DOI 10.1016/0006-291X(76)90029-2; Birnbaum LS, 2000, FOOD ADDIT CONTAM A, V17, P275, DOI 10.1080/026520300283351; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dekker RJ, 2005, AM J PATHOL, V167, P609, DOI 10.1016/S0002-9440(10)63002-7; DEKKER RJ, 2006, BLOOD; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Frericks M, 2006, BIOL CHEM, V387, P1219, DOI 10.1515/BC.2006.151; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Gouedard C, 2004, MOL CELL BIOL, V24, P5209, DOI 10.1128/MCB.24.12.5209-5222.2004; Haaland RE, 2005, MOL IMMUNOL, V42, P627, DOI 10.1016/j.molimm.2004.09.012; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Laiosa MD, 2003, J IMMUNOL, V171, P4582, DOI 10.4049/jimmunol.171.9.4582; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; POLAND A, 1980, MOL PHARMACOL, V17, P86; Puthier D, 2004, J IMMUNOL, V173, P6109, DOI 10.4049/jimmunol.173.10.6109; Schecter A, 2006, ENVIRON RES, V101, P419, DOI 10.1016/j.envres.2005.12.003; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staples JE, 1998, J IMMUNOL, V160, P3844; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Svensson C, 2002, BIOCHEM BIOPH RES CO, V291, P1194, DOI 10.1006/bbrc.2002.6582; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Temchura VV, 2005, EUR J IMMUNOL, V35, P2738, DOI 10.1002/eji.200425641; Tomita S, 2003, J IMMUNOL, V171, P4113, DOI 10.4049/jimmunol.171.8.4113; Vorderstrasse BA, 2001, TOXICOL APPL PHARM, V171, P157, DOI 10.1006/taap.2000.9122; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996	42	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12590	12597		10.1074/jbc.M611446200	http://dx.doi.org/10.1074/jbc.M611446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337447	hybrid			2022-12-25	WOS:000245942800028
J	Pauff, JM; Hemann, CF; Junemann, N; Leimkuhler, S; Hille, R				Pauff, James M.; Hemann, Craig F.; Juenemann, Nora; Leimkuehler, Silke; Hille, Russ			The role of arginine 310 in catalysis and substrate specificity in xanthine dehydrogenase from Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-MECHANISM; CRYSTAL-STRUCTURES; MOLYBDENUM; OXIDASE	The rapid reaction kinetics of wild-type xanthine dehydrogenase from Rhodobacter capsulatus and variants at Arg-310 in the active site have been characterized for a variety of purine substrates. With xanthine as substrate, k(red) (the limiting rate of enzyme reduction by substrate at high [S]) decreased similar to 20-fold in an R310K variant and 2 x 10(4)-fold in an R310M variant. Although Arg-310 lies on the opposite end of the substrate from the C-8 position that becomes hydroxylated, its interaction with substrate still contributed similar to 4.5 kcal/mol toward transition state stabilization. The other purines examined fell into two distinct groups: members of the first were effectively hydroxylated by the wild-type enzyme but were strongly affected by the exchange of Arg-310 to methionine (with a reduction in kred greater than 10(3)), whereas members of the second were much less effectively hydroxylated by wild-type enzyme but also much less significantly affected by the amino acid exchanges (with a reduction in kred less than 50-fold). The effect was such that the 4000-fold range in kred seen with wild-type enzyme was reduced to a mere 4-fold in the R310M variant. The data are consistent with a model in which "good" substrates are bound "correctly" in the active site in an orientation that allows Arg-310 to stabilize the transition state for the first step of the overall reaction via an electrostatic interaction at the C-6 position, thereby accelerating the reaction rate. On the other hand, "poor" substrates bound upside down relative to this "correct" orientation. In so doing, they are unable to avail themselves of the additional catalytic power provided by Arg-310 in wild-type enzyme but, for this reason, are significantly less affected by mutations at this position. The kinetic data thus provide a picture of the specific manner in which the physiological substrate xanthine is oriented in the active site relative to Arg-310 and how this residue is used catalytically to accelerate the reaction rate (rather than simply bind substrate) despite being remote from the position that is hydroxylated.	Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Potsdam; University System of Ohio; Ohio State University	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de; hille.1@osu.edu		Hemann, Craig/0000-0002-7380-4072; Leimkuhler, Silke/0000-0003-3238-2122	NIGMS NIH HHS [GM 075036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075036] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonin I, 2004, STRUCTURE, V12, P1425, DOI 10.1016/j.str.2004.05.014; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Hille R, 2005, ARCH BIOCHEM BIOPHYS, V433, P107, DOI 10.1016/j.abb.2004.08.012; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Hille R, 2002, TRENDS BIOCHEM SCI, V27, P360, DOI 10.1016/S0968-0004(02)02107-2; Hille R, 2006, EUR J INORG CHEM, P1913, DOI 10.1002/ejic.200600087; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; Stockert AL, 2002, J AM CHEM SOC, V124, P14554, DOI 10.1021/ja027388d; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Yamaguchi Y, 2007, J BIOCHEM, V141, P513, DOI 10.1093/jb/mvm053	16	33	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12785	12790		10.1074/jbc.M700364200	http://dx.doi.org/10.1074/jbc.M700364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327224	hybrid			2022-12-25	WOS:000245942800049
J	Pickersgill, L; Litherland, GJ; Greenberg, AS; Walker, M; Yeaman, SJ				Pickersgill, Laura; Litherland, Gary J.; Greenberg, Andrew S.; Walker, Mark; Yeaman, Stephen J.			Key role for ceramides in mediating insulin resistance in human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SATURATED FATTY-ACIDS; NECROSIS-FACTOR-ALPHA; HUMAN SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; GLUCOSE-UPTAKE; PERILIPIN-A; DIACYLGLYCEROL; ACCUMULATION	Elevated non-esterified fatty acids, triglyceride, diacylglycerol, and ceramide have all been associated with insulin resistance in muscle. We set out to investigate the role of intramyocellular lipid metabolites in the induction of insulin resistance in human primary myoblast cultures. Muscle cells were subjected to adenovirus-mediated expression of perilipin or incubated with fatty acids for 18 h, prior to insulin stimulation and measurement of lipid metabolites and rates of glycogen synthesis. Adenovirus-driven perilipin expression lead to significant accumulation of triacylglycerol in myoblasts, without any detectable effect on insulin sensitivity, as judged by the ability of insulin to stimulate glycogen synthesis. Similarly, incubation of cells with the monounsaturated fatty acid oleate resulted in triacylglycerol accumulation without inhibiting insulin action. By contrast, the saturated fatty acid palmitate induced insulin resistance. Palmitate treatment caused less accumulation of triacylglycerol than did oleate but also induced significant accumulation of both diacylglycerol and ceramide. Insulin resistance was also caused by cell-permeable analogues of ceramide, and palmitate-induced resistance was blocked in the presence of inhibitors of de novo ceramide synthesis. Oleate co-incubation completely prevented the insulin resistance induced by palmitate. Our data are consistent with ceramide being the agent responsible for insulin resistance caused by palmitate exposure. Furthermore, the triacylglycerol derived from oleate was able to exert a protective role in sequestering palmitate, thus preventing its conversion to ceramide.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Tufts Univ, Obes & Metab Lab, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Newcastle University - UK; Newcastle University - UK; Tufts University; United States Department of Agriculture (USDA)	Yeaman, SJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	S.J.Yeaman@ncl.ac.uk	Litherland, Gary J/K-9755-2015	Litherland, Gary/0000-0001-5264-0219	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647] Funding Source: NIH RePORTER; NIDDK NIH HHS [IH DK50647] Funding Source: Medline; Wellcome Trust [066495/Z/01/A] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; CHEN KS, 1991, T ASSOC AM PHYSICIAN, V104, P206; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Halse R, 2001, DIABETES, V50, P720, DOI 10.2337/diabetes.50.4.720; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; Phillips SA, 2005, OBES RES, V13, P1321, DOI 10.1038/oby.2005.160; Powell DJ, 2004, BIOCHEM J, V382, P619, DOI 10.1042/BJ20040139; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215; Summers SA, 2006, PROG LIPID RES, V45, P42, DOI 10.1016/j.plipres.2005.11.002; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thamer C, 2003, J CLIN ENDOCR METAB, V88, P1785, DOI 10.1210/jc.2002-021674; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	36	107	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12583	12589		10.1074/jbc.M611157200	http://dx.doi.org/10.1074/jbc.M611157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337731	hybrid			2022-12-25	WOS:000245942800027
J	Winter, AD; Eschenlauer, SCP; McCormack, G; Page, AP				Winter, Alan D.; Eschenlauer, Sylvain C. P.; McCormack, Gillian; Page, Antony P.			Loss of secretory pathway FK506-binding proteins results in cold-sensitive lethality and associate extracellular matrix defects in the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASES; BINDING-PROTEIN; FKBP FAMILY; GENE; CYCLOPHILINS; PROCOLLAGEN; COLLAGEN; CLONING; MEMBER; FK506	The FK506-binding proteins (FKBs) represent ubiquitous enzymes that catalyze the rate-limiting peptidyl prolyl cis-trans isomerization step in protein folding. The nematode Caenorhabditis elegans has eight FKBs, three of which (FKB-3, -4, and -5) have dual peptidyl prolyl cis-trans isomerase (PPIase) domains, signal peptides and ER retention signals. PPIase activity has been detected for recombinant FKB-3. Both FKB-3 and -5 are expressed in the exoskeleton-synthesizing hypodermis with transcript peaks that correspond to the molting and collagen synthesis cycles. FKB-4 is expressed at a low level throughout development. No phenotypes were observed in deletion mutants in each of the secretory pathway FKBs. Combined triple and fkb-4, -5 double deletion mutants were however found to arrest at 12 degrees C, but developed normally at 15-25 degrees C. This cold sensitive larval lethal effect was not maternally derived, occurred during embryogenesis, and could be rescued following the transgenic introduction of a wild type copy of either fkb-4 or fkb-5. The temperature-sensitive defects also affected molting, cuticle collagen expression, hypodermal seam cell morphology, and the structural integrity of the cuticular extracellular matrix. This study establishes that the secretory pathway FK506-binding PPIase enzymes are essential for normal nematode development, collagen biogenesis, and the formation of an intact exoskeleton under adverse physiological conditions.	Univ Glasgow, Fac Vet Med, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland; Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow	Page, AP (corresponding author), Univ Glasgow, Fac Vet Med, Inst Comparat Med, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	a.page@vet.gla.ac.uk			MRC [G117/476] Funding Source: UKRI; Medical Research Council [G117/476] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BARSTEAD RJ, 1999, C ELEGANS PRACTICAL, P97; Bell A, 2006, INT J PARASITOL, V36, P261, DOI 10.1016/j.ijpara.2005.11.003; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; BRENNER S, 1974, GENETICS, V77, P71; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Hao LM, 2006, DEV BIOL, V290, P323, DOI 10.1016/j.ydbio.2005.11.028; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KRAMER JM, 1997, C ELEGANS, V2, P471; McMahon L, 2003, MOL BIOL CELL, V14, P1366, DOI 10.1091/mbc.E02-08-0479; Mello C, 1995, METHOD CELL BIOL, V48, P451; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; Page AP, 2003, ADV PARASIT, V53, P85, DOI 10.1016/S0065-308X(03)53003-2; Patterson CE, 2000, MOL BIOL CELL, V11, P3925, DOI 10.1091/mbc.11.11.3925; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Suzuki Y, 2004, EUR J BIOCHEM, V271, P1372, DOI 10.1111/j.1432-1033.2004.04049.x; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210; Zeng BF, 1998, BIOCHEM J, V330, P109, DOI 10.1042/bj3300109	27	12	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12813	12821		10.1074/jbc.M700274200	http://dx.doi.org/10.1074/jbc.M700274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339317	hybrid, Green Accepted			2022-12-25	WOS:000245942800053
J	Glezer, I; Chernomoretz, A; David, S; Plante, MM; Rivest, S				Glezer, Isaias; Chernomoretz, Ariel; David, Samuel; Plante, Marie-Michele; Rivest, Serge			Genes Involved in the Balance between Neuronal Survival and Death during Inflammation	PLOS ONE			English	Article								Glucocorticoids are potent regulators of the innate immune response, and alteration in this inhibitory feedback has detrimental consequences for the neural tissue. This study profiled and investigated functionally candidate genes mediating this switch between cell survival and death during an acute inflammatory reaction subsequent to the absence of glucocorticoid signaling. Oligonucleotide microarray analysis revealed that following lipopolysaccharide (LPS) intracerebral administration at striatum level, more modulated genes presented transcription impairment than exacerbation upon glucocorticoid receptor blockage. Among impaired genes we identified ceruloplasmin (Cp), which plays a key role in iron metabolism and is implicated in a neurodegenative disease. Microglial and endothelial induction of Cp is a natural neuroprotective mechanism during inflammation, because Cp-deficient mice exhibited increased iron accumulation and demyelination when exposed to LPS and neurovascular reactivity to pneumococcal meningitis. This study has identified genes that can play a critical role in programming the innate immune response, helping to clarify the mechanisms leading to protection or damage during inflammatory conditions in the CNS.	[Glezer, Isaias; Chernomoretz, Ariel; Plante, Marie-Michele; Rivest, Serge] CHU Laval, Res Ctr, Mol Endocrinol Lab, Laurier, PQ, Canada; [Glezer, Isaias; Chernomoretz, Ariel; Plante, Marie-Michele; Rivest, Serge] Univ Laval, Dept Anat & Physiol, Laurier, PQ, Canada; [Chernomoretz, Ariel] Univ Buenos Aires, FCE&N, Dept Phys, Buenos Aires, DF, Argentina; [David, Samuel] McGill Univ, Montreal Gen Hosp, Ctr Res Neurosci, Res Inst,Hlth Ctr, Montreal, PQ H3G 1A4, Canada	Laval University; Laval University; University of Buenos Aires; McGill University	Rivest, S (corresponding author), CHU Laval, Res Ctr, Mol Endocrinol Lab, Laurier, PQ, Canada.	Serge.Rivest@crchul.ulaval.ca	Glezer, Isaias/D-2867-2013	Glezer, Isaias/0000-0002-9799-1933; Rivest, Serge/0000-0002-6082-770X	Canadian Institutes in Health Research (CIHR); Multiple Sclerosis Society of Canada	Canadian Institutes in Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Multiple Sclerosis Society of Canada	The Canadian Institutes in Health Research (CIHR) supported this research. I. G. is the recipient of a Postdoctoral Fellowship from the Multiple Sclerosis Society of Canada. A. C. is a member of the "Carrera del Investigador'' CONICET Argentina. S. R. holds a Canadian Research Chair in Neuroimmunology.	Aisen PS, 2002, LANCET NEUROL, V1, P279, DOI 10.1016/S1474-4422(02)00133-3; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Fischer M, 2005, NEW ENGL J MED, V353, P2352, DOI 10.1056/NEJMoa051620; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494; Glezer I, 2003, J NEUROSCI, V23, P11094; Glezer I, 2006, FASEB J, V20, P750, DOI 10.1096/fj.05-5234fje; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473-3099(02)00450-4; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kwon B, 2003, EXP MOL MED, V35, P8, DOI 10.1038/emm.2003.2; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; LeVine SM, 2004, ANN NY ACAD SCI, V1012, P252, DOI 10.1196/annals.1306.021; Luu-The V, 2005, BIOTECHNIQUES, V38, P287, DOI 10.2144/05382RR05; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Maier J, 2002, AM J PATHOL, V160, P271, DOI 10.1016/S0002-9440(10)64371-4; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; Norflus F, 1998, J CLIN INVEST, V101, P1881, DOI 10.1172/JCI2127; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Papassotiropoulos A, 2005, NEURODEGENER DIS, V2, P233, DOI 10.1159/000090362; Patel BN, 2002, J NEUROSCI, V22, P6578; Paxino G, 2001, MOUSE BRAIN STEREOTA; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Simmons CP, 2005, J IMMUNOL, V175, P579, DOI 10.4049/jimmunol.175.1.579; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Sorrells SF, 2007, BRAIN BEHAV IMMUN, V21, P259, DOI 10.1016/j.bbi.2006.11.006; Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Vizzardelli C, 2006, EUR J IMMUNOL, V36, P1504, DOI 10.1002/eji.200535488; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Zinser E, 2004, J EXP MED, V200, P345, DOI 10.1084/jem.20030973	49	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e310	10.1371/journal.pone.0000310	http://dx.doi.org/10.1371/journal.pone.0000310			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375196	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445100012
J	Song, HL; Ramus, SJ; Kjaer, SK; Hogdall, E; DiCioccio, RA; Whittemore, AS; McGuire, V; Hogdall, C; Jacobs, IJ; Easton, DF; Ponder, BAJ; Dunning, AM; Gayther, SA; Pharoah, PDP				Song, Honglin; Ramus, Susan J.; Kjaer, Susanne Kruger; Hogdall, Estrid; DiCioccio, Richard A.; Whittemore, Alice S.; McGuire, Valerie; Hogdall, Claus; Jacobs, Ian J.; Easton, Douglas F.; Ponder, Bruce A. J.; Dunning, Alison M.; Gayther, Simon A.; Pharoah, Paul D. P.			Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer	PLOS ONE			English	Article								Background. BRIP1 interacts with BRCA1 and functions in regulating DNA double strand break repair pathways. Germline BRIP1 mutations are associated with breast cancer and Fanconi anemia. Thus, common variants in the BRIP1 are candidates for breast and ovarian cancer susceptibility. Methods. We used a SNP tagging approach to evaluate the association between common variants (minor allele frequency >= 0.05) in BRIP1 and the risks of breast cancer and invasive ovarian cancer. 12 tagging SNPs (tSNPs) in the gene were identified and genotyped in up to 2,270 breast cancer cases and 2,280 controls from the UK and up to 1,513 invasive ovarian cancer cases and 2,515 controls from the UK, Denmark and USA. Genotype frequencies in cases and controls were compared using logistic regression. Results. Two tSNPs showed a marginal significant association with ovarian cancer: Carriers of the minor allele of rs2191249 were at reduced risk compared with the common homozygotes (Odds Ratio (OR) = 0.90 (95% CI, 0.82-1.0), P-trend = 0.045) and the minor allele of rs4988344 was associated with increased risk (OR = 1.15 (95% CI, 1.02-1.30), P-trend = 0.02). When the analyses were restricted to serous ovarian cancers, these effects became slightly stronger. These results were not significant at the 5% level after adjusting for multiple testing. None of the tSNPs was associated with breast cancer. Conclusions. It is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility. The possible association of rs2191249 and rs4988344 with ovarian cancer risks warrant confirmation in independent case-control studies.	[Song, Honglin; Ponder, Bruce A. J.; Dunning, Alison M.; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Dept Oncol, Canc Res UK, Cambridge, England; [Ramus, Susan J.; Jacobs, Ian J.; Gayther, Simon A.] UCL, Inst Womens Hlth, Translat Res Labs, London WC1E 6BT, England; [Kjaer, Susanne Kruger; Hogdall, Estrid] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; [DiCioccio, Richard A.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Whittemore, Alice S.; McGuire, Valerie] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Kjaer, Susanne Kruger; Hogdall, Claus] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, DK-2100 Copenhagen, Denmark; [Easton, Douglas F.] Univ Cambridge, Strangeways Res Lab, Genet Epidemiol Unit, Canc Res UK, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of London; University College London; Danish Cancer Society; Roswell Park Cancer Institute; Stanford University; Rigshospitalet; University of Copenhagen; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Song, HL (corresponding author), Univ Cambridge, Strangeways Res Lab, Dept Oncol, Canc Res UK, Cambridge, England.	honglin@srl.cam.ac.uk	Susan, Ramus/C-1607-2008; Pharoah, Paul/V-6658-2019; Jacobs, Ian J/F-1743-2013; Ramus, Susan/AAG-8352-2019	Pharoah, Paul/0000-0001-8494-732X; Jacobs, Ian J/0000-0002-8112-4624; Ramus, Susan/0000-0003-0005-7798; Hogdall, Claus/0000-0002-5959-8874; Kjaer, Susanne/0000-0002-8347-1398; Dunning, Alison Margaret/0000-0001-6651-7166; Jacobs, Ian/0000-0002-5005-2672; Hogdall, Estrid/0000-0003-4689-5658	Cancer Research UK; Roswell Park Alliance; Danish Cancer Society; National Cancer Institute [CA71766, CA16056, RO1 CA61107]; WellBeing; Eve Appeal; NATIONAL CANCER INSTITUTE [R01CA061107, P30CA016056] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); Roswell Park Alliance; Danish Cancer Society(Danish Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WellBeing; Eve Appeal; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grants from Cancer Research UK, the Roswell Park Alliance, the Danish Cancer Society and the National Cancer Institute (CA71766 and Core Grant CA16056 and RO1 CA61107). HS was funded by a grant from WellBeing; BAJP is a Gibb Fellow, DFE is a Principal Research Fellow and PDPP is a Senior Clinical Research Fellow of Cancer Research UK; SAG is a HEFCE Funded Senior lecturer; SJR is funded by the Mermaid component of the Eve Appeal.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173; Callahan R, 1998, BIOCHEM SOC SYMP, P211; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chen K C, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P619; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6; GARCIACLOSAS M, 2006, HUM GENET; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Lei HX, 2003, INT J CANCER, V104, P389, DOI 10.1002/ijc.10947; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Lewis AG, 2005, BREAST CANCER RES, V7, pR1005, DOI 10.1186/bcr1336; Luo LP, 2002, INT J CANCER, V98, P638, DOI 10.1002/ijc.10214; Lynch HT, 1998, SEMIN ONCOL, V25, P265; Pharoah PDP, 2002, BEST PRACT RES CL OB, V16, P449, DOI 10.1053/beog.2002.0296; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rutter JL, 2003, HUM MUTAT, V22, P121, DOI 10.1002/humu.10238; SEAL S, 2006, NAT GENET; Sigurdson AJ, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-9; Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330; Song HL, 2006, CARCINOGENESIS, V27, P2235, DOI 10.1093/carcin/bgl089; Vahteristo P, 2005, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-19; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986	26	51	52	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2007	2	3							e268	10.1371/journal.pone.0000268	http://dx.doi.org/10.1371/journal.pone.0000268			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DM	17342202	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444700003
J	Han, EKH; Leverson, JD; McGonigal, T; Shah, OJ; Woods, KW; Hunter, T; Giranda, VL				Han, E. K-H; Leverson, J. D.; McGonigal, T.; Shah, O. J.; Woods, K. W.; Hunter, T.; Giranda, V. L.			Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition	ONCOGENE			English	Article						A-443654; Akt; phosphorylation; rapamycin; mTOR	PROTEIN-KINASE; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PATHWAY; RAPAMYCIN; SURVIVAL; AKT/PKB; CANCER; PROGRESS	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis. We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines. This phenomenon is dose-dependent, manifests coincident with Akt inhibition and likely represents an alternative, rapid-feedback pathway that can be functionally dissociated from mTORC1 inhibition. Experiments performed in TSC2(-/-) cells indicate that TSC2 and IRS-1 cooperate with, but are dispensable for, A-443654-mediated Akt phosphorylation. This feedback event does require PI3K activity, however, as it can be inhibited by LY294002 or wortmannin. Small interfering RNA-mediated knockdown of mTOR or Rictor, components of the rapamycin-insensitive mTORC2 complex, but not the mTORC1 component Raptor, also inhibited Akt Ser-473 phosphorylation induced by A-443654. Our data thus indicate that Akt phosphorylation and activity are coupled in a manner not previously appreciated and provide a novel mode of Akt regulation that is distinct from the previously described rapamycin-induced IRS-1 stabilization mechanism.	Abbott Labs, Global Pharmaceut Res Div, Abbott Pk, IL 60064 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Abbott Laboratories; Salk Institute	Han, EKH (corresponding author), Abbott Labs, Global Pharmaceut Res Div, Dept R47S,Bldg AP9A, Abbott Pk, IL 60064 USA.	edward.k.han@abbott.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	27	130	137	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5655	5661		10.1038/sj.onc.1210343	http://dx.doi.org/10.1038/sj.onc.1210343			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334390				2022-12-25	WOS:000248801900011
J	Lalier, L; Cartron, PF; Pedelaborde, F; Olivier, C; Loussouarn, D; Martin, SA; Meflah, K; Menanteau, J; Vallette, FM				Lalier, L.; Cartron, P-F; Pedelaborde, F.; Olivier, C.; Loussouarn, D.; Martin, S. A.; Meflah, K.; Menanteau, J.; Vallette, F. M.			Increase in PGE(2) biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme	ONCOGENE			English	Article						gliomas; cyclooxygenase; prostaglandin synthase; apoptosis; Bax; PGE(2)	PROSTAGLANDIN-E SYNTHASE; CYCLOOXYGENASE-2 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; PARKINSONS-DISEASE; COLON-CANCER; DEATH; NEURODEGENERATION; NEUROTOXICITY; INHIBITION; CELLS	Prostaglandin E-2 plays multiple roles both in the physiology and the physiopathology of human brain, which are not completely understood. We have identi. ed in a subset of human glioblastoma multiforme (GBM) tumors, the most common form of adult brain cancer, an increased expression of mPGES-1, the enzyme which catalyses the isomerization of PGH(2) into PGE(2) downstream of cyclooxygenase 2 (COX-2). The sensitivity of primary cultures of GBM to apoptosis was augmented by the overexpression of mPGES-1, whereas the knockdown of its expression by shRNA decreased the apoptotic threshold in vitro and stimulated tumor growth in vivo. Adding extracellular PGE(2) in the culture medium failed to reproduce mPGES-1 effect on the cell viability in vitro. However, the intracellular injection of PGE2 induced a dose-dependent apoptosis in GBM cultures, which was dependent on the presence of Bax, a pro-apoptotic protein. We show that PGE(2) physically associates with Bax, triggering its apoptotic-like change in conformation and its subsequent association with mitochondria. Our results raise questions about the role of PGE(2) in the control of apoptosis and in its potential impact in central nervous system pathologies.	INSERM, U601, F-44035 Nantes 01, France; Univ Nantes, Fac Med, F-44035 Nantes, France; CHU Nantes, G&R Laennec Hosp, Dept Anatomopathol, F-44035 Nantes 01, France; CHU Nantes, G&R Laennec Hosp, Dept Neurosurg, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Vallette, FM (corresponding author), INSERM, U601, 9 Quai MONSOUSU, F-44035 Nantes 01, France.	francois.vallette@univ-nantes.fr	Lalier, Lisenn/K-9230-2015; Cartron, Pierre Francois/K-9802-2015; OLIVIER, Christophe/L-1598-2015; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Vallette, Francois M/0000-0002-3296-8572; Cartron, Pierre-Francois/0000-0002-3393-784X				BERRY CN, 1983, BIOCHEM PHARMACOL, V32, P2863, DOI 10.1016/0006-2952(83)90390-8; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Brown DM, 1996, J IMMUNOL, V157, P1359; Buccoliero AM, 2006, CLIN NEUROPATHOL, V25, P59; Cartron PF, 2004, FEBS LETT, V578, P41, DOI 10.1016/j.febslet.2004.10.080; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cha YI, 2006, DEV BIOL, V289, P263, DOI 10.1016/j.ydbio.2005.10.013; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Krunic N, 2000, DEV BRAIN RES, V121, P145, DOI 10.1016/S0165-3806(00)00033-X; Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Patsos HA, 2005, GUT, V54, P1741, DOI 10.1136/gut.2005.073403; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Shono T, 2001, CANCER RES, V61, P4375; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	43	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4999	5009		10.1038/sj.onc.1210303	http://dx.doi.org/10.1038/sj.onc.1210303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17369862				2022-12-25	WOS:000248322500012
J	Serriere-Lanneau, V; Teixeira-Clerc, F; Li, LY; Schippers, M; de Wries, W; Julien, B; Tran-Van-Nhieu, J; Manin, S; Poelstra, K; Chun, J; Carpentier, S; Levade, T; Mallat, A; Lotersztajn, S				Serriere-Lanneau, Valerie; Teixeira-Clerc, Fatima; Li, Liying; Schippers, Marlies; de Wries, Willie; Julien, Boris; Tran-Van-Nhieu, Jeanne; Manin, Sylvie; Poelstra, Klaas; Chun, Jerold; Carpentier, Stephane; Levade, Thierry; Mallat, Ariane; Lotersztajn, Sophie			The sphingosine 1-phosphate receptor S1P(2) triggers hepatic wound healing	FASEB JOURNAL			English	Article						liver; hepatic myofibroblasts	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHOLIPID RECEPTORS; MEDIATED PATHWAY; SPHINGOSINE-1-PHOSPHATE; MYOFIBROBLASTS; KINASE; LIVER; APOPTOSIS; CELLS; ACTIVATION	Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid produced by sphingosine kinase (SphK1 and 2). We previously showed that S1P receptors (S1P(1), S1P(2), and S1P(3)) are expressed in hepatic myofibroblasts (hMF), a population of cells that triggers matrix remodeling during liver injury. Here we investigated the function of these receptors in the wound healing response to acute liver injury elicited by carbon tetrachloride, a process that associates hepatocyte proliferation and matrix remodeling. Acute liver injury was associated with the induction of S1P2, S1P3, SphK(1), and SphK(2) mRNAs and increased SphK activity, with no change in S1P1 expression. Necrosis, inflammation, and hepatocyte regeneration were similar in S1P(2) (-/-) and wild-type (WT) mice. However, compared with WT mice, S1P(2) (-/-) mice displayed reduced accumulation of hMF, as shown by lower induction of smooth muscle alpha-actin mRNA and lower induction of TIMP-1, TGF-beta 1, and PDGF-BB mRNAs, overall reflecting reduced activation of remodeling in response to liver injury. The wound healing response was similar in S1P(3) (-/-) and WT mice. In vitro, S1P enhanced proliferation of cultured WT hMF, and PDGF-BB further enhanced the mitogenic effect of S1P. In keeping with these findings, PDGF-BB up-regulated S1P(2) and SphK1 mRNAs, increased SphK activity, and S1P(2) induced PDGF-BB mRNA. These effects were blunted in S1P2 (-/-) cells, and S1P(2) (-/-) hMF exhibited reduced mitogenic and comitogenic responses to S1P. These results unravel a novel major role of S1P(2) in the wound healing response to acute liver injury by a mechanism involving enhanced proliferation of hMF.	IMRB, INSERM, U841, Creteil, France; Univ Paris 12, Fac Med, Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France; Univ Groningen, Dept Pharmacokinet & Drug Delivery, Groningen, Netherlands; Scripps Res Inst, Dept Mol Biol, Helen L Dorris Child & Adolescent Neuropsychiat D, La Jolla, CA USA; INSERM, IFR31, U858, Toulouse, France; Univ Toulouse 3, IFR31, F-31062 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Groningen; Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U841, Inst Mondor Rech Biomed, F-94010 Creteil, France.	sophie.lotersztajn@creteil.inserm.fr	Lotersztajn, Sophie/K-9160-2017; Teixeira-Clerc, Fatima/AAB-5499-2021; VAN NHIEU, Jeanne TRAN/R-5235-2018; Chun, Jerold/Y-4670-2019; Julien, Boris/E-2374-2012; Teixeira-Clerc, Fatima/C-9884-2009; Levade, Thierry/O-8948-2014	Teixeira-Clerc, Fatima/0000-0003-1098-9222; lotersztajn, Sophie/0000-0002-0053-7807	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019674] Funding Source: NIH RePORTER; NIDA NIH HHS [DA019674] Funding Source: Medline; NINDS NIH HHS [NS048478] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ikeda H, 2004, BIOCHEM BIOPH RES CO, V320, P754, DOI 10.1016/j.bbrc.2004.04.207; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Li LY, 2003, GASTROENTEROLOGY, V125, P460, DOI 10.1016/S0016-5085(03)00906-5; Li LY, 2001, J BIOL CHEM, V276, P38152; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Osawa Y, 2005, HEPATOLOGY, V42, P1320, DOI 10.1002/hep.20967; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200	37	70	72	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2005	2013		10.1096/fj.06-6889com	http://dx.doi.org/10.1096/fj.06-6889com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17341687				2022-12-25	WOS:000247500300010
J	Ronkainen, VP; Ronkainen, JJ; Hannninen, SL; Leskinen, H; Ruas, JL; Pereira, T; Poellinger, L; Vuolteenaho, O; Tavi, P				Ronkainen, Veli-Pekka; Ronkainen, Jarkko J.; Hannninen, Sandra L.; Leskinen, Hanna; Ruas, Jorge L.; Pereira, Teresa; Poellinger, Lorenz; Vuolteenaho, Olli; Tavi, Pasi			Hypoxia inducible factor regulates the cardiac expression and secretion of apelin	FASEB JOURNAL			English	Article						hormones; infarction; ischemia; HIF	ADRENOMEDULLIN GENE-EXPRESSION; ORPHAN RECEPTOR APJ; PEPTIDE APELIN; IMMUNOCYTOCHEMICAL LOCALIZATION; MYOCARDIAL-INFARCTION; ENDOGENOUS LIGAND; BLOOD-PRESSURE; HIF-ALPHA; FACTOR-I; ACTIVATION	Apelin and its G-protein-coupled receptor APJ have various beneficial effects on cardiac function and blood pressure. The mechanisms that regulate apelin gene expression are not known. Because apelin gene expression has been shown to increase in cardiac ischemia, we investigated if apelin ( Apln) gene expression was sensitive to hypoxia. Here we show that hypoxia increases the apelin expression in rat myocardium and in cultured cardiomyocytes. Pharmacological activation of hypoxia inducible factor by desferrioxamine ( DFO) or expression of a constitutively active form of HIF-1 alpha increased apelin expression in cardiomyocyte cultures. The induction of apelin by hypoxia was abolished on transient expression of the HIF inhibitory PAS protein in cardiomyocytes. Increased apelin expression induced by hypoxia or DFO was accompanied by the processing of the cellular storage form proapelin into smaller apelin peptides and increased secretion of these biologically active forms of apelin. In a rat in vivo model, acute myocardial infarction ( 24 h) led to a transient increase in ventricular apelin mRNA levels. Our results indicate that apelin gene is regulated by hypoxia in cardiac myocytes via the HIF pathway, suggesting a role for apelin as a potential marker for acute cardiac hypoxia with a possible compensatory role in myocardial tissue suffering from oxygen deprivation.-Ronkainen, V.-P., Ronkainen, J. J., Hanninen, S. L., Leskinen, H., Ruas, J. L., Pereira, T., Poellinger, L., Vuolteenaho, O., Tavi, P. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin.	Oulu Univ, Dept Physiol, SF-90014 Oulu, Finland; Oulu Univ, Dept Pharmacol & Toxicol, SF-90014 Oulu, Finland; Bioctr Oulu, SF-90014 Oulu, Finland; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	University of Oulu; University of Oulu; University of Oulu; Karolinska Institutet	Tavi, P (corresponding author), Oulu Univ, Dept Physiol, POB 5000, SF-90014 Oulu, Finland.	pasi.tavi@oulu.fi	Ruas, Jorge/AAE-6094-2019; Pereira, Teresa/AAP-8197-2020	Ruas, Jorge/0000-0002-1110-2606; Pereira, Teresa/0000-0001-8654-2385				Ala-Kopsala M, 2004, CLIN CHEM, V50, P1576, DOI 10.1373/clinchem.2004.032490; Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c; Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427; Boucher J, 2004, REGUL PEPTIDES, V122, P51; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen MM, 2003, CIRCULATION, V108, P1432, DOI 10.1161/01.CIR.0000091235.94914.75; Chun YS, 2003, BIOCHEM J, V370, P149, DOI 10.1042/BJ20021087; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045; Kleinz MJ, 2005, REGUL PEPTIDES, V126, P233, DOI 10.1016/j.regpep.2004.10.019; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Nagaya N, 2000, AM J PHYSIOL-REG I, V278, pR1019, DOI 10.1152/ajpregu.2000.278.4.R1019; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Tavi P, 1998, CIRC RES, V83, P1165, DOI 10.1161/01.RES.83.11.1165; VUOLTEENAHO O, 1985, BIOCHEM BIOPH RES CO, V129, P82, DOI 10.1016/0006-291X(85)91406-8; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004	43	129	134	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1821	1830		10.1096/fj.06-7294com	http://dx.doi.org/10.1096/fj.06-7294com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17341685				2022-12-25	WOS:000246866500024
J	Capul, AA; Barron, T; Dobson, DE; Turco, SJ; Beverley, SM				Capul, Althea A.; Barron, Tamara; Dobson, Deborah E.; Turco, Salvatore J.; Beverley, Stephen M.			Two functionally divergent UDP-Gal nucleotide sugar transporters participate in phosphoglycan synthesis in Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; SIALIC ACID TRANSPORTER; SAND FLY INTERACTIONS; PROTOZOAN PARASITE LEISHMANIA; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; DONOVANI LIPOPHOSPHOGLYCAN; SACCHAROMYCES-CEREVISIAE; GALACTOSE TRANSPORTER; TRYPANOSOMA-BRUCEI	In the protozoan parasite Leishmania, abundant surface and secreted molecules, such as lipophosphoglycan (LPG) and proteophosphoglycans (PPGs), contain extensive galactose in the form of phosphoglycans (PGs) based on (Gal-Man-PO4) repeating units. PGs are synthesized in the parasite Golgi apparatus and require transport of cytoplasmic nucleotide sugar precursors to the Golgi lumen by nucleotide sugar transporters (NSTs). GDP-Man transport is mediated by the LPG2 gene product, and here we focused on transporters for UDP-Gal. Data base mining revealed 12 candidate NST genes in the L. major genome, including LPG2 as well as a candidate endoplasmic reticulum UDP-glucose transporter (HUT1L) and several pseudogenes. Gene knock-out studies established that two genes (LPG5A and LPG5B) encoded UDP-Gal NSTs. Although the single lpg5A(-) and lpg5B(-) mutants produced PGs, an lpg5A(-)/5B(-) double mutant was completely deficient. PG synthesis was restored in the lpg5A(-)/5B(-) mutant by heterologous expression of the human UDP-Gal transporter, and heterologous expression of LPG5A and LPG5B rescued the glycosylation defects of the mammalian Lec8 mutant, which is deficient in UDP-Gal uptake. Interestingly, the LPG5A and LPG5B functions overlap but are not equivalent, since the lpg5A(-) mutant showed a partial defect in LPG but not PPG phosphoglycosylation, whereas the lpg5B(-) mutant showed a partial defect in PPG but not LPG phosphoglycosylation. Identification of these key NSTs in Leishmania will facilitate the dissection of glycoconjugate synthesis and its role(s) in the parasite life cycle and further our understanding of NSTs generally.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Washington University (WUSTL); University of Kentucky	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	beverley@borcim.wustl.edu		Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI031078, R01 AI031078-15, AI31078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Barron TL, 2006, BBA-GEN SUBJECTS, V1760, P710, DOI 10.1016/j.bbagen.2005.10.007; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; BEVERLEY SM, 1987, P NATL ACAD SCI USA, V84, P484, DOI 10.1073/pnas.84.2.484; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; DEIBARRA AAL, 1982, PARASITOLOGY, V85, P523, DOI 10.1017/S0031182000056304; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; Dobson DE, 2003, J BIOL CHEM, V278, P28840, DOI 10.1074/jbc.M302728200; Dobson DE, 2003, J BIOL CHEM, V278, P15523, DOI 10.1074/jbc.M301568200; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Handford M, 2006, BRAZ J MED BIOL RES, V39, P1149, DOI 10.1590/S0100-879X2006000900002; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ishida N, 1999, J BIOCHEM, V126, P68, DOI 10.1093/oxfordjournals.jbchem.a022437; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; Kabuss R, 2005, GLYCOBIOLOGY, V15, P905, DOI 10.1093/glycob/cwi085; Kainuma M, 2001, YEAST, V18, P533, DOI 10.1002/yea.708; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kawakita M, 1998, J BIOCHEM, V123, P777; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Mahoney AB, 1999, BIOCHEMISTRY-US, V38, P9813, DOI 10.1021/bi990741g; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Montgomery J, 2002, MOL BIOCHEM PARASIT, V121, P75, DOI 10.1016/S0166-6851(02)00024-5; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; Parodi AJ, 1998, BRAZ J MED BIOL RES, V31, P601, DOI 10.1590/S0100-879X1998000500002; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Piani A, 1999, MICROBES INFECT, V1, P589, DOI 10.1016/S1286-4579(99)80058-6; Puthenveedu MA, 2005, CURR OPIN CELL BIOL, V17, P369, DOI 10.1016/j.ceb.2005.06.006; Reyes F, 2006, J BIOL CHEM, V281, P9145, DOI 10.1074/jbc.M512210200; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shakarian AM, 2000, EXP PARASITOL, V95, P79, DOI 10.1006/expr.2000.4511; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, SCIENCE, V301, P1241, DOI 10.1126/science.1087499; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; WANG WC, 1988, J BIOL CHEM, V263, P4576; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; Zhao W, 2006, J BIOL CHEM, V281, P31106, DOI 10.1074/jbc.M605564200	72	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14006	14017		10.1074/jbc.M610869200	http://dx.doi.org/10.1074/jbc.M610869200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347153	Green Accepted, hybrid			2022-12-25	WOS:000246245800010
J	Gloyd, M; Ghirlando, R; Matthews, LA; Guarne, A				Gloyd, Melanie; Ghirlando, Rodolfo; Matthews, Lindsay A.; Guarne, Alba			MukE and MukF form two distinct high affinity complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA INTERACTIONS; SMC PROTEINS; BACTERIAL; KLEISINS; HINGE; ULTRACENTRIFUGATION; ARCHITECTURE; CHROMOSOMES; ACTIVATION	The MukBFE complex is essential for chromosome segregation and condensation in Escherichia coli. MukB is functionally related to the structural maintenance of chromosomes (SMC) proteins. Similar to SMCs, MukB requires accessory proteins (MukE and MukF) to form a functional complex for DNA segregation. MukF is a member of the kleisin family, which includes proteins that commonly mediate the interaction between SMCs and other accessory proteins, suggesting that the similarities between the MukBFE and the SMC complexes extend beyond MukB. Although SMCs have been carefully studied, little is known about the roles of their accessory components. In the present work, we characterize the oligomeric states of MukE and MukF using size exclusion chromatography and analytical ultracentrifugation. MukE self-associates to form dimers (K-D 18 +/- 3 mu M), which in turn interact with the MukF dimer to form two distinct high affinity complexes having 2: 2 and 2: 4 stoichiometries (F: E). Intermediate complexes are not found, and thus we propose that the equilibrium between these two complexes determines the formation of a functional MukBFE with stoichiometry 2:2:2.	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Guarne, A (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, HSC 4N57A,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	guarnea@mcmaster.ca	Ghirlando, Rodolfo/A-8880-2009		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK033007, ZIADK033007] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2003, J BACTERIOL, V185, P3690, DOI 10.1128/JB.185.13.3690-3695.2003; Dervyn E, 2004, MOL MICROBIOL, V51, P1629, DOI 10.1111/j.1365-2958.2003.03951.x; Fennell-Fezzie R, 2005, EMBO J, V24, P1921, DOI 10.1038/sj.emboj.7600680; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano M, 2006, MOL CELL, V21, P175, DOI 10.1016/j.molcel.2005.11.026; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Kim JS, 2006, PROTEINS, V62, P322, DOI 10.1002/prot.20751; Lehmann AR, 2005, DNA REPAIR, V4, P309, DOI 10.1016/j.dnarep.2004.07.009; Matoba K, 2005, BIOCHEM BIOPH RES CO, V333, P694, DOI 10.1016/j.bbrc.2005.05.163; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Petrushenko ZM, 2006, J BIOL CHEM, V281, P34208, DOI 10.1074/jbc.M606723200; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Tao WT, 2000, MOL MICROBIOL, V38, P392, DOI 10.1046/j.1365-2958.2000.02138.x; Volkov A, 2003, MOL CELL BIOL, V23, P5638, DOI 10.1128/MCB.23.16.5638-5650.2003; Wang Q, 2006, J BACTERIOL, V188, P4431, DOI 10.1128/JB.00313-06; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873	26	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14373	14378		10.1074/jbc.M701402200	http://dx.doi.org/10.1074/jbc.M701402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355972	hybrid			2022-12-25	WOS:000246245800049
J	Martens, LK; Kirschner, KM; Warnecke, C; Scholz, H				Martens, Lina K.; Kirschner, Karin M.; Warnecke, Christina; Scholz, Holger			Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; TYROSINE PROTEIN-KINASE; WILMS-TUMOR SUPPRESSOR; AFFINITY NGF RECEPTOR; NERVE GROWTH-FACTOR; FACTOR (HIF)-1-ALPHA; ERYTHROPOIETIN GENE; MESSENGER-RNA; UP-REGULATION; EXPRESSION	Neurotrophins and their cognate receptors play a pivotal role in the development and function of the nervous system. High expression levels of the neurotrophin receptor TrkB and its ligands in neuroblastomas are associated with an unfavorable outcome. We report here that NTRK2, which encodes the TrkB receptor tyrosine kinase, is an oxygen-regulated gene, whose expression is stimulated by the hypoxia-inducible factor-1 (HIF-1). TrkB mRNA and protein levels were elevated nearly 30-fold in neuroblastoma-derived Kelly cells in hypoxia (1% O-2) versus normoxia (21% O-2). A luciferase reporter construct containing approximate to 2.1 kilobases of the human TrkB promoter was activated about 6-fold both in hypoxia and after stimulation with the hypoxia mimetic 2,2'-dipyridyl (100 mu M) at 21% O-2. Luciferase activity in the presence of 2,2'-dipyridyl was reduced significantly upon small interfering RNA knockdown of HIF-1 alpha but not of HIF-2 alpha. Accordingly, hypoxia failed to stimulate the TrkB promoter in mouse embryonic fibroblasts that lacked HIF-1 alpha. The hypoxia-responsive promoter region could be mapped to three HIF-1 binding elements that were located between -923 and -879 bp relative to the transcription start site. The migration of cultured neuroblastoma cells was increased similar to 2-fold upon incubation at 1 versus 21% O-2. This effect of hypoxia was abrogated with the tyrosine kinase inhibitor K252a (200 mu M). Our findings indicate that transcription of the NTRK2 gene is stimulated at low oxygen tension through a HIF-1-dependent mechanism. In conclusion, enhanced expression of TrkB could represent a critical switch for the previously reported dedifferentiation of neuroblastoma cells under hypoxic conditions.	Charite Univ Med Berlin, Inst Vegetav Physiol, D-10117 Berlin, Germany; Univ Erlangen Nurnberg, Div Nephrol & Hypertens, D-91054 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Erlangen Nuremberg	Scholz, H (corresponding author), Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Sciesielski, Lina/G-3716-2017	Sciesielski, Lina/0000-0003-3458-0309; Kirschner, Karin/0000-0003-0226-8636				Aoyama M, 2001, CANCER LETT, V164, P51, DOI 10.1016/S0304-3835(00)00715-1; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; Behar TN, 1997, EUR J NEUROSCI, V9, P2561, DOI 10.1111/j.1460-9568.1997.tb01685.x; Bernhardt WM, 2006, KIDNEY INT, V69, P114, DOI 10.1038/sj.ki.5000062; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Dame C, 2006, BLOOD, V107, P4282, DOI 10.1182/blood-2005-07-2889; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Eide FF, 1996, J NEUROSCI, V16, P3123; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Frede S, 2005, CANCER RES, V65, P4690, DOI 10.1158/0008-5472.CAN-04-3877; Hedborg F, 2003, FASEB J, V17, P598, DOI 10.1096/fj.02-0390com; HEDBORG F, 1995, EUR J CANCER, V31A, P435, DOI 10.1016/0959-8049(95)00025-E; Ho R, 2002, CANCER RES, V62, P6462; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jaboin J, 2002, CANCER RES, V62, P6756; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655; Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOGNER P, 1993, CANCER RES, V53, P2044; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li ZJ, 2005, CANCER RES, V65, P2070, DOI 10.1158/0008-5472.CAN-04-3606; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Narumiya S, 1998, BRAIN RES, V797, P278, DOI 10.1016/S0006-8993(98)00385-0; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Polleux F, 2002, DEVELOPMENT, V129, P3147; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rosenberger C, 2005, KIDNEY INT, V67, P531, DOI 10.1111/j.1523-1755.2005.67110.x; Ryan HE, 2000, CANCER RES, V60, P4010; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Sowter HM, 2003, CANCER RES, V63, P6130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12	63	69	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14379	14388		10.1074/jbc.M609857200	http://dx.doi.org/10.1074/jbc.M609857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374610	hybrid			2022-12-25	WOS:000246245800050
J	White, TA; Krishnan, N; Becker, DF; Tanner, JJ				White, Tommi A.; Krishnan, Navasona; Becker, Donald F.; Tanner, John J.			Structure and kinetics of monofunctional proline dehydrogenase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN REDOX STATE; PUTA PROTEIN; P53-INDUCED GENE-6; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA-BINDING; OXIDASE; APOPTOSIS; MEMBRANE; DOMAIN	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate. They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria. Here we report the first structure and biochemical data for a monofunctional PRODH. The 2.0-angstrom resolution structure of Thermus thermophilus PRODH reveals a distorted (beta alpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the carboxyl-terminal ends of the strands of the barrel. Although the catalytic core is similar to that of the PutA PRODH domain, the FAD conformation of T. thermophilus PRODH is remarkably different and likely reflects unique requirements for membrane association and communication with P5CDH. Also, the FAD of T. thermophilus PRODH is highly solvent-exposed compared with PutA due to a 4-angstrom shift of helix 8. Structure-based sequence analysis of the PutA/PRODH family led us to identify nine conserved motifs involved in cofactor and substrate recognition. Biochemical studies show that the midpoint potential of the FAD is -75 mV and the kinetic parameters for proline are K-m =27 mM and k(cat) = 13 s(-1). 3,4-Dehydro-L-proline was found to be an efficient substrate, and L-tetrahydro-2-furoic acid is a competitive inhibitor (K-I = 1.0 mM). Finally, we demonstrate that T. thermophilus PRODH reacts with O-2 producing superoxide. This is significant because superoxide production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	Univ Missouri, Dept Chem, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Nebraska, Redox Biol Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Lincoln	Tanner, JJ (corresponding author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.	tannerjj@missouri.edu		White, Tommi/0000-0001-7283-3755; Tanner, John/0000-0001-8314-113X	NIGMS NIH HHS [R01 GM061068, GM061068, GM065546, R01 GM061068-07, R01 GM065546, R01 GM065546-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061068, R01GM065546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker DF, 2001, BIOCHEMISTRY-US, V40, P4714, DOI 10.1021/bi0019491; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bottoms CA, 2002, PROTEIN SCI, V11, P2125, DOI 10.1110/ps.0213502; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BROWN ED, 1993, J BIOL CHEM, V268, P8972; CHEN CC, 1986, J BIOL CHEM, V261, P2599; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Donald SP, 2001, CANCER RES, V61, P1810; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gu D, 2004, J BIOL CHEM, V279, P31171, DOI 10.1074/jbc.M403701200; Hu CAA, 2007, MOL CELL BIOCHEM, V295, P85, DOI 10.1007/s11010-006-9276-6; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Inagaki E, 2006, J MOL BIOL, V362, P490, DOI 10.1016/j.jmb.2006.07.048; Krishnan N, 2006, J BACTERIOL, V188, P1227, DOI 10.1128/JB.188.4.1227-1235.2006; Krishnan N, 2005, BIOCHEMISTRY-US, V44, P9130, DOI 10.1021/bi050629k; Larson JD, 2006, PROTEIN SCI, V15, P2630, DOI 10.1110/ps.062425706; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YH, 2003, NAT STRUCT BIOL, V10, P109, DOI 10.1038/nsb885; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; MUROPASTOR AM, 1995, J BIOL CHEM, V270, P9819, DOI 10.1074/jbc.270.17.9819; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phang J. M., 2001, METABOLIC MOL BASES, P1821; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Surber MW, 1998, ARCH BIOCHEM BIOPHYS, V354, P281, DOI 10.1006/abbi.1998.0697; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuge H, 2005, J BIOL CHEM, V280, P31045, DOI 10.1074/jbc.C500234200; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vinod MP, 2002, BIOCHEMISTRY-US, V41, P6525, DOI 10.1021/bi025706f; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; White TA, 2005, ACTA CRYSTALLOGR F, V61, P737, DOI 10.1107/S1744309105019779; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; Zhang M, 2004, BIOCHEMISTRY-US, V43, P12539, DOI 10.1021/bi048737e; Zhang WM, 2007, BIOCHEMISTRY-US, V46, P483, DOI 10.1021/bi061935g; Zhang WM, 2004, BIOCHEMISTRY-US, V43, P13165, DOI 10.1021/bi048596g; Zhu WD, 2003, BIOCHEMISTRY-US, V42, P5469, DOI 10.1021/bi0272196; Zhu WD, 2002, ARCH BIOCHEM BIOPHYS, V408, P131, DOI 10.1016/S0003-9861(02)00535-0	58	83	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14316	14327		10.1074/jbc.M700912200	http://dx.doi.org/10.1074/jbc.M700912200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17344208	Green Accepted, hybrid			2022-12-25	WOS:000246245800043
J	Becker, HM; Deitmer, JW				Becker, Holger M.; Deitmer, Joachim W.			Carbonic anhydrase II increases the activity of the human electrogenic Na+/HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORT; INTRACELLULAR PH REGULATION; RENAL PROXIMAL TUBULE; NA+-HCO3-COTRANSPORTER; HYDROPHOBIC POCKET; O-18 EXCHANGE; GLIAL-CELLS; TRANSPORT; OOCYTES; CLONING	Several acid/ base-coupled membrane transporters, such as the electrogenic sodium-bicarbonate cotransporter (NBCe1), have been shown to bind to different carbonic anhydrase isoforms to create a "transport metabolon." We have expressed NBCe1 derived from human kidney in oocytes of Xenopus leavis and determined its transport activity by recording the membrane current in voltage clamp, and the cytosolic H+ and Na+ concentrations using ion-selective microelectrodes. When carbonic anhydrase isoform II (CAII) had been injected into oocytes, the membrane current and the rate of cytosolic Na+ rise, indicative for NBCe1 activity, increased significantly with the amount of injected CAII (2-200 ng). The CAII inhibitor ethoxyzolamide reversed the effects of CAII on the NBCe1 activity. Co-expressing wild-type CAII or NH2-terminal mutant CAII together with NBCe1 provided similar results, whereas co-expressing the catalytically inactive CAII mutant V143Y had no effect on NBCe1 activity. Mass spectrometric analysis and the rate of cytosolic H+ change following addition of CO2/HCO3- confirmed the catalytic activity of injected and expressed CAII in oocytes. Our results show that the transport capacity of NBCe1 is enhanced by the catalytic activity of CAII, in line with the notion that CAII forms a transport metabolon with NBCe1.	Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	University of Kaiserslautern	Becker, HM (corresponding author), Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, POB 3049, D-67653 Kaiserslautern, Germany.	h.becker@biologie.uni-kl.de	Becker, Holger/AAB-4322-2020					ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; BADGER MR, 1989, PLANT PHYSIOL, V89, P51, DOI 10.1104/pp.89.1.51; Becker HM, 2004, J BIOL CHEM, V279, P28057, DOI 10.1074/jbc.M402401200; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Becker HM, 2005, J BIOL CHEM, V280, P39882, DOI 10.1074/jbc.M503081200; Bevensee MO, 1997, J GEN PHYSIOL, V110, P467, DOI 10.1085/jgp.110.4.467; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BRUNE T, 1994, PFLUG ARCH EUR J PHY, V429, P64, DOI 10.1007/BF02584031; BURG M, 1977, AM J PHYSIOL, V233, pF307, DOI 10.1152/ajprenal.1977.233.4.F307; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; DEITMER JW, 1989, J PHYSIOL-LONDON, V411, P179, DOI 10.1113/jphysiol.1989.sp017567; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Heyer M, 1999, PFLUG ARCH EUR J PHY, V438, P322, DOI 10.1007/s004240050916; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Loiselle FB, 2004, AM J PHYSIOL-CELL PH, V286, pC1423, DOI 10.1152/ajpcell.00382.2003; Lu J, 2006, J BIOL CHEM, V281, P19241, DOI 10.1074/jbc.M602181200; McMurtrie HL, 2004, J ENZYM INHIB MED CH, V19, P231, DOI 10.1080/14756360410001704443; NAKOUL NL, 1998, AM J PHYSIOL, V274, pC543; Piermarini PM, 2007, J BIOL CHEM, V282, P1409, DOI 10.1074/jbc.M608261200; Pushkin A, 2004, J PHYSIOL-LONDON, V559, P55, DOI 10.1113/jphysiol.2004.065110; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SASAKI S, 1989, AM J PHYSIOL, V257, pF947, DOI 10.1152/ajprenal.1989.257.6.F947; Schmitt BM, 1999, AM J PHYSIOL-RENAL, V276, pF27, DOI 10.1152/ajprenal.1999.276.1.F27; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; SEKI G, 1992, PFLUG ARCH EUR J PHY, V422, P60, DOI 10.1007/BF00381514; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; Sterling D, 2001, JOP, V2, P165; SULTEMEYER DF, 1990, PLANT PHYSIOL, V94, P1250, DOI 10.1104/pp.94.3.1250; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430	35	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13508	13521		10.1074/jbc.M700066200	http://dx.doi.org/10.1074/jbc.M700066200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353189	hybrid			2022-12-25	WOS:000246060300040
J	DeMorrow, S; Glaser, S; Francis, H; Venter, J; Vaculin, B; Vaculin, S; Alpini, G				DeMorrow, Sharon; Glaser, Shannon; Francis, Heather; Venter, Julie; Vaculin, Bradley; Vaculin, Shelley; Alpini, Gianfranco			Opposing actions of endocannabinoids on cholangiocarcinoma growth - Recruitment of Fas and Fas ligand to lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA(9)-TETRAHYDROCANNABINOL INDUCES APOPTOSIS; RECEPTOR-INDEPENDENT MECHANISM; CANNABINOID CB2 RECEPTOR; SIGNAL-REGULATED KINASE; HUMAN NEUROGLIOMA CELLS; BREAST-CANCER CELLS; MEMBRANE DOMAINS; PROTEIN-KINASE; DEATH RECEPTOR; TUMOR-GROWTH	Cholangiocarcinomas are devastating cancers of biliary origin with limited treatment options. Modulation of the endocannabinoid system is being targeted to develop possible therapeutic strategies for a number of cancers; therefore, we evaluated the effects of the two major endocannabinoids, anandamide and 2-arachidonylglycerol, on numerous cholangiocarcinoma cell lines. Although anandamide was antiproliferative and proapoptotic, 2-arachidonylglycerol stimulated cholangiocarcinoma cell growth. Specific inhibitors for each of the cannabinoid receptors did not prevent either of these effects nor did pretreatment with pertussis toxin, a G(i/o) protein inhibitor, suggesting that anandamide and 2-arachidonylglycerol did not exert their diametric effects through any known cannabinoid receptor or through any other G(i/o) protein-coupled receptor. Using the lipid raft disruptors methyl-beta- cyclodextrin and filipin, we demonstrated that anandamide, but not 2-arachidonylglycerol, requires lipid raft-mediated events to inhibit cellular proliferation. Closer inspection of the lipid raft structures within the cell membrane revealed that although anandamide treatment had no observable effect 2-arachidonylglycerol treatment effectively dissipated the lipid raft structures and caused the lipid raft-associated proteins lyn and flotillin-1 to disperse into the surrounding membrane. In addition, anandamide, but not 2-arachidonylglycerol, induced an accumulation of ceramide, which was required for anandamide-induced suppression of cell growth. Finally we demonstrated that anandamide and ceramide treatment of cholangiocarcinoma cells recruited Fas and Fas ligand into the lipid rafts, subsequently activating death receptor pathways. These findings suggest that modulation of the endocannabinoid system may be a target for the development of possible therapeutic strategies for the treatment of this devastating cancer.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med, Coll Med, Temple, TX 76504 USA; Cent Texas Vet Hlth Care Syst, Temple, TX USA; Scott & White Hosp, Dept Med, Temple, TX USA; Scott & White Hosp, Dept Syst Biol & Translat Med, Temple, TX USA; Scott & White Hosp, Div Res & Educ, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Alpini, G (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med, Coll Med, Med Res Bldg,702 SWHK Dodgen Loop, Temple, TX 76504 USA.	galpini@tamu.edu			NIDDK NIH HHS [DK062975, K01 DK078532] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK078532, R01DK062975] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Alpini G, 2001, LIVER BIOL PATHOBIOL, V4E, P421; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; ARANCIA G, 1991, PHARMACOL RES, V24, P205, DOI 10.1016/1043-6618(91)90083-A; Arenz C, 2000, ANGEW CHEM INT EDIT, V39, P1440, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1440::AID-ANIE1440>3.0.CO;2-R; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bifulco M, 2004, FASEB J, V18, P1606, DOI 10.1096/fj.04-1754fje; Bisogno T, 2005, PHARMACOL BIOCHEM BE, V81, P224, DOI 10.1016/j.pbb.2005.01.027; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001; BURNS CP, 1988, CANCER INVEST, V6, P439, DOI 10.3109/07357908809080073; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, NEUROBIOL DIS, V5, P386, DOI 10.1006/nbdi.1998.0214; Doherty EM, 2005, J MED CHEM, V48, P71, DOI 10.1021/jm049485i; Fava G, 2005, CANCER RES, V65, P11437, DOI 10.1158/0008-5472.CAN-05-1470; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GAONI Y, 1971, J AM CHEM SOC, V93, P217, DOI 10.1021/ja00730a036; Gardner B, 2003, FASEB J, V17, P2157, DOI 10.1096/fj.03-0254fje; Giuliano M, 2006, INT J MOL MED, V17, P811; Griffin G, 1999, EUR J PHARMACOL, V377, P117, DOI 10.1016/S0014-2999(99)00402-1; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hinz B, 2004, BIOCHEM BIOPH RES CO, V324, P621, DOI 10.1016/j.bbrc.2004.09.095; Ishii I, 2002, NEUROREPORT, V13, P593, DOI 10.1097/00001756-200204160-00011; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; Kanno N, 2001, J HEPATOL, V34, P284, DOI 10.1016/S0168-8278(00)00025-8; Kern A, 2006, J BIOL CHEM, V281, P2405, DOI 10.1074/jbc.M505625200; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kusaka Y, 1988, Hum Cell, V1, P92; LeSage G, 1999, GASTROENTEROLOGY, V117, P191, DOI 10.1016/S0016-5085(99)70567-6; Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Mimeault M, 2003, PROSTATE, V56, P1, DOI 10.1002/pros.10190; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Pickens A, 1999, J GASTROINTEST SURG, V3, P374, DOI 10.1016/S1091-255X(99)80053-5; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarnataro D, 2005, FEBS LETT, V579, P6343, DOI 10.1016/j.febslet.2005.10.016; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sirica AE, 2005, HEPATOLOGY, V41, P5, DOI 10.1002/hep.20537; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P99; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; Tanaka S, 2000, HEPATOLOGY, V32, P523, DOI 10.1053/jhep.2000.9716; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRITTON TR, 1990, CANCER CELL-MON REV, V2, P95; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	84	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13098	13113		10.1074/jbc.M608238200	http://dx.doi.org/10.1074/jbc.M608238200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329257	hybrid			2022-12-25	WOS:000245942800078
J	Purohit, V; Roques, BP; Kim, B; Bambara, RA				Purohit, Vandana; Roques, Bernard P.; Kim, Baek; Bambara, Robert A.			Mechanisms that prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NUCLEOCAPSID PROTEIN; ACID-CHAPERONE ACTIVITY; STRONG STOP TRANSFER; DNA STRAND TRANSFER; IN-VITRO; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE	The RNase H activity of human immunodeficiency virus, type 1 ( HIV-1) reverse transcriptase ( RT) cleaves the viral genome concomitant with minus strand synthesis. We previously analyzed RT-mediated pausing and RNase H cleavage on a hairpin-containing RNA template system and reported that RT generated 3' end-directed primary and secondary cuts while paused at the base of the hairpin during synthesis. Here, we report that all of the prominent cleavage products observed during primer extension on this template correlated with pause induced cuts. Products that persisted throughout the reaction corresponded to secondary cuts, about eight nucleotides in from the DNA primer terminus. This distance allows little overlap of intact template with the primer terminus. We considered whether secondary cuts could inactivate further synthesis by promoting dissociation of the primer from the template. As anticipated, 3' end-directed secondary cuts decreased primer extendibility. This provides a plausible mechanism to explain the persistence of secondary cut products in our hairpin template system. Improving the efficiency of synthesis by increasing the concentration of dNTPs or addition of nucleocapsid protein ( NC) reduced pausing and the generation of pause related secondary cuts on this template. Further studies reveal that 3' end-directed primary and secondary cleavages were also generated when synthesis was stalled by the presence of 3'-azido-3'-deoxythymidine at the primer terminus, possibly contributing to 3'-azido-3'-deoxythymidine inhibition. Considered together, the data reveal a role for NC and other factors that enhance DNA synthesis in the prevention of RNase H cleavages that could be detrimental to viral replication.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Paris 05, Unite Pharmacochim Mol & Struct, INSERM U266,UFR Sci Pharmaceut & Biol, CNRS,UMR 8600, F-75270 Paris 06, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bambara, RA (corresponding author), 601 Elmwood Ave, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007232] Funding Source: NIH RePORTER; NIDA NIH HHS [T32-DA07232] Funding Source: Medline; NIGMS NIH HHS [GM49573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Archer RH, 2001, BIOCHEMISTRY-US, V40, P4087, DOI 10.1021/bi002328a; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Drummond JE, 1997, AIDS RES HUM RETROV, V13, P533, DOI 10.1089/aid.1997.13.533; Emini E. A., 1997, P637; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Hanson MN, 2005, J MOL BIOL, V353, P772, DOI 10.1016/j.jmb.2005.08.065; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KATI WM, 1992, J BIOL CHEM, V267, P25988; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LANDAULT C, 2006, J VIROL, V80, P2483; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Nikolenko GN, 2005, P NATL ACAD SCI USA, V102, P2093, DOI 10.1073/pnas.0409823102; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Purohit V, 2005, J BIOL CHEM, V280, P40534, DOI 10.1074/jbc.M507839200; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Smith CM, 1999, J VIROL, V73, P6573, DOI 10.1128/JVI.73.8.6573-6581.1999; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Telesnitsky A., 1997, P121; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1994, J BIOL CHEM, V269, P31491; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002	63	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12598	12609		10.1074/jbc.M700043200	http://dx.doi.org/10.1074/jbc.M700043200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337733	hybrid			2022-12-25	WOS:000245942800029
J	Zhang, LG; Nephew, KP; Gallagher, PJ				Zhang, Liguo; Nephew, Kenneth P.; Gallagher, Patricia J.			Regulation of death-associated protein kinase - Stabilization by HSP90 heterocomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE CHIP; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; ANDROGEN RECEPTOR; DAP-KINASE; E3 LIGASE; PHOSPHORYLATION; TARGET; HYPERMETHYLATION; IDENTIFICATION	Death-associated protein kinase ( DAPK) has been found associated with HSP90, and inhibition of HSP90 with 17-alkylamino-17-demethoxygeldanamycin reduced expression of DAPK. These results were extended to determine whether the degradation of DAPK in the absence of HSP90 activity is dependent on the ubiquitin-proteasome pathway. Our results show that treatment of cells with geldanamycin ( GA) leads to degradation of DAPK, and this degradation is attenuated by the proteasome inhibitor, lactacystin. GA-induced DAPK degradation is also dependent on phosphorylation of DAPK at Ser(308), and the cellular levels of phospho( Ser(308))-DAPK dramatically increase in response to GA treatment. Expression of two distinct ubiquitin E3 ligases, carboxyl terminus of HSC70-interacting protein ( CHIP) or DIP1/Mib1, enhanced DAPK degradation, and conversely, short interfering RNA depletion of either CHIP or DIP1/Mib1 attenuated DAPK degradation. In vitro ubiquitination assays confirmed that DAPK is targeted for ubiquitination by both CHIP and DIP. Consistent with these results, DAPK is found in two distinct immune complexes, one containing HSP90 and CHIP and a second complex containing only DIP1/Mib. Collectively, these results indicate that strict modulation of DAPK activities is critical for regulation of apoptosis and cellular homeostasis.	Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Bloomington, IN 47405 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu	Zhang, Liguo/E-2804-2014		NATIONAL CANCER INSTITUTE [R01CA085289] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062810] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085289, CA085289] Funding Source: Medline; NHLBI NIH HHS [HL54118, R01 HL054118, R01 HL054118-08] Funding Source: Medline; NIDDK NIH HHS [R01 DK062810-03, DK062810, R01 DK062810] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Chan AWH, 2005, ONCOL REP, V13, P937; Chen GM, 2006, OPHTHAL EPIDEMIOL, V13, P199, DOI 10.1080/09286580500477440; Chim CS, 2006, J HUM GENET, V51, P832, DOI 10.1007/s10038-006-0029-x; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Collins Y, 2006, INT J GYNECOL CANCER, V16, P195, DOI 10.1111/j.1525-1438.2006.00506.x; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Doucet Christine, 2005, BMC Biochem, V6, P27, DOI 10.1186/1471-2091-6-27; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Georgakis Georgios V, 2005, Future Oncol, V1, P273; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2006, J BIOL CHEM, V281, P39033, DOI 10.1074/jbc.M605097200; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Morishima Y, 2005, BIOCHEMISTRY-US, V44, P16333, DOI 10.1021/bi0515570; Peng HM, 2004, J BIOL CHEM, V279, P52970, DOI 10.1074/jbc.M406926200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Rees I, 2006, BBA-PROTEINS PROTEOM, V1764, P1073, DOI 10.1016/j.bbapap.2006.03.013; Schneider-Stock R, 2005, INT J BIOCHEM CELL B, V37, P1763, DOI 10.1016/j.biocel.2005.02.019; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; VOSO MT, 2006, HAEMATOLOGICA, V91, P1108; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	35	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11795	11804		10.1074/jbc.M610430200	http://dx.doi.org/10.1074/jbc.M610430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324930	Green Accepted, hybrid			2022-12-25	WOS:000245941900022
J	Lamanda, A; Cheaib, Z; Turgut, MD; Lussi, A				Lamanda, Andreas; Cheaib, Zeinab; Turgut, Melek Dilek; Lussi, Adrian			Protein Buffering in Model Systems and in Whole Human Saliva	PLOS ONE			English	Article								The aim of this study was to quantify the buffer attributes (value, power, range and optimum) of two model systems for whole human resting saliva, the purified proteins from whole human resting saliva and single proteins. Two model systems, the first containing amyloglucosidase and lysozyme, and the second containing amyloglucosidase and alpha-amylase, were shown to provide, in combination with hydrogencarbonate and di-hydrogenphosphate, almost identical buffer attributes as whole human resting saliva. It was further demonstrated that changes in the protein concentration as small as 0.1% may change the buffer value of a buffer solution up to 15 times. Additionally, it was shown that there was a protein concentration change in the same range (0.16%) between saliva samples collected at the time periods of 13: 00 and others collected at 9: 00 am and 17:00. The mode of the protein expression changed between these samples corresponded to the change in basic buffer power and the change of the buffer value at pH 6.7. Finally, SDS Page and Ruthenium II tris (bathophenantroline disulfonate) staining unveiled a constant protein expression in all samples except for one 50 kDa protein band. As the change in the expression pattern of that 50 kDa protein band corresponded to the change in basic buffer power and the buffer value at pH 6.7, it was reasonable to conclude that this 50 kDa protein band may contain the protein(s) belonging to the protein buffer system of human saliva.	[Lamanda, Andreas; Cheaib, Zeinab; Lussi, Adrian] Univ Bern, Dept Prevent Restorat & Pediat Dent, Bern, Switzerland; [Turgut, Melek Dilek] Hacettepe Univ, Fac Dent, Dept Pediat Dent, Ankara, Turkey	University of Bern; Hacettepe University	Lamanda, A (corresponding author), Univ Bern, Dept Prevent Restorat & Pediat Dent, Bern, Switzerland.	lamanda3@hotmail.com			University of Bern, Switzerland	University of Bern, Switzerland	This study was supported by the University of Bern, Switzerland. None of the authors have any financial arrangements with any commercial organisation that could benefit from this study.	ALFONSKY D, 1961, SALIVA ITS RELATION; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amerongen AV, 2004, CARIES RES, V38, P247, DOI 10.1159/000077762; Bardow A, 2000, ARCH ORAL BIOL, V45, P1, DOI 10.1016/S0003-9969(99)00119-3; BARGEN JA, 1937, J AM DENT ASSOC, V24, P1271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAWES C, 1981, J PHYSIOL-LONDON, V320, P139, DOI 10.1113/jphysiol.1981.sp013940; Daws C, 2001, CARIES RES, V35, P344, DOI 10.1159/000047473; Dugmore C R, 2003, Int J Paediatr Dent, V13, P295, DOI 10.1046/j.1365-263X.2003.00487.x; ECCLES JD, 1979, J PROSTHET DENT, V42, P649, DOI 10.1016/0022-3913(79)90196-3; Freidin L I, 1985, Stomatologiia (Mosk), V64, P16; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Ghafouri B, 2003, PROTEOMICS, V3, P1003, DOI 10.1002/pmic.200300426; Good N E, 1972, Methods Enzymol, V24, P53; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Hasselbalch KA, 1917, BIOCHEM Z, V78, P112; Hirtz C, 2005, PROTEOMICS, V5, P4597, DOI 10.1002/pmic.200401316; Hu S, 2005, PROTEOMICS, V5, P1714, DOI 10.1002/pmic.200401037; Huang CM, 2004, ARCH ORAL BIOL, V49, P951, DOI 10.1016/j.archoralbio.2004.06.003; HUANG XQ, 1990, COMPUT APPL BIOSCI, V6, P373; IZUTSU KT, 1981, J THEOR BIOL, V90, P397, DOI 10.1016/0022-5193(81)90320-9; Jensdottir T, 2004, Clin Oral Investig, V8, P91; Kojima T, 2000, J DENT RES, V79, P740, DOI 10.1177/00220345000790020701; Kreusser W, 1972, Verh Dtsch Ges Inn Med, V78, P1518; KURAMITSU S, 1980, J BIOCHEM-TOKYO, V87, P1215; Lamanda A, 2004, PROTEOMICS, V4, P599, DOI 10.1002/pmic.200300587; Larsen MJ, 1999, ARCH ORAL BIOL, V44, P111, DOI 10.1016/S0003-9969(98)00108-3; Lenander-Lumikari M, 2000, Adv Dent Res, V14, P40; LILIENTHAL B., 1955, JOUR DENTAL RES, V34, P516, DOI 10.1177/00220345550340040701; Lussi A, 2006, MG ORAL SCI, V20, P1, DOI 10.1159/000093343; Lussi A., 2004, Caries Research, V38, P34, DOI 10.1159/000074360; MEURMAN JH, 1994, ORAL SURG ORAL MED O, V78, P583, DOI 10.1016/0030-4220(94)90168-6; Nagler RM, 2005, ARCH ORAL BIOL, V50, P7, DOI 10.1016/j.archoralbio.2004.07.012; Nunn J H, 2003, Int J Paediatr Dent, V13, P98, DOI 10.1046/j.1365-263X.2003.00433.x; Pedersen AML, 2005, BMC CLIN PATHOL, V5, DOI 10.1186/1472-6890-5-4; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; SELLMAN S, 1949, Acta Odontol Scand, V8, P244, DOI 10.3109/00016354909014465; SIGAARDANDERSON O, 1963, ACID BASE STATUS BLO; STOELTING KR, 1999, PHARM PHYSL ANESTHET; Van Slyke DD, 1922, J BIOL CHEM, V52, P525; Vitorino R, 2004, PROTEOMICS, V4, P1109, DOI 10.1002/pmic.200300638; Wilmarth PA, 2004, J PROTEOME RES, V3, P1017, DOI 10.1021/pr049911o; Xie HW, 2005, MOL CELL PROTEOMICS, V4, P1826, DOI 10.1074/mcp.D500008-MCP200; Yao Y, 2003, J BIOL CHEM, V278, P5300, DOI 10.1074/jbc.M206333200; Zero DT, 2000, TOOTH WEAR SENSITIVI, P121; ZIPKIN I, 1949, J DENT RES, V28, P613, DOI 10.1177/00220345490280061301	46	26	29	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e263	10.1371/journal.pone.0000263	http://dx.doi.org/10.1371/journal.pone.0000263			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17327922	Green Published, gold			2022-12-25	WOS:000207444600023
J	Liu, H; Zhou, Y; Boggs, SE; Belinsky, SA; Liu, J				Liu, H.; Zhou, Y.; Boggs, S. E.; Belinsky, S. A.; Liu, J.			Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B	ONCOGENE			English	Article						synuclein-gamma; DNA methylation; DNMT3B; cigarette smoke extract; lung cancer; cell invasion	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; DNA METHYLTRANSFERASES; NOVO METHYLATION; PROTEIN-KINASE; GENE; EXPRESSION; HYPERMETHYLATION; HYPOMETHYLATION; IDENTIFICATION	The prometastatic oncogene synuclein-gamma ( SNCG) is not expressed in normal lung tissues, but it is highly expressed in lung tumors. Here, we show that cigarette smoke extract ( CSE) has strong inducing effects on SNCG gene expression in A549 lung cancer cells through demethylation of SNCG CpG island. CSE treatment also augments the invasive capacity of A549 cells in an SNCG-dependent manner. To elucidate the mechanisms underlying the demethylating effects of CSE, we examined expression levels of DNA methyltransferases ( DNMTs), 1, 3A and 3B in CSE-treated cells. We show that the mRNA expression of DNMT3B is specifically downregulated by CSE with a kinetics concurrent to SNCG reexpression. Utilizing siRNA to knockdown DNMT3B expression, we show that inhibition of DNMT3B directly increases SNCG mRNA expression. We further show that exogenous overexpression of DNMT3B in an SNCG-positive lung cancer cell line H292 suppresses SNCG mRNA and protein expression and induces de novo methylation of SNCG CpG island, whereas overexpression of DNMT1 or DNMT3A has no effects. Taken together, these new. findings demonstrate that tobacco exposure induces the abnormal expression of SNCG in lung cancer cells through downregulation of DNMT3B. This work sheds light on the molecular understanding of demethylation of this oncogene during cancer progression.	Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA 94304 USA; Lovelace Respriatory Res Inst, Albuquerque, NM USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Lovelace Respiratory Research Institute	Liu, J (corresponding author), Palo Alto Hlth Care Syst, Dept Vet Affairs, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELINSKY SA, 2004, NAT REV CANCER, V4, P11; Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAO D, 2005, MODERN PATHOL, V1, P1; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Fujiwara K, 2005, CLIN CANCER RES, V11, P1219; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Ji HJ, 1997, CANCER RES, V57, P759; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Mercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200; Oka M, 2006, J BIOL CHEM, V281, P9901, DOI 10.1074/jbc.M511100200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Palmisano WA, 2000, CANCER RES, V60, P5954; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; PFEIFER GP, 1986, FEBS LETT, V207, P75, DOI 10.1016/0014-5793(86)80015-1; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; THOMPSON E, 1940, DRUG NEWS PERSPECT, V18, P405; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Zhao W, 2006, INT J ONCOL, V28, P1081; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	44	74	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5900	5910		10.1038/sj.onc.1210400	http://dx.doi.org/10.1038/sj.onc.1210400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369845				2022-12-25	WOS:000249123100007
J	Spankuch, B; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Spaenkuch, B.; Kurunci-Csacsko, E.; Kaufmann, M.; Strebhardt, K.			Rational combinations of siRNAs targeting Plk1 with breast cancer drugs	ONCOGENE			English	Article						plk1-. siRNA; paclitaxel; drug sensitivity; Herceptin	POLO-LIKE KINASE; DOWN-REGULATION; IN-VIVO; TRASTUZUMAB RESISTANCE; INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; TUMOR-CELLS; GENE; GROWTH	Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a powerful tool to induce 'mitotic catastrophe' in cancer cells, together with these drugs to identify conditions for enhanced drug sensitivity. After transfection, the antineoplastic agents were added and cell proliferation, apoptosis and cell cycle distribution in breast cancer cells (MCF-7, SK-BR-3, MDA-MIB-435 and BT-474) and in primary human mammary epithelial cells were determined. Downregulation of cellular Plk1 levels led to an elevated percentage of cells in G(2)/M phase. The percentage of apoptotic nuclei in MCF-7, MDA-MB-435, SK-BR-3 and BT-474 cells was clearly increased after incubation with Plk1-specific siRNAs and paclitaxel. Interestingly, the caspase pathway was activated after treatment with Plk1-specific siRNAs and paclitaxel or Herceptin. Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner. In all experiments, very low concentrations across a wide range of clinically relevant concentrations were sufficient to induce an anti proliferative effect. The combination of Plk1-specific siRNAs with modern breast cancer drugs seems to represent rational combinations to be tested in preclinical trials.	Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Spankuch, B (corresponding author), Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	birgit.spaenkuch@t-online.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Check E, 2005, NAT MED, V11, P243, DOI 10.1038/nm0305-243; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Dai DH, 2005, CANCER RES, V65, P9517, DOI 10.1158/0008-5472.CAN-05-1613; Dubska L, 2005, FEBS LETT, V579, P4149, DOI 10.1016/j.febslet.2005.06.047; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Marches R, 2004, INT J CANCER, V112, P492, DOI 10.1002/ijc.20378; Mimura K, 2005, CLIN CANCER RES, V11, P4898, DOI 10.1158/1078-0432.CCR-04-2476; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nishii K, 1996, ONCOGENE, V13, P2225; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Spankuch B, 2005, CURR PHARM DESIGN, V11, P3405, DOI 10.2174/138161205774370834; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Templeton NS, 2002, BIOSCIENCE REP, V22, P283; Therasse P, 2002, EUR J CANCER, V38, P1817, DOI 10.1016/S0959-8049(02)00182-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	49	81	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5793	5807		10.1038/sj.onc.1210355	http://dx.doi.org/10.1038/sj.onc.1210355			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369857				2022-12-25	WOS:000248885100011
J	Bassermann, F; von Klitzing, C; Illert, AL; Munch, S; Morris, SW; Pagano, M; Peschel, C; Duyster, J				Bassermann, Florian; von Klitzing, Christine; Illert, Anna Lena; Muench, Silvia; Morris, Stephan W.; Pagano, Michele; Peschel, Christian; Duyster, Justus			Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G(2)/M involves cyclin B1/Cdk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SCF UBIQUITIN-LIGASE; XENOPUS EGG EXTRACTS; F-BOX PROTEINS; MITOTIC REGULATION; SOMATIC WEE1; BETA-TRCP; KINASE; INHIBITOR; MITOSIS	Nuclear interaction partner of ALK (NIPA) is an F-box-containing protein that defines a nuclear skp1 cullin F-box (SCF)type ubiquitin E3 ligase (SCFNIPA) implicated in the regulation of mitotic entry. The SCFNIPA complex targets nuclear cyclin B1 for ubiquitination in interphase, whereas phosphorylation of NIPA in late G(2) phase and mitosis inactivates the complex to allow for accumulation of cyclin B1. Here, we identify the region of NIPA that mediates binding to its substrate cyclin B1. In addition to the recently described serine residue 354, we specify 2 new residues, Ser-359 and Ser-395, implicated in the phosphorylation process at G(2)/M within this region. Moreover, we found cyclin B1/Cdk1 to phosphorylate NIPA at Ser-395 in mitosis. Mutation of both Ser-359 and Ser-395 impaired effective inactivation of the SCFNIPA complex, resulting in reduced levels of mitotic cyclin B1. These data are compatible with a process of sequential NIPA phosphorylation where cyclin B1/Cdk1 amplifies phosphorylation of NIPA once an initial phosphorylation event has dissociated the SCFNIPA complex. Thus, cyclin B1/Cdk1 may contribute to the regulation of its own abundance in early mitosis.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Technical University of Munich; University of Munich; St Jude Children's Research Hospital; St Jude Children's Research Hospital; New York University; New York University	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Ismaningerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Illert, Anna L/G-8127-2019	pagano, michele/0000-0003-3210-2442	NCI NIH HHS [R21-CA125173, R37-CA76584, CA 69129] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA125173, R01CA069129, R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bassermann F, 2005, CELL CYCLE, V4, P1515, DOI 10.4161/cc.4.11.2192; Bassermann F, 2005, CELL, V122, P45, DOI 10.1016/j.cell.2005.04.034; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; Desai A, 1999, METHOD CELL BIOL, V61, P385; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Ouyang T, 2003, J BIOL CHEM, V278, P30028, DOI 10.1074/jbc.M300883200; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	36	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15965	15972		10.1074/jbc.M610819200	http://dx.doi.org/10.1074/jbc.M610819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389604	hybrid			2022-12-25	WOS:000246794300005
J	Papp, S; Fadel, MP; Kim, H; McCulloch, CA; Opas, M				Papp, Sylvia; Fadel, Marc P.; Kim, Hugh; McCulloch, Christopher A.; Opas, Michal			Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; TYROSINE KINASES; ENDOPLASMIC-RETICULUM; FOCAL ADHESIONS; CYTOPLASMIC DOMAIN; MATRIX ADHESIONS; SARCOPLASMIC-RETICULUM; EXPRESSION; VINCULIN; GENE	Calreticulin is an endoplasmic reticulum Ca2+-storage protein, which influences gene expression and cell adhesion. In this study, we show that calreticulin induces fibronectin gene expression and matrix deposition, leading to differences in cell spreading and focal adhesion formation in cells differentially expressing calreticulin. We further show that these effects of calreticulin occur via a c-Src-regulated pathway and that c-Src activity is inversely related to calreticulin abundance. Since c-Src is an important regulator of focal contact turnover, we investigated the effect of c-Src inhibition on cells differentially expressing calreticulin. Inhibition of c-Src rescued the poorly adhesive phenotype of the calreticulin-underexpressing cells in that they became well spread, commenced formation of numerous focal contacts, and deposited a rich fibronectin matrix. Importantly, we show that c-Src activity is dependent on releasable Ca2+ from the endoplasmic reticulum, thus implicating Ca2+ sensitive pathways that are affected by calreticulin in cell-substratum adhesion. We propose that calreticulin affects fibronectin synthesis and matrix assembly via the regulation of fibronectin gene expression. In parallel, calcium-dependent effects of calreticulin on c-Src activity influence the formation and/or stability of focal contacts, which are instrumental in matrix assembly and remodeling.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Opas, M (corresponding author), Univ Toronto, Lab Med & Pathobiol, 1 Kings Coll Circle,Med Sci Bldg,Rm 6326, Toronto, ON M5S 1A8, Canada.	m.opas@utoronto.ca						Ballestrem C, 2006, J CELL SCI, V119, P866, DOI 10.1242/jcs.02794; Barker TH, 2004, J BIOL CHEM, V279, P23510, DOI 10.1074/jbc.M402169200; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; Breitenlechner CB, 2005, J MOL BIOL, V353, P222, DOI 10.1016/j.jmb.2005.08.023; BRICKELL PM, 1991, INT J EXP PATHOL, V72, P97; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cary LA, 1996, J CELL SCI, V109, P1787; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; DEAN DC, 1989, AM J RESP CELL MOL, V1, P5, DOI 10.1165/ajrcmb/1.1.5; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Goldmann WH, 1998, EXP CELL RES, V239, P235, DOI 10.1006/excr.1997.3915; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; ILLC D, 1995, NATURE, V377, P539; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Jung J, 2006, CALCIUM BINDING PROT, V1, P67; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KELLIE S, 1991, J CELL SCI, V99, P207; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; KWON HJ, 1992, CANCER RES, V52, P6926; Lin EH, 2004, EXP CELL RES, V293, P1, DOI 10.1016/j.yexcr.2003.09.008; LIU NG, 1994, J BIOL CHEM, V269, P28635; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; ROHRSCHNEIDER L, 1981, COLD SPRING HARB SYM, V46, P953; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sanders EJ, 2005, EXP EYE RES, V81, P551, DOI 10.1016/j.exer.2005.03.013; Sanders EJ, 2002, HISTOCHEM J, V34, P161, DOI 10.1023/A:1020994515099; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; SENGER DR, 1983, AM J PHYSIOL, V245, pC144, DOI 10.1152/ajpcell.1983.245.1.C144; Shen JS, 2005, METHODS, V35, P382, DOI 10.1016/j.ymeth.2004.10.011; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Szabo E., 2006, J APPL BIOMED, V4, P45; TAPLEY P, 1989, ONCOGENE, V4, P325; Volberg T, 2001, J CELL SCI, V114, P2279; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WU CY, 1993, J BIOL CHEM, V268, P21883; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	76	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16585	16598		10.1074/jbc.M701011200	http://dx.doi.org/10.1074/jbc.M701011200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389592	hybrid			2022-12-25	WOS:000246794300065
J	Sack, M; Paetz, A; Kunert, R; Bomble, M; Hesse, F; Stiegler, G; Fischer, R; Katinger, H; Stoeger, E; Rademacher, T				Sack, Markus; Paetz, Antje; Kunert, Renate; Bomble, Michael; Hesse, Friedemann; Stiegler, Gabriela; Fischer, Rainer; Katinger, Hermann; Stoeger, Eva; Rademacher, Thomas			Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures	FASEB JOURNAL			English	Article						Fc gamma RI ectodomain; surface plasmon resonance; antibody activity; recombinant pharmaceutical glycoprotein	IMMUNODEFICIENCY-VIRUS TYPE-1; OLIGOSACCHARIDE-PROTEIN INTERACTIONS; DEPENDENT CELLULAR CYTOTOXICITY; HUMAN MONOCLONAL-ANTIBODY; HAMSTER OVARY CELLS; COMPLEX N-GLYCANS; GAMMA RECEPTOR-I; SERUM HALF-LIFE; IMMUNOGLOBULIN-G; ENDOPLASMIC-RETICULUM	We report the production of an important human therapeutic antibody in plant cell suspension cultures and the functional analysis of that antibody, including a comparison with the same antibody produced in CHO cells. We established transgenic tobacco BY2 suspension cell cultures expressing the human monoclonal antibody 2F5, which shows broadly neutralizing activity against HIV-1. The antibody was directed to the endoplasmic reticulum of the plant cells and was isolated by cell disruption, followed by protein A chromatography. The plant- derived antibody was shown to be largely intact by SDS- PAGE and immunoblot. Antigen binding activity was investigated by electrophoretic mobility shift assay and quantitatively determined by ELISA and Biacore biosensor technology. Ligand binding properties were analyzed using the ectodomain of human Fc gamma RI for kinetic analysis. The plant- derived antibody showed similar kinetic properties and 89% of the binding capacity of its CHO-derived counterpart, but was only 33% as efficient in HIV- 1 neutralization assays. Our results show that plant suspension cultures can be used to produce human antibodies efficiently and that the analysis methods used in this study, including biosensor technology, provide useful functional data about antibody performance. This highlights important issues raised by the use of plant systems to produce human biologics. Sack, M., Paetz, A., Kunert, R., Bomble, M., Hesse, F., Stiegler, G., Fischer, R., Katinger, H., Stoeger, E., Rademacher, T. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures.	RTWH Aachen Univ, Inst Mol Biotechnol, D-52074 Aachen, Germany; Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, Vienna, Austria; Polymun Sci Immunobiol Forsch GmbH, Vienna, Austria; Fraunhofer IME, Aachen, Germany	RWTH Aachen University; University of Natural Resources & Life Sciences, Vienna	Rademacher, T (corresponding author), RTWH Aachen Univ, Inst Mol Biotechnol, Worringerweg 1, D-52074 Aachen, Germany.	rademacher@molbiotech.rwth-aachen.de	Sack, Markus/K-6681-2013; Hesse, Friedemann/Y-8632-2019; Kunert, Renate E/B-9185-2018; Sack, Markus/AAP-9252-2021	Sack, Markus/0000-0002-7380-9228; Hesse, Friedemann/0000-0003-0401-1842; Kunert, Renate E/0000-0002-3397-3621; 				[Anonymous], 2006, NAT BIOTECHNOL, V24, P233; Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012; Armbruster C, 2004, J ANTIMICROB CHEMOTH, V54, P915, DOI 10.1093/jac/dkh428; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Bakker H, 2006, P NATL ACAD SCI USA, V103, P7577, DOI 10.1073/pnas.0600879103; Bevaart L, 2006, BRIT J HAEMATOL, V132, P317, DOI 10.1111/j.1365-2141.2005.05884.x; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Cabanes-Macheteau M, 1999, GLYCOBIOLOGY, V9, P365, DOI 10.1093/glycob/9.4.365; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Dall'Acqua WF, 2006, J BIOL CHEM, V281, P23514, DOI 10.1074/jbc.M604292200; Elbers IJW, 2001, PLANT PHYSIOL, V126, P1314, DOI 10.1104/pp.126.3.1314; Ferrara C, 2006, J BIOL CHEM, V281, P5032, DOI 10.1074/jbc.M510171200; Fischer R, 1999, EUR J BIOCHEM, V262, P810, DOI 10.1046/j.1432-1327.1999.00435.x; Fischer R, 1999, BIOTECHNOL APPL BIOC, V30, P109; Gurbaxani B, 2006, MOL IMMUNOL, V43, P1462, DOI 10.1016/j.molimm.2005.07.032; Hellwig S, 2004, NAT BIOTECHNOL, V22, P1415, DOI 10.1038/nbt1027; Hinton PR, 2006, J IMMUNOL, V176, P346, DOI 10.4049/jimmunol.176.1.346; Holland M, 2006, BBA-GEN SUBJECTS, V1760, P669, DOI 10.1016/j.bbagen.2005.11.021; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Horn ME, 2004, PLANT CELL REP, V22, P711, DOI 10.1007/s00299-004-0767-1; Huether CM, 2005, PLANT BIOLOGY, V7, P292, DOI 10.1055/s-2005-837653; Jach G, 2001, PLANT J, V28, P483, DOI 10.1046/j.1365-313X.2001.01153.x; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kathuria S, 2002, HUM REPROD, V17, P2054, DOI 10.1093/humrep/17.8.2054; Ko KS, 2003, P NATL ACAD SCI USA, V100, P8013, DOI 10.1073/pnas.0832472100; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Kunert R, 2000, BIOTECHNOL BIOENG, V67, P97, DOI 10.1002/(SICI)1097-0290(20000105)67:1<97::AID-BIT11>3.0.CO;2-2; Li HJ, 2006, NAT BIOTECHNOL, V24, P210, DOI 10.1038/nbt1178; Lund J, 1996, J IMMUNOL, V157, P4963; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; Ma JKC, 2003, NAT REV GENET, V4, P794, DOI 10.1038/nrg1177; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Mehandru S, 2004, J VIROL, V78, P14039, DOI 10.1128/JVI.78.24.14039-14042.2004; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; Misaki R, 2003, GLYCOBIOLOGY, V13, P199, DOI 10.1093/glycob/cwg021; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Paetz A, 2005, BIOCHEM BIOPH RES CO, V338, P1811, DOI 10.1016/j.bbrc.2005.10.162; Palacpac NQ, 1999, P NATL ACAD SCI USA, V96, P4692, DOI 10.1073/pnas.96.8.4692; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Petruccelli S, 2006, PLANT BIOTECHNOL J, V4, P511, DOI 10.1111/j.1467-7652.2006.00200.x; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schouten A, 1996, PLANT MOL BIOL, V30, P781, DOI 10.1007/BF00019011; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sriraman R, 2004, PLANT BIOTECHNOL J, V2, P279, DOI 10.1111/j.1467-7652.2004.00078.x; Stoger E, 2005, CURR PHARM DESIGN, V11, P2439, DOI 10.2174/1381612054367535; Strasser R, 2004, FEBS LETT, V561, P132, DOI 10.1016/S0014-5793(04)00150-4; Triguero A, 2005, PLANT BIOTECHNOL J, V3, P449, DOI 10.1111/j.1467-7652.2005.00137.x; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; Wolbank S, 2003, J VIROL, V77, P4095, DOI 10.1128/JVI.77.7.4095-4103.2003; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1998, J IMMUNOL, V160, P3393; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151	57	68	76	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1655	1664		10.1096/fj.06-5863com	http://dx.doi.org/10.1096/fj.06-5863com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17327362				2022-12-25	WOS:000246866500007
J	Hothersall, J; Wu, J; Rahman, AS; Shields, JA; Haddock, J; Johnson, N; Cooper, SM; Stephens, ER; Cox, RJ; Crosby, J; Willis, CL; Simpson, TJ; Thomas, CM				Hothersall, Joanne; Wu, Ji'en; Rahman, Ayesha S.; Shields, Jennifer A.; Haddock, James; Johnson, Nicola; Cooper, Sian M.; Stephens, Elton R.; Cox, Russell J.; Crosby, John; Willis, Christine L.; Simpson, Thomas J.; Thomas, Christopher M.			Mutational analysis reveals that all tailoring region genes are required for production of polyketide antibiotic mupirocin by pseudomonas fluorescens - Pseudomonic acid B biosynthesis precedes pseudomonic acid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN REPB; ORIGIN-BINDING ACTIVITY; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; COMBINATORIAL BIOSYNTHESIS; IDENTIFICATION; CLUSTER; TRANSFORMATION; MUTAGENESIS; RESISTANCE	The Pseudomonas fluorescens mupirocin biosynthetic cluster encodes six proteins involved in polyketide biosynthesis and 26 single polypeptides proposed to perform largely tailoring functions. In-frame deletions in the tailoring open reading frames demonstrated that all are required for mupirocin production. A bidirectional promoter region was identified between mupF, which runs counter to other open reading frames and its immediate neighbor macpC, implying the 74-kb cluster consists of two transcriptional units. mupD/E and mupJ/K must be cotranscribed as pairs for normal function implying co-assembly during translation. MupJ and K belong to a widely distributed enzyme pair implicated, with MupH, in methyl addition. Deletion of mupF, a putative ketoreductase, produced a mupirocin analogue with a C-7 ketone. Deletion of mupC, a putative dienoyl CoA reductase, generated an analogue whose structure indicated that MupC is also implicated in control of the oxidation state around the tetrahydropyran ring of monic acid. Double mutants with Delta mupC and Delta mupO, Delta mupU, Delta mupV, or Delta macpE produced pseudomonic acid B but not pseudomonic acid A, as do the mupO, U, V, and macpE mutants, indicating that MupC must work after MupO, U, and V.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Birmingham; University of Bristol	Thomas, CM (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	c.m.thomas@bham.ac.uk	Simpson, Thomas J/P-5058-2015; Wu, Ji'En/A-6967-2012; Cox, Russell John/F-9190-2015	Cox, Russell John/0000-0002-1844-0157	Engineering and Physical Sciences Research Council [GR/S78124/01] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [B20055, BBS/B/07071] Funding Source: Medline	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALBERTINI AM, 1995, MICROBIOL-SGM, V141, P299, DOI 10.1099/13500872-141-2-299; Basu A, 2004, J BACTERIOL, V186, P335, DOI 10.1128/JB.186.2.335-342.2004; Basu A, 2002, J BACTERIOL, V184, P2204, DOI 10.1128/JB.184.8.2204-2214.2002; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; Butcher RA, 2007, P NATL ACAD SCI USA, V104, P1506, DOI 10.1073/pnas.0610503104; Calderone CT, 2006, P NATL ACAD SCI USA, V103, P8977, DOI 10.1073/pnas.0603148103; CHAIN EB, 1974, J CHEM SOC CHEM COMM, P847, DOI 10.1039/c39740000847; CHAIN EB, 1977, J CHEM SOC PERK T, V1, P294; CHAIN EB, 1977, J CHEM SOC P1, V1, P318; Chen XH, 2006, J BACTERIOL, V188, P4024, DOI 10.1128/JB.00052-06; CLAYTON JP, 1980, TETRAHEDRON LETT, V21, P881, DOI 10.1016/S0040-4039(00)71533-4; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Cooper SM, 2005, CHEM BIOL, V12, P825, DOI 10.1016/j.chembiol.2005.05.015; Cooper SM, 2005, CHEM COMMUN, P1179, DOI 10.1039/b414781b; Edwards DJ, 2004, CHEM BIOL, V11, P817, DOI 10.1016/j.chembiol.2004.03.030; El-Sayed AK, 2001, MICROBIOL-SGM, V147, P2127, DOI 10.1099/00221287-147-8-2127; El-Sayed AK, 2003, CHEM BIOL, V10, P419, DOI 10.1016/S1074-5521(03)00091-7; FELINE TC, 1977, J CHEM SOC T, V1, P309; Gu LC, 2006, J AM CHEM SOC, V128, P9014, DOI 10.1021/ja0626382; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; HUMBERT R, 1989, J BACTERIOL, V171, P1435, DOI 10.1128/jb.171.3.1435-1444.1989; Julien B, 2006, CHEM BIOL, V13, P1277, DOI 10.1016/j.chembiol.2006.10.004; Kahn M, 1979, Methods Enzymol, V68, P268; MARTIN FMN, 1989, J CHEM SOC P, V1, P207; MOIR A, 1979, J GEN MICROBIOL, V111, P165, DOI 10.1099/00221287-111-1-165; OHANLON PJ, 1983, J CHEM SOC P, V1, P2655; RAO R, 1988, J BIOL CHEM, V263, P15957; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P4563; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; VandeCasteele M, 1997, COMP BIOCHEM PHYS A, V118, P463, DOI 10.1016/S0300-9629(97)00007-8; Weissman KJ, 2005, NAT REV MICROBIOL, V3, P925, DOI 10.1038/nrmicro1287; Weitnauer G, 2001, CHEM BIOL, V8, P569, DOI 10.1016/S1074-5521(01)00040-0; WHATLING CA, 1995, MICROBIOL-UK, V141, P973, DOI 10.1099/13500872-141-4-973; WU JE, 2007, CHEM COMMUN; Xu J, 2005, MICROBIOL-SGM, V151, P2515, DOI 10.1099/mic.0.28138-0; Yanagisawa T, 2003, J BIOL CHEM, V278, P25887, DOI 10.1074/jbc.M302633200; Zhu LL, 2005, J ORG CHEM, V70, P631, DOI 10.1021/jo0483623	42	29	29	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15451	15461		10.1074/jbc.M701490200	http://dx.doi.org/10.1074/jbc.M701490200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383964	hybrid			2022-12-25	WOS:000246589600020
J	Campbell, EJ; Owen, CA				Campbell, Edward J.; Owen, Caroline A.			The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MUCUS PROTEINASE-INHIBITOR; CELL-SURFACE; CATALYTIC-ACTIVITY; ALPHA-1-PROTEINASE INHIBITOR; ACTIVATED NEUTROPHILS; SERINE PROTEINASES; BOUND ELASTASE; BFGF RELEASE; FACTOR FGF	Human leukocyte elastase (HLE) and cathepsin G (CG) are expressed at high levels on the surface of activated human neutrophils (PMN) in catalytically active but inhibitor-resistant forms having the potential to contribute to tissue injury. Herein we have investigated the mechanisms by which HLE and CG bind to PMN plasma membranes. I-125-Labeled HLE and CG bind to PMN at 0 degrees C in a saturable and reversible manner (KD = 5.38 and 4.36 x 10(-7) M and 11.5 and 8.1 x 10(6) binding sites/cell, respectively). Incubation of PMN with radiolabeled HLE and CG in the presence of a 200-fold molar excess of unlabeled HLE, CG, myeloperoxidase, lactoferrin, proteinase 3, phenylmethylsulfonyl fluoride (PMSF)-inactivated HLE, or PMSF-inactivated CG inhibited binding of radiolabeled ligands. This indicates that these PMN granule proteins share binding sites on PMN and that functional active sites of HLE and CG are not required for their binding to PMN. The sulfate groups of heparan sulfate-and chondroitin sulfate-containing proteoglycans are the PMN binding sites for HLE and CG since binding of HLE and CG to PMN was inhibited by incubating PMN with 1) trypsin, chondroitinase ABC, and heparitinases, but not other glycanases, and 2) purified chondroitin sulfates, heparan sulfate, and other sulfated molecules, but not with non-sulfated glycans. Thus, heparan sulfate-and chondroitin sulfate-containing proteoglycans are low affinity, high volume PMN surface binding sites for HLE and CG, which are well suited to bind high concentrations of active serine proteinases released from degranulating PMN.	Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT 84132 USA; Intermt Hlth Care, Salt Lake City, UT 84132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utah System of Higher Education; University of Utah; Intermountain Healthcare	Owen, CA (corresponding author), Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, 5 Francis St,905 Thorn Bldg, Boston, MA 02115 USA.	cowen@rics.bwh.harvard.edu	Owen, Caroline/H-5925-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063137, R01HL086814] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063137, HL63137, HL086814, R01 HL086814] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott RE, 1998, ARCH SURG-CHICAGO, V133, P1002, DOI 10.1001/archsurg.133.9.1002; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; ANTONILLI L, 1993, INT J CLIN PHARM RES, V13, P11; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BIRGENS HS, 1983, BRIT J HAEMATOL, V54, P383, DOI 10.1111/j.1365-2141.1983.tb02113.x; BIRGENS HS, 1984, SCAND J HAEMATOL, V33, P275; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BOYUM A, 1963, SCAND J CLIN LAB S97, V21, P77; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; Chan SCH, 2003, AM J RESP CRIT CARE, V168, P192, DOI 10.1164/rccm.200208-829OC; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; DILLON TJ, 1990, CLIN CHEM, V36, P392; DWENGER A, 1986, J CLIN CHEM CLIN BIO, V24, P299; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Ermolieff J, 1998, BIOCHEM J, V330, P1369, DOI 10.1042/bj3301369; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1992, BIOL CHEM H-S, V373, P503, DOI 10.1515/bchm3.1992.373.2.503; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; HORNEBECK W, 1994, PATHOL RES PRACT, V190, P895; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; Kostoulas G, 1997, BIOL CHEM, V378, P1481, DOI 10.1515/bchm.1997.378.12.1481; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Owen CA, 1998, J IMMUNOL, V160, P1436; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; OWEN CA, 1997, AM J PHYSIOL, V272, P385; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Petersen F, 1998, J IMMUNOL, V161, P4347; Powers J ., 1980, CIBA FDN S, V75, P51; PRYZWANSKY KB, 1979, CELL, V18, P1025, DOI 10.1016/0092-8674(79)90215-0; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; REDINI F, 1988, BIOCHEM PHARMACOL, V37, P4257, DOI 10.1016/0006-2952(88)90604-1; RINDLERLUDWIG R, 1978, NEUTRAL PROTEASES HU, P138; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT W, 1978, NEUTRAL PROTEASES HU, P77; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; TWUMASI DY, 1977, J BIOL CHEM, V252, P1917; Volpi N, 1996, BBA-GEN SUBJECTS, V1290, P299, DOI 10.1016/0304-4165(96)00033-5	57	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14645	14654		10.1074/jbc.M608346200	http://dx.doi.org/10.1074/jbc.M608346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17384412	hybrid			2022-12-25	WOS:000246245800078
J	Narita, K; Chien, J; Mullany, SA; Staub, J; Qian, X; Lingle, WL; Shridhar, V				Narita, Keishi; Chien, Jeremy; Mullany, Sally A.; Staub, Julie; Qian, Xiang; Lingle, Wilma L.; Shridhar, Viji			Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEPARAN-SULFATE; ACTIVATION; CARCINOMA; ERK	Heparan sulfate (HS) glycosaminoglycans are the oligosaccharide chains of heparan sulfate proteoglycans. The sulfation of HS glycosaminoglycan residues is required for its interaction with various heparin-binding growth factors to promote their biological activities to activate their high affinity receptor tyrosine kinases. We have identified HS glycosaminoglycan-6-O-endosulfatase HSulf-1 as a down-regulated gene in ovarian, breast, and several other cancer cell lines. Here we have shown that HSulf-1 inhibits autocrine activation of the EGFR-ERK ( epidermal growth factor receptor-extracellular signal-regulated kinase) pathway induced by serum withdrawal in MDA-MB-468 breast cancer cells. Short hairpin RNA-mediated down-regulation of HSulf-1 in HSulf-1 clonal lines of MDA-MB-468 led to a significant increase in autocrine activation of ERK compared with vector only control. The autocrine signaling was also inhibited with neutralization antibodies against amphiregulin and HB-EGF, the heparin-binding growth factor family of the EGF superfamily. Furthermore, HSulf-1-mediated inhibition of autocrine signaling was associated with reduced cyclin D1 levels, leading to decreased S phase fraction and increased G(2)-M fraction, as well as increased cell death. Finally, evaluation of HSulf-1 expression levels in primary invasive breast tumors by RNA in situ hybridization indicated that HSulf-1 is down-regulated in the majority (60%) of tumors, with a predominant association with lobular histology. These data suggest a potential role of HSulf-1 down-regulation in mammary carcinogenesis.	Mayo Clin, Coll Med, Ctr Canc, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin, Coll Med, Ctr Canc, Dept Lab Med & Expt Pathol, 200 1st St,SW, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Narita, Keishi/E-3539-2010; Xiangyang, Qian/Q-5174-2019; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Chien, Jeremy/0000-0003-4744-8374	NATIONAL CANCER INSTITUTE [R01CA106954] Funding Source: NIH RePORTER; NCI NIH HHS [CA106954-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agranovich MS, 2005, RUSS J MATH PHYS, V12, P1; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Bottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Dubey S, 2006, LANCET ONCOL, V7, P416, DOI 10.1016/S1470-2045(06)70693-3; Evron E, 2001, CANCER RES, V61, P2782; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Johnston SRD, 2005, J STEROID BIOCHEM, V95, P173, DOI 10.1016/j.jsbmb.2005.04.004; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Ma L, 2001, J PATHOL, V194, P413, DOI 10.1002/path.902; Mullen P, 2004, METH MOLEC MED, V88, P247; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Qian X, 2004, DIAGN MOL PATHOL, V13, P9, DOI 10.1097/00019606-200403000-00002; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yin F, 2001, ANTICANCER RES, V21, P413	28	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14413	14420		10.1074/jbc.M611395200	http://dx.doi.org/10.1074/jbc.M611395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363371	hybrid			2022-12-25	WOS:000246245800054
J	Ferrai, C; Munari, D; Luraghi, P; Pecciarini, L; Cangi, MG; Doglioni, C; Blasi, F; Crippa, MP				Ferrai, Carmelo; Munari, Davide; Luraghi, Paolo; Pecciarini, Lorenza; Cangi, Maria Giulia; Doglioni, Claudio; Blasi, Francesco; Crippa, Massimo P.			A transcription-dependent micrococcal nuclease-resistant fragment of the urokinase-type plasminogen activator promoter interacts with the enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; IN-VIVO; GENE-EXPRESSION; HISTONE MODIFICATIONS; ALPHA-AMANITIN; SP1; UPA; PROTEINS; DISTANCE; LINKING	We show the interaction between the enhancer and the minimal promoter of urokinase-type plasminogen activator gene during active transcription by coupling micrococcal nuclease digestion of cross-linked, sonicated chromatin, and chromatin immunoprecipitation. This approach allowed the precise identification of the interacting genomic fragments, one of which is resistant to micrococcal nuclease cleavage. The interacting fragments form a single transcriptional control unit, as indicated by their common protein content. Furthermore, we show that the enhancer-MP interaction persists during the early stages of transcription and is lost upon alpha-amanitin treatment, indicating the requirement for active transcription. Our results support a looping model of interaction between the enhancer and the MP of the urokinase-type plasminogen activator gene.	Ist Sci San Raffaele, Mol Genet Lab, I-20132 Milan, Italy; Ist Sci San Raffaele, Anat Pathol Unit, I-20132 Milan, Italy; Univ Vita Salute S Raffaele, I-20132 Milan, Italy; FIRC Inst Mol Oncol, I-20139 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IFOM - FIRC Institute of Molecular Oncology	Crippa, MP (corresponding author), Ist Sci San Raffaele, Mol Genet Lab, Via Olgettina 58, I-20132 Milan, Italy.	crippa.massimo@hsr.it	Ferrai, Carmelo/GVS-7378-2022; Cangi, M.Giulia/CAF-1459-2022; crippa, massimo/J-6514-2016; Pecciarini, Lorenza/GQI-3544-2022	Cangi, M.Giulia/0000-0002-9472-0935; crippa, massimo/0000-0003-3214-9670; Ferrai, Carmelo/0000-0002-8088-2757; DOGLIONI, Claudio/0000-0002-4969-5216; Blasi, Francesco/0000-0001-9406-1784				Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Chan HM, 2001, J CELL SCI, V114, P2363; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; DECESARE D, 1995, ONCOGENE, V11, P365; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Helenius MA, 2001, CANCER RES, V61, P5340; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Ibanez-Tallon I, 1999, ONCOGENE, V18, P2836, DOI 10.1038/sj.onc.1202644; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Levsky JM, 2002, SCIENCE, V297, P836, DOI 10.1126/science.1072241; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Patrinos GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/gad.289704; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROSS IL, 1994, IMMUNOL CELL BIOL, V72, P177, DOI 10.1038/icb.1994.26; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Turner B., 2001, CHROMATIN GENE REGUL; Turner BM, 2005, NAT STRUCT MOL BIOL, V12, P110, DOI 10.1038/nsmb0205-110; van Holde KE., 1989, SPRINGER SERIES MOL; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371	47	16	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12537	12546		10.1074/jbc.M700867200	http://dx.doi.org/10.1074/jbc.M700867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331942	hybrid			2022-12-25	WOS:000245942800022
J	Singhirunnusorn, P; Ueno, Y; Matsuo, M; Suzuki, S; Saiki, I; Sakurai, H				Singhirunnusorn, Pattama; Ueno, Yoko; Matsuo, Mitsuhiro; Suzuki, Shunsuke; Saiki, Ikuo; Sakurai, Hiroaki			Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; EPITHELIAL-CELLS; TYROSINE KINASE; ERBB RECEPTORS; LUNG-CANCER; HB-EGF; STRESS; TRANSACTIVATION; PHOSPHORYLATION; TRANSDUCTION	Epidermal growth factor receptor ( EGFR) has been shown to be activated by specific ligands as well as other cellular stimuli including tumor necrosis factor-alpha ( TNF-alpha). In the present study, we found that cellular stress suppressed ligand-mediated EGFR activity. Both TNF-alpha and osmotic stress rapidly induced phosphorylation of EGFR. This phosphorylation of EGFR and the activation of mitogen-activated protein kinases and NF-kappa B occurred independently of the shedding of extracellular membrane-bound EGFR ligands and intracellular EGFR tyrosine kinase activity. Transforming growth factor-beta-activated kinase 1 ( TAK1) was involved in the TNF-alpha-induced signaling pathway to EGFR. In addition, experiments using chemical inhibitors and small interfering RNA demonstrated that p38 alpha is a common mediator for the cellular stress-induced phosphorylation of EGFR. Surprisingly, the modified EGFR was not able to respond to its extracellular ligand due to transient internalization through the clathrin-mediated mechanism. Furthermore, turnover of p38 activation led to dephosphorylation and recycling back to the cell surface of EGFR. These results demonstrated that TNF-alpha has opposite bifunctional activities in modulating the function of the EGFR.	Toyama Univ, Grad Sch Med & Pharmaceut Sci, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan; Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Anat, Toyama 9300194, Japan; Toyama Univ, Century Ctr Excellence Program 21st, Toyama 9300194, Japan	University of Toyama; University of Toyama; University of Toyama	Sakurai, H (corresponding author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Inst Nat Med, Div Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@inm.u-toyama.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; Chan SK, 2006, EUR J CANCER, V42, P17, DOI 10.1016/j.ejca.2005.07.031; Chen WNU, 2004, J BIOL CHEM, V279, P18488, DOI 10.1074/jbc.M310874200; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; Chobotova K, 2005, J CLIN ENDOCR METAB, V90, P913, DOI 10.1210/jc.2004-0476; Choo MK, 2006, INT J CANCER, V118, P2758, DOI 10.1002/ijc.21734; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Iwamoto R, 2006, CELL STRUCT FUNCT, V31, P1, DOI 10.1247/csf.31.1; Janes KA, 2006, CELL, V124, P1225, DOI 10.1016/j.cell.2006.01.041; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Matsuo M, 2006, CANCER SCI, V97, P155, DOI 10.1111/j.1349-7006.2006.00152.x; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sweeney C, 2000, ONCOGENE, V19, P5568, DOI 10.1038/sj.onc.1203913; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Ueno Y, 2005, BRIT J CANCER, V92, P1690, DOI 10.1038/sj.bjc.6602548; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vergarajauregui S, 2006, TRAFFIC, V7, P686, DOI 10.1111/j.1600-0854.2006.00420.x; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; Winograd-Katz SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zwang Y, 2006, EMBO J, V25, P4195, DOI 10.1038/sj.emboj.7601297	52	38	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12698	12706		10.1074/jbc.M608723200	http://dx.doi.org/10.1074/jbc.M608723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17327237	hybrid			2022-12-25	WOS:000245942800039
J	Dramard, X; Heidmann, T; Jensen, S				Dramard, Xavier; Heidmann, Thierry; Jensen, Silke			Natural Epigenetic Protection against the I-factor, a Drosophila LINE Retrotransposon, by Remnants of Ancestral Invasions	PLOS ONE			English	Article								Transposable elements are major components of most eukaryotic genomes. Such sequences are generally defective for transposition and have little or no coding capacity. Because transposition can be highly mutagenic, mobile elements that remain functional are tightly repressed in all living species. Drosophila pericentromeric heterochromatin naturally contains transposition-defective, non-coding derivatives of a LINE retrotransposon related to the I-factor. The I-factor is a good model to study the regulation of transposition in vivo because, under specific conditions, current functional copies of this mobile element can transpose at high frequency, specifically in female germ cells, with deleterious effects including female sterility. However, this high transpositional activity becomes spontaneously repressed upon ageing or heat treatment, by a maternally transmitted, transgenerational epigenetic mechanism of unknown nature. We have analyzed, by quantitative real time RT-PCR, the RNA profile of the transposition-defective I-related sequences, in the Drosophila ovary during ageing and upon heat treatment, and also in female somatic tissues and in males, which are not permissive for I-factor transposition. We found evidence for a role of transcripts from these ancestral remnants in the natural epigenetic protection of the Drosophila melanogaster genome against the deleterious effects of new invasions by functional I-factors. These results provide a molecular basis for a probably widespread natural protection against transposable elements by persisting vestiges of ancient invasions.	[Dramard, Xavier; Heidmann, Thierry; Jensen, Silke] Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Jensen, S (corresponding author), Inst Gustave Roussy, CNRS, UMR 8122, Unite Retrovirus Endogenes & Elements Retroides E, Villejuif, France.	sjensen@igr.fr		Jensen, Silke/0000-0002-1858-8792	Ligue Nationale Contre le Cancer	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	X. D. is supported by a grant from the Ligue Nationale Contre le Cancer for PhD students.	Aravin A, 2005, FEBS LETT, V579, P5830, DOI 10.1016/j.febslet.2005.08.009; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Bazin C, 1999, MOL GEN GENET, V261, P480, DOI 10.1007/s004380050991; Birchler JA, 2000, CURR OPIN GENET DEV, V10, P211, DOI 10.1016/S0959-437X(00)00065-4; Blumenstiel JP, 2005, P NATL ACAD SCI USA, V102, P15965, DOI 10.1073/pnas.0508192102; BUCHETON A, 1978, HEREDITY, V41, P357, DOI 10.1038/hdy.1978.106; BUCHETON A, 1979, GENETICS, V93, P131; BUCHETON A, 1984, CELL, V38, P153, DOI 10.1016/0092-8674(84)90536-1; BUCHETON A, 2002, MOBILE DNA, V2, P796; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; Dimitri P, 2005, CYTOGENET GENOME RES, V110, P160, DOI 10.1159/000084948; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; Gauthier E, 2000, GENETICS, V156, P1867; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; JENSEN S, 1995, MOL GEN GENET, V248, P381, DOI 10.1007/BF02191637; Jensen S, 1999, GENETICS, V153, P1767; Jensen S, 2002, GENETICS, V162, P1197; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Kavi HH, 2005, FEBS LETT, V579, P5940, DOI 10.1016/j.febslet.2005.08.069; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUNING KG, 1981, HEREDITAS, V95, P181; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Malinsky S, 2000, GENETICS, V156, P1147; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Meyer P, 1996, ANNU REV PLANT PHYS, V47, P23, DOI 10.1146/annurev.arplant.47.1.23; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; Pelisson A, 2007, J VIROL, V81, P1951, DOI 10.1128/JVI.01980-06; Picard G, 1971, DIS, V46, P54; Ronsseray S, 1996, GENETICS, V143, P1663; Saito K, 2006, GENE DEV, V20, P2214, DOI 10.1101/gad.1454806; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Vagin Vasily V, 2004, RNA Biol, V1, P54; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; VAURY C, 1990, J MOL EVOL, V31, P424, DOI 10.1007/BF02106056; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; Verdel A, 2005, FEBS LETT, V579, P5872, DOI 10.1016/j.febslet.2005.08.083; Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141	46	23	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e304	10.1371/journal.pone.0000304	http://dx.doi.org/10.1371/journal.pone.0000304			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375190	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445100006
J	Hashmi, SK; Afridi, MB; Abbas, K; Sajwani, RA; Saleheen, D; Frossard, PM; Ishaq, M; Ambreen, A; Ahmad, U				Hashmi, Saman K.; Afridi, Maria B.; Abbas, Kanza; Sajwani, Rubina A.; Saleheen, Danish; Frossard, Philippe M.; Ishaq, Mohammad; Ambreen, Aisha; Ahmad, Usman			Factors Associated with Adherence to Anti-Hypertensive Treatment in Pakistan	PLOS ONE			English	Article							JOINT-NATIONAL-COMMITTEE; BLOOD-PRESSURE; MEDICATION ADHERENCE; THERAPEUTIC REGIMEN; HYPERTENSIVE MEN; RISK-FACTORS; NONCOMPLIANCE; PREVENTION; IMPACT; WOMEN	Objectives. Poor adherence is one of the biggest obstacles in therapeutic control of high blood pressure. The objectives of this study were (i) to measure adherence to antihypertensive therapy in a representative sample of the hypertensive Pakistani population and (ii) to investigate the factors associated with adherence in the studied population. Methods and Results. A cross-sectional study was conducted on a simple random sample of 460 patients at the Aga Khan University Hospital (AKUH) and National Institute of Cardiovascular Diseases, Karachi, from September 2005-May 2006. Adherence was assessed using the Morisky Medication Adherence Scale (MMAS), with scores ranging from 0 (non-adherent) to 4 (adherent). In addition to MMAS, patient self-reports about the number of pills taken over a prescribed period were used to estimate adherence as a percentage. AKU Anxiety and Depression Scale (AKU-ADS) was incorporated to find any association between depression and adherence. At a cut-off value of 80%, 77% of the cases were adherent. Upon univariate analyses, increasing age, better awareness and increasing number of pills prescribed significantly improved adherence, while depression showed no association. Significant associations, upon multivariate analyses, included number of drugs that a patient was taking (P<0.02) and whether he/she was taking medication regularly or only for symptomatic relief (P<0.00001). Conclusions. Similar to what has been reported worldwide, younger age, poor awareness, and symptomatic treatment adversely affected adherence to antihypertensive medication in our population. In contrast, monotherapy reduced adherence, whereas psychosocial factors such as depression showed no association. These findings may be used to identify the subset of population at risk of low adherence who should be targeted for interventions to achieve better blood pressure control and hence prevent complications.	[Saleheen, Danish; Frossard, Philippe M.; Ahmad, Usman] Aga Khan Univ, Dept Biol & Biomed Sci, Karachi, Pakistan; [Hashmi, Saman K.; Afridi, Maria B.; Abbas, Kanza; Sajwani, Rubina A.] Aga Khan Univ, Coll Med, Karachi, Pakistan; [Ishaq, Mohammad] Natl Inst Cardiovasc Dis, Karachi, Pakistan; [Ambreen, Aisha] Aga Khan Univ, Dept Family Med, Karachi, Pakistan	Aga Khan University; Aga Khan University; Aga Khan University	Frossard, PM (corresponding author), Aga Khan Univ, Dept Biol & Biomed Sci, Karachi, Pakistan.	philippe.frossard@aku.edu	Hashmi, Saman/GOK-2190-2022	Hashmi, Saman/0000-0002-0470-1846; Parekh, Maria/0000-0003-0465-8400	Department of Biological and Biomedical Sciences, Aga Khan University	Department of Biological and Biomedical Sciences, Aga Khan University	This research was partially supported by research funds from the Department of Biological and Biomedical Sciences, Aga Khan University.	Ali B S, 1998, J Pak Med Assoc, V48, P261; Almas Aysha, 2006, J Coll Physicians Surg Pak, V16, P23; Baune B T, 2006, Ann Gen Psychiatry, V5, P6, DOI 10.1186/1744-859X-5-6; Baune BT, 2005, EUR J EPIDEMIOL, V20, P411, DOI 10.1007/s10654-005-0675-x; Baune BT, 2004, SAUDI MED J, V25, P1683; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bloom BS, 2001, BMJ-BRIT MED J, V323, P647, DOI 10.1136/bmj.323.7314.647; Caro JJ, 1999, CAN MED ASSOC J, V160, P31; Cheng JWM, 2001, PHARMACOTHERAPY, V21, P828, DOI 10.1592/phco.21.9.828.34557; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; Dunbar-Jacob J, 1995, MANAGING CHRONIC ILL, P313; Egan BM, 2003, ARCH INTERN MED, V163, P681, DOI 10.1001/archinte.163.6.681; FALASCHETTI E, 2004, HLTH SURVEY ENGLAND, P181; Garfield F B, 1999, Curr Hypertens Rep, V1, P502, DOI 10.1007/s11906-996-0022-y; Gryglewska B, 2005, BLOOD PRESSURE, V14, P46, DOI 10.1080/08038020500428740; Hassan NB, 2006, J HUM HYPERTENS, V20, P23, DOI 10.1038/sj.jhh.1001930; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; Iskedjian M, 2002, CLIN THER, V24, P302, DOI 10.1016/S0149-2918(02)85026-3; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Krousel-Wood M, 2005, CURR OPIN CARDIOL, V20, P296, DOI 10.1097/01.hco.0000166597.52335.23; Krousel-Wood M, 2004, CURR OPIN CARDIOL, V19, P357, DOI 10.1097/01.hco.0000126978.03828.9e; LENNON C, 2001, INT J PHARM PRACT, V9, pR8; Mant J, 2006, J HUM HYPERTENS, V20, P551, DOI 10.1038/sj.jhh.1002046; MEINKSTER, 2006, J HUM HYPERTENS, V20, P295; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; *PAK MED RES COUNC, 1998, NAT HLTH SURV PAK 19, P50; Payne K A, 2000, Curr Hypertens Rep, V2, P515, DOI 10.1007/s11906-996-0035-6; Pratt R J, 2001, HIV Clin Trials, V2, P146; RUDD P, 1991, PATIENT COMPLIANCE M, P283; Thompson DW, 1996, NEUROL CLIN, V14, P309, DOI 10.1016/S0733-8619(05)70258-9; Wang PS, 2002, J GEN INTERN MED, V17, P504, DOI 10.1046/j.1525-1497.2002.00406.x; *WHO, 2003, HYP ADH LONG TERM TH, P27; *WHO, 2003, HYP ADH LONG TERM TH, P129; Yiannakopoulou EC, 2005, EUR J CARDIOV PREV R, V12, P243, DOI 10.1097/01.hjr.0000160601.41762.44; YOUSSEF RM, 2002, E MEDITERR HEALTH J, V8, P4	38	109	112	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e280	10.1371/journal.pone.0000280	http://dx.doi.org/10.1371/journal.pone.0000280			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356691	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444800003
J	Sekine, Y; Ikeda, O; Hayakawa, Y; Tsuji, S; Imoto, S; Aoki, N; Sugiyama, K; Matsuda, T				Sekine, Y.; Ikeda, O.; Hayakawa, Y.; Tsuji, S.; Imoto, S.; Aoki, N.; Sugiyama, K.; Matsuda, T.			DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118	ONCOGENE			English	Article						beta-estradiol; estrogen receptor; phosphatase; transcriptional regulation; breast cancer	DUAL-SPECIFICITY PHOSPHATASE; CELL ANTIGEN RECEPTOR; CROSS-TALK; TRANSCRIPTIONAL ACTIVATION; VACCINIA VIRUS; GERM-CELLS; PHOSPHORYLATION; PATHWAY; KINASE; TRANSDUCER	In the previous study, we demonstrated the involvement of dual specificity phosphatase 22 ( DUSP22/LMW-DSP2) in regulating the leukemia inhibitory factor/interleukin-6/ signal transducer and activator of transcription 3- mediated signaling pathway. In this study, we show beta-estradiol ( E2)- induced DUSP22 mRNA expression in estrogen receptor a ( ER alpha)- positive breast cancer cells, whereas E2- induced phosphorylation and activation of ERa was suppressed by overexpression of DUSP22 but not catalytically inactive mutants. Furthermore, small- interfering RNA- mediated reduction of DUSP22 expression enhanced ER alpha- mediated transcription and endogenous gene expression. In fact, DUSP22 associated with ERa in vivo and both endogenous proteins interacted in ERa- positive breast cancer T47D cells. These results strongly suggest that DUSP22 acts as a negative regulator of the ER alpha-amediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Fac Bioresources, Dept Life Sci, Lab Mol Food Chem & Biohem, Tsu, Mie 514, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Alonso A, 2004, J BIOL CHEM, V279, P32586, DOI 10.1074/jbc.M403442200; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; ALTIOK N, 2006, IN PRESS BREAST CANC; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Carreau S, 2002, MOL CELL ENDOCRINOL, V193, P137, DOI 10.1016/S0303-7207(02)00107-7; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 2001, REPROD FERT DEVELOP, V13, P211, DOI 10.1071/RD00128; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ikeda K, 2004, MOL ENDOCRINOL, V18, P1131, DOI 10.1210/me.2003-0308; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jenab S, 1998, ENDOCRINOLOGY, V139, P1883, DOI 10.1210/en.139.4.1883; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda T, 2001, BIOCHEM BIOPH RES CO, V283, P179, DOI 10.1006/bbrc.2001.4758; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Murphy K, 2005, GENE EXPR PATTERNS, V5, P475, DOI 10.1016/j.modgep.2004.12.007; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Proia DA, 2006, J BIOL CHEM, V281, P7089, DOI 10.1074/jbc.M511839200; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2004, BIOCHEM BIOPH RES CO, V315, P692, DOI 10.1016/j.bbrc.2004.01.109; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; THEODOSIOU A, 2002, GENOME BIOL, V26; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200	43	56	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6038	6049		10.1038/sj.onc.1210426	http://dx.doi.org/10.1038/sj.onc.1210426			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384676	Green Submitted			2022-12-25	WOS:000249277200007
J	Flotho, C; Steinemann, D; Mullighan, CG; Neale, G; Mayer, K; Kratz, CP; Schlegelberger, B; Downing, JR; Niemeyer, CM				Flotho, C.; Steinemann, D.; Mullighan, C. G.; Neale, G.; Mayer, K.; Kratz, C. P.; Schlegelberger, B.; Downing, J. R.; Niemeyer, C. M.			Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11	ONCOGENE			English	Article						leukemia; JMML; SNP; NF1	BONE-MARROW-CELLS; INACTIVATION; CHILDREN	Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disorder whose proliferative component is a result of RAS pathway deregulation caused by somatic mutation in the RAS or PTPN11 oncogenes or in patients with underlying neurofibromatosis type 1 (NF-1), by loss of NF1 gene function. To search for potential collaborating genetic abnormalities, we used oligonucleotide arrays to analyse over 116000 sing le-nucleotide polymorphisms across the genome in 16 JMML samples with normal karyotype. Evaluation of the SNP genotypes identified large regions of homozygosity on chromosome 17q, including the NF1 locus, in four of the five samples from patients with JMML and NF-1. The homozygous region was at least 55 million base pairs in each case. The genomic copy number was normal within the homozygous region, indicating uniparental disomy (UPD). In contrast, the array data provided no evidence for 17q UPD in any of the 11 JMML cases without NF-1. We used array-based comparative genomic hybridization to confirm 17q disomy, and microsatellite analysis was performed to verify homozygosity. Mutational analysis demonstrated that the inactivating NF1 lesion was present on both alleles in each case. In summary, our data indicate that a mitotic recombination event in a JMML-initiating cell led to 17q UPD with homozygous loss of normal NF1, provide confirmatory evidence that the NF1 gene is crucial for the increased incidence of JMML in NF-1 patients, and corroborate the concept that RAS pathway deregulation is central to JMML pathogenesis.	Univ Freiburg, Div Pediat Hematol Oncol, Freiburg, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Ctr Human Genet & Lab Med, Martinsried, Germany	University of Freiburg; Hannover Medical School; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Flotho, C (corresponding author), Univ Kinderklin, Mathildenstr 1, D-79106 Freiburg, Germany.	christian.flotho@cuniklinik-freiburg.de	Kratz, Christian/AAC-9726-2021; Mullighan, Charles/H-3253-2011; Downing, James R./N-8102-2018	Mullighan, Charles/0000-0002-1871-1850; 				Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; EMANUEL PD, 1991, BLOOD, V77, P925; Engle LJ, 2006, ONCOGENE, V25, P1594, DOI 10.1038/sj.onc.1209368; Flotho C, 1999, LEUKEMIA, V13, P32, DOI 10.1038/sj.leu.2401240; FLOTHO C, 2007, IN PRESS CURR DRUG T; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; MITELMAN F, 2006, MITELMAN DATABASE CH; Niemeyer CM, 1997, BLOOD, V89, P3534; Raghavan M, 2005, CANCER RES, V65, P375; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stephens K, 2006, BLOOD, V108, P1684, DOI 10.1182/blood-2005-11-011486; Tonnies H, 2003, BLOOD, V101, P3872, DOI 10.1182/blood-2002-10-3243; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	19	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5816	5821		10.1038/sj.onc.1210361	http://dx.doi.org/10.1038/sj.onc.1210361			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353900				2022-12-25	WOS:000248885100013
J	Park, IW; Reddy, MVR; Reddy, EP; Groopman, JE				Park, I-W; Reddy, M. V. R.; Reddy, E. P.; Groopman, J. E.			Evaluation of novel cell cycle inhibitors in mantle cell lymphoma	ONCOGENE			English	Article						mantle cell lymphoma; cell cycle; cytotoxicity; apoptosis; novel sulfonyl compounds (ON013100 and ON01370)	CDK INHIBITORS; CANCER CELLS; KINASE; PROTEIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; SURVIVAL; DIFFERENTIATION; EXPRESSION	Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compounds, ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, including cyclin-dependent kinase4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labelling and poly ADP-ribose polymerase assays, we found that these compounds caused apoptosis in MCL cells. In addition, using molecular analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family molecules. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, Boston, MA 02115 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Groopman, JE (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA109820] Funding Source: NIH RePORTER; NCI NIH HHS [CA109820] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSCH F, 1994, BLOOD, V84, P2725; Boutros R, 2005, EXP CELL RES, V310, P152, DOI 10.1016/j.yexcr.2005.07.009; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brauns SC, 2005, ANTICANCER RES, V25, P4197; Campo E, 1999, SEMIN HEMATOL, V36, P115; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; CROWE DL, 2005, HEAD NECK-J SCI SPEC, V21, P15; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; DEBOER CJ, 1995, ONCOGENE, V10, P1833; Elias B, 2005, ONCOGENE, V24, P2574, DOI 10.1038/sj.onc.1208488; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; FERBABDEZ V, 2005, J CLIN ONCOL, V23, P6364; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIMBY E, 2005, ANN ONC 9 INT C M S5, V16, pV168; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nozoe T, 2005, J CANCER RES CLIN, V131, P179, DOI 10.1007/s00432-004-0607-2; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swerdlow SH, 2002, HUM PATHOL, V33, P7, DOI 10.1053/hupa.2002.30221; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Tiemann M, 2005, BRIT J HAEMATOL, V131, P29, DOI 10.1111/j.1365-2141.2005.05716.x; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZUCCA E, 1995, ANN ONCOL, V6, P257, DOI 10.1093/oxfordjournals.annonc.a059155	36	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5635	5642		10.1038/sj.onc.1210350	http://dx.doi.org/10.1038/sj.onc.1210350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369860				2022-12-25	WOS:000248801900009
J	Takahashi, M; Ozaki, T; Takahashi, A; Miyauchi, M; Ono, S; Takada, N; Koda, T; Todo, S; Kamijo, T; Nakagawara, A				Takahashi, M.; Ozaki, T.; Takahashi, A.; Miyauchi, M.; Ono, S.; Takada, N.; Koda, T.; Todo, S.; Kamijo, T.; Nakagawara, A.			DFF45/ICAD restores cisplatin-induced nuclear fragmentation but not DNA cleavage in DFF45-deficient neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cisplatin; DFF45/ICAD; homozygous deletion; neuroblastoma	CASPASE-ACTIVATED DNASE; TUMOR-SUPPRESSOR GENES; CHROMATIN CONDENSATION; N-MYC; APOPTOSIS; INHIBITOR; DELETION; LINE; IDENTIFICATION; AMPLIFICATION	We have previously defined a homozygously deleted region at chromosome 1p36.2-p36.3 in human neuroblastoma cell lines, NB-1 and NB-C201, and identified six genes including DFF45/ICAD within this region. In this study, we found that NB-C201 cells are much more resistant to various genotoxic stresses such as cisplatin (CDDP) than CHP134 and SH-SY5Y cells that do not have the homozygous deletion. To examine a role(s) of DFF45 in the regulation of apoptosis in response to CDDP, we have established stably DFF45-expressing NB-C 201 cell clones (DFF45-1 and DFF45-3) and a control cell clone (NB-C201-C) using a retrovirus-mediated gene transfer. In contrast to NB-C201-C cells, DFF45-3 cells displayed apoptotic nuclear fragmentation in response to CDDP. Although CDDP-induced proteolytic cleavage of procaspase-3 and DFF45 in DFF45-3 cells, we could not detect a typical apoptotic DNA fragmentation. Additionally, deletion analysis revealed that C-terminal region of DFF45 is required for inducing nuclear fragmentation. Unexpectedly, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that DFF45 has undetectable effect on CDDP sensitivity of NB-C201 cells. Taken together, our present results suggest that DFF45/DFF40 system may be sufficient for CDDP-induced nuclear fragmentation but not DNA cleavage.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 060, Japan; Hisamitsu Pharmaceut Co Inc, Ctr Funct Genom, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Hokkaido University; Hisamitsu Pharmaceutical Co Ltd; Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CHENG NC, 1995, ONCOGENE, V10, P291; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu ZG, 2005, P NATL ACAD SCI USA, V102, P2778, DOI 10.1073/pnas.0405374102; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450	24	7	7	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5669	5673		10.1038/sj.onc.1210352	http://dx.doi.org/10.1038/sj.onc.1210352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353905				2022-12-25	WOS:000248801900013
J	Bakali, HMA; Herman, MD; Johnson, KA; Kelly, AA; Wieslander, A; Hallberg, BM; Nordlund, P				Bakali, H. M. Amin; Herman, Maria Dolores; Johnson, Kenneth A.; Kelly, Amelie A.; Wieslander, AKe; Hallberg, B. Martin; Nordlund, Par			Crystal structure of YegS, a homologue to the mammalian diacylglycerol kinases, reveals a novel regulatory metal binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS NAD KINASE; ESCHERICHIA-COLI; SN-1,2-DIACYLGLYCEROL KINASE; GENE ENCODES; ZINC-FINGER; ACTIVE-SITE; HAND MOTIFS; PROTEIN; CALCIUM; COMPLEX	The human lipid kinase family controls cell proliferation, differentiation, and tumorigenesis and includes diacylglycerol kinases, sphingosine kinases, and ceramide kinases. YegS is an Escherichia coli protein with significant sequence homology to the catalytic domain of the human lipid kinases. We have solved the crystal structure of YegS and shown that it is a lipid kinase with phosphatidylglycerol kinase activity. The crystal structure reveals a two-domain protein with significant structural similarity to a family of NAD kinases. The active site is located in the interdomain cleft formed by four conserved sequence motifs. Surprisingly, the structure reveals a novel metal binding site composed of residues conserved in most lipid kinases.	Karolinska Inst, Dept Med Biochem & Biophys, Div Biophys, S-17177 Stockholm, Sweden; Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Biophys, S-17177 Stockholm, Sweden.	par.nordlund@mbb.ki.se	Hallberg, B. Martin/C-5361-2009	Hallberg, B. Martin/0000-0002-6781-0345				Abe T, 2003, BIOCHEM J, V375, P673, DOI 10.1042/BJ20031052; Bakali HMA, 2006, ACTA CRYSTALLOGR F, V62, P295, DOI 10.1107/S1744309106004799; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang JS, 1997, CANCER RES, V57, P5465; Cheek S, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-6; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Dormitzer PR, 2002, EMBO J, V21, P885, DOI 10.1093/emboj/21.5.885; Evans W, 1997, CHEM BRIT, V33, P22; Garavaglia S, 2004, J BIOL CHEM, V279, P40980, DOI 10.1074/jbc.M406586200; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Imai S, 2005, J BIOL CHEM, V280, P39870, DOI 10.1074/jbc.M500669200; JACKSON BJ, 1986, J BIOL CHEM, V261, P3464; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4ESFEAMCB N, V26; Liu JY, 2005, J MOL BIOL, V354, P289, DOI 10.1016/j.jmb.2005.09.026; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Michiels J, 2002, TRENDS MICROBIOL, V10, P87, DOI 10.1016/S0966-842X(01)02284-3; Mori S, 2005, BIOCHEM BIOPH RES CO, V327, P500, DOI 10.1016/j.bbrc.2004.11.163; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owens RM, 2006, MOL MICROBIOL, V60, P1152, DOI 10.1111/j.1365-2958.2006.05174.x; Oxenoid K, 2002, BIOCHEMISTRY-US, V41, P12876, DOI 10.1021/bi020335o; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Selzner M, 2001, CANCER RES, V61, P1233; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Steinhauser D, 2004, BIOINFORMATICS, V20, P3647, DOI 10.1093/bioinformatics/bth398; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van den Berg S, 2006, J BIOTECHNOL, V121, P291, DOI 10.1016/j.jbiotec.2005.08.006; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Waggoner DW, 2004, J BIOL CHEM, V279, P38228, DOI 10.1074/jbc.M405932200; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	54	29	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19644	19652		10.1074/jbc.M604852200	http://dx.doi.org/10.1074/jbc.M604852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17351295	hybrid			2022-12-25	WOS:000247650600039
J	Hao, JJ; Narayanan, K; Muni, T; Ramachandran, A; George, A				Hao, Jianjun; Narayanan, Karthikeyan; Muni, Tanvi; Ramachandran, Amsaveni; George, Anne			Dentin matrix protein 4, a novel secretory calcium-binding protein that modulates odontoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; DENTIN SIALOPROTEIN; GAMMA-CRYSTALLIN; IN-VITRO; EYE LENS; EXPRESSION; TISSUE; CELLS; BIOMINERALIZATION; PHOSPHOPROTEIN	Formation of calcified tissues is a well regulated process. In dentin, the odontoblasts synthesize several biomolecules that function as nucleators or inhibitors of mineralization. To identify genes that are odontoblast-specific, a subtractive hybridization technique was employed that resulted in the identification of a previously undescribed novel gene synthesized by the odontoblasts. Based on the nomenclature in our laboratory, this gene has been named dentin matrix protein 4 (DMP4). The protein encoded by mouse DMP4 cDNA contained 579 amino acids, including a 26-amino acid signal peptide. Analysis of the protein sequence demonstrated the presence of a Greek key calcium- binding domain and one conserved domain of unknown function in all the species examined thus far. Calcium binding property was confirmed by Ca-45 binding assays and the corresponding change in conformation by far-ultraviolet circular dichroism. Northern analysis demonstrated high expression levels of a single 3-kb mRNA transcript in tooth, whereas low expression levels were detected in other tissues. In situ hybridization analysis showed high expression levels of DMP4 in odontoblasts and low levels in osteoblasts and ameloblasts during tooth development. Gain and loss of function experiments demonstrated that DMP4 had the potential to differentiate mesenchymal precursor cells into functional odontoblast-like cells.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE11657, DE 13836] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; George A, 1999, CONNECT TISSUE RES, V40, P49, DOI 10.3109/03008209909005277; GEORGE A, 1993, J BIOL CHEM, V268, P12624; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Hao JJ, 2005, BONE, V37, P578, DOI 10.1016/j.bone.2005.05.013; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; Hao JJ, 2002, J BIOL CHEM, V277, P19976, DOI 10.1074/jbc.M112223200; Harada H, 2006, BIOCHEM BIOPH RES CO, V340, P611, DOI 10.1016/j.bbrc.2005.12.053; HARLOW E, 1998, ANTIBODIES LAB MANUA, P421; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MACDOUGALL M, 1995, CONNECT TISSUE RES, V22, P71; Nalbant D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-11; Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296; Rajini B, 2001, J BIOL CHEM, V276, P38464, DOI 10.1074/jbc.M102164200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Thesleff I, 2001, Adv Dent Res, V15, P14; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Witkop C J Jr, 1966, Ala J Med Sci, V3, P382; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Xu LM, 2006, J BIOL CHEM, V281, P2257, DOI 10.1074/jbc.M507695200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	26	65	67	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15357	15365		10.1074/jbc.M701547200	http://dx.doi.org/10.1074/jbc.M701547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369251	hybrid			2022-12-25	WOS:000246589600011
J	Macgregor, A; Yamasaki, M; Rakovic, S; Sanders, L; Parkesh, R; Churchill, GC; Galione, A; Terrar, DA				Macgregor, Andrew; Yamasaki, Michiko; Rakovic, Stevan; Sanders, Luke; Parkesh, Raman; Churchill, Grant C.; Galione, Antony; Terrar, Derek A.			NAADP controls cross-talk between distinct Ca2+ stores in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; ENDOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; PANCREATIC ACINAR; BETA-CELLS; CALCIUM; RELEASE; CONTRACTION; RECEPTORS; COORDINATION	In cardiac muscle the sarcoplasmic reticulum (SR) plays a key role in the control of contraction, releasing Ca2+ in response to Ca2+ influx across the sarcolemma via voltage- gated Ca2+ channels. Here we report evidence for an additional distinct Ca2+ store and for actions of nicotinic acid adenine dinucleotide phosphate (NAADP) to mobilize Ca2+ from this store, leading in turn to enhanced Ca2+ loading of the SR. Photoreleased NAADP increased Ca2+ transients accompanying stimulated action potentials in ventricular myocytes. The effects were prevented by bafilomycin A (an H+-ATPase inhibitor acting on acidic Ca2+ stores), by desensitizing concentrations of NAADP, and by ryanodine and thapsigargin to suppress SR function. Bafilomycin A also suppressed staining of acidic stores with Lysotracker Red without affecting SR integrity. Cytosolic application of NAADP by means of its membrane permeant acetoxymethyl ester increased myocyte contraction and the frequency and amplitude of Ca2+ sparks, and these effects were inhibited by bafilomycin A. Effects of NAADP were associated with an increase in SR Ca2+ load and appeared to be regulated by beta-adrenoreceptor stimulation. The observations are consistent with a novel role for NAADP in cardiac muscle mediated by Ca2+ release from bafilomycin-sensitive acidic stores, which in turn enhances SR Ca2+ release by increasing SR Ca2+ load.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Yamasaki, M (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	michiko.yamasaki@pharmacology.oxford.ac.uk	Galione, Antony/E-5884-2011	Terrar, Derek/0000-0001-9408-6594; Galione, Antony/0000-0002-4132-7646	Biotechnology and Biological Sciences Research Council [BB/D012694/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline; BBSRC [BB/D012694/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Brailoiu E, 2006, J BIOL CHEM, V281, P15923, DOI 10.1074/jbc.M602249200; Cancela JM, 2003, PFLUG ARCH EUR J PHY, V446, P322, DOI 10.1007/s00424-003-1035-x; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 2002, BIOCHEM J, V362, P125, DOI 10.1042/0264-6021:3620125; Christensen KA, 2002, J CELL SCI, V115, P599; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Galione A, 2005, CELL CALCIUM, V38, P273, DOI 10.1016/j.ceca.2005.06.031; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Iino S, 1997, CIRC RES, V81, P879; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; MACGREGOR AT, 2006, IN PRESS CELL CALCIU; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; MORGAN AJ, 2006, METHODS CALCIUM SIGN, P265; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Patel S, 2004, BIOL CELL, V96, P19, DOI 10.1016/j.biolcel.2003.12.001; Petersen OH, 2005, CELL CALCIUM, V38, P161, DOI 10.1016/j.ceca.2005.06.023; RAKOVIC S, 2002, CYCLIC ADP RIBOSE NA, P45; VARRO A, 1993, BRIT J PHARMACOL, V109, P895, DOI 10.1111/j.1476-5381.1993.tb13702.x; Yamasaki M, 2005, FEBS J, V272, P4598, DOI 10.1111/j.1742-4658.2005.04860.x; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Zhang F, 2006, AM J PHYSIOL-HEART C, V291, pH274, DOI 10.1152/ajpheart.01064.2005	34	76	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15302	15311		10.1074/jbc.M611167200	http://dx.doi.org/10.1074/jbc.M611167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387177	hybrid			2022-12-25	WOS:000246589000069
J	Zhang, R; Zhang, HF; Lin, Y; Li, JH; Pober, JS; Min, W				Zhang, Rong; Zhang, Haifeng; Lin, Yan; Li, Jiehui; Pober, Jordan S.; Min, Wang			RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical for tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REGULATING KINASE 1; NECROSIS-FACTOR; CELL-DEATH; INDUCED ACTIVATION; APOPTOSIS; ASK1; RIP1; INHIBITOR; INDUCTION	Previously, we have shown that (A) under bar SK1-(i) under bar nteracting (p) under bar rotein 1 (AIP1, also known as DAB2IP), a novel member of the Ras-GAP (Ras-GTPase-activating protein) protein family, opens its conformation in response to tumor necrosis factor (TNF), allowing it to form a complex with TRAF2-ASK1 that leads to activation of ASK1-JNK/p38 signaling in endothelial cells (EC). In the present study, we show that a TNF-inducible 14-3-3-binding site on AIP1 is critical for the opening of its conformation and for the AIP1-mediated TNF signaling. Ser-604, located in the C-terminal domain of AIP1, was identified as a 14-3-3-binding site. TNF treatment of EC induces phosphorylation of AIP1 at Ser-604 as detected by a phospho-specific antibody, with a similar kinetics to ASK1-JNK/p38 activation. 14-3-3 associates with an open, active state of AIP1 assessed by an in vitro pulldown assay. Mutation of AIP1 at Ser-604 (AIP1-S604A) blocks TNF-induced complex formation of AIP1 with 14-3-3. TNF treatment normally induces association of AIP1 with TRAF2-ASK1. The interactions with TRAF2 and ASK1 do not occur with AIP1-S604A, suggesting that phosphorylation at this site not only creates a 14-3-3-binding site but also opens up AIP1, allowing binding to TRAF2 and ASK1. Overexpression of AIP1-S604A blocks TNF-induced ASK1-JNK activation. We further show that RIP1 (the Ser/Thr protein kinase receptor-interacting protein) associates with the GAP domain of AIP1 and mediates TNF-induced AIP1 phosphorylation at Ser-604 and JNK/p38 activation as demonstrated by both overexpression and small interfering RNA knockdown of RIP1 in EC. Furthermore, RIP1 synergizes with AIP1 (but not AIP1-S604A) in inducing both JNK/p38 activation and EC apoptosis. Our results demonstrate that RIP1-mediated AIP1 phosphorylation at the 14-3-3-binding site Ser-604 is essential for TNF-induced TRAF2-RIP1-AIP1-ASK1 complex formation and for the activation of ASK1-JNK/p38 apoptotic signaling.	Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunobiol Pathol & Dermatol, New Haven, CT 06510 USA	Yale University; Yale University	Min, W (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Dept Pathol, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295, R01HL036003, R37HL036003, R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL070295-6, R01HL-65978-5, HV28286, HL-36003] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guicciardi ME, 2003, J CLIN INVEST, V111, P1813, DOI 10.1172/JCI200318911; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	29	65	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14788	14796		10.1074/jbc.M701148200	http://dx.doi.org/10.1074/jbc.M701148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389591	hybrid			2022-12-25	WOS:000246589000014
J	Connors, WL; Jokinen, J; White, DJ; Puranen, JS; Kankaanpaa, P; Upla, P; Tulla, M; Johnson, MS; Heino, J				Connors, Wendy L.; Jokinen, Johanna; White, Daniel J.; Puranen, J. Santeri; Kankaanpaa, Pasi; Upla, Paula; Tulla, Mira; Johnson, Mark S.; Heino, Jyrki			Two synergistic activation mechanisms of alpha 2 beta 1 integrin-mediated collagen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-ADHESION; AVIDITY REGULATION; I COLLAGEN; RECEPTOR; CONFORMATION; PLATELETS; AFFINITY; BETA-1; DOMAIN	Activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA) induces ligand-independent aggregation of a cell surface collagen receptor, alpha 2 beta 1 integrin. Concomitantly, TPA increases the avidity of alpha 2 beta 1 for collagen and the number of conformationally activated alpha 2 beta 1 integrins. The structural change was shown using a monoclonal antibody 12F1 that recognizes the "open" active) conformation of the inserted domain in the alpha 2 subunit (alpha 2I). Amino acid residue Glu-336 in alpha 2 subunit is proposed to mediate the interaction between alpha 2I domain and beta 1 subunit. Glu-336 seems to regulate a switch between open and "closed" conformations, since the mutation alpha 2E336A inhibited the TPA-related increase in the number of 12F1 positive integrins. E336A also reduced cell adhesion to collagen. However, E336A did not prevent the TPA-related increase in adhesion to collagen or alpha 2 beta 1 aggregation. Thus, alpha 2 beta 1 integrin avidity is regulated by two synergistic mechanisms, first an alpha 2E336-dependent switch to the open alpha 2I conformation, and second an alpha 2E336-independent mechanism temporally associated with receptor aggregation.	Turku Univ, Dept Biochem & Food Chem, FI-20014 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland; Abo Akad Univ, Dept Biochem & Pharm, FI-20520 Turku, Finland	University of Turku; University of Jyvaskyla; Abo Akademi University	Heino, J (corresponding author), Turku Univ, Dept Biochem & Food Chem, FI-20014 Turku, Finland.	jyrki.heino@utu.fi						Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cambi A, 2006, MOL BIOL CELL, V17, P4270, DOI 10.1091/mbc.E05-12-1098; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; Connors WL, 2005, ANAL BIOCHEM, V337, P246, DOI 10.1016/j.ab.2004.10.044; Cruz MA, 2005, BLOOD, V105, P1986, DOI 10.1182/blood-2004-04-1365; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Grundstrom G, 2003, EXP CELL RES, V291, P463, DOI 10.1016/j.yexcr.2003.07.010; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Polanowska-Grabowska R, 1999, ARTERIOSCL THROM VAS, V19, P3044, DOI 10.1161/01.ATV.19.12.3044; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sarantos MR, 2005, J BIOL CHEM, V280, P28290, DOI 10.1074/jbc.M501662200; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Van de Walle GR, 2005, J BIOL CHEM, V280, P36873, DOI 10.1074/jbc.M508148200; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	47	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14675	14683		10.1074/jbc.M700759200	http://dx.doi.org/10.1074/jbc.M700759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374611	hybrid			2022-12-25	WOS:000246245800081
J	Seong, HA; Jung, H; Kim, KT; Ha, H				Seong, Hyun-A; Jung, Haiyoung; Kim, Kyong-Tai; Ha, Hyunjung			3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION INHIBITORY FACTOR; TGF-BETA; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIPROLIFERATIVE FUNCTION; MESENCHYMAL TRANSITION; PHOSPHORYLATION; ACTIVATION; SUPERFAMILY; RECEPTOR	We have reported previously that PDK1 physically interacts with STRAP, a transforming growth factor-beta ( TGF-beta) receptor-interacting protein, and enhances STRAP-induced inhibition of TGF-beta signaling. In this study we show that PDK1 coimmunoprecipitates with Smad proteins, including Smad2, Smad3, Smad4, and Smad7, and that this association is mediated by the pleckstrin homology domain of PDK1. The association between PDK1 and Smad proteins is increased by insulin treatment but decreased by TGF-beta treatment. Analysis of the interacting proteins shows that Smad proteins enhance PDK1 kinase activity by removing 14-3-3, a negative regulator of PDK1, from the PDK1-14-3-3 complex. Knockdown of endogenous Smad proteins, including Smad3 and Smad7, by transfection with small interfering RNA produced the opposite trend and decreased PDK1 activity, protein kinase B/Akt phosphorylation, and Bad phosphorylation. Moreover, coexpression of Smad proteins and wild-type PDK1 inhibits TGF-beta-induced transcription, as well as TGF-beta-mediated biological functions, such as apoptosis and cell growth arrest. Inhibition was dose-dependent on PDK1, but no inhibition was observed in the presence of an inactive kinase-dead PDK1 mutant. In addition, confocal microscopy showed that wild-type PDK1 prevents translocation of Smad3 and Smad4 from the cytoplasm to the nucleus, as well as the redistribution of Smad7 from the nucleus to the cytoplasm in response to TGF-beta. Taken together, our results suggest that PDK1 negatively regulates TGF-beta-mediated signaling in a PDK1 kinase-dependent manner via a direct physical interaction with Smad proteins and that Smad proteins can act as potential positive regulators of PDK1.	Chungbuk Natl Univ, Dept Biochem, Res Ctr Bioresource & Hlth, Biotechnol Res Inst,Sch Life Sci, Cheongju 361763, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Pohang University of Science & Technology (POSTECH)	Ha, H (corresponding author), Chungbuk Natl Univ, Dept Biochem, Res Ctr Bioresource & Hlth, Biotechnol Res Inst,Sch Life Sci, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; DEL PL, 1997, SCIENCE, V278, P687; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; DOSSARBASSOV D, 2005, SCIENCE, V307, P1098; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liu F, 2005, CELL CYCLE, V4, P63, DOI 10.4161/cc.4.1.1366; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamagata H, 2005, CANCER RES, V65, P157; Yao KS, 2005, CLIN CANCER RES, V11, P7264, DOI 10.1158/1078-0432.CCR-05-0135; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	48	32	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12272	12289		10.1074/jbc.M609279200	http://dx.doi.org/10.1074/jbc.M609279200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17327236	hybrid			2022-12-25	WOS:000245941900070
J	Takeda, K; Sasaki, AT; Ha, HJ; Seung, HA; Firtel, RA				Takeda, Kosuke; Sasaki, Atsuo T.; Ha, Hyunjung; Seung, Hyun-A; Firtel, Richard A.			Role of phosphatidylinositol 3-kinases in chemotaxis in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL POLARITY; LEADING-EDGE; NEUTROPHIL CHEMOTAXIS; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; PI 3-KINASE; PROTEIN; ACTIVATION; MIGRATION; KINASE	Experiments in several cell types revealed that local accumulation of phosphatidylinositol 3,4,5-triphosphate mediates the ability of cells to migrate during gradient sensing. We took a systematic approach to characterize the functions of the six putative Class I phosphatidylinositol 3-kinases ( PI3K1-6) in Dictyostelium by creating a series of gene knockouts. These studies revealed that PI3K1-PI3K3 are the major PI3Ks for chemoattractant-mediated phosphatidylinositol 3,4,5-triphosphate production. We studied chemotaxis of the pi3k1/2/3 triple knock-out strain ( pi3k1/2/3 null cells) to cAMP under two distinct experimental conditions, an exponential gradient emitted from a micropipette and a shallow, linear gradient in a Dunn chamber, using four cAMP concentrations ranging over a factor of 10,000. Under all conditions tested pi3k1/2/3 null cells moved slower and had less polarity than wild-type cells. pi3k1/2/3 null cells moved toward a chemoattractant emitted by a micropipette, although persistence was lower than that of wildtype or pi3k1/2 null cells. In shallow linear gradients, pi3k1/2 null cells had greater directionality defects, especially at lower chemoattractant concentrations. Our studies suggest that although PI3K is not essential for directional movement under some chemoattractant conditions, it is a key component of the directional sensing pathway and plays a critical role in linear chemoattractant gradients, especially at low chemoattractant concentrations. The relative importance of PI3K in chemotaxis is also dependent on the developmental stage of the cells. Our data suggest that the output of other signaling pathways suffices to mediate directional sensing when cells perceive a strong signal, but PI3K signaling is crucial for detecting weaker signals.	Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Firtel, RA (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, Nat Sci Bldg,Rm 6316,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu		Sasaki, Atsuo/0000-0003-2963-4501				Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; Bagorda A, 2006, THROMB HAEMOSTASIS, V95, P12, DOI 10.1160/TH05-07-0483; Barber MA, 2006, B CANC, V93, P10044; Bourne HR, 2005, NAT CELL BIOL, V7, P777, DOI 10.1038/ncb0805-777; Charest PG, 2006, CURR OPIN GENET DEV, V16, P339, DOI 10.1016/j.gde.2006.06.016; Chen LF, 2003, MOL BIOL CELL, V14, P5028, DOI 10.1091/mbc.E03-05-0339; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Comer FI, 2006, MOL BIOL CELL, V17, P357, DOI 10.1091/mbc.E05-08-0781; Corner FI, 2005, CURR BIOL, V15, P134, DOI 10.1016/j.cub.2005.01.007; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Kimmel AR, 2003, SCIENCE, V300, P1525, DOI 10.1126/science.1085439; Kriebel PW, 2003, CELL, V112, P549, DOI 10.1016/S0092-8674(03)00081-3; Kunisaki Y, 2006, J CELL BIOL, V174, P647, DOI 10.1083/jcb.200602142; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Loovers HM, 2006, MOL BIOL CELL, V17, P1503, DOI 10.1091/mbc.E05-09-0825; Meili R, 2000, CURR BIOL, V10, P708, DOI 10.1016/S0960-9822(00)00536-4; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nombela-Arrieta C, 2004, IMMUNITY, V21, P429, DOI 10.1016/j.immuni.2004.07.012; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park KC, 2004, EMBO J, V23, P4177, DOI 10.1038/sj.emboj.7600368; Postma M, 2004, J CELL SCI, V117, P2925, DOI 10.1242/jcs.01143; Reif K, 2002, TRENDS CELL BIOL, V12, P368, DOI 10.1016/S0962-8924(02)02330-9; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Sasaki AT, 2006, EUR J CELL BIOL, V85, P873, DOI 10.1016/j.ejcb.2006.04.007; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wessels D, 1998, CELL MOTIL CYTOSKEL, V41, P225, DOI 10.1002/(SICI)1097-0169(1998)41:3<225::AID-CM4>3.3.CO;2-9; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	42	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11874	11884		10.1074/jbc.M610984200	http://dx.doi.org/10.1074/jbc.M610984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17331950	hybrid			2022-12-25	WOS:000245941900030
J	Kreimann, EL; Morales, FC; de Orbeta-Cruz, J; Takahashi, Y; Adams, H; Liu, TJ; McCrea, PD; Georgescu, MM				Kreimann, E. L.; Morales, F. C.; de Orbeta-Cruz, J.; Takahashi, Y.; Adams, H.; Liu, T-J; McCrea, P. D.; Georgescu, M-M			Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function	ONCOGENE			English	Article						NHERF1/EBP50; beta-catenin; E-cadherin; transformation; colon cancer; mouse embryonic fibroblasts (MEFs)	E-CADHERIN; NHERF; PROTEINS; COMPLEX; IDENTIFICATION; INHIBITION; MEMBRANE; ADHESIVE; FAMILY; GROWTH	Anchorage-independent growth is a hallmark of tumor growth and results from enhanced proliferation and altered cell-cell and cell-matrix interactions. By using gene-deficient mouse embryonic fibroblasts ( MEFs), we showed for the first time that NHERF1/EBP50 (Na/H exchanger regulator factor 1/ezrin-radixin-moesin binding phosphoprotein 50), an adapter protein with membrane localization under physiological conditions, inhibits cell motility and is required to suppress anchorage-independent growth. Both NHERF1 PDZ domains are necessary for the tumor suppressor effect. NHERF1 associates directly through the PDZ2 domain with beta-catenin and is required for beta-catenin localization at the cell- cell junctions in MEFs. Mechanistically, the absence of NHERF1 selectively decreased the interaction of beta-catenin with E-cadherin, but not with N-cadherin. The ensuing disorganization of E-cadherinmediated adherens junctions as well as the observed moderate increase in beta-catenin transcriptional activity contributed most likely to the anchorage-independent growth of NHERF1-deficient MEFs. In vivo, NHERF1 is specifically localized at the apical brush-border membrane in intestinal epithelial cells and is required to maintain a fraction of the cortical beta-catenin at this level. Thus, NHERF1 emerges as a cofactor essential for the integrity of epithelial tissues by maintaining the proper localization and complex assembly of beta-catenin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Georgescu, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.	mgeorges@mdanderson.org	Georgescu, Maria-Magdalena/AAJ-6359-2020; Kreimann, Erica/W-2082-2019; Adams, Henry/AAV-6870-2021		NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Weinman EJ, 2003, BIOCHEMISTRY-US, V42, P12662, DOI 10.1021/bi035244l	21	85	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5290	5299		10.1038/sj.onc.1210336	http://dx.doi.org/10.1038/sj.onc.1210336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325659				2022-12-25	WOS:000248674200012
J	Kehn, K; Berro, R; Alhaj, A; Bottazzi, M; Yeh, WI; Klase, Z; Van Duyne, R; Fu, S; Kashanchi, F				Kehn, K.; Berro, R.; Alhaj, A.; Bottazzi, M. E.; Yeh, W-I; Klase, Z.; Van Duyne, R.; Fu, S.; Kashanchi, F.			Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells	ONCOGENE			English	Article						BRCA1; cyclin D1; cdk4; transcription; phosphorylation	ESTROGEN-RECEPTOR; DEPENDENT KINASES; DNA-BINDING; BRCA1; GENE; PHOSPHORYLATION; TRANSCRIPTION; FASCAPLYSIN; INHIBITION; EXPRESSION	The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRC A1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4- mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA- dependent activities of BRCA1.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Dept Microbiol, Inst Proteom Technol & Applicat, Washington, DC 20037 USA; Inst Genom Res TIGR, Dept Biochem, Rockville, MD USA	George Washington University; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St,NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013; Van Duyne, Rachel/I-7365-2019	Bottazzi, Maria Elena/0000-0002-8429-0476; Van Duyne, Rachel/0000-0003-2914-6874	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R21AI065236] Funding Source: NIH RePORTER; NIAID NIH HHS [AI043894, AI065236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aubry C, 2004, CHEM COMMUN, P1696, DOI 10.1039/b406076h; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Chen YM, 1996, CANCER RES, V56, P3168; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fan SJ, 2002, CANCER RES, V62, P141; Hejna M, 2002, ANN ONCOL, V13, P653, DOI 10.1093/annonc/mdf142; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Katoh M, 2004, INT J ONCOL, V25, P1495; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lin L, 2002, CANCER RES, V62, P5273; Mark WY, 2005, J MOL BIOL, V345, P275, DOI 10.1016/j.jmb.2004.10.045; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Moisan A, 2006, J BIOL CHEM, V281, P21119, DOI 10.1074/jbc.M600712200; Montminy M, 1996, METABOLISM, V45, P4, DOI 10.1016/S0026-0495(96)90068-2; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Santosh M, 1999, GONDWANA RES, V2, P1, DOI 10.1016/S1342-937X(05)70121-0; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Teh MT, 2002, CANCER RES, V62, P4773; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	32	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5060	5069		10.1038/sj.onc.1210319	http://dx.doi.org/10.1038/sj.onc.1210319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334399				2022-12-25	WOS:000248487400004
J	Baltz, KM; Krusch, M; Bringmann, A; Brossart, P; Mayer, F; Kloss, M; Baessler, T; Kumbier, I; Peterfi, A; Kupka, S; Kroeber, S; Menzel, D; Radsak, MP; Rammensee, HG; Salih, HR				Baltz, Katrin M.; Krusch, Matthias; Bringmann, Anita; Brossart, Peter; Mayer, Frank; Kloss, Mercedes; Baessler, Tina; Kumbier, Ingrid; Peterfi, Andrea; Kupka, Susan; Kroeber, Stefan; Menzel, Dagmar; Radsak, Markus P.; Rammensee, Hans-Georg; Salih, Helmut R.			Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions	FASEB JOURNAL			English	Article						tumor immunity; TNF family; TNFRSF18; immune escape	FACTOR RECEPTOR SUPERFAMILY; REGULATORY T-CELLS; TUMOR-IMMUNITY; FAMILY; ACTIVATION; EXPRESSION; SUPPRESSION; APOPTOSIS; IMMUNOSURVEILLANCE; DIFFERENTIATION	Glucocorticoid-induced TNF-related protein ( GITR) has been shown to stimulate T cell-mediated antitumor immunity in mice. However, the functional relevance of GITR and its ligand ( GITRL) for non-T cells has yet to be fully explored. In addition, recent evidence suggests that GITR plays different roles in mice and humans. We studied the role of GITR-GITRL interaction in human tumor immunology and report for the first time that primary gastrointestinal cancers and tumor cell lines of different histological origin express substantial levels of GITRL. Signaling through GITRL down-regulated the expression of the immunostimulatory molecules CD40 and CD54 and the adhesion molecule EpCAM, and induced production of the immunosuppressive cytokine TGF-beta by tumor cells. On NK cells, GITR is constitutively expressed and up-regulated following activation. Blocking GITR- GITRL interaction in cocultures of tumor cells and NK cells substantially increased cytotoxicity and IFN- gamma production of NK cells demonstrating that constitutive expression of GITRL by tumor cells diminishes NK cell antitumor immunity. GITRL-Ig fusion protein or cell surface-expressed GITRL did not induce apoptosis in NK cells, but diminished nuclear localized c-Rel and RelB, indicating that GITR might negatively modulate NK cell NF-B-k activity. Taken together, our data indicate that tumor-expressed GITRL mediates immunosubversion in humans.	Univ Tubingen, Dept Internal Med, D-72076 Tubingen, Germany; Univ Tubingen, Dept Surg, D-72076 Tubingen, Germany; Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany; Univ Tubingen, Ctr Clin Transfus Med, D-72076 Tubingen, Germany; Univ Mainz, Dept Internal Med, Mainz, Germany; Univ Tubingen, Dept Immunol, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen	Salih, HR (corresponding author), Univ Tubingen, Dept Internal Med, Otfried Mueller Str 10, D-72076 Tubingen, Germany.	helmut.salih@med.uni-tuebingen.de	Radsak, Markus P/L-3651-2013	Radsak, Markus P/0000-0002-3991-5721				Agostini M, 2005, INFECT IMMUN, V73, P7502, DOI 10.1128/IAI.73.11.7502-7508.2005; Appel S, 2004, BLOOD, V103, P538, DOI 10.1182/blood-2003-03-0975; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Calmels B, 2005, CANCER GENE THER, V12, P198, DOI 10.1038/sj.cgt.7700781; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Cohen AD, 2006, CANCER RES, V66, P4904, DOI 10.1158/0008-5472.CAN-05-2813; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Esparza EM, 2006, J BIOL CHEM, V281, P8559, DOI 10.1074/jbc.M512915200; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hanabuchi S, 2006, BLOOD, V107, P3617, DOI 10.1182/blood-2005-08-3419; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kim BJ, 2004, INVEST OPHTH VIS SCI, V45, P3170, DOI 10.1167/iovs.03-0919; Kim HJ, 2006, J IMMUNOL, V176, P3507, DOI 10.4049/jimmunol.176.6.3507; Kim JD, 2003, GENES IMMUN, V4, P564, DOI 10.1038/sj.gene.6364026; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Levin S, 2002, FAM COMMUNITY HEALTH, V25, P10, DOI 10.1097/00003727-200210000-00005; Levings MK, 2002, J EXP MED, V196, P1335, DOI 10.1084/jem.20021139; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818; Ramirez-Montagut T, 2006, J IMMUNOL, V176, P6434, DOI 10.4049/jimmunol.176.11.6434; Roncagalli R, 2005, NAT IMMUNOL, V6, P1002, DOI 10.1038/ni1242; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; Shevach EM, 2006, NAT REV IMMUNOL, V6, P613, DOI 10.1038/nri1867; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shin HH, 2002, FEBS LETT, V514, P275, DOI 10.1016/S0014-5793(02)02379-7; Shin HH, 2005, BONE, V36, P832, DOI 10.1016/j.bone.2005.02.014; Shin HH, 2004, BIOCHEM BIOPH RES CO, V316, P24, DOI 10.1016/j.bbrc.2004.02.012; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Turk MJ, 2004, J EXP MED, V200, P771, DOI 10.1084/jem.20041130; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	42	80	93	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2442	2454		10.1096/fj.06-7724com	http://dx.doi.org/10.1096/fj.06-7724com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17360848				2022-12-25	WOS:000248454400019
J	Burkhard, KA; Wilks, A				Burkhard, Kimberly A.; Wilks, Angela			Characterization of the outer membrane receptor ShuA from the heme uptake system of Shigella dysenteriae - Substrate specificity and identification of the heme protein ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; BINDING-PROTEIN; PSEUDOMONAS-AERUGINOSA; YERSINIA-ENTEROCOLITICA; NEISSERIA-MENINGITIDIS; CRYSTAL-STRUCTURE; HAEMOPHILUS-INFLUENZAE; CYTOPLASMIC MEMBRANE; HEMOGLOBIN RECEPTOR	Shigella dysenteriae, like many bacterial pathogens, has evolved outer membrane receptor-mediated pathways for the uptake and utilization of heme as an iron source. As a first step toward understanding the mechanism of heme uptake we have undertaken a site-directed mutagenesis, spectroscopic, and kinetic analysis of the outer membrane receptor ShuA of S. dysenteriae. Purification of the outer membrane receptor gave a single band of molecular mass 73 kDa on SDS-PAGE. Initial spectroscopic analysis of the protein in either detergent micelles or lipid bicelles revealed residual heme bound to the receptor, with a Soret maximum at 413 nm. Titration of the protein with exogenous heme gave a Soret peak at 437 nm in detergent micelles, and 402 nm in lipid bicelles. However, transfer of heme from hemoglobin yields a Soret maximum at 413 nm identical to that of the isolated protein. Further spectroscopic and kinetic analysis revealed that hemoglobin in the oxidized state is the most likely physiological substrate for ShuA. In addition, mutation of the conserved histidines, H86A or H420A, resulted in a loss of the ability of the receptor to efficiently extract heme from hemoglobin. In contrast the double mutant H86A/H420A was unable to extract heme from hemoglobin. These findings taken together confirm that both His-86 and His-420 are essential for substrate recognition, heme coordination, and transfer. Furthermore, the full-length TonB was shown to form a 1: 1 complex with either apo-ShuA H86A/H420A or the wild-type ShuA. These observations provide a basis for future studies on the coordination and transport of heme by the TonB-dependent outer membrane receptors.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Wilks, A (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	awilks@rx.umaryland.edu			NIAID NIH HHS [AI-48551] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048551] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Annamalai R, 2004, J BACTERIOL, V186, P3578, DOI 10.1128/JB.186.11.3578-3589.2004; Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Braun Volkmar, 2005, V12, P210, DOI 10.1159/000081697; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; Carter DM, 2006, J BIOL CHEM, V281, P35413, DOI 10.1074/jbc.M607611200; Cherla RP, 2003, FEMS MICROBIOL LETT, V228, P159, DOI 10.1016/S0378-1097(03)00761-4; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COPE LD, 1995, J BACTERIOL, V177, P2644, DOI 10.1128/jb.177.10.2644-2653.1995; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Fanucci GE, 2003, J AM CHEM SOC, V125, P13932, DOI 10.1021/ja0376442; Fanucci GE, 2003, P NATL ACAD SCI USA, V100, P11382, DOI 10.1073/pnas.1932486100; Ferguson AD, 2002, BBA-BIOMEMBRANES, V1565, P318, DOI 10.1016/S0005-2736(02)00578-3; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Fuller-Schaefer CA, 2005, J BACTERIOL, V187, P1732, DOI 10.1128/JB.187.5.1732-1739.2005; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; HENDERSON DP, 1994, INFECT IMMUN, V62, P5120, DOI 10.1128/IAI.62.11.5120-5125.1994; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; Jin HF, 1999, MICROBIOL-UK, V145, P905, DOI 10.1099/13500872-145-4-905; Khursigara CM, 2004, J BIOL CHEM, V279, P7405, DOI 10.1074/jbc.M311784200; Koster W, 2005, FRONT BIOSCI-LANDMRK, V10, P462, DOI 10.2741/1542; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; LEVITT M, 1995, COMPUT PHYS COMMUN, V91, P215, DOI 10.1016/0010-4655(95)00049-L; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lund O., 2002, CASP5 C, pA102; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057; Perkins-Balding D, 2004, MICROBIOL MOL BIOL R, V68, P154, DOI 10.1128/MMBR.68.1.154-171.2004; Perkins-Balding D, 2003, MICROBIOL-SGM, V149, P3423, DOI 10.1099/mic.0.26448-0; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Rossi MS, 2001, INFECT IMMUN, V69, P6707, DOI 10.1128/IAI.69.11.6707-6717.2001; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Srikumar R, 2004, MICROBIOL-SGM, V150, P1723, DOI 10.1099/mic.0.27046-0; Stojiljkovic I, 1996, J BACTERIOL, V178, P4670, DOI 10.1128/jb.178.15.4670-4678.1996; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Turner PC, 1998, INFECT IMMUN, V66, P5215, DOI 10.1128/IAI.66.11.5215-5223.1998; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005	56	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15126	15136		10.1074/jbc.M611121200	http://dx.doi.org/10.1074/jbc.M611121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387178	hybrid			2022-12-25	WOS:000246589000052
J	Guillemain, G; Filhoulaud, G; Da Silva-Xavier, G; Rutter, GA; Scharfmann, R				Guillemain, Ghislaine; Filhoulaud, Gaelle; Da Silva-Xavier, Gabriela; Rutter, Guy A.; Scharfmann, Raphael			Glucose is necessary for embryonic pancreatic endocrine cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ISLET BETA-CELL; GENE-EXPRESSION; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; RAT PANCREAS; ADULT-RATS; GROWTH; PROLIFERATION	Mature pancreatic cells develop during embryonic life from endodermal progenitors, and this developmental process depends on activation of a hierarchy of transcription factors. While information is available on mesodermal signals controlling pancreas development, little is known about environmental factors, such as the levels of nutrients including glucose, that may control this process. Here, we studied the effects of glucose on pancreatic cells development. We used an in vitro model where both endocrine and acinar cells develop from early pancreatic and duodenal homeobox- 1 ( PDX1)- positive embryonic pancreatic progenitors. We first showed that glucose does not have a major effect on global pancreatic cell proliferation, survival, and acinar cell development. On the other hand, glucose controlled both alpha and beta cell development. Specifically, the surface occupied by insulin- positive cells was 20- fold higher in pancreases cultured in presence than in absence of glucose, and this effect was dose- dependent over the range 0.5 - 10mM. Glucose did not appear to control beta cell development by activating the proliferation of early progenitors or beta cells themselves but instead tightly regulated cell differentiation. Thus, glucose did not modify the pattern of expression of Neurogenin3, the earliest marker of endocrine progenitor cells, but was necessary for the expression of the transcription factor NeuroD, a direct target of Neurogenin3 known to be important for proper pancreatic endocrine cell development. We conclude that glucose interferes with the pancreatic endocrine cells development by regulating the transition between Ngn3 and upstream NeuroD.	Univ Paris 05, Fac Med, INSERM, Necker Hosp,EMI 363, F-75730 Paris 15, France; U845, F-75730 Paris 15, France; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Cell Biol, London SW7 2AZ, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London	Guillemain, G (corresponding author), Fac Med Necker Enfants Malad, INSERM, E363, 156 Rue Vaugirard, F-75015 Paris, France.	guillemain@necker.fr	Guillemain, Ghislaine/P-7740-2017; scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X; Rutter, Guy/0000-0001-6360-0343; da Silva Xavier, Gabriela/0000-0002-0678-012X; Guillemain, Ghislaine/0000-0002-8256-9545	Diabetes UK [13/0004672] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Diabetes UK(Diabetes UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ainscow EK, 2002, J PHYSIOL-LONDON, V544, P429, DOI 10.1113/jphysiol.2002.022434; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; ATTALI M, 2007, IN PRESS DIABETES; Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058; Bernard C, 1999, FASEB J, V13, P1195, DOI 10.1096/fasebj.13.10.1195; Bhushan A, 2001, DEVELOPMENT, V128, P5109; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Collombat P, 2006, MECH DEVELOP, V123, P501, DOI 10.1016/j.mod.2006.05.006; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Duvillie B, 2003, DIABETES, V52, P2035, DOI 10.2337/diabetes.52.8.2035; Duvillie B, 2006, DIABETES, V55, P582, DOI 10.2337/diabetes.55.03.06.db05-0839; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edsbagge J, 2005, DEVELOPMENT, V132, P1085, DOI 10.1242/dev.01643; Garofano A, 1998, DIABETOLOGIA, V41, P1114, DOI 10.1007/s001250051038; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hattersley AT, 2005, DIABETES, V54, P2503, DOI 10.2337/diabetes.54.9.2503; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Kim SK, 1997, DEVELOPMENT, V124, P4243; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Limesand SW, 2005, AM J PHYSIOL-REG I, V288, pR1297, DOI 10.1152/ajpregu.00494.2004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez SC, 2006, DIABETES, V55, P1581, DOI 10.2337/db05-0678; McKinnon CM, 2006, J BIOL CHEM, V281, P39358, DOI 10.1074/jbc.M605022200; Miralles F, 1998, DEVELOPMENT, V125, P1017; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OWEN MR, 1993, BIOCHIM BIOPHYS ACTA, V1142, P11, DOI 10.1016/0005-2728(93)90079-U; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; Ravassard P, 1997, P NATL ACAD SCI USA, V94, P8602, DOI 10.1073/pnas.94.16.8602; Rutter CA, 2000, NEWS PHYSIOL SCI, V15, P149; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Scharfmann R, 2000, DIABETOLOGIA, V43, P1083, DOI 10.1007/s001250051498; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; van Eyll JM, 2004, J CELL SCI, V117, P2077, DOI 10.1242/jcs.01067; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Xavier GD, 2003, BIOCHEM J, V371, P761; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xavier GD, 2004, BIOCHEM J, V377, P149, DOI 10.1042/BJ20031260	68	51	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15228	15237		10.1074/jbc.M610986200	http://dx.doi.org/10.1074/jbc.M610986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376780	hybrid			2022-12-25	WOS:000246589000062
J	James, AM; Sharpley, MS; Manas, ARB; Frerman, FE; Hirst, J; Smith, RAJ; Murphy, MP				James, Andrew M.; Sharpley, Mark S.; Manas, Abdul-Rahman B.; Frerman, Frank E.; Hirst, Judy; Smith, Robin A. J.; Murphy, Michael P.			Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER FLAVOPROTEIN; HYDROPHOBIC ION INTERACTIONS; COENZYME-Q; COMPLEX-I; HEART-MITOCHONDRIA; MEMBRANES; FLUORESCENCE; NADH; SPECTROSCOPY; INHIBITORS	MitoQ(10) is a ubiquinone that accumulates within mitochondria driven by a conjugated lipophilic triphenylphosphonium cation (TPP (+)). Once there, MitoQ(10) is reduced to its active ubiquinol form, which has been used to prevent mitochondrial oxidative damage and to infer the involvement of reactive oxygen species in signaling pathways. Here we show MitoQ(10) is effectively reduced by complex II, but is a poor substrate for complex I, complex III, and electron-transferring flavoprotein (ETF): quinone oxidoreductase (ETF-QOR). This differential reactivity could be explained if the bulky TPP (+) moiety sterically hindered access of the ubiquinone group to enzyme active sites with a long, narrow access channel. Using a combination of molecular modeling and an uncharged analog of MitoQ(10) with similar sterics (tritylQ(10)), we infer that the interaction of MitoQ(10) with complex I and ETF-QOR, but not complex III, is inhibited by its bulky TPP (+) moiety. To explain its lack of reactivity with complex III we show that the TPP (+) moiety of MitoQ(10) is ineffective at quenching pyrene fluorophors deeply buried within phospholipid bilayers and thus is positioned near the membrane surface. This superficial position of the TPP (+) moiety, as well as the low solubility of MitoQ(10) in non-polar organic solvents, suggests that the concentration of the entire MitoQ(10) molecule in the membrane core is very limited. As overlaying MitoQ(10) onto the structure of complex III indicates that MitoQ(10) cannot react with complex III without its TPP (+) moiety entering the low dielectric of the membrane core, we conclude that the TPP (+) moiety does anchor the tethered ubiquinol group out of reach of the active site(s) of complex III, thus explaining its slow oxidation. In contrast the ubiquinone moiety of MitoQ(10) is able to quench fluorophors deep within the membrane core, indicating a high concentration of the ubiquinone moiety within the membrane and explaining its good antioxidant efficacy. These findings will facilitate the rational design of future mitochondria-targeted molecules.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Otago, Dept Chem, Dunedin 9001, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	James, Andrew M/A-2639-2015; Murphy, Michael P/C-2120-2009; Hirst, Judy/F-4803-2011	James, Andrew M/0000-0002-0515-9649; Murphy, Michael P/0000-0003-1115-9618; Hirst, Judy/0000-0001-8667-6797	MRC [MC_U105663141, MC_U105663142] Funding Source: UKRI; Medical Research Council [MC_U105663142, MC_U105663141] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P143; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; DuPlessis ER, 1998, BIOCHEMISTRY-US, V37, P10469, DOI 10.1021/bi980767s; ESTORNELL E, 1992, FEBS LETT, V311, P107, DOI 10.1016/0014-5793(92)81378-Y; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Griffin KJ, 1998, EUR J BIOCHEM, V255, P125, DOI 10.1046/j.1432-1327.1998.2550125.x; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KETTERER B, 1971, J MEMBRANE BIOL, V5, P225, DOI 10.1007/BF01870551; Koehorst RBM, 2004, BIOPHYS J, V87, P1445, DOI 10.1529/biophysj.104.043208; Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0; LESTER RL, 1959, J BIOL CHEM, V234, P2169; Liberman E A, 1969, Biofizika, V14, P452; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110; Ng Y, 2005, CARCINOGENESIS, V26, P1914, DOI 10.1093/carcin/bgi163; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; Rauchova H, 1997, ARCH BIOCHEM BIOPHYS, V344, P235, DOI 10.1006/abbi.1997.0150; Ross MF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P222, DOI 10.1007/s10541-005-0104-5; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x; Simkovic M, 2004, BIOCHEM J, V378, P633, DOI 10.1042/BJ20031272; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Tristram-Nagle S, 2004, CHEM PHYS LIPIDS, V127, P3, DOI 10.1016/j.chemphyslip.2003.09.002; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WATMOUGH NJ, 1991, BIOCHEMISTRY-US, V30, P1317, DOI 10.1021/bi00219a023; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Zhang J, 2006, P NATL ACAD SCI USA, V103, P16212, DOI 10.1073/pnas.0604567103	38	174	176	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14708	14718		10.1074/jbc.M611463200	http://dx.doi.org/10.1074/jbc.M611463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17369262	hybrid			2022-12-25	WOS:000246589000006
J	Rinaldo, S; Arcovito, A; Brunori, M; Cutruzzola, F				Rinaldo, Serena; Arcovito, Alessandro; Brunori, Maurizio; Cutruzzola, Francesca			Fast dissociation of nitric oxide from ferrous Pseudomonas aeruginosa cd1 nitrite reductase - A novel outlook on the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CD(1) NITRITE; ELECTRON-TRANSFER; LIGAND; HEMOGLOBIN; PROTEINS; KINETICS; BINDING; CYANIDE	The heme-containing periplasmic nitrite reductase (cd(1) NIR) is responsible for the production of nitric oxide (NO) in denitrifying bacterial species, among which are several animal and plant pathogens. Heme NIRs are homodimers, each subunit containing one covalently bound c-heme and one d(1)-heme. The reduction of nitrite to NO involves binding of nitrite to the reduced protein at the level of d(1)-heme, followed by dehydration of nitrite to yield NO and release of the latter. The crucial rate-limiting step in the catalytic mechanism is thought to be the release of NO from the d(1)-heme, which has been proposed, but never demonstrated experimentally, to occur when the iron is in the ferric form, given that the reduced NO-bound derivative was presumed to be very stable, as in other hemeproteins. We have measured for the first time the kinetics of NO binding and release from fully reduced cd(1) NIR, using the enzyme from Pseudomonas aeruginosa and its site-directed mutant H369A. Quite unexpectedly, we found that NO dissociation from the reduced d(1)-heme is very rapid, several orders of magnitude faster than that measured for b-type heme containing reduced hemeproteins. Because the rate of NO dissociation from reduced cd(1) NIR, measured in the present report, is faster than or comparable with the turnover number, contrary to expectations this event may well be on the catalytic cycle and not necessarily rate-limiting. This finding also provides a rationale for the presence in cd(1) NIR of the peculiar d(1)-heme cofactor, which has probably evolved to ensure fast product dissociation.	Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy; Consiglio Nazl Ricerche, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Cattolica Sacro Cuore, Ist Biochim & Biochim Clin, I-00198 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	rinaldo, serena/O-6989-2014; Arcovito, Alessandro/I-5552-2012; Cutruzzola', Francesca/G-4052-2011	rinaldo, serena/0000-0003-0682-023X; Arcovito, Alessandro/0000-0002-8384-4844; Cutruzzola', Francesca/0000-0002-4621-2135; Brunori, Maurizio/0000-0002-7795-1635				Antonini E., 1971, FRONT BIOL, V21, P19; Arai H, 2005, J BACTERIOL, V187, P3960, DOI 10.1128/JB.187.12.3960-3968.2005; Arcovito A, 2001, J BIOL CHEM, V276, P41073, DOI 10.1074/jbc.M105183200; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Azizi F, 2005, FREE RADICAL BIO MED, V39, P145, DOI 10.1016/j.freeradbiomed.2005.03.001; BARBER D, 1978, BIOCHEM J, V175, P239, DOI 10.1042/bj1750239; BARKIGIA KM, 1992, J AM CHEM SOC, V114, P1701, DOI 10.1021/ja00031a025; Barraud N, 2006, J BACTERIOL, V188, P7344, DOI 10.1128/JB.00779-06; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; Borisov VB, 2007, BIOCHEM BIOPH RES CO, V355, P97, DOI 10.1016/j.bbrc.2007.01.118; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Cutruzzola F, 2003, IUBMB LIFE, V55, P617, DOI 10.1080/15216540310001628672; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Hassett DJ, 2002, ADV DRUG DELIVER REV, V54, P1425, DOI 10.1016/S0169-409X(02)00152-7; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; MOORE EG, 1976, J BIOL CHEM, V251, P2788; PARR SR, 1975, BIOCHEM J, V151, P51, DOI 10.1042/bj1510051; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PARR SR, 1976, BIOCHEM J, V157, P423, DOI 10.1042/bj1570423; PARR SR, 1974, BIOCHEM J, V139, P273, DOI 10.1042/bj1390273; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; Rinaldo S, 2007, BIOLOGY OF THE NITROGEN CYCLE, P37, DOI 10.1016/B978-044452857-5.50004-7; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1992, BIOCHEM J, V285, P661, DOI 10.1042/bj2850661; SILVESTRINI MC, 1979, BIOCHEM J, V183, P701, DOI 10.1042/bj1830701; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun WL, 2002, BIOCHEM BIOPH RES CO, V291, P1, DOI 10.1006/bbrc.2002.6391; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; Wilson EK, 1999, BIOCHEMISTRY-US, V38, P7556, DOI 10.1021/bi990179u; Zajicek RS, 2006, BIOCHEMISTRY-US, V45, P11208, DOI 10.1021/bi0604983; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	35	42	43	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14761	14767		10.1074/jbc.M700933200	http://dx.doi.org/10.1074/jbc.M700933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389587	hybrid			2022-12-25	WOS:000246589000011
J	Guha, M; Srinivasan, S; Biswas, G; Avadhani, NG				Guha, Manti; Srinivasan, Satish; Biswas, Gopa; Avadhani, Narayan G.			Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; OXIDATIVE-PHOSPHORYLATION; INDUCED RESISTANCE; SKELETAL-MUSCLE; KINASE; EXPRESSION; APOPTOSIS; CANCER; INHIBITION; MUTATIONS	We have previously shown that disruption of mitochondrial membrane potential by depletion of mitochondrial DNA ( mtDNA) or treatment with a mitochondrial ionophore, carbonyl cyanide m-chlorophenylhydrazone, initiates a stress signaling, which causes resistance to apoptosis, and induces invasive behavior in C2C12 myocytes and A549 cells. In the present study we show that calcineurin (Cn), activated as part of this stress signaling, plays an important role in increased glucose uptake and glycolysis. Here we report that, although both insulin and insulin-like growth factor-1 receptor levels (IR and IGF1R, respectively) are increased in response to mitochondrial stress, autophosphorylation of IGF1R was selectively increased suggesting a shift in receptor pathways. Using an approach with FK506, an inhibitor of Cn, and mRNA silencing by small interference RNA we show that mitochondrial stress-activated Cn is critical for increased GLUT 4 and IGF1R expression and activation. The importance of the IGF1R pathway in cell survival under mitochondrial stress is demonstrated by increased apoptosis either by IGF1R mRNA silencing or by treatment with IGF1R inhibitors (AG1024 and picropodophyllin). This study describes a novel mechanism of mitochondrial stress-induced metabolic shift involving Cn with implications in resistance to apoptosis and tumor proliferation.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA022762, CA22762, R01 CA022762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ANTONI FA, 1993, BIOCHEM BIOPH RES CO, V194, P226, DOI 10.1006/bbrc.1993.1808; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cottrell D A, 2001, Novartis Found Symp, V235, P234; Devin A, 2001, EUR J BIOCHEM, V268, P3943, DOI 10.1046/j.1432-1327.2001.02306.x; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; JENSSEN N, 2003, J APPL PHYSIOL, V94, P1373; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macaulay SL, 2003, BIOCHEM J, V376, P123, DOI 10.1042/BJ20030130; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Meierhofer D, 2004, CARCINOGENESIS, V25, P1005, DOI 10.1093/carcin/bgh104; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Park SY, 2004, BIOCHEM BIOPH RES CO, V325, P1399, DOI 10.1016/j.bbrc.2004.10.182; Parrella P, 2001, CANCER RES, V61, P7623; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Ryder JW, 2005, J PHYSIOL-LONDON, V567, P379, DOI 10.1113/jphysiol.2005.090829; Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5; Semenza G L, 2001, Novartis Found Symp, V240, P251; Shefi-Friedman L, 2001, AM J PHYSIOL-ENDOC M, V281, pE16, DOI 10.1152/ajpendo.2001.281.1.E16; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027; SMITH RM, 1993, ARCH BIOCHEM BIOPHYS, V300, P238, DOI 10.1006/abbi.1993.1033; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; YAGEL S, 1989, CANCER RES, V49, P3553; Zeviani M, 1997, MOL HUM REPROD, V3, P133, DOI 10.1093/molehr/3.2.133; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	58	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14536	14546		10.1074/jbc.M611693200	http://dx.doi.org/10.1074/jbc.M611693200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355970	Green Accepted, hybrid			2022-12-25	WOS:000246245800067
J	Valentine, RA; Jackson, KA; Christie, GR; Mathers, JC; Taylor, PM; Ford, D				Valentine, Ruth A.; Jackson, Kelly A.; Christie, Graham R.; Mathers, John C.; Taylor, Peter M.; Ford, Dianne			ZnT5 variant B is a bidirectional zinc transporter and mediates zinc uptake in human intestinal Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; CLONING; FAMILY; MOUSE; GENE	Zinc is an essential micronutrient, so it is important to elucidate the molecular mechanisms of zinc homeostasis, including the functional properties of zinc transporters. Mammalian zinc transporters are classified in two major families: the SLC30 (ZnT) family and the SLC39 family. The prevailing view is that SLC30 family transporters function to reduce cytosolic zinc concentration, either through efflux across the plasma membrane or through sequestration in intracellular compartments, and that SLC39 family transporters function in the opposite direction to increase cytosolic zinc concentration. We demonstrated that human ZnT5 variant B (ZnT5B (hZTL1)), an isoform expressed at the plasma membrane, operates in both the uptake and the efflux directions when expressed in Xenopus laevis oocytes. We measured increased activity of the zinc-responsive metallothionein 2a (MT2a) promoter when ZnT5b was coexpressed with an MT2a promoter-reporter plasmid construct in human intestinal Caco-2 cells, indicating increased total intracellular zinc concentration. Increased cytoplasmic zinc concentration mediated by ZnT5B, in the absence of effects on intracellular zinc sequestration by the Golgi apparatus or endoplasmic reticulum, was also confirmed by a dramatically enhanced signal from the zinc fluorophore Rhodzin-3 throughout the cytoplasm of Caco-2 cells overexpressing ZnT5B at the plasma membrane when compared with control cells. Our findings demonstrate clearly that, in addition to mediating zinc efflux, ZnT5B at the plasma membrane can function to increase cytoplasmic zinc concentration, thus indicating a need to reevaluate the current paradigm that SLC30 family zinc transporters operate exclusively to decrease cytosolic zinc concentration.	Univ Newcastle Upon Tyne, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Dent Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Dundee, Coll Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Dundee	Valentine, RA (corresponding author), Univ Newcastle Upon Tyne, Sch Dent Sci, Framlington Pl, Newcastle Upon Tyne NE2 4BW, Tyne & Wear, England.	r.a.valentine@ncl.ac.uk	Taylor, Peter M/A-4667-2010	Mathers, John/0000-0003-3406-3002; Jackson, Kelly/0000-0001-9116-3769	BBSRC [BB/D01669X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01669X/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cragg RA, 2005, GUT, V54, P469, DOI 10.1136/gut.2004.041962; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; HELSTON RM, 2006, IN PRESS PLACENTA; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Jackson KA, 2007, J BIOL CHEM, V282, P10423, DOI 10.1074/jbc.M610535200; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kumanovics A, 2006, J BIOL CHEM, V281, P22566, DOI 10.1074/jbc.M604730200; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Peter GJ, 1999, BIOCHEM J, V343, P169, DOI 10.1042/0264-6021:3430169; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100	18	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14389	14393		10.1074/jbc.M701752200	http://dx.doi.org/10.1074/jbc.M701752200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355957	Green Accepted, hybrid			2022-12-25	WOS:000246245800051
J	Fu, J; Menzies, K; Freeman, RS; Taubman, MB				Fu, Jian; Menzies, Keon; Freeman, Robert S.; Taubman, Mark B.			EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINDAU TUMOR-SUPPRESSOR; HYPOXIA-INDUCIBLE FACTOR; FACTOR-RESPONSIVE GENE; DEPENDENT CELL-DEATH; RNA-POLYMERASE-II; PROLINE HYDROXYLATION; UBIQUITIN LIGASE; FACTOR HIF; COMPLEX; SM-20	EGLN3, a member of the EGLN family of prolyl hydroxylases, has been shown to catalyze hydroxylation of the alpha subunit of hypoxia-inducible factor-alpha, which targets hypoxia- inducible factor-alpha for ubiquitination by a ubiquitin ligase complex containing the von Hippel- Lindau ( VHL) tumor suppressor. We now report that EGLN3 levels increase during C2C12 skeletal myoblast differentiation. EGLN3 small interference RNAs and EGLN3 antisense oligonucleotides blocked C2C12 differentiation and decreased levels of myogenin, a member of the MyoD family of myogenic regulatory factors, which plays a critical role in myogenic differentiation. We also report that EGLN3 interacts with and stabilizes myogenin protein, whereas VHL associates with and destabilizes myogenin via the ubiquitin- proteasome system. The effect of VHL on myogenin stability and ubiquitination can be reversed, at least in part, by overexpression of EGLN3, suggesting that its binding to myogenin may prevent VHL- mediated degradation. These data demonstrate a novel role for EGLN3 in regulating skeletal muscle differentiation and gene expression. In addition, this report provides evidence for a novel pathway that regulates myogenin expression and skeletal muscle differentiation.	Univ Rochester, Med Ctr, Inst Cardiovasc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Fu, J (corresponding author), Univ Rochester, Med Ctr, Inst Cardiovasc Res, Rochester, NY 14642 USA.	jian_fu@urmc.rochester.edu			NHLBI NIH HHS [R01 HL43302] Funding Source: Medline; NINDS NIH HHS [R01 NS034400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034400] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAVIND L, 2001, GENOME BIOL, V3, P8; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; Czyzyk-Krzeska MF, 2004, TRENDS MOL MED, V10, P146, DOI 10.1016/j.molmed.2004.02.004; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freeman RS, 2003, MOL CELLS, V16, P1; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hopfer U, 2006, J BIOL CHEM, V281, P8645, DOI 10.1074/jbc.M513751200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Madden SL, 1996, CANCER RES, V56, P5384; Mason SD, 2004, PLOS BIOL, V2, P1540, DOI 10.1371/journal.pbio.0020288; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Mullen AJ, 2000, GENE, V242, P313, DOI 10.1016/S0378-1119(99)00519-3; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Straub JA, 2003, J NEUROCHEM, V85, P318, DOI 10.1046/j.1471-4159.2003.01688.x; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wolf G, 2002, LAB INVEST, V82, P1305, DOI 10.1097/01.LAB.0000029207.92039.2F; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Yun Z, 2005, MOL CELL BIOL, V25, P3040, DOI 10.1128/MCB.25.8.3040-3055.2005	64	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12410	12418		10.1074/jbc.M608748200	http://dx.doi.org/10.1074/jbc.M608748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344222	hybrid			2022-12-25	WOS:000245942800009
J	Scobie, HM; Marlett, JM; Rainey, GJA; Lacy, DB; Collier, RJ; Young, JAT				Scobie, Heather M.; Marlett, John M.; Rainey, G. Jonah A.; Lacy, D. Borden; Collier, R. John; Young, John A. T.			Anthrax Toxin Receptor 2 Determinants that Dictate the pH Threshold of Toxin Pore Formation	PLOS ONE			English	Article							CAPILLARY MORPHOGENESIS PROTEIN-2; PROTECTIVE ANTIGEN; CRYSTAL-STRUCTURE; KINASE-KINASE; TRANSLOCATION; ACTIVATION; DELIVERY; COMPLEX; CYCLASE; DOMAIN	The anthrax toxin receptors, ANTXR1 and ANTXR2, act as molecular clamps to prevent the protective antigen ( PA) toxin subunit from forming pores until exposure to low pH. PA forms pores at pH similar to 6.0 or below when it is bound to ANTXR1, but only at pH similar to 5.0 or below when it is bound to ANTXR2. Here, structure-based mutagenesis was used to identify non-conserved ANTXR2 residues responsible for this striking 1.0 pH unit difference in pH threshold. Residues conserved between ANTXR2 and ANTXR1 that influence the ANTXR2-associated pH threshold of pore formation were also identified. All of these residues contact either PA domain 2 or the neighboring edge of PA domain 4. These results provide genetic evidence for receptor release of these regions of PA as being necessary for the protein rearrangements that accompany anthrax toxin pore formation.	[Scobie, Heather M.; Marlett, John M.; Rainey, G. Jonah A.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; [Scobie, Heather M.] Univ Wisconsin, Cellular & Mol Biol Grad Program, Madison, WI USA; [Lacy, D. Borden] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN USA; [Collier, R. John] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Salk Institute; University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Harvard University; Harvard Medical School		jyoung@salk.edu	Lacy, D. Borden/AFQ-2203-2022	Young, John/0000-0003-1824-2561; Collier, R John/0000-0002-2427-4239; Lacy, Borden/0000-0003-2273-8121	NIH [AI48489, AI56013]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048489, P01AI056013] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grants AI48489 and AI56013 (JATY and RJC).	Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; CHEN KH, 2007, J BIOL CHEM     0124; CHOPRA AP, 2003, J BIOL CHEM; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liu SH, 2007, CELL MICROBIOL, V9, P977, DOI 10.1111/j.1462-5822.2006.00845.x; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Nassi S, 2002, BIOCHEMISTRY-US, V41, P1445, DOI 10.1021/bi0119518; Panchal RG, 2005, J BIOL CHEM, V280, P10834, DOI 10.1074/jbc.M412210200; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wei W, 2006, CELL, V124, P1141, DOI 10.1016/j.cell.2005.12.045; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200; Wolfe JT, 2005, J BIOL CHEM, V280, P39417, DOI 10.1074/jbc.M509049200	28	33	34	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e329	10.1371/journal.pone.0000329	http://dx.doi.org/10.1371/journal.pone.0000329			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389920	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445200012
J	Wilson, GA; Feil, EJ; Lilley, AK; Field, D				Wilson, Gareth A.; Feil, Edward J.; Lilley, Andrew K.; Field, Dawn			Large-Scale Comparative Genomic Ranking of Taxonomically Restricted Genes (TRGs) in Bacterial and Archaeal Genomes	PLOS ONE			English	Article							SHEWANELLA-ONEIDENSIS MR-1; ESCHERICHIA-COLI; ORPHAN GENES; HYPOTHETICAL GENES; EXPRESSION; PROTEIN; IDENTIFICATION; NUMBER; VALIDATION; SEQUENCE	Background. Lineage-specific, or taxonomically restricted genes (TRGs), especially those that are species and strain-specific, are of special interest because they are expected to play a role in defining exclusive ecological adaptations to particular niches. Despite this, they are relatively poorly studied and little understood, in large part because many are still orphans or only have homologues in very closely related isolates. This lack of homology confounds attempts to establish the likelihood that a hypothetical gene is expressed and, if so, to determine the putative function of the protein. Methodology/Principal Findings. We have developed "QIPP'' ("Quality Index for Predicted Proteins''), an index that scores the "quality'' of a protein based on non-homology-based criteria. QIPP can be used to assign a value between zero and one to any protein based on comparing its features to other proteins in a given genome. We have used QIPP to rank the predicted proteins in the proteomes of Bacteria and Archaea. This ranking reveals that there is a large amount of variation in QIPP scores, and identifies many high-scoring orphans as potentially "authentic'' (expressed) orphans. There are significant differences in the distributions of QIPP scores between orphan and non-orphan genes for many genomes and a trend for less well-conserved genes to have lower QIPP scores. Conclusions. The implication of this work is that QIPP scores can be used to further annotate predicted proteins with information that is independent of homology. Such information can be used to prioritize candidates for further analysis. Data generated for this study can be found in the OrphanMine at http://www.genomics.ceh.ac.uk/orphan_mine.	[Wilson, Gareth A.; Lilley, Andrew K.; Field, Dawn] CEH, Oxford, England; [Feil, Edward J.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	UK Centre for Ecology & Hydrology (UKCEH); University of Bath	Wilson, GA (corresponding author), CEH, Oxford, England.	gawi@ceh.ac.uk	Field, Dawn/C-1653-2010		Natural Environment Research Council [NER/S/A/2003/11341]	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was funded through a Natural Environment Research Council Ph. D studentship awarded to GW (NER/S/A/2003/11341).	Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Alimi JP, 2000, GENOME RES, V10, P959, DOI 10.1101/gr.10.7.959; Alm EJ, 2005, GENOME RES, V15, P1015, DOI 10.1101/gr.3844805; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amiri H, 2003, MOL BIOL EVOL, V20, P1575, DOI 10.1093/molbev/msg175; Charlebois RL, 2004, GENOME RES, V14, P2469, DOI 10.1101/gr.3024704; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; Corbin RW, 2003, P NATL ACAD SCI USA, V100, P9232, DOI 10.1073/pnas.1533294100; Courcelle J, 2001, GENETICS, V158, P41; Daubin V, 2004, GENOME RES, V14, P1036, DOI 10.1101/gr.2231904; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; FIELD D, 2007, NATURE BIOT IN PRESS; Foerstner KU, 2005, EMBO REP, V6, P1208, DOI 10.1038/sj.embor.7400538; Fukuchi S, 2004, DNA RES, V11, P219; Galperin MY, 2006, CURR OPIN BIOTECH, V17, P440, DOI 10.1016/j.copbio.2006.08.007; Galperin MY, 2004, NUCLEIC ACIDS RES, V32, P5452, DOI 10.1093/nar/gkh885; Gevaert K, 2002, MOL CELL PROTEOMICS, V1, P896, DOI 10.1074/mcp.M200061-MCP200; Gutierrez-Rios RM, 2003, GENOME RES, V13, P2435, DOI 10.1101/gr.1387003; Heizer EM, 2006, MOL BIOL EVOL, V23, P1670, DOI 10.1093/molbev/msl029; Hurst LD, 2006, NATURE, V442, pE11, DOI 10.1038/nature05137; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; Kolker E, 2005, P NATL ACAD SCI USA, V102, P2099, DOI 10.1073/pnas.0409111102; Kolker E, 2004, NUCLEIC ACIDS RES, V32, P2353, DOI 10.1093/nar/gkh555; Kosuge T, 2006, DNA RES, V13, P245, DOI 10.1093/dnares/dsl014; Manning PA, 1997, GENE, V192, P63, DOI 10.1016/S0378-1119(97)00036-X; Martiny JBH, 2005, ECOL LETT, V8, P1334, DOI 10.1111/j.1461-0248.2005.00837.x; Medini D, 2005, CURR OPIN GENET DEV, V15, P589, DOI 10.1016/j.gde.2005.09.006; Misra RV, 2005, NUCLEIC ACIDS RES, V33, pD329, DOI 10.1093/nar/gki028; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Nei M, 2005, MOL BIOL EVOL, V22, P2318, DOI 10.1093/molbev/msi242; Ochman H, 2003, MOL BIOL EVOL, V20, P2091, DOI 10.1093/molbev/msg229; Petrov DA, 1999, P NATL ACAD SCI USA, V96, P1475, DOI 10.1073/pnas.96.4.1475; Roberts RJ, 2004, PLOS BIOL, V2, P293, DOI 10.1371/journal.pbio.0020042; ROBERTS RJ, 2005, EXPT APPROACH GENOME; Romine MF, 2004, OMICS, V8, P239, DOI 10.1089/omi.2004.8.239; Ruby EG, 2005, P NATL ACAD SCI USA, V102, P3004, DOI 10.1073/pnas.0409900102; Shmuely H, 2004, BIOINFORMATICS, V20, P1248, DOI 10.1093/bioinformatics/bth075; Siew N, 2003, STRUCTURE, V11, P7, DOI 10.1016/S0969-2126(02)00938-3; Skovgaard M, 2001, TRENDS GENET, V17, P425, DOI 10.1016/S0168-9525(01)02372-1; Taoka M, 2004, MOL CELL PROTEOMICS, V3, P780, DOI 10.1074/mcp.M400030-MCP200; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Ussery DW, 2004, MICROBIOL-SGM, V150, P2015, DOI 10.1099/mic.0.27338-0; VONMERING C, 2006, NUCLEIC ACIDS RES, V10, P10; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wernegreen JJ, 2002, NAT REV GENET, V3, P850, DOI 10.1038/nrg931; Wilson GA, 2005, MICROBIOL-SGM, V151, P2499, DOI 10.1099/mic.0.28146-0; Yin YB, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-63; Zheng Y, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-243	52	19	20	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e324	10.1371/journal.pone.0000324	http://dx.doi.org/10.1371/journal.pone.0000324			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389915	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445200007
J	Vergoz, V; Roussel, E; Sandoz, JC; Giurfa, M				Vergoz, Vanina; Roussel, Edith; Sandoz, Jean-Christophe; Giurfa, Martin			Aversive Learning in Honeybees Revealed by the Olfactory Conditioning of the Sting Extension Reflex	PLOS ONE			English	Article							DOPAMINERGIC-NEURONS; PROBOSCIS EXTENSION; APIS-MELLIFERA; MINI-BRAIN; DROSOPHILA; RECEPTOR; MEMORY; OCTOPAMINE; BEES; PHARMACOLOGY	Invertebrates have contributed greatly to our understanding of associative learning because they allow learning protocols to be combined with experimental access to the nervous system. The honeybee Apis mellifera constitutes a standard model for the study of appetitive learning and memory since it was shown, almost a century ago, that bees learn to associate different sensory cues with a reward of sugar solution. However, up to now, no study has explored aversive learning in bees in such a way that simultaneous access to its neural bases is granted. Using odorants paired with electric shocks, we conditioned the sting extension reflex, which is exhibited by harnessed bees when subjected to a noxious stimulation. We show that this response can be conditioned so that bees learn to extend their sting in response to the odorant previously punished. Bees also learn to extend the proboscis to one odorant paired with sugar solution and the sting to a different odorant paired with electric shock, thus showing that they can master both appetitive and aversive associations simultaneously. Responding to the appropriate odorant with the appropriate response is possible because two different biogenic amines, octopamine and dopamine subserve appetitive and aversive reinforcement, respectively. While octopamine has been previously shown to substitute for appetitive reinforcement, we demonstrate that blocking of dopaminergic, but not octopaminergic, receptors suppresses aversive learning. Therefore, aversive learning in honeybees can now be accessed both at the behavioral and neural levels, thus opening new research avenues for understanding basic mechanisms of learning and memory.	[Vergoz, Vanina; Roussel, Edith; Sandoz, Jean-Christophe; Giurfa, Martin] Univ Toulouse 3, CNRS, Res Ctr Anim Cognit, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Giurfa, M (corresponding author), Univ Toulouse 3, CNRS, Res Ctr Anim Cognit, F-31062 Toulouse, France.	giurfa@cict.fr	Giurfa, Martin/H-5140-2016; Giurfa, Martin/AAS-4945-2020; Giurfa, Martin MG/A-7322-2008; Vergoz, Vanina/L-9638-2015; Sandoz, Jean-Christophe/A-6085-2012	Giurfa, Martin/0000-0001-7173-769X; Giurfa, Martin/0000-0001-7173-769X; Sandoz, Jean-Christophe/0000-0002-5423-9645	BEESHOP; French Research Council (CNRS); University Paul-Sabatier; Institute Universitaire de France; ACI Neurosciences Integratives (French Research Ministry)	BEESHOP; French Research Council (CNRS)(Centre National de la Recherche Scientifique (CNRS)); University Paul-Sabatier; Institute Universitaire de France; ACI Neurosciences Integratives (French Research Ministry)(Ministry of Research, France)	This work was supported by BEESHOP (European research grant 'Bees in Europe and Sustainable Honey Production'), the French Research Council (CNRS), the University Paul-Sabatier, the Institute Universitaire de France and the ACI Neurosciences Integratives (French Research Ministry).	ABRAMSON CI, 1986, J COMP PSYCHOL, V100, P108, DOI 10.1037/0735-7036.100.2.108; Beggs KT, 2005, INSECT BIOCHEM MOLEC, V35, P873, DOI 10.1016/j.ibmb.2005.03.005; BITTERMAN ME, 1983, J COMP PSYCHOL, V97, P107, DOI 10.1037/0735-7036.97.2.107; Blenau W, 1998, J NEUROCHEM, V70, P15; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; Breed MD, 2004, ANNU REV ENTOMOL, V49, P271, DOI 10.1146/annurev.ento.49.061802.123155; BURRELL BD, 1994, J COMP PHYSIOL A, V174, P581, DOI 10.1007/BF00217379; Chittka L, 2003, NATURE, V424, P388, DOI 10.1038/424388a; Davis RL, 2005, ANNU REV NEUROSCI, V28, P275, DOI 10.1146/annurev.neuro.28.061604.135651; Dukas R, 2003, OIKOS, V101, P157, DOI 10.1034/j.1600-0706.2003.12143.x; Dukas R, 2001, ECOL LETT, V4, P327, DOI 10.1046/j.1461-0248.2001.00228.x; FANSELOW MS, 1980, PAVLOVIAN J BIOL SCI, V15, P177; Farooqui T, 2003, J NEUROSCI, V23, P5370; Frisch K.v, 1914, ZOOLOGISCHE JB, V37, P1, DOI DOI 10.5962/BHL.TITLE.11736; Giurfa M, 2003, CURR OPIN NEUROBIOL, V13, P726, DOI 10.1016/j.conb.2003.10.015; Giurfa M, 2006, CURR BIOL, V16, pR892, DOI 10.1016/j.cub.2006.09.021; GOULD JL, 1987, ANIM BEHAV, V35, P1579, DOI 10.1016/S0003-3472(87)80038-6; GOULD JL, 1986, ANIM BEHAV, V34, P990, DOI 10.1016/S0003-3472(86)80157-9; Hammer M, 1998, LEARN MEMORY, V5, P146; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Humphries MA, 2003, J NEUROBIOL, V55, P315, DOI 10.1002/neu.10209; Jaber M, 1996, NEUROPHARMACOLOGY, V35, P1503, DOI 10.1016/S0028-3908(96)00100-1; Lenoir JC, 2006, INSECT SOC, V53, P80, DOI 10.1007/s00040-005-0838-5; LUNNEY GH, 1970, J EDUC MEAS, V7, P263, DOI 10.1111/j.1745-3984.1970.tb00727.x; Margulies C, 2005, CURR BIOL, V15, pR700, DOI 10.1016/j.cub.2005.08.024; Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801; Menzel R, 2001, TRENDS COGN SCI, V5, P62, DOI 10.1016/S1364-6613(00)01601-6; Menzel R, 1999, J COMP PHYSIOL A, V185, P323, DOI 10.1007/s003590050392; Neve KA, 2004, J RECEPT SIG TRANSD, V24, P165, DOI 10.1081/LRST-200029981; NUNEZ J, 1983, PHARMACOL BIOCHEM BE, V19, P921, DOI 10.1016/0091-3057(83)90391-X; Nunez J, 1997, PHYSIOL BEHAV, V63, P75, DOI 10.1016/S0031-9384(97)00391-0; NUNEZ JA, 1970, ACTA PHYSIOL LAT AM, V20, P140; Riemensperger T, 2005, CURR BIOL, V15, P1953, DOI 10.1016/j.cub.2005.09.042; Scheiner R, 2002, BEHAV BRAIN RES, V136, P545, DOI 10.1016/S0166-4328(02)00205-X; Schroll C, 2006, CURR BIOL, V16, P1741, DOI 10.1016/j.cub.2006.07.023; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; SMITH BH, 1991, J COMP PSYCHOL, V105, P345, DOI 10.1037/0735-7036.105.4.345; TAKEDA K, 1961, J INSECT PHYSIOL, V6, P168, DOI 10.1016/0022-1910(61)90060-9; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Unoki S, 2005, EUR J NEUROSCI, V22, P1409, DOI 10.1111/j.1460-9568.2005.04318.x; Unoki S, 2006, EUR J NEUROSCI, V24, P2031, DOI 10.1111/j.1460-9568.2006.05099.x; von Frisch K., 1967, DANCE LANGUAGE ORIEN; Waddell S, 2001, TRENDS GENET, V17, P719, DOI 10.1016/S0168-9525(01)02526-4	43	214	219	2	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e288	10.1371/journal.pone.0000288	http://dx.doi.org/10.1371/journal.pone.0000288			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372627	Green Published, gold			2022-12-25	WOS:000207444800011
J	Gonin-Laurent, N; Hadj-Hamou, NS; Vogt, N; Houdayer, C; Gauthiers-Villars, M; Dehainault, C; Sastre-Garau, X; Chevillard, S; Malfoy, B				Gonin-Laurent, N.; Hadj-Hamou, N. S.; Vogt, N.; Houdayer, C.; Gauthiers-Villars, M.; Dehainault, C.; Sastre-Garau, X.; Chevillard, S.; Malfoy, B.			RB1 and TP53 pathways in radiation-induced sarcomas	ONCOGENE			English	Article						ionising radiation; sarcoma; RB1; TP53; CDKN2A; MDMX	SOLID TUMORS; SOFT-TISSUE; PROMOTER METHYLATION; ORAL-CANCER; P53 PATHWAY; MDM2 GENES; RETINOBLASTOMA; OSTEOSARCOMA; INACTIVATION; EXPRESSION	The tumour suppressor genes, TP53 and RB1, and four genes involved in their regulation, INK4a, ARF, MDM2 and MDMX, were analysed in a series of 36 post-radiotherapy radiation- induced sarcomas. One- third of the tumours developed in patients carrying a germline mutation of RB1 that predisposed them to retinoblastoma and radiation- induced sarcomas. The genetic inactivation of RB1 and/ or TP53 genes was frequently observed in these sarcomas. These inactivations were owing to an interplay between point mutations and losses of large chromosome segments. Radiation- induced somatic mutations were observed in TP53, but not in RB1 or in the four other genes, indicating an early role of TP53 in the radio- sarcomagenesis. RB1 and TP53 genes were biallelically coinactivated in all sarcomas developing in the context of the predisposition, indicating that both genes played a major role in the formation of these sarcomas. In the absence of predisposition, TP53 was biallelically inactivated in one- third of the sarcomas, whereas at least one allele of RB1 was wild type. In both genetic contexts, the TP53 pathway was inactivated by genetic lesions and not by the activation of the ARF / MDM2/ MDMX pathway, as recently shown in retinoblastomas. Together, these findings highlight the intricate tissue- and aetiology-specific relationships between TP53 and RB1 pathways in tumorigenesis.	CNRS, UMR 7147, Paris 05, France; Ctr Rech, Inst Curie, Paris, France; Univ Paris 06, Paris, France; Inst Curie, Dept Genet, Paris, France; Inst Curie, Dept Pathol, Paris, France; DRR, DSV, CEA, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA	Malfoy, B (corresponding author), CNRS, UMR 7147, 26 Rue Ulm, Paris 05, France.	bernard.malfoy@curie.fr	Britzen-Laurent, Nathalie/M-3982-2013	Britzen-Laurent, Nathalie/0000-0002-0494-7117; Sastre-Garau, Xavier/0000-0001-5992-2083; Chevillard, Sylvie/0000-0001-5889-4041				Aerts I, 2004, EUR J CANCER, V40, P1522, DOI 10.1016/j.ejca.2004.03.023; Chatterjee SJ, 2004, J PATHOL, V203, P762, DOI 10.1002/path.1567; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Gonin-Laurent N, 2006, CARCINOGENESIS, V27, P1266, DOI 10.1093/carcin/bgi356; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; Houdayer C, 2004, HUM MUTAT, V23, P193, DOI 10.1002/humu.10303; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Kawaguchi K, 2006, MODERN PATHOL, V19, P106, DOI 10.1038/modpathol.3800502; Kawaguchi K, 2003, J PATHOL, V201, P487, DOI 10.1002/path.1419; Kawaguchi K, 2002, MODERN PATHOL, V15, P878, DOI 10.1097/01.MP.0000024264.48690.EA; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Marine JC, 2004, CELL CYCLE, V3, P900; Menu-Branthomme A, 2004, INT J CANCER, V110, P87, DOI 10.1002/ijc.20002; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; PatinoGarcia A, 1997, CANCER GENET CYTOGEN, V98, P50, DOI 10.1016/S0165-4608(96)00397-4; Perucca-Lostanlen D, 2004, GENE CHROMOSOME CANC, V39, P99, DOI 10.1002/gcc.10303; Ramos YFM, 2001, CANCER RES, V61, P1839; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Travis LB, 2002, ACTA ONCOL, V41, P323, DOI 10.1080/028418602760169361; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Wakeford R, 2004, ONCOGENE, V23, P6404, DOI 10.1038/sj.onc.1207896	29	32	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6106	6112		10.1038/sj.onc.1210404	http://dx.doi.org/10.1038/sj.onc.1210404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369843				2022-12-25	WOS:000249277200014
J	Matsubara, H; Takeuchi, T; Nishikawa, E; Yanagisawa, K; Hayashita, Y; Ebi, H; Yamada, H; Suzuki, M; Nagino, M; Nimura, Y; Osada, H; Takahashi, T				Matsubara, H.; Takeuchi, T.; Nishikawa, E.; Yanagisawa, K.; Hayashita, Y.; Ebi, H.; Yamada, H.; Suzuki, M.; Nagino, M.; Nimura, Y.; Osada, H.; Takahashi, T.			Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92	ONCOGENE			English	Article						miRNA; lung cancer; antisense; apoptosis	MESSENGER-RNA; MICRORNAS; MECHANISM	Amplification and overexpression of the miR- 17- 92 microRNAs ( miRNA) cluster at 13q31.3 has recently reported, with pointers to functional involvement in the development of B- cell lymphomas and lung cancers. In the present study, we show that inhibition of miR- 17- 5p and miR- 20a with antisense oligonucleotides ( ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR- 17- 92, suggesting the possibility of 'Oncomi R addiction to expression of these miRNAs in a subset of lung cancers. In marked contrast, antisense ONs against miR-18a and miR- 19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR- 17- 92 cluster in terms of their roles in cancer cell growth. During the course of this study, we also found that enforced expression of a genomic region, termed C2, residing 30 to miR- 17- 92 in the intron 3 of C13orf25 led to marked growth inhibition in association with double stranded RNA- dependent protein kinase activation. Finally, this study also revealed that the vast majority of C13orf25 transcripts are detected as Drosha- processed cleavage products on Northern blot analysis and that a novel polyadenylation site is present 30 to the miR- 17- 92 cluster and 50 to the C2 region. Taken together, the present findings contribute towards better understanding of the oncogenic roles of miR- 17- 92, which might ultimately lead to the future translation into clinical applications.	Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Dept Surg Oncol,Showa Ku, Nagoya, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014; Takahashi, Takashi/I-7262-2014; Yanagisawa, Kiyoshi/I-7263-2014; Nagino, Masato/I-7342-2014; Osada, Hiroyuki/AAY-6254-2020; Ebi, Hiromichi/AAA-7358-2019	Suzuki, Motoshi/0000-0003-0682-5006; Takahashi, Takashi/0000-0003-0615-7001; Ebi, Hiromichi/0000-0003-3155-7576				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Maeno K, 2006, ONCOGENE, V25, P271, DOI 10.1038/sj.onc.1209018; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zarudnaya MI, 2003, NUCLEIC ACIDS RES, V31, P1375, DOI 10.1093/nar/gkg241	19	281	321	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6099	6105		10.1038/sj.onc.1210425	http://dx.doi.org/10.1038/sj.onc.1210425			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384677				2022-12-25	WOS:000249277200013
J	Sakakura, C; Miyagawa, K; Fukuda, KI; Nakashima, S; Yoshikawa, T; Kin, S; Nakase, Y; Ida, H; Yazumi, S; Yamagishi, H; Okanoue, T; Chiba, T; Ito, K; Hagiwara, A; Ito, Y				Sakakura, C.; Miyagawa, K.; Fukuda, K. I.; Nakashima, S.; Yoshikawa, T.; Kin, S.; Nakase, Y.; Ida, H.; Yazumi, S.; Yamagishi, H.; Okanoue, T.; Chiba, T.; Ito, K.; Hagiwara, A.; Ito, Y.			Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis	ONCOGENE			English	Article						radioresistance; esophageal cancer; RUNX3; methylation	GROWTH-FACTOR-BETA; GENE-EXPRESSION PROFILES; GASTRIC-CANCER; RADIATION SENSITIVITY; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; APOPTOSIS; RADIOSENSITIVITY; CLASSIFICATION; COOPERATION	Radiotherapy is an effective treatment for some esophageal cancers, but the molecular mechanisms of radiosensitivity remain unknown. RUNX3, a novel tumor suppressor of gastric cancer, functions in transforming growth factor ( TGF)-beta-dependent apoptosis. We obtained paired samples from 62 patients with advanced esophageal cancers diagnosed initially as T3 or T4 with image diagnosis; one sample was obtained from a biopsy before presurgical radiotherapy, and the other was resected in surgical specimens after radiotherapy. RUNX3 was repressed in 67.7% cases of the pretreatment biopsy samples and 96.7% cases of the irradiated, resected samples. The nuclear expression of RUNX3 was associated with radiosensitivity and a better prognosis than cytoplasmic or no RUNX3 expression ( P < 0.003); cytoplasmic RUNX3 expression was strictly associated with radioresistance. RUNX3 was downregulated and its promoter was hypermethylated in all radioresistant esophageal cancer cell lines examined. Stable transfection of esophageal cancer cells with RUNX3 slightly inhibited cell proliferation in vitro, enhanced the antiproliferative and apoptotic effects of TGF-beta and increased radiosensitivity in conjunction with Bim induction. In contrast, transfection of RUNX3-expressing cells with a RUNX3 antisense construct or a Bim-specific small interfering RNA induced radioresistance. Treatment with 5-aza-2'-deoxycytidine restored RUNX3 expression, increased radiosensitivity and induced Bim in both control and radioresistant cells. These results suggest that RUNX3 silencing promotes radioresistance in esophageal cancers. Examination of RUNX3 expression in pretreatment specimens may predict radiosensitivity, and induction of RUNX3 expression may increase tumor radiosensitivity.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Physiol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Univ, Grad Sch Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Internal Med, Div Gastroenterol, Kamigyo Ku, Kyoto 6028566, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Sakakura, C (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kawaramachi Dori, Kyoto 6028566, Japan.	sakakura@koto.kpu-m.ac.jp		Nakase, Yuen/0000-0002-2351-2709				Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; BIARD DSF, 1994, CANCER RES, V54, P3361; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Coleman C N, 1996, Oncology (Williston Park), V10, P399; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; EIFEL PJ, 1994, INT J RADIAT ONCOL, V29, P9, DOI 10.1016/0360-3016(94)90220-8; Ewan KB, 2002, CANCER RES, V62, P5627; Fukuchi M, 2002, CANCER, V95, P737, DOI 10.1002/cncr.10727; Fukuda K, 2004, BRIT J CANCER, V91, P1543, DOI 10.1038/sj.bjc.6602187; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hanna E, 2001, CANCER RES, V61, P2376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsiao M, 1997, BIOCHEM BIOPH RES CO, V233, P329, DOI 10.1006/bbrc.1997.6450; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; *JAP SOC ES DIS, 1999, GEN RUL CLIN PATH ST; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kim AH, 2003, INT J ONCOL, V23, P1593; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Kitada S, 1996, ONCOGENE, V12, P187; Kitahara O, 2002, NEOPLASIA, V4, P295, DOI 10.1038/sj.neo.7900251; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumura Y, 1997, CANCER LETT, V115, P91, DOI 10.1016/S0304-3835(97)04714-9; Meyn RE, 1996, CANCER METAST REV, V15, P119, DOI 10.1007/BF00049491; Nakase Y, 2005, BRIT J CANCER, V92, P562, DOI 10.1038/sj.bjc.6602372; Natsugoe S, 2002, CLIN CANCER RES, V8, P1838; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Sakai K, 1996, PROTEIN EXPRES PURIF, V7, P67, DOI 10.1006/prep.1996.0010; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sakakura C, 2005, CLIN CANCER RES, V11, P6479, DOI 10.1158/1078-0432.CCR-05-0729; Sakakura C, 2002, BRIT J CANCER, V87, P1153, DOI 10.1038/sj.bjc.6600580; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Vodovotz Y, 2000, INT J CANCER, V90, P13, DOI 10.1002/(SICI)1097-0215(20000220)90:1<13::AID-IJC2>3.3.CO;2-L; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	41	46	47	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5927	5938		10.1038/sj.onc.1210403	http://dx.doi.org/10.1038/sj.onc.1210403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384682				2022-12-25	WOS:000249123100010
J	Tomlinson, D; Hurst, CD; Knowles, MA				Tomlinson, D. C.; Hurst, C. D.; Knowles, M. A.			Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer	ONCOGENE			English	Article						FGFR3; urothelial cell carcinoma; shRNA; therapeutic target	GROWTH-FACTOR RECEPTOR-3; UROTHELIAL CELL-CARCINOMA; MULTIPLE-MYELOMA PATIENTS; ACTIVATING MUTATIONS; GENE-MUTATIONS; TUMOR PROGRESSION; STAT ACTIVATION; LOW-GRADE; EXPRESSION; PROLIFERATION	More than 60% of low-grade non-invasive papillary urothelial cell carcinomas contain activating point mutations of fibroblast growth factor receptor 3 ( FGFR3). The phenotypic consequences of constitutive activation of FGFR3 in bladder cancer have not been elucidated and further studies are required to con. firm the consequences of inhibiting receptor activity in urothelial cells. We measured FGFR3 transcript levels and demonstrated that transcript levels were significantly more abundant in low-stage and grade tumours. We identified a tumour cell line, 97-7, expressing the most common FGFR3 mutation ( S249C) at similar FGFR3 transcript levels to low-stage and grade tumours. In these cells, S249C FGFR3 protein formed stable homodimers and was constitutively phosphorylated. We used retrovirus-mediated delivery of shRNA to knockdown S249C FGFR3. This induced cell. flattening, decreased cell proliferation and reduced clonogenicity on plastic and in soft agar. However, no effects of knockdown of wild-type FGFR3 were observed in telomerase immortalized normal human urothelial cells, indicating possible dependence of the tumour cell line on mutant FGFR3. Re-expression of S249C FGFR3 in shRNA-expressing 97-7 cells resulted in a reversal of phenotypic changes, con. firming the specificity of the shRNA. These results indicate that targeted inhibition of S249C FGFR3 may represent a useful therapeutic approach in superficial bladder cancer.	St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Tomlinson, Darren/0000-0003-4134-7484	Cancer Research UK [A5433] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; Bakkar AA, 2003, CANCER RES, V63, P8108; Bernard-Pierrot I, 2006, CARCINOGENESIS, V27, P740, DOI 10.1093/carcin/bgi290; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chen J, 2005, ONCOGENE, V24, P8259, DOI 10.1038/sj.onc.1208989; Chesi M, 2002, CURR OPIN HEMATOL, V9, P288, DOI 10.1097/00062752-200207000-00005; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Davies-Adetugbo AA, 1998, TROP MED INT HEALTH, V3, P9, DOI 10.1046/j.1365-3156.1998.00162.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gomez-Roman JJ, 2005, CLIN CANCER RES, V11, P459; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HOLMANG S, 1995, J UROLOGY, V153, P1823, DOI 10.1016/S0022-5347(01)67321-X; HOLMANG S, 1995, J UROLOGY, V153, P1826; Intini D, 2001, BRIT J HAEMATOL, V114, P362, DOI 10.1046/j.1365-2141.2001.02957.x; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kimura T, 2001, CANCER-AM CANCER SOC, V92, P2555, DOI 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Logie A, 2005, HUM MOL GENET, V14, P1153, DOI 10.1093/hmg/ddi127; Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Matsumoto M, 2004, ONCOL REP, V12, P967; Mhawrech-Fauceglia P, 2006, EJSO-EUR J SURG ONC, V32, P231, DOI 10.1016/j.ejso.2005.11.018; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2000, GENE CHROMOSOME CANC, V29, P378, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1045>3.0.CO;2-K; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Strausberg RL, 2004, NATURE, V429, P469, DOI 10.1038/nature02627; Tomlinson DC, 2005, CANCER RES, V65, P10441, DOI 10.1158/0008-5472.CAN-05-1718; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Trudel S, 2006, BLOOD, V107, P4039, DOI 10.1182/blood-2005-10-4179; van Rhijn BWG, 2001, CANCER RES, V61, P1265; van Rhijn BWG, 2003, CLIN CANCER RES, V9, P257; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zhu LJ, 2005, MOL CANCER THER, V4, P787, DOI 10.1158/1535-7163.MCT-04-0330	52	98	126	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5889	5899		10.1038/sj.onc.1210399	http://dx.doi.org/10.1038/sj.onc.1210399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384684	Green Accepted			2022-12-25	WOS:000249123100006
J	Crigler, L; Kazhanie, A; Yoon, TJ; Zakhari, J; Anders, J; Taylor, B; Virador, VM				Crigler, Lauren; Kazhanie, Amita; Yoon, Tae-Jin; Zakhari, Julia; Anders, Joanna; Taylor, Barbara; Virador, Victoria M.			Isolation of a mesenchymal cell population from murine dermis that contains progenitors of multiple cell lineages	FASEB JOURNAL			English	Article						epidermal precursors; murine organotypic culture; keratinocytes	KERATINOCYTE STEM-CELLS; HAIR FOLLICLE DEVELOPMENT; BONE-MARROW; PROTEIN-KINASE; IN-VIVO; SKIN; EXPRESSION; MOUSE; DIFFERENTIATION; MARKERS	The skin contains two known subpopulations of stem cells/epidermal progenitors: a basal keratinocyte population found in the interfollicular epithelium and cells residing in the bulge region of the hair follicle. The major role of the interfollicular basal keratinocyte population may be epidermal renewal, whereas the bulge population may only be activated and recruited to form a cutaneous epithelium in case of trauma. Using 3-dimensional cultures of murine skin under stress conditions in which only reserve epithelial cells would be expected to survive and expand, we demonstrate that a mesenchymal population resident in neonatal murine dermis has the unique potential to develop an epidermis in vitro. In monolayer culture, this dermal subpopulation has long-term survival capabilities in restricted serum and an inducible capacity to evolve into multiple cell lineages, both epithelial and mesenchymal, depending on culture conditions. When grafted subcutaneously, this dermal subpopulation gave rise to fusiform structures, reminiscent of disorganized muscle, that stained positive for smooth muscle actin and desmin; on typical epidermal grafts, abundant melanocytes appeared throughout the dermis that were not associated with hair follicles. The multipotential cells can be repeatedly isolated from neonatal murine dermis by a sequence of differential centrifugation and selective culture conditions. These results suggest that progenitors capable of epidermal differentiation exist in the mesenchymal compartment of an abundant tissue source and may have a function in mesenchymal-epithelial transition upon insult. Moreover, these cells could be available in sufficient quantities for lineage determination or tissue engineering applications.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Gyeongsang Natl Univ, Coll Med, Dept Dermatol, Jinju, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gyeongsang National University	Virador, VM (corresponding author), 9000 Rockville Pike,Bldg 10,Rm 2A33, Bethesda, MD 20892 USA.	vvirador@helix.nih.gov	Virador, Victoria M./A-8173-2009		Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Andriani F, 2004, INT J CANCER, V108, P348, DOI 10.1002/ijc.11525; Arosarena Oneida, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P233, DOI 10.1097/01.moo.0000170526.51393.c5; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Bickenbach JR, 2004, DIFFERENTIATION, V72, P371, DOI 10.1111/j.1432-0436.2004.07208003.x; Carroll JM, 2000, EXP DERMATOL, V9, P20, DOI 10.1034/j.1600-0625.2000.009001020.x; Ceradini DJ, 2005, TRENDS CARDIOVAS MED, V15, P57, DOI 10.1016/j.tcm.2005.02.002; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dunn KJ, 2005, PIGM CELL RES, V18, P167, DOI 10.1111/j.1600-0749.2005.00226.x; Eckfeldt CE, 2005, NAT REV MOL CELL BIO, V6, P726, DOI 10.1038/nrm1713; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Kalcheim C, 2005, CURR OPIN GENET DEV, V15, P371, DOI 10.1016/j.gde.2005.05.004; KARTASOVA T, 1995, J INVEST DERMATOL, V104, P611; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Li LW, 1999, MOL CELL BIOL, V19, P8547; LICHTI U, 1991, J INVEST DERMATOL, V96, pS81, DOI 10.1111/1523-1747.ep12472042; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; LICHTI U, 1995, J INVEST DERMATOL, V104, P614; Lyle S, 1998, J CELL SCI, V111, P3179; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Maas-Szabowski N, 2001, J INVEST DERMATOL, V116, P816, DOI 10.1046/j.1523-1747.2001.01349.x; MADISON KC, 1990, J INVEST DERMATOL, V95, P657, DOI 10.1111/1523-1747.ep12514333; Masson-Gadais B, 2006, J CELL PHYSIOL, V206, P831, DOI 10.1002/jcp.20529; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Medina RJ, 2006, J CELL BIOCHEM, V98, P174, DOI 10.1002/jcb.20757; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011; MORRIS RJ, 1990, CELL TISSUE KINET, V23, P587, DOI 10.1111/j.1365-2184.1990.tb01348.x; Ng WA, 1997, PEDIATR RES, V41, P285, DOI 10.1203/00006450-199702000-00021; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Pasonen-Seppanen S, 2001, HISTOCHEM CELL BIOL, V116, P287, DOI 10.1007/s004180100312; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; POTTEN CS, 1983, EXPERIENTIA, V39, P1125, DOI 10.1007/BF01943142; Rahimi F, 2005, FEBS J, V272, P2811, DOI 10.1111/j.1742-4658.2005.04703.x; Ramos CA, 2003, BIOTECHNIQUES, V34, P572, DOI 10.2144/03343rv01; Reddy ST, 2004, J INVEST DERMATOL, V123, P275, DOI 10.1111/j.0022-202X.2004.23215.x; ROGERS G, 1987, J INVEST DERMATOL, V89, P369, DOI 10.1111/1523-1747.ep12471760; Rokhlin OW, 1995, CANCER LETT, V98, P103, DOI 10.1016/0304-3835(95)90210-4; Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763; Spradling AC, 2004, NATURE, V428, P133, DOI 10.1038/428133b; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Terunuma A, 2003, J INVEST DERMATOL, V121, P1095, DOI 10.1046/j.1523-1747.2003.12531.x; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tosney KW, 2004, DEV DYNAM, V229, P99, DOI 10.1002/dvdy.10492; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Troy TC, 2005, DEV DYNAM, V232, P293, DOI 10.1002/dvdy.20223; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Wan H, 2003, J CELL SCI, V116, P4239, DOI 10.1242/jcs.00701; Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Webb A, 2004, DIFFERENTIATION, V72, P387, DOI 10.1111/j.1432-0436.2004.07208005.x; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; YUSPA SH, 1993, J INVEST DERMATOL, V101, pS27, DOI 10.1111/1523-1747.ep12362567; Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200; Zheng Y, 2005, J INVEST DERMATOL, V124, P867, DOI 10.1111/j.0022-202X.2005.23716.x; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	65	75	82	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2050	2063		10.1096/fj.06-5880com	http://dx.doi.org/10.1096/fj.06-5880com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384147	Green Accepted			2022-12-25	WOS:000247500300015
J	Seidel, M; Alderwick, LJ; Birch, HL; Sahm, H; Eggeling, L; Besra, GS				Seidel, Mathias; Alderwick, Luke J.; Birch, Helen L.; Sahm, Hermann; Eggeling, Lothar; Besra, Gurdyal S.			Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in corynebacterianeae, such as Corynebacterium glutamicum and Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; STRUCTURAL FEATURES; MASS-SPECTROMETRY; EMB PROTEINS; ARABINOGALACTAN; ETHAMBUTOL; LIPOARABINOMANNAN; SMEGMATIS; RECOGNITION; EXPRESSION	Arabinofuranosyltransferase enzymes, such as EmbA, EmbB, and AftA, play pivotal roles in the biosynthesis of arabinogalactan, and the anti-tuberculosis agent ethambutol (EMB) targets arabinogalactan biosynthesis through inhibition of Mt-EmbA and Mt-EmbB. Herein, we describe the identification and characterization of a novel arabinofuranosyltransferase, now termed AftB (Rv3805c), which is essential in Mycobacterium tuberculosis. Deletion of its orthologue NCgl2780 in the closely related species Corynebacterium glutamicum resulted in a viable mutant. Analysis of the cell wall-associated lipids from the deletion mutant revealed a decreased abundance of cell wall-bound mycolic acids, consistent with a partial loss of mycolylation sites. Subsequent glycosyl linkage analysis of arabinogalactan also revealed the complete absence of terminal beta(1 -> 2)-linked arabinofuranosyl residues. The deletion mutant biochemical phenotype was fully complemented by either Mt-AftB or Cg-AftB, but not with muteins of Mt-AftB, where the two adjacent aspartic acid residues, which have been suggested to be involved in glycosyltransferase activity, were replaced by alanine. In addition, the use of C. glutamicum and C. glutamicum Delta aftB in an in vitro assay utilizing the sugar donor beta-D-arabinofuranosyl-1-monophosphoryl-decaprenol together with the neoglycolipid acceptor alpha-D-Araf-(1 -> 5)-alpha-D-Araf-O-C-8 as a substrate confirmed AftB as a terminal beta(1 -> 2) arabinofuranosyltransferase, which was also insensitive to EMB. Altogether, these studies have shed further light on the complexities of Corynebacterianeae cell wall biosynthesis, and Mt-AftB represents a potential new drug target.	Res Ctr Jeulich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Besra, GS (corresponding author), Res Ctr Jeulich, Inst Biotechnol 1, D-52425 Julich, Germany.	g.besra@bham.ac.uk		Alderwick, Luke/0000-0002-1257-6053; Besra, Gurdyal/0000-0002-5605-0395	MRC [G0500590] Funding Source: UKRI; Medical Research Council [G0500590] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Alderwick LJ, 2006, GLYCOBIOLOGY, V16, P1073, DOI 10.1093/glycob/cwl030; Alderwick LJ, 2006, J BIOL CHEM, V281, P15653, DOI 10.1074/jbc.M600045200; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; BERG S, 2007, GLYCOBIOLOGY AD 0129; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; Coutinho P. M., 1999, RECENT ADV CARBOHYDR; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; Eggeling L, 2005, HDB CORYNEBACTERIUM, P535; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Huang HR, 2005, J BIOL CHEM, V280, P24539, DOI 10.1074/jbc.M504068200; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; Lee RE, 1998, BIOORG MED CHEM LETT, V8, P951, DOI 10.1016/S0960-894X(98)00147-4; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; Mikusova K, 2005, J BACTERIOL, V187, P8020, DOI 10.1128/JB.187.23.8020-8025.2005; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Radmacher E, 2005, MICROBIOL-SGM, V151, P1359, DOI 10.1099/mic.0.27804-0; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Seidel M, 2007, GLYCOBIOLOGY, V17, P210, DOI 10.1093/glycob/cwl066; Shi LB, 2006, J BIOL CHEM, V281, P19512, DOI 10.1074/jbc.M513846200; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877	46	89	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14729	14740		10.1074/jbc.M700271200	http://dx.doi.org/10.1074/jbc.M700271200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387176	hybrid			2022-12-25	WOS:000246589000008
J	Zhuang, HY; Matsunami, H				Zhuang, Hanyi; Matsunami, Hiroaki			Synergism of accessory factors in functional expression of mammalian odorant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE OLFACTORY RECEPTOR; MOLECULAR-BASIS; IDENTIFICATION; SPECIFICITY; PROTEINS; LIGANDS; NEURONS; FAMILY; CELLS; RECONSTITUTION	The discovery of odorant receptors led to endeavors in matching them with their cognate ligands. Although it has been challenging to functionally express odorant receptors in heterologous cells, previous studies have linked efficient odorant receptor expression with N-terminal modifications and accessory proteins, including the receptor-transporting proteins ( RTPs) and Ric8b. Here we have shown that a shorter form of RTP1, RTP1S, supports robust cell-surface and functional expression of representative odorant receptors. Using a combination of accessory proteins, including RTP1S, Ric8b, and G(alpha olf), a diverse set of untagged odorant receptors were successfully expressed heterologously due to the synergistic effects among the various accessory proteins. Furthermore, the addition of an N-terminal rhodopsin tag to the odorant receptors, along with the same set of accessory proteins, exhibits an additional level of synergism, inducing enhanced odorant receptor responses to odorants and thus defining a more efficient heterologous expression system. We then showed that the presence or absence of different N-terminal tags has little effect on the ligand specificity of odorant receptors, although the amount of receptor expressed can play a role in the ligand response profile. The accuracy of the odorant receptor heterologous expression system involving tagged odorant receptors and various accessory proteins promises success in high throughput de-orphaning of mammalian odorant receptors.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University	Matsunami, H (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, 264 CARL Bldg,Res Dr, Durham, NC 27710 USA.	hiroaki.matsunami@duke.edu			NIDCD NIH HHS [DC05782, DC008480] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005782, F31DC008480] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abaffy T, 2007, J BIOL CHEM, V282, P1216, DOI 10.1074/jbc.M609355200; Abaffy T, 2006, J NEUROCHEM, V97, P1506, DOI 10.1111/j.1471-4159.2006.03859.x; Barnea G, 2004, SCIENCE, V304, P1468, DOI 10.1126/science.1096146; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; Chen G, 2000, MOL PHARMACOL, V57, P125; Ford DJ, 2002, J PHARMACOL EXP THER, V300, P810, DOI 10.1124/jpet.300.3.810; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Grosmaitre X, 2006, P NATL ACAD SCI USA, V103, P1970, DOI 10.1073/pnas.0508491103; Hague C, 2004, P NATL ACAD SCI USA, V101, P13672, DOI 10.1073/pnas.0403854101; Imai T, 2006, SCIENCE, V314, P657, DOI 10.1126/science.1131794; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Ivic L, 2002, J NEUROBIOL, V50, P56, DOI 10.1002/neu.10016; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; Katada S, 2004, J NEUROCHEM, V90, P1453, DOI 10.1111/j.1471-4159.2004.02619.x; Kenakin T, 1996, PHARMACOL REV, V48, P413; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Lu M, 2003, TRAFFIC, V4, P416, DOI 10.1034/j.1600-0854.2003.00097.x; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Neuhaus EM, 2006, CHEM SENSES, V31, P445, DOI 10.1093/chemse/bjj049; Oka Y, 2006, NEURON, V52, P857, DOI 10.1016/j.neuron.2006.10.019; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Shirokova E, 2005, J BIOL CHEM, V280, P11807, DOI 10.1074/jbc.M411508200; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; Strotmann J, 2004, J NEUROSCI, V24, P7754, DOI 10.1523/JNEUROSCI.2588-04.2004; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Von Dannecker LEC, 2005, J NEUROSCI, V25, P3793, DOI 10.1523/JNEUROSCI.4595-04.2005; Von Dannecker LEC, 2006, P NATL ACAD SCI USA, V103, P9310, DOI 10.1073/pnas.0600697103; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	36	131	144	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15284	15293		10.1074/jbc.M700386200	http://dx.doi.org/10.1074/jbc.M700386200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387175	hybrid			2022-12-25	WOS:000246589000067
J	Bowler, MW; Montgomery, MG; Leslie, AGW; Walker, JE				Bowler, Matthew W.; Montgomery, Martin G.; Leslie, Andrew G. W.; Walker, John E.			Ground state structure of F-1-ATPase from bovine heart mitochondria at 1.9 a resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTARY CATALYTIC MECHANISM; NUCLEOTIDE-BINDING; ATP HYDROLYSIS; SITES; F(1)-ATPASE; REFINEMENT; F1-ATPASE; FLUORIDE; SYNTHASE; PROVIDES	The structure of bovine F-1-ATPase, crystallized in the presence of AMP-PNP and ADP, but in the absence of azide, has been determined at 1.9 angstrom resolution. This structure has been compared with the previously described structure of bovine F-1-ATPase determined at 1.95 angstrom resolution with crystals grown under the same conditions but in the presence of azide. The two structures are extremely similar, but they differ in the nucleotides that are bound to the catalytic site in the beta(DP)-subunit. In the present structure, the nucleotide binding sites in the beta(DP)- and beta(TP)-subunits are both occupied by AMP-PNP, whereas in the earlier structure, the beta(TP) site was occupied by AMP-PNP and the beta(DP) site by ADP, where its binding is enhanced by a bound azide ion. Also, the conformation of the side chain of the catalytically important residue, alpha Arg-373 differs in the beta(DP)- and beta(TP)- subunits. Thus, the structure with bound azide represents the ADP inhibited state of the enzyme, and the new structure represents a ground state intermediate in the active catalytic cycle of ATP hydrolysis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Leslie, AGW (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	andrew@mrc-lmb.cam.ac.uk; walker@mrc-dunn.cam.ac.uk	Bowler, Matthew/I-7461-2019; Bowler, Matthew/B-5722-2011	Bowler, Matthew/0000-0003-0465-3351; Bowler, Matthew/0000-0003-0465-3351; Walker, John/0000-0001-7929-2162	MRC [MC_U105663150, MC_U105184325] Funding Source: UKRI; Medical Research Council [MC_U105184325, MC_U105663150] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; Bowler MW, 2006, ACTA CRYSTALLOGR D, V62, P991, DOI 10.1107/S0907444906020877; Bowler MW, 2006, P NATL ACAD SCI USA, V103, P8646, DOI 10.1073/pnas.0602915103; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Kabaleeswaran V, 2006, EMBO J, V25, P5433, DOI 10.1038/sj.emboj.7601410; Kagawa R, 2004, EMBO J, V23, P2734, DOI 10.1038/sj.emboj.7600293; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LESLIE AG, 1992, JOINT CCP4 EACMB NEW, V26; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; WEBER J, 1993, J BIOL CHEM, V268, P20126	25	161	163	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14238	14242		10.1074/jbc.M700203200	http://dx.doi.org/10.1074/jbc.M700203200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17350959	hybrid			2022-12-25	WOS:000246245800034
J	Sastry, KSR; Karpova, Y; Prokopovich, S; Smith, AJ; Essau, B; Gersappe, A; Carson, JP; Weber, MJ; Register, TC; Chen, YQ; Penn, RB; Kulik, G				Sastry, Konduru S. R.; Karpova, Yelena; Prokopovich, Sergey; Smith, Adrienne J.; Essau, Brian; Gersappe, Avynash; Carson, Jonathan P.; Weber, Michael J.; Register, Thomas C.; Chen, Yong Q.; Penn, Raymond B.; Kulik, George			Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; EPIDERMAL-GROWTH-FACTOR; ANDROGEN RECEPTOR; RADICAL PROSTATECTOMY; SIGNALING PATHWAYS; BREAST-CANCER; CYCLIC-AMP; STRESS; LNCAP; CARCINOMA	The stress hormone epinephrine is known to elicit multiple systemic effects that include changes in cardiovascular parameters and immune responses. However, information about its direct action on cancer cells is limited. Here we provide evidence that epinephrine reduces sensitivity of cancer cells to apoptosis through interaction with beta(2)-adrenergic receptors. The antiapoptotic mechanism of epinephrine primarily involves phosphorylation and inactivation of the proapoptotic protein BAD by cAMP-dependent protein kinase. Moreover, BAD phosphorylation was observed at epinephrine concentrations found after acute and chronic psychosocial stress. Antiapoptotic signaling by epinephrine could be one of the mechanisms by which stress promotes tumorigenesis and decreases the efficacy of anti-cancer therapies.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Comparat Med Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	Wake Forest University; Wake Forest University; Wake Forest University; University of Virginia	Kulik, G (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	gkulik@wfubmc.edu	Sastry, Konduru Seetharama/GQY-6005-2022; Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Register, Thomas/0000-0002-4078-0166	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058506, R01HL058506] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala GE, 2006, CANCER RES, V66, P5159, DOI 10.1158/0008-5472.CAN-05-1847; Ben-Eliyahu S, 2000, NEUROIMMUNOMODULAT, V8, P154, DOI 10.1159/000054276; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cohen S, 1998, J NATL CANCER I, V90, P3, DOI 10.1093/jnci/90.1.3; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dent G, 2001, BRIT J PHARMACOL, V133, P1199, DOI 10.1038/sj.bjp.0704214; Garcia-Fernandez MO, 2003, PEPTIDES, V24, P893, DOI 10.1016/S0196-9781(03)00162-1; Gold SA, 2004, BIOL PSYCHOL, V67, P261, DOI 10.1016/j.biopsycho.2003.12.001; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grouzmann E, 2003, PFLUG ARCH EUR J PHY, V447, P254, DOI 10.1007/s00424-003-1140-x; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; ISAACS JT, 1992, J ANDROL, V13, P457; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701; Kimura K, 2001, CANCER RES, V61, P5611; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; McConkey DJ, 1996, CANCER RES, V56, P5594; Nagmani R, 2003, BIOCHEM PHARMACOL, V65, P1489, DOI 10.1016/S0006-2952(03)00105-9; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Perron L, 2004, CANCER CAUSE CONTROL, V15, P535, DOI 10.1023/B:CACO.0000036152.58271.5e; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; POYET P, 1986, PROSTATE, V9, P237, DOI 10.1002/pros.2990090304; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Sastry KSR, 2006, J BIOL CHEM, V281, P20891, DOI 10.1074/jbc.M602928200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Spiegel D, 2003, BIOL PSYCHIAT, V54, P269, DOI 10.1016/S0006-3223(03)00566-3; Su FX, 2005, BIOCHEM BIOPH RES CO, V329, P888, DOI 10.1016/j.bbrc.2005.02.056; Sumitomo M, 2001, CANCER RES, V61, P3294; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taub JS, 2003, CANCER RES, V63, P2037; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; THALMANN GN, 1994, CANCER RES, V54, P2577; Theodorescu D, 1997, CANCER, V80, P2109, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2; Tombal B, 2000, PROSTATE, V43, P303; Ullrich PM, 2003, J UROLOGY, V169, P1449, DOI 10.1097/01.ju.0000053243.87457.60; VANDEWALLE B, 1990, J CANCER RES CLIN, V116, P303, DOI 10.1007/BF01612908; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; Xu LL, 2000, CANCER RES, V60, P6568	51	144	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14094	14100		10.1074/jbc.M611370200	http://dx.doi.org/10.1074/jbc.M611370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353197	hybrid			2022-12-25	WOS:000246245800019
J	Zofall, M; Grewal, SIS				Zofall, Martin; Grewal, Shiv I. S.			HULC, a histone H2B ubiquitinating complex, modulates heterochromatin independent of histone methylation in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-4 METHYLATION; JMJC DOMAIN PROTEIN; TRANSCRIPTIONAL ACTIVATION; SCHIZOSACCHAROMYCES-POMBE; CHROMODOMAIN PROTEIN; CONJUGATING ENZYMES; EPIGENETIC CONTROL; UBIQUITYLATION; RAD6; GENE	Heterochromatin in fission yeast is targeted dynamically by opposing chromatin-modifying activities capable of alleviating or promoting transcriptional gene silencing. In this study, we report the biochemical and genetic characterization of a ubiquitin-conjugating enzyme Rhp6 (a homolog of budding yeast Rad6), which has been shown to negatively affect stability of heterochromatic structures. We show that Rhp6 is a component of the multisubunit protein complex (termed HULC) that also contains two RING finger proteins Rfp1 and Rfp2, sharing homology with budding yeast Bre1 protein and a unique serine-rich protein Shf1. HULC is required for ubiquitination of histone H2B at lysine 119 (H2B-K119), and it localizes to heterochromatic sequences. Moreover, our analyses suggest that Rhp6-induced changes in heterochromatic silencing are mediated predominantly through H2B ubiquitination (ubH2B), and they correlate with increased RNA polymerase II levels at repeat elements embedded within heterochromatin domains. Interestingly, heterochromatic derepression caused by Rhp6 occurs independently of the involvement of HULC subunits and ubH2B in methylation of histone H3 at lysine 4 (H3K4me). These analyses implicate ubH2B in modulation of heterochromatin, which has important implications for dynamics and many functions associated with heterochromatic structures.	NCI, Biochem & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grewal, SIS (corresponding author), NCI, Biochem & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2004, CURR OPIN GENET DEV, V14, P139, DOI 10.1016/j.gde.2004.02.004; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bjerling P, 2002, MOL CELL BIOL, V22, P2170, DOI 10.1128/MCB.22.7.2170-2181.2002; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Choi ES, 2002, MOL CELL BIOL, V22, P8366, DOI 10.1128/MCB.22.23.8366-8374.2002; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Djupedal I, 2005, GENE DEV, V19, P2301, DOI 10.1101/gad.344205; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Emre NCT, 2004, COLD SPRING HARB SYM, V69, P289, DOI 10.1101/sqb.2004.69.289; Emre NCT, 2005, MOL CELL, V17, P585, DOI 10.1016/j.molcel.2005.01.007; Freeman-Cook LL, 2005, GENETICS, V169, P1243, DOI 10.1534/genetics.104.032714; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Grewal SIS, 1998, GENETICS, V150, P563; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huisinga KL, 2006, CHROMOSOMA, V115, P110, DOI 10.1007/s00412-006-0052-x; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kato H, 2005, SCIENCE, V309, P467, DOI 10.1126/science.1114955; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Maruyama T, 2006, EMBO J, V25, P2420, DOI 10.1038/sj.emboj.7601110; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Naresh A, 2003, J BIOL CHEM, V278, P9185, DOI 10.1074/jbc.M212732200; Nielsen IS, 2002, EUKARYOT CELL, V1, P613, DOI 10.1128/EC1.4.613-625.2002; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Osley MA, 2006, RES PRO CEL, V41, P47, DOI 10.1007/006; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRAKASH L, 1989, GENOME, V31, P597, DOI 10.1139/g89-111; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2003, J BIOL CHEM, V278, P8487, DOI 10.1074/jbc.M209562200; Sadaie M, 2004, EMBO J, V23, P3825, DOI 10.1038/sj.emboj.7600401; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schotta Gunnar, 2004, Novartis Found Symp, V259, P22; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; VANHOLDE KE, 1989, CHROMATIN, P111; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005; Yamada T, 2005, MOL CELL, V20, P173, DOI 10.1016/j.molcel.2005.10.002; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zofall M, 2006, MOL CELL, V22, P681, DOI 10.1016/j.molcel.2006.05.010	74	41	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14065	14072		10.1074/jbc.M700292200	http://dx.doi.org/10.1074/jbc.M700292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363370	hybrid			2022-12-25	WOS:000246245800016
J	Dupre, DJ; Robitaille, M; Richer, M; Ethier, N; Mamarbachi, AM; Hebert, TE				Dupre, Denis J.; Robitaille, Melanie; Richer, Maxime; Ethier, Nathalie; Mamarbachi, Aida M.; Hebert, Terence E.			Dopamine receptor-interacting protein 78 acts as a molecular chaperone for G gamma subunits before assembly with G beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; HETEROTRIMERIC G-PROTEINS; FORM STABLE COMPLEXES; ENDOPLASMIC-RETICULUM; COUPLED RECEPTORS; ADENYLYL-CYCLASE; DIMER FORMATION; IDENTIFICATION; TRAFFICKING; MODULATION	Heterotrimeric G proteins play a central role in intracellular communication mediated by extracellular signals, and both G alpha and G beta gamma subunits regulate effectors downstream of activated receptors. The particular constituents of the G protein heterotrimer affect both specificity and efficiency of signal transduction. However, little is known about mechanistic aspects of G protein assembly in the cell that would certainly contribute to formation of heterotrimers of specific composition. It was recently shown that phosducin-like protein (PhLP) modulated both G beta gamma expression and subsequent signaling by chaperoning nascent G beta and facilitating heterodimer formation with G gamma subunits Lukov, G. L., Hu, T., McLaughlin, J. N., Hamm, H. E., and Willardson, B. M. ( 2005) EMBOJ. 24, 1965 - 1975; Humrich, J., Bermel, C., Bunemann, M., Harmark, L., Frost, R., Quitterer, U., and Lohse, M. J. ( 2005) J. Biol. Chem. 280, 20042 - 20050). Here we demonstrate using a variety of techniques that DRiP78, an endoplasmic reticulum resident protein known to regulate the trafficking of several seven transmembrane receptors, interacts specifically with the G gamma subunit but not G beta or G alpha subunits. Furthermore, we demonstrate that DRiP78 and the G beta subunit can compete for the G gamma subunit. DRiP78 also protects G gamma from degradation until a stable partner such as G beta is provided. Furthermore, DRiP78 interaction may represent a mechanism for assembly of specific G beta gamma heterodimers, as selectivity was observed among G gamma isoforms for interaction with DRiP78 depending on the presence of particular G beta subunits. Interestingly, we could detect an interaction between DRiP78 and PhLP, suggesting a role of DRiP78 in the assembly of G beta gamma by linking G gamma to PhLP center dot G beta complexes. Our results, therefore, suggest a role of DRiP78 as a chaperone in the assembly of G beta gamma subunits of the G protein.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Inst Cardiol Montreal, Montreal, PQ H1T 1C8, Canada	McGill University; Universite de Montreal; Universite de Montreal; Institut de Cardiologie de Montreal	Hebert, TE (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.	terence.hebert@mcgill.ca	Robitaille, Melanie/ABA-5861-2020; Dupre, Denis J/AAI-2631-2021	Robitaille, Melanie/0000-0001-9354-5162; Dupre, Denis J/0000-0001-6401-6157				Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Azpiazu I, 2002, METHOD ENZYMOL, V344, P112; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Chen JX, 2003, J HUM GENET, V48, P217, DOI 10.1007/s10038-003-0012-8; Chinault SL, 2003, J BIOL CHEM, V278, P20638, DOI 10.1074/jbc.M212701200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cook LA, 2001, PROTEIN SCI, V10, P2548, DOI 10.1110/ps.ps.26401; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Doering CJ, 2004, J BIOL CHEM, V279, P29709, DOI 10.1074/jbc.M308693200; Dupre DJ, 2006, J BIOL CHEM, V281, P34561, DOI 10.1074/jbc.M605012200; Dupre DJ, 2006, CELL SIGNAL, V18, P1549, DOI 10.1016/j.cellsig.2006.03.009; Ellis R J, 1990, Semin Cell Biol, V1, P1; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Humrich J, 2005, J BIOL CHEM, V280, P20042, DOI 10.1074/jbc.M409233200; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; Judd R. C., 2002, PROTEIN PROTOCOLS HD, P73; Knol JC, 2005, MOL CELL BIOL, V25, P8393, DOI 10.1128/MCB.25.18.8393-8400.2005; Lackner T, 2005, J VIROL, V79, P9746, DOI 10.1128/JVI.79.15.9746-9755.2005; Lacoste C, 2006, DEV BIOL, V294, P181, DOI 10.1016/j.ydbio.2006.02.039; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LeClerc PC, 2002, ENDOCRINOLOGY, V143, P4702, DOI 10.1210/en.2002-220679; Lukov GL, 2006, J BIOL CHEM, V281, P22261, DOI 10.1074/jbc.M601590200; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Miller LC, 2003, J BIOL CHEM, V278, P53072, DOI 10.1074/jbc.M306230200; Miller LC, 2003, J CELL SCI, V116, P2967, DOI 10.1242/jcs.00595; Natochin M, 2005, J BIOL CHEM, V280, P30236, DOI 10.1074/jbc.M500722200; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wang Q, 2001, J BIOL CHEM, V276, P39386, DOI 10.1074/jbc.M104981200	53	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13703	13715		10.1074/jbc.M608846200	http://dx.doi.org/10.1074/jbc.M608846200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363375	hybrid			2022-12-25	WOS:000246060300060
J	Edwards, SR; Wandless, TJ				Edwards, Sarah R.; Wandless, Thomas J.			The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANALOGS; SPECIFICITY; MICE	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein ( FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin ( mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. We synthesized two rapamycin derivatives that possess large sub-stituents at the C-16 position within the FRB-binding interface, and these derivatives were screened against a library of FRB mutants using a three-hybrid assay in Saccharomyces cerevisiae. Several FRB mutants responded to one of the rapamycin derivatives, and twenty of these mutants were further characterized in mammalian cells. The mutants most responsive to the ligand were fused to yellow fluorescent protein, and fluorescence levels in the presence and absence of the ligand were measured to determine stability of the fusion proteins. Wild-type and mutant FRB domains were expressed at low levels in the absence of the rapamycin derivative, and expression levels rose up to 10-fold upon treatment with ligand. The synthetic rapamycin derivatives were further analyzed using quantitative mass spectrometry, and one of the compounds was found to contain contaminating rapamycin. Furthermore, uncontaminated analogs retained the ability to inhibit mTOR, although with diminished potency relative to rapamycin. The ligand-dependent stability displayed by wild-type FRB and FRB mutants as well as the inhibitory potential and purity of the rapamycin derivatives should be considered as potentially confounding experimental variables when using these systems.	Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Wandless, TJ (corresponding author), Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA.	wandless@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068589] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068589-03, GM068589, R01 GM068589-04, R01 GM068589, R01 GM068589-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bayle JH, 2006, CHEM BIOL, V13, P99, DOI 10.1016/j.chembiol.2005.10.017; Biggar SR, 2000, J BIOL CHEM, V275, P25381, DOI 10.1074/jbc.M002991200; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Inoue T, 2005, NAT METHODS, V2, P415, DOI 10.1038/NMETH763; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Liberles SD, 1997, P NATL ACAD SCI USA, V94, P7825, DOI 10.1073/pnas.94.15.7825; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; LUENGO JI, 1995, CHEM BIOL, V2, P471, DOI 10.1016/1074-5521(95)90264-3; Park IH, 2005, EXP CELL RES, V309, P211, DOI 10.1016/j.yexcr.2005.05.017; Ryding ADS, 2001, J ENDOCRINOL, V171, P1, DOI 10.1677/joe.0.1710001; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Stankunas K, 2003, MOL CELL, V12, P1615, DOI 10.1016/S1097-2765(03)00491-X; Suh BC, 2006, SCIENCE, V314, P1454, DOI 10.1126/science.1131163; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	22	71	75	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13395	13401		10.1074/jbc.M700498200	http://dx.doi.org/10.1074/jbc.M700498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350953	Green Accepted, hybrid			2022-12-25	WOS:000246060300028
J	Furuta, K; Nakayama, K; Sugimoto, Y; Ichikawa, A; Tanaka, S				Furuta, Kazuyuki; Nakayama, Kazuhisa; Sugimoto, Yukihiko; Ichikawa, Atsushi; Tanaka, Satoshi			Activation of histidine decarboxylase through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; SODIUM-BUTYRATE; MAST-CELLS; HISTAMINE; EXPRESSION; LINE; APOPTOSIS; MICE; PURIFICATION; SEQUENCE	(L)-Histidine decarboxylase (HDC) is the rate-limiting enzyme for histamine synthesis in mammals. Although accumulating evidence has indicated the post-translational processing of HDC, it remains unknown what kinds of proteases are involved. We investigated the processing of HDC in a mouse mastocytoma, P-815, using a lentiviral expression system. HDC was expressed as a 74-kDa precursor form, which is cleaved to yield the 55- and 60-kDa forms upon treatment with butyrate. Alanine-scanning mutations revealed that two tandem aspartate residues (Asp(517) -Asp(518), Asp(550)- Asp(551)) are critical for the processing. Treatment with butyrate caused an increase in the enzyme activity of the cells expressing the wild type HDC, but not in the cells expressing the processing-incompetent mutant. An increase in histamine synthesis by butyrate was accompanied by formation of the 55- and 60-kDa form of HDC. In addition, the in vitro translated 74-kDa form of HDC was found to undergo a limited cleavage by purified human caspase-9, whereas the alanine-substituted mutants were not. Processing and enzymatic activation of HDC in P-815 cells was enhanced in the presence of a Zn2+ chelator, TPEN. Although treatment with butyrate and TPEN drastically augmented the protease activity of caspase-3, and -9, no apoptotic cell death was observed. Both enzymatic activation and processing of HDC were completely suppressed by a pan-caspase inhibitor, partially but significantly by a specific inhibitor for caspase-9, but not by a caspase-3 inhibitor. These results suggest that, in P-815 cells, histamine synthesis is augmented through the post-translational cleavage of HDC, which is mediated by caspase-9.	Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Immunobiol, Nishinomiya, Hyogo 6638179, Japan; Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Physiol Chem, Nishinomiya, Hyogo 6638179, Japan; Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan	Mukogawa Women's University; Mukogawa Women's University; Kyoto University	Tanaka, S (corresponding author), Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Immunobiol, Nishinomiya, Hyogo 6638179, Japan.	s_tanaka@mukogawa-u.ac.jp	Tanaka, Satoshi/H-6800-2019; Nakayama, Kazuhisa/ABF-2924-2020; TANAKA, Satoshi/B-1624-2011; Sugimoto, Yukihiko/AAV-6470-2021	Tanaka, Satoshi/0000-0002-3468-7694; TANAKA, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; Nakayama, Kazuhisa/0000-0001-7701-7183				BEAVEN MA, 1978, HISTAMINE ITS ROLE P; BELL PA, 1982, BIOCHEM BIOPH RES CO, V104, P1202, DOI 10.1016/0006-291X(82)91378-X; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Dartsch C, 1998, REGUL PEPTIDES, V77, P33, DOI 10.1016/S0167-0115(98)00045-7; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fleming JV, 2004, BIOCHEM J, V381, P769, DOI 10.1042/BJ20031553; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; FRIEND C, 1987, CANCER RES, V47, P378; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hirasawa N, 2001, EUR J PHARMACOL, V418, P23, DOI 10.1016/S0014-2999(01)00931-1; Ho LH, 2004, J IMMUNOL, V172, P7750, DOI 10.4049/jimmunol.172.12.7750; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; MARTIN SAM, 1986, BIOCHEM J, V234, P349, DOI 10.1042/bj2340349; MORI Y, 1980, EXP CELL RES, V127, P465, DOI 10.1016/0014-4827(80)90455-3; MORI Y, 1979, EXP CELL RES, V118, P15, DOI 10.1016/0014-4827(79)90578-0; Musio S, 2006, J IMMUNOL, V176, P17, DOI 10.4049/jimmunol.176.1.17; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; Ohtsu H, 1996, J BIOL CHEM, V271, P28439, DOI 10.1074/jbc.271.45.28439; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Rodriguez-Agudo D, 2000, BIOCHEM BIOPH RES CO, V271, P777, DOI 10.1006/bbrc.2000.2715; Safina F, 2002, J BIOL CHEM, V277, P14211, DOI 10.1074/jbc.M200702200; Samuelson LC, 2003, ANNU REV PHYSIOL, V65, P383, DOI 10.1146/annurev.physiol.65.092101.142213; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Suzuki S, 1998, FEBS LETT, V437, P44, DOI 10.1016/S0014-5793(98)01195-8; TAGUCHI Y, 1984, J BIOL CHEM, V259, P5214; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanaka S, 2004, EUR J IMMUNOL, V34, P1472, DOI 10.1002/eji.200324636; Tanaka S, 1997, FEBS LETT, V417, P203, DOI 10.1016/S0014-5793(97)01281-7; TANAKA S, 1995, BBA-PROTEIN STRUCT M, V1253, P9, DOI 10.1016/0167-4838(95)00185-W; Tanaka S, 2006, J PHARMACOL SCI, V101, P19, DOI 10.1254/jphs.FMJ06001X5; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; YAMAMOTO J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P431, DOI 10.1016/0167-4781(93)90011-2; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; Yatsunami K, 1995, J BIOL CHEM, V270, P30813, DOI 10.1074/jbc.270.51.30813; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	49	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13438	13446		10.1074/jbc.M609943200	http://dx.doi.org/10.1074/jbc.M609943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360717	hybrid			2022-12-25	WOS:000246060300033
J	Leonard, KC; Petrin, D; Coupland, SG; Baker, AN; Leonard, BC; LaCasse, EC; Hauswirth, WW; Korneluk, RG; Tsilfidis, C				Leonard, Kevin C.; Petrin, Dino; Coupland, Stuart G.; Baker, Adam N.; Leonard, Brian C.; LaCasse, Eric C.; Hauswirth, William W.; Korneluk, Robert G.; Tsilfidis, Catherine			XIAP Protection of Photoreceptors in Animal Models of Retinitis Pigmentosa	PLOS ONE			English	Article								Background. Retinitis pigmentosa (RP) is a blinding genetic disorder that is caused by the death of photoreceptors in the outer nuclear layer of the retina. To date, 39 different genetic loci have been associated with the disease, and 28 mutated genes have been identified. Despite the complexity of the underlying genetic basis for RP, the final common pathway is photoreceptor cell death via apoptosis. Methodology/Principal Findings. In this study, P23H and S334ter rhodopsin transgenic rat models of RP were used to test the neuroprotective effects of anti-apoptotic gene therapy. Adeno-associated viruses (AAV) carrying the X-linked inhibitor of apoptosis (XIAP) or green fluorescent protein (GFP) were delivered subretinally into the eye of transgenic rat pups. Histological and functional measures were used to assess neuroprotection. XIAP is known to block apoptosis by inhibiting the action of caspases-3, -7 and -9. The results show that XIAP gene therapy provides long-term neuroprotection of photoreceptors at both structural and functional levels. Conclusions/Significance. Our gene therapy strategy targets the apoptotic cascade, which is the final common pathway in all forms of retinitis pigmentosa. This strategy holds great promise for the treatment of RP, as it allows for the broad protection of photoreceptors, regardless of the initial disease causing mutation.	[Leonard, Kevin C.; Petrin, Dino; Coupland, Stuart G.; Baker, Adam N.; Leonard, Brian C.; Tsilfidis, Catherine] Univ Ottawa, Inst Eye, Ottawa, ON, Canada; [Leonard, Kevin C.; Petrin, Dino; Baker, Adam N.; Tsilfidis, Catherine] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Hauswirth, William W.] Univ Florida, Gainesville, FL USA; [LaCasse, Eric C.; Korneluk, Robert G.] Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; State University System of Florida; University of Florida; University of Ottawa; Children's Hospital of Eastern Ontario	Tsilfidis, C (corresponding author), Univ Ottawa, Inst Eye, Ottawa, ON, Canada.	ctsilfidis@ohri.ca			Canadian Institutes of Health Research (CIHR); Canadian Genetic Diseases Network (CGDN); Natural Sciences and Engineering Council of Canada (NSERC); Canadian Foundation Fighting Blindness Competing	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Genetic Diseases Network (CGDN); Natural Sciences and Engineering Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Foundation Fighting Blindness Competing	Canadian Institutes of Health Research (CIHR), and the Canadian Genetic Diseases Network (CGDN). KCL was supported by an Ontario Graduate Scholarship and a scholarship from the Natural Sciences and Engineering Council of Canada (NSERC) and DP was supported by the Canadian Foundation Fighting Blindness Competing	Adler R, 1996, ARCH OPHTHALMOL-CHIC, V114, P79, DOI 10.1001/archopht.1996.01100130075012; Bennett J, 1998, GENE THER, V5, P1156, DOI 10.1038/sj.gt.3300733; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; Cooper LB, 2006, OTOL NEUROTOL, V27, P484, DOI 10.1097/00129492-200606000-00009; Crocker SJ, 2003, NEUROBIOL DIS, V12, P150, DOI 10.1016/S0969-9961(02)00020-7; DAIGER S, 2006, RETNET RETINAL INFOR; Doonan F, 2003, J NEUROSCI, V23, P5723; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743; Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; John SK, 2000, MOL VIS, V6, P204; Jomary C, 2001, MOL CELL NEUROSCI, V18, P335, DOI 10.1006/mcne.2001.1036; Katai N, 1999, INVEST OPHTH VIS SCI, V40, P1802; Kennan A, 2005, TRENDS GENET, V21, P103, DOI 10.1016/j.tig.2004.12.001; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu CD, 1999, J NEUROSCI, V19, P4778; Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200; Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McKinnon SJ, 2002, MOL THER, V5, P780, DOI 10.1006/mthe.2002.0608; Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007; Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807; PAGON RA, 1988, SURV OPHTHALMOL, V33, P137, DOI 10.1016/0039-6257(88)90085-9; Petrin D, 2003, ADV EXP MED BIOL, V533, P385; Petrin D, 2003, INVEST OPHTH VIS SCI, V44, P2757, DOI 10.1167/iovs.02-0729; Phelan JK, 2000, MOL VIS, V6, P116; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Renwick J, 2006, GENE THER, V13, P339, DOI 10.1038/sj.gt.3302683; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saliba RS, 2002, J CELL SCI, V115, P2907; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Straten G, 2002, NEUROBIOL DIS, V11, P123, DOI 10.1006/nbdi.2002.0543; SUNG CH, 1994, J NEUROSCI, V14, P5818; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Timmers A, 2001, MOL VIS, V7, P131; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsang SH, 1997, INVEST OPHTH VIS SCI, V38, P943; Wasowicz M, 2002, INVEST OPHTH VIS SCI, V43, P813; Xu DG, 1999, J NEUROSCI, V19, P5026; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7	55	70	73	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e314	10.1371/journal.pone.0000314	http://dx.doi.org/10.1371/journal.pone.0000314			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375200	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445100016
J	Welch, TJ; Fricke, WF; McDermott, PF; White, DG; Rosso, ML; Rasko, DA; Mammel, MK; Eppinger, M; Rosovitz, MJ; Wagner, D; Rahalison, L; LeClerc, JE; Hinshaw, JM; Lindler, LE; Cebula, TA; Carniel, E; Ravel, J				Welch, Timothy J.; Fricke, W. Florian; McDermott, Patrick F.; White, David G.; Rosso, Marie-Laure; Rasko, David A.; Mammel, Mark K.; Eppinger, Mark; Rosovitz, M. J.; Wagner, David; Rahalison, Lila; LeClerc, J. Eugene; Hinshaw, Jeffrey M.; Lindler, Luther E.; Cebula, Thomas A.; Carniel, Elisabeth; Ravel, Jacques			Multiple Antimicrobial Resistance in Plague: An Emerging Public Health Risk	PLOS ONE			English	Article								Antimicrobial resistance in Yersinia pestis is rare, yet constitutes a significant international public health and biodefense threat. In 1995, the first multidrug resistant (MDR) isolate of Y. pestis (strain IP275) was identified, and was shown to contain a self-transmissible plasmid (pIP1202) that conferred resistance to many of the antimicrobials recommended for plague treatment and prophylaxis. Comparative analysis of the DNA sequence of Y. pestis plasmid pIP1202 revealed a near identical IncA/C plasmid backbone that is shared by MDR plasmids isolated from Salmonella enterica serotype Newport SL254 and the fish pathogen Yersinia ruckeri YR71. The high degree of sequence identity and gene synteny between the plasmid backbones suggests recent acquisition of these plasmids from a common ancestor. In addition, the Y. pestis pIP1202-like plasmid backbone was detected in numerous MDR enterobacterial pathogens isolated from retail meat samples collected between 2002 and 2005 in the United States. Plasmid-positive strains were isolated from beef, chicken, turkey and pork, and were found in samples from the following states: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York and Oregon. Our studies reveal that this common plasmid backbone is broadly disseminated among MDR zoonotic pathogens associated with agriculture. This reservoir of mobile resistance determinants has the potential to disseminate to Y. pestis and other human and zoonotic bacterial pathogens and therefore represents a significant public health concern.	[Fricke, W. Florian; Rasko, David A.; Eppinger, Mark; Rosovitz, M. J.; Ravel, Jacques] Inst Genom Res, Rockville, MD USA; [Welch, Timothy J.] ARS, Natl Ctr Cool & Cold Water Aquaculture, USDA, Kearneysville, WV USA; [McDermott, Patrick F.; White, David G.] US FDA, Res Off, Ctr Vet Med, Laurel, MD USA; [Rosso, Marie-Laure; Carniel, Elisabeth] Inst Pasteur, Yersinia Res Unit, Paris, France; [Rasko, David A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Mammel, Mark K.; LeClerc, J. Eugene; Cebula, Thomas A.] US FDA, Off Appl Res & Safety Assessment, Ctr Food Safety & Appl Nutr, Laurel, MD USA; [Wagner, David] No Arizona Univ, Flagstaff, AZ 86011 USA; [Rahalison, Lila] Inst Pasteur, Antananarivo, Madagascar; [Hinshaw, Jeffrey M.] N Carolina State Univ, Dept Zool, Fletcher, NC USA; [Lindler, Luther E.] DoD GEIS, Publ Hlth Lab Serv, Silver Spring, MD USA	J. Craig Venter Institute; United States Department of Agriculture (USDA); US Food & Drug Administration (FDA); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Food & Drug Administration (FDA); Northern Arizona University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar; University of North Carolina; North Carolina State University	Ravel, J (corresponding author), Inst Genom Res, Rockville, MD USA.	jravel@tigr.org	Ravel, Jacques/D-2530-2009; Wagner, David M/A-5125-2010; McDermott, Patrick F./ABE-4374-2021	McDermott, Patrick F./0000-0003-1868-8096; David, Rasko/0000-0002-7337-7154; Wagner, David/0000-0003-2684-6007; Fricke, W. Florian/0000-0003-1586-0962; Ravel, Jacques/0000-0002-0851-2233; Welch, Tim/0000-0003-1096-3006	National Institute of Allergy and Infectious Diseases, NIH, DHHS [N01-AI-30071]; ARS [1930-31000-002]	National Institute of Allergy and Infectious Diseases, NIH, DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	This research was supported by Federal funds from the National Institute of Allergy and Infectious Diseases, NIH, DHHS, under Contract No. N01-AI-30071 and by ARS CRIS project 1930-31000-002.	Anisimov AP, 2006, J MED MICROBIOL, V55, P1461, DOI 10.1099/jmm.0.46697-0; Butaye P, 2006, MICROBES INFECT, V8, P1891, DOI 10.1016/j.micinf.2005.12.020; Carattoli A, 2006, EMERG INFECT DIS, V12, P1145, DOI 10.3201/eid1207.051555; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; Galimand M, 2006, ANTIMICROB AGENTS CH, V50, P3233, DOI 10.1128/AAC.00306-06; Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106; Gupta A, 2003, J INFECT DIS, V188, P1707, DOI 10.1086/379668; Hinnebusch BJ, 2002, MOL MICROBIOL, V46, P349, DOI 10.1046/j.1365-2958.2002.03159.x; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Liebert CA, 1999, MICROBIOL MOL BIOL R, V63, P507, DOI 10.1128/MMBR.63.3.507-522.1999; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; Prentice MB, 2001, J BACTERIOL, V183, P2586, DOI 10.1128/JB.183.8.2586-2594.2001; Rasko DA, 2007, J BACTERIOL, V189, P52, DOI 10.1128/JB.01313-06; *US DEP HHS, 2006, NAT ANT RES MON SYST; Varma JK, 2006, J INFECT DIS, V194, P222, DOI 10.1086/505084; Wang YD, 1998, J BACTERIOL, V180, P4102, DOI 10.1128/JB.180.16.4102-4110.1998; Zhao S, 2003, J CLIN MICROBIOL, V41, P5366, DOI 10.1128/JCM.41.12.5366-5371.2003	18	301	317	3	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e309	10.1371/journal.pone.0000309	http://dx.doi.org/10.1371/journal.pone.0000309			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375195	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445100011
J	Peterson, AT; Benz, BW; Papes, M				Peterson, A. Townsend; Benz, Brett W.; Papes, Monica			Highly Pathogenic H5N1 Avian Influenza: Entry Pathways into North America via Bird Migration	PLOS ONE			English	Article								Given the possibility of highly pathogenic H5N1 avian influenza arriving in North America and monitoring programs that have been established to detect and track it, we review intercontinental movements of birds. We divided 157 bird species showing regular intercontinental movements into four groups based on patterns of movement-one of these groups ( breed Holarctic, winter Eurasia) fits well with the design of the monitoring programs (i.e., western Alaska), but the other groups have quite different movement patterns, which would suggest the importance of H5N1 monitoring along the Pacific, Atlantic, and Gulf coasts of North America.	[Peterson, A. Townsend] Univ Kansas, Nat Hist Museum, Lawrence, KS 66045 USA; Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA	University of Kansas; University of Kansas	Peterson, AT (corresponding author), Univ Kansas, Nat Hist Museum, Lawrence, KS 66045 USA.	town@ku.edu	Peterson, A. Townsend/I-5697-2013	Peterson, A. Townsend/0000-0003-0243-2379	U.S. Geological Survey	U.S. Geological Survey(United States Geological Survey)	Funding for this research was provided in part by a grant from the National Biological Information Infrastructure of the U.S. Geological Survey.	ABC, 2005, AV INFL SPREADS ROL; Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7; AOU, 1998, CHECK LIST N AM BIRD; Belshe RB, 2005, NEW ENGL J MED, V353, P2209, DOI 10.1056/NEJMp058281; BirdLife International, 2006, BIRDLIFE STAT AV INF; Brockmann D, 2006, NATURE, V439, P462, DOI 10.1038/nature04292; *CCWHC, 2006, CAN INT WILD BIRD IN; Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Cramp S, 1977, HDB BIRDS EUROPE MID, P1; del Hoyo J, 2013, HDB BIRDS WORLD; *FAO, 2005, UPD AV INFL SIT 01 0; Guo YJ, 2002, VACCINE, V20, pS28, DOI 10.1016/S0264-410X(02)00126-3; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Hsieh YC, 2006, J FORMOS MED ASSOC, V105, P1, DOI 10.1016/S0929-6646(09)60102-9; JNCC, 2006, POS STAT AV INFL; Kwon YK, 2005, J VET MED SCI, V67, P1193, DOI 10.1292/jvms.67.1193; Lavanchy D, 1998, Euro Surveill, V3, P23; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; Mermel LA, 2005, LANCET INFECT DIS, V5, P666, DOI 10.1016/S1473-3099(05)70246-2; *NAS, 2005, AV INFL INF; *NBII, 2006, NAT AV INFL SURV INF; Normile D, 2005, SCIENCE, V310, P417, DOI 10.1126/science.310.5747.417; *OIE, 2005, RAPP MISS MISS RUSS; Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Parry J, 2006, BRIT MED J, V332, P67, DOI 10.1136/bmj.332.7533.67-a; *PROMED, 2006, AV INFL EUR 36 HONG; STALLKNECHT DE, 1988, VET RES COMMUN, V12, P125, DOI 10.1007/BF00362792; Sturm-Ramirez KM, 2005, J VIROL, V79, P11269, DOI 10.1128/JVI.79.17.11269-11279.2005; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P1; Webster RG, 2006, EMERG INFECT DIS, V12, P3, DOI 10.3201/eid1201.051024; World Health Organization, 2005, H5N1 AV INFL TIM	31	47	49	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2007	2	2							e261	10.1371/journal.pone.0000261	http://dx.doi.org/10.1371/journal.pone.0000261			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DL	17330144	Green Published, gold			2022-12-25	WOS:000207444600021
J	Nakaya, K; Yamagata, HD; Arita, N; Nakashiro, K; Nose, M; Miki, T; Hamakawa, H				Nakaya, K.; Yamagata, H. D.; Arita, N.; Nakashiro, K-i; Nose, M.; Miki, T.; Hamakawa, H.			Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array	ONCOGENE			English	Article						oral cancer; CGH-array; tumor suppressor gene; homozygous deletion; FAT	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; COPY NUMBER; DROSOPHILA; MUTATIONS; BREAST; HEAD; NECK; AMPLIFICATION; EXPRESSION	Homozygous deletions (HD) provide an important resource for identifying the location of candidate tumor suppressor genes. To identify the tumor suppressor gene in oral cancer, we employed high-resolution comparative genomic hybridization (CGH)-array analysis. We identified a homozygous loss of FAT ( 4q35), a new member of the human cadherin superfamily, from genome-wide screening of copy number alterations in one primary oral cancer. This result was evaluated by genomic polymerase chain reaction in 13 oral cancer cell lines and 20 primary oral cancers and Southern blot in the cell lines. We found frequent exonic HD of FAT in the cell lines (3/13, 23%) and in primary oral cancers (16/20, 80%). FAT expression was absent in these cell lines. Homozygous deletion hot spots were observed in exon 1 (9/20, 45%) and exon 4 (7/20, 35%). Moreover, loss of gene expression was identified in other types of squamous cell carcinoma. The methylation status of the FAT CpG island in squamous cell carcinomas correlated negatively with its expression. Our results identify mutations in FAT as an important factor in the development of oral cancer and indicate the importance of FATs function in some squamous cell carcinomas.	Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Organ Funct Regenerat & Reconstruct Surg, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Pathol, Div Pathogenom, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Geriatr Med, Toon, Ehime 7910295, Japan	Ehime University; Ehime University; Ehime University; Ehime University	Yamagata, HD (corresponding author), Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan.	hideyama@m.ehime-u.ac.jp	Nakashiro, Koichi/AAV-6317-2020	Nakashiro, Koh-ichi/0000-0002-9975-902X				Beder LB, 2003, LAB INVEST, V83, P99, DOI 10.1097/01.LAB.0000047489.26246.E1; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Frijters ACJ, 1997, THEOR APPL GENET, V94, P390, DOI 10.1007/s001220050428; Garoia F, 2000, MECH DEVELOP, V94, P95, DOI 10.1016/S0925-4773(00)00306-3; HAUGHEY BH, 1992, AM J OTOLARYNG, V13, P168, DOI 10.1016/0196-0709(92)90117-C; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LEWIS GJ, 1989, E MIDLANDS GEOGRAPHE, V11, P3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Rook MS, 2004, AM J PATHOL, V164, P23, DOI 10.1016/S0002-9440(10)63092-1; SAMBROOK J, 1989, MOL CLONING, V2, P9; Siegelmann-Danieli N, 2005, TUMORI J, V91, P346, DOI 10.1177/030089160509100412; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Teni Tanuja, 2002, Pathology and Oncology Research, V8, P109; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; WATSON KL, 1994, J CELL SCI, P19; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	29	64	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5300	5308		10.1038/sj.onc.1210330	http://dx.doi.org/10.1038/sj.onc.1210330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325662				2022-12-25	WOS:000248674200013
J	Kusters, B; Kats, G; Roodink, I; Verrijp, K; Wesseling, P; Ruiter, DJ; de Waal, RMW; Leenders, WPJ				Kuesters, B.; Kats, G.; Roodink, I.; Verrijp, K.; Wesseling, P.; Ruiter, D. J.; de Waal, R. M. W.; Leenders, W. P. J.			Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis	ONCOGENE			English	Article						VEGF-A; metastasis; melanoma; tumor; emboli; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; INFLAMMATORY BREAST-CARCINOMA; VESSEL CO-OPTION; BRAIN METASTASIS; HUMAN-MELANOMA; TUMOR-CELLS; SPROUTING ANGIOGENESIS; CANCER METASTASIS; PROGNOSTIC-FACTOR; BONE-MARROW	How and why tumors metastasize is still a matter of debate. The assumption is that mutations render tumor cells with a metastatic phenotype, enabling entrance in and transport through lymph or blood vessels. Distant outgrowth is thought to occur only in a suitable microenvironment (the seed and soil hypothesis). However, the anatomical location of most metastases in cancer patients suggests entrapment of tumor cells in the first microcapillary bed that is encountered. We here investigated how vascular endothelial growth factor-A (VEGF-A) attributes to the metastatic process. We describe here that VEGF-A enhances spontaneous metastasis by inducing intravasation of heterogeneous tumor cell clusters, surrounded by vessel wall elements, via an invasion-independent mechanism. These tumor clusters generate metastatic tissue embolisms in pulmonary arteries. Treatment of tumor-bearing mice with the antiangiogenic compound ZD6474 prevented the development of this metastatic phenotype. This work shows that tumors with high constitutive VEGF-A expression metastasize via the formation of tumor emboli and provides an alternative rationale for anti-VEGF-A therapy, namely to inhibit metastasis formation.	Radboud Univ Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Leenders, WPJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	w.leenders@pathol.umcn.nl	Wesseling, P./H-8114-2014; Leenders, William P/O-9843-2014; Kusters, B./L-4465-2015; verrijp, kiek/F-4783-2018; Waal, R.M.W./L-4739-2015; Leenders, William/O-2541-2019; Ruiter, D.J./L-4617-2015	Wesseling, P./0000-0001-5453-5201; Leenders, William P/0000-0003-0066-220X; Leenders, William/0000-0003-0066-220X; 				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Auguste P, 2005, CRIT REV ONCOL HEMAT, V54, P53, DOI 10.1016/j.critrevonc.2004.11.006; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fidler IJ, 1999, CANCER METAST REV, V18, P387, DOI 10.1023/A:1006329410433; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Fidler IJ, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P203; FIDLER IJ, 1986, CANCER RES, V46, P5167; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gannon G, 2002, CANCER RES, V62, P603; GLAVES D, 1983, BRIT J CANCER, V48, P665, DOI 10.1038/bjc.1983.248; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj.bjc.6600315; Kanayama H, 1999, CLIN EXP METASTAS, V17, P831, DOI 10.1023/A:1006792007063; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; KIM ES, 2002, P NATL ACAD SCI USA, V12, P12; Kusters B, 2003, CANCER RES, V63, P5408; Kusters B, 2002, CANCER RES, V62, P341; Kusters B, 2001, INT J CANCER, V92, P176; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Leenders WPJ, 2002, ENDOTHELIUM-J ENDOTH, V9, P83, DOI 10.1080/10623320212006; LIOTTA LA, 1976, CANCER RES, V36, P889; MOFFETT BF, 1992, CANCER RES, V52, P1737; Neves S, 2001, CLIN NEUROPATHOL, V20, P38; Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015; Pezzella F, 2000, LANCET, V355, P1787; Pezzella F, 1997, AM J PATHOL, V151, P1417; Ruiter DJ, 2001, LANCET ONCOL, V2, P109, DOI 10.1016/S1470-2045(00)00229-1; Span PN, 2000, INT J BIOL MARKER, V15, P184, DOI 10.1177/172460080001500210; Sugino T, 2002, AM J PATHOL, V160, P1973, DOI 10.1016/S0002-9440(10)61147-9; SUGINO T, 1993, INT J CANCER, V55, P141, DOI 10.1002/ijc.2910550125; Sugino T, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-9; Tomlinson JS, 2001, CANCER RES, V61, P5231; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Vlems FA, 2003, EUR J SURG ONCOL, V29, P289, DOI 10.1053/ejso.2002.1394; Wedge SR, 2002, CANCER RES, V62, P4645; Weidner N, 2002, AM J PATHOL, V160, P1937, DOI 10.1016/S0002-9440(10)61141-8; Weidner N, 1998, J PATHOL, V184, P119, DOI 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D; Weidner Noel, 1996, P167; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Yano S, 2000, CANCER RES, V60, P4959	43	41	46	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5808	5815		10.1038/sj.onc.1210360	http://dx.doi.org/10.1038/sj.onc.1210360			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353901				2022-12-25	WOS:000248885100012
J	Tchantchou, F; Xu, YN; Wu, YJ; Christen, Y; Luo, Y				Tchantchou, Flaubert; Xu, Yanan; Wu, Yanjue; Christen, Yves; Luo, Yuan			EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; dementia; neuronal cells; memory	GINKGO-BILOBA EXTRACT; ELEMENT-BINDING PROTEIN; AMYLOID-BETA-PEPTIDE; DENTATE GYRUS; RANDOMIZED-TRIAL; DOUBLE-BLIND; IN-VIVO; SYNAPTIC PLASTICITY; CELLS; MEMORY	Standardized Ginkgo biloba extract EGb 761 exhibits beneficial effects to patients with Alzheimer's disease ( AD). It was previously demonstrated that EGb 761 inhibits amyloid beta ( A beta) oligomerization in vitro, protects neuronal cells against A beta toxicity, and improves cognitive defects in a mouse model of AD ( Tg 2576). In this study, the neurogenic potential of EGb 761 and its effect on cAMP response element binding protein ( CREB) were examined in a double transgenic mouse model ( TgAPP/ PS1). EGb 761 significantly increases cell proliferation in the hippocampus of both young ( 6 months) and old ( 22 months) TgAPP/ PS1 mice, and the total number of neuronal precursor cells in vitro in a dose-dependent manner. Furthermore, A beta oligomers inhibit phosphorylation of CREB and cell proliferation in the hippocampus of TgAPP/ PS1 mice. Administration of EGb 761 reduces A beta oligomers and restores CREB phosphorylation in the hippocampus of these mice. The present findings suggest that 1) enhanced neurogenesis by EGb 761 may be mediated by activation of CREB, 2) stimulation of neurogenesis by EGb 761 may contribute to its beneficial effects in AD patients and improved cognitive functions in the mouse model of AD, and 3) EGb 761 has therapeutic potential for the prevention and improved treatment of AD.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD USA; Ipsen, Paris, France	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Luo, Y (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	yluo@rx.umaryland.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001928] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01AT001928-03A1] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Barker N, 2000, ADV CANCER RES, V77, P1; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Beglopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P33, DOI 10.1016/j.tips.2005.11.010; Bender RA, 2001, EUR J NEUROSCI, V13, P679, DOI 10.1046/j.1460-9568.2001.01432.x; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Colciaghi F, 2004, NEUROBIOL DIS, V16, P454, DOI 10.1016/j.nbd.2004.03.011; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Dusek JA, 1997, P NATL ACAD SCI USA, V94, P7109, DOI 10.1073/pnas.94.13.7109; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gohil K, 2002, ANN NY ACAD SCI, V957, P70, DOI 10.1111/j.1749-6632.2002.tb02906.x; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mazza M, 2006, EUR J NEUROL, V13, P981, DOI 10.1111/j.1468-1331.2006.01409.x; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Parent JM, 1997, J NEUROSCI, V17, P3727; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Puzzo D, 2005, J NEUROSCI, V25, P6887, DOI 10.1523/JNEUROSCI.5291-04.2005; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Smith JV, 2002, CELL MOL BIOL, V48, P699; Smith JV, 2004, APPL MICROBIOL BIOT, V64, P465, DOI 10.1007/s00253-003-1527-9; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yamamoto-Sasaki M, 1999, BRAIN RES, V824, P300, DOI 10.1016/S0006-8993(99)01220-2; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101	58	146	158	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2400	2408		10.1096/fj.06-7649com	http://dx.doi.org/10.1096/fj.06-7649com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17356006				2022-12-25	WOS:000248454400015
J	Chamberlain, JS; Metzger, J; Reyes, M; Townsend, DW; Faulkner, JA				Chamberlain, Jeffrey S.; Metzger, Joseph; Reyes, Morayma; Townsend, DeWayne; Faulkner, John A.			Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma	FASEB JOURNAL			English	Article						muscular dystrophy; aging	DUCHENNE MUSCULAR-DYSTROPHY; CONTRACTION-INDUCED INJURY; SKELETAL-MUSCLE MYOPATHY; FULL-LENGTH DYSTROPHIN; ALVEOLAR RHABDOMYOSARCOMA; TRANSGENIC MDX; GENE-THERAPY; GLYCOPROTEIN COMPLEX; DIAPHRAGM MUSCLE; MOLECULAR-BASIS	Duchenne muscular dystrophy (DMD) is the most common, lethal genetic disorder of children. A number of animal models of muscular dystrophy exist, but the most effective model for characterizing the structural and functional properties of dystrophin and therapeutic interventions has been the mdx mouse. Despite the similar to 20 years of investigations of the mdx mouse, the impact of the disease on the life span of mdx mice and the cause of death remain unresolved. Consequently, a life span study of the mdx mouse was designed that included cohorts of male and female mdx and wild-type C57BL/10 mice housed under specific pathogen-free conditions with deaths restricted to natural causes and with examination of the carcasses for pathology. Compared with wild-type mice, both mdx male and female mice had reduced life spans and displayed a progressively dystrophic muscle histopathology. Surprisingly, old mdx mice were prone to develop muscle tumors that resembled the human form of alveolar rhabdomyosarcoma, a cancer associated with poor prognosis. Rhabdomyosarcomas have not been observed previously in nontransgenic mice. The results substantiate the mdx mouse as an important model system for studies of the pathogenesis of and potential remedies for DMD.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI USA	University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chamberlain, JS (corresponding author), Univ Washington, Sch Med, Dept Neurol, K243b HSB,Box 357720,1959, Seattle, WA 98195 USA.	jsc5@u.washington.edu		Chamberlain, Jeffrey/0000-0001-5299-0059	NIA NIH HHS [P01 AG015434] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015434] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe Shinichi, 2002, Anatomical Science International, V77, P145, DOI 10.1046/j.0022-7722.2002.00019.x; ABMAYR S, 2006, MOL MECH MUSCULAR DY; Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; Anderson JE, 1998, MUSCLE NERVE, V21, P1153, DOI 10.1002/(SICI)1097-4598(199809)21:9<1153::AID-MUS6>3.0.CO;2-6; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Chamberlain JS, 2002, HUM MOL GENET, V11, P2355, DOI 10.1093/hmg/11.20.2355; Cobos AR, 2001, J ANAT, V198, P283, DOI 10.1046/j.1469-7580.2001.19830283.x; Consolino CM, 2004, J APPL PHYSIOL, V96, P633, DOI 10.1152/japplphysiol.00587.2003; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DICK J, 1993, CLIN SCI, V84, P145, DOI 10.1042/cs0840145; Duchenne G., 1868, ARCH GEN MED, V11, P5; DUPONTVERSTEEGDEN EE, 1992, MUSCLE NERVE, V15, P1105, DOI 10.1002/mus.880151008; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; EMERY AEH, 1976, BMJ-BRIT MED J, V2, P637, DOI 10.1136/bmj.2.6036.637; Emery AEH, 2003, DUCHENNE MUSCULAR DY; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Faulkner JA, 1997, BASIC APPL MYOL, V7, P257; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hartmann N, 2001, J CELL BIOCHEM, P222; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; HUTTER OF, 1991, J MUSCLE RES CELL M, V12, P585, DOI 10.1007/BF01738447; Jakab Z, 2002, MED PEDIATR ONCOL, V39, P66, DOI 10.1002/mpo.10043; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; McClung JR, 2000, ANAT REC, V260, P378, DOI 10.1002/1097-0185(20001201)260:4<378::AID-AR70>3.0.CO;2-A; MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119; Meryon E, 1852, Med Chir Trans, V35, P73; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MOSER H, 1984, CURRENT CLIN PRACTIC, V20, P41; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; PASTORET C, 1993, NEUROMUSCULAR DISORD, V3, P471, DOI 10.1016/0960-8966(93)90099-6; PASTORET C, 1995, MUSCLE NERVE, V18, P1147, DOI 10.1002/mus.880181011; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Quinlan JG, 2004, NEUROMUSCULAR DISORD, V14, P491, DOI 10.1016/j.nmd.2004.04.007; Rossbach HC, 1999, J PEDIAT HEMATOL ONC, V21, P528, DOI 10.1097/00043426-199911000-00016; RUBIN E, 1994, PATHOLOGY, V1, P1343; Sebire NJ, 2003, PEDIATR DEVEL PATHOL, V6, P94, DOI 10.1007/s10024-002-0047-4; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; TONIN PN, 1991, CANCER RES, V51, P5100; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; VALENTINE BA, 1992, AM J MED GENET, V42, P352, DOI 10.1002/ajmg.1320420320; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Yue YP, 2004, HUM MOL GENET, V13, P1669, DOI 10.1093/hmg/ddh174; ZACHARIAS JM, 1991, J NEUROL SCI, V104, P190, DOI 10.1016/0022-510X(91)90309-U	77	239	244	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2195	2204		10.1096/fj.06-7353com	http://dx.doi.org/10.1096/fj.06-7353com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17360850	Green Submitted			2022-12-25	WOS:000247500300028
J	Farioli-Vecchioli, S; Tanori, M; Micheli, L; Mancuso, M; Leonardi, L; Saran, A; Ciotti, MT; Ferretti, E; Gulino, A; Pazzaglia, S; Tirone, F				Farioli-Vecchioli, Stefano; Tanori, Mirella; Micheli, Laura; Mancuso, Mariateresa; Leonardi, Luca; Saran, Anna; Ciotti, Maria Teresa; Ferretti, Elisabetta; Gulino, Alberto; Pazzaglia, Simonetta; Tirone, Felice			Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3	FASEB JOURNAL			English	Article						tumor suppressor gene; neurogenesis; cyclin D1; Math1	GRANULE CELL-DIFFERENTIATION; DEVELOPING MOUSE CEREBELLUM; CENTRAL-NERVOUS-SYSTEM; SONIC HEDGEHOG; HUMAN HOMOLOG; NEURONAL PRECURSORS; HETEROZYGOUS MICE; MAMMALIAN-CELLS; GROWTH-FACTOR; N-MYC	Medulloblastoma, the most common brain tumor in childhood, appears to originate from cerebellar granule cell precursors (GCPs), located in the external granular layer (EGL) of the cerebellum. The antiproliferative gene PC3 (Tis21/BTG2) promotes cerebellar neurogenesis by inducing GCPs to shift from proliferation to differentiation. To assess whether PC3 can prevent the neoplastic transformation of GCPs and medulloblastoma development, we crossed transgenic mice conditionally expressing PC3 (TgPC3) in GCPs with Patched1 heterozygous mice (Ptc(+/-)), a model of medulloblastoma pathogenesis characterized by hyperactivation of the Sonic Hedgehog pathway. Perinatal up-regulation of PC3 in Ptc(+/-)/TgPC3 mice results in a decrease of medulloblastoma incidence of similar to 40% and in a marked reduction of preneoplastic abnormalities, such as hyperplastic EGL areas and lesions. Moreover, overexpression of cyclin D1, hyperproliferation, and defective differentiation-observed in Ptc(+/-) GCPs-are restored to normality in Ptc(+/-)/TgPC3 mice. The PC3-mediated inhibition of cyclin D1 expression correlates with recruitment of PC3 to the cyclin D1 promoter, which is accompanied by histone deacetylation. Remarkably, down-regulation of PC3 is observed in preneoplastic lesions, as well as in human and murine medulloblastomas. As a whole, this indicates that PC3 may prevent medulloblastoma development by controlling cell cycle and promoting differentiation of GCPs.-Farioli-Vecchioli, S., Tanori, M., Micheli, L., Mancuso, M., Leonardi, L., Saran, A., Ciotti, M. T., Ferretti, E., Gulino, A., Pazzaglia, S., Tirone, F. Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3.	CNR, Inst Neurobiol & Mol Med, I-00143 Rome, Italy; ENEA CR Casaccia, Biotechnol Unit, Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Tirone, F (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso Fiorano 64, I-00143 Rome, Italy.	tirone@inmm.cnr.it	Micheli, Laura/AAY-1641-2020; vecchioli, stefano farioli/ABE-2288-2020; Tirone, Felice/P-6745-2014; Ferretti, Elisabetta/G-5413-2013	MICHELI, LAURA/0000-0001-8647-7261; Ferretti, Elisabetta/0000-0001-7265-6429; Saran, Anna/0000-0002-5587-064X; farioli vecchioli, stefano/0000-0001-7059-7779; Tirone, Felice/0000-0002-0980-4377	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Canzoniere D, 2004, J NEUROSCI, V24, P3355, DOI 10.1523/JNEUROSCI.3860-03.2004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Farah MH, 2000, DEVELOPMENT, V127, P693; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gazit R, 2004, DEVELOPMENT, V131, P903, DOI 10.1242/dev.00982; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lee Y, 2003, CANCER RES, V63, P5428; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Micheli L, 2005, MOL CELL BIOL, V25, P2242, DOI 10.1128/MCB.25.6.2242-2259.2005; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Passeri D, 2006, MOL CELL BIOL, V26, P5023, DOI 10.1128/MCB.01360-05; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pietsch T, 1997, CANCER RES, V57, P2085; Pogoriler J, 2006, DEVELOPMENT, V133, P3929, DOI 10.1242/dev.02556; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wetmore C, 2000, CANCER RES, V60, P2239; Weyer A, 2003, J NEUROSCI RES, V73, P400, DOI 10.1002/jnr.10655; Wolter M, 1997, CANCER RES, V57, P2581; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399	52	56	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2007	21	9					2215	2225		10.1096/fj.06-7548com	http://dx.doi.org/10.1096/fj.06-7548com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17371797				2022-12-25	WOS:000247500300030
J	Lin, Y; Stevens, C; Hupp, T				Lin, Yao; Stevens, Craig; Hupp, Ted			Identification of a dominant negative functional domain on DAPK-1 that degrades DAPK-1 protein and stimulates TNFR-1-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; P53 POINT MUTATION; CATHEPSIN-B; TNF-ALPHA; KINASE; EXPRESSION; CHECKPOINT; MICE; TRANSCRIPTION; SUPPRESSOR	DAPK-1 is a stress-activated tumor suppressor protein that plays a role in both proapoptotic or antiapoptotic signal transduction pathways. To define mechanisms of DAPK-1 protein regulation, we have determined that DAPK-1 protein has a long half-life, and therefore its activity is primarily regulated at the protein level. Changes in DAPK-1 protein levels occur by a cathepsin B-dependent pathway, prompting us to evaluate whether cathepsin B plays positive or negative role in DAPK-1 function. The transfection of p55-TNFR-1 induced complex formation between DAPK-1 and cathepsin B. Depletion of cathepsin B protein using small interfering RNA stimulated TNFR-1 dependent apoptosis. The minimal binding region on DAPK-1 for cathepsin B was mapped to amino acids 836-947. The transfection of the DAPK-1-( 836-947) miniprotein acted in a dominant negative manner inducing endogenous DAPK-1 protein degradation in a TNFR-1-dependent manner. These data suggest that DAPK-1 forms a multiprotein survival complex with cathepsin B countering the rate of TNFR-1-dependent apoptosis and highlights the importance of developing DAPK-1 inhibitors as agents to sensitize cells to stress-induced apoptosis.	Univ Edinburgh, CRUK Signal Transduct Grp P53, Edinburgh EH4 2XR, Midlothian, Scotland	University of Edinburgh	Hupp, T (corresponding author), Univ Edinburgh, CRUK Signal Transduct Grp P53, S Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	ted.hupp@ed.ac.uk		, yao/0000-0002-0493-0155				Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Araki T, 2004, HIPPOCAMPUS, V14, P326, DOI 10.1002/hipo.10184; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Finlan L, 2004, J BIOL CHEM, V279, P49395, DOI 10.1074/jbc.M405974200; Fleischer A, 2006, MOL IMMUNOL, V43, P1065, DOI 10.1016/j.molimm.2005.07.013; Gewies A, 2003, BRIT J CANCER, V89, P1574, DOI 10.1038/sj.bjc.6601297; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kadlcikova J, 2004, INT J EXP PATHOL, V85, P365, DOI 10.1111/j.0959-9673.2004.00405.x; Kastan MB, 2001, ACTA ONCOL, V40, P686; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138; Landon Linda A, 2004, Curr Drug Discov Technol, V1, P113, DOI 10.2174/1570163043335108; LEVIN AJ, 2006, CELL DEATH DIFFER; Li JH, 2005, J IMMUNOL, V175, P1858, DOI 10.4049/jimmunol.175.3.1858; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; LOFFLER BM, 1989, ANAL BIOCHEM, V177, P100, DOI 10.1016/0003-2697(89)90021-3; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Schneider-Stock R, 2006, J PATHOL, V209, P95, DOI 10.1002/path.1951; Shamloo M, 2005, J BIOL CHEM, V280, P42290, DOI 10.1074/jbc.M505804200; Shohat G, 2002, EUR CYTOKINE NETW, V13, P398; Stevens C, 2007, J BIOL CHEM, V282, P13791, DOI 10.1074/jbc.M605649200; Thoreen CC, 2005, CELL METAB, V1, P287, DOI 10.1016/j.cmet.2005.04.009; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wethkamp N, 2006, EUR J CANCER, V42, P264, DOI 10.1016/j.ejca.2005.10.019; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	52	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16792	16802		10.1074/jbc.M611559200	http://dx.doi.org/10.1074/jbc.M611559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17324927	hybrid			2022-12-25	WOS:000246946500011
J	Unno, H; Ichimaida, F; Suzuki, H; Takahashi, S; Tanaka, Y; Saito, A; Nishino, T; Kusunoki, M; Nakayama, T				Unno, Hideaki; Ichimaida, Fumiko; Suzuki, Hirokazu; Takahashi, Seiji; Tanaka, Yoshikazu; Saito, Atsushi; Nishino, Tokuzo; Kusunoki, Masami; Nakayama, Toru			Structural and mutational studies of anthocyanin malonyltransferases establish the features of BAHD enzyme catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALVIA-SPLENDENS FLOWERS; CRYSTAL-STRUCTURE; CDNA CLONING; ACYLTRANSFERASE; MECHANISM; COA; 5-O-GLUCOSIDE-6'''-O-MALONYLTRANSFERASE; ACETYLTRANSFERASE; MALONYLATION; EXPRESSION	The BAHD family is a class of acyl-CoA-dependent acyltransferases that are involved in plant secondary metabolism and show a diverse range of specificities for acyl acceptors. Anthocyanin acyltransferases make up an important class of the BAHD family and catalyze the acylation of anthocyanins that are responsible for most of the red-to-blue colors of flowers. Here, we describe crystallographic and mutational studies of three similar anthocyanin malonyltransferases from red chrysanthemum petals: anthocyanidin 3O-glucoside-6 ''-O-malonyltransferase ( Dm3MaT1), anthocyanidin 3-O-glucoside-3 '', 6 ''-O-dimalonyltransferase (Dm3MaT2), and a homolog ( Dm3MaT3). Mutational analyses revealed that seven amino acid residues in the N- and C-terminal regions are important for the differential acyl-acceptor specificity between Dm3MaT1 and Dm3MaT2. Crystallographic studies of Dm3MaT3 provided the first structure of a BAHD member, complexed with acyl-CoA, showing the detailed interactions between the enzyme and acyl-CoA molecules. The structure, combined with the results of mutational analyses, allowed us to identify the acyl-acceptor binding site of anthocyanin malonyltransferases, which is structurally different from the corresponding portion of vinorine synthase, another BAHD member, thus permitting the diversity of the acyl-acceptor specificity of BAHD family to be understood.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Sun Res Ctr, Osaka 6188503, Japan	Osaka University; Tohoku University	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp; nakayama@seika.che.tohoku.ac.jp	Suzuki, Hirokazu/AAG-2285-2020; Hideaki, UNNO/ABG-9471-2020	Suzuki, Hirokazu/0000-0002-9507-6467; Hideaki, UNNO/0000-0001-5917-269X; Takahashi, Seiji/0000-0002-2288-4340				Buglino J, 2004, J BIOL CHEM, V279, P30634, DOI 10.1074/jbc.M404011200; D'Auria JC, 2006, CURR OPIN PLANT BIOL, V9, P331, DOI 10.1016/j.pbi.2006.03.016; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; INO I, 1993, PHYTOCHEMISTRY, V32, P1425, DOI 10.1016/0031-9422(93)85151-G; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakayama T, 2003, J MOL CATAL B-ENZYM, V23, P117, DOI 10.1016/S1381-1177(03)00078-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Segel IH, 1975, ENZYME KINETICS, P623; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; St-Pierre B, 2000, RECENT ADV PHYTOCHEM, V34, P285, DOI 10.1016/S0079-9920(00)80010-6; Strack D., 1994, FLAVONOIDS ADV RES 1, P1; Suzuki H, 2004, PLANT J, V38, P994, DOI 10.1111/j.1365-313X.2004.02101.x; Suzuki H, 2004, PLANT SCI, V166, P89, DOI 10.1016/j.plantsci.2003.08.010; Suzuki H, 2003, BIOCHEMISTRY-US, V42, P1764, DOI 10.1021/bi020618g; Suzuki H, 2002, PLANT PHYSIOL, V130, P2142, DOI 10.1104/pp.010447; Suzuki H, 2001, J BIOL CHEM, V276, P49013, DOI 10.1074/jbc.M108444200; Suzuki H., 2003, PLANT BIOTECHNOL-NAR, V20, P229, DOI [10.5511/plantbiotechnology.20.229, DOI 10.5511/PLANTBIOTECHNOLOGY.20.229]; Taguchi G, 2005, PLANT J, V42, P481, DOI 10.1111/j.1365-313X.2005.02387.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Yonekura-Sakakibara K, 2000, PLANT CELL PHYSIOL, V41, P495, DOI 10.1093/pcp/41.4.495	30	69	76	5	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15812	15822		10.1074/jbc.M700638200	http://dx.doi.org/10.1074/jbc.M700638200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383962	hybrid			2022-12-25	WOS:000246589600056
J	Zhang, JP; Vinuela, A; Neely, MH; Hallett, PJ; Grant, SGN; Miller, GM; Isacson, O; Caron, MG; Yao, WD				Zhang, Jingping; Vinuela, Angel; Neely, Mark H.; Hallett, Penelope J.; Grant, Seth G. N.; Miller, Gregory M.; Isacson, Ole; Caron, Marc G.; Yao, Wei-Dong			Inhibition of the dopamine D1 receptor signaling by PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AGONIST-INDUCED DESENSITIZATION; D-ASPARTATE RECEPTORS; POSTSYNAPTIC DENSITY; CEREBRAL-CORTEX; D-1 RECEPTOR; PROTEIN; INTERNALIZATION; MEMBRANE; DYNAMIN	Dopamine D1 receptors play an important role in movement, reward, and learning and are implicated in a number of neurological and psychiatric disorders. These receptors are concentrated in dendritic spines of neurons, including the spine head and the postsynaptic density. D1 within spines is thought to modulate the local channels and receptors to control the excitability and synaptic properties of spines. The molecular mechanisms mediating D1 trafficking, anchorage, and function in spines remain elusive. Here we show that the synaptic scaffolding protein PSD-95 thought to play a role in stabilizing glutamate receptors in the postsynaptic density, interacts with D1 and regulates its trafficking and function. Interestingly, the D1-PSD-95 interaction does not require the well characterized domains of PSD-95 but is mediated by the carboxyl-terminal tail of D1 and the NH2 terminus of PSD-95, a region that is recognized only recently to participate in protein-protein interaction. Co-expression of PSD-95 with D1 in mammalian cells inhibits the D1-mediated cAMP accumulation without altering the total expression level or the agonist binding properties of the receptor. The diminished D1 signaling is mediated by reduced D1 expression at the cell surface as a consequence of an enhanced constitutive, dynamin-dependent endocytosis. In addition, genetically engineered mice lacking PSD-95 show a heightened behavioral response to either a D1 agonist or the psychostimulant amphetamine. These studies demonstrate a role for a glutamatergic scaffold in dopamine receptor signaling and trafficking and identify a new potential target for the modulation of abnormal dopaminergic function.	Harvard Univ, Sch Med, Dept Psychiat, New England Primate Res Ctr, Southborough, MA 01772 USA; Harvard Univ, Sch Med, McLean Hosp, Neuroregenerat Lab, Belmont, MA 02478 USA; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Harvard University; Harvard University; McLean Hospital; Wellcome Trust Sanger Institute; Duke University	Yao, WD (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, New England Primate Res Ctr, 1 Pine Hill Dr, Southborough, MA 01772 USA.	wei-dong_yao@hms.harvard.edu	Zhang, Jingping/ABA-4179-2020	Zhang, Jingping/0000-0002-7800-9617; Hallett, Penelope/0000-0002-8858-9096; Isacson, Ole/0000-0001-8091-8302; Grant, Seth/0000-0001-8732-8735	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168, K26RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS039793] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168, P51 RR000168-430106, P51 RR000168, K26 RR000168] Funding Source: Medline; NINDS NIH HHS [P50 NS039793, P50 NS039793-08, P50 NS039793-07, P50 NS39793] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bergson C, 1995, J NEUROSCI, V15, P7821; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bibb JA, 2005, CELL, V122, P153, DOI 10.1016/j.cell.2005.07.011; Bozzi Y, 2006, TRENDS NEUROSCI, V29, P167, DOI 10.1016/j.tins.2006.01.002; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CEPEDA C, 2006, SCI STKE, V333, pPE20; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Fiorentini C, 2003, J BIOL CHEM, V278, P20196, DOI 10.1074/jbc.M213140200; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hunt CA, 1996, J NEUROSCI, V16, P1380; Jassen AK, 2006, MOL PHARMACOL, V70, P71, DOI 10.1124/mol.105.021998; Jiang D, 1999, MOL PHARMACOL, V56, P675; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim OJ, 2002, J NEUROSCI, V22, P5920; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lachowicz JE, 1997, PHARMACOL TOXICOL, V81, P105, DOI 10.1111/j.1600-0773.1997.tb00039.x; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Li ZR, 2006, J BIOL CHEM, V281, P11066, DOI 10.1074/jbc.M600113200; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pei L, 2004, J NEUROSCI, V24, P1149, DOI 10.1523/JNEUROSCI.3922-03.2004; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Sesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Stein V, 2003, J NEUROSCI, V23, P5503; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	53	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15778	15789		10.1074/jbc.M611485200	http://dx.doi.org/10.1074/jbc.M611485200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369255	hybrid, Green Accepted			2022-12-25	WOS:000246589600053
J	Castello, PR; Drechsel, DA; Patel, M				Castello, Pablo R.; Drechsel, Derek A.; Patel, Manisha			Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; PARKINSONS-DISEASE; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; SUPEROXIDE; TOXICITY; MANEB; NEUROTOXICITY; GLUTATHIONE; MECHANISM	Paraquat (PQ(2+)) is a prototypic toxin known to exert injurious effects through oxidative stress and bears a structural similarity to the Parkinson disease toxicant, 1-methyl-4-pheynlpyridinium. The cellular sources of PQ(2+)- induced reactive oxygen species (ROS) production, specifically in neuronal tissue, remain to be identified. The goal of this study was to determine the involvement of brain mitochondria in PQ(2+)-induced ROS production. Highly purified rat brain mitochondria were obtained using a Percoll density gradient method. PQ(2+)-induced hydrogen peroxide (H2O2) production was measured by fluorometric and polarographic methods. The production of H2O2 was evaluated in the presence of inhibitors and modulators of the mitochondrial respiratory chain. The results presented here suggest that in the rat brain, ( a) mitochondria are a principal cellular site of PQ(2+)-induced H2O2 production, (b) PQ(2+)-induced H2O2 production requires the presence of respiratory substrates, (c) complex III of the electron transport chain is centrally involved in H2O2 production by PQ(2+), and (d) the mechanism by which PQ(2+) generates H2O2 depends on the mitochondrial inner transmembrane potential. These observations were further confirmed by measuringPQ(2+)-induced H2O2 production in primary neuronal cells derived from the midbrain. These findings shed light on the mechanism through which mitochondria may contribute to ROS production by other environmental and endogenous redox cycling agents implicated in Parkinson's disease.	Univ Colorado, Dept Pharmaceut Sci, Denver, CO 80262 USA; Ctr Hlth Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver	Patel, M (corresponding author), Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,C238, Denver, CO 80262 USA.	manisha.patel@uchsc.edu	Castello, Pablo R/AAL-7069-2021		NINDS NIH HHS [NS045748, R01 NS045748, R01 NS045748-05A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045748] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Aoki S, 2002, MED MYCOL, V40, P13, DOI 10.1080/mmy.40.1.13.19; Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012; Bishop AL, 2007, MOL MICROBIOL, V63, P507, DOI 10.1111/j.1365-2958.2006.05504.x; BLASZCZYNSKI M, 1985, ACTA MICROBIOL POL, V34, P243; Bonilla E, 2006, NEUROCHEM RES, V31, P1425, DOI 10.1007/s11064-006-9194-8; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Cicchetti F, 2005, NEUROBIOL DIS, V20, P360, DOI 10.1016/j.nbd.2005.03.018; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; FUKUSHIMA T, 1995, J NEUROSCI RES, V42, P385, DOI 10.1002/jnr.490420313; Gomez C, 2007, FRONT BIOSCI-LANDMRK, V12, P1079, DOI 10.2741/2128; GRANT HC, 1980, HISTOPATHOLOGY, V4, P185, DOI 10.1111/j.1365-2559.1980.tb02911.x; HUGHES JT, 1988, NEUROTOXICOLOGY, V9, P243; ILETT KF, 1974, TOXICOL APPL PHARM, V28, P216, DOI 10.1016/0041-008X(74)90007-6; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MASON RP, 1990, ENVIRON HEALTH PERSP, V87, P237, DOI 10.2307/3431031; Matsuno-Yagi A, 2001, J BIOL CHEM, V276, P19006, DOI 10.1074/jbc.M101446200; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MONTGOMERY MR, 1976, TOXICOL APPL PHARM, V36, P543, DOI 10.1016/0041-008X(76)90233-7; Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x; PALMEIRA CM, 1995, BBA-BIOENERGETICS, V1229, P187, DOI 10.1016/0005-2728(94)00202-G; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Richardson JR, 2005, TOXICOL SCI, V88, P193, DOI 10.1093/toxsci/kfi304; SATO B, 1995, BBA-MOL CELL RES, V1268, P20, DOI 10.1016/0167-4889(95)00035-Q; Shimizu K, 2001, BRAIN RES, V906, P135, DOI 10.1016/S0006-8993(01)02577-X; Taylor PJ, 2001, J ANAL TOXICOL, V25, P456, DOI 10.1093/jat/25.6.456; Thiruchelvam M, 2003, EUR J NEUROSCI, V18, P589, DOI 10.1046/j.1460-9568.2003.02781.x; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Veech RL, 2005, OXIDAT STRESS DIS, V18, P65; Votyakova TV, 2004, ARCH BIOCHEM BIOPHYS, V431, P138, DOI 10.1016/j.abb.2004.07.025; WINTERBOURN CC, 1984, ARCH BIOCHEM BIOPHYS, V235, P116, DOI 10.1016/0003-9861(84)90260-1; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	45	317	335	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14186	14193		10.1074/jbc.M700827200	http://dx.doi.org/10.1074/jbc.M700827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17389593	Green Accepted, hybrid			2022-12-25	WOS:000246245800029
J	Forrester, MT; Foster, MW; Stamler, JS				Forrester, Michael T.; Foster, Matthew W.; Stamler, Jonathan S.			Assessment and application of the biotin switch technique for examining protein S-nitrosylation under conditions of pharmacologically induced oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; ASCORBIC-ACID; IN-VIVO; VITAMIN-C; GLUTATHIONE; NITROSOTHIOLS; BINDING; GAPDH; MITOCHONDRIA	Protein S-nitrosylation has emerged as a principal mechanism by which nitric oxide exerts biological effects. Among methods for studying protein S-nitrosylation, the biotin switch technique (BST) has rapidly gained popularity because of the ease with which it can detect individual S-nitrosylated (SNO) proteins in biological samples. The identification of SNO sites by the BST relies on the ability of ascorbate to generate a thiol from an S-nitrosothiol, but not from alternatively S-oxidized thiols (e.g. disulfides, sulfenic acids). However, the specificity of this reaction has recently been challenged, prompting several claims that the BST may produce false-positive results and raising concerns about the application of the BST under oxidizing conditions. Here we perform a comparative analysis of the BST using differentially S-oxidized and S-nitrosylated forms of protein tyrosine phosphatase 1B, as well as intact and lysed human embryonic kidney 293 cells treated with S-oxidizing and S-nitrosylating agents, and verify that the assay is highly specific for SNO. Strikingly, exposure of samples to indirect sunlight from a laboratory window resulted in artifactual ascorbate-dependent signals that are likely promoted by the semidehydroascorbate radical; protection from sunlight eliminated the artifact. In contrast, exposure of SNO proteins to a strong ultraviolet light source (SNO photolysis) prior to the BST provided independent verification of assay specificity. By combining BST with photolysis, we have shown that anti-cancer drug-induced oxidative stress facilitates the S-nitrosylation of the major apoptotic effector glyceraldehyde-3-phosphate dehydrogenase. Collectively, these experiments demonstrate that SNO-dependent signaling pathways can be modulated by oxidative conditions and suggest a potential role for S-nitrosylation in antineoplastic drug action.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Med Scientist Training Program, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 2612, Durham, NC 27710 USA.	staml001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572				ARRICK BA, 1984, CANCER RES, V44, P4224; Barrett DM, 2005, J BIOL CHEM, V280, P14453, DOI 10.1074/jbc.M411523200; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Chvanov M, 2006, EMBO J, V25, P3024, DOI 10.1038/sj.emboj.7601207; Corrales FJ, 1999, J HEPATOL, V31, P887, DOI 10.1016/S0168-8278(99)80291-8; Dahm CC, 2006, J BIOL CHEM, V281, P10056, DOI 10.1074/jbc.M512203200; DAQUINO M, 1989, BIOCHEM BIOPH RES CO, V161, P1199, DOI 10.1016/0006-291X(89)91369-7; Davisson RL, 1996, HYPERTENSION, V28, P354, DOI 10.1161/01.HYP.28.3.354; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; FLEMING JE, 1983, Z NATURFORSCH C, V38, P859; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; FRISCHER H, 1993, J CLIN INVEST, V92, P2761, DOI 10.1172/JCI116894; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Hara MR, 2006, BBA-MOL BASIS DIS, V1762, P502, DOI 10.1016/j.bbadis.2006.01.012; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Holmes AJ, 2000, J CHEM SOC PERK T 2, P1639, DOI 10.1039/b004028m; Hou YC, 1998, BIOORG MED CHEM LETT, V8, P3065, DOI 10.1016/S0960-894X(98)00563-0; Huang B, 2006, FREE RADICAL BIO MED, V41, P562, DOI 10.1016/j.freeradbiomed.2006.03.006; Huang Y, 2005, NEURON, V46, P533, DOI 10.1016/j.neuron.2005.03.028; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V14, P91, DOI 10.1016/0891-5849(93)90513-T; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Landino LM, 2006, BIOCHEM BIOPH RES CO, V340, P347, DOI 10.1016/j.bbrc.2005.12.013; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; May JM, 2005, FREE RADICAL BIO MED, V39, P1449, DOI 10.1016/j.freeradbiomed.2005.07.006; MILES AM, 1995, BIOCHEMISTRY-US, V34, P6941, DOI 10.1021/bi00021a005; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; Permyakov EA, 2003, PROTEINS, V51, P498, DOI 10.1002/prot.10371; Rizzo MA, 2003, J CELL BIOL, V161, P243, DOI 10.1083/jcb.200301063; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; WALMSLEY TA, 1987, CLIN CHEM, V33, P1928; Wang GF, 2006, P NATL ACAD SCI USA, V103, P1295, DOI 10.1073/pnas.0508354103; WILLIAMS NH, 1982, AUST J CHEM, V35, P1133, DOI 10.1071/CH9821133; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200	47	172	179	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13977	13983		10.1074/jbc.M609684200	http://dx.doi.org/10.1074/jbc.M609684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376775	hybrid			2022-12-25	WOS:000246245800007
J	Morss, AS; Edelman, ER				Morss, Alisa S.; Edelman, Elazer R.			Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; HEPARAN-SULFATE PROTEOGLYCAN; DIABETES-MELLITUS; NONENZYMATIC GLYCOSYLATION; CULTURED HUMAN; IV COLLAGEN; OVEREXPRESSION; INSULIN; LAMININ; INVITRO	The effects of glucose extremes on vascular physiology and endothelial cell function have been examined across a range of time scales. Not unexpectedly, chronic glucose exposure induces long term tissue effects. Yet short term exposure can also impose lasting consequences. The persistence of vascular pathology after euglycemic restoration further suggests a glucose exposure memory. Slow turnover reservoirs such as basement membrane are candidates for prolongation of acute events. We hypothesized that glucose-induced vascular dysfunction is related to altered vasoactive compound handling within the endothelial cell-basement membrane co-regulatory unit. Endothelial cell basement membrane-associated fibroblast growth factor-2 increased linearly with culture glucose within days of elevated glucose exposure. Surprisingly, basement membrane fibroblast growth factor-2 binding kinetics remained unchanged. The glucose- induced increase in basement membrane fibroblast growth factor-2 was instead related to enhanced endothelial cell fibroblast growth factor-2 release and permeability. Cellular fibroblast growth factor-2 release occurred concomitant with apoptosis but was not blocked by caspase inhibitors. These data suggest that release was associated with sub-lethal early apoptotic cell membrane damage, perhaps related to reactive oxygen species formation. High glucose basement membrane in turn enhanced endothelial cell proliferation in a fibroblast growth factor-2-dependent manner. We now show that glucose- induced alterations in endothelial cell function promote changes in basement membrane composition, and these changes further affect endothelial cell function. These data highlight the interrelationship of cell and basement membrane in pathological conditions such as hyperglycemia. These phenomena may explain long term effects on the endothelium of short term exposure to glucose extremes.	MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Morss, AS (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,56-322, Cambridge, MA 02139 USA.	alisam@mit.edu	Clyne, Alisa/D-5471-2011	Clyne, Alisa/0000-0003-2462-2122; Edelman, Elazer/0000-0002-7832-7156	NHLBI NIH HHS [HL49309] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; BELL FP, 1974, EXP MOL PATHOL, V20, P57, DOI 10.1016/0014-4800(74)90043-4; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Boullion RD, 2003, COMPARATIVE MED, V53, P42; CAGLIERO E, 1991, DIABETES, V40, P102, DOI 10.2337/diabetes.40.1.102; CARROZZA JP, 1993, ANN INTERN MED, V118, P344, DOI 10.7326/0003-4819-118-5-199303010-00004; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; COHEN MP, 1977, BIOCHIM BIOPHYS ACTA, V500, P395, DOI 10.1016/0304-4165(77)90030-7; Cowan KN, 2005, FASEB J, V19, P1848, DOI 10.1096/fj.05-3706fje; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; Gibbs RV, 2003, ADV EXP MED BIOL, V535, P125; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; LABATROBERT J, 1990, FEBS LETT, V268, P386, DOI 10.1016/0014-5793(90)81291-U; Mandal AK, 2000, KIDNEY INT, V57, P2492, DOI 10.1046/j.1523-1755.2000.00108.x; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nissen NN, 1999, BIOCHEM J, V338, P637, DOI 10.1042/0264-6021:3380637; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Otero K, 2001, BIOCHEM J, V359, P567, DOI 10.1042/0264-6021:3590567; Roy S, 1996, INVEST OPHTH VIS SCI, V37, P258; Salameh A, 1997, J CARDIOVASC PHARM, V30, P182, DOI 10.1097/00005344-199708000-00006; SHIMOMURA H, 1987, DIABETES, V36, P374, DOI 10.2337/diabetes.36.3.374; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Tsilibary EC, 2003, J PATHOL, V200, P537, DOI 10.1002/path.1439; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Vogl-Willis CA, 2004, BBA-GEN SUBJECTS, V1672, P36, DOI 10.1016/j.bbagen.2004.02.005; WONG MKK, 1984, LAB INVEST, V51, P75	42	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14635	14644		10.1074/jbc.M608565200	http://dx.doi.org/10.1074/jbc.M608565200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17327226	hybrid			2022-12-25	WOS:000246245800077
J	Benfante, R; Flora, A; Di Lascio, S; Cargnin, F; Longhi, R; Colombo, S; Clementi, F; Fornasari, D				Benfante, Roberta; Flora, Adriano; Di Lascio, Simona; Cargnin, Francesca; Longhi, Renato; Colombo, Sara; Clementi, Francesco; Fornasari, Diego			Transcription factor PHOX2A regulates the human alpha 3 nicotinic receptor subunit gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; HOMEODOMAIN PROTEIN; FUNCTIONAL-CHARACTERIZATION; AUTONOMIC GANGLIA; MINIMAL PROMOTER; BINDING SITES; STEM-CELLS; EXPRESSION; DNA; DIFFERENTIATION	PHOX2A is a paired-like homeodomain transcription factor that participates in specifying the autonomic nervous system. It is also involved in the transcriptional control of the noradrenergic neurotransmitter phenotype as it regulates the gene expression of tyrosine hydroxylase and dopamine-beta-hydroxylase. The results of this study show that the human orthologue of PHOX2A is also capable of regulating the transcription of the human alpha 3 nicotinic acetylcholine receptor gene, which encodes the ligand-binding subunit of the ganglionic type nicotinic receptor. In particular, we demonstrated by chromatin immunoprecipitation and DNA pulldown assays that PHOX2A assembles on the SacI-NcoI region of alpha 3 promoter and, by co-transfection experiments, that it exerts its transcriptional effects by acting through the 60-bp minimal promoter. PHOX2A does not seem to bind to DNA directly, and its DNA binding domain seems to be partially dispensable for the regulation of alpha 3 gene transcription. However, as suggested by the findings of our co-immunoprecipitation assays, it may establish direct or indirect protein-protein interactions with Sp1, thus regulating the expression of alpha 3 through a DNA-independent mechanism. As the alpha 3 subunit is expressed in every terminally differentiated ganglionic cell, this is the first example of a " pan-autonomic" gene whose expression is regulated by PHOX2 proteins.	Univ Milan, Dept Pharmacol, Sch Med, I-20129 Milan, Italy; CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; CNR, Inst Chem & Mol Recognit, I-20131 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20129 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); University of Milan	Fornasari, D (corresponding author), Univ Milan, Dept Pharmacol, Sch Med, Via Vanvitelli 32, I-20129 Milan, Italy.	diego.fornasari@unimi.it	Benfante, Roberta/C-1513-2015	Benfante, Roberta/0000-0001-5396-5429; COLOMBO, SARA FRANCESCA/0000-0001-9714-3961; Fornasari, Diego/0000-0002-9668-3103				Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Billeter M, 1996, PROG BIOPHYS MOL BIO, V66, P211, DOI 10.1016/S0079-6107(97)00006-0; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Cargnin F, 2005, J BIOL CHEM, V280, P37439, DOI 10.1074/jbc.M508368200; Coppola E, 2005, EMBO J, V24, P4392, DOI 10.1038/sj.emboj.7600897; D'Elia AV, 2001, HUM MUTAT, V18, P361, DOI 10.1002/humu.1207; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2001, J NEUROSCI, V21, P7037, DOI 10.1523/JNEUROSCI.21-18-07037.2001; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034; HOWARD MJ, 1995, DEV BIOL, V170, P479, DOI 10.1006/dbio.1995.1231; Kim HS, 1998, J NEUROSCI, V18, P8247; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Liu Q, 1999, J NEUROSCI, V19, P9747; McDonough J, 2000, J BIOL CHEM, V275, P28962, DOI 10.1074/jbc.M004181200; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; RAIMONDI E, 1992, GENOMICS, V12, P849, DOI 10.1016/0888-7543(92)90324-L; Rychlik JL, 2003, J BIOL CHEM, V278, P49652, DOI 10.1074/jbc.M308577200; Shimakura J, 2006, BIOCHEM PHARMACOL, V71, P1581, DOI 10.1016/j.bcp.2006.03.001; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; TAYLOR P, 2006, GOODMAN GILMANS PHAR, P217; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Wang NS, 2002, PROG NEUROBIOL, V68, P341, DOI 10.1016/S0301-0082(02)00106-5; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xu HM, 2003, DEV BIOL, V262, P183, DOI 10.1016/S0012-1606(03)00361-0; Xu XH, 2006, MOL CELL BIOL, V26, P5636, DOI 10.1128/MCB.00456-06; Yang CY, 1998, J NEUROCHEM, V71, P1813; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	39	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13290	13302		10.1074/jbc.M608616200	http://dx.doi.org/10.1074/jbc.M608616200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344216	hybrid			2022-12-25	WOS:000246060300017
J	Lavrik, IN; Golks, A; Riess, D; Bentele, M; Eils, R; Krammer, PH				Lavrik, Inna N.; Golks, Alexander; Riess, Dagmar; Bentele, Martin; Eils, Roland; Krammer, Peter H.			Analysis of CD95 threshold signaling - Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CASPASE-8 ACTIVATION; MONOCLONAL-ANTIBODY; APOPTOSIS; INDUCTION; REGULATOR; MECHANISM; VARIANTS; FLICE; ERK	Recently we generated a mathematical model (Bentele, M., Lavrik, I., Ulrich, M., Stosser, S., Heermann, D. W., Kalthoff, H., Krammer, P. H., and Eils, R. ( 004) J. Cell Biol. 166, 839 - 851) of signaling in CD95(Fas/ APO-1)-mediated apoptosis. Mathematical modeling in combination with experimental data provided new insights into CD95-mediated apoptosis and allowed us to establish a threshold mechanism of life and death. Here, we further assessed the predictability of the model experimentally by a detailed analysis of the threshold behavior of CD95 signaling. Using the model predictions for the mechanism of the threshold behavior we found that the CD95 DISC (death-inducing signaling complex) is formed at the cell membrane upon stimulation with low concentrations of agonistic anti-APO-1 monoclonal antibodies; however, activation of procaspase-8 at the DISC is blocked due to high cellular FLICE-inhibitory protein recruitment into the DISC. Given that death signaling does not occur upon CD95 stimulation at low (threshold) anti-APO-1 concentrations, we also analyzed survival signaling, focusing on mitogen-activated protein kinase activation. Interestingly, we found that mitogen-activated protein kinase activation takes place under threshold conditions. These findings show that triggering of CD95 can signal both life or death, depending on the strength of the stimulus.	German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Theroet Bioinformat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, Neurnheimer Feld 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Lavrik, Inna N/C-1700-2009; Eils, Roland/B-6121-2009	Lavrik, Inna N/0000-0002-9324-309X; Eils, Roland/0000-0002-0034-4036				Bentele M, 2004, J CELL BIOL, V166, P839, DOI 10.1083/jcb.200404158; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; DHEIN J, 1992, J IMMUNOL, V149, P3166; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Sole C, 2004, J CELL BIOL, V167, P479, DOI 10.1083/jcb.200403093; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Zuliani C, 2006, CELL DEATH DIFFER, V13, P31, DOI 10.1038/sj.cdd.4401720	23	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13664	13671		10.1074/jbc.M700434200	http://dx.doi.org/10.1074/jbc.M700434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347143	hybrid			2022-12-25	WOS:000246060300056
J	Li, W; Adams, TE; Kjellberg, M; Stenflo, J; Huntington, JA				Li, Wei; Adams, Ty E.; Kjellberg, Margareta; Stenflo, Johan; Huntington, James A.			Structure of native protein C inhibitor provides insight into its multiple functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; HEPARIN-BINDING; CRYSTAL-STRUCTURE; HORMONE-BINDING; BASIC RESIDUES; ALPHA(1)-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGE; ACTIVE-SITE; SERPIN; ANTITHROMBIN	Protein C inhibitor (PCI) is a multifunctional serpin with wide ranging protease inhibitory functions, unique cofactor binding activities, and potential non-inhibitory functions akin to the hormone-transporting serpins. To gain insight into the molecular mechanisms utilized by PCI we developed a robust expression system in Escherichia coli and solved the crystal structure of PCI in its native state. The five monomers obtained from our two crystal forms provide an NMR-like ensemble revealing regions of inherent flexibility. The reactive center loop (RCL) of PCI is long and highly flexible with no evidence of hinge region incorporation into beta-sheet A, as seen for other heparin-binding serpins. We adapted an extrinsic fluorescence method for determining dissociation constants for heparin and find that the N-terminal tail of PCI and residues adjacent to helix H are not involved in heparin binding. The minimal heparin length capable of tight binding to PCI was determined to be chains of eight monosaccharide units. A large hydrophobic pocket occupied by hydrophobic crystal contacts was found in an analogous position to the hormone-binding site in thyroxine-binding globulin. In conclusion, the data presented here provide important insights into the mechanisms by which PCI exercises its multiple inhibitory and non-inhibitory functions.	Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Haematol,Div Struct Med, Cambridge CB2 2XY, England; Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden	University of Cambridge; Wellcome Trust Sanger Institute; Lund University; Skane University Hospital	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Haematol,Div Struct Med, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G0601596, G117/444] Funding Source: Medline; MRC [G117/444, G0601596] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; ECKE S, 1992, J BIOL CHEM, V267, P7048; Elisen MGLM, 1998, BLOOD, V91, P1542, DOI 10.1182/blood.V91.5.1542.1542_1542_1547; Elisen MGLM, 1996, THROMB HAEMOSTASIS, V75, P760; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Friedrich U, 2001, J BIOL CHEM, V276, P24122, DOI 10.1074/jbc.M011567200; Fujita M, 2002, THROMB RES, V105, P95, DOI 10.1016/S0049-3848(01)00398-X; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; GARG HG, 2005, CHEM BIOL HEPARIN HE, P367; Geiger M, 1996, IMMUNOPHARMACOLOGY, V32, P53, DOI 10.1016/0162-3109(96)00013-6; Geiger M, 1997, IMMUNOPHARMACOLOGY, V36, P279, DOI 10.1016/S0162-3109(97)00033-7; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Glasscock LN, 2003, BBA-PROTEINS PROTEOM, V1649, P106, DOI 10.1016/S1570-9639(03)00164-X; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; Horvath AJ, 2005, J BIOL CHEM, V280, P43168, DOI 10.1074/jbc.M505598200; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2003, STRUCTURE, V11, P205, DOI 10.1016/S0969-2126(02)00944-9; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 2006, TRENDS BIOCHEM SCI, V31, P427, DOI 10.1016/j.tibs.2006.06.005; Irving JA, 2002, BIOCHEMISTRY-US, V41, P4998, DOI 10.1021/bi0159985; Jerabek I, 2001, EUR J BIOCHEM, V268, P5989, DOI 10.1046/j.0014-2956.2001.02560.x; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; Johnson DJD, 2006, J BIOL CHEM, V281, P35478, DOI 10.1074/jbc.M607204200; Komiyama T, 1996, PROTEIN SCI, V5, P874; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; Langdown J, 2006, FEBS LETT, V580, P4709, DOI 10.1016/j.febslet.2006.07.057; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neese LL, 1998, ARCH BIOCHEM BIOPHYS, V355, P101, DOI 10.1006/abbi.1998.0716; Nishioka J, 1998, J BIOL CHEM, V273, P11281, DOI 10.1074/jbc.273.18.11281; O'Keeffe D, 2004, J BIOL CHEM, V279, P50267, DOI 10.1074/jbc.M408774200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRENDESGARCIA MJ, 2001, J THROMB HAEM    JUL; Rehault SM, 2005, BBA-PROTEINS PROTEOM, V1748, P57, DOI 10.1016/j.bbapap.2004.12.003; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; Suda SA, 2000, ARCH BIOCHEM BIOPHYS, V384, P31, DOI 10.1006/abbi.2000.2110; SUZUKI K, 1983, J BIOL CHEM, V258, P163; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103	58	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13759	13768		10.1074/jbc.M701074200	http://dx.doi.org/10.1074/jbc.M701074200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337440	hybrid			2022-12-25	WOS:000246060300066
J	Li, YJ; Lu, J; Prochownik, EV				Li, Youjun; Lu, Jie; Prochownik, Edward V.			Dual role for SUMO E2 conjugase Ubc9 in modulating the transforming and growth-promoting properties of the HMGA1b architectural transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A PROTEINS; C-MYC; TUMOR-SUPPRESSOR; TRANSGENIC MICE; TARGET GENES; INTERACTS; PROLIFERATION; EXPRESSION; HMGI(Y); I/Y	Members of the HMGA1 ( high mobility group A1) family of architectural transcription factors, HMGA1a and HMGA1b, play important roles in many normal cellular processes and in tumorigenesis. We performed a yeast two-hybrid screen for HMGA1-interacting proteins and identified the SUMO E2 conjugase Ubc9 as one such partner. The Ubc9-interacting domain of HMGA1 is bipartite, consisting of a proline-rich region near the N terminus and an acidic domain at the extreme C terminus, whereas the HMGA1-interacting domain of Ubc9 comprises a single region previously shown to associate with and SUMOylate other transcription factors. Consistent with these findings, endogenous HMGA1 proteins and Ubc9 could be co-immunoprecipitated from several human cell lines. Studies with HMGA1b proteins containing mutations of either or both Ubc9-interacting domains and with Ubc9-depleted cell lines indicated that the proline-rich domain of HMGA1b positively influences transformation and growth, whereas the acidic domain negatively influences these properties. None of the changes in HMGA1 protein functions mediated by Ubc9 appears to require SUMOylation. These findings are consistent with the idea that Ubc9 can act as both a positive and negative regulator of proliferation and transformation via its non-SUMO-dependent interaction with HMGA1 proteins.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Mol Genet & Biochem,Rangos Res Ctr,Med Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Mol Genet & Biochem,Rangos Res Ctr,Med Ctr, Rm 8124,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu			NATIONAL CANCER INSTITUTE [R01CA105033] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA105033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrieux J, 2006, CANCER GENET CYTOGEN, V164, P84, DOI 10.1016/j.cancergencyto.2005.06.018; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Dhar A, 2004, ONCOGENE, V23, P4466, DOI 10.1038/sj.onc.1207581; Dolde CE, 2002, BREAST CANCER RES TR, V71, P181, DOI 10.1023/A:1014444114804; Duprez E, 1999, J CELL SCI, V112, P381; Edberg DD, 2005, J BIOL CHEM, V280, P8961, DOI 10.1074/jbc.M407348200; Edberg DD, 2004, BIOCHEMISTRY-US, V43, P11500, DOI 10.1021/bi049833i; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; FRASCA F, 2006, CANCER RES, P2980; Giannini G, 2005, CANCER LETT, V228, P97, DOI 10.1016/j.canlet.2005.01.045; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Hommura F, 2004, MOL CANCER RES, V2, P305; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Li YJ, 2006, MOL CELL BIOL, V26, P3401, DOI 10.1128/MCB.26.9.3401-3413.2006; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu F, 2001, IMMUNOL RES, V24, P13, DOI 10.1385/IR:24:1:13; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Pierantoni GM, 2003, CARCINOGENESIS, V24, P1861, DOI 10.1093/carcin/bgg149; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sarhadi V, 2006, J PATHOL, V209, P206, DOI 10.1002/path.1960; Sornberger KS, 1999, CANCER GENET CYTOGEN, V114, P9, DOI 10.1016/S0165-4608(99)00054-0; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Takaha N, 2004, PROSTATE, V60, P160, DOI 10.1002/pros.20049; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wood LJ, 2000, CANCER RES, V60, P4256; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	53	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13363	13371		10.1074/jbc.M610919200	http://dx.doi.org/10.1074/jbc.M610919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350957	hybrid			2022-12-25	WOS:000246060300024
J	Sheppard, K; Akochy, PM; Salazar, JC; Soll, D				Sheppard, Kelly; Akochy, Pierre-Marie; Salazar, Juan C.; Soell, Dieter			The Helicobacter pylori amidotransferase GatCAB is equally efficient in glutamine-dependent transamidation of Asp-tRNA(Asn) and Glu-tRNA(Gln)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ASPARAGINYL-TRANSFER-RNA; LYS CATALYTIC TRIAD; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENETIC-CODE; BIOSYNTHESIS; MECHANISM	The amide aminoacyl-tRNAs, Gln-tRNA(Gln) and Asn-tRNA(Asn), are formed in many bacteria by a pretranslational tRNA-dependent amidation of the mischarged tRNA species, GlutRNA(Gln) or Asp-tRNA(Asn). This conversion is catalyzed by a heterotrimeric amidotransferase GatCAB in the presence of ATP and an amide donor ( Gln or Asn). Helicobacter pylori has a single GatCAB enzyme required in vivo for both Gln-tRNA(Gln) and Asn-tRNA(Asn) synthesis. In vitro characterization reveals that the enzyme transamidates Asp-tRNA(Asn) and Glu-tRNA(Gln) with similar efficiency ( k(cat/)K(m) of 1368.4 s(-1)/mM and 3059.3 s(-1)/mM respectively). The essential glutaminase activity of the enzyme is a property of the A-subunit, which displays the characteristic amidase signature sequence. Mutations of the GatA catalytic triad residues ( Lys(52), Ser(128), Ser(152)) abolished glutaminase activity and consequently the amidotransferase activity with glutamine as the amide donor. However, the latter activity was rescued when the mutant enzymes were presented with ammonium chloride. The presence of Asp-tRNA(Asn) and ATP enhances the glutaminase activity about 22-fold. H. pylori GatCAB uses the amide donor glutamine 129-fold more efficiently than asparagine, suggesting that GatCAB is a glutamine-dependent amidotransferase much like the unrelated asparagine synthetase B. Genomic analysis suggests that most bacteria synthesize asparagine in a glutamine-dependent manner, either by a tRNA-dependent or in a tRNA-independent route. However, all known bacteria that contain asparagine synthetase A form Asn-tRNA(Asn) by direct acylation catalyzed by asparaginyl-tRNA synthetase. Therefore, bacterial amide aminoacyl-tRNA formation is intimately tied to amide amino acid metabolism.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	dieter.soll@yale.edu	Garrido, Juan Carlos Salazar/H-2672-2017; Salazar, Juan/D-9368-2014	Garrido, Juan Carlos Salazar/0000-0002-2096-2050; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akochy PM, 2004, J BACTERIOL, V186, P767, DOI 10.1128/JB.186.3.767-776.2004; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bailly M, 2006, NUCLEIC ACIDS RES, V34, P6083, DOI 10.1093/nar/gkl622; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Cathopoulis TJT, 2007, ANAL BIOCHEM, V360, P151, DOI 10.1016/j.ab.2006.10.019; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; Chuawong P, 2006, BIOCHEMISTRY-US, V45, P8079, DOI 10.1021/bi060189c; Cummings L, 2002, FEMS MICROBIOL LETT, V216, P133, DOI 10.1016/S0378-1097(02)00955-2; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Feng L, 2005, J BIOL CHEM, V280, P8150, DOI 10.1074/jbc.M411098200; Fresquet V, 2004, BIOORG CHEM, V32, P63, DOI 10.1016/j.bioorg.2003.10.002; GATTI DL, 1991, J MOL BIOL, V218, P557, DOI 10.1016/0022-2836(91)90701-7; Harpel MR, 2002, BIOCHEMISTRY-US, V41, P6398, DOI 10.1021/bi012126u; Horiuchi KY, 2001, BIOCHEMISTRY-US, V40, P6450, DOI 10.1021/bi002599l; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; JAHN D, 1990, J BIOL CHEM, V265, P8059; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; McKinney MK, 2003, J BIOL CHEM, V278, P37393, DOI 10.1074/jbc.M303922200; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; Nakamura A, 2006, SCIENCE, V312, P1954, DOI 10.1126/science.1127156; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; Narngoong S, 2007, FEBS LETT, V581, P309, DOI 10.1016/j.febslet.2006.12.033; Oshikane H, 2006, SCIENCE, V312, P1950, DOI 10.1126/science.1128470; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Roy H, 2003, P NATL ACAD SCI USA, V100, P9837, DOI 10.1073/pnas.1632156100; Salazar JC, 2003, P NATL ACAD SCI USA, V100, P13863, DOI 10.1073/pnas.1936123100; Schmitt E, 2005, STRUCTURE, V13, P1421, DOI 10.1016/j.str.2005.06.016; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Schulze JO, 2006, J MOL BIOL, V361, P888, DOI 10.1016/j.jmb.2006.06.054; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Shin S, 2003, J BIOL CHEM, V278, P24937, DOI 10.1074/jbc.M302156200; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; WILCOX M, 1969, COLD SPRING HARB SYM, V34, P521, DOI 10.1101/SQB.1969.034.01.059; Wolf YI, 1999, GENOME RES, V9, P689; Wolfson AD, 1998, RNA, V4, P1019, DOI 10.1017/S1355838298980700	46	46	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11866	11873		10.1074/jbc.M700398200	http://dx.doi.org/10.1074/jbc.M700398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17329242	hybrid			2022-12-25	WOS:000245941900029
J	Yang, L; Lin, C; Sun, SY; Zhao, S; Liu, ZR				Yang, L.; Lin, C.; Sun, S-Y; Zhao, S.; Liu, Z-R			A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis	ONCOGENE			English	Article						P68 RNA helicase; TRAIL; phosphorylation; XAF1; caspase; DEAD box; PDGF autocrine	MALIGNANT GLIOMA-CELLS; LIGAND TRAIL; CANCER CELLS; MECHANISMS; EXPRESSION; GROWTH; DEATH; XAF1; XIAP; IDENTIFICATION	Tumor necrosis factor- related apoptosis- inducing ligand ( TRAIL) is a promising anticancer agent with the capability of inducing apoptosis specifically in tumor cells. However, cancer cells of many cancer types developed TRAIL resistance, limiting the applications of TRAIL in cancer therapies. We show here that p68 acquires a double tyrosine phosphorylation at Y593 and Y595 in TRAIL- resistant T98G glioblastoma cells. The double phosphorylations are induced by platelet- derived growth factor autocrine loop. The double phosphorylation mediates resistance to TRAIL- induced apoptosis. Our data suggest that the phosphorylated p68 protects the cells from programmed cell death by preventing procaspase- 8 from proteolytic cleavage. The double- phosphorylated p68 may also confer apoptosis resistance by upregulation of X- chromosome- linked inhibitor apoptosis protein- associated factor 1. In addition, exogenous expression of p68 mutant that carries mutations at the phosphorylation sites ( Y593/595F) dramatically sensitizes TRAIL- resistant cells to TRAIL- induced apoptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; Emory University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Plaza, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM063874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, VITAM HORM, V67, P453; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Clarke N, 2005, CELL CYCLE, V4, P914, DOI 10.4161/cc.4.7.1822; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hao CH, 2001, CANCER RES, V61, P1162; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Kim Y, 2003, MOL CELLS, V15, P283; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Potapova O, 1996, CANCER RES, V56, P280; Roth W, 2004, VITAM HORM, V67, P189; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; Wang J, 2000, J CELL SCI, V113, P753; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yang XZ, 2003, CANCER RES, V63, P1122; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	35	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6082	6092		10.1038/sj.onc.1210427	http://dx.doi.org/10.1038/sj.onc.1210427			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384675				2022-12-25	WOS:000249277200011
J	Junttila, MR; Ala-Aho, R; Jokilehto, T; Peltonen, J; Kallajoki, M; Grenman, R; Jaakkola, P; Westermarck, J; Kahari, VM				Junttila, M. R.; Ala-aho, R.; Jokilehto, T.; Peltonen, J.; Kallajoki, M.; Grenman, R.; Jaakkola, P.; Westermarck, J.; Kahari, V-M			p38 alpha and p38 delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells	ONCOGENE			English	Article						p38; mitogen-activated protein kinase; matrix metalloproteinase; squamous cell carcinoma	P38 MAP KINASE; COLLAGENASE-3 MMP-13; MATRIX METALLOPROTEINASES; SELECTIVE ACTIVATION; IN-VIVO; C-JUN; EXPRESSION; CANCER; P53; APOPTOSIS	Recent studies indicate that the specificity of p38 mitogen-activated protein kinase (MAPK)-mediated cellular stress responses is determined by the expression pattern of the distinct p38 isoforms. Here, we have analysed the function of distinct p38 isoforms in the growth and invasion of head and neck squamous cell carcinomas (HNSCCs). Activation of p38 MAPK by arsenite resulted in inactivation of the ERK1,2 signaling pathway by dephosphorylation of MEK1,2 in primary human epidermal keratinocytes (HEKs), whereas in HNSCC cells this p38-mediated inhibition of the ERK1,2 pathway was absent. Quantitation of p38 pathway component mRNA expression in HNSCC cell lines (n = 42) compared to HEKs ( n 8) revealed that p38 alpha and p38 delta isoforms are predominantly expressed in both cell types and that MKK3 is the primary upstream activator expressed. Inhibition of endogenous p38 alpha or p38 delta activity by adenoviral delivery of corresponding dominant-negative p38 isoforms potently reduced MMP-13 and MMP-1 expressions, and suppressed the invasion of HNSCC cells through collagen. Dominant-negative p38 alpha and p38 delta inhibited squamous cell carcinoma (SCC) cell proliferation and inhibition of p38 alpha activity also compromised survival of SCC cells. p38 alpha and p38 delta were predominantly expressed in HNSCCs ( n 24) and nonneoplastic epithelium in vivo (n = 6), with MKK3 being the primary upstream activator. Activation and expression of p38 alpha and p38 delta by tumor cells was detected in HNSCCs in vivo (n = 16). Adenoviral expression of dominant-negative p38 alpha or p38 delta in cutaneous SCC cells potently inhibited their implantation in skin of severe combined immunodeficiency mice and growth of xenografts in vivo. Our results indicate that p38 alpha and p38 delta specifically promote the malignant phenotype of SCC cells by regulating cell survival, proliferation and invasion, suggesting these p38 MAPK isoforms as potential therapeutic targets in HNSCCs.	Turku Univ, Dept Dermatol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Pathol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, Turku, Finland; Turku Grad Sch Biomed Sci, Turku, Finland; Univ Turku, Ctr Biotechnol, Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, Turku, Finland; Abo Akad Univ, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University	Kahari, VM (corresponding author), Turku Univ, Dept Dermatol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Peltonen, Juha/O-7159-2019; Westermarck, Jukka/AAL-6464-2020; Jaakkola, Panu M/B-4355-2012; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Westermarck, Jukka/0000-0001-7478-3018; Jaakkola, Panu/0000-0002-2365-4985; Kahari, Veli-Matti/0000-0003-2421-9368				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BRACHMAN DG, 1992, CANCER RES, V52, P4832; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Johannes R.E., 1997, SPC LIVE REEF FISH I, V3, P13; Johansson N, 2000, J CELL SCI, V113, P227; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Li SP, 2003, CANCER RES, V63, P3473; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Simon C, 1998, CANCER RES, V58, P1135; SOMERS KD, 1992, CANCER RES, V52, P5997; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	39	106	110	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5267	5279		10.1038/sj.onc.1210332	http://dx.doi.org/10.1038/sj.onc.1210332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334397				2022-12-25	WOS:000248674200010
J	Vlahakis, NE; Young, BA; Atakilit, A; Hawkridge, AE; Issaka, RB; Boudreau, N; Sheppard, D				Vlahakis, Nicholas E.; Young, Bradford A.; Atakilit, Amha; Hawkridge, Anne E.; Issaka, Rachel B.; Boudreau, Nancy; Sheppard, Dean			Integrin alpha 9 beta 1 directly binds to vascular endothelial growth factor (VEGF)- a and contributes to VEGF-A-induced angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; PATHOLOGICAL ANGIOGENESIS; RECEPTOR ACTIVATION; MICE LACKING; III REPEAT; EXPRESSION; MIGRATION; TENASCIN; INTEGRIN-ALPHA-9-BETA-1; PHOSPHORYLATION	Vascular endothelial growth factor A (VEGF-A) is a potent inducer of angiogenesis. We now show that VEGF-A-induced adhesion and migration of human endothelial cells are dependent on the integrin alpha 9 beta 1 and that VEGF-A is a direct ligand for this integrin. Adhesion and migration of these cells on the 165 and 121 isoforms of VEGF-A depend on cooperative input from alpha 9 beta 1 and the cognate receptor for VEGF-A, VEGF receptor 2 (VEGF-R2). Unlike alpha 3 beta 1 or alpha v beta 3 integrins, alpha 9 beta 1 was also found to bind the 121 isoform of VEGF-A. This interaction appears to be biologically significant, because alpha 9 beta 1-blocking antibody dramatically and specifically inhibited angiogenesis induced by VEGF-A165 or -121. Together with our previous findings that alpha 9 beta 1 directly binds to VEGF-C and -D and contributes to lymphangiogenesis, these results identify the integrin alpha 9 beta 1 as a potential pharmacotherapeutic target for inhibition of pathogenic angiogenesis and lymphangiogenesis.	Mayo Clin, Coll Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Mayo Clinic; University of California System; University of California San Francisco	Vlahakis, NE (corresponding author), Mayo Clin, Coll Med, Thorac Dis Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	vlahakis.nicholas@mayo.edu; dean.sheppard@ucsf.edu			NHLBI NIH HHS [R01 HL64353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 2000, AM J PATHOL, V156, P1469, DOI 10.1016/S0002-9440(10)65015-8; Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2002, NAT MED, V8, P14, DOI 10.1038/nm0102-14; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; MISHIMA K, 2007, MOL BIOL CELL, DOI DOI 10.1091/7BC.E06-09-0780; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Perruzzi CA, 2003, J INVEST DERMATOL, V120, P1100, DOI 10.1046/j.1523-1747.2003.12236.x; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Vlahakis NE, 2005, J BIOL CHEM, V280, P4544, DOI 10.1074/jbc.M412816200; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG JT, 1995, DEVELOPMENT, V121, P549; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Young BA, 2001, MOL BIOL CELL, V12, P3214, DOI 10.1091/mbc.12.10.3214; Zhang XF, 2005, J CELL PHYSIOL, V202, P205, DOI 10.1002/jcp.20106	40	97	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15187	15196		10.1074/jbc.M609323200	http://dx.doi.org/10.1074/jbc.M609323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363377	hybrid			2022-12-25	WOS:000246589000058
J	Prager, K; Wang-Eckhardt, LH; Fluhrer, R; Killick, R; Barth, E; Hampel, H; Haass, C; Walter, J				Prager, Kai; Wang-Eckhardt, Lihua; Fluhrer, Regina; Killick, Richard; Barth, Esther; Hampel, Heike; Haass, Christian; Walter, Jochen			A structural switch of presenilin 1 by glycogen synthase kinase 3 beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SUBCELLULAR-LOCALIZATION; PROTEOLYTIC FRAGMENTS; WILD-TYPE; IN-VIVO; C-MYC; CLEAVAGE; WNT	Presenilins (PS) are critical components of the gamma-secretase complex that mediates cleavage of type I membrane proteins including the beta-amyloid precursor protein to generate the amyloid beta-peptide. In addition, PS1 interacts with beta-catenin and facilitates its metabolism. We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3 beta (GSK3 beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin. The decreased interaction of PS1 with beta-catenin leads to stabilization of beta-catenin thereby increasing its nuclear signaling and the transcription of target genes, including c-MYC. Consistent with increased expression of c-myc, a PS1 mutant that mimics phosphorylated PS1 increased cell proliferation as compared with wild-type PS1. These results indicate a regulatory mechanism in which GSK3 beta-mediated phosphorylation induces a structural change of the hydrophilic loop of PS1 thereby negatively modulating the formation of a ternary complex between beta-catenin, PS1, and GSK3 beta, which leads to stabilization of beta-catenin.	Univ Bonn, Dept Neurol, D-53127 Bonn, Germany; Univ Munich, Dept Biochem, D-80336 Munich, Germany; Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England	University of Bonn; University of Munich; University of London; King's College London	Walter, J (corresponding author), Sigmund Freud Str 25, D-53127 Bonn, Germany.	Jochen.Walter@ukb.uni-bonn.de	Wang, Caihong/T-5837-2019; Fluhrer, Regina/F-2642-2011; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912; Killick, Richard/0000-0002-8815-3436				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Bamji SX, 2003, NEURON, V40, P719, DOI 10.1016/S0896-6273(03)00718-9; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Fluhrer R, 2004, J BIOL CHEM, V279, P1585, DOI 10.1074/jbc.M306653200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kaether C, 2006, TRAFFIC, V7, P408, DOI 10.1111/j.1600-0854.2006.00396.x; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Serban G, 2005, J BIOL CHEM, V280, P36007, DOI 10.1074/jbc.M507503200; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Uemura K, 2006, BIOCHEM BIOPH RES CO, V345, P951, DOI 10.1016/j.bbrc.2006.04.157; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351	48	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14083	14093		10.1074/jbc.M608437200	http://dx.doi.org/10.1074/jbc.M608437200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360711	hybrid, Green Published			2022-12-25	WOS:000246245800018
J	Roux, PP; Shahbazian, D; Vu, H; Holz, MK; Cohen, MS; Taunton, J; Sonenberg, N; Blenis, J				Roux, Philippe P.; Shahbazian, David; Vu, Hieu; Holz, Marina K.; Cohen, Michael S.; Taunton, Jack; Sonenberg, Nahum; Blenis, John			RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS; MAP2 KINASE; MECHANISMS; COMPLEX; GROWTH; MTOR; IDENTIFICATION; ACTIVATION; TARGET; RAS	Converging signals from the mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways are well established to modulate translation initiation. Less is known regarding the molecular basis of protein synthesis regulated by other inputs, such as agonists of the Ras/extracellular signal-regulated kinase (ERK) signaling cascade. Ribosomal protein (rp) S6 is a component of the 40S ribosomal subunit that becomes phosphorylated at several serine residues upon mitogen stimulation, but the exact molecular mechanisms regulating its phosphorylation and the function of phosphorylated rpS6 is poorly understood. Here, we provide evidence that activation of the p90 ribosomal S6 kinases (RSKs) by serum, growth factors, tumor promoting phorbol esters, and oncogenic Ras is required for rpS6 phosphorylation downstream of the Ras/ERK signaling cascade. We demonstrate that while ribosomal S6 kinase 1 (S6K1) phosphorylates rpS6 at all sites, RSK exclusively phosphorylates rpS6 at Ser(235/236) in vitro and in vivo using an mTOR independent mechanism. Mutation of rpS6 at Ser(235/236) reveals that phosphorylation of these sites promotes its recruitment to the 7-methylguanosine cap complex, suggesting that Ras/ERK signaling regulates assembly of the translation preinitiation complex. These data demonstrate that RSK provides an mTOR-independent pathway linking the Ras/ERK signaling cascade to the translational machinery.	Univ Montreal, IRIC, Stn Ctr Ville, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Universite de Montreal; Harvard University; Harvard Medical School; McGill University; University of California System; University of California San Francisco	Roux, PP (corresponding author), Univ Montreal, IRIC, Stn Ctr Ville, Dept Pathol & Cell Biol, POB 6128, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071434] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595, R37 CA046595, R01 CA046595] Funding Source: Medline; NIGMS NIH HHS [R01 GM071434, GM5140, R01 GM071434-04, GM071434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; NYGARD O, 1990, J BIOL CHEM, V265, P6030; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045	39	535	545	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14056	14064		10.1074/jbc.M700906200	http://dx.doi.org/10.1074/jbc.M700906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360704	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000246245800015
J	Spichal, L; Krystof, V; Paprskarova, M; Lenobel, R; Styskala, J; Binarova, P; Cenklova, V; De Veylder, L; Inze, D; Kontopidis, G; Fischer, PM; Schmuelling, T; Strnad, M				Spichal, Lukas; Krystof, Vladimir; Paprskarova, Martina; Lenobel, Rene; Styskala, Jakub; Binarova, Pavla; Cenklova, Vera; De Veylder, Lieven; Inze, Dirk; Kontopidis, George; Fischer, Peter M.; Schm elling, Thomas; Strnad, Miroslav			Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; HISTIDINE KINASE; PURINE ANALOGS; CELL-CYCLE; FAMILY; ACTIVATION; SHOOT; ASSAY	Cytokinins are a class of plant hormones that regulate the cell cycle and diverse developmental and physiological processes. Several compounds have been identified that antagonize the effects of cytokinins. Based on structural similarities and competitive inhibition, it has been assumed that these anticytokinins act through a common cellular target, namely the cytokinin receptor. Here, we examined directly the possibility that various representative classical anticytokinins inhibit the Arabidopsis cytokinin receptors CRE1/AHK4 (cytokinin response 1/Arabidopsis histidine kinase 4) and AHK3 ( Arabidopsis histidine kinase 3). We show that pyrrolo[2,3-d] pyrimidine and pyrazolo[ 4,3-d] pyrimidine anticytokinins do not act as competitors of cytokinins at the receptor level. Flow cytometry and microscopic analyses revealed that anticytokinins inhibit the cell cycle and cause disorganization of the microtubular cytoskeleton and apoptosis. This is consistent with the hypothesis that they inhibit regulatory cyclin-dependent kinase (CDK) enzymes. Biochemical studies demonstrated inhibition by selected anticytokinins of both Arabidopsis and human CDKs. X-ray determination of the crystal structure of a human CDK2-anticytokinin complex demonstrated that the antagonist occupies the ATP-binding site of CDK2. Finally, treatment of human cancer cell lines with anticytokinins demonstrated their ability to kill human cells with similar effectiveness as known CDK inhibitors.	AS CR, Inst Expt Bot, Lab Growth Regulators, Olomouc 78371, Czech Republic; Palacky Univ, Olomouc 78371, Czech Republic; AS CR, Inst Microbiol, Prague 14220 4, Czech Republic; AS CR, Inst Expt Bot, Lab Cell Biol & Cytoskeleton, Olomouc 77200, Czech Republic; Univ Ghent VIB, Dept Mol Genet, B-9052 Ghent, Belgium; Univ Ghent VIB, Flanders Inst Biotechnol, Dept Plant Syst Biol, B-9052 Ghent, Belgium; Cyclacel Ltd, Dundee DD1 5JJ, Scotland; Free Univ Berlin, Inst Biol Appl Genet, D-14195 Berlin, Germany	Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Palacky University Olomouc; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Cyclacel Pharmaceuticals Inc.; Free University of Berlin	Strnad, M (corresponding author), Slechtitelu 11, CZ-78371 Olomouc, Czech Republic.	miroslav.strnad@upol.cz	Inzé, Dirk/AAW-6381-2021; Spichal, Lukas/H-6873-2014; Strnad, Miroslav/H-1858-2014; Krystof, Vladimir/B-9499-2009; Fischer, Peter/E-5657-2010; LENOBEL, René/AAD-5606-2020; Binarova, Pavla/H-3562-2014; de veylder, lieven/AAM-9909-2020	Inzé, Dirk/0000-0002-3217-8407; Strnad, Miroslav/0000-0002-2806-794X; Krystof, Vladimir/0000-0001-5838-2118; Fischer, Peter/0000-0002-5866-9271; Binarova, Pavla/0000-0002-7203-2250; de veylder, lieven/0000-0003-1150-4426; Lenobel, Rene/0000-0001-7387-0056; Spichal, Lukas/0000-0001-6483-8628				Binarova P, 1998, PLANT J, V16, P697, DOI 10.1046/j.1365-313x.1998.00340.x; BINAROVA P, 1993, CELL BIOL INT, V17, P847, DOI 10.1006/cbir.1993.1147; Bogre L, 1997, PLANT PHYSIOL, V113, P841, DOI 10.1104/pp.113.3.841; D'Agostino IB, 2000, PLANT PHYSIOL, V124, P1706, DOI 10.1104/pp.124.4.1706; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOLEZEL J, 1992, PLANTA, V188, P93, DOI 10.1007/BF00198944; Ferreira FJ, 2005, CURR OPIN PLANT BIOL, V8, P518, DOI 10.1016/j.pbi.2005.07.013; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Fischer PM, 2004, CELL CYCLE, V3, P742; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GREGORINI G, 1980, PLANT PHYSIOL, V65, P363, DOI 10.1104/pp.65.2.363; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; HECHT SM, 1971, P NATL ACAD SCI USA, V68, P2608, DOI 10.1073/pnas.68.10.2608; Heyl A, 2003, CURR OPIN PLANT BIOL, V6, P480, DOI 10.1016/S1369-5266(03)00087-6; Heyl A, 2006, ANNU PLANT REV, V24, P93; Higuchi M, 2004, P NATL ACAD SCI USA, V101, P8821, DOI 10.1073/pnas.0402887101; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; IWAMURA H, 1979, PHYTOCHEMISTRY, V18, P217, DOI 10.1016/0031-9422(79)80058-8; Iwamura H., 1994, CYTOKININS CHEM ACTI, P43; LUCRETTI S, 1995, METHODS PLANT CELL B, P61; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Moravcova D, 2003, BIOORG MED CHEM LETT, V13, P2989, DOI 10.1016/S0960-894X(03)00631-0; Nishimura C, 2004, PLANT CELL, V16, P1365, DOI 10.1105/tpc.021477; Riefler M, 2006, PLANT CELL, V18, P40, DOI 10.1105/tpc.105.037796; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Romanov GA, 2005, ANAL BIOCHEM, V347, P129, DOI 10.1016/j.ab.2005.09.012; Romanov GA, 2002, FEBS LETT, V515, P39, DOI 10.1016/S0014-5793(02)02415-8; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SKOOG F, 1975, P NATL ACAD SCI USA, V72, P3508, DOI 10.1073/pnas.72.9.3508; SKOOG F, 1970, ANN REV PLANT PHYSIO, V21, P359, DOI 10.1146/annurev.pp.21.060170.002043; SKOOG F, 1973, PHYTOCHEMISTRY, V12, P25, DOI 10.1016/S0031-9422(00)84620-8; SKOOG F, 1967, PHYTOCHEMISTRY, V6, P1169, DOI 10.1016/S0031-9422(00)86080-X; Spichal L, 2004, PLANT CELL PHYSIOL, V45, P1299, DOI 10.1093/pcp/pch132; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; Ueguchi C, 2001, PLANT CELL PHYSIOL, V42, P751, DOI 10.1093/pcp/pce094; Verkest A, 2005, PLANT CELL, V17, P1723, DOI 10.1105/tpc.105.032383; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang SD, 2004, J MED CHEM, V47, P1662, DOI 10.1021/jm0309957; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928; Wu SY, 2003, STRUCTURE, V11, P399, DOI 10.1016/S0969-2126(03)00060-1; Yamada H, 2001, PLANT CELL PHYSIOL, V42, P1017, DOI 10.1093/pcp/pce127; Yonekura-Sakakibara K, 2004, PLANT PHYSIOL, V134, P1654, DOI 10.1104/pp.103.037176; Zhang K, 1996, PLANTA, V200, P2	48	19	19	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14356	14363		10.1074/jbc.M609750200	http://dx.doi.org/10.1074/jbc.M609750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17339323	hybrid			2022-12-25	WOS:000246245800047
J	Layer, G; Gaddam, SA; Ayala-Castro, CN; Choudens, SO; Lascoux, D; Fontecave, M; Outten, FW				Layer, Gunhild; Gaddam, S. Aparna; Ayala-Castro, Carla N.; Ollagnier-de Choudens, Sandrine; Lascoux, David; Fontecave, Marc; Outten, F. Wayne			SufE transfers sulfur from SufS to SufB for iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; SELENOCYSTEINE LYASE; ERWINIA-CHRYSANTHEMI; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; GENE-CLUSTER; PROTEIN; BIOSYNTHESIS	Iron-sulfur (Fe-S) clusters are key metal cofactors of metabolic, regulatory, and stress response proteins in most organisms. The unique properties of these clusters make them susceptible to disruption by iron starvation or oxidative stress. Both iron and sulfur can be perturbed under stress conditions, leading to Fe-S cluster defects. Bacteria and higher plants contain a specialized system for Fe-S cluster biosynthesis under stress, namely the Suf pathway. In Escherichia coli the Suf pathway consists of six proteins with functions that are only partially characterized. Here we describe how the SufS and SufE proteins interact with the SufBCD protein complex to facilitate sulfur liberation from cysteine and donation for Fe-S cluster assembly. It was previously shown that the cysteine desulfurase SufS donates sulfur to the sulfur transfer protein SufE. We have found here that SufE in turn interacts with the SufB protein for sulfur transfer to that protein. The interaction occurs only if SufC is present. Furthermore, SufB can act as a site for Fe-S cluster assembly in the Suf system. This provides the first evidence of a novel site for Fe-S cluster assembly in the SufBCD complex.	Univ Grenoble 1, CEA Grenoble, iRTSV LCBM, CNRS,UMR 5249, F-38054 Grenoble 09, France; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ Grenoble 1, CEA, CNRS, Lab Spect Masse Prot,Inst Biol Struct, F-38027 Grenoble 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Choudens, SO (corresponding author), Univ Grenoble 1, CEA Grenoble, iRTSV LCBM, CNRS,UMR 5249, 17 Ave Martyrs, F-38054 Grenoble 09, France.	sollagnier@cea.fr; wayne.outten@chem.sc.edu		Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Outten, Franklin/0000-0002-9095-0194				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Eccleston JF, 2006, J BIOL CHEM, V281, P8371, DOI 10.1074/jbc.M513455200; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fontecave M, 2005, J BIOL INORG CHEM, V10, P713, DOI 10.1007/s00775-005-0025-1; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; Huet G, 2005, J BACTERIOL, V187, P6137, DOI 10.1128/JB.187.17.6137-6146.2005; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kitaoka S, 2006, FEBS LETT, V580, P137, DOI 10.1016/j.febslet.2005.11.058; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Liu GH, 2005, PROTEIN SCI, V14, P1597, DOI 10.1110/ps.041322705; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Rangachari K, 2002, FEBS LETT, V514, P225, DOI 10.1016/S0014-5793(02)02369-4; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Wada K, 2005, FEBS LETT, V579, P6543, DOI 10.1016/j.febslet.2005.10.046; Yoshida A., 1970, METHODS ENZYMOLOGY A, V17, P176; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	32	119	120	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13342	13350		10.1074/jbc.M608555200	http://dx.doi.org/10.1074/jbc.M608555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350958	hybrid			2022-12-25	WOS:000246060300022
J	Caldeira, MV; Melo, CV; Pereira, DB; Carvalho, R; Correia, SS; Backos, DS; Carvalho, AL; Esteban, JA; Duarte, CB				Caldeira, Margarida V.; Melo, Carlos V.; Pereira, Daniela B.; Carvalho, Ricardo; Correia, Susana S.; Backos, Donald S.; Carvalho, Ana Luisa; Esteban, Jose A.; Duarte, Carlos B.			Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CEREBELLAR GRANULE CELLS; AMPA RECEPTORS; SURFACE EXPRESSION; RAT HIPPOCAMPUS; TRKB RECEPTORS; LATE-PHASE; PHOSPHORYLATION SITES; NEOCORTICAL NEURONS; SIGNAL-TRANSDUCTION	Brain-derived neurotrophic factor ( BDNF) plays an important role in synaptic plasticity in the hippocampus, but the mechanisms involved are not fully understood. The neurotrophin couples synaptic activation to changes in gene expression underlying long term potentiation and short term plasticity. Here we show that BDNF acutely up-regulates GluR1, GluR2, and GluR3 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid ( AMPA) receptor subunits in 7-day tropomyosin-related kinase in vitro cultured hippocampal neurons. The increase in GluR1 and GluR2 protein levels in developing cultures was impaired by K252a, a Trk inhibitor, and by translation ( emetine and anisomycin) and transcription ( alpha-amanitine and actinomycin D) inhibitors. Accordingly, BDNF increased the mRNA levels for GluR1 and GluR2 subunits. Biotinylation studies showed that stimulation with BDNF for 30 min selectively increased the amount of GluR1 associated with the plasma membrane, and this effect was abrogated by emetine. Under the same conditions, BDNF induced GluR1 phosphorylation on Ser-831 through activation of protein kinase C and Ca2+-calmodulin-dependent protein kinase II. Chelation of endogenous extracellular BDNF with TrkB-IgG selectively decreased GluR1 protein levels in 14-day in vitro cultures of hippocampal neurons. Moreover, BDNF promoted synaptic delivery of homomeric GluR1 AMPA receptors in cultured organotypic slices, by a mechanism independent of NMDA receptor activation. Taken together, the results indicate that BDNF up-regulates the protein levels of AMPA receptor subunits in hippocampal neurons and induces the delivery of AMPA receptors to the synapse.	Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	Universidade de Coimbra; University of Michigan System; University of Michigan	Duarte, CB (corresponding author), Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.	cbduarte@ci.uc.pt	Duarte, Carlos B/K-6358-2013; Esteban, Jose/L-4944-2014; Pereira, Daniela/AAZ-5285-2021; Backos, Donald/Q-4791-2018; Carvalho, Ana Luisa/K-6367-2013; Backos, Donald/N-5265-2019	Duarte, Carlos B/0000-0002-1474-0208; Esteban, Jose/0000-0002-3759-3300; Backos, Donald/0000-0001-6735-6210; Carvalho, Ana Luisa/0000-0001-8368-6666; Backos, Donald/0000-0001-6735-6210; Caldeira, Margarida/0000-0001-5107-1499; Vieira Melo, Carlos/0000-0001-5392-1258; B. Pereira, Daniela/0000-0003-4872-5505				Alder J, 2005, J NEUROSCI, V25, P3080, DOI 10.1523/JNEUROSCI.2970-04.2005; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Aoki C, 2000, J NEUROSCI RES, V59, P454, DOI 10.1002/(SICI)1097-4547(20000201)59:3<454::AID-JNR21>3.0.CO;2-H; Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brene S, 2000, EUR J NEUROSCI, V12, P1525, DOI 10.1046/j.1460-9568.2000.00040.x; Chen GQ, 1999, J NEUROSCI, V19, P7983; Drake CT, 1999, J NEUROSCI, V19, P8009; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; Ernfors P, 2003, TRENDS NEUROSCI, V26, P171, DOI 10.1016/S0166-2236(03)00064-X; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Frerking M, 1998, J NEUROPHYSIOL, V80, P3383, DOI 10.1152/jn.1998.80.6.3383; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Gomes AR, 2004, J NEUROCHEM, V90, P673, DOI 10.1111/j.1471-4159.2004.02519.x; Gomes AR, 2003, NEUROCHEM RES, V28, P1459, DOI 10.1023/A:1025610122776; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Groth RD, 2003, J NEUROSCI, V23, P8125; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Jourdi H, 2003, DEV BIOL, V263, P216, DOI 10.1016/j.ydbio.2003.07.008; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Messaoudi E, 1998, J NEUROPHYSIOL, V79, P496, DOI 10.1152/jn.1998.79.1.496; Messaoudi E, 2002, J NEUROSCI, V22, P7453; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Nagano T, 2003, MOL CELL NEUROSCI, V24, P340, DOI 10.1016/S1044-7431(03)00172-6; Narisawa-Saito M, 1999, NEUROSCIENCE, V88, P1009, DOI 10.1016/S0306-4522(98)00496-5; Narisawa-Saito M, 1999, P NATL ACAD SCI USA, V96, P2461, DOI 10.1073/pnas.96.5.2461; Nguyen PV, 1996, J NEUROSCI, V16, P3189; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pereira DB, 2006, J NEUROSCI RES, V83, P832, DOI 10.1002/jnr.20784; Poncer JC, 2002, J NEUROSCI, V22, P4406, DOI 10.1523/JNEUROSCI.22-11-04406.2002; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Strutz-Seebohm N, 2005, J PHYSIOL-LONDON, V565, P381, DOI 10.1113/jphysiol.2004.079582; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tanaka T, 1997, J NEUROSCI, V17, P2959; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Vicario-Abejon C, 2002, NAT REV NEUROSCI, V3, P965, DOI 10.1038/nrn988; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Zakharenko SS, 2003, NEURON, V39, P975, DOI 10.1016/S0896-6273(03)00543-9	62	182	185	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12619	12628		10.1074/jbc.M700607200	http://dx.doi.org/10.1074/jbc.M700607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337442	hybrid			2022-12-25	WOS:000245942800031
J	Plumb, DA; Dhir, V; Mironov, A; Ferrara, L; Poulsom, R; Kadler, KE; Thornton, DJ; Briggs, MD; Boot-Handford, RP				Plumb, Darren A.; Dhir, Vivek; Mironov, Aleksandr; Ferrara, Laila; Poulsom, Richard; Kadler, Karl E.; Thornton, David J.; Briggs, Michael D.; Boot-Handford, Raymond P.			Collagen XXVII is developmentally regulated and forms thin fibrillar structures distinct from those of classical vertebrate fibrillar collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOLUTION; MUTATIONS	We have generated an antiserum to the variable domain of mouse collagen XXVII, a recently discovered novel member of the fibrillar collagen family. Collagen XXVII protein was first detectable in the mouse at embryonic day 12.5 (E12.5). By E14.5, the protein localized to cartilage, developing dermis, cornea, the inner limiting membrane of the retina, and major arteries of the heart. However, at E18.5, collagen XXVII protein was no longer apparent in most tissues and appeared restricted mainly to cartilage where expression continued into adulthood. Type XXVII collagen immunolocalized to 10-nm-thick nonstriated fibrils that were distinct from fibrils formed by the classical fibrillar collagens. The transient nature of its expression and unusual fibrillar structure suggest that collagen XXVII plays a developmental role distinct from those of the classical fibrillar collagens.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Canc Res UK, London Res Inst, Histopathol Unit, London WC2A 3PX, England	University of Manchester; Cancer Research UK	Boot-Handford, RP (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.	ray.boot-handford@manchester.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Boot-Handford, Raymond/0000-0002-6167-8419; Thornton, David/0000-0001-7148-1970; Mironov, Aleksandr/0000-0002-1497-328X	Arthritis Research UK [17243, 15967] Funding Source: Medline; Wellcome Trust [084353] Funding Source: Medline	Arthritis Research UK(Versus Arthritis); Wellcome Trust(Wellcome TrustEuropean Commission)		Aouacheria A, 2004, J BIOL CHEM, V279, P47711, DOI 10.1074/jbc.M408950200; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; Holmes DF, 2005, J MOL BIOL, V345, P773, DOI 10.1016/j.jmb.2004.10.078; Huxley-Jones J, 2007, MATRIX BIOL, V26, P2, DOI 10.1016/j.matbio.2006.09.008; Kadler KE, 1996, BIOCHEM J, V316, P1; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Wada H, 2006, EVOL DEV, V8, P370, DOI 10.1111/j.1525-142X.2006.00109.x; Zhang XM, 2007, J BIOL CHEM, V282, P6792, DOI 10.1074/jbc.M607528200	18	50	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12791	12795		10.1074/jbc.C700021200	http://dx.doi.org/10.1074/jbc.C700021200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17331945	Green Accepted, hybrid			2022-12-25	WOS:000245942800050
J	Thummer, R; Klimmek, O; Schmitz, RA				Thummer, Robert; Klimmek, Oliver; Schmitz, Ruth A.			Biochemical studies of Klebsiella pneumoniae NifL reduction using reconstituted partial anaerobic respiratory chains of Wolinella succinogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NIFL; TRANSCRIPTIONAL ACTIVATOR NIFA; DEPENDENT NITROGEN CONTROL; BINDING PROTEIN NIFA; TERMINAL GAF DOMAIN; GENE-EXPRESSION; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; ELECTRON-TRANSPORT; REGULATORY PROTEIN	In the diazotroph Klebsiella pneumoniae the flavoprotein NifL inhibits the activity of the nif-specific transcriptional activator NifA in response to molecular oxygen and combined nitrogen. Sequestration of reduced NifL to the cytoplasmic membrane under anaerobic and nitrogen-limited conditions impairs inhibition of cytoplasmic NifA by NifL. To analyze whether NifL is reduced by electrons directly derived from the reduced menaquinone pool, we studied NifL reduction using artificial membrane systems containing purified components of the anaerobic respiratory chain of Wolinella succinogenes. In this in vitro assay using proteoliposomes containing purified formate dehydrogenase and purified menaquinone ( MK6) or 8-methylmenaquinone ( MMK6) from W. succinogenes, reduction of purified NifL was achieved by formate oxidation. Furthermore, the respective reduction rates, which were determined using equal amounts of NifL, have been shown to be directly dependent on the concentration of both formate dehydrogenase and menaquinones incorporated into the proteoliposomes, demonstrating a direct electron transfer from menaquinone to NifL. When purified hydrogenase and MK6 from W. succinogenes were inserted into the proteoliposomes, NifL was reduced with nearly the same rate by hydrogen oxidation. In both cases reduced NifL was found to be highly associated to the proteoliposomes, which is in accordance with our previous findings in vivo. On the bases of these experiments, we propose that the redox state of the menaquinone pool is the redox signal for nif regulation in K. pneumoniae by directly transferring electrons onto NifL under anaerobic conditions.	Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garden 19, D-24118 Kiel, Germany; Goethe Univ Frankfurt, Inst Mol Biowissensch, D-60438 Frankfurt, Germany	University of Kiel; Goethe University Frankfurt	Schmitz, RA (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garden 19, D-24118 Kiel, Germany.	rschmitz@ifam.uni-kiel.de		Schmitz-Streit, Ruth Anne/0000-0002-6788-0829				Arcondeguy T, 2000, J BIOL CHEM, V275, P38452, DOI 10.1074/jbc.M001935200; Arcondeguy T, 1999, FEMS MICROBIOL LETT, V180, P263, DOI 10.1016/S0378-1097(99)00497-8; Biel S, 2002, EUR J BIOCHEM, V269, P1974, DOI 10.1046/j.1432-1033.2002.02842.x; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; BROWN ED, 1993, J BIOL CHEM, V268, P8972; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; Dietrich V, 2002, EUR J BIOCHEM, V269, P1086, DOI 10.1046/j.0014-2956.2001.02662.x; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; DROSS F, 1992, EUR J BIOCHEM, V206, P93, DOI 10.1111/j.1432-1033.1992.tb16905.x; Egener T, 2002, MICROBIOL-SGM, V148, P3203, DOI 10.1099/00221287-148-10-3203; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Grabbe R, 2003, EUR J BIOCHEM, V270, P1555, DOI 10.1046/j.1432-1033.2003.03520.x; Grabbe R, 2001, J BACTERIOL, V183, P1385, DOI 10.1128/JB.183.4.1385-1393.2001; Gross R, 2004, J BIOL CHEM, V279, P274, DOI 10.1074/jbc.M310610200; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HILL S, 1981, NATURE, V290, P424, DOI 10.1038/290424a0; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Klopprogge K, 2002, ARCH MICROBIOL, V177, P223, DOI 10.1007/s00203-001-0379-x; KROGER A, 1994, PRACTICAL GUIDE MEMB; Lambert O, 1998, BIOPHYS J, V74, P918, DOI 10.1016/S0006-3495(98)74015-9; Lei S, 1999, J BACTERIOL, V181, P6535, DOI 10.1128/JB.181.20.6535-6539.1999; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2006, BIOCHEM SOC T, V34, P162, DOI 10.1042/BST0340162; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; MALOY S, 1987, SALMONELLA TYPHIMURI, P1513; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Martinez-Argudo I, 2005, BIOCHEM SOC T, V33, P152, DOI 10.1042/BST0330152; Martinez-Argudo I, 2004, MOL MICROBIOL, V52, P1731, DOI 10.1111/j.1365-2958.2004.04089.x; Martinez-Argudo I, 2004, J BACTERIOL, V186, P601, DOI 10.1128/JB.186.3.601-610.2004; Matsson M, 2000, BIOCHEMISTRY-US, V39, P8617, DOI 10.1021/bi000271m; MERRICK M, 1982, MOL GEN GENET, V185, P75, DOI 10.1007/BF00333793; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Money T, 2001, J BACTERIOL, V183, P1359, DOI 10.1128/JB.183.4.1359-1368.2001; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; OW DW, 1983, NATURE, V301, P307, DOI 10.1038/301307a0; Perry S, 2005, J MOL BIOL, V346, P935, DOI 10.1016/j.jmb.2004.12.033; Ray P, 2002, NUCLEIC ACIDS RES, V30, P3972, DOI 10.1093/nar/gkf528; Rees DC, 1999, J MOL BIOL, V293, P343, DOI 10.1006/jmbi.1999.3005; Reyes-Ramirez F, 2002, J BACTERIOL, V184, P6777, DOI 10.1128/JB.184.24.6777-6785.2002; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitz RA, 1997, FEMS MICROBIOL LETT, V157, P313, DOI 10.1111/j.1574-6968.1997.tb12791.x; Schmitz RA, 2002, J MOL MICROB BIOTECH, V4, P235; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; Stips J, 2004, EUR J BIOCHEM, V271, P3379, DOI 10.1111/j.1432-1033.2004.04272.x; Swem LR, 2006, J BIOL CHEM, V281, P6768, DOI 10.1074/jbc.M509687200; UNDEN G, 1988, ARCH MICROBIOL, V150, P499, DOI 10.1007/BF00422294; UNDEN G, 1982, BIOCHIM BIOPHYS ACTA, V682, P258, DOI 10.1016/0005-2728(82)90106-2; UNDEN G, 1986, METHOD ENZYMOL, V126, P387; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373; Zhang WM, 2007, BIOCHEMISTRY-US, V46, P483, DOI 10.1021/bi061935g; Zhang WM, 2004, BIOCHEMISTRY-US, V43, P13165, DOI 10.1021/bi048596g	63	8	8	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12517	12526		10.1074/jbc.M609826200	http://dx.doi.org/10.1074/jbc.M609826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329251	hybrid			2022-12-25	WOS:000245942800020
J	Saeki, M; Irie, Y; Ni, L; Itsuki, Y; Terao, Y; Kawabata, S; Kamisaki, Y				Saeki, Makio; Irie, Yasuyuki; Ni, Lin; Itsuki, Yuki; Terao, Yutaka; Kawabata, Shigetada; Kamisaki, Yoshinori			Calcineurin potentiates the activation of procaspase-3 by accelerating its proteolytic maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; PROGRAMMED CELL-DEATH; CYTOCHROME-C; CASPASE ACTIVATION; APOPTOSIS; COMPLEX; PROTEIN; DEPHOSPHORYLATION; APAF-1; CED-4	We have previously shown that procaspase-3 exists in a high molecular weight complex in neonatal rat brain. Here, we purify and identify the protein that interacts with procaspase-3 from rat neonatal cortex. We searched binding proteins to procaspase-3 from a cytosolic extract of neonatal rat brain using chromatogram, two-dimensional gel electrophoresis, and far Western immunoblot. Analysis by tandem mass spectrometry identified the protein as a regulatory subunit of calcineurin ( calcineurin B). Overexpression of calcineurin B in HEK293 cells potentiated processing of caspase-3 and apoptosis triggered by tumor necrosis factor-alpha and cycloheximide treatment. In a cell-free system, overexpression of calcineurin B in HEK293 cells markedly increased processing of caspase-3 by cytochrome c. Immunodepletion of calcineurin B from cytosolic extracts from Jurkat cells decreased processing of caspase-3 by cytochrome c. Knockdown of calcineurin B by RNA interference resulted in reduced apoptosis in HEK293 cells but not in caspase-3-deficient MCF-7 cells. These results suggest that calcineurin B potentiates the activation of procaspase-3 by accelerating its proteolytic maturation.	Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Shanghai Univ E Inst, Div Nitr Oxide & Inflammatory Med, Shanghai 201203, Peoples R China	Osaka University; Osaka University; Osaka University	Saeki, M (corresponding author), Osaka Univ, Dept Pharmacol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	msaeki@dent.osaka-u.ac.jp		Terao, Yutaka/0000-0002-4450-5583				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Feng B, 1999, BIOCHEMISTRY-US, V38, P12481, DOI 10.1021/bi990492w; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kurosu K, 2004, NEUROCHEM INT, V44, P199, DOI 10.1016/S0197-0186(03)00168-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Saeki M, 2002, J CELL BIOCHEM, V84, P708, DOI 10.1002/jcb.10086; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Springer JE, 2000, J NEUROSCI, V20, P7246; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yang SA, 2000, BIOCHEMISTRY-US, V39, P16147, DOI 10.1021/bi001321q; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	24	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11786	11794		10.1074/jbc.M609347200	http://dx.doi.org/10.1074/jbc.M609347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324936	hybrid			2022-12-25	WOS:000245941900021
J	Murakami, H; Goto, DB; Toda, T; Chen, ES; Grewal, SI; Martienssen, RA; Yanagida, M				Murakami, Hiroaki; Goto, Derek B.; Toda, Takashi; Chen, Ee Sin; Grewal, Shiv I.; Martienssen, Robert A.; Yanagida, Mitsuhiro			Ribonuclease Activity of Dis3 Is Required for Mitotic Progression and Provides a Possible Link between Heterochromatin and Kinetochore Function	PLOS ONE			English	Article								Background. Cellular RNA metabolism has a broad range of functional aspects in cell growth and division, but its role in chromosome segregation during mitosis is only poorly understood. The Dis3 ribonuclease is a key component of the RNA-processing exosome complex. Previous isolation of the dis3-54 cold-sensitive mutant of fission yeast Schizosaccharomyces pombe suggested that Dis3 is also required for correct chromosome segregation. Methodology/Principal Findings. We show here that the progression of mitosis is arrested in dis3-54, and that segregation of the chromosomes is blocked by activation of the mitotic checkpoint control. This block is dependent on the Mad2 checkpoint protein. Double mutant and inhibitor analyses revealed that Dis3 is required for correct kinetochore formation and function, and that this activity is monitored by the Mad2 checkpoint. Dis3 is a member of the highly conserved RNase II family and is known to be an essential subunit of the exosome complex. The dis3-54 mutation was found to alter the RNaseII domain of Dis3, which caused a reduction in ribonuclease activity in vitro. This was associated with loss of silencing of an ura4(+) reporter gene inserted into the outer repeats (otr) and central core (cnt and imr) regions of the centromere. On the other hand, centromeric siRNA maturation and formation of the RITS RNAi effector complex was normal in the dis3-54 mutant. Micrococcal nuclease assay also suggested the overall chromatin structure of the centromere was not affected in dis3-54 mutant. Conclusions/Significance. RNase activity of Dis3, a core subunit of exosome, was found to be required for proper kinetochore formation and establishment of kinetochore-microtubule interactions. Moreover, Dis3 was suggested to contribute to kinetochore formation through an involvement in heterochromatic silencing at both outer centromeric repeats and within the central core region. This activity is likely monitored by the mitotic checkpoint, and distinct from that of RNAi-mediated heterochromatin formation directly targeting outer centromeric repeats.	[Murakami, Hiroaki; Yanagida, Mitsuhiro] Kyoto Univ, Grad Sch Biostudies, Japan Sci & Technol Corp, CREST Res Program,Dept Gene Mech,Sakyo Ku, Kyoto, Japan; [Goto, Derek B.; Martienssen, Robert A.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Toda, Takashi] Lincolns Inn Fields Labs, London Res Inst, Canc Res UK, Lab Cell Regulat, London, England; [Chen, Ee Sin; Grewal, Shiv I.] NIH, Mol Cell Biol Lab, Bethesda, MD 20892 USA	Japan Science & Technology Agency (JST); Kyoto University; Cold Spring Harbor Laboratory; Cancer Research UK; National Institutes of Health (NIH) - USA	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Japan Sci & Technol Corp, CREST Res Program,Dept Gene Mech,Sakyo Ku, Kyoto, Japan.	yanagida@kozo.lif.kyoto-u.ac.jp	Goto, Derek B/B-7053-2009	Murakami, Hiroaki/0000-0002-6646-6263	Ministry of Education, Culture, Sports, Science and Technology; Japan Science and Technology Corporation (JST); National Institutes of Health [R01-GM067014]; Life Sciences Research Foundation; Cancer Research UK; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076396, R01GM067014] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Corporation (JST)(Japan Science & Technology Agency (JST)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Life Sciences Research Foundation; Cancer Research UK(Cancer Research UK); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a Specially Promoted Center of Excellence (COE) grant from the Ministry of Education, Culture, Sports, Science and Technology to M. Y., a Core Research for Evolutional Science and Technology (CREST) research grant from the Japan Science and Technology Corporation (JST) to M. Y., and a grant from the National Institutes of Health (R01-GM067014) to R. M. D. G. was a DOE-Energy Biosciences Research Fellow of the Life Sciences Research Foundation. T. T. is supported by Cancer Research UK.	ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Aoki K, 2006, CURR BIOL, V16, P1627, DOI 10.1016/j.cub.2006.06.065; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; Ding DQ, 1998, J CELL SCI, V111, P701; Doe CL, 1998, NUCLEIC ACIDS RES, V26, P4222, DOI 10.1093/nar/26.18.4222; Dziembowski A, 2007, NAT STRUCT MOL BIOL, V14, P15, DOI 10.1038/nsmb1184; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Frazao C, 2006, NATURE, V443, P110, DOI 10.1038/nature05080; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Garcia MA, 2002, EMBO J, V21, P6015, DOI 10.1093/emboj/cdf611; Garcia MA, 2001, EMBO J, V20, P3389, DOI 10.1093/emboj/20.13.3389; Goshima G, 2005, CURR BIOL, V15, P1979, DOI 10.1016/j.cub.2005.09.054; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; HAGAN IM, 1988, J CELL SCI, V89, P343; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Irvine DV, 2006, SCIENCE, V313, P1134, DOI 10.1126/science.1128813; Jin QW, 2002, MOL CELL BIOL, V22, P7168, DOI 10.1128/MCB.22.20.7168-7183.2002; Kadura S, 2005, MOL BIOL CELL, V16, P385, DOI 10.1091/mbc.E04-07-0558; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KLAR AJS, 1991, GENETICS, V129, P1033; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Li F, 2005, CURR BIOL, V15, P1448, DOI 10.1016/j.cub.2005.07.021; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lim JT, 1997, CANCER RES, V57, P921; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; Martienssen RA, 2005, TRENDS GENET, V21, P450, DOI 10.1016/j.tig.2005.06.005; Minoda A, 2005, MOL BIOL CELL, V16, P316, DOI 10.1091/mbc.E04-06-0519; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Nakaseko Y, 2001, CURR BIOL, V11, P537, DOI 10.1016/S0960-9822(01)00155-5; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; PATRIDGE JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2003, J CELL BIOL, V161, P295, DOI 10.1083/jcb.200212110; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Shiomi T, 1998, J BIOCHEM-TOKYO, V123, P883; Shobuike T, 2001, NUCLEIC ACIDS RES, V29, P1326, DOI 10.1093/nar/29.6.1326; Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; TODA T, 1983, J MOL BIOL, V168, P251, DOI 10.1016/S0022-2836(83)80017-5; Toyoda Y, 2002, CURR BIOL, V12, P347, DOI 10.1016/S0960-9822(02)00692-9; UMESONO K, 1983, J MOL BIOL, V168, P271, DOI 10.1016/S0022-2836(83)80018-7; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang SW, 2005, MOL CELL BIOL, V25, P2288, DOI 10.1128/MCB.25.6.2288-2296.2005; Win TZ, 2006, MOL CELL BIOL, V26, P1710, DOI 10.1128/MCB.26.5.1710-1721.2006; WOODS A, 1989, J CELL SCI, V93, P491; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017; Zuo YH, 2006, MOL CELL, V24, P149, DOI 10.1016/j.molcel.2006.09.004	65	65	68	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e317	10.1371/journal.pone.0000317	http://dx.doi.org/10.1371/journal.pone.0000317			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17380189	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000207445100019
J	Kimura, R; Fujimoto, A; Tokunaga, K; Ohashi, J				Kimura, Ryosuke; Fujimoto, Akihiro; Tokunaga, Katsushi; Ohashi, Jun			A Practical Genome Scan for Population-Specific Strong Selective Sweeps That Have Reached Fixation	PLOS ONE			English	Article							RECENT POSITIVE SELECTION; NATURAL-SELECTION; LINKAGE DISEQUILIBRIUM; ARTIFICIAL SELECTION; RACIAL-DIFFERENCES; SIGNATURES; HITCHHIKING; DENSITY; TISSUE; RACE	Phenotypic divergences between modern human populations have developed as a result of genetic adaptation to local environments over the past 100,000 years. To identify genes involved in population-specific phenotypes, it is necessary to detect signatures of recent positive selection in the human genome. Although detection of elongated linkage disequilibrium (LD) has been a powerful tool in the field of evolutionary genetics, current LD-based approaches are not applicable to already fixed loci. Here, we report a method of scanning for population-specific strong selective sweeps that have reached fixation. In this method, genome-wide SNP data is used to analyze differences in the haplotype frequency, nucleotide diversity, and LD between populations, using the ratio of haplotype homozygosity between populations. To estimate the detection power of the statistics used in this study, we performed computer simulations and found that these tests are relatively robust against the density of typed SNPs and demographic parameters if the advantageous allele has reached fixation. Therefore, we could determine the threshold for maintaining high detection power, regardless of SNP density and demographic history. When this method was applied to the HapMap data, it was able to identify the candidates of population-specific strong selective sweeps more efficiently than the outlier approach that depends on the empirical distribution. This study, confirming strong positive selection on genes previously reported to be associated with specific phenotypes, also identifies other candidates that are likely to contribute to phenotypic differences between human populations.	[Kimura, Ryosuke; Fujimoto, Akihiro; Tokunaga, Katsushi; Ohashi, Jun] Univ Tokyo, Dept Human Genet, Grad Sch Med, Tokyo, Japan; [Kimura, Ryosuke] Japan Soc Promot Sci, Tokyo, Japan	University of Tokyo; Japan Society for the Promotion of Science	Kimura, R (corresponding author), Univ Tokyo, Dept Human Genet, Grad Sch Med, Tokyo, Japan.	rkimura@m.u-tokyo.ac.jp	OHASHI, JUN/G-5907-2015; Kimura, Ryosuke/B-3354-2015		Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Bustamante CD, 2005, NATURE, V437, P1153, DOI 10.1038/nature04240; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Ettinger B, 1997, J CLIN ENDOCR METAB, V82, P429, DOI 10.1210/jc.82.2.429; Fay JC, 2000, GENETICS, V155, P1405; FU YX, 1993, GENETICS, V133, P693; Hamblin MT, 2002, AM J HUM GENET, V70, P369, DOI 10.1086/338628; Hanchard NA, 2006, AM J HUM GENET, V78, P153, DOI 10.1086/499252; Harris EF, 2001, AM J PHYS ANTHROPOL, V115, P223, DOI 10.1002/ajpa.1077; Hill JO, 1999, AM J CLIN NUTR, V69, P381; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Kayser M, 2003, MOL BIOL EVOL, V20, P893, DOI 10.1093/molbev/msg092; Kelley JL, 2006, GENOME RES, V16, P980, DOI 10.1101/gr.5157306; Kim Y, 2002, GENETICS, V160, P765; Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Morrison JA, 1996, J PEDIATR-US, V129, P637, DOI 10.1016/S0022-3476(96)70142-7; NEEL JV, 1962, AM J HUM GENET, V14, P353; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Nielsen R, 2005, GENOME RES, V15, P1566, DOI 10.1101/gr.4252305; Ohashi J, 2004, AM J HUM GENET, V74, P1198, DOI 10.1086/421330; Payseur BA, 2002, MOL BIOL EVOL, V19, P1143, DOI 10.1093/oxfordjournals.molbev.a004172; Pollinger JP, 2005, GENOME RES, V15, P1809, DOI 10.1101/gr.4374505; Sabeti PC, 2005, PLOS BIOL, V3, P1963, DOI 10.1371/journal.pbio.0030378; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Saltin B, 1995, Scand J Med Sci Sports, V5, P315; Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305; Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Soejima M, 2006, MOL BIOL EVOL, V23, P179, DOI 10.1093/molbev/msj018; STEVENS J, 1994, J CLIN EPIDEMIOL, V47, P495, DOI 10.1016/0895-4356(94)90296-8; Storz JF, 2004, MOL BIOL EVOL, V21, P1800, DOI 10.1093/molbev/msh192; Taaffe DR, 2001, J BONE MINER RES, V16, P1343, DOI 10.1359/jbmr.2001.16.7.1343; TAJIMA F, 1989, GENETICS, V123, P585; Teshima KM, 2006, GENOME RES, V16, P702, DOI 10.1101/gr.5105206; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; Wang ET, 2006, P NATL ACAD SCI USA, V103, P135, DOI 10.1073/pnas.0509691102; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; Wright SI, 2005, SCIENCE, V308, P1310, DOI 10.1126/science.1107891; Yanovski JA, 1996, AM J CLIN NUTR, V64, P833, DOI 10.1093/ajcn/64.6.833; Yoshiura K, 2006, NAT GENET, V38, P324, DOI 10.1038/ng1733; Zhang YY, 2005, AM J HUM BIOL, V17, P568, DOI 10.1002/ajhb.20427	48	66	68	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e286	10.1371/journal.pone.0000286	http://dx.doi.org/10.1371/journal.pone.0000286			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356696	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444800009
J	Grifoni, D; Garoia, F; Bellosta, P; Parisi, F; De Biase, D; Collina, G; Strand, D; Cavicchi, S; Pession, A				Grifoni, D.; Garoia, F.; Bellosta, P.; Parisi, F.; De Biase, D.; Collina, G.; Strand, D.; Cavicchi, S.; Pession, A.			aPKC zeta cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epithelia	ONCOGENE			English	Article						lethal giant larvae; Hugl-1; aPKC zeta; cell polarity; ovarian epithelial cancers; Drosophila	OVARIAN SURFACE EPITHELIUM; PROTEIN-KINASE-C; CELL POLARITY; SUPPRESSOR GENE; GIANT LARVAE; CANCER; EXPRESSION; COMPLEX; PROLIFERATION; HUGL-1	Atypical protein kinase C ( aPKC) and Lethal giant larvae ( Lgl) regulate apical-basal polarity in Drosophila and mammalian epithelia. At the apical domain, aPKC phosphorylates and displaces Lgl that, in turn, maintains aPKC inactive at the basolateral region. The mutual exclusion of these two proteins seems to be crucial for the correct epithelial structure and function. Here we show that a cortical aPKC loading induces Lgl cytoplasmic release and massive overgrowth in Drosophila imaginal epithelia, whereas a cytoplasmic expression does not alter proliferation and epithelial overall structure. As two aPKC isoforms ( iota and zeta) exist in humans and we previously showed that Drosophila Lgl is the functional homologue of the Human giant larvae-1 ( Hugl-1) protein, we argued if the same mechanism of mutual exclusion could be impaired in human epithelial disorders and investigated aPKC iota, aPKC zeta and Hugl-1 localization in cancers deriving from ovarian surface epithelium. Both in mucinous and serous histotypes, aPKC zeta showed an apical-to-cortical redistribution and Hugl-1 showed a membrane-to-cytoplasm release, perfectly recapitulating the Drosophila model. Although several recent works support a causative role for aPKCi overexpression in human carcinomas, our results suggest a key role for aPKC zeta in apical-basal polarity loosening, a mechanism that seems to be driven by changes in protein localization rather than in protein abundance.	Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, I-40126 Bologna, Italy; Alma Mater Studiorum, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; CUNY City Coll, Dept Biol, New York, NY 10031 USA; Univ Bologna, Osped Bellaria, Sez Anat Patol, Alma Mater Studiorum, I-40139 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	City University of New York (CUNY) System; City College of New York (CUNY); University of Bologna; Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, Via Selmi 3, I-40126 Bologna, Italy.	daniela.grifoni@unibo.it	Garoia, Flavio/AAL-4528-2020; de Biase, Dario/B-9274-2012; Messier, Claude/A-2322-2008; Garoia, Flavio/AAW-1313-2020; Grifoni, Daniela/A-3954-2012; Bellosta, Paola/AAA-3413-2020; Pession, Annalisa/B-9014-2012	de Biase, Dario/0000-0002-0609-8817; Messier, Claude/0000-0002-4791-1763; Bellosta, Paola/0000-0003-1913-5661; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Pession, Annalisa/0000-0001-9035-9698				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1990, J CELL SCI, P169; Chalmers AD, 2005, DEVELOPMENT, V132, P977, DOI 10.1242/dev.01645; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Filip S, 2006, NEOPLASMA, V53, P87; Gibson MC, 2006, NATURE, V442, P1038, DOI 10.1038/nature05014; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kovac J, 2007, GENE EXPR PATTERNS, V7, P187, DOI 10.1016/j.modgep.2006.07.002; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Okamura H, 2006, MICROSC RES TECHNIQ, V69, P469, DOI 10.1002/jemt.20306; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Pilot F, 2005, DEV DYNAM, V232, P685, DOI 10.1002/dvdy.20334; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Sarrio D, 2006, HUM PATHOL, V37, P1042, DOI 10.1016/j.humpath.2006.03.003; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Scott M, 2006, HISTOL HISTOPATHOL, V21, P81, DOI 10.14670/HH-21.81; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vanderhyden Barbara C, 2003, Reprod Biol Endocrinol, V1, P67, DOI 10.1186/1477-7827-1-67; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938	44	63	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5960	5965		10.1038/sj.onc.1210389	http://dx.doi.org/10.1038/sj.onc.1210389			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369850	Green Published			2022-12-25	WOS:000249123100013
J	Donnini, S; Finetti, F; Solito, R; Terzuoli, E; Sacchetti, A; Morbidelli, L; Patrignani, P; Ziche, M				Donnini, Sandra; Finetti, Federica; Solito, Raffaella; Terzuoli, Erika; Sacchetti, Andrea; Morbidelli, Lucia; Patrignani, Paola; Ziche, Marina			EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways	FASEB JOURNAL			English	Article						nitric oxide; prostaglandin E-2; invasiveness	NITRIC-OXIDE SYNTHASE; CANCER CELLS; CYCLOOXYGENASE-2 COX-2; TYROSINE KINASE; PROTEIN-KINASE; CROSS-TALK; ACTIVATION; EXPRESSION; HEAD; PHOSPHORYLATION	In squamous cell carcinoma, the levels of nitric oxide ( NO) derived from inducible NO synthase ( iNOS) and prostaglandin E-2 ( PGE(2)) derived from cyclooxygenase-2 ( COX-2) originated from tumor cells or tumor-associated inflammatory cells have been reported to correlate with tumor growth, metastasis, and angiogenesis. The present study examined the role of the iNOS signaling pathway in PGE(2)-mediated tumor invasiveness and proliferation in squamous cell carcinoma, A431, and SCC-9 cells. Cell invasion and proliferation promoted by PGE2 were blocked by iNOS silencing RNA or iNOS/guanylate cyclase ( GC) pharmacological inhibition. Consistently, iNOS-GC pathway inhibitors blocked mitogen-activated protein kinase-ERK1/2 phosphorylation, which was required to mediate PGE2 functions. In vivo, in A431 cells implanted in nude mice, GC inhibition also decreased the tumor proliferation index and ERK1/2 activation. PGE2 effects were confined to the selective stimulation of the EP2 receptor subtype, leading to epidermal growth factor receptor ( EGFR) transactivation via protein kinase A ( PKA) and c-Src activation. EP2-mediated ERK1/2 activation and cell functions were abolished by inhibitors of PKA, c-Src, and EGFR, as well as by inhibiting iNOS pathway. Silencing of iNOS also impaired EGFR-induced ERK1/2 phosphorylation. These results indicate that iNOS/GC signaling is a downstream player in the control of EP2/EGFR-mediated tumor cell proliferation and invasion.	Univ Siena, Pharmacol Angiogenesis Lab, Dept Mol Biol, I-53100 Siena, Italy; Univ G dAnnunzio, Dept Pharmacol, Chieti, Italy	University of Siena; G d'Annunzio University of Chieti-Pescara	Ziche, M (corresponding author), Univ Siena, Pharmacol Angiogenesis Lab, Dept Mol Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Sacchetti, Andrea/H-8763-2019; Finetti, Federica/J-9089-2016; Morbidelli, Lucia/K-4053-2016; Patrignani, Paola/B-4844-2011; Donnini, Sandra/K-9252-2019; Morbidelli, Lucia/AAC-7858-2020; Terzuoli, Erika/M-7346-2016	Morbidelli, Lucia/0000-0001-8148-7049; Patrignani, Paola/0000-0003-1419-2691; Donnini, Sandra/0000-0001-6617-1644; Terzuoli, Erika/0000-0001-9248-4505				Bae SH, 2001, CLIN CANCER RES, V7, P1410; BREYER RM, 2001, ANN REV PHARM TOXICO, V41, P561; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cantara S, 2004, FASEB J, V18, P1943, DOI 10.1096/fj.04-2114fje; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chen ZG, 2004, CLIN CANCER RES, V10, P5930, DOI 10.1158/1078-0432.CCR-03-0677; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Donnini S, 2004, LIFE SCI, V74, P2975, DOI 10.1016/j.lfs.2003.09.075; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2003, TRENDS PHARMACOL SCI, V24, P335, DOI 10.1016/S0165-6147(03)00162-7; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Galisteo M, 1999, J PHARMACOL EXP THER, V290, P1270; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Harborth J, 2001, J CELL SCI, V114, P4557; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HONDA A, 1993, J BIOL CHEM, V268, P7759; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; HOOD JD, 1999, AM J PHYSIOL, V274, pH1054; Iwakiri Y, 2002, AM J PHYSIOL-HEART C, V282, pH2084, DOI 10.1152/ajpheart.00675.2001; Jadeski LC, 2003, INT J CANCER, V106, P496, DOI 10.1002/ijc.11268; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; Lui VWY, 2002, ANTICANCER RES, V22, P1; Majima M, 2003, TRENDS PHARMACOL SCI, V24, P524, DOI 10.1016/j.tips.2003.08.005; Mutoh M, 2002, CANCER RES, V62, P28; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Salvemini D, 1996, J CLIN INVEST, V97, P2562, DOI 10.1172/JCI118704; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Shah J P, 1993, Curr Probl Surg, V30, P1; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Taraboletti G, 2000, FASEB J, V14, P1674; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Timoshenko AV, 2004, INT J CANCER, V108, P384, DOI 10.1002/ijc.11575; Timoshenko AV, 2003, EXP CELL RES, V289, P265, DOI 10.1016/S0014-4827(03)00269-6; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wendum D, 2004, VIRCHOWS ARCH, V445, P327, DOI 10.1007/s00428-004-1105-2; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yarden Y, 2001, EUR J CANCER, V37, pS3	57	77	79	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2418	2430		10.1096/fj.06-7581com	http://dx.doi.org/10.1096/fj.06-7581com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17384145				2022-12-25	WOS:000248454400017
J	Karunakaran, S; Diwakar, L; Saeed, U; Agarwal, V; Ramakrishnan, S; Iyengar, S; Ravindranath, V				Karunakaran, Smitha; Diwakar, Latha; Saeed, Uzma; Agarwal, Varsha; Ramakrishnan, Sujanitha; Iyengar, Soumya; Ravindranath, Vijayalakshmi			Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid	FASEB JOURNAL			English	Article						MAPK signaling; MPTP; DJ-1; oxidative stress; cell death	MITOCHONDRIAL COMPLEX-I; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; S-THIOLATION; AMINO-ACIDS; CELL-DEATH; MPTP; VIVO; NEURODEGENERATION; THIOREDOXIN	Parkinson's disease (PD), a neurodegenerative disorder, causes severe motor impairment due to loss of dopaminergic neurons in substantia nigra pars compacta (SNpc). MPTP, a neurotoxin that causes dopaminergic cell loss in mice, was used in an animal model to study the pathogenic mechanisms leading to neurodegeneration. We observed the activation of apoptosis signal regulating kinase (ASK1, MAPKKK) and phosphorylation of its downstream targets MKK4 and JNK, 12 h after administration of a single dose of MPTP. Further, Daxx, the death-associated protein, translocated to the cytosol selectively in SNpc neurons seemingly due to MPTP mediated down-regulation of DJ-1, the redox-sensitive protein that binds Daxx in the nucleus. Coadministration of alpha-lipoic acid (ALA), a thiol antioxidant, abolished the activation of ASK1 and phosphorylation of downstream kinases, MKK4, and JNK and prevented the down-regulation of DJ-1 and translocation of Daxx to the cytosol seen after MPTP. ALA also attenuated dopaminergic cell loss in SNpc seen after subchronic MPTP treatment. Our studies demonstrate for the first time that MPTP triggers death signaling pathway by activating ASK1 and translocating Daxx, in vivo, in dopaminergic neurons in SNpc of mice and thiol antioxidants, such as ALA terminate this cascade and afford neuroprotection.-Karunakaran, S., Diwakar, L., Saeed, U., Agarwal, V., Ramakrishnan, S., Iyengar, S., Ravindranath, V. Activation of apoptosis signal regulating kinase 1 ( ASK1) and translocation of death associated protein, Daxx in substantia nigra pars compacta in a mouse model of Parkinson's disease: Protection by alpha-lipoic acid.	Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Manesar 122050, India; Natl Brain Res Ctr, Div Syst Neurosci, Manesar 122050, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Ravindranath, V (corresponding author), Natl Brain Res Ctr, Div Mol & Cellular Neurosci, Manesar 122050, India.	vijir@nbrc.ac.in		Karunakaran, Smitha/0000-0002-9489-7431				Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; Annepu J, 2000, NEUROSCI LETT, V289, P209, DOI 10.1016/S0304-3940(00)01300-8; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Bezard E, 1999, EXP NEUROL, V155, P268, DOI 10.1006/exnr.1998.6995; Bharath S, 2002, NEUROTOXICOLOGY, V23, P479, DOI 10.1016/S0161-813X(02)00035-9; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Diwakar L, 2007, NEUROCHEM INT, V50, P418, DOI 10.1016/j.neuint.2006.09.014; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; HEINONEN K, 1973, BIOCHEM J, V136, P1011, DOI 10.1042/bj1361011; Hornykiewicz O, 1975, Natl Inst Drug Abuse Res Monogr Ser, P13; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Kenchappa RS, 2003, FASEB J, V17, P717, DOI 10.1096/fj.02-0771fje; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Nishida K, 2006, ANTIOXID REDOX SIGN, V8, P1729, DOI 10.1089/ars.2006.8.1729; Ouyang MX, 2006, J NEUROCHEM, V97, P234, DOI 10.1111/j.1471-4159.2006.03730.x; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; Ricchelli F, 2005, INT J BIOCHEM CELL B, V37, P1858, DOI 10.1016/j.biocel.2005.04.001; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Song JJ, 2004, J BIOL CHEM, V279, P30573, DOI 10.1074/jbc.M404512200; Sriram K, 1998, J NEUROSCI, V18, P10287; SRIRAM K, 1995, J NEUROCHEM, V64, P1203; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	112	123	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2226	2236		10.1096/fj.06-7580com	http://dx.doi.org/10.1096/fj.06-7580com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17369508				2022-12-25	WOS:000247500300031
J	Kislin, KL; Marron, MT; Li, G; Graner, MW; Katsanis, E				Kislin, Kerri L.; Marron, Marilyn T.; Li, Gang; Graner, Michael W.; Katsanis, Emmanuel			Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia	FASEB JOURNAL			English	Article						heat-shock proteins; peptide antigens; anticancer vaccine; T-cells; isoelectric focusing	HEAT-SHOCK PROTEINS; CHRONIC MYELOGENOUS LEUKEMIA; CD8(+) T-CELLS; DENDRITIC CELLS; ANTIGEN PRESENTATION; IMATINIB MESYLATE; CANCER VACCINES; TUMOR REJECTION; STRESS-PROTEINS; IMMUNITY	Chaperone proteins are effective antitumor vaccines when purified from a tumor source, some of which are in clinical trials. Such vaccines culminate in tumor-specific T cell responses, implicating the role of adaptive immunity. We have developed a rapid and efficient procedure utilizing an isoelectric focusing technique to obtain vaccines from tumor or normal tissues called chaperone-rich cell lysate (CRCL). Tumor-associated peptides, the currency of T cell-mediated anticancer immunity, are believed to be purveyed by chaperone vaccines. Our purpose was to demonstrate our ability to manipulate the peptide antigen repertoire of CRCL vaccines as a novel anticancer strategy. Our methods allow us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of CRCL to quantitatively acquire and deliver exogenous antigenic peptides (e. g., derived from the oncogenic BCR/ABL protein in chronic myelogenous leukemia). Using fluorescence-based and antigen-presentation assays, we determined that significant quantities of exogenously added peptide could accumulate in "designer" CRCL and could stimulate T cell activation. Further, we concluded that peptideembedded CRCL, devoid of other antigens, could generate potent immunity against pre-established murine leukemia. Designer CRCL allows for the development of personalized vaccines against cancers expressing known antigens, by embedding antigens into CRCL derived from normal tissue.	Duke Univ, Med Ctr, Pathol Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27706 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ USA; Duke Univ, Ctr Med, Durham, NC USA; Univ Arizona, Steele Childrens Res Ctr, Tucson, AZ USA	Duke University; University of Arizona; Duke University; University of Arizona	Graner, MW (corresponding author), Duke Univ, Med Ctr, Pathol Preston Robert Tisch Brain Tumor Ctr, Box 3156 Med Sci Res Bldg 173A, Durham, NC 27706 USA.	michael.graner@duke.edu	Katsanis, Emmanuel/D-9600-2011	Katsanis, Emmanuel/0000-0003-1466-6965	NATIONAL CANCER INSTITUTE [R01CA104926, P30CA023074, T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104926, CA023074-26, T32 CA09213] Funding Source: Medline; NIEHS NIH HHS [ES06694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker-LePain JC, 2004, J IMMUNOL, V172, P4195, DOI 10.4049/jimmunol.172.7.4195; Baker-LePain JC, 2003, CURR OPIN IMMUNOL, V15, P89, DOI 10.1016/S0952791502000067; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Calderwood SK, 2005, INT J HYPERTHER, V21, P713, DOI 10.1080/02656730500340794; Chen XC, 2006, BIOL BLOOD MARROW TR, V12, P275, DOI 10.1016/j.bbmt.2006.01.001; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Facciponte JG, 2005, IMMUNOL INVEST, V34, P325, DOI 10.1081/IMM-200064505; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Feng HP, 2003, BLOOD, V101, P245, DOI 10.1182/blood-2002-05-1580; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Graner M, 2000, CANCER IMMUNOL IMMUN, V49, P476, DOI 10.1007/s002620000138; Graner MW, 2003, CANCER IMMUNOL IMMUN, V52, P226, DOI 10.1007/s00262-002-0359-2; He L, 2001, CANCER IMMUNOL IMMUN, V50, P31, DOI 10.1007/PL00006680; HORIMOTO M, 1995, BRIT J CANCER, V72, P676, DOI 10.1038/bjc.1995.393; Indrova M, 2004, FOLIA BIOL-PRAGUE, V50, P184; Kobie JJ, 2003, CANCER RES, V63, P1860; Kunisawa J, 2003, MOL CELL, V12, P565, DOI 10.1016/j.molcel.2003.08.009; Li Z, 1997, Semin Immunol, V9, P315, DOI 10.1006/smim.1997.0087; Li ZH, 2005, CLIN CANCER RES, V11, P4460, DOI 10.1158/1078-0432.CCR-05-0250; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Liau LM, 2005, CLIN CANCER RES, V11, P5515, DOI 10.1158/1078-0432.CCR-05-0464; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Manjili MH, 2002, CANCER RES, V62, P1737; Mosca PJ, 2005, CANC TREAT, V123, P369; Nicchitta CV, 2004, CELL STRESS CHAPERON, V9, P325, DOI 10.1379/CSC-62.1; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Nieda M, 1998, BLOOD, V91, P977, DOI 10.1182/blood.V91.3.977.977_977_983; Oki Yasuhiro, 2004, Expert Rev Vaccines, V3, P403, DOI 10.1586/14760584.3.4.403; Park JE, 2006, CANCER RES, V66, P1161, DOI 10.1158/0008-5472.CAN-05-2609; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Shah M, 1998, HISTOCHEM J, V30, P509, DOI 10.1023/A:1003259907014; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Speiser DE, 2003, SEMIN CANCER BIOL, V13, P461, DOI 10.1016/j.semcancer.2003.09.010; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; tenBosch GJA, 1996, BLOOD, V88, P3522, DOI 10.1182/blood.V88.9.3522.bloodjournal8893522; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang XY, 2004, METHODS, V32, P13, DOI 10.1016/S1046-2023(03)00181-6; Wang XY, 2001, J IMMUNOL, V166, P490, DOI 10.4049/jimmunol.166.1.490; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Wells AD, 2000, IMMUNOL TODAY, V21, P129, DOI 10.1016/S0167-5699(99)01558-3; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Yotnda P, 1998, J CLIN INVEST, V101, P2290, DOI 10.1172/JCI488; Yu JS, 2001, CANCER RES, V61, P842; Zeng Y, 2005, BLOOD, V105, P2016, DOI 10.1182/blood-2004-05-1915; Zeng Y, 2004, INT J CANCER, V110, P251, DOI 10.1002/ijc.20115; Zeng Y, 2003, BLOOD, V101, P4485, DOI 10.1182/blood-2002-10-3108	58	14	18	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2173	2184		10.1096/fj.06-7843com	http://dx.doi.org/10.1096/fj.06-7843com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17327358				2022-12-25	WOS:000247500300026
J	Michelotti, GA; Brinkley, DM; Morris, DP; Smith, MP; Louie, RJ; Schwinn, DA				Michelotti, Gregory A.; Brinkley, D. Marshall; Morris, Daniel P.; Smith, Michael P.; Louie, Raphael J.; Schwinn, Debra A.			Epigenetic regulation of human alpha(1d)-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation	FASEB JOURNAL			English	Article						transcription; cell-specific; promoter	CPG-BINDING-PROTEIN; SUBTYPE MESSENGER-RNAS; DE-NOVO METHYLATION; BREAST-CANCER CELLS; LOWER URINARY-TRACT; GROWTH-FACTOR; ALPHA(1B)-ADRENERGIC RECEPTOR; CARDIAC-HYPERTROPHY; PROMOTER REGION; ALPHA(1)-ADRENERGIC RECEPTORS	A growing body of evidence implicates alpha(1)-adrenergic receptors (alpha(1)ARs) as potent regulators of growth pathways. The three alpha(1)AR subtypes (alpha(1a)AR, alpha(1b)AR, alpha(1d)AR) display highly restricted tissue expression that undergoes subtype switching with many pathological stimuli, the mechanistic basis of which remains unknown. To gain insight into transcriptional pathways governing cell-specific regulation of the human alpha(1d)AR subtype, we cloned and characterized the alpha(1d)AR promoter region in two human cellular models that display disparate levels of endogenous alpha(1d)AR expression (SK-N-MC and DU145). Results reveal that alpha(1d)AR basal expression is regulated by Sp1-dependent binding of two promoter-proximal GC boxes, the mutation of which attenuates alpha(1d)AR promoter activity 10-fold. Mechanistically, chromatin immunoprecipitation data demonstrate that Sp1 binding correlates with expression of the endogenous gene in vivo, correlating highly with alpha(1d)AR promoter methylation-dependent silencing of both episomally expressed reporter constructs and the endogenous gene. Further, analysis of methylation status of proximal GC boxes using sodium bisulfite sequencing reveals differential methylation of proximal GC boxes in the two cell lines examined. Together, the data support a mechanism of methylation-dependent disruption of Sp1 binding in a cell-specific manner resulting in repression of basal alpha(1d)AR expression.	Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Cardiol & Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Michelotti, GA (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA.	miche007@mc.duke.edu		Schwinn, Debra/0000-0002-9696-5231; Michelotti, Gregory/0000-0002-7908-1979	NHLBI NIH HHS [R01 HL049103, R37 HL049103, R37 HL049103-13, R37 HL049103-12, R37 HL049103-11, HL49103] Funding Source: Medline; NIA NIH HHS [AG17566, R01 AG017566] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049103, R37HL049103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017566] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN KB, 1992, J VASC SURG, V16, P391, DOI 10.1016/0741-5214(92)90372-F; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; ANYUKHOVSKY EP, 1994, CIRC RES, V74, P937, DOI 10.1161/01.RES.74.5.937; Aoyama T, 2004, J BIOL CHEM, V279, P28789, DOI 10.1074/jbc.M401273200; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bahouth SW, 2002, MOL PHARMACOL, V61, P379, DOI 10.1124/mol.61.2.379; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brero A, 2006, CURR TOP MICROBIOL, V301, P21; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; de Mey C, 1998, EUR UROL, V34, P18, DOI 10.1159/000052284; Doerfler W, 2006, CURR TOP MICROBIOL, V301, P125; Dunn CJ, 2002, DRUG AGING, V19, P135, DOI 10.2165/00002512-200219020-00004; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAO B, 1994, J BIOL CHEM, V269, P15762; GAO Y, 1993, APPL SUPERCOND, V1, P131, DOI 10.1016/0964-1807(93)90389-J; GEE JE, 1992, J BIOL CHEM, V267, P11163; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gonzalez-Cabrera PJ, 2004, ENDOCRINOLOGY, V145, P5157, DOI 10.1210/en.2004-0728; Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104; Hampel C, 2002, J UROLOGY, V167, P1513, DOI 10.1016/S0022-5347(05)65355-4; Holmes R, 2006, CYTOGENET GENOME RES, V113, P122, DOI 10.1159/000090823; Ibarra M, 1997, EUR J PHARMACOL, V322, P221, DOI 10.1016/S0014-2999(97)00092-7; Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Keffel S, 2000, BIOCHEM BIOPH RES CO, V272, P906, DOI 10.1006/bbrc.2000.2850; Koshimizu T, 2003, PHARMACOL THERAPEUT, V98, P235, DOI 10.1016/S0163-7258(03)00033-0; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710; LI HT, 1995, CIRCULATION, V92, P918, DOI 10.1161/01.CIR.92.4.918; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Majumder S, 2006, J CELL BIOCHEM, V97, P1300, DOI 10.1002/jcb.20738; Malloy BJ, 1998, J UROLOGY, V160, P937, DOI 10.1016/S0022-5347(01)62836-2; Michelotti GA, 2003, J BIOL CHEM, V278, P8693, DOI 10.1074/jbc.M211986200; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200; Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430; Mulero-Navarro S, 2006, CARCINOGENESIS, V27, P1099, DOI 10.1093/carcin/bgi344; Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6; O'Connell TD, 2001, MOL PHARMACOL, V59, P1225, DOI 10.1124/mol.59.5.1225; Podgoreanu MV, 2005, J THORAC CARDIOV SUR, V130, P330, DOI 10.1016/j.jtcvs.2004.11.052; Price D, 2001, EUR UROL, V40, P5, DOI 10.1159/000049889; Price DT, 2000, J UROLOGY, V164, P2145, DOI 10.1016/S0022-5347(05)66987-X; PRICE DT, 1994, MOL PHARMACOL, V45, P171; PRICE DT, 1994, MOL PHARMACOL, V46, P221; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237; REILLY PM, 1993, CRIT CARE MED, V21, pS55, DOI 10.1097/00003246-199302001-00011; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Rudner XL, 1999, CIRCULATION, V100, P2336, DOI 10.1161/01.CIR.100.23.2336; RUFFOLO RR, 1985, PHARMACOL BIOCHEM BE, V22, P827, DOI 10.1016/0091-3057(85)90535-0; Sado T, 2005, HUM MOL GENET, V14, pR59, DOI 10.1093/hmg/ddi117; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Schwinn DA, 2000, BJU INT, V85, P6, DOI 10.1046/j.1464-410X.2000.00061.x; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Shibata K, 2003, J BIOL CHEM, V278, P672, DOI 10.1074/jbc.M201375200; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wang GL, 2003, J BIOL CHEM, V278, P40550, DOI 10.1074/jbc.M302879200; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Xin XH, 1999, MOL PHARMACOL, V56, P1152, DOI 10.1124/mol.56.6.1152; Xin XH, 1997, MOL PHARMACOL, V51, P764, DOI 10.1124/mol.51.5.764; Yun J, 2003, CARDIOVASC RES, V57, P443, DOI 10.1016/S0008-6363(02)00696-X; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288	79	35	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1979	1993		10.1096/fj.06-7118com	http://dx.doi.org/10.1096/fj.06-7118com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17384146	Green Accepted			2022-12-25	WOS:000247500300008
J	Meloni, G; Faller, P; Vasak, M				Meloni, Gabriele; Faller, Peter; Vasak, Milan			Redox silencing of copper in metal-linked neurodegenerative disorders reaction of Zn(7)metallothionein-3 with Cu2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; ALZHEIMERS-DISEASE BRAIN; OXIDATIVE STRESS; AMYLOID-BETA; METALLOTHIONEIN-III; TERMINAL DOMAIN; STRUCTURAL-CHARACTERIZATION; PHOTOPHYSICAL PROPERTIES; BIOINORGANIC CHEMISTRY; TRANSCRIPTION FACTOR	Dysregulation of copper and zinc homeostasis in the brain plays a critical role in Alzheimer disease (AD). Copper binding to amyloid-beta peptide (A beta) is linked with the neurotoxicity of A beta and free radical damage. Metallothionein-3 (MT-3) is a small cysteine- and metal-rich protein expressed in the brain and found down-regulated in AD. This protein occurs intra- and extracellularly, and it plays an important role in the metabolism of zinc and copper. In cell cultures Zn7MT-3, by an unknown mechanism, protects neurons from the toxicity of A beta. We have, therefore, used a range of complementary spectroscopic and biochemical methods to characterize the interaction of Zn7MT-3 with free Cu2+ ions. We show that Zn7MT-3 scavenges free Cu2+ ions through their reduction to Cu+ and binding to the protein. In this reaction thiolate ligands are oxidized to disulfides concomitant with Zn2+ release. The binding of the first four Cu2+ is cooperative forming a Cu(I)(4)-thiolate cluster in the N-terminal domain of Cu-4, Zn4MT-3 together with two disulfides bonds. The Cu-4-thiolate cluster exhibits an unusual stability toward air oxygen. The results of UV-visible, CD, and Cu(I) phosphorescence at 77 K suggest the existence of metal-metal interactions in this cluster. We have demonstrated that Zn7MT-3 in the presence of ascorbate completely quenches the copper-catalyzed hydroxyl radical (OH.) production. Thus, zinc-thiolate clusters in Zn7MT-3 can efficiently silence the redox-active free Cu2+ ions. The biological implication of our studies as to the protective role of Zn7MT-3 from the Cu2+ toxicity in AD and other neurodegenerative disorders is discussed.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Lab Chimie Coordinat, F-31077 Toulouse, France	University of Zurich	Vasak, M (corresponding author), Univ Zurich, Dept Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	mvasak@bioc.unizh.ch	Faller, Peter/B-9614-2018	Faller, Peter/0000-0001-8013-0806; Meloni, Gabriele/0000-0003-4976-1401				Adlard PA, 2006, J ALZHEIMERS DIS, V10, P145; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; AVDEEF A, 1978, INORG CHEM, V17, P2182, DOI 10.1021/ic50186a031; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Belle C, 2005, J INORG BIOCHEM, V99, P1929, DOI 10.1016/j.jinorgbio.2005.06.013; Bogumil R, 1998, EUR J BIOCHEM, V255, P172, DOI 10.1046/j.1432-1327.1998.2550172.x; Bogumil R, 1996, EUR J BIOCHEM, V238, P698, DOI 10.1111/j.1432-1033.1996.0698w.x; Brezova V, 2003, J PHYS CHEM B, V107, P2415, DOI 10.1021/jp027743m; Brown DR, 2004, DALTON T, P1907, DOI 10.1039/b401985g; Burkitt MJ, 2001, ARCH BIOCHEM BIOPHYS, V394, P117, DOI 10.1006/abbi.2001.2509; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Cai L, 2005, CURR MED CHEM, V12, P2753, DOI 10.2174/092986705774462950; Calderone V, 2005, P NATL ACAD SCI USA, V102, P51, DOI 10.1073/pnas.0408254101; CASASFINET JR, 1991, FEBS LETT, V281, P205, DOI 10.1016/0014-5793(91)80394-I; Cookson MR, 1999, BRAIN PATHOL, V9, P165; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FELIX K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P104, DOI 10.1016/0167-4838(93)90042-P; FORD PC, 1993, ACCOUNTS CHEM RES, V26, P220, DOI 10.1021/ar00028a013; Ford PC, 1999, CHEM REV, V99, P3625, DOI 10.1021/cr960109i; Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Kawashima T, 2000, DEMENT GERIATR COGN, V11, P251, DOI 10.1159/000017247; KHAN MMT, 1967, J AM CHEM SOC, V89, P4176, DOI 10.1021/ja00992a036; Kitzberger R, 2005, METAB BRAIN DIS, V20, P295, DOI 10.1007/s11011-005-7910-8; Knipp M, 2005, BIOCHEMISTRY-US, V44, P3159, DOI 10.1021/bi047636d; KYLE KR, 1991, J AM CHEM SOC, V113, P2954, DOI 10.1021/ja00008a026; Manevich Y, 1997, RADIAT RES, V148, P580, DOI 10.2307/3579734; Martin BL, 2006, MOL CELL BIOCHEM, V283, P129, DOI 10.1007/s11010-006-2390-7; MASTERS BA, 1994, J NEUROSCI, V14, P5844; Maynard CJ, 2005, INT J EXP PATHOL, V86, P147, DOI 10.1111/j.0959-9673.2005.00434.x; MEHROTRA PK, 1978, INORG CHEM, V17, P2187, DOI 10.1021/ic50186a032; Meloni G, 2005, J BIOCHEM BIOPH METH, V64, P76, DOI 10.1016/j.jbbm.2005.05.005; Ohta T, 2000, INORG CHEM, V39, P4358, DOI 10.1021/ic000018a; Oz G, 2001, BIOCHEMISTRY-US, V40, P11433, DOI 10.1021/bi010827l; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; POUNTNEY DL, 1994, FEBS LETT, V345, P193, DOI 10.1016/0014-5793(94)00452-8; POUNTNEY DL, 1994, BIOCHEMISTRY-US, V33, P9699, DOI 10.1021/bi00198a040; PRESTA A, 1994, CHIRALITY, V6, P521, DOI 10.1002/chir.530060703; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Raveh O, 2000, FREE RADICAL BIO MED, V29, P131, DOI 10.1016/S0891-5849(00)00332-4; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Romero-Isart N, 2002, J BIOL CHEM, V277, P37023, DOI 10.1074/jbc.M205730200; Roschitzki B, 2003, BIOCHEMISTRY-US, V42, P9822, DOI 10.1021/bi034816z; Roschitzki B, 2002, J BIOL INORG CHEM, V7, P611, DOI 10.1007/s00775-002-0339-1; SABIN F, 1992, INORG CHEM, V31, P1941, DOI 10.1021/ic00036a040; Sogawa CA, 2001, ACTA MED OKAYAMA, V55, P1; STEVENSON KL, 1988, INORG CHEM, V27, P3472, DOI 10.1021/ic00293a009; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Vaher M, 2001, J INORG BIOCHEM, V83, P1, DOI 10.1016/S0162-0134(00)00183-5; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; Varma S D, 1990, Lens Eye Toxic Res, V7, P49; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; Wang H, 2006, FEBS LETT, V580, P795, DOI 10.1016/j.febslet.2005.12.099; WESER U, 1985, STRUCT BOND, V61, P145; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje	67	101	104	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16068	16078		10.1074/jbc.M701357200	http://dx.doi.org/10.1074/jbc.M701357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389590	hybrid			2022-12-25	WOS:000246794300015
J	Fitsialos, G; Chassot, AA; Turchi, L; Dayem, MA; LeBrigand, K; Moreilhon, C; Meneguzzi, G; Busca, R; Mari, B; Barbry, P; Ponzio, G				Fitsialos, Giorgos; Chassot, Anne-Amandine; Turchi, Laurent; Dayem, Manal A.; LeBrigand, Kevin; Moreilhon, Chimene; Meneguzzi, Guerrino; Busca, Roser; Mari, Bernard; Barbry, Pascal; Ponzio, Gilles			Transcriptional signature of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL MIGRATION; NF-KAPPA-B; TGF-BETA; GENE-EXPRESSION; CARCINOMA-CELLS; FACTOR-ALPHA; VAV FAMILY; CROSS-TALK; TNF-ALPHA; ACTIVATION	Covering denuded dermal surfaces after injury requires migration, proliferation, and differentiation of skin keratinocytes. To clarify the major traits controlling these intermingled biological events, we surveyed the genomic modifications occurring during the course of a scratch wound closure of cultured human keratinocytes. Using a DNA microarray approach, we report the identification of 161 new markers of epidermal repair. Expression data, combined with functional analysis performed with specific inhibitors of ERK, p38(MAPK) and phosphatidylinositol 3-kinase ( PI3K), demonstrate that kinase pathways exert very selective functions by precisely controlling the expression of specific genes. Inhibition of the ERK pathway totally blocks the wound closure and inactivates many early transcription factors and EGF-type growth factors. p38(MAPK) inhibition only delays "healing," probably in line with the control of genes involved in the propagation of injury-initiated signaling. In contrast, PI3K inhibition accelerates the scratch closure and potentiates the scratch-dependent stimulation of three genes related to epithelial cell transformation, namely HAS3, HBEGF, and ETS1. Our results define in vitro human keratinocyte wound closure as a repair process resulting from a fine balance between positive signals controlled by ERK and p38(MAPK) and negative ones triggered by PI3K. The perturbation of any of these pathways might lead to dysfunction in the healing process, similar to those observed in pathological wounding phenotypes, such as hypertrophic scars or keloids.	INSERM U634, F-06107 Nice 2, France; Univ Nice Sophia Antipolis, IFR50, Fac Med, F-06107 Nice 2, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Sophia Antipolis, France; Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Ponzio, G (corresponding author), INSERM U634, 28 Ave de Valombrose, F-06107 Nice 2, France.	ponzio@unice.fr	Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Li, Chia Cheng/D-9906-2015; Barbry, Pascal/O-5021-2016; Chassot, Anne-Amandine/O-2102-2016; Mari, Bernard P/GVS-3100-2022; Ponzio, Gilles/Q-1256-2016; Mari, Bernard P/F-8960-2013	Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483; Chassot, Anne-Amandine/0000-0003-1242-9456; Mari, Bernard P/0000-0002-0422-9182; Ponzio, Gilles/0000-0003-2741-0248; Mari, Bernard P/0000-0002-0422-9182; Meneguzzi, Guerrino/0000-0002-1609-6540; Turchi, Laurent/0000-0003-2020-5831				Amendt C, 2002, J CELL SCI, V115, P2189; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Bechtel MJ, 1998, BRIT J DERMATOL, V138, P22; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Blomme EAG, 1999, J INVEST DERMATOL, V112, P788, DOI 10.1046/j.1523-1747.1999.00561.x; Bryant M, 2000, HUM GENE THER, V11, P2143, DOI 10.1089/104303400750001444; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Cole J, 2001, WOUND REPAIR REGEN, V9, P360, DOI 10.1046/j.1524-475x.2001.00360.x; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Darboux I, 1998, BIOCHEM BIOPH RES CO, V246, P210, DOI 10.1006/bbrc.1998.8183; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; Das A, 2006, J BIOL CHEM, V281, P39105, DOI 10.1074/jbc.M607720200; Didier G, 2002, BIOINFORMATICS, V18, P490, DOI 10.1093/bioinformatics/18.3.490; Dudoit S, 2000, Biostatistics, V1, P1, DOI 10.1093/biostatistics/1.1.1; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fathke C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-4; Feezor RJ, 2004, PHYSIOL GENOMICS, V16, P341, DOI 10.1152/physiolgenomics.00101.2003; Florin L, 2004, ONCOGENE, V23, P7005, DOI 10.1038/sj.onc.1207938; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Grose R, 2003, METH MOLEC MED, V78, P191; Harper EG, 2005, J CELL SCI, V118, P3471, DOI 10.1242/jcs.02475; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Ishida Y, 2004, J IMMUNOL, V172, P1848, DOI 10.4049/jimmunol.172.3.1848; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kampfer H, 2000, EUR CYTOKINE NETW, V11, P626; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; KER RMK, 2001, BIOSTATISTICS, V2, P183; Kurschat P, 2006, J BIOL CHEM, V281, P2721, DOI 10.1074/jbc.M507860200; Lan L, 2005, J INVEST DERMATOL, V124, P602, DOI 10.1111/j.0022-202X.2005.23620.x; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Li Y, 2006, J INVEST DERMATOL, V126, P2096, DOI 10.1038/sj.jid.5700350; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081; Lyu J, 2006, CORNEA, V25, pS24, DOI 10.1097/01.ico.0000247209.01262.4e; Mallipeddi R, 2002, CLIN EXP DERMATOL, V27, P616, DOI 10.1046/j.1365-2230.2002.01130.x; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Myagmar BE, 2005, BIOCHEM BIOPH RES CO, V329, P1046, DOI 10.1016/j.bbrc.2005.02.069; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Okuse T, 2005, WOUND REPAIR REGEN, V13, P491, DOI 10.1111/j.1067-1927.2005.00069.x; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Patel GK, 2006, J INVEST DERMATOL, V126, P497, DOI 10.1038/sj.jid.5700101; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; Reichelt J, 2004, J INVEST DERMATOL, V123, P973, DOI 10.1111/j.0022-202X.2004.23426.x; Reichelt J, 2001, MOL BIOL CELL, V12, P1557, DOI 10.1091/mbc.12.6.1557; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Richardson RJ, 2006, NAT GENET, V38, P1329, DOI 10.1038/ng1894; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Santos M, 2002, J BIOL CHEM, V277, P35371, DOI 10.1074/jbc.M205143200; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Sato M, 2006, ACTA DERM-VENEREOL, V86, P300, DOI 10.2340/00015555-0101; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; Steude J, 2002, J INVEST DERMATOL, V119, P1254, DOI 10.1046/j.1523-1747.2002.19616.x; Sulyok S, 2004, MOL CELL ENDOCRINOL, V225, P127, DOI 10.1016/j.mce.2004.07.011; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; Theilgaard-Monch K, 2004, J IMMUNOL, V172, P7684, DOI 10.4049/jimmunol.172.12.7684; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Turchi L, 2003, J INVEST DERMATOL, V121, P1291, DOI 10.1111/j.1523-1747.2003.12627.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uno K, 2004, BIOCHEM BIOPH RES CO, V315, P928, DOI 10.1016/j.bbrc.2004.01.146; Usui ML, 2005, WOUND REPAIR REGEN, V13, P468, DOI 10.1111/j.1067-1927.2005.00067.x; Wang T, 2007, BIOCHEM BIOPH RES CO, V352, P203, DOI 10.1016/j.bbrc.2006.11.006; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921	93	96	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15090	15102		10.1074/jbc.M606094200	http://dx.doi.org/10.1074/jbc.M606094200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363378	hybrid			2022-12-25	WOS:000246589000049
J	Lemieux, GA; Blumenkron, F; Yeung, N; Zhou, P; Williams, J; Grammer, AC; Petrovich, R; Lipsky, PE; Moss, ML; Werb, Z				Lemieux, George A.; Blumenkron, Fernando; Yeung, Nolan; Zhou, Pei; Williams, Jason; Grammer, Amrie C.; Petrovich, Robert; Lipsky, Peter E.; Moss, Marcia L.; Werb, Zena			The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RII; PRIMARY HUMAN MONOCYTES; SOLUBLE CD23; B-CELLS; PRECURSOR PROTEIN; FC-EPSILON-RII/CD23; DISEASE; CD11B; ACTIVATION; INHIBITION	The low affinity IgE receptor, Fc epsilon RII (CD23), is both a positive and negative regulator of IgE synthesis. The proteinase activity that converts the membrane-bound form of CD23 into a soluble species (sCD23) is an important regulator of the function of CD23 and may be an important therapeutic target for the control of allergy and inflammation. We have characterized the catalytic activity of ADAM (a disintegrin and metalloproteinase) 10 toward human CD23. We found that ADAM10 efficiently catalyzes the cleavage of peptides derived from two distinct cleavage sites in the CD23 backbone. Tissue inhibitors of metalloproteinases and a specific prodomain-based inhibitor of ADAM10 perturb the release of endogenously produced CD23 from human leukemia cell lines as well as primary cultures of human B-cells. Expression of a mutant metalloproteinase- deficient construct of ADAM10 partially inhibited the production of sCD23. Similarly, small inhibitory RNA knockdown of ADAM10 partially inhibited CD23 release and resulted in the accumulation of the membrane-bound form of CD23 on the cells. ADAM10 contributes to CD23 shedding and thus could be considered a potential therapeutic target for the treatment of allergic disease.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Cognosci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; NIAMS, B Cell Biol Grp, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; NIEHS, NIH, Durham, NC 27710 USA; BioZyme Inc, Apex, NC 27523 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Moss, ML (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	mmoss@biozyme-inc.com; zena.werb@ucsf.edu	Zhou, Pei/O-6704-2019	Zhou, Pei/0000-0002-7823-3416; Grammer, Amrie/0000-0001-7142-2284	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731, R01HL075602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101564, Z01ES102487] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL75602, R01 HL075602-01, HL07731, T32 HL007731, R01 HL075602] Funding Source: Medline; NIAID NIH HHS [P01 AI053194-01, P01 AI053194, AI053194] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Aubry JP, 1997, J IMMUNOL, V159, P614; BARTLETT WC, 1995, J IMMUNOL, V154, P4240; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BONEFOY JY, 1997, INT REV IMMUNOL, V16, P13; Christie G, 1997, EUR J IMMUNOL, V27, P3228, DOI 10.1002/eji.1830271221; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kilmon MA, 2001, J IMMUNOL, V167, P3139, DOI 10.4049/jimmunol.167.6.3139; LecoanetHenchoz S, 1997, EUR J IMMUNOL, V27, P2290, DOI 10.1002/eji.1830270924; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P19; LETELLIER M, 1989, MOL IMMUNOL, V26, P1105, DOI 10.1016/0161-5890(89)90054-0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Marolewski AE, 1998, BIOCHEM J, V333, P573, DOI 10.1042/bj3330573; Mayer RJ, 2000, CLIN EXP ALLERGY, V30, P719; MOSSALAYI MD, 1992, EMBO J, V1, P4323; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Rezzonico R, 2000, BLOOD, V95, P3868; Rezzonico R, 2001, BLOOD, V97, P2932, DOI 10.1182/blood.V97.10.2932; SANTAMARIA LF, 1993, HUM IMMUNOL, V37, P23, DOI 10.1016/0198-8859(93)90139-R; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Solomon KA, 1999, J IMMUNOL, V163, P4105; TEXIDO G, 1994, J IMMUNOL, V153, P3028; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; Weskamp G, 2006, NAT IMMUNOL, V7, P1293, DOI 10.1038/ni1399; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Williams J W, 1979, Methods Enzymol, V63, P437; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	45	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14836	14844		10.1074/jbc.M608414200	http://dx.doi.org/10.1074/jbc.M608414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389606	hybrid, Green Accepted			2022-12-25	WOS:000246589000019
J	Seki, A; Fang, GW				Seki, Akiko; Fang, Guowei			CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CYTOSKELETON-ASSOCIATED PROTEIN; CELL-CYCLE; PROTEOLYSIS; MITOSIS; CDC20; COMPLEX/CYCLOSOME; IDENTIFICATION; DEGRADATION; INHIBITION	We reported here an efficient and generally applicable genomic analysis that uses transcriptional profiling to identify candidate substrates of regulatory enzymes, such as kinases and ubiquitin ligases. We applied this strategy to the anaphase-promoting complex/cyclosome ( APC/C), a ubiquitin ligase that controls sister chromatid separation and exit from mitosis. We found that a microtubule-associated protein, CKAP2, is a substrate of APC/C and demonstrated that ubiquitination and degradation of CKAP2 in vitro require a KEN-box and is mediated by Cdh1, an activator of APC/C. We showed that the levels of CKAP2 fluctuated across the cell cycle in culture cells, high in mitosis and low during mitotic exit. Overexpression of Cdh1 reduced the levels of CKAP2 in a KEN-box-dependent manner, while knockdown of Cdh1 increased the half-life of CKAP2. CKAP2 associated with centrosomal microtubules in late G(2), but only after the separation of the duplicated centrosomes. During mitosis, CKAP2 associated with spindle poles and with spindle microtubules from prophase through anaphase and disappeared from microtubules during cytokinesis. The function of CKAP2 during mitosis does not seem essential, as efficient knockdown of CKAP2 neither altered the cell cycle distribution of the cells, nor generated observable mitotic defects. On the other hand, ectopic expression of either the wild-type or a non-degradable CKAP2 led to a mitotic arrest with monopolar spindles containing highly bundled microtubules. We concluded that CKAP2 is a physiological substrate of APC/C during mitotic exit and that a tight regulation of the CKAP2 protein level is critical for the normal mitotic progression.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Fang, GW (corresponding author), Stanford Univ, Dept Biol Sci, 337 Campus Dr,Lokey Bldg,Rm 137, Stanford, CA 94305 USA.	gwfang@stanford.edu			NIGMS NIH HHS [GM062852] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062852] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae CD, 2003, J CANCER RES CLIN, V129, P621, DOI 10.1007/s00432-003-0484-0; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Ciechanover A, 2005, ANGEW CHEM INT EDIT, V44, P5944, DOI 10.1002/anie.200501428; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1999, PHILOS T ROY SOC B, V354, P1583, DOI 10.1098/rstb.1999.0502; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Jeon SM, 2006, BIOCHEM BIOPH RES CO, V348, P222, DOI 10.1016/j.bbrc.2006.07.046; Jin Y, 2004, CANCER SCI, V95, P815, DOI 10.1111/j.1349-7006.2004.tb02187.x; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Maouche-Chretien L, 1998, ONCOGENE, V17, P1245, DOI 10.1038/sj.onc.1202048; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Stewart S, 2005, MOL CELL BIOL, V25, P10516, DOI 10.1128/MCB.25.23.10516-10527.2005; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Stroschein SL, 2001, GENE DEV, V15, P2822; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Tsuchihara K, 2005, CANCER RES, V65, P6685, DOI 10.1158/0008-5472.CAN-04-4223; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200	34	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15103	15113		10.1074/jbc.M701688200	http://dx.doi.org/10.1074/jbc.M701688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376772	hybrid			2022-12-25	WOS:000246589000050
J	Zhu, H; Toso, R; Camire, RM				Zhu, Hua; Toso, Raffaella; Camire, Rodney M.			Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; COAGULATION-FACTOR-V; BOVINE FACTOR-V; FACTOR-XA; FACTOR-VIII; CLEAVAGE REQUIREMENTS; PROTHROMBIN ACTIVATOR; ELECTRON-MICROSCOPY; BLOOD-COAGULATION; COFACTOR FUNCTION	Blood coagulation factor V circulates as a procofactor with little or no procoagulant activity. It is activated to factor Va by thrombin following proteolytic removal of a large central B-domain. Although this reaction is well studied, the mechanism by which bond cleavage and B-domain release facilitate the transition to the active cofactor state has not been defined. Here we show that deletion or substitution of specific B-domain sequences drives the expression of procoagulant function without the need for proteolytic processing. Conversion to the constitutively active cofactor state is related, at least in part, to a cluster of amino acids that is highly basic and well conserved across the vertebrate lineage. Our findings demonstrate that discrete sequences in the B-domain serve to stabilize the inactive procofactor state, with proteolysis primarily functioning to remove these inhibitory constraints. These unexpected results provide new insight into the mechanism of factor V activation.	Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, 302E Abramson Res Ctr,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, T32HL007439] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL-07439-26, P01 HL-74124-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2004, P NATL ACAD SCI USA, V101, P8918, DOI 10.1073/pnas.0403072101; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Davidson CJ, 2003, J THROMB HAEMOST, V1, P1487, DOI 10.1046/j.1538-7836.2003.00334.x; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; ESMON CT, 1979, J BIOL CHEM, V254, P964; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOSTER WB, 1983, J BIOL CHEM, V258, P5608; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Gomori G, 1942, J LAB CLIN MED, V27, P955; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P7527, DOI 10.1073/pnas.0932632100; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KANE WH, 1981, J BIOL CHEM, V256, P1002; KANE WH, 2006, HEMOSTASIS THROMBOSI, P177; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Khan AR, 1999, P NATL ACAD SCI USA, V96, P10968, DOI 10.1073/pnas.96.20.10968; Khan AR, 1998, PROTEIN SCI, V7, P815; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; Le TNM, 2005, THROMB HAEMOSTASIS, V93, P420, DOI 10.1160/TH040-11-0707; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; MARQUETTE KA, 1995, BLOOD, V86, P3026; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Pierre LS, 2005, MOL BIOL EVOL, V22, P1853, DOI 10.1093/molbev/msi181; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; Rao VS, 2003, BLOOD, V102, P1347, DOI 10.1182/blood-2002-12-3839; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; Toso R, 2006, J BIOL CHEM, V281, P8773, DOI 10.1074/jbc.M511419200; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VOS HL, 2005, J THROMB HAEMOST, V3	58	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15033	15039		10.1074/jbc.M701315200	http://dx.doi.org/10.1074/jbc.M701315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387173	hybrid			2022-12-25	WOS:000246589000042
J	Guan, LJ; Song, K; Pysz, MA; Curry, KJ; Hizli, AA; Danielpour, D; Black, AR; Black, JD				Guan, Lingjie; Song, Kyung; Pysz, Marybeth A.; Curry, Kathryn J.; Hizli, A. Asli; Danielpour, David; Black, Adrian R.; Black, Jennifer D.			Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-Kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CAP-DEPENDENT INITIATION; INDUCED AKT ACTIVATION; PROSTATE-CANCER CELLS; MESSENGER-RNA; INDUCED APOPTOSIS; OXIDATIVE STRESS; S6 KINASE; TYROSINE PHOSPHORYLATION; 4E-BINDING PROTEIN-1; (S/T)P SITES	We reported previously that protein kinase C alpha (PKC alpha), a negative regulator of cell growth in the intestinal epithelium, inhibits cyclin D1 translation by inducing hypophosphorylation/ activation of the translational repressor 4E-BP1. The current study explores the molecular mechanisms underlying PKC/PKC alpha-induced activation of 4E-BP1 in IEC-18 nontransformed rat ileal crypt cells. PKC signaling is shown to promote dephosphorylation of Thr(45) and Ser(64) on 4E-BP1, residues directly involved in its association with eIF4E. Consistent with the known role of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway in regulation of 4E-BP1, PKC signaling transiently inhibited PI3K activity and Akt phosphorylation in IEC-18 cells. However, PKC/PKC alpha-induced activation of 4E-BP1 was not prevented by constitutively active mutants of PI3K or Akt, indicating that blockade of PI3K/ Akt signaling is not the primary effector of 4E-BP1 activation. This idea is supported by the fact that PKC activation did not alter S6 kinase activity in these cells. Further analysis indicated that PKC-mediated 4E-BP1 hypophosphorylation is dependent on the activity of protein phosphatase 2A (PP2A). PKC signaling induced an similar to 2-fold increase in PP2A activity, and phosphatase inhibition blocked the effects of PKC agonists on 4E-BP1 phosphorylation and cyclin D1 expression. H2O2 and ceramide, two naturally occurring PKC alpha agonists that promote growth arrest in intestinal cells, activate 4E-BP1 in PKC/PKC alpha-dependent manner, supporting the physiological significance of the findings. Together, our studies indicate that activation of PP2A is an important mechanism underlying PKC/PKC alpha-induced inhibition of cap-dependent translation and growth suppression in intestinal epithelial cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Res Labs, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Case Western Reserve University; Case Western Reserve University	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org		HIZLI DENIZ, AYSEN ASLI/0000-0003-0490-7737	NATIONAL CANCER INSTITUTE [F32CA113048, P30CA016056, R01CA102074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060632, R01DK054909, R56DK060632] Funding Source: NIH RePORTER; NCI NIH HHS [CA102074, CA16056, CA113048] Funding Source: Medline; NIDDK NIH HHS [DK60632, DK54909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdala-Valencia H, 2006, J IMMUNOL, V177, P6379, DOI 10.4049/jimmunol.177.9.6379; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvi F, 2007, CELL MOL LIFE SCI, V64, P263, DOI 10.1007/s00018-006-6363-5; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Aschrafi A, 2003, BBA-MOL CELL BIOL L, V1634, P30, DOI 10.1016/j.bbalip.2003.08.004; Awasthi S, 2001, AM J PHYSIOL-LUNG C, V281, pL108, DOI 10.1152/ajplung.2001.281.1.L108; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cerbon J, 2003, BIOCHEM J, V373, P917, DOI 10.1042/BJ20021732; Chen CL, 2006, MOL PHARMACOL, V70, P510, DOI 10.1124/mol.106.024059; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Engler JA, 1999, DIGEST DIS SCI, V44, P1902, DOI 10.1023/A:1018815327769; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Giron-Calle J, 2002, J PHARMACOL EXP THER, V301, P87, DOI 10.1124/jpet.301.1.87; Gotoh Y, 2002, CELL PROLIFERAT, V35, P221, DOI 10.1046/j.1365-2184.2002.00241.x; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907; Nien WL, 2007, MOL CELL ENDOCRINOL, V263, P10, DOI 10.1016/j.mce.2006.08.015; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Palmantier R, 2001, CANCER RES, V61, P2445; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Ragolia L, 2003, AM J PHYSIOL-CELL PH, V284, pC119, DOI 10.1152/ajpcell.00247.2002; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Samari HR, 2005, BIOCHEM J, V386, P237, DOI 10.1042/BJ20040609; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Schmelz EM, 1999, CANCER RES, V59, P5768; Selzner M, 2001, CANCER RES, V61, P1233; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; Sipeki S, 2006, BIOCHEM BIOPH RES CO, V339, P122, DOI 10.1016/j.bbrc.2005.10.194; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Sun M, 2001, CANCER RES, V61, P5985; TAHER MM, 1993, ARCH BIOCHEM BIOPHYS, V303, P260, DOI 10.1006/abbi.1993.1281; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Weigel G, 1997, THROMB RES, V87, P363, DOI 10.1016/S0049-3848(97)00140-0; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zhou CX, 2003, MOL CANCER THER, V2, P789	115	66	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14213	14225		10.1074/jbc.M610513200	http://dx.doi.org/10.1074/jbc.M610513200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360714	hybrid			2022-12-25	WOS:000246245800032
J	Makino, Y; Uenishi, R; Okamoto, K; Isoe, T; Hosono, O; Tanaka, H; Kanopka, A; Poellinger, L; Haneda, M; Morimoto, C				Makino, Yuichi; Uenishi, Rie; Okamoto, Kensaku; Isoe, Tsubasa; Hosono, Osamu; Tanaka, Hirotoshi; Kanopka, Arvydas; Poellinger, Lorenz; Haneda, Masakazu; Morimoto, Chikao			Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1) - A negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; FACTOR-I; T-CELLS; ALPHA; HYDROXYLATION; IDENTIFICATION; HIF-1-ALPHA; MECHANISMS; RESPONSES	The inhibitory PAS (Per/Arnt/Sim) domain protein (IPAS), a dominant negative regulator of hypoxia-inducible transcription factors (HIFs), is potentially implicated in negative regulation of angiogenesis in such tissues as the avascular cornea of the eye. We have previously shown IPAS mRNA expression is up-regulated in hypoxic tissues, which at least in part involves hypoxia-dependent alternative splicing of the transcripts from the IPAS/HIF-3 alpha locus. In the present study, we demonstrate that a hypoxia-driven transcriptional mechanism also plays a role in augmentation of IPAS gene expression. Isolation and analyses of the promoter region flanking to the first exon of IPAS gene revealed a functional hypoxia response element at position -834 to -799, whereas the sequence upstream of the HIF-3 alpha first exon scarcely responded to hypoxic stimuli. A transient transfection experiment demonstrated that HIF-1 alpha mediates IPAS promoter activation via the functional hypoxia response element under hypoxic conditions and that a constitutively active form of HIF-1 alpha is sufficient for induction of the promoter in normoxic cells. Moreover, chromatin immunoprecipitation and electrophoretic mobility shift assays showed binding of the HIF-1 complex to the element in a hypoxia-dependent manner. Taken together, HIF-1 directly up-regulates IPAS gene expression through a mechanism distinct from RNA splicing, providing a further level of negative feedback gene regulation in adaptive responses to hypoxic/ischemic conditions.	Asahikawa Med Coll, Dept Internal Med, Sect Metab & Biosyst Sci, Asahikawa, Hokkaido 0788510, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Inst Biotechnol, LT-2028 Vilnius, Lithuania; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Asahikawa Medical College; University of Tokyo; Japan Science & Technology Agency (JST); Vilnius University; Karolinska Institutet	Makino, Y (corresponding author), Asahikawa Med Coll, Dept Internal Med, Sect Metab & Biosyst Sci, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	makino@asahikawa-med.ac.jp						Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jelkmann W, 2003, J ENDOCRINOL INVEST, V26, P832, DOI 10.1007/BF03345232; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Makino Y, 2003, J IMMUNOL, V171, P6534, DOI 10.4049/jimmunol.171.12.6534; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P845; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang RS, 2006, FASEB J, V20, P1275, DOI 10.1096/fj.06-5839fje	42	85	89	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14073	14082		10.1074/jbc.M700732200	http://dx.doi.org/10.1074/jbc.M700732200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355974	hybrid			2022-12-25	WOS:000246245800017
J	Yan, Q; Liu, WB; Qin, JC; Liu, JP; Chen, HG; Huang, XQ; Chen, LL; Sun, SM; Deng, M; Gong, LL; Li, Y; Zhang, L; Liu, Y; Feng, H; Xiao, YM; Liu, Y; Li, DWC				Yan, Qin; Liu, Wen-Bin; Qin, Jichao; Liu, Jinping; Chen, He-Ge; Huang, Xiaoqin; Chen, Lili; Sun, Shuming; Deng, Mi; Gong, Lili; Li, Yong; Zhang, Lan; Liu, Yan; Feng, Hao; Xiao, Yamei; Liu, Yun; Li, David W. -C.			Protein phosphatase-1 modulates the function of Pax-6, a transcription factor controlling brain and eye development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; ALPHA-A-CRYSTALLIN; INDUCED APOPTOSIS; GENE-EXPRESSION; EYELESS GENE; MOUSE LENS; INDUCTION; PHOSPHORYLATION; TRANSACTIVATION; DROSOPHILA	Pax-6 is an evolutionarily conserved transcription factor and acts high up in the regulatory hierarchy controlling eye and brain development in humans, mice, zebrafish, and Drosophila. Previous studies have shown that Pax-6 is a phosphoprotein, and its phosphorylation by ERK, p38, and homeodomain-interacting protein kinase 2 greatly enhances its transactivation activity. However, the protein phosphatases responsible for the dephosphorylation of Pax-6 remain unknown. Here, we present both in vitro and in vivo evidence to show that protein serine/threonine phosphatase-1 is a major phosphatase that directly dephosphorylates Pax-6. First, purified protein phosphatase-1 directly dephosphorylates Pax-6 in vitro. Second, immunoprecipitation-linked Western blot revealed that both protein phosphatase-1 alpha and protein phosphatase-1 alpha interact with Pax-6. Third, overexpression of protein phosphatase-1 in human lens epithelial cells leads to dephosphorylation of Pax-6. Finally, inhibition of protein phosphatase-1 activity by calyculin A or knockdown of protein phosphatase-1 alpha and protein phosphatase-1 alpha by RNA interference leads to enhanced phosphorylation of Pax-6. Moreover, our results also demonstrate that dephosphorylation of Pax-6 by protein phosphatase-1 significantly modulates its function in regulating expression of both exogenous and endogenous genes. These results demonstrate that protein phosphatase 1 acts as a major phosphatase to dephosphorylate Pax-6 and modulate its function.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA; Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Hunan Normal University	Li, DWC (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	dwli1688@hotmail.com	chen, hege/GYV-5810-2022; Gong, Lili/F-8452-2014; Yan, Qin/F-5161-2012; Li, David/AAN-9205-2021; liu, wen/HGE-3071-2022; Yan, Qin/K-3539-2013; Deng, Mi/K-8699-2012	Gong, Lili/0000-0002-6533-5333; Yan, Qin/0000-0002-6344-6398; Deng, Mi/0000-0003-4291-0144; Qin, Jichao/0000-0002-2961-7624	NEI NIH HHS [R01 EY015765, R01 EY15765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bastians H, 1996, J CELL SCI, V109, P2865; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chauhan BK, 2002, J BIOL CHEM, V277, P11539, DOI 10.1074/jbc.M110531200; Chauhan BK, 2002, GENES CELLS, V7, P1267, DOI 10.1046/j.1365-2443.2002.00602.x; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; Davis JA, 1996, J NEUROSCI, V16, P5082; Dellovade TL, 1998, J COMP NEUROL, V402, P402; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Duncan MK, 2000, INVEST OPHTH VIS SCI, V41, P464; Duncan MK, 2000, J CELL SCI, V113, P3173; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Grogg MW, 2005, NATURE, V438, P858, DOI 10.1038/nature04175; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kim EA, 2006, J BIOL CHEM, V281, P7489, DOI 10.1074/jbc.M507227200; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Krucher NA, 2006, EXP CELL RES, V312, P2757, DOI 10.1016/j.yexcr.2006.05.002; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; LI WC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015; Mallick BN, 2000, J NEUROCHEM, V74, P1574, DOI 10.1046/j.1471-4159.2000.0741574.x; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Zygar CA, 1998, DEVELOPMENT, V125, P3509	49	42	48	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13954	13965		10.1074/jbc.M611476200	http://dx.doi.org/10.1074/jbc.M611476200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374606	hybrid			2022-12-25	WOS:000246245800005
J	Gardsvoll, H; Ploug, M				Gardsvoll, Henrik; Ploug, Michael			Mapping of the vitronectin-binding site on the urokinase receptor - Involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; LIGAND-BINDING; CELL-ADHESION; COMBINATORIAL CHEMISTRY; FUNCTIONAL EPITOPE; ANTHRAX TOXIN; PEPTIDE; IDENTIFICATION; MUTAGENESIS; POTENTIATION	The urokinase-type plasminogen activator receptor (uPAR) has been implicated as a modulator of several biochemical processes that are active during tumor invasion and metastasis, e. g. extracellular proteolysis, cell adhesion, and cell motility. The structural basis for the high affinity interaction between the urokinase-type plasminogen activator (uPA) and uPAR, which focuses cell surface-associated plasminogen activation in vivo, is now thoroughly characterized by site- directed mutagenesis studies and x-ray crystallography. In contrast, the structural basis for the interaction between uPAR and the extracellular matrix protein vitronectin, which is involved in the regulation of cell adhesion and motility, remains to be clarified. In this study, we have identified the functional epitope on uPAR that is responsible for its interaction with the full-length, extended form of vitronectin by using a comprehensive alanine-scanning library of purified single-site uPAR mutants (244 positions tested). Interestingly, the five residues identified as "hot spots" for vitronectin binding form a contiguous epitope consisting of two exposed loops connecting the central four-stranded beta-sheet in uPAR domain I (Trp(32), Arg(58), and Ile(63)) as well as a proximal region of the flexible linker peptide connecting uPAR domains I and II (Arg(91) and Tyr(92)). This binding topology provides the molecular basis for the observation that uPAR can form a ternary complex with uPA and vitronectin. Furthermore, it raises the intriguing possibility that the canonical receptor and inhibitor for uPA (uPAR and PAI-1) may have reached a convergent solution for binding to the somatomedin B domain of vitronectin.	Rigshosp, Finsen Lab, Copenhagen Bioctr, DK-2200 Copenhagen N, Denmark	Rigshospitalet	Ploug, M (corresponding author), Rigshosp, Finsen Lab, Copenhagen Bioctr, Bldg 3,3rd Floor,Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark.	m-ploug@finsenlab.dk		Ploug, Michael/0000-0003-2215-4265				Barinka C, 2006, J MOL BIOL, V363, P482, DOI 10.1016/j.jmb.2006.08.063; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Bolon I, 2004, AM J PATHOL, V164, P2299, DOI 10.1016/S0002-9440(10)63786-8; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; Gardsvoll H, 2007, PROTEIN EXPRES PURIF, V52, P384, DOI 10.1016/j.pep.2006.11.013; Gardsvoll H, 2006, J BIOL CHEM, V281, P19260, DOI 10.1074/jbc.M513583200; Gargiulo L, 2005, J BIOL CHEM, V280, P25225, DOI 10.1074/jbc.M412605200; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Jacobsen B, 2007, PROTEIN EXPRES PURIF, V52, P286, DOI 10.1016/j.pep.2006.08.011; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Jorgensen TJD, 2004, BIOCHEMISTRY-US, V43, P15044, DOI 10.1021/bi048706j; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Li Y, 2003, J BIOL CHEM, V278, P29925, DOI 10.1074/jbc.M300751200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Romer J, 2004, CURR PHARM DESIGN, V10, P2359, DOI 10.2174/1381612043383962; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	49	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13561	13572		10.1074/jbc.M610184200	http://dx.doi.org/10.1074/jbc.M610184200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355965	hybrid			2022-12-25	WOS:000246060300045
J	Mirza, M; Robinson, P; Kremneva, E; Copeland, O; Nikolaeva, O; Watkins, H; Levitsky, D; Redwood, C; EL-Mezgueldi, M; Marston, S				Mirza, Mahmooda; Robinson, Paul; Kremneva, Elena; Copeland, O'neal; Nikolaeva, Olga; Watkins, Hugh; Levitsky, Dimitry; Redwood, Charles; EL-Mezgueldi, Mohammed; Marston, Steven			The effect of mutations in alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy on the regulatory mechanism of cardiac muscle thin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CARDIOMYOPATHY; ACTIN-FILAMENTS; SMOOTH-MUSCLE; SKELETAL; MYOSIN; SUBFRAGMENT-1; SEPARATION; ASP175ASN; STATES; GENES	E40K and E54K mutations in alpha-tropomyosin cause inherited dilated cardiomyopathy. Previously we showed, using Ala-Ser alpha-tropomyosin (AS-alpha-Tm) expressed in Escherichia coli, that both mutations decrease Ca2+ sensitivity. E40K also reduces V-max of actin-Tm-activated S-1 ATPase by 18%. We investigated cooperative allosteric regulation by native Tm, AS-alpha-Tm, and the two dilated cardiomyopathy-causing mutants. AS-alpha-Tm has a lower cooperative unit size (6.5) than native-alpha-tropomyosin (10.0). The E40K mutation reduced the size of the cooperative unit to 3.7, whereas E54K increased it to 8.0. For the equilibrium between On and Off states, the K-T value was the same for all actin-Tm species; however, the K-T value of actin-Tm-troponin at pCa 5 was 50% less for AS-alpha-Tm E40K than for AS-alpha-Tm and AS-alpha-Tm E54K. K-b, the "closed" to "blocked" equilibrium constant, was the same for all tropomyosin species. The E40K mutation reduced the affinity of tropomyosin for actin by 1.74-fold, but only when in the On state (in the presence of S-1). In contrast the E54K mutation reduced affinity by 3.5-fold only in the Off state. Differential scanning calorimetry measurements of AS-alpha-Tm showed that domain 3, assigned to the N terminus of tropomyosin, was strongly destabilized by both mutations. Additionally with AS-alpha-Tm E54K, we observed a unique new domain at 55 degrees C accounting for 25% of enthalpy indicating stabilization of part of the tropomyosin. The disease-causing mechanism of the E40K mutation may be accounted for by destabilization of the On state of the thin filaments; however, the E54K mutation has a more complex effect on tropomyosin structure and function.	Imperial Coll London, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Oxford, Dept Cardiovasc Med, Oxford OX3 7BN, England; Russian Acad Sci, AN Bach Inst Biochem, Moscow 119071, Russia; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Imperial College London; University of Leicester; University of Oxford; Research Center of Biotechnology RAS; Russian Academy of Sciences; Lomonosov Moscow State University	Marston, S (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.marston@imperial.ac.uk		Watkins, Hugh/0000-0002-5287-9016	British Heart Foundation [RG/07/012/24110] Funding Source: Medline; Wellcome Trust Funding Source: Medline	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Ansari S, 2003, J MUSCLE RES CELL M, V24, P513, DOI 10.1023/B:JURE.0000009812.74980.13; BAILEY K, 1948, BIOCHEM J, V43, P271, DOI 10.1042/bj0430271; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Chang AN, 2005, J BIOL CHEM, V280, P34343, DOI 10.1074/jbc.M505014200; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Greenfield NJ, 2003, BIOCHEMISTRY-US, V42, P614, DOI 10.1021/bi026989e; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; Heller MJ, 2003, J BIOL CHEM, V278, P41742, DOI 10.1074/jbc.M303408200; Hilario E, 2004, EUR J BIOCHEM, V271, P4132, DOI 10.1111/j.1432-1033.2004.04351.x; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Kremneva E, 2006, FEBS J, V273, P588, DOI 10.1111/j.1742-4658.2005.05092.x; Kremneva E, 2004, BIOPHYS J, V87, P3922, DOI 10.1529/biophysj.104.048793; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Levitsky DI, 2000, EUR J BIOCHEM, V267, P1869, DOI 10.1046/j.1432-1327.2000.01192.x; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2003, J BIOL CHEM, V278, P6696, DOI 10.1074/jbc.M210690200; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Messer AE, 2007, J MOL CELL CARDIOL, V42, P247, DOI 10.1016/j.yjmcc.2006.08.017; Mirza M, 2005, J BIOL CHEM, V280, P28498, DOI 10.1074/jbc.M412281200; Mogensen J, 2004, J AM COLL CARDIOL, V44, P2033, DOI 10.1016/j.jacc.2004.08.027; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; ROBINSON P, 2007, BIOPHYS J, V91, P362; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; STEWART M, 1975, NATURE, V257, P331, DOI 10.1038/257331a0; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WU B, 1997, BIOCHEM BIOPH RES CO, V236, P760	43	63	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13487	13497		10.1074/jbc.M701071200	http://dx.doi.org/10.1074/jbc.M701071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360712	hybrid			2022-12-25	WOS:000246060300038
J	Schacherer, J; Ruderfer, DM; Gresham, D; Dolinski, K; Botstein, D; Kruglyak, L				Schacherer, Joseph; Ruderfer, Douglas M.; Gresham, David; Dolinski, Kara; Botstein, David; Kruglyak, Leonid			Genome-Wide Analysis of Nucleotide-Level Variation in Commonly Used Saccharomyces cerevisiae Strains	PLOS ONE			English	Article								Ten years have passed since the genome of Saccharomyces cerevisiae-more precisely, the S288c strain-was completely sequenced. However, experimental work in yeast is commonly performed using strains that are of unknown genetic relationship to S288c. Here, we characterized the nucleotide-level similarity between S288c and seven commonly used lab strains (A364A, W303, FL100, CEN.PK, Sigma 1278b, SK1 and BY4716) using 25mer oligonucleotide microarrays that provide complete and redundant coverage of the similar to 12 Mb Saccharomyces cerevisiae genome. Using these data, we assessed the frequency and distribution of nucleotide variation in comparison to the sequenced reference genome. These data allow us to infer the relationships between experimentally important strains of yeast and provide insight for experimental designs that are sensitive to sequence variation. We propose a rational approach for near complete sequencing of strains related to the reference using these data and directed re-sequencing. These data and new visualization tools are accessible online in a new resource: the Yeast SNPs Browser (YSB; http://gbrowse.princeton.edu/cgi-bin/gbrowse/yeast_strains_snps) that is available to all researchers.	[Schacherer, Joseph; Ruderfer, Douglas M.; Gresham, David; Dolinski, Kara; Botstein, David; Kruglyak, Leonid] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Schacherer, Joseph; Ruderfer, Douglas M.; Kruglyak, Leonid] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA; [Gresham, David; Dolinski, Kara; Botstein, David] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Kruglyak, L (corresponding author), Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.	leonid@genomics.princeton.edu	Ruderfer, Douglas M/M-5795-2016; Dolinski, Kara/GPP-4026-2022	Ruderfer, Douglas M/0000-0002-2365-386X; Dolinski, Kara/0000-0002-7010-0264	National Institute of General Medical Sciences [R01 GM046406, P50 GM071508]; NIH [R37 MH059520]; James S. McDonnell Foundation [99-11T]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046406, P50GM071508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059520] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S. McDonnell Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by National Institute of General Medical Sciences grant R01 GM046406 and center grant P50 GM071508 (D. B.), NIH grant R37 MH059520 and James S. McDonnell Foundation grant 99-11T (L. K.).	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Ben-Ari G, 2006, PLOS GENET, V2, P1815, DOI 10.1371/journal.pgen.0020195; Brachmann CB, 1998, YEAST, V14, P115; CHARRON MJ, 1986, MOL CELL BIOL, V6, P3891, DOI 10.1128/MCB.6.11.3891; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Deutschbauer AM, 2005, NAT GENET, V37, P1333, DOI 10.1038/ng1674; Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1016/S1567-1356(02)00133-2; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; Gresham D, 2006, SCIENCE, V311, P1932, DOI 10.1126/science.1123726; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; Huang SB, 2005, P NATL ACAD SCI USA, V102, P13410, DOI 10.1073/pnas.0506176102; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; Liti G, 2005, YEAST, V22, P177, DOI 10.1002/yea.1200; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; LOUIS EJ, 1990, GENETICS, V124, P533; MORTIMER RK, 1986, GENETICS, V113, P35; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; Stein LD, 2002, GENOME RES, V12, P1599, DOI 10.1101/gr.403602; THOMAS BJ, 1989, GENETICS, V123, P725; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; Winzeler EA, 2003, GENETICS, V163, P79; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu H, 2004, MOL CELL BIOL, V24, P7082, DOI 10.1128/MCB.24.16.7082-7090.2004	34	84	88	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2007	2	3							e322	10.1371/journal.pone.0000322	http://dx.doi.org/10.1371/journal.pone.0000322			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DR	17389913	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445200005
J	Hsiao, CD; You, MS; Guh, YJ; Ma, M; Jiang, YJ; Hwang, PP				Hsiao, Chung-Der; You, May-Su; Guh, Ying-Jey; Ma, Ming; Jiang, Yun-Jin; Hwang, Pung-Pung			A Positive Regulatory Loop between foxi3a and foxi3b Is Essential for Specification and Differentiation of Zebrafish Epidermal Ionocytes	PLOS ONE			English	Article							TRANSCRIPTION FACTOR FOXI1; BRANCHIAL CHLORIDE CELLS; MITOCHONDRIA-RICH CELLS; ACID-BASE REGULATION; XENOPUS-EMBRYOS; DANIO-RERIO; SOMITE DEVELOPMENT; NEURAL INDUCTION; NOTCH LIGANDS; JAGGED GENES	Background. Epidermal ionocytes play essential roles in the transepithelial transportation of ions, water, and acid-base balance in fish embryos before their branchial counterparts are fully functional. However, the mechanism controlling epidermal ionocyte specification and differentiation remains unknown. Methodology/Principal Findings. In zebrafish, we demonstrated that Delta-Notch-mediated lateral inhibition plays a vital role in singling out epidermal ionocyte progenitors from epidermal stem cells. The entire epidermal ionocyte domain of genetic mutants and morphants, which failed to transmit the DeltaC-Notch1a/Notch3 signal from sending cells (epidermal ionocytes) to receiving cells (epidermal stem cells), differentiates into epidermal ionocytes. The low Notch activity in epidermal ionocyte progenitors is permissive for activating winged helix/forkhead box transcription factors of foxi3a and foxi3b. Through gain-and loss-of-function assays, we show that the foxi3a-foxi3b regulatory loop functions as a master regulator to mediate a dual role of specifying epidermal ionocyte progenitors as well as of subsequently promoting differentiation of Na+,K+-ATPase-rich cells and H+-ATPase-rich cells in a concentration-dependent manner. Conclusions/Significance. This study provides a framework to show the molecular mechanism controlling epidermal ionocyte specification and differentiation in a low vertebrate for the first time. We propose that the positive regulatory loop between foxi3a and foxi3b not only drives early ionocyte differentiation but also prevents the complete blockage of ionocyte differentiation when the master regulator of foxi3 function is unilaterally compromised.	[Hsiao, Chung-Der; You, May-Su; Ma, Ming; Jiang, Yun-Jin] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Hsiao, Chung-Der; Guh, Ying-Jey; Hwang, Pung-Pung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; [Guh, Ying-Jey] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Academia Sinica - Taiwan; National Defense Medical Center	Jiang, YJ (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 10 Kent Ridge Crescent, Singapore 117548, Singapore.	yjjiang@imcb.a-star.edu.sg; pphwang@gate.sinica.edu.tw	Jiang, Yun-Jin/E-3995-2010; MA, MING/E-7811-2012; Hsiao, Chung-Der/W-4535-2019; Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022; hwang, pp/A-3641-2011	Jiang, Yun-Jin/0000-0003-0499-7306; Hsiao, Chung-Der/0000-0002-6398-8672; 	Academia Sinica; National Science Council	Academia Sinica(Academia Sinica - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan)	Visiting scientist schloarship from A-Star and distinguished postdoctoral schloarship from Academia Sinica to CDH; grants from National Science Council and Academia Sinica to PPH.	Ackermann GE, 2003, FRONT BIOSCI-LANDMRK, V8, pD1227, DOI 10.2741/1092; Al-Awqati Q, 2004, J CLIN INVEST, V113, P1528, DOI 10.1172/JCI200422029; Appel B, 1998, DEVELOPMENT, V125, P371; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; Blomqvist SR, 2004, J CLIN INVEST, V113, P1560, DOI 10.1172/JCI200420665; Briggs JP, 2002, AM J PHYSIOL-REG I, V282, pR3, DOI 10.1152/ajpregu.00589.2001; Canfield VA, 2002, MECH DEVELOP, V116, P51, DOI 10.1016/S0925-4773(02)00135-1; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chang IC, 2001, PHYSIOL BIOCHEM ZOOL, V74, P111, DOI 10.1086/319304; Chen E, 2004, CURR PHARM BIOTECHNO, V5, P409, DOI 10.2174/1389201043376652; COULY G, 1990, DEVELOPMENT, V108, P543; Crosnier C, 2005, DEVELOPMENT, V132, P1093, DOI 10.1242/dev.01644; Dang ZC, 2000, J EXP BIOL, V203, P379; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Deblandre GA, 1999, DEVELOPMENT, V126, P4715; Dornseifer P, 1997, MECH DEVELOP, V63, P159, DOI 10.1016/S0925-4773(97)00037-3; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; GHYSEN A, 1993, BIOESSAYS, V15, P293, DOI 10.1002/bies.950150502; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; GRECO AM, 1995, J EXP BIOL, V198, P2557; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Haddon C, 1998, DEVELOPMENT, V125, P4637; Hans S, 2004, DEVELOPMENT, V131, P5091, DOI 10.1242/dev.01346; Hansen A, 2002, DEV DYNAM, V223, P483, DOI 10.1002/dvdy.10074; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Herzog W, 2003, DEV BIOL, V254, P36, DOI 10.1016/S0012-1606(02)00124-0; Hiroi J, 2005, J EXP BIOL, V208, P2023, DOI 10.1242/jeb.01611; Hsiao CD, 2002, MECH DEVELOP, V119, pS161, DOI 10.1016/S0925-4773(03)00110-2; Hulander M, 2003, DEVELOPMENT, V130, P2013, DOI 10.1242/dev.00376; HWANG PP, 1985, J EXP ZOOL, V236, P115, DOI 10.1002/jez.1402360202; Imai Y, 2001, GENESIS, V30, P160, DOI 10.1002/gene.1055; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jiang YJ, 1996, DEVELOPMENT, V123, P205; Julich D, 2005, DEV BIOL, V286, P391, DOI 10.1016/j.ydbio.2005.06.040; Kaneko T, 2002, FISHERIES SCI, V68, P1, DOI 10.1046/j.1444-2906.2002.00382.x; Katoh F, 2003, J EXP BIOL, V206, P793, DOI 10.1242/jeb.00159; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kiernan AE, 2005, DEVELOPMENT, V132, P4353, DOI 10.1242/dev.02002; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kotrschal K, 1997, CHEM SENSES, V22, P111, DOI 10.1093/chemse/22.2.111; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Lantz KA, 2005, CLIN SCI, V108, P195, DOI 10.1042/CS20040309; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244; Lin LY, 2006, AM J PHYSIOL-CELL PH, V290, pC371, DOI 10.1152/ajpcell.00281.2005; Lorent K, 2004, DEVELOPMENT, V131, P5753, DOI 10.1242/dev.01411; Ma M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030018; Matsuda Y, 2005, DEVELOPMENT, V132, P2783, DOI 10.1242/dev.01853; Matsuo-Takasaki M, 2005, DEVELOPMENT, V132, P3885, DOI 10.1242/dev.01959; Pan TC, 2005, AM J PHYSIOL-REG I, V289, pR1202, DOI 10.1152/ajpregu.00816.2004; Perry SF, 2003, J EXP ZOOL PART A, V300A, P53, DOI 10.1002/jez.a.10309; Perry SF, 1998, COMP BIOCHEM PHYS A, V119, P9, DOI 10.1016/S1095-6433(97)00411-X; Pujic Z, 2006, DEV BIOL, V293, P330, DOI 10.1016/j.ydbio.2005.12.056; Read EM, 1998, INT J DEV BIOL, V42, P763; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sakuragui MM, 2003, J COMP PHYSIOL B, V173, P309, DOI 10.1007/s00360-003-0337-9; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schier AF, 1996, DEVELOPMENT, V123, P165; Smithers L, 2000, MECH DEVELOP, V90, P119, DOI 10.1016/S0925-4773(99)00231-2; Solomon KS, 2003, DEV DYNAM, V228, P301, DOI 10.1002/dvdy.10373; Solomon KS, 2003, DEVELOPMENT, V130, P929, DOI 10.1242/dev.00308; Song HD, 2004, P NATL ACAD SCI USA, V101, P16240, DOI 10.1073/pnas.0407241101; Stern CD, 2005, DEVELOPMENT, V132, P2007, DOI 10.1242/dev.01794; Takke C, 1999, DEVELOPMENT, V126, P3005; Thisse B, 2004, METHOD CELL BIOL, V77, P505; Varsamos S, 2005, COMP BIOCHEM PHYS A, V141, P401, DOI 10.1016/j.cbpb.2005.01.013; Wall SM, 2005, CURR OPIN NEPHROL HY, V14, P480, DOI 10.1097/01.mnh.0000168390.04520.06; Westin J, 1997, DEV GENES EVOL, V207, P51, DOI 10.1007/s004270050091; Wettstein DA, 1997, DEVELOPMENT, V124, P693; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Yan JZ, 2006, MOL CELL BIOL, V26, P155, DOI 10.1128/MCB.26.1.155-168.2006; Zecchin E, 2007, DEV BIOL, V301, P192, DOI 10.1016/j.ydbio.2006.09.041; Zecchin E, 2005, DEV DYNAM, V233, P638, DOI 10.1002/dvdy.20366	83	114	115	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2007	2	3							e302	10.1371/journal.pone.0000302	http://dx.doi.org/10.1371/journal.pone.0000302			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DQ	17375188	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445100004
J	Nicholls, B; Racey, PA				Nicholls, Barry; Racey, Paul A.			Bats Avoid Radar Installations: Could Electromagnetic Fields Deter Bats from Colliding with Wind Turbines?	PLOS ONE			English	Article							AUDITORY SYSTEM RESPONSE; THRESHOLDS; HEARING; THERMOREGULATION; SENSATIONS; MICROWAVES	Large numbers of bats are killed by collisions with wind turbines, and there is at present no direct method of reducing or preventing this mortality. We therefore determine whether the electromagnetic radiation associated with radar installations can elicit an aversive behavioural response in foraging bats. Four civil air traffic control (ATC) radar stations, three military ATC radars and three weather radars were selected, each surrounded by heterogeneous habitat. Three sampling points matched for habitat type and structure, dominant vegetation species, altitude and surrounding land class were located at increasing distances from each station. A portable electromagnetic field meter measured the field strength of the radar at three distances from the source: in close proximity (<200 m) with a high electromagnetic field (EMF) strength>2 volts/metre, an intermediate point within line of sight of the radar (200-400 m) and with an EMF strength<2 v/m, and a control site out of sight of the radar (>400 m) and registering an EMF of zero v/m. At each radar station bat activity was recorded three times with three independent sampling points monitored on each occasion, resulting in a total of 90 samples, 30 of which were obtained within each field strength category. At these sampling points, bat activity was recorded using an automatic bat recording station, operated from sunset to sunrise. Bat activity was significantly reduced in habitats exposed to an EMF strength of greater than 2 v/m when compared to matched sites registering EMF levels of zero. The reduction in bat activity was not significantly different at lower levels of EMF strength within 400 m of the radar. We predict that the reduction in bat activity within habitats exposed to electromagnetic radiation may be a result of thermal induction and an increased risk of hyperthermia.	[Nicholls, Barry; Racey, Paul A.] Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland	University of Aberdeen	Nicholls, B (corresponding author), Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland.	b.nicholls@abdn.ac.uk			Mammals Trust UK (MTUK); Department for Environment, Food and Rural Affairs (DEFRA)	Mammals Trust UK (MTUK); Department for Environment, Food and Rural Affairs (DEFRA)(Department for Environment, Food & Rural Affairs (DEFRA))	Funding for this project was provided by The Mammals Trust UK (MTUK), and the Department for Environment, Food and Rural Affairs (DEFRA).	ADAIR ER, 1983, MICROWAVES THERMOREG, P359; Ahlen I, 2003, WIND TURBINES BATS P; Alcalde J., 2003, BARBASTELLA, V2, P3; Arnett E.B., 2005, RELATIONSHIPS UNPUB; Bach L, 2002, AUSWIRKUNGEN WINDENE; Balmori A, 2005, ELECTROMAGN BIOL MED, V24, P109, DOI 10.1080/15368370500205472; Barlow J, 2003, MAR MAMMAL SCI, V19, P265, DOI 10.1111/j.1748-7692.2003.tb01108.x; Blick DW, 1997, BIOELECTROMAGNETICS, V18, P403, DOI 10.1002/(SICI)1521-186X(1997)18:6<403::AID-BEM1>3.0.CO;2-6; BROWN DO, 1994, BIOELECTROMAGNETICS, V15, P143, DOI 10.1002/bem.2250150206; Burchard JF, 1996, J DAIRY SCI, V79, P1549, DOI 10.3168/jds.S0022-0302(96)76516-5; Curry RC, 2000, P NAT AV WIND POW PL, P18; D'Andrea JA, 2003, BIOELECTROMAGNETICS, pS39, DOI 10.1002/bem.10169; Davydov AF, 2004, J EVOL BIOCHEM PHYS+, V40, P241, DOI 10.1023/B:JOEY.0000042626.18724.9d; DOWNS NC, 1999, BAT RES NEWS, V40, P41; Elder JA, 2003, BIOELECTROMAGNETICS, pS162, DOI 10.1002/bem.10163; ENDL P, 2005, UNTERSUCHUNGEN UNPUB; Erickson W., 2002, SYNTHESIS COMP BASEL; FENTON MB, 1970, CAN J ZOOLOG, V48, P847, DOI 10.1139/z70-148; FOSTER KR, 1974, SCIENCE, V185, P256, DOI 10.1126/science.185.4147.256; FREY AH, 1963, AM J MED ELECTRON, V2, P28; FREY AH, 1962, J APPL PHYSIOL, V17, P689, DOI 10.1152/jappl.1962.17.4.689; FREY AH, 1961, AEROSPACE MED, V32, P1140; GREENBERG B, 1981, BIOELECTROMAGNETICS, V2, P315, DOI 10.1002/bem.2250020404; HENDLER E, 1963, TEMP ITS MEAS, P211; HENSHAW RE, 1966, PHYSIOL ZOOL, V39, P223, DOI 10.1086/physzool.39.3.30152849; HODOS W, 2001, NAT AV WIND POW PLAN, P88; Humphrey SR, 1976, SPECIAL PUBLICATION, V4, P1; Johnson GD, 2003, AM MIDL NAT, V150, P332, DOI 10.1674/0003-0031(2003)150[0332:MOBAAL]2.0.CO;2; Johnson Gregory D., 2005, Bat Research News, V46, P45; Jones G, 2005, CURR BIOL, V15, pR484, DOI 10.1016/j.cub.2005.06.051; JUSTESEN DR, 1979, B NEW YORK ACAD MED, V55, P1058; JUSTESEN DR, 1982, BIOELECTROMAGNETICS, V3, P117, DOI 10.1002/bem.2250030115; Kerns Jessica, 2004, STUDY BIRD BAT COLLI; Kraus SD, 1997, NATURE, V388, P525, DOI 10.1038/41451; Kunz TH, 2003, BAT ECOLOGY, P3; LIN J C, 1976, Journal of Microwave Power, V11, P295; LIN JC, 1977, RADIO SCI, V12, P237, DOI 10.1029/RS012i06Sp00237; Lin JC, 2001, IEEE ANTENN PROPAG M, V43, P166, DOI 10.1109/74.979546; LIN JC, 1990, BIOL EFFECTS MED APP, P275; LIN JC, 2002, MOBILE COMPUT COMMUN, V6, P9; NEUWEILER G, 2000, PHYSIOL ZOOL, V39, P223; REEDER WG, 1951, J MAMMAL, V32, P389, DOI 10.2307/1375787; Ryan BF, 1994, MINITAB HDB; SOMMER HC, 1964, AEROSPACE MED, V35, P834; SPEAKMAN JR, 1994, J THEOR BIOL, V171, P325, DOI 10.1006/jtbi.1994.1235; Timm R.M., 1989, Bulletin of the Chicago Academy of Sciences, V14, P1; TRAXLER A., 2004, VOGELSCHLAG MEIDEVER; Trippel EA, 1999, CAN J FISH AQUAT SCI, V56, P113, DOI 10.1139/cjfas-56-1-113; *UNEP EUROBATS, 2006, AGR CONS POP EUR BAT; Walsh AL, 1996, J APPL ECOL, V33, P508, DOI 10.2307/2404980; Wickramasinghe LP, 2004, CONSERV BIOL, V18, P1283, DOI 10.1111/j.1523-1739.2004.00152.x; Zar JH, 1999, BIOSTATISTICAL ANAL	52	24	29	2	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e297	10.1371/journal.pone.0000297	http://dx.doi.org/10.1371/journal.pone.0000297			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372629	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444800020
J	Smemo, S; Borevitz, JO				Smemo, Scott; Borevitz, Justin O.			Redundancy in Genotyping Arrays	PLOS ONE			English	Article								Despite their unprecedented density, current SNP genotyping arrays contain large amounts of redundancy, with up to 40 oligonucleotide features used to query each SNP. By using publicly available reference genotype data from the International HapMap, we show that 93.6% sensitivity at <5% false positive rate can be obtained with only four probes per SNP, compared with 98.3% with the full data set. Removal of this redundancy will allow for more comprehensive whole-genome association studies with increased SNP density and larger sample sizes.	[Borevitz, Justin O.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; [Smemo, Scott] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Borevitz, JO (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.	borevitz@uchicago.edu	Borevitz, Justin/B-5423-2012	Borevitz, Justin/0000-0001-8408-3699	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007197] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; CARVALHO B, 2006, BIOSTATISTICS; Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Heller MJ, 2002, ANNU REV BIOMED ENG, V4, P129, DOI 10.1146/annurev.bioeng.4.020702.153438; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; Meaburn E, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj027; Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741	10	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e287	10.1371/journal.pone.0000287	http://dx.doi.org/10.1371/journal.pone.0000287			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17356697	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444800010
